kalra
v
g
apollo
hospit
pediatr
hematolog
oncolog
delhi
india
apollo
hospit
pediatr
delhi
india
backgroundobject
propofol
frequent
use
unit
procedur
sedat
howev
prospect
random
compar
trial
rct
compar
especi
import
develop
countri
due
limit
resourc
train
pediatrician
usual
perform
procedur
sedat
object
compar
ketaminemidazolam
group
propofol
group
b
sed
agent
intrathec
chemotherapi
designmethod
rct
conduct
juli
institut
ethic
approv
children
age
year
requir
intraven
sedat
intrathec
chemotherapi
includ
patient
random
use
comput
gener
random
tabl
obtain
written
consent
initi
dose
use
ketamin
midazolam
mgkg
propofol
per
standard
recommend
time
sedat
dose
requir
depth
sedat
use
modifi
ramsey
scale
vital
paramet
time
smooth
recoveri
emerg
phenomenon
document
result
total
patient
enrol
group
group
b
nine
patient
failur
sedat
group
b
thirteen
group
b
requir
top
sedat
mean
time
sedat
b
shorter
mean
heart
rate
higher
transient
drop
satur
note
patient
b
mean
depth
sedat
greater
b
mean
time
recoveri
b
shorter
emerg
symptom
experienc
patient
b
conclus
combin
appear
safer
effect
use
propofol
significantli
faster
onset
quicker
recoveri
smoother
emerg
sedat
recommend
initi
dose
provid
inadequ
sedat
r
ortiz
c
w
r
rc
g
escuela
oncolog
tegucigalpa
hondura
la
mascota
oncolog
managua
nicaragua
oncolog
guatemala
guatemala
infantil
reid
cabral
oncolog
santo
domingo
dominican
republ
bloom
oncolog
el
salvador
el
salvador
de
san
pedro
sula
oncolog
san
pedro
sula
hondura
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
intern
outreach
memphi
usa
backgroundobject
treatment
matur
malign
incom
countri
challeng
increas
risk
toxic
associ
advanc
diseas
present
limit
support
care
ahopca
collabor
group
central
america
implement
modifi
treatment
regimen
designmethod
newli
diagnos
patient
histolog
immunocytolog
diagnosi
matur
malign
diagnos
institut
reatment
murphi
stage
prephas
block
b
methotrex
dose
hour
infus
stage
iii
prephas
block
b
b
b
stage
iv
prephas
block
b
b
b
methotrex
dose
hour
infus
patient
poor
clinic
condit
induct
given
second
prephas
proceed
block
aa
poor
respond
first
cycl
given
aa
bb
block
remain
cycl
ifosfamid
dose
block
aa
difficult
case
discuss
result
median
month
patient
regist
elig
four
patient
hiv
eight
previous
treat
three
case
wrong
diagnosi
three
case
treat
anoth
treatment
protocol
case
immunohistochem
character
distribut
stage
iii
iv
na
overal
surviv
whole
group
stage
stage
iii
stage
event
includ
death
induct
abandon
relapseprogress
death
complet
remiss
second
malign
death
unknown
caus
conclus
simplifi
adapt
treatment
feasibl
associ
accept
result
set
limit
resourc
effort
improv
result
focu
educ
commun
provid
earli
sign
diseas
prompt
referr
improv
histolog
techniqu
critic
decreas
number
wrong
diagnosi
allow
proper
classif
j
brok
vt
td
r
n
c
mm
van
den
b
de
k
f
colleg
great
ormond
street
institut
child
health
cancer
section
london
unit
kingdom
cancer
institut
dept
biometr
amsterdam
netherland
cambridg
dept
paediatr
cambridg
unit
kingdom
univers
hospit
dept
haematolog
oncolog
homburg
germani
institut
dhaematolog
doncolog
paediatr
lyon
franc
maxima
center
pediatr
oncolog
utrecht
netherland
nacion
cancer
paediatr
research
center
rio
de
janeiro
brazil
de
la
timon
enfant
depart
pediatr
hematolog
oncolog
marseil
franc
colleg
great
ormond
street
institut
child
health
dept
radiolog
london
unit
kingdom
ircc
istituto
nazional
dei
tumori
dept
hematolog
pediatr
milano
itali
backgroundobject
children
wilm
tumor
wt
requir
regular
relaps
surveil
usual
abdomin
ultrasound
chest
start
surgeri
map
site
time
mode
detect
first
wt
relaps
use
siop
wt
studi
databas
assess
prognost
factor
mortal
data
use
evalu
current
surveil
recommend
designmethod
patient
wt
regist
siop
wt
studi
treat
chemotherapi
per
protocol
includ
analys
result
regist
patient
relaps
relaps
site
involv
lung
andor
abdomen
liver
bone
central
nervou
system
relaps
occur
within
year
histolog
tumour
relaps
faster
overal
surviv
rate
ci
surveil
imag
captur
relaps
remain
relaps
present
clinic
symptom
outsid
routin
relaps
identifi
abdomin
ultrasound
chest
ct
scan
chestabdomen
abdomin
mri
major
relaps
detect
medic
examin
relaps
accompani
symptom
multivari
analys
overal
surviv
relaps
statist
significantli
p
poorer
surgeri
relaps
interv
month
symptomat
present
outsid
plan
higher
tumour
volum
initi
surgeri
advanc
stagehistolog
risk
group
conclus
wt
relaps
predominantli
involv
lung
gener
occur
within
year
nephrectomi
without
symptom
routin
surveil
imag
captur
major
relaps
patient
seem
better
surviv
absenc
prospect
trial
evid
indic
current
recommend
imag
interv
effect
durat
focu
first
year
nephrectomi
p
lupo
r
b
b
k
colleg
medicin
pediatr
houston
usa
univers
radiat
scienc
sweden
backgroundobject
perinat
factor
associ
sarcoma
st
studi
howev
specif
contribut
factor
includ
fetal
growth
remain
unknown
factor
examin
larg
cohort
studi
assess
evalu
risk
specif
st
subtyp
therefor
sought
identifi
role
perinat
famili
factor
risk
st
larg
birth
cohort
designmethod
identifi
individu
swedish
birth
registri
born
subject
link
swedish
cancer
registri
incid
st
case
identifi
evalu
perinat
famili
factor
obtain
statist
sweden
includ
fetal
growth
gestat
age
presenc
congenit
anomali
parent
age
poisson
regress
use
estim
incid
rate
ratio
irr
confid
interv
ci
associ
select
factor
st
overal
well
common
subtyp
result
children
adolesc
young
adult
diagnos
st
million
congenit
anomali
associ
st
risk
ci
associ
stronger
ci
recent
year
high
fetal
growth
also
associ
st
time
period
ci
born
preterm
week
associ
develop
embryon
rhabdomyosarcoma
ci
notabl
advanc
patern
age
year
invers
associ
risk
develop
synovi
sarcoma
ci
conclus
cohort
studi
congenit
anomali
advers
birth
outcom
like
develop
st
compar
unaffect
contemporari
associ
may
point
disrupt
development
pathway
influenc
risk
st
find
could
implic
novel
mechan
underli
suscept
st
may
inform
futur
surveil
prevent
treatment
effort
gisselsson
j
c
medicin
lund
clinic
genet
lund
sweden
backgroundobject
chart
genet
intratumour
divers
childhood
cancer
multipl
anatom
locat
andor
time
point
treatment
order
delin
common
rout
cancer
cell
evolut
reveal
candid
mechan
behind
treatment
resist
gain
inform
intrapati
variabl
clinic
biomark
designmethod
patient
includ
base
avail
two
inform
sampl
primari
tumour
taken
minimum
intersampl
distanc
mm
total
patient
neuroblastoma
wilm
tumour
sarcoma
far
subject
multiregion
analysi
tumour
tissu
high
resolut
whole
genom
genotyp
array
patient
complement
select
case
whole
exom
sequenc
target
deep
dna
sequenc
rna
sequenc
two
tumour
sampl
analyz
per
patient
total
inform
tumour
sampl
genotyp
far
result
major
case
exhibit
intratumour
genet
divers
branch
evolut
includ
variabl
sever
suggest
clinic
biomark
subclon
major
arena
genom
evolut
primari
tumor
clear
featur
converg
evolut
includ
trisomi
monosomi
whole
chromosom
well
specif
somat
gene
alter
mutat
wilm
tumor
delet
neuroblastoma
amplif
rhabdomyosarcoma
genet
pattern
uniqu
anatom
individu
patient
function
consequ
gene
express
rna
protein
level
four
gener
pattern
tumour
evolut
identifi
least
one
strongli
correl
clinic
aggress
conclus
even
young
patient
cancer
genet
dynam
diseas
space
time
intratumour
genet
divers
common
signific
sourc
error
biomark
assess
certain
evolutionari
pattern
may
use
futur
clinic
predictor
butler
l
van
der
j
r
f
van
amalia
children
hospit
laboratori
pediatr
oncolog
pediatr
nijmegen
netherland
center
pediatr
oncolog
pediatr
utrecht
netherland
univers
medic
center
radboud
insitut
molecular
life
scienc
depart
human
genet
nijmegen
netherland
backgroundobject
genom
character
acut
lymphoblast
leukemia
greatli
improv
recognit
patient
high
relaps
risk
despit
success
intensifi
treatment
patient
relaps
associ
therapi
resist
remain
signific
problem
studi
aim
identifi
therapeut
target
synerg
drug
treat
designmethod
use
base
screen
identifi
novel
gene
control
tumor
cell
sensit
toward
prednisolon
asparaginas
key
compon
current
treatment
protocol
facilit
rapid
translat
clinic
practic
focus
screen
kinas
potenti
candid
pharmacolog
inhibit
result
valid
use
target
knockout
inhibitor
result
base
screen
identifi
gene
modul
sensit
toward
test
drug
induc
resist
well
enhanc
suscept
toward
drug
induc
apoptosi
effect
asparaginas
treatment
imping
chang
cell
metabol
result
amino
acid
starvat
consist
notion
found
gene
either
directli
involv
amino
acid
respons
rout
aminoacid
metabol
inde
target
knockout
sensit
cell
asparaginas
treatment
wherea
deplet
suffici
render
cell
resist
surprisingli
sensit
prednisolon
control
kinas
involv
receptor
signal
receptor
signal
consist
find
use
clinic
approv
compound
modul
pathway
dramat
potenti
effect
prednisolon
inhibit
sensit
prednisolon
mediat
apoptosi
fold
conclus
conclud
result
base
screen
use
delin
pathway
contribut
therapi
resist
ii
identifi
target
select
inhibit
improv
therapi
respons
ds
tsang
es
jt
luca
p
te
radiat
oncolog
st
jude
children
research
hospit
memphi
tn
usa
radiat
oncolog
cleveland
clinic
cleveland
oh
usa
epidemiolog
harvard
th
chan
school
public
health
boston
usa
hygien
epidemiolog
medic
statist
school
medicin
nation
kapodistrian
univers
athen
nkua
athen
greec
backgroundobject
goal
studi
report
incid
manag
risk
factor
pseudoprogress
radiat
therapi
rt
patient
pediatr
glioma
lgg
designmethod
retrospect
studi
includ
patient
age
year
intracrani
lgg
treat
rt
singl
institut
pseudoprogress
defin
increas
tumour
size
least
dimens
two
three
consecut
mr
imag
studi
overal
surviv
os
surviv
ef
measur
first
day
rt
ef
defin
surviv
without
true
progress
secondari
glioma
result
patient
develop
pseudoprogress
cumul
incid
ci
median
time
pseudoprogress
month
rt
interquartil
rang
iqr
tumour
pseudoprogress
observ
eventu
stabil
reduct
size
time
symptomat
pseudoprogress
manag
subtot
resect
shuntommaya
reservoir
placement
corticosteroid
patient
respect
patient
pilocyt
astrocytoma
pa
greater
odd
develop
pseudoprogress
rel
tumour
odd
ratio
ci
p
among
patient
pa
cumul
incid
pseudoprogress
subgroup
pseudoprogress
associ
improv
ef
vs
p
os
vs
p
conclus
pseudoprogress
radiat
therapi
common
particularli
patient
pilocyt
astrocytoma
associ
improv
surviv
awar
incid
tempor
dynam
pseudoprogress
may
help
avoid
unnecessari
salvag
treatment
tf
eleveld
l
j
da
l
r
ga
p
van
hn
r
jj
translat
research
princess
maxima
centr
childhood
oncolog
utrecht
netherland
oncogenom
academ
medic
center
univers
amsterdam
amsterdam
netherland
pediatr
oncolog
emma
hospit
academ
medic
center
univers
amsterdam
amsterdam
netherland
backgroundobject
recent
shown
mutat
affect
pathway
occur
frequent
neuroblastoma
relaps
tumor
hypothes
activ
pathway
could
associ
poor
prognosi
tumor
progress
henc
object
detect
activ
state
pathway
tumor
correl
prognosi
find
character
addit
mutat
serv
biomark
pathway
activ
designmethod
gener
gene
signatur
identifi
activ
state
pathway
cell
line
tumor
data
correl
whole
genom
sequenc
data
identifi
novel
mutat
influenc
activ
pathway
candid
mutat
induc
cell
line
use
gene
edit
character
vitro
vivo
result
show
primari
neuroblastoma
tumor
activ
pathway
correl
poor
surviv
associ
known
activ
mutat
alk
bona
fide
pathway
gene
integr
analysi
identifi
mutat
cic
dmd
activ
pathway
vitro
show
activ
pathway
caus
tumor
progress
vivo
conclus
result
identifi
novel
biomark
activ
reinforc
pathway
promis
target
high
risk
neuroblastoma
research
determin
whether
identifi
mutat
also
function
biomark
sensit
mek
inhibit
nelson
c
j
nation
medic
center
center
cancer
immunolog
research
dc
usa
backgroundobject
surviv
patient
wilm
tumor
wt
howev
patient
anaplast
histolog
wt
ahwt
patient
favor
histolog
wt
fhwt
suffer
recurr
patient
surviv
addit
therapi
risk
toxic
infertil
factor
upregul
number
malign
implic
chemoresist
recurr
investig
preval
accumul
role
wt
growth
respons
treatment
echinomycin
known
inhibitor
wt
model
designmethod
immunofluoresc
stain
perform
wt
sampl
score
scale
accord
percentag
cell
posit
stain
cell
line
employ
system
tumor
growth
nsg
mice
compar
type
effect
echinomycin
viabil
assess
three
wt
cell
line
includ
two
ahwt
sampl
use
mtt
assay
effect
liposom
echinomycin
tumor
growth
assess
ahwt
xenograft
model
result
fifti
percent
wt
sampl
highest
hif
stain
intens
score
cell
stain
posit
mice
inject
cell
result
tumor
incid
tumor
grew
inject
cell
p
echinomycin
toxic
three
wt
case
cell
cultur
pm
ahwt
xenograft
treat
show
signific
growth
inhibit
compar
vehicl
conclus
preval
wt
sampl
presenc
essenti
tumor
growth
mice
echinomycin
treatment
ahwt
xenograft
impair
tumor
growth
therefor
echinomycin
hold
promis
target
agent
wt
g
cresswel
r
r
nm
k
w
franci
crick
institut
bioinformat
comput
biolog
laboratori
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
cancer
london
unit
kingdom
backgroundobject
previous
demonstr
genet
heterogen
wilm
tumor
wt
occur
despit
low
number
genet
chang
per
tumor
frequent
multifoc
bilater
signific
treatment
challeng
poorli
understood
mechan
furthermor
circa
relaps
predict
current
stratif
criteria
address
issu
need
understand
better
evolutionari
process
wt
develop
current
experiment
approach
tumor
evolut
utilis
wgswe
sequenc
tumor
wgswe
may
effici
approach
tumor
rel
mutat
designmethod
combin
target
sequenc
illumina
coreexom
snp
array
assess
profil
mutat
statu
panel
gene
develop
mixtur
method
model
frequenc
infer
cellular
aberr
cna
segment
infer
subclon
cluster
segment
similar
cellular
subclon
compar
across
multipl
sampl
evolutionari
trajectori
calcul
tumor
combin
snp
array
sequenc
data
avail
wt
snp
array
data
addit
wt
result
infer
clone
per
wt
show
wide
rang
evolutionari
trajectori
subset
case
show
mark
evolutionari
diverg
may
explain
diagnost
difficulti
diffus
anaplasia
anoth
subset
show
strike
converg
evolut
cna
point
mutat
conclus
accur
evolutionari
trajectori
infer
wt
regardless
tumor
multifoc
bilater
without
wgswe
despit
low
number
passeng
well
driver
mutat
per
tumor
mani
tumor
show
surprisingli
high
number
clonestumor
compar
adult
cancer
wide
rang
evolutionari
trajectori
gener
unlik
adult
cancer
case
converg
evolut
suggest
previous
unsuspect
strong
select
pressur
subset
wt
n
bharathi
cancer
therapi
develop
institut
biotechnolog
beaverton
usa
backgroundobject
rhabdomyosarcoma
rm
common
soft
tissu
sarcoma
childhood
yet
often
also
occur
adolesc
young
adult
clinic
surviv
amongst
metastat
rm
patient
remain
dismal
yet
unimprov
year
sever
decad
previous
identifi
class
specif
histon
deacetylas
inhibitor
entinostat
pharmacolog
agent
transcript
suppress
fusion
gene
found
mani
alveolar
rhabdomyosarcoma
purpos
studi
examin
whether
entinostat
may
provid
real
therapeut
benefit
patient
embryon
rhabdomyosarcoma
erm
alveolar
rhabdomyosarcoma
arm
designmethod
investig
compar
efficaci
entinostat
hdac
inhibitor
full
spectrum
posit
arm
fusion
neg
erm
use
vitro
vivo
model
includ
orthotop
allograft
patient
deriv
xenograft
understand
mechan
entinostat
action
arm
erm
rnaseq
crispr
studi
carri
result
find
entinostat
effect
silenc
entinostat
delay
tumor
engraft
arm
radiat
treatment
combin
chemotherapi
vincristin
entinostat
strong
activ
armserm
orthotop
allograft
xenograft
mechanist
interrog
rnaseq
crispr
studi
suggest
inhibit
primari
mechan
downregul
arm
cytoreduct
erm
myogen
differenti
effect
therapi
erm
driven
crosstalk
tumor
microenviron
conclus
studi
support
emerg
clinic
trial
concept
use
entinostat
chemotherapi
arm
erm
address
clinic
need
preclin
evid
suggest
entinostat
may
provid
therapeut
benefit
rm
present
vitro
vivo
evid
document
entinostat
therapeut
effect
rm
tumor
also
understand
mechan
underli
activ
arm
erm
e
hiyama
f
univers
hospit
peditr
surgeri
hiroshima
japan
univers
natur
scienc
center
basic
research
develop
hiroshima
japan
backgroundobject
hepatoblastoma
hb
preval
liver
malign
molecular
pathogenesi
incomplet
understood
hb
incid
significantli
high
children
extrem
weight
hb
patient
diagnos
old
age
show
poor
outcom
designmethod
describ
integr
molecular
studi
perform
exom
transcriptom
well
copi
number
methyl
analys
total
hbl
case
among
also
perform
sequenc
wg
methyl
wgm
analysi
case
result
exom
wg
analysi
reveal
hb
tumor
mutat
younger
patient
show
fewer
somat
mutat
differ
mutat
rate
patient
weight
normal
birth
weight
mutat
signatur
reveal
two
characterist
pattern
domin
alter
exon
mutat
wnt
signal
gene
includ
fap
gene
howev
rna
sequenc
show
activ
wnt
signal
gene
case
show
mutat
number
mutat
less
base
methyl
pattern
hbl
cluster
four
distinct
subtyp
name
show
similar
pattern
liver
tissu
highli
correl
upd
interestingli
case
extrem
weight
exhibit
involv
case
diagnos
older
age
case
aliv
half
case
show
poor
outcom
conclus
integr
molecular
analysi
unmask
new
correl
dna
methyl
includ
upd
gene
mutat
gene
express
copi
number
profil
enabl
stratif
clinic
risk
patient
hb
molecular
analysi
provid
new
import
cluster
hb
patient
stratifi
futur
clinic
trial
hargreav
ls
jf
k
sk
cancer
societi
lifestyl
gene
copenhagen
denmark
cancer
societi
childhood
cancer
survivorship
research
survivorship
unit
copenhagen
denmark
univers
hospit
rigshospitalet
paediatr
adolesc
medicin
denmark
denmark
backgroundobject
follow
discoveri
diethylstilboestrol
ie
synthet
oestrogen
caus
cancer
children
expos
utero
studi
investig
effect
matern
contracept
use
risk
cancer
children
inconsist
result
aim
studi
assess
associ
matern
use
hormon
contracept
childhood
leukaemia
use
uniqu
danish
registri
designmethod
follow
nationwid
cohort
live
born
children
individu
linkag
danish
registri
redeem
prescript
data
nation
regist
medicin
product
statist
provid
inform
matern
hormon
contracept
use
categor
never
birth
refer
month
prior
concept
month
concept
birth
recent
use
cox
proport
hazard
model
use
estim
hazard
ratio
hr
confid
interv
ci
adjust
potenti
confound
result
observ
mean
year
children
diagnos
leukaemia
increas
risk
leukaemia
found
children
born
women
recent
use
type
hormon
contracept
hr
ci
compar
children
never
user
specif
leukaemia
risk
doubl
hr
ci
increas
mainli
observ
recent
use
combin
product
progestinoestrogen
combin
type
leukaemia
hr
ci
leukaemia
hr
ci
compar
never
user
conclus
matern
use
hormon
contracept
earli
pregnanc
may
increas
risk
leukaemia
children
k
nakata
w
c
k
k
b
intern
cancer
center
cancer
control
center
osaka
japan
school
hygien
tropic
medicin
cancer
surviv
group
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
cancer
programm
london
unit
kingdom
health
england
nation
cancer
registr
analysi
servic
oxford
unit
kingdom
cancer
control
inform
nation
cancer
center
center
cancer
registri
tokyo
japan
backgroundobject
studi
aim
compar
time
trend
cancer
incid
surviv
children
diagnos
japan
england
use
cancer
registri
data
designmethod
analysi
base
children
cancer
age
prefectur
cancer
registri
japan
children
diagnos
england
incid
rate
asr
calcul
use
weight
world
standard
popul
poisson
regress
model
use
evalu
chang
incid
rate
time
overal
surviv
estim
use
method
result
incid
childhood
cancer
combin
decreas
japan
throughout
asr
per
million
vs
mainli
explain
decreas
registr
infant
neuroblastoma
incid
cancer
england
increas
plateau
asr
incid
hodgkin
lymphoma
renal
tumour
ewe
sarcoma
england
twice
high
japan
incid
germ
cell
tumour
hepat
tumour
neuroblastoma
acut
myeloid
leukaemia
aml
higher
japan
england
mani
cancer
surviv
improv
countri
differ
surviv
countri
narrow
time
improv
surviv
chronic
myeloid
leukaemia
cml
particularli
dramat
countri
howev
surviv
remain
less
countri
aml
brain
tumour
soft
tissu
sarcoma
malign
bone
tumour
neuroblastoma
children
age
year
conclus
signific
differ
incid
sever
cancer
england
japan
suggest
ethnic
variat
suscept
decreas
incid
infant
neuroblastoma
japan
coincid
cessat
nation
screen
programm
great
improv
surviv
cml
countri
coincid
introduct
effect
therapi
imatinib
tolkkinen
j
l
n
cancer
registri
finnish
cancer
registri
helsinki
finland
helsinki
depart
public
health
helsinki
finland
univers
hospit
divis
pediatr
oncolog
stem
cell
transplant
helsinki
finland
univers
hospit
depart
pediatr
adolesc
medicin
helsinki
finland
tamper
school
health
scienc
tamper
finland
backgroundobject
parent
socioeconom
statu
suggest
influenc
childhood
cancer
mortal
even
countri
studi
investig
parent
socioeconom
factor
influenc
childhood
cancer
mortal
finland
designmethod
use
nationwid
registri
identifi
patient
diagnos
cancer
age
outcom
death
primari
cancer
year
identif
parent
inform
socioeconom
factor
retriev
central
popul
registri
statist
finland
poisson
regress
model
adjust
time
age
cancer
diagnosi
diagnost
period
result
mortal
lower
highest
quartil
combin
parent
dispos
incom
hr
ci
compar
lowest
quartil
ad
parent
educ
model
result
still
statist
signific
compar
individu
finnish
decent
mortal
higher
patient
hr
ci
mother
hr
ci
father
hr
ci
immigr
born
aboard
mortal
also
higher
matern
hr
ci
patern
nativ
languag
hr
ci
finnish
swedish
result
origin
birth
nativ
languag
remain
signific
even
adjust
parent
incom
employ
statu
educ
conclus
finland
despit
public
health
care
comprehens
social
secur
high
parent
incom
predict
lower
mortal
childhood
cancer
compar
low
parent
incom
parent
immigr
statu
born
abroad
predictor
increas
mortal
underli
factor
relat
patient
pathway
explor
better
understand
prevent
dispar
futur
e
desand
l
j
b
nanci
registr
nation
de
tumeur
solid
de
lenfant
nanci
franc
gustav
roussi
doncologi
de
lenfant
et
de
ladolesc
villejuif
franc
registr
nation
de
cancer
de
inserm
cress
pari
franc
de
de
purpan
de
registr
de
toulous
franc
backgroundobject
franc
countri
need
view
access
care
modal
treatment
adolesc
young
adult
aya
cancer
aim
evalu
pathway
qualiti
care
gener
popul
set
designmethod
aya
case
diagnos
cancer
age
year
live
french
administr
area
cover
identifi
french
cancer
registri
data
diagnosi
treatment
delay
manag
multidisciplinari
decision
approach
mdt
pathway
care
collect
medic
record
result
overal
adolesc
young
adult
includ
time
diagnosi
significantli
longer
young
adult
adolesc
week
vs
week
especi
sarcoma
decis
treatment
initi
made
within
context
mdt
adolesc
young
adult
mdt
meet
adolesc
involv
pediatr
adult
oncologist
vs
young
adult
aya
case
consult
gener
practition
referr
specialist
investig
main
institut
involv
manag
aya
cancer
univers
hospit
privat
hospit
main
servic
adult
oncolog
unit
adolesc
young
adult
cancer
care
dedic
aya
unit
overal
adolesc
young
adult
includ
clinic
studi
conclus
compar
previou
french
studi
period
desand
e
et
al
organ
care
adolesc
cancer
shift
toward
increas
involv
pediatrician
especi
year
increas
manag
within
context
mdt
special
cancer
health
institut
increas
particip
clinic
studi
r
phillip
l
c
york
centr
review
dissemin
york
unit
kingdom
backgroundobject
risk
stratifi
manag
febril
neutropenia
fn
also
known
fever
neutropenia
allow
intens
manag
case
earli
discharg
case
valid
predict
rule
import
geograph
tempor
chanc
variabl
may
affect
deriv
rule
calibr
advis
valid
across
differ
data
sourc
allow
explor
possibl
reason
differ
calibr
appli
designmethod
use
data
deriv
predict
infecti
complic
children
cancer
picnicc
collabor
assess
valu
picnicc
microbiolog
defin
infect
mdi
predict
rule
new
dataset
combin
data
use
differ
approach
recalibr
bootstrap
estim
varianc
multivari
risk
predict
model
six
compon
tumour
type
temperatur
clinic
sever
unwel
haemoglobin
white
cell
count
absolut
monocyt
count
result
seven
data
set
six
locat
report
episod
fever
neutropenia
includ
raw
model
likelihood
mdi
expectedobserv
ratio
ci
moder
ci
compar
ci
deriv
cohort
analysi
show
mark
heterogen
differ
approach
led
similar
estim
larg
assess
threshold
defin
low
risk
model
pool
sensit
ci
pool
specif
ci
clear
explan
heterogen
found
assess
statu
contin
conclus
picnicc
risk
predict
model
microbiolog
defin
infect
show
mark
variat
valid
across
multipl
data
set
argu
local
valid
predict
rule
use
mouffak
h
k
g
hospit
aphp
depart
pediatr
hematolog
oncolog
pari
franc
hospit
aphp
depart
pharmaci
pari
franc
backgroundobject
nausea
vomit
cinv
toxic
impact
children
qualiti
life
complic
cancer
treatment
imprecis
intern
recommend
difficulti
nausea
detect
children
low
prioriti
sometim
given
symptom
risk
manag
cinv
purpos
studi
assess
children
nausea
vomit
chemotherapi
treatment
designmethod
conduct
monocentr
retrospect
survey
children
treat
french
paediatr
cancer
refer
center
patient
ask
cinv
experi
term
frequenc
sever
time
symptom
children
could
answer
question
ask
parent
result
juli
octob
children
age
survey
children
receiv
highli
emetogen
chemotherapi
receiv
moder
emetogen
chemotherapi
receiv
low
emetogen
chemotherapi
overal
popul
analys
patient
indic
alreadi
experienc
nausea
andor
vomit
chemotherapi
treatment
experienc
first
chemotherapi
administr
eight
percent
children
describ
anticipatori
symptom
describ
acut
cinv
experienc
delay
cinv
patient
receiv
highli
emetogen
chemotherapi
expos
symptom
popul
children
experienc
nausea
vomit
treatment
experienc
vomit
systemat
frequent
conclus
studi
show
children
experienc
cinv
treatment
symptom
occur
even
antiemet
prophylaxi
accord
local
guidelin
guidelin
updat
accord
intern
guidelin
year
emetogen
risk
adult
cancer
strongli
decreas
thank
therapeut
innov
cinv
manag
improv
improv
requir
paediatr
prospect
optimis
exist
start
convinc
rais
awar
among
medic
commun
j
e
g
p
hind
nation
medic
center
oncolog
washington
usa
nation
medic
center
divis
biostatist
studi
methodolog
washington
usa
north
chapel
hill
divis
gener
medicin
clinic
epidemiolog
chapel
nc
usa
north
chapel
hill
shep
center
health
servic
research
chapel
nc
usa
nation
medic
center
depart
nurs
research
qualiti
outcom
washington
usa
backgroundobject
children
treatment
cancer
experi
multipl
troubl
interrel
symptom
analyz
interrelated
symptom
might
chang
treatment
import
focu
cancer
symptom
research
appli
advanc
analyt
approach
interrelated
could
identifi
clinic
relev
patient
profil
aim
identifi
pediatr
profil
respect
fatigu
depress
anxieti
pain
b
chang
profil
statu
throughout
chemotherapi
cycl
c
baselin
fatigu
item
score
could
significantli
predict
symptom
profil
designmethod
longitudin
three
data
point
design
children
year
complet
promi
pediatr
short
form
measur
fatigu
depress
anxieti
pain
fatigu
item
symptom
distress
scale
latent
class
analysi
lca
latent
transit
analysi
lta
appli
prospect
symptom
data
result
children
particip
year
male
symptom
mean
score
remain
rel
unchang
first
two
data
point
significantli
declin
final
data
point
end
cours
chemotherapi
lpa
result
indic
model
less
sever
symptom
sever
symptom
fatigu
score
significantli
predict
profil
child
member
lta
find
indic
small
proport
sampl
chang
profil
group
across
three
data
point
conclus
children
experienc
troubl
symptom
cancer
treatment
homogen
group
four
measur
symptom
studi
repres
least
two
rel
stabl
profil
identifi
high
accuraci
earli
child
cours
chemotherapi
transit
profil
statu
significantli
predict
baselin
fatigu
measur
c
pilotto
j
da
wp
udin
depart
medic
biolog
scienc
udin
itali
nottingham
children
brain
tumour
research
centr
nottingham
unit
kingdom
nottingham
school
medicin
nottingham
unit
kingdom
children
hospit
depart
paediatr
neurolog
nottingham
unit
kingdom
backgroundobject
consensu
treatment
withdraw
brain
tumour
relat
epilepsi
children
young
peopl
describ
experi
epilept
seizur
children
brain
tumour
treat
centr
relat
risk
factor
seizur
treatment
withdraw
antiepilept
drug
a
designmethod
retrospect
case
note
review
newli
diagnos
brain
tumour
patient
refer
region
paediatr
servic
carri
determin
patient
tumour
seizur
characterist
treatment
outcom
result
data
children
young
peopl
analys
male
median
age
tumour
present
year
iqr
median
follow
month
iqr
anatom
distribut
posterior
fossa
cerebr
hemispher
supratentori
midlin
spinal
cord
metastat
experienc
seizur
signific
risk
factor
seizur
occurr
cortic
tumour
locat
ic
month
median
seizur
follow
seizur
free
sf
a
sf
a
experienc
continu
epilept
seizur
treat
a
patient
withdraw
a
median
durat
a
withdraw
month
month
median
follow
withdraw
month
month
seizur
relaps
acut
event
conclus
suggest
a
withdrawn
period
three
month
seizur
freedom
particular
children
one
acut
symptomat
seizur
uncompl
cours
without
epileptogen
complic
time
withdraw
propos
servic
evalu
target
futur
studi
acknowledg
prof
richard
grundi
dr
sophi
wiln
emcyp
children
brain
tumour
research
centr
nottingham
c
mazewski
g
l
p
jr
univers
school
children
healthcar
atlanta
depart
pediatr
alpharetta
usa
jude
research
hospit
biostatist
tn
usa
hospit
westmead
paediatr
child
health
westmead
australia
heart
healthcar
system
radiolog
fla
usa
alabama
neurolog
ala
usa
children
hospit
radiolog
wa
usa
hopkin
univers
patholog
md
usa
hospit
lo
angel
patholog
lo
ca
usa
children
hospit
hematolog
oncolog
wa
usa
jude
research
hospit
oncolog
tn
usa
hospit
univers
pittsburgh
school
medicin
neurolog
surgeri
pa
usa
backgroundobject
primari
object
determin
children
month
old
hrmb
spnet
treat
intens
chemotherapi
plu
hdmtx
result
higher
complet
respons
cr
rate
regimen
without
methotrex
womtx
designmethod
enrol
patient
patient
receiv
induct
cycl
hdmtx
follow
consolid
cycl
carboplatinthiotepa
autolog
stem
cell
rescu
ascr
complet
consolid
radiat
rt
treat
physician
discret
result
patient
elig
central
patholog
review
evalu
respons
central
radiolog
induct
patient
hrmb
treat
womtx
achiev
cr
versu
treat
hdmtx
consolid
without
hdmtx
achiev
cr
hrmb
desmoplast
larg
cell
induct
achiev
cr
womtx
hdmtx
consolid
treat
without
hdmtx
achiev
cr
p
spnet
induct
without
hdmtx
achiev
cr
without
hdmtx
consolid
estim
event
free
surviv
ef
elig
hdmtx
arm
arm
womtx
patient
median
year
rang
year
estim
ef
rate
elig
spnet
methotrex
arm
womtx
eleven
patient
median
year
year
survivor
never
irradi
irradi
relaps
relaps
conclus
cr
rate
ef
better
hrmb
treat
hdmtx
versu
treat
regimen
womtx
ef
hrmb
patient
hdmtx
arm
better
ef
report
literatur
cog
headstart
l
e
g
c
c
c
c
l
children
hospit
pediatr
hematolog
oncolog
bone
marrow
transplant
calgari
canada
sick
children
pediatr
brain
tumor
program
toronto
canada
jude
children
research
hospit
neuro
oncolog
program
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
sick
children
pediatr
laboratori
medecin
toronto
canada
kimmel
cancer
center
neuro
patholog
baltimor
usa
robert
h
luri
children
hospit
chicago
patholog
chicago
usa
medic
colleg
cornel
univers
diagnost
imag
new
york
usa
sloan
ketter
cancer
center
neurolog
surgeri
new
york
usa
children
hospit
medic
center
program
cincinnati
usa
backgroundobject
nodular
desmoplast
medulloblastoma
medulloblastoma
extens
nodular
ndmben
associ
favor
outcom
younger
children
howev
neurotox
remain
signific
concern
vulner
group
patient
designmethod
prospect
conduct
multicent
trial
convent
chemotherapi
ndmben
patient
old
base
modifi
hit
skk
regimen
exclud
intraventricular
methotrex
aim
achiev
similar
outcom
reduc
neurotox
design
requir
patient
target
pf
secondari
object
includ
feasibl
time
central
patholog
review
evalu
molecular
profil
neurocognit
outcom
result
patient
male
femal
enrol
nineteen
patient
nd
mben
histolog
median
age
diagnosi
month
four
patient
residu
diseas
baselin
case
review
within
day
least
central
neuropathologist
studi
close
earli
higher
expect
relaps
rate
last
patient
relaps
local
distant
combin
median
time
month
diagnosi
rang
one
patient
die
diseas
median
time
year
rang
year
pf
se
nd
histolog
older
age
may
associ
wors
pf
none
mben
patient
relaps
detail
molecular
analysi
util
dna
methyl
array
sequenc
tumor
match
germlin
underway
character
biolog
heterogen
could
predict
differenti
respons
conclus
propos
modifi
regimen
chemotherapi
without
intraventricular
methotrex
fail
achiev
desir
pf
lead
prematur
closur
studi
result
molecular
character
ndmben
cohort
may
help
uncov
patient
may
still
benefit
regimen
r
hill
j
e
g
k
ts
institut
cancer
research
wolfson
childhood
cancer
research
centr
newcastl
upon
tyne
unit
kingdom
north
children
hospit
patholog
depart
newcastl
upon
tyne
unit
kingdom
nottingham
children
brain
tumour
research
centr
nottingham
unit
kingdom
sheffield
sheffield
institut
translat
neurosci
sheffield
unit
kingdom
institut
child
health
neural
develop
unit
london
unit
kingdom
backgroundobject
medulloblastoma
relaps
occur
patient
almost
univers
fatal
account
childhood
cancer
death
designmethod
undertook
comprehens
characteris
clinic
featur
medulloblastoma
recurr
eg
cohort
relaps
patient
relat
featur
diagnosi
eg
prognost
factor
aim
establish
whether
diseas
characterist
diagnosi
associ
natur
recurr
subsequ
diseas
cours
result
diseas
cours
follow
relaps
surviv
rare
patient
receiv
neurosurgeri
csi
chemotherapi
across
diseas
demograph
notabl
surviv
rate
observ
follow
treatment
diagnosi
patient
year
diagnosi
overal
surviv
cohort
associ
desmoplasticnodular
histolog
csi
relaps
patient
relaps
follow
patient
longer
year
mean
year
rang
shorter
time
year
year
acquisit
metastaticdist
recurr
occur
similar
rate
across
subgroup
patient
howev
final
incid
metastat
recurr
relaps
frequent
metastat
fisher
exact
wherea
mbshh
less
frequent
reflect
lower
rate
metastasi
present
mbshh
patient
associ
leptomening
diseas
p
fisher
exact
mycn
amplif
diagnosi
p
demonstr
nodular
diffus
distant
relaps
conclus
recurr
remain
signific
challeng
medulloblastoma
cure
observ
subset
infant
patient
subgroup
predict
clear
potenti
inform
diseas
monitoringmanag
work
essenti
understand
biologyclin
behavior
recurr
exploit
improv
therapi
da
c
pilotto
e
aa
mj
j
r
p
hernaiz
g
j
nottingham
children
brain
tumour
research
centr
nottingham
unit
kingdom
udin
depart
medic
biolog
scienc
udin
itali
univers
hospit
nh
trust
nottingham
unit
kingdom
padua
depart
pediatr
padua
itali
univers
vienna
depart
pediatr
adolesc
medicin
vienna
austria
univers
hospit
depart
pediatr
copenhagen
denmark
hospit
philadelphia
depart
pediatr
pennsylvania
usa
univers
hospit
nh
trust
depart
radiolog
nottingham
unit
kingdom
teach
hospit
nh
trust
depart
ophthalmolog
paediatr
oncolog
leed
unit
kingdom
st
thoma
nh
foundat
trust
neurofibromatosi
depart
neurolog
london
unit
kingdom
de
gustav
roussi
villejuif
franc
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
depart
pediatr
oncolog
hematolog
berlin
germani
mari
hospit
depart
genet
manchest
unit
kingdom
backgroundobject
optic
pathway
glioma
opg
develop
children
neurofibromatosi
type
threaten
vision
loss
surviv
consensu
appropri
strategi
select
newli
diagnos
patient
treatment
observ
designmethod
repres
case
scenario
deriv
matrix
newli
diagnos
children
opg
previous
enter
siop
lgg
trial
use
strategi
select
consensu
survey
respond
specialist
first
survey
case
second
survey
case
intern
expert
group
respond
select
case
initi
observ
initi
treatment
randomis
two
r
justifi
select
free
text
comment
qualit
analysi
free
text
comment
describ
reason
carri
two
review
mediat
follow
ground
theori
approach
alloc
reason
theme
develop
induct
result
greater
agreement
survey
respond
occur
initi
observ
case
initi
treatment
case
less
consensu
occur
case
associ
free
text
comment
justifi
select
r
alloc
review
theme
agreement
k
consensu
select
observ
justifi
risk
progress
visual
function
treatment
visual
function
random
visual
function
risk
progress
sitedimens
tumour
age
gender
conclus
survey
qualit
analysi
identifi
new
consensu
justifi
criteria
initi
observ
versu
treatment
scenario
consensu
reach
criteria
propos
elig
criteria
futur
trial
randomis
trial
indic
initi
manag
could
includ
behalf
siop
opg
nottingham
uk
workshop
particip
center
berlin
copenhagen
go
hamburg
leed
nottingham
padua
pari
vienna
merchant
ch
h
jude
children
research
hospit
depart
radiat
oncolog
memphi
usa
florida
proton
therapi
institut
depart
radiat
oncolog
jacksonvil
usa
jude
children
research
hospit
depart
biostatist
memphi
usa
jude
children
research
hospit
depart
psycholog
memphi
usa
backgroundobject
patient
craniopharyngioma
treat
radiat
therapi
risk
deficit
cognit
function
proton
therapi
reduc
volum
dose
normal
tissu
exposur
compar
photon
therapi
cognit
test
result
two
prospect
trial
use
compar
proton
photon
cohort
designmethod
patient
age
year
craniopharyngioma
enrol
prospect
trial
includ
proton
photon
therapi
serial
cognit
test
proton
therapi
administ
use
passiv
scatter
method
target
residu
tumor
tumor
bed
surround
clinic
target
volum
margin
ctv
photon
therapi
administ
use
conform
method
target
ctv
test
academ
achiev
read
math
administ
treatment
test
score
model
normal
tissu
dose
variabl
compar
score
modal
result
patient
treat
proton
therapi
compar
treat
photon
therapi
whole
brain
dose
median
rang
lower
proton
cohort
compar
photon
cohort
p
differ
compar
score
base
modal
mean
brain
dose
includ
model
patient
treat
photon
therapi
greater
declin
read
math
score
rate
chang
pointscg
gymonth
read
score
proton
photon
p
rate
chang
math
score
proton
photon
p
score
estim
base
median
dose
baselin
vs
month
read
math
vs
vs
proton
compar
vs
vs
photon
conclus
result
prospect
trial
proton
therapi
craniopharyngioma
demonstr
preserv
academ
achiev
compar
treatment
use
photon
n
winick
p
p
e
j
w
b
texa
southwestern
medic
center
pediatr
dalla
usa
univers
pediatr
durham
usa
florida
biostatist
gainesvil
usa
hopkin
universitysidney
kimmel
cancer
center
patholog
baltimor
usa
north
texa
health
scienc
center
pediatr
ft
worth
usa
children
cancer
program
pediatr
scarborough
usa
mississippi
medic
center
pediatr
jackson
usa
hospit
philadelphia
pediatr
philadelphia
usa
isaac
perlmutt
cancer
center
new
york
univers
langon
pediatr
new
york
usa
hospit
wisconsin
pediatr
milwauke
usa
backgroundobject
legaci
pog
trial
assess
impact
di
outcom
low
lr
standard
sr
subset
nci
high
risk
hr
pt
treat
therapi
includ
six
cours
iv
mtx
hr
designmethod
ncisr
patient
receiv
ncihr
pt
induct
ncisr
pt
except
trisomi
chromosom
ncihr
pt
met
refin
age
wbc
criteria
exclud
elig
particip
di
random
consolid
includ
cours
iv
mtx
leucovorin
rescu
random
di
iv
mtx
cours
week
di
includ
weekli
vincristin
daunomycin
week
daili
dexamethason
peg
asparaginas
week
intrathec
mtx
week
cyclophosphamid
week
subcutan
daili
x
week
week
end
induct
minim
residu
diseas
mrd
measur
use
alter
therapi
result
administr
di
improv
ccr
signific
effect
overal
surviv
os
di
os
versu
without
di
mrd
highli
predict
outcom
yr
ccr
among
mrd
patient
withwithout
di
patient
withwithout
di
p
conclus
delay
intensif
phase
enhanc
ccr
rate
broad
popul
patient
includ
without
end
induct
mrd
impact
os
expect
ef
rate
obtain
studi
lower
obtain
contemporari
trial
burk
w
l
j
e
e
n
w
hospit
wisconsin
pediatr
milwauke
usa
armi
medic
research
materiel
command
pediatr
fort
detrick
usa
florida
biostatist
gainesvil
usa
hospit
colorado
pediatr
aurora
usa
children
cancer
program
pediatr
scarborough
usa
children
hospit
pediatr
salt
lake
citi
usa
southwestern
pediatr
dalla
usa
york
univers
pediatr
new
york
usa
hospit
philadelphia
pediatr
philadelphia
usa
pediatr
san
francisco
usa
backgroundobject
modern
chemotherapi
regimen
patient
pediatr
acut
lymphoblast
leukemia
cure
howev
subset
patient
identifi
remain
high
risk
vhr
relaps
expect
df
appropri
candid
intens
therapeut
strategi
design
improv
surviv
aim
determin
random
fashion
substitut
cyclophosphamid
etoposid
cpmetop
experiment
arm
would
improv
df
children
adolesc
young
adult
vhr
compar
modifi
regimen
control
arm
ca
designmethod
patient
year
age
newli
diagnos
vhr
random
fashion
cpmcytarabinemercaptopurin
ca
cpm
day
etop
day
exp
part
consolid
con
delay
intensif
di
arm
includ
dose
schedul
day
vincristin
day
con
di
prospect
interim
monitor
rule
efficaci
futil
includ
futil
would
determin
result
signific
differ
grade
advers
event
delay
start
interim
mainten
arm
tabl
use
data
cutoff
date
total
event
occur
arm
ca
vs
result
test
statist
studi
stop
futil
interim
monitor
boundari
cross
hazard
ratio
ci
figur
vhr
arm
close
februari
conclus
substitut
therapi
vhr
patient
cog
random
cpmetop
part
con
di
improv
ef
w
slayton
k
j
l
n
j
b
v
e
n
w
florida
pediatr
fl
usa
children
hospit
pediatr
bc
canada
oncolog
group
statist
offic
depart
biostatist
fl
usa
oncolog
group
statist
offic
biostatist
fl
usa
lo
angel
pediatr
lo
ca
usa
farber
cancer
instituteharvard
pediatr
usa
hpkin
univers
school
medicin
hematopatholog
md
usa
alabama
depar
patholog
genet
usa
state
univers
wexner
medic
center
patholog
oh
usa
children
hospit
patholog
oh
usa
florida
medicin
fl
usa
washington
patholog
wa
usa
jude
research
hospit
radiat
therapi
tn
usa
hospit
hershey
pediatr
pa
usa
utah
pediatr
salt
lake
ut
usa
texa
southwestern
medic
center
pediatr
dalla
tx
usa
francisco
pediatr
san
ca
usa
york
univers
nyu
langon
cancer
center
new
ny
usa
pennsylvania
pediatr
pa
usa
backgroundobject
ph
patient
treat
intens
chemotherapi
plu
continu
imatinib
surviv
ef
rate
cog
compar
imatinib
dasatinib
increas
potenc
better
cn
penetr
activ
clone
designmethod
test
chemotherapi
plu
dasatinib
ph
subject
year
cohort
subject
receiv
dasatinib
week
week
block
cohort
subject
receiv
dasatinib
continu
stem
cell
transplant
sct
recommend
subject
sibl
donor
hr
subject
defin
minim
residu
diseas
end
induct
consolid
remain
sr
subject
treat
chemotherapi
plu
dasatinib
subject
receiv
cranial
radiotherapi
crt
case
receiv
crt
result
evalu
subject
ef
overal
surviv
os
rate
efso
rate
sr
subject
underw
sct
hr
subject
underw
sct
subject
cumul
incid
rate
isol
combin
cn
relaps
vs
p
treat
continu
imatinib
differ
outcom
seen
subject
receiv
imatinib
continu
cohort
df
vs
os
vs
p
delet
present
test
subject
associ
significantli
inferior
ef
vs
os
vs
conclus
trend
toward
increas
rate
cn
relaps
similar
rate
efso
obtain
intens
chemotherapi
imatinib
crt
intens
chemotherapi
plu
dasatinib
without
crt
delet
associ
inferior
efso
la
mattano
e
n
sp
wl
e
pharma
consult
pediatr
hematologyoncolog
connecticut
usa
florida
cog
data
biostatist
florida
usa
utah
primari
children
hospit
pediatr
hematologyoncolog
salt
lake
utah
usa
medic
center
pediatr
hematologyoncolog
san
california
usa
southwesternsimmon
cancer
center
pediatr
hematologyoncolog
texa
usa
hospit
philadelphia
pediatr
hematologyoncolog
pennsylvania
usa
langon
cancer
center
hassenfeld
children
center
new
york
new
york
usa
children
cancer
program
pediatr
oncolog
main
usa
backgroundobject
therapeut
toxic
attribut
glucocorticoid
asparaginas
asnas
methotrex
mtx
disproportion
affect
adolesc
dexamethason
awd
dex
doubl
delay
intensif
di
reduc
vs
continu
dex
cd
singl
di
rapid
earli
respond
rer
designmethod
patient
receiv
cog
augment
therapi
random
induct
ind
dex
vs
prednison
pdn
interim
mainten
im
mtx
vs
mtxasparaginas
emtxasnas
rer
receiv
singl
slow
earli
respond
ser
doubl
imdi
initi
receiv
monthli
dex
mainten
mtc
puls
patient
receiv
di
awd
patient
receiv
di
cd
amend
patient
receiv
di
awd
patient
assign
ind
pdn
patient
receiv
di
awd
mtc
pdn
puls
result
confirm
patient
cumul
incid
ci
increas
age
awd
vs
cd
among
random
rer
patient
ci
differ
glucocorticoid
dex
vs
pdn
mtx
assign
vs
emtxasnas
among
random
ser
patient
ci
differ
regimen
ef
significantli
higher
among
random
patient
vs
without
vs
p
find
present
differ
age
rang
rerser
subset
within
especi
rer
vs
ser
vs
p
cohort
across
group
asnas
allergi
significantli
associ
reduc
risk
hr
conclus
patient
develop
significantli
increas
ef
suggest
host
differ
increas
sensit
develop
render
cell
g
narula
b
p
p
n
memori
center
medic
oncolog
pediatr
divis
mumbai
india
memori
center
hematopatholog
mumbai
india
memori
center
cytogenet
mumbai
india
backgroundobject
childhood
develop
countri
os
exceed
remain
challeng
develop
countri
sinc
multipl
center
india
collabor
devis
protocol
uniform
manag
use
comprehens
adapt
standard
arm
protocol
pilot
institut
sinc
interim
analysi
done
designmethod
prospect
maintain
record
patient
treat
uniform
strategi
analyz
done
base
nci
criteria
adapt
prednisolon
respons
flowcytometr
mrd
data
analyz
descript
analyt
tool
method
result
children
regist
studi
period
thirteen
exclud
due
ambigu
classif
protocol
deviat
median
age
yr
median
bulki
diseas
seen
tumor
lysi
csf
involv
hypodiploidi
cytogenet
abnorm
trisomi
abnorm
poor
occur
initi
standard
risk
sr
intermedi
ir
high
hr
evalu
posit
project
os
median
month
rang
ef
mortal
occur
intens
phase
treatment
event
arm
os
sr
ir
hr
p
ef
p
respect
statu
predict
posit
versu
neg
case
p
conclus
protocol
help
improv
outcom
childhood
histor
result
posit
predict
poorer
ef
earli
mortal
relaps
remain
biggest
challeng
n
oosterom
den
r
r
de
w
van
den
center
pediatr
oncolog
depart
pediatr
oncolog
utrecht
netherland
medic
center
depart
clinic
chemistri
rotterdam
netherland
medic
center
depart
clinic
chemistri
amsterdam
netherland
children
univers
univers
medic
center
groningen
depart
pediatr
oncolog
groningen
netherland
backgroundobject
methotrex
mtx
potent
drug
treatment
pediatr
acut
lymphoblast
leukemia
mtx
cytotox
impair
dna
rna
synthesi
inhibit
enzym
dihydrofol
reductas
dhftr
thymidyl
synthas
tym
twenti
percent
patient
receiv
mtx
regimen
develop
oral
mucos
associ
toxic
genet
variant
within
thymidyl
synthas
tym
gene
studi
result
contradictori
inconsist
studi
associ
three
previous
describ
variant
within
tym
gene
relat
oral
mucos
prospect
cohort
dutch
children
designmethod
analyz
pair
repeat
singl
nucleotid
polymorph
present
within
pair
repeat
allel
c
pair
delet
ttaaag
within
tym
gene
germlin
dna
pediatr
patient
treat
gram
mtx
dcog
protocol
clinic
relev
oral
mucos
defin
grade
accord
nation
cancer
institut
criteria
data
analyz
individu
delet
polymorph
c
combin
analyz
accord
predict
express
level
tym
low
express
versu
median
express
high
express
result
delet
polymorph
associ
develop
oral
mucos
respect
patient
carri
low
express
tym
genotyp
trend
toward
develop
oral
mucos
although
significantli
conclus
could
confirm
associ
tym
polymorph
mucos
howev
strong
effect
size
suggest
possibl
role
low
express
genotyp
mucos
need
address
f
de
vathair
c
n
r
c
c
h
c
b
g
roussi
inserm
unit
team
radiat
cancer
villejuif
franc
roussi
pediatri
villejuif
franc
curi
pediatri
pari
franc
kremlin
paediatr
endocrinolog
le
kremlin
franc
backgroundobject
stroke
one
major
potenti
long
term
iatrogen
risk
childhood
cancer
radiat
therapi
nevertheless
present
knowledg
insuffici
predict
risk
stroke
follow
radiat
therapi
fraction
high
dose
radiat
brain
known
designmethod
carri
analysi
cohort
survivor
solid
childhood
cancer
treat
franc
treat
radiotherapi
follow
year
averag
french
nation
hospit
medic
insur
databas
patient
develop
perman
stroke
could
valid
match
control
cohort
gender
age
childhood
cancer
durat
radiat
dose
distribut
cerebr
arteri
individu
reconstruct
case
control
treat
radiotherapi
use
medic
record
anthropometr
phantom
result
compar
children
treat
radiat
therapi
control
chemotherapi
children
receiv
less
gy
averag
cerebr
arteri
ci
time
higher
risk
stroke
wherea
receiv
gy
cerebr
arteri
risk
time
higher
risk
factor
higher
ischem
stroke
haemorrhag
one
take
account
paramet
allow
improv
risk
predict
high
radiat
dose
strongli
increas
stroke
risk
exampl
receiv
childhood
cerebr
arteri
volum
increas
long
term
risk
stroke
conclus
studi
confirm
averag
radiat
dose
cerebr
arteri
best
paramet
predict
long
term
risk
stroke
classic
paramet
may
use
predict
massimino
l
f
v
e
e
b
r
c
n
e
l
f
c
ircc
istituto
nazional
dei
tumori
pediatr
milano
itali
ircc
istituto
nazional
dei
tumori
radiotherapi
milano
itali
backgroundobject
hypothyroid
frequent
neckmediastinum
rt
whose
effect
also
depend
circul
tsh
sensit
marker
thyroid
damag
evalu
protect
effect
pharmacolog
mbl
neckmediastinum
rt
hl
rel
preliminari
result
medium
year
promis
aim
updat
definit
messag
commun
designmethod
children
schedul
mbl
rt
hl
underw
thyroid
ultrasound
tsh
evalu
beginningend
rt
day
end
rt
patient
receiv
everi
day
check
ensur
tsh
mmml
blood
test
ultrasound
repeat
year
primari
hypothyroid
defin
tsh
normal
rang
result
mbl
hl
patient
median
month
thyroid
statu
respect
rt
end
divid
patient
accord
tsh
either
mmml
throughout
radiat
treatment
repres
cohort
respect
though
numer
small
cohort
well
match
genderagediseas
stagechemotherapi
coursesthyroid
bed
rtdurat
surviv
rate
significantli
differ
doubl
previou
public
mbl
group
cohort
non
cohort
respect
hl
group
respect
appear
colloid
cystssolid
nodul
differ
two
group
conclus
thyroid
dysfunct
may
develop
month
year
rt
end
children
lengthi
treatment
endocrin
disord
neg
effect
growth
develop
adulthood
show
hypothyroid
possibl
easili
cheapli
prevent
two
popul
great
risk
rt
l
bn
cl
dk
jl
ml
mj
kk
ch
mm
ca
dm
w
jude
children
research
hospit
depart
surgeri
memphi
usa
jude
children
research
hospit
depart
epidemiolog
cancer
control
memphi
usa
jude
children
research
hospit
depart
biostatist
memphi
usa
jude
children
research
hospit
depart
psycholog
memphi
usa
jude
children
research
hospit
depart
oncolog
memphi
usa
jude
children
research
hospit
depart
radiat
oncolog
memphi
usa
sloan
ketter
cancer
center
depart
epidemiolog
endocrinolog
new
york
usa
jude
children
research
hospit
depart
endocrinolog
memphi
usa
backgroundobject
data
regard
efficaci
ovarian
transposit
ot
preserv
ovarian
function
among
childhood
cancer
survivor
limit
aim
determin
effect
ot
ovarian
function
among
survivor
childhood
hodgkin
lymphoma
hl
treat
pelvic
radiotherapi
designmethod
femal
particip
st
jude
lifetim
cohort
studi
sjlife
year
diagnosi
age
year
treat
pelvic
radiotherapi
hl
clinic
evalu
prematur
menopaus
pm
multivari
logist
regress
use
studi
associ
demograph
risk
factor
well
ot
pm
survivor
histori
surgic
menopaus
bilater
oophorectomi
age
year
exclud
result
elig
femal
hl
treat
pelvic
radiotherapi
particip
sjlife
includ
underw
ot
pelvic
radiotherapi
median
age
year
rang
hl
diagnosi
year
rang
studi
pelvic
radiotherapi
cgi
hr
ci
p
cumul
cyclophosphamid
equival
dose
hr
ci
p
associ
pm
signific
associ
ot
occurr
pm
hr
ci
p
among
women
pm
median
age
menopaus
significantli
differ
patient
year
rang
without
year
rang
p
ot
conclus
ot
seem
modifi
risk
pm
histor
cohort
survivor
hl
treat
gonadotox
therapi
research
younger
cohort
need
given
continu
improv
radiotherapi
deliveri
techniqu
modern
fertil
preserv
modal
matur
oocyt
cryopreserv
offer
patient
risk
whenev
feasibl
l
j
n
pm
k
children
hospit
pediatr
oncolog
helsinki
finland
cancer
registri
childhood
cancer
helsinki
finland
univers
hospit
depart
pediatr
helsinki
finland
hospit
helsinki
univers
central
hospit
divis
pediatr
stem
cell
transplant
helsinki
finland
backgroundobject
aim
evalu
rel
risk
second
malign
neoplasm
smn
among
survivor
childhood
cancer
diagnos
age
investig
whether
modern
treatment
regimen
result
reduct
occurr
second
malign
neoplasm
designmethod
childhood
cancer
patient
second
malign
neoplasm
diagnos
identifi
finnish
cancer
registri
risk
second
malign
evalu
use
standard
incid
ratio
sir
effect
tempor
characterist
includ
diagnost
era
length
diseas
relat
characterist
assess
result
observ
subsequ
malign
among
survivor
follow
rel
risk
develop
second
malign
nearli
five
time
higher
expect
sir
ci
sir
equal
gender
risk
smn
stay
elev
patient
treat
modern
era
sir
ci
sir
highest
within
one
year
primari
cancer
sir
ci
decreas
linearli
reach
popul
cancer
risk
year
conclus
childhood
cancer
survivor
elev
risk
smn
elev
risk
appli
also
diagnos
recent
era
reach
plateau
year
patient
encourag
take
part
cancer
screen
program
avoid
exposur
carcinogen
tobacco
gupta
p
r
j
p
hospit
sick
children
haematologyoncolog
toronto
canada
toronto
institut
medic
scienc
toronto
canada
clinic
evalu
scienc
mental
health
addict
research
program
toronto
canada
clinic
evalu
scienc
cancer
research
program
toronto
canada
oncolog
group
ontario
pogo
research
unit
toronto
canada
backgroundobject
though
physic
late
effect
childhood
cancer
survivor
risk
advers
mental
health
outcom
less
clear
exist
evid
contradictori
health
servic
data
offer
object
method
measur
mental
health
outcom
designmethod
use
provinci
registri
detail
diseas
treatment
outcom
data
assembl
cohort
childhood
cancer
survivor
diagnos
year
treat
ontario
pediatr
cancer
centr
patient
link
healthcar
data
captur
inpati
outpati
emerg
depart
ed
visit
primari
outcom
rate
mental
healthcar
visit
primari
care
psychiatrist
ed
hospit
secondari
outcom
includ
time
sever
mental
health
event
ed
visit
hospit
suicid
overal
psychiatr
diagnost
categori
outcom
compar
survivor
match
control
use
recurr
event
surviv
analys
predictor
advers
outcom
model
result
compar
control
survivor
significantli
higher
rate
mental
health
visit
vs
adjust
rel
rate
rr
confid
interv
ci
higher
rate
associ
femal
gender
rr
ci
adolesc
age
diagnosi
rr
ci
cancer
type
treatment
intens
treatment
target
central
nervou
system
signific
predictor
hazard
sever
mental
health
event
differ
survivor
control
though
rare
group
survivor
increas
risk
sever
event
due
psychot
disord
hr
ci
p
conclus
childhood
cancer
survivor
experi
higher
rate
mental
health
visit
gener
popul
like
experi
sever
mental
health
event
risk
attribut
specif
diagnosi
aspect
treatment
increas
risk
sever
psychot
disord
requir
confirm
cohort
v
gupta
sk
v
tb
medic
banara
hindu
univers
pediatr
varanasi
india
medic
banara
hindu
univers
cardiolog
varanasi
india
medic
banara
hindu
univers
biostatist
varanasi
india
backgroundobject
anthracyclin
caus
cardiotox
children
sever
measur
includ
drug
tri
reduc
cardiac
toxic
lack
random
trial
prompt
studi
assess
role
ace
inhibitor
enalapril
anthracyclin
induc
cardiotox
children
hematolog
malign
designmethod
random
doubl
blind
placebo
control
trial
conduct
univers
teach
hospit
month
trial
patient
leukemia
lymphoma
random
receiv
either
enalapril
group
placebo
group
b
month
patient
receiv
anthracyclin
doxorubicin
andor
daunorubicin
cumul
dose
per
protocol
cardiac
biomark
ctni
probnp
ckmb
left
ventricular
eject
fraction
lvef
assess
base
line
month
primari
outcom
decreas
left
ventricular
eject
fraction
decreas
signific
secondari
outcom
chang
cardiac
biomark
develop
heart
failur
arrhythmia
side
effect
dizzi
hypotens
result
cardiac
biomark
increas
month
patient
increas
group
b
signific
pro
bnp
vs
p
valu
ctni
vs
p
valu
signific
ckmb
vs
p
valu
patient
group
show
increas
probnp
level
pgml
compar
patient
group
b
lvef
decreas
group
group
b
vs
p
decreas
lvef
seen
patient
group
b
none
group
p
valu
lvef
remain
group
month
patient
develop
heart
failur
conclus
enalapril
role
reduc
acut
cardiac
toxic
anthracyclin
administr
studi
need
assess
long
term
protect
kumar
r
india
institut
medic
scienc
depart
medic
bra
irch
new
delhi
india
india
institut
medic
scienc
depart
lab
bra
irch
new
delhi
india
backgroundobject
myeloid
sarcoma
ms
rare
entiti
preced
appear
concomitantli
acut
myeloid
leukemia
convent
treat
line
acut
myeloid
leukemia
aml
howev
pauciti
data
larger
number
patient
led
difficulti
understand
natur
manag
designmethod
present
studi
undertaken
among
children
ms
present
larg
tertiari
care
center
india
june
feb
patient
treat
uniform
chemotherapi
treatment
protocol
radiotherapi
use
manag
result
among
patient
aml
attend
pediatr
oncolog
clinic
patient
ms
present
median
age
year
year
incid
common
among
male
f
cytogenet
paramet
avail
patient
good
risk
cytogenet
found
patient
significantli
higher
non
ms
associ
cohort
wherein
good
risk
cytogenet
observ
subject
patient
good
risk
group
ms
cohort
median
month
median
event
free
surviv
month
ms
group
versu
month
non
ms
associ
aml
overal
surviv
month
versu
month
ms
group
versu
non
ms
group
respect
conclus
ms
present
aml
patient
distinctli
worldwid
preval
cohort
ms
higher
proport
good
risk
cytogenet
strike
associ
present
adopt
aml
like
treatment
strategi
patient
result
favor
outcom
comparison
non
ms
associ
cohort
l
zhang
z
z
yao
c
g
c
w
l
r
z
l
l
q
key
laboratori
experiment
institut
hematolog
blo
depart
pediatr
tianjin
china
backgroundobject
object
studi
evalu
efficaci
safeti
use
acid
atra
arsen
trioxid
ato
treat
paediatr
patient
newli
diagnos
acut
promyelocyt
leaukemia
apl
additionli
assess
whether
cytosin
arabinosid
could
omit
base
trial
designmethod
patient
assign
receiv
atra
plu
ato
induct
follow
idarubicin
ida
ato
patient
randomli
assign
receiv
cours
daunorubicin
dnr
group
group
follow
mainten
therapi
year
result
may
decemb
consecut
pediatr
old
patient
genet
confirm
new
diagnosi
apl
admit
hospit
among
patient
male
femal
patient
achiev
complet
remiss
cr
except
one
gave
treatment
induct
therapi
toxic
event
revers
appropri
manag
patient
die
consolid
one
patient
relaps
addit
differ
outcom
two
group
median
month
ef
os
factor
impact
relaps
surviv
studi
differ
median
arsen
concentr
plasma
urin
hair
nail
sampl
patient
arsen
treatment
ceas
month
normal
control
conclus
result
studi
indic
ato
safe
effect
paediatr
apl
omit
least
use
regimen
similar
analysi
arsen
level
plasma
urin
hair
nail
patient
indic
signific
accumul
arsen
ato
discontinu
month
n
hijiya
c
h
c
h
hj
z
f
kh
w
robert
h
luri
children
hospit
chicago
depart
hematologyoncolog
chicago
usa
rogachev
feder
research
center
pediatr
oncolog
immunolog
pediatr
oncolog
immunolog
moscow
russia
hematolog
oncolog
univers
milano
mbbm
foundat
depart
pediatr
asst
monza
itali
univers
school
medicin
depart
pediatr
japan
istituto
giannina
gaslini
depart
gener
special
pediatr
function
depart
genova
itali
children
medic
center
divis
medicin
yokohama
japan
nation
univers
colleg
seoul
nation
univers
children
hospit
depart
pediatr
seoul
republ
korea
children
hospit
divis
hematolog
oncolog
bone
marrow
transplant
columbu
usa
istanbul
medic
faculti
depart
pediatr
hematolog
oncolog
istanbul
turkey
jesu
pediatr
oncolog
servic
madrid
spain
linda
univers
cancer
center
pediatr
hematologyoncolog
loma
linda
usa
hospitali
pellegrin
de
enfant
pediatr
oncolog
hematolog
unit
bordeaux
franc
medic
sungkyunkwan
univers
school
medicin
depart
pediatr
seoul
republ
korea
pharmaceut
corpor
clinic
depart
east
hanov
usa
pharma
ag
statist
deartment
basel
switzerland
pharma
ag
gdo
trial
manag
oncolog
basel
switzerland
hospit
div
hematologyoncolog
depart
pediatr
bangkok
thailand
backgroundobject
ongo
phase
studi
evalu
nilotinib
pediatr
patient
cml
designmethod
elig
patient
cml
chronic
acceler
phase
cpap
resistantintoler
imatinibdasatinib
patient
enrol
patient
receiv
oral
nilotinib
bid
round
nearest
cycl
data
primari
analysi
patient
complet
cycl
discontinu
report
primari
endpoint
resistantintoler
cohort
major
molecular
respons
rate
mmr
intern
scale
cycl
coprimari
endpoint
cohort
mmr
rate
cycl
complet
cytogenet
respons
ccyr
rate
cycl
result
patient
resistantintoler
enrol
receiv
nilotinib
median
age
cohort
median
time
month
respect
result
resistantintoler
cohort
patient
mmr
cycl
ci
mmr
baselin
median
time
mmr
rang
month
among
patient
mmr
data
cutoff
patient
ccyr
cycl
ccyr
baselin
one
patient
progress
apblast
crisi
month
result
patient
rate
mmr
cycl
ccyr
cycl
ci
median
time
respons
month
mmr
ccyr
among
patient
respons
respect
data
cutoff
patient
ae
ae
incid
overal
headach
pyrexia
blood
bilirubin
increas
rate
seriou
ae
discontinu
respect
death
report
conclus
nilotinib
bid
efficaci
pediatr
patient
resistantintoler
ae
profil
compar
adult
cm
mw
n
paczesni
univers
school
medicin
pediatr
indianapoli
usa
univers
school
medicin
medicin
indianapoli
usa
backgroundobject
current
method
predict
respiratori
failur
allogen
hematopoiet
cell
transplant
hct
recipi
biomark
may
effect
risk
recognit
understand
etiolog
serv
therapeut
target
studi
aim
identifi
prognost
biomark
develop
respiratori
failur
designmethod
singl
center
analysi
exist
cohort
repositori
plasma
sampl
day
use
measur
four
protein
elisa
receptor
interleukin
tumor
necrosi
factor
receptor
osteopontin
opn
data
present
median
compar
use
wilcoxon
rank
sum
test
roc
curv
also
done
protein
result
total
adult
pediatr
allogen
hct
recipi
includ
develop
respiratori
failur
within
year
median
day
respiratori
failur
median
four
protein
significantli
higher
group
develop
respiratori
failur
multipl
time
point
day
vs
vs
vs
day
vs
vs
vs
opn
vs
day
vs
p
vs
opn
vs
day
vs
p
vs
opn
vs
roc
curv
indic
protein
allow
good
discrimin
develop
respiratori
failur
within
day
transplant
auc
conclus
opn
significantli
elev
multipl
time
point
develop
respiratori
failur
hct
n
roy
moulik
l
van
j
marsden
hospit
paediatr
oncolog
greater
london
unit
kingdom
backgroundobject
hepat
sinusoid
obstruct
syndrom
so
diseas
vod
seriou
complic
autolog
stem
cell
transplant
asct
histor
high
mortal
rate
defibrotid
shown
proven
benefit
treatment
modest
role
preventionw
report
experi
so
paediatr
asct
designmethod
case
record
consecut
patient
undergo
asct
follow
hdct
review
relev
data
retriev
analys
use
convent
statist
defibrotid
use
treatment
case
so
avail
prophylaxi
so
patient
receiv
busulfan
base
condit
due
fund
issu
result
fourteen
children
diagnos
so
incid
significantli
higher
receiv
busulfan
base
condit
mean
time
diagnosi
so
day
follow
stem
cell
rescueseven
patient
bilirubin
micromolesl
normal
ultrasound
coagulopathi
note
case
child
develop
involv
nine
children
mild
so
five
case
moder
sever
so
need
picu
support
patient
so
significantli
delay
platelet
recoveri
higher
transfus
requir
longer
hospit
stay
unavail
defibrotid
prophylaxi
patient
receiv
busulfan
significantli
increas
incid
so
vs
signific
differ
clinic
cours
sever
observ
children
develop
so
despit
defibrotid
prophylaxi
compar
without
so
relat
mortal
seen
either
group
conclus
hepat
so
commonli
seen
children
receiv
busulfan
condit
chang
practic
use
defibrotid
prophylaxi
seem
increas
incid
sever
so
overal
outcom
excel
support
care
treatment
defibrotid
p
vergara
j
lui
calvo
mackenna
unidad
de
trasplant
de
osea
santiago
chile
nacion
de
oncologia
pediatrica
oncologia
ciudad
de
guatemala
guatemala
jude
children
research
hospit
depart
global
pediatr
medicin
memphi
usa
backgroundobject
patient
undergo
hematopoiet
stem
cell
transplant
hsct
high
risk
clinic
deterior
due
immunosuppress
expect
complic
pediatr
earli
warn
system
pew
clinic
acuiti
tool
aid
earli
identif
clinic
deterior
hospit
patient
tool
commonli
use
hospit
care
hsct
patient
set
previous
appli
hsct
patient
hospit
latin
america
object
studi
describ
implement
pew
hsct
unit
lui
calvo
mackenna
hospit
hlcm
pediatr
hospit
santiago
chile
designmethod
pew
use
boston
children
hospit
previous
valid
hsct
patient
modifi
hlcm
multidisciplinari
team
physician
nurs
oncolog
bmt
pediatr
intens
care
unit
picu
adjust
practic
variat
hospit
modifi
pew
initi
trial
pilot
adjust
implement
part
clinic
practic
unit
period
analyz
complianc
pew
document
error
rate
abnorm
red
score
unplan
picu
transfer
result
total
nurs
nurs
technician
staff
physician
resid
train
pew
complianc
pew
document
averag
pew
calcul
per
day
error
common
error
interpret
heart
rate
oxygen
use
month
data
collect
total
red
pew
among
patient
requir
unplan
picu
transfer
conclus
describ
success
implement
pew
pediatr
hsct
unit
latin
america
low
error
rate
appropri
identif
clinic
deterior
sustain
program
requir
continu
reinforc
monitor
achiev
complianc
depani
j
c
j
birmingham
cancer
research
uk
clinic
trial
institut
cancer
genom
scienc
birmingham
unit
kingdom
cambridg
hospit
nh
trust
paediatr
oncolog
haematolog
cambridg
unit
kingdom
colleg
london
hospit
nh
trust
children
young
peopl
cancer
servic
london
unit
kingdom
southern
california
keck
school
medicin
lo
ca
usa
oncolog
group
statist
data
center
monrovia
ca
usa
upon
tyne
hospit
nh
foundat
trust
paediatr
adolesc
haematolog
oncolog
newcastl
upon
tyne
unit
kingdom
backgroundobject
extracrani
malign
germ
cell
tumour
mgct
uk
gcii
studi
use
carboplatin
demonstr
equival
surviv
protocol
gciii
singl
arm
observ
studi
use
new
risk
stratif
replac
consolid
chemotherapi
standard
number
cycl
introduc
surveil
stage
mgct
aim
treatment
possibl
whilst
maintain
excel
surviv
use
carboplatin
designmethod
patient
diagnosi
mgct
stratifi
three
risk
group
low
lr
intermedi
ir
high
hr
use
combin
stage
prognost
factor
patient
afp
stage
iv
diseas
except
testi
germinoma
stage
thorac
classifi
hr
stage
tumour
lr
monitor
receiv
chemotherapi
diseas
progress
ir
patient
receiv
cycl
jeb
etoposid
iv
bleomycin
iv
carboplatin
iv
hr
patient
receiv
cycl
carboplatin
dose
calcul
give
auc
result
patient
mgct
treat
studi
femal
median
age
year
year
lr
ir
hr
seven
lr
patient
diseas
progress
median
month
cure
chemotherapi
five
year
irhr
patient
ci
ir
hr
overal
surviv
ci
ir
hr
jeb
well
toler
manag
toxic
patient
develop
signific
nephrotox
discern
differ
carboplatin
dose
whether
calcul
bodi
creatinin
clearanc
conclus
jeb
chemotherapi
use
risk
stratif
result
excel
surviv
manag
toxic
carboplatin
evalu
cisplatin
paediatr
gct
larg
randomis
prospect
studi
f
pashankar
l
c
univers
school
medicin
pediatr
new
usa
farber
cancer
cancer
institut
boston
children
hospit
pediatr
boston
usa
southern
california
prevent
medicin
lo
angel
usa
jude
children
research
hospit
pediatr
memphi
usa
healthcar
atlanta
pediatr
atlanta
usa
jude
research
hospit
global
pediatr
medicin
memphi
usa
backgroundobject
current
standard
regimen
relaps
pediatr
malign
germ
cell
tumor
mgct
adult
salvag
regimen
commonli
use
tip
paclitaxel
ifosfamid
cisplatin
associ
overal
surviv
dose
cisplatin
young
children
howev
associ
signific
short
long
term
toxic
carboplatin
shown
effect
pediatr
gct
less
toxic
tip
regimen
modifi
substitut
carboplatin
cisplatin
primari
aim
evalu
respons
cycl
paclitaxel
ifosfamid
carboplatin
tic
children
relaps
refractori
mgct
designmethod
phase
ii
studi
conduct
children
oncolog
group
novemb
june
includ
children
relaps
mgct
previous
receiv
regimen
contain
cisplatin
tic
consist
paclitaxel
day
ifosfamid
day
carboplatin
auc
day
endpoint
trial
respons
cycl
result
patient
male
median
age
year
enrol
recist
criteria
patient
achiev
partial
respons
pr
protocol
therapi
respons
rate
patient
stabl
diseas
sd
patient
progress
diseas
patient
pr
elev
marker
enrol
afp
b
hcg
patient
least
log
reduct
tumor
marker
patient
sd
elev
marker
enrol
afp
bhcg
least
log
decreas
conclus
evalu
cycl
tic
therapi
indic
reason
efficaci
particularli
one
use
metric
appropri
afp
declin
regimen
either
carboplatin
regimen
cisplatin
adult
regimen
consid
salvag
therapi
children
c
faur
conter
c
j
f
b
c
f
j
l
paediatri
lyon
franc
oncolog
group
statist
monrovia
usa
anderson
cancer
center
oncolog
houston
usa
shore
univers
health
system
oncolog
evanston
usa
health
scienc
center
oncolog
toronto
canada
univers
pediatri
new
usa
southern
california
statist
lo
angel
usa
hospit
children
surgeri
indianapoli
usa
roussi
pediatri
villejuif
franc
sick
children
pediatri
toronto
canada
young
person
cancer
servic
pediatri
london
unit
kingdom
univers
hospit
nh
foundat
trust
pediatri
cambridg
unit
kingdom
children
cancer
blood
disord
center
pediatri
boston
usa
backgroundobject
wherea
among
pediatr
oncologist
ovarian
yolk
sac
tumor
consid
chemo
sensit
tumor
often
cite
advers
prognost
factor
adult
women
ovarian
germ
cell
tumor
designmethod
magic
dataset
includ
pediatr
clinic
trial
unit
state
unit
kingdom
franc
adult
gynecolog
clinic
trial
unit
state
patient
figo
stage
ic
treat
chemotherapi
elig
age
model
continu
categor
variabl
children
adolesc
adult
addit
analys
establish
optim
age
conduct
tumor
code
pure
yst
yst
teratoma
mix
yst
yst
malign
germ
cell
compon
put
yst
mix
germ
cell
tumor
afp
ngml
histolog
stage
iiiii
vs
iv
preoper
afp
level
ngml
chemotherapeut
regimen
carboplatin
vs
cisplatin
analyz
covari
result
two
hundr
fifti
one
patient
median
age
rang
identifi
children
adolesc
adult
histolog
pure
mix
put
case
respect
twenti
six
patient
stage
iv
similarli
distribut
median
follow
year
overal
ef
os
ci
respect
age
affect
risk
event
death
model
either
categor
continu
variabl
analysi
fail
identifi
age
affect
risk
none
covari
investig
prognost
impact
ef
os
conclus
excel
outcom
across
age
appar
impact
probabl
event
death
allow
pediatr
gynecolog
oncologist
enrol
patient
onto
joint
pediatr
adult
trial
j
brok
k
ormond
street
hospit
children
nh
foundat
trust
clinic
radiolog
london
unit
kingdom
colleg
great
ormond
street
institut
child
uk
clinic
oncolog
london
unit
kingdom
armand
trousseau
hospit
paediatr
surgeri
pari
franc
backgroundobject
children
pulmonari
metastas
wilm
tumour
alloc
treatment
regimen
base
upon
lung
lesion
size
respons
chemotherapi
upcom
umbrella
chest
ct
use
measur
lung
lesion
threshold
mm
determin
treatment
intens
studi
aim
measur
variabl
radiolog
assess
pulmonari
nodul
size
designmethod
ct
thorac
patient
diagnosi
enrol
multicentr
improv
popul
outcom
renal
tumour
childhood
import
studi
assess
five
radiologist
chest
paediatr
differ
centr
uk
netherland
assess
nodul
size
two
occas
month
apart
reader
blind
patient
symptom
origin
radiolog
report
modifi
bland
altman
graph
creat
measur
inter
limit
agreement
nodul
detect
reader
result
differ
nodul
seen
least
one
reader
individu
assess
scan
month
apart
nodul
seen
reader
assess
limit
agreement
millimetr
reader
diamet
transvers
diamet
distanc
assess
respect
mean
differ
measur
limit
agreement
across
three
dimens
reader
respect
appli
umbrella
criteria
seven
patient
would
alloc
treatment
arm
across
radiolog
assess
conclus
demonstr
variabl
detect
measur
pulmonari
nodul
ct
thorax
import
implic
diagnosi
risk
stratifi
treatment
metastat
diseas
yoshida
n
h
children
medic
center
patholog
yokohama
japan
children
medic
center
surgeri
yokohama
japan
children
medic
center
regen
medicin
yokohama
japan
backgroundobject
pulmonari
metastasi
resect
hepatoblastoma
use
indocyanin
green
fluoresc
imag
icg
effect
lesion
detect
ct
nonpalp
oper
howev
detail
evalu
sensit
specif
icg
test
insuffici
designmethod
subject
specimen
submit
patholog
depart
pulmonari
metastat
lesion
hepatoblastoma
resect
use
icg
imag
test
kanagawa
children
medic
center
januari
march
total
oper
case
collat
oper
record
patholog
report
studi
sensit
specif
icg
test
result
among
specimen
specimen
sensit
icg
test
also
specimen
specif
posit
predict
valu
specimen
resect
case
specimen
far
oper
record
could
confirm
region
gener
smaller
mm
diamet
even
region
rel
wide
icg
uptak
pattern
weak
heterogen
poorli
margin
microscop
specimen
often
contain
necrosi
fibrosi
granuloma
infiltr
inflammatori
cell
hemorrhag
thrombu
andor
unspecifi
mesenchym
tissu
sometim
suggest
presenc
preced
metastat
lesion
conclus
studi
demonstr
icg
test
high
sensit
occasion
yield
specimen
specif
low
specimen
show
rel
uniform
icg
uptak
pattern
absenc
viabl
tumor
predict
find
suggest
high
icg
test
reliabl
techniqu
detect
pulmonari
metastas
consid
high
sensit
import
closer
commun
surgeon
pathologist
icg
uptak
pattern
specimen
might
improv
use
test
ij
dunkel
md
gl
j
te
rf
j
dh
c
mm
sloan
ketter
cancer
center
pediatr
new
york
usa
oncolog
group
biostatist
arcadia
usa
jp
garrahan
bueno
air
argentina
pediatr
san
francisco
usa
cancer
hospit
foundat
pediatr
oncolog
cairo
egypt
cancer
institut
radiat
oncolog
rockvil
usa
jude
children
research
hospit
radiat
oncolog
memphi
usa
children
medic
center
pediatr
fort
worth
usa
hospit
lo
angel
pediatr
lo
angel
usa
sloan
ketter
cancer
center
pharmaci
new
york
usa
children
hospit
pediatr
chicago
usa
sloan
ketter
cancer
center
ophthalmolog
new
york
usa
jude
children
research
hospit
pediatr
memphi
usa
children
cancer
center
pediatr
houston
usa
backgroundobject
metastat
rb
associ
poor
prognosi
cog
open
prospect
intern
trial
studi
whether
intensifi
system
chemotherapi
without
radiat
therapi
rt
would
improv
outcom
popul
designmethod
patient
region
rb
stage
receiv
cycl
chemotherapi
vincristin
mgkgday
cisplatin
mgkgday
cyclophosphamid
mgkg
x
day
etoposid
mgkg
x
day
follow
rt
cgi
two
strata
patient
metastat
rb
stage
central
nervou
system
cn
involv
stage
cn
metastasestrilater
rb
also
receiv
cycl
chemotherapi
patient
partial
respons
receiv
cycl
carboplatin
calvert
formula
maximum
mgkgday
day
thiotepa
mgkgday
etoposid
mgkgday
day
autolog
hematopoiet
stem
cell
rescu
day
patient
metastat
rb
achiev
inadequ
respons
chemotherapi
receiv
rt
result
sixti
subject
stratum
enrol
elig
includ
analys
data
current
toxic
signific
expect
includ
therapi
relat
death
surviv
ef
month
ci
subject
stage
diseas
ci
subject
stage
diseas
ci
subject
stage
diseas
observ
result
significantli
improv
ef
stratum
compar
histor
result
use
plan
studi
conclus
intens
therapi
highli
effect
patient
region
rb
metastat
rb
involv
cn
effect
therapi
requir
patient
cn
rb
j
v
f
k
g
c
remk
cancer
consortium
dktk
german
cancer
research
center
dkfz
depart
pediatr
germani
clinic
medic
univers
hospit
depart
pediatr
oncolog
dusseldorf
germani
hein
univers
medic
faculti
depart
neuropatholog
germani
molecular
proteom
laboratori
dusseldorf
germani
hospit
institut
molecular
medicin
germani
de
medicina
da
universidad
de
lisboa
faculdad
de
medicina
lisbon
portug
de
santa
centro
hospitalar
lisboa
nort
depart
neurosurgeri
lisbon
portug
backgroundobject
pilocyt
astrocytoma
pa
compris
common
primari
brain
tumor
childhood
profil
sequenc
studi
point
toward
diseas
oncogen
activ
mapk
signal
typic
driven
braf
alter
incomplet
resect
tumor
recur
frequent
despit
radiat
andor
chemotherapi
less
favor
therapeut
respons
observ
adult
compar
pediatr
counterpart
thu
util
proteogenom
approach
reveal
biolog
heterogen
pa
across
identifi
novel
therapeut
target
designmethod
proteogenom
approach
encompass
rna
sequenc
rnaseq
proteom
profil
pediatr
adult
patient
pa
unsupervis
hierarch
cluster
hcl
analys
appli
determin
biolog
heterogen
diseas
integr
genom
combin
downstream
pathway
analysi
use
identifi
specif
pathway
activ
biolog
subgroup
lastli
perform
drug
screen
encompass
convent
chemotherapeut
target
therapeut
current
evalu
phase
iii
iv
clinic
trial
valid
novel
molecular
target
pa
primari
cultur
model
result
pediatr
adult
pa
segreg
two
main
subgroup
identifi
unsupervis
hcl
use
rnaseq
proteom
profil
adult
tumor
form
singl
entiti
observ
addit
heterogen
pediatr
tumor
segreg
two
subgroup
initi
analys
show
adult
pa
display
factor
involv
translat
initi
ciliogenesi
accord
geneset
enrich
analysi
wherea
pediatr
pa
show
signific
enrich
pathway
involv
glycolysi
signal
transmiss
akt
signal
conclus
proteogenom
approach
reveal
clear
biolog
heterogen
pediatr
adult
pa
ongo
drug
screen
experi
use
determin
therapeut
preferenti
activ
pediatr
adult
pa
cultur
biolog
insight
may
improv
biolog
stratif
reveal
novel
therapeut
target
specif
use
tumor
high
risk
progress
diseas
j
grill
e
l
le
k
c
p
mc
le
p
g
gustav
roussi
pediatr
adolesc
oncolog
cnr
umr
pari
franc
roussi
devri
val
desson
cnr
umr
villejuif
franc
gustav
roussi
cnr
umr
pari
franc
pediatr
adlesc
medicin
copenhagen
denmark
de
la
rein
fabiola
oncologi
bruxel
belgium
roussi
clinic
research
direct
villejuif
franc
roussi
centr
oscar
lambret
biostatistiqu
villejuif
franc
necker
enfant
malad
neurochirurgi
pari
franc
neuropathologi
pari
franc
backgroundobject
dipg
genom
far
mostli
done
autopsi
sampl
restrospect
studi
frame
biomed
random
trial
three
target
therapi
erlotinib
everolimu
dasatinib
base
three
biomark
identif
egfr
pten
pdgfra
systemat
whole
exom
rna
sequenc
stereotact
biopsi
perform
diagnosi
implement
inform
result
trial
defin
addit
target
could
use
guid
therapi
relaps
designmethod
result
first
patient
franc
danemark
belgium
present
percent
sampl
could
profil
dna
rna
frozen
materi
avail
tumor
one
sampl
contribut
result
tumor
sampl
one
includ
studi
basi
histolog
show
loss
trimethyl
respect
histon
mutat
sampl
mutat
gene
gene
structur
copi
number
aberr
found
mutat
sampl
gain
chromosom
whole
chromosom
frequent
mutat
sampl
transloc
rare
identifi
none
recurr
mutat
almost
exclus
found
mutat
sampl
two
histon
wt
sampl
one
mutat
sampl
dipg
either
mutat
dipg
mutat
pathway
recetor
mutat
amplif
found
dipg
conclus
studi
refin
descript
differ
subtyp
dipg
may
support
specif
treatment
adapt
respect
potenti
biomark
support
inca
phrc
imagin
margo
g
robinson
v
p
j
c
v
b
p
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
development
neurobiolog
memphi
usa
cancer
research
center
dkfz
appli
bioinformat
heidelberg
germani
southwestern
medic
center
dalla
pediatr
hematolog
oncolog
dalla
usa
hospit
clinic
minnesota
pediatr
hematolog
oncolog
minneapoli
usa
univers
neurolog
palo
alto
usa
san
diego
radi
children
hospit
neurosci
san
diego
usa
cilento
children
hospit
paediatr
oncolog
brisban
australia
jude
children
research
hospit
biostatist
memphi
usa
hospit
sick
children
haematolog
oncolog
toronto
canada
hospit
sick
children
neurosurgeri
toronto
canada
jude
children
research
hospit
radiat
oncolog
memphi
usa
cancer
research
center
dkfz
pediatr
neurooncolog
heidelberg
germani
jude
children
research
hospit
patholog
memphi
usa
backgroundobject
surviv
children
call
infant
medulloblastoma
mb
vastli
inferior
older
children
mb
differ
princip
due
therapi
howev
radiat
requisit
surviv
therefor
imper
understand
infant
benefit
fail
current
approach
herein
comprehens
describ
molecular
landscap
infantil
medulloblastoma
imb
show
differ
molecular
makeup
translat
major
differ
outcom
designmethod
amass
discoveri
cohort
valid
cohort
imb
analyz
dna
methyl
array
sequenc
match
normal
discoveri
cohort
came
pool
intern
seri
valid
clinic
trial
result
imb
divid
three
subgroup
shh
wnt
mb
observ
distribut
cohort
similar
discoveri
valid
frequent
mutat
cohort
valid
sufu
mycn
amplif
mutat
rare
display
rel
recurr
mutat
exhibit
multipl
larg
copi
number
aberr
valid
cohort
progress
free
surviv
pf
superior
vs
p
valu
histolog
metastat
diseas
within
subgroup
prognost
pf
ongo
analysi
occur
determin
molecular
heterogen
within
subgroup
prognost
conclus
infant
benefit
therapi
futur
clinic
trial
need
prospect
divid
therapeut
goal
need
shift
toward
optim
current
chemotherapeut
backbon
paradigm
shift
therapi
infant
necessari
k
von
hoff
c
g
j
p
f
c
p
b
sm
medic
center
pediatr
hematolog
oncolog
hamburg
germani
univers
vienna
institut
neurolog
vienna
austria
jude
children
research
hospit
depart
oncolog
memphi
usa
hospit
motol
depart
pediatr
hematolog
oncolog
pragu
czech
republ
cancer
yonsei
univers
colleg
medicin
dept
radiat
oncolog
seoul
republ
korea
univers
depart
pediatr
budapest
hungari
memori
health
institut
depart
patholog
warsaw
poland
cancer
research
center
dkfz
divis
clinic
cooper
unit
neuropatholog
heidelberg
germani
colleg
london
institut
child
health
london
unit
kingdom
univers
rome
depart
oncolog
anatomopatholog
scienc
rome
itali
neurom
institut
pozzilli
itali
hospit
sick
children
divis
patholog
toronto
canada
timon
aix
marseil
univers
depart
patholog
neuropatholog
marseil
franc
hopkin
univers
depart
patholog
baltimor
usa
bonn
depart
neuropatholog
bonn
germani
jude
children
research
hospit
depart
patholog
memphi
usa
cancer
research
center
dkfz
divis
pediatr
neurooncolog
heidelberg
germani
hospit
depart
pediatr
hematolog
oncolog
heidelberg
germani
backgroundobject
diagnosi
cn
primit
neuroectoderm
tumor
remov
updat
classif
cn
tumor
cohort
patient
previou
diagnosi
new
entiti
recurr
genet
alter
delin
also
identifi
patient
previou
diagnos
util
current
treatment
paradigm
confin
diagnost
group
known
designmethod
intern
collabor
addit
tumor
sampl
patient
previou
diagnosi
dna
methyl
profil
blind
neuropatholog
panel
review
clinic
data
newli
case
previous
publish
case
irrespect
histor
diagnosi
pool
analyz
result
given
number
repres
preliminari
data
ongo
project
dna
methyl
profil
classifi
newli
tumor
histor
diagnosi
defin
non
entiti
etmr
blind
neuropatholog
panel
diagnosi
fulli
overlap
methyl
result
correspondingli
analyz
etmr
group
embryon
tumor
display
vari
degre
neuron
ganglion
differenti
correspond
combin
data
set
histor
diagnosi
uncommon
common
mostli
diagnos
astroblastoma
ependymoma
pf
os
respect
patient
patient
patient
patient
methyl
profil
conclus
consensu
diagnost
criteria
treatment
strategi
need
intern
collabor
aim
prospect
molecular
clinic
data
collect
inform
develop
specif
trial
eg
control
treatment
e
pfaff
l
sm
dtw
cancer
research
center
dkfz
pediatr
neurooncolog
heidelberg
germani
univers
hospit
depart
pediatr
hematolog
immunolog
heidelberg
germani
langon
medic
center
divis
neuropatholog
new
york
usa
langon
medic
center
depart
neurolog
new
york
usa
langon
medic
center
laura
isaac
perlmutt
cancer
center
new
york
usa
sloan
ketter
cancer
center
depart
pediatr
new
york
usa
backgroundobject
tumor
pineal
region
compris
sever
differ
entiti
distinct
clinic
histopatholog
featur
pineocytoma
pc
grade
pineal
parenchym
tumor
intermedi
differenti
pptid
papillari
tumor
pineal
region
ptpr
grade
predominantli
affect
adult
associ
favor
prognosi
pineoblastoma
pb
highli
aggress
tumor
grade
iv
famili
primit
embryon
tumorspnet
occur
infant
children
adolesc
especi
infant
patient
metastat
diseas
outcom
poor
despit
aggress
multimod
treatment
therapeut
action
molecular
target
identifi
date
wherea
pb
aris
sporad
cancer
predisposit
syndrom
includ
germlin
mutat
associ
pb
latter
context
trilater
retinoblastoma
investig
biolog
relationship
entiti
pineal
tumor
base
dna
methyl
copi
number
analysi
designmethod
perform
dna
methyl
profil
pineal
tumor
normal
pineal
tissu
control
includ
analysi
result
unsupervis
cluster
reveal
clear
separ
known
entiti
pc
ptpr
pptid
within
group
distinct
subgroup
could
distinguish
includ
previous
hypothes
group
interestingli
tumor
initi
diagnos
either
pb
pineal
pnet
form
number
biolog
discret
subgroup
character
one
group
harbor
recurr
alter
drosha
endoribonucleas
involv
mirna
process
upstream
implic
central
role
alter
mirna
biogenesi
develop
pb
conclus
use
methyl
profil
identifi
biolog
distinct
subgroup
pineal
tumor
includ
novel
find
provid
foundat
molecular
function
character
includ
role
mirna
process
defect
oncogenesi
zapotocki
j
p
c
n
u
u
e
v
hospit
sick
children
pediatr
divis
hematologyoncolog
toronto
canada
margaret
hospit
radiat
oncolog
toronto
canada
backgroundobject
intracrani
ependymoma
third
frequent
pediatr
brain
tumor
compris
distinct
biolog
entiti
aris
posterior
fossa
pf
supratentori
st
region
aim
identifi
predictor
surviv
neurocognit
outcom
larg
consecut
cohort
three
decad
designmethod
data
demograph
treatment
surviv
neurocognit
function
collect
consecut
patient
intracrani
ependymoma
diagnos
sickkid
result
signific
differ
surviv
pf
st
ependymoma
observ
pf
pf
ci
pf
os
ci
st
pf
ci
st
os
ci
independ
predictor
favour
outcom
pf
ependymoma
includ
gross
total
resect
gtr
upfront
radiotherapi
p
analysi
consecut
year
epoch
reveal
signific
improv
pf
os
time
compar
pertain
rate
gtr
increas
use
upfront
radiat
increas
observ
period
pf
ependymoma
none
observ
variabl
prognost
st
ependymoma
proport
patient
recurr
ependymoma
salvag
increas
pf
p
complet
resect
recurr
strong
favour
predictor
surviv
upfront
radiat
primari
diagnosi
recurr
significantli
influenc
neurocognit
outcom
especi
young
children
conclus
data
larg
homogen
treat
cohort
clearli
indic
improv
surviv
posterior
fossa
ependymoma
time
relat
aggress
surgeri
upfront
radiat
howev
first
time
larg
consecut
cohort
show
approach
result
reduc
neurocognit
outcom
time
data
suggest
children
posterior
fossa
ependymoma
receiv
upfront
radiat
concomitantli
priorit
earli
neuropsycholog
test
intervent
kimura
k
h
h
k
n
k
k
j
unives
pediatr
tokyo
japan
univers
graduat
school
biomed
scienc
pediatr
hiroshima
japan
center
child
health
develop
biolog
tokyo
japan
school
kyoto
univers
patholog
tumor
biolog
kyoto
japan
center
child
health
develop
pediatr
hematolog
oncolog
tokyo
japan
prefectur
univers
graduat
school
medic
scienc
pediatr
kyoto
japan
children
medic
center
hematologyoncolog
saitama
japan
luke
intern
hospit
pediatr
tokyo
japan
univers
pediatr
tokyo
japan
hospit
organ
nagoya
medic
center
clinic
research
center
nagoya
japan
children
medic
center
hematologyoncolog
shibukawa
japan
medic
univers
tokyo
laboratori
dna
inform
human
genom
center
tokyo
japan
backgroundobject
pediatr
acut
lymphoblast
leukemia
aggress
although
genet
basi
pediatr
well
character
comprehens
studi
yet
explor
epigenet
profil
potenti
contribut
clinicopatholog
featur
designmethod
describ
epigenet
landscap
conduct
methyl
array
analysi
use
illumina
humanmethylationep
array
whole
transcriptom
sequenc
wt
sequenc
gene
cohort
case
follow
analys
perform
use
r
result
normal
probe
select
identifi
variabl
methyl
probe
standard
deviat
across
sampl
unsupervis
consensu
cluster
use
select
probe
clearli
identifi
distinct
sampl
cluster
combin
analys
express
fusion
data
wt
reveal
cluster
character
cluster
high
express
cluster
fusionshigh
express
cluster
respect
although
number
frequent
affect
gene
rel
low
cluster
pten
abnorm
particularli
enrich
cluster
mutat
frequent
observ
cluster
furthermor
note
patient
cluster
display
advers
prognosi
wherea
patient
cluster
show
excel
clinic
outcom
p
conclus
base
dna
methyl
profil
pediatr
cluster
distinct
subtyp
exhibit
remark
correl
fusion
gene
statu
gene
express
pattern
genet
signatur
clinic
outcom
although
cohort
current
studi
limit
result
suggest
biolog
phenotyp
mediat
genet
epigenet
regul
therefor
explor
aberr
dna
methyl
along
genet
alter
might
help
develop
new
therapeut
strategi
e
guest
b
n
j
r
e
p
merci
hospit
hematologyoncologybon
marrow
transplant
kansa
citi
usa
merci
hospit
center
pediatr
genom
medicin
kansa
citi
usa
hopkin
univers
school
medicin
biostatist
baltimor
usa
hopkin
univers
school
medicin
pediatr
oncolog
baltimor
usa
backgroundobject
rearrang
high
risk
recurr
molecular
driver
acut
lymphoblast
leukemia
among
infant
less
year
age
sought
determin
variat
genom
breakpoint
partner
gene
correl
risk
treatment
failur
infant
designmethod
perform
whole
genom
sequenc
wg
averag
depth
mrna
sequenc
blood
marrow
sampl
infant
infant
enrol
children
oncolog
group
trial
case
partner
gene
enl
select
studi
infant
experienc
treatment
failur
pair
relaps
sampl
align
sequenc
data
done
use
bwa
transloc
detect
wg
done
use
manta
fusion
transcript
detect
rnaseq
perform
use
fusioncatch
result
whole
genom
sequenc
detect
transloc
sampl
precis
nucleotid
breakpoint
sampl
locat
breakag
within
intron
exon
case
contrast
breakpoint
locat
within
enl
variabl
relaps
observ
enl
group
breakpoint
unchang
pair
sampl
relaps
known
fusion
transcript
detect
sampl
biolog
consist
identifi
dna
breakpoint
exon
skip
altern
splice
site
observ
reciproc
fusion
transcript
frequent
detect
never
detect
enl
fusion
domin
detect
case
relaps
without
relaps
conclus
breakpoint
infant
conserv
within
narrow
genom
window
contrast
breakpoint
partner
gene
enl
fusion
common
among
case
relaps
cezar
f
nacion
cancer
paediatr
program
rio
de
janeiro
brazil
backgroundobject
pediatr
acut
myeloid
leukemia
phenotyp
genet
heterogen
diseas
identif
gene
fusion
allow
definit
molecular
subtyp
import
role
prognosi
treatment
respons
aml
major
genom
abnorm
character
rearrang
identifi
fish
mll
break
apart
partner
gene
defin
prognosi
outcom
context
standard
multiplex
techniqu
identifi
frequent
partner
partial
tandem
duplic
ptd
gene
designmethod
analyz
case
de
novo
identif
identifi
partner
studi
pcr
reaction
order
standard
method
describ
burmeist
et
al
modif
necessari
reagent
chang
perform
includ
test
taq
dna
polymeras
chang
cycl
program
sanger
sequenc
perform
confirm
result
result
two
hundr
aml
case
includ
studi
infant
case
frequent
morpholog
subtyp
myelomonocyt
case
identifi
partner
identifi
follow
frequenc
fusion
posit
fusion
identifi
posit
present
conclus
propos
techniqu
success
standard
laboratori
possibl
reliabl
identif
partner
gene
less
cost
compar
fish
r
van
c
r
e
b
de
g
laurey
univers
hospit
depart
pediatr
stem
cell
transplant
ghent
belgium
backgroundobject
burkitt
lymphoma
bl
rare
pediatr
tumor
character
transloc
myc
chromosom
one
immunoglobulin
loci
sinc
exposur
time
carcinogen
shorter
children
genet
factor
assum
import
tumor
develop
depart
relat
children
diagnos
bl
strongli
suggest
predispos
factor
designmethod
whole
genom
sequenc
perform
constitut
materi
patient
parent
grandpar
variant
call
use
genom
analysi
toolkit
gatk
follow
priorit
filter
gemini
paila
et
al
result
first
data
reduct
done
select
rare
variant
share
patient
relat
parent
absent
spousal
control
three
deleteri
variant
identifi
includ
data
reduct
base
inherit
model
reveal
compound
heterozyg
variat
addit
mutat
follow
de
novo
model
base
probabl
mendelian
error
mutat
seem
plausibl
third
approach
use
publish
cancer
gene
panel
zhang
et
al
variant
found
segreg
famili
conclus
collect
data
show
multipl
candid
bl
predispos
variant
found
famili
investig
becom
appar
variant
play
major
role
develop
cancer
downregul
express
alter
gene
silenc
identifi
variant
howev
need
function
valid
examin
larg
popul
famili
importantli
approach
expand
pediatr
cancer
entiti
improv
understand
tumorigenesi
enabl
genet
counsel
contribut
novel
diagnost
applic
therapeut
option
tl
gl
share
senior
author
ta
k
g
n
j
van
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
children
hospitalacadem
medic
center
pediatr
oncolog
amsterdam
netherland
medic
center
laboratori
genet
metabol
diseas
amsterdam
netherland
children
hospit
pediatr
oncolog
rotterdam
netherland
center
pediatr
oncolog
translat
research
utrecht
netherland
backgroundobject
neuroblastoma
stage
low
risk
tumor
overal
surviv
natur
cours
consist
initi
growth
multifoc
diseas
follow
regress
howev
precis
clinic
cours
initi
growth
regress
phase
poorli
describ
perform
retrospect
cohort
studi
describ
clinic
cours
identifi
patient
risk
advers
outcom
compar
regress
rate
treat
untreat
patient
designmethod
chart
patient
diagnos
neuroblastoma
stage
two
dutch
oncolog
center
evalu
therapi
respons
outcom
clinic
metabol
radiolog
regress
tumor
liver
metastas
patient
high
risk
criteria
exclud
result
identifi
patient
year
overal
surviv
median
follow
month
rang
treatment
given
patient
first
week
diagnosi
patient
die
rapid
liver
growth
compress
neonat
highest
risk
die
neonat
die
none
older
patient
die
regress
phase
primari
tumor
complet
regress
patient
median
month
rang
liver
size
normal
median
month
rang
architectur
normal
median
month
rang
differ
regress
rate
seen
treat
untreat
patient
late
progress
stage
observ
patient
persist
elev
catecholamin
two
three
current
complet
remiss
conclus
neonat
risk
die
rapid
liver
growth
patient
persist
elev
catecholamin
risk
progress
stage
radiolog
regress
primari
tumor
liver
architectur
slow
take
month
simon
b
f
b
cologn
pediatr
oncolog
hematolog
cologn
germani
cologn
nuclear
medicin
cologn
germani
univeristi
hospit
pediatr
oncolog
hematolog
berlin
germani
backgroundobject
random
trial
mibg
therapi
treatment
neuroblastoma
avail
therefor
analyz
nation
neuroblastoma
data
base
impact
mibg
therapi
local
radiotherapi
singl
agent
immunotherapi
therapi
neuroblastoma
designmethod
patient
two
consecut
nation
neuroblastoma
trial
includ
met
key
criteria
stage
neuroblastoma
age
diagnosi
month
induct
chemotherapi
diagnosi
mibg
therapi
prior
myeloabl
chemotherapi
schedul
mibg
posit
lesion
local
radiotherapi
gy
deliv
unresect
mibg
posit
residu
primari
site
singl
agent
immunotherapi
stratifi
accord
open
trial
result
total
patient
includ
median
observ
time
year
presenc
mibg
posit
metastas
end
induct
chemotherapi
associ
inferior
ef
vs
impact
os
vs
among
patient
residu
mibg
posit
metastat
diseas
ef
similar
patient
underw
mibg
therapi
patient
os
better
mibg
therapi
compar
mibg
therapi
multivari
analysi
patient
includ
variabl
mycn
mibg
therapi
local
radiotherapi
immunotherapi
reveal
independ
impact
mycn
amplif
hr
treatment
p
hr
ef
mycn
amplif
hr
treatment
hr
os
conclus
mibg
therapi
improv
outcom
neuroblastoma
patient
incomplet
metastat
respons
induct
chemotherapi
result
warrant
prospect
multicent
trial
mibg
therapi
addit
analysi
confirm
long
term
effect
immunotherapi
blom
van
e
van
der
l
center
pediatr
oncolog
research
utrecht
netherland
research
hematopoiesi
amsterdam
netherland
medisch
centrum
laboratori
genet
metabol
diseas
amsterdam
netherland
research
experiment
immunohematolog
amsterdam
netherland
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
backgroundobject
thrombocytopenia
major
toxic
metaiodobenzylguanidin
mibg
whether
caus
radiat
dose
mechan
clear
previous
show
mibg
transport
via
serotonin
transport
sert
platelet
via
net
neuroblastoma
test
select
serotonin
reuptak
inhibitor
ssri
inhibit
mibg
accumul
platelet
effect
mibg
accumul
neuroblastoma
mous
model
designmethod
uptak
mibg
serotonin
isol
human
platelet
inhibit
panel
ssri
mibg
uptak
platelet
presum
via
sert
compar
uptak
neuroblastoma
cell
via
net
ie
inhibitor
concentr
reduc
uptak
select
ratio
mibg
uptak
neuroblastoma
cell
platelet
calcul
mibg
tumor
accumul
without
ssri
net
inhibitor
studi
neuroblastoma
xenograft
ssri
contain
plasma
nude
mice
use
test
inhibitori
potenc
mibg
uptak
human
platelet
ex
vivo
result
inhibit
serotonin
mibg
uptak
platelet
appear
compar
ssri
suggest
substrat
share
transport
system
ssri
time
potent
inhibit
platelet
mibg
uptak
neuroblastoma
cell
imipramin
classic
tricycl
antidepress
show
select
inhibit
mibg
platelet
mibg
neuroblastoma
uptak
extent
mibg
accumul
neuroblastoma
xenograft
significantli
affect
ssri
administr
diminish
mice
treat
desipramin
net
inhibitor
ssri
drug
level
murin
circul
highli
exceed
requir
effect
inhibit
platelet
mibg
uptak
conclus
ssri
effect
reduc
mibg
uptak
platelet
leav
tumor
load
unaffect
administr
ssri
may
prevent
mibg
relat
thrombocytopenia
similar
mechan
involv
megakaryocyt
b
hero
h
f
cologn
pediatr
oncolog
hematolog
cologn
germani
medicin
greifswald
pediatr
hematolog
oncolog
greifswald
germani
berlin
pediatr
oncolog
hematolog
berlin
germani
backgroundobject
chemotherapi
autolog
rescu
consid
standard
treatment
high
risk
neuroblastoma
patient
random
trial
recent
show
improv
outcom
regimen
use
busulfan
melphalan
ladenstein
et
al
lancet
oncol
per
protocol
chemotherapi
trial
german
neuroblastoma
group
gpoh
consist
melphalan
etoposid
carboplatin
mec
howev
patient
eg
ototox
busulfan
melphalan
recommend
altern
evalu
feasibl
toxic
busulfan
melphalan
patient
treat
gpoh
induct
treatment
use
infus
cisplatin
etoposid
ifosfamid
designmethod
data
high
risk
neuroblastoma
patient
regist
german
neuroblastoma
trial
receiv
chemotherapi
autolog
rescu
first
line
treatment
analyz
result
chemotherapi
melphalan
etoposid
carboplatin
mec
given
patient
patient
receiv
busulfan
melphalan
mibg
therapi
appli
patient
receiv
mec
nine
patient
receiv
median
resp
day
prior
high
dose
chemotherapi
hematolog
recoveri
differ
group
median
leukocyt
take
cohort
day
platelet
take
mec
vs
day
ns
detail
toxic
data
avail
patient
mec
reveal
signific
differ
toxic
grade
fever
infect
stomat
liver
enzym
diseas
vod
report
mec
sixteen
patient
receiv
mec
three
receiv
die
high
dose
chemotherapi
relat
complic
ns
includ
vod
six
patient
mec
conclus
chemotherapi
busulfan
melphalan
feasibl
gpoh
induct
treatment
expect
vod
observ
often
otherwis
toxic
compar
l
kelley
c
p
l
g
r
k
h
pu
von
von
recht
der
technisch
cccm
munich
comprehens
cancer
german
translat
cancer
research
consortium
dktk
depart
paediatr
germani
stuttgart
olgahospit
paediatr
immunolog
stuttgart
germani
und
pediatr
hematolog
oncolog
germani
zentrum
klinik
onkologi
berlin
germani
anna
kinderspit
depart
hematolog
oncolog
vienna
austria
beider
basel
pediatr
oncolog
hematolog
basel
switzerland
klinik
allgemein
und
germani
krankenhau
der
stadt
wien
der
medizinischen
wien
vienna
austria
recht
der
isar
technisch
institut
allgemein
pathologi
und
pathologisch
anatomi
munich
germani
recht
der
isar
klinik
und
poliklinik
und
germani
klinikum
zentrum
und
unfallchirurgi
depart
berlin
germani
basel
institut
pathologi
basel
switzerland
stuttgart
olgahospit
radiologisch
institut
stuttgart
germani
kassel
pediatr
hematolog
oncolog
kassel
germani
backgroundobject
object
studi
investig
age
group
adolesc
young
adult
aya
regard
correl
patholog
fractur
pf
prognosi
patient
primari
central
osteosarcoma
extrem
designmethod
retrospect
analyz
patient
age
local
metastat
primari
central
osteosarcoma
extrem
treat
regist
intend
treatment
includ
postop
chemotherapi
surgeri
univari
surviv
analysi
perform
compar
multivari
surviv
analysi
conduct
cox
proport
hazard
model
result
patient
document
pf
presenc
pf
correl
younger
age
tumor
site
p
local
within
affect
bone
p
histolog
subtyp
p
rel
tumor
size
sex
bodi
mass
index
primari
metastas
type
oper
local
surgic
remiss
respons
chemotherapi
univari
surviv
analysi
overal
surviv
oa
patient
without
pf
vs
respect
surviv
ef
vs
local
surviv
lrf
vs
multivari
cox
analysi
pf
result
independ
prognost
factor
overal
surviv
hazard
ratio
ci
lrf
howev
result
independ
prognost
factor
ef
ci
conclus
observ
presenc
pf
correl
inferior
oa
lrf
pf
remain
independ
prognost
factor
multivari
analysi
surviv
analys
suggest
local
recurr
might
common
patient
pf
therefor
analysi
need
exclud
influenc
factor
howev
presenc
pf
seem
influenc
type
oper
perform
r
zamzam
w
cancer
hospit
egypt
health
econom
outcom
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
chief
oper
offic
cairo
egypt
cancer
hospit
egypt
chief
execut
offic
cairo
egypt
backgroundobject
healthcar
crucial
medic
condit
fail
improv
outcom
osteosarcoma
aim
work
develop
standard
system
measur
valu
health
care
deliv
osteosarcoma
patient
develop
uniform
set
health
outcom
osteosarcoma
use
consist
approach
measur
cost
care
deliveri
designmethod
porter
outcom
measur
hierarchi
use
defin
domain
health
outcom
osteosarcoma
cost
tdabc
method
use
determin
total
cost
care
deliv
osteosarcoma
patient
throughout
journey
cure
result
standard
health
outcom
report
system
develop
osteosarcoma
base
outcom
matter
patient
degre
health
measur
remiss
statu
defin
protocol
criteria
respons
treatment
defin
poor
good
respons
patholog
function
outcom
defin
use
mst
system
return
normal
activ
measur
amp
tool
process
recoveri
measur
evalu
advers
event
use
ctcae
determin
delay
care
cycl
report
medic
medic
error
assess
time
recoveri
sustain
health
defin
measur
qualiti
life
use
pedsql
questionnair
palli
care
use
po
survey
measur
sequela
treatment
process
map
done
osteosarcoma
care
cycl
includ
total
process
map
cover
activ
care
deliveri
cost
calcul
base
tdabc
method
process
map
conclus
develop
standard
system
measur
osteosarcoma
outcom
total
cost
care
fundament
improv
valu
health
care
deliv
osteosarcoma
patient
k
vijaysekharan
g
b
n
n
memori
hospit
medic
oncolog
pediatr
mumbai
india
memori
hospit
surgic
oncolog
bone
soft
tissu
tumor
mumbai
india
memori
hospit
radiodiagnosi
mumbai
india
memori
hospit
patholog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
nuclear
medicin
mumbai
india
backgroundobject
surviv
relaps
pnet
continu
suboptim
year
consid
patient
initi
pnet
larger
proport
primari
metastat
diseas
relaps
factor
determin
outcom
relaps
patient
need
clariti
analysi
patient
relaps
pnet
treat
hybrid
salvag
regimen
consist
topotecancyclophosphamid
irinotecantemozolomid
designmethod
retrospect
analysi
patient
relaps
pnet
treat
cur
intent
jan
dec
patient
receiv
total
cycl
chemotherapi
local
therapi
surgeryradiotherapi
initi
cycl
subset
patient
also
receiv
oral
metronom
mainten
therapi
month
result
salvag
regimen
employ
total
relaps
patient
rest
opt
palliat
upfront
median
age
treat
patient
year
male
median
time
first
relaps
month
end
primari
treatment
patient
complet
salvag
therapi
patient
progress
abandon
treatment
median
follow
studi
cohort
month
analyz
cohort
second
relaps
time
last
follow
patient
die
includ
one
due
toxic
patient
aliv
activ
diseas
diseas
os
respect
entir
cohort
older
patient
year
better
ef
time
first
relaps
site
primari
diseas
metastat
statu
primari
diagnosi
type
relaps
local
vs
metastat
gender
impact
outcom
conclus
salvag
chemotherapi
relaps
pnet
shown
encourag
result
earli
phase
retrospect
studi
reason
well
toler
regimen
produc
promis
result
tumor
otherwis
poor
outcom
claren
j
n
c
py
p
mc
le
n
l
antoin
lacassagn
radiotherapi
nice
franc
necker
chirurgi
et
traumatologiqu
pari
franc
oscar
lambret
radiotherapi
lill
franc
roussi
radiotherapi
villejuif
franc
universitair
du
cancer
de
toulous
radiotherapi
toulous
franc
et
doncologi
centr
pediatri
lyon
franc
de
bordeaux
radiotherapi
bordeaux
franc
oscar
lambret
public
health
lill
franc
roussi
pediatri
villejuif
franc
radiotherapi
lyon
franc
backgroundobject
primari
ewe
sarcoma
es
rib
repres
frequent
thorac
tumor
children
young
adult
specif
data
publish
remain
scarc
main
object
studi
evalu
surviv
accord
local
treatment
defin
precis
prognost
factor
tumor
designmethod
french
patient
includ
studi
local
es
rib
without
pleural
effus
elig
data
collect
prospect
databas
addit
systemat
retrospect
review
patient
record
perform
obtain
precis
clinic
radiolog
therapeut
data
includ
databas
result
patient
median
age
year
treat
median
year
percent
initi
pleural
effus
local
treatment
includ
surgeri
patient
mostli
induct
chemotherapi
sixti
patient
irradi
tumor
bed
hemithorax
hrt
diseas
free
surviv
df
overal
surviv
os
respect
patient
relaps
median
time
month
diagnosi
pleural
effus
incomplet
surgic
resect
proven
independ
prognost
factor
df
os
case
initi
pleural
effus
document
os
without
hrt
versu
hrt
deliv
radiat
tumor
bed
increas
significantli
os
case
poor
histolog
respons
conclus
pleural
effus
diagnosi
incomplet
resect
two
independ
risk
factor
surviv
local
es
rib
hemithorac
irradi
increas
significantli
overal
surviv
case
pleural
effus
proven
impact
boost
tumor
bed
accord
histolog
respons
qualiti
surgeri
confirm
patient
k
westmoreland
n
van
der
b
c
g
g
pediatr
hematolog
oncolog
lilongw
malawi
north
carolina
pediatr
hematolog
oncolog
chapel
hill
usa
north
carolina
patholog
chapel
hill
usa
oncolog
lilongw
malawi
patholog
lilongw
malawi
malawi
school
medicin
patholog
lilongw
malawi
north
carolina
microbiolog
immunolog
chapel
hill
usa
north
carolina
patholog
chapel
hill
usa
north
carolina
oncolog
infecti
diseas
chapel
hill
usa
malawi
school
medicin
oncolog
lilongw
malawi
backgroundobject
burkitt
lymphoma
bl
commonest
pediatr
cancer
africa
ssa
molecular
confirm
pediatr
bl
standard
set
often
imposs
ssa
set
due
limit
patholog
absent
molecular
diagnost
tool
difficulti
obtain
diagnost
tissu
particularli
viscer
site
designmethod
prospect
enrol
pediatr
patient
year
age
possibl
lymphoma
kamuzu
central
hospit
lilongw
base
hematopathologist
review
diagnost
specimen
unit
state
case
categor
gold
standard
bl
possibl
confirm
bl
gold
standard
bl
defin
histolog
base
classic
morpholog
immunophenotyp
plasma
viru
load
measur
baselin
quantit
polymeras
chain
reaction
gold
standard
bl
compar
use
result
identifi
gold
standard
bl
case
case
analysi
case
possibl
bl
exclud
due
cytolog
specimen
prohibit
detail
immunophenotyp
median
age
bl
case
year
iqr
year
iqr
median
lactat
dehydrogenas
ldh
level
diagnosi
iul
iqr
bl
iul
iqr
median
plasma
diagnosi
iqr
bl
iqr
posit
predict
valu
ldh
upper
limit
normal
uln
bl
case
neg
predict
valu
ldh
uln
case
conclus
ldh
implement
diagnost
tool
assist
confirm
pediatr
bl
ssa
ongo
work
includ
develop
valid
clinic
diagnost
algorithm
molecularli
confirm
pediatr
bl
larger
cohort
malawian
children
b
cheriyalink
parambil
g
b
memori
hospit
pediatr
oncolog
mumbai
india
backgroundobject
classic
hodgkin
lymphoma
chl
excel
os
though
long
term
surviv
declin
year
due
relaps
late
effect
therapi
recent
strategi
seek
limit
anthracyclin
alkyl
agent
bleomycin
radiat
therapi
studi
clinic
profil
outcom
children
advanc
chl
strategi
designmethod
children
chl
februari
decemb
retrospect
analyz
stage
positron
emiss
computer
tomographi
bulki
site
x
baselin
receiv
involv
field
radiat
ifrt
iax
ibx
iiax
iie
iiia
ir
iibx
iib
iiix
iiie
iiib
iv
high
risk
hr
patient
receiv
cycl
oepa
vincristin
etoposid
prednisolon
doxorubicin
follow
earli
complet
metabol
respons
cmr
receiv
cycl
copdac
cyclophosphamid
vincristin
prednisolon
dacarbazin
hr
partial
respons
pr
cycl
copdac
refractori
end
treatment
progress
diseas
time
consid
salvag
option
result
hundr
seventeen
children
elig
median
age
year
bulki
median
ldh
median
hemoglobin
gdl
serum
albumin
gmdl
patient
evalu
earli
cmr
progress
seventeen
among
pr
case
second
pet
achiev
cmr
receiv
ifrt
bulki
diseas
delay
cmr
median
month
os
ef
ir
hr
higher
toxic
febril
sever
viral
hypothyroid
occur
mortal
gender
bulki
diseas
albumin
earli
pet
respons
signific
impact
os
ef
though
trend
toward
improv
ef
seen
patient
hb
conclus
primari
chemotherapi
base
oepacopdac
ifrt
advanc
chl
good
os
ef
manag
toxic
effect
need
intensifi
primari
chemotherapi
advanc
chl
attain
better
diseas
control
avoid
therapi
known
late
toxic
batra
r
india
institut
medic
scienc
medic
oncolog
new
delhi
india
backgroundobject
poor
complianc
report
retinoblastoma
rb
resourc
constraint
set
prospect
databas
patient
track
system
pdpt
may
improv
complianc
henc
treatment
outcom
rb
designmethod
pdpt
introduc
januari
centr
wherein
patient
contact
telephon
miss
outpati
visit
encourag
complet
treatment
contact
inform
updat
visit
compar
complianc
patient
rb
treat
prior
pdpt
adequ
therapi
effect
therapi
defin
complianc
treatment
period
stage
cycl
chemotherapi
eua
stage
enucl
stage
enucl
cycl
chemotherapi
stage
enucl
cycl
chemotherapi
radiat
year
recurr
addit
adequ
therapi
respect
result
two
hundr
fourteen
patient
rb
treat
june
decemb
phase
januari
decemb
phase
respect
median
age
month
sex
distribut
male
similar
phase
patient
stage
iii
rb
lowest
complianc
proport
patient
receiv
adequ
stage
vs
stage
vs
stage
vs
stage
vs
stage
vs
effect
therapi
stage
vs
stage
vs
p
stage
vs
stage
vs
stage
vs
significantli
higher
phase
annual
cost
per
patient
usd
per
extra
effect
treat
patient
conclus
pdpt
significantli
improv
complianc
patient
rb
minim
ad
cost
improv
seen
even
stage
iii
diseas
lowest
complianc
f
j
n
k
schroeder
univers
school
medicin
st
loui
usa
medic
centr
oncolog
mwanza
tanzania
univers
pediatr
hematolog
oncolog
durham
usa
univers
global
health
durham
usa
backgroundobject
oncolog
patient
navig
program
success
implement
hospit
throughout
us
enhanc
qualiti
care
financi
guidanc
treatment
coordin
psychosoci
support
low
resourc
set
barrier
receiv
cancer
care
increas
patient
navig
set
potenti
significantli
impact
outcom
howev
limit
research
efficaci
program
set
bugando
medic
centr
bmc
mwanza
tanzania
patient
navig
program
establish
identifi
potenti
pediatr
oncolog
patient
assist
patient
famili
throughout
diagnosi
treatment
process
goal
reduc
time
oncolog
evalu
diagnosi
ultim
improv
surviv
outcom
designmethod
retrospect
analysi
hospit
record
conduct
pediatr
oncolog
patient
seen
bmc
separ
present
date
establish
navig
program
collect
data
includ
demograph
diagnosi
time
present
oncolog
evalu
diagnosi
treatment
complet
year
surviv
outcom
result
total
patient
file
review
program
initi
patient
group
differ
age
gender
diagnosi
distribut
establish
patient
navig
program
averag
time
oncolog
evalu
decreas
day
time
diagnosi
decreas
day
treatment
abandon
decreas
p
year
surviv
increas
p
conclus
pediatr
cancer
earli
diagnosi
critic
initi
chemotherapi
improv
outcom
studi
shown
patient
navig
program
potenti
significantli
impact
patient
outcom
includ
comprehens
pediatr
cancer
care
program
agulnik
f
dj
soberani
rh
e
v
c
n
jude
children
research
hospit
depart
global
pediatr
medicin
memphi
usa
nacion
de
hematologyoncolog
guatemala
guatemala
backgroundobject
hospit
pediatr
oncolog
patient
high
risk
clinic
declin
mortal
particularli
countri
pediatr
earli
warn
system
pew
clinic
assess
tool
aid
earli
identif
deterior
multidisciplinari
team
implement
modifi
pew
unidad
nacion
de
unop
pediatr
oncolog
hospit
guatemala
publish
data
demonstr
intervent
reduc
clinic
deterior
event
picu
util
studi
investig
cost
pew
implement
unop
designmethod
variabl
cost
run
maintain
picu
floor
ward
unop
calcul
use
hospit
administr
data
pew
implement
cost
base
studi
expenditur
number
picu
avert
due
reduc
unplan
picu
transfer
clinic
deterior
event
calcul
adjust
chang
total
hospit
hospit
save
per
due
reduc
variabl
cost
expenditur
unplan
picu
transfer
calcul
cost
adjust
inflat
standard
use
intern
dollar
result
fewer
picu
due
unplan
transfer
pew
implement
compar
differ
variabl
cost
unplan
picu
transfer
per
day
picu
minu
ward
total
cost
implement
pew
unop
repres
cost
per
hospit
reduct
variabl
picu
cost
support
care
measur
unop
abl
save
net
per
inpati
admiss
annual
net
save
result
pew
implement
conclus
implement
pew
unop
pediatr
oncolog
hospit
locat
incom
countri
result
net
work
demonstr
hospit
invest
pew
program
improv
qualiti
pediatr
cancer
care
reduc
hospit
cost
butia
mutai
mtete
p
p
p
p
nk
p
j
central
hospit
pediatr
oncolog
lilongw
malawi
colleg
medicin
children
foundat
malawi
pediatr
oncolog
lilongw
malawi
colleg
medicin
texa
children
cancer
hematolog
center
houston
usa
colleg
medicin
texa
children
hospit
pediatr
palli
care
houston
usa
colleg
medicin
texa
children
hospit
section
palli
care
houston
usa
backgroundobject
world
health
organ
defin
effect
pediatr
palli
care
ppc
total
care
child
bodi
mind
spirit
involv
interdisciplinari
support
entir
famili
use
commun
resourc
assess
manag
children
pain
remain
global
prioriti
intern
children
palli
care
network
also
identifi
creation
intervent
model
care
ppc
top
global
research
prioriti
addit
literatur
demonstr
participatori
action
research
par
result
sustain
health
care
deliveri
model
program
maxim
commun
involv
establish
intervent
model
care
ppc
treatment
total
pain
malawi
need
designmethod
qualit
data
obtain
interview
collect
analyz
identifi
method
address
patient
total
pain
particip
includ
bereav
parent
children
incur
hematologiconcolog
diagnos
medic
provid
tertiari
care
public
hospit
oncolog
unit
two
independ
review
conduct
themat
data
analys
result
five
intervent
mitig
total
pain
identifi
particip
describ
parent
abandon
spiritu
commun
express
urgent
need
spiritu
support
particip
cite
need
financi
support
food
secur
support
home
visit
enhanc
commun
educ
minim
stigma
univers
suggest
parent
recommend
support
group
address
emotionalpsycholog
distress
four
medic
provid
advoc
play
therapi
address
patient
stress
pain
provid
cite
need
ongo
psychosoci
support
train
conclus
use
par
promot
commun
involv
creation
ppc
program
treat
total
pain
malawi
feasibl
enlighten
area
focu
financi
support
spiritu
support
play
therapi
home
visit
parent
support
group
identifi
immedi
need
guid
next
step
develop
novel
ppc
program
popul
tf
eleveld
l
j
da
l
r
ga
p
van
hn
r
jj
translat
research
princess
maxima
centr
childhood
oncolog
utrecht
netherland
oncogenom
amc
amsterdam
amsterdam
netherland
pediatr
oncolog
emma
hospit
amc
amsterdam
amsterdam
netherland
backgroundobject
recent
show
mutat
affect
pathway
occur
frequent
neuroblastoma
relaps
tumor
hypothes
activ
pathway
associ
poor
prognosi
tumor
progress
henc
object
detect
activ
state
pathway
tumor
correl
prognosi
find
mutat
serv
biomark
pathway
activ
designmethod
gener
gene
signatur
identifi
activ
state
pathway
cell
line
tumor
data
correl
whole
genom
sequenc
data
identifi
novel
mutat
activ
pathway
candid
mutat
induc
cell
line
use
gene
edit
character
vitro
vivo
result
primari
neuroblastoma
tumor
activ
pathway
correl
poor
surviv
associ
mutat
alk
known
gene
integr
analysi
identifi
mutat
cic
dmd
activ
pathway
vitro
show
activ
pathway
caus
tumor
progress
vivo
conclus
identifi
novel
biomark
activ
reinforc
pathway
promis
target
neuroblastoma
research
determin
whether
identifi
mutat
also
function
biomark
sensit
mek
inhibit
b
truong
z
j
k
san
francisco
pediatr
san
francisco
usa
pennsylvania
school
medicin
pediatr
philadelphia
usa
medic
school
boston
children
cancer
blood
disord
center
boston
usa
backgroundobject
neuroblastoma
second
common
extracrani
malign
childhood
long
recogn
biolog
clinic
heterogen
diseas
base
recent
studi
demonstr
signific
relationship
primari
tumor
site
prognosi
tumor
biolog
featur
hypothes
thorac
adren
neuroblastoma
repres
differ
diseas
subset
differ
genom
featur
designmethod
util
target
dataset
evalu
genet
profil
adren
versu
thorac
primari
tumor
also
evalu
associ
common
germlin
variat
primari
site
separ
cohort
adren
thorac
primari
tumor
appropri
platform
employ
evalu
differ
copi
number
alter
mutat
rna
express
pathway
enrich
common
germlin
variat
primari
site
binari
variabl
associ
evalu
test
prior
evid
vitro
transform
capabl
appli
call
driver
mutat
alk
prior
associ
test
result
observ
higher
rate
mycn
amplif
chromosom
gain
chromosom
delet
among
adren
tumor
highli
predict
function
signatur
observ
rna
data
adren
neuroblastoma
less
like
harbor
alk
driver
mutat
thorac
case
among
case
ci
among
case
without
mycn
amplif
ci
common
germlin
snp
previous
associ
neuroblastoma
found
strongli
associ
predisposit
origin
adren
rather
thorac
site
conclus
genom
featur
differ
adren
thorac
neuroblastoma
unfavor
somat
featur
mycn
amplif
segment
chromosom
aberr
common
among
adren
tumor
though
alk
driver
mutat
common
among
thorac
tumor
presenc
specif
germlin
variant
increas
likelihood
adren
thorac
site
origin
reinforc
differ
two
subgroup
diseas
morini
r
j
font
de
v
vf
ar
mv
b
g
l
gaslini
children
hospit
laboratori
molecular
biolog
genoa
itali
nazional
tumori
pediatr
oncolog
milan
itali
children
hospit
paediatr
haematologyoncolog
rome
itali
de
sanitaria
la
fe
laboratori
cellular
molecular
biolog
valencia
spain
universitario
la
fe
pediatr
oncolog
valencia
spain
institut
cancer
patholog
children
cancer
research
group
leed
unit
kingdom
gaslini
children
hospit
pediatr
oncolog
genoa
itali
gaslini
children
hospit
patholog
genoa
itali
gaslini
children
hospit
laboratori
oncolog
genoa
itali
institut
pediatr
oncolog
pari
franc
pediatr
oncolog
hematolog
berlin
germani
backgroundobject
respons
patient
hr
neuroblastoma
nb
front
line
induct
chemotherapi
crucial
determin
subsequ
treatment
absenc
earli
molecular
marker
predict
sensitivityresist
treatment
led
us
studi
exosom
small
vesicl
consid
bioprint
tumor
cell
liquid
biopsi
investig
whether
exosom
mirna
earli
biomark
respons
designmethod
collect
exosom
plasma
sampl
patient
induct
chemotherapi
express
evalu
rtqpcr
target
panel
data
analys
includ
featur
select
pathway
analysi
result
express
significantli
modul
respons
chemotherapi
provid
first
evid
may
serv
biomark
chemotherap
respons
cluster
analysi
distinguish
two
group
patient
effect
divid
good
partial
respond
minor
respond
correl
two
group
clinic
biolog
featur
investig
pathway
analysi
determin
whether
chemotherapi
influenc
express
mirna
known
involv
sensitivityresist
drug
commonli
employ
analysi
reveal
differenti
express
associ
sensitivityresist
drug
respons
map
result
individu
patient
identifi
distinct
group
subject
potenti
unresponsiveresist
induct
drug
profil
middl
phase
induct
therapi
investig
find
mirna
predictor
respons
may
allow
time
chang
induct
protocol
unrespons
patient
conclus
demonstr
repres
biomark
respons
potenti
indic
sensitivityresist
specif
drug
patient
result
pave
way
broad
applic
liquid
biopsi
appli
neuroblastoma
target
treatment
l
van
zogchel
e
van
j
van
wc
l
tj
mm
van
hn
ce
van
der
gam
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
netherland
landstein
laboratori
univers
amsterdam
depart
experiment
immunohematolog
amsterdam
netherland
children
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
backgroundobject
circul
tumor
dna
ctdna
use
diseas
monitor
sever
type
cancer
aim
studi
investig
whether
ctdna
use
respons
monitor
neuroblastoma
designmethod
plasma
sampl
patient
analyz
detect
hypermethyl
dna
dna
isol
total
cell
free
dna
cfdna
determin
qpcr
albumin
amount
ctdna
determin
qpcr
methyl
bisulfit
convers
detect
ctdna
compar
patient
characterist
bm
pb
mrd
qpcr
mibg
scan
urinari
catecholamin
result
diagnost
sampl
ctdna
detect
includ
patient
iocal
diseas
induct
chemotherapi
stage
patient
sampl
ctdna
detect
suspect
relaps
sampl
ctdna
detect
amount
cfdna
significantli
higher
patient
neuroblastoma
time
diagnosi
relaps
compar
healthi
control
highest
amount
patient
stage
signific
correl
ctdna
pb
bm
mrd
tumor
level
high
tumor
detect
discrep
observ
sampl
studi
detail
discrep
indic
either
low
tumor
burden
tumor
metastas
without
minim
bm
involv
conclus
hypermethyl
use
monitor
ctdna
patient
neuroblastoma
highli
correl
diseas
statu
diagnosi
data
indic
poorer
correl
tumor
load
low
sampl
like
ctdna
origin
primari
tumor
metastas
may
special
interest
diseas
monitor
patient
relaps
organ
bm
h
lode
h
n
medicin
greifswald
pediatr
hematolog
oncolog
greifswald
germani
biolog
apeiron
biolog
vienna
austria
backgroundobject
antibodi
ab
effect
treatment
neuroblastoma
nb
patient
approv
ema
without
mechan
action
induct
cellular
cytotox
adcc
program
inhibitori
receptor
express
activ
cancer
cell
express
ligand
report
first
time
effect
mechan
blockad
context
therapi
preclin
model
designmethod
express
nb
cell
leukocyt
analyz
flow
cytometri
presenc
without
mechan
induct
analyz
ab
effect
blockad
immun
respons
evalu
use
ab
vitro
nivolumab
syngen
nb
mous
model
mice
treat
ip
combin
ip
compar
control
result
cultur
nb
cell
leukocyt
et
concentr
ngml
without
iuml
induc
fold
upregul
respect
inhibit
specif
adcc
abrog
upregul
increas
adcc
importantli
blockad
nivolumab
revers
inhibit
adcc
final
mice
treat
combin
blockad
show
strongest
reduct
tumor
growth
longest
surviv
rate
well
highest
level
nb
cell
lysi
mediat
serum
leukocyt
treat
mice
compar
control
conclus
upregul
inhibitori
checkpoint
combin
blockad
result
synergist
treatment
effect
preclin
model
suggest
clinic
evalu
combin
checkpoint
inhibit
e
dolman
lt
te
na
b
la
l
da
rw
j
hn
jj
center
pediatr
oncolog
translat
research
utrecht
netherland
medic
center
utrecht
cell
biolog
utrecht
netherland
sophia
children
hospit
pediatr
oncolog
hematolog
rotterdam
netherland
medic
univers
amsterdam
oncogenom
amsterdam
netherland
children
amsterdam
medic
univers
amsterdam
pediatr
oncolog
amsterdam
netherland
backgroundobject
protein
b
cell
lymphomaleukaemia
highli
express
major
neuroblastoma
previou
preclin
studi
shown
treatment
neuroblastoma
inhibitor
lead
program
cell
death
result
contribut
initi
phase
trial
studi
safeti
pharmacokinet
venetoclax
children
relaps
refractori
neuroblastoma
current
studi
focus
identif
valid
target
combin
strategi
prevent
overcom
neuroblastoma
resist
venetoclax
designmethod
target
drug
combin
treatment
venetoclax
identifi
screen
compound
use
normal
neuroblastoma
cell
line
neuroblastoma
cell
line
made
resist
venetoclax
top
hit
subsequ
test
extens
vitro
vivo
valid
screen
result
result
drug
screen
identifi
inhibitor
idasanutlin
one
strongest
venetoclax
neuroblastoma
cell
cellular
tumor
antigen
subsequ
vitro
valid
show
idasanutlin
caus
cyclin
depend
kinas
inhibitor
growth
arrest
neuroblastoma
cell
induc
x
protein
bax
apoptot
respons
neuroblastoma
cell
presenc
venetoclax
vivo
combin
venetoclax
idasanultin
result
remark
improv
anticanc
effect
compar
singl
agent
therapi
almost
complet
regress
neuroblastoma
xenograft
combin
screen
addit
reveal
inhibitor
protein
kinas
kinas
mek
anaplast
lymphoma
kinas
alk
histon
deacetylas
hdac
synerg
venetoclax
depend
genom
background
neuroblastoma
tumor
conclus
find
indic
clinic
use
venetoclax
treatment
children
neuroblastoma
tumor
improv
combin
therapi
target
inhibitor
optim
target
combin
strategi
depend
presenc
addit
genom
event
drive
neuroblastoma
tumor
e
mullen
e
yy
g
j
g
p
j
j
c
j
children
cancer
blood
disord
center
pediatr
oncolog
boston
usa
robert
h
luri
children
hospit
chicago
patholog
chicago
usa
florida
biostatist
gainsvil
usa
british
columbia
hematolog
oncolog
vancouv
canada
tennesse
colleg
medicin
pediatr
oncolog
chattanooga
usa
children
hospit
ohio
state
univers
medic
center
biopatholog
center
columbu
usa
univers
school
medicin
pediatr
radiolog
saint
loui
usa
michigan
pediatr
surgeri
ann
arbor
usa
children
hospit
pediatr
oncolog
cincinnati
usa
univers
radiat
oncolog
chicago
usa
health
centr
dalhousi
univers
pediatr
hematolog
oncolog
halifax
canada
nation
health
system
pediatr
hematolog
oncolog
dc
usa
backgroundobject
gain
found
neg
prognost
marker
multipl
retrospect
european
north
american
studi
follow
week
vincristinedactinomycindoxorubicin
protocol
stratifi
stage
iv
fhwt
patient
intensifi
five
drug
therapi
addit
cyclophosphamideetoposid
regimen
slow
incomplet
respons
sir
pulmonari
metastasi
extrapulmonari
metastasi
epm
andor
gain
combin
loh
continu
pulmonari
radiat
withheld
rapid
complet
respons
rcr
analyz
impact
statu
novel
treatment
algorithm
designmethod
statu
success
analyz
evalu
patient
multiplex
probe
amplif
event
free
surviv
ef
overal
surviv
os
summar
year
compar
use
test
result
gain
overal
gain
n
ef
ci
os
ci
without
gain
n
ef
ci
os
ci
patient
sir
gain
ef
compar
sr
without
gain
os
patient
rcr
gain
wors
outcom
rcr
without
gain
ef
vs
os
vs
relaps
rcr
gain
predominantli
pulmonari
patient
epm
gain
ef
gain
ef
conclus
gain
associ
inferior
ef
rcr
stage
iv
fhwt
patient
isol
pulmonari
metastasi
patient
appropri
candid
radiat
omiss
regimen
may
mitig
advers
impact
gain
stage
iv
risk
categori
n
daw
yy
ja
f
j
e
p
k
e
p
ej
jr
adc
z
r
c
j
univers
texa
md
anderson
cancer
center
divis
pediatr
houston
usa
florida
statist
gainsvil
usa
robert
h
luri
children
hospit
chicago
radiat
oncolog
chicago
usa
assur
review
ctr
diagnost
imag
lincoln
usa
children
hospit
medic
center
hematologyoncolog
cincinnati
usa
robert
h
luri
children
hospit
chicago
patholog
chicago
usa
mott
children
hospit
surgeri
ann
arbor
usa
children
hospit
surgeri
seattl
usa
cancer
center
hematologyoncolog
boston
usa
reed
nation
militari
medic
center
hematologyoncolog
bethesda
usa
alberta
hospit
hematologyoncolog
edmonton
canada
healthcar
hematologyoncolog
bluffton
usa
jude
children
research
hospit
pharmaceut
servic
memphi
usa
research
laboratori
oncolog
north
wale
usa
univers
texa
md
anderson
cancer
center
radiat
oncolog
houston
usa
perelman
school
medicin
radiat
oncolog
philadelphia
usa
colleg
medicinedan
l
duncan
comprehens
cancer
center
hematologyoncolog
houston
usa
health
centr
pediatr
bioethic
halifax
canada
nation
medic
center
center
cancer
blood
disord
washington
usa
backgroundobject
nation
wilm
tumor
surviv
patient
stage
diffus
anaplast
wilm
tumor
dawt
treat
vincristin
doxorubicin
cyclophosphamid
etoposid
plu
radiotherapi
xrt
regimen
ci
evalu
intens
regimen
contain
carboplatin
addit
adjust
dose
chemotherapi
use
regimen
regimen
dosag
chemotherapi
reduc
due
toxic
exceed
predefin
stop
rule
analyz
effect
dose
reduct
surviv
ef
overal
surviv
os
toxic
designmethod
patient
stage
dawt
without
measur
diseas
receiv
regimen
patient
stage
iv
measur
diseas
option
receiv
vincristin
combin
irinotecan
vi
upfront
window
partial
respons
vi
incorpor
regimen
regimen
cumul
dose
doxorubicin
cyclophosphamid
etoposid
reduc
revis
regimen
due
toxic
result
elig
patient
treat
revis
revis
ef
patient
ci
os
ci
ef
stage
ii
iii
iv
diseas
ci
ci
ci
respect
ef
patient
treat
ci
compar
ci
patient
treat
revis
one
grade
toxic
attribut
treatment
two
revis
number
grade
toxic
per
patient
revis
conclus
patient
stage
dawt
regimen
show
trend
toward
superior
ef
compar
revis
compar
rate
grade
toxic
k
nakata
mp
n
f
r
r
w
j
c
v
g
k
great
ormond
street
institut
child
health
development
biolog
cancer
programm
london
unit
kingdom
control
osaka
intern
cancer
center
depart
cancer
strategi
osaka
japan
dei
hospit
paediatr
adolesc
cancer
unit
msida
malta
gener
hospit
paediatr
depart
watford
unit
kingdom
dept
paediatr
oncolog
haematolog
copenhagen
denmark
health
england
nation
cancer
registr
analysi
servic
oxford
unit
kingdom
cancer
genom
univers
birmingham
cancer
research
uk
clinic
trial
unit
birmingham
unit
kingdom
manchest
children
hospit
depart
paediatr
histopatholog
manchest
unit
kingdom
hospit
wale
depart
cellular
patholog
cardiff
unit
kingdom
backgroundobject
sinc
patient
wilm
tumour
wt
regist
five
consecut
uk
clinic
trial
import
review
trial
data
focu
congenit
abnorm
ca
later
designmethod
categoris
patient
wt
five
mutual
exclus
group
wt
aniridia
withwithout
urogenit
malform
wa
urogenitalren
malform
includ
syndrom
um
includ
syndrom
hh
congenit
abnorm
without
ca
compar
distribut
sex
age
diagnosi
stage
histolog
overal
surviv
os
group
bilater
vs
unilater
tumour
compar
similar
outcom
result
number
proport
group
wa
um
hh
bilater
unilater
patient
wa
um
group
younger
median
age
diagnosi
higher
proport
bilater
diseas
compar
vs
vs
respect
hh
patient
show
signific
differ
compar
group
um
male
predomin
mf
ratio
vs
signific
differ
os
group
compar
wa
um
hh
vs
compar
unilater
diseas
bilater
group
femal
excess
mf
ratio
vs
younger
age
diagnosi
vs
poorer
os
vs
improv
case
diagnos
sinc
conclus
one
nine
patient
wt
congenit
abnorm
patient
diagnos
earlier
age
frequent
bilater
tumour
surviv
rate
seem
similar
compar
unilater
bilater
wt
younger
poorer
surviv
j
hol
van
k
b
de
h
van
c
n
van
den
center
paediatr
oncolog
paediatr
oncolog
utrecht
netherland
cancer
institut
biostatist
amsterdam
netherland
great
ormond
street
institut
child
health
paediatr
oncolog
london
unit
kingdom
nacion
de
cancer
inca
paediatr
program
rio
de
janeiro
brazil
carlo
haya
paediatr
oncolog
spain
dhematologi
et
doncologi
centr
paediatr
oncolog
lyon
franc
univers
medic
center
paediatr
oncolog
haematolog
homburg
germani
backgroundobject
age
suggest
prognost
factor
recurr
mortal
patient
wilm
tumour
wt
studi
assess
prognost
valu
age
cutoff
risk
stratif
paediatr
patient
unilater
wt
treat
accord
recent
intern
societi
paediatr
oncolog
siop
protocol
designmethod
patient
year
stage
wt
deriv
databas
patient
receiv
preoper
chemotherapi
includ
prognost
valu
age
diagnosi
per
yearcategor
surviv
ef
overal
surviv
os
assess
use
kaplan
meier
method
test
multivari
cox
regress
model
martingal
residu
plot
use
assess
function
form
age
multivari
analysi
adjust
gender
biopsi
yesno
patholog
stage
histolog
classif
tumour
volum
surgeri
result
patient
met
inclus
criteria
stage
stage
ii
stage
iii
stage
iv
median
age
diagnosi
year
interquartil
rang
iqr
median
year
iqr
estim
ef
os
ci
ci
respect
assess
martingal
residu
plot
suggest
linear
trend
age
ef
os
signific
differ
ef
os
found
age
p
multivari
analys
increas
age
associ
poorer
ef
linear
trend
p
os
lower
patient
year
compar
patient
year
ci
linear
trend
found
higher
stage
histolog
risk
group
volum
associ
poorer
os
ef
univari
multivari
analys
conclus
surviv
worsen
increas
age
patient
wt
howev
result
seem
justifi
use
age
cutoff
risk
stratif
pretreat
patient
k
j
colleg
london
ucl
great
ormond
street
institut
child
health
london
unit
kingdom
backgroundobject
improv
popul
outcom
renal
tumour
childhood
import
studi
collect
data
mode
present
facilit
intern
benchmark
wilm
tumour
wt
surviv
rate
relat
patienttumour
demograph
differ
model
primari
care
designmethod
data
extract
case
report
form
submit
uk
republ
ireland
princip
treatment
centr
childhood
cancer
case
central
patholog
review
registr
form
categori
mode
tumour
present
routin
child
health
examin
congenit
abnorm
screen
symptom
symptom
result
patient
regist
wt
diagnosi
rout
twenti
patient
rout
rout
median
age
diagnosi
wt
respect
stage
distribut
rout
stage
rout
stage
rout
stage
differ
proport
high
risk
histolog
versu
lowintermedi
risk
rout
respect
median
tumour
volum
diagnosi
patient
measur
rout
rout
rout
conclus
major
patient
present
symptom
patient
diagnos
screen
child
health
check
younger
less
metastat
diseas
stage
iii
diseas
frequent
children
present
symptom
also
highest
median
tumour
volum
ongo
data
collect
mode
present
extend
across
europ
allow
benchmark
includ
tumour
size
stage
diagnosi
offer
evid
regard
need
paediatr
expertis
primari
care
symptomat
children
mp
j
w
r
k
r
l
j
c
k
great
ormond
street
institut
child
health
univers
colleg
london
london
unit
kingdom
resid
program
univers
foggia
foggia
itali
clinic
genet
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
paediatr
nephrolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
backgroundobject
wilm
tumour
wt
survivor
especi
patient
associ
syndrom
genitourinari
anomali
due
constitut
mutat
increas
risk
renal
diseas
describ
renal
function
children
wt
mutat
guid
challeng
oncolog
manag
designmethod
retrospect
analysi
patient
wt
mutat
treat
great
ormond
street
hospit
uk
review
genotyp
phenotyp
tumour
histolog
later
treatment
renal
outcom
result
identifi
patient
mutat
delet
missens
nonsens
frameshift
splice
site
male
bilater
diseas
median
age
diagnosi
three
patient
genitourinari
malform
phenotyp
anomali
two
patient
underw
bilater
nephrectomi
unilater
nephrectomi
bilateralunilater
nss
unilater
nephrectomi
contralater
nss
histolog
subtyp
patient
bilater
show
mix
stromal
regress
blastem
rest
tumour
associ
nephrogen
rest
intralobar
none
anaplasia
median
durat
patient
aliv
remiss
relaps
six
patient
requir
dialysi
due
chronic
kidney
diseas
due
bilater
nephrectomi
one
upfront
one
relaps
renal
transplant
list
two
patient
develop
chronic
kidney
diseas
retain
normal
increas
albuminuria
four
patient
frameshift
delet
normal
kidney
paramet
year
conclus
despit
known
high
frequenc
chronic
kidney
diseas
patient
wt
constitut
mutat
patient
sustain
normal
guid
oncolog
manag
regard
balanc
decis
nss
without
compromis
oncolog
risk
larger
intern
studi
need
refin
predict
genotyp
longev
renal
function
c
c
g
v
roussi
children
adolesc
oncolog
unit
villejuif
franc
roussi
clinic
research
oper
depart
villejuif
franc
roussi
biostatist
epidemiolog
unit
villejuif
franc
roussi
cell
therapi
unit
villejuif
franc
backgroundobject
report
data
thiotepa
follow
autolog
stem
cell
rescu
ascr
pediatr
set
aim
defin
safeti
profil
ascr
larg
pediatr
cohort
solid
tumor
designmethod
analys
data
prospect
record
patient
solid
tumor
treat
follow
ascr
januari
children
adolesc
oncolog
unit
gustav
roussi
sinusoid
obstruct
syndrom
so
prophylaxi
perform
toxic
report
accord
ctcae
result
administ
patient
tandem
hdc
patient
median
age
diagnosi
year
repres
diseas
medulloblastoma
osteosarcoma
neuroblastoma
ewe
sarcoma
rhabdomyosarcoma
deliv
relaps
patient
total
cours
perform
dose
patient
respect
common
toxic
digest
grade
mucos
diarrhoea
patient
respect
neurolog
toxic
grade
report
patient
three
patient
experienc
so
mild
median
day
neutrophil
platelet
recoveri
day
respect
median
durat
hospitalis
day
toxic
mortal
rate
observ
directli
relat
patient
so
toxic
profil
differ
singl
tandem
relaps
treatment
conclus
ascr
global
well
toler
children
adolesc
solid
tumor
even
tandem
hdc
heavili
patient
prophylaxi
so
mandatori
digest
neurolog
toxic
need
care
support
care
manag
eah
loeffen
ec
van
rl
lcm
md
van
de
wje
obot
anthracyclin
cardiotox
work
children
univers
medic
center
univers
groningen
depart
pediatr
oncologyhematolog
groningen
netherland
children
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
backgroundobject
one
establish
side
effect
anthracyclin
chemotherapi
agent
use
variou
pediatr
oncolog
treatment
protocol
cardiotox
propos
strategi
minimis
cardiotox
lengthen
infus
durat
aim
develop
recommend
infus
durat
anthracyclin
chemotherapi
agent
children
cancer
designmethod
use
exist
cochran
sytemat
review
start
point
first
search
perform
nation
multidisciplinari
panel
person
form
repres
relev
field
includ
patient
repres
use
establish
grade
system
evid
apprais
recent
evid
decis
framework
panel
formul
evid
summari
recommend
result
studi
adult
pediatr
includ
low
low
qualiti
evid
regard
outcom
overal
surviv
clinic
heart
failur
progress
free
surviv
subclin
heart
failur
unanim
categor
critic
panel
agre
weak
recommend
push
infus
anthracyclin
chemotherapi
recommend
defin
precis
infus
time
period
current
possibl
research
recommend
formul
call
larg
random
trial
pharmacokinet
studi
conclus
guidelin
provid
recommend
regard
infus
durat
anthracyclin
chemotherapi
children
cancer
given
evid
shortag
studi
address
question
research
need
l
n
matinyan
n
v
oncolog
hematolog
blokhin
russian
oncolog
research
center
anesthesiolog
moscow
russia
oncolog
hematolog
blokhin
russian
oncolog
research
center
oncolog
depart
moscow
russia
oncolog
hematolog
blokhin
russian
oncolog
research
center
endovascular
surgeri
depart
moscow
russia
backgroundobject
superselect
ophthalm
arteri
chemotherapi
soac
melphalan
significantli
reduc
need
enucl
patient
retinoblastoma
complic
soac
procedur
express
hemodynam
instabl
bronchospasm
presum
due
reflex
significantli
limit
wider
implement
techniqu
children
experi
soac
advers
reaction
observ
describ
designmethod
februari
februari
pediatr
oncolog
hematolog
institut
soac
procedur
perform
gener
anesthesia
patient
age
month
caroti
interna
catheter
continu
iv
infus
epinephrin
mcgkgmin
start
sign
reflex
observ
bolu
epinephrin
mcgkg
administ
result
death
major
complic
reflex
trigger
procedur
reaction
occur
second
subsequ
procedur
character
hypoxia
reduc
lung
complianc
bronchospasm
follow
subsequ
deterior
oxygen
satur
ventil
oxygen
initi
advers
reaction
success
treat
min
patient
epinephrin
mcgkg
bolu
one
procedur
interrupt
due
prolong
hemodynam
instabl
patient
requir
prolong
vasopressor
support
earli
postop
period
case
children
acut
ishem
stroke
confirm
mri
conclus
advers
reaction
commonli
observ
soac
retinoblastoma
believ
advers
clinic
sign
repres
autonom
reflex
respons
patient
consid
reaction
occur
second
subsequ
procedur
anesthesiologist
must
vigil
advers
reaction
deal
quickli
effect
howev
investig
need
improv
understand
manifest
manag
clinic
signific
describ
reflex
j
valduga
l
c
v
p
p
hospitali
universitair
de
oncologi
et
nanci
franc
berard
lyon
franc
de
de
lorrain
nanci
franc
hospitali
universitair
de
plateform
daid
la
recherch
cliniqu
parc
nanci
franc
et
oncologi
ihop
oncologi
et
lyon
franc
backgroundobject
increas
surviv
rate
preserv
fertil
young
patient
treat
cancer
essenti
ovarian
transposit
ot
preserv
ovarian
function
damag
pubert
women
howev
littl
data
avail
possibl
pregnanc
ot
especi
perform
pre
period
designmethod
retrospect
analysi
women
underw
ot
age
yr
perfom
data
puberti
menstruat
pregnanc
ovarian
reserv
collect
result
ot
perform
patient
pelvic
craniospin
irradi
associ
chemotherapi
case
mean
age
time
analysi
yr
median
yr
mean
age
time
ot
year
ci
prepurbet
patient
underw
second
procedur
order
replac
transpos
ovari
i
origin
posit
incid
amenorrhea
end
treatment
prepubert
patient
time
ot
spontan
menarch
among
patient
attempt
obtain
pregnanc
ot
perform
period
pelvic
irradi
gy
rate
spontan
abort
endocrin
function
preserv
nulligest
evalu
patient
ovarian
reserv
alter
two
third
case
conclus
result
show
ot
cancer
treatment
possibl
safe
young
femal
includ
prepubert
preserv
ovarian
function
even
younger
patient
pregnanc
occur
spontan
even
without
resort
detransposit
studi
need
evalu
fertil
ot
perform
period
order
elabor
recommend
concern
indic
techniqu
e
michiel
f
van
j
van
g
children
hospit
pediatr
oncolog
rotterdam
netherland
backgroundobject
pediatr
cancer
patient
current
spend
time
home
studi
studi
pain
children
receiv
chemotherapi
outpati
clinicstherefor
object
studi
explor
children
experi
pain
receiv
chemotherapi
outpati
clinic
sever
pain
effect
qualiti
life
qol
designmethod
longitudin
observ
studi
children
visit
outpati
clinic
receiv
pain
questionnair
cover
last
day
first
day
follow
outpati
chemotherapi
administr
children
ask
complet
least
time
set
questionnair
minimum
time
set
questionnair
one
week
valid
brief
pain
inventori
dutch
version
use
children
age
year
parent
complet
questionnair
year
numer
rate
scale
use
measur
pain
intens
children
age
year
use
face
pain
demograph
data
use
pain
medic
effect
pain
qol
document
result
particip
complet
questionnair
diagnos
includ
lymphoma
brain
tumor
malign
questionnair
pain
report
children
clinic
signific
pain
defin
score
averag
pain
score
worst
pain
notic
patient
questionnair
percent
children
experienc
pain
least
measur
questionnair
clinic
signific
pain
report
analges
medic
use
higher
pain
score
pronounc
effect
qol
conclus
pain
still
preval
children
treat
outpati
set
effect
qol
signific
pain
treatment
still
suboptim
gupta
r
k
c
j
c
j
k
hospit
sick
children
haematologyoncolog
toronto
canada
clinic
evalu
scienc
cancer
research
program
toronto
canada
hospit
sick
children
paediatr
advanc
care
team
toronto
canada
hospit
eastern
ontario
pediatr
palli
care
outreach
team
ottawa
canada
health
scienc
centr
paediatr
haematologyoncolog
london
canada
region
health
centr
paediatr
oncolog
newmarket
canada
oncolog
group
ontario
pogo
research
unit
toronto
canada
institut
cancer
research
health
servic
research
program
toronto
canada
cancer
institut
pediatr
palli
care
boston
usa
backgroundobject
children
cancer
risk
receiv
hi
eol
care
associ
high
symptom
burden
impact
palli
care
pc
deliv
generalist
special
pediatr
palli
care
sppc
eol
care
pattern
unknown
previou
studi
limit
small
sampl
size
low
respons
rate
designmethod
assembl
retrospect
cohort
ontario
children
cancer
die
receiv
care
pediatr
institut
sppc
team
clinic
pc
databas
patient
link
healthcar
data
captur
inpati
outpati
emerg
visit
clinic
pc
databas
identifi
patient
receiv
sppc
remain
patient
categor
receiv
either
gener
pc
gpc
pc
depend
presenc
physician
bill
inpati
code
determin
predictor
sppc
involv
whether
either
sppc
gpc
associ
outcom
icu
admiss
day
death
mechan
ventil
day
death
hospit
death
sensit
analys
exclud
mortal
trm
case
result
patient
met
inclus
criteria
children
less
like
receiv
sppc
servic
includ
hematolog
cancer
odd
ratio
confid
interv
ci
p
lowest
incom
quintil
increas
distanc
treatment
center
p
multivari
analysi
sppc
associ
decreas
odd
eol
icu
admiss
gpc
impact
similar
associ
seen
indic
exclud
trm
littl
impact
conclus
sppc
gpc
associ
lower
intens
care
eol
access
sppc
remain
uneven
without
random
trial
result
provid
strongest
evid
date
support
creation
sppc
team
use
support
advocaci
polici
effort
g
bisogno
c
jh
c
z
h
h
v
minard
gl
de
padua
depart
pediatr
padova
itali
hospit
wale
heath
park
depart
pediatr
oncolog
cardiff
unit
kingdom
universitari
vall
dhebron
depart
pediatr
oncolog
barcelona
spain
institut
et
doncologi
lyon
franc
children
medic
center
depart
pediatr
oncolog
amsterdam
netherland
marsden
hospit
depart
paediatr
oncolog
london
unit
kingdom
nazional
dei
tumori
pediatr
oncolog
unit
milano
itali
fondazion
della
speranza
solid
tumor
laboratori
padova
itali
chirurgi
pari
franc
manchest
children
hospit
depart
pediatr
histopatholog
manchest
unit
kingdom
depart
paediatr
haematolog
oncolog
oslo
norway
gustav
roussi
depart
doncologi
de
lenfant
et
ladolesc
villejuif
franc
rappaport
children
hospit
pediatr
hematolog
oncolog
bone
marrow
transplant
divis
haifa
israel
ospedaliera
di
padova
depart
woman
child
health
padova
itali
oncologico
veneto
uo
sperimentazioni
biostatistica
e
nucleo
ricerca
clinica
padova
itali
backgroundobject
stratif
system
recent
close
protocol
factor
use
defin
risk
group
children
local
rm
assign
treatment
histolog
ir
group
nodal
involv
patient
age
tumor
site
size
valu
stratif
ad
fusion
statu
prepar
next
epssg
protocol
designmethod
total
patient
enrol
yr
follow
includ
analysi
initi
step
valid
current
system
examin
accuraci
discrimin
group
patient
differ
prognosi
follow
multivari
analysi
order
select
independ
prognost
variabl
final
role
fusion
statu
evalu
cohort
patient
avail
data
result
ef
low
standard
high
high
risk
group
respect
risk
factor
within
stratif
system
prognost
valu
within
univari
analysi
multivari
analysi
ir
group
tumor
site
identifi
independ
risk
factor
interact
tumor
size
patient
age
emerg
discrimin
patient
worst
prognosi
fusion
statu
includ
model
better
risk
determin
evid
conclus
current
stratif
system
demonstr
good
discrimin
calibr
new
cohort
patient
adopt
next
epssg
protocol
inclus
statu
instead
histolog
b
vaarwerk
c
mc
g
k
rr
van
jhm
children
hospit
academ
medic
centr
pediatr
oncolog
amsterdam
netherland
curi
depart
pediatr
adolesc
young
adult
oncolog
pari
franc
hospit
wale
depart
pediatr
oncolog
cardiff
unit
kingdom
univers
pediatr
hematolog
oncolog
divis
padova
itali
ormond
street
hospit
children
depart
radiolog
london
unit
kingdom
children
hospit
academ
medic
centr
pediatr
radiolog
amsterdam
netherland
backgroundobject
complet
treatment
patient
local
rhabdomyosarcoma
rm
subject
intens
radiolog
tumor
surveil
howev
clinic
signific
surveil
unclear
retrospect
analyz
valu
surveil
compar
surviv
patient
relaps
detect
routin
imag
patient
relaps
first
suspect
symptom
designmethod
studi
patient
relaps
rm
complet
treatment
local
rm
treat
larg
pediatr
oncolog
hospit
franc
netherland
unit
kingdom
itali
enrol
studi
surviv
time
relaps
compar
test
patient
relaps
detect
routin
imag
imag
group
patient
relaps
first
suspect
clinic
symptom
symptom
group
result
preliminari
data
patient
relaps
rm
treat
franc
netherland
reveal
patient
imag
group
patient
symptom
group
patient
miss
median
time
relaps
year
survivor
surviv
ci
patient
imag
group
patient
symptom
group
conclus
although
systemat
routin
imag
standard
care
treatment
rm
analys
indic
major
patient
relaps
rm
detect
clinic
symptom
furthermor
surviv
advantag
observ
patient
relaps
detect
emerg
clinic
symptom
preliminari
result
show
valu
surveil
controversi
particularli
sinc
repeat
imag
also
entail
potenti
harm
psycholog
impact
risk
anesthesia
final
result
includ
data
patient
unit
kingdom
itali
present
c
bergeron
jhm
h
v
j
ds
gian
b
institut
et
doncologi
lyon
franc
hospit
wale
depart
haematolog
oncolog
cardiff
unit
kingdom
universitari
vall
depart
pediatr
spain
children
medic
univers
depart
pediatr
oncolog
amsterdam
netherland
univers
hospit
depart
pediatr
adolesc
medicin
oslo
norway
ircc
istituto
nazional
tumori
pediatr
oncolog
unit
milano
itali
depart
lyon
franc
hospit
bristol
nh
foundat
trust
depart
paediatr
surgeri
bristol
unit
kingdom
gustav
roussi
doncologi
de
lenfant
et
ladolesc
villejuif
franc
marsden
nh
foundat
trust
children
young
peopl
unit
london
unit
kingdom
oncologico
veneto
ircc
clinic
trial
biostatist
unit
padova
itali
padova
pediatr
oncolog
divis
padova
itali
backgroundobject
evalu
reduct
burden
treatment
patient
enrol
epssg
rm
protocol
initi
microscop
complet
surgeri
embryon
rhabdomyosarcoma
erm
designmethod
patient
erm
initi
microscop
complet
resect
group
ln
neg
prospect
enrol
group
age
year
tumour
size
cm
group
b
age
year
tumour
size
cm
region
ln
investig
imag
without
systemat
surgic
sampl
group
patient
receiv
cours
vincristin
va
week
group
b
receiv
cours
ifosfamid
vincristin
iva
plu
va
total
week
radiotherapi
plan
os
ef
calcul
use
method
result
decemb
april
patient
male
enrol
studi
group
group
b
tumour
locat
non
uteru
vagina
vulva
extrem
head
neck
orbit
other
patholog
review
one
case
nodular
fasciiti
exclud
analysi
median
month
eight
relaps
occur
group
b
patient
older
year
paratesticular
tumour
three
die
diseas
yr
ef
os
ci
respect
group
group
b
conclus
erm
patient
treat
without
alkyl
agent
radiotherapi
excel
surviv
place
systemat
rplnd
andor
modern
imag
evalu
region
nodal
involv
patient
year
paratesticular
erm
requir
discuss
van
noesel
b
gl
de
n
r
g
center
pediatr
oncolog
dept
solid
tumor
utrecht
netherland
curi
pediatr
adolesc
young
adult
depart
pari
franc
manchest
children
hospit
pediatr
oncolog
manchest
unit
kingdom
data
centr
istituto
oncologico
veneto
ircc
data
centr
padova
itali
data
centr
istituto
oncologico
veneto
ircc
epssg
data
centr
padova
itali
esper
depart
pediatr
belgium
univers
patholog
depart
padova
itali
manchest
children
hospit
depart
patholog
manchest
unit
kingdom
univers
pediatr
hematolog
oncolog
divis
padova
itali
ircc
istituto
nazional
tumori
pediatr
oncolog
milan
itali
backgroundobject
mpnst
third
frequent
pediatr
soft
tissu
sarcoma
mpnst
associ
neurofibromatosi
type
retrospect
studi
show
poor
outcom
poor
respons
convent
chemotherapi
present
result
patient
local
mpnst
enrol
prospect
epssg
studi
risk
adapt
strategi
designmethod
cohort
local
mpnst
patient
european
countri
treat
treatment
group
surgic
group
cm
radiotherapi
group
gy
tumor
gy
tumor
periop
chemotherapi
group
chemotherapi
cours
ifosfamid
day
doxorubicin
day
result
stage
tumor
resect
resect
resect
evalu
patient
chemotherapi
respons
complet
cr
partial
pr
minor
mr
progress
total
respons
chemotherapi
cr
pr
mr
ef
surgic
group
radiat
group
periop
group
outcom
evalu
patient
median
month
aliv
cr
aliv
diseas
die
ef
ci
os
ci
diagnos
patient
conclus
outcom
pediatr
mpnst
patient
poor
result
prospect
inter
treatment
protocol
compar
slightli
better
histor
retrospect
studi
novel
treatment
strategi
necessari
improv
outcom
mpnst
modak
mp
n
p
j
nk
j
sloan
ketter
cancer
center
pediatr
new
york
usa
sloan
ketter
cancer
center
radiolog
new
york
usa
sloan
ketter
cancer
center
medic
physic
new
york
usa
backgroundobject
desmoplast
small
round
cell
tumor
dsrct
rare
sarcoma
adolesc
young
adult
surviv
despit
aggress
multimod
therapi
warrant
search
novel
treatment
murin
monoclon
antibodi
recogn
cell
surfac
antigen
bind
dsrct
restrict
normal
tissu
reactiv
dsrct
recurr
often
present
multifoc
periton
implant
hypothes
intraperiton
ip
radioimmunotherapi
rit
virtu
prolong
resid
time
slow
transfer
circul
may
select
target
ip
dsrct
designmethod
conduct
phase
studi
radioiodin
evalu
toxic
pharmacokinet
biodistribut
efficaci
cohort
patient
treat
escal
dose
ip
prior
dose
ip
use
acquir
pet
imag
biodistribut
data
toxic
monitor
clinic
biochem
pharmacokinet
studi
use
serial
blood
draw
result
dsrct
patient
treat
dose
maximum
toler
dose
reach
toxic
advers
event
transient
grade
transamin
neutropenia
thrombocytopenia
blood
periton
respect
mean
project
absorb
dose
blood
kidney
liver
lung
spleen
radmci
respect
patient
analyz
dehalogen
insignific
blood
remain
recommend
phase
ii
dose
surviv
pf
patient
undergo
gross
total
resect
follow
rit
radiotherapi
month
patient
surviv
pf
median
month
contrast
patient
gross
residu
diseas
pf
month
overal
surviv
also
better
former
p
conclus
success
determin
biodistribut
organ
exposur
ip
rit
satisfactori
safeti
profil
activ
dsrct
phase
ii
trial
commenc
shortli
orbach
v
b
f
g
gl
de
c
n
v
curi
pediatr
adolesc
young
adult
depart
pari
franc
curi
depart
biostatist
pari
franc
dhematologi
et
doncologi
centr
patholog
depart
lyon
franc
manchest
children
hospit
paediatr
oncolog
manchest
unit
kingdom
ircc
istituto
nazional
tumori
pediatr
oncolog
unit
milan
itali
de
biopathologi
bordeaux
franc
univers
pediatr
hematolog
oncolog
divis
padova
itali
istituto
oncologico
veneto
clinic
trial
biostatist
unit
padova
itali
dhematologi
et
doncologi
centr
pediatr
oncolog
lyon
franc
roussi
de
de
lenfant
et
de
ladolesc
villejuif
franc
manchest
children
hospit
depart
diagnost
paediatr
histopatholog
manchest
unit
kingdom
backgroundobject
genom
index
gi
tool
use
array
compar
genom
hybrid
acgh
tumor
cell
correl
genom
instabl
recent
develop
gi
emerg
independ
prognost
factor
associ
risk
metastat
relaps
adult
synovi
sarcoma
ss
aim
assess
role
gi
pediatr
patient
ss
designmethod
pediatricadolescentyoung
adult
year
local
ss
central
patholog
review
specif
fusion
transcript
prospect
includ
european
protocol
contribut
acgh
select
definit
gi
total
number
alter
segment
gain
loss
c
number
involv
chromosom
acgh
result
group
correspond
case
alter
flat
profil
group
case
mani
alter
complex
cgh
profil
result
sampl
avail
patient
median
age
cohort
year
rang
commonest
primari
site
extrem
patient
receiv
either
surgeri
adjuv
therapi
periop
therapi
surgeri
radiotherapi
summari
group
median
follow
month
rang
tumor
event
occur
patient
die
respect
vs
group
event
free
surviv
ef
rate
vs
p
free
surviv
mf
vs
p
multivari
analysi
gi
statu
adjust
site
tumor
size
remain
independ
prognost
ef
rel
risk
rr
p
rr
mf
conclus
gi
may
explain
aggress
behavior
pediatr
ss
although
tumor
event
rare
high
gi
select
patient
poorer
outcom
may
requir
therapi
intensif
futur
protocol
found
sourc
p
angelini
v
e
b
p
k
g
g
e
u
hospit
sick
children
haematologyoncolog
toronto
canada
goteborg
paediatr
haematolog
oncolog
goteborg
sweden
soleil
du
chu
du
quebec
paediatr
haematolog
oncolog
quebec
canada
padua
paediatr
haematolog
oncolog
padua
itali
univers
south
carolina
charleston
usa
new
south
wale
paediatr
haematolog
oncolog
sidney
australia
colleg
winsconsin
haematolog
oncolog
milwauke
usa
medic
centr
paediatr
haematolog
oncolog
sheba
israel
virginia
univers
paediatr
haematolog
oncolog
morgantown
usa
children
health
care
paediatr
haematolog
oncolog
madera
usa
children
hospit
depart
clinic
haematologyoncolog
north
adelaid
australia
medic
center
depart
pediatr
hematolog
oncolog
hamburg
germani
hospit
philadelphia
research
institut
philadelphia
usa
hospit
clevelan
medic
centr
oncolog
cleveland
usa
cancer
institut
paediatr
oncolog
milan
itali
hospit
pittsburgh
haematolog
adn
oncolog
pittsburgh
usa
health
scienc
univers
paediatr
haematolog
adn
oncolog
portland
usa
hospit
research
institut
manitoba
paediatr
haematolog
oncolog
winnipeg
canada
hospit
sick
children
toronto
canada
backgroundobject
biallel
mismatch
repair
diseas
bmmrd
aggress
cancer
predisposit
syndrom
patient
succumb
multipl
hypermut
cancer
childhood
sinc
hypermut
cancer
respond
immun
checkpoint
inhibitor
ici
treat
patient
recurr
hypermut
cancer
ici
assess
toxic
tumour
respons
surviv
designmethod
part
intern
bmmrd
consortium
collabor
bmmrd
patient
recurrentprogress
cancer
receiv
nivolumab
pembrolizumab
clinic
data
prospect
collect
tumour
mutat
analysi
format
analysi
perform
result
twenti
patient
male
median
age
start
ici
year
cancer
receiv
ici
tumor
hypermut
nine
patient
develop
acut
flare
symptom
follow
first
ici
administr
includ
patient
brain
tumor
heavi
burden
diseas
one
bone
metastasi
colon
cancer
patient
requir
steroid
use
die
within
day
week
first
administr
patient
develop
autoimmun
phenomena
relat
ici
patient
evid
diseas
object
respons
observ
brain
tumor
metastat
tumour
one
year
surviv
whole
cohort
glioma
patient
solid
tumor
aliv
continu
respons
median
month
patient
still
aliv
therapi
conclus
first
cohort
prospect
follow
patient
bmmrd
hypermut
cancer
treat
ici
encourag
initi
respons
prolong
surviv
cohort
warrant
prospect
genet
base
studi
ici
children
role
flare
reaction
follow
initi
treatment
need
investig
cf
c
f
e
g
b
e
biagi
center
tettamanti
pediatr
oncolog
monza
mb
itali
raffael
telethon
institut
gene
therapi
safeti
gene
therapi
insert
mutagenesi
research
unit
milan
itali
backgroundobject
adopt
transfer
autolog
chimer
antigen
receptor
car
cell
engin
viral
vector
demonstr
unexpect
posit
result
achiev
durabl
respons
relaps
refractori
patient
affect
leukemia
recent
establish
platform
gene
manipul
killer
cik
cell
complianc
good
manufactur
practic
gmp
studi
evalu
feasibl
reproduc
protocol
preclin
efficaci
safeti
sb
modifi
cell
designmethod
improv
sb
transposon
platform
genet
modifi
cik
cell
express
car
specif
acut
lymphoblast
leukemia
blast
evalu
preclin
efficaci
safeti
vitro
vivo
result
larg
scale
manufactur
process
verifi
start
ml
peripher
blood
altern
pbmc
isol
buffi
coat
reach
stabl
express
modifi
cell
display
specif
effect
cytotox
product
prolifer
toward
primari
tumor
manufactur
three
lot
academ
cell
factori
author
agenzia
italiana
del
farmaco
median
express
cell
rang
cell
show
antitumor
respons
persist
xenograft
mous
model
common
bear
featur
gene
rearrang
surviv
model
lymphoma
cell
induc
complet
erad
dissemin
tumor
infus
cell
prove
safe
well
toler
infus
cell
persist
time
hematopoiet
perfus
organ
highli
polyclon
distribut
integr
site
cell
product
demonstr
conclus
may
offer
valid
sustain
altern
viral
approach
patient
rr
b
cell
malign
hsct
studi
provid
design
phase
iii
studi
relaps
refractori
post
hematopoiet
stem
cell
transplant
n
turazzi
g
v
g
cf
e
tettamanti
reserach
univers
milano
bicocca
sgerardo
hospitalfondazion
mbbm
depart
pediatr
monza
itali
basel
depart
biomedicin
basel
switzerland
backgroundobject
acut
lymphoblast
leukemia
common
malign
children
approach
pave
way
treatment
relapsedrefractori
howev
emerg
relaps
treat
patient
report
receptor
activ
factor
fundament
matur
surviv
express
restrict
matur
b
cell
precursor
plasmablast
recent
studi
report
malign
includ
moreov
leukem
cell
express
baff
suggest
autocrin
signal
loop
baff
also
express
leukem
nich
support
prolifer
surviv
blast
studi
aim
develop
chimer
antigen
receptor
car
approach
target
molecul
designmethod
target
molecul
develop
differ
invers
vh
vl
length
spacer
domain
killer
cik
cell
heterogen
popul
enrich
highli
cytotox
cell
engin
improv
sleep
beauti
platform
use
effector
popul
result
show
express
primari
sampl
maintain
relaps
stabli
express
shortest
vhvlcar
exert
highest
activ
averag
cytokin
releas
produc
cell
toward
vitro
importantli
detect
specif
lysi
primari
blast
combin
invshcar
detect
superior
activ
toward
primari
blast
lysi
respect
compar
singl
popul
per
se
furthermor
demonstr
abil
invshcar
lysat
blast
collect
relaps
conclus
taken
togeth
find
make
receptor
safe
attract
target
second
line
immunotherapi
case
relaps
doubl
target
approach
mc
cf
c
e
biagi
center
tettamanti
pediatr
clinic
monza
mb
itali
backgroundobject
acut
myeloid
leukemia
aml
still
associ
dismal
prognosi
immunotherapi
employ
cell
redirect
chimer
antigen
receptor
car
could
repres
valid
altern
current
strategi
broadli
express
aml
blast
repres
suitabl
antigen
target
cell
aim
studi
preclin
evalu
efficaci
safeti
profil
redirect
cytokin
induc
killer
cik
cell
alon
combin
standard
chemotherapeut
agent
designmethod
gener
cik
cell
non
viral
transposon
system
start
healthi
mononuclear
cell
primari
aml
sampl
vitro
activ
cell
assess
cytotox
prolifer
cytokin
product
assay
upon
challeng
aml
sampl
vivo
efficaci
cik
cell
evalu
nsg
mice
transplant
aml
cell
primari
sampl
moreov
investig
potenti
benefit
combin
cik
cell
standard
aml
induct
therapi
result
cell
result
potent
activ
term
specif
kill
prolifer
cytokin
product
observ
alreadi
establish
induct
protocol
significantli
reduc
leukem
burden
around
bone
marrow
cell
graft
mice
sinc
diseas
total
erad
current
investig
efficaci
cell
chemotherapi
resistantresidu
aml
cell
preliminari
data
shown
surviv
advantag
ad
cell
top
chemotherapi
conclus
demonstr
vitro
activ
cell
aim
evalu
efficaci
vivo
chemotherapi
resistantresidu
aml
cell
corrobor
initi
observ
envisag
safer
clinic
translat
transient
car
express
mrna
investig
limit
potenti
effect
normal
hematopoiet
stemmyeloid
progenitor
cell
j
fisher
p
nd
wisidagamag
j
institut
child
health
cancer
section
london
unit
kingdom
backgroundobject
toxic
constrain
develop
immunotherapi
target
highli
express
tumour
antigen
produc
challeng
sometim
fatal
toxic
strength
chimer
antigen
receptor
express
cell
also
limit
offer
escap
healthi
cell
cell
differenti
healthi
transform
cell
manner
determin
differ
express
phosphoantigen
stress
versu
healthi
cell
nativ
tcr
therefor
redund
tumour
context
need
replac
artifici
construct
sought
determin
efficaci
safeti
cell
express
car
model
designmethod
demonstr
lack
toxic
car
express
cell
compar
convent
second
gener
car
cytotox
aml
cell
line
healthi
myeloid
cell
myeloid
progenitor
assess
phenotyp
assess
flow
cytometri
secondari
expans
potenti
determin
irradi
target
cell
mechanist
inform
obtain
use
system
determin
cytokin
product
signal
profil
phosflow
follow
stimulu
car
result
cell
express
car
retain
cytotox
show
activ
healthi
cell
engag
clinic
use
number
cell
gener
blood
draw
precis
control
cytokin
product
activatori
signal
achiev
select
stimulu
car
andor
tcr
car
express
cell
phenotyp
favour
adopt
transfer
significantli
lower
exhaust
marker
express
cell
express
convent
car
capabl
mount
secondari
expans
follow
antigen
conclus
approach
offer
mean
safe
recapitul
immunotherapi
tumour
antigen
previous
reject
ground
toxic
k
pda
hospit
mannheim
institut
patholog
mannheim
germani
background
object
background
rhabdomyosarcoma
rm
common
soft
tissu
malign
childhood
adolesc
outcom
children
advanc
rm
still
poor
immunotherapi
may
offer
new
perspect
patient
design
method
object
reveal
tumor
resist
mechan
rm
cell
line
rm
redirect
cytotox
cell
express
chimer
antigen
receptor
car
specif
fetal
acetylcholin
receptor
fachr
almost
tumor
associ
antigen
use
futhermor
sensit
rm
tumor
cell
cytokin
induc
killer
cell
cik
nk
cell
test
method
chimer
ctc
gener
retrovir
transduct
peripher
blood
lymphocyt
fachr
specif
car
cik
nk
cell
enrich
cultiv
kill
effici
name
immun
cell
surviv
rm
cell
determin
apoptosi
test
rm
check
express
gene
immunosuppress
well
receptor
use
fac
western
blot
result
fachr
specif
chimer
show
rm
tumor
cell
lysi
vitro
vivo
less
effici
rm
cell
resist
trail
molecular
featur
associ
resist
rm
ctc
lack
essenti
costimul
tumour
cell
interact
express
inhibitori
molecul
like
b
inhibitor
apoptosi
iap
famili
member
rm
cell
tissu
inhibit
iap
sirna
pharmacolog
substanc
improv
kill
effici
chimer
cell
vitro
vivo
mention
resist
mechan
spontan
circumv
cik
nk
cell
rm
cell
highli
sensit
conclus
blockad
mechan
use
nk
cik
therapeut
strategi
well
chimer
cell
evalu
therapeut
strategi
rm
sultan
k
r
v
montreal
canada
de
psycholog
canada
backgroundobject
parent
children
treat
cancer
vulner
varieti
issu
includ
heighten
distress
lack
control
distress
treatment
identifi
risk
factor
futur
distress
increas
difficulti
famili
child
long
run
help
parent
treatment
manual
intervent
develop
appli
populationthi
present
identifi
review
critic
exist
manual
intervent
concentr
program
develop
process
criteria
qualiti
psycholog
treatment
identifi
previou
achiev
well
avenu
futur
improv
designmethod
systemat
search
run
databas
electron
manual
identifi
exist
program
correspond
inclus
criteria
orbit
framework
use
evalu
compar
program
develop
process
criteria
apa
task
forc
psycholog
treatment
use
evalu
consist
coher
program
result
ten
manual
intervent
report
identifi
code
program
yield
clinic
effect
eg
bright
idea
sccip
analysi
reveal
lack
clinic
signal
may
due
varieti
factor
subset
program
lack
precis
concept
definit
explicit
model
chang
defin
target
social
valid
accept
seldom
document
prior
efficaci
test
importantli
dosag
treatment
intens
never
systemat
studi
conclus
fine
methodolog
design
necessari
program
test
suffici
appropri
program
develop
systemat
psychosoci
intervent
help
parent
build
one
anoth
therefor
explicitli
refer
sound
model
chang
model
chang
also
translat
clearli
format
tool
interact
style
program
futur
program
also
address
underserv
popul
eg
father
optim
contact
rate
eg
initi
scheper
k
jude
children
research
hospit
psycholog
memphi
usa
backgroundobject
pediatr
cancer
diagnosi
challeng
event
may
impact
children
parent
perceiv
relationship
aim
studi
examin
possibl
differ
child
parent
percept
parent
childhood
cancer
survivor
healthi
peer
b
determin
concord
child
parent
percept
parent
designmethod
particip
children
age
year
children
histori
cancer
healthi
peer
one
parent
patient
year
diagnosi
children
parent
bond
instrument
pbi
parent
parent
relationship
questionnair
prq
report
percept
parent
two
separ
mancova
pbi
prq
conduct
determin
possibl
differ
cancer
comparison
group
control
child
agegend
parent
sesgend
concord
pbi
scale
parent
care
overprotect
prq
scale
involv
attach
commun
parent
confid
relat
frustrat
assess
pearson
correl
coeffici
result
survivor
childhood
cancer
parent
differ
percept
parent
compar
healthi
peer
magnitud
effect
dyad
significantli
differ
childhood
cancer
survivor
healthi
peer
child
report
care
relationship
posit
significantli
associ
involv
attach
commun
parent
confid
r
rang
neg
associ
relat
frustrat
children
perceiv
parent
overprotect
parent
report
significantli
relat
frustrat
conclus
histori
childhood
cancer
appear
influenc
parent
behavior
perceiv
children
parent
howev
children
experienc
parent
overprotect
frustrat
relationship
might
warrant
futur
intervent
lmh
steur
n
nka
van
im
van
der
dwmw
te
c
van
den
wje
gjl
rrl
univers
medic
center
depart
pediatr
oncologyhematolog
amsterdam
netherland
center
pediatr
oncolog
utrecht
netherland
children
hospit
academ
medic
center
psychosoci
depart
amsterdam
netherland
children
hospit
erasmu
medic
center
depart
pediatr
oncolog
rotterdam
netherland
children
hospit
radboud
univers
medic
center
depart
pediatr
oncolog
nijmegen
netherland
children
hospit
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
children
hospit
univers
medic
center
groningen
depart
pediatr
oncolog
groningen
netherland
childhood
oncolog
group
hagu
netherland
backgroundobject
parent
child
qualiti
life
qol
bidirect
relat
improv
qol
famili
parent
function
also
address
studi
aim
describ
parent
qol
sleep
distress
investig
predictor
parent
qol
childhood
designmethod
parent
children
age
year
treat
accord
dutch
childhood
oncolog
group
treatment
protocol
includ
expect
final
sampl
size
parent
function
qol
sleep
distress
assess
shortli
end
induct
treatment
questionnair
short
medic
outcom
studi
sleep
scale
distress
thermomet
score
compar
healthi
norm
sleep
score
standard
deviat
sd
differ
norm
reflect
clinic
relev
distress
score
higher
indic
clinic
distress
predictor
parent
qol
select
backward
regress
analys
result
nineti
parent
mean
age
year
mother
children
mean
age
year
girl
includ
respons
rate
parent
report
significantli
lower
mental
qol
overal
sleep
problem
distress
p
physic
qol
differ
norm
clinic
relev
lower
mental
qol
found
sd
sd
parent
clinic
relev
sleep
problem
sd
sd
compar
healthi
norm
respect
clinic
distress
present
parent
compar
norm
lower
child
age
higher
parent
age
parent
sleep
problem
parent
distress
predict
lower
mental
qol
explain
varianc
male
child
gender
child
sleep
problem
predict
lower
physic
qol
explain
varianc
conclus
parent
children
risk
lower
qol
impair
psychosoci
function
aim
improv
function
whole
famili
intervent
target
parent
risk
warrant
acknowledg
grant
sponsor
dutch
cancer
societi
b
maru
e
f
p
k
sick
children
psycholog
toronto
canada
health
network
biostatist
toronto
canada
children
hospit
psycholog
calgari
canada
sick
children
haematologyoncolog
toronto
canada
sick
children
pscyholog
toronto
canada
backgroundobject
pediatr
cancer
diagnosi
treatment
affect
psycholog
adjust
parent
healthi
sibl
systemat
rigor
assess
intervent
target
psychosoci
need
sibl
rare
object
assess
effect
manual
group
intervent
sibl
cope
togeth
sct
sibl
parent
adjust
explor
factor
relat
intervent
effect
designmethod
conduct
block
random
control
trial
rct
two
arm
experiment
arm
eg
attent
control
group
cg
healthi
sibl
averag
age
year
rang
children
cancer
month
diagnosi
particip
group
eight
weekli
session
eg
follow
sct
educ
social
therapeut
plan
game
craft
cg
consist
game
craft
sibl
symptom
depress
anxieti
parent
symptom
anxieti
baselin
intervent
end
month
later
multivari
analys
mix
effect
model
use
examin
intervent
effect
time
control
covari
eg
gender
onoff
ill
child
treatment
result
signific
group
gender
interact
total
depress
score
indic
femal
sibl
eg
report
significantli
lower
score
girl
cg
across
time
p
also
case
subscal
ineffect
p
anhedonia
p
signific
differ
group
gender
interact
also
found
total
anxieti
score
parent
p
parent
femal
eg
report
lower
score
equival
parent
cg
conclus
group
intervent
sibl
children
cancer
result
improv
psycholog
adjust
sibl
parent
particularli
sibl
femal
research
fund
canadian
network
barrera
e
p
f
k
sick
children
psycholog
toronto
canada
health
network
biostatist
toronto
canada
sick
children
heamatologyoncolog
toronto
canada
children
hospit
psycholog
calgari
canada
backgroundobject
pediatr
cancer
diagnosi
treatment
result
reduc
qualiti
life
qol
healthi
sibl
intervent
target
sibl
qol
rigor
examin
intervent
lack
object
assess
efficaci
manual
group
intervent
eg
sibl
cope
togeth
sct
sibl
qualiti
life
compar
attent
control
group
cg
identifi
factor
relat
intervent
effect
designmethod
conduct
random
control
trial
rct
two
arm
eg
cg
healthi
sibl
averag
age
year
rang
children
cancer
month
diagnosi
particip
eg
follow
sct
educ
social
therapeut
plan
game
craft
cg
consist
game
craft
proxi
report
pediatr
qualiti
life
questionnair
pedsql
complet
baselin
end
intervent
month
later
total
subscal
score
gener
multivari
analys
mix
effect
model
use
examin
intervent
effect
time
control
covari
eg
gender
result
improv
pedsql
proxi
score
total
subscal
note
time
group
p
respect
sibl
eg
report
significantli
better
school
pedsql
score
overal
sibl
cg
vs
p
effect
signific
group
gender
interact
proxi
school
pedsql
score
indic
compar
eg
girl
cg
rate
wors
score
p
conclus
particip
group
sibl
children
cancer
result
improv
overal
qol
howev
particip
specif
group
intervent
address
sibl
need
improv
school
qol
particularli
femal
challeng
research
need
address
research
fund
canadian
network
l
edward
royal
marsden
nh
foundat
trust
paediatr
psycholog
support
sutton
unit
kingdom
backgroundobject
aim
project
complet
develop
valid
brief
psychosoci
memori
distress
thermomet
dt
use
paediatricyoung
adult
cancer
patient
designmethod
tool
version
screen
tool
develop
five
along
accompani
parent
proxi
version
pilot
pilot
studi
carri
patient
parent
test
accept
usabl
tool
amend
made
tool
accord
feedback
valid
cross
section
questionnair
project
conduct
collabor
paediatr
oncolog
centr
particip
child
patient
parent
proxi
valid
dt
strength
difficulti
questionnair
sdq
hospit
anxieti
depress
scale
had
psycholog
distress
health
util
index
memori
learn
valid
paediatr
qualiti
life
scale
pedsql
result
use
sensit
sdq
age
group
rang
had
specif
rang
sdq
plu
specif
had
sensit
age
group
sensit
conclus
dt
valid
accept
use
rapid
screen
instrument
paediatr
cancer
patient
uk
result
indic
use
monitor
chang
psycholog
distress
memori
problem
time
recommend
work
determin
use
tool
clinic
screen
tool
research
project
approv
royal
marsden
research
develop
committe
surrey
border
ethic
committe
mrec
jayasingh
l
c
k
h
g
h
f
p
l
l
children
hospit
gynaecolog
melbourn
australia
children
hospit
children
cancer
centr
melbourn
australia
children
hospit
endocrinolog
melbourn
australia
melbourn
obstetr
gynaecolog
melbourn
australia
univers
hospit
endocrinolog
singapor
singapor
women
hospit
reproduct
servic
melbourn
australia
children
hospit
androlog
melbourn
australia
children
hospit
surgeri
melbourn
australia
univers
medicin
melbourn
australia
ivf
clinic
research
melbourn
australia
children
hospit
clinic
ethic
servic
melbourn
australia
backgroundobject
littl
publish
data
regard
fertil
preserv
paediatr
popul
includ
data
famili
feel
regret
accept
fertil
decis
aim
describ
uptak
fertil
preserv
procedur
royal
children
hospit
melbourn
sinc
impact
decis
regret
famili
designmethod
bidirect
cohort
studi
august
introduc
formalis
oncofertil
servic
three
level
govern
novel
technolog
research
clinic
ethic
govern
oncofertil
data
record
fertil
preserv
databas
famili
complet
valid
decis
regret
scale
regard
fertil
decis
score
repres
high
regret
result
three
hundr
ten
patient
underw
fertil
preserv
procedur
mean
age
year
rang
year
male
procedur
occur
includ
ovarian
tissu
preserv
follicl
densiti
patient
matur
oocyt
within
tissu
testicular
tissu
preserv
matur
sperm
within
tissu
sperm
cryopreserv
oocyt
collect
gnrh
analogu
alon
invas
procedur
done
moder
high
risk
infertil
minor
complic
occur
delay
cancer
treatment
one
hundr
thirti
eight
particip
parent
patient
complet
decision
regret
survey
report
low
regret
mean
score
sd
rang
fertil
preserv
procedur
independ
predictor
low
regret
p
ci
expect
posit
fertil
outcom
within
next
gener
high
conclus
paediatr
fertil
preserv
procedur
safe
associ
low
regret
famili
demand
steadili
increas
import
provid
accur
transpar
realist
inform
support
famili
prior
diagnosi
throughout
survivorship
c
wakefield
e
c
k
j
r
nsw
school
women
children
health
sydney
australia
cancer
centr
sydney
children
hospit
sydney
australia
wale
hospit
hereditari
cancer
clinic
sydney
australia
cancer
institut
depart
psychosoci
oncolog
palli
care
boston
usa
backgroundobject
despit
increas
recognit
potenti
role
genet
risk
assess
childhood
cancer
survivorship
need
survivor
famili
understudi
studi
assess
survivor
parent
belief
caus
cancer
causal
attribut
servic
use
futur
servic
need
unmet
inform
need
designmethod
particip
survivor
parent
survivor
complet
questionnair
option
interview
use
multipl
logist
regress
determin
clinicaldemograph
associ
perceiv
import
access
geneticist
unmet
inform
need
result
survivor
offer
genet
test
chose
undergo
test
offer
genet
test
total
sampl
survivor
parent
endors
genet
run
famili
caus
cancer
particip
indic
import
import
receiv
inform
survivorship
care
survivor
parent
indic
import
access
genet
specialist
survivor
parent
indic
unmet
need
genet
inform
relat
cancer
survivor
greater
fear
cancer
recurr
longer
time
sinc
diagnosi
associ
greater
likelihood
indic
access
genet
counsellorgeneticist
import
particip
believ
cancer
genet
greater
fear
recurr
like
unmet
inform
need
survivor
satisfi
care
less
like
indic
unmet
inform
need
unsatisfi
conclus
find
suggest
survivor
parent
need
servic
inform
larg
unmet
meet
need
use
innov
model
care
may
improv
satisfact
survivorship
care
yt
cheung
nd
da
kk
mj
tm
p
mm
kr
jude
children
research
hospit
epidemiolog
cancer
control
memphi
usa
jude
children
research
hospit
diagnost
imag
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
radiat
oncolog
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
backgroundobject
compar
neurocognit
function
survivor
hodgkin
lymphoma
hl
commun
control
examin
associ
pulmonari
deficit
cardiac
abnorm
designmethod
hl
survivor
treat
thorac
radiat
mean
sd
age
year
year
control
complet
neuropsycholog
test
compar
group
systemat
grade
pulmonari
deficit
obstruct
restrict
diffus
deficit
cardiac
abnorm
structur
function
defect
arrhythmia
conduct
analyz
predictor
neurocognit
function
use
gener
linear
model
adjust
age
analys
stratifi
examin
effect
smoke
neurocognit
function
survivor
withwithout
morbid
result
survivor
perform
poorer
control
mean
sd
v
recal
v
sustain
attent
v
process
speed
v
moder
disabl
pulmonari
deficit
cardiac
abnorm
present
survivor
survivor
pulmonari
deficit
perform
wors
survivor
without
morbid
sustain
attent
v
visual
process
speed
v
process
speed
v
cardiac
abnorm
associ
neurocognit
function
survivor
without
pulmonari
deficit
current
smoker
impair
smoker
p
survivor
pulmonari
deficit
smoke
contribut
wors
perform
conclus
roughli
year
survivor
hl
wors
neurocognit
outcom
control
pulmonari
deficit
smoke
associ
wors
outcom
futur
work
evalu
impact
pulmonari
insuffici
neurocognit
outcom
hl
survivor
educ
neurocognit
effect
smoke
c
wakefield
v
e
j
k
k
r
c
g
r
nsw
school
women
children
health
sydney
australia
cancer
centr
sydney
children
hospit
sydney
australia
wale
hospit
depart
medic
oncolog
sydney
australia
cancer
institut
depart
psychosoci
oncolog
palli
care
boston
usa
cancer
institut
lowi
cancer
research
centr
sydney
australia
backgroundobject
use
xenograft
pdx
assess
chemosensit
agent
may
improv
child
cancer
care
potenti
enabl
individu
clinic
howev
unknown
whether
applic
new
methodolog
clinic
practic
meet
wider
commun
accept
studi
particip
investig
accept
pdx
affect
childhood
cancer
commun
designmethod
stage
identifi
commonli
perceiv
advantagesdisadvantag
pdx
individu
affect
childhood
cancer
survivor
parent
stage
interview
individu
survivor
parent
survivor
survey
match
commun
member
young
adult
parent
issu
highlight
stage
comput
regress
identifi
factor
influenc
accept
result
accept
number
mice
use
result
pdx
highli
accept
affect
cancer
lean
toward
use
pdx
commun
particip
survivor
survivor
parent
will
use
pdx
will
pay
p
wait
longer
sacrific
mice
commun
particip
remain
high
survivorssurvivor
parent
consid
pdx
disadvantag
commun
particip
higher
would
pay
use
mice
consid
child
rather
better
understand
predict
higher
increas
harm
anim
least
endors
disadvantag
conclus
although
clinic
efficaci
pdx
yet
establish
consent
rate
like
high
pdx
use
clinic
practic
especi
patient
child
maximum
accept
number
mice
align
well
plan
usag
although
maximum
accept
lower
like
clinic
achiev
r
foster
r
w
c
r
dk
k
w
l
g
k
k
loui
children
hospit
depart
psycholog
st
loui
mo
usa
univers
school
medicin
depart
pediatr
st
loui
mo
usa
jude
children
research
hospit
depart
biostatist
memphi
tn
usa
texa
md
anderson
cancer
center
depart
radiat
physic
houston
tx
usa
jude
children
research
hospit
depart
epidemiolog
cancer
control
memphi
tn
usa
sloan
ketter
cancer
center
depart
pediatr
intern
medicin
new
york
ny
usa
hutchinson
cancer
research
center
clinic
research
divis
wa
usa
nation
health
system
neuropsycholog
divis
washington
dc
usa
washington
univers
school
medicin
depart
psychiatri
behavior
scienc
pediatr
washington
dc
usa
backgroundobject
studi
aim
identifi
social
problem
among
adolesc
survivor
wilm
tumor
wt
determin
whether
treatment
exposur
chronic
health
condit
psycholog
concern
relat
peer
interact
frequenc
qualiti
designmethod
childhood
cancer
survivor
studi
ccss
analyz
survivor
wt
diagnos
median
rang
age
year
time
sinc
year
age
year
sibl
survivor
overal
ccss
cohort
year
survivor
compar
sibl
frequenc
qualiti
peer
interact
behavior
problem
inventori
bpi
adjust
race
household
incom
survivor
treatment
exposur
chronic
medic
condit
ctcae
psycholog
outcom
bpi
examin
via
multinomi
logist
regress
adjust
sex
race
household
incom
age
diagnosi
calcul
adjust
rel
risk
arr
confid
interv
ci
result
compar
sibl
fewer
survivor
report
zero
one
friend
vs
howev
survivor
rate
greater
difficulti
get
along
friend
p
survivor
anxietydepress
ci
headstrong
behavior
ci
attent
problem
ci
social
withdraw
ci
fewer
friend
compar
survivor
without
problem
survivor
antisoci
behavior
ci
anxietydepress
ci
headstrong
behavior
ci
attent
problem
ci
social
withdraw
ci
describ
greater
difficulti
get
along
friend
compar
survivor
without
problem
treatment
exposur
eg
chemotherapi
radiat
endocrin
cardiovascular
problem
impact
number
friend
time
spent
friend
abil
get
along
friend
conclus
despit
multipl
friendship
relationship
qualiti
adolesc
survivor
wt
appear
wors
sibl
adolesc
survivor
requir
support
develop
social
skill
enhanc
relationship
qualiti
lmh
steur
nka
van
im
van
der
dwmw
te
c
van
den
wje
gjl
rrl
univers
medic
center
depart
pediatr
oncologyhematolog
amsterdam
netherland
center
pediatr
oncolog
utrecht
netherland
children
hospit
academ
medic
center
psychosoci
depart
amsterdam
netherland
children
hospit
erasmu
medic
center
depart
pediatr
oncolog
rotterdam
netherland
children
hospit
radboud
univers
medic
center
depart
pediatr
oncolog
nijmegen
netherland
children
hospit
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
children
hospit
univers
medic
center
groningen
depart
pediatr
oncolog
groningen
netherland
childhood
oncolog
group
hagu
netherland
backgroundobject
sleep
may
predictor
qualiti
life
qol
fatigu
children
acut
lymphoblast
leukemia
studi
aim
investig
extent
sleep
problem
relat
qol
fatigu
children
treatment
designmethod
patient
age
year
treat
accord
dutch
childhood
oncolog
group
treatment
protocol
includ
expect
final
sampl
size
sleep
qol
fatigu
assess
shortli
end
induct
treatment
questionnair
children
sleep
habit
questionnair
pediatr
qualiti
life
inventori
gener
multidimension
fatigu
scale
addit
sleep
object
measur
use
actigraphi
calcul
total
sleep
questionnair
score
use
healthi
norm
score
exceed
reflect
clinic
relev
actigraphi
outcom
sleep
durat
sleep
effici
wake
sleep
onset
waso
compar
norm
regress
model
construct
associ
sleep
qol
fatigu
result
children
mean
age
year
girl
includ
respons
rate
questionnair
assess
children
actigraphi
data
avail
children
clinic
relev
sleep
problem
found
patient
compar
healthi
norm
respect
patient
longer
sleep
durat
versu
minut
p
lower
sleep
effici
versu
waso
versu
minut
p
adjust
sleep
problem
gender
sleep
problem
significantli
associ
lower
b
ci
psychosoci
qol
b
ci
b
ci
b
ci
cognit
fatigu
b
ci
conclus
clinic
relev
sleep
problem
common
treatment
neg
associ
qol
fatigu
intervent
studi
aim
improv
sleep
need
improv
qol
fatigu
children
acknowledg
grant
sponsor
dutch
cancer
societi
n
k
viswanathan
mission
hospit
research
center
pediatr
madurai
india
backgroundobject
adult
chronic
hepat
c
viru
hcv
infect
outcom
dramat
improv
directli
act
antivir
agent
daa
like
sofosbuvir
data
guidelin
use
daa
children
year
age
object
studi
analyz
efficaci
safeti
therapi
children
malign
hcv
infect
refractori
alfa
plu
ribavirin
designmethod
cohort
includ
children
cancer
genotyp
hcv
infect
fail
standard
treatment
plu
ribavirin
twelv
chemotherapi
treat
patient
receiv
tripl
drug
combin
fix
dose
mg
po
daili
weekli
sc
inj
ribavirin
mgkgday
dose
week
hcv
titer
follow
week
start
treatment
result
thirteen
children
chronic
hcv
infect
genotyp
treat
femal
median
age
year
rang
underli
malign
b
burkitt
lymphoma
hodgkin
lymphoma
viral
load
diagnosi
rang
million
iuml
sustain
virolog
respons
svr
defin
neg
hcv
rna
week
complet
treatment
achiev
patient
evalu
svr
one
patient
die
within
month
due
progress
malign
one
lost
week
median
month
rang
one
patient
oral
aphthou
ulcer
requir
interrupt
alon
week
patient
grade
neutropenia
signific
elev
ast
alt
therapi
conclus
sofosbuvir
contain
tripl
drug
therapi
effect
safe
treatment
hcv
infect
children
malign
g
naidu
r
b
sa
witwatersrand
chri
hani
baragwanath
academ
hospit
paediatr
johannesburg
south
africa
research
mening
respiratori
pathogen
research
univers
witwatersrand
johannesburg
south
africa
research
depart
scienc
nation
research
foundat
vaccin
prevent
faculti
health
nation
institut
communic
divis
nation
health
laboratori
mening
respiratori
pathogen
research
univers
witwatersrand
johannesburg
south
africa
backgroundobject
introduct
treatment
cancer
children
challeng
therapi
compromis
alreadi
state
aim
studi
establish
infecti
complic
children
treat
nhl
protocol
designmethod
method
hospit
record
children
nhl
review
age
hiv
statu
count
hiv
viral
load
cancer
stage
sex
anthropometri
record
temperatur
durat
fever
white
cell
count
neutrophil
lymphocyt
monocyt
count
blood
cultur
clinic
syndrom
record
septic
episod
result
children
nhl
male
median
age
month
septic
episod
child
year
among
children
children
p
incid
bacteraemia
vs
p
bacteraemia
vs
p
pneumonia
vs
p
tuberculosi
vs
p
invas
fungal
infect
vs
compar
cohort
mean
maximum
temperatur
higher
children
longer
durat
neutropenia
p
lymphopenia
p
children
ten
cohort
die
sepsi
stage
diseas
load
rna
copiesml
multipl
pathogen
isol
children
die
includ
resist
bacteria
pneumonia
conclus
arv
reduc
mortal
morbid
patient
lymphoma
remain
major
issu
use
chemotherapi
patient
result
increas
rate
infect
children
hiv
surviv
longer
due
better
antiretrovir
support
therapi
malign
may
becom
increasingli
common
problem
p
jain
v
v
n
ganga
ram
delhi
pediatr
hematolog
oncolog
bmt
unit
delhi
india
backgroundobject
febril
respiratori
ill
fri
common
immunocompromis
children
receiv
treatment
malign
data
viral
respiratori
pathogen
caus
febril
neutropenia
limit
etiolog
signific
respiratori
viru
detect
impact
hospit
stay
antibiot
use
evalu
designmethod
immunocompromis
children
age
receiv
treatment
pediatr
oncolog
unit
present
fri
prospect
analys
children
evalu
clinic
respiratori
secret
obtain
detect
virus
bacteria
polymeras
chain
reaction
result
total
episod
evalu
elig
children
treat
male
femal
ratio
median
age
year
cough
common
respiratori
symptom
associ
tachypnoea
atleast
one
respiratori
pathogen
identifi
sampl
test
posit
dual
respiratori
pathogen
common
isol
follow
other
coronaviru
bocaviru
influenzaviru
respiratori
bacteria
adenoviru
febril
neutropenia
fn
present
total
fri
episod
viral
respiratori
pathogen
identifi
etiolog
febril
neutropen
episod
cultur
posit
sepsi
underli
caus
detect
caus
fn
could
identifi
durat
hospitalis
significantli
shorter
sole
respiratori
pathogen
etiolog
fn
compar
sepsi
p
children
could
manag
lesser
number
antibiot
compar
caus
fn
establish
mortal
compar
children
sepsi
underli
caus
conclus
respiratori
virus
common
fri
febril
neutropenia
isol
respiratori
viru
minim
antibiot
use
hospit
stay
k
bansal
r
institut
medic
educ
research
pediatr
dept
advanc
pediatr
centr
chandigarh
india
institut
medic
educ
research
dept
advanc
pediatr
centr
chandigarh
india
backgroundobject
access
often
lack
develop
countri
evalu
administ
safe
extend
hydrationleucovorin
rescu
monitor
designmethod
prospect
studi
mtx
infus
administ
patient
b
allnhl
respect
six
dose
leucovorin
instead
recommend
level
optim
reduc
standard
time
start
administ
hydrat
continu
instead
recommend
serum
creatinin
exceed
time
baselin
volum
hydrat
increas
measur
three
time
point
studi
approv
institut
ethic
committe
inform
consent
obtain
result
studi
includ
patient
mean
age
year
rang
patient
underweight
cycl
patient
cycl
rise
creatinin
time
baselin
augment
alkalin
indic
optim
toxic
includ
mucos
diarrhea
febril
neutropenia
mean
hour
respect
grade
rise
creatinin
observ
cycl
respect
toxic
day
neutropenia
thrombocytopenia
anemia
mucos
increas
voriconazol
singl
mortal
observ
season
conclus
administr
without
measur
extend
hydrat
addit
dose
leucovorin
monitor
serum
creatinin
feasibl
manag
toxic
studi
could
replic
addit
center
gener
evid
suggest
guidelin
administr
numer
center
develop
countri
lack
access
h
abdel
rahman
say
abdel
h
el
n
cancer
cairo
egypt
pediatr
oncolog
guizah
egypt
cancer
cairo
egypt
pediatr
oncolog
cairo
egypt
univers
pediatr
cairo
egypt
institut
pediatr
oncolog
cairo
egypt
cancer
cairo
uinivers
medic
biostatis
cairo
egypt
backgroundobject
improv
surviv
pediatr
cancer
link
aggress
treatment
regimen
increas
complic
may
requir
pediatr
intens
care
unit
picu
admiss
nearli
pediatr
cancer
patient
may
requir
intens
care
servic
account
approxim
picu
admissionsth
aim
current
studi
evalu
predictor
outcom
among
pediatr
cancer
patient
treat
picu
nation
cancer
institut
nci
cairo
univers
patient
risk
factor
designmethod
retrospect
studi
includ
patient
picu
admiss
record
period
juli
june
data
analysi
includ
patient
demograph
patient
assess
accord
pediatr
risk
mortal
iii
prism
well
pediatr
organ
logist
dysfunct
pelod
day
picu
admiss
moreov
surviv
correl
risk
factor
includ
age
diagnosi
diseas
statu
sepsi
use
mechan
ventil
need
inotrop
result
patient
age
rang
month
year
median
year
evid
male
predomin
sixti
percent
patient
hematolog
malign
averag
length
stay
day
rang
day
risk
factor
associ
wors
outcom
includ
high
prism
pleod
score
respect
surviv
outcom
wors
patient
mechan
ventil
andor
inotrop
support
conclus
high
prism
iii
well
pelod
score
type
malign
diseas
main
predictor
outcom
picu
among
pediatr
cancer
patient
earli
recognit
sign
organ
failur
referr
picu
may
shorten
icu
length
stay
morbid
complic
worsen
outcom
h
hafez
r
l
cancer
institut
cairo
univers
pediatr
hematologyoncolog
cairo
egypt
cancer
hospit
egypt
cche
pediatr
hematologyoncolog
cairo
egypt
cancer
institut
cairo
univers
biostatist
cairo
egypt
backgroundobject
despit
steadi
improv
support
care
last
year
treatment
relat
toxic
remain
major
challeng
childhood
acut
leukemia
therapi
especi
middl
incom
countri
aim
studi
describ
incid
risk
factor
associ
earli
death
first
day
treatment
among
children
acut
leukemia
designmethod
retrospect
studi
includ
newli
diagnos
patient
acut
leukemia
present
nation
cancer
institut
cairo
univers
jan
dec
patient
data
collect
analyz
total
earli
death
rate
propos
caus
death
result
studi
includ
patient
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
mix
phenotyp
acut
leukemia
total
death
rate
among
whole
group
induct
death
rate
patient
aml
higher
total
induct
death
rate
respect
compar
earli
death
attribut
infect
cerebrovascular
accid
earli
death
significantli
higher
patient
year
old
p
poor
respons
therapi
p
use
enhanc
support
care
measur
avail
intens
care
unit
significantli
reduc
overal
induct
mortal
rate
respect
versu
conclus
induct
death
pediatr
acut
leukemia
remain
major
challeng
develop
countri
constitut
increas
fraction
death
accordingli
use
well
equip
center
better
support
care
guidelin
essenti
improv
surviv
group
patient
al
brown
kp
oa
im
cc
mc
w
mj
pj
colleg
medicin
depart
pediatr
oncolog
tx
usa
colleg
medicin
depart
pediatr
psycholog
tx
usa
arizona
colleg
nurs
az
usa
univers
school
nurs
nc
usa
minnesota
school
nurs
mn
usa
backgroundobject
surviv
rate
pediatr
acut
lymphoblast
leukemia
pall
exceed
mani
patient
experi
cognit
impair
prognost
marker
cognit
impair
lack
purpos
pilot
studi
identifi
cerebrospin
fluid
csf
biomark
symptom
cognit
impair
pall
chemotherapi
designmethod
csf
sampl
collect
patient
untarget
metabolom
detect
metabolit
ga
chromatographi
gc
spectrometri
ms
liquid
chromatographi
lc
msm
cognit
function
evalu
first
month
treatment
use
scale
u
test
logist
regress
use
compar
metabolit
valu
case
whose
rate
declin
normal
rang
first
month
treatment
difficulti
rang
control
rate
normal
rang
fals
discoveri
rate
fdr
account
multipl
comparison
result
cohort
diagnos
patient
display
symptom
cognit
impair
signific
alter
fdr
observ
six
metabolit
includ
tyrosin
lactat
fold
chang
fc
glutam
histidin
metabolit
associ
remain
adjust
age
sex
race
treatment
intens
notabl
four
six
metabolit
identifi
studi
involv
dopamin
neurotransmitt
metabol
compar
patient
treatment
factor
alon
area
curv
auc
csf
biomark
significantli
improv
abil
distinguish
patient
symptom
cognit
impair
normal
cognit
function
tyrosin
conclus
identifi
novel
csf
biomark
symptom
cognit
impair
among
patient
treat
pall
find
may
translat
clinic
improv
manag
cognit
outcom
introduc
opportun
deliv
target
intervent
patient
prior
irrevers
cognit
impair
c
fouquet
f
h
l
l
necker
servic
de
chirurgi
pari
franc
centr
dinvestig
cliniqu
pari
franc
curi
laboratoir
de
recherch
translationnel
en
oncologi
pari
franc
robert
de
pari
franc
necker
servic
anatomi
pathologiqu
pari
franc
pellegrin
bordeaux
franc
gustav
roussi
de
de
lenfant
et
de
ladolesc
villejuif
franc
embryologi
et
de
malform
pari
franc
backgroundobject
cancer
aris
earli
childhood
result
embryon
layer
repres
unlik
adult
tumor
development
implement
accid
variou
tissu
accid
bound
age
tissu
turnov
designmethod
launch
june
ted
tumeur
et
developp
studi
nation
prospect
retrospect
registr
case
combin
paediatr
cancer
congenit
abnorm
data
extract
perform
clinic
characterist
patient
depict
result
march
patient
enrol
ted
databas
french
medic
centr
number
case
slightli
higher
boy
sex
ratio
frequent
tumor
leukaemia
brain
tumor
nephroblastoma
differ
describ
nation
registri
childhood
cancer
data
concern
development
abnorm
tumor
avail
patient
among
predisposit
syndrom
record
despit
evid
alreadi
known
associ
type
neurofibromatosi
optic
glioma
syndrom
nephroblastoma
syndrom
leukaemia
gonosom
abnorm
malign
germin
tumor
new
interest
associ
found
highlight
common
embryon
origin
ie
neuroblastoma
depigment
phenotyp
somat
mosaic
ie
bladder
rhabdomyosarcoma
hypospadia
earli
cancer
diagnos
compar
median
age
paediatr
cancer
occurr
vs
year
old
patient
record
databas
benefit
genet
counsel
conclus
ted
one
import
exhaust
studi
report
associ
birth
defect
paediatr
cancer
repres
key
collect
describ
new
mechan
genet
pathway
involv
tumorigenesi
malform
effort
actual
deploy
better
identifi
clinic
genet
cluster
cypriano
e
ml
av
n
f
c
c
oncolog
institutegraaccunifesp
pediatr
oncolog
sao
paulo
brazil
backgroundobject
approxim
children
adolesc
diagnos
cancer
live
countri
limit
resourc
chanc
cure
much
lower
report
develop
countri
data
cancer
registri
reveal
surviv
os
rate
children
year
age
object
evalu
characterist
year
os
pediatr
patient
singl
institut
designmethod
establish
institut
cancer
registri
fulli
organ
matur
enough
provid
reliabl
data
patient
popul
data
surviv
estim
extract
patient
chart
activ
search
public
record
exclud
surviv
analysi
patient
receiv
one
treatment
modal
return
servic
origin
result
patient
regist
boy
age
distribut
diagnosi
follow
year
age
year
old
year
common
cancer
type
brain
tumor
leukemia
bone
tumor
notic
shift
patient
profil
reflect
institut
growth
first
decad
malign
amen
outpati
treatment
common
wherea
second
decad
regist
mark
increas
high
complex
case
brain
tumor
os
patient
surviv
reach
intern
standard
hodgkin
lymphoma
wilm
tumor
conclus
organ
registri
allow
us
studi
epidemiolog
profil
patient
document
institut
os
superior
state
sao
paulo
led
us
conclud
organ
dedic
oncolog
center
abl
narrow
surviv
gap
brazilian
patient
counterpart
develop
world
e
v
pinto
l
g
natali
dafn
argentina
natali
dafn
argentina
bueno
air
argentina
counsil
scientif
technolog
investig
conicet
facultad
latinoamericana
de
ciencia
social
flacso
bueno
air
argentina
backgroundobject
dispar
access
accur
time
childhood
cancer
diagnosi
usual
develop
countri
fail
delay
diagnos
major
caus
poor
surviv
qualiti
life
natali
dafn
flexer
foundat
fndf
provid
integr
assist
famili
face
pediatr
cancer
argentina
studi
contain
preliminari
data
ongo
studi
aim
analyz
incid
modul
lost
diagnost
opportun
ldo
famili
assist
fndf
along
period
designmethod
retrospect
analysi
famili
yo
children
got
cancer
diagnos
includ
demograph
diseas
health
insur
data
medic
institut
involv
diagnos
process
compar
group
without
ldo
addit
data
extract
parent
narrat
result
total
famili
whose
diagnost
trajectori
exhaust
regist
includ
report
one
two
three
three
ldo
argentinian
sampl
fairli
repres
distribut
childhood
cancer
countri
regard
age
provinc
resid
sex
type
cancer
socialpriv
health
insur
public
health
coverag
retinoblastoma
low
age
posit
correl
absenc
ldo
p
southern
northern
region
vast
provinc
low
socioeconom
index
low
popul
densiti
exhibit
higher
proport
ldo
mean
countri
type
institut
publicpriv
independ
presenc
ldo
consult
privat
center
becam
frequent
number
ldo
increas
p
conclus
substanti
number
famili
experi
problem
obtain
childhood
cancer
diagnosi
argentina
diseas
demograph
determin
may
influenc
possibl
ldo
address
problem
help
develop
specif
local
intervent
improv
diagnos
process
j
sastri
hospit
children
haematolog
oncolog
glasgow
unit
kingdom
backgroundobject
campaign
headsmart
brain
tumour
awar
launch
respons
nation
survey
carri
indic
referr
practic
uk
paediatr
brain
tumour
rank
poorli
intern
comparison
aim
campaign
rais
public
profession
awar
order
reduc
total
diagnost
interv
tdi
median
mean
week
less
week
match
shortest
publish
tdi
audit
carri
evalu
effect
campaign
year
later
addit
compar
local
glasgow
referr
practic
align
nation
data
designmethod
data
gather
patient
age
diagnos
cn
tumour
glasgow
may
march
data
collect
perform
analysi
onlin
patient
record
access
nhsggc
clinic
portal
tdi
calcul
use
variou
patient
note
includ
gp
letter
hospit
record
result
sinc
initi
survey
consider
reduct
tdi
median
mean
week
patient
glasgow
investig
studi
howev
still
higher
nation
median
mean
week
greatest
observ
improv
time
taken
diagnos
patient
first
present
healthcar
median
reduc
week
glasgow
patient
conclus
increas
public
profession
awar
brain
tumour
led
clear
improv
tdi
nationwid
sinc
howev
data
analys
studi
suggest
continu
work
data
collect
requir
glasgow
ensur
tdi
close
resembl
nationwid
result
acknowledg
j
ferguson
data
manger
k
carpent
ak
ps
js
children
clinic
centr
excel
adolesc
servic
gaboron
botswana
children
cancer
hematolog
center
pediatr
houstan
usa
colleg
medicin
pediatr
houston
usa
children
cancer
hematolog
center
childhood
cancer
epidemiolog
prevent
program
houstan
usa
backgroundobject
incom
countri
lmic
time
access
care
major
barrier
treatment
childhood
cancer
may
lead
patient
present
extens
diseas
studi
aim
elucid
factor
influenc
diagnost
treatment
delay
within
botswana
designmethod
util
botswana
pediatr
oncolog
databas
bpod
studi
retrospect
analyz
demograph
timelin
data
pediatr
oncolog
patient
age
present
princess
marina
hospit
pmh
januari
result
median
total
diagnost
delay
defin
date
symptom
onset
date
diagnosi
week
ten
week
time
took
patient
reach
pmh
follow
onset
symptom
account
major
delay
week
patient
present
tertiari
care
facil
median
time
biopsi
patholog
result
week
presenc
metastasi
upon
diagnosi
significantli
correl
longer
total
diagnost
delay
age
sex
distanc
cancer
center
hiv
statu
medic
aid
statu
cancer
diagnosi
signific
effect
diagnost
delay
conclus
pediatr
cancer
patient
botswana
experienc
signific
delay
present
pmh
treatment
overal
diagnost
delay
compar
found
report
lmic
howev
diagnost
delay
correl
risk
metastat
diseas
uniqu
find
compar
exist
literatur
prospect
research
necessari
fulli
understand
factor
influenc
diagnost
treatment
delay
develop
strategi
address
factor
bansal
j
r
b
r
r
n
institut
medic
educ
research
pediatr
dept
advanc
pediatr
centr
chandigarh
india
institut
medic
educ
research
nuclear
medicin
chandigarh
india
institut
medic
educ
research
radiotherapi
chandigarh
india
institut
medic
educ
research
cytolog
chandigarh
india
institut
medic
educ
research
histopatholog
chandigarh
india
backgroundobject
protocol
reduc
current
favour
hodgkin
lymphoma
hl
abvd
popular
develop
countri
easeconvent
lack
data
administr
protocol
develop
countri
designmethod
studi
retrospect
base
protocol
administ
center
india
perform
diagnosi
follow
twofour
cours
copdac
administ
treatment
group
tg
respect
radiotherapi
indic
inadequ
result
patient
hl
treat
fulfil
studi
criteria
patient
year
rang
underweight
median
observ
time
month
inadequ
observ
patient
radiotherapi
administ
patient
episod
patient
result
death
episod
observ
follow
oepa
event
includ
relaps
aml
tg
respect
os
respect
outcom
compar
favor
os
center
earlier
experi
abvdcopp
patient
relaps
associ
bulki
diseas
episod
trend
associ
anemia
involv
nodal
region
conclus
chemotherapi
oepacopdac
base
respons
permit
reduct
therapi
compar
favour
patient
receiv
abvdcopp
center
past
febril
neutropenia
result
mortal
concern
occur
commonli
follow
oepa
system
administr
oepa
develop
countri
r
khedr
h
cancer
institut
cairo
univers
children
cancer
hospit
pediatr
oncolog
cairo
egypt
cancer
hospit
clinic
research
depart
cairo
egypt
cancer
institut
cairo
univers
children
cancer
hospit
radiodiagnosi
depart
cairo
egypt
cancer
hospit
clinic
pharmaci
depart
cairo
egypt
cancer
institut
cairo
univers
children
cancer
hospit
nuclear
medicin
cairo
egypt
cancer
institut
cairo
univers
children
cancer
hospit
surgic
patholog
cairo
egypt
cancer
institut
cairo
univers
children
cancer
hospit
radiothaerapi
depart
cairo
egypt
backgroundobject
major
challeng
advanc
stage
hodgkin
lymphoma
optim
balanc
overal
surviv
treatment
relat
toxic
aim
studi
describ
pediatr
popul
advanc
hodgkin
lymphoma
hl
countri
treatment
outcom
designmethod
retrospect
singl
center
studi
data
analysi
children
advanc
stage
hl
iib
iiib
bulk
diseas
stage
iv
done
demograph
data
stage
number
cycl
doxorubicin
bleomycin
vinblastin
dacarbazin
abvd
receiv
whether
consolid
radiotherapi
rth
administ
positron
emiss
tomographi
pet
perform
baselin
second
cycl
detect
earli
respons
without
chang
treatment
plan
result
three
hundr
patient
newli
diagnos
hodgkin
lymphoma
enrol
data
analysi
male
femal
ratio
present
patient
ann
arbor
stage
distribut
follow
iib
iiia
iiib
iva
ivb
one
hundr
patient
earli
unfavor
diseas
treat
abvd
rth
one
hundr
nine
patient
receiv
rth
overal
surviv
os
event
free
surviv
ef
patient
ci
ci
p
valu
respect
os
ef
patient
advanc
stage
hl
whole
studi
popul
ci
ci
respect
conclus
patient
cure
therapi
yet
therapi
frequent
associ
risk
signific
long
term
toxic
innov
approach
need
patient
high
risk
failur
current
therapi
q
mi
g
children
medic
center
hemotolog
amd
oncolog
shanghai
china
backgroundobject
studi
provid
descript
review
improv
understand
treatment
outcom
pediatr
anaplast
larg
cell
lymphoma
alcl
china
designmethod
clinic
data
outcom
patient
year
newli
alcl
treat
larg
singl
institut
china
januari
june
retrospect
analyz
surviv
ef
analyz
use
method
risk
diseas
progress
relaps
evalu
use
logist
regress
analysi
signific
defin
p
result
elig
patient
median
age
year
rang
year
two
patient
stage
stage
ii
stage
iii
stage
ivth
median
time
month
rang
month
patient
surviv
without
diseas
last
ef
patient
treat
treat
regimen
ef
ef
patient
without
b
symptom
patient
experienc
diseas
progress
relaps
median
time
initi
diagnosi
tumor
failur
month
rang
month
median
last
evalu
patient
still
aliveaft
diseas
progress
relaps
univari
analysi
sex
b
symptom
identifi
risk
factor
diseas
progress
relaps
nevertheless
b
symptom
hr
ci
wererisk
factor
multivari
analysi
conclus
present
featur
children
adolesc
alcl
ef
rate
studi
similar
report
western
countri
refin
therapeut
strategi
improv
surviv
patient
diseas
progress
relaps
prioriti
futur
clinic
studi
kl
bride
l
dm
sl
ml
sa
bl
dt
children
hospit
philadelphia
pediatr
philadelphia
usa
medic
bay
pediatr
san
francisco
usa
children
hospit
patholog
seattl
usa
backgroundobject
target
immunotherapi
becom
critic
success
treatment
mani
cancer
particularli
therapeut
antibodi
cytotox
abil
effect
immunotherapi
develop
acut
lymphoblast
leukemia
found
cell
surfac
activ
cell
termin
differenti
b
cell
rel
low
level
normal
lymphoid
myeloid
cell
daratumumab
dara
human
monoclon
antibodi
bind
success
use
patient
refractori
multipl
myeloma
designmethod
ensur
relev
target
measur
express
flow
cytometri
patient
earli
precursor
etp
diagnosi
induct
chemotherapi
also
xenograft
primari
blast
differ
patient
mice
random
dara
mous
intraperiton
weekli
vs
isotyp
mice
per
arm
sampl
develop
peripher
blood
pb
blast
fac
diseas
burden
assess
fac
enumer
pb
blast
weekli
splenic
blast
sacrific
result
express
patient
sampl
surfac
express
remain
unchang
induct
mean
mfi
diagnosi
vs
vs
log
p
etp
sampl
respond
mark
improv
diseas
burden
sampl
mice
advanc
diseas
die
immedi
exposur
dara
presum
tumor
lysi
repeat
experi
treat
inject
prior
develop
peripher
blast
sampl
demonstr
efficaci
daratumumab
respond
high
diseas
burden
respond
low
diseas
burden
toxic
high
diseas
respond
conclus
summari
dara
highli
effect
novel
monotherapi
preclin
model
q
e
g
te
c
l
g
km
l
meyer
univers
medic
center
depart
pediatr
adolesc
medicin
ulm
germani
univers
medic
center
intern
medicin
iii
ulm
germani
padova
depart
women
children
health
padova
itali
univers
medicin
depart
pediatr
oncolog
hematolog
berlin
germani
univers
medic
center
depart
obstetr
gynecolog
ulm
germani
institut
depart
tumor
cell
biolog
stockholm
sweden
backgroundobject
mutat
tumor
suppressor
gene
infrequ
initi
diagnosi
pediatr
acut
lymphoblast
leukemia
enrich
relaps
associ
inferior
outcom
evalu
mutat
target
direct
therapi
investig
effect
small
molecul
designmethod
patient
xenograft
nodscidhual
cell
line
precursor
bcp
sampl
analyz
liquid
chromatographi
sanger
sequenc
sensit
dna
damag
agent
doxorubicin
small
molecul
kindli
provid
aprea
stockholm
sweden
investig
apoptosi
activ
iodid
posit
restor
immunoprecipit
antibodi
activ
express
downstream
molecul
analyz
defici
cell
gener
lentivir
shrna
mediat
xenograft
bear
nodscid
mice
treat
vehicl
result
leukemia
observ
poor
respons
doxorubicin
sensit
contrast
highli
sensit
leukemia
show
insensit
induc
structur
restor
mutant
function
activ
indic
conform
phosphoryl
increas
express
target
molecul
noxa
puma
final
lead
leukemia
cell
apoptosi
knockdown
led
abrog
cell
death
indic
target
mutant
moreov
strong
synerg
induc
cell
death
observ
upon
combin
doxorubicin
exposur
importantli
preclin
set
treat
bear
recipi
mice
observ
signific
reduct
leukemia
load
demonstr
clear
vivo
activ
conclus
restor
mutant
wild
type
conform
reactiv
tumor
suppressor
function
lead
apoptosi
induct
target
mutat
might
provid
effect
novel
strategi
therapeut
intervent
subtyp
c
mcate
n
j
mb
colleg
medicin
pediatr
houston
usa
children
hospit
pharmacolog
houston
usa
backgroundobject
diseas
vod
describ
follow
treatment
acut
lymphoblast
leukemia
previou
studi
incorpor
daili
mainten
chemotherapi
demonstr
high
incid
vod
typic
present
prolong
exposur
continu
use
singl
burst
intensif
howev
vod
associ
brief
cours
poorli
describ
describ
experi
vod
set
designmethod
subject
identifi
de
novo
patient
texa
children
cancer
center
medic
record
search
diagnos
vod
within
day
receiv
day
subject
demograph
clinic
data
collect
median
rang
calcul
result
new
patient
identifi
vod
predomin
sex
ethnic
race
note
vod
diagnos
day
start
isol
thrombocytopenia
note
patient
present
day
prior
vod
patient
clinic
stabl
outpati
patient
still
take
refractori
platelet
transfus
note
patient
present
day
prior
vod
stabl
outpati
still
take
fever
note
patient
within
hour
document
suspect
infect
day
prior
vod
intermedi
thiopurin
methyltransferas
genotyp
note
patient
data
avail
conclus
vod
gener
present
earli
follow
initi
intensif
phase
treatment
disproport
sever
thrombocytopenia
transfus
refractori
typic
preced
vod
diagnosi
sever
day
occur
clinic
stabl
outpati
identifi
risk
factor
earli
sign
symptom
vod
popul
hasten
appropri
diagnosistreat
case
may
allow
discontinu
offend
e
hiyama
k
k
k
j
k
k
univers
hospit
peditr
surgeri
hiroshima
japan
children
cancer
group
liver
tumor
committe
tokyo
japan
backgroundobject
japanes
studi
group
pediatr
liver
tumor
jplt
studi
hepatoblastoma
hbl
launch
close
main
aim
studi
launch
evalu
efficaci
cisplatinpirarubicin
hb
standard
risk
hb
tumor
involv
three
fewer
sector
liver
intermedi
risk
hb
tumor
involv
sector
liver
invas
portal
hepat
vein
high
risk
hb
tumor
involv
sector
liver
metastasi
designmethod
hb
children
younger
year
age
elig
inclus
studi
cisplatinpirarubicin
regimen
cita
kept
first
line
studi
examin
outcom
late
effect
hb
patient
three
group
standard
intermedi
high
risk
group
result
among
case
pretext
ii
iii
iv
includ
case
metastat
tumor
efso
case
standard
risk
hb
case
intermedi
high
risk
hb
respect
except
case
underw
primari
resect
complet
resect
primari
cita
perform
standard
risk
intermedi
risk
high
risk
patient
late
phase
complic
case
maldevelop
cardiac
complic
ototox
second
malign
conclus
compar
multicent
cooper
protocol
cita
regimen
achiev
similar
rate
surviv
resect
standard
risk
patient
promis
strategi
includ
adequ
liver
transplant
new
target
drug
develop
intermedi
high
risk
hb
oneil
md
c
mr
langham
rl
hm
farber
cancer
institut
pediatr
oncolog
boston
usa
california
davi
comprehens
cancer
center
pediatr
oncolog
sacramento
usa
southern
california
keck
school
medicin
research
prevent
medicin
lo
angel
usa
data
children
oncolog
group
statist
monrovia
usa
winship
cancer
institut
pediatr
oncolog
atlanta
usa
bonheur
children
hospit
univers
tennesse
depart
surgeri
memphi
usa
children
hospit
univers
utah
depart
surgeri
salt
lake
citi
usa
univers
school
monro
carel
jr
children
hospit
pediatr
oncolog
nashvil
usa
backgroundobject
hepatoblastoma
hb
common
pediatr
liver
neoplasm
greater
newli
diagnos
patient
present
elev
serum
alpha
afp
level
declin
afp
level
throughout
therapi
routin
util
marker
respons
howev
exact
relationship
afp
declin
outcom
well
establish
designmethod
children
oncolog
group
cog
protocol
design
patient
newli
diagnos
hb
includ
stratum
patient
diseas
resect
diagnosi
follow
two
adjuv
cycl
cisplain
vincristin
afp
level
obtain
per
protocol
diagnosi
therapi
routin
followup
visit
everi
month
analyz
afp
level
diagnosi
declin
respons
therapi
normal
per
institut
standard
indic
complet
remiss
result
subject
enrol
stratum
elig
analysi
mean
afp
diagnosi
ngml
exclud
two
patient
lack
baselin
valu
median
rang
ngml
afp
valu
normal
subject
follow
patient
therapi
patient
patient
month
respect
two
subject
fail
normal
afp
differ
outcom
base
time
normal
afp
level
patient
recur
progress
success
afp
level
minor
transient
increas
level
ngml
afp
observ
necessarili
indic
relaps
conclus
patient
upfront
resect
diseas
afp
level
predict
overal
outcom
afp
indic
relaps
highli
sensit
l
valanejad
kiefer
n
children
hospit
medic
center
divis
pediatr
gener
thorac
surgeri
cincinnati
usa
children
hospit
medic
center
center
autoimmun
genom
etiolog
cincinnati
usa
backgroundobject
hepatoblastoma
hbl
pediatr
liver
cancer
affect
children
age
three
reduct
tumor
suppressor
protein
tsp
seen
mani
type
liver
cancer
surprisingli
found
aggress
hbl
character
elev
tsp
goal
determin
mechan
aggress
hbl
neutral
activ
elev
tsp
elucid
mechan
elev
tsp
aggress
cancer
examin
inhibit
mechan
inhibit
hbl
designmethod
use
biochem
approach
analyz
larg
cohort
hbl
sampl
modif
tsp
rb
complex
tsp
examin
use
size
exclus
chromatographi
gel
electrophoresi
chang
chromatin
structur
examin
use
chip
assay
result
hbl
sampl
mild
phenotyp
reduc
level
tsp
aggress
hbl
character
elev
tsp
underw
modif
elimin
tumor
suppress
activ
found
gene
tsp
contain
uniqu
base
pair
chromosom
domain
aggress
liver
cancer
domain
alcd
human
genom
contain
alcd
locat
chromosom
region
tsp
certain
cancer
relat
gene
alcd
observ
mous
genom
alcd
correspond
gene
activ
elev
complex
bind
directli
alcd
inhibit
cultur
hepatoblastoma
cell
elimin
complex
inhibit
normal
express
correspond
gene
result
inhibit
prolifer
conclus
activ
alcd
key
event
develop
aggress
hbl
phenotyp
also
involv
modif
block
tumor
suppress
activ
activ
mechan
develop
aggress
hbl
suggest
inhibitor
might
use
treatment
hbl
sekiguchi
k
n
r
k
k
k
j
univers
tokyo
depart
pediatr
japan
research
institut
child
health
develop
depart
biolog
japan
univers
depart
patholog
tumor
biolog
kyoto
japan
univers
tokyo
hospit
depart
pediatr
surgeri
japan
institut
medic
univers
tokyo
human
genom
center
japan
univers
depart
pediatr
surgeri
fukuoka
japan
children
medic
center
depart
hematologyoncolog
saitama
japan
red
cross
gunma
blood
center
director
maebashi
japan
medic
center
depart
advanc
diagnosi
nagoya
japan
children
medic
center
depart
patholog
yokohama
japan
backgroundobject
hepatoblastoma
hbl
common
liver
tumor
children
despit
intens
multimod
therapi
prognosi
hbl
remain
poor
underscor
import
understand
hbl
pathogenesi
develop
novel
therapeut
modal
howev
mutat
rate
hbl
rel
low
molecular
target
except
pathway
establish
understand
molecular
basi
hbl
still
limit
designmethod
perform
methyl
array
analysi
singl
nucleotid
polymorph
snp
copi
number
cn
analysi
sampl
hbl
part
sampl
also
subject
sequenc
we
sampl
rna
sequenc
sampl
result
identifi
mutationsdelet
sampl
subject
recurr
mutat
gene
fusion
detect
consensu
cluster
sampl
base
methyl
data
indic
presenc
distinct
cluster
cluster
character
high
express
associ
promot
hypomethyl
mark
low
diagnost
age
intriguingli
cluster
includ
case
uniparent
disomytrisomi
chromosom
cluster
one
case
gain
cluster
includ
case
stage
pretext
iv
requir
liver
transplant
cluster
exhibit
low
express
promot
hypermethyl
less
frequent
cn
alter
patient
rel
low
serum
afp
level
enrich
cluster
consist
low
express
known
poor
prognost
factor
sever
kind
tumor
patient
cluster
show
better
surviv
other
vs
p
conclus
integr
studi
hbl
identifi
methyl
subgroup
well
correl
biolog
clinic
featur
may
use
clinic
risk
stratif
search
new
molecular
target
j
k
j
e
perez
miami
miller
school
medicin
surgeri
miami
usa
backgroundobject
pancreat
tumor
rare
children
limit
data
avail
aim
describ
patient
tumor
characterist
report
surviv
diseas
designmethod
data
nation
cancer
databas
children
younger
year
pancreat
tumor
analyz
associ
treatment
hazard
death
assess
use
method
cox
regress
model
result
identifi
children
pancreat
tumor
male
white
insur
median
age
diagnosi
iqr
year
tumor
distribut
follow
pseudopapillari
neoplasm
endocrin
tumor
pancreatoblastoma
pancreat
adenocarcinoma
sarcoma
neuroblastoma
sixti
patient
underw
surgeri
achiev
resect
patient
lymph
node
examin
posit
sampl
twenti
percent
receiv
adjuv
therapi
chemotherapi
chemoradi
therapi
receiv
palli
treatment
pancreatoblastoma
sarcoma
receiv
chemotherapi
chemoradi
therapi
respect
overal
surviv
pancreat
tumor
overal
surviv
tumor
histolog
pseudopapillari
neoplasm
neuroblastoma
pancreatoblastoma
endocrin
tumor
sarcoma
pancreat
adenocarcinoma
respect
univari
analysi
male
hr
ci
sarcoma
hr
ci
endocrin
tumor
hr
ci
adenocarcinoma
hr
ci
p
manag
hr
ci
p
signific
predictor
wors
surviv
though
manag
hr
ci
p
remain
independ
predictor
wors
surviv
multivari
analysi
conclus
overal
surviv
children
pancreat
tumor
grim
vari
surviv
rate
among
differ
tumor
surgic
manag
pancreat
tumor
children
associ
surviv
l
lemel
g
p
f
c
le
g
p
curi
depart
young
adult
pari
franc
curi
de
somatiqu
pari
franc
curi
de
pathologi
pari
franc
universitair
de
enfant
rein
ulb
libr
de
bruxel
unit
brussel
belgium
hautepierr
depart
pediatr
strasbourg
franc
de
grenobl
depart
pediatr
grenobl
franc
oscar
lambret
head
neck
surgeri
depart
lill
franc
saint
univers
montreal
depart
pediatr
montreal
canada
depart
medic
oncolog
bordeaux
franc
hospitali
universitair
poitier
pediatr
oncolog
depart
poitier
franc
curi
medic
oncolog
inserm
research
pari
franc
publiqu
de
armand
trousseau
pediatr
hematolog
oncolog
pari
franc
denfant
de
braboi
depart
pediatr
vandoeuvr
le
nanci
franc
um
epidemiolog
cohort
unit
villejuif
franc
curi
depart
young
french
pediatr
rare
tumor
group
group
fractur
pari
franc
backgroundobject
nut
midlin
carcinoma
aggress
tumor
defin
presenc
nut
rearrang
fusion
oncogen
poor
prognosi
rare
cancer
underdiagnos
poorli
treat
primari
object
studi
describ
clinic
radiolog
biolog
featur
nut
midlin
carcinoma
secondari
object
describ
variou
treatment
assess
efficaci
designmethod
retrospect
multicent
studi
base
review
medic
record
children
adult
nut
midlin
carcinoma
specif
rearrang
posit
nuclear
stain
result
seri
patient
median
age
year
rang
year
primari
tumor
locat
chest
patient
head
neck
patient
patient
multifoc
tumor
nine
patient
present
region
lymph
node
involv
distant
metastas
patient
initi
misdiagnos
diagnosi
nmc
therefor
subsequ
correct
target
molecular
biolog
analys
specif
nut
antibodi
posit
case
test
specif
transloc
found
patient
transient
respons
chemotherapi
observ
patient
patient
treat
surgeri
receiv
radiotherapi
cur
intent
three
patient
receiv
target
therapi
end
one
patient
still
remiss
year
diagnosi
median
overal
surviv
month
ci
conclus
nut
midlin
carcinoma
aggress
diseas
refractori
convent
therapi
earli
diagnosi
antibodi
immunostain
case
undifferenti
poorli
differenti
carcinoma
identifi
specif
rearrang
nut
gene
use
diagnosi
lead
propos
optim
therapeut
strategi
earli
inclus
target
therapi
studi
j
bloyd
childhood
cancer
organ
lexington
usa
backgroundobject
object
present
empow
parent
childhood
cancer
patient
survivor
effect
engag
polici
maker
rais
awar
childhood
cancer
need
addit
resourc
present
share
person
experi
form
partnership
state
legisl
governor
pass
legisl
make
kentucki
nation
model
chang
mr
bloyd
mother
burkitt
lymphoma
leukemia
survivor
paxton
work
ky
governor
erni
fletcher
well
us
senat
major
leader
mitch
mcconnel
dc
grassroot
advocaci
lobbyistconsult
american
heart
associ
campaign
tobacco
free
kid
american
right
prior
son
diagnosi
designmethod
mr
bloyd
use
experi
case
studi
reveal
pitfal
pearl
effect
grassroot
advocaci
result
mr
bloyd
led
way
kentucki
draft
legisl
creat
new
pediatr
cancer
research
trust
fund
initi
fund
innov
approach
give
kentucki
resid
opportun
donat
via
annual
state
incom
tax
return
result
leadership
mr
bloyd
appoint
governor
board
elect
presid
mr
bloyd
also
led
way
chang
kentucki
cancer
action
plan
includ
specif
object
regard
childhood
cancer
research
survivorship
commemor
intern
childhood
cancer
day
jami
recent
partner
governor
matt
bevin
first
ladi
launch
ky
pediatr
cancer
advocaci
day
state
capitol
conclus
although
childhood
cancer
number
one
caus
death
diseas
children
issu
goe
larg
unnot
state
polici
maker
effect
advocaci
grassroot
level
power
chang
polit
landscap
make
childhood
cancer
prioriti
issu
di
lallo
children
hospit
parent
advisori
children
cancer
centr
parkvil
australia
background
object
background
decemb
oshin
kiszko
diagnos
rare
brain
tumour
medulloblastoma
oshin
six
year
old
die
decemb
follow
surgeri
decemb
cur
treatment
compris
intens
chemotherapi
craniospin
radiotherapi
indic
oshin
parent
advis
accordingli
oshin
parent
initi
oppos
administr
chemotherapi
subsequ
agre
limit
chemotherapi
otherwis
prefer
pursu
altern
therapi
declin
radiotherapi
circumst
litig
took
place
oshin
parent
treat
hospit
object
consider
legaleth
issu
emerg
legal
guardian
seek
limit
medic
treatment
infant
patient
exercis
parent
entitl
protect
child
welfar
identif
legal
ethic
issu
becom
especi
acut
indic
medic
treatment
take
form
special
medic
procedur
term
understood
law
analysi
court
ultim
defer
wish
oshin
legal
guardian
concern
medic
treatment
prefer
recommend
child
treat
medic
profession
designmethod
nil
result
nil
conclus
best
interest
approach
consider
patient
welfar
offer
specif
hierarchi
valu
applic
best
interest
approach
case
individu
patient
multifacet
intric
especi
context
special
medic
procedur
best
interest
valu
fact
therefor
complex
ethic
legal
issu
intrud
otherwis
clinic
question
wish
legal
guardian
protect
law
lightli
derog
h
gupta
k
p
kidscan
medic
project
support
servic
program
delhi
india
kidscan
qualiti
control
research
impact
delhi
india
backgroundobject
drug
cost
signific
compon
overal
financi
burden
manag
childhood
cancer
divers
healthcar
dynam
india
lead
signific
albeit
variabl
part
burden
pass
famili
cankid
grassroot
level
organ
provid
holist
support
pediatr
oncolog
patient
center
india
support
medic
current
constitut
biggest
outlay
annual
expenditur
therefor
vital
us
find
way
cut
cost
without
compromis
qualiti
treatment
aim
studi
quantifi
cost
reduct
achiev
use
variou
strategi
designmethod
medic
assist
team
cankid
select
procur
chemotherapysupport
drug
directli
pharmaceut
compani
cankid
support
hospit
unit
drug
requir
deliv
local
stockist
parent
compani
gener
principl
gener
approv
drug
gener
control
india
procur
bulk
purchas
facilit
better
negoti
price
valu
addit
complimentari
vial
diagnost
bill
central
lead
avoid
higher
tax
state
level
attempt
made
purpos
studi
quantifi
overal
econom
benefit
use
strategi
five
commonli
prescrib
key
drug
imatinib
filgrastim
voriconazol
meropenem
result
year
cankid
provid
medic
assist
patient
total
outlay
use
gener
drug
cost
reduct
nativ
asparaginas
innov
product
use
apart
use
mention
strategi
reduct
retail
price
final
purchas
gener
drug
achiev
conclus
signific
cost
reduct
achiev
partnership
pharmaceut
industri
enabl
support
group
reach
patient
hamid
foundat
pediatr
oncolog
dhaka
bangladesh
backgroundobject
lmic
struggl
multitud
indigen
issu
make
difficult
rais
fundrais
capac
small
organ
focus
specif
caus
childhood
cancer
countri
bangladesh
malnutrit
educ
communic
diseas
receiv
lion
share
public
fund
attent
special
caus
childhood
cancer
forc
resort
privat
sourc
fund
unequ
distribut
wealth
keep
countri
wealth
hand
select
make
decis
project
fund
caus
commun
extend
famili
choos
support
result
special
program
support
childhood
cancer
get
ignor
designmethod
track
record
swindler
commun
individu
also
slow
trust
privat
organ
ngo
unless
person
connect
administr
organ
form
ashic
foundat
got
start
small
budget
fund
privat
fund
founder
organ
maheen
hamid
daughter
founder
afzal
salma
choudhuri
share
famili
journey
last
two
decad
includ
relationship
build
local
medic
commun
tap
intern
network
partner
build
credibl
ashic
program
consist
dedic
servic
provid
mani
factor
help
build
trustworthi
organ
result
today
organ
get
current
annual
budget
privat
donat
includ
individu
institut
conclus
sever
parent
run
organ
lmic
may
abl
benefit
effect
strategi
employ
ashic
foundat
organ
plan
leverag
new
market
tool
increas
fundrais
capac
kumar
p
g
k
kidscan
resourc
mobilis
depart
new
delhi
india
backgroundobject
cankid
kidscan
ck
grassroot
level
organ
work
chang
childhood
cancer
india
alon
yana
social
support
protocol
execut
social
support
team
work
cancer
centr
across
india
provid
holist
support
rang
servic
provid
best
standard
treatment
care
support
henc
requir
fundrais
implement
resourc
mobil
roadmap
designmethod
adapt
fundrais
strategi
evolv
corpor
atmospher
brought
limelight
corpor
social
respons
csr
organ
projectprogram
creat
develop
accord
csr
need
build
expertis
work
differ
stakehold
develop
fundrais
roadmapdonor
manag
sale
forc
donor
build
corpu
fund
commun
involv
seven
care
center
cancer
children
focus
interventionsdon
kind
involv
commun
time
food
suppli
event
awar
diseas
base
nation
campaign
survivor
specif
campaign
statewid
car
ralliesnetwork
fundrais
dinner
fundrais
tool
crowd
bite
size
fundraisingus
network
networkfundrais
target
settingschool
institut
partnership
result
five
year
trend
increas
fund
rais
usd
usd
usd
hospit
support
increas
previou
two
year
comparison
rais
project
fundsincreas
previou
year
fund
rais
strong
databas
continu
group
individu
relationship
futur
conclus
donor
focuss
project
led
renew
partnership
reduc
relianc
foreign
fundingteam
strengthen
essenti
sustainabilitymultipl
fundrais
tool
help
increas
donat
flexibl
implement
programseffect
low
cost
model
fundraisingcommun
involv
shoulder
burden
fundrais
kennedi
n
l
j
kid
cancer
research
program
new
york
usa
kid
cancer
europ
research
program
london
unit
kingdom
backgroundobject
intern
clinic
trial
becom
increasingli
import
paediatr
cancer
facilit
faster
accrual
rate
provid
wider
access
children
test
new
therapi
challeng
increas
design
monitor
complex
regulatori
burden
cost
remain
signific
present
opportun
chariti
stimul
support
intern
collabor
academia
industri
govern
agenc
designmethod
research
advocaci
intern
chariti
base
us
uk
identifi
unmet
need
children
neuroblastoma
call
propos
issu
intern
research
commun
submit
idea
combin
immunotherapi
intern
panel
scientif
review
select
propos
recommend
award
anoth
clinic
trial
test
target
drug
plan
us
consortium
expand
includ
uk
europ
due
chariti
support
influenc
seven
addit
chariti
us
uk
support
trial
result
two
intern
clinic
trial
test
novel
therapi
neuroblastoma
influenc
support
chariti
advocaci
due
open
one
test
target
radiotherapi
immunotherapi
combin
use
antibodi
antibodi
nivolumab
accru
relaps
refractori
neuroblastoma
patient
us
uk
germani
second
alk
inhibitor
lorlatinib
children
neuroblastoma
accru
patient
us
uk
franc
conclus
chariti
advoc
support
innov
intern
clinic
trial
provid
essenti
role
stimul
trial
accru
time
manner
address
need
therapeut
option
across
border
children
cancer
l
moor
childhood
cancer
foundat
sa
gauteng
south
region
saxonwold
south
africa
backgroundobject
sector
south
africa
becom
increasingli
competit
result
scrambl
avail
fund
choc
childhood
cancer
foundat
south
africa
choc
largest
childhood
cancer
ngo
oper
african
contin
develop
nation
awar
fundrais
campaign
entitl
heart
children
cancer
primari
aim
rais
awar
childhood
cancer
fund
organis
designmethod
heart
children
cancer
campaign
link
iccd
februari
choc
identifi
need
formal
give
structur
campaign
campaign
went
blue
align
corpor
ident
organis
merchandis
develop
heart
theme
round
plastic
pin
could
worn
day
lead
februari
design
togeth
chocol
fit
valentin
day
theme
item
brand
heart
children
cancer
slogan
campaign
encourag
peopl
go
blue
day
wear
badg
pin
support
childhood
cancer
choc
link
nation
media
social
media
advertis
campaign
includ
light
tabl
mountain
cape
town
nation
monument
pretoria
blue
colour
theme
result
increas
number
peopl
made
awar
choc
childhood
cancer
evid
number
media
articlesinterview
number
particip
align
campaign
increas
sale
heart
children
cancer
merchandis
conclus
heart
children
cancer
campaign
effect
awar
fundrais
campaign
seen
increas
support
choc
childhood
cancer
l
moor
childhood
cancer
foundat
sa
gauteng
south
region
saxonwold
south
africa
backgroundobject
import
organis
leverag
support
wide
varieti
incom
sourc
effect
way
implement
holist
school
give
programm
mutual
benefici
organis
school
increas
pressur
children
today
effect
contribut
citizen
societi
opportun
chariti
get
maximum
benefit
social
movement
enorm
choc
extrem
success
leverag
opportun
fundrais
effort
designmethod
initi
broken
four
key
section
monetari
activ
commun
servic
opportun
social
respons
club
collect
donat
key
activ
promot
school
includ
civvi
day
children
pay
donat
wear
cloth
choic
school
often
link
nationalintern
awar
campaign
relat
childhood
cancer
collect
item
need
implement
core
programm
opportun
social
respons
club
engag
choc
oper
site
assist
variou
activ
paint
clean
prepar
meal
administr
task
provid
opportun
individu
learner
gain
passiv
activ
commun
hour
assist
campaign
event
fundrais
initi
result
steadi
increas
number
school
learner
get
involv
choc
initi
monetari
incom
increas
current
account
overal
incom
receiv
increas
amount
donat
receiv
huge
impact
reduc
expenditur
conclus
well
plan
implement
school
fundrais
campaign
see
steadi
growth
period
time
compris
signific
portion
organis
incom
open
opportun
gain
access
incom
sourc
whilst
assist
shape
futur
leader
becom
activ
member
societi
contribut
social
chang
mozzilli
e
l
v
f
l
g
beaba
direct
sao
paulo
brazil
beaba
creativ
paulo
brazil
game
studio
develop
santo
brazil
camargo
cancer
center
pediatr
oncolog
paulo
brazil
de
pediatr
oncolog
brazil
game
design
develop
santo
brazil
memor
rsrch
ctr
pediatr
oncolog
chicago
usa
backgroundobject
increasingli
technolog
world
digit
inform
childhood
cancer
easili
access
pediatr
patient
famili
healthcar
provid
still
miss
scenario
decid
bring
stakehold
patient
caregiv
healthcar
profession
creativ
entrepreneur
togeth
creat
applic
tablet
mobil
devic
would
help
children
demystifi
cancer
treatment
designmethod
interdisciplinar
involv
combin
two
academ
disciplin
one
activ
design
think
human
center
methodolog
rapid
ideat
abil
visual
adapt
result
near
real
time
agil
ux
methodolog
integr
user
experi
design
develop
team
patient
center
design
project
manag
platform
collabor
commun
tool
result
develop
applic
minigam
io
android
platform
languag
easili
access
children
attract
color
interfac
child
identifi
himherself
custom
design
charact
guid
differ
step
treatment
initi
highlight
appstor
result
almost
million
view
acquisit
expans
interdisciplinar
stakehold
importantli
develop
empathi
compass
patient
conclus
interdisciplinar
effect
particip
stakehold
project
allow
integr
access
inform
facilit
understand
identif
codif
avail
inform
result
gener
easili
access
knowledg
target
popul
greatest
transform
technolog
advanc
new
way
associ
knowledg
human
factor
order
educ
empow
improv
qualiti
life
children
fight
cancer
wwwbeabaorggam
na
bethesda
usa
backgroundobject
object
present
inform
empow
parent
childhood
cancer
patient
pain
remedi
anxieti
altern
rais
awar
among
oncologist
research
potenti
natur
altern
could
provid
patient
respond
posit
convent
medicin
present
share
person
experi
introduc
cbd
hemp
oil
substitut
pain
treatment
anxieti
daughter
sabrina
treatment
neuroblastoma
mr
mother
neuroblastoma
patient
sabrina
battl
diseas
nine
year
pass
octob
age
designmethod
mr
present
experi
case
studi
success
introduc
cannabidiol
hemp
oil
combat
sabrina
pain
anxieti
order
inform
parent
spark
interest
doctor
research
explor
potenti
benefit
substitut
hemp
oil
natur
occur
substanc
opioid
address
pain
anxieti
inpati
procedur
result
treat
sabrina
home
hospit
mr
confirm
util
natur
product
could
produc
equival
respons
versu
pharmaceut
sabrina
case
treatment
sabrina
exhibit
express
discomfort
provid
cbd
manag
pain
deceas
progress
conclus
mr
believ
option
ad
present
parent
altern
provid
pain
relief
reduc
anxieti
child
treatment
also
studi
conduct
determin
rel
effect
cbd
hemp
oil
natur
occur
medicin
anoth
choic
parent
doctor
l
r
l
c
j
c
b
gonzalez
jp
p
univers
medic
center
epidemiolog
new
york
citi
nyc
usa
escuela
pediatr
oncolog
tegucigalpa
hondura
mario
catarino
riva
pediatr
oncolog
san
pedro
sula
hondura
univers
medic
center
pediatr
oncolog
new
york
citi
usa
univers
medic
center
pediatr
oncolog
social
work
new
york
citi
usa
univers
medic
center
pediatr
oncolog
psycholog
new
york
citi
usa
mexicana
universidad
centro
americana
red
jesuita
de
servicio
migrant
en
ny
managua
nicaragua
derecho
humano
progreso
hondura
univers
medic
center
epidemiolog
new
york
citi
usa
univers
medic
center
pediatr
bmt
new
york
citi
usa
backgroundobject
past
year
number
central
american
children
migrat
overland
us
reach
unpreced
level
migrat
children
migrat
undergo
chemotherapi
interrupt
intend
care
report
collabor
pediatr
oncolog
team
send
receiv
countri
permit
continu
care
despit
complex
legal
circumst
designmethod
year
old
girl
undergo
mainten
therapi
b
cell
precursor
standard
risk
hondura
abandon
therapi
travel
overland
us
resettl
nyc
ran
medic
develop
fever
admit
relaps
columbia
electron
discuss
ny
honduran
oncologist
began
relaps
therapi
quickli
achiev
remiss
unrel
donor
search
yield
hla
match
sibl
test
reveal
hla
match
one
year
old
brother
live
remot
honduran
villag
natur
famili
migrat
us
inelig
tourist
visa
stem
cell
hondura
could
enter
us
ny
oncologist
work
close
jesuit
human
right
organ
ny
commun
organ
honduran
oncologist
volunt
immigr
lawyer
petit
boy
us
entri
result
year
old
grant
humanitarian
parol
us
homeland
secur
within
month
hla
test
marrow
donor
assent
prepar
fli
done
video
call
boy
travel
day
later
bmt
proceed
without
complic
girl
discharg
day
donor
return
hondura
compli
parol
day
girl
famili
chose
return
hondura
follow
honduran
oncologist
close
electron
commun
ny
team
conclus
propos
technolog
facilit
binat
oncolog
continu
care
model
treatment
migrat
n
scobi
c
sullen
switzerland
parent
repres
sullen
unit
kingdom
backgroundobject
partner
acceler
order
remov
year
entri
dogma
within
clinic
trial
design
age
entri
adult
trial
flexibl
base
consider
biolog
safeti
trial
specif
teenag
young
adult
less
common
even
childrenadolesc
tend
group
children
thu
exclud
adult
trial
contend
inclus
trial
base
medic
need
rather
arbitrari
age
limit
designmethod
age
clinic
trial
entri
reduc
year
adult
earli
phase
cancer
drug
studi
unless
medicalscientif
reason
upper
lower
age
limit
criteria
iii
aya
diseas
present
paediatr
adult
biolog
trial
enrol
adolesc
alway
conduct
set
adolesc
still
includ
paediatr
ii
iii
relev
maximis
therapeut
opportun
young
adult
permit
particip
paediatr
phase
especi
paediatr
type
cancer
indic
propos
regulatori
market
authoris
applic
given
cancer
drug
includ
adolesc
time
adult
authoris
result
improv
access
adolesc
new
cancer
drug
better
understand
biolog
respons
moa
explor
differ
exist
adolesc
adult
posit
influenc
paediatr
drug
develop
earli
sign
activ
paediatr
diseas
present
adolesc
posit
influenc
adult
drug
develop
increas
likelihood
achiev
proof
conceptproof
principl
drug
brand
new
mechan
action
conclus
safe
recruit
teenag
adult
earli
drug
trial
ye
either
adult
phase
phase
trial
sharma
p
n
kidscan
treatment
support
program
new
delhi
india
backgroundobject
survey
nutrit
practic
children
cancer
india
establish
defici
provis
nutrit
servic
variabl
exist
practic
nutrit
assess
intervent
address
problem
cankid
profit
childhood
cancer
organis
develop
ppsn
model
designmethod
use
siop
podc
algorithm
start
point
nutrit
assess
intervent
ppsn
model
provid
necessari
resourc
resourc
includ
dietitian
staffth
dietician
manag
nutrit
statu
child
prospect
assess
counsel
risk
stratificationth
social
support
team
parent
support
group
psg
worker
work
dietician
deliv
programinform
educ
commun
materi
nutrit
hygienenutrit
supplement
desir
home
base
industri
supplement
providedin
addit
advocaci
stakehold
engag
promot
nation
group
call
poshan
result
dietician
provid
support
cancer
center
india
last
psg
worker
train
nutrit
session
awar
gener
nutrit
session
hygien
mainten
recip
exhibit
focu
group
discuss
conduct
equip
anthropometr
measur
provid
nutrit
manag
guidebook
famili
languag
snake
ladder
game
child
educ
develop
feed
program
provid
beneficiari
per
month
center
supplement
support
provid
patient
base
risk
parent
children
particip
nutrit
awar
campaign
across
india
nutrit
week
celebr
awar
gener
commun
level
conclus
ppsn
model
feasibl
deliv
nutrit
support
set
studi
measur
impact
plan
au
sudjoko
onkolog
anak
indonesia
secretari
jakarta
barat
indonesia
backgroundobject
increas
public
awar
children
cancer
import
earli
detect
subsequ
care
mission
indonesian
childhood
cancer
foundat
yayasan
onkolog
anak
indonesia
yoai
indonesia
archipelago
island
straddl
equat
mani
spars
inhabit
howev
popul
oncologist
specialist
children
cancer
found
outsid
urban
area
mani
children
cancer
must
travel
far
find
treatment
jakarta
capit
indonesia
yoai
taken
initi
offer
outreach
promot
seminar
laymen
profession
far
flung
commun
road
show
designmethod
road
show
give
inform
present
public
awar
children
cancer
cooper
commun
health
center
school
relev
organ
scientif
seminar
offer
doctor
nurs
student
academ
medic
institut
cooper
hospit
univers
present
held
result
road
show
help
rais
awar
children
cancer
need
region
outsid
urban
area
assist
forward
need
also
encourag
doctor
becom
specialist
field
childhood
oncolog
conclus
yoai
road
show
past
two
year
hospit
jakarta
also
citi
bandung
jogyakarta
solo
surabaya
padang
medan
garut
cirebon
goal
move
cover
whole
provinc
indonesia
p
tutelman
c
j
j
ek
f
c
k
l
p
h
health
centr
centr
pediatr
pain
research
halifax
canada
hospit
sick
children
child
health
evalu
scienc
toronto
canada
hospit
sick
children
anesthesia
pain
medicin
toronto
canada
health
centr
halifax
canada
inc
cancer
knowledg
network
toronto
canada
ottawa
nurs
ottawa
canada
hospit
sick
children
haematologyoncolog
toronto
canada
laval
famili
emerg
medicin
quebec
citi
canada
healthcar
consult
halifax
canada
backgroundobject
social
media
increasingli
use
dissemin
health
inform
connect
expert
patient
rais
awar
medic
condit
fund
canadian
cancer
societi
kidscancerpain
social
media
campaign
partnership
cancer
knowledg
network
aim
deliv
inform
pediatr
cancer
pain
parent
studi
evalu
use
thunderclap
crowdspeak
social
media
platform
rais
awar
kidscancerpain
designmethod
thunderclap
campaign
introduc
kidscancerpain
creat
thunderclap
organ
social
media
event
support
share
similar
messag
via
twitter
andor
facebook
day
time
support
invit
via
emailnewslett
blast
onlin
promot
target
invit
join
support
author
thunderclap
send
messag
parent
want
see
child
pain
help
us
make
cancer
less
pain
kid
kidscancerpain
via
twitterfacebook
account
set
datetim
result
juli
uniqu
social
media
account
twitter
facebook
join
kidscancerpain
thunderclap
held
juli
et
result
social
reach
peopl
make
largest
childhood
cancer
thunderclap
date
support
individu
organ
includ
cancer
health
researchacadem
pain
group
eg
canadian
cancer
societi
wego
health
etc
major
support
canada
follow
unit
state
australia
unit
kingdom
thunderclap
kidscancerpain
trend
twitter
canada
ie
becam
viral
topic
support
use
messag
modifi
messag
content
post
support
unavail
due
privaci
set
account
conclus
thunderclap
novel
rapid
way
build
widespread
awar
pediatr
cancer
pain
kidscancerpain
campaign
challeng
opportun
discuss
k
yamashita
cancer
associ
japan
chairman
japan
luke
intern
hospit
pediatr
tokyo
japan
backgroundobject
develop
public
variou
booklet
guidelin
serv
need
patient
famili
one
import
task
children
cancer
associ
japan
known
ccaj
sinc
four
guidelin
ie
support
patient
famili
educ
patient
support
survivor
palli
care
publish
plan
start
develop
fifth
guidelin
focus
sibl
whose
difficulti
well
known
enough
attent
given
guidelin
conclud
dec
publish
feb
designmethod
work
group
organ
member
sibl
childhood
cancer
patient
mother
farther
survivor
pediatrician
nurs
social
worker
primari
school
teacher
nurseri
teacher
start
total
meet
wg
held
enthusiast
discuss
made
conclus
dec
addit
open
discuss
made
annual
open
symposium
held
conjunct
annual
congress
jspho
jspon
reflect
final
draft
result
guidelin
titl
sibl
childhood
cancer
patient
need
main
publish
feb
guidelin
written
manner
address
care
sibl
describ
variou
situat
sibl
face
treatment
patient
last
section
design
address
sibl
key
messag
alon
card
sibl
write
exchang
messag
also
enclos
attach
conclus
guidelin
expect
help
deepen
understand
sibl
childhood
cancer
patient
surround
includ
parent
also
serv
trigger
effect
dialogu
sibl
jan
g
c
van
de
terwisscha
van
r
van
h
center
pediatr
surgeri
utrecht
netherland
center
pediatr
oncolog
utrecht
netherland
medic
center
pediatr
surgeri
amsterdam
netherland
universiteit
medic
center
pediatr
surgeri
amsterdam
netherland
medic
center
pediatr
surgeri
rotterdam
netherland
medic
center
pediatr
surgeri
groningen
netherland
univers
mathemat
institut
leiden
netherland
univers
medic
center
pediatr
surgeri
nijmegen
netherland
backgroundobject
establish
surgeri
relat
complic
mortal
sequela
larg
cohort
patient
neuroblastoma
nbl
evalu
impact
extent
resect
surviv
local
recurr
patient
designmethod
retrospect
cohort
studi
includ
patient
underw
primari
tumor
resect
nbl
netherland
start
central
care
surgeri
relat
complic
mortal
sequela
document
patient
overal
surviv
os
event
free
surviv
ef
cumul
incid
relaps
cir
total
number
local
recurr
nlr
estim
complet
resect
result
surgeri
perform
children
perop
complic
rate
postop
complic
rate
picu
support
surgic
complic
necessari
secondari
surgeri
perform
five
children
die
surgeri
relat
caus
complic
occur
children
sequela
total
children
stratifi
patient
complet
resect
ef
os
cir
nlr
resect
ef
os
cir
nlr
resect
ef
os
cir
nlr
conclus
larg
seri
surgeri
relat
advers
event
children
treat
neuroblastoma
present
surgeri
neuroblastoma
associ
signific
morbid
mortalityfor
patient
signific
differ
found
overal
surviv
event
free
surviv
cumul
incid
relaps
total
number
local
recurr
complet
resect
h
wang
children
capit
medic
univers
surgic
oncolog
beij
china
backgroundobject
gross
total
resect
gtr
even
advanc
neuroblastoma
although
still
controversi
may
relev
higher
rate
complic
gtr
goal
surgeri
case
import
know
better
possibl
complic
particularli
injuri
kidney
urinari
tract
common
abdomin
neuroblastoma
designmethod
consecut
patient
underw
primari
tumor
resect
enrol
hospit
hospit
januari
januari
review
medic
record
data
case
identifi
kidney
urinari
tract
injuri
result
case
patient
age
month
year
inss
stage
patient
accept
preoper
case
underw
intraop
nephrectomi
due
renal
vascular
encas
due
invas
parenchyma
nephrectomi
plane
case
found
ischemia
kidney
atrophi
case
show
renal
atrophi
three
month
postoper
case
show
differ
amount
ischemia
affect
case
show
hydronephrosi
dilat
uret
normal
renal
case
found
minim
abnorm
disloc
kidney
renal
caculu
calc
deposit
outlin
kidney
undistinguish
case
underw
renal
arteri
reconstrut
intraoper
sever
injuri
arteri
ischemia
kiney
one
show
normal
blood
suppli
kidney
renal
atrophi
conclus
surgic
complic
kidney
urinari
tract
commonth
continu
improv
manipul
surgeri
importantimag
indic
help
tailor
surgic
strategi
neuroblastoma
mishra
g
gandhi
cancer
institut
research
centr
pediatr
surgic
oncolog
delhi
india
gandhi
cancer
institut
research
centr
pediatr
hematolog
oncolog
delhi
india
gandhi
cancer
institut
research
centr
pediatr
hematolog
oncolog
delhi
india
backgroundobject
except
outcom
neuroblastoma
nb
dismal
especi
develop
countri
aim
studi
analyz
overal
surviv
os
diseas
free
surviv
df
low
intermedi
high
risk
group
nb
manag
institut
last
year
designmethod
retrospect
analysi
hospit
record
patient
nb
done
januari
dec
patient
median
age
yr
f
ratio
primari
site
adren
paraspin
retroperiton
mediastin
olfactori
cervic
unknown
came
opinion
lost
follow
admiss
includ
patient
came
surgeri
radiat
remain
studi
result
inrg
risk
stratif
show
low
risk
intermedi
risk
high
risk
idrf
present
patient
two
neonat
stage
iv
succumb
earli
remain
low
intermedi
risk
patient
well
combin
chemotherapi
surgeri
close
observ
alon
surgeri
done
patient
spontan
regress
seen
low
risk
patient
high
risk
group
underw
autolog
stem
cell
transplant
differenti
therapi
aliv
well
anti
therapi
avail
low
intermedi
high
risk
group
patient
respect
drop
high
risk
group
patient
long
term
follow
conclus
despit
tremend
challeng
resourc
challeng
nation
treatment
nb
feasibl
high
volum
pediatr
oncolog
centr
facil
autolog
stem
cell
transplant
result
compar
publish
literatur
c
elbourn
r
j
k
children
john
oxford
depart
paediatr
surgeri
oxford
unit
kingdom
children
john
oxford
depart
paediatr
surgeri
oxford
unit
kingdom
children
john
oxford
oxford
tissu
bank
oxford
unit
kingdom
children
john
oxford
depart
paediatr
oncolog
oxford
unit
kingdom
backgroundobject
ten
young
peopl
age
diagnos
cancer
everi
day
eight
cure
one
becom
infertil
result
treatment
cryopreserv
gonad
tissu
preserv
fertil
endogen
hormon
product
extrem
success
avail
increas
number
children
aim
share
experi
servic
designmethod
initi
develop
provid
women
girl
cancer
abil
preserv
ovarian
tissu
undergo
intens
treatment
servic
rapidli
expand
incorpor
testicular
cryopreserv
boy
inclus
children
haematolog
condit
undergo
cur
bone
marrow
transplant
referr
receiv
across
england
wale
assess
specialist
multidisciplinari
team
children
famili
receiv
counsel
specialist
paediatr
consult
surgic
team
possibl
retriev
gonad
tissu
via
testicular
biopsi
laparoscop
unilater
oophorectomi
perform
concomitantli
requir
procedur
tissu
receiv
directli
theatr
process
onsit
tissu
bank
team
children
day
case
procedur
result
sinc
begin
children
undergon
gonad
tissu
retriev
cryopreserv
testicular
biopsi
perform
boy
unilater
laparoscop
oophorectomi
perform
girl
age
undergon
concurr
procedur
includ
central
venou
line
insert
lymph
node
biopsi
bone
marrow
aspir
girl
cancer
haematolog
diseas
includ
girl
sickl
cell
anaemia
thalassaemia
servic
grown
tenfold
continu
expand
conclus
laparoscop
oophorectomi
testicular
biopsi
facilit
gonad
tissu
cryopreserv
safe
effect
servic
provid
hope
children
famili
undergo
treatment
cancer
haematolog
diseas
baker
c
f
p
h
r
hospit
sick
children
paediatr
surgeri
edinburgh
unit
kingdom
hospit
sick
children
paediatr
oncolog
edinburgh
unit
kingdom
infirmari
edinburgh
reproduct
medicin
edinburgh
unit
kingdom
backgroundobject
advanc
treatment
childhood
cancer
show
ever
improv
surviv
rate
treatment
childhood
malign
howev
lead
prematur
gonad
failur
present
centr
experi
use
cortic
strip
harvest
ovarian
tissu
cryopreserv
retain
remaind
ovari
situ
designmethod
paper
describ
surgic
techniqu
periop
care
regimen
detail
demograph
data
case
ten
year
period
review
complic
discuss
outcom
method
cryopreserv
use
ovarian
tissu
result
thirti
patient
identifi
undergon
laparoscop
ovarian
cortic
strip
harvest
data
avail
median
age
oper
rang
signific
bleed
adhesion
obstruct
injuri
organ
report
case
convert
open
procedur
return
theatr
earli
postop
pain
found
featur
thought
secondari
gonad
trauma
five
patient
sinc
die
result
underli
diagnosi
three
menstruat
document
date
two
patient
known
fallen
pregnant
natur
sinc
surgeri
one
pregnanc
progress
childbirth
conclus
laparoscop
ovarian
cortic
strip
harvest
safe
procedur
although
perform
part
integr
servic
fertil
laboratori
specialist
suitabl
accredit
oversight
offer
possibl
conceiv
natur
via
reimplant
patient
risk
earli
infertil
result
treatment
sw
warmann
j
children
hospit
pediatr
surgeri
pediatr
urolog
tuebingen
germani
children
hospit
pediatr
oncolog
tuebingen
germani
hospit
diagnost
intervent
radiolog
tuebingen
germani
backgroundobject
bilater
surgeri
nss
surgic
approach
choic
bilater
renal
tumor
children
howev
central
locat
tumor
involv
renal
hilu
repres
surgic
challeng
designmethod
evalu
children
bilater
renal
tumor
involv
renal
hilu
oper
center
serv
surgic
refer
center
pediatr
renal
tumor
result
fifteen
children
evalu
girl
boy
median
age
month
children
undergon
neoadjuv
chemotherapi
median
oper
time
minut
perform
bilater
nss
case
unilater
nss
children
singl
kidney
contralater
tumor
nephrectomi
elsewher
unilater
nss
contralater
tumor
nephrectomi
children
reason
two
nephrectomi
loss
function
nss
prior
referr
one
case
cava
thrombosi
plu
extraren
diseas
case
one
patient
undergo
bilater
surgeri
perform
singl
stage
approach
median
vascular
exclus
time
patient
hilu
involv
minut
children
requir
urinari
leakag
histolog
reveal
intermedi
risk
patient
high
risk
patient
nephroblastomatosi
patient
one
child
high
risk
nephroblastoma
blastem
type
diffus
anaplasia
cava
thrombu
diseas
combin
pulmon
abdomin
relaps
die
month
surgeri
patient
aliv
without
evid
diseas
organ
function
median
month
conclus
children
bilater
renal
tumor
treat
especi
undergo
surgeri
center
special
expertis
field
condit
surgeri
central
bilater
renal
tumor
execut
satisfactori
surgic
function
oncolog
outcom
p
ehrlich
e
g
k
sen
r
r
e
j
c
j
e
j
michigan
surgeri
ann
arbor
usa
michigan
radiolog
ann
arbor
usa
univers
st
loui
radiolog
st
lou
usa
washington
surgeri
seattl
usa
univers
surgeri
boston
usa
hospit
philadelphia
radiolog
philadelphia
usa
children
hopsit
surgeri
salt
lake
citi
usa
children
hopsit
surgeri
long
island
usa
children
hospit
surgeri
cincinnati
usa
farber
oncolog
boston
usa
children
hospit
oncolog
cincinnati
usa
children
hospit
oncolog
halifax
canada
radiat
oncolog
chicago
usa
oncolog
group
renal
tumor
philadelpahia
usa
nation
medic
center
onoclog
washington
dc
usa
british
columbia
oncolog
vancouv
canada
backgroundobject
children
oncolog
group
cog
studi
show
patient
whose
pulmonari
lesion
complet
respons
cr
week
vincristin
dactinomycin
doxorubicin
avoid
pulmonari
xrt
outstand
overal
surviv
patient
achiev
cr
receiv
pulmonari
xrt
possibl
patient
benign
lesion
necrot
wilm
tumor
wilm
tumor
may
requir
xrt
purpos
exploratori
studi
examin
feasibl
extent
surgic
resect
prsd
patient
enrol
designmethod
patient
enrol
cog
stage
iv
wt
due
pulmonari
metastasi
either
prsd
less
lesion
week
chemotherapi
elig
initi
week
chest
ct
review
surgeon
radiologist
evalu
number
locat
resect
residu
lesion
studi
resect
consid
feasibl
lesion
peripher
requir
wedg
resect
could
perform
thorascop
resect
would
requir
total
lobectomi
consid
feasibl
result
patient
enrol
either
prsd
less
lesion
sd
pr
patient
residu
lesion
surgeri
consid
feasibl
thorascop
surgeri
deem
feasibl
total
extent
surgeri
includ
singl
wedg
resect
patient
wedg
section
singl
lobe
patient
wedg
resect
differ
lobe
singl
lung
patient
would
requir
wedg
resect
lung
conclus
thorascop
resect
pulmonari
noldu
consid
feasibl
pdsd
week
cheotherapi
select
prsd
patient
mayb
good
candid
surgeri
could
avoid
xrt
cozzi
f
univers
rome
pediatr
surgeri
unit
rome
itali
backgroundobject
renal
dysfunct
children
unilater
renal
tumor
urt
may
surrog
marker
low
nephron
number
endow
therefor
includ
baselin
renal
function
among
match
criteria
use
compar
renal
function
outcom
surgeri
nss
versu
nephrectomi
balanc
group
children
urt
designmethod
review
prospect
maintain
databas
children
urt
treat
institut
thirteen
patient
underw
nss
match
thirteen
patient
underw
nephrectomi
propens
score
includ
age
surgeri
stage
age
sex
histolog
type
estim
glomerular
filtrat
rate
egfr
number
preoper
patient
renal
dysfunct
egfr
renal
function
outcom
evalu
longitudin
studi
egfr
result
surgeri
patient
group
present
renal
dysfunct
studi
show
renal
function
advantag
nss
nephrectomi
egfr
vs
longitudin
studi
egfr
show
stabl
renal
function
nephrectomi
signific
increas
nss
last
patient
nephrectomi
none
nss
present
renal
dysfunct
conclus
children
urt
treat
nss
comparison
children
treat
nephrectomi
may
present
surgeri
better
recoveri
renal
function
reach
valu
within
rang
two
kidney
renal
function
similar
children
urt
treat
nephrectomi
may
present
renal
dysfunct
k
elmalik
e
r
j
l
f
b
l
r
midland
children
young
person
integr
cancer
servic
paediatr
surgeri
leicest
unit
kingdom
children
hospit
paediatr
surgeri
sheffield
unit
kingdom
children
hospit
paediatr
radiolog
sheffield
unit
kingdom
midland
children
young
person
integr
cancer
servic
paediatr
radiolog
leicest
unit
kingdom
midland
children
young
person
integr
cancer
servic
paediatr
surgeri
nottingham
unit
kingdom
backgroundobject
manag
wilm
tumour
uniqu
uk
siop
protocol
follow
howev
current
biopsi
perform
team
investig
potenti
influenc
biopsi
local
recurr
aim
studi
examin
techniqu
biopsi
designmethod
three
centr
retrospect
data
analysi
use
medic
record
histopatholog
report
three
centr
studi
limit
due
variabl
document
within
three
site
long
period
time
result
hundr
forti
case
renal
tumour
identifi
femal
male
averag
age
diagnosi
wilm
tumour
other
ccsk
cystic
nephroma
renal
cell
carcinoma
stage
stage
stage
stage
risk
stratif
show
high
risk
intermedi
low
risk
approach
biopsi
open
percutan
nine
percutan
case
sheath
use
needl
gaug
rang
radiologist
perform
biopsi
case
surgeon
multipl
core
taken
sampl
ultrasound
guidanc
utilis
major
guid
biopsi
one
patient
develop
bleed
biopsi
howev
none
underw
emerg
nephrectomi
conclus
first
studi
look
techniqu
biopsi
renal
tumour
result
show
techniqu
safe
whether
perform
radiologist
surgeon
surgeon
radiologist
need
improv
document
fine
detail
perform
percutan
biopsi
bn
kd
ch
mk
yh
v
dwq
sw
yt
fkc
sy
kte
ahp
loh
univers
singapor
faculti
scienc
singapor
singapor
women
children
hospit
depart
paediatr
subspecialti
haematolog
oncolog
servic
singapor
singapor
women
children
hospit
depart
patholog
laboratori
medicin
singapor
singapor
women
children
hospit
paediatr
solid
tumour
research
laboratori
singapor
singapor
univers
singapor
yong
loo
lin
school
medicin
singapor
singapor
women
children
hospit
depart
paediatr
surgeri
singapor
singapor
cancer
centr
singapor
divis
radiat
oncolog
singapor
singapor
backgroundobject
wilm
tumor
demonstr
signific
epidemiolog
histolog
outcom
differ
ethnic
group
yet
clinicopatholog
molecular
profil
poorli
studi
asian
also
incid
biolog
risk
factor
asian
popul
known
aim
character
featur
wilm
tumor
patient
multiraci
cohort
designmethod
clinic
chart
histolog
slide
patient
malign
renal
tumor
seen
institut
januari
decemb
review
genotyp
use
identifi
loss
heterozygos
clinicopatholog
molecular
characterist
surviv
outcom
asian
patient
compar
result
malign
renal
tumor
wilm
tumor
asian
mean
age
diagnosi
year
sd
year
girl
among
asian
femal
respect
unfavor
histolog
occur
frequent
asian
respect
focal
diffus
anaplasia
compar
asian
yet
nephrogen
rest
encount
asian
patient
perilobar
intralobar
present
advanc
diseas
nation
wilm
tumor
studi
nwt
stage
iii
stage
iv
compar
asian
stage
iii
stage
iv
lymph
node
metastas
rate
similar
asian
asian
patient
bilater
tumor
one
patient
stage
v
diseas
follow
treatment
nwt
regimen
overal
surviv
differ
asian
patient
respect
test
conclus
asian
patient
equal
gender
ratio
less
unfavor
histolog
anaplasia
less
advanc
diseas
present
biolog
base
differ
potenti
implic
treatment
recommend
asian
patient
warrant
studi
collin
murthi
j
children
hospit
westmead
paediatr
surgeri
westmead
australia
children
hospit
westmead
radiolog
westmead
australia
sydney
sydney
medic
school
sydney
australia
children
hospit
westmead
paediatr
oncolog
thorac
surgeri
westmead
australia
sydney
children
cancer
research
unit
sydney
australia
backgroundobject
imag
guid
local
pulmonari
lesion
suspect
metastas
infect
prior
thoracoscop
biopsi
aid
identif
minim
invas
approach
techniqu
use
facilit
identif
lesion
thoracoscopi
includ
methylen
blue
tattoo
hookwir
localis
ct
guidanc
describ
surgic
result
use
techniqu
alon
combin
improv
intra
oper
localis
lesion
thoracoscopi
designmethod
retrospect
audit
includ
case
ct
guid
localis
surgic
excis
pulmonari
lesion
identifi
institut
surgic
radiolog
databas
review
method
ct
localis
singl
hookwir
methylen
blue
versu
intraop
find
includ
success
techniqu
abil
identifi
lesion
histopatholog
find
result
eighteen
children
male
femal
age
rang
year
underw
ct
guid
local
prior
surgic
excis
pulmonari
lesion
eleven
case
involv
use
hookwir
methylen
blue
case
use
methylen
blue
case
use
hook
wire
histolog
metastat
nodul
fungal
infect
remain
chang
lymph
node
thoracoscop
resect
suspici
lesion
possibl
except
one
case
methylen
blue
use
spilt
throughout
thorax
case
previous
unidentifi
pleural
base
lesion
biopsi
diagnost
infect
two
case
techniqu
use
one
techniqu
fail
one
hookwir
one
methylen
blue
howev
lesion
success
biopsi
due
local
techniqu
conclus
preoper
imag
guid
localis
pulmonari
lesion
facilit
minim
invas
thoracoscop
identif
biopsi
lesion
recommend
use
hookwir
tattoo
improv
chanc
localis
lesion
accur
biopsi
irtan
l
h
md
n
j
c
aphp
pediatr
surgeri
pari
franc
roussi
institut
pediatr
oncolog
villejuif
franc
institut
pediatr
oncolog
pari
franc
aphp
pediatr
oncolog
pari
franc
institut
oncolog
pari
franc
pediatr
oncolog
pari
franc
enfant
malad
aphp
pediatr
surgeri
pari
franc
institut
pediatr
radiolog
pari
franc
backgroundobject
patient
metastat
osteosarcoma
poor
outcom
surgic
remov
lung
metastas
thought
improv
surviv
dramat
increas
qualiti
allow
detect
endless
smaller
nodul
whose
exact
natur
remain
difficult
assess
aim
determin
presenc
least
one
nodul
diagnosi
impact
surviv
describ
evolut
manag
lung
nodul
cours
treatment
designmethod
analysi
perform
patient
three
centr
includ
trial
treat
methotrex
base
chemotherapi
chest
perform
diagnosi
lung
surgeri
end
treatment
relaps
case
recurr
central
review
result
among
patient
diagnos
median
age
year
patient
classifi
diagnosi
metastat
local
doubt
case
central
review
nodul
found
diagnosi
patient
patient
classifi
metastat
doubt
patient
consid
local
median
number
nodul
per
patient
median
size
mm
nodul
round
case
calcifi
assess
nodul
still
detect
patient
nodul
diagnosi
appear
one
patient
nodul
diagnosi
among
patient
oper
overal
surviv
osef
patient
least
one
nodul
diagnosi
versu
nodul
respect
os
ef
conclus
detect
lung
nodul
diagnosi
osteosarcoma
regardless
evolut
manag
seem
neg
impact
os
g
seitz
j
e
pediatr
adolesc
medicin
depart
pediatr
surgeri
marburg
germani
pediatr
adolesc
medicin
depart
gener
pediatr
neonatolog
marburg
germani
stuttgart
zentrum
und
frauenmedizin
pediatr
immunolog
stuttgart
germani
hospit
depart
pediatr
surgeri
urolog
tuebingen
germani
hospit
depart
pediatr
hematolog
oncolog
frankfurtmain
germani
backgroundobject
rhabdomyosarcoma
rm
femal
genit
tract
rare
vagin
tumor
seem
favor
prognosi
local
control
may
consist
surgeri
andor
radiotherapi
might
associ
sever
side
effect
young
children
aim
studi
evalu
treatment
outcom
patient
treat
within
four
cooper
soft
tissu
sarcoma
cw
trial
designmethod
patient
suffer
local
rm
femal
genit
tract
vaginauteru
enrol
analyz
patient
treat
accord
cw
studi
protocol
result
overal
surviv
rate
event
free
suviv
ef
median
age
year
median
year
patient
embryon
one
patient
alveolar
histolog
forti
patient
year
ef
fourteen
year
ef
fourti
tumor
locat
vagina
ef
uteru
ef
tumor
better
ef
n
n
posit
lymph
node
diagnosi
detect
patient
ef
primari
resect
carri
patient
ef
secondari
resect
patient
ef
complet
resect
influenc
outcom
radiotherapi
use
patient
ef
patient
treat
sole
chemotherapi
conclus
outcom
patient
suffer
rm
femal
genit
tract
compar
local
urogenit
tract
almost
patient
local
control
tumor
locat
uteru
seem
trend
toward
better
ef
locat
vagina
tumor
size
age
posit
predict
factor
outcom
extent
surgic
resect
impact
outcom
b
l
c
p
w
anderson
cancer
center
surgeri
houston
texa
usa
anderson
cancer
center
biostatist
houston
texa
usa
anderson
cancer
center
pediatr
houston
texa
usa
cleveland
clinic
pediatr
hematolog
oncolgi
blood
marrow
transplant
oh
usa
backgroundobject
desmoplast
small
round
cell
tumor
dsrct
rare
form
sarcoma
primarili
affect
adolesc
patient
frequent
present
hundr
periton
tumor
implant
histor
patient
reach
overal
surviv
inabl
obtain
complet
abdomin
resect
impact
surviv
dsrct
use
combin
system
chemotherapi
cytoreduct
surgeri
hypertherm
intraperiton
chemotherapi
adjuv
radiotherapi
almost
patient
pelvic
tumor
diagnosi
hypothes
pelvic
peritonectomi
neoadjuv
chemotherapi
essenti
control
primari
tumor
designmethod
review
patient
underw
complet
cisplatin
dsrct
sinc
pelvic
peritonectomi
routin
perform
march
compar
patient
receiv
pelvic
peritonectomi
regardless
macroscop
visibl
diseas
pelvi
patient
receiv
neoadjuv
adjuv
chemotherapi
receiv
adjuv
radiotherapi
result
patient
rang
age
year
follow
postop
year
pelvic
peritonectomi
ad
standard
oper
approach
patient
develop
local
recurr
recurr
locat
pelvi
alon
without
distant
diseas
local
recurr
rate
decreas
make
chang
among
patient
least
month
median
surviv
month
median
overal
surviv
month
median
postop
surviv
month
vs
month
significantli
longer
patient
patient
conclus
complet
cytoreduct
includ
routin
pelvic
peritonectomi
substanti
reduc
local
recurr
rate
dsrct
techniqu
local
control
rate
achiev
dsrct
patient
underw
f
guerin
g
tn
terwisscha
van
g
guillen
v
h
gl
de
g
h
hospit
aphp
paediatr
surgeri
le
kremlin
bicetr
franc
hospit
padua
paediatr
surgeri
padova
itali
hospit
sick
children
paediatr
surgeri
bristol
unit
kingdom
centrum
voor
kinderoncologi
paediatr
surgeri
utrecht
netherland
universitari
vall
dhebron
paediatr
surgeri
barcelona
spain
roussi
cancer
campu
paediatr
oncolog
villejuif
franc
royal
marsden
nh
foundat
trust
clinic
oncolog
sutton
unit
kingdom
manchest
children
hopsit
patholog
manchest
unit
kingdom
oncologico
veneto
uo
sperimentazioni
biostatistica
e
nucleo
ricerca
clinica
padova
itali
hospit
padua
paediatr
oncolog
padova
itali
backgroundobject
evalu
impact
local
treatment
therapi
outcom
patient
duct
rhabdomyosarcoma
designmethod
analyz
data
patient
liver
bile
duct
includ
rm
protocol
delay
surgeri
andor
extern
beam
radiat
therapi
ebrt
perform
least
cours
chemotherapi
result
one
patient
embryon
rm
tumour
median
age
diagnosi
year
year
patient
primari
surgeri
ir
ir
ii
ir
iii
consist
bile
duct
excis
bde
whippl
procedur
four
also
receiv
ebrt
first
complet
remiss
except
one
ir
ii
ebrt
local
relaps
death
patient
receiv
ebrt
alon
one
local
relaps
death
patient
underw
secondari
surgeri
addit
ebrt
bde
includ
whippl
procedur
bde
partial
hepatectomi
partial
hepatectomi
four
patient
underw
ebrt
without
recurr
among
patient
receiv
ebrt
one
metastat
relaps
die
ten
patient
receiv
ebrt
relaps
local
die
summari
local
relaps
occur
among
patient
ebrt
among
without
ebrt
median
year
year
patient
aliv
five
patient
die
local
metastat
relaps
os
ef
conclus
local
relaps
often
fatal
analysi
show
differ
outcom
surgeri
alon
surgeri
howev
possibl
sequela
ebrt
hepat
pedicl
could
balanc
safeti
bde
roux
en
loop
e
hiyama
k
univers
hospit
peditr
surgeri
hiroshima
japan
children
cancer
group
liver
tumor
committe
tokyo
japan
backgroundobject
aim
evalu
intervent
surgic
treatment
spontan
tumor
ruptur
hepat
tumor
jplt
japanes
studi
group
pediatr
liver
tumor
studi
designmethod
patient
hepat
malign
enrol
studi
show
spontan
tumor
ruptur
diagnosi
age
diagnosi
sex
patholog
liver
diseas
pretext
classif
clinic
present
assess
embol
perform
select
fashion
possibl
treatment
complic
surviv
examin
result
pretext
ii
iii
iv
includ
metastat
tumor
age
rang
diagnosi
month
male
femal
histolog
examin
reveal
hepatoblastoma
hepatocellular
carcinoma
sarcoma
transarteri
embol
perform
case
wherea
show
uncontrol
bleed
case
die
massiv
bleed
remain
case
pretext
ii
case
underw
primari
resect
tumor
case
tumor
biopsi
follow
preoper
chemotherapi
case
receiv
chemotherapi
without
tumor
biopsi
case
preoper
chemotherapi
die
tumor
progress
surgeri
remain
case
underw
tumor
resect
includ
receiv
liver
transplant
postop
chemotherapi
perform
case
includ
high
dose
chemotherapi
howev
case
show
recurr
case
die
conclus
spontan
tumor
ruptur
unfavor
prognost
factor
pediatr
liver
tumor
adequ
surgic
intervent
treatment
control
tumor
bleed
aggress
chemotherapi
might
necessari
improv
outcom
patient
njere
l
z
e
b
c
georg
univers
london
paediatr
surgeri
london
unit
kingdom
georg
univers
london
patholog
london
unit
kingdom
backgroundobject
determin
invas
procedur
necessari
follow
incident
find
appendic
carcinoid
tumour
appendicectomi
designmethod
search
medlin
embas
cinahl
cochran
databas
systemat
review
undertaken
english
languag
literatur
mesh
term
use
carcinoid
neuroendocrin
tumour
tumor
appendix
appendicectomi
appendectomi
child
paediatr
paediatr
articl
found
met
inclus
criteria
hospit
record
patholog
databas
identifi
confirm
histolog
diagnosi
appendicular
carcinoid
januari
decemb
result
total
case
identifi
literatur
experi
femal
male
give
us
ratio
frequenc
appendicectomi
appendicectomi
twenti
increas
risk
posit
lymph
node
tumour
size
compar
risk
posit
lymph
node
tumour
size
patient
met
criteria
right
hemicolectomi
rhc
follow
appendicectomi
median
rang
recurr
note
neither
secondari
procedur
observ
mortal
carcinoid
note
group
surviv
advantag
therefor
confer
anoth
procedur
mean
rang
conclus
appendicectomi
alon
adequ
treatment
appendicular
carcinoid
children
irrespect
size
posit
lymph
node
mesenter
involv
unless
posit
margin
investig
help
long
unnecessari
ilari
g
f
g
g
salesi
children
hospit
pediatr
surgeri
ancona
itali
camillo
forlanini
gener
hospit
pediatr
surgeri
roma
itali
backgroundobject
malign
melanoma
mm
children
rare
incid
risk
melanoma
develop
larg
congenit
nevi
wide
accept
melanoma
occurr
intermedi
congenit
nevi
report
purpos
studi
discuss
surgic
indic
nevi
diagnosi
treatment
melanoma
designmethod
retrospect
review
children
age
month
year
underw
surgic
excis
nevi
indic
excis
includ
clinic
appear
site
difficult
monitor
exposur
frequent
trauma
diagnosi
mm
patient
underw
sentinel
biopsi
slnb
melanoma
thick
mm
associ
excis
tumor
site
cm
margin
primari
closur
skin
graft
result
case
first
surgic
excis
includ
mm
margin
normal
skin
around
lesion
mm
diagnos
patient
one
infant
underw
partial
excis
larg
congenit
nevu
month
also
submit
excision
biopsi
inguin
nodal
mass
result
metastat
melanoma
die
cerebr
metastasi
patient
underw
scar
excis
cm
margin
slnb
mm
diagnosi
patient
slbn
posit
perform
dissect
show
micromestas
contrari
third
patient
parent
refus
surgic
propos
treatment
remain
diseas
free
month
remain
three
patient
diseas
free
year
respect
conclus
mm
children
less
rare
commonli
believ
behaviour
diseas
differ
adulthood
clinic
trial
need
defin
biolog
find
suitabl
surgic
treatment
mm
children
crocoli
c
md
de
g
c
g
v
p
children
hospit
ircc
surgeri
rome
itali
children
hospit
ircc
oncohematolog
rome
itali
padova
pediatr
surgeri
padova
itali
gb
rossi
hematolog
verona
itali
padova
pediatr
hematolog
oncolog
padova
itali
civil
pediatr
hematolog
oncolog
pescara
itali
civili
pediatr
surgeri
brescia
itali
nazional
tumori
pediatr
oncolog
milan
itali
backgroundobject
solid
pseudopapillari
pancreat
tumor
sppt
extrem
rare
entiti
pediatr
patient
even
role
radic
surgic
resect
primari
treatment
well
establish
data
follow
children
undergon
pancreat
resect
scant
designmethod
retrospect
review
italian
pediatr
rare
tumor
registri
trep
perform
short
day
long
term
complic
differ
surgic
resect
well
long
term
follow
evalu
result
januari
februari
patient
enrol
median
age
diagnosi
year
rang
median
delay
diagnosi
month
rang
fourteen
children
occasion
diagnosi
wherea
complain
abdomin
pain
refer
recurr
vomit
tumor
aros
head
pancrea
bodytail
resect
complet
patient
duodenocephalopancreasectomi
spleen
preserv
distal
resect
n
distal
resect
splenectomi
case
microscop
spillag
record
follow
median
month
rang
local
recurr
diseas
occur
one
patient
intraop
spillag
patient
aliv
three
pancreat
fistula
occur
bodytail
group
conserv
manag
wherea
complic
occur
head
group
one
ileal
ischemia
undergon
endovascular
treatment
one
wirsung
duct
stenosi
undergon
surgic
revis
one
chilou
fistula
manag
conserv
conclus
surgeri
prove
therapeut
option
tumor
henc
complet
resect
mandatori
extens
resect
includ
duodenocephalopancreasectomi
safe
perform
special
centr
long
term
follow
must
center
oncolog
radic
residu
pancreat
function
j
wang
x
j
j
q
hospit
zhejiang
univers
school
medicin
depart
surgic
oncolog
hangzhou
china
backgroundobject
pancreat
tumor
rare
neoplasm
children
whippl
procedur
consid
standard
treatment
tumor
local
pancreat
head
howev
radic
procedur
still
controversi
pediatr
popul
sinc
pancreat
tumor
children
benign
malign
herein
present
case
pancreat
head
resect
dpphr
tumor
local
pancreat
head
children
designmethod
retrospect
singl
institut
studi
perform
case
tumor
local
pancreat
head
center
jan
dec
includ
tumor
type
pancreatoblastoma
male
femal
age
tumor
spt
male
femal
age
case
underw
dpphr
procedur
patient
pancreatoblastoma
case
spt
receiv
postop
chemotherapi
case
spt
receiv
close
without
chemotherapi
result
dpphr
perform
success
duodenum
kept
intact
case
eight
case
underw
pancreaticojejunostomi
sinc
common
bile
duct
injur
pancreat
head
resect
two
case
underw
pancreaticojejunostomi
plu
cholangiojejunostomi
case
receiv
tumor
resect
pancreat
pseudocyst
observ
case
tumor
resect
group
earli
postop
complic
time
recurr
observ
case
pancreatoblastoma
chemotherapi
recurr
tumor
local
pancreat
bodi
duodenum
wall
identifi
second
oper
conclus
pancreat
head
resect
combin
appropri
chemotherapi
safe
effect
tumor
local
pancreat
head
children
jp
luenga
c
g
nacion
de
bogota
colombia
backgroundobject
present
experi
diagnosi
treatment
pediatr
thyroid
cancer
cancer
center
bogota
colombia
designmethod
review
case
refer
institut
pediatr
thyroid
cancer
complet
inform
chart
analysi
analyz
demograph
characterist
symptom
present
diagnosi
treatment
recurr
mortal
delay
diagnosi
treatment
result
patient
year
old
mean
age
diagnosi
year
age
percent
femal
two
patient
posit
famili
histori
syndrom
present
thyroid
nodul
cervic
node
fine
needl
aspir
biopsi
use
diagnosi
patient
underw
total
thyroidectomi
papillari
thyroid
cancer
frequent
histolog
find
follow
medullari
thyroid
cancer
clear
cell
follicular
carcinoma
percent
patient
posit
node
underw
cervic
lymphadenectomi
central
compart
central
modifi
radic
lymphadenectomi
complic
rate
recurr
metastasi
mortal
seri
mean
time
diagnosi
thyroidectomi
month
rang
mean
time
iodin
abl
therapi
month
rang
conclus
pediatr
thyroid
cancer
frequent
adolesc
femal
present
nodul
cervic
node
frequent
histolog
papillari
carcinoma
patient
usual
need
type
lymphadenectomi
addit
total
thyroidectomi
nodal
diseas
mortal
remain
low
even
though
mani
patient
experienc
delay
surgic
treatment
iodin
abl
therapi
due
healthcar
issu
p
g
n
b
md
c
f
c
j
sarnacki
hospit
faculti
medicin
jacqu
pre
lyon
jean
monnet
univers
pediatr
surgeri
franc
pari
deni
robert
assist
publiqu
de
pari
pediatr
surgeri
pari
franc
lyon
hospic
civil
de
univers
franc
emr
lyon
univers
surgic
oncolog
lyon
franc
curi
adolesc
young
adult
oncolog
pari
franc
roussi
cancer
center
oncolog
surgeri
villejuif
franc
roussi
cancer
center
oncolog
child
adolesc
villejuif
franc
pari
deni
loui
assist
publiqu
de
pari
digest
surgeri
colomb
franc
univers
hospit
pediatr
surgeri
nant
franc
hospit
digest
surgeri
strasbourg
franc
hospit
pediatr
surgeri
strasbourg
franc
univers
hospit
nice
franc
clermont
chu
clermont
ferrand
digest
surgeri
clermont
ferrand
franc
pari
necker
assist
publiqu
de
pari
pediatr
surgeri
pari
franc
backgroundobject
efficaci
role
cytoreduct
surgeri
hypertherm
periton
perfus
chemotherapi
hipec
remain
unknown
pediatr
tumor
designmethod
retrospect
multicentr
nation
studi
analyz
pediatr
patient
periton
tumor
spread
treat
cytoreduct
surgeri
hipec
part
multimod
therapi
franc
result
patient
male
femal
select
median
age
year
seven
periton
mesothelioma
desmoplast
small
round
cell
tumor
dsrct
histolog
type
twenti
patient
receiv
prior
convent
chemotherapi
hipec
complet
macroscop
resect
achiev
case
incomplet
resect
classifi
case
case
fourteen
patient
complic
within
day
hipec
requir
urgent
laparotomi
case
thirteen
patient
receiv
adjuv
chemotherapi
receiv
total
abdomin
radiotherapi
surgeri
fifteen
patient
relaps
median
time
month
procedur
eventu
die
median
time
month
relaps
six
patient
aliv
progress
diseas
seven
patient
aliv
complet
remiss
median
month
mean
overal
surviv
os
diseas
free
surviv
df
month
month
patient
periton
mesothelioma
significantli
better
os
df
histolog
type
conclus
french
nation
seri
outcom
hipec
encourag
essenti
treatment
periton
mesothelioma
children
intern
random
trial
evalu
outcom
cytoreduct
surgeri
hipec
treatment
periton
tumor
spread
children
mandatori
rc
ribeiro
v
oliveira
children
cancer
hospit
pediatr
surgeri
depart
barreto
brazil
backgroundobject
use
minim
invas
surgeri
mi
greatli
expand
pediatr
surgeri
howev
applic
pediatr
cancer
still
matter
debat
purpos
describ
experi
use
minim
invas
surgeri
mi
techniqu
tertiari
center
specif
oncolog
pediatr
surgeri
unit
designmethod
retrospect
analysi
patient
undergo
mi
pediatr
oncolog
surgeri
unit
singl
institut
develop
countri
juli
februari
mi
procedur
consid
made
laparoscopi
diagnost
stage
therapeut
intent
demograph
featur
primari
diagnosi
surgic
procedur
time
length
complic
convers
rate
review
result
children
rang
month
age
underw
mi
procedur
period
laparoscopi
perform
tumor
resect
case
diagnost
purpos
case
stage
case
ten
addit
laparoscop
procedur
perform
complic
malign
treatment
median
surgic
time
length
minut
rang
minut
proctocolectomi
longest
procedur
case
safeti
principl
oncolog
surgeri
respect
one
convers
open
surgeri
relat
bleed
resect
mesenter
cyst
complic
observ
proctocolectomi
patient
present
anastomot
fistula
one
patient
episod
bowel
obstruct
anoth
trocar
site
recurr
observ
conclus
applic
mi
techniqu
pediatr
cancer
patient
safe
effect
diagnost
stage
treat
modal
mi
techniqu
safe
reproduc
fulfil
object
qualiti
cancer
surgeri
proper
equip
remain
limit
factor
along
challeng
maintain
learn
curv
wide
divers
procedur
elgendi
cancer
hospit
egypt
surgic
oncolog
depart
cairo
egypt
univers
surgic
oncolog
unit
tanta
egypt
cancer
hospit
egypt
pediatr
oncolog
depart
cairo
egypt
cancer
cairo
univers
pediatr
oncolog
depart
cairo
egypt
cancer
hospit
egypt
radiolog
depart
cairo
egypt
backgroundobject
evalu
outcom
patient
hepatoblastoma
treat
surgic
resect
hospit
year
designmethod
prospect
studi
januari
decemb
evalu
done
pretreat
extent
stage
system
pretext
tumor
biopsi
serum
alpha
fetoprotein
overal
surviv
os
event
free
surviv
ef
univari
prognost
factor
estim
use
log
rank
test
recurr
death
consid
event
result
studi
includ
patient
male
femal
median
age
diagnosi
year
pretext
ii
iii
respect
sixti
four
patient
standard
risk
sr
high
risk
hr
thirteen
patient
metastat
diagnosi
lung
bone
upfront
resect
done
patient
wherea
underw
surgeri
neoadjuv
chemotherapi
accord
risk
stratif
fifti
two
patient
underw
right
left
segmentectomi
mesohepatectomi
trisegmentectomi
follow
till
end
june
median
month
reveal
patient
event
among
local
recurr
distant
relaps
lung
brain
patient
die
postop
year
os
sr
hr
p
metastat
year
ef
sr
hr
metastat
conclus
surgic
resect
combin
system
chemotherapi
fundament
improv
outcom
year
os
ef
respect
siopel
risk
stratif
distant
metastasi
independ
impact
surviv
rate
p
kerimov
cancer
research
center
nn
blokhina
surgic
separ
tumor
thoracoabdomin
local
moscow
russia
backgroundobject
laparoscop
liver
resect
tumor
liver
patholog
children
use
rel
recent
literatur
report
laparoscop
liver
resect
children
tumor
organ
patholog
designmethod
clinic
patient
age
month
year
underw
radic
laparoscop
resect
liver
boy
girl
averag
age
patient
year
follow
patholog
diagnos
hepatoblastoma
case
liver
hyperplasia
case
metastasi
neuroblastoma
case
hemangioma
liver
case
result
hemihepatectomi
perform
patient
patient
diagnosi
hepatoblastoma
child
nodular
hyperplasia
averag
durat
oper
minut
averag
blood
loss
convers
stay
intens
care
reanim
room
dayssegment
perform
patient
patient
hepatoblastoma
detect
hyperplasia
case
neuroblastoma
case
hemangioma
case
averag
durat
oper
minut
averag
blood
loss
ml
convers
stay
intens
care
unit
intens
care
day
immedi
remot
postop
complic
among
patient
malign
liver
diseas
progress
diseas
entir
period
median
month
conclus
case
malign
patholog
strict
select
patient
requir
accord
indic
well
complianc
principl
open
surgeri
first
radic
intervent
laparoscop
oper
allow
minim
postop
complic
shorten
cours
postop
period
turn
make
possibl
start
special
antitumor
treatment
shortest
possibl
time
posit
influenc
result
therapi
fumino
k
h
prefectur
univers
medicin
pediatr
surgeri
kyoto
japan
prefectur
univers
medicin
pediatr
cardiovascular
surgeri
kyoto
japan
prefectur
univers
medicin
thorac
surgeri
kyoto
japan
prefectur
univers
medicin
pediatr
kyoto
japan
backgroundobject
giant
mediastin
germ
cell
tumor
mgct
children
rare
tumor
often
form
larg
mass
diagnosi
especi
malign
mgct
invad
surround
vital
tissu
requir
advanc
surgic
approach
retrospect
review
surgic
strategi
giant
mgct
designmethod
five
children
median
age
year
rang
giant
mgct
treat
institut
medic
chart
retrospect
review
result
initi
diagnosi
made
tumor
marker
imag
inspect
case
benign
teratoma
girl
treat
upfront
surgeri
malign
mgct
boy
show
elev
underw
radic
tumorectomi
chemotherapi
detail
radic
tumor
excis
perform
support
skill
pediatr
cardiovascular
surgeon
basic
approach
follow
cardiopulmonari
support
cp
cp
standbi
via
median
sternotomi
pericardium
phrenic
nerv
resect
en
bloc
tumor
follow
diaphragmat
plicat
open
biopsi
perform
via
later
thoracotomi
patient
malign
show
dens
adhes
fistula
format
lung
radic
resect
lobectomi
via
incis
requir
although
major
postop
complic
includ
pericardi
effus
chylothorax
requir
thoracoscop
repair
hoars
pyothoraxchylothorax
note
death
sever
sequela
occur
seri
conclus
mgct
could
initi
diagnos
base
tumor
marker
imag
find
therefor
open
biopsi
avoid
sever
adhes
surgeri
preoper
cp
ensur
safeti
advanc
surgeri
surgic
team
includ
pediatr
surgeon
also
pediatr
cardiovascular
surgeon
thorac
surgeon
requir
success
treatment
agarwala
k
ak
v
india
institut
medic
scienc
pediatr
surgeri
delhi
india
india
institut
medic
scienc
medic
oncolog
delhi
india
india
institut
medic
scienc
radiolog
delhi
india
india
institut
medic
scienc
radiodiagnosi
delhi
india
india
institut
medic
scienc
cardiovascular
thorac
surgeri
delhi
india
backgroundobject
evalu
incid
outcom
treatment
recurr
rec
malign
germ
cell
tumor
mgct
designmethod
prospect
maintain
data
patient
mgct
manag
pediatr
solid
tumor
clinic
june
decemb
analyz
evalu
incid
recurr
outcom
evalu
term
overal
surviv
os
diseas
free
surviv
df
result
mgct
case
gonad
extragonad
treat
period
recurr
primarili
treat
us
recur
refer
us
resect
recurr
incid
recurr
similar
among
gonad
tumor
incid
recurr
maximum
testicular
least
among
ovarian
tumort
testicular
os
rf
patient
among
aliv
die
give
os
howev
survivor
df
remain
progress
diseas
last
chose
discontinu
treatment
os
extragonad
gonad
recurr
recurr
primari
treatment
us
aliv
os
df
among
refer
surgeri
elsewher
aliv
os
achiev
df
conclus
incid
similar
gonad
tumor
vs
though
os
achiev
df
os
better
vs
patient
oper
elsewher
came
us
recurr
chemo
patient
patient
heavili
e
schmid
mj
r
sw
j
hospit
depart
pediatr
surgeri
pediatr
urolog
tuebingen
germani
hospit
depart
pediatr
oncolog
haematolog
tuebingen
germani
backgroundobject
rhabdoid
tumor
rt
rhabdomyosarcoma
rm
aggress
pediatr
malign
entiti
show
intrins
refractori
standard
chemotherapi
advanc
tumor
stage
associ
poor
prognosi
altern
therapeut
approach
optim
alreadi
establish
treatment
protocol
urgent
need
condit
receptor
agonist
frequent
use
analgesia
oncolog
patient
recent
propos
exert
role
influenc
tumor
cell
growth
could
promis
candid
optim
alreadi
establish
treatment
far
relat
data
pediatr
solid
tumor
designmethod
effect
combin
doxorubicin
treatment
two
rhabdomyosarcoma
two
rhabdoid
tumor
cell
line
measur
use
follow
outcom
data
cell
growth
inhibit
doxorubicin
uptak
efflux
apoptosi
reactiv
oxygen
speci
ro
product
flow
cytometri
gene
express
studi
pcr
cell
migrat
wound
heal
assay
apoptosi
express
receptor
western
blot
result
exposur
doxorubicin
significantli
increas
express
wherea
increas
doxorubicin
uptak
decreas
doxorubicin
efflux
moreov
combin
treatment
doxorubicin
result
suppress
tumor
cell
growth
enhanc
apoptosi
cell
line
mediat
increas
gener
ro
apoptosi
protein
furthermor
treatment
doxorubicin
result
signific
decreas
migrat
comparison
doxorubicin
alon
conclus
summari
new
innov
therapeut
approach
display
strong
effect
rhabdomyosarcoma
rhabdoid
tumor
cell
line
combin
therapi
doxorubicin
merit
investig
auspici
anticanc
drug
rt
rm
especi
convent
treatment
regimen
show
limit
effect
clinic
set
p
vall
infantil
de
mexico
federico
gomez
surgeri
surgic
oncolog
servic
mexico
citi
mexico
backgroundobject
surgic
treatment
complex
pediatr
oncolog
case
often
beyond
scope
expertis
gener
pediatr
surgeon
overcom
situat
formal
train
pediatr
surgic
oncolog
pso
establish
sever
comprehens
cancer
center
across
variou
countri
formal
assess
credenti
certif
establish
goal
paper
present
process
develop
board
certifi
exam
designmethod
model
clinic
practic
pso
defin
stratifi
patient
could
care
gener
pediatr
surgeon
one
refer
pso
specialist
compet
pso
fellow
specialist
identifi
integr
profil
certifi
process
plan
mexican
board
oncolog
nation
committe
specialti
board
result
team
examin
assembl
item
bank
done
suffici
amount
mcq
test
clinic
vignett
design
oral
exam
blueprint
compon
examin
complet
pilot
test
actual
examin
took
place
session
mexico
citi
mexico
februari
psychometr
analysi
mcq
item
conduct
standard
establish
three
examine
sat
first
iter
obtain
pass
score
conclus
overlap
compet
two
specialti
construct
clinic
model
practic
involv
stakehold
avoid
potenti
conflict
model
allow
us
clarifi
boundari
develop
compet
facilit
blueprint
perform
examine
expect
profil
content
specif
could
discuss
within
ipso
commun
assembl
propos
global
curriculum
subspeci
acknowledg
work
support
faimer
institut
aldiss
f
surrey
school
health
faculti
health
medic
scienc
guildford
unit
kingdom
colleg
london
hospit
nh
foundat
trust
cancer
clinic
trial
unit
london
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
centr
outcom
experi
research
children
ill
disabl
london
unit
kingdom
backgroundobject
deliveri
end
life
care
requir
broad
rang
health
care
servic
may
includ
hospit
hospic
primari
care
commun
profession
ambul
servic
dedic
palli
care
team
support
provid
essenti
deliveri
good
commun
care
coordin
effect
network
specialist
nurs
key
worker
role
identifi
provid
servic
aim
evalu
role
key
worker
end
life
care
children
young
peopl
cancer
perspect
parent
key
worker
designmethod
depth
interview
eight
parent
fourteen
key
worker
interview
transcript
analys
use
framework
analysi
result
four
main
theme
identifi
coordin
care
continu
care
posit
relationship
commun
key
worker
provid
clinic
emot
educ
practic
support
famili
coordin
care
clinic
experi
expertis
relationship
famili
profession
key
worker
facilit
profession
parent
get
know
one
anoth
becom
emot
close
posit
relationship
key
worker
built
trust
open
honest
commun
parent
provid
individualis
support
reassur
support
reassur
conjunct
key
worker
coordin
resourc
enabl
parent
children
choic
receiv
care
support
palli
phase
challeng
lack
hour
palli
care
avail
commun
establish
complex
palli
care
packag
home
provid
effect
bereav
support
famili
key
worker
offer
hour
call
servic
famili
conclus
key
worker
facilit
individualis
coordin
care
support
posit
key
relationship
central
support
given
receiv
parent
j
bai
fwk
l
univers
nhw
school
nurs
atlanta
usa
state
univers
school
medicin
detroit
usa
state
univers
karmano
cancer
institut
detroit
usa
backgroundobject
children
cancer
undergo
distress
procedur
port
start
traumat
experi
procedur
result
neg
healthcar
outcom
children
cancer
limit
data
exist
trajectori
distress
time
impact
distress
trajectori
children
qualiti
life
qol
cancer
studi
aim
character
longitudin
trajectori
distress
children
cancer
identifi
risk
factor
persist
distress
relationship
distress
trajectori
children
qol
designmethod
children
cancer
select
parent
studi
children
underw
continu
port
start
procedur
child
distress
level
procedur
assess
multipl
rater
use
revis
face
scale
assess
risk
factor
includ
demograph
clinic
variabl
baselin
parent
disposit
attribut
empath
concern
depress
neg
posit
emot
parent
report
children
qol
use
pedsqltm
cancer
modul
last
procedur
trajectori
model
use
identifi
child
distress
cluster
logist
regress
analyz
risk
factor
distress
trajectori
cluster
u
test
conduct
examin
associ
distress
trajectori
group
qol
result
trajectori
model
found
two
distinct
trajectori
cluster
distress
low
distress
group
persist
distress
group
logist
regress
show
parent
neg
emot
predict
significantli
higher
distress
level
odd
test
show
persist
distress
group
lower
procedur
anxieti
painhurt
worri
conclus
target
intervent
toward
parent
may
help
improv
qol
children
persist
distress
follow
pain
procedur
dm
bakula
cm
mn
kl
hc
jm
state
univers
psycholog
stillwat
usa
state
univeristi
psycholog
stillwat
usa
backgroundobject
burden
stress
pediatr
cancer
leav
parent
children
vulner
psycholog
distress
eg
depress
anxieti
posttraumat
stress
extant
research
suggest
relationship
exist
parent
distress
child
distress
parent
distress
tend
children
distress
although
drotar
review
relationship
studi
review
may
longer
consid
contemporari
aim
project
provid
current
comprehens
review
literatur
import
relationship
designmethod
review
publish
pediatr
literatur
conduct
via
psychinfo
pubm
articl
chosen
review
examin
parent
child
distress
avail
english
result
articl
identifi
meet
inclus
criteria
articl
report
signific
posit
relationship
parent
distress
child
distress
articl
report
relationship
exist
parent
child
distress
articl
report
assess
relationship
parent
child
distress
articl
support
exist
relationship
sampl
size
rang
util
longitudin
design
report
modest
correl
coeffici
conclus
avail
research
indic
inde
relationship
parent
psycholog
distress
child
psycholog
distress
although
unclear
whether
relationship
direct
transact
natur
find
consist
transact
stress
cope
model
adjust
chronic
health
condit
although
intervent
shown
consist
reduct
subsequ
child
distress
eg
pai
et
al
review
suggest
intervent
may
capabl
reduc
child
distress
howev
given
studi
report
analys
relationship
find
may
incomplet
research
need
assess
mechan
relationship
exist
c
bartholdson
institutet
women
health
stockholm
sweden
backgroundobject
care
children
cancer
involv
complex
decis
life
death
moral
distress
occur
one
idea
ethic
correct
act
accordingli
well
one
know
ethic
correct
make
decis
studi
moral
distress
pediatr
rare
overal
aim
describ
healthcar
profession
experi
moral
distress
pediatr
oncolog
sweden
designmethod
data
collect
perform
use
translat
cultur
adapt
paediatr
version
moral
distress
instrument
contain
statement
difficult
ethic
situat
healthcar
profession
pediatr
cancer
center
sweden
complet
questionnair
rate
level
disturb
frequenc
relat
statement
total
moral
distress
score
calcul
sum
composit
score
ie
level
disturb
x
frequenc
descript
analysi
data
conduct
use
packag
social
scienc
spss
result
total
particip
answer
questionnair
respons
rate
nurs
report
similar
level
disturb
intens
wherea
physician
report
slightli
lower
score
mean
valu
profession
group
notabl
high
furthermor
nurs
state
higher
frequenc
distress
event
compar
physician
mean
valu
profession
group
lower
end
scale
nurs
also
report
higher
level
total
moral
distress
score
compar
profess
conclus
ethic
distress
situat
disturb
healthcar
profession
lot
pediatr
cancer
care
sweden
howev
situat
occur
often
nurs
seem
experi
situat
distress
other
understand
experi
relat
moral
distress
ethic
support
tailor
assist
healthcar
profession
j
behan
f
b
rs
univers
ingram
school
nurs
montreal
canada
b
r
institut
rotari
cancer
india
institut
medic
scienc
depart
medic
oncolog
new
delhi
india
super
special
hospit
paediatr
oncolog
new
delhi
india
backgroundobject
participatori
approach
adopt
better
understand
children
actual
desir
particip
decis
discuss
action
pediatr
oncolog
set
new
delhi
india
nest
within
emerg
field
childhood
ethic
studi
guid
moral
experi
framework
seek
understand
children
valu
belief
realiz
everyday
live
designmethod
focus
ethnographi
conduct
pediatr
oncolog
set
includ
privat
public
hospit
period
key
inform
interview
conduct
follow
seri
particip
observ
interview
children
cancer
retriev
key
document
data
consolid
sourc
conduct
withinbetween
sourc
emerg
code
categor
theme
compar
analys
result
key
inform
consult
share
understand
moral
experi
children
cancer
key
text
analysi
inform
contextu
descript
set
interview
conduct
children
observ
cancer
care
particip
vari
cancer
diagnos
rang
age
conceptu
particip
develop
base
children
actual
desir
navig
world
within
pediatr
oncolog
set
children
verbal
nonnegativerb
express
prefer
particip
elicit
variou
dimens
discuss
action
children
express
vari
view
regard
concern
health
cancer
treatment
assent
nutrit
hous
children
particip
vari
discuss
involv
ask
question
listen
bodi
languagefaci
express
speak
children
action
includ
develop
understand
ill
express
likesdislik
desir
address
problem
recollect
experi
receiv
treatment
engag
teach
play
conclus
children
activ
particip
matter
affect
advanc
understand
valu
belief
may
enhanc
clinic
encount
beukhof
n
van
de
children
hospitalacadem
medic
center
pediatr
oncolog
amsterdam
netherland
backgroundobject
treatment
child
leukemia
current
take
place
hospit
mean
child
come
hospit
daili
weekli
treatment
period
least
year
januari
pilotstudi
start
children
receiv
intraven
chemotherapi
home
aim
give
chemotherapi
safe
effici
home
improv
qualiti
life
children
famili
designmethod
partnership
depart
pediatr
oncolog
emma
children
hospit
amsterdam
kinderthuiszorg
children
home
care
organ
mediq
tefa
specialist
medic
devic
possibl
give
intraven
chemotherapi
home
perform
explor
compar
studi
use
questionnair
social
impact
treatment
shorten
valid
baselin
questionnair
taken
start
pilot
repeat
week
end
pilot
month
pilot
consist
parent
children
year
took
place
januari
result
baselin
result
show
children
parent
enthusiast
chemotherapi
given
home
get
treatment
home
children
parent
expect
plan
life
better
parent
expect
take
time
work
expect
child
miss
school
result
pilot
present
siop
conclus
special
nurs
practition
pediatr
oncolog
hospit
home
possibl
creat
administ
chemotherapi
children
home
hope
standard
care
futur
c
castor
h
k
univers
depart
health
scienc
lund
sweden
univers
hospit
rigshospitalet
paediatr
adolesc
medicin
copenhagen
denmark
backgroundobject
famili
often
prefer
home
care
hospit
care
number
home
care
servic
children
increas
aim
studi
explor
healthcar
profession
concept
care
sick
children
home
care
servic
designmethod
induct
qualit
design
use
seven
focu
group
interview
healthcar
profession
multidisciplinari
home
care
servic
perform
data
analys
stepwis
use
phenomenograph
analysi
result
three
descript
categori
emerg
challeng
opportun
child
perspect
accord
new
prerequisit
provid
home
care
children
challeng
reward
task
healthcar
profession
use
care
adult
conceiv
evok
profession
person
challeng
feel
inadequaci
fear
profession
growth
increas
compet
satisfact
concept
whether
home
hospit
best
place
care
differ
adapt
child
care
conceiv
import
cooper
paediatr
depart
teamwork
import
organis
aspect
conclus
suffici
number
refer
children
enabl
healthcar
profession
part
implement
process
might
facilit
home
care
servic
sick
children
enough
time
good
teamwork
must
emphasis
earli
referr
continu
cooper
paediatr
clinic
complement
individualis
support
child
refer
prerequisit
make
low
number
paediatr
patient
facilit
confid
compet
studi
fund
swedish
childhood
cancer
foundat
swedish
research
council
health
work
life
welfar
se
egeland
h
lie
e
univers
norway
depart
paediatr
haematolog
unit
paediatr
adolesc
medicin
norway
oslo
oslo
univers
norway
oslo
norway
backgroundobject
mani
children
cancer
fear
pain
procedur
vap
commonli
use
cancer
treatment
yet
littl
known
children
experi
vap
needl
insert
procedur
aim
aim
explor
level
distress
pain
needl
insert
among
young
patient
explor
patient
distress
pain
correl
parent
nurs
designmethod
sampl
includ
patient
year
cancer
treat
two
norwegian
hospit
vap
month
patient
old
enough
parent
nurs
perform
procedur
complet
questionnair
procedur
questionnair
consist
three
distress
pain
scale
higher
score
indic
greater
distresspain
data
analys
use
descript
statist
correl
result
young
children
year
median
distress
score
rang
pain
score
rang
median
distress
pain
score
children
year
rang
rang
adolesc
age
rang
rang
respect
ten
children
report
high
distress
andor
pain
score
distress
level
correl
pain
level
patient
rate
nurs
rate
parent
rate
patient
rate
distress
pain
correl
proxi
rate
parent
p
p
nurs
p
p
conclus
report
distress
pain
associ
vap
procedur
greater
among
youngest
children
compar
older
children
howev
clinician
awar
great
individu
differ
offer
cvk
involv
insert
highli
distress
children
j
gardl
e
edwinson
lund
univers
depart
health
scienc
lund
sweden
backgroundobject
due
need
complet
immobl
radiotherapi
children
often
requir
daili
gener
anesthesia
sever
week
aim
studi
test
inform
prepar
procedur
children
cancer
undergo
radiotherapi
feasibl
effect
term
need
gener
anesthesia
anxieti
designmethod
control
clinic
trial
children
age
year
receiv
prepar
includ
seven
part
compar
children
control
group
receiv
tradit
care
feasibl
term
recruit
complianc
accept
assess
effect
assess
primari
outcom
number
children
underw
treatment
without
gener
anesthesia
respect
fraction
valid
instrument
measur
children
anxieti
emot
behavior
secondari
outcom
result
prepar
part
deliv
intend
without
addit
staff
without
dropout
intervent
group
therefor
found
feasibl
accept
three
children
plan
gener
anesthesia
intervent
group
complet
treatment
includ
fraction
awak
children
receiv
gener
anesthesia
regardless
group
show
significantli
higher
neg
emot
behavior
statist
signific
found
concern
number
children
receiv
gener
anesthesia
anxieti
conclus
avoid
gener
anesthesia
children
cancer
go
radiotherapi
give
benefit
term
fewer
risk
restrict
life
child
fewer
disturb
daili
life
famili
lower
cost
health
care
give
children
individu
prepar
may
decreas
need
gener
anesthesia
radiotherapi
treatment
acknowledg
would
like
express
gratitud
particip
children
swedish
childhood
cancer
foundat
fund
j
gardl
edwinson
e
lund
univers
depart
health
scienc
lund
sweden
backgroundobject
aim
explor
inform
prepar
procedur
children
cancer
undergo
radiotherapi
decreas
impact
parent
famili
function
parent
anxieti
reduc
hospit
cost
compar
tradit
care
designmethod
studi
part
control
clinic
trial
consist
control
group
includ
parent
children
receiv
tradit
care
intervent
group
includ
parent
children
receiv
prepar
includ
seven
part
valid
instrument
measur
parent
famili
function
anxieti
hospit
cost
calcul
result
parent
intervent
group
show
statist
significantli
better
commun
throughout
child
radiotherapi
last
fraction
parent
social
function
show
improv
statist
signific
parent
children
receiv
gener
anesthesia
regardless
group
show
statist
signific
higher
level
anxieti
hospit
cost
lower
intervent
group
conclus
children
abl
go
rt
without
ga
impli
individu
child
fewer
risk
restrict
famili
benefit
term
less
impact
function
less
anxieti
hospit
mean
lower
cost
increas
avail
anesthesia
personnel
enabl
priorit
area
care
acknowledg
would
like
express
gratitud
particip
parent
swedish
childhood
cancer
foundat
fund
f
gibson
n
j
v
l
k
ormond
street
hospit
children
nh
foundat
trust
univers
surrey
centr
outcom
experi
research
children
ill
disabl
orchid
school
health
scienc
london
unit
kingdom
georg
hospit
commun
children
nurs
children
servic
london
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
loui
dunda
centr
oncolog
outreach
palli
care
london
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
gosh
art
london
unit
kingdom
consult
na
melbourn
australia
ormond
street
hospit
children
nh
foundat
trust
charl
west
divis
london
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
centr
outcom
experi
research
children
ill
disabl
orchid
london
unit
kingdom
backgroundobject
blood
test
distress
children
prove
detriment
psycholog
develop
needl
phobia
anticipatoryprocedur
distress
prepar
blood
take
onset
ill
therefor
invalu
minimis
distress
designmethod
aim
develop
tool
help
prepar
children
blood
test
studi
design
use
creativ
artsart
make
util
phase
rang
activ
children
look
import
blood
within
bodi
need
take
blood
particip
made
blood
use
unconvent
ingredi
invent
comic
blood
charact
made
map
bodi
blood
quest
game
subsequ
develop
phase
assess
use
effect
small
group
children
parent
haematolog
disord
inattend
hospit
foundat
work
app
prototyp
emerg
result
phase
hospitalis
children
age
particip
rang
creativ
activ
draw
experi
help
design
blood
quest
game
look
like
phase
children
play
game
prior
blood
taken
complet
questionnair
use
effect
children
test
game
found
fun
inform
half
report
play
game
made
feel
better
blood
taken
half
felt
game
suit
children
age
conclus
collabor
children
illustr
enabl
idea
elabor
allow
children
genuin
influenc
research
shape
prototyp
game
app
present
focu
creativ
step
result
blood
quest
app
avail
ipad
free
download
appl
app
store
j
granhagen
jungner
e
k
p
institutet
women
children
health
stockholm
sweden
institut
interpret
translat
studi
depart
swedish
languag
multilingu
stockholm
sweden
backgroundobject
overcom
languag
barrier
multilingu
paediatr
cancer
care
improv
care
situat
reduc
cost
knowledg
need
commun
perform
facilit
situat
languag
barrier
well
situat
improv
purpos
studi
investig
commun
languag
barrier
healthcar
profession
hcp
paediatr
cancer
care
patientsfamili
limit
profici
countri
offici
languag
designmethod
combin
commun
interpret
scienc
medic
nurs
scienc
interdisciplinari
project
increas
knowledg
complex
commun
languag
barrier
nation
survey
perform
use
languag
barrier
commun
questionnair
lbcq
hcp
physician
regist
nurs
nurs
assist
paediatr
cancer
centr
sweden
invit
particip
statist
analys
perform
use
spss
result
total
questionnair
collect
respons
rate
major
respond
report
use
interpret
high
degre
increas
patient
safeti
patientpar
particip
care
despit
respond
report
never
seldom
use
interpret
take
arriv
statu
medic
histori
report
never
seldom
use
interpret
educ
patient
famili
conclus
identifi
weak
commun
hcp
patientsfamili
limit
profici
offici
languag
identifi
area
commun
need
strengthen
result
show
hcp
awar
use
interpret
increas
patient
safeti
particip
paediatr
cancer
care
howev
insuffici
use
interpret
exampl
take
arriv
statu
medic
histori
educ
patient
famili
repres
risk
patient
safeti
mc
hook
mj
c
km
p
w
minnesota
school
nurs
minneapoli
usa
univers
school
nurs
nc
usa
colleg
medicin
hematologyoncolog
tx
usa
arizona
school
nurs
az
usa
minnesota
cancer
blood
disord
program
mn
usa
backgroundobject
cancer
treatment
symptom
play
major
role
determin
health
children
cancer
symptom
toxic
often
result
complic
treatment
delay
therapi
dose
reduct
compromis
leukemia
therapi
jeopard
chanc
surviv
critic
understand
symptom
experi
treatment
need
explor
symptom
differ
occur
determin
may
suscept
symptom
toxic
object
studi
examin
specif
symptom
trajectori
first
month
childhood
leukemia
treatment
designmethod
research
design
use
evalu
symptom
associ
experienc
patient
age
year
receiv
treatment
new
diagnosi
acut
lymphoblast
leukemia
four
site
symptom
trajectori
explor
four
time
period
initi
therapi
month
therapi
symptom
measur
includ
fatigu
sleep
disturb
pain
nausea
depress
parent
children
age
complet
proxi
measur
latent
class
growth
analysi
use
classifi
patient
distinct
group
similar
symptom
trajectori
base
respons
pattern
measur
time
result
among
particip
age
year
year
year
sex
evenli
distribut
hispan
three
latent
class
symptom
trajectori
identifi
classifi
mild
moder
sever
symptom
trajectori
demograph
characterist
signific
relationship
membership
latent
class
symptom
trajectori
raceethn
demograph
characterist
includ
leukemia
risk
level
show
signific
relationship
conclus
studi
uniqu
group
patient
similar
symptom
identifi
rather
group
symptom
research
use
latent
class
growth
analysi
need
fund
nation
institut
health
ca
md
jeppesen
n
h
univers
hospit
depart
pediatr
oncolog
aalborg
denmark
univers
hospit
clinic
nurs
research
unit
aalborg
denmark
backgroundobject
children
adolesc
cancer
often
suffer
constip
due
chemotherapi
treatment
opioid
constip
may
caus
pain
anal
fissur
septicemia
delay
therapi
studi
also
show
constip
contribut
poor
qualiti
life
mani
special
task
requir
attent
nurs
doctor
manag
constip
may
neglect
furthermor
nausea
pain
may
make
oral
intak
lax
difficult
designmethod
aim
studi
reduc
sever
complic
caus
constip
children
adolec
cancer
studi
intervent
studi
first
phase
problem
explor
audit
patient
record
parent
report
stool
diari
use
bristol
scale
focu
group
interview
pediatr
oncolog
doctor
nurs
interview
parent
patient
second
phase
practic
guidelin
develop
base
result
phase
one
third
phase
intervent
guidelin
implement
result
phase
one
data
parent
show
difficult
accommod
extens
oral
inform
time
diagnosi
difficult
ensur
suffici
intak
lax
diari
help
clarifi
stool
pattern
stress
import
use
common
asses
tool
data
health
care
profession
demonstr
import
systemat
observ
document
care
constip
conclus
phase
one
shown
systemat
manag
constip
need
use
asses
tool
parent
health
care
profession
may
support
phase
two
guidelin
develop
integr
continu
use
bristol
scale
maintain
focu
constip
care
addit
write
inform
pamphlet
parent
promot
use
stool
diari
k
kelli
j
k
c
nation
health
system
nurs
research
qualiti
outcom
washington
dc
usa
univers
nell
hodgson
woodruff
school
nurs
atlanta
ga
usa
merci
hospit
divis
oncolog
bone
marrow
transplant
kansa
citi
mo
usa
univers
school
nurs
durham
nc
usa
backgroundobject
use
research
evalu
parent
understand
child
cancer
clinician
assess
parent
respons
educ
qualit
research
describ
parent
percept
new
diagnosi
educ
roger
etal
note
preponder
interview
data
relat
parent
clinician
relat
origin
studi
aim
return
data
complet
secondari
analysi
parent
descript
question
diagnosi
child
cancer
designmethod
use
secondari
qualit
analysi
review
dataset
parent
assur
adequ
fit
research
question
data
conduct
retrospect
interpret
data
first
independ
code
two
member
studi
team
code
decis
discuss
weekli
investig
call
consensu
agreement
reach
investig
result
straightforward
process
neg
respons
question
alway
accur
assess
parent
understand
parent
sometim
report
confus
overwhelm
ask
parent
question
indic
unmet
inform
need
parent
learn
eg
parent
ask
mani
question
verifi
understand
clinician
parent
quickli
learn
could
get
question
answer
includ
written
onlin
educ
materi
parent
also
express
question
ask
includ
worri
child
diagnosi
treatment
abil
care
child
balanc
life
event
conclus
understand
respond
reason
behind
parent
could
facilit
parent
learn
cope
given
nuanc
ascrib
parent
research
need
also
understand
children
adolesc
cancer
fund
children
oncolog
cancer
instituten
clinic
trial
network
group
oper
center
grant
alex
lemonad
stand
foundat
e
l
federico
children
hospit
oncolog
usa
backgroundobject
commun
breakdown
clinician
lead
caus
medic
error
dr
atul
gawand
describ
implement
checklist
improv
team
commun
ultim
decreas
patient
complic
institut
oncolog
round
offer
dedic
time
multidisciplinari
team
famili
gather
set
daili
goal
interrupt
common
creat
risk
lost
misinterpret
inform
respons
daili
round
checklist
design
promot
close
loop
commun
conclus
round
gawand
checklist
manifesto
hb
penguin
book
india
designmethod
checklist
pilot
provid
tool
prompt
oncolog
team
summar
confirm
patient
plan
leav
bedsid
checklist
read
aloud
take
second
complet
summar
patient
inform
includ
treatment
plan
upcom
diagnost
testsprocedur
antimicrobi
fever
plan
nutrit
linestub
lab
discharg
plan
feasibl
round
checklist
establish
checklist
creat
interfac
patient
medic
record
offer
capabl
store
patient
inform
access
medic
list
lab
current
inform
result
round
checklist
prompt
team
paus
recap
plan
day
promot
clear
commun
ensur
respons
clearli
delin
clinician
report
potenti
error
identifi
discharg
plan
initi
earlier
unnecessari
redund
lab
test
medic
intercept
conclus
checklist
cost
effect
tool
improv
patient
outcom
decreas
untoward
complic
institut
daili
round
checklist
found
improv
effici
round
promot
climat
safeti
famili
center
care
futur
direct
includ
develop
qualiti
report
determin
checklist
impact
safeti
patient
staff
satisfact
clear
delin
role
respons
cost
save
mahajan
b
yk
hospit
children
paediatr
depart
mumbai
india
j
wadia
hospit
children
administr
mumbai
india
j
wadia
hospit
children
pediatr
hematolog
oncolog
mumbai
india
backgroundobject
caregiv
often
experi
difficulti
help
children
cancer
cope
emot
impact
ill
psycholog
distress
low
resourc
countri
child
famili
often
stagger
hospit
hospit
citi
citi
seek
care
thu
creat
emot
financi
hardship
assess
level
burden
cope
among
caregiv
children
diagnos
cancer
one
mumbai
hospit
designmethod
quantit
exploratori
studi
questionnair
conduct
caregiv
measur
physic
psycholog
social
occup
spiritu
econom
burden
cope
strategi
level
burden
cope
strategi
select
demograph
variabl
data
analys
measur
use
test
coeffici
correl
techniqu
result
per
cent
caregiv
parent
mother
father
other
high
level
burden
among
caregiv
observ
mainli
parent
mother
emot
strain
due
child
ill
abil
manag
famili
cohes
predict
distress
concurr
prospect
greater
use
self
cope
strategi
relat
higher
level
distress
father
high
level
burden
due
financi
employ
problem
relat
number
hospit
admiss
child
signific
conclus
find
show
cancer
treatment
attribut
increas
caregiv
burden
impact
stress
parent
qualiti
life
unfortun
caregiv
adopt
cope
strategi
fleet
due
fear
relaps
uncertainti
child
diseas
condit
health
care
provid
identifi
gap
provis
holist
clinic
care
overcom
caregiv
burden
support
caregiv
adopt
appropri
cope
strategi
belinda
j
j
b
j
k
jude
children
research
hospit
divis
nurs
research
memphi
usa
jude
children
research
hospit
divis
cancer
predisposit
memphi
usa
backgroundobject
advanc
genet
technolog
reveal
grow
number
herit
disord
associ
increas
risk
develop
cancer
childhood
dialogu
cancer
genet
test
implic
genet
risk
statu
children
rest
primarili
parent
vital
understand
parent
children
commun
genet
test
herit
cancer
studi
object
determin
whether
parent
commun
children
genet
test
syndrom
lf
rare
highli
penetr
cancer
predispos
condit
designmethod
interview
examin
parent
decis
regard
pursuit
lf
test
children
commun
surround
test
result
transcript
evalu
use
ground
theori
approach
determin
parent
decis
initi
convers
children
hold
convers
result
studi
evalu
interview
parent
whose
children
test
posit
lf
parent
emphas
import
involv
child
ren
convers
undergo
lf
genet
test
disclosur
test
result
mani
parent
cancer
famili
base
neg
past
experi
consist
exclus
convers
regard
cancer
parent
state
would
approach
commun
cancer
children
open
inclus
manner
nevertheless
evalu
interview
show
parent
actual
disclos
lf
test
result
child
ren
conclus
parent
express
desir
open
convers
child
ren
regard
lf
genet
test
discuss
alway
occur
commun
essenti
enabl
understand
genet
risk
statu
complianc
treatment
prevent
surveil
measur
develop
educ
materi
intervent
facilit
convers
genet
test
genet
risk
statu
cancer
need
n
mariam
cancer
institut
nurs
kampala
uganda
backgroundobject
treatment
adher
play
critic
role
cancer
manag
lead
better
clinic
outcom
treatment
adher
signific
issu
uganda
cancer
institut
uci
mani
patient
abandon
treatment
complet
primari
reason
believ
poor
commun
lack
social
financi
support
role
nurs
case
manag
cm
develop
improv
patient
outcom
address
issu
object
describ
role
nurs
case
manag
improv
treatment
adher
clinic
outcom
patient
treat
uganda
cancer
institut
designmethod
barrier
treatment
adher
identifi
role
cm
develop
address
issu
base
person
experi
cm
pediatr
ward
year
uci
result
uci
cancer
treatment
center
uganda
treat
patient
annual
uganda
surround
countri
treatment
begin
week
diagnosi
due
complex
health
care
navig
process
limit
resourc
famili
cm
ongo
challeng
frequent
led
treatment
abandon
cm
first
contact
patient
arriv
uci
given
contact
inform
contact
us
assess
famili
social
financi
resourc
explain
diagnosi
treatment
plan
includ
number
hospit
visit
treatment
durat
close
monitor
patient
progress
facilit
commun
patient
famili
clinician
hospit
visit
provid
counsel
direct
nurs
importantli
advoc
patient
relay
patient
concern
clinician
mobil
fund
possibl
connect
famili
commun
resourc
conclus
oncolog
treatment
increasingli
complex
present
uniqu
challeng
oncolog
nurs
resourc
limit
countri
like
uganda
nurs
case
manag
play
import
role
improv
outcom
l
morrissey
c
l
j
r
g
p
children
hospit
hematologyoncolog
nurs
boston
usa
jude
research
hospit
internationa
outreach
program
memphi
usa
jude
research
hospit
intern
outreach
program
memphi
usa
california
san
francisco
ucsf
hospit
nurs
san
francisco
usa
unaffili
amsterdam
netherland
antil
teach
hospitl
nh
trust
nurs
london
unit
kingdom
baptist
hospit
oncolog
nurs
banso
cameroon
children
cancer
hospit
oncolog
nurs
karachi
pakistan
backgroundobject
siop
podc
nurs
workgroup
publish
baselin
standard
describ
element
nurs
care
essenti
promot
optim
patient
outcom
siop
baselin
standard
taskforc
develop
valid
survey
measur
degre
nurs
standard
met
paediatr
oncolog
program
worldwid
compar
respons
low
mid
high
incom
countri
hic
identifi
trend
incom
level
designmethod
valid
survey
address
six
baselin
standard
electron
distribut
conveni
sampl
pediatr
oncolog
nurs
countri
survey
translat
four
languag
administ
respons
compar
base
world
bank
defin
incom
level
result
respons
rate
nurs
countri
achiev
result
reveal
nurs
staf
level
oncolog
ward
intens
care
unit
l
mic
significantli
lower
hic
p
nurs
lic
nurs
care
oncolog
patient
rotat
frequent
vs
p
less
like
receiv
formal
orient
program
signific
differ
exist
inclus
nurs
multidisciplinari
meet
p
resourc
safe
care
infus
pump
person
protect
equip
often
insuffici
l
mic
evid
base
polici
avail
report
lic
compar
hic
p
conclus
result
siop
podc
baselin
standard
survey
indic
signific
gap
exist
staf
level
educ
resourc
institut
support
l
mic
pediatr
oncolog
nurs
survey
result
use
advoc
increas
nurs
support
l
mic
pediatr
cancer
unit
research
determin
adher
baselin
standard
pediatr
oncolog
nurs
link
favor
patient
outcom
newman
colleg
wisconsin
pediatr
oncolog
milwauke
usa
backgroundobject
provid
pediatr
oncolog
face
challeng
commun
devast
news
cancer
diagnosi
prognosi
initi
convers
regard
prognosi
gener
consid
respons
physician
patient
famili
member
subsequ
turn
nurs
clarif
inform
present
nurs
exclud
initi
convers
may
feel
though
work
dark
tri
answer
question
contradict
physician
said
littl
report
regard
pediatr
oncolog
nurs
experi
commun
purpos
research
examin
nurs
experi
commun
prc
associ
interprofession
collabor
qualiti
care
nurs
moral
distress
designmethod
approach
util
onlin
survey
incorpor
valid
measur
prc
interprofession
collabor
qualiti
care
moral
distress
accompani
focu
group
use
meet
studi
object
result
find
demonstr
nurs
strongli
agre
prognost
disclosur
critic
decis
make
challeng
determin
role
nurs
year
experi
train
prc
work
outpati
inpatientoutpati
indic
higher
level
collabor
report
posit
experi
prc
signific
correl
identifi
experi
prc
collabor
significantli
associ
measur
qualiti
care
moral
distress
conclus
nurs
work
activ
particip
prc
nurs
sens
prognost
discuss
occur
clariti
need
nurs
feel
confid
approach
physician
colleagu
ensur
parent
understand
satisfact
around
commun
futur
research
educ
aim
develop
interprofession
train
enhanc
commun
collabor
among
nurs
physician
ensur
highest
qualiti
commun
care
patient
famili
rc
ribeiro
l
ff
v
oliveira
children
cancer
hospit
qualiti
depart
barreto
brazil
children
cancer
hospit
pediatr
surgeri
depart
barreto
brazil
backgroundobject
use
central
venou
cathet
cvc
essenti
children
treat
malign
diseas
mainten
cathet
reflect
qualiti
nurs
care
cathet
obstruct
accident
dislodg
due
traction
complic
consid
qualiti
indic
oncolog
pediatr
hospit
set
purpos
analyz
complic
relat
cvc
remov
hospit
pediatr
oncolog
patient
develop
countri
hospit
designmethod
prospect
analysi
use
report
system
sa
interact
pediatr
oncolog
hospit
develop
countri
databas
februari
august
analyz
demograph
featur
rate
cvc
remov
due
complic
accident
dislodg
cathet
obstruct
number
patient
cvc
per
day
multipli
result
cvc
insert
children
period
cathet
remov
thirteen
due
reason
nine
relat
accident
dislodg
four
obstruct
averag
cathet
life
day
total
cathet
day
regard
cvc
event
pediatr
ward
averag
cvc
insert
per
month
incid
cvc
remov
per
bone
marrow
transplant
unit
averag
cvc
patient
per
month
remov
incid
per
cathet
day
pediatr
intens
care
unit
averag
cvc
patient
per
month
repres
occup
remov
incid
per
cathet
day
overal
hospit
cvc
remov
incid
per
cathet
day
conclus
cvc
remov
use
indic
nurs
care
pediatr
oncolog
hospit
give
assert
relat
improv
decreas
rate
improv
children
nurs
care
l
ollett
k
j
north
children
hospit
paediatr
oncolog
newcastl
unit
kingdom
backgroundobject
paediatr
oncolog
nurs
often
first
point
contact
overwhelm
parent
patient
often
assess
telephon
regard
acut
oncolog
emerg
advicesymptom
manag
nurs
expect
make
clinic
decis
regard
patient
care
without
visual
assess
patient
use
systemat
uniform
approach
great
north
children
hospit
princip
treatment
centr
ptc
adopt
use
unit
kingdom
oncolog
nurs
societi
ukon
telephon
triag
kit
audit
effect
tool
conduct
designmethod
ukon
telephon
triag
kit
provid
pathway
nurs
assess
telephon
nurs
use
traffic
light
toxic
grade
system
initi
emerg
treatment
advic
addit
patient
score
amber
toxic
requir
hour
call
back
promot
earli
intervent
patient
safeti
retrospect
peer
review
telephon
triag
call
evalu
includ
diagnosi
time
call
durat
call
main
complaint
toxic
grade
patient
journey
four
month
period
januari
percept
challeng
use
tool
clinic
environ
also
explor
result
call
receiv
within
four
month
period
signific
impact
servic
provis
averag
call
last
ten
minut
data
indic
nurs
staff
gave
concis
advic
symptom
manag
use
valid
tool
nurs
report
use
toxic
grade
gave
confid
consist
advic
offer
highlight
area
improv
includ
document
regard
patient
detail
establish
contact
within
hour
initi
telephon
call
conclus
ukon
triag
tool
invalu
resourc
within
ptc
set
data
collect
discuss
manag
alloc
resourc
appropri
educ
peer
review
session
highlight
import
document
telephon
call
back
recommend
k
b
l
r
r
packard
children
hospit
center
nurs
excel
stanford
usa
depart
pediatr
palo
alto
usa
school
nurs
san
francisco
usa
depart
pediatr
san
francisco
usa
backgroundobject
surviv
rate
among
adolesc
young
adult
aya
cancer
patient
improv
minim
past
decad
aya
experi
treatment
rate
high
lead
relaps
even
death
open
commun
posit
famili
relationship
involv
aya
treatment
decis
ill
manag
support
treatment
adher
howev
limit
research
explor
aya
involv
experi
treatment
tdm
purpos
ongo
studi
explor
describ
aya
experi
cancer
tdm
designmethod
twelv
aya
treatment
cancer
within
one
year
diagnosi
particip
interpret
ethnograph
studi
includ
interview
inform
particip
observ
particip
ask
reflect
major
tdm
experi
eg
clinic
trial
surgeri
decis
sinc
diagnosi
analysi
includ
field
note
analyt
memo
code
interview
transcript
use
atlasti
result
preliminari
find
drawn
interview
aya
male
femal
year
old
aya
distinguish
major
treatment
decis
care
prefer
involv
vari
involv
decis
accept
decis
involv
discuss
assum
share
primari
role
chang
time
aya
prefer
parent
involv
appreci
support
tdm
friend
famili
member
support
involv
tdm
factor
influenc
tdm
includ
uncertainti
treatment
altruism
qualiti
life
conclus
find
highlight
rang
involv
aya
tdm
overal
felt
inform
part
discuss
view
share
make
treatment
decis
aya
prefer
particip
tdm
may
vari
time
type
decis
parent
play
particularli
import
support
role
l
l
roja
p
lui
calvo
mackenna
unidad
de
oncologia
santiago
chile
backgroundobject
chemotherapi
administr
high
risk
procedur
nurs
staff
potenti
teratogen
carcinogen
mutagen
damag
toxic
effect
associ
exposur
oncolog
unit
hospit
lui
calvo
mackenna
protocol
administr
base
recommend
intern
organ
unit
necessari
person
protect
element
ppe
safe
administr
everi
nurs
join
unit
receiv
comprehens
orient
program
emphas
safe
administr
chemotherapi
content
reinforc
annual
continu
educ
program
adher
protocol
complianc
monitor
monthli
appli
checklist
checklist
assess
aspect
safeti
manag
patient
nurs
staff
item
relat
staff
protect
assess
whether
nurs
use
ppe
describ
protocol
monitor
conduct
august
show
nurs
use
ppe
defin
protocol
designmethod
septemb
educ
intervent
oncolog
nurs
carri
focus
chemotherapi
safe
handl
administr
octob
year
checklist
reappli
result
oncolog
nurs
use
ppe
accord
chemotherapi
administr
protocol
nurs
assess
use
eye
protect
use
glove
conclus
despit
inform
train
nurs
receiv
low
adher
polici
protocol
mainli
impact
potenti
risk
health
nurs
new
intervent
propos
know
reason
low
adher
nurs
scheper
sm
sint
h
l
cm
jude
children
research
hospit
depart
psycholog
memphi
usa
maxima
center
pediatr
oncolog
psychosoci
research
care
innov
utrecht
netherland
children
academ
medic
center
psychosoci
depart
amsterdam
netherland
children
radboud
univers
medic
center
medic
psycholog
nijmegen
netherland
backgroundobject
parent
children
cancer
increas
risk
experienc
distress
import
identifi
famili
need
support
earli
stage
studi
aim
assess
father
mother
distress
measur
distress
thermomet
parent
month
assess
distress
month
could
predict
psychosoci
assess
tool
pat
risk
profil
approxim
one
month
designmethod
sampl
mother
father
complet
sampl
compar
healthi
refer
group
mother
father
consist
thermomet
score
rang
clinic
distress
problem
domain
total
practic
social
emot
physic
cognit
parent
year
year
age
pat
famili
psychosoci
risk
screener
assess
within
pediatr
cancer
group
parent
elev
total
targetedclin
compar
parent
low
univers
result
parent
children
cancer
often
report
clinic
distress
parent
healthi
children
thermomet
score
father
versu
p
mother
versu
p
report
problem
domain
p
except
parent
domain
children
year
age
furthermor
parent
distress
predict
famili
psychosoci
risk
parent
elev
total
report
problem
parent
low
thermomet
score
father
mother
domain
p
conclus
result
studi
point
toward
import
famili
psychosoci
risk
screen
diagnosi
need
appli
tailor
intervent
later
parent
distress
reduc
prevent
j
n
shen
h
children
medic
center
nurs
shanghai
china
children
medic
center
nurs
shanghai
china
backgroundobject
previou
studi
investig
applic
frequenc
hospit
region
found
differ
hospit
north
china
other
singl
hospit
fulli
repres
region
thu
studi
want
know
nation
clinic
applic
core
intervent
perform
pediatr
oncolog
nurs
analysi
varianc
region
designmethod
onlin
survey
applic
frequenc
core
intervent
conduct
expert
consensu
base
nurs
intervent
classif
nic
send
pediatr
oncolog
nurs
nation
wide
select
hospit
januari
februari
result
clinic
nurs
complet
questionnair
applic
rate
core
intervent
domain
differ
basic
complex
physiolog
domain
north
china
vs
east
west
china
p
behavior
famili
domain
north
china
vs
east
china
p
health
system
domain
north
china
vs
west
china
p
class
nurs
differ
region
perform
differ
frequent
p
elimin
immobl
manag
nutrit
support
promot
electrolyt
manag
respiratori
manag
skinwound
manag
thermoregul
tissu
perfus
manag
patient
educ
psycholog
comfort
promot
lifespan
care
conclus
core
intervent
pediatr
oncolog
nurs
frequent
perform
practic
show
differ
group
region
especi
north
china
homogen
train
trainer
need
think
reason
differ
clinic
applic
region
shown
studi
order
develop
differ
proport
train
content
found
shanghai
municip
educ
commiss
gaoyuan
nurs
grant
support
e
sniderman
p
robert
h
luri
children
hospit
chicago
divis
stem
cell
transplant
chicago
usa
merci
hospit
pediatr
oncolog
kansa
citi
usa
hospit
children
pediatricspediatr
oncolog
siem
reap
cambodia
backgroundobject
angkor
hospit
children
ahc
one
two
facil
cambodia
offer
comprehens
cancer
care
children
howev
treatment
current
limit
retinoblastoma
wilm
tumor
partial
due
nurs
limit
ahc
pediatr
oncolog
program
current
expand
part
hospit
strateg
plan
develop
nurs
curriculum
ongo
mentor
train
oncolog
nurs
identifi
prioriti
designmethod
conjunct
volunt
oversea
volunt
oncolog
nurs
practition
np
visit
ahc
two
year
period
formal
assess
current
knowledg
base
resourc
challeng
pediatr
oncolog
nurs
perform
use
siop
podc
baselin
standard
paediatr
oncolog
nurs
care
low
middl
incom
countri
ahc
nurs
educ
oncolog
team
member
collabor
assess
process
result
formal
assess
identifi
gap
knowledg
unsaf
chemotherapi
administr
practic
misconcept
regard
chemotherapi
safeti
inform
creation
curriculum
adapt
need
resourc
hospit
seven
modul
creat
taught
month
content
includ
introduct
childhood
cancerdiseas
chemotherapi
support
care
symptom
manag
infect
control
emerg
palli
care
pain
manag
psychosoci
consider
futur
modul
focu
late
effect
central
line
care
sever
interact
teach
strategi
help
creat
dynam
teach
environ
modul
taught
director
educ
pediatr
oncologist
ahc
well
visit
intern
nursesnp
conclus
nurs
special
educ
train
pediatr
oncolog
essenti
success
comprehens
cancer
care
formal
assess
use
intern
accept
standard
pediatr
oncolog
nurs
care
adapt
educ
limit
resourc
set
collabor
local
team
member
key
step
ensur
high
qualiti
cancer
care
provid
children
cambodia
l
soan
e
colleg
london
children
young
peopl
servic
london
unit
kingdom
royal
marsden
nh
foundat
trust
oak
centr
children
young
peopl
london
unit
kingdom
backgroundobject
year
children
diagnos
cancer
unit
kingdom
surviv
rate
survivor
known
increas
risk
poorer
psychosoci
physic
outcom
peer
effect
occur
soon
treatment
mani
year
later
therefor
recommend
survivor
follow
pathway
ltfu
life
crucial
stage
pathway
occur
late
adolesc
patient
move
child
adult
servic
process
one
proactiv
transit
rather
sudden
transfer
meet
recommend
model
transit
introduc
children
tya
princip
treatment
centr
two
year
period
servic
evalu
carri
assess
accept
effect
model
designmethod
use
mix
method
approach
sampl
tya
age
year
old
attend
tya
ltfu
clinic
identifi
data
collect
measur
accept
effect
mode
onlin
patient
experi
patient
telephon
interviewsqualit
quantit
analysi
clinic
consultationsqualit
quantit
analysi
patient
contact
cn
ltfu
outsid
clinic
result
model
transit
though
larg
accept
signific
challeng
time
went
beyond
patient
famili
particular
mother
whose
role
carer
also
transit
need
time
multidisciplinari
approach
facilit
patient
knowledg
self
confid
transit
identifi
key
factor
accept
effect
model
conclus
servic
evalu
highlight
key
factor
establish
transit
model
identifi
area
ensur
transit
truli
holist
c
sullivan
l
segovia
p
vivero
g
jude
children
research
hospit
dept
global
pediatr
medicin
memphi
usa
calvo
mackenna
hospit
latin
american
center
pediatr
oncolog
nurisng
educ
santiago
chile
calvo
mackenna
hospit
latin
american
center
pediatr
oncolog
nurs
educ
santiago
chile
jude
children
research
hospitalunivers
tenness
health
scienc
center
dept
global
pediatr
medicinecolleg
nurs
memphi
usa
backgroundobject
ten
year
ago
latin
american
center
pediatr
oncolog
nurs
educ
creat
calvo
mackenna
hospit
santiago
chile
initi
intern
outreach
program
st
jude
research
hospit
sjcrh
enhanc
qualiti
pediatr
oncolog
nurs
care
latin
america
establish
pediatr
oncolog
nurs
educ
role
designmethod
program
consist
week
theoreticalskil
train
clinic
observ
hour
pediatr
oncolog
nurs
support
care
educ
theoret
portion
includ
lectur
pediatr
oncolog
educ
use
adult
learn
principl
onsit
ongo
mentor
provid
develop
tailor
educ
program
qualiti
project
program
evalu
consist
success
demonstr
curriculum
develop
deliveri
result
date
nurs
educ
mexico
central
america
south
america
caribbean
complet
program
network
latin
american
nurs
educ
develop
ongo
mentoringcollabor
graduat
activ
member
repres
hospit
countri
present
impact
nurs
addit
qualiti
improv
project
correct
patient
identif
ongo
sever
site
conclus
latin
american
center
pediatr
oncolog
nurs
educ
proven
success
sustain
model
promot
excel
pediatr
oncolog
nurs
educ
qualiti
latin
america
develop
pediatr
oncolog
nurs
educ
role
c
sullivan
k
l
segovia
p
vivero
j
r
navarro
j
jude
children
research
hospit
dept
global
pediatr
medicin
memphi
usa
hospit
colorado
nurs
educ
denver
usa
calvo
mackenna
hospit
latin
american
center
pediatr
oncolog
nurisng
educ
santiago
chile
calvo
mackenn
hospit
latin
american
center
pediatr
oncolog
nurs
educ
santiago
chile
doctor
hospit
complianc
edinburg
usa
children
hospit
hematologyoncolog
palo
alto
usa
civil
de
guadalajara
dr
juan
menchaca
pediatr
oncologyeduc
guadalajara
mexico
nurs
amsterdam
netherland
antil
backgroundobject
associ
pediatr
hematolog
oncolog
nurs
aphon
receiv
numer
inquiri
nurs
countri
lmic
interest
chemotherapybiotherapi
certif
cours
aphon
certif
recommend
american
academi
pediatr
align
siop
podc
nurs
baselin
standard
recommend
formal
train
chemotherapi
prepar
handl
global
respons
intern
interest
intern
task
forc
set
evalu
feasibl
adapt
pilot
spanish
cours
throughout
latin
america
designmethod
survey
nurs
latin
america
verifi
interest
need
cours
recommend
adapt
incorpor
two
bilingu
chilean
nurs
educ
took
english
cours
st
jude
children
research
hospit
sjcrh
task
forc
chemotherapi
committe
spanish
wg
modifiedexpand
cours
next
year
materi
profession
translat
support
sjcrh
instructor
identifi
teach
cours
result
inaugur
pilot
held
chile
nurs
follow
second
pilot
central
american
nurs
english
instructor
cours
de
centro
america
sjcrh
nurs
februari
addit
pilot
schedul
argentina
sociedad
latina
americana
de
nurs
april
mexico
nurs
may
nurs
chilean
pilot
nurs
ahopca
pilot
pass
exam
comparison
result
four
pilot
present
conclus
sinc
children
adolesc
cancer
live
lmic
paramount
nurs
special
train
chemotherapybiotherapi
aphon
survey
document
interest
need
standard
chemotherapybiotherapi
educ
across
latin
america
pilot
demonstr
cours
appropri
nurs
practic
futur
plan
includ
develop
instructor
commun
promot
sustain
standard
spanish
cours
explor
expans
region
j
sun
n
h
children
medic
center
nurs
shanghai
china
children
medic
center
nurs
shanghai
china
children
medic
center
pediatr
shanghai
china
backgroundobject
previou
studi
use
expert
consensu
identifi
core
intervent
done
pediatr
nurs
core
intervent
intervent
nurs
mostli
perform
disciplinetherefor
studi
identifi
intervent
perform
pediatr
nurs
record
hospit
inform
system
analysi
characterist
designmethod
research
team
select
bed
pediatr
unit
drawn
nurs
intervent
nurs
record
doctor
order
septemb
decemb
use
nurs
intervent
classif
nic
match
count
frequenciesthen
give
intervent
time
difficulti
code
accord
nic
time
code
refer
averag
time
need
perform
intervent
minut
less
minut
minut
minut
hour
difficulti
code
refer
minim
educ
level
necessari
perform
intervent
case
assist
educ
certif
result
uniqu
statement
nurs
record
doctor
order
drawn
match
intervent
nurs
record
doctor
order
intervent
belong
domain
class
averag
difficulti
averag
time
conclus
nurs
pediatr
unit
perform
total
intervent
still
intervent
need
nurs
assist
done
nurs
call
nurs
manag
think
suitabl
stuf
result
studi
expect
use
understand
improv
pediatr
nurs
standard
nurs
intervent
found
clinic
manag
optim
project
shanghai
shen
kang
hospit
develop
center
shanghai
municip
educ
commiss
gaoyuan
nurs
grant
support
l
wiener
zadeh
pediatr
oncolog
branch
bethesda
usa
institut
mental
health
offic
director
bethesda
usa
backgroundobject
interdisciplinari
group
expert
stakehold
develop
standard
psychosoci
care
pediatr
cancer
one
standard
support
high
qualiti
paper
recommend
youth
cancer
famili
member
routin
receiv
systemat
assess
psychosoci
need
valid
reliabl
measur
avail
parent
report
famili
child
psychosoci
need
limit
psychometr
valid
measur
assess
distress
medic
ill
children
studi
guid
develop
brief
electron
distress
screen
call
check
designmethod
phase
triad
youth
age
cancer
chronic
ill
complet
distress
thermomet
dt
measur
depress
anxieti
pain
fatigu
find
identifi
item
includ
new
version
pediatr
distress
screen
phase
ii
cognit
interview
conduct
patient
age
group
health
care
provid
gave
input
develop
summari
report
result
substanti
discrep
parent
child
specif
distress
symptom
dt
indic
parent
input
alon
suffici
identifi
child
distress
guid
referr
frequent
endors
symptom
includ
check
cognit
interview
test
accuraci
qualiti
item
identifi
error
respons
choic
differ
word
recommend
base
age
found
suggest
design
format
respons
option
incorpor
conclus
check
assess
emot
physic
social
practic
spiritu
concern
pediatr
patient
well
suicid
ideat
adher
accompani
provid
document
summar
patient
caregiv
report
child
distress
real
time
allow
provid
triag
servic
test
reliabl
valid
measur
varianc
respons
check
assess
concord
symptom
rate
patient
caregiv
follow
jayasingh
c
l
l
children
hospit
gynaecolog
melbourn
australia
melbourn
obstetr
gynaecolog
melbourn
australia
dame
univers
medicin
sydney
australia
children
hospit
clinic
ethic
servic
melbourn
australia
children
hospit
children
cancer
centr
melbourn
australia
univers
medicin
melbourn
australia
children
hospit
endocrinolog
melbourn
australia
children
hospit
surgeri
melbourn
australia
backgroundobject
fertil
preserv
decis
children
difficult
need
decis
support
clinician
famili
aim
develop
evalu
electron
decision
support
tool
clinician
parent
children
cancer
royal
children
hospit
melbourn
designmethod
electron
decis
support
system
develop
base
literatur
consult
stakehold
clinician
tool
outlin
clinician
role
respons
link
educ
guidanc
includ
alert
best
practic
clinician
complet
survey
accept
result
compar
previou
survey
clinician
parent
decis
aid
base
intern
patient
decis
aid
standard
parent
children
cancer
previous
made
fertil
preserv
decis
invit
complet
survey
review
decis
aid
result
oncofertil
clinician
involv
fertil
consult
review
clinician
decis
support
system
compar
clinician
satisfact
fertil
consult
increas
confid
p
want
improv
fertil
consult
skill
state
clinician
tool
clearli
outlin
respons
state
would
alway
often
use
parent
consent
decis
aid
studi
review
parent
tool
report
appeal
clearli
present
clearli
clearli
explain
child
fertil
choic
tool
improv
fertil
relat
knowledg
parent
report
would
help
help
extrem
help
avail
make
fertil
preserv
decis
conclus
clinician
tool
appear
accept
clinician
howev
develop
requir
parent
decis
aid
accept
improv
knowledg
parent
prospect
assess
clinic
set
plan
ac
ferrant
nm
l
c
v
research
institut
nationwid
children
hospit
center
biobehavior
health
oh
usa
jude
children
research
hospit
depart
psycholog
tn
usa
backgroundobject
infertil
one
common
late
effect
certain
cancer
treatment
howev
limit
research
infertil
survivor
pediatr
cancer
thu
assess
knowledg
infertil
risk
percept
person
infertil
risk
knowledg
current
fertil
statu
examin
associ
demograph
ie
gender
age
incom
level
medic
factor
ie
diagnosi
type
neurotox
treatment
designmethod
survivor
pediatr
cancer
year
particip
onlin
survey
assess
knowledg
infertil
risk
percept
person
infertil
risk
knowledg
current
fertil
statu
particip
age
diagnos
age
leukemia
lymphoma
pediatr
brain
tumor
solid
tumor
least
year
result
survivor
awar
gener
risk
infertil
vari
type
diagnosi
p
treatment
survivor
brain
tumor
receiv
neurotox
treatment
less
like
know
survivor
perceiv
person
risk
infertil
unrel
examin
factor
almost
half
survivor
know
current
fertil
statu
common
younger
survivor
p
survivor
brain
tumor
lower
incom
conclus
adult
survivor
pediatr
cancer
awar
gener
risk
infertil
half
perceiv
risk
knew
fertil
statu
sever
demograph
medic
factor
relat
knowledg
domain
futur
research
continu
identifi
strategi
provid
reproduct
counsel
survivor
pediatr
cancer
treatment
optim
fertil
preserv
rate
risk
acknowledg
thank
research
institut
nationwid
children
hospit
ctsa
grant
provid
resourc
je
dijkstra
pinto
leit
jg
de
rl
emm
van
den
wc
mc
sj
van
der
van
de
mm
van
den
amc
center
user
experi
design
ict
utrecht
netherland
center
psychosoci
research
utrecht
netherland
center
ict
utrecht
netherland
center
psychosoci
care
utrecht
netherland
center
paediatr
oncolog
utrecht
netherland
ceo
nieuwegein
netherland
center
children
advisori
council
utrecht
netherland
backgroundobject
princess
center
pediatr
oncolog
stimul
develop
lead
care
key
principl
reduct
medic
traumat
stress
adequ
commun
famili
focu
treatment
children
cancer
stress
child
famili
often
overload
inform
alway
tailor
need
daili
life
taken
hospit
visit
miss
overview
control
lead
avoid
medic
traumat
stress
aim
design
tool
provid
overview
tailor
inform
treatment
schedul
designmethod
first
phase
analyz
need
differ
famili
persona
creat
focu
group
healthcar
profession
profil
differ
famili
type
contextu
inquiri
perform
map
activ
differ
stage
treatment
lead
knowledg
inform
share
famili
depth
interview
provid
insight
prefer
children
famili
obtain
inform
diseas
treatment
result
discuss
group
famili
focu
group
identifi
persona
reflect
differ
famili
deal
diseas
diseas
inform
interact
health
care
profession
studi
first
phase
lead
guidelin
tool
commun
wilm
tumor
treatment
schedul
address
differ
conclus
result
visual
tailor
treatment
inform
tool
increas
patient
particip
empower
creat
overview
treatment
program
understand
children
parent
aim
support
make
decis
prepar
procedur
use
persona
profil
differ
famili
address
specif
need
next
step
design
tool
investig
whether
tool
lead
reduct
medic
traumat
stress
n
caltabellotta
c
v
n
l
children
hospit
center
biobehavior
health
columbu
usa
jude
children
research
hospit
depart
psycholog
memphi
usa
children
hospit
divis
hematologyoncolog
columbu
usa
backgroundobject
one
three
male
experi
fertil
problem
pediatr
cancer
treatment
yet
less
pubert
male
pursu
fertil
preserv
fp
treatment
although
parent
respons
make
major
decis
includ
fp
pediatr
ill
unknown
parent
discuss
parenthood
fp
son
awar
attitud
concern
aim
studi
examin
attitud
parenthood
fp
among
aya
male
parent
within
first
seven
year
cancer
survivorship
designmethod
particip
aya
male
mother
father
complet
question
base
health
belief
model
particip
rank
item
likert
scale
aya
male
son
parent
analys
compar
attitud
male
aya
survivor
year
parent
two
distinct
group
within
pair
pair
item
pertain
parenthood
benefitsbarri
fp
result
eighti
percent
aya
male
endors
want
biolog
child
survivor
agre
futur
without
child
would
make
sad
percent
aya
male
thought
speak
fp
parent
would
embarrass
minor
report
convers
mother
andor
father
sperm
bank
although
aya
male
concern
could
pass
cancer
futur
children
neither
mother
father
share
concern
conclus
although
male
aya
survivor
desir
biolog
children
treatment
report
difficulti
discuss
parent
report
barrier
fp
parent
may
unawar
futur
research
need
identifi
factor
contribut
perceiv
barrier
strategi
facilit
convers
parenthood
fp
aya
male
parent
p
lin
c
v
head
medic
affair
oncolog
stain
upon
thame
unit
kingdom
global
heor
oncolog
cambridg
usa
hospit
wale
consult
haematologist
cardiff
unit
kingdom
manchest
paediatr
oncolog
manchest
unit
kingdom
medic
center
senior
consult
paediatr
oncolog
new
kolkata
india
backgroundobject
asparaginas
key
compon
treatment
patient
acut
lymphoblast
leukemia
uk
patient
newli
diagnos
receiv
follow
asparaginas
case
hypersensit
although
nativ
asp
longer
use
first
choic
asparaginas
therapi
standard
care
avail
analysi
evalu
patient
newli
diagnos
compar
nativ
asparaginas
designmethod
combin
decis
treehealth
state
transit
markov
model
develop
compar
treatment
sequenc
start
versu
follow
case
hypersensit
pediatr
young
adult
year
adult
year
patient
model
use
protocol
analys
stratifi
pediatr
patient
patient
age
vs
year
transplant
elig
adult
model
key
model
paramet
surviv
risk
hypersensit
clinic
input
key
expert
analysi
os
ef
assum
equival
dose
per
ukal
protocol
use
scenario
analys
examin
per
smpc
includ
variat
compar
surviv
hypersensit
rate
increment
ratio
icer
increment
life
year
qali
gain
produc
result
scenario
demonstr
follow
result
reduc
cost
increas
qali
total
cost
save
total
qali
gain
versu
follow
scenario
analys
highlight
robust
result
differ
total
qali
driven
primarili
differ
hypersensit
rate
conclus
analysi
demonstr
part
chemotherapi
compar
children
young
adult
adult
newli
diagnos
k
ghanem
el
c
n
r
h
univers
beirut
depart
pediatr
adolesc
medicin
beirut
lebanon
backgroundobject
best
outcom
childhood
acut
lymphoblast
leukemia
achiev
adequ
balanc
diseas
control
toxic
children
cancer
center
lebanon
implement
st
jude
protocol
minor
modif
treat
patient
year
old
protocol
result
excel
overal
surviv
howev
excess
toxic
observ
includ
cmv
retin
dissemin
varicella
cn
thrombosi
designmethod
prospect
trial
decreas
dexamethason
dosag
continu
intensif
therapi
intermediatehigh
risk
patient
stop
monthli
dexamethason
puls
year
instead
year
initi
continu
therapi
asparaginas
dose
decreas
induct
patient
intensif
therapi
patient
prophylact
cranial
irradi
given
result
number
enrol
patient
median
month
rang
month
cumul
incid
isol
cn
relaps
increas
se
se
gray
p
patient
cn
relaps
without
initi
cn
involv
five
patient
achiev
second
remiss
one
patient
current
third
remiss
develop
second
isol
cn
relaps
cn
relaps
occur
year
treatment
initi
incid
cmv
retin
dissemin
varicella
cn
thrombosi
decreas
respect
cumul
incid
death
statist
differ
two
period
versu
gray
p
conclus
decreas
dexamethason
asparaginas
dosag
childhood
therapi
aim
avoid
toxic
result
signific
increas
isol
cn
relaps
gupta
r
india
institut
medic
scienc
new
delhi
lab
oncolog
new
delhi
india
india
institut
medic
scienc
new
delhi
medic
oncolog
new
delhi
india
backgroundobject
mani
patient
acut
lymphoblast
leukemia
nt
respond
satisfactorili
standard
therapi
current
poor
respond
subject
aggress
chemotherapi
base
minim
residu
diseas
mrd
statu
recent
moorman
et
al
propos
molecular
genet
criteria
better
undertook
studi
assess
util
neg
pediatr
particularli
respect
mrd
statu
designmethod
new
case
neg
pediatr
enrol
month
classifi
standard
intermedi
high
risk
treat
per
institut
protocol
patient
mrd
posit
flow
cytometri
end
induct
chemotherapi
treat
high
risk
genom
dna
analyz
copi
number
alter
cna
gene
use
multiplex
ligat
depend
probe
amplif
assess
use
moorman
criteria
event
free
surviv
ef
overal
surviv
os
note
result
case
median
age
year
year
final
analyz
cna
detect
case
case
mrd
posit
remain
mrd
low
intermedi
high
risk
case
genet
profil
could
identifi
two
subgroup
significantli
differ
ef
os
mrd
neg
intermedi
risk
group
genet
profil
also
separ
two
subgroup
significantli
differ
ef
mrd
posit
group
howev
os
differ
analysi
subgroup
reveal
signific
differ
conclus
genet
profil
identifi
distinct
subgroup
case
indic
patient
segreg
therapi
assign
base
importantli
empir
therapi
mrd
posit
case
may
appropri
adequ
particularli
poor
molecular
lb
l
k
z
first
affili
hospit
sum
pediatr
guangzhou
china
backgroundobject
benefit
vincristin
vcr
plu
dexamethason
dxm
mainten
controversi
multicent
clinic
trial
base
protocol
design
evalu
benefit
vcr
dxm
puls
mainten
therapi
report
result
singl
center
designmethod
children
diagnos
featur
enrol
depart
aug
dec
treat
protocol
base
protocol
includ
induct
consolid
mainten
therapi
begin
mainten
therapi
patient
complet
remiss
randomli
assign
either
protocol
protocol
b
protocol
patient
given
convent
methotrex
mtx
patient
protocol
b
given
mtx
week
substitut
vcr
dxm
week
everi
week
cycl
primari
outcom
measur
surviv
studi
regist
http
wwwclinicaltrialsgov
identifi
result
patient
die
therapi
random
remain
patient
randomli
assign
protocol
protocol
b
median
month
children
protocol
protocol
b
relaps
child
protocol
die
infect
mainten
treatment
surviv
ef
protocol
protocol
b
respect
overal
surviv
os
protocol
protocol
b
respect
conclus
benefit
intermit
mm
mainten
therapi
vincristin
dexamethason
children
risk
receiv
chemotherapi
base
bfm
protocol
c
li
l
z
j
j
x
r
x
l
r
h
c
mhl
chines
univers
hong
kong
paediatr
hong
kong
hong
kong
sar
children
hospit
capit
medic
univers
hematolog
oncolog
beij
china
hospit
soochow
univers
hematolog
oncolog
suzhou
china
hospit
chongq
medic
univers
hematolog
oncolog
chongq
china
china
second
univers
sichuan
univers
hematolog
oncolog
chengdu
china
hematolog
hospit
blood
chines
academi
medic
scienc
peke
union
medic
colleg
pediatr
hematolog
tianjin
china
tongji
medic
huazhong
univers
scienc
technolog
pediatr
wuhan
china
institut
pediatr
hematolog
oncolog
beij
china
univers
peopl
hospit
beij
china
hospit
fudan
univers
hematolog
oncolog
shanghai
china
chines
univers
hong
kong
anatom
cellular
patholog
hong
kong
hong
kong
sar
backgroundobject
gene
fusion
happen
childhood
prospect
multicent
trial
chines
children
leukemia
group
cclg
studi
patient
treat
standard
protocol
outcom
genet
subgroup
studi
designmethod
newli
diagnos
patient
recruit
hospit
china
patient
stratifi
risk
group
accord
age
wbc
genet
subtyp
prednison
respons
two
hospit
pilot
mrd
studi
flow
pcr
adjust
treatment
accord
mrd
respons
group
assign
intermedi
risk
ir
diagnosi
result
patient
identifi
posit
pcr
also
karyotyp
mean
age
wbc
diagnosi
year
male
femal
diagnosi
patient
cn
cn
statu
compar
ir
patient
group
higher
good
prednison
respons
vs
less
vs
better
remiss
vs
mrd
respons
assess
ir
patient
mrd
neg
significantli
higher
group
vs
p
relaps
bm
without
cn
relaps
death
occur
patient
due
relaps
due
infect
trend
better
ef
group
vs
signific
conclus
incid
chines
children
cn
relaps
observ
earli
respons
treatment
better
subset
also
trend
better
surviv
support
grant
nation
natur
scienc
foundat
china
no
f
seyfri
r
j
j
km
lh
univers
medic
center
pediatr
adolesc
medicin
ulm
germani
cancer
institut
medic
oncolog
boston
usa
univers
medic
center
intern
medicin
iii
ulm
germani
backgroundobject
precursor
acut
lymphoblast
leukemia
defici
cell
death
pathway
associ
treatment
failur
famili
protein
regul
apoptosi
therebi
serv
target
novel
direct
therapi
inhibitor
bind
lead
releas
famili
molecul
apoptosi
induct
assess
efficaci
investig
factor
mediat
suscept
resist
indic
activ
designmethod
sensit
investig
cell
line
xenograft
express
apoptosi
regul
detect
western
blot
analysi
defici
leukemia
gener
mitochondri
apoptosi
signal
assess
activ
evalu
vivo
result
vast
major
sampl
show
sensit
cell
death
nanomolar
rang
interestingli
express
regul
significantli
associ
effect
knockout
leukemia
result
sensit
point
mediat
resist
next
character
function
interplay
apoptosi
regul
profil
mitochondri
depend
associ
sensit
contrast
low
addict
regul
sampl
importantli
preclin
vivo
set
xenograft
mous
model
prolong
surviv
upon
vivo
indic
high
mitochondri
contrast
low
insensit
leukemia
conclus
taken
togeth
show
sensit
howev
resist
occur
character
level
target
molecul
importantli
function
assess
mitochondri
indic
sensit
activ
vivo
provid
marker
upfront
identif
patient
would
benefit
novel
effect
strategi
inhibitor
f
gome
andrad
sardou
f
vicent
do
santo
g
dallapicola
e
pereira
e
ms
nacion
de
research
center
rio
de
janeiro
brazil
backgroundobject
initi
somat
mutat
detect
dri
neonat
blood
spot
cord
blood
sampl
affect
children
leukemia
prove
acquir
prenat
howev
epidemiolog
studi
carri
explor
infant
acut
myeloid
leukemia
includ
infant
children
month
age
diagnosi
aim
describ
molecular
character
case
investig
contribut
gene
mutat
probabl
overal
surviv
po
designmethod
one
hundr
syndrom
case
assess
throughout
multicentr
network
studi
mutat
hotspot
region
ra
pathway
affect
gene
nra
kra
analyz
well
fusion
gene
rearrang
respect
associ
aml
major
patient
treat
follow
although
clinic
trial
result
eleven
case
congenit
leukemia
age
month
old
case
age
month
old
mostli
morpholog
differenti
observ
blast
cell
myelomonocyt
monocyt
megakaryocyt
phenotyp
present
low
white
blood
cell
wbc
count
diagnosi
acut
myelomonocyt
leukemia
frequent
molecular
abnorm
mainli
follow
ra
pathway
gene
mutat
observ
affect
mostli
case
age
month
old
associ
cumul
po
statist
differ
surviv
rate
among
year
associ
molecular
alter
conclus
despit
present
fewer
genet
abnorm
older
pediatr
aml
death
rate
high
data
indic
diagnosi
manag
rais
question
consid
action
f
gome
andrad
e
pereira
f
vicent
do
santo
sardou
g
dallapicola
e
ms
nacion
de
research
center
rio
de
janeiro
brazil
backgroundobject
biolog
character
childhood
acut
myeloid
leukemia
import
outcom
predictor
brazil
littl
known
frequenc
aml
subgroup
although
account
leukemia
aim
investig
contribut
type
ii
gene
mutat
probabl
overal
surviv
po
brazil
designmethod
seven
hundr
three
de
novo
pediatr
aml
case
assess
throughout
multicentr
network
studi
mutat
hotspot
region
nra
kra
gene
analyz
well
fusion
gene
associ
aml
patient
treat
protocol
follow
sinc
year
acut
promyelocyt
leukemia
apl
treat
differ
aml
syndrom
exclud
result
signific
differ
gene
mutat
age
rang
year
old
year
old
nonrandom
associ
type
iii
mutat
lower
white
blood
cell
count
associ
wherea
higher
wbc
p
cumul
po
year
total
aml
apl
po
differ
observ
brazilian
region
region
better
po
wherea
region
present
poorest
po
mutat
confer
advers
prognosi
independ
prognost
factor
conclus
identif
genet
subgroup
contribut
molecular
epidemiolog
biolog
aml
worldwid
reflect
profil
pediatr
aml
case
brazil
surviv
data
specif
subtyp
latin
countri
found
rare
literatur
inclus
marker
character
aml
great
predict
valu
os
salem
k
n
egypt
children
cancer
hospit
egypt
cytogenet
cairo
egypt
egypt
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
egypt
children
cancer
hospit
egypt
hematolgi
cairo
egypt
egypt
children
cancer
hospit
egypt
immunolgi
cairo
egypt
egypt
children
cancer
hospit
egypt
pediatr
oncolgi
cairo
egypt
cancer
hospit
research
cairo
egypt
backgroundobject
acut
myeloid
leukemia
aml
patient
hyperdiploid
triploidtetraploid
tt
karyotyp
repres
rel
poorli
understood
entiti
aim
studi
characterist
group
regard
karyotyp
clinic
laboratori
featur
treatment
outcom
designmethod
retrospect
analyz
data
patient
de
novo
aml
treat
children
cancer
hospit
egypt
cog
adopt
protocol
juli
januari
patient
syndrom
acut
promyelocyt
leukemia
exclud
result
thirti
four
patient
chromosom
seven
case
core
bind
factor
transloc
exclud
analysi
hyperdiploid
tt
case
case
three
case
pure
hyperdiploid
gene
rearrang
found
case
trisomi
case
gain
chromosom
case
chromosom
abnorm
case
none
patient
monosomi
delet
two
patient
die
earli
induct
exclud
analysi
two
year
overal
surviv
significantli
lower
compar
rearrang
normal
karyotyp
core
bind
factor
aml
inv
respect
year
diseas
free
surviv
hyperdiploid
group
rearrang
normal
karyotyp
inv
respect
relaps
occur
patient
hyperdiploidi
compar
rearrang
normal
karyotyp
inv
respect
cumul
incid
relaps
hyperdiploid
group
ci
conclus
hyperdiploid
tt
karyotyp
rare
advers
risk
abnorm
pediatr
aml
compar
genet
group
rs
tong
al
wh
j
jn
te
univers
school
medicin
pediatr
mo
usa
hospit
sick
children
hematologyoncolog
canada
health
centr
pediatr
ns
canada
backgroundobject
syndrom
ds
neonat
higher
incid
acut
myeloid
leukemia
character
mutat
exon
alford
ka
et
al
blood
given
unstabl
surfac
immunophenotyp
leukemia
never
bona
fide
method
detect
minim
residu
diseas
mrd
follow
chemotherapi
sequenc
mutat
would
provid
platform
howev
limit
high
sequenc
ec
circumv
detect
mutat
limit
detect
young
al
et
al
leukemia
collabor
children
oncolog
group
cog
appli
ec
parallel
flow
cytometri
improv
mrd
detect
designmethod
exon
amplifi
pcr
result
amplicon
ligat
barcod
enabl
sampl
multiplex
well
random
index
allow
ec
librari
sequenc
illumina
miseq
analyz
use
publish
comput
method
wong
et
al
natur
result
date
sampl
patient
enrol
cog
studi
analyz
diagnosi
end
induct
nonsynonym
mutat
detect
diagnosi
sampl
averag
variant
allel
frequenc
vaf
rang
mrd
detect
pair
sampl
averag
vaf
rang
conclus
ec
capabl
detect
monitor
mrd
interestingli
detect
mrd
pair
sampl
yet
patient
except
high
surviv
rate
suggest
secondari
event
addit
mutat
involv
relaps
focu
addit
research
c
vya
g
gandhi
cancer
institut
research
new
india
depart
pediatr
delhi
india
backgroundobject
acut
myeloid
leukemiamyelodysplast
syndrom
devast
complic
cancer
treatment
view
pauciti
literatur
india
report
incid
risk
factor
period
year
institut
designmethod
retrospect
analysi
patient
year
age
treat
pediatr
unit
institut
januari
decemb
amongst
patient
develop
identifi
inform
pertain
primari
malign
treatment
detail
along
clinic
hematolog
cytogenet
featur
outcom
obtain
result
amongst
children
patient
develop
male
femal
median
age
year
median
latenc
period
month
incid
solid
tumour
haematolog
malign
respect
p
primari
malign
sarcoma
bone
soft
tissu
lymphoma
acut
lymphoblast
leukemia
median
cumul
equival
dose
cyclophosphamid
doxorubicin
etoposid
rang
mg
rang
rang
respect
two
patient
receiv
radiotherapi
primari
site
domin
fab
morpholog
cytogenet
abnorm
transloc
five
patient
opt
treatment
achiev
remiss
three
patient
die
toxic
death
relaps
two
patient
aliv
diseas
free
median
surviv
month
conclus
observ
high
incid
children
sarcoma
compar
haematolog
malign
shorter
latenc
period
presenc
transloc
implic
epipodophyllotoxin
probabl
caus
agent
view
poor
outcom
strategi
identifi
host
risk
factor
practis
precis
medicin
need
consid
ahmad
n
fs
n
children
hospit
institut
child
health
lahor
haematolog
oncolog
lahor
pakistan
backgroundobject
children
hospit
lahor
tertiari
govern
centr
paediatr
oncolog
bed
receiv
new
cancer
patient
per
year
purpos
studi
analyz
treatment
outcom
children
biopsi
proven
hodgkin
lymphoma
discuss
variou
factor
caus
poor
outcom
compar
develop
countri
designmethod
retrospect
review
patient
enrol
januari
june
done
data
regard
age
stage
histopatholog
treatment
outcom
impact
delay
present
analyz
patient
treat
accord
protocol
receiv
cours
oepacopdac
result
total
patient
age
rang
yr
includ
f
ratio
present
advanc
stage
stage
ii
present
histopatholog
examin
show
mix
cellular
nodular
sclerosi
lymphocyt
predomin
lymphocyt
deplet
case
wherea
report
specifi
subtyp
bone
marrowlung
involv
patient
total
complet
treatment
left
medic
advic
lama
expir
due
sepsi
progress
diseas
relaps
progress
diseas
conclus
surviv
good
whole
group
iscayahl
data
mortal
reduc
earli
diagnosi
aggress
infect
control
measur
develop
countri
late
referr
strongli
associ
metastat
diseas
prognosi
significantli
improv
public
awar
seek
earli
treatment
establish
safe
effect
share
care
oncolog
pathway
multidisciplinari
team
approach
provid
strong
social
support
intens
psychosoci
counsel
effici
run
day
care
oncolog
help
increas
patient
complianc
cai
children
medic
shanghai
jiao
tong
school
med
pediatr
hematolog
oncolog
shanghai
china
backgroundobject
reliabl
assess
residu
mass
remain
diagnost
problem
patient
lymphoma
nhl
object
studi
assess
impact
biopsi
residu
mass
chemotherapi
pediatr
matur
nhl
designmethod
patient
matur
nhl
suspici
residu
mass
mid
end
treatment
subject
second
biopsi
treat
follow
medic
center
clinic
characterist
imag
patholog
treatment
prognosi
review
retrospect
result
total
children
includ
burkitt
lymphoma
diffus
larg
b
cell
lymphoma
lymphoma
unclassifi
median
age
diagnosi
year
year
median
time
diagnosi
second
biopsi
month
month
biopsi
confirm
presenc
viabl
tumor
patient
specif
posit
predict
valu
ppv
convent
imag
detect
residu
diseas
poor
three
histolog
posit
patient
experienc
progress
diseas
relaps
other
achiev
complet
remiss
cr
complet
therapi
patient
achiev
cr
median
year
year
median
surviv
pf
time
month
month
pf
rate
pf
rate
group
group
conclus
residu
mass
uncommon
children
matur
nhl
integr
tactic
import
accur
determin
residu
diseas
convent
imag
low
specif
ppv
biopsi
necessari
differenti
viabl
tumor
necrosi
fibrosi
solid
foundat
subsequ
treatment
also
help
clinician
avoid
overtreat
predict
prognosi
f
r
j
e
p
de
univers
pediatr
palo
alto
usa
nacion
de
oncologia
pediatrica
guatemala
guatemala
jude
children
research
hospit
oncolog
memphi
usa
mascota
hospit
oncologia
pediatrica
managua
nicaragua
de
san
jose
costa
rica
escuela
materno
infantil
tegucigalpa
hondura
de
benjamin
bloom
san
salvador
el
salvador
universitario
santo
domingo
dominican
republ
medicin
univers
center
biostatist
clinic
epidemiolog
milan
itali
medicin
univers
biostatist
clinic
epidemiolog
milan
israel
illinoi
colleg
medicin
st
jude
midwest
affili
depart
pediatr
peoria
usa
backgroundobject
high
risk
hodgkin
lymphoma
children
curabl
chemotherapi
radiat
multipl
chemotherapeut
drug
often
avail
purchas
incom
countri
lmic
ahopca
implement
modifi
treatment
guidelin
aim
reduc
abandon
conserv
surviv
designmethod
patient
high
risk
hodgkin
lymphoma
iib
iiib
iv
diagnos
august
march
costa
rica
el
salvador
guatemala
hondura
nicaragua
dominican
republ
contribut
report
patient
stage
ultrasound
comput
tomographi
chemotherapi
regimen
modifi
stanfordv
substitut
cyclophosphamid
mechlorethamin
respons
evalu
perform
week
chemotherapi
patient
receiv
either
cr
pr
radiat
therapi
ifrt
result
patient
elig
evalu
enrol
median
time
year
boy
median
age
year
year
iib
iiib
iv
finish
therapi
get
ifrt
due
death
abandon
progress
diseas
pd
got
ifrt
later
week
end
chemotherapi
without
affect
outcom
overal
patient
pd
relaps
die
abandon
ef
os
whole
cohort
ef
iib
iiib
iv
stage
conclus
treatment
abandon
remain
import
failur
vs
previous
describ
substitut
cyclophosphamid
mechlorethamin
stanfordv
bring
expect
result
os
earlier
stage
better
stage
iv
substitut
drug
lmic
relat
avail
danger
affect
outcom
new
regimen
avail
drug
implement
advocaci
complianc
drug
avail
need
n
pradhan
g
g
b
memori
centr
pediatr
oncolog
mumbai
india
memori
centr
medic
oncolog
mumbai
india
backgroundobject
alcl
rare
form
nhl
children
evalu
clinic
epidemiolog
profil
outcom
pediatr
alcl
patient
tata
memori
center
mumbai
india
designmethod
retrospect
studi
year
data
alcl
patient
regist
centr
patient
treat
centr
receiv
vinblastin
base
chemotherapi
cyclophosphamid
doxorubicin
cytarabin
vinblastin
ifosfamid
etoposid
methotrex
vinblastin
intens
phase
consist
altern
regimen
cycl
intrathec
cytarabin
intrathec
methotrex
follow
oral
methotrex
mainten
therapi
six
month
stage
diseas
one
year
stage
diseas
result
includ
patient
year
alcl
male
femal
ratio
number
patient
diseas
diagnosi
respect
patient
present
common
site
diseas
involv
lymph
node
bone
skin
patient
diseas
immunohistochemistri
outcom
analysi
detail
patient
avail
remain
complet
remiss
cr
achiev
achiev
partial
respons
pr
progress
diseas
six
patient
relaps
achiev
second
remiss
aliv
cr
last
five
patient
die
remiss
thirteen
die
due
diseas
advanc
stage
ef
os
respect
median
month
conclus
pediatr
alcl
reason
outcom
vinblastin
base
chemotherapi
advanc
stage
diseas
associ
higher
risk
mortal
requir
innov
therapi
salem
h
r
egypt
children
cancer
hospit
egypt
clinic
patholog
cairo
egypt
egypt
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
clinic
patholog
cairo
egypt
cancer
hospit
egypt
research
depart
cairo
egypt
backgroundobject
burkitt
leukemia
bl
character
transloc
myc
gene
one
immunoglobulin
gene
clinic
signific
secondari
chromosom
abnorm
associ
characterist
transloc
remain
unknown
aim
analyz
impact
secondari
chromosom
abnorm
treatment
outcom
pediatr
bl
designmethod
patient
bl
present
children
cancer
hospit
cche
juli
till
march
review
karyotyp
myc
statu
fish
result
correl
surviv
analysi
result
patient
bl
diagnos
treat
accord
fablmb
protocol
major
male
year
age
present
associ
central
nervou
system
involv
diagnos
patient
inform
karyotyp
patient
demonstr
transloc
myc
igh
gene
patient
transloc
igk
igl
found
respect
secondari
chromosom
abnorm
detect
patient
duplic
chromosom
found
patient
follow
chromosom
abnorm
patient
chromosom
delet
patient
chromosom
delet
patient
five
year
os
year
ef
whole
group
exclud
patient
treatment
relat
mortal
relaps
tumor
progress
chemotherapi
seen
patient
year
relaps
free
surviv
patient
complex
karyotyp
patient
karyotyp
conclus
frequenc
secondari
chromosom
abnorm
seri
concord
public
duplic
common
follow
delet
complex
karyotyp
significantli
associ
higher
incid
relaps
poor
outcom
yb
choi
l
ji
keon
k
ki
k
hong
univers
hospit
pediatr
seoul
republ
korea
medic
center
pediatr
seoul
republ
korea
medic
center
laboratori
medicin
genet
seoul
republ
korea
backgroundobject
natur
killer
nk
cell
precis
control
network
activ
inhibit
signal
surfac
receptor
studi
evalu
impact
kir
genotyp
outcom
follow
allogen
hsct
malign
diseas
children
designmethod
donor
activ
kir
recipi
kir
ligand
match
consid
compat
donor
one
activ
receptor
cognat
ligand
present
recipi
deem
activ
kir
donor
classifi
kir
haplotyp
b
donor
accord
gene
content
haplotyp
donor
defin
individu
possess
gene
group
kir
haplotyp
individu
possess
one
haplotyp
gene
defin
haplotyp
b
donor
result
patient
receiv
allogen
hsct
sibl
n
unrel
donor
n
haploident
donor
n
januari
decemb
transplant
perform
patient
acut
myeloid
leukemia
n
acut
lymphoblast
leukemia
n
neuroblastoma
n
solid
tumor
n
pair
match
remain
pair
mismatch
surviv
recipi
match
recipi
mismatch
p
recipi
receiv
hsct
haplotyp
b
donor
surviv
benefit
compar
receiv
hsct
haplotyp
donor
vs
p
conclus
analysi
reveal
allogen
hsct
activ
match
decreas
relaps
improv
surviv
therefor
success
hsct
outcom
kir
genotyp
perform
select
nk
cell
alloreact
donor
ash
r
k
c
c
k
c
b
de
children
medic
center
israel
pediatr
hematolog
oncolog
rosh
haain
israel
g
epidemiolog
biostatist
unit
genova
itali
maxima
center
pmc
paediatr
oncolog
pediatr
oncolog
utrecht
netherland
albert
de
grenobl
de
grenobl
franc
children
hospit
krakow
pediatr
oncolog
krakow
poland
scientif
clinic
center
pediatr
depart
clinic
oncolog
moscow
russian
feder
russia
ladi
children
hospit
pediatr
oncolog
dublin
ireland
lindgren
children
hospit
childhood
cancer
research
unit
stockholm
sweden
ormond
hospit
children
radiolog
london
unit
kingdom
giannina
gaslini
neuroradiolog
unit
genova
itali
children
children
cancer
blood
disord
paediatr
haematologist
oncologist
sydney
australia
giannina
gaslini
depart
genova
itali
backgroundobject
spinal
canal
invas
sci
occur
children
peripher
neuroblast
tumor
pnt
patient
favor
clinic
biolog
featur
cure
often
patient
especi
prone
develop
late
neurolog
function
orthoped
sequela
question
optim
treatment
solv
yet
prospect
siopen
studi
registri
aim
collect
data
patient
aim
increas
knowledg
natur
histori
pnt
present
sci
evalu
combin
effect
differ
risk
factor
outcom
ultim
develop
common
treatment
guidelin
designmethod
siopen
studi
intend
collect
clinic
biolog
therapeut
data
symptomat
asymptomat
patient
pnt
sci
minimum
patient
expect
age
adjust
standard
tool
symptom
grade
function
impact
ctcae
flacc
pain
score
asia
scale
result
june
februari
total
patient
regist
countri
median
age
month
mf
ratio
common
histolog
nb
poorli
differenti
three
patient
mycn
gene
amplif
patient
symptomat
symptom
includ
motor
deficit
pain
bladder
bowel
function
primari
tumour
site
locat
thorax
thoracoabdomin
site
major
diseas
patient
treat
accord
siopeninstitut
protocol
median
month
month
diagnosi
pain
disappear
patient
present
symptom
motor
deficit
persist
patient
avail
respons
conclus
first
cooper
studi
design
collect
data
evalu
combin
effect
differ
risk
factor
neurolog
function
orthoped
outcom
pnt
patient
present
sci
hakkert
j
f
r
h
j
center
trst
utrecht
netherland
medisch
centrum
oncogenom
amsterdam
netherland
medic
ghent
univers
paediatr
oncogenom
ghent
belgium
institut
biomed
research
cancer
epigenet
biolog
program
barcelona
spain
backgroundobject
induct
treatment
regimen
patient
neuroblastoma
contain
chemotherapeut
caus
doubl
strand
dna
break
tumor
suppressor
gene
involv
repair
doubl
strand
break
dna
studi
effect
express
tumor
progress
chemoresist
neuroblastoma
designmethod
perform
illumina
methyl
assay
neuroblastoma
tumor
sampl
sought
differenti
methyl
cpg
high
risk
low
risk
tumor
mtt
assay
perform
studi
effect
target
gene
methyl
chemoresist
shrna
knock
util
investig
tumor
drive
effect
target
gene
express
result
found
top
hit
significantli
differenti
methyl
cpg
high
risk
low
risk
neuroblastoma
surpris
sinc
known
bonafid
tumor
suppressor
gene
neuroblastoma
howev
gene
seem
function
tumor
driver
hypomethyl
strongli
correl
high
express
shrna
knockdown
led
increas
dna
damag
cell
death
cell
line
high
express
hypothes
hypomethyl
would
lead
resist
chemotherapeut
sinc
induc
doubl
strand
break
would
effici
repair
inde
cell
line
hypomethyl
show
resist
wide
use
chemotherapeut
conclus
hypomethyl
high
risk
neurblastoma
tumor
knockdown
lead
dna
damag
cell
death
cell
line
depend
suggest
essenti
tumor
progress
hypomethyl
tumor
hypomethyl
shown
caus
resist
chemotherapeut
indic
hypomethyl
might
involv
therapi
resist
patient
high
risk
neuroblastoma
hindl
b
wh
cp
tech
univers
health
scienc
center
cancer
center
lubbock
usa
backgroundobject
patient
neuroblastoma
nb
treat
chemotherapi
often
relaps
diseas
temozolomid
tmz
agent
irinotecan
irn
topoisomeras
inhibitor
clinic
activ
relapserefractori
nb
hypothes
dna
repair
gene
increas
express
nb
model
would
provid
potenti
therapeut
target
enhanc
chemotherapi
designmethod
taqman
low
densiti
array
tlda
use
analyz
mrna
express
dna
repair
gene
cell
line
gene
differenti
express
valid
expand
nb
cell
line
panel
vitro
cytotox
assay
use
digit
imag
microscopi
scan
system
dimscan
doubl
strand
dna
break
apoptosi
dna
fragment
assess
use
cleav
tunel
respect
vitro
test
use
activ
metabolit
irn
subcutan
xenograft
pdx
nunu
mice
treat
tmz
irn
via
oral
gavag
tail
vein
inject
intraperiton
inject
respect
result
methyltransferas
mgmt
upregul
rel
nb
cell
line
tlda
p
mgmt
express
posit
correl
vitro
p
mgmt
inhibitor
enhanc
vitro
cytotox
phosphoryl
cleavag
apoptosi
tunel
delay
tumor
growth
increas
median
surviv
p
rel
tmzirn
pdx
establish
time
death
progress
diseas
conclus
high
mgmt
express
associ
neuroblastoma
resist
mgmt
inhibitor
synergist
enhanc
activ
tmzirn
vitro
vivo
clinic
achiev
dose
studi
evalu
mgmt
therapeut
target
recurr
neuroblastoma
warrant
e
szychot
n
p
l
biassoni
last
author
morgenstern
last
author
ormond
street
hospit
children
nh
foundat
trust
paediatr
oncolog
haematolog
london
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
radiolog
london
unit
kingdom
ormond
street
hospit
children
nh
foundat
trust
patholog
london
unit
kingdom
sick
children
paediatr
oncolog
toronto
canada
backgroundobject
assess
metastat
respons
scintigraphi
import
treatment
decis
manag
patient
neuroblastoma
howev
relev
primari
tumour
mibg
respons
explor
aim
compar
clinic
histolog
percentag
viabl
tumour
characterist
primari
tumour
becam
entir
induct
chemotherapi
ic
respond
primari
tumour
remain
designmethod
retrospect
review
patient
metastat
month
diagnosi
treat
great
ormond
street
hospit
patient
receiv
rapid
cojec
ic
per
siopen
patient
go
surgeri
ic
alon
exclud
histopatholog
specimen
assess
percentag
viabl
tumour
primari
tumour
mibg
respons
assess
qualit
posit
neg
intermedi
mibg
uptak
assess
diagnosi
ic
estim
surviv
ef
use
comparison
test
result
seven
patient
tumour
diagnosi
exclud
patient
show
complet
primari
tumour
mibg
respons
partial
respons
respons
statist
signific
differ
clinic
demograph
respond
primari
tumour
mibg
respons
correl
extent
metastat
diseas
diagnosi
mean
percentag
viabl
tumour
cell
significantli
greater
respond
vs
ef
significantli
better
complet
respond
vs
p
ef
better
patient
whose
tumour
show
viabl
tumour
ic
compar
viabl
tissu
vs
p
conclus
primari
mibg
respons
correl
tumour
necrosi
patient
outcom
howev
suffici
alon
use
confirm
complet
necrosi
justifi
decis
resect
tumour
k
vrenken
j
van
ingen
f
van
laboratori
pediatr
oncolog
pediatr
nijmegen
netherland
backgroundobject
despit
intens
treatment
close
patient
neuroblastoma
relaps
recurr
diseas
character
poorli
differenti
therapi
resist
cell
retino
acid
ra
differenti
improv
surviv
mani
patient
fail
respond
henc
aim
identifi
novel
therapeut
target
enhanc
sensit
ra
promot
neuroblastoma
differenti
similar
neural
crest
develop
neuroblastoma
progress
provid
appeal
start
point
neural
crest
develop
transcript
program
transit
emt
drive
cellular
plastic
affect
migrat
pluripot
hypothes
similar
mechan
maintain
neuroblastoma
cell
poorli
differenti
state
therfor
target
emt
may
overcom
therapi
resist
designmethod
gene
express
profil
investig
associ
emt
transcript
factor
neuroblastoma
overal
surviv
subsequ
use
varieti
differ
vitro
method
includ
spheroid
invas
assay
studi
effect
mediat
knockout
emt
transcript
factor
neuroblastoma
differenti
respons
ra
addit
mice
use
identifi
effect
knockout
vivo
colon
result
express
emt
transcript
factor
associ
neuroblastoma
diseas
progress
moreov
gene
directli
control
highli
predict
diseas
outcom
two
independ
neuroblastoma
patient
cohort
support
idea
increas
activ
contribut
neuroblastoma
progress
consist
knockout
promot
cellular
differenti
reduc
self
renew
capac
invas
matrix
vivo
colon
addit
growth
knockout
cell
strongli
inhibit
ra
treatment
accompani
enhanc
tumor
cell
differenti
conclus
summari
result
identifi
key
player
regul
neuroblastoma
differenti
respons
ra
futur
research
focu
emt
regulatori
network
effect
target
enhanc
therapi
respons
patient
advanc
neuroblastoma
mj
li
dx
jh
c
hf
q
zhejiang
univers
school
medicin
divis
surgic
depart
pediatr
surgeri
hangzhou
china
zhejiang
univers
school
medicin
divis
depart
pediatr
hangzhou
china
zhejiang
univers
school
medicin
divis
depart
pediatr
surgeri
hangzhou
china
zhejiang
univers
school
medicin
divis
surgic
depart
pediatr
surgeri
hangzhou
china
zhejiang
univers
school
medicin
depart
radiolog
hangzhou
china
zhejiang
univers
school
medicin
depart
patholog
hangzhou
china
backgroundobject
aim
studi
evalu
clinic
efficaci
safeti
neoadjuv
transcathet
arteri
chemoembol
tace
combin
system
chemotherapi
treatment
advanc
wilm
tumor
designmethod
januari
decemb
patient
median
age
year
male
femal
advanc
wilm
tumor
treat
preoper
tace
system
chemotherapi
characterist
patient
tumor
diamet
greater
cm
involv
periaort
lymph
node
tumor
thrombu
inferior
vena
cavaright
atrium
distal
metastasi
diffus
anaplast
histolog
ah
chemoembol
emuls
tace
consist
pirarubicin
vindesin
cisplatin
iodiz
oil
intraven
chemotherapi
vindesin
ifosfamid
actinomycin
etoposid
administ
week
tace
nephrectomi
perform
week
preoper
therapi
postop
radiat
therapi
chemotherapi
base
tumor
histolog
surgic
stage
result
cardiotox
renal
hepat
dysfunct
neoadjuv
therapi
found
grade
marrow
suppress
develop
patient
term
respons
evalu
criteria
pr
sd
pd
patient
observ
distant
metastasi
disappear
four
six
case
patient
underw
tumor
resect
preoper
therapi
complet
surgic
remov
tumor
achiev
patient
ef
os
ci
ci
respect
median
year
rang
year
conclus
neoadjuv
tace
combin
system
chemotherapi
provid
promis
choic
treatment
advanc
wilm
tumor
j
l
c
w
n
k
r
k
n
smeulder
ormond
street
hospit
paediatr
urolog
london
unit
kingdom
ormond
street
hospit
paediatr
oncolog
london
unit
kingdom
verona
epidemiolog
medic
statist
verona
itali
ormond
street
hospit
histopatholog
london
unit
kingdom
ormond
street
hospit
radiolog
london
unit
kingdom
ormond
street
hospit
paediatr
nephrolog
london
unit
kingdom
backgroundobject
surgeri
nss
bilater
wilm
tumour
bwt
balanc
complet
maxim
preserv
renal
parenchyma
studi
explor
risk
factor
incomplet
resect
oncolog
impact
designmethod
retrospect
review
patient
bwt
treat
great
ormond
street
hospit
aug
patient
demograph
imag
treatment
surgeri
histolog
clinic
outcom
record
lesion
diamet
volum
number
locat
distanc
vessel
type
nss
assess
multivari
logist
regress
stata
associ
incomplet
resect
effect
mortal
relaps
treatment
burden
result
patient
mean
age
month
surgeri
receiv
nss
excis
lesion
total
nephrectomi
tn
patient
chemotherapi
per
protocol
data
avail
patient
mean
rang
surgeri
die
renal
outcom
mean
patient
bilater
tn
complet
nephrectomi
recurr
dialysi
renal
transplant
progress
patient
hypertens
elev
creatinin
hypertens
elev
creatinin
alon
patient
normal
renal
paramet
posit
margin
occur
patient
lesion
tn
nss
partial
nephrectomi
tumorectomi
histolog
regress
nephrogen
rest
mix
anaplasia
blastema
epitheli
tumorectomi
odd
ratio
ci
increas
number
lesionskidney
unit
associ
significantli
increas
risk
flankabdomin
radiotherapi
intensifi
chemotherapi
significantli
increas
risk
relaps
death
conclus
multipl
lesion
tumorectomi
compar
partial
nephrectomi
associ
patient
bwt
increas
treatment
burden
risk
late
effect
g
bellini
di
e
c
di
f
f
campania
luigi
vanvitelli
experiment
medicin
napl
itali
campania
luigi
vanvitelli
gener
specialist
surgeri
napl
itali
backgroundobject
process
osteoblast
precursor
dedifferenti
caus
osteosarcoma
common
tumor
childhood
contrast
tumor
type
tam
macrophag
polar
macrophag
reduc
metastasi
improv
surviv
osteosarcoma
patient
mifamurtid
immunomodulatori
drug
given
togeth
standard
adjuv
chemotherapi
osteosarcoma
improv
outcom
aim
studi
evalu
role
mifamurtid
macrophag
polar
modul
dedifferenti
osteosarcoma
cell
line
designmethod
macrophag
obtain
peripher
blood
mononucl
cell
healthi
subject
activ
mifamurtid
collect
cell
qpcr
biochem
western
blot
elisa
analys
evalu
effect
mifamurtid
marker
ino
marker
iron
releas
osteoblast
marker
ocn
opg
rankl
phosphoryl
result
macrophag
show
signific
reduct
polar
marker
ino
polar
marker
signific
increas
cytokin
moreov
show
signific
increas
iron
transport
accord
increas
iron
uptak
typic
phenotyp
signific
increas
fold
iron
releas
accord
polar
cell
macrophag
show
signific
increas
osteoblast
marker
opg
signific
reduct
rankl
moreov
show
signific
reduct
prolifer
activ
sever
tumor
instead
constitut
activ
conclus
collect
data
suggest
mifamurtid
switch
macrophag
polar
toward
intermedi
phenotyp
reduc
activ
inhibit
cellular
prolifer
induc
tumor
cell
dedifferenti
zamzam
r
n
cancer
hospit
egypt
cchenat
cancer
cairo
univers
pediatr
hematologyoncolog
cairo
egypt
cancer
hospit
egypt
cche
pediatr
hematologyoncolog
cairo
egypt
cancer
hospit
egypt
health
econom
outcom
cairo
egypt
cancer
hospit
egypt
cche
research
cairo
egypt
backgroundobject
chemotherapi
osteosarcoma
standard
care
still
confus
regard
optim
dose
intens
retrospect
studi
aim
determin
impact
chemotherapi
dose
intens
tumor
necrosi
outcom
children
local
osteosarcoma
cche
designmethod
dose
intens
di
determin
calcul
total
dose
drug
methotrex
doxorubicin
cisplatin
divid
time
durat
week
rel
dose
intens
rdi
calcul
divid
deliv
di
standard
di
per
cche
osteosarcoma
protocol
impact
chemotherapi
rdi
histolog
respons
determin
use
logist
regress
rdi
also
correl
surviv
rf
point
di
use
log
rank
test
cox
regress
done
analysi
result
one
hundr
three
patient
year
old
local
osteosarcoma
present
hospit
june
patient
poor
respond
patient
show
good
respons
histolog
respons
affect
chemotherapi
rdi
logist
regress
p
overal
surviv
rf
patient
receiv
drug
phase
rdi
show
improv
rf
receiv
show
rf
patient
good
histolog
respons
show
rf
poor
respond
show
rf
upon
multivari
analysi
histolog
respons
maintain
signific
p
rdi
lost
signific
p
conclus
rel
dose
intens
good
predictor
histolog
respons
great
impact
relaps
free
surviv
therefor
recommend
deliv
optim
dose
intens
achiev
better
outcom
h
tsuchiya
n
k
k
h
univers
graduat
school
medic
scienc
orthopaed
surgeri
kanazawa
japan
backgroundobject
variou
method
exist
reconstruct
larg
bone
defect
tumor
excis
tumor
prosthes
biolog
reconstruct
use
allograft
autograft
recycl
bone
develop
reconstruct
method
use
autograft
treat
liquid
nitrogen
purpos
studi
evalu
clinic
outcom
techniqu
treat
osteosarcoma
around
knee
children
epiphys
spare
tumor
resect
designmethod
retrospect
review
children
boy
girl
osteosarcoma
around
knee
averag
age
year
rang
mean
period
month
rang
case
lesion
distal
femur
patient
proxim
tibia
two
distinct
freez
techniqu
resect
freez
case
pedicl
freez
case
use
base
locat
tumor
complic
oncolog
outcom
evalu
grade
use
musculoskelet
tumour
societi
mst
score
system
result
mean
mst
score
rang
complic
requir
addit
surgeri
observ
patient
complic
consist
fractur
local
recurr
aris
surround
soft
tissu
one
superfici
infect
manag
irrig
iv
antibiot
limb
shorten
cm
observ
patient
patient
underw
subsequ
limb
lengthen
one
surgic
retriev
manag
soft
tissu
recurr
clinic
patient
abl
run
normal
final
oncolog
statu
cdf
ned
dod
conclus
outcom
surgeri
use
steril
liquid
nitrogen
childhood
osteosarcoma
around
knee
satisfactori
promis
procedur
prove
benefici
children
osteosarcoma
n
khanna
g
j
b
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
medic
oncolog
mumbai
india
memori
hospit
patholog
mumbai
india
memori
hospit
radiolog
mumbai
india
memori
hospit
nuclear
medicin
mumbai
india
memori
hospit
surgic
oncolog
mumbai
india
backgroundobject
dsrct
rare
aggress
mesenchym
neoplasm
evalu
profil
treatment
respons
pattern
failur
prognost
factor
patient
dsrct
treat
tata
memori
hospit
tmh
designmethod
april
novemb
patient
histolog
proven
dsrct
age
group
yr
median
yr
treat
tmh
thirti
eight
male
major
diseas
metastat
diseas
present
seen
commonest
site
liver
cur
treatment
offer
patient
local
treatment
cytoreduct
surgeri
cr
alon
patient
cr
follow
adjuv
radiotherapi
rt
patient
patient
receiv
rt
alon
one
patient
underw
hypertherm
intraperiton
chemotherapi
hipec
cr
four
patient
progress
induct
chemotherapi
henc
undergo
local
treatment
result
median
month
progress
free
surviv
pf
overal
surviv
os
respect
last
follow
aliv
diseas
free
univari
analysi
patient
offer
local
treatment
form
cr
without
rt
improv
os
vs
p
superior
os
seen
patient
complet
cytoreduct
achiev
vs
time
relaps
patient
dissemin
diseas
five
patient
develop
sever
treatment
relat
toxic
conclus
dsrct
associ
poor
outcom
local
treatment
form
complet
cr
complet
cr
follow
adjuv
rt
confer
best
outcom
n
nakagawa
k
k
h
prefectur
univers
medicin
pediatr
kyoto
japan
prefectur
univers
medicin
pediatr
surgeri
kyoto
japan
prefectur
univers
medicin
cancer
prevent
kyoto
japan
backgroundobject
one
current
strategi
adult
malign
tumor
precis
medicin
base
individu
gene
mutat
despit
advanc
therapi
outcom
recurr
metastat
rhabdomyosarcoma
rm
remain
poor
treatment
relat
side
effect
still
problem
embryon
rm
erm
report
heterogen
tumor
display
variou
gene
mutat
investig
heterogen
could
contribut
develop
precis
medicin
erm
potent
select
dual
rafmek
inhibitor
studi
examin
activ
rm
tumor
cell
line
withwithout
ra
mutat
designmethod
human
rm
cell
line
rd
use
studi
ra
pathway
mutat
cell
line
identifi
direct
sequenc
cell
surviv
evalu
assay
cell
cycl
analyz
flow
cytometri
apoptosi
detect
use
flow
cytometri
appropri
stain
annexin
v
erk
phosphoryl
rb
analyz
immunoblot
result
inhibit
growth
cell
ra
mutat
affect
cell
lack
ra
pathway
mutat
cell
cycl
arrest
phase
induc
rm
cell
line
ra
mutat
within
h
exposur
pharmacolog
level
immunoblot
analys
drug
appear
suppress
erk
phosphoryl
cell
found
induc
rb
ra
mutat
cell
conclus
promis
therapeut
option
molecular
target
ra
mutat
rm
result
suggest
precis
medicin
approach
target
individu
variabl
gene
could
effect
therapeut
strategi
rm
ka
schultz
g
j
p
k
l
da
minnesota
cancer
blood
disord
mn
usa
nation
medic
center
patholog
washington
dc
usa
hospit
wisconsin
patholog
wi
usa
hospit
philadelphia
patholog
pa
usa
children
health
system
patholog
fl
usa
healthcar
atlanta
aflac
cancer
blood
disord
center
ga
usa
florida
colleg
medicin
fl
usa
univers
surgic
patholog
st
mo
usa
backgroundobject
background
pleuropulmonari
blastoma
ppb
common
primari
malign
lung
tumor
infanc
earli
childhood
type
ir
ppb
pure
cystic
wherea
type
ii
iii
ppb
mix
cysticsolid
entir
solid
respect
type
ii
iii
ppb
sarcoma
often
rhabdomyosarcomat
cartilagin
differenti
ppb
link
underli
germlin
tumor
specif
mutat
designmethod
method
case
primit
sarcoma
resembl
ppb
primari
site
peritoneum
identifi
patholog
case
file
washington
univers
medic
center
children
nation
medic
center
sequenc
perform
use
standard
techniqu
result
total
five
case
periton
ppb
identifi
patient
present
median
age
year
primari
site
origin
fallopian
tube
case
one
aros
seros
surfac
colon
one
pelvic
sidewal
one
case
appear
analog
type
ir
ppb
analog
type
ii
iii
ppb
mutat
identifi
germlin
andor
tumor
dna
conclus
discuss
periton
ppb
repres
new
manifest
syndrom
whose
patholog
featur
may
ident
type
ii
iii
ppb
sarcoma
cartilagin
rhabdomyosarcomat
differenti
pattern
also
seen
renal
sarcoma
cervic
embryon
rhabdomyosarcoma
cartilagin
featur
cell
tumor
heterolog
element
may
includ
rhabdomyosarcomat
cartilagin
compon
newli
recogn
tumor
distinguish
howev
unusu
origin
periton
caviti
differenti
diagnosi
malign
mix
tumor
carcinosarcoma
typic
seen
women
year
age
older
tumor
aris
abdomenpelvi
heterogen
rhabdomyosarcomat
andor
cartilagin
differenti
prompt
consider
germlin
tumor
test
b
vaarwerk
jh
van
der
wb
jc
rr
van
k
h
c
mn
c
mcg
v
jhm
children
hospit
academ
medic
centr
pediatr
oncolog
amsterdam
netherland
children
hospit
academ
medic
centr
pediatr
clinic
research
offic
amsterdam
netherland
curi
pediatr
adolesc
young
adult
depart
pari
franc
marsden
hospit
children
young
peopl
depart
sutton
unit
kingdom
hospit
wale
depart
pediatr
oncolog
cardiff
unit
kingdom
children
hospit
academ
medic
centr
pediatr
radiolog
amsterdam
netherland
ormond
street
hospit
children
depart
radiolog
london
unit
kingdom
hospit
vall
dhebron
pediatr
oncolog
barcelona
spain
univers
hospit
depart
pediatr
adolesc
medicin
oslo
norway
universitair
de
enfant
pediatr
haematolog
oncolog
depart
brussel
belgium
colleg
london
hospit
nh
foundat
trust
depart
oncolog
london
unit
kingdom
manchest
children
hospit
patholog
depart
manchest
unit
kingdom
depart
pediatr
oncolog
lyon
franc
royal
hospit
children
depart
pediatr
oncolog
bristol
unit
kingdom
depart
pediatr
adolesc
oncolog
villejuif
franc
backgroundobject
earli
respons
induct
chemotherapi
use
current
european
guidelin
evalu
efficaci
chemotherapi
subsequ
adapt
treatment
pediatr
patient
rhabdomyosarcoma
howev
exist
literatur
predict
valu
radiolog
respons
surviv
contradictori
therefor
retrospect
analys
associ
earli
respons
surviv
data
studi
designmethod
ir
group
iii
macroscop
residu
patient
enrol
studi
respons
assess
cours
chemotherapi
assess
patient
progress
diseas
cours
chemotherapi
exclud
surviv
ff
overal
surviv
os
assess
three
group
completeparti
object
respons
cox
proport
hazard
result
cours
chemotherapi
patient
completeparti
respons
object
respons
respons
patient
ff
ci
os
ci
cox
proport
hazard
regress
analysi
reveal
signific
differ
ff
os
rate
respons
group
adjust
hazard
ratio
object
respons
respons
ff
os
respect
conclus
result
provid
evid
earli
radiolog
respons
chemotherapi
predict
surviv
patient
rhabdomyosarcoma
treatment
adapt
base
earli
respons
except
patient
progress
diseas
therefor
incorpor
futur
studi
dv
wakefield
jt
luca
b
cy
n
jude
children
research
hospit
radiat
oncolog
memphi
usa
tennesse
west
cancer
center
radiat
oncolog
memphi
usa
univers
winshop
cancer
institut
radiat
oncolog
atlanta
usa
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
surgic
oncolog
memphi
usa
backgroundobject
pauciti
data
exist
detail
role
local
therapi
radiotherapi
rt
surgeri
follow
locoregion
recurr
lr
pediatr
rhabdomyosarcoma
rm
evalu
outcom
prognost
factor
use
cohort
patient
lr
manag
without
repeat
rt
rert
designmethod
patient
lr
rm
treat
elig
inclus
patient
stage
risk
group
histolog
transloc
statu
primari
locat
histolog
surgic
extent
rt
dose
failur
pattern
document
overal
os
local
distant
failur
free
surviv
lff
dff
describ
use
estim
result
median
year
lr
patient
aliv
evid
diseas
salvag
therapi
includ
rert
surgeri
case
patient
receiv
chemotherapi
lr
median
os
pf
lr
month
patient
low
risk
favor
primari
site
improv
pf
os
lff
dff
year
follow
salvag
therapi
respect
median
lff
os
rert
vs
rert
patient
vs
vs
mo
patient
favor
site
group
diseas
failur
embryon
histolog
improv
lff
rert
patient
experienc
grade
acut
toxic
late
toxic
includ
second
malign
chemotherapi
induc
end
organ
failur
patient
respect
lr
failur
compon
cancer
relat
death
vs
rert
vs
rert
group
p
conclus
salvag
rt
may
reduc
risk
lr
patient
favor
diseas
relaps
characterist
although
distant
failur
remain
common
acut
toxic
minim
second
malign
chemotherapi
induc
end
organ
failur
caus
late
mortal
ap
alcasaba
g
p
c
c
j
e
philippin
philippin
gener
hospit
paediatr
manila
philippin
philippin
philippin
gener
hospit
ophthalmolog
manila
philippin
philippin
medic
center
pediatr
davao
philippin
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
children
medic
center
pediatr
manila
philippin
backgroundobject
retinoblastoma
surviv
philippin
remain
poor
due
low
detect
rate
late
referr
incomplet
treatment
develop
retinoblastoma
program
involv
treatment
protocol
tumor
board
meet
patient
navig
data
manag
educ
campaign
increas
referr
decreas
present
public
referr
hospit
mindanao
model
later
implement
three
referr
center
luzon
review
program
impact
patient
outcom
philippin
gener
hospit
baselin
data
show
censu
diseas
surviv
abandon
rate
designmethod
prospect
data
collect
consecut
patient
diagnos
januari
decemb
studi
march
result
total
patient
diagnos
unilater
bilater
trilater
mean
age
month
f
major
diseas
intern
retinoblastoma
stage
system
stage
stage
stage
ii
stage
iii
stage
iv
unknown
lag
time
month
studi
aliv
die
refus
abandon
treatment
transfer
care
center
lost
overal
surviv
respect
surviv
highest
stage
respect
lower
stage
iii
respect
iv
respect
overal
surviv
slightli
lower
respect
follow
similar
trend
stage
overal
surviv
conclus
retinoblastoma
outcom
improv
model
demonstr
increas
patient
referr
treatment
adher
surviv
provid
data
support
addit
replic
extens
effort
nation
protocol
retinoblastoma
b
chawla
f
r
r
india
institut
medic
scienc
rp
centr
ophthalm
scienc
new
delhi
india
india
institut
medic
scienc
paediatr
oncolog
depart
paediatr
new
delhi
india
india
institut
medic
scienc
depart
radiat
oncolog
new
delhi
india
backgroundobject
optic
nerv
invas
signific
risk
factor
metastasi
retinoblastoma
purpos
studi
evalu
clinic
outcom
retinoblastoma
patient
invas
optic
nerv
time
diagnosi
treat
uniform
protocol
consist
therapi
designmethod
patient
retinoblastoma
evid
optic
nerv
invas
mri
scan
orbit
brain
studi
demograph
clinic
detail
record
treatment
protocol
consist
chemotherapi
enucl
orbit
extern
beam
radiotherapi
adjuv
chemotherapi
system
chemotherapi
consist
intraven
vincristin
etoposid
carboplatin
cycl
follow
chemotherapi
optic
nerv
statu
mri
scan
outcom
paramet
surviv
probabl
caus
death
result
forti
eight
children
studi
unilater
boy
median
age
present
month
median
follow
month
children
die
kaplan
meier
surviv
probabl
one
year
four
year
respect
common
caus
death
cn
relaps
conclus
advanc
case
retinoblastoma
optic
nerv
invas
manag
treatment
protocol
although
short
term
result
encourag
long
term
outcom
need
evalu
dh
jo
jh
ho
cs
e
sr
yj
kd
jh
nation
univers
colleg
medicin
depart
ophthalmolog
seoul
republ
korea
nation
univers
hospit
fight
blind
farb
clinic
research
institut
seoul
republ
korea
research
institut
bioscienc
biotechnolog
immunotherapi
research
center
daejeon
republ
korea
nation
univers
colleg
medicin
depart
cancer
research
institut
seoul
republ
korea
backgroundobject
studi
aim
investig
therapeut
potenti
natur
killer
nk
cell
therapi
retinoblastoma
common
intraocular
malign
tumor
children
patient
retinoblastoma
inevit
perform
enucl
total
remov
eyebal
convent
treatment
option
fail
context
novel
treatment
option
desper
requir
treat
patient
retinoblastoma
designmethod
cell
commerci
avail
cell
line
cord
nk
cell
prepar
vitro
cytotox
assay
vivo
intracardiac
inject
vitro
cytotox
evalu
cocultur
nk
cell
retinoblastoma
cell
differ
retinoblastoma
cell
line
use
calcein
assay
evalu
vivo
efficaci
retinoblastoma
cell
cell
differ
retinoblastoma
cell
line
inject
vitreou
caviti
balbc
nude
mice
n
per
group
day
intravitr
inject
tumor
cell
nk
cell
cell
administ
via
intracardiac
rout
carboplatin
mgkg
administ
intraperiton
rout
administr
weekli
basi
vivo
cytotox
evalu
use
visual
grade
system
histolog
examin
result
nk
cell
demonstr
consider
vitro
cytotox
retinoblastoma
cell
addit
tumor
form
less
sever
manner
mice
treat
nk
cell
one
treat
carboplatin
salin
neg
control
also
remark
mice
treat
combin
nk
cell
carboplatin
demonstr
minim
tumor
format
intraocular
space
compar
one
treat
nk
cell
carboplatin
conclus
taken
togeth
nk
cell
demonstr
vitro
vivo
cytotox
retinoblastoma
expect
nk
cell
therapi
might
involv
treatment
retinoblastoma
sonoda
k
h
e
k
h
univers
graduat
school
medicin
pediatr
surgeri
kyoto
japan
univers
graduat
school
medicin
pediatr
kyoto
japan
univers
graduat
school
medicin
human
health
scienc
kyoto
japan
univers
center
ip
cell
research
applic
kyoto
japan
backgroundobject
hepatoblastoma
hb
common
malign
liver
tumor
childhood
recent
progress
surgic
techniqu
neoadjuv
adjuv
chemotherapi
markedli
improv
prognosi
patient
hb
howev
surviv
rate
patient
metastat
relaps
diseas
remain
unsatisfactori
integr
membran
glycoprotein
promot
tumor
growth
angiogenesi
metastasi
regard
promis
candid
immunotherapi
variou
malign
designmethod
express
level
two
hb
cell
line
clinic
sampl
examin
flow
cytometr
immunohistochem
analys
effect
block
rabbit
polyclon
antibodi
shrna
knockdown
evalu
vitro
assay
vivo
subcutan
transplant
immunodefici
mice
result
cell
detect
hb
cell
line
clinic
sampl
knockdown
significantli
inhibit
vitro
tumor
viabil
via
induct
apoptosi
markedli
suppress
vivo
tumor
format
immunodefici
mice
polyclon
antibodi
also
show
effect
vivo
activ
detail
underli
mechan
investig
conclus
notabl
effect
block
facilit
novel
immunotherapi
hb
k
umeda
h
k
h
e
k
univers
graduat
school
medicin
pediatr
kyoto
japan
univers
graduat
school
medicin
pediatr
surgeri
kyoto
japan
children
hospit
hematolog
oncolog
shizuoka
japan
backgroundobject
liver
transplant
lt
perform
primari
surgeri
primari
lt
subsequ
recurr
tumor
primari
resect
rescu
lt
recent
contribut
elev
cure
rate
patient
unresect
hepatoblastoma
hb
prognosi
patient
recurr
hb
lt
extrem
dismal
howev
mani
unresolv
problem
includ
risk
factor
relaps
treatment
strategi
relaps
designmethod
retrospect
analyz
clinic
outcom
patient
hb
underw
lt
result
os
rate
patient
serum
afp
level
lt
declin
serum
afp
level
lt
comparison
diagnosi
significantli
higher
remiss
group
relaps
group
os
rate
patient
declin
afp
lt
higher
patient
declin
afp
os
rate
patient
undergo
rescu
lt
compar
patient
undergo
primari
lt
primari
lt
group
six
ten
patient
declin
afp
aliv
remiss
wherea
patient
declin
afp
experienc
relaps
rescu
lt
group
three
patient
declin
afp
chemotherapi
rang
aliv
remiss
wherea
three
six
patient
respons
chemotherapi
experienc
relaps
conclus
respons
chemotherapi
might
reliabl
marker
predict
relaps
even
patient
undergo
rescu
lt
terenziani
md
de
f
g
r
g
p
di
f
f
f
p
ircc
istituto
nazional
dei
tumori
pediatr
oncolog
milano
itali
pediatrico
g
gaslini
pediatr
genova
itali
pediatrico
bambino
pediatr
roma
itali
ircc
istituto
nazional
dei
tumori
clinic
epidemiolog
trial
organ
milano
itali
ircc
istituto
nazional
dei
tumori
pediatr
surgeri
milano
itali
padova
pediatr
padova
itali
pediatrico
bambino
diagnost
patholog
laboratori
medicin
roma
itali
padova
pediatr
surgeri
padova
itali
ircc
istituto
nazional
dei
tumori
diagnost
patholog
laboratori
medicin
milano
itali
di
napoli
pediatr
oncolog
napoli
itali
pediatrico
bambino
pediatr
surgeri
roma
itali
univers
hospit
pediatr
oncolog
bologna
itali
degli
studi
di
palermo
pediatr
surgeri
palermo
itali
civico
di
cristina
pediatr
oncolog
palermo
itali
backgroundobject
describ
result
therapeut
approach
pediatr
bep
bleomycin
etoposid
cisplatin
associazion
italiana
ematologia
oncologia
pediatrica
aieop
studi
testicular
germ
cell
tumor
tgct
designmethod
march
decemb
male
year
enrol
aieop
studi
treatment
defin
specif
chemotherapi
regimen
number
cycl
alloc
mean
assign
diagnosi
consider
stage
patient
underw
orchiectomi
diagnosi
stage
receiv
chemotherapi
patient
stage
ii
iii
receiv
three
cycl
total
dose
platinum
plu
etoposid
bleomycin
bep
patient
stage
iv
receiv
four
cycl
total
dose
platinum
plu
etoposid
blemoycin
chemotherapi
retroperiton
andor
lung
residu
diseas
remov
surgeri
result
one
hundr
thirteen
patient
evalu
median
age
year
old
rang
month
year
stage
follow
stage
stage
ii
stage
iii
stage
iv
overal
surviv
os
surviv
ef
year
whole
seri
ci
ci
stage
ci
stage
ci
ci
respect
median
follow
month
conclus
confirm
excel
prognosi
tgct
children
adolesc
reduct
cumul
dose
etoposid
seem
compromis
surviv
outcom
patient
stage
investig
need
draw
conclus
r
lopez
e
g
c
e
j
nj
j
ss
z
ben
g
bisogno
padua
depart
pediatr
hematolog
oncolog
padua
itali
curi
doncologi
pari
franc
universitario
cruce
pediatr
oncolog
hematolog
unit
bilbao
spain
kyriak
children
hospit
oncolog
depart
athen
greec
univers
gdansk
depart
hematolog
oncolog
gdansk
poland
univers
depart
pediatr
sweden
univers
medic
school
univers
children
hospit
depart
pediatr
hematolog
oncolog
bratislava
slovak
republ
stefan
institut
depart
environment
scienc
ljubljana
slovenia
universitair
de
enfant
rein
fabiola
depart
brussel
belgium
hospit
depart
pediatr
oncolog
stuttgart
germani
vilniu
univers
center
pediatr
oncolog
hematolog
vilniu
lithuania
hospitalar
de
depart
pediatr
porto
portug
hospit
centr
rijeka
depart
divis
hematolog
oncolog
rijeka
croatia
univers
gdansk
depart
pediatr
oncolog
oncolog
poland
univers
nd
depart
pediatr
budapest
hungari
hebrew
univers
medic
center
depart
pediatr
hematolog
oncolog
bone
marrow
transplant
jerusalem
israel
hospit
queen
johanna
children
oncohaematolog
clinic
sofia
bulgaria
backgroundobject
rare
tumor
vrt
childhood
repres
diagnost
treatment
challeng
particular
pleuropulmonari
blastoma
ppb
rare
potenti
aggress
intrathorac
neoplasm
confus
tumor
malform
lesion
correct
diagnosi
first
step
establish
right
treatment
aim
present
studi
assess
abil
diagnos
patient
ppb
european
countri
compar
number
expect
ppb
case
number
regist
case
designmethod
expect
number
ppb
calcul
basi
pediatr
epidemiolog
data
wwweurostatit
report
incid
ppb
number
observ
patient
ppb
obtain
send
questionnair
physician
identifi
nation
contact
vrt
european
countri
result
twenti
countri
provid
data
overal
ppb
case
observ
compar
expect
case
low
number
patient
ppb
regist
mainli
eastern
countri
particular
bulgaria
slovenia
croatia
bosnia
lithuania
observ
case
patient
expect
diagnos
finland
sweden
israel
especi
franc
poland
itali
nation
registri
cooper
group
dedic
vrt
exist
addit
experi
countri
suggest
incid
ppb
may
higher
previous
report
conclus
studi
demonstr
differ
number
observedexpect
case
ppb
exist
across
european
countri
suggest
may
relat
presenc
nation
vrt
cooper
group
z
zhu
children
hospit
affili
capit
medic
univers
depart
surgic
oncolog
beij
china
backgroundobject
pancreatoblastoma
rare
malign
pancreat
tumor
children
standard
manag
therapi
still
discuss
summar
experi
manag
pancreatoblastoma
children
adolesc
designmethod
retrospect
observ
studi
primari
pancreatoblastoma
patient
year
age
treat
beij
children
hospit
bch
result
patient
pancreatoblastoma
diagnos
median
age
year
girl
boy
diagnosi
pancreatoblastoma
identifi
histolog
examin
common
syndrom
abdomin
mass
follow
abdomin
pain
elev
serum
afp
level
note
case
patient
diseas
initi
unresect
present
accept
neoadjuv
chemotherapi
consist
cdv
opec
plado
iev
avcp
patient
underw
surgeri
includ
pancreaticoduodenectomi
whippl
procedur
pancreaticoduodenectomi
procedur
distal
pancreatectomi
distal
pancreatectomi
en
bloc
splenectomi
end
end
pancreatojejunostomi
children
diseas
free
median
month
rang
month
conclus
pancreatoblastoma
children
adolesc
curabl
malign
tumor
complet
resect
combin
chemotherapi
associ
surviv
unresect
tumor
diagnosi
preoper
chemotherapi
opec
recommend
reduc
tumor
volum
gholamin
k
r
institut
technolog
caltech
biolog
biolog
engin
pasadena
usa
neurosurgeri
stanford
usa
institut
stem
cell
biolog
regen
medicin
stanford
usa
neurosurgeri
stanoford
usa
backgroundobject
dipg
common
malign
brainstem
tumor
children
resist
dipg
standard
treatment
along
inoper
tumor
anatom
locat
leav
dipg
patient
dismal
prognosi
multipl
studi
reveal
dipg
patient
month
surviv
detect
metastasi
previou
work
show
human
antibodi
mab
drug
increas
phagocyt
activ
macrophag
cancer
cell
therapeut
effect
dipg
xenograft
howev
efficaci
therapi
invers
correl
tumor
size
presenc
metastasi
onset
treatment
therefor
test
synergist
effect
mab
combin
mab
anoth
antibodi
increas
recruit
macrophag
tumor
site
dipg
xenograft
dissemin
designmethod
dipg
cell
infect
express
viru
inject
pon
nod
scid
gamma
mice
engraft
verifi
via
bioluminesc
bli
imag
mice
posit
signal
forebrain
spine
random
treatment
mab
alon
ab
alon
mab
coupl
mab
control
efficaci
treatment
measur
use
bli
imag
surviv
analysi
result
bli
imag
reveal
signific
declin
flux
measur
mice
receiv
combin
treatment
p
bli
signal
spinal
forebrain
strongli
diminish
mice
combin
treatment
compar
group
signific
extens
surviv
seen
group
compar
three
group
p
conclus
combinatori
treatment
ab
ab
effect
remov
dipg
primari
site
also
dissemin
diseas
h
ijaz
rl
mh
mp
jl
ac
b
aj
ra
p
ka
children
hospit
philadelphia
divis
oncolog
philadelphia
usa
pennsylvania
perelman
school
medicin
philadelphia
usa
children
hospit
philadelphia
center
data
driven
discoveri
biomedicin
philadelphia
usa
backgroundobject
cancer
acquir
mechan
telomer
mainten
tmm
unlimit
replic
potenti
cancer
includ
subset
pediatr
brain
tumor
use
tmm
altern
lengthen
telomer
alt
howev
cancer
cell
line
alt
repres
mixtur
histotyp
aim
gener
character
patient
deriv
pediatr
brain
tumor
cell
line
without
alt
designmethod
children
brain
tumor
tissu
consortium
cbttc
databas
queri
pediatr
adolesc
brain
tumor
type
like
alt
tumor
freez
media
patient
deriv
cell
line
gener
adher
suspens
line
correspond
primari
tumor
sampl
analyz
alt
assay
cca
genom
analysi
target
set
gene
result
cbttc
biorepositori
primari
glioma
pnet
sampl
avail
process
patient
deriv
cell
line
includ
pair
date
grow
well
variou
stage
develop
valid
analysi
cell
line
correspond
primari
tumor
reveal
alt
posit
sequenc
show
mutant
mutant
tumor
alt
posit
expect
alt
posit
tumor
like
occur
older
patient
vs
year
old
p
hemispher
wg
avail
tumor
includ
alt
alt
posit
tumor
damag
mutat
atrx
conclus
cbttc
make
possibl
gener
patient
deriv
cell
line
set
pediatr
primari
brain
tumor
collabor
scienc
panel
repres
report
characterist
alt
posit
pediatr
brain
tumor
respect
associ
mutat
frequenc
locat
loka
p
c
ormond
street
hospit
haematolog
oncolog
clinic
trial
unit
london
unit
kingdom
ormond
street
hospit
dermatolog
london
unit
kingdom
backgroundobject
braf
mek
inhibitor
emerg
therapi
childhood
malign
cutan
side
effect
well
describ
adult
patient
children
undertook
document
spectrum
cutan
side
effect
seen
children
treat
agent
tertiari
hospit
well
onset
durat
sever
skin
find
designmethod
retrospect
chart
review
children
treat
either
braf
dabrafenib
mek
inhibitor
trametinib
basic
demograph
clinic
characterist
collect
patient
record
skin
find
assess
collabor
paediatr
dermatologist
result
children
age
year
mean
year
treat
either
braf
mek
inhibitor
refractori
relaps
intracrani
malign
neurofibromatosi
type
optic
glioma
neurofibroma
langerhan
cell
histiocytosi
lch
leptomening
melanocytosismelanoma
identifi
one
patient
receiv
combin
brafmek
inhibitor
therapi
mean
treatment
durat
week
braf
week
mek
inhibitor
therapi
six
children
treat
dabrafenib
develop
new
melanocyt
naevi
week
also
develop
persist
erythema
en
erupt
onset
week
diffus
alopecia
onset
week
singl
case
keratosi
pilari
acneiform
facial
rash
six
children
mek
inhibitor
develop
paronychia
onset
week
also
develop
hair
thin
onset
week
generalis
xerosi
onset
week
four
patient
develop
acneiform
erupt
child
requir
dose
reduct
therapi
due
cutan
side
effect
two
patient
discontinu
treatment
one
patient
die
diseas
progress
conclus
cutan
advers
effect
braf
mek
inhibitor
therapi
common
well
toler
paediatr
patient
experi
prophylact
manag
benefici
hl
k
g
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
depart
neuroradiolog
germani
institut
biostatist
clinic
research
germani
bonn
depart
pediatr
oncolog
hematolog
bonn
germani
backgroundobject
qualiti
life
qol
craniopharyngioma
cp
frequent
impair
tumour
andor
factor
endocrin
deficit
hypothalam
involv
hi
designmethod
prospect
analyz
parent
cp
patient
qol
mo
yr
cp
diagnosi
relat
growth
hormon
gh
substitut
hi
cp
patient
recruit
fulfil
inclus
criteria
histolog
cp
diagnosi
age
diagnosi
yr
avail
qol
data
one
three
yr
diagnosi
qol
assess
use
pediatr
qualiti
life
pedqol
questionnair
result
parent
estim
qol
children
wors
patient
pedqol
domain
emot
stabil
bodi
imag
physic
function
social
function
friend
famili
hi
associ
lower
qol
mo
diagnosi
bodi
imag
p
social
functionfriend
p
neg
impact
hi
qol
greater
parent
assess
qol
time
point
gh
substitut
relev
effect
weight
height
develop
cp
patient
yr
present
baselin
yr
diagnosi
gh
substitut
reduc
qol
pedqol
domain
autonomi
p
cognit
p
physic
function
p
social
functionfriend
p
compar
gh
cp
patient
qol
stabil
yr
gh
treat
patient
wherea
non
patient
experienc
decreas
qol
pedqol
domain
physic
function
social
functionfriend
conclus
parent
assess
qol
cp
survivor
wors
children
hi
major
risk
factor
reduc
qol
treatment
strategi
cp
aim
prevent
hypothalam
damag
gh
substitut
consid
effect
option
amelior
immin
impair
qol
cp
tippelt
j
r
n
bo
k
von
rd
r
r
u
g
hospit
essen
pediatr
oncolog
hematolog
essen
germani
hospit
neuss
children
hospit
neuss
germani
neuroradiolog
germani
medic
center
pediatr
hematolog
oncolog
hamburg
germani
bonn
institut
neuropatholog
bonn
germani
heidelberg
pediatr
hematolog
oncolog
heidelberg
germani
leipzig
radiooncolog
leipzig
germani
institut
biostatist
clinic
research
germani
bonn
pediatr
hematolog
oncolog
bonn
germani
backgroundobject
despit
multimod
relaps
therapi
prognosi
patient
recurr
medulloblastoma
mb
poor
aim
analysi
evalu
prognost
factor
surviv
pf
overal
surviv
os
patient
recurr
mb
enrol
german
hit
studi
designmethod
patient
recurr
mb
juli
august
includ
analysi
data
analyz
relaps
age
gender
histolog
subgroup
metastas
stage
relaps
therapi
diseas
state
last
follow
analysi
use
estim
pfso
recurr
possibl
prognost
factor
pfso
investig
perform
univari
multivari
analys
result
analysi
includ
patient
male
median
age
recurr
year
median
pf
primari
diagnosi
year
suffer
local
metastat
relaps
first
recurr
patient
receiv
chemotherapi
intraven
oral
intrathec
patient
underw
total
partial
tumor
resect
patient
receiv
radiotherapi
median
pf
recurr
year
median
os
year
rate
respect
multivari
analys
metastat
relaps
hazard
ratio
hr
pf
os
nonappl
radiotherapi
hr
applic
oral
chemotherapi
hr
turn
poor
prognost
paramet
conclus
multimod
therapi
led
os
patient
recurr
mb
local
recurr
diseas
system
intraven
chemotherapi
associ
prolong
pfso
futur
studi
identifi
prognost
relev
molecular
subgroup
new
target
antiangiogen
therapi
therefor
highli
recommend
support
german
children
cancer
foundat
ds
tsang
es
jt
luca
p
te
jude
children
research
hospit
depart
radiat
oncolog
memphi
usa
clinic
depart
radiat
oncolog
cleveland
usa
th
chan
school
public
health
depart
epidemiolog
boston
usa
univers
athen
nkua
depart
epidemiolog
medic
statist
athen
greec
backgroundobject
goal
studi
character
incid
pseudoprogress
radiat
therapi
rt
pediatr
glioma
lgg
designmethod
patient
age
intracrani
pediatr
lgg
grade
treat
rt
singl
institut
includ
retrospect
review
pseudoprogress
defin
investig
increas
tumour
size
dimens
two
mr
imag
studi
serial
growth
two
dimens
three
studi
account
compet
risk
true
progress
death
surviv
ef
defin
surviv
without
true
progress
secondari
glioma
result
patient
develop
pseudoprogress
cumul
incid
ci
median
time
pseudoprogress
month
rt
interquartil
rang
iqr
rang
symptomat
pseudoprogress
manag
subtot
resect
shuntommaya
corticosteroid
patient
respect
median
time
procedur
month
rt
iqr
remain
asymptomat
patient
observ
shrinkag
stabil
median
durat
pseudoprogress
month
iqr
among
asymptomat
patient
patient
pilocyt
astrocytoma
pa
increas
odd
develop
pseudoprogress
rel
histolog
odd
ratio
ci
p
among
patient
pa
n
cumul
incid
pseudoprogress
ci
group
pseudoprogress
associ
improv
ef
vs
p
overal
surviv
vs
p
conclus
pseudoprogress
irradi
common
especi
patient
pilocyt
astrocytoma
appear
prognost
surviv
knowledg
incid
tempor
cours
pseudoprogress
may
help
avoid
unnecessari
salvag
treatment
n
herold
hed
k
l
j
p
g
ji
institutet
women
children
health
stockholm
sweden
institutet
mbb
stockholm
sweden
univers
hospit
depart
infecti
diseas
heidelberg
germani
institutet
stockholm
sweden
backgroundobject
acut
myelogen
leukaemia
aml
account
approxim
childhood
cancer
despit
highli
toxic
multidrug
regimen
patient
cure
deoxycytosin
analogu
cytarabin
togeth
anthracyclin
constitut
backbon
therapi
treatment
failur
frequent
caus
resist
specif
lack
intracellular
accumul
triphosphoryl
activ
metabolit
leukem
blast
nelarabin
spark
hope
improv
dismal
surviv
children
relaps
leukaemia
lymphoma
remiss
rate
like
effect
mediat
nelarabin
toxic
reli
intracellular
convers
previous
shown
hydrolys
confer
resist
leukaemia
mous
model
retrospect
analys
aml
patient
suggest
effect
designmethod
use
phenotyp
cell
prolifer
inhibit
assay
screen
approxim
small
molecul
compound
identifi
lead
substanc
synergis
wildtyp
cell
inhibit
confirm
use
vitro
activ
assay
recombin
target
engag
assess
shift
assay
cetsa
crystallographi
result
identifi
lower
nanomolar
small
molecul
inhibitor
sensitis
wildtyp
leukem
cell
nelarabin
ie
complet
abolish
resist
leav
cell
unaffect
result
could
recapitul
vivo
use
paediatr
aml
mous
model
conclus
suggest
might
play
dual
role
futur
leukaemia
therapi
biomark
guid
dose
adjust
aim
reduc
toxic
low
express
target
drug
candid
amen
clinic
trial
base
inhibitor
improv
efficaci
nelarabin
treatment
high
express
f
howard
k
h
british
columbia
school
nurs
vancouv
canada
columbia
cancer
agenc
radiat
oncolog
vancouv
canada
health
scienc
centr
divis
plastic
surgeri
halifax
canada
backgroundobject
tradit
interpret
random
control
trial
rct
reli
statist
signific
oppos
clinic
signific
includ
use
minim
clinic
import
differ
mcid
rais
question
studi
design
rigor
util
result
degre
clinic
signific
appli
report
rct
pediatr
cancer
determin
object
review
systemat
assess
report
clinic
signific
base
delta
valu
report
sampl
size
calcul
identifi
factor
associ
clinic
signific
rct
pediatr
oncolog
literatur
designmethod
systemat
review
involv
comprehens
search
medlin
embas
cochran
childhood
cancer
group
special
regist
central
incept
juli
elig
studi
includ
rct
primari
cancer
treatment
pediatr
patient
diagnos
cancer
result
rct
repres
random
question
includ
minor
random
question
report
conclus
base
clinic
signific
random
question
explicitli
identifi
delta
valu
sampl
size
calcul
base
mcid
statist
signific
primari
outcom
base
random
question
half
report
confid
interv
standard
error
bar
point
estim
question
median
publish
journal
impact
factor
plan
sampl
size
larger
random
question
report
clinic
signific
oppos
conclus
minor
rct
publish
pediatr
oncolog
literatur
report
methodolog
attribut
relat
clinic
signific
drawn
studi
conclus
base
clinic
signific
integr
clinic
signific
studi
design
subsequ
report
futur
pediatr
oncolog
trial
enhanc
decis
make
clinic
practic
polici
xq
luo
lz
wq
yd
jp
lh
cg
hq
gh
xq
ry
first
affili
hospit
sun
univers
pediatr
guangzhou
china
hospit
central
south
univers
pediatr
changsha
china
second
xiangya
hospit
central
south
univers
pediatr
changsha
china
gener
hospit
pediatr
guangzhou
china
second
affili
hospit
sun
univers
pediatr
guangzhou
china
hospit
southern
medic
univers
pediatr
guangzhou
china
children
hospit
pediatr
shenzhen
china
third
affili
hospit
zhongshan
univers
pediatr
guangzhou
china
first
peopl
hospit
huizhou
pediatr
huizhou
china
hospit
southern
medic
univers
pediatr
guangzhou
china
central
hospit
pediatr
huizhou
china
backgroundobject
indigo
naturali
formula
rif
tradit
chines
medicin
tetraarsen
tetrasulfid
indirubin
tanshinon
iia
major
activ
ingredi
rif
taken
oral
reduc
hospit
day
surviv
ef
adult
patient
acut
promyelocyt
leukemia
apl
treat
protocol
contain
rif
retino
acid
atra
chemotherapeut
agent
rifatrachemotherapi
compar
patient
arsen
trioxid
ato
atrachemotherapi
howev
efficaci
safeti
rif
pediatr
counterpart
evalu
unclear
whether
rif
replac
ato
designmethod
sccg
south
china
children
leukemia
group
protocol
start
august
patient
age
enrol
except
intracrani
hemorrhag
central
nervou
system
leukemia
coma
convuls
nervou
paralysi
diagnosi
patient
random
ato
rif
group
receiv
anthracyclin
induct
consolid
therapi
follow
week
mainten
therapi
apl
wbc
diagnosi
receiv
addit
consolid
phase
result
among
patient
diagnos
met
enrol
criteria
will
random
headach
vomitnausea
commonest
advers
effect
occur
patient
group
induct
consolid
therapi
respect
signific
infect
includ
sepsi
pneumonia
cellul
etc
observ
patient
induct
patient
consolid
ato
rif
group
respect
p
two
case
ato
group
one
abound
treatment
deviat
protocol
advers
effect
efss
median
year
group
conclus
protocol
contain
arsen
either
ato
rif
atra
chemotherapi
obtain
good
outcom
childhood
apl
includ
c
j
k
straathof
great
ormond
street
institut
child
health
development
biolog
cancer
cancer
section
london
unit
kingdom
cancer
institut
haematolog
london
unit
kingdom
backgroundobject
new
treatment
strategi
neuroblastoma
need
improv
outcom
reduc
late
effect
use
engag
bite
redirect
patient
recogn
elimin
neuroblastoma
tumour
cell
prove
attract
novel
treatment
option
inde
bite
blinatumumab
shown
great
promis
treatment
leukemia
describ
select
optim
bite
format
use
treatment
neuroblastoma
designmethod
fourteen
bite
variant
construct
use
singl
chain
variabl
fragment
scfv
deriv
three
differ
human
antibodi
two
differ
human
antibodi
fuse
three
differ
size
linker
first
bite
characteris
measur
thermal
stabil
profil
use
differenti
scan
fluorimetri
antigen
specif
bind
affin
neg
tumour
cell
line
use
flow
cytometri
scatchard
analysi
function
comparison
perform
determin
tumour
cell
lysi
rang
bite
concentr
result
bite
format
test
demonstr
specif
bite
base
scfv
highest
bind
affin
lowest
valu
ie
concentr
achiev
half
maxim
cytolyt
activ
cell
contrast
differ
bind
affin
scfv
test
translat
signific
differ
abil
redirect
cell
lysi
bite
medium
long
linker
mediat
lysi
cell
lower
concentr
bite
shorter
linker
conclus
studi
demonstr
bind
affin
scfv
well
linker
length
determin
potenc
bite
select
bite
format
detail
studi
respons
includ
prolifer
cytokin
secret
profil
current
ongo
data
set
inform
select
optim
bite
format
taken
forward
develop
novel
clinic
therapeut
neuroblastoma
k
william
f
martin
j
e
e
c
r
h
p
j
r
c
nation
medic
center
ceti
washington
dc
usa
nhlbi
bethesda
usa
children
hospit
bmt
houston
usa
hopkin
school
medicin
bmt
baltimor
usa
backgroundobject
relaps
hematolog
malign
hematopoiet
cell
transplant
hct
confer
high
mortal
progress
diseas
diseas
gvhd
henc
hypothes
lymphocyt
would
specif
diminish
immun
escap
could
safe
decreas
cancer
burden
designmethod
expand
lymphocyt
reactiv
taa
prame
survivin
immunogen
hematolog
malign
prospect
studi
elig
patient
receiv
infus
sequenti
dose
level
per
dose
result
product
gener
lack
alloreact
vitro
product
contain
cell
predominantli
effector
memori
express
activ
marker
express
exhaust
marker
specif
show
greatest
respons
prame
elispot
ten
hct
recipi
age
year
relaps
hodgkin
diseas
aml
receiv
dose
patient
relaps
month
hct
allo
auto
post
infus
advers
event
attribut
gvhd
one
patient
withdrew
prior
studi
complet
due
progress
diseas
set
steroid
sepsi
respons
evalu
patient
pd
pr
cr
cr
patient
aml
receiv
adjunct
vidaza
patient
achiev
neg
post
first
time
without
addit
therapi
immunosequenc
receptor
detect
multipl
tcr
deriv
infus
product
week
infus
conclus
uniqu
immunotherapeut
well
toler
without
caus
gvhd
cytokin
releas
syndrom
despit
aggress
multipli
relaps
diseas
evalu
patient
demonstr
evid
diseas
control
complet
respons
suggest
may
efficaci
relaps
hematolog
malign
hct
p
zage
j
california
san
diego
moor
cancer
center
pediatr
san
diego
usa
backgroundobject
children
aggress
pediatr
solid
tumor
neuroblastoma
rhabdomyosaroma
ewe
sarcoma
poor
outcom
new
therapi
need
aberr
express
activ
growth
factor
receptor
includ
fibroblast
growth
factor
receptor
fgfr
famili
associ
mani
malign
therefor
hypothes
inhibit
fgfr
famili
member
use
novel
inhibitor
would
effect
pediatr
solid
tumor
designmethod
evalu
effect
viabil
neuroblastoma
rhabdomyosarcoma
ewe
sarcoma
cell
use
continu
live
cell
imag
measur
cell
confluenc
caspas
activ
also
evalu
effect
cell
migrat
invas
use
scratch
wound
matrigel
chamber
invas
assay
effect
intracellular
signal
western
blot
result
treatment
pediatr
solid
tumor
cell
result
decreas
cell
confluenc
calcul
valu
vari
induct
apoptosi
treatment
subleth
concentr
inhibit
migrat
invas
vitro
test
cell
line
compar
untreat
cell
treatment
also
result
decreas
phosphoryl
akt
test
cell
line
sensit
cell
line
demonstr
increas
level
complet
inhibit
erk
phosphoryl
treatment
resist
cell
line
demonstr
minim
inhibit
erk
phosphoryl
sensit
cell
line
demonstr
increas
level
resist
cell
line
demonstr
decreas
unchang
level
suggest
potenti
marker
respons
mechan
resist
conclus
effect
pediatr
solid
tumor
includ
neuroblastoma
rhabdomyosarcoma
ewe
sarcoma
sensit
appear
mediat
effect
rasmapk
jakstat
pathway
therefor
repres
potenti
novel
therapeut
agent
pediatr
solid
tumor
preclin
clinic
studi
warrant
mc
dolendo
e
c
philippin
medic
center
pediatr
davao
citi
philippin
jude
children
research
hospit
global
pediatr
oncolog
depart
memphi
usa
philippin
medic
center
famili
medicin
davao
citi
philippin
backgroundobject
childhood
cancer
import
health
concern
philippin
estim
new
case
annual
although
surviv
rate
improv
infect
relat
morbid
mortal
continu
threat
time
recognit
infect
immedi
administr
antibiot
shown
improv
surviv
project
aim
improv
time
antibiot
administr
children
cancer
concomit
infect
institut
feedback
differ
stakehold
perform
designmethod
qualiti
improv
cycl
implement
southern
philippin
medic
center
pediatr
oncolog
unit
mindanao
chart
admit
patient
meet
inclus
criteria
review
term
demograph
clinic
profil
timeli
antibiot
administr
outcom
period
baselin
data
perform
group
feedback
given
repeat
data
collect
done
three
month
result
total
chart
review
begin
qualiti
improv
cycl
chart
review
group
feedback
given
antibiot
initi
delay
baselin
case
decreas
repeat
measur
p
valu
patient
die
baselin
data
collect
die
repeat
measur
p
valu
length
hospit
stay
baselin
repeat
measur
similar
around
day
conclus
group
feedback
significantli
reduc
delay
antibiot
administr
also
lesser
number
unimprov
expir
patient
probabl
due
reduct
delay
continu
qualiti
improv
initi
need
multifacet
intervent
necessari
improv
sustain
improv
improv
time
antibiot
administr
children
cancer
order
improv
outcom
reduc
morbid
mortal
g
kapoor
gandhi
cancer
institut
research
centr
pediatr
hematolog
oncolog
delhi
india
backgroundobject
chemotherapi
induc
vomit
remain
one
distress
advers
effect
cancer
therapi
neg
impact
complianc
nutrit
antiemet
data
relat
olanzepin
approv
antipsychot
drug
mainli
restrict
adult
retrospect
pediatr
studi
low
cost
easi
avail
oral
prepar
make
ideal
use
set
object
studi
studi
efficaci
olanzapin
breakthrough
vomit
assess
safeti
among
children
year
age
receiv
moder
high
emetogen
chemotherapi
mec
hec
respect
per
pogo
guidelin
designmethod
observ
studi
done
month
obtain
ethic
approv
acut
breakthrough
emesi
defin
vomit
occur
within
last
dose
chemotherapi
despit
adequ
prophylaxi
includ
receptor
antagonist
dexamethason
aprepit
hec
dose
olanzapin
mgkg
per
oral
day
consecut
day
patient
prior
antiemet
antipsychot
medic
surgic
disord
like
contribut
vomit
exclud
complet
partial
respons
defin
emet
episod
respect
use
rescu
medic
advers
event
grade
per
ctcae
version
result
studi
analys
chemotherapi
block
among
children
median
age
year
male
variou
hematolog
solid
malign
receiv
mec
hec
complet
partial
respons
observ
among
block
respect
much
better
report
metoclopramid
statist
differ
efficaci
observ
age
gender
emetogen
regimen
p
includ
somnol
grade
orthostat
collaps
grade
transamin
grade
conclus
excel
efficaci
safeti
inexpens
agent
like
olanzapin
make
suitabl
option
breakthrough
emesi
children
develop
countri
warrant
larg
control
prospect
studi
j
c
r
k
kulkarni
health
center
pediatr
hematolog
depart
pediatr
halifax
canada
backgroundobject
dysfunct
defin
inabl
flush
andor
draw
blood
common
complic
associ
central
venou
cathet
cvc
tissu
plasminogen
activ
tpa
often
instil
revers
episod
cvc
dysfunct
howev
data
associ
requir
tpa
unclear
hypothes
cvc
relat
variabl
associ
requir
use
tpa
episod
cvc
dysfunct
pediatr
oncolog
patient
designmethod
popul
base
studi
case
record
pediatr
oncolog
patient
maritim
canada
manag
izaac
walton
killam
health
centr
januari
decemb
review
ethic
approv
data
characterist
first
cvc
pool
pediatr
oncolog
hospit
databas
ii
electron
medic
record
iii
pharmaci
databas
iv
central
line
databas
patient
episod
cvc
dysfunct
first
cvc
requir
dose
tpa
identifi
analysi
done
use
spss
version
result
least
cvc
requir
patient
one
dose
tpa
mean
requir
patient
episod
dysfunct
relat
first
cvc
univari
analysi
age
year
diagnosi
classifi
leukemia
lymphoma
sarcoma
brain
tumor
other
use
tunnel
line
significantli
associ
use
tpa
gender
multivari
analysi
age
year
confid
interv
ci
diagnosi
sarcoma
use
tunnel
line
independ
associ
requir
tpa
conclus
present
studi
identifi
independ
risk
factor
ascertain
diagnosi
associ
use
tpa
episod
dysfunct
associ
first
cvc
valid
predict
risk
model
ascertain
diagnosi
could
develop
identifi
high
risk
patient
ft
p
c
k
el
h
abu
n
w
j
medic
center
center
pediatr
adolesc
depart
pediatr
hematologyoncologyhemostaseolog
mainz
germani
hospit
cologn
depart
intern
center
integr
oncolog
bonn
germani
sport
univers
cologn
institut
cardiovascular
research
sport
depart
molecular
cellular
sport
medicin
germani
medic
center
center
pediatr
adolesc
depart
pediatr
cardiolog
mainz
germani
backgroundobject
due
variou
factor
skelet
muscl
function
pediatr
adult
cancer
patient
impair
result
decreas
muscular
strength
previou
studi
adult
cancer
patient
shown
specif
exercis
intervent
increas
muscular
strength
relat
posit
effect
muscl
mass
fatigu
qualiti
life
purpos
mucki
studi
determin
whether
combin
resist
endur
train
improv
muscl
strength
pediatr
cancer
patient
intens
cancer
treatment
phase
ict
designmethod
base
pilot
experiment
phase
feasibl
exercis
program
develop
conveni
studi
design
establish
aim
enrol
childhood
cancer
patient
age
year
part
random
control
intervent
studi
design
individu
within
exercis
group
eg
particip
supervis
exercis
train
train
take
place
time
per
week
period
week
ict
individu
control
group
cg
obtain
usual
care
intervent
muscl
strength
upper
lower
limb
aerob
perform
bodi
composit
fatigu
qualiti
life
determin
result
recruit
start
novemb
far
patient
includ
patient
random
eg
alreadi
complet
exercis
intervent
compar
knee
flexor
strength
increas
eg
averag
wherea
decreas
cg
p
preliminari
result
regard
benefit
exercis
intervent
mention
paramet
show
posit
trend
post
intervent
interview
patient
report
enjoy
exercis
program
would
recommend
other
conclus
earli
result
mucki
studi
support
feasibl
combin
resist
endur
train
evalu
muscular
strength
ict
e
avdonina
research
center
pediatr
hematolog
oncolog
immunolog
rehabilit
centr
russko
pole
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
genet
depart
moscow
russia
institut
molecular
russian
academi
moscow
genet
depart
moscow
russia
backgroundobject
advanc
treatment
children
leukemia
mostli
determin
use
intens
chemotherapi
howev
therapi
result
suppress
immun
risk
factor
develop
seriou
infecti
complic
significantli
worsen
prognosi
underli
diseas
studi
polymorph
gene
involv
regul
immun
respons
prospect
direct
designmethod
dna
isol
leukocyt
children
leukemia
children
sever
infect
group
children
without
complic
treatment
group
microarray
design
determin
snp
follow
gene
genotyp
procedur
includ
polymeras
chain
reaction
pcr
fluoresc
label
dna
target
follow
hybrid
microarray
imag
analysi
fisher
exact
test
use
statist
analysi
result
genotyp
allel
frequenc
two
group
patient
compar
found
minor
allel
gene
less
frequent
patient
group
patient
group
thu
confer
decreas
risk
infect
odd
ratio
allel
g
gene
frequent
group
regard
group
ci
combin
allel
g
allel
gene
strengthen
associ
haplotyp
gt
much
frequent
group
group
ci
conclus
thu
polymorph
gene
gene
identifi
genet
marker
may
influenc
risk
develop
infecti
complic
treatment
pediatr
leukemia
k
balistreri
foster
mj
b
c
k
children
hospit
center
biobehavior
health
columbu
usa
hospit
sick
children
child
health
evalu
scienc
toronto
canada
univers
nurs
nashvil
usa
univers
depart
psycholog
human
develop
nashvil
usa
colorado
denver
biostatist
informat
denver
usa
children
hospit
depart
psycholog
columbu
usa
ohio
state
univers
pediatr
columbu
usa
backgroundobject
death
child
cancer
traumat
famili
sever
prolong
parent
grief
may
undermin
famili
resourc
meet
uniqu
need
surviv
sibl
therefor
extrafamili
social
resourc
may
assum
particular
import
examin
whether
relationship
peer
teacher
mitig
risk
depress
intern
symptom
bereav
sibl
designmethod
children
femal
age
recruit
three
uscanadian
hospit
month
sibl
death
cancer
cc
also
recruit
school
classmat
rate
much
like
yield
mean
peer
accept
score
home
visit
children
complet
social
support
scale
children
children
depress
inventori
cdi
parent
complet
child
behavior
checklist
regress
analys
test
varianc
depressionintern
symptom
account
group
extrafamili
relationship
interact
result
group
differ
percept
peer
teacher
friend
support
peer
accept
peer
friend
support
neg
associ
depressiveintern
symptom
teacher
support
neg
associ
depress
symptom
regardless
group
ps
peer
accept
neg
associ
intern
symptom
signific
interact
found
group
peer
accept
predict
depress
symptom
bereav
sibl
report
elev
cdi
score
regardless
peer
accept
neg
associ
found
cc
conclus
bereav
sibl
appear
maintain
peer
accept
support
peer
teacher
friend
extrafamili
support
benefit
bereav
sibl
cc
contrast
depress
symptom
elev
bereav
sibl
whether
classmat
futur
research
seek
elucid
direction
associ
identifi
factor
undermin
percept
well
avail
extrafamili
support
c
barton
hey
children
hospit
nh
foundat
trust
paediatr
oncolog
liverpool
unit
kingdom
backgroundobject
clinic
train
educ
programm
traine
fellow
paediatr
oncolog
variabl
countri
centr
within
singl
nation
standard
howev
establish
far
possibl
ensur
traine
acquir
rel
uniform
experi
knowledg
studi
report
describ
current
perspect
deliveri
assess
train
paediatr
oncolog
describ
recent
literatur
designmethod
nh
evid
portal
use
search
pubm
psychinfo
embas
cinhal
use
clearli
defin
search
term
possibl
term
match
meshencyclopaedia
databas
result
result
includ
directli
relev
deliveri
assess
paediatr
oncolog
educ
train
countri
five
contin
repres
weight
significantli
toward
higher
incom
countri
problem
traine
experi
receiv
train
includ
lack
time
focu
servic
provis
heterogen
case
exposur
rel
traine
difficulti
gain
experi
centr
tertiari
quaternari
special
servic
establish
maintain
balanc
particular
area
identifi
need
greater
experi
includ
present
brain
tumour
survivorship
late
effect
palli
care
particular
challeng
assess
paediatr
oncolog
traine
includ
heterogen
career
path
eg
less
full
time
train
academ
research
matern
leav
lack
valid
patientfamili
assess
tool
commun
differ
structur
train
program
lack
formal
qualif
conclus
abil
paediatr
oncologist
travel
countri
contin
research
employ
testament
valid
profession
certif
special
despit
lack
formal
assess
research
area
focu
common
success
theme
paediatr
oncolog
program
w
burn
k
l
c
de
psycholog
montreal
canada
univers
health
center
research
center
canada
de
pediatr
montreal
canada
univers
health
center
canada
backgroundobject
studi
suggest
psychosoci
impact
pediatr
cancer
parent
often
extend
beyond
end
child
cancer
treatment
parent
continu
experi
individu
dyadic
effect
studi
parent
children
acut
lymphoblast
leukemia
aim
describ
coupl
adjust
psycholog
distress
relationship
adjust
describ
perceiv
impact
cancer
coupl
relationship
identifi
extent
perceiv
impact
cancer
coupl
relat
parent
adjust
designmethod
particip
studi
childhood
survivor
parent
intact
coupl
ie
togeth
ill
recal
n
survivor
medic
inform
collect
medic
record
parent
complet
questionnair
brief
symptom
abbrevi
dyadic
adjust
scale
impact
cancer
coupl
mother
father
score
compar
eg
manova
use
interdepend
model
apim
examin
degre
parent
perceiv
chang
relationship
dynam
associ
adjust
actor
effect
partner
adjust
partner
effect
result
distress
norm
sampl
parent
frequenc
rang
gener
mother
father
agre
report
relationship
satisfact
perceiv
natur
relationship
chang
posit
neg
chang
follow
ill
find
dyadic
model
indic
mother
adjust
relat
perceiv
relationship
chang
father
adjust
primarili
relat
partner
percept
conclus
given
find
appear
mother
may
act
bridg
connect
ill
experi
survivor
father
could
explain
mother
percept
relationship
chang
influenc
partner
adjust
revers
true
father
acknowledg
cole
foundat
montreal
cihr
frq
l
desjardin
u
j
k
hospit
sick
children
psycholog
toronto
canada
health
scienc
center
london
canada
columbia
children
hospit
psycholog
vancouv
canada
colorado
denver
biostatist
informat
denver
usa
backgroundobject
pediatr
brain
tumor
survivor
pbtss
experi
impair
social
compet
anxiou
depress
symptom
insult
relat
variabl
eg
diagnosi
treatment
relat
variabl
eg
age
gender
social
inform
process
eg
execut
function
social
skill
emot
control
may
associ
social
compet
pbtss
current
studi
examin
longitudin
associ
baselin
variabl
peer
nomin
friendship
pbtss
approxim
one
year
later
designmethod
caregiv
children
n
age
low
grade
glioma
medulloblastoma
complet
rate
child
adjust
baselin
pbtss
classmat
complet
three
best
friend
measur
approxim
month
later
preliminari
descript
statist
examin
friendship
nomin
reciproc
friendship
pbtss
bivari
analys
examin
associ
baselin
independ
anxiou
depress
symptom
emot
control
global
execut
composit
total
social
skill
diagnosi
treatment
age
gender
depend
variabl
friendship
result
averag
pbtss
nomin
best
friend
two
classmat
rang
pbtss
nomin
classmat
best
friend
averag
pbtss
one
reciproc
best
friend
nomin
rang
pbtss
reciproc
best
friend
nomin
greater
depress
symptom
pbtss
associ
fewer
peer
nomin
friendship
r
p
reciproc
friendship
p
fewer
social
skill
also
associ
reciproc
friendship
p
conclus
depress
symptom
social
skill
baselin
associ
friendship
pbtss
year
later
within
context
multifacet
model
inform
contribut
understand
social
compet
could
guid
psychosoci
intervent
survivor
hagan
k
e
e
c
k
children
hospit
center
biobehavior
health
columbu
usa
toledo
depart
psycholog
toledo
usa
state
univers
depart
psycholog
atlanta
usa
ohio
state
univers
pediatr
columbu
usa
sick
children
child
health
evalu
scienc
toronto
canada
cancer
institut
harvard
medic
center
divsion
pediatr
oncolog
boston
usa
backgroundobject
pediatr
brain
tumor
survivor
pbt
risk
neg
peer
interact
less
accept
fewer
friend
rel
healthi
peer
famili
influenc
social
compet
explor
relev
featur
school
climat
eg
structur
safeti
peer
teacher
support
aim
investig
pbt
comparison
classmat
cc
teacher
percept
school
explor
whether
school
climat
moder
peer
relationship
problem
pbt
designmethod
pbt
male
age
least
year
post
treatment
radiat
chemotherapi
neurosurgeri
recruit
three
site
us
canada
pbt
classmat
particip
teacher
complet
delawar
school
climat
survey
sociometr
measur
peer
interact
revis
class
play
accept
friendship
one
cc
match
gender
age
race
identifi
class
depend
compar
school
climat
rate
pbt
cc
correl
examin
agreement
student
teacher
result
pbt
view
school
climat
neg
cc
p
moder
agreement
relat
student
engag
school
safeti
subscal
r
p
littl
agreement
found
teacher
student
rate
school
climat
multivari
analys
test
differ
student
teacher
percept
school
climat
moder
differ
peer
interact
accept
friendship
pbt
cc
conclus
find
suggest
despit
neg
peer
experi
pbt
perceiv
school
climat
differ
cc
howev
substanti
disagr
student
teacher
highlight
import
gather
inform
student
school
climat
rather
teacher
administr
integr
percept
classmat
may
provid
reliabl
estim
school
level
variabl
may
mitig
social
risk
pbt
hock
l
j
c
p
l
hospit
philadelphia
oncolog
philadelphia
usa
children
health
system
nemour
center
healthcar
deliveri
scienc
de
usa
backgroundobject
pediatr
brain
tumor
survivor
pbt
risk
neurocognit
deficit
theoret
model
childhood
cancer
survivorship
suggest
associ
famili
function
survivor
neurocognit
outcom
time
prospect
studi
test
hypothesi
better
famili
function
end
treatment
would
associ
posit
chang
survivor
neurocognit
function
month
later
designmethod
fifti
pbt
age
complet
brief
neurocognit
assess
within
four
month
complet
therapi
approxim
nine
month
later
parent
complet
measur
famili
function
neurocognit
domain
assess
includ
work
memori
process
speed
auditori
memori
famili
function
factor
assess
includ
gener
famili
function
condit
manag
difficulti
perceiv
caregiv
compet
model
evalu
whether
famili
function
variabl
predict
slope
chang
survivor
neurocognit
function
time
result
model
predict
auditori
memori
consist
hypothes
better
caregiv
compet
p
less
condit
manag
difficulti
p
associ
faster
improv
auditori
memori
time
model
predict
work
memori
opposit
direct
hypothes
wors
caregiv
compet
p
greater
condit
manag
difficulti
p
associ
faster
improv
work
memori
time
model
predict
process
speed
signific
conclus
famili
function
variabl
end
treatment
may
play
role
trajectori
survivor
neurocognit
function
time
natur
role
aspect
famili
function
consid
need
studi
particularli
longer
conclus
treatment
famili
function
import
factor
monitor
time
jankowska
j
k
medicum
nicolau
copernicu
univers
pediatr
oncolog
hematolog
depar
bydgoszcz
poland
voivodship
paediatr
hospit
hematolog
rheumatolog
depart
bydgoszcz
poland
medic
scienc
depart
pediatr
hematolog
transplantolog
poland
medicum
nicolau
copernicu
univers
depart
rehabilit
poland
univers
institut
interdisciplinari
studi
warszawa
poland
medicum
nicolau
copernicu
univers
pediatr
oncolog
hematolog
depart
bydgoszcz
poland
backgroundobject
identif
need
prefer
process
prognost
discuss
among
parent
paediatr
oncolog
designmethod
parent
children
treat
three
oncolog
center
poland
particip
one
six
focu
group
discuss
complet
survey
measur
prefer
manner
deliveri
prognost
informationto
develop
survey
item
key
theme
abstract
publish
literatur
quantit
data
analyz
use
descript
statist
qualit
data
audiotap
analyz
result
parent
invit
onto
studi
participatedth
major
parent
prefer
detail
prognost
inform
present
open
honest
manner
factor
found
influenc
parent
hope
physician
willing
answer
question
provid
inform
offer
date
treatment
provid
emot
support
convers
factor
report
potenti
decreas
hope
includ
pessimist
attitud
imperson
context
disclosur
doctor
appear
nervou
uncomfort
use
euphem
parent
prefer
posit
frame
discuss
child
prognosi
parent
want
doctor
provid
opportun
ask
question
acknowledg
individu
discuss
prognosi
conclus
major
parent
prefer
individu
realist
approach
doctorprefer
may
vari
accord
demograph
psycholog
diseas
variablesstudi
find
highlight
import
train
healthcar
profession
content
time
potenti
bias
associ
inform
deliveri
jatia
j
u
g
g
memori
center
impacct
pediatr
oncolog
divis
mumbai
india
memori
center
pediatr
oncolog
divis
mumbai
india
backgroundobject
children
undergo
treatment
larg
tertiari
cancer
hospit
india
come
part
countri
divers
background
educ
statu
vernacular
languag
familycommun
tradit
diagnosi
cancer
aftermath
make
educ
lowest
prioriti
sinc
institut
innov
educ
intervent
program
run
profession
teacher
group
design
clinic
wait
area
larg
visual
auditori
mean
reduc
depend
languag
abl
cater
wide
short
survey
conduct
assess
impact
attitud
educ
designmethod
children
attend
clinic
center
treatment
issu
standard
questionnair
period
particip
voluntari
background
inform
attend
statu
educ
program
attitud
school
futur
ambit
time
taken
intent
rejoin
school
assess
result
form
distribut
respond
attend
program
group
age
year
vs
treatment
statu
prior
school
attend
medium
instruct
hindi
marathi
bengali
among
join
back
school
group
question
futur
career
respond
compar
attende
p
career
choic
divers
attende
respect
doctor
popular
attende
specif
special
exot
career
prefer
conclus
innov
educ
intervent
program
run
wait
area
impact
prefer
toward
futur
educ
career
attende
posit
open
divers
attitud
hb
larsen
mkf
mh
c
kv
p
c
l
lw
h
k
pediatr
hematolog
oncolog
bonkolab
denmark
pediatr
hematolog
oncolog
denmark
pediatr
hematolog
oncolog
denmark
cancer
societi
unit
survivorship
denmark
clinic
ergotherapi
physic
therapi
denmark
univers
hospit
depart
pediatr
aarhu
denmark
pediatr
hematolog
denmark
backgroundobject
background
aim
rehabilit
children
cancer
social
academ
physic
diminish
treatment
induc
isol
margin
nationwid
psychosoci
intervent
studi
respect
rehabilit
includ
social
physic
activ
educ
children
teenag
cancer
includ
children
sinc
intervent
educ
present
cancer
school
class
altern
two
ambassador
classmat
physic
activ
program
purpos
examin
feasibl
educ
ambassador
intervent
compon
ongo
respect
studi
designmethod
method
inclus
first
consecut
children
year
newli
diagnos
cancer
intervent
group
feasibl
includ
particip
rate
accept
timefram
frequenc
durat
safeti
result
result
children
consent
particip
median
time
diagnosi
inclus
six
day
within
median
day
educ
class
present
cancer
conduct
teacher
satisfact
content
level
durat
median
seven
classmat
appli
ambassadorship
median
time
ambassador
assign
children
nine
day
median
ambassador
travel
distanc
km
none
patient
ambassador
discontinu
studi
particip
none
ambassador
experienc
advers
emot
reaction
need
psycholog
intervent
total
number
ambassador
median
number
per
child
conclus
conclus
feasibl
accept
safe
involv
healthi
classmat
intens
treatment
children
cancer
intervent
compon
well
suit
rehabilit
intervent
children
cancer
school
class
challeng
practic
organ
travel
distanc
parent
languag
barrier
cultur
accept
diseas
burden
inclus
classmat
psychosoci
motiv
support
network
cancer
treatment
provid
novel
approach
cancer
rehabilit
children
k
long
e
ac
univers
psycholog
brain
scienc
boston
usa
farber
cancer
institut
harvard
medic
school
pediatr
psychosoci
oncolog
boston
usa
univers
school
public
health
boston
usa
children
health
system
center
healthcar
deliveri
scienc
wilmington
usa
jefferson
univers
sidney
kimmel
medic
colleg
philadelphia
usa
backgroundobject
absenc
standard
psychosoci
screener
limit
healthcar
provid
abil
identifi
interven
sibl
may
clinic
level
distress
brotherssist
cancer
treatment
english
spanish
version
sibl
modul
psychosoci
assess
tool
pat
screener
famili
psychosoci
risk
develop
project
also
examin
associ
sibl
risk
factor
sibl
famili
adjust
designmethod
famili
children
cancer
parent
sibl
particip
qualit
interview
inform
item
content
provid
feedback
word
format
iter
version
new
pat
sibl
modul
purpos
sampl
ensur
variabl
across
sibl
age
sd
year
sibl
gender
femal
time
sinc
cancer
diagnosi
sd
month
parent
primari
languag
spanishbilingu
data
collect
continu
satur
reach
new
screen
modul
final
phase
parent
children
cancer
complet
pat
sibl
modul
measur
sibl
parent
famili
function
date
famili
complet
phase
result
sixteen
distinct
pat
sibl
modul
develop
base
time
diagnosi
languag
english
spanish
sibl
age
year
higher
score
pat
sibl
modul
ie
greater
sibl
risk
associ
poorer
sibl
psychosoci
function
assess
strength
difficulti
questionnair
total
problem
scale
emot
symptom
scale
hyperact
scale
peer
problem
scale
prosoci
scale
r
wors
famili
function
famili
assess
devic
associ
parent
mental
health
assess
brief
symptom
inventori
signific
conclus
new
pat
sibl
modul
show
promis
screener
psychosoci
risk
among
sibl
children
cancer
michaud
c
c
c
farber
cancer
institut
perini
famili
survivor
center
boston
usa
colleg
london
neuroepidemiolog
age
london
unit
kingdom
backgroundobject
childhood
cancer
survivor
cc
elev
risk
behavior
adjust
problem
screen
promot
mean
identifi
problem
practic
accur
screen
method
clinic
set
well
establish
develop
brief
parent
intak
form
bpif
assess
accuraci
compar
parent
report
brief
pediatr
symptom
designmethod
parent
cc
age
complet
bpif
survivorship
visit
bpif
ask
parent
report
emot
attent
behavior
school
problem
likert
scale
includ
scale
captur
depressionintern
attent
extern
problem
base
norm
data
score
categor
signific
elev
moder
elev
signific
elev
result
parent
report
survivor
moder
signific
elev
survivor
identifi
least
behavior
problem
bpif
use
report
problem
v
problem
bpif
show
high
sensit
survivor
whose
parent
report
behavior
problem
screen
bpif
show
low
specif
conclus
parent
report
bpif
accur
identifi
symptomat
cancer
survivor
high
sensit
compar
bpif
could
lessen
burden
patient
staff
still
identifi
survivor
behavior
problem
low
specif
anoth
detail
measur
use
second
screener
survivor
screen
bpif
futur
studi
compar
bpif
child
behavior
checklist
cbcl
measur
see
accur
identifi
behavior
problem
broadli
c
peterson
n
michigan
univers
psycholog
ypsilanti
usa
backgroundobject
approxim
half
childhood
cancer
survivor
cc
risk
neurocognit
late
effect
ncle
parent
report
high
need
inform
learn
behavior
vari
amount
understand
specif
survivorship
inform
need
prefer
amount
time
type
deliveri
inform
need
inform
intervent
studi
assess
parent
inform
need
intervent
prefer
associ
psycholog
function
perceiv
util
inform
intervent
designmethod
parent
cc
complet
measur
demographictreat
inform
child
behavior
neurocognit
function
famili
burden
knowledg
ncle
current
prefer
sourc
survivorship
inform
interest
use
resourc
result
parent
report
low
inform
never
heard
ncle
want
lot
inform
ncle
report
receiv
inform
diagnosi
report
find
inform
never
receiv
inform
parent
want
inform
immedi
diagnosi
treatment
consent
month
conclud
treatment
parent
report
frequent
relianc
sourc
besid
medic
team
eg
internet
parent
need
repeat
inform
frequent
interv
survivorship
topic
includ
behavior
school
issu
fertil
transit
sibl
issu
commun
late
effect
team
respond
would
use
onlin
program
avail
regress
analys
indic
greater
survivorship
inform
need
associ
increas
famili
burden
poorer
child
cognit
behavior
emot
function
famili
burden
specif
ncle
significantli
predict
inform
need
b
se
p
beyond
demograph
treatment
variabl
conclus
famili
report
high
need
inform
throughout
survivorship
strongli
predict
burden
parent
experi
manag
late
effect
result
indic
target
intervent
highli
burden
parent
would
feasibl
accept
dissemin
jf
halvorsen
l
h
ta
b
univers
scienc
technolog
ntnu
depart
psycholog
trondheim
norway
univers
scienc
technolog
ntnu
region
centr
child
youth
mental
health
child
welfar
st
olav
univers
hospit
trondheim
norway
geffen
school
medicin
ucla
depart
pediatr
lo
angel
usa
technolog
societi
dept
health
research
trondheim
norway
director
health
divis
health
econom
financ
trondheim
norway
univers
scienc
technolog
ntnu
depart
sociolog
polit
scienc
trondheim
norway
univers
scienc
technolog
ntnu
depart
laboratori
medicin
st
olav
univers
hospit
trondheim
norway
univers
scienc
technolog
ntnu
depart
psycholog
st
olav
univers
hospit
trondheim
norway
backgroundobject
studi
investig
qualiti
life
hrqol
psycholog
distress
adolesc
young
adult
aya
survivor
childhood
cancer
associ
factor
treatment
modal
educ
demograph
factor
year
designmethod
particip
includ
cancer
survivor
recruit
cancer
registri
norway
crn
healthi
control
recruit
student
popul
particip
complet
questionnair
pediatr
qualiti
life
inventori
hopkin
symptom
use
measur
hrqol
distress
respect
result
survivor
report
mean
level
hrqol
control
except
wors
physic
function
compar
control
survivor
overal
femal
survivor
particular
higher
odd
report
psycholog
distress
symptom
survivor
higher
mean
level
distress
femal
survivor
report
poorer
physic
health
femal
control
survivor
report
distress
level
significantli
poorer
hrqol
regard
physic
function
wors
total
pedsql
score
control
score
age
hrqol
femal
gender
low
educ
level
perceiv
low
econom
statu
significantli
predict
hrqol
distress
conclus
survivor
report
similar
mean
level
hrqol
distress
control
except
physic
function
cancer
survivor
demograph
variabl
predict
hrqol
distress
group
survivor
requir
closer
attent
paid
factor
associ
poor
hrqol
psycholog
distress
survivor
includ
femal
gender
lower
educ
level
lower
incom
acknowledg
studi
support
grant
liaison
committe
central
norway
region
health
author
rha
norwegian
univers
scienc
technolog
ntnu
well
norwegian
cancer
organ
c
sharkey
g
k
k
state
univers
psycholog
stillwat
usa
nation
health
system
neurolog
dc
usa
backgroundobject
children
diagnos
cancer
may
experi
psycholog
neurocognit
difficulti
yet
studi
examin
relationship
outcom
howev
adjust
difficulti
includ
anxieti
contribut
poor
cognit
perform
thu
present
retrospect
studi
aim
compar
relationship
anxieti
symptom
neurocognit
function
children
leukemia
brain
tumor
bt
due
import
multipl
inform
concord
across
rater
also
assess
designmethod
children
leukemia
femal
year
children
brain
tumor
femal
year
complet
youth
wechsler
scale
part
clinic
neuropsycholog
assess
parent
teacher
complet
achenbach
rate
scale
result
bt
survivor
significantli
lower
process
speed
leukemia
survivor
p
although
differ
exist
overal
anxieti
across
survivorship
group
differ
rater
agreement
leukemia
bt
group
specif
bt
survivor
anxieti
correl
p
anxieti
problem
correl
p
contrastingli
among
leukemia
survivor
anxieti
unrel
p
among
bt
survivor
report
anxieti
unrel
cognit
perform
p
wherea
among
leukemia
survivor
anxiousdepress
symptom
posit
associ
work
memori
iq
p
anxieti
problem
posit
relat
iq
p
anxieti
problem
posit
relat
process
speed
p
conclus
relationship
anxieti
symptom
cognit
perform
concord
multipl
inform
anxieti
symptom
differ
bt
leukemia
group
associ
quantit
cognit
perform
within
leukemia
although
unexpect
direct
yet
concord
bt
thu
multipl
inform
essenti
investig
posit
relationship
anxieti
symptom
neurocognit
function
warrant
among
leukemia
survivor
stern
jb
ed
cl
gh
le
sm
south
florida
child
famili
studi
tampa
usa
south
florida
psycholog
tampa
usa
south
florida
school
psycholog
tampa
usa
hopkinsal
children
hospit
pediatr
oncolog
st
petersburg
usa
pittsburgh
psycholog
pediatr
pittsburgh
usa
commonwealth
univers
psycholog
richmond
usa
backgroundobject
object
obes
rate
pediatr
cancer
survivor
pc
alarmingli
high
healthi
lifestyl
chang
may
prevent
futur
health
complic
improv
qualiti
life
pc
intervent
address
neg
impact
cancer
therapi
pc
health
behavior
nih
fund
rct
test
efficaci
intervent
improv
caregiv
child
bmi
dietari
intak
physic
activ
caregiv
control
euc
designmethod
method
total
pc
two
site
consent
enrol
age
lymphoma
diagnosi
least
month
cancer
treatment
treatment
bmi
percentil
greater
bmi
percentil
famili
random
either
intervent
one
enhanc
usual
care
euc
session
assess
conduct
baselin
intervent
fu
result
result
comparison
euc
parent
parent
show
signific
decreas
pre
post
fu
bmi
ratio
total
number
daili
calori
parent
also
show
similar
posit
chang
child
feed
behavior
percept
child
vulner
similar
decreas
bmi
ile
ratio
found
pc
pre
post
test
pc
also
show
signific
increas
number
daili
step
wherea
euc
pc
decreas
caregiv
report
posit
session
conclus
conclus
result
suggest
intervent
target
parent
longer
term
effect
caregiv
impact
pc
implic
intervent
strategi
discuss
whether
length
time
treatment
play
moder
factor
treatment
effect
consid
e
steven
bm
l
lp
children
hospit
philadelphia
pediatr
divis
oncolog
philadelphia
usa
univers
pennsylvania
perelman
school
medicin
philadelphia
usa
backgroundobject
rel
younger
cohort
progress
rate
surviv
slower
adolesc
young
adult
age
aya
barrier
clinic
trial
enrol
may
includ
limit
knowledg
clinic
trial
may
relat
limit
engag
treatment
process
difficulti
health
care
provid
caregiv
includ
share
studi
sought
explor
psychosoci
matur
knowledg
diseas
relat
correl
attitud
toward
clinic
trial
designmethod
aya
complet
measur
demograph
cancer
diagnosistreat
knowledg
clinic
trial
psychosoci
matur
consider
futur
consequ
attitud
perceiv
benefit
barrier
toward
clinic
trial
particip
covari
includ
age
age
diagnosi
sex
cancer
type
liquid
solid
brain
treatment
statu
onoff
treatment
preliminari
correl
anova
conduct
multivari
regress
mediationmoder
analys
use
hypothesi
test
result
aya
mean
age
sd
male
white
mean
knowledg
score
correct
frequent
incorrect
item
includ
type
trial
voluntari
greater
knowledg
significantli
associ
perceiv
benefit
p
relationship
significantli
moder
cancer
type
knowledg
mediat
relationship
consider
futur
consequ
perceiv
benefit
cancer
type
identifi
predictor
perceiv
barrier
aya
brain
tumor
perceiv
significantli
barrier
compar
liquid
tumor
conclus
aya
moder
knowledg
cancer
clinic
trial
critic
area
misunderstand
inform
consent
process
tailor
toward
psychosoci
matur
address
perceiv
benefit
barrier
may
differ
diagnosi
decis
support
tool
may
effect
resourc
improv
knowledg
enhanc
full
understand
clinic
trial
potenti
benefit
increas
aya
engag
treatment
decis
p
weaver
c
michigan
univers
clinic
psycholog
ypsilanti
usa
backgroundobject
research
shown
marit
statu
famili
size
commonli
endors
psychosoci
risk
factor
famili
children
newli
diagnos
howev
famili
children
chronic
ill
research
suggest
famili
densiti
object
indic
demand
parent
resourc
compar
late
effect
childhood
cancer
survivor
cc
particularli
neurocognit
late
effect
ncle
may
present
ongo
demand
burden
neg
psychosoci
outcom
famili
survivor
may
exacerb
high
densiti
famili
present
studi
examin
associ
among
parent
adjust
famili
burden
moder
famili
densiti
parent
cc
designmethod
parent
mother
cc
complet
measur
assess
perceiv
emot
resourc
parent
guiltworri
famili
burden
ncle
addit
demograph
variabl
densiti
defin
household
total
ratio
identifi
current
studi
famili
dens
result
regress
analys
reveal
parent
report
perceiv
emot
resourc
report
significantli
less
guiltworri
p
famili
burden
greater
subject
experi
guiltworri
associ
greater
famili
burden
feel
guiltworri
associ
greater
famili
burden
parent
higher
densiti
famili
howev
despit
famili
densiti
parent
perceiv
suffici
emot
resourc
manag
demand
associ
child
ill
experienc
less
famili
burden
find
observ
beyond
effect
socioeconom
statu
conclus
result
highlight
buffer
impact
perceiv
emot
resourc
manag
caregiv
demand
cc
famili
even
within
rel
higher
densiti
famili
intervent
focu
high
densiti
famili
parent
mayb
greater
risk
experienc
feel
guiltworri
result
greater
overal
famili
burden
k
westmoreland
van
der
p
p
n
p
b
pediatr
hematolog
oncolog
lilongw
malawi
north
carolina
pediatr
hematolog
oncolog
chapel
hill
usa
oncolog
lilongw
malawi
colleg
medicin
children
foundat
malawi
oncolog
lilongw
malawi
children
hospit
pediatr
hematolog
oncolog
houston
usa
colleg
medicin
children
foundat
malawi
countri
director
lilongw
malawi
north
carolina
health
polici
manag
chapel
hill
usa
cancer
program
director
lilongw
malawi
north
carolina
oncolog
infecti
diseas
chapel
hill
usa
malawi
school
medicin
oncolog
infecti
diseas
lilongw
malawi
backgroundobject
outcom
measur
inform
system
pediatr
questionnair
translat
chichewa
valid
use
malawi
among
first
studi
africa
ssa
report
qualiti
life
hrqol
pediatr
cancer
patient
designmethod
pediatr
lymphoma
patient
interview
kamuzu
central
hospit
lilongw
malawi
questionnair
administ
patient
within
three
day
present
chemotherapi
initi
particip
report
six
hrqol
domain
mobil
anxieti
depress
fatigu
peer
relationship
pain
interfer
answer
four
question
item
per
domain
use
likert
scale
pain
intens
question
score
domain
transform
mean
standard
deviat
base
origin
promi
refer
sampl
median
interquartil
rang
iqr
report
domain
use
compar
cohort
publish
pediatr
cancer
patient
unit
state
result
patient
complet
baselin
questionnair
median
age
year
iqr
children
report
low
level
mobil
median
iqr
high
anxieti
median
iqr
high
depress
symptom
median
iqr
high
fatigu
median
iqr
averag
satisfact
peer
relationship
median
iqr
high
pain
interfer
median
iqr
highest
score
pain
intens
given
patient
compar
unit
state
pediatr
cancer
popul
malawi
cohort
statist
signific
wors
hrqol
mobil
anxieti
depress
fatigu
pain
interfer
domain
p
conclus
baselin
hrqol
pediatr
lymphoma
patient
malawi
poor
hrqol
domain
except
peer
relationship
emphas
urgent
need
clinic
research
program
specif
address
hrqol
among
children
undergo
cancer
treatment
ssa
k
winsn
e
c
k
r
loret
de
l
health
scienc
univers
pediatr
hematolog
oncolog
portland
usa
health
scienc
univers
pediatr
critic
care
portland
usa
health
scienc
univers
pediatr
psychiatri
portland
usa
backgroundobject
delirium
affect
patient
pediatr
intens
care
unit
picu
caus
increas
length
stay
decreas
attent
school
stress
disord
diagnost
statist
manual
mental
disord
dsm
v
defin
delirium
disturb
conscious
reduc
abil
focu
sustain
shift
attent
due
underli
medic
condit
hypothes
delirium
recogn
pho
popul
design
prospect
studi
use
valid
screen
tool
determin
frequenc
delirium
hospit
pho
patient
identifi
associ
clinic
factor
designmethod
baselin
frequenc
delirium
diagnosi
determin
use
data
mine
program
electron
medic
record
emr
pho
picu
nurs
train
use
richmond
assess
sedat
scale
rass
cornel
assess
pediatr
delirium
pho
patient
inpati
unit
picu
screen
delirium
everi
shift
score
enter
emr
addit
specif
variabl
collect
patient
help
identifi
potenti
risk
factor
delirium
result
frequenc
delirium
diagnosi
uniqu
patient
pho
unit
andor
picu
feasibl
phase
identifi
uniqu
patient
among
posit
delirium
screen
one
prompt
psychiatr
intervent
two
month
prospect
studi
began
jan
uniqu
patient
among
consecut
case
enrol
pt
posit
delirium
screen
initi
analysi
occur
six
month
conclus
delirium
exist
pho
popul
howev
frequenc
yet
determin
routin
delirium
screen
improv
recognit
diagnosi
delirium
therebi
allow
us
promptli
interven
prevent
delirium
order
avoid
potenti
long
term
consequ
b
zebrack
c
michigan
school
social
work
ann
arbor
usa
lo
angel
depart
social
welfar
lo
angel
usa
backgroundobject
clinician
encourag
provid
person
care
inclus
patient
voic
compon
evid
gener
critic
primari
purpos
studi
assess
adolesc
young
adult
aya
cancer
patient
prefer
cancer
inform
support
resourc
designmethod
util
modifi
delphi
techniqu
aya
cancer
patient
identifi
barrier
optim
aya
cancer
care
cancer
resourc
address
need
specif
characterist
cancer
resourc
find
help
delphi
panel
consist
conveni
sampl
patient
age
year
diagnos
cancer
age
year
eight
year
cancer
treatment
time
studi
survey
data
collect
three
consecut
iter
round
cours
six
month
result
find
indic
aya
patient
prefer
resourc
reduc
feel
loneli
creat
sens
commun
belong
provid
opportun
meet
aya
patient
among
top
barrier
optim
cancer
care
aya
identifi
lack
cancer
care
provid
special
aya
care
lack
connect
aya
patient
commun
lack
abil
navig
health
system
particip
also
describ
aspect
cancer
inform
support
care
resourc
believ
address
aya
concern
conclus
inform
deriv
studi
help
develop
cancer
inform
support
resourc
better
reach
intend
audienc
point
view
aya
cancer
patient
optim
cancer
care
util
inform
support
resourc
requir
cancer
support
program
foster
meaning
connect
among
aya
patient
result
also
suggest
patient
resourc
equip
aya
practic
knowledg
skill
necessari
navig
health
system
advoc
anwarali
r
b
children
cancer
hospit
nurs
educ
servic
karachi
pakistan
backgroundobject
nurs
pillar
health
care
organ
front
line
provid
care
patient
mani
organ
seek
enhanc
qualiti
patient
care
improv
nurs
knowledg
compet
pediatr
oncolog
nurs
work
pressur
novic
nurs
tend
miss
small
valuabl
piec
inform
eventu
result
sentinel
event
thu
indu
children
cancer
hospit
nurs
educ
servic
karachi
pakistan
creat
essenti
memori
cueflash
help
nurs
refer
guid
designmethod
extens
literatur
review
conduct
use
key
word
flash
card
memori
aid
nurs
pediatr
oncolog
patient
care
use
boolean
word
suggest
effect
flashcard
select
flashcard
made
print
person
usag
nurs
clinic
area
project
shall
evalu
qualit
approach
ask
nurs
flash
card
benefici
result
nurs
literatur
suggest
learn
tool
nurs
healthcar
profession
use
effect
handi
referr
vital
inform
memori
aid
assist
novic
nurs
learn
refresh
basic
concept
retain
knowledg
learnt
skill
aid
assist
nurs
perform
better
care
decreas
number
sentinel
event
nurs
benefit
memori
aid
chemotherapi
medic
calcul
vital
sign
height
weight
basal
surfac
area
pain
assess
manag
conclus
use
memori
aid
innov
way
ongo
learn
pediatr
oncolog
clinic
area
effect
flash
card
aid
refer
quick
inform
requir
rather
make
mistak
card
use
refer
guid
precept
pediatr
oncolog
nurs
intern
clinic
area
memori
aid
expect
increas
level
compet
confid
among
pediatr
oncolog
nurs
provid
qualiti
care
r
appiah
nurs
komfo
anoky
teach
hospit
ghana
background
chemotherapi
one
effect
treatment
oncolog
condit
chemo
drug
studi
undertaken
evalu
knowledg
staff
nurs
pediatr
ward
komfo
anoky
teach
hospit
chemotherapi
method
studi
descript
studi
structur
questionnair
open
close
end
question
use
system
random
sampl
use
select
respond
respond
knowledg
chemotherapi
remain
said
nt
knowledg
chemotherapi
regard
side
effect
knowledg
remain
said
nt
knowledg
specif
chemo
treat
specif
type
oncolog
condit
abl
give
correct
answer
total
respond
abl
give
correct
answer
result
end
survey
minor
respond
adequ
knowledg
chemotherapi
percentag
total
respond
adequ
knowledg
side
effect
chemotherapi
minor
respond
adequ
knowledg
specif
chemo
treat
specif
oncolog
condit
conclut
recommend
workshop
servic
train
session
chemotherapi
organ
nurs
staff
pediatr
ward
komfo
anoky
teach
hospit
j
bai
univers
nell
hodgson
woodruff
school
nurs
atlanta
usa
univers
school
medicin
atlanta
usa
univers
winship
cancer
institut
atlanta
usa
backgroundobject
develop
dna
sequenc
bioinformat
technolog
grow
bodi
literatur
show
gut
microbiom
gm
play
critic
role
maintain
children
health
prevent
treat
children
diseas
current
applic
gm
childhood
cancer
still
unknown
systemat
review
aim
understand
gm
applic
gastrointestin
symptom
gi
psychoneurolog
symptom
pn
efficaci
target
intervent
children
treat
cancer
designmethod
pubm
embas
cochran
librari
american
societi
clinic
oncolog
abstract
search
elig
studi
includ
studi
type
target
popul
children
cancer
gm
studi
primari
secondari
outcom
publish
english
mix
method
assess
tool
use
assess
methodolog
qualiti
result
seven
studi
met
elig
criteria
includ
two
studi
two
cohort
studi
three
random
control
trail
find
show
children
cancer
show
significantli
lower
divers
gm
eg
bifidobacteria
lactobacillu
clostridium
xiva
iv
healthi
control
total
count
healthi
gm
eg
bacteroid
bifidobacterium
decreas
significantli
children
cancer
dysbiosi
gm
show
potenti
associ
gi
pn
use
probiot
bifidobacterium
lactobacilli
prebiot
supplement
fructooligosaccharid
significantli
improv
dysbiosi
gm
significantli
influenc
advers
event
eg
abdomin
distent
diarrhea
children
treat
cancer
conclus
children
treat
cancer
experienc
dysbiosi
gm
improv
prebiot
probiot
supplement
studi
need
investig
relationship
gm
gi
pn
evalu
effect
prebiot
probiot
intervent
dysbiosi
gm
children
cancer
bauter
j
de
van
g
l
c
univers
hospit
pediatr
oncolog
stem
cell
transplant
ghent
belgium
univers
hospit
hematolog
stem
cell
transplant
ghent
belgium
backgroundobject
complex
hematopoiet
stem
cell
transplant
hsct
common
toxic
side
effect
necessit
specif
continu
educ
train
nurs
involv
hsct
aim
project
develop
basic
educ
framework
nurs
medic
student
paramed
involv
pediatr
adult
hsct
recipi
designmethod
educ
cours
format
easili
access
onlin
creat
result
theoret
part
consist
differ
topic
aim
hsct
indic
donorstem
cell
sourc
differ
type
hsct
highlight
pediatr
adult
issu
follow
test
use
accredit
purpos
upon
complet
user
abl
understand
process
hsct
knowledg
differ
condit
regimen
abl
identifi
common
side
effect
toxic
relat
hsct
addit
insight
support
care
concept
prevent
treatment
strategi
make
sure
cours
meet
local
need
conclus
tool
allow
nurs
involv
hsct
flexibl
learn
option
choos
time
place
studi
provid
electron
link
detail
learn
materi
nurs
complet
cours
basic
level
understand
principl
treatment
support
care
hsct
patient
futur
supplementari
advanc
level
tool
develop
cardena
nacion
de
cancerologia
cundinamarca
bogota
colombia
backgroundobject
background
two
import
factor
complet
withdraw
toxic
death
associ
suboptim
servic
health
care
provid
identifi
explain
failur
treatment
differ
mortal
among
children
cancer
develop
countri
treati
countri
econom
limit
one
complet
withdraw
treatment
object
determin
risk
factor
treatment
famili
caregiv
children
cancer
nation
cancer
institut
designmethod
descript
transvers
studi
quantit
approach
particip
famili
caregiv
children
cancer
implement
two
instrument
survey
character
care
dyad
famili
caregiv
person
chronic
diseas
nation
univers
group
chronic
care
instrument
evalu
factor
influenc
adher
pharmacolog
treatment
patient
design
valid
nurs
result
risk
factor
identifi
social
econom
factor
relat
provid
health
system
equip
relat
therapi
treatment
relat
patient
relat
diseas
conclus
studi
pretend
interven
time
manner
need
famili
children
cancer
way
creat
line
action
nurs
prevent
treatment
b
zhang
n
children
medic
center
hematolog
oncolog
shanghai
china
children
medic
center
nurs
depart
shanghai
china
backgroundobject
grow
evid
suggest
hematolog
oncolog
diseas
condit
allogen
hematopoiet
stem
cell
transplant
allo
hsct
relat
complic
could
induc
metabol
chang
nutrit
declin
patient
physic
function
also
predispos
chronic
ill
howev
studi
examin
chang
nutrit
statu
associ
factor
among
chines
pediatr
allo
hsct
patient
designmethod
studi
design
longitudin
studi
determin
chang
nutrit
statu
chines
pediatr
patient
period
day
data
collect
use
questionnair
survey
includ
demograph
inform
anthropometr
measur
bodi
composit
repeat
measur
anova
use
analyz
chang
nutrit
statu
mix
linear
model
use
evalu
associ
potenti
relat
factor
result
first
day
hsct
anthropometr
measur
bmiz
bodi
mass
index
z
tsf
tricep
skin
fold
thick
decreas
significantli
first
day
p
gradual
increas
p
wc
waist
circumfer
demonstr
gradual
upward
trend
day
day
p
bf
percent
bodi
fat
increas
significantli
first
day
hsct
p
summit
day
chang
tsf
associ
time
diagnosi
sourc
stem
cell
hla
match
bmiz
transplant
chang
wc
associ
time
gender
sourc
stem
cell
hla
match
bmiz
transplant
chang
bf
associ
time
gender
hla
match
bmiz
transplant
conclus
nutrit
statu
chines
pediatr
allo
hsct
patient
chang
significantli
associ
time
gender
diagnosi
sourc
stem
cell
hla
match
bmiz
transplant
transplant
period
wit
accumul
bodi
fat
central
obes
especi
girl
hong
hr
sh
nation
colleg
health
scienc
depart
nurs
republ
korea
cathol
univers
korea
colleg
nurs
seoul
republ
korea
st
mari
cathol
univers
korea
bmt
center
seoul
republ
korea
backgroundobject
even
though
parent
child
leukemia
tremend
challeng
place
struggl
caregiv
parent
children
leukemia
experi
posit
outcom
purpos
studi
identifi
predictor
posttraumat
growth
parent
children
leukemia
designmethod
particip
parent
mother
father
children
leukemia
recruit
c
univers
hospit
korea
may
august
particip
complet
measur
posttraumat
growth
core
belief
deliber
rumin
resili
distress
disclosur
social
support
mean
life
satisfact
life
result
variabl
except
distress
disclosur
posit
correl
posttraumat
growth
resili
core
belief
social
support
signific
predictor
relat
posttraumat
growth
parent
children
leukemia
explain
varianc
posttraumat
growth
conclus
result
show
sever
factor
affect
posttraumat
growth
parent
children
leukemia
therefor
nurs
intervent
program
includ
strengthen
resili
revis
core
belief
well
util
social
support
system
provid
popul
order
promot
posit
psycholog
chang
beyond
parent
traumat
event
relat
children
leukemia
l
jibb
j
k
ka
v
n
p
univers
ottawa
school
nurs
ottawa
canada
hospit
sick
children
child
health
evalu
scienc
toronto
canada
hospit
sick
children
oncolog
haematolog
toronto
canada
hospit
sick
children
child
life
toronto
canada
toronto
hospit
sick
children
lawrenc
bloomberg
faculti
univers
toronto
child
health
evalu
scienc
toronto
canada
hospit
sick
children
nurs
toronto
canada
univers
michael
g
degroot
school
medicin
hamilton
canada
backgroundobject
subcutan
port
scp
access
needl
amongst
pain
distress
experi
youth
cancer
respons
develop
virtual
realiti
vr
intervent
hardwar
ie
display
handheld
control
softwar
underwat
program
head
movement
allow
explor
distract
youth
scp
access
studi
aim
refin
intervent
accept
youth
caus
advers
event
safe
allow
commun
youth
healthcar
provid
vr
immers
designmethod
two
iter
cycl
usabl
test
use
eleven
youth
year
femal
varieti
cancer
diagnos
took
part
test
session
observ
took
field
note
youth
use
intervent
scp
access
think
aloud
impress
youth
answer
question
address
intervent
advers
event
observ
discuss
session
develop
consensu
theme
relat
studi
aim
refer
necessari
result
youth
like
vr
hardwar
softwar
report
easi
use
advers
event
occur
cycl
reveal
full
engag
vr
environ
ie
head
movement
limit
requir
remain
still
procedur
cycl
reveal
need
distract
intervent
compon
eg
game
music
option
notif
relat
statu
procedur
softwar
chang
rectifi
issu
made
conclus
next
step
includ
feasibl
test
examin
intervent
effect
pain
distress
scp
access
random
control
trial
expect
accept
safe
vr
intervent
decreas
pain
distress
improv
qualiti
care
deliv
young
cancer
patient
would
like
thank
patient
particip
studi
fund
provid
sickkid
garron
famili
cancer
centr
olsson
clinic
univers
gothenburg
pediatr
sweden
backgroundobject
qualit
research
adolesc
young
adult
cancer
patient
express
concern
lack
inform
sexual
treatment
purpos
studi
explor
extent
adolesc
young
adult
cancer
survivor
found
inform
support
concern
sex
designmethod
studi
specif
questionnair
develop
method
use
question
develop
includ
expert
valid
profession
valid
former
cancer
patient
questionnair
contain
sever
area
adolesc
young
adult
life
affect
cancer
studi
focus
inform
support
regard
sexual
issu
questionnair
sent
adolesc
young
adult
cancer
survivor
treat
north
west
sweden
result
adolesc
young
adult
cancer
survivor
report
health
care
profession
approach
sexual
issu
cancer
treatment
case
among
adolesc
young
adult
cancer
survivor
express
question
sex
treatment
adolesc
young
adult
cancer
survivor
want
inform
satisfi
inform
major
want
inform
sexual
issu
person
physician
nurs
written
inform
fewer
want
internet
inform
support
almost
half
cancer
survivor
report
sex
treatment
due
risk
infect
conclus
result
studi
encourag
health
care
profession
care
adolesc
young
adult
cancer
patient
rais
question
sexual
activ
treatment
give
adolesc
young
adult
cancer
patient
gener
basic
inform
sexual
issu
along
individu
recommend
may
avoid
misunderstand
regard
sexual
activ
cancer
treatment
c
wilson
c
b
hospit
sick
children
oncologyhaematolog
toronto
canada
hospit
sick
children
oncologyhaematolog
torono
canada
backgroundobject
group
nurs
within
paediatr
haematologyoncolog
unit
wit
steadi
increas
believ
burnout
emot
exhaust
staff
phenomenon
evidenc
verbal
express
concern
among
peer
well
increas
staff
turnov
oncolog
nurs
support
physic
emot
journey
patient
laugh
cri
celebr
rishel
ongo
stress
burnout
associ
nurs
job
dissatisfact
potter
et
al
abl
recogn
sign
symptom
burnout
compass
fatigu
well
provid
proper
support
staff
incorpor
well
behaviour
life
help
increas
job
satisfact
resili
designmethod
current
statene
assess
done
nurs
anonym
submit
stressor
experienc
identifi
unit
next
step
project
focu
group
five
focu
group
held
regist
nurs
haematologyoncolog
inpati
unit
per
session
separ
focu
group
held
rn
recent
left
unit
discuss
recordedtranscrib
analyz
survey
complet
develop
base
find
focu
group
survey
provid
richer
data
stressor
potenti
intervent
would
help
build
resili
base
find
survey
current
research
benchmark
similar
institut
program
build
resili
develop
implement
evalu
result
need
assess
identifi
stressor
lack
break
number
new
initi
chang
chemotherapi
protocol
commun
interprofession
team
emot
stress
moral
distress
lead
burnout
increas
workload
expect
conclus
conclus
discov
far
stressor
program
develop
need
brozou
j
e
c
hein
univers
children
dusseldorf
pediatr
hematolog
clinic
immunolog
dusseldorf
germani
hein
univers
medic
faculti
dusseldorf
insitutut
human
genet
dusseldorf
germani
muenster
institut
medic
informat
muenster
germani
backgroundobject
consider
percentag
childhood
cancer
due
cancer
predisposit
syndrom
cp
ratio
cpss
caus
inherit
versu
de
novo
germlin
mutat
unknown
thu
recurr
risk
sibl
addit
attitud
affect
parent
toward
genet
test
unclear
designmethod
initi
ongo
prospect
studi
perform
sequenc
we
trio
identifi
cp
inherit
pattern
newli
diagnos
cancer
children
result
famili
particip
refus
particip
children
present
congenit
malign
tumor
high
likelihood
underli
cp
famili
pedigre
malign
reveal
famili
member
year
rel
cancer
year
cancer
histori
rel
cancer
famili
one
rel
develop
breast
cancer
sarcoma
lymphat
malign
colon
cancer
date
trio
analyz
depth
median
coverag
bioinformat
pipelin
establish
actual
gene
list
compris
gene
ongo
updat
base
data
st
jude
studi
group
zhang
et
al
nejm
variant
classifi
three
pathogen
categori
far
children
lf
child
syndrom
cmmrd
apc
associ
polyposi
identifi
experiment
analys
variou
variant
unknown
signific
progress
conclus
test
underli
cp
extraordinari
interest
affect
famili
vast
major
opt
right
know
particularli
interest
recurr
risk
offspr
thu
trio
sequenc
becom
common
practic
c
goudi
n
h
l
w
sick
children
pediatr
oncolog
toronto
canada
hospit
eastern
ontario
pediatr
oncolog
ottawa
canada
univers
human
genet
montreal
canada
univers
health
center
medic
human
genet
montreal
canada
backgroundobject
estim
children
cancer
underli
cancer
predisposit
syndrom
cp
mani
unrecogn
identifi
cancer
suscept
appropri
refer
genet
team
vital
optim
patient
care
incorpor
potenti
prevent
measur
adapt
therapi
improv
surveil
counsel
around
famili
risk
mani
challeng
limit
likelihood
physician
identifi
cpss
technolog
advanc
cancer
geneticsgenom
rapidli
outpac
knowledg
clinician
address
issu
develop
mipogg
electron
educ
applic
smart
devic
includ
decision
algorithm
design
help
identifi
children
cancer
increas
risk
underli
cp
designmethod
pediatr
cancer
includ
intern
classif
childhood
cancer
classif
cn
tumor
revis
extens
literatur
review
undertaken
highlight
clinic
andor
molecular
characterist
increas
likelihood
genet
predisposit
characterist
use
design
simpl
algorithm
follow
binari
tree
structur
ye
answer
algorithm
ultim
advis
one
two
possibl
outcom
referr
suggest
referr
necessari
link
educ
modul
algorithm
critic
review
expert
panel
valid
retrospect
chart
review
ensur
sensit
posit
predict
valu
result
algorithm
final
present
exampl
includ
osteosarcoma
rhabdomyosarcoma
wilm
tumor
highlight
perform
algorithm
valid
studi
also
outlin
rational
tumor
requir
direct
referr
genet
servic
conclus
mipogg
offer
clinic
target
approach
design
easili
identifi
patient
risk
cp
without
need
extens
sophist
investig
clinic
tool
potenti
optim
manag
children
cancer
across
health
care
system
global
farrag
f
egypt
cancer
assiut
univers
depart
pediatr
oncolog
assiut
egypt
assiut
univers
depart
pediatr
assiut
egypt
backgroundobject
mani
cultur
report
usag
complementari
altern
medic
therapi
camt
cancer
patient
patient
wast
time
money
seek
advic
potenti
harm
altern
medicin
designmethod
studi
includ
pediatr
oncolog
patient
phase
therapi
south
egypt
cancer
institut
person
interview
care
giver
consent
done
focus
educ
level
monthli
incom
resid
addit
type
reason
experi
start
camt
use
result
studi
includ
patient
male
femal
mean
age
year
diagnos
includ
leukemia
tumor
patient
live
rural
area
mother
well
educ
camt
report
patient
caus
delay
present
week
patient
purpos
complimentari
case
altern
medic
therapi
case
camt
type
herbal
nutrit
magic
religi
massag
multipl
camt
use
patient
advis
use
camt
mostli
famili
therapist
patient
reason
use
camt
either
treat
complic
cancer
initi
undiagnos
diseas
pain
increas
immun
chemotherapi
relax
patient
report
camt
effect
better
convent
medic
therapi
start
use
mostli
earli
phase
diagnosi
treatment
patient
deni
physician
ask
use
camt
camt
usag
rel
richer
famili
detect
relationship
use
camt
patient
sex
diagnosi
resid
matern
educ
level
conclus
full
medic
histori
includ
camt
essenti
pediatr
oncolog
patient
j
c
k
v
n
c
j
c
r
c
u
v
gupta
univers
west
indi
patholog
kingston
jamaica
children
hospit
oncolog
kingston
jamaica
hospit
oncolog
castri
st
lucia
william
medic
scienc
complex
oncolog
port
spain
trinidad
tobago
margaret
hospit
oncolog
nassau
bahama
cato
memori
hospit
oncolog
kingstown
st
vincent
grenadin
elizabeth
hospit
oncolog
bridgetown
barbado
hospit
west
indi
oncolog
kingston
jamaica
hospit
sick
children
infecti
diseas
toronto
canada
hospit
sick
children
haematologyoncolog
toronto
canada
backgroundobject
children
cancer
caribbean
esc
face
uniqu
challeng
includ
distribut
across
small
popul
vast
distanc
esc
childhood
cancer
outcom
unknown
designmethod
initi
sci
establish
childhood
cancer
outcom
databas
across
seven
centr
six
countri
bahama
barbado
jamaica
st
lucia
st
vincent
trinidad
tobago
train
data
manag
site
activ
enter
patient
demograph
diseas
treatment
outcom
data
data
collect
commenc
retrospect
collect
subsequ
prospect
collect
data
analys
result
children
diagnos
median
age
year
interquartil
rang
year
patient
diagnos
leukemia
lymphoma
solid
tumour
rel
pauciti
children
brain
tumour
seen
event
free
surviv
ef
entir
cohort
overal
surviv
os
children
acut
lymphoblast
leukemia
wilm
tumour
experienc
better
ef
dismal
outcom
seen
children
acut
myeloid
leukemia
aml
rhabdomyosarcoma
medulloblastoma
death
known
caus
attribut
diseas
treatment
complic
death
within
day
diagnosi
rel
common
acut
leukemia
aml
despit
tradit
prognost
advers
impact
outcom
includ
higher
age
higher
white
blood
cell
count
lineag
conclus
esc
childhood
cancer
outcom
superior
mani
set
still
significantli
inferior
countri
outcom
base
data
sci
intervent
improv
support
care
diagnost
modifi
leukemia
treatment
protocol
underway
continu
data
collect
allow
evalu
intervent
ensur
maxim
outcom
improv
f
moreno
c
g
g
roha
oncopediatr
nation
cancer
ministri
health
ciudad
autonoma
de
bueno
air
argentina
cancer
institut
ciudad
autonoma
de
bueno
air
bueno
air
argentina
epidemiolog
analysi
nation
cancer
ministri
health
ciudad
autonoma
de
bueno
air
argentina
backgroundobject
inform
epidemiolog
childhood
cancer
mandatori
plan
polici
argentin
nation
pediatr
cancer
registri
roha
registri
nation
coverag
activ
sinc
aim
current
studi
analyz
overal
surviv
os
children
diagnos
cancer
argentina
major
pediatr
cancer
subtyp
designmethod
newli
diagnos
pediatr
cancer
case
regist
roha
estim
coverag
case
os
estim
use
method
result
total
new
cancer
diagnos
children
age
year
report
registri
os
cancer
ci
specif
os
common
cancer
subtyp
leukemia
ci
lymphoma
relat
neoplasm
ci
brain
neoplasm
ci
sarcoma
ci
neuroblastoma
ci
renal
tumor
ci
malign
bone
tumor
ci
conclus
os
children
diagnos
cancer
argentina
even
though
percentag
lower
report
countri
distribut
pediatr
cancer
subtyp
similar
improv
result
remain
challeng
system
p
roger
c
k
c
j
c
c
ys
p
p
b
r
children
hospit
pediatr
vancouv
canada
univers
pediatr
hamilton
canada
sick
children
oncolog
toronto
canada
manitoba
oncolog
winnipeg
canada
hospic
palli
care
associ
palli
care
ottawa
canada
oncolog
group
ontario
oncolog
toronto
canada
cancer
agenc
cancer
control
research
vancouv
canada
health
centr
apphon
halifax
canada
health
centr
oncolog
halifax
canada
cancer
agenc
oncolog
vancouv
canada
univers
oncolog
montreal
canada
alberta
busi
edmonton
canada
alberta
pediatr
edmonton
canada
backgroundobject
health
care
need
aya
cancer
differ
older
younger
patient
report
indic
essenti
evalu
project
system
chang
undertaken
improv
care
popul
goal
project
report
indic
assess
current
state
aya
cancer
care
canada
designmethod
measur
health
system
perform
select
indic
data
obtain
administr
databas
nation
survey
area
focu
includ
epidemiolog
activ
care
palliat
psychosoci
issu
survivorship
research
result
epidemiolog
last
year
rel
increas
new
cancer
case
year
old
rel
surviv
absolut
increas
earli
activ
care
among
year
old
began
treatment
day
diagnosi
breast
cancer
approxim
age
group
wait
similar
period
aya
breast
colon
cancer
treat
teach
hospit
compar
older
adult
palliat
aya
cancer
death
occur
hospit
psychosoci
issu
emot
support
rate
neg
aya
male
femal
survivorship
cancer
survivor
gener
popul
share
similar
achiev
rate
educ
cancer
survivor
report
higher
unemploy
research
averag
annual
invest
cancer
research
million
total
cancer
research
invest
canada
june
therapeut
cancer
clinic
trial
cancer
preval
among
aya
conclus
opportun
improv
care
aya
cancer
identifi
gap
research
invest
challeng
report
aya
indic
identifi
eg
lack
data
inabl
analyz
type
cancer
age
report
avail
systemperformanceca
taylor
j
c
r
p
colleg
medicin
section
houston
usa
arizona
school
nurs
tucson
usa
minnesota
school
nurs
minneapoli
usa
univers
school
nurs
durham
usa
backgroundobject
methotrex
mtx
critic
import
chemotherapeut
agent
acut
lymphoblast
leukemia
therapi
howev
neurotox
nt
lead
treatment
modif
may
jeopard
surviv
affect
patient
object
studi
evalu
demograph
clinic
factor
associ
incid
acut
mtx
nt
among
pediatr
patient
designmethod
pediatr
patient
undergo
therapi
three
major
childhood
cancer
treatment
center
unit
state
texa
children
cancer
center
univers
arizona
children
minnesota
enrol
prospect
studi
toxic
mtx
nt
defin
neurolog
event
eg
aphasia
seizur
follow
intrathec
andor
intraven
iv
mtx
result
modif
andor
iv
mtx
therapi
logist
regress
use
gener
odd
ratio
confid
interv
ci
impact
demograph
treatment
featur
mtx
nt
result
patient
experienc
acut
mtx
nt
patient
experienc
nt
hispan
compar
without
mtx
nt
median
age
diagnosi
significantli
higher
p
mtx
nt
group
year
vs
year
respect
hispan
time
ci
like
experi
mtx
nt
adjust
sex
age
diagnosi
risk
stratif
independ
hispan
ethnic
risk
stratif
remain
statist
signific
predictor
mtx
nt
conclus
larg
cohort
found
hispan
ethnic
strongli
associ
increas
risk
mtx
nt
add
grow
bodi
evid
indic
hispan
patient
encount
signific
dispar
treatment
outcom
understand
mechan
predictor
dispar
critic
improv
outcom
surviv
patient
g
aun
children
cancer
research
instituteunivers
texa
health
scienc
divis
san
antonio
usa
backgroundobject
exposur
anthracyclin
doxorubicin
dox
childhood
cancer
treatment
unequivoc
link
develop
cardiovascular
diseas
clinic
strategi
mitig
cardiac
morbid
childhood
cancer
survivor
includ
pretreat
iron
chelat
dexrazoxan
dex
use
liposom
doxorubicin
strategi
decreas
acut
cardiac
toxic
howev
due
long
latent
period
exposur
develop
cardiac
diseas
cardiac
outcom
survivor
treat
use
strategi
mostli
unknown
thu
use
yet
wide
adopt
clinic
practic
report
evalu
dex
clinic
relev
murin
model
earli
anthracyclin
exposur
follow
monitor
cardiac
function
surviv
throughout
lifespan
age
adult
mice
designmethod
begin
week
age
mice
n
per
group
equal
number
male
femal
treat
weekli
intraperiton
inject
follow
salin
control
mgkg
dox
mgkg
mgkg
dox
mgkg
follow
complet
therapi
mice
monitor
normal
laboratori
condit
physic
paramet
includ
bodi
weight
surviv
cardiac
function
use
standard
echocardiographi
evalu
everi
three
month
month
age
age
adult
mous
result
compar
control
mice
treat
dox
exhibit
significantli
reduc
bodi
weight
decreas
surviv
decreas
cardiac
function
decreas
eject
ef
contrast
mice
treat
dex
dox
exhibit
normal
bodi
weight
decreas
enhanc
surviv
normal
cardiac
function
normal
ef
compar
anim
conclus
studi
perform
mice
indic
dexrazoxan
significantli
mitig
cardiac
damag
induc
earli
anthracyclin
exposur
throughout
lifespan
old
age
clinic
practic
incorpor
widespread
use
cardioprotect
strategi
l
kahalley
md
mf
w
j
h
c
colleg
medicin
pediatr
houston
usa
clinic
radiat
oncolog
rochest
usa
colleg
medicin
neurosurgeri
houston
usa
univers
texa
md
anderson
cancer
center
radiat
oncolog
houston
usa
colleg
medicin
dan
l
duncan
institut
clinic
translat
research
houston
usa
backgroundobject
cranial
radiotherapi
associ
neurocognit
toxic
proton
beam
radiotherapi
pbrt
reduc
volum
normal
tissu
receiv
radiat
dose
may
lead
better
neurocognit
outcom
examin
chang
neurocognit
score
time
pediatr
brain
tumor
patient
treat
craniospin
pbrt
focal
pbrt
surgeri
designmethod
patient
receiv
annual
neurocognit
evalu
year
examin
full
scale
iq
fsiq
work
memori
index
wmi
process
speed
index
psi
score
separ
gener
linear
mix
model
examin
chang
score
time
treatment
group
result
score
avail
patient
group
differ
demograph
clinic
variabl
male
infratentori
tumor
mean
year
mean
year
tumor
type
includ
glioma
medulloblastoma
ependymoma
germ
cell
craniopharyngioma
median
rt
dose
gy
gy
fsiq
wmi
psi
score
remain
stabl
time
treatment
group
allp
mean
three
group
within
normal
limit
across
score
avail
time
point
even
though
fsiq
declin
significantli
group
fsiq
slope
group
differ
significantli
slope
group
conclus
within
earli
survivorship
pbrt
associ
signific
cognit
declin
outcom
similar
whether
patient
receiv
pbrt
csi
focal
radiotherapi
global
iq
within
normal
limit
age
process
speed
work
memori
domain
known
particularli
radiosensit
also
consist
across
group
csi
emerg
cognit
risk
factor
consist
photon
outcom
research
find
hope
replic
larger
sampl
later
outcom
need
underway
j
n
l
cancer
registri
institut
statist
epidemiolog
cancer
research
helsinki
finland
helsinki
univers
hospit
depart
obstetr
gynecolog
helsinki
finland
institut
health
welfar
nation
institut
health
welfar
helsinki
finland
backgroundobject
previou
studi
shown
elev
risk
preterm
deliveri
among
femal
cancer
survivor
aim
assess
pregnanc
relat
condit
possibl
underli
elev
risk
preterm
labor
cancer
survivor
designmethod
nationwid
cancer
birth
registri
merg
identifi
first
deliveri
cancer
survivor
diagnos
year
age
first
deliveri
match
femal
control
januari
decemb
multipl
uncondit
logist
regress
model
use
estim
risk
pregnanc
relat
condit
adjust
matern
age
year
deliveri
gestat
age
smoke
result
found
significantli
elev
risk
hospit
due
threaten
preterm
labor
ci
fear
childbirth
ci
mental
disord
diseas
nervou
system
ci
among
survivor
compar
control
increas
risk
overal
hospit
ci
hospit
stay
exceed
day
ci
also
found
risk
prematur
ruptur
membran
vagin
bleed
gestat
diabet
increas
highest
risk
hospit
due
threaten
preterm
labor
seen
among
survivor
deliv
year
cancer
treatment
survivor
diagnos
young
adult
age
year
conclus
cancer
survivor
increas
risk
preterm
deliveri
possibl
explain
spontan
preterm
labor
due
prematur
contract
cervic
shorten
health
profession
treat
women
awar
risk
gener
howev
result
reassur
come
pregnanc
among
cancer
survivor
n
e
l
marjerrison
univers
kinesiolog
hamilton
canada
children
hospit
pediatr
hematologyoncolog
hamilton
canada
univers
age
societi
hamilton
canada
univers
pediatr
hamilton
canada
backgroundobject
age
survivor
cancer
childhood
scc
seriou
chronic
health
condit
literatur
remain
unclear
whether
lifestyl
factor
includ
physic
activ
pa
relat
health
outcom
object
studi
examin
relationship
pa
establish
late
effect
treatment
adult
survivor
childhood
cancer
designmethod
retrospect
chart
review
includ
adult
scc
current
enrol
mcmaster
aftercar
program
perform
inform
diagnosi
treatment
pa
lifestyl
behaviour
well
physiolog
measur
abstract
predictor
establish
late
effect
cancer
therapi
examin
use
logist
regress
multivari
model
built
known
risk
factor
determin
priori
signific
predictor
univari
analys
result
patient
includ
report
behaviour
met
pa
recommend
indic
pa
particip
multivari
analysi
signific
independ
associ
shown
normal
left
ventricular
eject
fraction
lvef
adequ
pa
well
femal
sex
account
doxorubicin
chest
radiat
well
factor
low
bone
miner
densiti
bmd
associ
pa
ideal
bodi
mass
index
bmi
bodi
fat
percentag
associ
cranial
radiat
p
femal
sex
p
high
bmi
associ
pa
normal
bmd
p
bmi
modifi
risk
factor
associ
lipid
level
univari
analysi
conclus
despit
ongo
healthi
activ
live
counsel
scc
clinic
meet
pa
guidelin
identifi
novel
independ
associ
pa
lvef
bmd
bmi
scc
shown
strongli
associ
marker
health
mani
establish
predict
treatment
factor
pa
import
predictor
healthi
age
among
scc
z
sadighi
e
j
c
r
jude
children
research
hospit
neurolog
memphi
usa
neurolog
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
character
neurolog
outcom
site
tumor
durat
present
symptom
patient
pediatr
low
grade
glioma
lgg
assess
designmethod
institut
review
retrospect
studi
conduct
patient
diagnos
lgg
st
jude
children
research
hospit
neurolog
impair
sever
defin
common
terminolog
criteria
advers
event
version
compar
first
last
visit
tumor
locat
symptom
interv
psi
month
use
test
wilcoxon
rank
sum
test
fisher
exact
test
result
patient
lgg
spinal
cord
posterior
fossa
pf
brainstem
optic
pathway
midlin
cerebr
hemispher
includ
median
age
diagnosi
rang
year
median
psi
month
median
time
last
year
cerebr
hemispher
fewest
median
neurolog
impair
compar
locat
baselin
p
last
compar
locat
patient
psi
month
higher
incid
ataxia
dysmetria
psi
month
overal
wors
motor
weak
cerebr
hemispher
dysmetria
optic
pathway
midlin
dysmetria
ear
vestibular
disturb
spinal
cord
pf
brainstem
psi
month
spinal
cord
pf
brainstem
worsen
vagal
nerv
deficit
conclus
neurolog
outcom
pediatr
lgg
vari
locat
delay
diagnosi
minim
affect
neurolog
outcom
l
martynov
n
v
p
oncolog
hematolog
blokhin
russian
oncolog
research
center
anesthesiolog
depart
moscow
russia
russian
oncolog
research
center
anesthesiolog
depart
moscow
russia
oncolog
hematolog
blokhin
russian
oncolog
research
center
oncolog
depart
moscow
russia
backgroundobject
pediatr
oncolog
lung
frequent
target
metastasi
diagnost
therapeut
surgeri
requir
guarante
optim
condit
surgeri
collaps
oper
lung
requir
thu
one
lung
ventil
olv
perform
novel
devic
olv
cohen
arndt
bronchial
blocker
bb
allow
achiev
olv
avoid
traumatis
trachea
complic
designmethod
surgeri
patient
year
old
perform
olv
maintain
use
bb
bb
introduc
lumen
video
endotrach
tube
place
bronchu
video
control
instal
arndt
bb
conduct
endoscop
control
case
right
main
bronchu
case
left
main
bronchu
block
time
bb
instal
lung
collaps
score
instal
thoracoscop
port
hemodynam
profil
surgeri
frequenc
postop
complic
sore
throat
aphonia
evalu
result
mean
time
intub
bb
instal
second
case
possibl
achiev
satisfactori
lung
collaps
case
aspir
air
channel
bb
perform
collaps
right
lung
present
difficulti
due
anatom
featur
higher
embranch
right
upper
lobe
bronchu
case
use
bb
prefer
design
secur
fix
carina
make
less
like
displac
surgeri
surgeri
left
lung
cohen
bb
prefer
conclus
use
bb
requir
expens
equip
video
endoscop
control
well
train
staff
skill
bb
instal
maintain
olv
bb
promis
techniqu
achiev
effect
collaps
lung
minim
traumatis
fewer
complic
postop
rapid
rehabilit
patient
surgeri
c
sorg
e
j
v
hospit
pediatr
surgeri
pediatr
urolog
germani
backgroundobject
rhabdomyosarcoma
rm
common
soft
tissu
tumor
children
outcom
children
advanc
tumor
diseas
still
poor
curcumin
natur
occur
phenol
investig
complementari
oncolog
research
phytochem
antiprolif
effect
designmethod
alveolar
zf
embryon
rd
srh
rm
cell
line
treat
curcumin
alon
combin
curcumin
vincristin
curcumin
vincristin
combin
curcumin
photodynam
therapi
curcumin
light
human
skelet
muscl
cell
line
skmc
serv
control
cell
viabil
assess
mtt
assay
apoptosi
rate
evalu
via
fac
analysi
migrat
investig
wound
heal
assay
clonogen
surviv
rm
cell
detect
coloni
form
assay
result
combin
curcumin
vincristin
led
effect
cell
line
appear
decreas
cell
prolifer
migrat
potenti
well
increas
apoptosi
rate
combin
therapi
photodynam
therapi
result
highli
signific
decreas
cell
viabil
rm
cell
line
even
low
concentr
curcumin
result
also
show
curcumin
inhibit
clone
effici
rm
cell
conclus
summari
studi
provid
first
evid
curcumin
especi
combin
standard
chemotherapi
photodynam
therapi
promis
agent
treatment
rm
vivo
studi
pend
ch
chui
centr
children
pte
ltd
surgic
oncolog
singapor
singapor
backgroundobject
neuroblastoma
aris
adren
gland
adrenalectomi
treatment
choic
howev
contralater
adren
gland
often
also
risk
lead
develop
postop
adren
insuffici
ai
review
risk
ai
patient
underw
neuroblastoma
surgeri
designmethod
retrospect
analysi
patient
neuroblastoma
supraren
region
defin
retroperiton
zone
superior
renal
vein
arteri
ai
defin
chronic
transient
patient
categor
base
diseas
distribut
right
adren
diseas
b
left
adren
diseas
c
right
adren
left
diseas
left
adren
right
diseas
e
bilater
adren
diseas
f
paravertebr
diseas
demograph
data
surgic
record
postop
chart
review
result
patient
develop
ai
chronic
transient
none
unilater
patient
group
b
develop
ai
half
bilater
patient
group
e
develop
ai
patient
group
f
develop
ai
unilater
adren
diseas
coupl
contralater
diseas
patient
group
c
compar
patient
group
develop
ai
suggest
left
adren
gland
vulner
surgic
damag
right
adren
gland
like
preserv
due
shorter
cours
right
adren
vein
conclus
preserv
adren
function
consid
neuroblastoma
surgeri
due
caution
render
left
adren
gland
right
adrenalectomi
vulner
vasculatur
earli
hydrocortison
replac
institut
ai
suspect
cozzi
f
univers
rome
pediatr
surgeri
unit
rome
itali
backgroundobject
current
treatment
microscop
residu
diseas
neg
lymph
node
surgeri
nss
wilm
tumor
includ
radiotherapi
chemotherapi
aim
present
studi
test
hypothesi
children
posit
margin
nss
may
success
treat
without
radiotherapi
designmethod
children
renal
tumor
underw
surgeri
institut
eight
patient
unilater
wilm
tumor
unilater
renal
oncocytoma
underw
partial
nephrectomi
addit
children
unilater
wilm
tumor
bilater
wilm
tumor
underw
one
multipl
enucl
two
children
partial
nephrectomi
enucl
present
posit
surgic
margin
without
lymph
node
involv
treat
chemotherapi
without
radiotherapi
result
child
bilater
wilm
tumor
underw
oper
consist
new
enucl
follow
chemotherapi
without
radiotherapi
patient
aliv
well
age
year
children
posit
margin
treat
without
radiotherapi
aliv
well
age
year
patient
egfr
within
rang
renal
function
hypertens
albuminuria
conclus
children
posit
surgic
margin
nss
wilm
tumor
may
success
treat
without
radiotherapi
larger
number
patient
need
determin
whether
approach
gener
applic
g
cernaianu
b
hospit
cologn
pediatr
surgeri
germani
hospit
cologn
pediatr
oncolog
hematolog
germani
backgroundobject
renal
hilu
main
lymphat
drainag
rout
adren
medulla
inspect
prepar
renal
arteri
debulk
tumor
tissu
renal
hilu
constitut
surgic
challeng
neuroblastoma
howev
associ
renal
arteri
exposur
resect
high
risk
neuroblastoma
first
line
resect
abdomin
surgeri
renal
hilu
clearli
defin
designmethod
fourti
patient
relaps
progress
neuroblastoma
first
line
surgeri
enrol
german
neuroblastoma
trial
evalu
analyz
frequenc
renal
arteri
exposur
resect
renal
hilu
mean
surgic
report
result
tumor
involv
renal
vessel
patient
right
r
left
l
side
inspect
arteri
oper
document
right
side
left
side
patient
exposur
renal
arteri
associ
higher
resect
rate
renal
hilu
compar
case
without
exposur
r
vs
l
vs
conclus
surgic
analysi
reveal
high
frequenc
tumor
renal
hilu
low
rate
renal
arteri
inspect
renal
arteri
inspect
associ
higher
resect
rate
tumor
renal
hilu
result
studi
emphas
import
renal
arteri
inspect
instrument
surgic
qualiti
first
resect
abdomin
high
risk
neuroblastoma
renal
hilu
vice
versa
inspect
renal
arteri
might
also
indic
oper
techniqu
like
achiev
complet
tumor
resect
collin
k
b
j
children
hospit
westmead
paediatr
surgeri
westmead
australia
sydney
sydney
medic
school
sydney
australia
children
hospit
westmead
paediatr
oncolog
thorac
surgeri
westmead
australia
sydney
children
cancer
research
unit
sydney
australia
backgroundobject
clinic
radiolog
follow
paediatr
solid
tumour
patient
aim
includ
earli
identif
relaps
standardis
three
monthli
frequent
imag
often
employ
howev
surveil
imag
well
studi
risk
high
cumul
dose
radiat
protocol
includ
potenti
secondari
malign
studi
aim
identifi
role
imag
play
establish
relaps
solid
tumour
popul
designmethod
studi
involv
retrospect
audit
patient
manag
hospit
period
present
common
solid
tumour
osteosarcoma
rhabdoyosarcoma
ewe
sarcoma
neuroblastoma
wilm
tumour
sarcoma
hepatoblastoma
data
collect
oncolog
radiolog
databas
well
medic
record
result
identifi
patient
oncolog
databas
fail
meet
inclus
criteria
achiev
radiolog
remiss
incomplet
record
throughout
follow
period
exclud
left
includ
patient
patient
relaps
case
relaps
identifi
clinic
pet
combin
ctmri
case
imag
form
pet
alon
bone
scan
mibg
alon
cxr
mri
alon
ultrasound
case
secondari
malign
identifi
follow
period
total
number
ct
scan
perform
follow
period
result
mean
number
ct
studi
per
patient
equat
one
episod
ct
identifi
relaps
per
ct
scan
conclus
conclud
radiolog
investig
play
role
alongsid
clinic
histori
examin
establish
relaps
studi
requir
minimis
radiat
exposur
protocol
maximis
clinic
benefit
j
godzinski
g
g
j
b
von
kp
van
de
n
hospit
paediatr
surgeri
wroclaw
poland
univers
paediatr
traumatolog
emerg
medicin
wroclaw
poland
trousseau
chirurgi
pediatriqu
pari
franc
hospit
padua
pediatr
surgeri
children
health
depart
padoua
itali
tuebingen
paediatr
surgeri
tuebingen
germani
georg
univers
hospit
paediatr
surgeri
london
unit
kingdom
teach
hospit
nh
trust
paediatr
surgeri
leed
unit
kingdom
munich
depart
pediatr
munich
germani
maxima
paediatr
surgeri
utrecht
netherland
nki
amsterdam
netherland
univers
depart
pediatr
oncolog
hematolog
homburg
germani
backgroundobject
surgeri
play
import
role
treatment
nephroblastoma
major
multicentr
studi
precis
recommend
guidelin
surgic
treatment
aim
studi
evalu
rate
type
potenti
import
violat
iatrogen
failur
surgic
guidelin
designmethod
retrospect
review
record
patient
age
month
unilater
nephroblastoma
regist
candid
violationsiatrogen
failur
preoper
open
biopsi
intraop
tumour
ruptur
sampl
less
region
lymph
node
factor
result
stage
patient
longer
chemotherapi
radiotherapi
factor
repres
sampl
may
lead
incorrect
lower
stage
consequ
insuffici
aggress
durat
postop
treatment
result
preoper
open
biopsi
perform
patient
main
reason
stage
iii
stage
iii
patient
intra
oper
tumour
ruptur
report
patient
adequ
sampl
less
lymph
node
region
lymph
node
report
patient
lymph
node
sampl
factor
reason
stage
case
howev
underestim
rate
lymph
node
involv
seem
probabl
conclus
surgic
guidelin
correctli
follow
major
patient
main
problem
consid
incorrect
sampl
lymph
node
result
possibl
downstag
patient
less
aggress
postop
treatment
higher
risk
relaps
iatrogen
upstag
patient
due
open
biopsi
intraop
tumour
ruptur
less
frequent
howev
major
event
possibl
avoid
arul
k
children
hospit
nh
foundat
trust
dept
surgeri
birmingham
unit
kingdom
backgroundobject
establish
uk
practic
follow
complet
resect
unilater
benign
ovarian
tumour
risk
develop
metachron
tumour
contralater
ovari
low
therefor
requir
follow
howev
challeng
paper
show
rate
metachron
tumour
contralater
wish
establish
exactli
follow
arrang
whether
case
metachron
tumour
group
patient
could
help
shape
futur
uk
guidelin
designmethod
retrospect
studi
girl
ovarian
teratoma
present
us
identifi
histolog
databas
clinic
data
age
diagnosi
biochem
tumour
marker
histolog
appoint
radiolog
collect
hospit
record
analys
result
girl
underw
surgeri
ovarian
teratoma
median
age
year
rang
yr
patient
present
abdomin
pain
asymptomat
lower
abdomin
swell
four
rais
tumour
marker
histolog
reveal
matur
teratoma
immatur
teratoma
two
unclassifi
eleven
patient
evid
torsion
radiolog
follow
ultrasound
occur
patient
median
month
rang
month
year
time
singl
case
radiolog
recurr
addit
case
remain
patient
present
clinic
sign
ovarian
tumour
conclus
seri
singl
case
metachron
ovarian
tumour
suggest
need
chang
practic
howev
prospect
studi
uk
patient
would
requir
definit
establish
rate
recurr
benign
ovarian
tumor
uncommon
children
taskinen
et
al
journal
paediatr
k
khanna
v
n
india
institut
medic
scienc
pediatr
surgeri
new
delhi
india
harding
medic
colleg
associ
kalawati
saran
children
hospit
paediatr
surgeri
new
delhi
india
hospit
paediatr
surgeri
delhi
india
india
institut
medic
scienc
paediatr
surgeri
new
delhi
india
backgroundobject
incid
matur
congenit
teratoma
site
live
birth
cervicofaci
highlight
challeng
involv
periop
intraop
manag
larg
cervicofaci
teratoma
infant
designmethod
four
infant
oper
larg
cervicofaci
teratoma
june
till
februari
includ
result
four
infant
age
rang
day
day
present
huge
cervicofaci
teratoma
averag
tumor
size
rang
two
neonat
present
epignathu
teratoma
cleft
palat
intranas
extens
intra
cranial
extens
ct
scan
two
present
giant
cervicofaci
teratoma
compress
flatten
underli
skull
bone
intracrani
extens
preoper
level
normal
age
two
requir
day
nasogastr
ng
feed
preoper
intub
challeng
anaesthetist
aid
fiberopt
bronchoscopi
intub
case
averag
blood
loss
mean
oper
time
underw
complet
excis
histopatholog
confirm
diagnosi
matur
teratoma
conclus
larg
congenit
cervicofaci
teratoma
infant
usual
benign
may
pose
surgic
emerg
airway
compromis
detail
imag
requir
delin
extent
lesion
plan
surgeri
good
preoper
nutrit
statu
guid
time
surgeri
intub
flexometal
endotrach
tube
may
requir
larg
tumor
size
distort
normal
anatomi
increas
vascular
pose
surgic
risk
harmon
scalpel
aid
excis
earli
institut
postop
ng
feed
physiotherapi
help
speedi
recoveri
return
function
normal
appear
j
daley
r
b
island
hospit
depart
pediatr
provid
usa
island
hospit
divis
pediatr
provid
usa
island
hospit
depart
radiolog
provid
usa
backgroundobject
ablat
techniqu
includ
thermal
chemic
ablat
commonli
use
therapeut
option
treatment
malign
lesion
adult
ablat
may
use
cur
intent
incorpor
multimod
treatment
regimen
palli
treatment
pain
lesion
although
well
establish
adult
malign
littl
data
regard
use
techniqu
pediatr
oncolog
patient
studi
retrospect
analyz
use
ablat
adjuv
therapi
pediatr
oncolog
popul
institut
designmethod
retrospect
chart
review
identifi
pediatr
patient
malign
lesion
treat
ablat
clinic
inform
treatment
detail
regard
ablat
procedur
collect
institut
review
board
approv
result
patient
treat
ablat
institut
year
age
five
patient
diagnos
osteosarcoma
addit
patient
solid
tumor
vari
histolog
major
patient
diffus
metastat
relaps
diseas
ablat
session
perform
palli
purpos
perform
cur
intent
microwav
radiofrequ
cryoablat
use
ablat
lesion
rang
size
cm
common
site
ablat
includ
lung
liver
soft
tissu
ablat
report
technic
success
limit
complic
includ
pneumothorax
symptomat
patient
achiev
pain
relief
local
progress
occur
previous
treat
lesion
patient
die
diseas
conclus
ablat
perform
safe
effect
children
limit
toxic
ablat
may
provid
effect
local
diseas
control
addit
palliat
appropri
select
pediatr
patient
tumor
site
differenti
consider
must
acknowledg
adult
children
ablat
repres
minim
invas
treatment
approach
consid
treatment
cours
children
metastat
solid
tumor
yt
lee
cpc
ph
blk
h
hpa
women
children
hospit
depart
paediatr
surgeri
singapor
singapor
women
children
hospit
depart
diagnost
intervent
imag
singapor
singapor
women
children
hospit
depart
orthopaed
surgeri
singapor
singapor
women
children
hospit
oper
theatr
singapor
singapor
backgroundobject
posterior
retroperitoneosco
adrenalectomi
report
option
adren
tumor
resect
commonli
perform
children
due
extrem
posit
advoc
flatten
lumbar
lordosi
order
achiev
adequ
retroperiton
space
children
smaller
lordosi
angl
flatten
lordosi
creation
optim
retroperiton
space
may
achiev
less
hip
flexion
use
pediatr
lumbar
lordosi
measur
develop
modifi
prone
jackknif
posit
report
experi
setup
posterior
retroperitoneoscop
adrenalectomi
adren
tumor
designmethod
lordosi
angl
measur
sagitt
comput
tomographi
ct
magnet
reson
imag
mri
studi
pediatr
patient
adren
tumor
compar
normal
refer
data
use
develop
modifi
prone
jackknif
posit
select
patient
adren
tumor
underw
posterior
retroperitoneoscop
adrenalectomi
posit
patient
demograph
diagnos
oper
time
complic
analgesia
requir
length
hospit
analyz
result
ct
mri
studi
analyz
patient
adren
tumor
diagnos
institut
median
lordosi
angl
rang
four
patient
underw
retroperitoneoscop
adrenalectomi
june
decemb
histolog
diagnos
neuroblastoma
adren
hyperplasia
pheochromocytoma
adren
angiomatoid
fibrou
histiocytoma
median
age
year
rang
year
median
oper
time
minut
rang
minut
convers
open
surgeri
requir
one
patient
bleed
adren
vein
patient
requir
postop
opioid
analgesia
median
length
hospit
surgeri
day
rang
day
conclus
pediatr
patient
achiev
flatten
lumbar
lordosi
less
extrem
posit
posterior
retroperitoneoscop
adrenalectomi
modifi
prone
jackknif
posit
feasibl
oper
pediatr
patient
small
adren
tumor
advantag
short
oper
time
minim
requir
opioid
analgesia
short
length
hospit
qureshi
g
n
memori
hospit
pediatr
surgic
oncolog
mumbai
india
memori
hospit
radiolog
mumbai
india
memori
hospit
patholog
mumbai
india
memori
hospit
medic
oncolog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
backgroundobject
although
wilm
tumour
common
paediatr
renal
tumour
renal
tumour
encount
occasion
may
pose
diagnost
therapeut
challeng
aim
studi
determin
incid
analyz
treatment
overal
outcom
tumour
children
designmethod
materi
method
patient
primari
renal
tumour
treat
januari
decemb
wilm
patient
tumour
identifi
prospect
maintain
databas
patient
present
recurr
diseas
exclud
treatment
outcom
analysi
result
tumour
includ
renal
cell
carcinoma
clear
cell
sarcoma
ewe
sarcoma
malign
rhabdoid
tumour
congenit
mesoblast
nephroma
synovi
sarcoma
metanephr
adenoma
patient
underw
nephroureterectomi
either
upfront
n
preoper
chemotherapi
n
adjuv
therapi
offer
base
histolog
patient
diseas
relaps
seen
nine
patient
eight
die
diseas
includ
three
patient
malign
rhabdoid
tumour
median
surviv
rang
seven
month
year
project
year
overal
surviv
patient
respect
conclus
tumour
constitut
less
renal
tumour
treatment
depend
specif
histolog
surviv
rang
month
sever
year
accur
diagnosi
essenti
select
decid
intens
treatment
sharoev
n
j
k
j
luka
clinic
research
centr
russia
oncolog
moscow
russia
luka
clinic
research
centr
russia
neonatolog
moscow
russia
luka
clinic
research
centr
russia
pediatr
surgeri
moscow
russia
luka
clinic
research
centr
russia
administr
moscow
russia
backgroundobject
despit
advanc
pediatr
oncolog
manag
neonat
infant
younger
year
malign
solid
tumor
pose
challeng
aim
achiev
optim
outcom
patient
appli
multidisciplinari
approach
comprehens
care
object
review
demonstr
use
multidisciplinari
team
particular
group
patient
designmethod
neonat
infant
age
year
malign
solid
tumor
manag
care
multidisciplinari
team
center
includ
review
patient
data
prospect
collect
analyz
result
total
patient
age
day
year
mean
month
diagnos
follow
neurogen
tumor
brain
tumor
nephroblastoma
retinoblastoma
soft
tissu
sarcoma
hepat
tumor
germ
cell
tumor
other
four
case
tumor
detect
intranat
fetal
ultrasound
scan
case
time
make
accur
diagnos
took
day
follow
patient
present
accord
intern
accept
guidelin
protocol
patient
underw
combin
modal
therapi
includ
surgic
resect
tumor
metastas
treatment
complet
patient
overal
surviv
rate
follow
rang
month
patient
continu
receiv
chemotherapi
conclus
experi
implement
multidisciplinari
team
care
neonat
infant
younger
year
malign
solid
tumor
practic
approach
make
time
diagnosi
initi
promptli
appropri
treatment
thu
allow
achiev
high
surviv
rate
studi
longer
follow
warrant
evalu
overal
effect
approach
bhatnagar
hospit
bombay
hospit
pediatr
surgeri
mumbai
india
backgroundobject
accord
indian
demograph
profil
pediatr
adolesc
popul
repres
entir
popul
pediatr
malign
much
research
littl
known
malign
tumor
adolesc
popul
pois
children
adult
call
lost
tribe
attempt
made
studi
demograph
diseas
pattern
overal
outcom
pediatr
malign
solid
tumor
designmethod
patient
age
year
diagnosi
malign
tumor
regist
two
tertiari
care
hospit
mumbai
india
januari
decemb
includ
basic
demograph
inform
clinic
diagnost
detail
histolog
group
treatment
outcom
surviv
retrospect
studi
result
patient
variou
type
tumor
encount
young
girl
ovarian
tumor
ewe
sarcoma
ganglioneuroblastoma
osteosarcoma
papillari
pseudotumor
pancrea
adolesc
boy
show
rhabdomyosarcoma
ewe
sarcomapnet
n
testicular
malign
germ
cell
tumor
osteosarcoma
carcinosarcoma
abdomen
pretherapi
stage
tumor
reveal
tumor
found
stage
metastat
nodul
present
lung
abdomen
n
bonebon
marrow
n
upfront
chemotherapi
given
patient
except
resect
primari
could
achiev
patient
radiotherapi
util
adjuv
therapi
includ
primari
metastat
site
metastatectomi
perform
patient
overal
surviv
even
though
tumor
free
conclus
high
incid
advanc
malign
seen
adolesc
age
boy
girl
tumor
encount
age
group
differ
type
biolog
behaviour
well
respons
therapi
attempt
earli
detect
treatment
vital
import
prevent
present
advanc
age
ahad
r
india
institut
medic
new
delhi
pediatr
new
delhi
india
backgroundobject
children
acut
leukemia
increas
risk
infect
oppos
view
regard
tuberculosi
etiolog
patient
aim
studi
determin
preval
tuberculosi
infect
children
acut
leukemia
determin
mantoux
convers
rate
chemotherapi
determin
diseas
rate
treatment
outcom
tuberculosi
designmethod
prospect
cohort
studi
india
institut
medic
scienc
new
delhi
mantoux
test
tuberculin
unit
given
prior
chemotherapi
determin
preval
tuberculosi
infect
children
monitor
develop
tuberculosi
diseas
one
year
repeat
mantoux
test
month
follow
chemotherapi
develop
symptom
tuberculosi
risk
factor
bcg
vaccin
famili
histori
age
socioeconom
statu
malnutrit
assess
result
one
hundr
children
acut
lymphoblast
leukemia
acut
myeloid
leukemia
age
one
fourteen
year
averag
year
studi
four
percent
tuberculosi
infect
diagnosi
chemotherapi
among
mantoux
neg
children
becam
mantoux
posit
chemotherapi
isoniazid
given
month
infect
children
none
develop
tuberculosi
follow
mantoux
posit
children
older
year
age
howev
none
risk
factor
statist
signific
associ
tuberculosi
infect
conclus
mantoux
posit
increas
increas
age
low
preval
tuberculosi
infect
attribut
younger
popul
studi
none
children
receiv
isoniazid
develop
diseas
emphas
efficaci
chemoprophylaxi
antitubercular
effect
chemotherapi
like
antimicrobi
like
quinolon
use
febril
neutropenia
may
play
role
r
k
faisal
specialist
hospit
research
center
pediatr
hematologyoncolog
riyadh
saudi
arabia
backgroundobject
relaps
rate
children
major
hindranc
achiev
excel
overal
surviv
ratesto
assess
role
tripl
trisomi
dna
index
diagnosi
time
pattern
site
relaps
designmethod
retrospect
review
pediatr
year
diagnosi
patient
medic
chart
diagnos
treat
institut
result
patient
avail
dna
index
data
hyperdiploid
hdall
dna
index
remain
patient
hdall
group
relaps
median
year
month
year
first
complet
remiss
isol
hematopoiet
bm
extramedullari
testi
cn
group
relaps
isol
hematopoiet
cn
testi
remain
combin
hematopoiet
bm
cn
testi
relaps
hdall
group
frequent
involv
isol
hematopoiet
site
unlik
group
trisomi
tripl
trisomi
exhibit
signific
role
provid
protect
relaps
relaps
hdall
group
occur
earli
median
year
compar
group
trend
statist
signific
overal
surviv
hdall
group
statist
significantli
better
group
tripl
trisomi
trisomi
significantli
associ
hdall
conclus
significantli
differ
pattern
relaps
site
exist
hdall
group
time
relaps
cohort
pediatr
patient
j
g
k
faisal
specialist
hospit
research
center
pediatr
hematologyoncolog
riyadh
saudi
arabia
backgroundobject
conduct
retrospect
studi
assess
incid
allerg
reaction
asparaginas
pediatr
patient
determin
prognost
signific
designmethod
medic
chart
pediatr
patient
diagnos
regist
king
faisal
specialist
hospit
research
centr
riyadh
saudi
arabia
review
retrospect
fashion
outcom
data
analyz
backdrop
incid
allerg
reaction
asparaginas
result
five
hundr
four
patient
enrol
studi
median
age
diagnosi
year
girl
clinic
allerg
reaction
asparaginas
identifi
continu
measur
activ
level
observ
patient
occur
consolid
phase
categor
sever
moder
mild
significantli
common
high
risk
group
standard
risk
vs
rate
first
relaps
incid
first
relaps
higher
experi
allerg
reaction
vs
protect
effect
achiev
statist
signific
among
high
risk
patient
mortal
rate
significantli
lower
patient
record
allerg
reaction
asparaginas
other
howev
signific
differ
observ
probabl
five
year
event
free
surviv
ef
former
later
vs
whole
cohort
conclus
earli
switch
erwinia
type
reaction
asperginas
improv
surviv
decreas
relaps
patient
rs
almeida
fs
ea
n
de
pesquisa
aggeu
departamento
de
imunologia
recif
brazil
feder
de
pernambuco
centro
de
pesquisa
aggeu
departamento
de
imunologia
recif
brazil
de
paulo
departamento
de
biotecnologia
anim
piracicaba
brazil
de
medicina
de
pretouniversidad
de
paulo
de
imunologia
preto
brazil
de
medicina
integr
professor
fernando
figueira
centro
de
pesquisa
aggeu
departamento
de
imunologia
recif
brazil
backgroundobject
acut
lymphoblast
leukemia
hematolog
malign
account
childhood
affect
distinct
matur
stage
cell
microrna
mirna
small
rna
essenti
role
gene
express
regul
normal
hematopoiesi
studi
aim
investig
differenti
mirna
express
bone
marrow
bm
mononuclear
cell
patient
childhood
blood
cell
healthi
adult
neonat
individu
control
group
cg
designmethod
patient
male
femal
median
age
year
refer
instituto
de
medicina
integr
professor
fernando
figueira
recif
northeast
brazil
bm
collect
cg
data
adult
neonat
retriev
gene
express
omnibu
geo
databas
total
rna
extract
trizol
use
librari
construct
illumina
small
rna
kit
mirna
sequenc
hiseq
plataform
illumina
data
analyz
bioinformat
fastqc
qualiti
control
cutadapt
remov
adapt
mirna
identif
edger
differenti
express
de
use
mirbas
data
human
refer
genom
fals
discoveri
rate
fdr
consid
de
analysi
mirna
target
predict
perform
mirwalk
david
tool
appli
function
annot
fa
mirna
target
result
mirna
de
identifi
two
group
fourteen
thousand
three
hundr
gene
target
predict
fa
reveal
enrich
kegg
pathway
correct
p
includ
metabol
pathway
pathway
cancer
signal
pathway
endocytosi
mapk
signal
pathway
other
relat
immun
system
cancer
cell
function
conclus
mirna
play
role
biolog
pathway
relat
cancer
develop
immun
system
regul
acknowledg
support
anwar
children
hospit
ich
paediatr
hematologyoncolog
lahor
pakistan
children
hospit
ich
paediatr
haematolog
oncolog
lahor
pakistan
background
object
background
acut
lymphoblast
leukemia
commonest
malign
among
childrendiffer
protocol
use
differ
part
world
treat
object
main
object
studi
discuss
present
outcom
children
acut
lymphoblast
leukemia
design
method
studi
design
present
retrospect
studi
look
demograph
outcom
children
present
hematolog
oncolog
depart
children
hospit
lahor
januari
decemb
materi
method
children
bone
marrow
biopsi
proven
includ
data
regard
age
gender
risk
categor
outcom
record
analyz
children
stratifi
high
risk
year
age
factor
cn
diseas
mediastin
mass
present
lahor
group
protocol
acut
lymphoblast
leukemia
bfm
ukallxi
base
use
treatment
result
total
patient
includ
seventi
percent
male
major
year
age
patient
year
one
hundr
sixteen
high
risk
diseas
standard
risk
initi
wbc
bfm
risk
factor
patient
cn
diseas
mediastin
mass
present
seventi
eight
patient
complet
treatment
left
medic
advic
die
twenti
nine
relaps
among
relaps
treatment
conclus
high
risk
diseas
common
present
children
centr
initi
high
wbc
count
massiv
organomegali
male
predomin
abandon
anoth
major
factor
affect
overal
surviv
rate
howev
overal
surviv
almost
treat
patient
r
bhuta
b
p
k
j
island
hospit
pediatr
hematologyoncolog
provid
usa
medic
center
pediatr
hematolgoyoncolog
new
york
citi
usa
backgroundobject
integr
part
standard
treatment
patient
acut
lymphoblast
leukemia
includ
use
vincristin
signific
side
effect
vincristin
rare
sever
neurotox
occur
result
omiss
chemotherapeut
agent
treatment
studi
specif
look
patient
vincristin
remov
therapi
plan
assess
sever
side
effect
diseas
respons
designmethod
retrospect
chart
review
identifi
patient
institut
sever
polyneuropathi
requir
discontinu
vincristin
demograph
inform
detail
individu
treatment
cours
relat
vincristin
administr
collect
institut
review
board
approv
result
four
children
year
old
diagnos
receiv
treatment
per
dana
farber
cancer
institut
protocol
first
patient
develop
sever
visual
loss
secondari
optic
nerv
atrophi
vocal
cord
dysfunct
inabl
ambul
due
sever
peripher
neuropathi
prompt
discontinu
vincristin
dose
second
patient
develop
sever
constip
inabl
ambul
secondari
peripher
neuropathi
discontinu
vincristin
dose
genet
test
reveal
charcot
mari
tooth
type
patient
develop
inabl
ambul
due
signific
motor
neuropathi
vincristin
discontinu
dose
dose
respect
four
children
improv
symptom
discontinu
vincristin
current
month
therapi
remain
remiss
conclus
sever
vincristin
toxic
result
vision
loss
optic
nerv
atrophi
vocal
cord
dysfunct
constip
inabl
ambul
peripher
motor
neuropathi
requir
remov
agent
standard
treatment
plan
discontinu
vincristin
within
first
year
treatment
subset
patient
result
improv
symptom
continu
remiss
k
k
k
b
univers
medic
colleg
institut
pediatr
depart
clinic
immunolog
krakow
poland
univers
medic
colleg
institut
pediatr
depart
oncolog
krakow
poland
children
hospit
cracow
clinic
immunolog
krakow
poland
backgroundobject
common
childhood
malign
acut
lymphoblast
leukemia
particularli
precursor
leukem
cell
remain
bone
marrow
major
caus
relaps
therefor
state
minim
residu
diseas
monitor
mrd
induct
therapi
consid
strong
predict
factor
treatment
outcom
multicolor
flow
cytometri
mfc
commonli
use
techniqu
monitor
mrd
designmethod
mrd
assess
mfc
patient
diagnos
patient
children
treat
accord
accord
oncolog
hematolog
depart
children
univers
hospit
krakow
level
residu
leukem
cell
qualiti
antigen
express
mean
fluoresc
intens
mfi
assess
leukem
cell
diagnosi
day
day
induct
chemotherapi
achiev
expect
sensit
method
least
nucleat
cell
collect
sampl
qualiti
assess
base
percentag
erythroblast
poor
qualiti
good
qualiti
result
correl
surfac
antigen
express
respons
prednison
therapi
found
mfi
patient
good
prednison
yet
patient
poor
prednison
mfi
leukem
blast
alter
suggest
insensit
chemotherapi
frequent
antigen
shift
seen
express
wherea
stabl
percentag
leukem
cell
day
therapi
neg
correl
earli
clinic
outcom
conclus
studi
show
quantit
mrd
result
import
also
qualit
chang
immunophenotyp
residu
leukem
cell
might
give
addit
clinic
inform
especi
poor
qualiti
sampl
admixtur
peripher
blood
c
cacciotti
u
children
hospit
depart
pediatr
hamilton
canada
backgroundobject
children
cancer
commonli
receiv
red
blood
cell
rbc
transfus
iron
overload
trio
common
complic
signific
iron
burden
document
rbc
transfus
despit
heavi
transfus
studi
evalu
trio
children
cancer
guidelin
screen
exist
designmethod
retrospect
chart
review
observ
studi
perform
evalu
screen
practic
trio
children
year
leukemialymphoma
addit
demograph
data
ferritin
valu
number
rbc
transfus
extract
result
studi
cohort
includ
elig
patient
standard
risk
sr
high
risk
hr
aml
mean
age
diagnosi
year
rang
year
overal
patient
receiv
transfus
median
rang
median
rang
aml
median
rang
transfus
patient
aml
like
receiv
transfus
respect
comparison
ferritin
level
measur
patient
elev
evalu
iron
overload
ferriscan
perform
patient
conclus
iron
burden
routin
evalu
despit
high
number
rbc
transfus
screen
trio
incorpor
routin
practic
children
leukemialymphoma
f
casal
v
l
di
ml
r
di
p
della
campania
lvanvitelli
sun
depart
gener
specialist
surgeri
napl
itali
ii
univers
napl
depart
biolog
napl
itali
cancer
institut
fondazion
pascal
exp
oncolog
napl
itali
backgroundobject
leukem
cell
produc
higher
amount
ro
healthi
cell
express
low
level
antioxid
enzym
catalas
cat
superoxid
dismutas
sod
recent
demonstr
rmnsod
recombin
new
isoform
mnsod
recent
isol
human
liposarcoma
cell
line
abl
trigger
apoptosi
human
cell
without
toxic
effect
healthi
cell
present
studi
aim
verifi
rmnsod
abl
induc
apoptosi
stop
stage
cell
cycl
pediatr
patient
acut
lymphoblast
leukaemia
display
synerg
action
daunorubicin
designmethod
cell
collect
three
patient
diagnos
pediatr
oncolog
univers
luigi
vanvitelli
cell
viabil
apoptosi
cell
cycl
lymphoblast
cell
line
atcc
analyz
muse
kit
rmnsod
treatment
ro
analysi
detect
nac
apoptot
fragment
demonstr
confoc
imag
result
observ
low
concentr
rmnsod
abl
trigger
apoptosi
cell
line
cell
pediatr
patient
detail
observ
apoptosi
rate
pediatr
patient
cell
cell
line
instead
cell
cycl
analysi
show
cell
fraction
decreas
phase
moreov
synerg
activ
rmnsod
daunorubicin
induc
apoptosi
cell
compar
treatment
singl
substanc
rmnsod
daunorubicin
confoc
microscopi
analysi
reveal
intern
rmnsod
cell
evid
apoptot
alter
nuclear
fragment
conclus
conclus
rmnsod
exert
toxic
activ
cancer
cell
enhanc
drug
effect
thu
allow
util
lower
concentr
standard
chemotherapi
increas
apoptosi
level
f
casal
c
h
p
f
di
e
v
della
campania
lvanvitelli
sun
depart
children
gener
special
surgeri
napl
itali
della
campania
lvanvitelli
sun
depart
gener
patholog
napl
itali
backgroundobject
microrna
mirna
involv
differenti
process
variou
hematopoiet
lineag
dysregul
clearli
link
cancer
particularli
leukemia
drug
resist
process
mirna
ortholog
caenorhad
elegan
implic
sever
development
process
neg
regul
mani
protein
pathway
deregul
express
would
impair
human
mous
hematopoiesi
recent
homolog
analyz
result
highli
express
hematopoiet
stem
cell
studi
found
regul
pool
size
confer
competit
advantag
engraft
hematopoiet
cell
mirna
function
dualli
oncogen
gene
depend
cancer
type
cellular
context
aim
studi
analyz
express
correl
biolog
profil
mirna
patient
designmethod
examin
express
level
children
diagnos
treat
pediatr
oncolog
univers
luigi
vanvitelli
two
cell
line
jurkat
mononuclear
cell
isol
bone
marrow
sampl
wherea
biolog
fluid
serum
spit
collect
children
test
express
level
quantit
diagnosi
complet
remiss
day
result
preliminari
data
show
express
sampl
upregul
wherea
express
sampl
downregul
sampl
interestingli
overexpress
sampl
result
high
risk
conclus
data
support
hypothesi
aberr
express
might
contribut
leukemogenesi
overexpress
import
biolog
profil
high
risk
leukem
patient
k
k
p
j
k
derwich
univers
medic
scienc
pediatr
hematolog
transplantolog
poznan
poland
univers
medic
scienc
pediatr
hematolog
student
paediatr
societi
poznan
poland
backgroundobject
aim
studi
retrospect
analysi
advers
event
children
acut
lymphoblast
leukaemia
treat
depart
pediatr
oncolog
haematolog
transplantolog
poznan
poland
designmethod
children
girl
boy
age
med
yr
stratifi
treat
new
york
ny
protocol
respect
accord
ic
bfm
criteria
pt
girl
boy
age
med
yr
classifi
result
among
children
treat
ny
protocol
achiev
sr
hr
pt
treatment
failur
due
therapi
complic
hr
relaps
occur
pt
sr
hr
among
children
treat
ic
bfm
achiev
pt
among
advers
event
relaps
observ
month
diagnosi
med
month
bm
cn
testi
hr
mediastinum
hr
mix
relaps
ir
ir
sr
death
due
earli
sepsi
treatment
complic
relapseprogress
car
accid
conclus
bm
relaps
frequent
children
regardless
protocol
patient
treat
ic
bfm
suffer
isol
cn
mix
relaps
often
death
due
treatment
complic
sr
group
p
k
derwich
j
w
j
e
univers
medic
scienc
pediatr
hematolog
transplantolog
poznan
poland
medic
univers
depart
paediatr
oncolog
haematolog
wroclaw
poland
medic
colleg
depart
paediatr
oncolog
haematolog
cracow
poland
univers
bialystok
depart
paediatr
oncolog
haematolog
bialystok
poland
univers
silesia
depart
haematolog
oncolog
katowic
poland
backgroundobject
although
good
prognosi
children
still
risk
relaps
current
protocol
relaps
treatment
highli
effect
break
resist
therefor
need
altern
therapi
nelarabin
may
caus
signific
benefit
patient
lead
second
remiss
aim
retrospect
analysi
result
achiev
relaps
patient
treat
prepar
ppllsg
designmethod
polish
center
pediatr
oncolog
patient
boy
diagnos
age
year
median
year
relaps
treat
accord
patient
patient
due
resist
protocol
introduc
result
relaps
seen
month
median
mth
diagnosi
first
line
pt
complet
treatment
pt
mth
isol
bone
marrow
bm
mix
relaps
node
nervou
system
due
failur
previou
treatment
pt
second
line
treatment
pt
relaps
allohsct
pt
multipl
relaps
introduc
singl
drug
pt
nectar
pt
pt
pt
pt
cycl
given
signific
advers
effect
toxic
observ
among
pt
achiev
pt
pt
allohsct
perform
anoth
relaps
pt
progress
current
pt
aliv
pt
die
due
progress
infect
toxic
allohsct
conclus
effect
altern
drug
patient
relaps
combin
signific
toxic
dhaliw
g
p
p
n
g
b
p
memori
hospit
hematopatholog
mumbai
india
memori
hospit
pediatr
oncolog
mumbai
india
backgroundobject
minim
residu
diseas
mrd
wide
use
monitor
even
treatment
modif
henc
methodolog
mrd
assess
need
accur
fast
sensit
afford
previou
studi
shown
base
mrd
reach
beyond
sensit
present
studi
high
sensit
cost
effect
assay
designmethod
studi
case
pediatr
year
bcpall
regist
protocol
modifi
mrd
monitor
bm
sampl
pi
pc
subsequ
sfu
use
singl
tube
assay
mrd
defin
cluster
event
minimum
two
immunophenotyp
abnorm
result
studi
pediatr
year
bcpall
case
high
sensit
monitor
high
number
event
acquir
rang
mrd
sampl
sfu
sampl
mrd
posit
median
mrd
level
rang
categor
posit
mrd
result
sampl
mrd
respect
furthermor
sampl
million
result
compar
initi
event
versu
event
acquir
eighteen
sampl
turn
initi
eleven
initi
sinc
highlight
import
acquisit
million
cell
increas
sensit
assay
conclus
establish
singl
tube
assay
high
sensit
applic
mrd
sampl
studi
show
acquisit
event
million
cell
reduc
sensit
assay
significantli
n
dhingra
n
p
hp
r
india
institut
medic
scienc
hematolog
new
delhi
india
backgroundobject
adolesc
acut
lymphoblast
leukemia
distinct
pediatr
counterpart
term
diseas
biolog
outcom
high
success
rate
pediatr
thu
far
elud
cohort
patient
describ
experi
manag
adolesc
patient
develop
nation
designmethod
medic
record
adolesc
age
year
treat
per
uniform
augment
bfm
protocol
retrospect
review
result
patient
met
inclus
criteria
evalu
median
age
year
ratio
patient
median
present
wbc
count
rang
patient
present
wbc
count
advers
cytogenet
seen
patient
favour
cytogenet
remaind
normal
patient
whose
baselin
cn
statu
avail
cn
cn
cn
traumat
tap
without
blast
earli
treatment
respons
assess
day
bone
marrow
perform
patient
nine
patient
die
induct
refractori
diseas
therapi
omiss
due
infecti
complic
observ
remiss
rate
end
induct
relaps
document
patient
cn
medullari
combin
estim
year
surviv
ci
conclus
adolesc
studi
poor
outcom
increas
preval
featur
male
preponder
phenotyp
elev
present
wbc
count
poor
therapi
respons
day
identifi
ja
digiorg
p
e
e
j
ms
cn
de
prof
dr
jp
garrahan
hematolog
oncolog
ciudad
de
bueno
air
argentina
de
prof
dr
jp
garrahan
immunolog
rheumatolog
ciudad
de
bueno
air
argentina
de
prof
dr
jp
garrahan
cytogenet
ciudad
de
bueno
air
argentina
backgroundobject
minim
residu
diseas
mrd
use
stratif
pediatr
detect
igtcr
rearrang
reliabl
tool
mrd
detect
case
quantif
transcript
use
addit
target
aim
compar
mrd
result
detect
methodolog
evalu
predict
valu
target
prognost
factor
designmethod
total
sampl
patient
analyz
mrd
igtcr
perform
follow
standard
euromrd
recommend
minormajor
transcript
quantif
perform
describ
eac
program
result
quantifi
igtcr
sampl
sampl
avail
analysi
techniqu
correl
coeffici
p
concord
result
method
observ
posit
neg
sampl
howev
sampl
show
mrd
posit
median
case
posit
igtcr
sampl
posit
method
sampl
show
igtcr
valu
median
r
outcom
fourteen
patient
achiev
complet
remiss
cr
two
patient
die
cr
relaps
remain
cr
median
month
observ
relaps
patient
target
group
ccr
patient
found
patient
igtcr
time
point
correl
better
outcom
p
conclus
correl
observ
mrd
method
almost
sampl
posit
neg
igtcr
regard
prognost
valu
mrd
target
igtcr
show
signific
correl
outcom
measur
igtcr
time
significantli
associ
outcom
dinofia
j
r
j
k
e
sp
hospit
philadelphia
depart
divis
oncolog
philadelphia
usa
children
hospit
depart
cancer
blood
disord
center
seattl
usa
hospit
philadelphia
offic
clinic
qualiti
improv
philadelphia
usa
backgroundobject
patient
newli
diagnos
acut
lymphoblast
leukemia
children
hospit
philadelphia
chop
discharg
day
chemotherapi
mani
stay
week
first
month
therapi
call
induct
goal
qualiti
improv
project
reduc
length
stay
lo
patient
newli
diagnos
less
day
start
chemotherapi
designmethod
clinician
nurs
administr
educ
data
regard
safeti
earlier
discharg
hospit
plan
implement
earlier
discharg
goal
chop
famili
educ
plan
procedur
chemotherapi
side
effect
surveil
manag
usual
take
place
inpati
set
transit
outpati
clinic
lo
follow
administr
first
chemotherapi
measur
addit
averag
number
emerg
depart
ed
visit
inpati
intens
care
unit
icu
admiss
telephon
call
parent
sick
visit
oncolog
clinic
within
induct
cours
collect
ensur
metric
rise
follow
implement
new
practic
result
mean
lo
follow
administr
first
dose
chemotherapi
reduc
day
month
prior
intervent
implement
day
month
intervent
introduc
chang
averag
number
ed
visit
inpati
icu
admiss
telephon
call
parent
sick
visit
oncolog
clinic
induct
follow
patient
initi
discharg
conclus
feasibl
safe
discharg
newli
diagnos
patient
hospit
within
day
initi
treatment
ehsani
h
e
univers
medic
scienc
pediatr
hematolog
oncolog
tehran
iran
univers
medic
scienc
pediatrpharmacoeconom
pharmaceut
administration
hematolog
oncolog
tehran
iran
chariti
hospit
pediatr
oncolog
tehran
iran
backgroundobject
health
system
adopt
financ
enhanc
access
care
patient
cancer
cost
treatment
blur
imag
hospit
third
parti
payer
cost
compon
care
analyz
differenti
justifi
cost
act
wast
full
practic
studi
direct
indirect
cost
base
unit
kingdom
protocol
pediatr
manag
iran
designmethod
retrospect
studi
design
use
studi
children
manag
ukal
protocol
special
pediatr
hospit
data
collect
patient
medic
record
msonorm
border
none
health
system
adopt
financ
enhanc
access
care
patient
cancer
cost
treatment
blur
imag
hospit
third
parti
payer
cost
compon
care
analyz
differenti
justifi
cost
act
wast
full
practic
aim
studi
direct
indirect
cost
base
unit
kingdom
protocol
pediatr
manag
iran
result
total
direct
medic
cost
per
patient
us
dollar
cost
inpati
bed
usd
drug
expenditur
usd
direct
cost
incur
studi
particip
usd
total
indirect
cost
due
product
loss
conclus
treatment
pediatr
less
costli
iran
compar
countri
physician
polici
maker
health
care
system
administr
devis
appropri
strategi
reduc
direct
medic
cost
econom
burden
special
hospit
day
chemotherapi
cost
base
find
e
x
xingdi
hu
p
medic
oncolog
cambridg
usa
analyt
statist
gheor
cambridg
usa
global
heor
oncolog
cambridg
usa
backgroundobject
variou
protocol
exist
treatment
acut
lymphoblast
leukemia
adolesc
young
adult
aya
age
year
evid
suggest
protocol
includ
asparaginas
part
chemotherapi
regimen
associ
better
outcom
convent
adult
regimen
hyperfraction
cyclophosphamid
vincristin
doxorubicin
dexamethason
evid
regard
protocol
versu
aya
patient
limit
object
studi
estim
protocol
versu
treatment
aya
patient
us
payer
perspect
designmethod
markov
model
develop
estim
overal
surviv
cost
life
year
qali
lifetim
horizon
model
health
state
first
complet
remiss
first
complet
remiss
first
relaps
second
complet
remiss
second
relaps
death
model
input
surviv
advers
event
health
util
cost
obtain
publish
sourc
measur
increment
ratio
icer
increment
costsqali
gain
determinist
probabilist
sensit
analys
perform
evalu
uncertainti
around
model
input
valu
result
analysi
suggest
protocol
result
increas
qali
reduc
cost
qali
gain
cost
save
compar
protocol
sensit
analysi
indic
probabl
receiv
stem
cell
transplant
second
complet
remiss
key
driver
threshold
probabl
protocol
rel
conclus
protocol
compar
treatment
aya
patient
cost
barrier
use
protocol
aya
patient
refer
ram
r
et
al
j
hematol
e
hopper
medic
oncolog
cambridg
usa
global
clinic
develop
lead
shire
cambridg
usa
global
franchis
medic
lead
hematolog
tumor
switzerland
backgroundobject
pegyl
pegaspargas
foundat
compon
combin
therapi
acut
lymphoblast
leukemia
compar
nativ
asparaginas
offer
sustain
asparaginas
activ
less
frequent
dose
reduc
immunogen
object
assess
compar
clinic
benefit
vs
newli
diagnos
pediatr
patient
regard
event
free
surviv
ef
overal
surviv
os
designmethod
systemat
literatur
review
undertaken
identifi
avail
evid
newli
diagnos
patient
treat
pediatr
protocol
use
nativ
asp
random
observ
studi
includ
outcom
ef
os
safetyimmunogen
also
examin
pool
estim
calcul
patient
risk
level
result
total
studi
met
criteria
abstract
use
use
nativ
asp
patient
treat
nativ
asp
ef
confid
interv
ci
vs
ci
os
ci
vs
ci
favor
patient
ef
ci
vs
ci
os
ci
vs
ci
nativ
asp
respect
safeti
consist
product
class
asparaginas
conclus
result
assess
support
favor
efficaci
profil
vs
nativ
asp
treatment
newli
diagnos
pediatr
patient
benefit
less
frequent
administr
safeti
consist
known
class
profil
n
garcia
de
basqu
countri
upvehu
physic
anthropolog
anim
physiolog
leioa
spain
hospit
donostia
pediatr
donostia
spain
health
research
institut
pediatr
barakaldo
spain
hospit
la
paz
oncohaematolog
madrid
spain
hospit
miguel
servet
pediatr
zaragoza
spain
hospit
cruce
pediatr
barakaldo
spain
backgroundobject
recent
sever
genom
wide
associ
studi
gwa
found
genet
variant
associ
pediatr
acut
lymphoblast
leukemia
risk
studi
mainli
focus
code
region
nowaday
known
signific
variant
associ
cancer
risk
situat
region
rna
locat
microrna
mirna
rna
molecul
dysregul
suggest
role
risk
despit
mirna
snp
interfer
mirna
level
function
studi
suscept
done
show
signific
result
therefor
variant
mirna
could
contribut
childhood
predisposit
nowaday
larg
number
new
mirna
annot
therefor
aim
studi
determin
snp
new
mirna
involv
suscept
designmethod
blood
sampl
pediatr
patient
complet
remiss
healthi
control
spanish
origin
analyz
select
snp
describ
maf
snp
mirna
veracod
goldeng
platform
use
mirwalk
rnafold
web
server
consensu
path
databas
use
perform
bioinformat
analysi
result
snp
associ
risk
possibl
effect
mapk
signal
pathway
conclus
therefor
studi
found
associ
risk
snp
could
novel
marker
suscept
project
support
upvehu
ufi
basqu
govern
jl
garcia
nacion
de
enfermedad
pediatr
oncolog
lima
peru
backgroundobject
know
use
clofarabin
regimen
refractoryrelaps
leukemia
patient
set
find
best
scenario
use
designmethod
retrospect
review
medic
chart
pediatr
patient
year
old
refractoryrelaps
acut
leukemia
clinic
data
laboratori
result
bone
marrow
result
minim
residu
diseas
mrd
flow
cytometri
studi
record
result
thirti
three
cours
clofarabin
regimen
administr
patient
refractoryrelaps
acut
leukemia
acut
lymphoblast
leukemia
clofarabin
cyclofosfamid
etoposid
cce
combin
use
patient
one
patient
first
relaps
achiev
complet
remiss
cr
neg
mrd
patient
second
relaps
evalu
patient
cr
one
neg
mrd
test
done
four
patient
third
relaps
none
cr
one
patient
fourth
relaps
cr
posit
mrd
seven
patient
refractori
diseas
one
cr
posit
mrd
relaps
patient
cr
achiev
one
neg
mrd
cce
regimen
use
patient
mrd
posit
diseas
neg
mrd
achiev
patient
went
bone
marrow
transplant
bmt
therapi
sever
hematolog
toxic
seen
cours
given
follow
febril
neutropenia
hepat
toxic
patient
dead
chemotherapi
conclus
cce
regimen
use
mrd
posit
diseas
achiev
good
rate
negativ
diseas
give
option
bmt
therapi
g
giagnuolo
f
g
mr
g
g
r
hospit
pediatr
napoli
itali
backgroundobject
outcom
relapsedrefractori
acut
lymphoblast
leukemia
childhood
still
poor
current
chemotherapi
regimen
associ
signific
toxic
scanti
respons
recent
physician
attent
direct
toward
altern
drug
differ
mechan
action
compar
standard
chemotherapi
inotuzumab
ozogamicin
monoclon
antibodi
conjug
toxin
calecheamicin
complex
receptor
rapidli
intern
intracellular
calicheamicin
releas
calicheamicin
bind
dna
induc
cleavag
apoptosi
herein
describ
case
young
girl
hypodiploid
relaps
second
time
allogen
bone
marrow
transplant
bmt
sinc
patient
earli
relaps
month
bmt
resist
previou
chemotherapi
opt
immunotherapi
inotuzumab
bridg
second
allogen
bmt
designmethod
drug
administ
monotherapi
dosag
mgmqcours
given
weekli
time
everi
day
patient
obtain
hematolog
remiss
first
cours
minim
residu
diseas
mrd
neg
second
third
cours
administ
haploident
transplant
result
treatment
inotuzumab
well
toler
patient
show
grade
iv
hematolog
toxic
first
cours
grade
hepatotox
subsequ
cycl
transplant
vod
prophylaxi
defibrotid
administ
transplant
toxic
report
engraft
occur
day
mrd
neg
document
day
unfortun
month
second
transplant
patient
relaps
conclus
good
toxic
profil
efficaci
mrd
suggest
larger
use
inotuzumab
possibl
combin
chemotherapi
biolog
drug
bmt
associ
could
allow
surviv
patient
relapsedrefractori
studi
need
evalu
optim
use
inotuzumab
improv
cure
rate
patient
b
gupta
n
g
georg
medic
univers
pediatr
lucknow
india
backgroundobject
chemotherapi
interrupt
mainten
phase
may
lead
relaps
henc
avoidablein
present
studi
role
parvoviru
infect
caus
chemotherapi
interrupt
evalu
designmethod
cohort
children
mainten
phase
chemotherapi
evalu
cycl
month
month
igm
igg
pcr
done
parvoviru
infect
episod
cytopenia
requir
chemotherapi
interrupt
result
total
patient
new
entrant
studi
alreadi
variou
phase
patient
found
parvoviru
posit
pcr
variou
phase
mainten
chemotherapi
test
ground
clinic
suspicion
parvoviru
posit
patient
requir
multipl
blood
tranfus
wherea
amongst
parvoviru
neg
patient
requir
multipl
tranfus
p
mainten
phase
patient
episod
neutropenia
patient
parvoviru
one
twenti
two
cycl
mainten
phase
observ
delay
day
parvoviru
found
posit
cycl
p
conclus
parvoviru
infect
emerg
import
caus
cytopenia
lead
chemotherapi
interrupt
mainten
phase
chemotherapi
screen
patient
pcr
case
unexplain
cytopenia
recommend
n
gupta
n
p
hp
r
india
institut
medic
scienc
hematolog
new
delhi
india
backgroundobject
infecti
morbid
mortal
major
concern
patient
hematolog
malign
invas
fungal
infect
ifi
induct
chemotherapi
acut
lymphoblast
leukemia
advers
impact
outcom
experi
fungal
infect
children
adolesc
induct
tertiari
care
centr
north
india
discuss
designmethod
record
patient
age
year
underw
induct
institut
retrospect
review
patient
primari
prophylaxi
fluconazol
incid
characterist
ifi
identifi
assess
therapi
delay
interrupt
group
impact
ifi
outcom
result
patient
evid
ifi
baselin
induct
chemotherapi
per
standard
definit
patient
possibl
probabl
proven
fungal
infect
respect
posit
galactomannan
antigen
document
aspergillu
speci
isol
proven
case
common
site
infect
lung
follow
patient
involv
cutan
aspergillosi
therapi
omiss
interrupt
induct
occur
case
induct
mortal
attribut
progress
fungal
infect
case
median
durat
follow
patient
achiev
remiss
month
rang
month
six
patient
earli
relaps
die
conclus
high
incid
fungal
infect
particularli
invas
aspergillosi
observ
invas
fungal
infect
induct
lead
morbid
mortal
patient
contribut
therapi
interrupt
would
influenc
long
term
outcom
r
vianna
jtdsd
mf
vdn
ec
csd
rh
aldm
ff
ca
fn
nacion
de
pediatr
surgeri
rio
de
janeiro
brazil
backgroundobject
evalu
follow
complic
long
term
cathet
implant
pediatr
oncolog
patient
subclavian
vein
punctur
arm
porttunnel
cathet
insert
techniqu
designmethod
sinc
long
term
central
venou
cathet
year
insert
pediatr
oncolog
patient
arm
first
choic
site
insert
dissect
basilica
brachial
axillar
vein
venou
access
sinc
punctur
subclavian
vein
use
first
option
venou
access
case
util
reservoirtunnel
cathet
posit
arm
retrospect
review
cathet
implant
pediatr
oncolog
patient
children
rang
month
year
old
median
year
old
complic
infect
thrombosi
ruptur
compar
techniqu
result
long
term
cathet
insert
total
implant
tunnel
cathet
case
identifi
dissect
arm
vein
subclavian
punction
jugular
punction
case
nt
identifi
caus
cathet
remov
infect
thrombosi
obstruct
ruptur
exterior
other
infect
rate
port
cathet
dissect
techniqu
subclavian
punctur
tunnel
cathet
dissect
techniqu
subclavian
punctur
jugular
punctur
trombosi
rate
port
cathet
dissect
techniqu
tunnel
cathet
dissect
techniqu
conclus
use
arm
place
reservoirtunnel
cathet
wide
use
sinc
provid
safe
comfort
good
qualiti
life
oncolog
treatment
children
use
subclavian
vein
punctur
venou
access
arm
reservoirtunnel
cathet
insert
shown
good
choic
without
major
complic
literatur
compar
result
j
p
r
lindgren
children
karolinska
pediatr
oncolog
stockholm
sweden
univers
hospit
paediatr
oncolog
helsinki
finland
univers
hospit
paediatr
oncolog
kuopio
finland
univers
hospit
paediatr
adolesc
oulu
finland
univers
hospit
univers
oulu
pedego
research
unit
depart
paediatr
adolesc
oulu
finland
backgroundobject
folin
acid
fa
need
administr
methotrex
order
rescu
normal
cell
toxic
low
fa
dose
associ
increas
toxic
includ
neurotox
wherea
high
dose
may
relat
decreas
antileukem
effect
protocol
use
finland
includ
fa
given
everi
hour
hour
hdmtx
continu
serum
mtx
concentr
extend
alkalin
prehydr
hour
use
one
two
dose
given
patient
rapid
clearanc
mtx
studi
associ
low
dose
fa
sever
clinic
toxic
especi
neurotoxici
designmethod
patient
file
children
male
mean
age
diagnosi
year
standard
intermedi
risk
acut
lymphoblast
leukaemia
treat
protocol
two
finnish
center
review
data
clearanc
fa
dose
clinic
toxic
special
focu
neurotox
collect
analys
result
patient
receiv
total
cours
cours
ci
one
two
dose
fa
administ
singl
dose
given
cours
ci
none
patient
clinic
neurotox
magnet
reson
imag
brain
perform
end
treatment
patient
leukoencephalopathi
detect
small
mm
bilater
high
signal
intens
lesion
frontal
area
detect
one
patient
low
fa
dose
associ
sever
clinic
toxic
steadi
state
mtx
concentr
age
gender
patient
conclus
singl
dose
fa
hdmtx
seem
suffici
prevent
neurotox
children
receiv
extend
alkalin
prehydr
rapid
clearanc
mtx
hassan
n
abdel
zagazig
pediatr
zagazig
egypt
zagazig
clinic
patholog
zagazig
egypt
backgroundobject
dna
repair
system
crucial
role
maintain
genom
integr
stabil
defect
repair
pathway
may
promot
develop
cancer
includ
leukemia
current
research
activ
focus
polymorph
dna
repair
gene
import
compon
suscept
cancer
among
repair
group
gene
polymorph
report
induc
defect
function
capac
dna
polymeras
parp
ligas
iii
enzym
result
defect
dna
repair
aim
assess
whether
gene
polymorph
contribut
develop
childhood
evalu
prognost
signific
regard
induct
remiss
relationship
pretreat
risk
factor
designmethod
case
control
studi
carri
clinic
patholog
pediatr
oncolog
depart
zagazig
univers
egypt
period
march
februari
nineti
subject
includ
children
age
sex
match
healthi
children
control
grouppati
subject
complet
histori
take
thorough
clinic
examin
routin
laboratori
investig
accord
local
standard
genotyp
gene
polymorph
perform
studi
particip
use
polymeras
chain
reaction
restrict
fragment
length
polymorph
result
signific
differ
patient
control
regard
differ
genotyp
apart
signific
associ
arg
gln
gln
gln
genotyp
common
immunophenotyp
signific
differ
among
genotyp
relat
demograph
clinic
laboratori
data
patient
well
remiss
rate
conclus
relat
gene
polymorph
risk
develop
children
apart
signific
associ
certain
genotyp
common
immunophenotyp
gene
polymorph
prognost
signific
childhood
larger
studi
still
need
support
find
r
garrot
r
herraiz
cristob
e
urbaneja
pino
p
fj
h
universitario
valladolid
servicio
de
valladolid
spain
universitario
valladolid
de
valladolid
spain
universitario
valladolid
de
valladolid
spain
universitario
valladolid
jefe
servicio
de
cuidado
intensivo
valladolid
spain
gener
de
salud
junta
de
castilla
servicio
de
salud
valladolid
spain
universitario
valladolid
jefe
de
servicio
de
valladolid
spain
backgroundobject
analyz
differ
urban
rural
children
popul
incid
surviv
children
year
old
diagnos
leukemia
region
spain
period
designmethod
leukemia
case
extract
registri
childhood
tumor
popul
base
annual
mean
childhood
popul
children
year
old
case
classifi
age
sex
leukemia
incid
adjust
age
world
popul
asrw
ci
differ
standard
rate
surviv
analysi
includ
case
surviv
rate
calcul
analysi
comparison
test
rural
popul
consid
one
habit
result
leukemia
diagnos
could
identifi
ruralurban
popul
rural
urban
leukemia
incid
significantli
greater
rural
area
asrw
vs
incid
analysi
age
show
greater
significantli
rural
leukemia
incid
year
old
children
asrw
vs
p
global
surviv
mean
year
quartil
urban
leukemia
surviv
significantli
less
rural
vs
surviv
differ
sex
year
old
children
rural
urban
popul
year
old
group
femal
surviv
greater
rural
area
year
old
group
surviv
greater
male
rural
area
conclus
found
higher
incid
childhood
leukemia
rural
area
due
increas
incid
year
old
children
surviv
greater
rural
area
children
older
year
diagnosi
differ
incid
surviv
could
help
investig
epigenet
environment
factor
childhood
leukemia
hirabayashi
n
k
k
k
h
n
j
luke
intern
hospit
depart
pediatr
tokyo
japan
tokyo
depart
pediatr
tokyo
japan
center
child
health
develop
children
cancer
center
tokyo
japan
univers
ryukyu
center
bone
marrow
transplant
okinawa
japan
luke
intern
univers
institut
medic
innov
tokyo
japan
school
kyoto
univers
depart
patholog
tumor
biolog
kyoto
japan
medic
univers
tokyo
laboratori
dna
inform
human
genom
center
tokyo
japan
center
child
health
develop
depart
pediatr
hematolog
oncolog
research
tokyo
japan
backgroundobject
somat
mosaic
mutat
gene
encod
isocitr
dehydrogenas
caus
maffucci
syndrom
rare
nonhereditari
disord
patient
develop
multipl
enchondroma
combin
hemangioma
although
malign
transform
enchondroma
chondrosarcoma
secondari
neoplasm
brain
tumor
acut
myeloid
leukemia
seriou
complic
report
acut
lymphoblast
leukemia
secondari
neoplasm
limit
designmethod
studi
present
girl
maffucci
syndrom
develop
precursor
bcp
secondari
neoplasm
mutat
leukem
cell
relaps
hemanigoma
screen
sanger
sequenc
addit
whole
exom
sequenc
snp
array
done
leukem
cell
relaps
result
girl
diagnos
maffucci
syndrom
short
right
arm
hemangioma
infant
age
year
fever
anemia
sever
pain
system
bodi
bone
marrow
examin
reveal
necrot
bone
marrow
chondromatosi
sever
anemia
month
later
diagnos
receiv
chemotherapi
howev
relaps
age
year
month
cessat
mainten
therapi
mutat
analysi
reveal
leukem
cell
relaps
somat
mutat
encod
detect
hemangioma
leukem
cell
kra
mutat
encod
delet
detect
leukem
cell
conclus
patient
maffucci
syndrom
might
risk
associ
secondari
genet
event
affect
lymphocyt
differenti
observ
suggest
secondari
mutat
may
account
develop
patient
maffucci
syndrom
prospect
registr
patient
suspect
genet
predisposit
mandatori
identifi
mechan
leukemogenesi
variat
penetr
cy
jamal
mb
sheikh
mujib
medic
univers
paediatr
haematolog
oncolog
dhaka
bangladesh
backgroundobject
acut
lymphoblast
leukemia
commonest
malign
childhood
common
obstacl
treatment
febril
neutropenia
complic
identifi
bacteria
caus
infect
isol
rate
antibacteri
sensit
pattern
hospit
febril
neutropen
children
differ
cycl
chemotherapi
designmethod
cross
section
studi
conduct
depart
paediatr
haematolog
oncolog
bsmmu
dhaka
bangladesh
sixti
febril
neutropen
episod
diagnos
case
age
year
includ
complet
blood
count
blood
cultur
urin
microscopi
cultur
serum
alanin
aminotransferas
serum
creatinin
done
everi
patient
chest
stool
microscopi
cultur
pu
wound
throat
aural
swab
cultur
sensit
done
select
patient
result
bacteri
infect
confirm
cultur
episod
febril
neutropen
episod
fifteen
organ
isol
studi
subject
sampl
blood
pu
aural
swab
wound
swab
throat
swab
respect
isol
gram
neg
organ
isol
klebsiella
spp
e
coli
acinetobact
pseudomona
one
enterobact
speci
isol
klebsiella
spp
ecoli
acinetobact
spp
resist
amoxicillin
isol
ecoli
resist
cotrimoxazol
ceftazidim
ceftriaxon
cefotaxim
ciprofloxacin
acinetobact
spp
isol
sensit
imipenem
colistin
sulphat
resist
cotrimoxazol
cephradin
pseudomona
spp
show
sensiv
imipenem
amikacin
ciprofloxacin
colistin
resistant
ceftazidim
conclus
speci
klebsiella
predomin
caus
bacteri
agent
follow
escherichia
coli
acinetobact
spp
pseudomona
spp
enterobact
spp
show
resist
commonli
prescrib
antibiot
ceftazidim
gentamicin
ceftriaxon
ciprofloxacin
sensit
imipenem
k
katsibardi
k
g
n
h
n
sophia
children
hospit
pediatr
hematolog
oncolog
athen
greec
sophia
children
hospit
orthopaed
unit
athen
greec
backgroundobject
bone
abnorm
low
bone
miner
densiti
osteoporosi
bone
fractur
frequent
occur
children
chemotherapi
acut
lymphoblast
leukemia
pathogenesi
seem
multifactori
due
chemotherapeut
agent
leukem
process
designmethod
children
diagnos
evalu
regard
occurr
bone
abnorm
within
period
januari
decemb
sever
bone
abnorm
defin
signific
bone
pain
associ
activ
restrict
signific
loss
bone
miner
result
object
osteoporosi
orand
bone
fractur
result
period
children
diagnos
girl
median
age
year
rang
year
among
twelv
experienc
bone
abnorm
bone
pain
activ
restrict
gait
disturb
observ
eight
patient
half
diagnosi
mainten
four
patient
experienc
bone
fractur
two
diagnosi
one
reinduct
one
mainten
osteoporosi
document
two
patient
mainten
four
patient
girl
boy
six
ten
thirteen
fifteen
year
old
develop
asept
necrosi
femor
head
sever
limp
patient
treat
conserv
arthroplasti
perform
patient
mainten
complet
four
children
receiv
zoledron
acid
median
number
dose
month
median
durat
symptom
improv
slowli
resolv
end
treatment
bone
miner
densiti
measur
dual
energi
absorptiometri
dexa
return
level
median
period
seven
month
conclus
document
high
incid
bone
diseas
children
bisphosphon
therapi
zoledron
acid
seem
decreas
skelet
pain
increas
bone
densiti
earli
recognit
patient
risk
time
applic
adequ
prevent
therapeut
measur
essenti
prevent
debilit
complic
patient
khera
p
n
pediatr
chandigarh
india
lab
hematolog
chandigarh
india
hematolog
chandigarh
india
backgroundobject
toxic
relat
singl
nucleotid
polymorph
snp
gene
code
metabol
enzym
thiopurin
tpmt
analysi
recommend
prior
mainten
therapi
acut
lymphoblast
leukemia
howev
inosin
triphosph
pyrophosphatas
itpa
nucleosid
motif
snp
appear
import
asian
popul
designmethod
prospect
mendelian
randomis
studi
consecut
patient
jan
jun
enter
mainten
phase
evalu
tpmt
itpa
pcr
rflp
haematolog
hepat
toxic
monitor
monthsth
two
group
without
snp
mutat
mut
compar
result
sixti
three
patient
year
underw
molecular
analysi
fifti
eight
follow
month
eighteen
patient
snp
mutat
itpa
nudt
tpmt
mutat
one
patient
c
itpa
mutat
except
itpa
heterozyg
mean
cumul
dose
lower
mut
compar
group
neutropen
event
greater
mut
week
full
dose
mp
lower
mut
versu
risk
neutropenia
week
pronounc
ci
week
chemotherapi
greater
mut
group
versu
itpa
nudt
snp
subgroup
similar
cumul
dose
chemotherapi
interrupt
differ
averag
cumul
dose
methotrex
group
malnourish
correl
dose
signific
hepatotox
note
conclus
polymorph
metabol
enzym
notabl
relat
ethnic
ancestri
tpmt
snp
appear
signific
role
popul
itpa
nudt
polymorph
appear
import
snp
north
indian
popul
optim
chemotherapi
dose
mk
kim
mr
j
sm
jw
cj
cancer
yonsei
univers
health
system
depart
pediatr
seoul
republ
korea
backgroundobject
signal
pathway
acut
leukemia
aberrantli
activ
caus
leukemogenesi
relaps
treatment
upregul
pathway
common
hyperact
ra
strongli
associ
treatment
resist
leukemia
small
molecul
therapi
open
new
window
cancer
treatment
target
one
subject
may
limit
bind
directli
rg
domain
axin
enhanc
destruct
complex
activ
result
degrad
ra
current
studi
effect
acut
leukemia
studi
leukem
cell
human
msc
hbmsc
designmethod
leukem
cell
jurka
cultur
media
variou
concentr
microm
erlotinib
microm
comparison
cell
prolifer
assay
done
immunoblot
check
compar
monocultur
hbmsc
downstream
target
wnt
pathway
met
studi
immunoblot
result
suppress
leukem
cell
evid
start
concentr
microm
downregul
cell
line
downregul
downstream
target
evalu
downregul
monocultur
evid
concentr
hbmsc
show
similar
pattern
monocultur
hbmsc
affect
conclus
preclin
studi
suggest
may
option
patient
acut
leukemia
especi
experi
relaps
effect
destabil
ra
acut
leukemia
differ
effect
concentr
may
mean
need
studi
leukemia
cell
line
effect
crosstalk
need
research
nat
chem
biol
kindli
provid
choi
hh
koo
yt
yj
hj
mw
ds
kw
kh
medic
center
pediatr
seoul
republ
korea
nation
univers
colleg
medicin
pediatr
busan
republ
korea
backgroundobject
although
mani
studi
tri
clarifi
cellular
interact
human
mesenchym
stem
cell
msc
cancer
cell
vitro
model
role
msc
growth
tumor
cell
vivo
still
fulli
understood
studi
examin
effect
naiv
msc
interferon
ifn
msc
growth
acut
lymphoblast
leukemia
cell
vivo
model
designmethod
establish
four
distinct
stabl
cell
line
express
firefli
luciferas
fluci
gene
infect
lentiviru
jurkat
cell
measur
luciferas
activ
use
ivi
optic
imag
techniqu
determin
effect
msc
leukem
mass
format
result
allfluci
cell
togeth
msc
inocul
nodscid
mice
intraperiton
ip
injectionmuch
higher
luciferas
activ
observ
allfluci
cell
msc
compar
allfluci
cell
inocul
alon
addit
allfluci
cell
differ
number
msc
ratio
mice
although
bioluminesc
intens
gradual
increas
group
mice
msc
show
higher
bioluminesc
intens
lower
number
msc
indic
possibl
msc
play
import
role
stimul
leukem
prolifer
determin
effect
prime
growth
leukem
cell
msc
allfluci
cell
togeth
msc
inocul
nodscid
mice
via
ip
inject
lower
luciferas
activ
observ
allfluci
cell
msc
compar
allfluci
cell
naiv
msc
conclus
result
suggest
prime
may
activ
msc
potenti
effect
studi
need
elucid
precis
role
msc
microenviron
leukemia
cell
kumar
g
n
b
georg
medic
univers
pediatr
oncolog
lucknow
india
backgroundobject
children
philadelphia
chromosom
posit
ph
acut
lymphoblast
leukemia
consid
poor
prognosi
high
risk
featur
studi
conduct
evalu
frequenc
demograph
outcom
induct
chemotherapi
patient
resourc
constraint
set
designmethod
among
children
regist
januari
june
flowcytometri
transloc
could
done
demograph
data
ph
patient
compar
patient
outcom
ph
patient
compar
b
cell
similar
high
risk
treatment
protocol
ph
patient
addit
receiv
imatinib
mesyl
soon
diagnosi
confirm
statist
analysi
done
fischer
exact
test
outcom
kaplan
meyer
curv
surviv
analysi
result
patient
ph
differ
demonstr
age
sex
ph
median
age
year
male
respect
median
tlc
present
significantli
higher
ph
compar
phneg
patient
vs
respect
p
significantli
higher
proport
ph
patient
cn
leukemia
compar
phneg
patient
p
though
induct
death
higher
ph
patient
compar
high
risk
patient
reach
statist
signific
p
post
induct
show
remiss
ph
compar
high
risk
patient
conclus
children
ph
significantli
higher
tlc
cn
diseas
present
compar
patient
induct
death
failur
reach
remiss
induct
higher
ph
compar
high
risk
despit
similar
treatment
protocol
addit
imatinib
mesyl
lvc
marqu
e
p
f
g
e
g
phop
programa
de
hematologia
oncologia
pediatrica
rio
de
janeiro
brazil
backgroundobject
adhes
glycoprotein
wide
expressend
hematopoiet
cell
murin
acut
lymphoblast
leukemia
model
express
associ
organ
infiltr
influenc
surviv
also
identifi
direct
transcript
target
well
target
ra
pathway
promot
altern
splice
throughout
posit
feedback
loop
investig
whether
cellular
express
differ
matur
subtyp
pediatr
could
predict
ra
mutat
designmethod
test
seri
patient
childhood
leukemia
acut
myeloid
leukemia
aml
less
year
age
evalu
immunophenotyp
profil
multiparamet
flow
cytometri
use
sanger
sequenc
detect
mutat
codon
nkra
express
evalu
median
fluoresc
intens
mfi
leukem
blast
cell
patient
percentil
mfi
valu
use
cutoff
high
low
express
result
associ
high
express
organomegali
express
among
subtyp
aml
case
higher
express
p
signific
differ
express
mut
case
wild
type
wt
nkra
mut
case
nkra
wt
wherea
aml
nkra
mut
case
lower
express
nkra
wt
case
conclus
cellular
statu
relev
tumor
profil
express
associ
subtyp
express
compar
aml
nkra
mutat
seem
associ
differ
express
pediatr
aml
p
mogensen
hospit
copenhagen
dept
metabol
diabet
dept
pediatr
oncolog
research
copehagen
denmark
background
object
background
survivor
childhood
acut
lymphoblast
leukemia
threefold
risk
develop
type
diabet
probabl
caus
intens
chemotherapi
includ
corticosteroid
howev
unknown
per
se
contribut
earli
dysmetabol
manifest
studi
undertook
determin
glycem
lipid
profil
time
diagnosi
onset
therapi
design
method
materi
method
patient
median
age
year
rang
year
male
diagnos
univers
hospit
rigshospitalet
denmark
sinc
fast
blood
sampl
collect
time
diagnosi
onset
therapi
lipid
analys
perform
retrospect
blood
sampl
collect
sinc
fast
plasma
glucos
fast
plasma
insulin
measur
prospect
subgroup
insulin
resist
calcul
base
fast
glucos
insulin
result
preliminari
result
preliminari
data
baselin
show
median
quartil
valu
bmi
cholesterol
mmoll
hdl
mmoll
ldl
mmoll
triglycerid
mmoll
median
fast
glucos
insulin
mmoll
mmoll
insulin
resist
conclus
seem
influenc
metabol
paramet
includ
lipid
profil
start
therapi
current
correl
analysi
ongo
order
understand
mechan
behind
find
je
montoya
vasquez
nacion
de
enfermedad
paediatr
oncolog
lima
peru
backgroundobject
children
syndrom
ds
increas
risk
develop
acut
leukemia
children
without
syndrom
usual
type
patient
develop
toxic
sever
infecti
toxic
death
aim
studi
examin
overal
surviv
os
surviv
df
year
children
ds
acut
lymphoblast
leukemia
designmethod
januari
decemb
infant
children
younger
year
ds
diagnos
treat
instituto
nacion
de
enfermedad
inen
retrospect
review
medic
chart
evalu
demograph
clinic
characterist
treatment
outcom
descript
data
os
df
analyz
use
stata
statist
softwar
estim
surviv
rate
method
analyz
result
test
cox
proport
hazard
model
result
median
follow
time
month
rang
os
df
standard
error
se
se
respect
univari
analysi
younger
age
year
risk
group
significantli
associ
lower
os
df
rate
multivari
analysi
show
younger
age
independ
predict
factor
os
df
group
patient
wors
outcom
term
df
conclus
studi
younger
age
children
ds
poor
treatment
outcom
effort
need
improv
surviv
patient
mudaliar
b
j
wadia
hospit
pediatr
mumbai
india
backgroundobject
incid
histolog
distribut
malign
infant
much
differ
older
children
studi
done
establish
incid
type
malign
infant
refer
tertiari
care
centr
report
chang
observ
last
three
decad
designmethod
data
retriev
referr
record
maintain
oncolog
depart
analys
compar
assess
incid
type
malign
present
infant
result
period
total
children
refer
infant
includ
neonat
sampl
male
femal
neuroblastoma
sacrococcyg
teratoma
hepatoblastoma
wilm
tumor
leukaemia
major
referr
span
year
represent
percentag
infant
first
second
third
decad
major
case
sacrococyg
tumour
neuroblastoma
leukaemia
respect
commonest
referr
three
decad
ratio
solid
leukaemia
respect
three
decad
case
refer
hemangioendothelioma
fibrosarcoma
hamartoma
infantil
myofibromatosi
mesoblast
nephroma
retinoblastoma
medulloblastoma
atrt
rare
malign
infant
like
cml
pancreatoblastoma
case
diagnos
adrenocort
cancer
ovarian
granulos
cell
tumor
conclus
three
decad
progress
increas
number
case
refer
malign
children
proport
infant
childhood
adolesc
malign
remain
last
decad
embryon
tumor
like
neuroblastoma
nephroblastoma
retinoblastoma
hepatoblastoma
preval
infanc
earli
onset
predominantli
embryon
natur
suggest
origin
possibl
genet
factor
last
two
decad
incid
leukaemia
show
increas
infanc
compar
solid
tumour
may
due
increas
awarenessearli
referr
hh
myint
g
p
p
b
sd
memori
tata
memori
centr
pediatr
oncolog
mumbai
india
memori
centr
patholog
mumbai
india
backgroundobject
mix
phenotyp
acut
leukemia
mpal
account
acut
leukemia
age
group
poor
prognosi
current
avail
treatment
modal
studi
evalu
profil
outcom
rare
subset
pediatr
leukemia
designmethod
record
children
acut
leukemia
review
criteria
mpal
patient
treat
uniformli
modifi
protocol
includ
cytarabin
age
cranial
radiat
age
data
collect
subject
descript
analysi
tool
result
among
children
acut
leukemia
mpal
median
age
diagnosi
year
f
ratio
median
wbc
ldh
elev
case
median
bulki
diseas
bmyeloid
commonest
case
follow
tmyeloid
bt
lymphoid
abnorm
cytogenet
detect
bmyeloid
case
rearrang
nineteen
patient
evalu
outcom
treat
elsewher
refus
treatment
opt
oral
palli
chemotherapi
seventeen
underw
bone
marrow
achiev
morpholog
remiss
fourteen
patient
mrd
statu
avail
neg
remain
anoth
becam
neg
remark
case
sustain
remiss
last
none
underw
bone
marrow
transplant
project
overal
surviv
progress
free
surviv
median
month
conclus
mpal
repres
less
childhood
acut
leukemia
bmyeloid
commonest
outcom
remain
poor
without
transplant
relapserefractori
diseas
chemotherapi
incorpor
cytarabin
block
effect
achiev
defin
respons
rate
evalu
patient
correl
better
outcom
naseer
p
k
c
v
jerbai
wadia
hospit
children
depart
pediatr
mumbai
india
backgroundobject
febril
neutropenia
fn
pediatr
oncolog
emerg
common
organ
bacteria
fungu
rare
viru
tropic
countri
like
india
particularli
raini
season
lethal
dengu
viru
common
organ
complic
fn
manag
dengu
fever
df
fn
differ
convent
manag
earli
diagnosi
warrant
clinic
profil
outcom
patient
fn
df
pediatr
malign
tertiari
care
center
analyz
designmethod
case
fn
children
leukemia
admit
tertiari
care
center
august
till
decemb
analyz
diagnosi
df
sever
df
fn
base
guidelin
clinic
profil
outcom
patient
analyz
result
patient
fn
unit
df
sever
df
fever
present
febril
seizur
one
patient
typic
rash
present
third
space
fluid
accumul
patient
averag
durat
hospit
stay
day
compar
fn
patient
two
patient
requir
picu
stay
ionotrop
support
recov
mortal
thrombocytopenia
present
patient
mean
platelet
count
abnorm
liver
function
seen
dengu
ag
posit
mean
durat
diagnosi
day
dengu
igm
elisa
posit
patient
conclus
earli
diagnosi
df
fn
import
treatment
focus
fluid
resuscit
monitor
rather
antibiot
reduc
mean
durat
hospit
stay
henc
high
index
suspicion
df
requir
fn
patient
avoid
life
threaten
complic
strategi
prevent
mosquito
bite
need
implement
reduc
morbid
associ
df
children
fn
endem
area
k
k
w
pediatr
jagiellonian
univers
medic
colleg
depart
oncolog
hematolog
krakow
poland
pediatr
jagiellonian
univers
medic
colleg
depart
clinic
immunolog
transplantolog
krakow
poland
backgroundobject
monitor
minim
residu
diseas
mrd
induct
treatment
current
recogn
import
prognost
factor
acut
lymphoblast
leukemia
achiev
mrd
day
induct
assess
multicolor
flow
cytometri
mfc
power
predictor
surviv
patient
assess
mrd
time
point
also
crucial
howev
identif
low
amount
residu
cell
usual
disturb
excess
regener
bone
marrow
hypoplasia
main
goal
studi
verifi
use
monoclon
antibodi
panel
appli
studi
flow
cytometri
defin
aberr
phenotyp
profil
blast
designmethod
prospect
studi
use
flow
cytometri
sinc
sinc
flow
cytometri
sinc
detect
mrd
two
hundr
forti
one
children
boy
girl
treat
accord
protocol
patient
respect
enrol
studi
analysi
mrd
perform
day
day
induct
chemotherapi
consolid
day
well
end
therapi
sensit
detect
time
point
least
cell
result
patient
suitabl
assess
leukem
blast
suggest
effici
mrd
detect
two
week
end
mainten
chemotherapi
optim
time
reliabl
assess
mrd
conclus
result
show
even
limit
panel
antibodi
use
studi
allow
defin
leukem
phenotyp
monitor
level
mrd
set
time
point
despit
chang
express
antigen
treatment
f
punzo
c
e
v
e
f
f
degli
studi
della
campania
luigi
vanvitelli
depart
child
gener
specialist
surgeri
napoli
itali
degli
studi
della
campania
luigi
vanvitelli
depart
experiment
divis
pharmacolog
napoli
itali
backgroundobject
endocannabinoidendovanilloid
ecev
system
propos
possibl
target
treat
sever
malign
includ
lymphoblast
diseas
ecev
system
compos
two
coupl
receptor
transient
potenti
vanilloid
channel
endogen
exogen
ligand
enzym
express
mainli
central
nervou
system
predominantli
immun
peripher
cell
investig
role
ecev
system
acut
lymphoblast
leukemia
designmethod
cultur
primari
lymphoblast
children
jurkatt
cell
line
treat
select
agonist
agonist
rtx
measur
apoptosi
treatment
rtx
hour
perform
citofluorimetr
annexin
v
assay
evalu
express
level
target
gene
caspas
pcr
western
blot
result
observ
effect
treatment
stimul
vanilloid
receptor
caus
depend
increas
apoptosi
effect
strike
hour
treatment
decreas
time
moreov
mrna
protein
level
increas
hour
exposur
concentr
primari
lymphoblast
cell
cultur
jurkatt
cell
line
conclus
conclus
observ
effect
induc
ecev
compound
target
gene
primari
lymphoblast
obtain
patient
jurkatt
cell
line
result
show
stimul
activ
increas
apoptosi
vitro
indic
new
therapeut
approach
might
possibl
modul
endocannabinoidendovanilloid
system
cd
quisp
e
j
c
e
c
sanchez
la
n
p
de
prof
dr
juan
p
garrahan
hematolog
oncolog
bueno
air
argentina
de
prof
dr
juan
p
garrahan
genet
bueno
air
argentina
de
prof
dr
juan
p
garrahan
immunolog
rheumatolog
bueno
air
argentina
backgroundobject
abnorm
frequent
acut
myeloid
leukemia
aml
myelodysplasia
howev
usual
detect
acut
lymphoblast
leukemia
monosomytot
associ
advers
outcom
aml
prognost
signific
clearli
defin
analyz
clinicalbiolog
characterist
outcom
patient
compar
prognost
valu
aml
designmethod
aml
patient
admit
detect
aml
patient
evalu
clinicalbiolog
featur
outcom
pef
estim
compar
result
differ
observ
age
wbc
count
compar
aml
vs
uniqu
abnorm
detect
aml
case
divid
group
chromosom
complet
remiss
cr
achiev
aml
case
die
earli
present
null
respons
achiev
cr
relaps
die
cr
remain
cr
regard
achiev
cr
die
earli
patient
present
null
respons
patient
achiev
cr
relaps
die
cr
remain
cr
pef
aml
vs
aml
without
abnorm
case
pef
se
without
abnorm
pef
se
patient
alon
compar
case
chromosom
vs
chromosom
pef
se
respect
conclus
confer
signific
inferior
outcom
aml
patient
influenc
surviv
probabl
howev
patient
achiev
signific
better
surviv
rate
hypodiploid
plu
case
aa
rahman
f
csh
cy
fateha
sheikh
mujib
medic
univers
pediatr
hematolog
oncolog
dhaka
bangladesh
institut
cancer
research
hospit
paediatr
oncolog
dhaka
bangladesh
sheikh
mujib
medic
univers
depart
dermatolog
dhaka
bangladesh
backgroundobject
viral
infect
recogn
problem
children
standard
chemotherapi
acut
lymphoblast
leukemia
cytomegaloviru
cmv
import
caus
morbid
mortal
immunocompromis
individu
data
regard
incid
manifest
cmv
diseas
pediatr
patient
scanti
cytomegaloviru
retin
cmvr
rare
report
children
receiv
hematopoiet
stem
cell
transplant
hsct
quit
rare
mainten
phase
therapi
herein
report
case
bilater
cytomegaloviru
retin
children
mainten
phase
therapi
highlight
import
eye
examin
care
patient
diagnos
acut
lymphoblast
leukemia
designmethod
period
januari
decemb
found
three
case
cmv
retin
children
depart
refer
ophthalmologist
reduc
vision
cmvr
diagnos
presenc
characterist
lesion
fundoscopi
immunocompromis
state
confirm
ophthalmologist
posit
cmv
dna
blood
sampl
result
identifi
total
three
male
children
cmvr
one
year
period
age
rang
yr
underli
caus
immunocompromis
chemotherapi
leukemia
identifi
cmvr
mainten
phase
therapi
three
children
neutropen
period
day
month
get
treatment
febril
neutropenia
cytomegaloviru
retin
bilater
three
children
discontinu
immunosuppress
medic
administr
anticytomegaloviru
drug
led
regress
activ
retin
later
children
die
within
month
diagnos
cytomegaloviru
retin
remain
one
child
aliv
improv
vision
conclus
present
case
suggest
pediatr
patient
mainten
phase
may
immunosuppress
immedi
ophthalmolog
examin
cmv
test
warrant
case
disturb
visual
acuiti
j
ranasingh
w
l
k
ridgeway
hospit
children
gener
paediatr
colombo
sri
lanka
cancer
institut
pediatr
clinic
oncolog
maharagama
sri
lanka
backgroundobject
acut
lymphoblast
leukemia
common
childhood
malign
account
childhood
cancer
newli
diagnos
patient
acut
leukemia
incid
vari
children
male
predomin
object
evalu
present
featur
time
durat
diagnos
children
present
nation
cancer
institut
nci
sri
lanka
designmethod
retrospect
cross
section
studi
carri
paediatr
nci
patient
less
year
confirm
data
collect
use
interview
administ
questionnair
health
record
result
total
children
includ
male
age
rang
month
year
major
b
cd
surfac
antigen
detect
none
detect
other
cd
patient
diagnos
within
first
day
three
patient
took
month
longest
time
taken
month
steroid
treatment
frequent
common
symptom
intermitt
fever
complain
patient
common
symptom
neck
lump
joint
pain
myalgia
loss
appetit
lethargi
respiratori
tract
infect
rash
acut
gastroenter
abdomin
mass
ecchymosi
limp
investig
anaemia
headach
gener
lymphadenopathi
chest
pain
etc
patient
white
cell
count
leucocytosi
platelet
count
thrombocytosi
haemoglobin
howev
find
statist
signific
conclus
patient
diagnos
within
first
day
common
symptom
intermitt
fever
complaint
patient
ruckert
lg
jj
vs
paulo
depart
genet
preto
brazil
medic
center
groningen
experiment
hematolog
groningen
netherland
paulo
depart
pediatr
preto
brazil
backgroundobject
acut
lymphoid
leukemia
common
childhood
malign
philadelphia
chromosom
ph
present
childhood
case
ph
posit
leukemia
express
tyrosin
kinas
respons
constitut
activ
ra
pathway
mediat
leukem
cell
prolifer
even
high
cure
rate
lot
patient
develop
resist
treatment
relaps
previous
publish
data
suggest
associ
hyperactiv
ra
pathway
favor
treatment
outcom
point
new
research
approach
particip
neg
feedback
mechan
control
activ
activ
thu
assum
loss
would
lead
increas
activ
therefor
hyperactiv
ra
pathway
object
evalu
impact
knockdown
leukem
cell
line
designmethod
chronic
myeloid
leukemia
cml
acut
myeloid
leukemia
aml
cell
line
transduc
lentivir
particl
gene
knockdown
flow
cytometri
qpcr
western
blot
apoptosi
assay
perform
result
knockdown
cell
show
decreas
prolifer
show
increas
apoptosi
level
correl
signific
upregul
p
howev
increas
seen
show
chang
apoptosi
express
despit
increas
regard
aml
cell
show
increas
express
p
besid
disadvantag
growth
show
downregul
increas
suggest
hyperactiv
ra
pathway
might
protect
effect
opposit
behavior
reveal
interest
path
involv
cell
line
opposit
metabol
pattern
reli
oxid
phosphoryl
glycolyt
cell
conclus
result
suggest
might
play
role
metabol
imbal
leukem
cell
studi
necessari
investig
correl
financi
support
fapesp
process
lbp
rdp
e
vk
lg
ca
scride
preto
school
medicin
univers
paulo
pediatr
preto
brazil
backgroundobject
gene
delet
associ
wors
prognosi
children
acut
lymphoblast
leukemia
detect
made
labori
expens
techniqu
make
difficult
perform
treatment
center
especi
develop
countri
studi
analyz
presenc
delet
gene
children
simplifi
techniqu
evalu
associ
prognosi
designmethod
analyz
consecut
bm
sampl
obtain
children
treat
accord
brazilian
treatment
protocol
median
month
cdna
use
routin
transloc
studi
amplifi
use
pair
primer
flank
exon
gene
product
obtain
electrophores
agaros
gel
associ
delet
surviv
ef
assess
kaplan
meier
curv
multivari
analysi
cox
regress
model
result
delet
gene
observ
sampl
none
ten
year
ef
versu
p
group
without
delet
respect
rel
risk
unfavor
event
ci
presenc
delet
multivari
analysi
show
delet
independ
prognost
factor
p
analyz
associ
age
number
wbc
diagnosi
conclus
present
studi
suggest
use
simplifi
low
cost
delet
analysi
techniqu
capabl
detect
patient
higher
risk
relaps
may
use
stratif
patient
b
lineag
futur
treatment
protocol
larger
multicentr
studi
necessari
confirm
result
g
k
univers
silesia
upper
silesia
centr
child
health
depart
chemotherapi
katowic
poland
backgroundobject
angiogenesi
process
essenti
growth
develop
human
tissu
vegf
key
role
angiogenesi
stimulationth
purpos
studi
assess
angiogenesi
children
acut
lymphoblast
leukemia
base
serum
vegf
level
determin
diagnosi
remiss
day
subject
subdivis
differ
risk
group
designmethod
forti
children
age
newli
diagnos
treat
accord
allic
protocol
enrol
studi
classifi
group
irg
hrg
control
healthi
children
vegf
serum
concentr
determin
diagnosi
day
treatment
result
baselin
serum
level
vegf
determin
entir
studi
group
healthi
control
median
vegf
serum
level
pgml
studi
patient
compar
one
control
pgml
compar
one
control
pgml
median
valu
serum
vegf
diagnosi
compar
srg
control
group
significantli
higher
irg
hrg
compar
control
group
remiss
median
serum
vegf
level
significantli
higher
studi
group
compar
control
median
serum
vegf
level
group
srg
significantli
higher
remiss
median
valu
serum
vegf
day
higher
group
irg
hrg
without
statist
signif
conclus
signific
higher
level
serum
vegf
children
comparison
healthi
control
diagnosi
remiss
could
suggest
intensif
angiogenesi
bone
marrow
diagnosi
tendenc
higher
serum
vegf
level
group
less
satisfi
prognosi
suggest
need
studi
sosothikul
n
k
p
p
king
chulalongkorn
memori
hospit
depart
pediatr
bangkok
thailand
backgroundobject
thromboembol
seriou
complic
associ
morbid
childhood
acut
lymphoblast
leukemia
risk
thrombot
complic
childhood
rang
wide
worldwideto
studi
preval
risk
factor
thrombosi
childhood
designmethod
retrospect
descript
studi
patient
thrombosi
children
diagnos
king
chulalongkorn
memori
hospit
thailand
result
preval
thrombosi
case
childhood
twelv
patient
diagnos
thromboembol
male
femal
age
rang
year
median
year
thromboembol
event
occur
induct
phase
chemotherapi
patient
high
risk
high
risk
like
develop
thromboembol
event
clinic
manifest
thrombosi
event
cerebr
thrombosi
follow
deep
vein
thrombosi
risk
factor
thrombot
event
administr
asparaginas
follow
indwel
central
line
older
children
age
year
higher
risk
develop
cerebr
thrombosi
manag
thrombot
event
heparin
mgkgdose
twice
day
month
switch
warfarin
risk
factor
resolv
doppler
ultrasound
comput
tomographi
magnet
reson
imag
method
use
thrombosi
detect
follow
resolv
median
time
resolv
cerebr
thrombosi
deep
vein
thrombosi
month
respect
transfus
fresh
frozen
plasma
start
asparaginas
treatment
current
recommend
prevent
recurr
thrombot
event
conclus
preval
thrombosi
childhood
quit
high
especi
older
children
interfer
treatment
plan
thrombosi
among
childhood
often
observ
patient
receiv
asparaginas
central
line
insert
prevent
strategi
group
patient
consid
e
g
e
ea
n
e
stiakaki
univers
hospit
heraklion
pediatr
heraklion
crete
greec
backgroundobject
circul
endotheli
progenitor
cell
cepc
play
signific
role
mainten
vascular
integr
balanc
mechan
regul
leukocyt
traffick
addit
patient
underw
chemotherapi
increas
incid
hypertens
obes
nevertheless
numer
studi
shown
neg
correl
cepc
obes
underlin
poor
vascular
repair
object
studi
cepc
childhood
survivor
acut
lymphoblast
leukemia
solid
tumor
st
investig
level
correl
patient
bodi
mass
index
bmi
blood
pressur
bp
designmethod
four
colour
flow
cytometri
perform
determin
subpopul
cepc
peripher
blood
children
st
children
without
malign
control
group
bmi
bp
patient
calcul
percentil
establish
specif
age
gender
result
patient
characterist
level
cepc
show
signific
differ
time
post
treatment
solid
tumor
level
cepc
year
significantli
higher
follow
year
correl
bmi
cepc
st
group
show
statist
signific
differ
overweightobes
survivor
studi
bp
statu
st
signific
differ
conclus
level
cepc
increas
year
treatment
solid
tumor
find
need
investig
relat
metabol
factor
childhood
cancer
survivor
p
subramanian
p
g
n
g
b
memori
centr
hematopatholog
laboratori
mumbai
india
memori
centr
medic
oncolog
mumbai
india
backgroundobject
investig
valu
assess
minim
residu
diseas
mrd
bone
marrow
flow
cytometri
fc
childhood
cell
acut
lymphoblast
leukemia
studi
relev
minim
residu
diseas
mrd
evalu
group
show
late
mrd
respons
determin
overal
ef
use
larger
studi
cog
brent
wood
et
al
ash
show
relev
predict
ef
designmethod
studi
mrd
bone
marrow
sampl
children
age
year
treat
use
modifi
protocol
etpal
immunophenotyp
patient
receiv
dexamethason
place
prednisolon
mrd
perform
use
assay
navio
flow
cytomet
analysi
perform
kaluza
softwar
beckman
coulter
result
median
age
patient
year
rang
initi
immunophenotyp
etpal
patient
posit
median
level
rang
posit
significantli
high
etpal
compar
vs
median
patient
month
month
patient
categoris
mrd
neg
neg
mrd
posit
posit
level
thu
categor
twenti
patient
relaps
six
die
etpal
within
month
median
ef
patient
significantli
inferior
compar
month
vs
reach
vs
conclus
conclud
posit
predictor
earli
relaps
childhood
l
j
j
j
e
k
w
g
k
g
j
univers
silesia
depart
pediatr
hematolog
oncolog
zabrz
poland
univers
silesia
depart
microbiolog
immunolog
zabrz
poland
univers
warsaw
depart
pediatr
hematolog
oncolog
warsaw
poland
lodz
depart
pediatr
hematolog
diabetolog
lodz
poland
wroclaw
depart
bone
marrow
pediatr
hematolog
oncolog
wroclaw
poland
medic
poznan
depart
pediatr
oncolog
transplantolog
poznan
poland
specialist
pediatr
hospit
olsztyn
poland
gdansk
depart
pediatr
oncolog
endocrinolog
gdansk
poland
univers
silesia
depart
pediatr
katowic
poland
bialystok
depart
pediatr
oncolog
bialystok
poland
medicum
bydgoszcz
depart
pediatr
hematolog
oncolog
bydgoszcz
poland
specialist
pediatr
hospit
kielc
poland
center
pediatr
oncolog
chorzow
poland
medic
univers
depart
hematolog
oncolog
szczecin
poland
lublin
depart
pediatr
hematolog
oncolog
lublin
poland
backgroundobject
small
proport
childhood
acut
lymphoblast
leukemia
leukem
blast
switch
immunophenotyp
toward
monocyt
lineag
aim
studi
determin
frequenc
immunophenotyp
featur
patient
poland
designmethod
studi
group
compris
pediatr
patient
age
year
median
year
treat
accord
protocol
polish
center
bone
marrow
peripher
blood
sampl
stain
diagnosi
follow
monoclon
antibodi
panel
data
analyz
use
infinicyt
softwar
cytogno
sl
spain
facsdiva
bd
bioscienc
usa
result
monocyt
lineag
switch
induct
treatment
observ
patient
usual
associ
high
express
case
weak
partial
express
case
express
case
diagnosi
patient
detect
aberr
monocytoid
cell
follow
weak
express
found
express
patient
decreas
comparison
diagnosi
furthermor
least
partial
express
detect
residu
blast
patient
addit
patient
express
observ
diagnosi
maintain
treatment
final
mrd
level
day
significantli
higher
patient
compar
remain
patient
posit
mrd
level
mrd
median
mrd
level
respect
p
conclus
conclus
rare
subset
case
detect
mainli
induct
treatment
significantli
higher
mrd
level
day
suggest
slower
respons
induct
treatment
patient
investig
follow
need
determin
monocyt
lineag
switch
signific
clinic
valu
tandon
g
b
p
p
memori
centr
paediatr
mumbai
india
memori
centr
haematopatholog
mumbai
india
memori
centr
cytogenet
mumbai
india
backgroundobject
hypodiploidi
constitut
poorer
prognosi
current
avail
therapi
studi
evalu
profil
outcom
cytogenet
mrd
correl
subset
paediatr
designmethod
data
children
hypodiploidi
convent
cytogenet
retrospect
analyz
electron
medic
record
patient
chart
children
treat
differ
institut
protocol
princip
differ
use
cytarabin
cranial
radiat
earlier
era
routin
use
mrd
methotrex
latter
result
b
diagnos
children
studi
period
hypodiploidi
median
age
year
f
median
leukocyt
count
ldh
bulki
diseas
cn
involv
hr
respect
high
low
hypodiploidi
seen
respect
modal
number
mn
near
haploid
normal
cytogenet
cytogenet
trisomi
mll
patient
evalu
outcom
achiev
remiss
fail
induct
children
mrd
posit
becam
neg
post
median
month
project
os
ef
respect
cn
statu
nci
risk
prednisolon
respons
signific
high
low
hypodiploidi
better
outcom
near
haploidi
p
correl
improv
os
ef
p
translat
significantli
improv
os
ef
p
isol
medullari
relaps
commonest
form
treatment
failur
conclus
hypodiploidi
remain
subset
childhood
better
surviv
within
subset
near
haploidi
portend
poor
outcom
c
trehan
institut
medic
educ
research
pediatr
chandigarh
india
backgroundobject
chemotherapi
result
depress
humor
immun
predispos
patient
sever
infect
may
recurr
occasion
life
threaten
studi
evalu
immunoglobulin
level
children
acut
lymphoblast
leukemia
designmethod
observ
prospect
studi
perform
june
octob
children
relaps
diseas
known
underli
immunodefici
state
exclud
immunoglobulin
level
igg
igm
iga
analyz
follow
time
point
patient
diagnosi
ii
end
induct
consolid
therapi
iii
end
delay
intensif
phase
chemotherapi
result
thirti
five
children
mean
age
year
b
precursor
cell
cell
evalu
immunoglobulin
level
diagnosi
normal
age
igg
upper
side
normal
igm
igg
level
decreas
induct
consolid
therapi
igm
declin
lower
limit
normal
age
children
low
igm
level
igg
fall
normal
age
level
fall
intensif
therapi
time
iga
level
alter
forti
percent
children
episod
fn
episod
fn
episod
fn
whilst
children
fn
children
greater
episod
fn
lower
level
immunoglobulin
conclus
chemotherapi
result
alter
immun
profil
igg
igm
level
decreas
initi
chemotherapi
nearli
children
low
igm
level
end
intens
therapi
larger
patient
cohort
would
help
delin
sever
fall
risk
group
patient
need
repeat
evalu
immunoglobulin
profil
therapi
look
recoveri
immun
function
replac
therapi
may
deserv
recommend
patient
recurr
episod
infect
unal
f
univers
medic
school
divis
pediatr
hematolog
ankara
turkey
children
cancer
blood
disord
center
bone
marrow
failur
md
program
boston
turkey
backgroundobject
thrombocytopenia
autosom
domin
thrombocytopenia
recent
identifi
famili
report
leukemia
predisposit
normal
size
autosom
dominantli
inherit
thrombocytopenia
report
patient
designmethod
current
boy
refer
center
diagnosi
acut
lymphoblast
leukemia
year
age
result
previou
histori
reveal
period
diagnosi
immun
thrombocytopenia
itp
preceed
year
past
medic
histori
prior
diagnosi
median
platelet
count
receiv
specif
treatment
itp
famili
histori
reveal
thrombocytopenia
plt
mpv
fl
father
etiolog
identifi
hemogram
admiss
reveal
hgb
gdl
wbc
plt
mcv
fl
mpv
fl
bone
marrow
aspir
reveal
diffus
leukem
infiltr
type
blast
immunephenotyp
calla
posit
cell
cytogenet
reveal
xy
karyotyp
cn
cytolog
neg
st
jude
total
xv
protocol
initi
cessat
treatment
protocol
still
could
achiev
normal
paltelet
count
plt
deb
test
fanconi
anemia
neg
molecular
reveal
mutat
patient
father
conclus
thrombocytopenia
consid
famili
domin
inherit
pattern
patient
follow
leukemia
develop
e
p
l
j
j
e
univers
hospit
depart
pediatr
bratislava
slovak
republ
univers
medic
school
univers
children
hospit
depart
pediatr
oncolog
hematolog
bratislava
slovak
republ
univers
hospit
depart
pediatr
oncolog
hematolog
bystrica
slovak
republ
hospit
kosic
depart
pediatr
hematolog
oncolog
slovak
republ
cancer
institut
depart
clinic
oncolog
bratislava
slovak
republ
univers
univers
hospit
motol
depart
paediatr
haematolog
faculti
medicin
pragu
czech
republ
leukaemia
investig
pragu
clip
pragu
czech
republ
backgroundobject
treatment
childhood
acut
lymphoblast
leukemia
detect
minim
residu
diseas
mrd
signific
determin
patient
outcom
aim
studi
evalu
impact
routin
mrd
test
stratif
criteria
allic
bfm
protocol
designmethod
patient
year
enrol
ic
bfm
protocol
patient
stratifi
standard
srg
intermedi
irg
group
hrg
accord
age
wbc
presenc
hypodiploidi
prednison
respons
bone
marrow
respons
induct
therapi
assess
primarili
morpholog
secondli
flow
cytometri
day
mrd
test
perform
day
week
protocol
first
block
respect
routin
mrd
surviv
evalu
patient
includ
final
patient
mrd
test
determin
result
base
mrd
stratif
criteria
patient
stratifi
hrg
patient
irg
srg
overal
surviv
surviv
rate
death
event
respect
studi
group
determin
mrd
test
day
mrd
posit
statist
significantli
associ
precursor
type
bone
marrow
respons
day
event
accuraci
mrd
neg
significantli
associ
fusion
gene
signific
associ
mrd
test
day
analyz
factor
conclus
result
show
prognost
valu
mrd
detect
predict
event
studi
group
also
confirm
previou
find
treatment
impact
prognosi
children
induct
acknowledg
mz
sr
j
e
j
de
pediatr
oncolog
mexico
citi
mexico
backgroundobject
transloc
rare
chromosom
disord
occur
mainli
acut
myeloid
leukemia
myelodysplast
syndrom
blast
crisi
chronic
myeloid
leukemia
recent
karyotyp
along
gene
found
ewe
sarcoma
observ
type
alter
tl
gene
present
karyotyp
repres
unfavor
prognost
sign
high
resist
chemotherapi
high
percentag
relaps
designmethod
present
first
case
pediatr
patient
acut
lymphoblast
leukemia
relaps
secondari
chromosom
result
femal
type
fab
bone
marrow
show
lymphoblast
leukem
cell
express
tdt
cytogenet
studi
perform
without
show
alter
treatment
given
st
jude
xiii
favor
evolut
week
moment
patient
present
pancytopenia
hemoglobin
g
per
dl
platelet
per
leucocyt
count
per
bone
marrow
show
lymphoblast
immunophenotyp
present
tdt
lambda
express
cytogenet
report
decid
start
treatment
nopho
atedox
complet
remiss
within
first
cycl
chemotherapi
present
hematopoiet
stem
cell
transplant
hsct
program
conclus
case
report
pediatr
patient
first
case
report
abnorm
secondari
find
repres
therapeut
challeng
propos
treat
kind
patient
acut
myeloblast
leukemia
salvag
therapi
hsct
j
de
pediatr
oncolog
mexico
citi
mexico
backgroundobject
posterior
revers
encephalopathi
syndrom
pre
uncommon
side
effect
chemotherapeut
agent
particularli
methotrex
clinic
present
depend
area
brain
hypoperfus
date
standard
treatment
myriad
drug
procedur
propos
purpos
studi
report
experi
treatment
syndrom
patient
acut
lymphoblast
leukemia
designmethod
perform
retrospect
record
review
includ
patient
lla
neurolog
focal
symptom
two
week
methotrex
treatment
regardless
rout
administr
studi
period
octob
decemb
demograph
clinic
characterist
describ
mean
proport
accord
variabl
type
result
review
chart
elig
patient
eight
femal
male
present
pre
averag
age
year
seven
patient
standard
risk
onset
symptom
start
averag
day
intraven
intrathec
methotrex
none
case
simultan
rout
administr
patient
local
ischemia
treat
citicolin
mgkgd
day
seizur
treat
valproat
month
mgkgd
area
brain
edema
treat
dexametason
mgkgd
day
patient
brain
ischemia
without
seizur
treat
hyperbar
oxygen
therapi
five
patient
multipl
simultan
therapi
accord
clinic
imag
characterist
symptom
recoveri
present
day
postreat
averag
none
patient
perman
neurolog
sequela
conclus
accord
find
complet
recoveri
pre
achiev
therapi
start
earli
base
symptom
mri
find
contraind
present
multipl
simultan
therapi
safe
prescrib
n
verma
v
georg
medic
univers
pediatr
lucknow
india
georg
medic
univers
pediatr
lucknow
india
backgroundobject
children
suffer
acut
lymphoblast
leukemia
econom
weaker
section
ew
unabl
reach
apex
cancer
institut
corpor
hospit
treatment
either
treat
govern
medic
center
die
absenc
optim
treatment
dearth
inform
outcom
induct
chemotherapi
group
children
designmethod
data
children
belong
ew
annual
incom
less
usd
treat
govern
hospit
north
india
jan
juli
retrospect
review
children
administ
risk
stratifi
induct
chemotherapi
drug
induct
standard
risk
drug
induct
high
risk
treatment
provid
free
cost
support
govern
ngo
result
total
newli
diagnos
regist
pediatr
oncolog
clinic
kgmu
jan
juli
belong
ew
boy
girl
eleven
children
abandon
treatment
induct
children
took
treatment
per
protocol
diseas
diseas
present
children
undernourish
moder
sever
undernutrit
hypoalbuminemia
complic
induct
chemotherapi
encount
children
lead
treatment
interrupt
day
death
children
caus
death
includ
infect
tumor
lysi
syndrom
bleed
children
complet
induct
chemotherapi
morpholog
remiss
conclus
outcom
induct
children
ew
poor
signific
proport
children
undernourish
despit
provis
free
treatment
abandon
rate
high
risk
complic
death
also
higher
children
j
yadav
r
india
institut
medic
scienc
pediatr
delhi
india
india
institut
medic
scienc
microbiolog
delhi
india
india
institut
medic
scienc
radiolog
delhi
india
backgroundobject
febril
neutropenia
frequent
life
threaten
complic
chemotherapi
among
children
cancer
fungal
infect
emerg
concern
due
improv
surviv
secondari
better
support
care
aggress
chemotherapi
studi
plan
ascertain
preval
predictor
invas
fungal
infect
follow
revis
eortc
criteria
object
ascertain
preval
invas
fungal
infect
ifi
febril
neutropen
episod
children
acut
leukemia
determin
predictor
ifi
identifi
etiolog
fungal
speci
caus
ifi
designmethod
observ
studi
children
year
age
chemotherapi
acut
leukemia
febril
neutropenia
enrol
diagnosi
ifi
base
eortc
criteria
classifi
proven
probabl
possibl
ifi
preval
report
mean
ci
form
etiolog
speci
present
form
frequenc
distribut
result
episod
involv
children
febril
neutropenia
screen
enrol
seventeen
episod
fulfil
eortc
criteria
ifi
give
preval
document
case
classifi
probabl
multivari
analysi
abnorm
cxr
clinic
sinus
found
import
predictor
ifi
common
fungu
isol
aspergillu
sp
follow
candida
sp
aspergillu
candida
speci
commonli
isol
sputum
blood
respect
common
isol
oral
scrap
candida
follow
aspergillu
episod
isol
aspergillu
posit
galactomannan
antigen
test
case
six
blood
cultur
posit
sepsi
conclus
preval
invas
fungal
infect
studi
abnorm
chest
x
ray
clinic
sinus
found
import
predictor
ifi
b
yilmaz
n
g
e
b
univers
pendik
train
research
hospit
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
acut
lymphoblast
leukemia
common
form
cancer
children
account
approxim
pediatr
cancer
surviv
approxim
develop
countri
examin
patient
surviv
rate
caus
mortal
designmethod
total
patient
acut
lymphoblast
leukemia
year
diagnos
includ
studi
patient
secondari
malign
age
children
relaps
diseas
exclud
patient
stratifi
treat
accord
total
xv
studi
protocol
result
mean
durat
month
found
overal
surviv
found
seventeen
patient
lost
follow
unfortun
common
caus
death
complic
patient
see
differ
risk
mortal
among
risk
group
log
rank
standard
risk
better
surviv
two
risk
group
children
cell
leukemia
better
surviv
compar
type
cell
leukemia
although
static
signific
log
rank
p
vs
vs
burkitt
leukemia
conclus
infecti
complic
still
major
caus
death
develop
countri
etc
turkey
treatment
children
patient
die
mainli
infecti
diseas
sepsi
lead
present
differ
success
leukemia
treatment
develop
countri
zakaria
el
h
zagazig
pediatr
zagazig
egypt
zagazig
clinic
patholog
zagazig
egypt
backgroundobject
novel
receptor
vascular
endotheli
growth
factor
vegf
express
endotheli
tumor
cell
promot
prolifer
chemotaxi
leukem
cell
respons
vegf
inhibit
function
may
provid
new
therapeut
strategi
treatment
aim
studi
express
profil
normal
b
lineag
leukem
lymphoblast
prognost
valu
role
minim
residu
diseas
detect
designmethod
prospect
studi
conduct
forti
newli
diagnos
patient
acut
leukemia
femal
mean
age
year
forti
age
sex
match
subject
control
group
express
flow
cytometri
done
diagnosi
end
induct
therapi
result
forti
five
case
posit
express
neg
statist
signific
differ
case
posit
express
regard
clinic
present
morpholog
immunophenotyp
cn
infiltr
statist
signific
differ
regard
relaps
relaps
case
posit
prognosi
case
posit
express
die
posit
signific
correl
cd
age
bone
marrow
blast
cell
ldh
level
signific
correl
wbc
count
hb
level
signific
differ
posit
neg
case
regard
overal
surviv
rate
surviv
month
posit
case
neg
case
high
signific
differ
conclus
high
express
bone
marrow
blast
consid
marker
bad
prognosi
children
could
use
diseas
monitor
acknowledg
author
thank
particip
studi
unstint
cooper
b
k
j
k
n
j
w
univers
lodz
depart
hematolog
diabetolog
lodz
poland
univers
warsaw
depart
hematolog
warsaw
poland
univers
katowic
depart
hematolog
oncolog
zabrz
zabrz
poland
univers
katowic
depart
hematolog
chemotherapi
katowic
poland
univers
wroclaw
depar
bone
marrow
pediatr
oncolog
hematolog
wroclaw
poland
univers
lublin
depart
pediatr
oncolog
transplant
lublin
poland
pediatr
oncolgi
chorzow
depart
pediatr
hematolog
oncolog
chorzow
poland
backgroundobject
asparaginas
crucial
agent
acut
lymphoblast
leukemia
howev
use
limit
due
hypersens
moreov
gener
antibodi
lead
inactiv
drug
without
symptom
allergi
impli
risk
ineffect
treatment
aim
studi
evalu
incid
silent
inactiv
allergi
asparaginas
children
newli
diagnos
designmethod
june
start
systemat
monitor
asparaginas
activ
patient
treat
polish
pediatr
center
current
report
summar
month
studi
durat
present
children
treat
accord
allic
protocol
enrol
studi
case
overt
allergyinsuffici
drug
activ
asparaginas
prepar
changedfro
nativ
ecoli
asparaginas
pegyl
e
coli
asparaginas
subsequ
erwinas
asparaginas
activ
nativ
prepar
use
time
weekli
determin
use
elisa
method
subsequ
dose
pegyl
asparaginas
day
administr
result
total
asparaginas
measur
perform
among
children
prepar
chang
patient
pegyl
asparaginas
patient
subsequ
erwinas
children
treat
nativ
e
coli
asparaginas
children
treat
pegyl
asparaginas
silent
inactiv
found
basi
previou
analyz
indic
import
asparaginas
outcom
state
implement
systemat
monitor
asparaginas
activ
improv
effect
treatment
studi
children
conclus
preliminari
data
analysi
indic
children
exhibit
insuffici
asparaginas
activ
treatment
accord
ic
protocol
despit
lack
clinic
appar
allergi
clinic
relev
studi
import
effect
therapi
advis
continu
studi
achbergerova
j
p
l
e
z
e
univers
hospit
depart
pediatr
hematolog
oncolog
bratislava
slovak
republ
cancer
institut
depart
clinic
oncolog
bratislava
slovak
republ
univers
hospit
depart
pediatr
oncolog
hematolog
banska
bystrica
slovak
republ
univers
hospit
depart
pediatr
oncolog
hematolog
kosic
slovak
republ
backgroundobject
acut
myeloid
leukemia
aml
rel
rare
children
slovak
republ
approxim
new
case
childhood
aml
diagnos
per
year
sought
describ
incid
cytogenet
aberr
associ
aml
evalu
overal
surviv
among
children
adolesc
aml
popul
designmethod
total
children
adolesc
age
year
diagnos
aml
children
treat
accord
aml
bfm
strategi
one
three
slovak
centr
pediatr
hematolog
oncolog
bone
marrow
sampl
analyz
central
laboratori
use
convent
cytogenet
fluoresc
hybrid
fish
molecular
genet
method
retrospect
analysi
base
laboratori
clinic
data
slovak
clinic
cancer
registri
children
adolesc
result
incid
select
cytogenet
aberr
follow
present
inv
mll
rearrang
nine
case
aml
children
syndrom
surviv
ef
overal
surviv
os
rate
cohort
death
event
respect
patient
stratifi
high
risk
group
os
ef
death
event
respect
standard
risk
group
rate
os
death
ef
event
achiev
patient
posit
abbrev
achiev
better
rate
os
ef
contrast
patient
without
genet
chang
conclus
base
result
plan
new
strategi
aim
improv
outcom
children
central
treatment
singl
center
optim
time
stem
cell
transplant
implement
addit
genet
test
aml
bfm
central
laboratori
germani
acknowledg
e
e
ebeid
cancer
institut
pediatr
oncolog
cairo
egypt
cancer
institut
clinic
patholog
cairo
egypt
backgroundobject
acut
myeloid
leukemia
aml
remain
challeng
diseas
develop
countri
identifi
overal
surviv
os
diseas
free
surviv
df
correl
differ
risk
factor
well
demonstr
common
caus
mortal
designmethod
retrospect
descript
studi
includ
newli
diagnos
aml
patient
age
less
year
receiv
treatment
nation
cancer
institut
cairo
univers
egypt
period
januari
till
decemb
factor
includ
age
gender
initi
wbc
cytogenet
cn
statu
antifung
prophylaxi
collect
result
year
df
median
surviv
month
year
os
median
surviv
month
confid
interv
respect
earli
death
seen
patient
mainli
due
infect
late
death
seen
patient
mainli
due
progress
diseas
infect
infect
relat
mortal
irm
repres
mortal
caus
patient
patient
show
pictur
possibl
fungal
pneumonia
patient
induct
chemotherapi
post
first
consolid
post
second
consolid
regard
antifung
prophylaxi
primari
prophylaxi
fluconazol
given
patient
regard
secondari
prophylaxi
patient
receiv
itraconazol
patient
receiv
voriconazol
analysi
data
reveal
statist
signific
correl
df
respons
induct
chemotherapi
p
valu
presenc
chloroma
p
valu
voriconazol
prophylaxi
p
valu
correl
os
statist
signific
respons
induct
chemotherapi
p
associ
favor
cytogenet
inv
p
valu
chloroma
p
valu
voriconazol
prophylaxi
p
valu
conclus
infect
relat
mortal
import
caus
poor
surviv
outcom
studi
popul
result
warrant
use
primari
prophylaxi
pediatr
patient
aml
czogala
k
b
j
r
k
k
k
j
b
w
pediatr
jagiellonian
univers
medic
colleg
depart
pediatr
oncolog
hematolog
poland
pediatr
jagiellonian
univers
medic
colleg
depart
medic
genet
poland
univers
poland
depart
bone
marrow
pediatr
oncolog
hematolog
wroclaw
poland
univers
warsaw
depart
hematolog
oncolog
warsaw
poland
univers
poznan
depart
pediatr
hematolog
transplantolog
poznan
poland
univers
silesia
depart
pediatr
hematolog
oncolog
zabrz
poland
univers
bialystok
depart
pediatr
oncolog
bialystok
poland
univers
lublin
depart
pediatr
hematolog
oncolog
lublin
poland
pediatr
oncolog
center
depart
hematolog
oncolog
chorzow
poland
univers
lodz
depart
hematolog
diabetolog
lodz
poland
medic
univers
depart
hematolog
oncolog
szczecin
poland
children
hospit
depart
hematolog
oncolog
kielc
poland
children
hospit
depart
pediatr
hematolog
oncolog
depart
pediatr
hematolog
oncolog
poland
backgroundobject
acut
promyelocyt
leukemia
apl
character
transloc
compris
childhood
acut
myeloid
leukemia
aim
studi
analysi
treatment
outcom
apl
children
poland
designmethod
patient
genet
confirm
apl
treat
poland
analyz
period
elig
studi
treat
interim
period
period
ii
median
observ
time
month
month
respect
period
ii
patient
period
receiv
standard
chemotherapi
retino
acid
atra
period
ii
two
patient
treat
induct
chemotherapi
atra
arsen
trioxid
ato
one
patient
without
chemotherapi
analyz
surviv
rate
treatment
failur
result
probabl
overal
surviv
os
event
free
surviv
ef
relaps
free
surviv
rf
respect
analyz
patient
four
earli
death
day
diagnosi
caus
sever
coagul
disord
observ
white
blood
cell
count
diagnosi
significantli
higher
children
die
earli
compar
patient
median
rang
vs
one
patient
die
sever
infect
cours
diseas
progress
month
diagnosi
relaps
occur
one
patient
month
first
remiss
patient
die
diseas
progress
event
occur
patient
period
death
year
conclus
treatment
outcom
analyz
group
similar
result
report
studi
group
main
caus
death
coagul
disord
begin
diseas
earli
accur
diagnosi
follow
specif
treatment
enabl
reduc
number
earli
death
eissa
k
si
cancer
pediatr
hematiologyoncolog
cairo
egypt
cancer
flow
cytometri
lab
cairo
egypt
cancer
cytogenet
lab
cairo
egypt
cancer
molecular
genet
lab
cairo
egypt
cancer
clinic
pharmaci
cairo
egypt
cancer
clinic
research
depart
cairo
egypt
backgroundobject
myeloid
leukemia
occur
children
one
year
age
distinct
clinic
biolog
featur
occur
older
children
hyperleukocytosi
diseas
cn
involv
well
mix
lineag
leukemia
gene
rearrang
diagnosi
common
designmethod
retrospect
analysi
clinic
biolog
featur
infant
aml
treat
cancer
center
period
juli
till
decemb
result
total
patient
diagnos
patient
syndrom
exclud
thirti
two
male
femal
male
femal
ratio
mean
age
diagnosi
rang
month
initi
total
leukocyt
count
tlc
rang
mean
diseas
present
patient
nine
patient
cn
diseas
present
monocyt
differenti
present
amegakaryoblast
leukemia
patient
mll
gene
rearrang
present
patient
frequent
found
patient
cytogenet
abnorm
inv
diagnos
less
frequent
patient
respect
patient
inv
morpholog
multipl
trisomi
identifi
patient
patient
experienc
signific
chemotherapi
toxic
requir
icu
admiss
whole
cohort
patient
achiev
complet
remiss
induct
patient
still
aliv
first
complet
remiss
cr
conclus
deal
infant
myeloid
leukemia
real
challeng
especi
countri
limit
resourc
improv
support
care
refin
risk
stratif
identifi
requir
intens
chemotherapi
includ
transplant
requir
improv
outcom
best
surviv
enter
cr
induct
f
gome
andrad
f
vicent
do
santo
sardou
g
dallapicola
e
pereira
e
ms
nacion
de
research
center
rio
de
janeiro
brazil
backgroundobject
deregul
ra
signal
cascad
often
caus
somat
mutat
gene
encod
protein
influenc
activ
pathway
includ
nra
kra
aim
describ
comprehens
mutat
screen
key
exon
gene
cohort
unselect
pediatr
acut
myeloid
leukemia
case
diagnosi
evalu
prognost
valu
probabl
overal
surviv
po
designmethod
hotspot
region
nra
kra
directli
sequenc
screen
mutat
surviv
analysi
perform
subset
patient
treat
follow
guidelin
clinic
trial
result
ra
pathway
mutat
found
studi
cohort
mainli
repres
follow
nra
kra
mutat
rare
among
rearrang
case
rare
observ
concomit
one
gene
two
boy
year
old
present
mutat
nra
kra
respect
die
less
month
diagnosi
cumul
po
exclud
acut
promyelocyt
leukemia
patient
skin
color
consid
white
present
better
outcom
po
respect
well
patient
age
year
old
po
po
mutat
exon
found
overal
analysi
associ
advers
prognosi
identifi
multivari
analysi
independ
prognost
factor
hazard
ratio
confid
interv
conclus
although
need
action
improv
overal
surviv
rate
patient
aberr
like
guid
stratif
may
direct
develop
novel
therapeut
target
therapi
k
viswanathan
n
v
k
mission
hospit
research
centr
pediatr
madurai
india
backgroundobject
pauciti
data
outcom
childhood
aml
india
object
studi
analyz
outcom
childhood
aml
pediatr
cancer
center
establish
compar
outcom
two
differ
treatment
designmethod
review
data
children
consecut
diagnos
includ
apl
one
one
acut
megakaryoblast
leukemia
aml
chloroma
male
femal
median
age
year
rang
first
patient
seen
group
treat
modifi
regimen
next
patient
group
ii
receiv
less
intens
regimen
induct
cytarabin
plu
daunorubicin
reduc
dose
mitoxantron
consolid
nine
receiv
allogen
stem
cell
transplant
sct
first
remiss
two
second
match
sibl
parent
result
one
patient
move
anoth
center
none
abandon
treatment
achiev
complet
remiss
cr
overal
patient
aliv
includ
receiv
sct
patient
chloroma
median
month
rang
estim
overal
surviv
os
refractori
patient
relaps
patient
patient
die
diseas
death
induct
remiss
higher
respect
group
vs
group
ii
statist
signific
estim
os
higher
group
ii
vs
statist
signific
p
conclus
base
regimen
result
excess
mortal
indian
children
aml
use
less
intens
induct
consolid
allogen
stem
cell
transplant
intermedi
patient
like
improv
surviv
jayabos
n
k
mission
hospit
research
centr
pediatr
madurai
india
backgroundobject
myeloid
sarcoma
ms
defin
extramedullari
lesion
acut
myeloblast
leukemia
aml
report
incid
prognost
signific
ms
variabl
data
ms
indian
children
object
studi
review
clinic
featur
children
ms
singl
institut
seen
period
year
designmethod
retrospect
review
data
case
aml
includ
isol
ms
seen
clinic
molecular
featur
detail
treatment
outcom
result
among
consecut
diagnos
case
aml
patient
ms
three
isol
ms
without
aml
exclud
three
aml
ms
median
age
year
rang
male
femal
three
dissemin
ms
involv
two
asymptomat
pelvic
intracrani
lesion
none
leukem
cell
spinal
fluid
seven
patient
cytogenet
done
three
case
isol
ms
ten
patient
receiv
treatment
per
modifi
protocol
one
less
intens
cytarabin
pu
daunorubicin
consolid
cytarabin
one
infant
treat
accord
cog
eleven
patient
dose
intrathec
cytarabin
five
local
radiat
first
remiss
one
second
remiss
two
allogen
stem
cell
transplant
sct
one
second
remiss
eight
patient
aliv
includ
isol
ms
two
sct
median
surviv
patient
month
rang
conclus
ms
occur
approxim
indian
children
aml
frequent
associ
may
associ
occult
asymptomat
dissemin
lesion
prognost
signific
unclear
isol
ms
may
better
prognosi
c
kai
children
hospit
affili
shanghai
jiaotong
univers
hematolog
oncolog
shanghai
china
backgroundobject
investig
clinic
efficaci
prognost
factor
subtyp
children
acut
myeloid
leukemia
aml
designmethod
retrospect
analysi
clinic
data
subtyp
hospit
januari
decemb
carri
efficaci
prognosi
relaps
factor
analyz
result
clinic
data
case
collect
among
case
treat
cours
includ
male
case
femal
case
case
case
median
age
overal
surviv
rate
os
surviv
rate
ef
ef
compar
intern
risk
stratif
ef
singl
factor
analysi
show
extramedullari
infiltr
assess
treatment
prognost
factor
multivari
analysi
show
extramedullari
infiltr
ci
less
cours
hr
ci
independ
risk
factor
affect
surviv
conclus
strengthen
treatment
adequ
cours
key
improv
overal
cur
effect
children
subtyp
extramedullari
infiltr
risk
factor
surviv
recurr
subtyp
advis
children
initi
symptom
molecular
biolog
poor
prognost
factor
choos
hematopoiet
stem
cell
transplant
earli
possibl
mpasa
p
p
colleg
medicin
children
foundat
paediatr
haematolog
oncolog
lilongw
malawi
oncolog
lilongw
malawi
backgroundobject
childhood
acut
myeloid
leukaemia
aml
challeng
treat
low
incom
countri
lic
like
malawi
limit
support
care
resourc
preclud
use
effect
treatment
protocol
use
high
incom
countri
malawi
aml
treat
support
without
chemotherapi
howev
inadequ
blood
product
support
commun
palli
servic
result
poor
symptom
control
particularli
bleed
order
allevi
symptom
diseas
control
use
modifi
chemotherapi
protocol
childhood
aml
herebi
share
experi
use
protocol
kamuzu
central
hospit
designmethod
februari
decemb
children
aml
without
subtyp
treat
modifi
induct
protocol
compris
doxorubicin
day
cytarabin
twice
day
day
ciprofloxacin
itraconazol
use
infect
prophylaxi
diagnosi
aml
establish
assess
bone
marrow
morpholog
data
collect
demograph
baselin
clinic
hematolog
featur
toxic
remiss
statu
surviv
end
induct
result
nine
children
treat
induct
protocol
median
age
year
rang
male
baselin
median
hematolog
paramet
white
cell
count
rang
platelet
rang
neutrophil
rang
haemoglobin
rang
seven
patient
suffer
febril
neutropenia
two
patient
suffer
mucos
median
time
count
recoveri
day
rang
median
durat
admiss
day
rang
evalu
patient
post
induct
overal
surviv
complet
remiss
rate
respect
median
lanski
score
admiss
discharg
rang
rang
respect
conclus
modifi
chemotherapi
regimen
hold
promis
deliver
safe
effect
regimen
control
aml
lic
k
nakashima
k
univers
school
medicin
depart
pediatr
fukuoka
japan
children
cancer
group
aml
committe
tokyo
japan
luke
intern
hospit
depart
pediatr
tokyo
japan
univers
school
medicin
depart
pediatr
osaka
japan
univers
graduat
school
medicin
depart
pediatr
nagoya
japan
univers
school
medicin
depart
pediatr
mie
japan
univers
graduat
school
medicin
depart
pediatr
hirosaki
japan
center
child
health
develop
divis
leukemia
children
cancer
center
tokyo
japan
univers
depart
human
health
scienc
kyoto
japan
univers
medic
scienc
depart
pediatr
shiga
japan
backgroundobject
high
surviv
rate
report
recent
clinic
trial
children
acut
myeloid
leukemia
aml
syndrom
ds
chemotherapi
howev
certain
number
children
complic
congenit
heart
diseas
chd
gastrointestin
anomali
sever
infect
andor
complic
thu
inelig
clinic
trial
designmethod
data
outcom
children
scarc
retrospect
analyz
clinic
characterist
outcom
children
exclud
japanes
clinic
studi
conduct
januari
decemb
jplsg
result
thirteen
children
boy
girl
identifi
inelig
follow
reason
chd
pulmonari
fibrosi
hypox
encephalopathi
rapid
progress
transient
abnorm
myelopoiesi
complic
hemophagocytosi
age
excess
year
diagnosi
median
age
diagnosi
month
rang
month
year
mutat
detect
three
four
screen
case
among
twelv
case
treat
cur
intent
four
case
receiv
chemotherapi
three
sever
chd
fail
achiev
remiss
die
diseas
one
pulmonari
fibrosi
success
achiev
remiss
eventu
die
infecti
complic
eight
case
underw
standard
chemotherapi
six
aliv
remiss
wherea
two
relaps
one
die
diseas
anoth
aliv
diseas
patient
hypox
encephalopathi
receiv
best
support
care
die
diseas
final
six
remain
continu
remiss
one
aliv
diseas
six
die
five
leukemia
one
infect
conclus
optim
dose
intens
cur
chemotherapi
children
harbor
sever
comorbid
explor
v
nemirovchenko
g
state
budgetari
institut
nnblokhin
russian
cancer
research
center
russian
academi
medic
scienc
children
hematolog
moskow
russia
backgroundobject
major
children
acut
myeloid
leukemia
aml
respond
initi
chemotherapi
achiev
complet
remiss
yet
minor
experi
surviv
larg
proport
patient
eventu
relaps
diseas
combin
epigenet
drug
dna
hypomethyl
agent
histon
deacetylas
inhibitor
retino
acid
chemotherapi
may
improv
result
treatment
children
aml
designmethod
report
outcom
children
underw
chemotherapi
de
novo
aml
median
age
year
forti
children
includ
protocol
protocol
protocol
standard
intermedi
high
risk
group
vast
major
high
risk
patient
got
induct
therapi
intensif
consolid
mainten
therapi
protocol
valproic
acid
vpa
acid
atra
ad
chemo
protocol
patient
includ
protocol
receiv
chemotherapi
epigenet
drug
vpa
atra
decitabin
result
number
good
respons
day
therapi
achiev
complet
remiss
patient
induct
protocol
probabl
diseas
free
surviv
median
follow
month
protocol
median
follow
month
median
follow
month
overal
surviv
median
follow
month
protocol
median
follow
month
median
follow
month
conclus
use
drug
therapeut
use
part
combin
therapeut
modal
ruckert
lg
jj
vs
paulo
depart
genet
preto
brazil
medic
center
groningen
experiment
hematolog
groningen
netherland
paulo
depart
pediatr
preto
brazil
backgroundobject
acut
lymphoid
leukemia
common
childhood
malign
philadelphia
chromosom
ph
present
childhood
case
ph
posit
leukemia
express
tyrosin
kinas
respons
constitut
activ
ra
pathway
mediat
leukem
cell
prolifer
even
high
cure
rate
lot
patient
develop
resist
treatment
relaps
previous
publish
data
suggest
associ
hyperactiv
ra
pathway
favor
treatment
outcom
point
new
research
approach
particip
neg
feedback
mechan
control
activ
activ
thu
assum
loss
would
lead
increas
activ
therefor
hyperactiv
ra
pathway
object
evalu
impact
knockdown
human
hematopoiet
stem
cell
kra
mutat
designmethod
cord
blood
cell
transduc
lentivir
particl
gene
knockdown
flow
cytometri
differenti
marker
cfc
assay
perform
result
transduc
kra
show
reduct
growth
compar
one
transduc
shscr
compar
cell
group
present
higher
cumul
growth
cobbleston
area
format
follow
pattern
shown
cumul
growth
sort
week
cultur
cell
differenti
mainli
granulocyt
cell
knockdown
shift
differenti
toward
myelomonocyt
cell
cfc
assay
neither
coloni
format
unit
unit
strongli
affect
knockdown
kra
mutant
cell
sever
impact
format
cell
show
knockdown
well
kra
mutat
sever
impact
type
coloni
format
unit
conclus
result
suggest
impact
human
hematopoiet
stem
cell
differenti
besid
act
togeth
kra
mutat
event
prolifer
coloni
format
capac
financi
support
fapesp
process
yaman
bajin
b
v
f
univers
depart
divis
pediatr
hematolog
ankara
turkey
backgroundobject
chronic
myeloid
leukemia
cml
rare
malign
childhood
compos
pediatr
leukemia
tyrosin
kinas
inhibitor
tki
revolutionaz
cml
treatment
made
possibl
avoid
allogen
stem
cell
transplant
sct
patient
aim
investig
tki
respons
patient
diagnos
cml
depart
designmethod
patient
diagnos
cml
underw
sct
still
sinc
hacettep
univers
depart
pediatr
hematolog
includ
four
patient
underw
sct
period
exclud
clinic
featur
tki
respons
patient
evalu
result
nine
patient
age
diagnos
median
year
year
two
girl
boy
treatment
start
imatinib
case
two
patient
respond
imatinib
major
molecular
respons
mmr
achiev
month
respect
two
patient
diagnos
within
three
month
mr
check
yet
patient
respond
imatinib
therapi
month
sinc
elig
donor
replac
imatinib
dasatinib
therapi
one
patient
achiev
mmr
imatinib
month
develop
leukopenia
imatinib
replac
dasatinib
case
patient
achiev
mmr
dasatinib
except
one
case
dasatinib
replac
nilotinib
mmr
achiev
within
month
nilotinib
treatment
one
patient
need
interrupt
dasatinib
therapi
gastrointestin
bleed
week
interrupt
dasatinib
start
bleed
observ
still
molecular
remiss
conclus
tki
effect
cml
treatment
mmr
could
achiev
chang
drug
advers
event
occur
elig
donor
could
found
sct
option
h
j
j
yang
children
hospit
hematologyoncolog
shanghai
china
backgroundobject
acut
promyelocyt
leukemia
apl
rare
children
due
lack
result
ato
concern
ato
relat
toxic
main
protocol
children
newli
diagnos
apl
still
combin
atra
chemotherapi
studi
demonstr
efficaci
ato
treatment
children
apl
studi
retrospect
analyz
children
newli
diagnos
apl
treat
ato
mulicent
designmethod
evalu
efficaci
children
acut
promyelocyt
leukemia
apl
treat
arsen
trioxid
ato
retrospect
review
newli
diagnos
apl
patient
treat
mainli
acid
atra
ato
hospit
accord
differ
risk
stratif
nccn
patient
separ
group
low
risk
group
high
risk
group
result
overal
patient
achiev
hematolog
complet
remiss
hcr
one
case
patient
fail
enter
hcr
earli
death
median
durat
requir
achiev
hcr
day
rang
day
median
date
achiev
molecular
complet
remiss
day
rang
day
ef
os
patient
respect
ef
low
risk
group
high
risk
group
patient
ato
relat
side
effect
mild
includ
abnorm
liver
test
electrocardiogram
invert
support
therapi
end
chemotherapi
cours
urin
arsen
concentr
remain
low
chronic
arsen
toxic
second
malign
found
period
conclus
atra
plu
ato
regimen
promis
better
treatment
childhood
apl
posit
fusion
gene
necessari
make
risk
stratif
apl
patient
z
afifi
children
hospit
oncolog
salt
lake
citi
usa
backgroundobject
systemat
data
optim
treatment
aya
dlbcl
lack
mani
treat
favor
outcom
howev
pediatr
base
chemotherapi
regimen
yield
equal
superior
result
present
seri
aya
dlbcl
refer
medic
oncologist
children
hospit
consider
treatment
pediatr
protocol
designmethod
retrospect
review
patient
diagnos
dlbcl
age
year
pmbcl
exclud
clinic
characterist
stage
treatment
detail
outcom
data
collect
compar
publish
data
young
adult
year
age
treat
result
six
aya
dlbcl
identifi
five
male
age
diagnosi
rang
year
four
year
old
site
present
bone
abdomen
none
bone
marrow
cn
involv
stage
murphyst
jude
correspond
ann
arbor
stage
six
patient
aliv
lymphoma
free
last
follow
year
median
year
none
receiv
radiat
therapi
patient
treat
per
fablmb
regimen
group
therapi
copad
group
therapi
cop
cumul
chemotherapi
dose
patient
receiv
group
b
therapi
cyclophosphamid
doxorubicin
prednison
vincristin
mg
methotrex
cytarabin
intrathec
chemotherapi
administr
methotrex
cytarabin
hydrocortison
compar
regimen
cours
consist
fold
cumul
dose
cyclophosphamid
hydroxydaunorubicin
vincristin
mg
conclus
aya
dlbcl
pediatr
chemotherapi
regimen
provid
altern
elimin
use
radiat
therapi
provid
lower
cumul
anthracylin
alkyl
dose
pediatr
regimen
may
reduc
risk
long
term
cardiac
second
cancer
effect
e
ataseven
z
b
fb
b
b
h
tepecik
research
train
hospit
pediatr
hematolog
oncolog
izmir
turkey
univers
faculti
medicin
depart
radiat
oncolog
turkey
backgroundobject
childhood
hodgkin
lymphoma
hl
type
cancer
lymphoid
systemaccord
turkish
pediatr
oncolog
group
tpog
statist
lymphoma
common
solid
tumor
childhood
hodgkin
lymphomaswith
current
chemotherapi
radiotherapi
regimen
children
hl
surviv
studi
aim
evalu
clinic
characterist
treatment
outcom
hl
case
treat
institut
designmethod
evalu
record
patient
hl
treat
retrospectivelydemograph
clinic
featur
treatment
result
overal
surviv
os
event
free
surviv
ef
rate
evalu
result
patient
elig
patient
fm
mean
age
yearsmost
common
complaint
lump
neck
b
symptom
present
common
b
symptom
found
feverhistopatholog
diagnosi
reveal
mix
nodular
sclerosisstag
distribut
follow
stage
patient
common
metastat
site
lung
patient
treat
accord
gpoh
protocol
remain
patient
treat
regimen
abvd
moppabvd
mopp
copp
radiotherapi
perform
primari
tumor
site
casesrelaps
occur
patient
treat
moplac
chemotherapyremiss
achiev
patient
die
diseas
patient
refus
treatmentmedian
year
year
ef
os
respectivelybetween
gpoh
abvd
moppabvd
treatment
group
signific
differ
found
surviv
relaps
rate
conclus
result
compar
literatur
seen
common
type
mix
cellular
accord
previou
os
os
increas
surviv
rate
lower
origin
protocolsit
thought
might
due
fact
patient
studi
belong
era
lower
overal
os
ef
barnaba
v
anoky
teach
hospit
cild
health
director
kumasi
ghana
anoky
teach
hospit
child
health
director
kumasi
ghana
background
object
burkett
lymphoma
bl
frequent
subtyp
lymphoma
seen
childhood
africa
bl
highli
aggress
doubl
time
approxim
hour
respond
favor
diagnos
accur
treat
earli
prompt
recognit
initi
therapi
essenti
improv
surviv
studi
seek
review
clinic
present
imag
find
patent
burkett
lymphoma
pediatr
popul
designmethod
retrospect
studi
review
clinic
histopatholog
record
patient
burkett
lymphoma
paediatr
cancer
unit
komfo
anoky
teach
hospit
januari
decemb
result
children
diagnos
male
femal
ratio
median
age
rang
maximum
durat
symptom
week
commonest
symptom
swell
major
site
involv
abdomen
jaw
combin
jaw
abdomen
bodi
site
present
symptom
includ
fever
weight
loss
proptosi
night
sweat
anaemia
difficulti
breath
stage
iii
commonest
stage
seen
present
patient
stage
iv
rarest
stage
whilst
stage
ii
seen
intent
treatment
patient
palliat
patient
cur
intent
conclus
although
burkett
lymphoma
rel
cheap
easi
treat
compar
cancer
patient
present
advanc
diseas
impact
surviv
increas
educ
earli
warn
sign
parent
healthcar
personnel
need
undertaken
reduc
advanc
diseas
present
eissa
cancer
pediatr
hematiologyoncolog
cairo
egypt
cancer
institut
egypt
patholog
depart
cairo
egypt
backgroundobject
follicular
lymphoma
fl
rare
occur
children
pediatr
variant
pfl
recent
includ
updat
classif
lymphoid
malign
patient
usual
present
low
stage
diseas
neg
designmethod
retrospect
analysi
case
diagnos
fl
present
cancer
center
period
juli
decemb
result
period
year
patient
diagnos
fl
cancer
center
patient
male
present
stage
ii
diseas
morpholog
grade
first
case
year
old
male
present
cervic
lymphadenopathi
b
symptom
tumor
posit
neg
receiv
rituximab
immunotherapi
plu
cyclophosphamid
doxorubicin
vincristin
prednison
follow
juli
till
second
case
year
old
male
atyp
lymphoid
hyperplasia
diagnos
year
prior
diagnosi
fl
april
tumor
posit
neg
low
express
receiv
chemotherapi
involv
field
radiotherapi
ifrt
addit
place
follow
sinc
april
third
case
year
old
male
present
bilater
cervic
parotid
lymph
node
enlarg
biopsi
show
posit
reaction
neoplast
cell
diffus
highlight
neoplast
cell
posit
label
index
high
receiv
chemotherapi
current
follow
sinc
june
conclus
patient
pfl
present
center
local
diseas
respond
well
chemotherapi
durabl
complet
remiss
trial
less
intens
chemotherapi
omiss
radiotherapi
inclus
new
agent
bendamustin
rituximab
base
therapi
attempt
minim
late
effect
n
eker
g
b
e
b
univers
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
hodgkin
lymphoma
hl
one
frequent
cancer
adolesc
young
adult
curabl
case
aim
studi
assess
demograph
clinic
data
prognost
factor
result
children
diagnos
hodgkin
lymphoma
follow
center
pediatr
oncolog
marmara
univers
medic
faculti
istanbul
turkey
year
designmethod
children
hl
diagnos
treat
center
retrospect
analyz
result
total
children
mean
age
year
treat
hl
patient
male
femal
among
present
stage
iii
iv
diseas
b
symptom
mix
cellular
type
hl
multiag
chemotherapi
mainstay
treatment
patient
treat
risk
adapt
abvd
adriamycin
bleomycin
vinblastin
dacarbazin
cyclophoshamid
vincristin
procarbazin
prednison
adriamycin
bleomycin
vinblastin
chemotherapi
also
receiv
involv
field
radiotherapi
th
follow
ten
patient
relaps
overal
surviv
rate
respect
stage
treatment
risk
group
presenc
b
symptom
histopatholog
subtyp
signific
effect
overal
surviv
univari
analysi
relaps
diseas
signific
factor
overal
surviv
conclus
hodgkin
lymphoma
cure
chemotherapi
combin
low
dose
ifrt
howev
relaps
diseas
still
signific
factor
overal
surviv
n
b
j
j
medic
center
intern
medicin
pediatr
springfield
usa
medic
center
biostat
epidemiolog
springfield
usa
medic
damour
center
cancer
care
pediatr
springfield
usa
backgroundobject
venou
thromboembol
vte
understudi
pediatr
cancer
patient
studi
evalu
risk
vte
children
cancer
identifi
diagnost
group
designmethod
singl
center
retrospect
cohort
studi
includ
patient
year
old
diagnos
cancer
follow
date
diagnosi
date
vte
age
end
studi
whichev
occur
first
institut
tumor
registri
captur
primari
diagnosi
cancer
secondari
diagnosi
vte
extract
use
icd
code
patient
exclud
care
adult
provid
insuffici
document
inaccur
identifi
patient
diagnos
hl
demograph
treatment
variabl
obtain
manual
chart
review
result
studi
includ
patient
split
group
hl
lymphoma
cancer
vte
diagnos
patient
vte
occur
among
hl
patient
patient
cancer
patient
correspond
hazard
ratio
hl
vs
ci
hl
vs
cancer
ci
patient
hl
develop
vte
major
upper
bodi
vein
median
time
hl
diagnosi
vte
day
day
vte
incid
occur
prior
radiat
within
cohort
patient
hl
vte
receiv
chemotherapi
per
regimen
patient
refractori
hl
proceed
autolog
bone
marrow
transplant
prior
vte
first
line
therapi
hl
patient
hl
vte
neg
famili
histori
thrombophilia
workup
perform
patient
unremark
conclus
cohort
hl
repres
group
vte
larger
cohort
confirm
result
children
may
candid
prophylact
anticoagul
initi
treatment
yj
gao
h
x
j
ag
j
xl
xj
rm
jy
children
medic
center
depart
hematolog
oncolog
shanghai
china
central
south
univers
depart
pediatr
hematolog
oncolog
changsha
china
hospit
shanghai
depart
hematolog
oncolog
shanghai
china
china
second
univers
hospit
sichuan
univers
depart
pediatr
hematolog
oncolog
chengdu
china
medic
univers
cancer
institut
hospit
depart
pediatr
oncolog
tianjin
china
tongji
medic
huazhong
univers
scienc
technolog
depart
pediatr
hematolog
oncolog
wuhan
china
hospit
soochow
univers
depart
hematolog
oncolog
soochow
china
hospit
shandong
univers
depart
pediatr
hematolog
oncolog
jinan
china
hospit
depart
pediatr
hematolog
oncolog
shanghai
china
union
hospit
depart
pediatr
hematolog
oncolog
wuhan
china
backgroundobject
provid
descript
review
improv
understand
clinic
characterist
outcom
pediatr
anaplast
larg
cell
lymphoma
alcl
china
result
serv
baselin
data
guid
futur
therapeut
protocol
develop
designmethod
retrospect
evalu
clinic
characterist
outcom
children
year
newli
alcl
boy
girl
treat
ten
larg
singl
institut
china
januari
june
result
two
patient
stage
diseas
stage
ii
stage
iii
stage
iv
phenotyp
demonstr
predomin
phenotyp
case
patient
treat
regimen
chines
protocol
pediatr
alcl
case
treat
regimen
median
month
rang
month
surviv
ef
patient
ef
patient
without
b
symptom
respect
patient
experienc
diseas
progress
relaps
median
time
initi
diagnosi
tumor
failur
month
rang
month
last
evalu
patient
still
aliv
diseas
progress
relaps
conclus
present
featur
outcom
children
adolesc
alcl
studi
similar
report
countri
establish
therapeut
strategi
improv
surviv
patient
diseas
progress
relaps
prioriti
futur
clinic
studi
k
green
ormond
street
hospit
children
oncolog
london
unit
kingdom
ormond
street
hospit
children
haematolog
london
unit
kingdom
backgroundobject
children
bnhl
good
outcom
intens
upfront
chemotherapi
diseas
relaps
progress
associ
poor
outcom
earli
diseas
assess
escal
chemotherapi
necessari
clear
radiolog
respons
valu
imag
surveil
biopsi
residu
imag
abnorm
detect
prevent
diseas
relapseprogress
unclear
evalu
whether
patient
bnhl
residu
radiolog
abnorm
receiv
imag
biopsi
investig
affect
clinic
outcom
designmethod
retrospect
data
children
diagnos
bnhl
uk
tertiari
paediatr
oncolog
centr
collect
patient
age
diagnosi
gender
histolog
myc
statu
bone
marrow
cn
involv
record
chemotherapi
regim
record
includ
escal
group
b
c
imag
clinic
letter
analys
residu
diseas
categoris
accord
formal
radiolog
report
result
children
age
year
diagnos
bnhl
male
femal
children
bone
marrow
posit
children
cn
posit
children
myc
posit
children
receiv
group
b
treatment
group
c
treatment
children
demonstr
poor
respons
cop
chemotherapi
escal
group
c
end
treatment
children
residu
diseas
children
almost
certainli
residu
diseas
children
abnorm
find
underw
biopsi
exclud
activ
diseas
none
children
undergo
follow
imag
demonstr
diseas
relaps
one
child
die
treatment
without
achiev
remiss
conclus
none
patient
residu
imag
abnorm
treatment
complet
diseas
relaps
progress
question
clinic
need
long
term
imag
particularli
involv
radiat
biopsi
provid
reassur
without
alter
patient
manag
v
gupta
r
tb
sk
medic
banara
hindu
univers
pediatr
varanasi
india
medic
banara
hindu
univers
statist
varanasi
india
medic
banara
hindu
univers
surgeri
varanasi
india
backgroundobject
hodgkin
lymphoma
display
characterist
epidemiolog
clinic
patholog
featur
differ
geograph
area
object
analyz
demograph
profil
diseas
characterist
event
free
surviv
ef
overal
surviv
os
risk
factor
relaps
patient
hodgkin
lymphoma
hl
treat
chemotherapi
protocol
designmethod
retrospect
observ
studi
carri
univers
teach
hospit
children
age
year
diagnos
hodgkin
lymphoma
jan
dec
includ
studi
result
patient
mean
age
year
median
age
year
rang
year
diagnos
treat
hl
studi
period
male
femal
ratio
patient
earli
advanc
stage
diseas
respect
b
symptom
present
patient
mean
durat
symptom
month
median
month
rang
month
mix
cellular
commonest
histolog
type
overal
surviv
os
event
free
surviv
ef
respect
os
earli
stage
advanc
stage
diseas
respect
patient
without
bulki
diseas
ef
earli
stage
advanc
stage
diseas
respect
patient
bulki
diseas
without
bulki
diseas
older
age
year
bulki
diseas
low
hemoglobin
gdl
high
leucocyt
count
time
diagnosi
protocol
use
copp
risk
factor
relaps
conclus
patient
popul
younger
age
advanc
diseas
b
symptom
bulki
diseas
still
achiev
good
os
ef
chemotherapi
alon
protocol
patient
bulki
diseas
poor
overal
event
free
surviv
radiotherapi
includ
protocol
bulki
diseas
surviv
rate
improv
gupta
children
hospit
pediatr
oncolog
birmingham
unit
kingdom
backgroundobject
present
retrospect
analysi
pediatr
patient
hl
receiv
treatment
center
period
year
aim
studi
respons
chemotherapi
pediatr
patient
hl
designmethod
patient
diagnos
hl
divid
treatment
group
depend
stage
diseas
patient
group
receiv
cycl
vincristin
etoposid
prednisolon
doxorubicin
oepa
group
receiv
cycl
oepa
cycl
either
cyclophosphamid
vincristin
prednisolon
dacarbazin
copdac
group
receiv
cycl
oepa
cycl
copdac
patient
inadequ
respons
receiv
radiotherapi
earli
pet
respons
treatment
analyz
result
patient
group
group
group
patient
complet
metabol
respons
cmr
seen
partial
respons
patient
pet
done
patient
relaps
death
event
free
surviv
ef
overal
surviv
os
group
patient
patient
group
cmr
seen
patient
patient
relaps
ef
os
group
patient
patient
group
cmr
seen
patient
partial
respons
patient
patient
relaps
ef
os
group
patient
respect
conclus
ef
patient
treat
hl
overal
surviv
studi
emphas
excel
outcom
pediatr
hl
treatment
howev
studi
larger
cohort
patient
follow
longer
time
requir
gupta
children
hospit
paediatr
oncolog
birmingham
unit
kingdom
backgroundobject
retrospect
analysi
pediatr
patient
hodgkin
lymphoma
receiv
treatment
period
year
studi
respons
differ
chemotherapi
regimen
henc
identifi
regimen
best
outcom
designmethod
patient
hl
divid
treatment
group
depend
stage
patient
group
receiv
cycl
vincristin
etoposid
prednisolon
doxorubicin
oepa
cycl
cyclophosphamid
vincristin
prednisolon
cvp
group
receiv
cycl
oepa
either
cyclophosphamid
vincristin
prednisolon
dacarbazin
copdac
cyclophosphamid
vincristin
procarbazin
prednisolon
copp
cyclophosphamid
doxorubicin
vincristin
prednisolon
chop
group
receiv
cycl
oepa
cycl
copdac
copp
result
patient
patient
treat
cycl
oepa
relaps
ef
os
cycl
cvp
relaps
ef
os
patient
group
treat
cycl
oepa
copdac
relaps
ef
os
treat
cycl
oepa
cycl
copp
ef
os
treat
cycl
oepa
chop
relaps
die
ef
os
patient
group
treat
cycl
oepa
cycl
copdac
relaps
ef
os
treat
cycl
oepa
cycl
copp
relaps
die
ef
os
conclus
group
patient
treatment
oepa
chemotherapi
group
patient
oepa
x
copp
group
patient
oepa
x
copdac
x
shown
better
outcom
inc
f
e
h
k
n
eylul
univers
institut
oncolog
dept
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiodiagnost
izmir
turkey
backgroundobject
evalu
patient
musculoskelet
complaint
admiss
andor
skelet
involv
diagnosi
center
designmethod
medic
record
whole
patient
diagnosi
lymphoma
solid
tumor
analyz
retrospect
patient
admit
musculoskelet
complaint
skelet
involv
diagnosi
select
analysi
patient
characterist
complaint
skelet
involv
site
misdiagnos
differanti
diagnosi
diffucul
analyz
result
patient
diagnosi
lymphoma
solid
tumor
clinic
one
hundr
ninetyfour
admit
musculoskelet
system
complaint
andor
skelet
involv
diagnosi
median
age
diagnosi
patient
median
durat
complaint
definit
diagnosi
done
patient
admit
mean
time
doctor
oncolog
diagnosi
follow
ewe
sarcoma
lhh
neuroblastoma
osteosarcoma
lymphoma
rhabdomyosarcoma
misdiagnosis
follow
artir
artralgia
myalgia
muscl
spasm
lymphaden
growth
pain
jra
osteomyel
bone
edema
arf
trauma
avascular
necrosi
fmf
scoliosi
domin
complaint
other
walk
weight
night
skelet
system
pain
symptom
extrem
leg
sensori
sphincter
spinal
cord
physic
examin
nonartricular
bone
rash
blast
peripher
blood
bone
marrow
blood
count
ldh
crp
ana
abnorm
find
bone
conclus
musculoskelet
complaint
rheumat
diagnos
atyp
clinic
featur
reevalu
possibl
underli
malign
suspicion
malign
must
rule
simpl
investig
medic
histori
physic
examin
laboratori
radiolog
evalu
import
diagnosi
n
jadhav
b
p
j
j
e
institut
post
graduat
medic
educ
research
medic
oncolog
pondicherri
india
backgroundobject
hodgkin
lymphoma
one
success
stori
modern
oncolog
cure
rate
high
possibl
current
modal
treatment
abvd
establish
standard
care
adult
contrari
standard
care
paediatr
hodgkin
also
random
trial
compar
abvd
vers
non
abvd
regimen
designmethod
consecut
patient
diagnos
hodgkin
lymphoma
treat
region
cancer
center
jipmer
analyz
retrospect
data
retriev
record
section
patient
analyz
clinic
profil
outcom
abvd
non
abvd
base
treatment
protocol
result
total
patient
regist
octob
till
januari
median
age
present
year
male
femal
ratio
common
present
complain
neck
mass
seen
patient
median
symptom
durat
month
prior
first
contact
oncologist
b
symptom
seen
patient
bulki
diseas
involv
seen
patient
patient
present
earli
stage
earli
stage
unfavor
common
histolog
classic
hodgkin
mix
cellular
posit
patient
treat
abvd
protocol
patient
receiv
rt
bulki
diseas
part
combin
modal
treatment
toxic
seen
patient
febril
neutropenia
bleomycin
lung
overal
till
date
patient
regular
follow
cr
conclus
outcom
pediatr
hodgkin
promis
despit
late
present
oncologist
setup
respons
rate
abvd
non
abvd
regimen
compar
associ
differ
toxic
z
karaka
p
g
univers
istanbul
medic
faculti
pediatr
hematologyoncolog
istanbul
turkey
univers
istanbul
medic
faculti
pediatr
gastroenterolog
istanbul
turkey
univers
istanbul
medic
faculti
pediatr
intens
care
istanbul
turkey
univers
istanbul
medic
faculti
pediatr
infect
istanbul
turkey
backgroundobject
describ
uncommon
occur
burkitt
lymphoma
boy
cryptogen
cirrhosi
discuss
treatment
lymphoma
presenc
liver
failur
designmethod
first
refer
cervic
massmed
histori
reveal
regular
diagnosi
idiopath
cirrhosi
yearsth
patholog
diagnosi
burkitt
lymphoma
bl
evalu
stage
ii
bfm
nhl
studi
protocol
began
result
hepat
failur
develop
full
dose
prophas
two
day
reduc
aa
block
chemotherapi
could
continu
th
day
transfer
pediatr
intens
care
due
hepat
respiratori
failur
massiv
ascit
diagnos
sinusoid
obstruct
syndrom
sepsisklebsiella
pneumonia
detect
hemocultur
effect
treatment
clinic
th
day
therapyconsid
life
threaten
complic
even
reduc
dose
chemotherapi
discuss
local
tumor
council
decid
continu
singl
six
rituximab
therapycomplet
remiss
achiev
first
cours
rituximab
first
cure
liver
function
impair
next
rituximab
could
given
one
month
laterh
still
remiss
bl
stabl
sign
chronic
liver
failureh
candid
liver
transplant
aliv
donor
liver
transplant
liver
transplant
council
decid
follow
end
chemotherapi
patient
stabl
conclus
burkitt
lymphoma
tumor
success
result
chemotherapi
case
presenc
comcomit
liver
failur
treatment
tumor
could
difficult
target
therapi
might
effect
altern
instead
convent
treatment
protocol
extraordinari
present
e
mp
ms
g
scarzello
g
p
hospit
padua
pediatr
unit
padua
itali
istituto
oncologico
veneto
nuclear
medicin
radiat
therapi
unit
padua
itali
hospit
padua
nuclear
medicin
depart
padua
itali
backgroundobject
recent
studi
demonstr
qualit
measur
obtain
ad
interim
evalu
positron
emiss
tomographi
pet
could
predict
clinic
respons
patient
hodgkin
lymphoma
hl
aim
studi
evalu
pet
measur
predict
respons
pediatr
patient
hl
designmethod
measur
standard
uptak
valu
suv
metabol
tumor
volum
mtv
total
lesion
glicolysi
tlg
pet
imag
obtain
stage
chemotherapi
cours
coppabv
abvd
patient
treat
accord
protocol
patient
defin
good
respond
gr
complet
remiss
cr
end
otherwis
defin
nr
statist
analysi
perform
test
result
pet
dataset
children
analyz
mean
month
end
patient
cr
nr
relaps
patient
refractori
first
line
therapi
suffer
nodular
sclerosi
hl
stage
iii
iv
pet
imag
done
diagnosi
show
higher
burden
diseas
nr
patient
compar
gr
patient
mtv
vs
p
tlg
vs
also
higher
without
statist
signific
chemotherapi
cours
tlg
remain
higher
pr
group
vs
mtv
slightli
higher
gr
group
vs
conclus
mtv
tlg
two
paramet
could
predict
clinic
respons
patient
hl
larger
cohort
studi
need
confirm
preliminari
data
oscanoa
nacion
edgardo
rebagliati
oncolog
lima
peru
backgroundobject
time
diagnosi
td
lag
time
time
patient
first
symptom
recognit
diagnosi
cancer
delay
td
allow
tumor
progress
poor
outcom
lymphoma
nhl
studi
although
remain
controversi
object
aim
studi
defin
clinic
factor
associ
td
includ
parent
delay
pd
medic
delay
md
children
adolesc
diagnos
nhl
lima
peru
designmethod
total
patient
younger
year
age
diagnos
nhl
januari
octob
retrospect
evalu
clinic
demograph
variabl
type
diagnosi
clinic
stage
sex
age
parent
characterist
analyz
evalu
effect
td
pd
md
result
patient
includ
studi
median
age
year
rang
male
histolog
subtyp
matur
nhl
lymphoblast
nhl
tnk
lymphoma
anaplast
larg
cell
lymphoma
lymphoma
stage
iii
iv
tumor
seen
case
td
rang
week
month
median
week
median
pd
md
week
respect
among
histolog
subtyp
could
found
signific
differ
td
age
parent
age
level
educ
metastat
diseas
clinic
stage
sex
affect
significantli
td
conclus
countri
median
td
compar
describ
develop
countri
index
suspicion
childhood
cancer
remain
low
necessari
establish
strategi
optim
earli
diagnosi
base
associ
factor
fg
f
alpaslan
p
uyar
n
baran
c
karadeniz
univers
medic
faculti
pediatr
oncolog
ankara
turkey
yildirim
beyazit
research
hospit
medic
genet
ankara
turkey
univers
medic
faculti
pediatr
ankara
turkey
univers
medic
faculti
patholog
ankara
turkey
univers
medic
faculti
public
health
ankara
turkey
backgroundobject
aim
studi
investig
express
methyl
statu
seven
distinct
gene
tumor
suppress
properti
childhood
adolesc
lymphoma
designmethod
total
patient
hodgkin
lymphoma
hl
lymphoma
nhl
reactiv
lymph
node
prolifer
control
year
depart
pediatr
oncolog
includ
research
express
statu
gene
measur
qpcr
method
rna
isol
paraffin
block
tumor
tissu
cdna
convers
dna
isol
perform
sampl
low
gene
express
follow
methyl
pcr
studi
specif
promotor
region
gene
order
investig
methyl
pattern
result
found
gene
significantli
less
express
patient
control
group
howev
express
gene
patient
control
group
statist
differ
methyl
ratio
gene
exclud
significantli
higher
hl
nhl
group
control
conclus
show
gene
epigenet
silenc
via
hypermethyl
tumor
tissu
sampl
children
hl
nhl
due
find
gene
express
patient
control
group
conclud
specif
malign
gene
similarli
express
patient
control
group
relat
malign
could
neither
found
futur
studi
may
show
gene
candid
biomark
therapeut
target
childhood
adolesc
lymphoma
studi
support
research
grant
turkish
pediatr
oncolog
group
tpog
j
seelisch
j
k
l
c
k
hospit
sick
children
hematologyoncolog
toronto
canada
jude
children
research
hospit
oncolog
memphi
usa
park
cancer
institut
hematologyoncolog
buffalo
usa
hospit
leipzig
nuclear
medicin
leipzig
germani
medic
center
hematologyoncolog
hall
germani
children
hospit
pediatr
radiolog
provid
usa
children
hospit
radiolog
boston
usa
backgroundobject
waldey
ring
wr
involv
pediatr
hodgkin
lymphoma
hl
rare
phenomenon
unclear
definit
intern
pediatr
hl
specialist
form
wr
work
group
cayahl
childhood
adolesc
young
adult
hl
exist
literatur
review
case
collect
consensu
recommend
wr
involv
establish
designmethod
systemat
review
conduct
literatur
involv
wr
hl
result
titlesabstract
review
paper
full
text
includ
pediatr
nineteen
pediatr
case
collect
group
conclus
histor
involv
wr
determin
examin
ideal
ent
biopsi
confirm
current
standard
clinic
criteria
defin
involv
render
clinic
evalu
highli
subject
diagnost
ct
standard
care
newli
diagnos
hl
review
modal
requir
determin
diseas
presenc
wr
given
normalreact
lymphoid
tissu
may
avid
pet
alon
abnorm
asymmetri
anatomi
metabol
activ
assess
pet
avid
wr
structur
approach
primari
mass
involv
consid
mri
excel
assess
head
neck
tissu
consid
delin
find
indetermin
pet
find
initi
stage
confirm
ctmri
review
earli
respons
assess
metabol
activ
normal
earli
respons
assess
involv
like
consid
ongo
treatment
tonsil
demonstr
physiolog
increas
metabol
activ
make
respons
assess
challeng
thu
standard
deauvil
criteria
appli
suggest
disappear
asymmetr
uptak
symmetr
uptak
palatin
tonsil
markedli
exceed
uptak
adenoid
region
consid
adequ
respons
clinic
trial
final
involv
determin
central
review
prospect
databas
wr
involv
maintain
jj
seo
medic
center
pediatr
seoul
republ
korea
backgroundobject
pediatr
lymphoma
pnhl
compris
heterogen
group
lymphoid
neoplasm
known
differ
aspect
adult
diseas
geograph
differ
incid
perform
studi
delin
characterist
outcom
pnhl
east
asia
design
method
medic
record
patient
pnhl
treat
particip
institut
beij
shanghai
nagoya
seoul
tpog
center
taiwan
januari
decemb
review
retrospect
demograph
clinic
featur
surviv
outcom
put
prognost
factor
analyz
result
median
age
diagnosi
year
common
patholog
subtyp
burkitt
lymphoma
bl
follow
lymphoblast
lymphoma
anaplast
larg
cell
lymphoma
alcl
diffus
larg
b
cell
lymphoma
dlbcl
patient
advanc
diseas
diagnosi
bone
marrow
bm
cn
involv
frequent
observ
bl
overal
surviv
surviv
ef
rate
respect
median
month
follow
ef
rate
excel
bl
dlbcl
respect
lower
alcl
ptcl
respect
p
cn
involv
high
ldh
iuml
advanc
diseas
diagnosi
associ
significantli
poorer
outcom
p
nineti
one
patient
experienc
relaps
median
month
diagnosi
patient
alcl
ptcl
relaps
frequent
subtyp
p
patient
relaps
within
month
diagnosi
relaps
bl
show
significantli
poorer
outcom
conclus
clinic
characterist
treatment
outcom
pnhl
east
asian
countri
similar
observ
western
countri
peculiar
clinic
aspect
observ
well
intern
studi
expect
provid
platform
futur
collabor
studi
nhl
east
asia
h
shen
q
hospit
zhejiang
univers
school
medicin
hangzhou
china
backgroundobject
monoclon
antibodi
mab
target
therapi
one
promis
strategi
cure
cancer
novel
antibodi
gener
use
hybridoma
techniqu
human
b
lymphoma
raji
cell
immunogen
laboratori
present
potenti
therapeut
agent
hematolog
malign
designmethod
investig
reactiv
profil
identifi
target
antigen
flow
cytometri
intern
studi
method
appli
papain
digest
flow
cytometri
capac
specif
bind
activ
complement
determin
complement
depend
cytotox
cdc
result
result
show
antibodi
murin
new
clone
react
extracellular
portion
protein
antigen
strictli
express
lymphoma
cell
burkitt
lymphoma
dlbcl
cll
cell
patient
quickli
intern
target
cell
bind
antigen
antibodi
incub
target
cell
raji
degre
intern
differ
time
point
respect
vl
vh
gene
insert
plasmid
recombin
plasmid
encod
transfect
cho
cell
western
blot
analysi
show
cultur
supernat
bound
extract
raji
cell
activ
cdc
raji
cell
dose
depend
manner
inhibit
rate
raji
cell
concentr
respect
conclus
novel
antibodi
target
extracellular
portion
potenti
therapeut
agent
malign
k
stanley
k
g
g
r
hospit
pittsburgh
upmc
depart
pediatr
hematolog
oncolog
pittsburgh
usa
hospit
pittsburgh
upmc
depart
transplant
surgeri
pittsburgh
usa
hospit
pittsburgh
upmc
depart
patholog
pittsburgh
usa
backgroundobject
lymphocyt
deplet
induct
immunosuppress
decreas
reject
sever
reduc
mainten
immunosuppress
requir
itx
alon
liver
children
whether
ptld
rate
vari
induct
agent
unknown
designmethod
retrospect
chart
review
subject
receiv
itx
januari
present
children
hospit
pittsburgh
upmc
result
itx
underw
alemtuzumab
induct
underw
rabbit
globulin
ratg
induct
subject
older
compar
subject
median
age
year
rang
vs
year
rang
ns
experienc
lower
incid
earli
acut
cellular
reject
vs
ns
fisher
exact
higher
incid
ptld
vs
ns
fisher
exact
alemtuzumab
ratg
group
similar
regard
liver
contain
graft
vs
ptld
onset
first
year
vs
associ
ebv
vs
incid
monomorph
ptld
vs
locat
intestin
allograft
vs
subject
treat
immunosuppress
reduct
within
alemtuzumab
group
treatment
also
includ
rituximab
chemotherapi
combin
cyclophosphamid
steroid
children
enterectomi
rejectiongraft
failur
ptld
ptld
resolv
subject
one
child
die
infect
within
ratg
group
treatment
includ
rituximab
chemotherapi
children
enterectomi
rejectiongraft
failur
ptld
six
children
die
due
ptld
infect
renal
failur
conclus
ratg
induct
associ
trend
toward
lower
ptld
incid
compar
alemtuzumab
gk
viswanathan
p
n
n
sd
g
g
pg
centr
research
educ
cancer
tata
memori
centr
tmc
hematopatholog
laboratori
mumbai
india
memori
hospit
memori
centr
tmc
pediatr
mumbai
india
backgroundobject
lymphoma
minim
dissemin
diseas
mdd
defin
morpholog
identifi
blast
peripher
blood
pb
andor
bone
marrow
bm
along
presenc
bm
involv
detect
flowcytometr
immunophenotyp
publish
literatur
rare
subgroup
spars
studi
aim
identifi
mdd
use
studi
clinic
featur
designmethod
retrospect
analysi
children
diagnos
mediastin
andor
lymph
node
biopsi
predominantli
lymphomat
present
blast
pbbm
done
clinic
laboratori
data
studi
perform
flowcytomet
result
mean
age
year
year
f
ratio
mean
hemoglobin
wbc
count
platelet
count
respect
csf
examin
neg
case
indic
rariti
cn
involv
subgroup
mdd
seen
case
rang
mean
rang
morpholog
identifi
bone
marrow
blasthematogon
count
group
without
mdd
group
mdd
seven
case
mdd
show
blast
bm
indic
sensit
necess
insensit
identifi
mdd
conclus
mdd
present
blast
pbbm
underlin
import
perform
case
blast
even
case
blast
morpholog
identif
minim
dissemin
diseas
import
limit
publish
data
avail
studi
show
inferior
event
free
surviv
mdd
compar
patient
without
mdd
need
bm
examin
residu
diseas
detect
mdd
posit
case
intensif
therapi
posit
fu
h
x
x
hospit
fudan
univers
hematolog
oncolog
shanghai
china
backgroundobject
rituximab
becom
standard
medicin
treatment
adult
patient
dlbcl
current
limit
number
clinic
trial
children
show
rituximab
combin
bfm
protocol
safe
good
efficaci
absenc
similar
studi
china
childhood
patient
newli
diagnos
encourag
us
studi
efficaci
rituximab
chines
popul
designmethod
studi
explor
effici
rituximab
childhood
found
newli
diagnos
matur
stage
iii
stage
children
treat
protocol
combin
rituximab
compar
histor
data
protocol
result
studi
recuit
male
femal
averag
age
year
treat
chemotherapi
among
histor
control
patient
treat
chemotherapi
femal
compar
patient
treat
protocol
ef
patient
higher
vs
respect
among
subgroup
patient
ef
patient
stage
iii
vs
stage
vs
patient
treat
respect
differ
statist
signific
neither
among
patient
whose
ldh
level
ul
diagnosi
protocol
reach
surviv
nevertheless
ef
patient
group
statist
differ
patient
treat
among
patient
ldh
ul
diagnosi
ef
group
significantli
higher
group
conclus
found
rituximab
improv
surviv
ef
childhood
ldh
ul
china
l
amo
n
merci
hospit
hematologyoncologybmt
usa
backgroundobject
alcl
form
lymphoma
repres
childhood
lymphoma
leukem
cn
involv
alcl
extrem
rare
addit
alcl
rare
report
associ
hlh
hlh
disord
immun
dysregul
involv
macrophag
activ
cytokin
releas
caus
dysfunct
object
case
seri
report
diseas
cours
two
patient
fulmin
hlh
secondari
alcl
leukem
cn
involv
designmethod
present
two
patient
admit
pediatr
intens
care
unit
picu
system
failur
requir
intub
continu
renal
replac
therapi
crrt
due
metabol
acidosi
met
diagnost
laboratori
criteria
hlh
bone
marrow
peripher
blood
evalu
fish
analysi
show
alk
gene
rearrang
consist
alcl
leukemia
phase
patient
year
old
male
brain
mri
done
show
numer
enhanc
lesion
consist
metastasi
patient
year
old
femal
csf
analysi
show
evid
diseas
alk
posit
cell
addit
found
non
enhanc
lesion
deep
white
matter
brain
mri
result
patient
treat
hlh
direct
therapi
follow
alcl
direct
therapi
receiv
addit
treatment
cn
intrathec
chemotherapi
patient
also
receiv
craniospin
irradi
csi
patient
therapi
evid
diseas
conclus
case
seri
highlight
two
patient
rare
present
hlh
associ
alcl
leukem
cn
involv
diagnosi
hlh
consid
alcl
patient
present
leukem
phase
also
suggest
leukem
phase
may
lead
elev
cytokin
caus
hlh
n
yazici
f
hc
b
gn
univers
depart
pediatr
adana
turkey
univers
depart
radiat
oncolog
adana
turkey
univers
depart
patholog
adana
turkey
univers
depart
radiolog
adana
turkey
univers
depart
pediatr
surgeri
adana
turkey
univers
depart
nuclear
medicin
adana
turkey
backgroundobject
differ
center
use
differ
protocol
accord
physic
condit
turkey
hodgkin
lymphoma
usual
choic
protocol
depend
success
superior
surviv
origin
regimen
howev
local
factor
differ
imposs
take
result
studi
treatment
result
german
pediatr
hodgkin
diseas
regimen
present
designmethod
depart
petbt
routin
use
stage
everi
patient
end
chemotherapi
regimen
use
origin
version
radiotherapi
use
involv
field
http
patient
hospit
minimum
day
diagnosi
adapt
treatment
rest
treatment
continu
outpati
basi
result
januari
patient
hodgkin
lymphoma
thirti
three
untreat
mean
age
year
year
male
seventeen
mix
cellular
type
case
risk
group
rg
median
follow
month
patient
stage
hodgkin
diseas
diagnosi
relaps
month
follow
still
follow
second
remiss
year
patient
ataxia
telengiectasia
exitu
pulmonari
complic
exclud
mortal
seri
protocol
patient
overal
surviv
year
respect
conclus
result
protocol
center
success
origin
protocol
despit
local
factor
think
treatment
relat
toxic
reduc
modif
patient
omit
radiotherapi
complet
metabol
respons
petct
chemotherapi
without
procarbazin
male
patient
zakaria
faisal
univers
colleg
medicin
al
ahsa
saudi
arabia
backgroundobject
background
abdomen
one
frequent
site
lymphoma
children
role
surgeri
limit
resect
tumour
diagnost
procedur
case
dissemin
diseas
laparotomi
without
total
excis
tumour
improv
surviv
moreov
may
caus
complic
delay
initi
chemotherapi
aim
work
studi
undertaken
assess
role
surgeri
manag
children
adolesc
present
lymphoma
order
creat
certain
criteria
select
proper
surgic
modal
manag
patient
designmethod
patient
method
retrospect
studi
done
patient
abdomin
lymphoma
period
seven
year
patient
file
review
regard
full
clinic
examin
laboratori
radiolog
investig
well
surgic
diagnost
procedur
collect
data
tabul
statist
analyz
use
spss
program
packag
result
twenti
seven
patient
present
huge
mass
gener
lymphadenopathi
besid
abdomin
affect
remain
patient
present
symptom
acut
abdomen
total
laparotomi
done
patient
underw
emerg
laparotomi
acut
abdomen
patient
elect
abdomin
explor
lymph
node
biopsi
taken
patient
laparoscopi
procedur
perform
patient
diagnost
tool
total
remain
patient
underw
true
cut
needl
biopsi
diagnosi
diseas
conclus
surgeri
still
role
treatment
lymphoma
whether
non
hodgkin
hodgkin
howev
dissemin
metastat
diseas
aggress
debulk
tumour
avoid
chemotherapi
institut
primarili
surgic
resect
caus
signific
chang
morbid
mortal
zvyagintseva
e
petrov
research
research
oncolog
institut
depart
chemotherapi
combin
treatment
malign
tumor
children
saint
petersburg
russia
petrov
research
institut
oncolog
depart
chemotherapi
combin
treatment
malign
tumor
children
saint
petersburg
russia
petrov
research
institut
oncolog
depart
chemotherapi
combin
treatment
malign
tumor
children
st
petersburg
russia
backgroundobject
overal
surviv
rate
childhood
hodgkin
lymphoma
hl
around
therefor
late
sequela
treatment
especi
endocrin
diseas
becom
import
aim
investig
late
side
effect
childhood
hodgkin
lymphoma
therapi
thyroid
gland
among
childhood
cancer
survivor
designmethod
report
analyz
function
thyroid
gland
patient
success
treat
childhood
hd
accord
two
differ
protocol
therapi
patient
divid
three
group
depend
treatment
group
therapi
accord
protocol
group
therapi
accord
spbhl
protocol
beacopp
radiotherapi
rt
treatment
method
correl
appear
thyroid
dysfunct
result
median
year
thyroid
dysfunct
detect
patient
thyroid
abnorm
hypothyroid
n
thyroid
nodul
thyroid
malign
irradi
gy
dose
radiat
found
constitut
risk
factor
thyroid
abnorm
conclus
studi
confirm
high
incid
thyroid
abnorm
patient
treat
hodgkin
lymphoma
combin
therapi
chemotherapi
headneckthorax
radiotherapi
strengthen
import
zvyagintseva
petrov
research
research
oncolog
institut
state
pediatr
medic
univers
depart
chemotherapi
combin
treatment
malign
tumor
children
saint
petersburg
russia
petrov
research
research
oncolog
institut
depart
chemotherapi
combin
treatment
malign
tumor
children
st
petersburg
russia
backgroundobject
surviv
rate
diagnosi
hodgkin
lymphoma
hl
improv
substanti
past
year
adolesc
year
old
seem
experi
poorer
surviv
object
provid
descript
review
improv
understand
treatment
outcom
hodgkin
lymphoma
designmethod
retrospect
review
patient
age
year
old
hl
treat
institut
perform
surviv
analysi
perform
use
method
result
median
age
year
boy
girl
patient
stage
patient
advanc
diseas
stage
half
patient
diseas
major
patient
nodular
sclerosi
patient
lymphocyt
predomin
mix
cellular
case
morpholog
type
diagnos
patient
treat
therapi
chemotherapi
radiat
accord
spbhl
protocol
seven
patient
treat
beacopp
radiat
dose
rang
gy
overal
surviv
surviv
surviv
surviv
respect
conclus
present
featur
adolesc
hl
effici
studi
better
young
adult
overal
surviv
wors
children
overal
surviv
adolesc
hodgkin
lymphoma
curabl
diseas
requir
person
manag
oncohematolog
unit
kuleva
petrov
research
research
oncolog
institut
state
pediatr
medic
univers
depart
chemotherapi
combin
treatment
malign
tumor
children
saint
petersburg
russia
petrov
research
research
oncolog
institut
state
pediatr
medic
univers
depart
chemotherapi
combin
treatment
malign
tumor
children
st
petersburg
russia
petrov
research
research
oncolog
institut
depart
chemotherapi
combin
treatment
malign
tumor
children
st
petersburg
russia
backgroundobject
hodgkin
lymphoma
approxim
malign
tumor
patient
age
treatment
program
group
use
aim
studi
identifi
prognost
unfavor
factor
young
adult
hl
designmethod
studi
includ
data
patient
age
year
averag
age
year
men
women
sex
ratio
patient
stage
patient
advanc
diseas
stage
half
patient
diseas
major
patient
nodular
sclerosi
patient
lymphocyt
predomin
mix
cellular
case
morpholog
type
diagnos
patient
receiv
cycl
primari
chemotherapi
median
cycl
abvd
patient
beacopp
mopp
copp
one
patient
follow
radiat
patient
radiat
dose
rang
gy
result
correl
matrix
includ
factor
signific
impact
overal
surviv
stage
iv
diseas
p
extranod
lesion
p
involv
pericardium
p
valu
esr
mm
h
p
white
blood
cell
count
l
p
level
lymphocyt
less
p
fibrinogen
valu
g
l
p
effect
therapi
p
volum
tumor
p
conclus
use
identifi
unfavor
prognost
factor
possibl
stratifi
patient
risk
group
determin
treatment
program
zvyagintseva
e
petrov
research
institut
oncolog
depart
chemotherapi
combin
treatment
malign
tumor
children
saint
petersburg
russia
backgroundobject
side
effect
treatment
modal
childhood
hodgkin
lymphoma
hl
focus
modern
research
thyroid
dysfunct
report
especi
follow
head
neck
irradi
aim
determin
critic
point
radiat
dose
neck
thyroid
gland
children
adolesc
hodgkin
lymphoma
predict
dosimetr
variabl
youden
method
designmethod
one
hundr
patient
prove
hl
age
year
includ
studi
patient
divid
three
group
depend
treatment
group
therapi
accord
protocol
group
therapi
accord
spbhl
protocol
beacopp
radiotherapi
rt
elig
criteria
inclus
current
analysi
diagnosi
cancer
age
year
treatment
chemotherapi
rt
neckthorax
time
interv
month
complet
therapi
thyroid
function
test
thyroid
gland
ultrasound
examin
evalu
group
result
mean
period
year
rang
one
hundr
patient
receiv
total
dose
gy
headneckthorax
rt
point
gy
radiat
dose
neck
thyroid
gland
children
adolesc
hodgkin
lymphoma
predict
dosimetr
variabl
found
roc
curv
area
ci
p
maximum
youden
index
conclus
total
dose
gy
neck
thyroid
gland
critic
valu
develop
thyroid
dysfunct
ivanova
petrov
research
institut
state
pediatr
medic
st
russia
depart
children
chemoterapi
combin
modal
therapi
saint
petersburg
russia
backgroundobject
predict
valu
hodgkin
lymphoma
tumor
burden
discuss
year
howev
evid
base
modern
research
becom
possibl
use
recent
year
purpos
studi
assess
influenc
rel
tumor
burden
outcom
designmethod
studi
includ
data
patient
age
year
old
middl
age
year
hodgkin
lymphoma
boy
girl
patient
ii
stage
iii
stage
diseas
b
symptom
occur
patient
patient
identifi
diseas
patient
treat
accord
pediatr
protocol
patient
accord
accord
spblh
program
seven
teenag
treat
accord
beacorp
scheme
chemotherapi
regimen
follow
subtot
radiat
dose
gy
patient
result
overal
surviv
year
rang
surviv
optimum
level
accord
roc
method
rel
tumor
burden
establish
roc
curv
area
p
maximum
youden
index
overal
surviv
cohort
patient
volum
tumor
volum
less
overal
surviv
p
conclus
rel
tumor
burden
paramet
significantli
chang
surviv
rate
adolesc
hodgkin
lymphoma
determin
intercorrel
includ
final
multifactor
analysi
abugideiri
j
n
c
e
r
b
n
cancer
institut
emori
univers
depart
radiat
oncolog
atlanta
usa
cancer
institut
emori
univers
depart
biostatist
bioinformat
atlanta
usa
backgroundobject
evalu
factor
associ
acut
kidney
injuri
aki
pediatr
patient
total
bodi
irradi
tbi
base
myeloabl
condit
allogen
hematopoiet
stem
cell
transplant
hsct
designmethod
record
review
consecut
pediatr
patient
rang
year
underw
myeloabl
condit
hematolog
malign
singl
institut
januari
may
tbi
total
dose
rang
tbi
rang
aki
defin
doubl
baselin
creatinin
first
day
tbi
univari
multivari
analys
perform
determin
associ
variabl
result
aki
develop
patient
tbi
total
dose
dose
rate
dose
per
fraction
signific
predictor
aki
chemotherapi
patient
receiv
regimen
contain
cytoxan
aki
increas
addit
fludarabin
neither
infect
acut
gvhd
associ
increas
aki
aki
increas
patient
low
glomerular
filtrat
rate
gfr
major
patient
aki
normal
creatinin
hsct
howev
persist
renal
dysfunct
tbi
associ
higher
incid
transplant
relat
mortal
trm
p
wors
overal
surviv
os
p
remain
signific
multivari
analysi
p
conclus
high
incid
aki
note
seri
despit
signific
factor
identifi
agent
increas
incid
aki
seri
variabl
must
identifi
potenti
caus
aki
aki
appear
result
renal
damag
major
patient
howev
persist
renal
dysfunct
associ
wors
os
trm
addit
attent
must
paid
factor
facilit
normal
kidney
function
aki
f
ansari
gurgaon
pediatr
hematoncolog
stem
cell
transplant
bhiwandi
india
backgroundobject
monoclon
antibodi
mab
evalu
treatment
acut
diseas
gvhd
patient
undergo
hematopoiet
stem
cell
transplant
hsct
mainli
adult
match
donor
year
pauciti
data
pediatr
patient
aim
evalu
efficaci
chimer
mab
basiliximab
pediatr
patient
acut
gut
gvhd
match
haploident
hsct
designmethod
materi
evalu
patient
acut
gut
gvhd
match
haploident
sct
patient
transplant
match
sibl
n
haploident
n
donor
acut
lymphoblast
leukemia
n
acut
myeloid
leukemia
n
fanconi
anemia
n
thalassemia
n
immunodefici
n
basiliximab
given
dose
x
mg
x
mg
consecut
day
acut
gut
gvhd
develop
basiliximab
repeat
day
case
persist
gvhd
median
four
basiliximab
infus
rang
given
patient
result
basiliximab
eight
patient
respond
basiliximab
complet
respons
cr
acut
gut
gvhd
partial
respons
pr
three
patient
respond
conclus
data
suggest
basiliximab
effect
treat
acut
gut
gvhd
pediatr
matchedhaploident
sct
sh
ansari
institut
blood
diseas
bone
marrow
transplant
bone
marrow
transplant
karachi
pakistan
backgroundobject
hematopoiet
stem
cell
transplant
hsct
rescu
procedur
patient
malign
non
malign
disord
treat
cytotox
regimen
patient
aberr
defect
hematopoiet
cell
includ
marrow
failur
autoimmun
disord
situat
howev
hsct
also
therapeut
effect
erad
patient
diseas
object
studi
assess
outcom
bone
marrow
transplant
pediatr
popul
malign
non
malign
hematolog
disord
designmethod
total
pediatr
patient
underw
transplant
januari
decemb
nation
institut
blood
diseas
bone
marrow
transplant
variou
hematolog
disord
malign
haematopoiet
stem
cell
well
peripher
blood
transplant
method
employ
allogen
transplantaion
sibl
donor
two
year
surviv
calcul
use
surviv
function
result
mean
period
day
acut
episod
graft
versu
host
diseas
gvhd
observ
chronic
gvhd
patient
overal
surviv
among
patient
undergo
stem
cell
transplant
past
five
year
six
month
diseas
free
surviv
aplast
anemia
aa
beta
thalassemia
major
btm
hematolog
malign
fanconi
anemia
conclus
studi
overal
surviv
among
patient
undergo
stem
cell
transplant
past
five
year
less
incid
acut
chronic
gvhd
report
part
world
c
bark
k
g
k
b
e
ah
children
hospit
pediatr
hematolog
oncolog
muenster
germani
children
hospit
gener
pediatr
muenster
germani
hospit
muenster
medic
control
muenster
germani
backgroundobject
pediatr
cancer
treatment
hematopoiet
stem
cell
transplant
hsct
carri
consider
risk
morbid
analyz
intens
care
unit
icu
admiss
children
adolesc
treat
cancer
undergo
hsct
develop
complic
designmethod
patient
year
hematolog
oncolog
disord
statu
post
allogen
hsct
receiv
care
depart
pediatr
hematolog
oncolog
admit
icu
condit
identifi
search
univers
medic
control
databas
demograph
diseas
relat
paramet
medic
cours
icu
stay
outcom
analyz
caus
death
paramet
potenti
impact
outcom
analyz
multivari
analysi
result
studi
period
patient
admiss
icu
medic
condit
major
patient
hematolog
malign
post
allogen
hsct
median
age
year
rang
main
reason
icu
admiss
respiratori
insuffici
cardiovascular
insuffici
sepsi
mortal
icu
relat
organ
failur
acut
complic
irrevers
progress
underli
malign
mortal
rate
day
post
discharg
icu
respect
paramet
significantli
associ
death
icu
includ
statu
post
allogen
hsct
prior
icu
admiss
number
day
icu
presenc
infect
occurr
number
organ
failur
number
support
organ
system
conclus
outcom
pediatr
cancerhsct
patient
admit
acut
condit
dismal
report
center
literatur
patient
benefit
icu
care
surviv
predominantli
compromis
evolut
complic
w
czogala
j
children
hospit
krakow
transplant
depart
krakow
poland
univers
medic
colleg
depart
chair
clinic
immunolog
transplant
krakow
poland
backgroundobject
epstein
barr
viru
ebv
infect
remain
consider
reason
sever
complic
patient
allogen
stem
cell
transplant
unrel
donor
mud
hst
clinic
statu
complic
vari
neglig
viraemia
life
threaten
ptld
designmethod
perform
transplant
ward
children
age
year
clinic
infect
statu
examin
everi
day
pcr
blood
serum
bodi
fluid
orand
tissu
examin
case
clinic
diseas
statu
unclear
result
escal
ebv
replic
confirm
patient
ebv
infect
mud
hst
develop
primari
infect
patient
ebv
reactiv
probabl
ebv
diseas
confirm
ebv
diseas
posttranspl
lympheprolif
diseas
ptld
reduct
immunosuppress
drug
implement
first
choic
procedur
case
non
symptom
ebv
infect
mud
hst
subsequ
replic
clinic
develop
occur
rituximab
dose
implement
case
treatment
success
case
one
confirm
diseas
one
ptld
low
dna
viru
detect
blood
yet
coexist
massiv
ebv
replic
tonsil
tissu
one
case
ptld
lymphat
tissu
throat
involv
observ
treatment
resist
chemotherapi
ad
treatment
case
non
signific
variabl
viraemia
detect
tonsil
remain
infect
boy
die
regardless
treatment
conclus
systemat
viru
replic
develop
monitor
effect
ptld
prophylaxi
low
viraemia
detect
exlud
tissu
involv
presenc
suspect
symptom
diagnost
enlarg
perez
garcia
olaya
g
lopez
n
ramirez
l
melchor
nacion
de
pediatria
insurgent
bone
marrow
transplant
mexico
citi
mexico
backgroundobject
chanc
find
hla
genotyp
ident
sibl
donor
unrel
donnor
avail
countri
yet
cord
blood
stem
cell
sourc
limit
dose
use
high
dose
po
transplant
cyclophosphamid
introduc
baltimor
group
approxim
year
ago
rapidli
adopt
worldwid
manipul
haploident
stem
cell
transplant
ex
vivo
demonstr
good
result
sever
studi
achiev
year
overal
surviv
year
os
gvhd
incid
object
determin
feasibl
overal
surviv
po
transplant
cyclophosphamid
designmethod
prospect
longitudin
studi
perform
patient
lack
match
sibl
donor
umbil
cord
blood
unit
nucleat
cell
kg
recipi
bodi
weight
hla
match
antigen
molecular
type
order
prefer
donor
select
mother
b
father
c
brother
sister
patient
sever
condit
eleg
studi
aprov
investig
comite
written
inform
consent
obtain
parent
guardian
patient
donor
result
forti
patient
eleg
age
year
male
femal
dose
median
day
neutrophil
graft
day
primari
failur
three
year
overal
surviv
acut
graft
versu
host
diseas
chronic
graft
versu
host
diseas
incid
viral
infect
adenoviru
cytomegaloviru
bk
viru
common
immun
show
delay
delay
year
postransplant
conclus
ptci
option
countri
face
lack
unrel
donor
umbil
cord
blood
good
dose
factibl
procedur
studi
achiev
order
demonstr
better
sourc
e
ramo
elbal
plaza
jp
del
pozo
mv
martinez
galera
llinar
mdm
j
monserrat
blanquer
ja
campillo
minguela
jm
moraleda
jl
fuster
universitario
virgen
de
la
arrixaca
stem
cell
transplant
cell
therapi
unit
el
palmar
murcia
spain
universitario
virgen
de
la
arrixaca
murcia
biohealth
research
institut
el
palmar
murcia
spain
universitario
virgen
de
la
arrixaca
immunolog
servic
el
palmar
murcia
spain
backgroundobject
prognosi
system
relaps
sr
aggress
pediatr
solid
tumor
poor
haploident
stem
cell
transplant
ex
vivo
deplet
alloreact
nk
cell
may
exert
antitumor
effect
analyz
procedur
result
six
patient
year
old
sr
ewe
sarcoma
es
neuroblastoma
osteosarcoma
designmethod
three
patient
es
osteosarcoma
second
complet
remiss
resect
lung
metastas
second
line
chemotherapi
activ
diseas
donor
select
parent
base
kir
genotyp
donor
recipi
kir
express
donor
flow
cytometri
ex
vivo
manipul
graft
consist
doubl
deplet
condit
consist
fludarabin
busulfan
thiotepa
radioact
mibg
follow
fludarabin
melphalan
thiotepa
atg
prophylaxi
diseas
gvhd
done
mycophenol
cyclosporin
methotrex
result
averag
infus
graft
failur
occur
two
patient
deplet
rescu
match
hla
sibl
allograft
patient
die
complic
one
develop
acut
grade
iiiiv
gvhd
respond
photopheresi
four
patient
suffer
tumor
progress
die
month
two
patient
es
transplant
aliv
diseas
free
month
respect
conclus
safe
option
heavili
patient
mortal
seri
graft
reject
associ
deplet
deplet
patient
transplant
real
chanc
surviv
n
roy
moulik
j
marsden
hospit
paediatr
oncolog
greater
london
unit
kingdom
backgroundobject
high
dose
chemotherapi
autolog
stem
cell
transplant
asct
form
integr
part
treatment
protocol
childhood
cancer
increasingli
use
relaps
refractori
solid
tumour
well
brain
tumour
lymphoma
childrenth
clinic
cours
complic
autolog
transplant
childhood
cancer
describ
designmethod
retrospect
studi
children
undergo
high
dose
chemotherapi
autolog
stem
cell
transplant
januari
march
includ
relev
data
retriev
patient
record
analys
use
convent
statist
result
children
f
mean
age
year
underw
asct
variou
cancer
commonli
neuroblastoma
neutrophil
platelet
engraft
asct
seen
day
respect
platelet
recoveri
longer
patient
neuroblastoma
receiv
bumel
condit
compar
diagnosi
p
common
complic
includ
mucos
febril
neutropenia
cultur
posit
sepsi
seen
case
wherea
patient
need
parenter
nutrit
mucos
hepat
renal
dysfunct
observ
case
respect
hepat
sinusoid
obstruct
syndrom
so
seen
patient
busulfan
base
condit
median
durat
parenter
nutrit
antibioticswer
day
respectivelytwelv
patient
need
escal
care
hdupicu
sepsi
so
mean
durat
hospitalis
day
significantli
differ
among
variou
condit
regimen
p
transplant
relat
mortal
within
follow
asct
conclus
complic
asct
childhood
cancer
occur
period
cytopenia
condit
engraft
frequent
relat
underli
diagnosi
condit
regimen
despit
commonli
occur
complic
immedi
outcom
asct
excel
optimum
support
care
f
sinatora
n
di
e
c
c
g
c
padua
depart
women
children
health
padova
itali
padua
depart
development
psycholog
socialis
padova
itali
backgroundobject
studi
focus
analysi
quantit
qualit
data
patient
undergo
hsct
childhood
bingen
et
al
aim
studi
investig
percept
ill
experi
patient
survivor
famili
correl
quantit
qualit
data
designmethod
three
differ
popul
answer
singl
question
diseas
experi
write
brief
composit
groupa
test
transplant
year
includ
patient
parent
sibl
groupb
compos
pediatr
hsct
survivor
parent
sibl
groupbov
includ
adult
survivor
least
year
pediatr
transplant
child
behavior
checklist
achenbach
rescorla
short
form
health
survey
ware
et
al
also
administ
ver
lancia
use
qualit
analys
result
semant
differ
group
indic
disrupt
familiar
uniti
way
diseas
face
major
impact
mental
health
famili
member
despit
year
hsct
second
group
theme
familiar
disrupt
well
inabl
refer
directli
diseas
fear
death
associ
clinic
score
scale
consid
third
group
show
signific
differ
respect
gender
type
transplant
conclus
result
seem
suggest
clinician
take
account
impact
diseas
hsct
could
mental
health
phase
care
moreov
care
approach
focu
attent
diseas
affect
whole
famili
relationship
member
n
singh
gurgaon
pediatr
hematoncolog
stem
cell
transplant
gurgaon
india
backgroundobject
estim
patient
requir
allogen
hsct
india
odd
patient
receiv
one
keep
cogniz
resourc
constraint
major
reason
discord
lie
lack
altern
donor
whilst
unrel
donor
marrow
cord
suffic
ethnic
major
europ
usa
registri
provid
less
hsct
recipi
due
cost
avail
match
aim
initi
pediatr
haploident
famili
donor
hsct
program
institut
design
method
materi
chose
cyclophosphamid
ptci
base
approach
except
one
tcr
alpha
beta
cd
deplet
use
pbsc
graft
sourc
carri
transplant
patient
last
year
fanconi
wiskott
aldrich
receiv
pbsc
ptci
day
follow
cyclosporinetacrolimu
mmf
except
one
condit
regimen
compris
fludarabinebusulphanmelphalan
aml
fludarabinethiotepamelphalan
fludarabinecyclotbi
fa
fludarabin
busulphanatg
thalassemia
result
patient
surviv
beyond
day
success
engraft
full
donor
chimer
patient
undergo
second
haploident
hct
engraft
well
acut
gvhd
grade
develop
patient
day
nrm
overal
surviv
year
major
caus
nrm
infect
gram
neg
bacilli
account
death
chronic
gvhd
occur
evalu
patient
stringent
monitor
cmv
preemptiv
therapi
none
succumb
cmv
diseas
conclus
hct
base
ptci
pbsc
graft
feasibl
probabl
viabl
form
altern
donor
hct
resourc
constrain
set
v
khandelw
p
r
superspeci
hospit
haematooncolog
bmt
delhi
india
superspeci
hospit
transfus
medicin
delhi
india
superspeci
hospit
haematolog
delhi
india
backgroundobject
analyz
retrospect
outcom
allogen
hematopoeit
stem
cell
transplant
hsct
high
risk
acut
pediatr
leukemia
designmethod
transplant
done
patient
period
year
median
age
year
rang
diagnosi
acut
lymphoblast
leukemia
patient
acut
myeloid
acut
promyelocyt
leukemia
one
first
remiss
second
third
refractori
diseas
transplant
type
haploident
condit
regimen
bufluci
vitro
cell
deplet
flumelatgthiotepa
patient
gvhd
prophylaxi
cyclosporin
methotrex
ptci
tacrolimusmmf
tacrolimusmmf
patient
result
transplant
receiv
bone
marrow
receiv
csf
mobil
peripher
blood
stem
cell
median
million
cellskg
infus
total
transplant
engraft
median
time
neutrophil
platelet
engraft
day
day
respect
seven
patient
develop
hemorrhag
cystitisacut
gvhd
gr
ii
iv
seen
chronic
gvhd
patient
cmv
reactiv
seen
patient
chimer
day
avail
case
full
donor
hematopoiesi
primari
reject
seen
secondari
reject
patient
fourteen
patient
die
caus
relaps
n
infect
n
gvhd
n
median
follow
period
day
overal
surviv
os
whole
group
discrimin
os
accord
remiss
statu
conclus
allogen
hsct
pediatr
high
risk
leukemia
show
encourag
resultsptci
base
haploident
hsct
also
one
option
develop
countri
cost
effect
r
wali
h
n
sj
khanum
memori
cancer
hospit
paediatr
oncolog
lahor
pakistan
backgroundobject
hodgkin
lymphoma
hl
common
cancer
children
adolesc
young
adult
peak
incid
age
overal
surviv
os
rate
newli
diagnos
hl
approxim
howev
subset
patient
hl
refractori
diseas
first
line
therapi
experi
diseas
relaps
patient
convent
salvag
therapi
autolog
stem
cell
transplant
often
consid
standard
care
analysi
report
outcom
patient
designmethod
retrospect
analysi
done
patient
hodgkin
lymphoma
refractori
relaps
diseas
shaukat
khanum
hospit
septemb
till
decemb
irb
approv
patient
high
dose
chemotherapi
follow
stem
cell
rescu
select
analysi
result
total
patient
regist
hospit
sixti
patient
either
primari
progressiverefractori
diseas
relaps
finish
first
line
chemotherapi
high
dose
chemotherapi
follow
stem
cell
given
patient
thirteen
patient
pd
earli
relaps
late
relaps
number
salvag
regimen
use
includ
epic
dhac
gemcitibinevinorelbin
done
take
patient
high
dose
show
cr
pr
pd
patient
twenti
one
patient
remiss
transplant
dead
due
septicemia
patient
progress
treatment
overal
surviv
year
event
free
surviv
year
conclus
retrospect
analysi
show
good
outcom
patient
progress
refractori
relaps
diseas
surviv
superior
chemo
sensit
diseas
abdallah
n
faculti
egypt
patholog
depart
alexandria
egypt
faculti
medicin
oncolog
alexandria
egypt
faculti
medicin
patholog
alexandria
egypt
backgroundobject
neuroblastoma
common
extracrani
solid
malign
childhood
diseas
favour
biolog
featur
curabl
surgeri
alon
high
risk
diseas
essenti
incur
new
treatment
strategi
need
patient
temozolamid
shown
clinic
activ
neuroblastoma
mgmt
overexpress
resist
factor
drug
designmethod
mgmt
express
assess
immunohistochem
formalin
fix
paraffin
embed
block
neuroblastoma
case
correl
clinicopatholog
paramet
age
site
histopatholog
stage
well
prognost
factor
fate
treatment
protocol
overal
surviv
os
diseas
free
surviv
df
result
neuroblast
tumor
studi
age
rang
year
femal
male
case
abdomin
case
thorac
signific
correl
found
mgmt
express
patient
age
tumor
site
histolog
type
grade
differenti
stage
signific
correl
note
mgmt
express
data
includ
fate
df
os
well
treatment
protocol
conclus
mgmt
express
prognost
factor
neuroblastoma
result
must
valid
larger
number
case
akta
p
e
z
n
eylul
univers
institut
oncolog
izmir
turkey
backgroundobject
tumor
microenviron
signific
current
topic
invas
spread
metastasi
surviv
cancer
cell
neuroblastoma
usual
poor
term
stroma
inflammatori
element
show
wide
spectrum
clinic
behavior
aggress
form
spontan
regress
tumor
microenviron
consid
evalu
aim
studi
compar
microenviron
associ
gene
express
low
intermedi
high
risk
neuroblastoma
normal
control
cell
matur
ganglioma
designmethod
cflar
egfr
kinas
express
level
analyz
pcr
rna
cdna
sampl
fresh
tumor
tissu
fold
chang
analysi
evalu
compar
control
group
result
case
includ
month
mean
age
month
femal
male
high
intermedi
low
risk
case
three
case
matur
ganglioneuroma
gene
express
profil
high
risk
case
compar
control
express
increas
cflar
egfr
decreas
express
increas
intermedi
risk
case
express
increas
case
found
ganglioneuroma
case
high
express
egfr
stood
low
risk
case
express
decreas
case
gene
role
immun
escap
show
differ
ganglioneuroma
significantli
increas
low
risk
case
plr
show
express
differ
neuroblastoma
conclus
ganglioneuroma
low
intermadi
high
risk
neuroblastoma
consid
spectrum
fgf
show
gradient
increas
suggest
candid
risk
defin
malign
marker
increas
express
also
suggest
remark
immun
escap
role
neuroblastoma
z
altun
p
n
eylul
univers
basic
oncolog
izmir
turkey
eylul
univers
pediatr
oncolog
izmir
turkey
backgroundobject
major
problem
advanc
neuroblastoma
presenc
minim
residu
diseas
mrd
investig
effect
peroxisom
receptor
ppr
agonist
antidiabet
rosiglitazon
rgz
regul
cell
prolifer
differenti
neuron
stem
cell
differenti
use
mrd
model
designmethod
pprgamma
express
express
kelli
neuroblastoma
cell
use
mrd
model
use
increas
dose
recurr
cisplatin
cddp
year
cddp
um
rgz
combin
appli
viabil
cell
determin
use
apoptosi
differenti
use
immunohistochem
flow
cytometr
nestin
result
mrd
model
cell
viabil
apoptosi
cddp
express
similar
mrd
model
normal
cell
cddp
treat
kelli
cell
differenti
slightli
increas
combin
differenti
differ
cddp
rgz
treatment
mrd
model
cell
caus
less
differenti
differenti
surviva
cell
similar
cddp
treat
control
cell
applic
reveal
remain
cell
less
differenti
cp
alon
particular
express
cell
caus
reduct
administr
mrd
model
conclus
cddp
rgz
combin
neuroblastoma
kelli
cell
cell
death
similar
level
wherea
express
cell
rgz
kill
cell
cddp
combin
effect
decreas
nestin
express
neuron
stem
cell
differenti
marker
mrd
model
examin
effect
antidiabet
agent
rosiglitazon
vivo
model
metastat
neuroblastoma
may
provid
new
perspect
neuroblastoma
therapi
acknowledg
studi
support
tpog
n
amayiri
e
h
e
hussein
cancer
center
pediatr
hematolog
oncolog
amman
jordan
pediatr
oncolog
depart
amman
jordan
hussein
cancer
center
stem
cell
pediatr
jordan
amman
jordan
hospit
sick
canada
divis
toronto
canada
backgroundobject
headstart
protocol
hs
chemotherapi
strategi
infant
malign
cn
tumor
report
variabl
success
toxic
profil
ratio
rare
report
incom
countri
lmic
aim
evalu
hs
experi
khcc
jordan
designmethod
retrospect
review
chart
children
diagnos
cn
tumor
treat
hs
data
collect
includ
patient
demograph
chemotherapi
complic
cost
result
eighteen
patient
median
age
month
diagnosi
identifi
twelv
six
twelv
diseas
four
gtr
patholog
atrt
pnet
medulloblastoma
three
patient
nt
complet
induct
cycl
atrt
progress
pnet
fail
collect
fifteen
patient
complet
induct
chemotherapi
eleven
went
crpr
two
stabil
two
progress
seven
patient
nt
receiv
sct
tumor
progress
financi
caus
fail
stem
cell
collect
famili
declin
unknown
six
patient
receiv
radiotherapi
two
residu
atrt
follow
sct
two
atrt
financi
limit
two
atrt
medulloblastoma
upon
tumor
progress
chemotherapi
cycl
administ
median
interv
day
complic
induct
consolid
phase
febril
neutropenia
document
infect
picu
admiss
mucosit
respect
three
patient
develop
hear
deficit
one
tubulopathi
last
follow
patient
aliv
three
patient
medulloblastoma
one
receiv
csi
chemotherapi
relaps
two
patient
atrt
aliv
receiv
focal
radiat
residu
tumor
death
occur
median
hospit
day
median
cost
treatment
conclus
toxic
hs
manag
lmic
financi
cost
high
limit
surviv
better
select
criteria
eg
high
risk
medulloblastoma
financi
support
may
outbal
surviv
cost
e
andreev
rogachev
nation
research
center
pediatr
oncolog
immunolog
pediatr
surgeri
oncolog
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
pediatr
oncolog
moscow
russia
backgroundobject
one
promis
area
pediatr
oncolog
mi
children
thoracoabdomin
neuroblastomaw
investig
compar
result
laparoscopi
laparotomi
treatment
designmethod
radic
surgic
treatment
perform
patient
laparoscopi
perform
patient
treat
accord
risk
factor
idrf
size
tumor
use
select
patientsto
compar
effect
laparotomi
laparoscopi
patient
neuroblastoma
without
idrf
follow
item
retrospect
compar
largest
tumor
dimens
volum
blood
loss
time
requir
initi
postop
feed
locoregion
recurr
rate
surviv
etc
result
patient
without
idrf
risk
high
risk
underw
laparotomi
patient
without
idrf
risk
high
risk
underw
laparoscopymedian
age
month
laparotomi
month
laparoscopi
median
durat
surgeri
min
median
postop
time
requir
resum
meal
consumpt
significantli
longer
laparotomi
group
day
laparoscopi
group
day
median
blood
loss
significantli
higher
laparotomi
group
ml
laparoscopi
group
ml
p
median
time
draenag
remov
higher
laparotomi
group
ml
laparoscopi
group
day
p
median
time
analgesia
higher
laparotomi
group
day
laparoscopi
group
day
median
time
antibacteri
therapi
higher
laparotomi
group
day
laparoscopi
group
day
median
time
monthsw
differ
intraop
postop
complic
local
reccur
mortal
postop
period
conclus
mi
children
intraabdomin
neuroblastoma
effect
techniqu
enabl
carri
radic
surgeri
absenc
contraind
idrf
provid
minim
invas
good
cosmet
effect
without
worsen
oncolog
prognosi
arsenian
henriksson
g
mv
ruiz
j
h
h
j
institutet
tumor
cell
biolog
stockholm
sweden
institutet
oncologypatholog
stockholm
sweden
backgroundobject
neuroblastoma
nb
aris
develop
sympathet
nervou
system
one
aggress
solid
tumor
earli
childhood
amplif
mycn
oncogen
found
around
nb
patient
associ
rapid
tumor
progress
poor
prognosi
recent
find
show
target
mycn
small
molecul
includ
result
metabol
chang
includ
mitochondri
dysfunct
lead
accumul
lipid
droplet
nb
cell
zirath
et
al
pna
designmethod
investig
downstream
effect
mycn
target
perform
quantit
proteom
nb
cell
mycn
downregul
use
short
hairpin
rna
mycn
identifi
protein
around
use
identif
novel
pathway
involv
neuroblastoma
pathogenesi
also
perform
metabol
flux
analysi
result
found
primari
metabol
process
includ
protein
lipid
nucleic
acid
metabol
process
significantli
affect
activ
upon
mycn
downregul
analysi
impact
mycn
express
glycolysi
mitochondri
capac
perform
metabol
flux
measur
use
seahors
xf
analys
data
show
nb
cell
high
metabol
potenti
primarili
use
oxid
phosphoryl
energi
consumpt
also
found
mycn
posit
regul
respiratori
capac
also
significantli
enhanc
glycolysi
importantli
demonstr
mycn
posit
regul
abil
nb
cell
oxid
exogen
fatti
acid
conclus
taken
togeth
find
show
mycn
express
enhanc
bioenerget
capabl
nb
cell
shift
metabol
process
depend
avail
nutrit
data
highlight
import
metabol
pathway
tumor
aggress
may
basi
futur
cancer
therapi
patient
nb
c
huang
x
z
w
q
x
c
x
children
hospit
hematolog
oncolog
capit
medic
univers
bei
jing
china
backgroundobject
summar
clinic
featur
neuroblastoma
amplif
analys
evalu
effect
chemotherapi
earli
stage
designmethod
research
analyz
medic
record
patient
amplif
nb
feb
dec
beij
children
hospit
regimen
accord
protocol
hospit
base
protocol
data
review
medic
histori
analysis
virat
biomark
primari
site
object
effect
chemotherapi
result
case
admit
research
primari
site
tumor
retroperiton
adren
area
case
posit
bone
marrow
cytomorpholig
examin
proport
tumor
rang
case
case
case
report
lactat
dehydrogenas
ldh
level
higher
normal
case
case
diamet
tumor
lager
case
case
measur
volum
case
case
rang
case
larger
case
finish
cours
chemotherapi
case
reduc
among
case
case
bone
marrow
examin
revers
neg
accord
imageolog
examin
overal
respons
rate
cours
chemotherapi
case
achiev
vgpr
case
achiev
pr
case
achiev
mr
case
nr
case
show
pd
conclus
nb
gene
amplif
sensit
chemotherapi
chemotherapi
minish
burden
tumor
earli
stage
huge
burden
huge
size
tumor
ripe
opportun
receiv
surgeri
autolog
stem
cell
transplant
patient
go
receiv
chemotherapi
remiss
diseas
cho
j
univers
hospit
pediatr
sapporo
japan
cancer
center
pediatr
sapporo
japan
backgroundobject
neuroblastoma
aggress
malign
heterogen
tumor
children
case
month
old
case
primari
tumor
aris
mediastinum
tend
better
prognosi
sometim
detect
chanc
case
mediastin
neuroblastoma
imag
examin
mild
respiratori
ill
older
children
clarifi
characterist
import
appropri
treatment
designmethod
analyz
patient
neuroblastoma
diagnos
hokkaido
univers
hospit
hokkaido
cancer
center
retrospect
case
month
old
case
detect
mass
screen
appar
symptom
exclud
analyt
factor
includ
primari
site
detect
stage
patholog
molecular
biolog
treatment
outcom
result
patient
neuroblastoma
case
mediastin
neuroblastoma
detect
chanc
month
old
nine
case
detect
examin
pneumonia
bronchiti
abdomen
ct
scan
health
checkup
serum
nse
level
cut
ngml
vma
urin
cut
hva
cut
eight
case
total
resect
thoracoscop
surgeri
open
thorac
surgeri
two
limit
partial
resect
even
open
thorac
surgeri
one
biopsi
diagnosi
eight
case
inss
stage
one
case
stage
case
stage
six
case
ganglioneuroblastoma
ganglioneuroma
mycn
gene
amplifi
case
chemotherapi
perform
case
case
chemotherapi
even
partial
resect
aliv
year
diagnosi
conclus
almost
everi
case
mediastin
neuroblastoma
detect
chanc
month
old
show
characterist
low
risk
group
good
prognosi
expect
without
drastic
treatment
cimolai
r
p
j
p
w
c
de
prof
dr
juan
p
garrahan
hematolog
oncolog
bueno
air
argentina
de
prof
dr
juan
p
garrahan
immunolog
rheumatolog
depart
bueno
air
argentina
backgroundobject
outcom
neuroblastoma
nb
depend
sever
well
stablish
prognost
factor
bone
marrow
bm
evalu
convent
cytolog
diagnosi
treatment
limit
sensit
suitabl
minim
residu
diseas
mrd
detect
measur
describ
sensit
specif
marker
mrd
analysi
aim
perform
molecular
mrd
evalu
differ
time
point
order
evalu
prognost
valu
popul
patient
designmethod
quantit
perform
bm
sampl
patient
treat
garrahan
pediatr
hospit
first
second
line
treatment
protocol
median
sampl
per
patient
evalu
rang
median
time
rang
month
prognost
impact
mrd
diagnosi
cycl
cycl
time
evalu
use
fisher
result
detect
evalu
sampl
diagnosi
cycl
correl
found
outcom
mrd
statu
time
point
howev
molecular
bm
remiss
detect
associ
better
outcom
mrd
neg
cycl
versu
mrd
neg
time
versu
conclus
despit
limit
number
patient
includ
studi
neg
mrd
bm
sampl
cycl
everi
time
treatment
seem
identifi
group
patient
signific
better
outcom
associ
found
diagnosi
cycl
treatment
preliminari
result
suggest
use
mrd
marker
popul
patient
nb
liu
l
j
q
tongji
medic
huazhong
univers
scienc
technolog
pediatr
wuhan
china
hospit
tongji
medic
colleg
hua
zhong
univers
scienc
pediatr
wuhan
china
medic
huazhong
univers
scienc
technolog
experiment
medicin
center
wuhan
china
southwestern
medic
center
radiat
oncolog
dalla
usa
medic
huazhong
univers
scienc
technolog
pediatr
wuhan
china
backgroundobject
neuroblastoma
one
common
malign
pediatr
solid
tumor
prognosi
neuroblastoma
still
poor
mycn
amplif
risk
factor
stabil
close
link
aurora
studi
investig
effect
molecular
mechan
senesc
induc
alisertib
small
molecul
select
inhibit
aurora
high
risk
neuroblastoma
designmethod
senesc
detect
stain
relat
protein
express
analyz
western
blot
vivo
experi
carri
tumor
xenograft
model
mice
result
could
induc
neuroblastoma
cell
senesc
via
inhibit
phosphoryl
aurora
could
also
inhibit
tumor
growth
prolong
surviv
time
xenograft
tumor
mice
howev
senesc
cell
tend
recov
cell
cycl
arrest
treatment
vitro
found
activ
signal
transduc
activ
transcript
pathway
could
promot
tumor
progress
recurr
senesc
neuroblastoma
cell
inhibit
small
molecul
inhibitor
senesc
revers
could
suppress
conclus
induc
cellular
senesc
neuroblastoma
activ
pathway
senesc
cell
result
provid
new
relaps
mechan
neuroblastoma
explor
novel
therapeut
target
cellular
senesc
signal
k
dong
x
r
hospit
fudan
univers
surgeri
shanghai
china
backgroundobject
circul
tumor
cell
ctc
shown
associ
prognosi
therapeut
efficaci
mani
tumor
detect
peripher
blood
circul
tumor
cell
neuroblastoma
discus
valu
prognosi
treatment
evalu
designmethod
newli
diagnos
case
neuroblastoma
circul
tumor
cell
collect
neg
enrich
method
combin
relationship
number
circul
tumor
cell
clinic
factor
analyz
addit
peripher
blood
ctc
type
solid
tumor
examin
assess
differ
neuroblastoma
result
children
distant
metastas
number
ctc
higher
type
tumor
number
ctc
high
middl
low
risk
group
children
statist
differ
mean
rank
diff
number
ctc
children
posit
lower
children
p
urin
vma
relationship
ctc
number
serum
nse
posit
correl
ctc
number
spearman
test
r
ci
p
signific
differ
distant
metastasi
group
group
p
whose
ctc
number
number
significantli
went
patient
chemotherapi
month
roc
curv
show
ci
cutoff
surviv
time
ctc
number
time
dignos
shorter
conclus
number
peripher
blood
ctc
children
neuroblastoma
higher
solid
tumor
ctc
number
associ
cog
classif
distant
metastasi
serum
nse
level
surviv
time
children
peripher
blood
ctc
number
shorter
number
druy
g
e
l
l
scientif
practic
center
pediatr
oncolog
laboratori
cytogenet
molecular
genet
moscow
russia
institut
medic
cell
technolog
laboratori
cellular
therapeut
oncohematolog
disord
yekaterinburg
russia
center
nuclear
medicin
pet
diagnost
yekaterinburg
russia
children
hospit
depart
pediatr
oncolog
yekaterinburg
russia
state
medic
univers
chair
laboratori
medicin
yekaterinburg
russia
backgroundobject
clinic
heterogen
hallmark
neuroblastoma
nb
tert
hyperexpress
identifi
advers
prognost
marker
signific
microrna
express
profil
nb
undiscov
aim
investig
prognost
signific
tert
express
primari
nb
design
method
rna
sampl
nb
tissu
subject
qrtpcr
tert
express
evalu
copi
number
variat
determin
mlpa
fish
correspond
tert
express
level
surviv
ef
prove
establish
threshold
level
tl
util
group
separ
subsequ
surviv
analysi
median
time
achiev
year
result
abund
tert
express
lack
express
result
superior
frequenc
advers
event
respect
ef
group
patient
tert
express
group
tert
patient
express
group
patient
harbor
tert
overexpress
lack
express
group
dismal
outcom
ef
compar
patient
without
abnorm
group
neither
ef
p
analog
cumul
incid
progress
group
tert
neither
p
mycn
amplifi
mna
case
accumul
group
tert
gain
chromosom
delet
prevail
group
neither
accordingli
mna
delet
prognost
signific
correspond
group
p
classifi
propos
distinguish
patient
unequ
outcom
mna
mycn
singl
copi
patient
divid
group
tert
group
neither
separ
base
presenc
absenc
delet
p
conclus
level
tert
express
togeth
cytogenet
data
allow
discrimin
patient
group
significantli
differ
outcom
fahi
k
c
l
l
g
jt
sick
children
gener
thorac
surgeri
toronto
canada
toronto
depart
laboratori
medicin
pathobiolog
toronto
canada
sick
children
center
imag
guid
innov
therapeut
intervent
toronto
canada
bay
region
research
institut
intervent
thunder
bay
canada
sick
children
depart
hematologyoncolog
toronto
canada
sick
children
depart
patholog
toronto
canada
backgroundobject
magnet
reson
guid
high
intens
focus
ultrasound
mrghifu
technolog
use
extracorpor
focus
ultrasound
transduc
converg
high
intens
focus
ultrasound
hifu
energi
onto
specif
tissu
target
via
mr
guidanc
focus
ultrasound
energi
induc
local
thermal
necrosi
benign
malign
tissu
simultan
mr
thermometri
monitor
temperatur
surround
structur
avoid
unintend
thermal
injuri
aim
evalu
effect
mrghifu
mous
model
neuroblastoma
nbl
designmethod
nodscid
mice
inocul
nbl
cell
line
left
hind
limb
tumor
growth
monitor
size
reach
largest
dimens
tumor
treat
mrghifu
acoust
watt
second
control
tumor
imag
treat
immedi
mice
euthan
tumor
immers
fix
neutral
buffer
formalin
paraffin
embed
stain
h
e
elastin
trichrom
gross
histolog
evalu
result
tumor
reach
mm
size
treat
mm
untreat
mm
hifu
treatment
increas
temperatur
tumor
rang
histolog
chang
treat
tumor
includ
confluent
necrosi
diffus
singl
cell
necrosi
larg
area
intratumor
hemorrhag
untreat
tumor
sporad
singl
cell
necrosi
small
area
intratumor
hemorrhag
area
confluent
necrosi
conclus
mrghifu
use
caus
local
thermal
necrosi
tumor
mous
model
nbl
work
underway
investig
effect
mrghifu
tumor
growth
mous
surviv
mrghifu
may
offer
potenti
addit
local
therapi
patient
recurr
refractori
high
risk
nbl
elhemali
e
h
cancer
institut
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
elmonofia
univers
pediatr
oncolog
cairo
egypt
cancer
institut
children
cancer
hospit
egypt
clinic
patholog
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
backgroundobject
neuroblastoma
common
extracrani
solid
tumor
children
account
death
cancer
pediatr
age
group
approxim
half
newli
diagnos
children
high
risk
treatment
failur
studi
aim
evalu
impact
salvag
chemotherapi
ice
ifosfamid
carboplatin
etoposid
versu
tc
topotecancyclophosphamid
administ
neuroblastoma
high
risk
patient
residu
bone
marrow
diseas
primari
tumor
control
first
line
treatment
regimen
designmethod
present
retrospect
studi
includ
match
group
elig
stage
neuroblastoma
patient
persist
bone
marrow
diseas
group
consist
patient
group
patient
receiv
ice
wherea
less
intens
tc
administ
group
data
analysi
includ
epidemiolog
variabl
patholog
subtyp
nmyc
gene
statu
primari
tumor
respons
correl
bone
marrow
diseas
clearanc
regimen
result
higher
tendenc
complet
bone
marrow
clearanc
report
patient
receiv
ice
compar
tc
versu
respect
howev
differ
statist
signific
p
conclus
tc
regimen
appear
ice
salvag
treatment
attempt
clear
bone
marrow
neuroblastoma
residu
privileg
less
toxic
given
outpati
basi
yet
random
trial
larger
studi
sampl
size
surviv
impact
analysi
warrant
p
dijkstra
van
l
k
center
pediatr
oncolog
ped
oncolog
utrecht
netherland
center
pediatr
oncolog
honour
program
umcu
utrecht
netherland
backgroundobject
improv
neuroblastoma
nbl
treatment
within
center
compar
nbl
treatment
center
qualiti
indic
may
help
surrog
marker
effect
treatment
studi
report
data
qualiti
indic
diagnost
thyroid
protect
use
tumor
board
meet
may
correl
treatment
effect
toxic
designmethod
retrospect
analysi
perform
dutch
patient
treat
nbl
nation
central
facil
princess
center
medic
record
review
extract
inform
demograph
treatment
qualiti
care
indic
variabl
record
includ
present
complet
use
thyroid
prophylaxi
mibg
imag
chemotherapi
interv
use
meet
analysi
surgic
procedur
topic
anoth
studi
includ
analysi
result
data
patient
treat
avail
analysi
patient
classifi
inss
stage
case
stage
ii
stage
iii
stage
iv
stage
iv
percent
patient
nbl
stratifi
treatment
median
time
present
complet
diagnost
urinari
catecholamin
patholog
day
rang
day
prescript
treatment
prior
record
patient
interv
diagnosi
end
origin
plan
interv
final
found
evalu
discuss
meet
conclus
identif
analysi
neuroblastoma
treatment
feasibl
may
provid
tool
improv
treatment
time
compar
treatment
qualiti
variou
center
j
p
hundsdoerf
c
f
f
pc
h
w
h
univers
medicin
depart
nuclear
medicin
berlin
germani
univers
medicin
pediatr
oncolog
berlin
germani
helmholtz
zentrum
institut
radiopharmaceut
cancer
research
dresden
germani
medicin
greifswald
institut
diagnost
radiolog
neuroradiolog
greifswald
germani
medicin
greifswald
depart
pediatr
oncolog
hematolog
greifswald
germani
backgroundobject
treatment
children
neuroblastoma
nb
occur
accord
clinic
genet
factor
studi
evalu
signific
metabol
tumor
volum
mtv
aspher
asp
pretherapeut
im
individu
predict
outcom
designmethod
retrospect
analysi
children
median
age
year
primari
diagnosi
nb
consecut
examin
pretherapeut
im
primari
tumor
mtv
asp
defin
use
threshold
cox
regress
roc
analysi
determin
km
analys
test
surviv
ef
perform
asp
mtv
laboratori
paramet
urinari
homovanil
ratio
hvac
clinic
age
stage
genet
factor
predict
accuraci
optim
multifactori
model
determin
harrel
c
lr
result
median
month
diseas
progressionrelaps
death
asp
hazard
ratio
hr
increas
mtv
hr
mycn
hr
signific
predictor
ef
univari
cox
asp
also
multivari
analysi
hr
mean
ef
high
vs
low
asp
vs
month
high
ml
vs
low
mtv
vs
month
combin
risk
model
either
high
asp
high
hvac
high
mtv
high
hvac
best
predict
ef
conclus
explor
studi
pretherapeut
laboratori
marker
tumor
metabol
activ
neuroblastoma
asp
mtv
urinari
ratio
allow
identifi
children
high
low
risk
progressionrelaps
treat
accord
current
therapi
protocol
iehara
h
prefectur
univers
medicin
pediatr
kyoto
japan
prefectur
univers
medicin
biostatist
kyoto
japan
citi
gener
hospit
pediatr
surgeri
oasaka
japan
cancer
center
research
institut
clinic
oncolog
saitama
japan
center
child
health
develop
patholog
tokyo
japan
medic
univers
pediatr
oncolog
fukushima
japan
center
child
health
develop
center
clinic
research
develop
tokyo
japan
medic
center
koseikan
saga
medic
center
koseikan
saga
japan
prefectur
univers
medicin
pediatr
surgeri
kyoto
japan
backgroundobject
aim
reduc
incid
treatment
complic
improv
outcom
neuroblastoma
patient
use
preoper
chemotherapi
without
myeloabl
chemotherapi
make
treatment
decis
time
oper
base
risk
factor
idrf
designmethod
prospect
studi
conduct
patient
inss
stage
without
mycn
amplif
includ
children
month
age
favor
histolog
month
age
unfavor
histolog
treat
induct
regimen
b
vincristinecyclophosphamidepirarubicin
c
vincristinecyclophosphamidecarboplatin
idrf
present
patient
underw
surgeri
resect
tumor
judg
base
idrf
everi
cours
respons
rate
insuffici
treatment
chang
cours
regimen
vincristinecyclophosphamidepirarubicincisplatin
patient
stage
without
mycn
amplif
includ
children
month
month
age
favor
histolog
dna
index
treat
cours
regimen
possibl
surgic
resect
perform
base
idrf
cours
target
sampl
size
result
plan
interim
analysi
elig
patient
enrol
trial
stage
stage
median
age
month
rang
month
surviv
rate
whole
studi
popul
stage
patient
stage
patient
ci
ci
ci
respect
ten
percent
whole
studi
popul
show
ileu
show
pleural
effus
ascit
earli
complic
surgeri
howev
complic
surgeri
trial
decid
continu
conclus
treatment
strategi
increas
incid
complic
trial
decid
continu
inomistova
n
g
cancer
institut
laboratori
experiment
oncolog
kiev
ukrain
cancer
institut
depart
pediatr
oncolog
kiev
ukrain
backgroundobject
neuroblastoma
malign
paediatr
tumour
sympathet
nervou
system
often
accompani
mycn
amplif
mna
studi
affect
chemotherapi
effici
help
understand
mechan
neuroblastoma
progress
designmethod
case
group
compris
children
neuroblastoma
control
group
healthi
donor
polymorph
detect
pcr
dna
peripher
blood
patient
healthi
donor
express
level
el
analys
tumour
sampl
use
taqman
primer
probe
result
polymorph
distribut
patient
neuroblastoma
compli
equilibrium
genotyp
observ
patient
advanc
stage
iii
iv
stage
earlier
occurr
age
neuroblastoma
median
month
month
month
patient
mna
genotyp
patient
neuroblastoma
highest
el
observ
tumour
unfavour
clinic
featur
earli
occurr
age
advanc
stage
recurr
metastat
foci
lower
el
observ
mna
tumour
sampl
patient
genotyp
analys
overal
surviv
os
establish
patient
genotyp
significantli
lower
os
vs
vs
assess
optim
criterion
patient
distribut
accord
el
auc
analys
os
accord
polymorph
el
os
significantli
higher
patient
low
el
compar
group
p
conclus
genotyp
associ
unfavour
prognosi
neuroblastoma
patient
low
el
higher
os
analysi
polymorph
express
along
biomark
import
step
improv
neuroblastoma
risk
stratif
jannier
l
l
ew
universitair
de
strasbourg
oncolog
strasbourg
franc
universitair
de
strasbourg
patholog
strasbourg
franc
strasbourg
strasbourg
franc
backgroundobject
neuroblastoma
second
frequent
pediatr
solid
tumor
high
risk
neuroblastoma
nmyc
amplifi
andor
metastat
patient
overal
surviv
hope
cure
case
relaps
hypoxia
appear
correl
aggress
phenotyp
resist
chemotherapi
recent
describ
neuroblastoma
specif
studi
describ
precis
pathway
involv
pathway
activ
seem
link
poor
prognost
tumor
recent
atrx
mutat
also
describ
associ
neuroblastoma
possibl
link
hypoxia
designmethod
retrospect
studi
design
character
target
immunohistochemistri
ihc
akt
mtor
atrx
neuroblastoma
patient
strasbourg
center
sign
parent
inform
consent
result
six
biomark
analyz
ihc
pakt
perk
atrx
patient
neg
overexpress
patient
among
patient
high
risk
patient
among
pakt
posit
patient
also
posit
perk
posit
perk
patient
patient
mainli
local
vessel
patient
concomit
perk
posit
stain
loss
atrx
observ
patient
without
correl
marker
conclus
preliminari
studi
show
implic
hypoxia
signal
pathway
mainli
neuroblastoma
kachanov
e
n
g
v
e
research
center
pediatr
hematolog
oncolog
immunolog
clinic
oncolog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
surgeri
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
cytogenet
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
radiolog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
patholog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
radiat
oncolog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
nuclear
medicin
moscow
russia
backgroundobject
aim
studi
analyz
clinic
characterist
result
therapi
patient
neuroblastoma
treat
russian
feder
center
designmethod
patient
neuroblastoma
treat
period
month
diagnosi
establish
basi
intern
criteria
fish
done
assess
statu
patient
stratifi
treat
accord
german
protocol
patient
stratifi
group
therapi
consist
cycl
multiag
chemotherapi
surgeri
radiat
therapi
residu
primari
tumor
induct
chemotherapi
cycl
mainten
therapi
cycl
acid
result
male
femal
ratio
median
age
month
rang
common
site
primari
tumor
retroperitoneum
stage
distribut
stage
case
stage
stage
segment
chromosom
aberr
patient
receiv
per
protocol
therapi
treat
protocol
modif
complic
surgeri
done
patient
macroscop
residu
tumor
observ
radiat
therapi
done
induct
therapi
patient
achiev
complet
good
partial
respons
differ
respons
rate
stage
stage
median
month
rang
progressionrelaps
observ
case
os
ef
whole
cohort
ef
patient
treat
without
protocol
violat
conclus
intensif
therapi
patient
neuroblastoma
compar
patient
observ
group
allow
achiev
satisfactori
result
given
therapi
provid
without
violat
shamanskaya
g
v
research
center
pediatr
hematolog
oncolog
immunolog
clinic
oncolog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
surgeri
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
radiolog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
nuclear
medicin
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
patholog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
cytogenet
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
radiat
oncolog
moscow
russia
backgroundobject
cn
relaps
patient
neuroblastoma
extrem
unfavor
clinic
event
aim
studi
analyz
frequenc
occurr
factor
predispos
develop
cn
involv
patient
neuroblastoma
time
first
relaps
designmethod
patient
neuroblastoma
receiv
treatment
period
includ
analys
patient
stratifi
risk
group
treat
accord
german
protocol
prepar
regimen
includ
melphalanetoposidecarboplatin
mec
till
june
treosulfanmelphalan
treomel
sinc
juli
result
patient
analyz
progressionrelaps
cn
involv
observ
isol
cn
involv
note
median
age
time
neuroblastoma
diagnosi
patient
cn
involv
month
rang
male
femal
ratio
primari
tumor
locat
abdomen
case
unknown
primari
patient
stage
diseas
mycn
amplif
detect
median
time
diagnosi
till
progressionrelaps
month
rang
comparison
two
group
relaps
patient
cn
involv
lack
cn
involv
sex
age
site
primari
tumor
mycn
gene
statu
skull
metastas
bone
marrow
involv
onset
diseas
number
metastat
compart
respons
induct
therapi
type
prepar
regimen
cem
vs
treomel
show
statist
signific
differ
overal
surviv
develop
studi
group
conclus
cn
involv
time
relaps
frequent
event
neuroblastoma
introduct
cn
mri
standard
time
relapseprogress
allow
time
detect
metastas
optim
therapeut
strategi
p
kogner
j
j
p
l
j
pj
ji
rh
b
institutet
childhood
cancer
research
unit
stockholm
sweden
univers
medic
biochemistri
cell
biolog
sweden
univers
clinic
genet
sweden
univers
patholog
sweden
institutet
oncolog
patholog
stockholm
sweden
institutet
pediatr
radiolog
stockholm
sweden
institutet
pediatr
surgeri
stockholm
sweden
backgroundobject
person
medicin
implement
success
target
therapi
requir
understand
complex
molecular
mechan
activ
import
genet
factor
neuroblastoma
develop
aggress
suggest
novel
target
therapi
embryon
childhood
tumor
underli
fanconi
anemia
avail
convent
chemotherapi
poor
outcom
designmethod
patient
bonemarrow
multipl
bone
intracrani
metastas
start
siopen
sever
toxic
alreadi
second
found
due
underli
fanconi
anemia
confirm
analysi
germlin
c
subsequ
tumor
sequenc
reveal
novel
somat
neuroblastoma
alk
c
mutat
search
therapeut
opportun
biolog
natur
character
preclin
result
show
novel
alk
tyrosin
kinas
domain
mutat
threonin
gener
potent
mutant
observ
cell
cultur
model
system
cell
show
alk
activ
neurit
outgrowth
downstream
signal
activ
mediat
foci
format
transform
analysi
final
show
better
abil
abrog
compar
crizotinib
toxic
multiorgan
complic
handledsubsid
target
treatment
start
compassion
use
elev
urinari
normal
first
cycl
hemoglobin
normal
platelet
improv
stabl
level
metastat
diseas
gradual
resolv
mri
show
primari
tumor
radic
remov
month
treatment
complet
radiolog
urinari
catecholamin
bonemarrow
investig
confirm
complet
respons
month
treatment
without
signific
mild
note
conclus
show
alk
activ
promot
neuroblastoma
aggress
monotherapi
ceritinib
induc
complet
respons
child
metastat
neuroblastoma
unabl
receiv
convent
treatment
c
k
k
n
van
b
de
g
laurey
univers
hospit
depart
pediatr
stem
cell
transplant
ghent
belgium
univers
hospit
depart
laboratori
medicin
ghent
belgium
univers
hospit
center
medic
genet
ghent
cmgg
ghent
belgium
backgroundobject
genet
suscept
cancer
subject
consider
interest
unravel
etiolog
natur
histori
cancer
play
essenti
role
understand
molecular
biolog
cancer
famili
cluster
childhood
cancer
among
strongest
suggest
situat
genet
suscept
designmethod
exom
sequenc
use
identifi
novel
cancer
predisposit
gene
famili
boy
affect
neuroblastoma
second
cousin
ganglioneuroma
interestingli
previous
identifi
de
novo
constitut
transloc
boy
absent
affect
second
cousin
laurey
et
al
laurey
et
al
result
predispos
variant
put
forward
candid
select
rarenovel
variant
share
affect
second
cousin
mother
first
cousin
found
spousal
control
amongst
other
identifi
deleteri
mutat
g
locat
end
lectin
domain
highli
conserv
region
potenti
interfer
ligand
interact
homodimer
interestingli
hoffmann
colleagu
shown
bind
interf
interact
protect
natur
killer
cytotox
indic
mutat
within
may
affect
immun
surveil
cancer
predisposit
gene
hoffmann
et
al
seishima
et
al
jongman
et
al
silico
analysi
reveal
somat
mutat
frequenc
vari
medulloblastoma
head
neck
carcinoma
conclus
ongo
work
highlight
valu
use
index
famili
multipl
children
affect
cancer
valuabl
sourc
identifi
novel
cancer
predisposit
gene
tl
gl
share
senior
author
j
luca
jr
v
g
r
c
v
w
k
l
jude
children
research
hospit
radiat
oncolog
memphi
usa
california
san
francisco
radiat
oncolog
san
francisco
usa
california
san
francisco
pediatr
san
francisco
usa
jude
children
research
hospit
biostatist
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
jude
children
research
hospit
bone
marrow
transplant
cellular
therapi
memphi
usa
backgroundobject
sinusoid
obstruct
syndrom
so
morbid
complic
high
risk
neuroblastoma
hrnb
therapi
evalu
associ
extern
beam
radiotherapi
ebrt
chemotherapi
clinic
factor
so
incid
durat
sever
hrnb
patient
designmethod
newli
diagnos
hrnb
patient
treat
multipl
institut
induct
consolid
chemotherapi
autolog
stem
cell
transplant
radiotherapi
mainten
therapi
retrospect
review
examin
patient
laboratori
treatment
characterist
day
so
prophylaxi
treatment
complic
intub
failur
etc
document
gener
linear
regress
use
assess
associ
covari
incid
durat
sever
so
result
sixteen
patient
diagnos
so
median
time
transplant
so
day
rang
median
durat
so
day
rang
case
so
preced
ebrt
median
time
ebrt
transplant
patient
without
so
week
respect
p
earlier
time
ebrt
prescript
dose
gy
liver
dose
dmean
impact
incid
durat
recurr
sever
so
induct
vs
consolid
mec
vs
bumel
mec
vs
p
chemotherapi
impact
durat
so
death
occur
one
patient
receiv
consolid
so
incid
complic
differ
across
treat
patient
howev
treat
patient
develop
so
requir
icu
support
compar
treat
patient
conclus
cohort
ebrt
dose
volum
time
transplant
impact
incid
sever
recurr
durat
so
induct
transplant
condit
impact
durat
sever
so
j
z
lu
children
hospit
hematologyoncolog
shanghai
china
children
hospit
surgeri
shanghai
china
backgroundobject
neuroblastoma
second
common
extracrani
malign
solid
tumor
occur
childhood
metastasi
one
major
caus
death
neuroblastoma
patient
transit
emt
import
mechan
initi
tumor
invas
subsequ
metastasi
studi
investig
mechan
emt
induc
transform
growth
factor
tgf
human
neuroblastoma
cell
designmethod
present
studi
focus
regulatori
effect
emt
human
neuroblastoma
cell
correl
transcript
factor
gli
use
quantit
western
blot
analysi
immunocytochemistri
cell
transfect
etc
result
identifi
mrna
protein
express
level
significantli
decreas
significantli
increas
cell
treat
differ
concentr
scratch
test
transwel
migrat
assay
reveal
cell
migrat
increas
significantli
increasingli
higher
concentr
mean
induc
emt
cell
increas
cell
migrat
interfer
express
affect
express
key
molecul
emt
investig
found
express
transcript
factor
gli
increas
significantli
emt
induc
cell
interf
express
inhibit
emt
induc
cell
target
inhibitor
transcript
factor
reduc
prolifer
cell
promot
cell
apoptosi
conclus
author
conclud
induc
emt
cell
increas
cell
migrat
emt
induc
cell
may
depend
smad
signal
pathway
transcript
factor
gli
particip
emt
induc
smad
independ
signal
pathway
j
mazar
c
children
hospit
biomed
research
orlando
usa
central
florida
materi
scienc
advanc
materi
process
center
orlando
usa
central
florida
nanosci
technolog
center
orlando
usa
backgroundobject
associ
poor
prognosi
human
neuroblastoma
reflect
low
overal
surviv
rate
children
gene
amplif
result
investig
novel
molecular
formul
nanoceria
curcumin
demonstr
properti
synthes
appli
treatment
neuroblastoma
activ
formul
explor
neuroblastoma
cell
designmethod
test
formul
util
neuroblastoma
cell
line
well
cell
line
effect
induc
neuroblastoma
cell
curcumin
examin
mt
caspas
ro
tunel
assay
well
western
blot
analysi
chang
gene
express
huvec
cell
serv
control
cell
evid
effect
ceria
nanoparticl
result
ceria
nanoparticl
coat
dextran
load
curcumin
found
induc
substanti
cell
death
neuroblastoma
cell
produc
minor
toxic
toward
healthi
cell
death
neuroblastoma
cell
confirm
due
apoptosi
induc
via
ratio
disrupt
reactiv
oxygen
speci
accumul
addit
express
analyz
shown
sampl
treat
ceria
due
ceria
oxygen
buffer
capac
conclus
treatment
human
neuroblastoma
cell
ceria
nanoparticl
success
induc
cell
death
addit
coat
nanoceria
dextran
appear
enhanc
phenotyp
analysi
caus
cell
death
suggest
apoptosi
induc
due
stabil
indic
induct
hypox
condit
signific
accumul
reactiv
oxygen
speci
overal
ceria
treatment
show
pronounc
effect
cell
tradit
resist
drug
therapi
oller
mf
g
garcia
sm
r
de
ricardo
gutierrez
oncolog
unit
capit
feder
argentina
de
ricardo
gutierrez
patholog
capit
feder
argentina
backgroundobject
describ
clinic
biolog
histolog
featur
overal
surviv
os
patient
p
stage
iv
siv
nbl
treat
hospit
de
ricardo
hnrg
oncolog
unit
bueno
air
argentina
designmethod
retrospect
descript
analysi
medic
record
p
siv
nbl
admit
april
decemb
variabl
evalu
sex
age
primari
site
tumor
size
histolog
statu
urinari
catecholamin
statu
treatment
overal
surviv
diagnosi
p
receiv
chemotherapi
induct
cyclophosphamid
vincristin
doxorubicin
cisplatin
local
resect
perform
follow
high
dose
chemotherapi
autolog
stem
cell
transplant
primari
radiotherapi
retino
acid
mainten
method
analysi
use
determin
overal
surviv
os
result
p
diagnos
nbl
stage
iv
nbl
averag
age
present
month
ratio
men
women
primari
site
adren
gland
tumor
size
common
histolog
poorli
differenti
nbl
statu
fish
perform
twenti
tumor
sampl
amplifi
thirteen
p
complet
treatment
aliv
sixteen
p
complet
treatment
die
due
tumor
progress
induct
infecti
complic
take
place
relaps
get
bone
marrow
repres
conclus
result
obtain
indic
studi
patient
stage
iv
nbt
present
amplif
global
os
patient
reach
complet
treatment
os
compar
result
intern
cooper
group
addit
improv
surviv
observ
associ
amelior
healthcar
last
year
w
przybyla
g
k
lo
univers
hospit
rikshospitalet
depart
pediatr
divis
pediatr
adolesc
medicin
oslo
norway
univers
hospit
radiumhospitalet
depart
patholog
oslo
norway
oslo
medic
institut
clinic
medicin
oslo
norway
backgroundobject
next
gener
sequenc
contribut
person
pediatr
oncolog
near
futur
particular
biolog
clinic
heterogen
diseas
requir
therapeut
approach
like
neuroblastoma
nb
one
major
challeng
pediatr
oncolog
nb
specif
copi
number
variat
rearrang
singl
gene
report
includ
amplif
mycn
mutat
alk
gene
hypothes
compar
genom
analysi
mutat
copi
number
variat
provid
novel
inform
gene
signal
pathway
relev
heterogen
relaps
nb
designmethod
sampl
tumor
normal
dna
nb
patient
avail
exist
diagnost
biobank
clinic
patholog
inform
like
age
histopatholog
known
routin
diagnost
addit
fish
analys
determin
mycn
amplif
statu
possibl
chromosom
loss
gain
sampl
primari
tumor
analyz
whole
exom
sequenc
use
illumina
platform
mean
coverag
addit
dna
sampl
investig
array
compar
genom
hybrid
acgh
appli
affymetrix
snp
platform
cytoscan
hd
array
result
preliminari
result
reveal
high
concord
acgh
profil
copi
number
inform
provid
sequenc
detail
studi
perform
investig
specif
genom
biomark
studi
cancer
mutat
hotspot
predict
driver
mutat
mutat
signatur
sampl
conclus
project
repres
first
exom
sequenc
approach
nb
norway
compar
array
sequenc
data
express
relev
gene
enlarg
cohort
sampl
differ
time
point
treatment
expect
data
reveal
novel
insight
genom
nb
final
pave
way
toward
cancer
platform
action
gene
target
makena
h
b
b
cp
tech
univers
health
scienc
center
cancer
center
lubbock
usa
backgroundobject
mainten
therapi
acid
immunotherapi
given
complet
intens
cytotox
therapi
improv
outcom
neuroblastoma
patient
synthet
retinoid
fenretinid
achiev
multipl
complet
respons
relapserefractori
neuroblastoma
clinic
trial
low
system
toxic
consid
mainten
therapi
clinic
trial
difluoromethylornithin
dfmo
irrevers
inhibitor
ornithin
decarboxylas
minim
singl
agent
clinic
respons
data
use
mainten
therapi
neuroblastoma
evalu
cytotox
activ
dfmo
fenretinid
neuroblastoma
cell
line
designmethod
test
sixteen
neuroblastoma
cell
line
bone
marrow
level
hypoxia
use
dimscan
cytotox
assay
polyamin
measur
spectrometri
apoptosi
tunel
flow
cytometri
result
clinic
achiev
level
dfmo
significantli
decreas
p
polyamin
putrescin
measur
spectrometri
achiev
modest
cytotox
log
cytotox
prolong
exposur
day
cultur
enhanc
dfmo
cytotox
clinic
achiev
level
fenretinid
induc
cell
kill
log
cytotox
neuroblastoma
cell
line
test
even
lower
concentr
fenretinid
induc
log
cytotox
fourteen
cell
line
test
dfmo
show
signific
increas
p
apoptosi
tunel
assay
apoptosi
fenretinid
significantli
higher
p
compar
dfmo
control
conclus
dfmo
singl
agent
minim
cytotox
activ
neuroblastoma
e
rosenfeld
g
j
e
b
colleg
medicin
surgeri
houston
usa
backgroundobject
order
obtain
adequ
tissu
diagnosi
tissu
bank
neuroblastoma
surgic
wedg
biopsi
commonli
perform
past
decad
experi
percutan
needl
core
biopsi
evolv
purpos
studi
compar
adequaci
safeti
biopsi
techniqu
designmethod
follow
retrospect
review
patient
underw
biopsi
intermedi
neuroblastoma
institut
recent
cohort
procedur
detail
outcom
collect
statist
analysi
perform
use
wilcoxon
rank
test
consid
signific
data
recent
cohort
compar
previous
publish
data
histor
cohort
result
sinc
percutan
needl
core
biopsi
commonli
util
recent
cohort
vs
histor
major
percutan
biopsi
perform
surgeon
intraven
access
port
placement
anesthet
number
needl
core
sampl
obtain
increas
median
histor
cohort
recent
cohort
surgic
case
laparoscop
previous
open
one
patient
percutan
needl
core
biopsi
biopsi
adequaci
recent
cohort
similar
percutan
surgic
specimen
percutan
vs
surgic
improv
adequaci
percutan
specimen
compar
histor
cohort
percutan
vs
surgic
transfus
requir
percutan
vs
surgic
p
complic
percutan
vs
surgic
p
higher
follow
surgic
biopsi
oper
time
hospit
length
stay
time
chemotherapi
initi
similar
larger
tumor
like
percutan
biopsi
cm
percutan
vs
cm
surgic
conclus
multipl
core
obtain
percutan
needl
core
biopsi
adequ
complet
tissu
diagnosi
neuroblastoma
safe
perform
consid
altern
surgic
wedg
biopsi
mr
safarinejad
center
urolog
diseas
diagnosi
privat
clinic
special
urolog
androlog
iran
urolog
terhran
iran
backgroundobject
protein
kazal
motif
reck
gene
new
transform
suppressor
gene
link
malign
examin
associ
reck
gene
polymorph
clinicopatholog
characterist
wilm
tumor
designmethod
two
singl
nucleotid
polymorph
snp
analyz
use
protocol
studi
subject
includ
patient
wilm
tumor
healthi
subject
control
ratio
gather
patient
wilm
tumor
within
last
decad
result
polymorph
genotyp
frequenc
distribut
equilibrium
patient
p
p
control
p
p
signific
alter
genotyp
distribut
allel
frequenc
wilm
tumor
patient
healthi
control
detect
snp
statist
signific
associ
presenc
c
allel
wilm
tumor
ci
p
accord
logist
regress
analysi
wilm
tumor
patient
reck
tc
cc
genotyp
increas
risk
wilm
tumor
ci
p
ci
p
respect
polymorph
patient
control
subject
equilibrium
snp
polymorph
p
p
p
singl
locu
analysi
genotyp
distribut
allel
frequenc
demonstr
statist
signific
differ
case
control
find
signific
associ
polymorph
genotyp
wilm
tumor
conclus
found
statist
signific
differ
genotyp
distribut
allel
frequenc
reck
gene
wilm
tumor
patient
control
snp
mr
safarinejad
center
urolog
diseas
diagnosi
privat
clinic
special
urolog
androlog
iran
urolog
terhran
iran
backgroundobject
primari
yolk
sac
endoderm
sinu
tumor
est
rare
malign
commonli
driven
test
ovari
best
knowledg
six
case
prostat
est
report
literatur
designmethod
last
decad
six
case
prostat
est
manuscript
report
experi
rare
neoplasm
brief
literatur
review
also
done
case
underw
six
cours
combin
chemotherapi
follow
session
retroperiton
lymph
node
dissect
cystoprostatectomi
ileal
conduit
urinari
divers
result
none
case
histori
previou
testi
cancer
primari
present
patient
metastat
diseas
commonli
liver
patient
local
tumor
lung
liver
also
remov
surgic
median
free
tumor
surviv
month
two
patient
die
rapidli
within
diagnosi
metastat
diseas
present
conclus
despit
signific
advanc
imag
treatment
modal
last
two
decad
yolk
sac
tumor
prostat
remain
signific
challeng
physician
deal
children
sorrentino
c
g
institut
oncolog
genoa
itali
institut
neuroradiolog
genoa
itali
hospit
nuclear
medicin
genova
itali
backgroundobject
case
neuroblastoma
nb
present
metastas
mostli
skelet
bone
marrow
level
involv
central
nervou
system
cn
rare
usual
associ
metastas
theca
skull
base
orbit
occurr
cn
parenchym
local
except
event
dismal
prognost
outcom
designmethod
recent
observ
two
case
stage
nb
develop
parenchym
cn
metastas
clinic
cours
result
treat
accord
protocol
symptom
relaps
sever
headach
vomit
patient
magnet
reson
imag
mri
comput
tomographi
ct
perform
time
relaps
suggest
hemorrhag
natur
lesion
local
tempor
cerebellar
lobe
respect
cn
relaps
document
stop
therapi
former
patient
three
month
later
latter
hemorrhag
characterist
lesion
made
difficult
immedi
recogn
tumor
natur
sever
caus
ie
vascular
malform
lesion
iatrogen
damag
may
ident
imag
featur
perform
patient
show
intens
peripher
uptak
tracer
level
hemorrhag
lesion
former
patient
surgeri
avoid
favor
chemotherapeut
approach
consist
multipl
subsequ
regimen
prohibit
slow
diseas
progress
death
ensu
nine
month
later
latter
relaps
confirm
histolog
follow
incomplet
neurosurg
remov
mass
aliv
temozolomid
treatment
two
month
surgeri
conclus
detect
cn
parenchym
metastas
nb
patient
diagnosi
clinic
cours
rare
mri
method
choic
studi
brain
lesion
case
hemorrhag
lesion
appear
sensit
tool
may
help
clarifi
earlier
tumor
natur
sorrentino
c
g
ml
c
p
di
c
e
l
institut
oncolog
genoa
itali
institut
biostatist
epidemiolog
genoa
itali
institut
neurooncolog
genoa
itali
di
cristina
hospit
unit
palermo
itali
vittorio
emanuel
pediatr
unit
catania
itali
hospit
pediatr
oncolog
hematolog
unit
catanzaro
itali
univers
pediatr
unit
padova
itali
backgroundobject
patient
diagnos
peripher
neuroblast
tumor
pnt
may
occasion
develop
secondari
tumor
instead
detect
synchron
malign
patient
much
rarer
mainli
occur
subject
harbor
cancer
predisposit
condit
sbw
syndrom
designmethod
period
total
npt
case
enrol
italian
neuroblastoma
registri
develop
secondari
tumor
synchron
tumor
result
histolog
pnt
latter
case
neuroblastoma
intermix
ganglioneuroblastoma
ganglioneuroma
one
synchron
tumor
includ
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
pilocyt
astrocytoma
pancreatoblastoma
pb
one
case
sbw
present
patient
diagnos
pb
patient
local
pnt
diseas
five
underw
tumor
resect
therapi
sixth
one
tumor
regress
spontan
children
diagnost
leukemia
treat
accord
specif
protocol
radic
tumor
surgeri
perform
patient
pb
astrocytoma
patient
present
complet
remiss
median
month
rang
conclus
observ
case
illustr
clinic
condit
rare
occurr
worth
better
understood
inform
may
deriv
retrospect
andor
studi
larger
patient
popul
siopen
might
offer
van
rooijen
mmp
van
mp
van
kcjp
center
pediatr
oncolog
utrecht
netherland
backgroundobject
sinc
august
pmc
start
therapi
patient
high
risk
neuroblastoma
nb
immunotherapi
combin
antibodi
isot
signific
side
effect
pain
hypotens
fever
hypersensit
reaction
capillari
leak
syndrom
pediatr
oncolog
nurs
make
signific
contribut
treatment
includ
educ
famili
patient
receiv
therapi
designmethod
studi
investig
aspect
import
educ
immunotherapi
whether
educ
appropri
children
age
year
old
base
analysi
studi
regard
educ
young
children
exist
educ
materi
dcog
evalu
sever
point
improv
propos
result
addit
brochur
develop
includ
aspect
treatment
logist
side
effect
issuanc
extens
inform
film
young
children
undergo
immunotherapi
schedul
octob
conclus
clear
commun
patient
expect
toxic
well
proactiv
comprehens
support
care
integr
compon
ensur
success
complet
antibodi
infus
parent
children
experi
less
stress
enhanc
collabor
parent
children
medic
team
reason
proper
educ
patient
famili
intens
therapi
crucial
alic
l
yu
andrew
l
gilman
al
e
septemb
antibodi
isotretinoin
neuroblastoma
new
england
journal
medicin
bartholomew
j
et
al
dinutuximab
novel
immunotherapi
treatment
pediatr
patient
high
risk
neuroblastoma
journal
pediatr
oncolog
nurs
verli
van
n
f
van
gj
h
h
g
medic
center
pediatr
amsterdam
netherland
medic
center
laboratori
genet
metabol
diseas
amsterdam
netherland
center
pediatr
oncologyhematolog
pediatr
oncologyhematolog
utrecht
netherland
univers
medic
center
medic
statist
bioinformat
leiden
netherland
univers
mathemat
institut
leiden
netherland
medic
center
utrecht
pediatr
utrecht
netherland
children
hospitalerasmu
medic
center
pediatr
oncologyhematolog
rotterdam
netherland
univers
medic
center
pediatr
oncologyhematolog
amsterdam
netherland
backgroundobject
prognosi
patient
neuroblastoma
divers
indic
need
accur
prognost
paramet
neuroblastoma
excret
catecholamin
metabolit
howev
correl
prognosi
hardli
investig
therefor
perform
analysi
panel
elev
urinari
catecholamin
metabolit
correl
prognosi
designmethod
retrospect
studi
panel
urinari
catecholamin
metabolit
test
n
valid
n
cohort
patient
neuroblastoma
stage
diagnosi
result
multivari
cox
regress
model
analys
reveal
independ
risk
factor
surviv
ef
overal
surviv
os
ef
os
stage
patient
significantli
better
compar
stage
patient
elev
ef
versu
os
versu
p
also
clinic
subgroup
elev
associ
poor
surviv
outcom
high
risk
patient
stage
older
year
patient
mycn
amplif
age
independ
risk
factor
ef
os
thu
independ
given
therapi
among
high
risk
patient
elev
age
month
extrem
poor
prognosi
compar
patient
age
ef
respect
p
os
respect
p
conclus
elev
diagnosi
associ
high
risk
diseas
poor
prognosi
high
risk
patient
age
elev
diagnosi
signific
risk
factor
ef
os
also
abl
identifi
subgroup
high
risk
patient
favor
extrem
poor
prognosi
acknowledg
studi
support
villa
joep
foundat
verli
van
r
r
van
j
r
j
van
g
medic
center
pediatr
amsterdam
netherland
center
pediatr
oncologyhematolog
pediatr
oncologyhematolog
utrecht
netherland
medic
center
laboratori
genet
metabol
diseas
amsterdam
netherland
medic
center
oncogenom
amsterdam
netherland
backgroundobject
catecholamin
measur
urin
patient
neuroblastoma
standard
practic
panel
marker
use
patient
elev
catecholamin
diagnosi
catecholamin
neg
patient
neg
time
relaps
recent
two
cell
type
neuroblastoma
identifi
adrenerg
adrn
cell
express
marker
differenti
mesenchym
me
cell
lack
marker
van
groningen
et
al
submit
phenotyp
dualiti
might
regul
catecholamin
excret
explain
switch
catecholamin
posit
catecholamin
neg
patient
studi
investig
vitro
catecholamin
excret
relat
adrn
cell
type
designmethod
studi
catecholamin
excret
neuroblastoma
cell
line
me
adrn
includ
two
pair
cell
line
addit
sknbe
cell
mesenchym
transit
induc
also
use
subsequ
presenc
catecholamin
biosynthet
enzym
tyrosin
hydroxylas
th
ddc
dbh
cell
line
determin
result
among
adrn
cell
line
cell
line
excret
catecholamin
me
cell
line
excret
catecholamin
pair
adrn
cell
line
excret
catecholamin
me
cell
line
partner
catecholamin
excret
also
detect
sknbe
cell
adrn
phenotyp
howev
stop
transit
mesenchym
phenotyp
induc
enzym
profil
reveal
excret
cell
line
express
th
protein
absent
cell
line
conclus
catecholamin
excret
absent
neuroblastoma
cell
seem
exclus
featur
th
express
acknowledg
studi
support
grant
villa
joep
foundat
j
yu
j
x
x
j
j
hospit
zhejiang
univers
school
medicin
depart
ultrasound
hangzhou
china
hospit
zhejiang
univers
school
medicin
depart
surgic
oncolog
hangzhou
china
backgroundobject
investig
efficaci
ultrasonographi
diagnosi
neonat
adren
neuroblastoma
nb
designmethod
neonat
adren
neuroblastoma
confirm
patholog
center
novemb
februari
includ
studi
includ
boy
girl
case
unilater
ultrasonograph
imag
data
analyz
retrospect
result
case
detect
ultrasound
firstli
age
gestat
age
day
postpartum
case
detect
prenat
routin
examin
major
ultrasonograph
characterist
border
clear
size
mass
case
parenchym
mass
case
calcif
case
without
calcif
case
cystic
mass
case
cystic
solid
mass
nb
consid
first
diagnosi
case
case
cystic
adren
neuroblastoma
misdiagnos
mesenter
cyst
conclus
ultrasound
use
prefer
imag
method
fetal
neonat
adren
neuroblastoma
contribut
earli
diagnosi
manag
wang
z
c
c
l
z
hospit
chongq
medic
univers
depart
pediatr
surgic
oncolog
chongq
china
backgroundobject
paraneoplast
syndrom
pss
kind
rare
syndrom
clinic
characterist
rare
discuss
children
analyz
data
clinic
manifest
diagnos
treatment
prognosi
children
pss
investig
diagnosi
treatment
could
improv
designmethod
eight
patient
pss
enrol
juli
februari
rang
examin
use
evalu
patient
patholog
examin
perform
patient
addit
either
complet
tumor
resect
punctur
biopsi
chemotherapi
corticosteroid
therapi
support
treatment
also
appli
differ
patient
result
three
patient
suffer
paraneoplast
neurolog
syndrom
pnss
present
ectop
cush
syndrom
patient
respiratori
failur
vasoact
intestin
polypeptid
vip
intract
diarrhea
two
patient
confirm
ganglioneuroblastoma
gnb
neuroblastoma
nb
ganglioneuroma
gn
patient
tumor
complet
resect
punctur
biopsi
tumor
six
patient
receiv
chemotherapi
receiv
futher
support
treatment
receiv
futher
corticosteroid
therapi
except
patient
discontinu
therapi
patient
suffer
pnss
achiev
complet
remiss
remain
patient
complet
classifi
good
partial
remiss
conclus
children
present
pnss
syndrom
om
cerebellar
ataxia
ectop
cush
syndrom
dyspnea
unexplain
intract
diarrhea
hypokalemia
dysplasia
clinician
consid
possibl
neuroblastoma
f
yamazaki
c
k
c
k
h
j
k
univers
school
medicin
depart
pediatr
tokyo
japan
cancer
center
research
institut
depart
clinic
genom
tokyo
japan
center
child
health
develop
children
cancer
center
tokyo
japan
citi
gener
hospit
depart
pediatr
hematolog
oncolog
osaka
japan
backgroundobject
appropri
combin
induct
chemotherapi
chemotherapi
hdc
regimen
patient
neuroblastoma
remain
unestablish
previous
report
feasibl
efficaci
regimen
use
two
cycl
thiotepa
total
melphalan
total
singl
graft
neuroblastoma
present
studi
analyz
outcom
regimen
patient
neuroblastoma
two
japanes
institut
designmethod
medic
record
consecut
patient
neuroblastoma
receiv
regimen
follow
autolog
peripher
blood
stem
cell
rescu
review
result
median
patient
age
diagnosi
month
tumor
observ
patient
patient
stage
tumor
patient
underw
surgic
resect
primari
lesion
radiotherapi
residu
lesion
regimen
induct
chemotherapi
time
surgeri
vari
depend
institut
median
period
year
rang
nine
patient
subsequ
receiv
plan
tandem
hdc
cord
blood
transplant
fifteen
patient
includ
patient
treat
tandem
hdc
surviv
without
recurr
surviv
ef
rate
overal
surviv
os
rate
year
diagnosi
respect
three
patient
die
toxic
none
patient
develop
secondari
malign
notabl
ef
os
rate
year
patient
tumor
significantli
superior
tumor
p
p
multivari
analysi
increas
probabl
ef
demonstr
patient
good
remiss
statu
hdc
conclus
regimen
compris
thiotepa
melphalan
effect
regimen
patient
neuroblastoma
mycn
amplif
c
yang
w
hospit
chongq
medic
univers
depart
pediatr
surgic
oncolog
chongq
china
hospit
chongq
medic
univers
depart
pediatr
surgic
oncolog
chongq
china
backgroundobject
transcript
protein
yap
essenti
hippo
tumorigenesi
variou
cancer
howev
express
function
yap
neuroblastoma
remain
elus
show
yap
highli
express
neuroblastoma
nb
express
level
correl
advanc
tumor
stage
designmethod
examin
express
yap
clinic
tumor
specimen
adjac
tissu
analyz
relationship
tumor
stage
cell
viabil
assay
coloni
format
assay
invas
assay
perfom
sirna
interf
express
yap
possibl
relat
downstream
protein
detect
westerblot
human
xenograft
establish
low
concentr
cisplatin
high
concentr
cisplatin
low
concentr
cisplatin
peptid
treat
group
tumor
volum
calcul
mice
sacrif
tumor
peel
weight
yap
express
apoptosi
perform
result
knockdown
yap
significantli
impair
neuroblastoma
prolifer
tumorigenesi
invas
vitro
inject
yap
inhibitor
peptid
dramat
prevent
neuroblastoma
subcutan
tumor
growth
effici
downregul
yap
express
tumor
addit
less
prolif
apoptot
cell
found
peptid
treatment
group
furthermor
yap
inhibit
significantli
inhibit
neuroblastoma
prolifer
tumorigenesi
invas
vitro
combin
peptid
cisplatin
effici
impair
nb
subcutan
tumor
growth
effect
cisplatin
notabl
combin
therapi
caus
lesser
liver
toxic
mice
compar
cisplatin
treatment
group
conclus
collect
work
identifi
yap
novel
regul
neuroblastoma
prolifer
tumorigenesi
invas
indic
yap
potenti
therapeut
target
neuroblastoma
yoneda
k
j
citi
gener
hospit
pediatr
surgeri
osaka
japan
gener
medic
center
pediatr
surgeri
osaka
japan
citi
gener
hospit
pediatr
hematolog
oncolog
osaka
japan
backgroundobject
improv
treatment
result
neuroblastoma
minim
treatment
complic
top
prioriti
retrospect
evalu
risk
factor
surgic
treatment
neuroblastoma
order
minim
surgic
complic
designmethod
neuroblastoma
patient
treat
institut
classifi
accord
cog
risk
classif
select
divid
patient
two
group
accord
presenc
group
absenc
group
b
surgic
complic
result
median
age
diagnosi
month
rang
year
inss
stage
patient
stage
stage
eight
retroperiton
five
adren
two
mediastin
one
cervic
neuroblastoma
four
tumor
show
intraspin
extens
surgic
complic
two
nephrectomi
one
renal
atrophi
one
bowel
obstruct
one
ejacul
disord
one
horner
syndrom
one
resect
intern
jugular
vein
tumor
resect
least
group
includ
complet
resect
wherea
complet
resect
three
resect
patient
without
surgeri
group
b
five
six
patient
group
five
nine
patient
group
b
tumor
risk
factor
idrf
one
tumor
group
b
chang
idrf
present
present
preoper
chemotherapi
patient
aliv
without
diseas
median
month
rang
month
conclus
resect
presenc
preoper
idrf
seem
surgic
risk
factor
neuroblastoma
patient
aliv
without
diseas
conserv
surgeri
avoid
complic
may
accept
even
residu
tumor
remain
surgeri
p
zage
j
r
california
san
diego
moor
cancer
center
pediatr
san
diego
usa
colleg
medicin
pediatr
surgeri
houston
usa
patholog
birmingham
usa
texa
health
scienc
center
houston
neurobiolog
anatomi
houston
usa
colleg
medicin
patholog
houston
usa
backgroundobject
ubiquitin
ligas
involv
growth
factor
receptor
gfr
traffick
whose
gene
found
chromosom
region
commonli
delet
neuroblastoma
tumor
previous
observ
associ
gene
protein
express
neuroblastoma
patient
outcom
neuroblastoma
tumor
histolog
howev
function
role
neuroblastoma
tumor
differenti
known
designmethod
screen
cell
line
neuroblastoma
tumor
sampl
protein
express
use
western
blot
quantit
immunohistochemistri
analyz
associ
gene
express
express
known
marker
neuroblastoma
tumor
differenti
use
publicli
avail
databas
measur
express
western
blot
cell
line
induct
differenti
retino
acid
treatment
determin
effect
overexpress
deplet
retino
differenti
use
continu
imag
neurit
morpholog
immunohistochemistri
western
blot
marker
differenti
effect
signal
rasmapk
pathway
measur
use
western
blot
result
express
associ
differenti
patient
tumor
sampl
gene
protein
express
associ
express
level
known
marker
neuroblastoma
differenti
retino
acid
treatment
result
increas
express
retino
neuroblastoma
cell
deplet
associ
increas
phosphoryl
erk
increas
prolifer
inhibit
retino
neuroblastoma
differenti
conclus
demonstr
associ
express
tumor
cell
differenti
gene
express
databas
neuroblastoma
tumor
sampl
data
suggest
express
requir
retino
differenti
potenti
effect
erk
activ
associ
neuroblastoma
differenti
combin
establish
role
gfr
traffick
suggest
receptor
traffick
may
contribut
respons
neuroblastoma
tumor
therapi
outcom
patient
neuroblastoma
yt
j
chang
xd
hospit
jilin
univers
depart
pediatr
oncolog
changchun
china
backgroundobject
current
standard
therapi
patient
neuroblastoma
consist
intens
induct
chemotherapi
surgeri
myeloabl
consolid
chemotherapi
autolog
stem
cell
transplant
local
irradi
immunotherapi
howev
autolog
transplant
expens
recent
antibodi
easili
access
china
improv
surviv
rate
patient
neuroblastoma
develop
countri
basi
consider
design
studi
test
feasibl
ad
novel
delay
intensif
chemotherapi
induct
regimen
designmethod
patient
enrol
studi
receiv
chemotherapi
accord
design
trial
end
therapi
patient
receiv
three
cycl
delay
intensif
chemotherapi
delay
intensif
chemotherapi
consist
two
one
cycl
cycl
consist
vincristin
day
cyclophosphamid
day
cisplatin
day
etoposid
day
cycl
similar
cycl
howev
differ
day
doxorubicin
substitut
etoposid
result
total
patient
enrol
patient
exclud
studi
remain
patient
patient
complet
consolid
chemotherapi
final
enrol
fifteen
patient
long
term
survivor
five
patient
aliv
tumor
whilst
eight
patient
die
ef
os
ci
ci
respect
conclus
high
rate
surviv
among
patient
neuroblastoma
achiev
delay
intensif
chemotherapi
without
occurr
second
malign
studi
warrant
investig
outcom
ef
patient
neuroblastoma
q
zhao
medic
univers
cancer
institut
hospit
depart
pediatr
cancer
tianjin
china
backgroundobject
neuroblastoma
nb
common
malign
tumor
infanc
common
extracrani
solid
tumor
childhood
improv
diagnosi
treatment
surviv
rate
patient
nb
reach
nb
surviv
rate
still
less
pathogenesi
nb
still
explicit
therefor
great
signific
explor
mechan
nb
tumorigenesi
discoveri
new
therapeut
target
nb
one
kinas
famili
member
import
regul
centriol
replic
abnorm
express
found
sever
cancer
recent
studi
unravel
novel
function
mediat
invas
metastasi
hela
cell
line
howev
function
nb
develop
progress
remain
elucid
designmethod
evalu
express
level
nb
tissu
detect
function
nb
seri
experi
vitro
vivo
result
express
level
nb
tissu
remark
high
express
neg
correl
surviv
rate
nb
suggest
potenti
tumor
promot
factor
nb
function
studi
indic
suppress
cell
prolifer
invas
cell
nb
cell
line
inhibit
transit
emt
signal
pathway
anim
experi
demonstr
cell
dramat
suppress
tumorigenesi
metastasi
conclus
promot
cell
prolifer
invas
metastasi
nb
cell
induc
transit
activ
signal
pathway
may
promis
therapeut
target
nb
jp
caneba
e
cv
villafuert
jm
w
n
p
ap
philippin
philippin
gener
hospit
pediatr
manila
philippin
philippin
philippin
gener
hospit
surgeri
manila
philippin
philippin
philippin
gener
hospit
patholog
manila
philippin
philippin
philippin
gener
hospit
radiolog
manila
philippin
backgroundobject
philippin
gener
hospit
countri
nation
referr
center
wilm
tumor
wt
surviv
low
larg
due
treatment
delay
abandon
inoper
tumor
infect
march
pediatr
surgeri
pediatr
oncolog
patholog
radiolog
group
adopt
wt
treatment
approach
guidelin
designmethod
review
medic
record
patient
march
august
studi
endpoint
decemb
result
patient
mean
age
year
f
ratio
eighteen
patient
local
diseas
metastat
given
neoadjuv
chemo
mean
week
week
respect
patient
nephrectomi
due
abandon
progress
diseas
patient
lymph
node
sampl
tumor
spillag
surgic
stage
stage
stage
ii
stage
iii
stage
iv
patholog
risk
grade
low
intermedi
high
three
report
favor
histolog
misdiagnos
neuroblastoma
angiomyolipoma
multicyst
renal
dysplasia
thirteen
wt
patient
receiv
siop
adjuv
treatment
protocol
due
poor
respons
progress
diseas
abandon
treatment
six
patient
underw
radiat
studi
endpoint
wt
patient
complet
treatment
treatment
abandon
therapi
relaps
local
die
due
gastroenter
month
treatment
year
ef
year
os
abandon
sensit
os
respect
conclus
adopt
wt
protocol
guidelin
markedli
improv
surviv
set
address
diagnost
treatment
delay
howev
effort
still
need
curb
abandon
improv
protocol
adher
misdiagnosi
z
v
alfawaz
faisal
specialist
hospit
research
centr
pediatr
hematologyoncolog
riyadh
saudi
arabia
faisal
specialist
hospit
research
centr
patholog
laboratori
medicin
riyadh
saudi
arabia
faisal
specialist
hospit
research
centr
pediatr
surgeri
riyadh
saudi
arabia
faisal
specialist
hospit
research
centr
nurs
riyadh
saudi
arabia
faisal
specialist
hospit
research
oncolog
jeddah
saudi
arabia
backgroundobject
wilm
tumor
wt
common
renal
malign
children
outcom
data
wt
region
limit
retrospect
studi
evalu
clinic
outcom
pediatr
patient
pt
wt
king
faisal
specialist
hospit
research
centr
riyadh
kfsh
conduct
designmethod
data
wt
pt
age
year
diagnos
treat
kfsh
review
histopatholog
confirm
case
includ
result
case
identifi
case
exclud
due
insuffici
data
median
age
diagnosi
year
femal
male
unilater
diseas
observ
pt
bilater
present
featur
includ
abdomin
abdomin
vascular
pt
stage
relaps
seen
stage
iii
iv
os
pt
stage
ii
iii
iv
v
ef
stage
ii
iii
iv
v
p
valu
ef
pt
base
stage
result
corrobor
previous
present
data
saudi
arabian
pediatr
hematologyoncolog
societi
sapho
nation
os
ef
respect
report
favor
histolog
seen
anaplasia
p
valu
os
ef
pt
compar
favor
histolog
anaplasia
pt
os
ef
age
respect
conclus
despit
variabl
healthcar
servic
referr
pattern
given
half
pt
refer
center
advanc
diseas
amen
upfront
resect
outcom
wt
compar
toth
nation
data
well
intern
report
review
includ
specif
relaps
patient
molecular
studi
warrant
underway
b
aydin
c
b
n
univers
cancer
institut
pediatr
oncolog
ankara
turkey
univers
faculti
medicin
pediatr
surgeri
ankara
turkey
backgroundobject
outcom
patient
bwt
improv
due
preoper
chemotherapi
oper
techniqu
preserv
renal
parenchyma
studi
result
tpog
wilm
tumor
regimen
bwt
outcom
patient
singl
center
retrospect
review
designmethod
patient
synchron
bwt
treat
preoper
chemotherapi
vincristin
actinomycin
chemotherapi
continu
safe
nephron
spare
surgeri
nss
could
perform
long
radiolog
tumor
respons
continu
chemotherapi
intensifi
ad
doxorubicin
altern
va
everi
week
result
median
patient
month
month
median
durat
preoper
chemotherapi
day
rang
day
day
preoper
chemotherapi
modifi
patient
vad
regimen
patient
receiv
vad
regimen
due
metastas
thrombi
vena
cava
possibl
spontan
tumor
ruptur
diagnosi
patient
radic
nephrectomi
greater
tumor
nss
contralater
kidney
eight
patient
bilater
nss
ef
os
rate
va
vad
statist
differ
postop
tumor
stage
stage
ii
iii
os
rate
stage
ii
iii
unfavor
histolog
nephroblastomatosi
report
patient
os
ef
rate
patient
anaplasia
rate
patient
fh
tumor
p
os
ef
rate
patient
one
patient
die
bilater
nephrectomi
conclus
result
compar
literatur
va
effect
bwt
initi
preoper
treatment
vad
combin
might
help
better
local
control
select
advanc
stage
tumor
j
brok
k
ji
f
colleg
great
ormond
street
institut
child
health
cancer
section
london
unit
kingdom
children
hospit
medic
univers
ohio
divis
pediatr
oncolog
cincinatti
usa
ircc
istituto
nazional
dei
itali
depart
hematolog
pediatr
milano
itali
backgroundobject
surviv
rate
patient
wilm
tumour
wt
approxim
refin
use
current
avail
intervent
howev
subgroup
patient
initi
histopatholog
relaps
diseas
poor
prognosi
challeng
identifi
prioritis
develop
new
innov
approach
subgroup
designmethod
conduct
systemat
literatur
search
publish
phase
ii
clinic
trial
regist
patient
wt
characteris
trial
activ
quantifi
respons
rate
highlight
avenu
develop
result
identifi
trial
phase
three
phase
iii
phase
ii
trial
enrol
patient
wt
alongsid
malign
number
annual
recruit
wt
chang
significantli
less
potenti
candid
vast
major
trial
conduct
north
america
differ
intervent
investig
includ
convent
chemotherapi
therapi
overal
wt
reveal
degre
tumour
control
five
patient
demonstr
complet
remiss
patient
partial
respons
patient
stabl
diseas
none
includ
novel
therapi
emerg
promis
intervent
convent
chemotherapi
abl
induc
complet
partial
respons
conclus
conclud
earli
phase
trial
recruit
wt
expect
clinic
outcom
includ
patient
dismal
improv
avail
recruit
trial
wt
especi
europ
need
hy
cheng
children
hospit
surgic
oncolog
beij
china
backgroundobject
investig
clinic
characterist
prognost
factor
malign
rhabdoid
tumour
kidney
mrtk
children
designmethod
twelv
patient
mrtk
diagnos
treat
hospit
januari
decemb
variabl
examin
tumor
stage
sex
age
diagnosi
surgic
radic
radiotherapi
chemotherapeut
regimen
result
median
age
case
month
month
time
diagnosi
patient
male
common
present
complaint
mass
pain
gross
hematuria
tumor
ruptur
posit
lymph
node
distant
parenchym
metastas
median
month
rang
month
die
survivedth
surviv
rate
whole
patient
underw
surgeri
patient
treat
combin
radiat
therapi
signific
improv
efficaci
differ
surviv
male
femal
younger
older
children
case
surviv
includ
one
case
stage
stage
iii
patient
underw
one
cycl
chemotherapi
surgeri
surviv
month
conclus
infant
children
dismal
prognosi
surgic
radic
seem
prognost
valu
mrtk
molecular
diagnost
research
warrant
refin
diagnost
classifi
prognost
relev
mrtk
subtyp
faizan
n
p
children
hospit
institut
child
health
paediatr
haematologyoncolog
lahor
pakistan
children
hospit
institut
child
health
paediatr
surgeri
lahor
pakistan
children
hospit
institut
child
health
paediatr
radiolog
lahor
pakistan
backgroundobject
determin
demograph
present
need
surgic
intervent
etiolog
paediatr
patient
histolog
proven
malign
abdomin
mass
children
designmethod
retrospect
observ
studi
carri
hematolog
oncolog
depart
children
hospit
institut
child
health
lahor
pakistan
children
histolog
proven
malign
abdomin
mass
januari
till
decemb
includ
data
regard
age
gender
surgic
intervent
requir
final
diagnosi
analyz
neonat
patient
relaps
diagnosi
confirm
histolog
exclud
form
studi
consecut
sampl
techniqu
use
data
analyz
use
spss
result
total
children
diagnos
malign
abdomin
tumor
elig
studi
major
male
age
age
commonest
present
abdomin
distens
palpabl
abdomin
mass
major
mother
note
abdomin
distens
mass
clinic
palpabl
note
oncologist
abdomin
pain
present
fever
diagnosi
made
trucut
biopsi
primari
surgic
intervent
requir
etiolog
malign
abdomin
mass
wilm
tumor
neuroblastoma
non
hodgkin
lymphoma
germ
cell
tumor
rhabdomyosarcoma
hepatoblastoma
hepatocellular
carcinoma
renal
synovi
cell
carcinoma
adrenocort
tumor
patient
papillari
renal
cell
carcinoma
undifferenti
synovi
sarcoma
liver
diagnos
one
patient
conclus
wilm
tumor
follow
non
hodgkin
lymphoma
common
solid
abdomin
malign
paediatr
age
group
present
mostli
advanc
stage
palpabl
abdomin
mass
need
surgeri
avoid
trucut
biopsi
present
diagnosi
need
train
pediatrician
famili
physician
along
mother
earli
recognit
abdomin
distens
mass
earli
diagnosi
better
prognosi
j
geller
yy
j
n
f
e
p
e
z
k
p
e
j
c
j
children
hospit
medic
center
pediatr
cincinnati
usa
oncolog
group
biostatist
gainsvil
usa
robert
h
luri
children
hospit
chicago
radiat
oncolog
chicago
usa
anderson
cancer
center
pediatr
houston
usa
asasur
review
ctr
radiolog
lincoln
usa
robert
h
luri
children
hospit
chicago
patholog
chicago
usa
mott
children
hospit
surgeri
ann
arbor
usa
cancer
center
pediatr
boston
usa
reed
nation
militari
medic
center
pediatr
bethesda
usa
anderson
cancer
center
radiat
oncolog
houston
usa
hospit
philadelphia
radiat
oncolog
philadelphia
usa
children
hospit
surgeri
seattl
usa
alberta
hospit
pediatr
edmonton
canada
healthcar
oncolog
bluffton
usa
jude
children
research
hospit
pharmaci
memphi
usa
oncolog
north
wale
usa
health
centr
pediatr
bioethic
halifax
canada
nation
medic
center
pediatr
washington
dc
usa
backgroundobject
nation
wilm
tumor
studi
overal
surviv
os
patient
advanc
malign
rhabdoid
tumor
mrt
evalu
intens
regimen
contain
vincristin
doxorubicin
cyclophosphamid
altern
cyclophosphamid
carboplatin
etoposid
regimen
radiotherapi
goal
improv
surviv
ef
os
designmethod
patient
stage
mrt
elig
studi
design
detect
os
use
histor
os
fix
standard
comparison
patient
stage
iv
measur
diseas
option
receiv
vincristin
combin
irinotecan
vi
upfront
window
result
patient
mrt
enrol
primari
tumor
median
age
month
rang
month
stage
distribut
ii
iii
iv
tumor
respons
seen
patient
receiv
vi
window
therapi
among
relapseprogress
median
time
progress
month
ef
os
estim
entir
cohort
ci
ef
estim
accord
stage
stage
ii
ci
stage
iii
ci
stage
iv
ef
estim
ci
renal
tumor
tumor
impact
age
radiotherapi
germlin
statu
toxic
evalu
conclus
regimen
improv
surviv
collect
group
patient
mrt
though
may
improv
outcom
patient
diseas
salvag
patient
relaps
progress
mrt
novel
therapeut
strategi
integr
target
biolog
combin
chemotherapi
need
fn
f
rebelo
r
f
nacion
de
pediatr
surgeri
rio
de
janeiro
brazil
nacion
de
pediatr
oncolog
rio
de
janeiro
brazil
backgroundobject
retrospect
analyz
pediatr
patient
clear
cell
sarcoma
kidney
admit
institut
februari
decemb
designmethod
case
report
form
pediatr
patient
age
rang
year
retrospect
analyz
collect
data
includ
demograph
clinic
present
surgic
oncolog
manag
follow
patient
data
updat
march
result
among
patient
diagnos
non
wilm
renal
tumor
patient
boy
girl
histopatholog
diagnosi
ccsk
median
age
diagnosi
month
rang
month
year
present
symptom
includ
abdomin
mass
first
notic
famili
case
patient
hematuria
patient
abdomin
pain
median
time
initi
symptom
suspect
diagnosi
day
rang
day
day
mean
tumor
volum
evalu
patient
rang
patient
present
metastasi
diagnosi
twenti
four
patient
radic
nefrectomi
either
upfront
case
neoadjuv
chemotherapi
case
patient
free
surgic
margin
case
without
report
lymphadenectomi
perform
case
posit
surgic
stage
ii
iii
overal
surviv
year
surviv
stage
stage
stage
ii
stage
iii
eight
patient
diseas
relaps
bone
brain
lung
local
bone
lung
patient
die
diseas
conclus
multidisciplinari
care
treatment
result
good
signific
differ
surviv
relat
initi
stage
h
halepota
khan
univers
paediatr
surgeri
karachi
pakistan
backgroundobject
determin
outcom
renal
tumor
inferior
vena
cava
ivc
intracardiac
ic
extens
institut
subset
patient
present
technic
challeng
surgeon
especi
constrain
resourc
designmethod
retrospect
cross
section
studyal
patient
year
age
januari
till
june
includ
result
studi
period
patient
renal
tumor
manag
patient
present
ivc
ic
extens
major
involv
right
kidney
common
age
present
rang
year
children
male
femal
level
tumor
extens
ivc
diaphragm
diaphragm
extend
ic
wilm
tumor
common
tumor
type
follow
renal
cell
carcinoma
patient
wilm
tumor
ivc
extens
diaphragm
patient
recurr
year
follow
one
lung
metastasi
due
tumor
spillag
one
patient
stage
diseas
expir
patient
receiv
preoper
chemotherapi
underw
direct
thrombectomi
patient
extens
receiv
preoper
chemotherapi
show
recurr
year
patient
renal
cell
carcinoma
rhabdoid
tumor
conclus
studi
incid
ivc
ic
tumor
extens
much
higher
report
seriesthi
high
incid
explain
mani
patient
refer
patient
studi
surgic
complic
studi
patient
requir
cardiopulmonari
bypass
preoper
chemotherapi
reduc
thrombu
ivc
patient
receiv
chemotherapi
well
preoper
radiotherapi
case
metastat
diseas
patient
diseas
free
five
year
follow
r
john
j
lg
medic
colleg
pediatr
hematolog
oncolog
vellor
india
medic
colleg
pediatr
surgeri
vellor
india
backgroundobject
analyz
clinic
profil
children
wilm
tumor
treat
modifi
siop
protocol
compar
histor
patient
treat
nwt
protocol
designmethod
clinic
radiolog
biopsi
data
children
diagnos
wilm
tumor
treat
use
siop
wt
protocol
minor
modif
posterior
flank
core
biopsi
collect
medic
record
outcom
cohort
compar
children
treat
nwt
protocol
two
centr
includ
centr
report
sen
et
al
result
median
age
diagnosi
month
f
metastat
diseas
renal
veinivc
thrombosi
bilater
tumour
favour
histolog
mean
tumour
volum
reduc
follow
neoadjuv
chemotherapi
children
underw
surgeri
complet
treatment
children
tumour
spill
one
recurr
biopsi
site
mean
follow
month
os
ef
compar
data
histor
cohort
os
vs
stage
vs
vs
vs
vs
vs
os
local
diseas
vs
metastat
diseas
vs
conclus
signific
improv
os
stage
wilm
tumour
treat
protocol
compar
histor
cohort
treat
upfront
surgeri
follow
chemotherapi
centr
patient
present
larg
tumour
use
neoadjuv
chemotherapi
follow
surgeri
prefer
outcom
cohort
treat
protocol
localis
diseas
compar
data
develop
countri
howev
less
metastat
diseas
r
kebudi
f
g
g
z
b
c
f
gun
b
e
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
istanbul
turkey
istanbul
medic
faculti
pediatr
istanbul
turkey
sultan
suleyman
educ
research
hospit
pediatr
istanbul
turkey
cerrahpasa
medic
faculti
pediatr
istanbul
turkey
etfal
educ
research
hospit
pediatr
oncolog
istanbul
turkey
pendik
educ
research
hospit
pediatr
istanbul
turkey
univers
oncolog
institut
pediatr
istanbul
turkey
univers
pediatr
istanbul
turkey
oncolog
institut
radiat
oncolog
istanbul
turkey
istanbul
medic
faculti
pediatr
surgeri
istanbul
turkey
univers
cerrahpasa
medic
faculti
pediatr
surgeri
istanbul
turkey
cerrahpasa
medic
faculti
radiolog
istanbul
turkey
istanbul
medic
faculti
patholog
istanbul
turkey
backgroundobject
bilater
wilm
tumor
bwt
compris
wilm
tumor
children
outcom
children
bwt
report
inferior
children
unilater
tumor
diagnosi
designmethod
multicentr
studi
patient
bwt
treat
seven
center
istanbul
retrospect
evalu
demograph
characterist
treatment
outcom
result
thirti
one
patient
femal
male
median
age
month
treat
evalu
nine
patient
variou
congenit
condit
eight
patient
metastasi
lung
liver
diagnosi
eighteen
patient
biopsi
patient
unilater
nephrectomi
diagnosi
five
patient
diagnos
bwt
radiolog
anaplasia
found
patient
receiv
chemotherapi
vincristin
actinomycin
vad
initi
radiolog
respons
vad
given
day
better
twenti
five
patient
underw
surgeri
unilater
nephrectomi
unilater
nephrectomyparti
contralater
nephrectomi
unilater
nephrectomycontralater
tumor
excis
bilater
partial
nephrectomi
unilater
partial
nephrectomi
contralater
tumor
excis
bilater
tumor
excis
unilater
tumor
excis
fifteen
patient
receiv
radiotherapi
three
patient
never
surgeri
aliv
diseas
month
diagnosi
two
patient
develop
chronic
renal
failur
four
patient
die
due
progress
diseas
overal
surviv
event
free
surviv
median
follow
month
surviv
significantli
lower
metastat
patient
vs
anaplasia
histopatholog
vs
conclus
treatment
bwt
challeng
goal
good
surviv
spare
normal
renal
parenchyma
unnecessari
surgic
resect
possibl
seri
surviv
nonmetastat
patient
favor
histolog
quit
high
surviv
patient
adequ
renal
function
r
kizyma
z
b
b
r
ukrainian
special
children
medic
centr
surgerypediatr
oncolog
lviv
ukrain
nation
medic
univers
pediatr
lviv
ukrain
ukrainian
special
children
medic
centr
intens
care
depart
lviv
ukrain
backgroundobject
object
analys
studi
review
clinic
present
manag
children
wilm
tumor
factor
influenc
outcom
lviv
region
despit
good
overal
prognosi
patient
nephroblastoma
children
develop
countri
present
advanc
stage
diseas
diagnosi
designmethod
retrospect
chart
review
children
renal
tumour
mostli
western
part
ukrain
treat
observ
surgeri
depart
institut
perform
diagnosi
confirm
convent
ct
mri
sonographi
perform
accord
site
involv
treatment
protocol
base
siop
recommend
result
half
patient
present
larg
primari
tumour
metastat
spread
diseas
case
diagnos
stage
iii
case
stage
iv
stage
diagnos
patient
stage
ii
children
four
case
bilater
diseas
stage
v
observ
domin
tumour
refer
stage
iii
neoadjuv
chemotherapi
regimen
use
standart
upfront
surgeri
nephrectomi
biopsi
perform
major
case
unfavour
histolog
type
includ
clear
cell
sarcoma
reveal
adjuv
high
risk
chemotherapi
use
radiotherapi
consid
children
mostli
due
massiv
tumour
spread
diagnosi
overal
surviv
os
event
free
surviv
ef
rate
respect
primari
tumour
stage
statist
signific
factor
influenc
overal
surviv
conclus
approach
neoadjuv
chemotherapi
nephroblastoma
feasibl
compar
upfront
surgeri
realm
develop
countri
consid
statist
larger
amount
advanc
stage
tumour
present
mehmood
khanum
memori
cancer
hospit
research
centr
radiat
oncolog
lahor
pakistan
backgroundobject
compar
result
siop
studi
designmethod
retrospect
review
children
wilm
tumor
wt
treat
shaukat
khanum
memori
cancer
hospit
research
centr
lahor
pakistan
januari
decemb
kaplan
meier
method
test
employ
surviv
analysi
result
mean
age
year
old
sex
ratio
eighti
percent
children
present
painless
abdomin
tumor
first
sign
tumor
mainli
unilater
right
ultrasound
comput
tomographi
show
heterogen
tumor
medium
size
cm
develop
lower
pole
kidney
venou
thrombosi
diagnos
patient
patient
metastat
diseas
present
patient
receiv
preoper
chemotherapi
follow
nephrectomi
postop
stage
ii
iii
respect
accord
siop
risk
classif
low
intermedi
high
histolog
risk
postop
chemotherapi
receiv
adjuv
radiotherapi
given
patient
overal
surviv
local
stage
metastat
stage
percent
relaps
averag
month
late
treatment
relat
side
effect
seen
conclus
studi
show
less
overal
surviv
siop
due
bigger
rate
metastat
form
late
diagnosi
moschovi
k
g
athen
medic
school
pediatr
hematologyoncolog
unit
athen
greec
athen
medic
school
imag
agia
sophia
children
hospit
athen
greec
athen
medic
school
patholog
agia
sophia
children
hospit
athen
greec
backgroundobject
nephroblastoma
wilm
tumor
common
renal
malign
childhood
median
age
diagnosi
approxim
year
occurr
infanc
adolesc
quit
rare
less
frequent
tumor
includ
mesoblast
nephroma
clear
cell
sarcoma
rhabdoid
tumor
adenocarcinoma
designmethod
review
children
renal
tumor
treat
center
last
year
evalu
demograph
featur
histopatholog
result
outcom
result
total
case
renal
tumor
case
nephroblastoma
three
case
mesoblast
nephroma
one
clear
cell
sarcoma
one
rhabdoid
tumor
one
anaplast
sarcoma
specif
regard
nephroblastoma
age
diagnosi
rang
mean
children
children
children
children
old
three
case
nephroblastoma
develop
context
genet
syndrom
specif
two
case
syndrom
one
wagr
syndrom
patient
resid
larg
urban
center
resid
provinc
relaps
observ
two
case
f
year
initi
diagnosi
respect
relaps
second
case
occur
two
year
pregnanc
case
second
remiss
one
case
syndrom
remain
remiss
ten
year
diagnosi
three
case
die
two
diseas
syndrom
renal
one
rhabdoid
tumor
conclus
nephroblastoma
nowaday
curabl
diseas
observ
higher
mean
age
diagnosi
record
intern
data
may
denot
delay
diagnosi
thu
need
higher
level
awar
sinc
relaps
occur
decad
initi
diagnosi
requir
delafoy
c
c
g
v
roussi
children
adolesc
oncolog
unit
villejuif
franc
roussi
clinic
research
oper
depart
villejuif
franc
roussi
biostatist
epidemiolog
unit
villejuif
franc
roussi
cell
therapi
unit
villejuif
franc
backgroundobject
data
report
yet
chemotherapi
hdc
autolog
stem
cell
rescu
ascr
wilm
tumor
wt
aim
defin
feasibl
safeti
profil
hdc
ascr
pediatr
cohort
wt
designmethod
analys
data
patient
wt
treat
hdc
ascr
children
adolesc
oncolog
unit
gustav
roussi
toxic
report
accord
ctcae
result
ten
patient
receiv
hdc
ascr
singl
carboplatin
mec
thiotepa
tandem
hdc
thiotepa
ascr
follow
week
etoposid
tandem
thiotepa
median
age
ascr
year
hdc
perform
relaps
patient
patient
stage
wt
observ
toxic
digest
grade
mucos
diarrhoea
patient
respect
one
grade
renal
toxic
display
mec
neurolog
toxic
observ
sinusoid
obstruct
syndrom
median
durat
neutrophil
recoveri
hospitalis
day
respect
death
observ
toxic
profil
similar
singl
tandem
hdc
whenev
need
treatment
could
complet
lung
andor
liver
radiotherapi
signific
delay
last
patient
aliv
complet
remiss
patient
die
progress
diseas
conclus
singl
tandem
hdc
seem
feasibl
accept
toxic
profil
wt
prospect
nation
intern
studi
need
defin
best
condit
regimen
evalu
role
hdc
set
h
pena
nacion
de
oncolog
mexico
citi
mexico
backgroundobject
determin
experi
therapeut
arm
autolog
hematopoiet
stem
cell
rescu
wilm
tumour
patient
nation
institut
pediatr
inp
mexico
citi
designmethod
perform
retrospect
studi
analysi
year
experi
inp
patient
wilm
tumour
anal
patient
relaps
result
total
relaps
diagnos
includ
patient
wilm
tumour
relaps
receiv
treatment
intens
chemotherapi
radiat
therapi
autolog
hematopoiet
stem
cell
transplant
mean
age
diagnosi
month
mean
relaps
time
diagnosi
month
favor
histolog
report
patient
case
metastat
diagnosi
case
lung
metastasi
one
patient
also
liver
patient
receiv
intens
chemotherapi
ifosfamid
day
etoposid
day
carboplatin
day
ice
well
abdominalpulmonari
radiat
therapi
treatment
relapseth
overal
surviv
ci
caus
death
progress
diseas
case
mortal
report
conclus
treatment
relaps
wilm
tumor
combin
therapi
radiat
chemotherapi
stem
cell
transplant
effect
relat
intens
treatment
report
case
b
pereira
r
p
p
nicolau
b
de
coelho
soar
nacion
de
cancer
pediatr
hematolog
oncolog
programa
rio
de
janeiro
brazil
nacion
de
cancer
patholgi
divis
rio
de
janeiro
brazil
nacion
de
cancer
carcinogenesi
molecular
program
rio
de
janeiro
brazil
bioscienc
nation
laboratori
brazilian
center
research
energi
materi
campina
brazil
backgroundobject
risk
stratif
wilm
tumor
wt
larg
base
tumor
stage
histolog
blastem
compon
predomin
chemotherapi
pretreat
wt
classifi
patiet
high
risk
wt
present
hypomethyl
profil
compar
match
normal
kidney
aim
explor
relat
global
dna
methyl
repres
human
genom
wt
blastem
compon
prognost
factor
designmethod
sampl
ffpe
sporad
unilater
wt
patient
treat
accord
siop
wt
protocol
inca
brazil
review
pathologist
defin
area
blastema
normal
renal
cortex
tissu
prognost
factor
age
gender
risk
classificaion
relaps
explor
regard
methyl
defin
pyrosequenc
averag
methyl
cpg
site
locat
use
analyz
result
compar
wt
blastem
median
normal
kidney
median
sampl
reveal
hypomethyl
wt
p
age
gender
stage
risk
classif
show
relat
methyl
level
within
wt
sampl
nevertheless
tumor
patient
relaps
present
lower
methyl
leven
patient
without
relaps
roc
curv
analysi
use
valu
methyl
level
show
area
curv
auc
sensit
specif
conclus
suggest
methyl
level
evalu
blastem
compon
wt
use
marker
patient
wt
present
relaps
report
hypomethyl
compar
patient
without
relaps
ramadwar
b
g
n
memori
hospit
patholog
mumbai
india
memori
hospit
paediatr
surgeri
mumbai
india
memori
hospit
medic
oncolog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
radiolgi
mumbai
india
backgroundobject
tumour
categori
constitut
sever
rare
benign
highli
aggress
tumour
kidney
children
aim
review
histopatholog
tumour
emphasi
diagnost
challeng
clinic
relev
precis
diagnosi
designmethod
review
histopatholog
immunohistochemistri
ihc
patient
diagnos
renal
tumour
period
clinic
detail
note
electron
medic
record
result
variou
renal
tumour
seri
patient
rhabdoid
tumour
clear
cell
sarcoma
congenit
mesoblast
nephroma
ewe
sarcoma
pnet
transloc
associ
renal
cell
carcinoma
cystic
partial
differenti
nephroblastoma
papillari
rcc
burkitt
lymphoma
granulocyt
sarcoma
rhabdoid
tumour
show
loss
ihc
remain
tumour
pose
diagnost
problem
distinct
clear
cell
sarcoma
wlim
tumour
could
resolv
undifferenti
round
cell
tumour
pose
problem
differenti
pnet
wilm
tumour
synovi
sarcoma
respect
teratoid
wilm
teratoma
could
distinguish
patient
rhabdoid
tumour
underw
resect
patient
present
extens
brain
lung
metastasi
rest
inoper
tumour
patient
clear
cell
sarcoma
could
undergo
resect
relaps
form
bone
brain
metastasi
conclus
rhabdoid
tumour
clear
cell
sarcoma
commonest
tumour
seri
cmn
repres
benign
tumour
rhabdoid
tumour
aggress
tumour
tumour
undifferenti
round
cell
morpholog
pose
diagnost
problem
clear
cell
sarcoma
also
pose
diagnost
problem
due
morpholog
lack
specif
immunoprofil
diagnosi
rhabdoid
tumour
facilit
distinct
morpholog
loss
express
ihc
thu
studi
emphasis
need
precis
diagnosi
biopsi
due
impact
treatment
decis
wide
varieti
differ
tumour
entiti
k
k
polad
r
research
instutut
nn
blokhin
ram
children
oncolog
moscow
russia
backgroundobject
nephroblastoma
one
common
solid
tumor
childhood
incid
tumor
thrombosi
nephroblastoma
accord
variou
larg
studi
literatur
rare
individu
descript
case
thrombosi
children
nephroblastoma
spread
thrombu
atrium
designmethod
clinic
treat
children
nephroblastoma
ivc
thrombosi
age
children
rang
year
year
thrombu
reach
right
atrium
treatment
includ
preoper
chemotherapi
surgeri
nephrectomi
thrombectomi
postop
radiat
therapi
chemotherapi
result
surviv
stage
iii
nephroblastoma
differ
surviv
nephroblastoma
tumor
ivc
thrombosi
preoper
chemotherapi
complet
regress
tumor
thrombu
achiev
case
partial
regress
preoper
chemotherapi
reduc
intraop
blood
loss
frequenc
surgic
complic
condit
radic
oper
local
lesion
differ
section
ivc
affect
surviv
current
children
aliv
without
evid
recurr
diseas
progress
conclus
complex
therapi
allow
achiev
good
overal
surviv
children
nephroblastoma
ivc
thrombosi
sarrawi
h
r
k
f
hussein
cancer
center
pediatr
amman
jordan
backgroundobject
patient
wilm
tumor
wt
present
ruptur
tumor
specif
symptom
radiolog
diagnosi
patholog
confirm
optim
manag
necessari
improv
outcom
patient
designmethod
conduct
retrospect
pediatr
patient
diagnos
wt
ruptur
wilm
tumor
diagnos
base
radiolog
andor
patholog
find
result
twenti
seven
patient
male
analys
median
age
diagnosi
year
rang
patholog
local
stage
irrespect
ruptur
follow
ii
iii
median
durat
symptom
present
week
rang
twenti
three
patient
favor
histolog
distant
metastasi
found
patient
present
upfront
nephrectomi
done
patient
ruptur
wt
identifi
radiolog
patient
intraop
patient
ruptur
patholog
confirm
patient
twenti
five
patient
receiv
postop
radiotherapi
whether
flank
whole
abdomen
relaps
develop
patient
die
one
relaps
patient
upstag
receiv
radiotherapi
os
ef
respect
univari
analysi
show
rel
wors
ef
patient
age
less
year
analysi
differ
outcom
observ
accord
durat
symptom
use
radiotherapi
upfront
nephrectomi
conclus
similar
previou
report
show
major
patient
ruptur
cure
regimen
abdomin
radiat
correl
import
diagnos
patient
current
stage
system
optim
captur
patient
need
revis
lg
tago
e
bu
teach
hospit
child
health
accra
ghana
backgroundobject
wilm
tumour
fourth
commonest
childhood
malign
ghana
surviv
wilm
tumour
africa
report
object
studi
describ
present
wilm
tumour
extent
spread
present
patient
outcom
designmethod
retrospect
studi
clinic
note
includ
result
investig
children
diagnos
wilm
tumour
paediatr
oncolog
unit
teach
hospit
accra
januari
decemb
review
data
analys
time
lag
symptom
onset
present
start
treatment
evid
metastas
histopatholog
featur
patient
outcom
result
case
note
retriev
case
seen
period
major
patient
three
five
year
old
male
femal
ratio
five
bilater
diseas
commonest
present
complaint
painless
abdomin
mass
patient
delay
seek
medic
help
present
month
major
patient
maximum
tumour
diamet
imag
case
metastas
present
lung
andor
liver
patient
receiv
treatment
case
except
two
involv
neoadjuv
chemotherapi
prior
nephrectomi
case
found
stage
iii
surgeri
classifi
intermedi
risk
histopatholog
high
risk
receiv
adjuv
radiotherapi
patient
abandon
treatment
whilst
complet
treatment
current
aliv
patient
relaps
treatment
complet
patient
die
either
treatment
relaps
conclus
although
children
wilm
tumour
set
present
advanc
stage
diseas
stage
iii
v
appropri
treatment
includ
radiotherapi
outcom
encourag
van
peer
c
van
de
terwisscha
van
j
van
van
den
center
pediatr
oncolog
pediatr
oncolog
utrecht
netherland
backgroundobject
optim
surviv
rate
well
qualiti
cure
pediatr
kidney
tumor
attent
treatment
relat
morbid
mortal
becom
increasingli
import
intussuscept
rare
import
complic
tumornephrectomi
children
caus
morbid
mortal
prolong
hospit
studi
describ
two
recent
case
institut
provid
comprehens
review
literatur
designmethod
narr
review
search
report
case
post
tumornephrectomi
intussuscept
publish
novemb
use
pubm
embas
librari
result
total
pediatr
renal
tumor
case
develop
intussuscept
tumornephrectomi
identifi
median
age
month
rang
median
time
onset
postop
day
rang
patient
describ
detail
suffer
ileoil
intussuscept
ileocol
frequent
present
symptom
biliou
vomit
preced
treatment
approach
could
document
case
ie
preoper
chemotherapi
administ
patient
well
document
case
success
manual
reduct
describ
patient
need
resect
patient
surviv
without
recurr
intussuscept
conclus
pediatr
renal
tumor
patient
small
bowel
obstruct
seem
reflect
postnephrectomi
intussuscept
case
contrast
ileocol
idiopath
intussuscept
observ
healthi
children
symptom
intussuscept
mimic
chemotherapi
relat
toxic
gener
symptom
therebi
initi
signific
delay
diagnosi
awar
intussuscept
renal
tumor
surgeri
warrant
c
lai
j
q
hospit
zhejiang
univers
school
medicin
depart
radiolog
hangzhou
china
hospit
zhejiang
univers
school
medicin
depart
surgic
oncolog
hangzhou
china
backgroundobject
evalu
efficaci
preoper
tace
children
advanc
wilm
tumor
designmethod
late
case
advanc
wilm
tumor
inclus
criteria
tumor
diamet
medial
border
midlin
imag
studi
suggest
tumor
invas
adjac
organ
abdomin
aortic
lymph
node
metastasi
ascit
inferior
vena
cava
tumor
thrombosi
lung
liver
bone
distant
metastas
bilater
wilm
tumor
studi
group
preoper
arteri
chemoembol
group
case
preoper
intraven
chemotherapi
group
case
earli
surgeri
group
case
result
preoper
tace
group
averag
reduct
tumor
preoper
chemotherapi
tumor
shrinkag
tumor
volum
reduct
rate
two
group
statist
significantthre
group
patient
complet
resect
rate
preoper
tace
group
preoper
chemotherapi
group
differ
statist
signific
conclus
preoper
tace
higher
tumor
shrinkag
rate
shorter
peroperatin
treatment
time
less
system
toxic
higher
rate
complet
tumor
resect
tace
safe
effect
advanc
wilm
tumor
z
hu
j
h
x
x
j
municip
central
hospit
depart
pediatr
surgeri
jinhua
china
hospit
zhejiang
univers
school
medicin
depart
surgic
oncolog
hangzhou
china
backgroundobject
evalu
efficaci
transarteri
chemoembol
tace
combin
surgeri
treatment
wilm
tumor
children
designmethod
case
wilm
tumor
admit
depart
pediatr
surgeri
jinhua
municip
central
hospit
januari
decemb
three
case
bilater
tumor
case
solitari
tumor
exclud
case
unilater
wilm
tumor
randomli
alloc
preoper
tace
group
preoper
tace
surgeri
n
control
group
preoper
chemotherapi
surgeri
n
shrinkag
volum
tumor
blood
loss
surgeri
tumor
spillag
oper
time
postop
complic
analyz
result
compar
control
group
shrinkag
volum
tumor
higher
preoper
tace
group
vs
p
blood
loss
surgeri
less
vs
p
myelosuppress
rate
lower
vs
p
number
less
tumor
spillag
tace
group
statist
diffenc
two
group
mean
time
month
tumor
recurr
distant
metastasi
observ
conclus
preoper
tace
combin
surgeri
safe
effect
modal
treatment
wilm
tumor
children
w
yao
k
k
x
hospit
fudan
univers
pediatr
surgeri
shanghai
china
backgroundobject
investig
clinic
featur
prognosi
renal
cell
carcinoma
rcc
associ
translocationtf
gene
fusion
children
designmethod
retrospect
review
case
jan
dec
evalu
clinic
data
collect
analyz
result
xp
transloc
rcc
identifi
male
femal
mean
age
year
rang
year
clinic
symptom
includ
painless
hematuria
case
abdomin
pain
microscop
hematuria
case
incident
find
patient
accord
tnm
stage
system
patient
stage
patient
stage
ii
patient
stage
iii
patient
stage
iv
lumber
metastasi
tumor
side
mean
radic
nephrectomi
lymphadenectomi
perform
patient
lymphat
invas
confirm
case
tumor
biopsi
perform
patient
one
patient
receiv
postop
chemotherapi
patient
observ
surgeri
patient
biopsi
one
receiv
radiotherapi
one
gave
treatment
patient
follow
averag
month
rang
month
still
aliv
die
surgeri
conclus
xp
transloc
rcc
rare
subtyp
renal
tumor
children
associ
poor
prognosi
lymphat
metastasi
radic
nephrectomi
lymphadenectomi
main
treatment
patient
akta
p
e
h
n
eylul
univers
institut
oncolog
izmir
turkey
eylul
univers
experiment
anim
scienc
izmir
turkey
eylul
univers
orthoped
izmir
turkey
backgroundobject
osteosarcoma
usual
occur
childhood
young
adulthood
aggress
tumor
achiev
great
success
limb
salvag
surgeri
howev
residu
tumor
may
remain
microscop
level
increas
likelihood
recurr
apart
surgeri
residu
tumor
observ
despit
methotrex
cisplatin
chemotherapi
regimen
therefor
new
approach
need
treatment
osteosarcoma
studi
cadmium
cement
place
local
surgic
resect
evalu
prevent
efficaci
residu
tumor
recurr
vivo
anim
model
designmethod
tumorigen
osteosarcoma
cell
line
cultiv
vitro
xenograft
tumor
model
form
give
tumor
cell
subcucat
athym
nude
mice
tumor
growth
control
tumor
near
total
resect
tumor
group
near
total
resect
group
serum
cement
near
total
resect
group
cadmium
cement
group
conduct
randomli
anim
group
anim
observ
day
recurr
tumor
site
sacrif
presenc
residu
check
histopatholog
group
result
tumor
form
within
one
month
subcutan
inject
recurr
tumor
form
anim
near
total
resect
group
near
total
resect
group
serum
cement
small
tumor
format
observ
cadmium
group
system
toxic
effect
observ
conclus
data
suggest
local
applic
cadmium
cement
might
help
local
therapi
osteosarcoma
surgeri
postop
local
treatment
agent
within
orthoped
biyomechan
substanc
might
option
addit
treatment
overcom
recurr
osteosarcoma
next
step
test
chemotherapoet
agent
methotrex
cispatin
cemnent
vivo
anim
model
e
blanco
b
univers
hospit
nh
foundat
trust
paediatr
haematologyoncolog
oxford
unit
kingdom
univers
hospit
nh
foundat
trust
oxford
sarcoma
servic
oxford
unit
kingdom
oxford
oxford
sarcoma
servic
oxford
unit
kingdom
backgroundobject
giant
cell
tumour
bone
gctb
benign
local
aggress
tumour
predominantli
treat
surgic
recent
neoadjuv
treatment
monoclon
antibodi
denosumab
enabl
surgeri
unresect
case
consid
denosumab
disturb
interact
inhibit
bone
lysi
promot
osteogenesi
overexpress
gctb
stromal
cell
drive
boni
destruct
associ
tumour
oxford
sarcoma
servic
select
utilis
denosumab
optimis
oper
reduc
surgic
associ
morbid
designmethod
present
case
patient
undergo
denosumab
treatment
unresect
sacral
gctb
becam
pregnant
treatment
result
patient
present
cauda
equina
syndrom
biopsi
extens
vertebr
lesion
confirm
sacral
gctb
resect
would
requir
sacrific
nerv
root
loss
bowel
bladder
function
denosumab
commenc
excel
metabol
radiolog
neurolog
respons
cycl
petct
demonstr
reduct
suvmax
resolut
presacr
soft
tissu
mass
sacral
ossif
complet
metabol
respons
seen
cycl
denosumab
cycl
treatment
stop
pregnanc
time
patient
symptom
stabl
despit
tumour
increas
greater
sagitt
axi
normal
babi
born
elect
cesarean
section
without
skelet
metabol
abnorm
denosumab
recommenc
rapid
radiolog
respons
cycl
peak
cycl
dose
frequenc
reduc
alter
bone
mineralis
densiti
necessit
plan
definit
local
therapi
proton
beam
therapi
conclus
denosumab
provid
excel
tumour
control
unresect
gctb
report
object
evid
effect
hiatu
risk
resist
low
consider
toxic
definit
manag
remain
import
consider
p
b
f
c
k
j
r
k
karajanni
langon
medic
center
radiat
oncolog
new
york
usa
langon
medic
center
patholog
new
york
usa
sloan
ketter
cancer
center
patholog
new
york
usa
langon
medic
center
pediatr
new
york
usa
medic
center
pediatr
new
york
usa
sloan
ketter
cancer
center
pediatr
new
york
usa
backgroundobject
pediatr
bone
sarcoma
present
uniqu
diagnost
challeng
consider
morpholog
overlap
differ
entiti
choic
optim
treatment
howev
depend
upon
accur
diagnosi
dna
methyl
profil
emerg
power
new
diagnost
tool
brain
tumor
diagnost
accuraci
exceed
standard
histopatholog
develop
valid
methyl
base
classifi
differenti
osteosarcoma
os
ewe
sarcoma
es
synovi
sarcoma
ss
designmethod
dna
methyl
statu
cpg
site
os
es
ss
sampl
measur
use
illumina
array
train
set
sarcoma
sampl
develop
random
forest
classifi
differenti
methyl
cpg
site
fdr
q
valu
classifi
valid
ss
sampl
cancer
genom
atla
tcga
os
sampl
es
sampl
recent
publish
seri
et
al
cancer
lett
result
dna
methyl
profil
reveal
three
distinct
molecular
cluster
enrich
singl
sarcoma
subtyp
within
valid
cohort
sampl
tcga
accur
classifi
synovi
sarcoma
sensit
specif
one
sampl
classifi
os
sensit
specif
one
sampl
es
seri
classifi
es
sensit
specif
singl
mismatch
osteosarcoma
sampl
classifi
es
later
determin
misdiagnos
es
base
data
demonstr
high
express
addit
clinic
sampl
misdiagnos
ss
base
initi
histolopatholog
accur
recogn
os
methyl
classifi
conclus
os
es
ss
distinct
epigenet
profil
valid
classifi
provid
increas
diagnost
accuraci
includ
case
standard
histopatholog
inconclus
n
kitagawa
k
h
e
k
j
h
k
children
medic
center
depart
surgeri
yokohama
japan
children
medic
center
depart
orthoped
surgeri
yokohama
japan
children
medic
center
depart
hematolog
oncolog
regen
medicin
yokohama
japan
children
medic
center
depart
radiolog
yokohama
japan
children
medic
center
depart
patholog
yokohama
japan
backgroundobject
distant
metastasi
one
import
prognost
factor
osteosarcoma
metastas
usual
occur
lung
perform
aggress
pulmonari
metastasecomi
prognosi
patient
still
unsatisfactori
aim
studi
find
prognost
factor
patient
osteosarcoma
accompani
pulmonari
metastasi
designmethod
retrospect
chart
review
patient
osteosarcoma
perform
patient
underw
neoadjuv
adjuv
chemotherapi
surgeri
primari
lesion
metastat
lung
lesion
remov
mainli
wedg
resect
open
thoracotomi
sometim
lobectomi
tumor
larg
result
patient
lung
metastas
thirteen
patient
extrapulmonari
metastasi
epm
metastat
site
bone
soft
tissu
diaphragm
brain
surviv
rate
patient
without
metastasi
compar
pulmonari
metastasi
patient
pulmonari
metastasi
surviv
rate
patient
without
epm
patient
epm
patient
without
epm
surviv
rate
achiev
surgic
metastasectomi
compar
without
metastasectomi
patient
epm
surviv
rate
achiev
surgic
metastasectomi
compar
without
conclus
result
suggest
pulmonari
metastasi
import
prognost
factor
patient
osteosarcoma
epm
also
contribut
factor
patient
without
epm
pulmonari
metastasectomi
recommend
howev
patient
epm
prognosi
still
poor
even
metastasectomi
perform
form
new
strategi
need
v
kobi
v
citi
oncolog
center
pediatr
oncolog
kiev
ukrain
experiment
oncolog
depart
osteolog
kiev
ukrain
backgroundobject
due
growth
child
increas
bodi
mass
mechan
load
endoprothesi
significantli
increas
extens
prosthesi
increas
arm
forc
endoprosthesi
stem
time
lead
fractur
femor
endoprosthesi
stem
need
reoper
replac
endoprosthesi
designmethod
period
oper
patient
malign
femur
bone
tumor
age
year
averag
age
year
fractur
femor
bone
endoprosthesi
stem
period
year
arthroplasti
materi
titanium
endoprosthesi
alloy
rod
diamet
femor
stem
mm
result
patient
fractur
femor
endoprosthesi
stem
reimplant
stem
mostli
stem
larger
diamet
deterior
limb
function
cement
endoprosthesi
stem
remov
without
cut
bone
contain
fragment
stem
prosthesi
longitudin
osteotomi
perform
extract
fragment
endoprothesi
stem
conclus
implant
knee
endoprothes
children
prefer
given
cement
endoprosthesi
high
risk
fractur
endoprosthesi
leg
much
less
traumat
remov
replac
endoprosthesi
stem
later
patient
stop
grow
endoprosthesi
implant
n
kurucu
c
n
univers
faculti
medicin
depart
pedatr
oncolog
ankara
turkey
ankara
oncolog
research
trane
hospit
depart
biochemistri
ankara
turkey
ankara
oncolog
research
trane
hospit
depart
pediatr
oncolog
ankara
turkey
backgroundobject
adhes
molecul
involv
carcinogenesi
metastas
aim
studi
analysi
serum
level
adhes
molecul
relationship
clinic
laboratori
prognost
factor
designmethod
patient
diagnos
bone
soft
tissu
sarcoma
healthi
control
includ
studi
serum
selectin
cadherin
level
analyz
elisa
method
diagnosi
induct
end
treatment
mean
level
patient
differ
time
compar
control
group
relationship
serum
level
presenc
metastas
percentag
necrosi
cours
diseas
evalu
result
male
femal
median
age
year
diagnos
osteosarcoma
ewe
sarcoma
rhabdomyosarcoma
six
synovi
sarcoma
two
tumor
locat
long
bone
patient
twenti
patient
metastat
diseas
diagnosi
mean
selectin
cadherin
level
patient
diagnosi
significantli
p
higher
control
group
patient
selectin
level
higher
compar
control
diagnost
group
osteosarcoma
ewe
sarcoma
signific
decreas
cadherin
level
observ
end
treatment
compar
level
diagnosi
level
patient
pulmonari
metastasi
higher
level
patient
level
significantli
higher
relaps
diseas
relationship
adhes
molecul
level
mean
percentag
necrosi
conclus
selectin
level
observ
bone
soft
tissu
sarcoma
may
use
marker
diagnosi
find
suggest
elev
level
associ
metastat
relaps
diseas
respect
kutluk
c
b
n
b
univers
cancer
institut
faculti
medicin
depart
pediatr
oncolog
ankara
turkey
backgroundobject
surviv
rate
childhood
cancer
improv
significantli
last
sever
decad
improv
global
level
econom
analysi
critic
import
cost
diagnosi
treatment
patient
osteosarcoma
investig
studi
designmethod
pediatr
osteosarcoma
case
sequenti
diagnos
includ
direct
cost
ambulatori
inpati
care
start
diagnosi
decemb
patient
analyz
detail
includ
examin
imag
laboratori
oper
patholog
medicin
medic
suppli
hospit
accommod
servic
cost
inpati
outpati
care
result
patient
mean
median
minimum
maximum
age
mf
ratio
year
respect
includ
patient
local
metastat
diseas
diagnosi
overal
surviv
os
patient
os
patient
local
diseas
patient
metastat
diseas
median
time
month
total
cost
patient
usd
includ
usd
inpati
cost
usd
outpati
cost
averag
cost
usd
per
patient
distribut
cost
usd
differ
group
oper
servic
medicin
laboratori
examin
examin
patholog
suppli
imag
hospit
fee
conclus
better
understand
cost
care
pediatr
cancer
invest
purpos
detail
econom
analysi
need
exampl
cost
care
pediatr
osteosarcoma
patient
calcul
studi
averag
cost
per
patient
found
studi
seem
reason
countri
kind
analysi
help
plan
childhood
cancer
care
countri
plan
invest
childhood
cancer
control
e
senzhapova
hematolog
oncolog
institut
fsbi
nn
blokhin
russian
cancer
research
center
pediatr
hematolog
oncolog
institut
moscow
russia
diagnost
treatment
tumor
institut
fsbi
nn
blokhin
russian
cancer
research
center
experiment
diagnost
treatment
tumor
institut
moscow
russia
backgroundobject
aim
studi
estim
mgmt
protein
express
biopsi
specimen
tumor
tissu
sampl
poor
respons
grade
ii
tumor
cell
necrosi
rate
neoadjuv
chemotherapi
surgeri
primari
site
designmethod
protein
express
assess
immunohistochem
method
use
clone
abcam
dako
genetex
thermo
mgmt
posit
specimen
defin
weak
moder
strong
colour
tumor
nuclei
cytoplasm
mgmt
number
posit
tumor
cell
mgmt
posit
specimen
defin
moder
strong
colour
tumor
nuclei
cytoplasm
membran
number
posit
tumor
cell
patient
treat
accord
chemotherapi
primari
metastat
osteosarcoma
diagnos
patient
local
diseas
result
posit
sampl
reveal
biopsi
specimen
postop
specimen
group
metastas
group
without
metastas
p
mgmt
posit
neg
variant
posit
neg
neg
variant
neg
neg
variant
p
conclus
data
suggest
basic
mechan
drug
resist
present
decreas
express
constant
mgmt
express
increas
number
posit
neg
variant
posit
neg
neg
variant
neg
neg
variant
postop
specimen
n
mari
hospit
abuja
nurs
serivc
abuja
nigeria
backgroundobject
cancer
one
major
caus
death
children
adolesc
account
death
children
nigeria
nurs
care
patient
often
receiv
adequ
attent
report
highlight
challeng
nurs
care
children
low
resourc
set
aim
rais
awar
influenc
advocaci
action
designmethod
retrospect
review
children
treat
cancer
inpati
children
ward
period
novemb
novemb
period
total
children
admit
ward
nurs
care
patient
review
result
children
cancer
account
admiss
ward
addit
nurs
workload
patient
sever
import
challeng
limit
encount
requir
attent
effort
nurs
staff
includ
financi
burden
parent
inabl
cope
cost
psycholog
issu
involv
parent
patient
aggress
anxieti
depress
withdraw
difficulti
commun
diseas
cours
treatment
complic
treatment
challeng
significantli
increas
nurs
burden
patient
often
part
patient
treatment
plan
conclus
import
includ
identifi
challeng
counsel
treatment
plan
children
cancer
particularli
low
resourc
set
burden
nurs
care
enorm
develop
implement
care
multidisciplinari
care
plan
help
address
challeng
k
ohalloran
mr
hospit
upmc
pediatr
resid
program
pittsburgh
usa
hospit
upmc
pediatr
hematologyoncolog
pittsburgh
usa
backgroundobject
osteosarcoma
follow
retinoblastoma
known
occur
howev
pattern
osteosarcoma
recurr
subset
patient
well
describ
report
case
patient
histori
bilater
germlin
retinoblastoma
osteosarcoma
unusu
site
soft
tissu
osteosarcoma
recurr
designmethod
case
report
result
month
age
patient
diagnos
bilater
germlin
retinoblastoma
despit
famili
histori
underw
chemotherapi
vincristin
carboplatin
etoposid
given
diseas
progress
howev
underw
enucl
right
eye
remain
remiss
year
time
develop
knee
pain
found
osteosarcoma
tumor
metastat
diseas
note
chest
ct
underw
week
doxorubicin
cisplatin
methotrex
per
less
year
later
pulmonari
metastas
found
follow
metastasectomi
start
dinutuximab
phase
ii
trial
two
week
follow
initi
dinutuximab
present
antebcubit
fossa
mass
found
biopsi
repres
soft
tissu
recurr
osteosarcoma
pet
scan
subsequ
reveal
vertebr
left
poplit
soft
tissu
right
lower
lobe
lung
lesion
genet
test
posit
mutat
subsequ
start
ifosfamid
due
mix
respons
poor
prognosi
howev
undergo
palli
radiat
therapi
oral
sorafenib
conclus
case
suggest
survivor
germlin
retinoblastoma
develop
second
primari
malign
subsequ
relaps
may
unusu
site
pattern
recurr
case
furthermor
illustr
underli
genet
mutat
rb
gene
mutat
may
impact
respons
therapi
includ
chemotherapi
palomo
colli
perez
jf
gaytan
c
cicero
castorena
infantil
de
oncolog
mexico
de
especialidad
del
la
mujer
pediatr
queretaro
mexico
region
de
alta
especialidad
ixtapaluca
pediatr
ixtapaluca
mexico
backgroundobject
osteosarcoma
common
bone
malign
frequent
children
adolesc
neoadjuv
chemotherapi
osteosarcoma
offer
seri
advantag
treatment
microscop
metastas
shrink
primari
tumor
possibl
surgeri
preoper
treatment
allow
vivo
evalu
treatment
postop
treatment
adjust
accord
histolog
respons
designmethod
conduct
retrospect
studi
base
medic
record
patient
osteosarcoma
receiv
neoadjuv
treatment
hospit
infantil
de
federico
himfg
aim
studi
evalu
dose
intens
di
calcul
dose
per
unit
time
purpos
analysi
time
set
day
start
day
chemotherapi
accord
differ
treatment
map
treatment
consist
administr
two
cycl
cisplatin
doxorubicin
methotrex
second
one
consist
four
cycl
cisplatin
doxorubicin
administr
everi
three
week
neoadjuv
di
calcul
drug
administr
result
medic
record
collect
period
time
howev
eleven
elimin
sinc
chemotherapi
inform
incomplet
death
prior
day
end
day
inform
remain
medic
record
analyz
studi
popul
femal
male
regard
age
diagnosi
median
year
metastas
diagnosi
observ
patient
averag
time
diagnosi
surgeri
week
map
protocol
week
cisplatindoxorubicin
rel
di
doxorubicin
cisplatin
methotrex
conclus
di
inadequ
mani
case
toxic
lack
suffici
bed
hospit
result
delay
surgeri
asb
sy
h
aa
r
mohammad
jave
khanum
memori
cancer
hospit
research
center
pediatr
oncolog
lahor
pakistan
backgroundobject
osteosarcoma
common
bone
tumor
children
limit
inform
outcom
pediatr
osteosarcoma
pakistan
conduct
studi
determin
outcom
children
osteosarcoma
diagnos
treat
institut
year
designmethod
conduct
retrospect
chart
review
patient
osteosarcoma
receiv
treatment
institut
januari
decemb
analysi
use
surviv
analysi
use
spss
version
result
osteosarcoma
diagnos
patient
patient
abandon
treatment
within
first
month
diagnosi
final
studi
popul
patient
receiv
treatment
cisplatin
doxorubicin
methotrex
per
euromo
protocol
mean
age
diagnosi
year
sd
male
femal
ratio
patient
diseas
lower
extrem
upper
extrem
axial
involv
mortal
diseas
progress
infecti
complic
cardiac
complic
patient
diseas
progress
treatment
relaps
end
treatment
overal
surviv
os
event
free
surviv
ef
entir
popul
eight
year
respect
median
month
metastat
case
os
ef
respect
none
patient
axial
tumor
surviv
upper
extrem
lower
extrem
tumor
os
ef
respect
differ
surviv
base
gender
conclus
surviv
osteosarcoma
ef
lower
expect
measur
improv
care
infect
cardiac
complic
improv
outcom
effort
reduc
abandon
also
need
h
sa
aa
r
mohammad
wali
jave
khanum
memori
cancer
hospit
research
center
pediatr
oncolog
lahor
pakistan
backgroundobject
treatment
abandon
common
caus
cancer
relat
mortal
develop
countri
especi
condit
requir
mutil
surgeri
conduct
studi
determin
pattern
treatment
abandon
patient
osteosarcoma
treat
institut
year
designmethod
conduct
retrospect
chart
review
patient
diagnos
osteosarcoma
institut
januari
decemb
compar
characterist
patient
continu
treatment
abandon
spss
version
use
analysi
result
osteosarcoma
diagnos
patient
patient
abandon
treatment
thu
patient
year
complet
treatment
half
patient
abandon
prior
start
chemotherapi
remain
left
follow
chemotherapi
mean
age
treat
group
abandon
group
total
male
patient
abandon
femal
abandon
likelihood
ratio
abandon
femal
p
none
patient
afghanistan
abandon
sindh
baluchistan
kpk
punjab
abandon
treatment
patient
metastat
diseas
abandon
inform
avail
patient
patient
die
diseas
progress
patient
came
back
progress
diseas
lost
conclus
high
rate
treatment
abandon
osteosarcoma
patient
institut
half
case
occur
time
surgeri
better
counsel
prepar
patient
amput
may
reduc
abandon
rate
femal
also
show
higher
trend
abandon
diseas
prognosi
geograph
distanc
institut
nt
affect
abandon
need
better
patient
abandon
know
outcom
takeuchi
n
k
k
h
h
univers
graduat
school
medic
scienc
orthopaed
surgeri
kanazawa
japan
backgroundobject
osteosarcoma
usual
occur
metaphys
locat
must
excis
adjac
joint
replac
endoprosthesi
recent
advanc
imag
accur
tumor
excis
rigid
fixat
use
lock
plate
use
tumor
excis
select
patient
reconstruct
defect
tumor
excis
variou
method
includ
allograft
distract
osteogenesi
autograft
vascularis
fibular
graft
implant
appli
autograft
treat
liquid
nitrogen
procedur
introduc
use
sinc
report
advantag
frozen
autograft
includ
simplic
possibl
preserv
protein
includ
bone
morphogenet
protein
bmp
investig
postop
epiphysi
growth
follow
surgeri
childhood
osteosarcoma
around
knee
joint
designmethod
retrospect
review
patient
osteosarcoma
underw
tumor
excis
transmetaphys
transphys
transepiphys
excis
reconstruct
use
autograft
treat
liquid
nitrogen
mean
patient
age
rang
year
mean
period
rang
month
nine
tumor
distal
femur
four
proxim
tibia
epiphysi
transvers
growth
rate
discrep
ewd
collaps
epiphysi
evalu
use
whole
stand
leg
radiograph
function
outcom
complic
oncolog
statu
also
investig
result
mean
epiphysi
growth
rate
rang
mean
ewd
rang
mm
mean
lld
rang
mm
two
patient
underw
limb
lengthen
appar
collaps
residu
epiphysi
mean
mst
score
rang
conclus
epiphysi
transvers
growth
continu
surgeri
childhood
osteosarcoma
surgeri
children
consid
l
vasquez
r
f
j
hospit
pediatr
oncolog
lima
peru
institut
neoplast
diseas
inen
pediatr
oncolog
lima
peru
backgroundobject
aim
studi
evalu
relationship
latenc
diagnosi
ld
treatment
delay
td
surviv
outcom
children
osteosarcoma
designmethod
retrospect
analysi
consecut
treat
patient
two
major
tertiari
center
childhood
cancer
peru
januari
decemb
diagnosi
osteosarcoma
perform
ld
measur
time
start
symptom
definit
diagnosi
td
defin
delay
week
frontlin
treatment
protocol
caus
td
evalu
medic
neutropenia
sever
infect
lack
avail
bed
surgic
prosthesi
social
problem
overal
surviv
os
surviv
ef
estim
compar
accord
ld
td
known
prognost
factor
result
total
patient
includ
studi
median
ld
week
rang
associ
clinic
stage
tumor
size
ld
detect
children
parent
without
formal
job
significantli
longer
ld
delay
ld
associ
wors
outcom
multivari
analysi
confirm
os
ef
significantli
wors
td
longer
week
hazard
ratio
ci
ci
respect
patient
complet
treatment
protocol
initi
establish
time
td
caus
reason
differ
surviv
rate
group
conclus
longer
ld
children
osteosarcoma
seem
influenc
os
ef
delay
caus
oncolog
treatment
independ
associ
poor
prognosi
base
result
effort
need
decreas
treatment
delay
countri
biswa
n
r
b
india
institut
medic
scienc
radiat
oncolog
new
delhi
india
india
institut
medic
scienc
medic
oncolog
new
delhi
india
india
institut
medic
scienc
ocular
patholog
new
delhi
india
india
institut
medic
scienc
ophthalmolog
new
delhi
india
backgroundobject
orbit
rhabdomyosarcoma
rm
favour
prognost
tumour
cure
rate
achiev
combin
chemotherapi
local
radiotherapi
trial
set
intend
report
treatment
outcom
patient
orbit
rm
treat
institut
designmethod
treatment
plan
patient
diagnos
orbit
rm
induct
chemotherapi
vac
actinomycin
cyclophosphamid
cours
follow
orbit
radiotherapi
follow
chemotherapi
vac
regimen
total
cours
clinic
data
collect
retrospect
chart
review
overal
surviv
os
progress
free
surviv
pf
analyz
method
result
twenti
five
patient
met
studi
criterion
male
median
age
present
year
common
symptom
median
durat
month
proptosi
visual
disturb
ocular
pain
eyelid
swell
ptosi
patient
respect
orbit
biopsi
reveal
embryon
alveolar
rm
patient
respect
stage
patient
ir
clinic
group
ii
iii
iv
diseas
respect
system
chemotherapi
vac
administ
patient
cours
orbit
radiotherapi
given
patient
median
dose
gray
mean
month
patient
diseas
progress
two
patient
could
success
salvag
chemotherapi
ice
carboplatin
etoposid
orbit
exenter
last
patient
due
progress
diseas
due
chemotherapi
relat
toxic
median
pf
month
median
os
reach
actuari
rate
pf
os
respect
year
year
conclus
combin
chemotherapi
vac
orbit
radiotherapi
led
modest
clinic
outcom
patient
orbit
rm
centr
possibl
due
high
incid
alveolar
rm
metastat
diseas
poor
treatment
complianc
toxic
death
butler
g
l
b
c
h
jc
c
l
n
mp
h
v
gustav
roussi
pediatr
villejuif
franc
biopatholog
lyon
franc
curi
biopatholog
pari
franc
curi
pediatr
pari
franc
hospit
biopatholog
pari
franc
hospit
french
nation
registri
center
nanci
franc
pediatr
lyon
franc
hospit
biopatholog
pari
franc
hospit
pediatr
surgeri
franc
oscar
lambert
pediatr
lill
franc
hospit
pediatr
rouen
franc
de
la
timon
pediatr
marseil
franc
hospit
pediatr
bordeaux
franc
hospit
pediatr
nant
franc
hospit
pediatr
nanci
franc
gustav
roussi
biostatist
villejuif
franc
de
enfant
pediatr
toulous
franc
curi
radiolog
pari
franc
backgroundobject
rhabdomyosarcoma
rm
common
soft
tissu
tumor
childhood
major
subtyp
alveolar
embryon
tumor
rm
infant
rm
particular
entiti
specif
clinic
present
outcom
recent
molecular
rearrang
involv
gene
describ
congenit
spindl
cell
rm
sscrm
designmethod
retrospect
studi
review
clinic
histolog
molecular
data
infant
age
less
month
diagnosi
treat
franc
rm
regist
record
french
nation
cancer
registri
histolog
central
review
molecular
analysi
perform
tumor
tissu
patient
result
infant
includ
median
age
month
diagnosi
metastat
patient
congenit
malform
consid
survivor
median
year
os
ef
rate
patient
ci
ci
infant
experienc
treatment
failur
relaps
mostli
progress
earli
transloc
identifi
patient
rm
record
local
common
spindl
cell
histolog
appear
two
aliv
first
cr
molecular
analysi
remain
patient
ongo
cgh
array
fish
neg
rnaseq
infant
present
grade
iii
iv
toxic
infant
receiv
ifosfamid
among
age
less
month
one
tubular
toxic
neurolog
toxic
record
infant
treat
ifosfamid
conclus
result
suggest
subtyp
neonat
rm
exist
specif
clinic
histolog
sscrm
andor
molecular
present
fusion
e
elnadi
moham
g
h
abdel
e
n
e
univers
egypt
children
cancer
hospit
egypt
children
cancer
hospit
egypt
cairo
egypt
egypt
children
cancer
hospit
egypt
radiotherapi
cairo
egypt
children
cancer
hospit
egypt
surgic
oncolog
cairo
egypt
cancer
children
cancer
hospit
pediatr
oncolog
cairo
egypt
cancer
institut
children
cancer
hospit
pediatr
oncolog
cairo
egypt
children
cancer
hospitl
nuclear
medicin
cairo
egypt
children
cancer
hospit
surgic
oncolog
cairo
egypt
cancer
children
cancer
hospit
patholog
cairo
egypt
cancer
children
cancer
hospit
radiolog
cairo
egypt
cancer
hospit
egypt
research
cairo
egypt
backgroundobject
use
evalu
rm
sarcoma
adult
children
role
stage
pediatr
rm
clearli
establish
studi
aim
investig
role
pet
evalu
respons
treatment
correl
surviv
pediatr
patient
rm
designmethod
retrospect
studi
includ
children
intermedi
risk
rm
present
cche
period
jan
june
stratifi
treat
base
cog
protocol
studi
patient
initi
pet
scan
w
w
result
report
patient
initi
pet
exclud
neg
pet
patient
analyz
age
rang
year
year
old
median
eighti
seven
case
embryon
patholog
alveolar
type
fifti
one
patient
pet
ct
week
patient
neg
patient
posit
sixti
six
patient
pet
ct
w
patient
neg
pet
patient
still
posit
os
neg
patient
year
comparison
pet
posit
case
p
valu
ef
neg
patient
posit
patient
p
valu
os
neg
patient
pet
posit
patient
p
valu
ef
neg
patient
ef
posit
patient
p
valu
conclus
patient
neg
pet
better
outcom
result
insignific
due
small
number
pet
neg
patient
pet
scan
tool
predict
outcom
rm
elsherif
e
h
g
e
oncolog
fellow
pediatr
oncolog
cairo
egypt
professor
pediatr
faculti
medicin
consult
pediatr
oncolog
pediatr
oncolog
cairo
egypt
pediatr
oncolog
nci
consult
pediatr
oncolog
pediatr
oncolog
cairo
egypt
radiolog
consult
radiolog
cairo
egypt
clinic
patholog
head
clinic
patholog
depart
clinic
patholog
cairo
egypt
surgeri
surgic
oncolog
cairo
egypt
radiotherapi
consult
radiotherapi
cairo
egypt
research
specialist
clinic
research
cairo
egypt
pediatr
oncolog
nci
head
pediatr
oncolog
depart
pediatr
oncolog
cairo
egypt
backgroundobject
childhood
vagin
tumor
rare
compris
less
pediatr
cancer
rhabdomyosarcoma
rm
germ
cell
tumor
adenocarcinoma
common
malign
vagina
analyz
outcom
children
vagin
tumor
treat
singl
institut
designmethod
retrospect
chart
review
pediatr
patient
vagin
tumor
treat
june
till
june
result
nineteen
patient
median
age
year
rang
year
studi
three
differ
histolog
subtyp
identifi
rm
patient
germ
cell
tumor
case
clear
cell
adenocarcinoma
one
patient
vagin
bleed
common
clinic
present
report
patient
surgeri
done
patient
uterin
salvag
underw
hysterectomi
thirteen
patient
remain
median
month
one
patient
rm
die
diseas
progress
year
os
ef
patient
rm
respect
germ
cell
tumor
os
ef
conclus
vagin
tumor
rare
pediatr
popul
gener
good
prognosi
treatment
chemotherapi
either
conserv
surgeri
brachytherapi
may
achiev
excel
outcom
germ
cell
tumor
rhabdomyosarcoma
j
c
n
r
cp
indelicato
florida
colleg
medicin
radiat
oncolog
gainesvil
usa
florida
colleg
medicin
radiat
oncolog
jacksonvil
usa
florida
colleg
medicin
orthopaed
rehabilit
gainesvil
usa
backgroundobject
aggress
fibromatosi
also
call
desmoid
tumor
local
aggress
diseas
affect
patient
across
age
although
radiotherapi
establish
role
diseas
manag
comparison
suggest
effect
invers
proport
patient
age
goal
comprehens
describ
local
control
across
age
use
larg
cohort
designmethod
retrospect
analyz
patient
treat
radiotherapi
desmoid
tumor
singl
institut
demograph
inform
abstract
patient
chart
analysi
logist
regress
cox
proport
hazard
model
use
analyz
effect
variou
factor
local
control
follow
radiotherapi
result
total
patient
identifi
median
year
rang
year
overal
surviv
rate
overal
local
control
rate
patient
femal
white
year
old
diagnosi
year
older
cohort
split
evenli
patient
initi
versu
recurr
diseas
time
radiotherapi
univari
analysi
factor
predict
increas
risk
local
recurr
young
age
diagnosi
local
control
local
control
local
control
p
use
fraction
compar
radiotherapi
fraction
versu
local
control
p
logist
regress
confirm
relationship
increas
age
increas
probabl
local
control
p
conclus
younger
patient
aggress
fibromatosi
exhibit
frequent
local
failur
older
patient
suggest
tumor
biolog
may
differ
age
younger
patient
may
benefit
altern
approach
local
therapi
escal
c
jackson
v
j
j
v
l
jl
rockefel
univers
st
gile
laboratori
human
genet
infecti
rockefel
branch
new
york
usa
cornel
medic
center
divis
pediatr
new
york
usa
sloan
ketter
cancer
center
depart
pediatr
new
york
usa
malad
hospit
pediatr
unit
pari
franc
malad
hospit
genet
depart
pari
franc
malad
hospit
patholog
unit
pari
franc
pasteur
unit
epidemiolog
physiopatholog
oncogen
virus
pari
franc
malad
hospit
laboratori
human
genet
infecti
necker
inserm
pari
franc
descart
univers
imagin
institut
pari
franc
hugh
medic
institut
howard
hugh
medic
institut
new
york
usa
backgroundobject
meiotic
pathway
conserv
human
chromosom
crossov
error
meiosi
caus
chromosom
delet
chromosom
germlin
termin
macrodelet
implic
human
congenit
malform
development
delay
herein
deciph
novel
cancer
predisposit
phenotyp
endem
kaposi
sarcoma
attribut
heterozyg
macrodelet
girl
origin
west
indi
designmethod
compar
genom
hybrid
cgh
array
patient
signific
macrodelet
megabas
pair
mbp
investig
mode
inherit
affymetrix
human
snp
singl
nucleotid
polymorph
array
perform
patient
mother
father
avail
data
analyz
use
penncnv
softwar
human
genotyp
perform
nest
polymeras
chain
reaction
pcr
compar
sequenc
analysi
util
demonstr
origin
viral
strain
result
herein
describ
novel
de
novo
heterozyg
macrodelet
refer
genom
associ
endem
kaposi
sarcoma
predisposit
viral
strain
belong
african
b
subtyp
cluster
strain
previous
character
cameroon
uganda
similar
previous
report
case
germlin
chromosom
termin
delet
patient
dental
malposit
development
growth
intellectu
delay
novel
phenotyp
featur
includ
kaposi
sarcoma
oral
malform
furrow
tongu
scoliosi
thoracolumbar
mitral
valv
dysplasia
kom
conclus
occurr
kaposi
sarcoma
child
otherwis
normal
resist
infecti
agent
without
tumor
lesion
point
select
immunodefici
defect
organogenesi
describ
chromosom
termin
macrodelet
first
report
immunodefici
cancer
predisposit
syndrom
kom
syndrom
associ
chromosom
region
j
lope
k
l
p
children
hospit
paediatr
surgeri
urolog
birmingham
unit
kingdom
children
hospit
paediatr
oncolog
birmingham
unit
kingdom
backgroundobject
recent
studi
show
surviv
local
rm
patient
though
recent
public
advoc
conserv
surgeri
surgic
centr
emphasi
place
achiev
complet
local
control
diseas
surgeri
possibl
principl
behind
consid
radic
surgeri
belief
import
clear
margin
avoid
radiotherapi
designmethod
review
note
patient
identifi
patholog
databas
rm
treat
center
last
year
result
treat
patient
local
rm
f
median
age
yr
origin
uteru
vagina
bladder
prostat
patient
chemotherapi
surgeri
decis
base
imag
examin
anaesthesia
laparoscopi
cystoscopi
one
team
two
surgeon
perform
radic
hysterectomi
vaginectomi
pelvic
exenter
partial
cystectomi
total
cystectomi
patient
urinari
undivers
two
patient
surgeri
unresect
tumour
near
total
resolut
bladder
neck
tumour
four
patient
radiotherapi
unresect
tumour
posit
resect
margin
mean
follow
year
year
surviv
two
patient
suffer
local
recurr
patient
post
partial
vaginectomi
later
requir
pelvic
exenter
radiotherapi
year
recurr
free
patient
post
partial
cystectomi
chemotherapi
post
relaps
year
recurr
free
conclus
seri
surviv
local
recurr
conserv
surgeri
initi
radic
surgeri
perform
patient
although
trend
conserv
surgeri
believ
judg
high
surviv
rate
come
good
surgic
local
control
reserv
radiotherapi
incomplet
resect
n
pushker
r
india
institut
medic
scienc
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
india
institut
medic
scienc
dept
ocular
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
backgroundobject
alveolar
sarcoma
asp
sarcoma
constitut
sarcoma
occur
commonli
lower
extrem
rare
orbit
commonli
misdiagnos
due
rariti
nonspecif
clinic
find
designmethod
retrospect
review
medic
record
histopatholog
imag
find
case
asp
paediatr
orbit
treat
centr
jan
dec
year
result
four
case
asp
orbit
present
childhood
analys
median
age
present
month
rang
year
male
femal
patient
patient
present
proptosi
left
eye
median
durat
symptom
month
rang
month
year
initi
clinic
imag
diagnosi
low
flow
vascular
malform
capillari
haemangioma
case
pseudotumor
case
imag
reveal
well
defin
lesion
case
bone
eros
extraorbit
extens
case
lesion
involv
later
orbit
superior
orbit
inferior
orbit
case
ultrasound
reveal
homogen
lesion
regular
intern
architectur
one
case
underw
exenter
underw
orbitotomi
tumor
excis
conclus
orbit
asp
rare
malign
childhood
may
masquerad
benign
tumor
orbit
hy
p
p
seog
k
june
k
hyun
jong
k
p
hyeon
jin
cancer
center
pediatr
oncolog
center
republ
korea
cancer
center
depart
patholog
republ
korea
cancer
center
orthopaed
oncolog
clinic
republ
korea
univers
chuncheon
sacr
heart
hospit
depart
pediatr
chuncheon
republ
korea
backgroundobject
osteosarcoma
treatment
extent
tumor
necrosi
time
surgeri
follow
preoper
chemotherapi
known
strongli
associ
surviv
rate
conduct
retrospect
studi
see
differ
tumor
necrosi
treatment
outcom
come
addit
ifosfamid
convent
regimen
designmethod
patient
treat
nation
cancer
center
evalu
regimen
cours
neoadjuv
chemotherapi
includ
intraven
methotrex
cisplatin
doxorubicin
ifosfamid
adjuv
chemotherapi
tailor
accord
tumor
necrosi
good
respond
receiv
cours
doxorubicin
ifosfamid
methotrex
cisplatin
poor
respond
receiv
addit
cours
ifosfamid
methotrex
cisplatin
regimen
aost
regimen
perform
result
total
patient
includ
studi
median
age
time
diagnosi
year
twelv
patient
treat
three
drug
remain
patient
treat
drug
regimen
yield
higher
proport
good
respond
compar
vs
year
surviv
rate
former
group
latter
group
surviv
former
group
latter
group
conclus
differ
regimen
regard
necrosi
rate
overal
surviv
surviv
howev
small
sampl
size
could
preclud
statist
differ
consid
appar
differ
treatment
result
two
group
studi
larger
scale
warrant
reach
solid
conclus
e
pozzo
r
h
leuven
depart
develop
regener
leuven
belgium
leuven
univers
hospit
leuven
depart
human
genet
leuven
belgium
leuven
univers
hospit
leuven
depart
patholog
leuven
belgium
hospit
leuven
depart
paediatr
leuven
belgium
backgroundobject
childhood
rhabdomyosarcoma
rm
classifi
embryon
erm
alveolar
arm
spindl
cell
srm
srm
uncommon
subtyp
rm
genet
characterist
recent
molecular
analys
describ
andor
rearrang
major
infantil
srm
overal
good
prognosi
sought
identifi
presenc
molecular
aberr
infantil
srm
patient
investig
correl
observ
clinic
outcom
designmethod
sampl
children
diagnos
rm
hospit
analyz
fluoresc
situ
hybrid
fish
assess
clinicopatholog
characterist
surviv
patient
diagnos
rm
month
age
consid
studi
result
nine
patient
diagnos
infantil
rm
three
histolog
identifi
infantil
srm
site
primari
diseas
infantil
srm
patient
includ
paravertebr
gluteal
periscapular
muscl
fish
analysi
reveal
absenc
andor
rearrang
patient
alloc
rm
subgroup
treatment
follow
chemotherapeut
cours
patient
underw
surgic
remov
patient
requir
radiotherapi
one
patient
receiv
month
mainten
therapi
cyclophosphamid
vinorelbin
avoid
mutil
effect
radiotherapi
two
patient
three
toxic
includ
nephrotox
temporari
neurotox
compar
infantil
erm
arm
patient
surviv
month
median
patient
srm
aliv
well
one
month
date
patient
develop
local
recurr
distant
metastas
conclus
although
patient
infantil
srm
neg
rearrang
good
prognosi
surviv
affect
studi
need
identifi
novel
molecular
aberr
infantil
srm
could
correl
prognosi
surviv
ramzan
hospit
pediatr
hematolog
oncolog
bmt
jaipur
india
backgroundobject
smooth
muscl
tumor
smt
rare
children
difficult
treat
mtor
inhibitor
like
rapamycin
sirolimu
type
target
therapi
stop
protein
help
cell
divid
surviv
mtor
inhibitor
studi
treat
perivascular
epithelioid
cell
tumor
pecoma
epithelioid
hemangioendothelioma
use
rapamycin
mention
literatur
treatment
smt
designmethod
report
month
old
infant
first
product
marriag
swell
tip
nose
face
sinc
birth
result
ct
scan
show
lobul
soft
tissu
mass
pet
ct
reveal
local
fdg
avid
lobul
heterogen
enhanc
mass
involv
right
side
nose
upper
lip
adjoin
cheek
pre
maxillari
region
calcif
histopatholog
show
spindl
cell
fusiform
nuclei
indistinct
eosinophil
cytoplasm
arrang
fascicl
suggest
spindl
cell
sarcoma
like
embryon
rhabdomyosarcoma
howev
immunohistochemistri
strongli
posit
sma
neg
desmin
myogenin
caldesmon
ki
low
intermedi
grade
smooth
muscl
tumor
start
vincristin
actinomycin
cyclophosphamid
vac
chemotherapi
week
mass
reduc
size
clinic
anoth
week
vac
given
week
chemo
ct
scan
still
show
mass
mm
start
rapamycin
mg
daili
week
facial
swell
significantli
reduc
clinic
ct
show
residu
mass
current
infant
rapamycin
well
conclus
rapamycin
treatment
promis
case
smt
role
drug
investig
larg
clinic
trial
smt
k
rao
j
e
miami
miller
school
medicinejackson
memori
hospit
pediatr
surgeri
miami
usa
backgroundobject
determin
whether
surgeri
type
prognost
indic
surviv
fibrosarcoma
designmethod
review
patient
year
age
diagnos
fibrosarcoma
type
surgeri
surveil
epidemiolog
end
result
seer
databas
analys
demonstr
surviv
dss
clinic
patholog
variabl
signific
covari
predictor
dss
determin
univari
analysi
analyz
use
cox
regress
result
identifi
pediatr
patient
mean
age
diagnosi
year
gender
predilect
ratio
white
black
major
classifi
local
tumor
region
involv
distant
metastas
major
patient
requir
surgeri
requir
radiat
overal
dss
year
year
year
patient
surgeri
site
tumor
grade
seer
stage
radiat
signific
use
univari
surviv
analys
multivari
cox
regress
show
tumor
stage
independ
determin
surviv
howev
surgic
procedur
type
local
versu
aggress
resect
show
signific
conclus
fibrosarcoma
rare
pediatr
popul
although
stage
independ
determin
surviv
surgic
procedur
type
local
versu
aggress
resect
show
signific
multivari
model
aggress
surgic
resect
fibrosarcoma
associ
increas
surviv
k
rao
j
j
h
e
miami
miller
school
medicinejackson
memori
hospit
pediatr
surgeri
miami
usa
backgroundobject
lymph
node
involv
associ
increas
local
recurr
rate
decreas
surviv
rate
pediatr
rhabdomyosarcoma
sought
determin
whether
lymph
node
ratio
lnr
predict
mortal
dsm
designmethod
identifi
patient
year
age
diagnos
rhabdomyosarcoma
surveil
epidemiolog
end
result
seer
databas
calcul
lnr
take
number
node
posit
total
number
node
examin
use
estim
plot
dsm
clinic
patholog
variabl
cox
regress
evalu
lnr
model
result
studi
present
case
lymph
node
data
greater
three
node
examin
median
age
diagnosi
year
male
white
stage
present
local
region
distantli
metastas
percent
patient
receiv
radiat
therapi
surgeri
median
number
node
examin
mean
lnr
mean
surviv
month
overal
dsm
year
year
largest
threshold
lnr
associ
dsm
surviv
lnr
versu
lnr
p
lymph
node
statu
stage
lnr
signific
determin
dsm
univari
analysi
use
cox
regress
signific
covari
lnr
stage
remain
independ
determin
dsm
conclus
pediatr
rhabdomyosarcoma
rare
lnr
independ
determin
dsm
use
threshold
may
offer
valu
dsm
prognost
b
rekhi
c
g
j
n
memori
hospit
surgic
patholog
mumbai
india
memori
hospit
surgic
oncolog
mumbai
india
memori
hospit
medic
oncolog
mumbai
india
memori
hospit
radiat
oncolog
mumbai
india
backgroundobject
spindl
cellscleros
rhabdomyosarcoma
rm
rel
newli
recogn
subtyp
rm
immunohistochem
high
myogenin
express
associ
alveolar
rm
arm
aggress
clinic
cours
designmethod
studi
aim
evalu
clinicopatholog
immunohistochem
featur
case
rm
immunohistochem
express
myogenin
grade
base
percentag
tumor
cell
display
posit
intranuclear
immunostain
grade
grade
grade
grade
detail
avail
patient
variou
clinicopatholog
paramet
correl
overal
surviv
result
case
includ
variou
subtyp
except
pleomorph
rm
occur
first
two
decad
case
male
head
neck
region
follow
extrem
common
subtyp
arm
case
follow
embryon
rm
spindl
cell
scleros
rm
pleomorph
rm
immunohistochem
desmin
express
tumor
myogenin
tumor
high
myogenin
express
equal
posit
tumor
cell
significantli
associ
case
arm
compar
subtyp
p
high
express
seen
case
pure
scleros
combin
spindl
cell
scleros
rmss
compar
subtyp
signific
differ
high
myogenin
express
surviv
year
overal
surviv
children
especi
first
decad
patient
tumor
size
less
without
metastasi
earli
tumor
stage
show
significantli
better
surviv
outcom
conclus
signific
associ
high
myogenin
express
case
armss
high
express
case
spindl
cellscleros
rm
children
first
decad
smaller
size
tumor
present
earli
stage
rel
better
outcom
high
myogenin
express
found
relat
aggress
clinic
outcom
n
rostovtsev
children
hospit
surgeri
depart
chelyabinsk
russia
backgroundobject
aim
research
assess
effect
period
intraop
phototox
radachlorin
mediat
photodynam
therapi
pdt
treat
malign
tumor
character
far
near
infrar
absorpt
band
nm
children
use
photosensit
radachlorin
nm
absorpt
band
agent
show
high
photodynam
activ
good
contrast
ratio
fine
clearanc
designmethod
period
seventeen
patient
primari
soft
tissu
sarcoma
case
embryon
rhabdomyosarcoma
case
mix
rhabdomyosarcoma
case
alveolar
fibrosarcoma
treat
pdt
predominantli
inpati
intraop
one
case
alveolar
fibrosarcoma
pdt
perform
outpati
basi
children
admit
hospit
advanc
stage
diseas
tumor
rang
cm
diamet
mainli
sometim
result
treatment
base
chlorin
photosensit
mediat
pdt
caus
system
local
event
well
toler
patient
includ
children
concomit
diseas
due
fast
accumul
radachlorin
tumor
possibl
use
laser
hour
intraven
administr
agent
therapeut
effect
observ
patient
includ
complet
tumor
resorpt
case
partial
resorpt
case
conclus
chlorin
photosensit
high
photodynam
activ
fine
therapeut
effect
quickli
excret
bodi
due
fast
clearanc
induc
prolong
light
sensit
eras
problem
cutan
phototox
thank
fast
accumul
tumor
high
contrast
gradient
tumor
normal
tissu
chlorin
photosensit
make
possibl
reduc
number
pdt
session
achiev
posit
therapeut
outcom
h
say
egypt
cancer
institut
pediatr
oncolog
assiut
egypt
egypt
cancer
institut
clinic
patholog
assiut
egypt
backgroundobject
neoangiogenesi
play
import
role
growth
spread
pediatr
solid
tumor
level
circul
endotheli
cell
cec
endotheli
progenitor
cell
epc
document
indic
vascular
function
cancer
evalu
role
cell
pediatr
solid
tumor
prognost
impact
designmethod
prospect
studi
includ
patient
differ
pediatr
solid
tumor
treat
differ
type
chemotherapi
addit
age
sex
match
healthi
children
control
blood
sampl
collect
diagnosi
day
day
chemotherapi
sampl
assess
cec
epc
use
flowcytometri
result
mean
level
cec
epc
patient
diagnosi
significantli
higher
control
versu
epc
respect
p
highest
level
cec
observ
patient
rhabdomyosarcoma
rm
overal
increas
report
cec
first
cycl
chemotherapi
significantli
correl
treatment
respons
overal
surviv
conclus
highest
level
cec
observ
patient
respond
therapi
magnitud
increas
cec
day
chemotherapi
might
use
earli
predictor
respons
therapi
outcom
studi
larger
popul
necessari
confirm
g
von
c
ss
b
r
f
j
e
stuttgart
cancer
zentrum
und
frauenmedizin
pediatr
immunolog
stuttgart
germani
hospit
marburg
depart
pediatr
surgeri
marburg
germani
zentrum
und
olgahospit
institut
radiolog
stuttgart
germani
kiel
institut
paidopatholog
kiel
germani
stuttgart
institut
radiotherapi
stuttgart
germani
muenster
depart
pediatr
hematolog
oncolog
germani
wroclaw
depart
pediatr
hematologyoncolog
bmt
wroclaw
poland
anna
kinderspit
pediatr
oncolog
wien
austria
zurich
depart
pediatr
oncolog
switzerland
frankfurt
hospit
children
adolesc
frankfurt
germani
hospit
depart
pediatr
surgeri
urolog
tuebingen
germani
depart
pediatr
hematolog
oncolog
germani
backgroundobject
alveolar
soft
part
sarcoma
asp
mesenchym
tumour
character
x
lead
designmethod
clinic
data
children
adolesc
asp
treat
accord
recommend
adult
type
nrst
five
prospect
trial
cooper
weichteilsarkom
studiengrupp
cw
analyz
result
median
age
year
rang
tumour
mainli
locat
extrem
patient
local
ld
metastat
diseas
md
patient
ld
md
receiv
primari
resect
ld
ro
md
primari
tumour
ld
patient
receiv
rt
addit
patient
aliv
patient
complet
remiss
cr
cht
primari
resect
biopsi
given
patient
ld
md
patient
respons
assess
partial
stabl
diseas
progress
patient
secondari
resect
perform
rt
ad
patient
cr
comparison
patient
without
secondari
resect
median
year
rang
patient
local
patient
md
aliv
complet
remiss
other
mostli
stabl
diseas
yr
overal
surviv
os
event
free
surviv
ef
respect
age
year
ir
size
primari
delay
resect
correl
favor
prognosi
concern
ef
os
conclus
prognosi
patient
asp
treat
prospect
trial
compar
prognosi
patient
rhabdomyosarcoma
primari
delay
complet
tumour
resect
correl
long
term
surviv
spira
f
malbari
p
c
j
einstein
colleg
medicin
bronx
usa
hospit
montefior
depart
neurolog
bronx
usa
tumor
foundat
research
medic
program
new
york
usa
hospit
montefior
depart
pediatr
hematologyoncolog
marrow
blood
cell
transplant
bronx
usa
hospit
montefior
depart
neurosurgeri
bronx
usa
backgroundobject
neurofibromatosi
type
rel
common
autosom
domin
tumor
predisposit
syndrom
malign
peripher
nerv
sheath
tumor
mpnst
lead
caus
death
young
adult
report
incid
mpnst
among
individu
vari
littl
inform
regard
risk
factor
develop
mpnst
patient
popul
designmethod
individu
regist
children
tumor
foundat
neurofibromatosi
registri
email
anonym
survey
regard
person
famili
histori
mpnst
age
onset
symptomatolog
particip
voluntari
inform
verifi
individu
health
record
result
survey
sent
registr
respons
respons
rate
among
respond
least
one
blood
rel
diagnos
mpnst
develop
mpnst
significantli
higher
incid
mpnst
among
respond
report
neg
famili
histori
mpnst
presenc
posit
famili
histori
mpnst
found
risk
factor
develop
mpnst
ci
addit
patient
mpnst
posit
famili
histori
mpnst
significantli
like
develop
diseas
prior
age
neg
famili
histori
mpnst
vs
patient
also
like
develop
mpnst
age
howev
differ
signific
vs
conclus
result
suggest
posit
famili
histori
mpnst
repres
risk
factor
develop
mpnst
data
support
consider
implement
enhanc
screen
popul
furthermor
sinc
result
also
suggest
earlier
onset
diseas
individu
posit
famili
histori
mpnst
screen
care
consid
particularli
patient
less
year
c
ugaz
olivar
j
c
l
l
nacion
de
enfermedad
lima
lima
peru
rebagliati
lima
lima
peru
backgroundobject
rhabdomyosarcoma
rm
still
one
neoplasm
poor
prognosi
countri
despit
improv
worldwid
cure
rate
aim
studi
determin
surviv
associ
prognost
factor
entiti
designmethod
retrospect
cohort
studi
infant
children
younger
year
rm
treat
instituto
nacion
de
enfermedad
neoplasica
inen
hospit
rebagliati
may
decemb
review
result
total
children
identifi
patient
male
femal
median
age
year
rang
month
year
frequent
histolog
type
embryon
patient
metastat
diseas
onset
median
month
overal
surviv
os
rate
local
metastat
rm
standard
error
se
se
respect
surviv
ef
local
metastat
rm
se
se
respect
eleven
patient
surviv
data
multivari
analysi
presenc
metastas
histolog
type
posit
surgic
margin
risk
group
group
stage
significantli
affect
os
signific
improv
os
accord
decad
age
gender
proven
tumor
size
histolog
subtyp
affect
significantli
os
conclus
surviv
rate
patient
rm
lower
report
develop
countri
although
evid
improv
recent
year
necessari
optim
multidisciplinari
manag
diseas
dc
weber
f
antun
u
r
scherrer
institut
center
proton
therapi
villigen
switzerland
backgroundobject
data
exist
regard
clinic
outcom
patient
ewe
sarcoma
ew
treat
scan
proton
therapi
pt
report
localdist
control
rate
survivorship
late
toxic
children
adolesc
young
adult
aya
treat
paul
scherrer
institut
designmethod
patient
median
age
year
identifi
total
male
femal
patient
receiv
median
dose
gyrb
rang
size
tumor
rang
cm
median
common
primari
site
axialpelv
four
patient
present
metastasi
diagnosi
twenti
patient
median
follow
month
rang
result
actuari
rate
local
control
lc
surviv
mf
overal
surviv
os
respect
local
recurr
occur
field
patient
primari
six
patient
die
tumor
progress
age
year
favor
factor
lc
os
borderlin
signific
signific
mf
tumor
volum
ml
favor
prognost
factor
df
os
acut
toxic
limit
grade
skin
erythema
mucos
grade
late
toxic
observ
actuari
rate
grade
surviv
conclus
preliminari
data
suggest
outcom
children
aya
ew
good
pt
well
toler
late
advers
event
local
distant
tumor
control
older
patient
larg
tumor
volum
remain
problemat
challeng
patient
h
yali
g
children
medic
center
scmc
affili
shanghai
jiaotong
univers
school
medicin
hematologyoncolog
shanghai
china
backgroundobject
object
studi
determin
treatment
outcom
pediatr
patient
rhabdomyosarcoma
treat
shanghai
children
medic
center
scmc
designmethod
retrospect
chart
review
pediatr
patient
old
rhabdomyosarcoma
rm
diagnos
perform
accord
patholog
subtyp
tnm
stage
postop
patholog
stage
patient
divid
four
group
group
group
group
distant
metastat
group
surviv
analysi
cox
regress
multivari
analysi
use
assess
prognost
factor
overal
surviv
os
surviv
ef
result
median
age
diagnosi
month
median
live
patient
month
median
patient
month
common
primari
site
aros
other
includ
abdomen
trunk
retroperitoneum
etc
os
ef
patient
metastat
diseas
respect
multivari
analysi
metastat
diseas
present
tumor
size
associ
wors
ef
p
metastat
diseas
present
associ
wors
os
p
estim
ef
rate
four
group
group
group
group
distant
metastat
group
respect
p
estim
os
rate
four
group
respect
p
conclus
rm
patient
distinct
group
differ
outcom
scmc
quit
similarli
worldwid
data
howev
studi
need
rm
survivor
analysi
prognosi
factor
ap
alcasaba
b
g
e
p
j
philippin
philippin
gener
hospit
paediatr
manila
philippin
children
medic
center
pediatr
manila
philippin
philippin
philippin
gener
hospit
opthalmolog
manila
philippin
luke
medic
center
pediatr
quezon
citi
philippin
backgroundobject
retinoblastoma
high
incid
philippin
per
million
children
year
luzon
countri
largest
island
case
expect
annual
two
govern
pediatr
cancer
unit
manila
start
retinoblastoma
program
octob
involv
adopt
uniform
protocol
patient
navig
data
manag
health
worker
educ
earli
warn
sign
report
profil
children
diagnos
januari
decemb
designmethod
prospect
data
collect
consecut
patient
review
result
total
case
seen
unilater
retinoblastoma
bilater
trilater
mean
age
month
diagnosi
unilater
bilater
trilater
f
ratio
averag
lag
time
initi
symptom
diagnosi
month
reason
delay
includ
financi
constraint
ignor
diseas
misdiagnosi
multipl
referr
fear
patient
came
metro
manila
southern
luzon
area
chief
complaint
leukocoria
orbit
mass
buphthalmo
post
enucl
strabismu
blind
data
major
diseas
intern
retinoblastoma
stage
system
stage
stage
stage
ii
stage
iii
stage
unknown
conclus
address
delay
diagnosi
low
detect
rate
nationwid
educ
campaign
tackl
earli
warn
sign
retinoblastoma
avail
govern
financi
aid
includ
nation
health
insur
coverag
enucl
chemotherapi
radiat
patient
referr
system
commun
local
hospit
retinoblastoma
treatment
center
establish
bisht
india
institut
medic
scienc
anatomi
new
delhi
india
backgroundobject
retinoblastoma
rb
common
childhood
intraocular
malign
incid
increas
past
year
believ
due
effect
environment
factor
caus
oxid
stress
os
sperm
dna
integr
essenti
fertil
proper
embryon
develop
birth
healthi
offspr
sperm
highli
vulner
oxid
damag
nuclear
mitochondri
dna
due
minim
cytosol
defici
dna
damag
repair
mechan
yogamedit
increasingli
use
adjunct
modern
medicin
treatment
sever
clinic
condit
present
studi
analyz
effect
yogamedit
semin
os
sperm
dna
integr
father
children
affect
rb
designmethod
total
men
recruit
studi
semen
sampl
collect
base
line
day
month
month
month
yogamedit
intervent
reactiv
oxygen
speci
ro
dna
fragment
index
dfi
level
estim
day
month
month
month
result
reduct
mean
dfi
level
month
month
month
semin
mean
ro
level
month
month
month
level
month
month
month
respect
base
line
level
day
yogamedit
intervent
conclus
yogamedit
may
significantli
lower
os
oxid
dna
damag
level
mutagen
base
sperm
dna
thu
yogamedit
simpl
lifestyl
intervent
therapeut
maintainingrestor
sperm
dna
integr
henc
reduc
preval
childhood
cancer
poor
sperm
dna
integr
could
one
reason
h
dimara
j
k
j
k
l
sick
children
ophthalmolog
vision
scienc
toronto
canada
eye
unit
ophthalmolog
kikuyu
kenya
univers
nairobi
ophthalmolog
nairobi
kenya
backgroundobject
genet
test
counsel
becom
integr
part
manag
herit
cancer
like
childhood
eye
cancer
retinoblastoma
studi
aim
determin
attitud
knowledg
experi
concern
retinoblastoma
genet
among
survivor
parent
children
retinoblastoma
canada
kenya
designmethod
data
collect
focu
group
brief
demograph
questionnair
studi
set
canada
hospit
sick
children
kenya
kenyatta
nation
hospit
kikuyu
eye
unit
themat
analysi
use
identifi
key
theme
discuss
set
result
three
focu
group
conduct
toronto
n
five
kenya
n
theme
common
canadian
kenyan
popul
includ
signific
confus
genet
herit
retinoblastoma
b
need
improv
commun
healthcar
team
genet
c
need
improv
access
psychosoci
support
help
cope
uniqu
theme
includ
genet
diagnosi
caus
signific
interrupt
famili
relationship
kenya
b
genet
test
counsel
valu
famili
canada
conclus
even
canada
genet
test
counsel
well
establish
retinoblastoma
survivor
parent
found
signific
gap
knowledg
genet
similarli
kenya
particip
confus
genet
herit
retinoblastoma
improv
commun
healthcar
team
provid
psychosoci
support
could
help
enhanc
inform
uptak
understand
famili
canada
kenya
patient
perspect
popul
also
reveal
issu
use
refin
cancer
genet
servic
set
b
galli
k
l
c
hospit
sick
children
ophthalmolog
vision
scienc
toronto
canada
univers
health
network
health
informat
research
toronto
canada
children
hospit
ophthalmolog
beij
china
backgroundobject
commun
play
critic
role
effect
retinoblastoma
care
yet
commun
detail
clinic
encount
member
patient
circl
care
individu
provid
support
retinoblastoma
patient
care
includ
parent
legal
guardian
remain
complex
oner
despit
best
intent
poor
commun
wast
time
money
ii
result
misunderstand
retinoblastoma
treatment
prognosi
iii
contribut
famili
stress
face
devast
diagnos
difficult
choic
designmethod
set
develop
innov
solut
enhanc
retinoblastoma
circl
care
commun
prototyp
retinoblastoma
data
repositori
develop
test
extens
care
provid
iter
refin
decad
sickkid
show
cornerston
databas
timelin
enhanc
understand
parent
children
retinoblastoma
concern
purpos
qualiti
care
result
internet
version
repositori
call
electron
patient
illustr
clinic
timelin
r
etino
b
lastoma
depictrb
readi
global
deploy
consent
diagnosi
new
retinoblastoma
patient
given
depictrb
account
treatment
centr
identifi
summari
data
clinic
encount
enter
point
care
patient
depictrb
account
secur
telu
server
includ
depictrb
draw
map
tumour
treatment
eye
select
imag
key
understand
cancer
prognost
stage
base
algorithm
write
access
secur
assign
clinic
member
circl
care
parent
other
read
access
support
effect
dialogu
conclus
anecdot
feedback
suggest
depictrb
enhanc
commun
modul
commun
within
retinoblastoma
circl
care
depictrbha
potenti
reduc
wast
improv
understand
retinoblastoma
treatment
cours
empow
parentsleg
guardian
inform
decis
maker
k
hougham
h
c
hospit
sick
children
ophthalmolog
vision
scienc
toronto
canada
backgroundobject
retinoblastoma
aggress
childhood
eye
cancer
retinoblastoma
patient
individu
affect
retinoblastoma
includ
parentsleg
guardian
indic
deepli
incentiv
keep
abreast
research
help
designmethod
initi
canadian
retinoblastoma
patient
engag
strategi
respons
keen
interest
patient
commun
involv
research
part
strategi
creat
canadian
retinoblastoma
research
eregistri
purpos
eregistri
engag
canadian
retinoblastoma
patient
research
commun
registr
invit
give
permiss
part
passiv
particip
receiv
gener
inform
retinoblastoma
eg
lay
summari
part
b
activ
particip
contact
specif
research
studi
children
might
suitabl
subject
team
member
eg
research
assist
result
sinc
launch
novemb
peopl
agre
particip
canadian
retinoblastoma
research
registri
registr
enrol
part
b
registri
percent
n
registr
retinoblastoma
survivor
registr
parentleg
guardian
someon
diagnos
retinoblastoma
registr
year
age
older
percent
n
registr
larg
urban
center
part
enrol
registr
invit
share
research
topic
interest
quarter
n
registr
provid
suggest
research
topic
includ
second
cancer
genet
psycholog
side
effect
conclus
initi
data
indic
registr
keen
receiv
gener
inform
well
invit
specif
research
studi
ii
target
recruit
effort
may
requir
reach
younger
peopl
affect
retinoblastoma
retinoblastoma
survivor
iii
although
interest
retinoblastoma
research
retinoblastoma
patient
specif
research
prioriti
dh
jo
jh
ho
cs
e
jh
nation
univers
colleg
medicin
depart
ophthalmolog
seoul
republ
korea
nation
univers
hospit
fight
blind
farb
clinic
research
institut
seoul
republ
korea
backgroundobject
studi
aim
develop
novel
orthotop
transplant
model
retinoblastoma
model
beagl
mimic
vitreou
seed
patient
retinoblastoma
definit
method
investig
characterist
vitreou
seed
biopsi
absolut
prohibit
designmethod
cell
x
cell
differ
retinoblastoma
cell
line
intravitr
inject
eye
beagl
week
inject
enucl
eye
process
analys
retinoblastoma
cell
isol
vitreou
caviti
evalu
prolifer
characterist
retinoblastoma
cell
furthermor
rna
sequenc
perform
investig
overal
pattern
gene
express
retinoblastoma
cell
isol
vitreou
caviti
result
week
inject
retinoblastoma
cell
clump
retinoblastoma
cell
observ
vitreou
caviti
beagl
isol
cell
clump
demonstr
similar
shape
parent
cell
viabil
analys
also
show
isol
cell
possess
characterist
retinoblastoma
cell
addit
differenti
express
gene
could
valuabl
therapeut
target
identifi
comparison
gene
express
retinoblastoma
cell
isol
vitreou
caviti
parent
cell
conclus
beagl
retinoblastoma
model
mimic
vitreou
seed
patient
retinoblastoma
method
identifi
characterist
vitreou
seed
model
valuabl
investig
kashyap
l
n
b
r
india
institut
medic
scienc
ocular
patholog
delhi
india
india
institut
medic
scienc
ocular
patholog
new
delhi
india
india
institut
medic
scienc
ophthalmolog
delhi
india
backgroundobject
mitochondri
defect
play
import
role
develop
progress
cancer
genet
defect
oxpho
recogn
import
caus
human
diseas
object
studi
elucid
role
atp
atp
protein
prognost
signific
retinoblastoma
rb
designmethod
immunohistochemistri
perform
primari
antibodi
atp
atp
retinoblastoma
tissu
express
confirm
western
blot
fresh
tissu
express
correl
clinic
histopatholog
paramet
tumor
stage
result
protein
express
case
primari
retinoblastoma
case
immunohistochemistri
histopatholog
high
risk
factor
includ
massiv
choroid
invas
scleral
invas
optic
nerv
cut
end
identifi
case
express
atp
atp
statist
signific
variou
histopatholog
high
risk
factor
tumor
invas
hrf
p
conclus
first
studi
predict
relev
role
atp
atp
protein
might
use
therapeut
marker
retinoblastoma
may
use
attract
futur
anticanc
target
primari
retinoblastoma
tumor
r
kebudi
bay
h
akdeniz
b
f
yaman
e
univers
cerrahpasa
medic
faculti
oncolog
institut
pediatr
istanbul
turkey
istanbul
faculti
medicin
depart
ocular
oncolog
istanbul
turkey
oncolog
institut
pediatr
istanbul
turkey
istanbul
faculti
medicin
depart
radiolog
istanbul
turkey
oncolog
institut
cancer
genet
istanbul
turkey
oncolog
institut
radiat
oncolog
istanbul
turkey
backgroundobject
treatment
decis
bilater
retinoblastoma
brb
depend
tumor
burden
potenti
vision
statu
contralater
eye
ocular
salvag
late
effect
import
issu
studi
evalu
demograph
featur
genet
treatment
modal
late
effect
brb
designmethod
patient
brb
treat
istanbul
univers
oncolog
institut
opthalmolog
depart
retrospect
assess
patient
multidisciplinarili
evalu
chemotherapi
adjuv
local
opthalm
therapi
transpupillari
thermotherapi
cryotherapi
plaqu
radiotherapi
enucl
chemotherapi
protocol
use
vincristin
cisplatin
etoposid
cyclophosphamid
vincristin
etoposid
carboplatin
sinc
sinc
intraarteri
intravitr
ct
use
genet
test
done
sanger
dna
sequenc
mlpa
analysi
result
brb
male
femal
eye
median
age
month
evalu
three
extraocular
diseas
two
trilater
rb
seventeen
famili
histori
retinoblastoma
kind
mutat
observ
nonsens
frameshift
splice
site
accord
icrb
classif
eye
group
e
group
group
c
group
b
group
enucl
done
eye
mostli
group
e
radiotherapi
use
eye
tissu
deform
cataract
observ
irradi
patient
five
develop
second
cancer
sarcoma
meningioma
median
year
four
irradi
site
yr
surviv
conclus
chemoreduct
system
intraarteri
local
ophtalm
therapi
enabl
preserv
vision
group
b
c
tumor
tumor
group
e
tumor
requir
enucl
radiotherapi
avoid
case
chemotherapi
promis
maintain
ocular
salvag
patient
follow
late
effect
genet
counsel
done
genet
work
support
scientif
research
project
coordin
unit
istanbul
univers
project
number
b
k
w
e
u
children
memori
health
institut
oncolog
warsaw
poland
children
memori
health
institut
ophthalmolog
warsaw
poland
children
memori
health
institut
radiolog
warsaw
poland
backgroundobject
intraarteri
chemotherapi
retinoblastoma
accept
effect
treatment
method
sinc
method
introduc
center
aim
present
tumor
control
complic
follow
iac
retinoblastoma
designmethod
materi
method
patient
intraocular
rb
unilater
treat
iac
primari
treatment
system
chemotherapi
gener
patient
bilater
diseas
group
e
unilater
diseas
receiv
system
chemotherapi
prior
iac
patient
achiev
complet
tumor
control
treatment
underw
laser
therapi
intravitr
melphalan
inject
need
total
eye
treat
iac
consist
melphalan
singl
agent
topotecan
carboplatin
dose
drug
determin
patient
age
angioanatomi
success
treatment
defin
tumor
inactiv
ocular
surviv
result
result
cather
success
procedur
inject
chemotherapi
melphalan
topotecan
topotecan
topotecan
carboplatin
eye
receiv
median
intaarteri
chemotherapi
cours
eye
preserv
feasibl
eye
hematolog
toxic
one
cerebro
vascular
event
episod
optic
neuriti
observ
one
patient
tumor
progress
system
chemotherapi
iac
develop
distant
metastas
conclus
conclus
iac
allow
eye
globe
preserv
rb
patient
seri
b
mamtaz
j
f
institut
cancer
research
hospit
paediatr
oncolog
dhaka
bangladesh
institut
cancer
research
hospit
cancer
epidemiolog
dhaka
bangladesh
sheikh
mujib
medic
univers
paediatr
haematolog
oncolog
dhaka
bangladesh
backgroundobject
retinoblastoma
rb
common
intraocular
malign
childhood
account
childhood
malign
malign
develop
first
year
life
rb
curabl
diagnos
earli
treat
appropri
bangladesh
mani
children
rb
die
due
delay
diagnosi
treatment
nation
institut
cancer
research
hospit
nicrh
tertiari
care
special
cancer
hospit
govern
sector
bangladesh
children
rb
refer
manag
part
countryth
aim
studi
see
preval
rb
among
children
attend
patient
depart
paediatr
oncolog
nicrh
also
proport
patient
abl
take
treatment
designmethod
observ
studi
conduct
januari
decemb
paediatr
oncolog
depart
nicrh
mohakhali
dhaka
bangladesh
children
rb
age
less
yr
sex
includ
studi
data
collect
patient
registri
result
total
patient
attend
outpati
depart
pediatr
oncolog
studi
period
among
case
rb
male
femal
common
age
group
year
unilater
case
bilater
patient
rb
took
treatment
attend
children
rb
advanc
stage
conclus
awar
import
earli
diagnosi
treatment
rb
import
awar
save
valuabl
live
well
vision
mani
children
x
ml
jp
j
v
mailman
school
public
health
epidemiolog
pediatr
oncolog
new
york
usa
infantil
de
mexico
ophthalmolog
mexico
mexico
infantil
de
mexico
oncolog
mexico
mexico
mailman
school
public
health
biostatist
new
york
usa
infantil
de
mexico
patholog
mexico
mexico
mailman
school
public
health
epidemiolog
new
york
usa
de
imss
siglo
xxi
unidad
de
mexico
df
mexico
backgroundobject
retinoblastoma
one
pediatr
malign
whose
incid
vari
geograph
prior
ecolog
studi
suggest
uv
exposur
sunlight
might
contribut
increas
incid
though
individu
level
exposur
never
examin
previous
sunlight
infanc
recommend
prevent
vitamin
vitd
defici
rodent
model
retinoblastoma
suggest
vitd
inhibit
angiogenesi
designmethod
epirbmx
mother
children
retinoblastoma
interview
diagnosi
report
child
daili
weekli
sunlight
exposur
age
period
month
month
month
examin
whether
durat
sunlight
exposur
vari
unilater
bilater
retinoblastoma
case
similarli
age
healthi
control
unilater
unilater
bilater
bilater
case
examin
whether
extent
diseas
vari
report
durat
sun
exposur
sun
result
sun
increas
age
case
control
within
age
group
case
less
sun
control
greater
matern
educ
associ
less
sun
particularli
age
month
p
control
matern
educ
case
less
sun
control
compar
control
unilater
less
sun
age
p
bilater
less
sun
age
month
p
earlier
age
control
matern
educ
unilater
sun
bilater
especi
age
month
p
unilater
matern
educ
invers
associ
intern
intraocular
retinoblastoma
classif
iirc
st
jude
stage
sun
sun
posit
associ
iirc
unilater
month
though
less
adjust
matern
educ
associ
st
jude
stage
bilater
sun
unrel
extent
intra
extraocular
diseas
conclus
central
mexico
sun
exposur
invers
associ
incid
retinoblastoma
unilater
retinoblastoma
sun
exposur
year
life
appear
posit
associ
extent
intraocular
diseas
c
alvarez
g
hospit
oncolog
pediatr
lima
peru
clinic
oncolog
pediatr
lima
peru
hospit
oncolog
pediatr
lima
peru
backgroundobject
bilater
retinoblastoma
current
multimod
treatment
reduc
tumor
maximum
prevent
blind
designmethod
descript
retrospect
studi
children
bilater
retinoblastoma
rebagliati
clinic
result
case
popul
oncolog
children
rebagl
hospit
earli
detect
cancer
children
program
oncosalud
clinic
mean
age
month
newborn
fortyeigth
month
male
femal
sex
ratio
boy
thirteen
twelv
girl
infant
schooler
one
case
famili
histori
bilater
retinoblastoma
gene
clinic
leukocoria
proptosi
headach
seizur
three
case
metastasi
bone
marrow
brain
sphenoid
case
cervic
node
intern
stage
right
eye
e
left
eye
b
c
e
rees
clasif
right
eye
iv
v
left
eye
iii
iv
v
enucl
debut
case
case
receiv
system
chemotherapi
onward
focal
therapi
ad
preserv
unilater
vision
case
receiv
chemotherapi
focal
therapi
four
cryotherapi
three
receiv
laser
one
receiv
brachytherapi
one
thermotherapi
one
chemotherapi
melphalan
one
thermotherapi
alon
time
report
twenti
one
case
remiss
four
death
due
denial
bilater
enucl
persist
chemotherapi
overal
surviv
month
diseas
free
surviv
month
conclus
bilater
retinoblastoma
preval
preschool
male
leukocoria
frequent
sign
introduct
focal
treatment
togeth
surgeri
system
chemotherapi
help
preserv
vision
less
compromis
eye
avoid
blind
c
h
pena
nacion
de
oncolog
mexico
citi
mexico
backgroundobject
retinoblastoma
rb
commun
intraocular
neoplasia
high
mortal
advanc
diseas
topotecan
topoisomeras
activ
varieti
adult
childhood
solid
tumor
csf
penetr
activ
lacton
form
topotecan
signific
neurolog
toxic
observ
determin
efficaci
intrathec
topotecan
patient
advanc
rb
designmethod
patient
newli
diagnos
orbitari
cn
metastat
rb
enrol
studi
treatment
base
ifosfamid
day
etoposid
day
carboplatin
auc
day
concomit
intrathec
topotecan
administ
twice
weekli
cycl
intens
chemotherapi
result
enrol
patient
unilater
extraocular
rb
mean
age
month
metastas
cn
diseas
cerebr
magnet
reson
mr
patient
advanc
orbit
diseas
patient
found
posit
cf
neoplas
cell
achiev
csf
respons
negativ
patolog
studi
one
two
cycl
intrathec
topotecan
chemotherapi
submit
enucl
cycl
treatment
patient
present
progress
cn
confirm
mri
die
tumor
activ
four
free
diseas
mesur
clinic
imagen
csf
one
present
sign
neurolog
toxic
one
patient
present
hematolog
infecti
grade
iv
toxic
conclus
remiss
diseas
achiev
four
patient
without
sever
irrevers
advers
event
complet
respons
measur
imag
csf
negativ
confirm
two
cycl
treatment
topotecan
must
evalu
larg
studi
prove
efficaci
b
pinto
nasr
mc
silva
de
miranda
b
palma
v
mora
c
rodrigu
l
leontina
v
faria
domingu
de
f
regla
ac
evangelista
do
nacion
cancer
inca
oncogenet
rio
de
janeiro
brazil
grand
rio
oncogenet
rio
de
janeiro
brazil
hugg
oncogenet
rio
de
janeiro
brazil
backgroundobject
estim
frequenc
variant
gene
test
associ
differ
clinic
trait
patient
retinoblastoma
rb
designmethod
retrospect
chart
review
patient
perform
review
three
continu
trait
age
diagnosi
dx
age
first
symptom
dx
lag
categor
trait
later
surviv
famili
histori
intraextraocular
tumor
treatment
secondari
tumor
perform
complet
sanger
sequenc
multiplex
probe
amplif
mlpa
gene
blood
sampl
patient
molecular
diagnosi
defin
posit
inconclus
test
effect
molecular
diagnosi
later
surviv
squar
root
sqrt
continu
trait
use
anova
test
use
test
associ
pair
categor
trait
result
anova
sqrt
age
data
show
patient
bilater
rb
signific
earlier
diagnosi
dx
first
symptom
unilater
dx
p
patient
pathogen
variant
present
earlier
dx
averag
inconclus
one
p
signific
effect
surviv
found
lag
time
p
deceas
patient
greater
lag
averag
test
pair
categor
trait
alpha
except
molecular
diagnosi
later
famili
histori
rb
surviv
intraextraocular
tumor
pathogen
variant
associ
higher
frequenc
bilater
unilater
frequent
type
pathogen
variant
nonsens
splice
patient
splice
variant
bilater
tumor
conclus
frequenc
variant
similar
literatur
possibl
trend
patient
splice
variant
develop
bilater
rb
detect
h
reed
p
j
colleg
medicin
pediatr
houston
usa
backgroundobject
retinoblastoma
rare
highli
treatabl
childhood
malign
cure
rate
countri
sinc
sole
childhood
cancer
treatment
center
botswana
locat
princess
marina
hospit
pmh
gaboron
oper
baylor
colleg
medicin
texa
children
cancer
hematolog
center
pmh
record
indic
patient
diagnos
retinoblastoma
surviv
despit
avail
mani
appropri
treatment
option
studi
assess
retinoblastoma
screen
practic
among
physician
botswana
order
identifi
opportun
improv
earli
detect
designmethod
questionnair
assess
demograph
retinoblastoma
screen
knowledg
barrier
perform
red
reflex
exam
distribut
physician
practic
botswana
use
redcap
onlin
softwar
result
physician
submit
respons
pediatrician
like
correctli
identifi
red
reflex
exam
techniqu
odd
ratio
confid
interv
ci
report
confid
perform
red
reflex
exam
respond
report
perform
red
reflex
exam
allmost
time
children
year
half
respond
report
access
work
ophthalmoscop
time
never
physician
work
privatemiss
sector
like
ministri
health
moh
physician
reliabl
access
work
ophthalmoscop
frequent
barrier
perform
red
reflex
exam
includ
time
constraint
access
ophthalmoscop
traininglack
confid
perform
red
reflex
exam
conclus
although
dispar
surviv
like
multifactori
improv
screen
may
lead
better
outcom
increas
earli
detect
multipl
opportun
intervent
improv
retinoblastoma
screen
botswana
identifi
includ
physician
educ
particularli
among
pediatr
patient
access
ophthalmoscop
among
moh
physician
reschk
p
sovinz
w
n
p
hospit
essen
depart
pediatr
hematolog
oncolog
essen
germani
muenster
institut
biostatist
clinic
research
muenster
germani
hospit
berlin
depart
pediatr
hematolog
oncolog
berlin
germani
hospit
graz
depart
pediatr
hematolog
oncolog
graz
austria
hospit
essen
depart
radiotherapi
essen
germani
hospit
essen
depart
diagnost
intervent
radiolog
neuroradiolog
essen
germani
hospit
essen
depart
ophthalmolog
essen
germani
hospit
essen
institut
human
genet
essen
germani
backgroundobject
retinoblastoma
frequent
malign
intraocular
tumor
childhood
five
year
overal
surviv
rate
high
develop
countri
howev
secondari
primari
malign
compromis
vision
still
complic
clinic
trial
multicent
prospect
data
rare
designmethod
prospect
multicent
observ
clinic
studi
patient
newli
diagnos
pediatr
eye
cancer
germani
austria
collect
data
result
genet
analysi
stage
diseas
first
diagnosi
tnm
irss
icrb
stage
system
choic
therapi
outcom
refer
evalu
neuroradiolog
genet
cytolog
radiotherapi
histopatholog
establish
improv
compar
investig
perform
differ
particip
center
result
recruit
rate
exceed
expect
registr
year
patient
retinoblastoma
unilater
bilater
three
uveal
melanoma
two
medulloepithelioma
ciliari
bodi
two
retin
astrocytoma
one
herit
retinoblastoma
predisposit
retinoblastoma
includ
total
eye
affect
retinoblastoma
frequent
icrb
group
e
frequent
irss
stage
irss
icrb
e
eye
primarili
enucl
wherea
icrb
eye
treat
focal
overal
eye
surviv
remain
month
associ
icrb
group
p
logrank
test
eye
enucl
conclus
rb
registri
clinic
registri
appropri
improv
patient
counsel
provid
basi
develop
intervent
clinic
trial
data
help
improv
therapi
protocol
thu
conserv
vision
reduc
late
term
side
effect
increas
qualiti
life
serov
n
v
b
v
institut
pediatr
oncolog
heamatolog
nn
blokhin
russian
cancer
r
head
neck
tumor
moscow
russia
clinic
experiment
radiolog
n
n
blokhin
cancer
research
center
laboratori
intervent
radiolog
moscow
russia
eye
microsurgeri
complex
ocular
oncolog
moscow
russia
clinic
oncolog
n
n
blokhin
cancer
research
center
patholog
moscow
russia
backgroundobject
develop
metastasi
retinoblastoma
rb
depend
histopatholog
risk
characterist
tumor
invas
optic
nerv
retrolaminar
prolifer
massiv
invas
choroid
sclera
structur
anterior
chamber
demonstr
histopatholg
featur
retinoblastoma
eye
enucl
treatment
includ
melphalan
special
focu
type
tumor
recurr
present
designmethod
eye
patient
enucl
prior
combin
treatment
includ
select
chemotherapi
institut
result
eye
insuffici
minimum
tumor
invas
choroid
andor
prelaminar
invas
optic
nerv
andor
massiv
vitreou
tumor
spread
adjuv
therapi
administr
patient
group
eye
massiv
tumor
invas
choroid
andor
includ
anterior
segment
andor
begin
optic
nerv
eye
second
line
chemotherapi
administr
patient
group
eye
type
iv
regress
eye
enucl
connect
develop
secondari
complic
glaucoma
hemophthalmu
subatrophi
eye
far
none
patient
develop
metastat
diseas
conclus
common
reason
secondari
enucl
eye
intraocular
tumor
progress
includ
anterior
segment
eye
recurr
tumor
case
massiv
tumor
invas
choroid
andor
includ
anterior
segment
andor
begin
optic
nerv
eye
potenti
risk
develop
metastat
diseas
r
seth
v
b
india
institut
medic
scienc
pediatr
delhi
india
india
institut
medic
scienc
ophthalmolog
delhi
india
india
institut
medic
scienc
radiat
oncolog
delhi
india
backgroundobject
retinoblastoma
rb
common
primari
intraocular
tumor
infanc
childhood
survivor
ocular
visual
problem
increas
risk
subsequ
malign
well
document
data
long
term
health
statu
rb
survivor
limit
particularli
true
india
designmethod
children
complet
treatment
retinoblastoma
least
year
ago
follow
cancer
treatment
clinic
evalu
result
seri
patient
median
age
month
male
preponder
major
unilater
diseas
enucl
done
almost
three
fourth
underw
bilater
enucl
major
patient
receiv
chemotherapi
receiv
radiat
growth
affect
one
third
major
receiv
radiat
diminish
vision
notic
orbit
hypoplasia
contract
socket
seen
case
hear
impair
global
intellig
delay
second
neoplasm
seen
abnorm
seen
conclus
common
late
effect
rb
survivor
includ
diminish
vision
salvag
eye
intellectu
disabl
contract
socket
need
time
institut
prosthesi
avoid
late
effect
like
hypoplasia
contract
socket
better
cosmesi
enhanc
self
esteem
second
neoplasm
concern
lifelong
follow
counsel
healthi
lifestyl
need
rb
survivor
l
singh
millia
islamia
aiim
ocular
patholog
bioscienc
new
delhi
india
india
institut
medic
scienc
ocular
patholog
new
delhi
india
millia
islamia
bioscienc
new
delhi
india
backgroundobject
retinoblastoma
rb
malign
tumor
sensori
retina
common
eye
cancer
childhood
due
defect
rb
gene
immun
system
play
import
role
control
erad
cancer
recent
studi
suggest
program
death
ligand
pathway
activ
play
major
role
tumor
escap
mechan
host
immun
therefor
investig
express
human
retinoblastoma
cancer
defin
clinic
signific
patient
prognosi
surgeri
designmethod
protein
express
evalu
prospect
case
primari
enucl
retinoblastoma
specimen
immunohistochemistri
valid
western
blot
mrna
express
investig
quantit
real
time
pcr
qpcr
express
correl
clinic
histopatholog
paramet
patient
surviv
result
immunohistochemistri
show
cytoplasm
express
case
wherea
show
nuclear
express
case
western
blot
confirm
immunoreact
result
repres
case
protein
mrna
level
determin
ihc
real
time
qpcr
close
correl
express
show
signific
correl
poor
tumour
differenti
tumor
invas
p
signific
differ
overal
surviv
patient
express
conclus
data
suggest
express
may
new
biomark
patient
retinoblastoma
tumor
origin
sensori
retin
cell
studi
provid
first
data
role
immun
checkpoint
retinoblastoma
patient
studi
necessari
confirm
observ
evalu
predict
valu
retinoblastoma
context
inhibit
mk
singh
n
india
institut
medic
scienc
ocular
patholog
delhi
india
india
institut
medic
scienc
ophthalmolog
delhi
india
backgroundobject
retinoblastoma
rb
malign
tumor
develop
retina
children
occur
age
five
year
nuclear
factor
kappa
b
shown
play
role
cell
prolifer
apoptosi
cytokin
product
oncogenesi
nuclear
transcript
factor
famili
thought
play
import
role
develop
certain
cancer
therefor
aim
studi
investig
localis
express
protein
retinoblastoma
designmethod
prospect
analysi
primari
retinoblastoma
case
period
one
year
express
rela
analyz
immunohistochemistri
ihc
formalin
fix
retinoblastoma
specimen
mrna
express
analyz
fresh
primari
enucl
retinoblastoma
tissu
real
time
polymeras
chain
reaction
qpcr
result
correl
clinic
patholog
paramet
result
express
protein
found
retinoblastoma
case
normal
retina
protein
frequent
detect
invas
tumour
tumour
increas
express
statist
signific
choroid
invas
invas
tumor
hrf
mrna
express
found
upregul
case
mrna
express
correl
well
immunostain
conclus
studi
demonstr
express
protein
repres
reliabl
prognost
marker
retinoblastoma
might
relat
retinoblastoma
tumorigenesi
progress
pathway
target
combin
therapi
may
repres
novel
approach
retinoblastoma
varan
h
c
institut
oncolog
dept
pediatr
oncolog
ankara
turkey
faculti
medicin
dept
ocular
oncolog
ankara
turkey
faculti
medicin
dept
radiolog
ankara
turkey
backgroundobject
retinoblastoma
common
intraocular
malign
children
present
result
chemotherapi
iac
melphalan
topotecan
treatment
newli
diagnos
retinoblastoma
patient
designmethod
studi
retrospect
analys
clinic
featur
outcom
patient
eye
treat
octob
februari
tumor
control
globe
salvag
analyz
complet
blood
count
examin
day
iact
system
toxic
result
median
age
diagnosi
month
rang
month
girl
boy
chemotherapi
melphalan
topotecan
primari
treatment
eye
secondari
eye
eye
receiv
therapi
classifi
accord
intern
classif
retinoblastoma
icrb
group
n
b
n
c
n
n
e
n
iac
mean
month
rang
month
complet
regress
achiev
tumor
eye
four
eye
enucl
treat
group
treat
group
globe
salvag
achiev
case
casesth
surviv
rate
treatment
requir
iact
follow
enucl
eye
local
therapi
eye
sever
system
side
effect
observ
conclus
preliminari
result
support
globe
salvag
avoid
toxic
relat
system
chemotherapi
may
achiev
given
safeti
high
efficaci
expect
replac
convent
strategi
yousef
r
hussein
cancer
center
depart
surgeri
ophthalmolog
amman
jordan
hussein
cancer
center
pediatr
oncolog
amman
jordan
hussein
cancer
center
cell
therapi
appli
genom
amman
jordan
backgroundobject
retinoblastoma
rb
childhood
cancer
develop
retina
due
mutat
gene
herein
tri
identifi
oncogen
mutat
gene
inherit
pattern
rb
jordanian
rb
patient
designmethod
peripher
blood
retinoblastoma
patient
collect
genom
dna
extract
dna
sequenc
conduct
next
gener
sequenc
analysi
sanger
sequenc
quantit
multiplex
pcr
pcr
result
cohort
affect
patient
studi
twenti
patient
unilater
rb
bilater
rb
overal
patient
germlin
diseas
mutat
detect
one
parent
inherit
diseas
bilater
group
patient
germlin
diseas
inherit
mutat
unilater
group
germlin
diseas
inherit
mutat
interest
inherit
case
patern
mutat
seen
affect
patient
one
patient
mosaic
mutat
detect
one
inherit
case
mother
mosaic
mutat
inherit
case
unaffect
carrier
parent
conclus
even
bilater
rb
patient
cohort
germlin
diseas
unilater
diseas
germlin
patient
germlin
diseas
inherit
diseas
affect
unaffect
carrier
therefor
molecular
screen
import
genet
counsel
regard
risk
inherit
retinoblastoma
unilater
bilater
case
aguiar
fa
do
j
ss
da
cml
da
iw
da
src
de
je
de
e
r
v
dm
c
cancer
center
cipe
paulo
brazil
sao
paulo
genet
sao
paulo
brazil
cancer
center
pediatr
oncolog
sao
paulo
brazil
cancer
center
patholog
depart
sao
paulo
brazil
pediatr
oncolog
sao
paulo
brazil
cancer
center
cipe
sao
paulo
brazil
hospit
pediatr
depart
belo
horizont
brazil
children
hospit
pediatr
depart
brazil
pediatr
oncolog
sao
paulo
brazil
backgroundobject
hepatoblastoma
common
primari
liver
tumor
children
account
pediatr
cancer
although
molecular
data
hb
tumorigenesi
still
scarc
rariti
recent
new
insight
gain
molecular
biolog
main
object
studi
investig
mutat
burden
hb
designmethod
sequenc
perform
discoveri
cohort
hb
match
liver
tissu
agil
sureselect
target
enrich
bioinformat
analysi
exom
data
identifi
somat
variant
gene
chosen
valid
use
target
sequenc
panel
sureselectxt
target
enrich
system
illumina
sequenc
librari
gene
panel
compos
detect
gene
gene
relat
hb
cancer
use
investig
addit
hb
sampl
valid
group
complement
screen
somat
mutat
perform
analysi
agil
twelv
hb
sampl
screen
copi
number
alter
result
total
somat
mutat
valid
gene
consid
entir
hb
group
somat
analysi
reveal
pathogen
mutat
gene
recurr
missens
mutat
gene
role
mutat
explor
ihq
studi
protein
well
gene
express
analysi
analysi
show
mainli
aneuploidi
focal
aberr
could
also
map
conclus
data
highlight
rel
stabl
tumor
genom
type
pediatr
liver
tumor
present
low
mutat
burden
regard
potenti
pathogen
mutat
copi
number
alter
grant
fapesp
fapesp
cnpq
dsouza
l
valanejad
k
r
n
children
hospit
medic
center
cancer
blood
diseas
institut
usa
children
hospit
medic
center
pediatr
surgeri
cincinnati
usa
children
hospit
medic
center
gastroenterolog
cincinnati
usa
backgroundobject
one
critic
step
develop
hepatoblastoma
hbl
loss
control
prolifer
hepatocyt
examin
larg
bank
hbl
sampl
found
oncogen
gankyrin
elev
examin
hbl
patient
high
rate
prolifer
goal
project
examin
role
gankyrin
activ
liver
prolifer
designmethod
test
role
gankyrin
liver
prolifer
gener
gankyrin
knockout
mice
gank
lko
examin
liver
prolifer
use
two
model
prolifer
surgeri
liver
injuri
liver
prolifer
monitor
use
combin
approach
includ
measur
dna
replic
mitosi
express
cell
cycl
gene
oncogen
immunostain
western
blot
assay
use
result
gank
lko
mice
normal
liver
gross
examin
serum
hepat
function
test
howev
analys
show
gank
lko
mice
reduc
express
gene
involv
liver
regener
liver
cancer
consist
find
found
liver
prolifer
partial
hepatectomi
ph
dramat
inhibit
gank
lko
mice
look
underli
mechan
found
tumor
suppressor
protein
tsp
reduc
gankyrin
control
mice
ph
elev
gank
lko
mice
elev
tsp
gank
lko
mice
inhibit
liver
prolifer
similar
inhibit
liver
prolifer
observ
gank
lko
mice
liver
injuri
mediat
carbon
tetrachlorid
conclus
gankyrin
power
oncogen
hbl
studi
demonstr
delet
gankyrin
suffici
inhibit
liver
prolifer
anim
model
import
mechan
behind
carcinogenesi
result
strongli
suggest
inhibitor
gankyrin
investig
potenti
target
therapi
hbl
b
e
h
j
w
p
children
memori
health
institut
oncolog
warsaw
poland
children
memori
health
institut
pediatr
surgeri
organ
transplant
warsaw
poland
children
memori
health
institut
patolog
warsaw
poland
backgroundobject
liver
transplant
ltx
establish
role
treatment
children
hepatoblastoma
aim
present
treatment
result
complic
ltx
hepatoblastoma
designmethod
children
underw
liver
transplant
unresect
hepatoblastoma
age
transplant
rang
year
patient
postext
iii
postext
iv
six
patient
stage
iv
diseas
bilater
lung
metastas
patient
receiv
preoper
chemotherapi
accord
siopel
recommend
six
patient
evid
metastat
diseas
ltx
twenti
children
receiv
graft
relat
donor
cadaver
graft
patient
receiv
chemotherapi
transplant
median
cours
cisplatin
vincristin
fu
result
patient
aliv
median
year
patient
surviv
year
four
patient
die
one
year
ltx
bone
marrow
aplasia
unknown
etiolog
patient
relaps
refractori
chemotherapi
month
ltx
relaps
occur
lung
patient
bone
metastas
also
observ
chemotherapi
well
toler
one
patient
underw
year
month
primari
second
ltx
conclus
data
confirm
ltx
treatment
option
children
unresect
hepatoblastoma
r
e
v
e
wachtel
nacion
de
enfermedad
pediatr
oncolog
lima
peru
nacion
de
enfermedad
chief
abdomin
surgic
depart
lima
peru
nacion
de
enfermedad
pediatr
oncolog
lima
peru
backgroundobject
hepatoblastoma
hb
repres
solid
pediatr
malign
inen
purpos
studi
evalu
clinic
featur
outcom
patient
designmethod
retrospect
descript
studi
januari
decemb
patient
year
age
diagnos
hb
patient
exclud
surviv
analysi
perform
use
method
result
median
age
year
rang
year
mf
ratio
fifti
patient
complet
remiss
progress
diseas
patient
recur
die
stage
accord
pretext
ii
iii
iv
nineteen
patient
pulmonari
metastas
diagnosi
year
overal
surviv
os
event
free
surviv
ef
os
group
metastat
group
os
pretext
ii
iii
iv
os
accord
initi
treatment
neoadjuv
chemotherapi
surgeri
siopel
carboplatindoxorubicin
initi
surgeri
ef
patient
respect
conclus
hb
rare
tumor
institut
multidisciplinari
team
approach
crucial
improv
survivorship
lung
metastas
condit
wors
prognosi
improv
surviv
sinc
siopel
treatment
mp
e
l
ss
iw
da
cml
src
de
dm
c
krepischi
bioscienc
univers
paulo
genet
evolutionari
biolog
paulo
brazil
camargo
cancer
center
intern
research
center
paulo
brazil
camargo
cancer
center
depart
patholog
paulo
brazil
camargo
cancer
center
depart
pediatr
oncolog
paulo
brazil
oncolog
institut
feder
univers
paulo
depart
pediatr
paulo
brazil
center
research
energi
materi
cnpem
campina
brazil
backgroundobject
liver
tumor
children
account
pediatr
solid
tumor
hepatocellular
carcinoma
predomin
adult
common
liver
cancer
children
hepatoblastoma
mechan
underli
hepatoblastoma
develop
still
poorli
explor
prognosi
advanc
tumor
stage
remain
poor
suggest
embryon
tumor
associ
blockag
hepatocyt
differenti
tumor
carri
low
mutat
burden
impair
epigenet
mechan
core
embryogenesi
develop
stand
altern
rout
tumorigenesi
main
object
studi
explor
role
gene
associ
methyl
hydroxymethyl
hepatoblastoma
designmethod
cohort
tumor
consist
hepatoblastoma
control
group
liver
tissuesth
express
gene
epigenet
machineri
analyz
qpcr
taqman
quantif
assay
quest
dna
elisa
kit
appli
assess
level
tumor
compar
control
result
gene
found
tumor
signific
increas
level
also
evid
hepatoblastoma
sampl
compar
tissu
data
suggest
hepatoblastoma
could
present
pluripot
pattern
gene
express
address
issu
express
level
three
gene
associ
pluripot
andnanog
evalu
alter
detect
conclus
upregul
dna
methyl
gene
tet
increas
level
support
hypothesi
hepatoblastoma
exhibit
epigenet
signatur
immatur
cell
suggest
blockag
hepat
cell
differenti
genesi
howev
absenc
pluripot
marker
show
commit
differenti
process
hypothesi
hepatoblastoma
transit
stage
hepat
differenti
probabl
hepatoblast
fund
fapesp
cape
oue
n
colleg
medicin
pediatr
surgeri
hyogo
japan
backgroundobject
growth
hormon
gh
report
affect
tumor
growth
increas
risk
neoplasia
leukemia
howev
associ
gh
hepatoblastoma
hb
rare
report
present
two
case
hb
develop
gh
therapi
designmethod
patient
medic
record
collect
retrospect
review
result
patient
boy
patient
boy
administ
gh
therapi
growth
retard
due
poor
gh
secret
shown
toler
test
abdomin
distent
right
upper
quadrant
observ
month
year
gh
therapi
initi
patient
respect
imag
studi
includ
abdomin
comput
tomographi
ct
reveal
huge
tumor
left
hepat
lobe
serum
markedli
elev
case
gh
therapi
discontinu
tumor
biopsi
immedi
perform
confirm
diagnosi
hb
tumor
complet
resect
sever
cours
chemotherapi
use
cisplatin
doxorubicin
accord
protocol
japan
pediatr
liver
tumor
studi
group
addit
chemotherapi
patient
aliv
without
diseas
year
year
respect
gh
secret
normal
growth
observ
case
treatment
hb
conclus
patient
hb
notic
soon
initi
gh
therapi
gh
may
acceler
growth
alreadi
present
hb
patient
hb
develop
year
gh
therapi
therefor
gh
may
initi
hb
tumorigenesi
case
gh
therapi
immedi
discontinu
gh
like
acceler
tumor
growth
normal
gh
secret
tumor
resect
may
indic
hb
tumor
secret
type
gh
antagonist
riva
j
c
c
e
v
bioscienc
univers
paulo
genet
evolutionari
biolog
paulo
brazil
camargo
cancer
center
depart
pediatr
oncolog
paulo
brazil
oncolog
institut
graacc
depart
pediatr
paulo
brazil
de
tratamento
de
infantil
itaci
pediatr
depart
paulo
univers
medic
school
paulo
brazil
backgroundobject
cytogenet
alter
lead
chang
chromosom
copi
number
aneuploidi
hallmark
cancer
cell
hepatoblastoma
hb
uncommon
embryon
liver
tumor
account
approxim
childhood
hepat
cancer
mostli
diagnos
children
age
month
current
valid
prognost
therapeut
biomark
hb
patient
hb
sporad
case
although
incid
elev
certain
genet
syndrom
includ
famili
adenomat
polyposi
explor
cytogenom
profil
hb
investig
cohort
hepatoblastoma
microarray
aim
identifi
relev
chromosom
region
gene
designmethod
platform
perform
character
copi
number
profil
two
differ
commerci
hb
cell
line
well
two
hepatocellular
carcinoma
lineag
result
analysi
reveal
quit
stabl
genom
kind
embryon
tumor
four
hb
present
detect
chromosom
imbal
wherea
four
exhibit
mainli
arm
aneuploidi
preval
gain
affect
entir
chromosom
focal
alter
could
delimit
includ
amplif
two
tumor
share
minimum
common
region
mb
harbor
gene
complex
rearrang
delet
larg
mb
segment
delet
two
hb
present
higher
load
chromosom
rearrang
compar
hb
group
conclus
character
liver
tumor
cell
line
highlight
quiet
chromosom
landscap
embryon
liver
tumor
compar
adult
counterpart
hepatocellular
carcinoma
carri
sever
cytogenet
chang
complex
genom
data
suggest
aneuploidi
possibl
play
limit
role
hb
tumorigenesi
rather
link
process
acquisit
entir
chromosom
amplif
oncogen
tumor
suppressor
loss
fund
cape
fapesp
j
j
shalkow
r
e
institut
pediatr
surgic
oncolog
mexico
mexico
institut
pediatr
radiolog
mexico
mexico
health
childhood
cancer
mexico
mexico
institut
pediatr
patholog
mexico
mexico
health
oncolog
mexico
mexico
backgroundobject
infantil
hepat
hemangioendothelioma
ihe
common
benign
liver
tumor
infanc
present
symptom
may
includ
abdomin
distent
hepatomegali
associ
cutan
hemangioma
congest
heart
failur
chf
anemia
thrombocytopenia
recent
propranolol
proven
good
therapeut
altern
designmethod
retrospect
review
case
ihe
treat
propranolol
surgic
oncolog
depart
nation
institut
pediatr
mexico
demograph
clinic
data
outcom
collect
result
girl
boy
diagnos
birth
except
one
prenat
ultrasound
present
palpabl
abdomin
mass
chf
associ
cutan
hemangioma
liver
involv
one
develop
thrombocytopenia
case
present
hypothyroid
diagnosi
confirm
doppler
us
treat
propranolol
mgkgday
cardiac
evalu
advers
reaction
treatment
respons
seen
month
radiograph
respons
propranolol
gradual
wane
nine
patient
aliv
without
recurr
year
eight
show
complet
respons
one
respond
requir
hepat
embol
one
patient
die
due
sever
coagulopathi
syndrom
conclus
propranolol
offer
excel
therapeut
altern
ihe
probabl
due
properti
vasoconstrict
decreas
express
vegf
apoptosi
capillari
endotheli
cell
surviv
recurr
seri
patient
complet
clinic
radiograph
respons
without
advers
reaction
treatment
n
timchenko
l
l
children
hospit
medic
center
divis
pediatr
gener
thorac
surgeri
cincinnati
usa
children
hospit
medic
center
divis
patholog
cincinnati
usa
jude
children
research
hospit
depart
pharmaceut
scienc
memphi
usa
backgroundobject
aggress
form
hepatoblastoma
hbl
associ
poor
prognosi
tumor
suppressor
protein
tsp
usual
elimin
hbl
examin
larg
cohort
hbl
patient
identifi
group
aggress
hbl
sampl
express
high
level
tsp
one
tsp
goal
work
determin
role
modifi
aggress
liver
cancer
determin
molecular
mechan
caus
develop
liver
cancer
designmethod
test
role
liver
cancer
gener
mous
model
investig
develop
spontan
liver
cancer
mice
also
treat
diethylnitrosamin
den
liver
cancer
examin
approach
liver
cancer
also
investig
addit
model
aggress
liver
cancer
dko
mice
result
found
convert
protein
tsp
oncogen
use
mice
liver
sampl
patient
hbl
hcc
found
mous
human
dephosphoryl
correspondingli
caus
hepatocyt
cell
express
marker
stem
cell
tumor
initi
hepatocyt
tih
pathway
transform
hepatocyt
tih
includ
increas
hepatocyt
prolifer
hepatocyt
enlarg
hepatocyt
inclus
express
contain
glycogen
molecular
mechan
transform
associ
epigenet
alter
format
high
mw
complex
conclus
patient
aggress
hbl
ser
convert
tumor
suppressor
protein
oncogen
activ
tumor
promot
activ
oncogen
form
includ
transform
hepatocyt
tumor
initi
cell
express
marker
stem
cell
find
provid
molecular
basi
develop
therapi
treat
aggress
liver
cancer
j
wang
q
j
j
x
hospit
zhejiang
univers
school
medicin
depart
surgic
oncolog
hangzhou
china
backgroundobject
infantil
hepat
hemangioma
ihh
common
tumor
liver
infanc
children
diffus
lesion
like
greater
risk
death
especi
case
sever
congest
heart
failur
chf
abdomin
compart
syndrom
ac
aggress
treatment
crucial
improv
mortal
studi
efficaci
hepat
arteri
blockag
treatment
high
risk
ihh
evalu
designmethod
nineteen
patient
diffus
ihh
age
admit
center
jan
sep
includ
studi
clinic
data
retrospect
analyz
glucocorticoid
methylprednisolon
plu
propranolol
administr
treatment
symptom
includ
chf
ac
could
reliev
even
deterior
hour
drug
administr
patient
high
risk
group
hepat
arteri
blockag
suggest
high
risk
group
five
case
underw
surgeri
case
hepat
arteri
ligat
one
case
block
embol
case
refus
hepat
arteri
blockag
method
kept
glucocorticoid
plu
propranolol
treatment
result
case
underw
hepat
arteri
blockag
chf
ac
reliev
promptli
surgeri
case
includ
case
hepat
arteri
ligat
case
hepat
arteri
embol
case
deterior
heart
failur
die
eventu
case
high
risk
group
refus
hepat
arteri
blockag
die
deterior
chf
ac
conclus
sever
congest
heart
failur
abdomin
compart
syndrom
high
risk
factor
children
diffus
infantil
hepat
hemangioma
blockag
blood
flow
hepat
arteri
simpl
method
reliev
chf
ac
hepat
arteri
blockag
combin
drug
therapi
may
improv
mortal
high
risk
ihh
wang
c
j
q
w
children
medic
center
hematologyoncolog
shanghai
china
backgroundobject
investig
efficaci
protocol
pediatr
hepatoblastoma
prognost
factor
designmethod
consecut
case
divid
either
low
risk
group
high
risk
group
accord
group
criteria
complet
remiss
defin
neg
imag
fetoprotein
retrospect
analysi
perform
clinic
featur
short
outcom
prognost
factor
result
case
includ
male
femal
enrol
median
age
diagnosi
year
old
accord
pretext
stage
case
stage
stage
case
exist
distant
metastasi
first
present
includ
lung
andor
pleura
metastasi
median
cycl
chemotherapi
low
risk
group
high
risk
group
afp
back
normal
median
cycl
chemotherapi
total
plu
surgeri
cycl
post
total
tumor
resect
until
august
median
time
month
case
achiev
complet
remiss
case
reach
remiss
progress
anoth
relaps
total
case
alreadi
die
estim
five
year
ef
os
five
year
ef
os
low
risk
group
high
risk
group
respect
five
year
os
rate
respect
without
distant
metastasi
cycl
chemotherapi
post
tumor
resect
afp
return
normal
still
high
case
five
year
os
rate
respect
p
conclus
result
protocol
reason
compar
worldwid
research
besid
stage
metastasi
patholog
subtyp
postop
afp
cycl
chemotherapi
back
normal
also
prognost
factor
arafah
g
n
w
pediatr
oncolog
cairo
egypt
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
surgic
oncolog
cairo
egypt
patholog
cairo
egypt
radiodiagnosi
cairo
egypt
clinic
trial
unit
cairo
egypt
clinic
research
cairo
egypt
backgroundobject
surviv
rate
children
malign
extra
cranial
germ
cell
tumor
mgct
increas
significantli
excel
outcom
distribut
uniformli
across
heterogen
distribut
stage
histolog
featur
primari
tumor
site
sustain
favor
outcom
therapi
reduct
low
intermedi
risk
encourag
lesser
toxic
therapi
decreas
long
term
side
effect
designmethod
elig
patient
mgct
retrospect
analysi
done
case
stratifi
treat
cche
accord
protocol
adopt
low
intermedi
risk
mgct
juli
till
end
decemb
case
follow
june
result
low
intermedi
risk
mgct
mean
age
year
low
risk
lr
patient
testicular
ovarian
yolk
sac
tumor
predomin
male
case
main
histolog
type
femal
case
mix
gct
follow
dysgerminoma
intermedi
risk
ir
case
male
femal
ratio
two
extragonad
case
male
sacrococcyg
tumor
gonad
case
male
femal
yolk
sac
tumor
predomin
male
case
main
histolog
type
femal
case
yolk
sac
tumor
mix
gct
dysgerminoma
five
year
os
lr
ir
respect
five
year
ef
lr
ir
respect
conclus
reduct
therapi
compromis
favor
outcom
low
intermedi
risk
group
excel
salvag
potenti
long
term
surviv
rais
concern
late
side
effect
encourag
therapi
reduct
tt
nguyen
nguyen
thanh
truc
children
hospit
n
hochiminh
citi
vietnam
backgroundobject
report
initi
experi
sacrococcyg
tumor
sct
treat
hospit
year
period
refer
clinic
present
surgic
attent
short
outcom
like
urinari
defec
function
tumor
recurr
background
statement
problem
eg
incid
difficulti
diagnosi
poor
antenat
diagnosi
late
referr
difficulti
referr
rariti
sct
indic
need
concentr
specialist
center
need
long
term
follow
designmethod
infant
sacrococcyg
tumor
surgeri
hospit
till
select
detail
gender
prenat
investig
present
preoper
investig
initi
surgic
outcom
short
term
follow
note
patient
follow
greater
one
year
includ
result
case
sacrococcyg
tumor
male
femal
chief
complaint
sacrococcyg
mass
prenat
diagnosi
establish
among
case
cesarean
remain
case
without
prenat
diagnosi
deliv
normal
case
deliv
term
preoper
investig
includ
ultrasound
ct
scan
mri
afp
bhcg
done
mean
age
diagnosi
day
surgeri
complet
resect
coccycgectomi
without
coccycgectomi
mean
length
stay
day
complic
includ
wound
infect
case
wound
dehisc
case
rectal
perfor
need
temporari
stoma
short
term
year
constip
note
patient
local
benign
malign
recurr
averag
time
recurr
moth
benign
malign
defin
afp
high
associ
recurr
institut
tumor
conclus
sacrococcyg
tumor
surgeri
infant
rel
safe
procedur
without
potenti
complic
n
peter
jk
chandigarh
india
pediatr
surgeri
chandigarh
india
chandigarh
pediatr
surgeri
chandigarh
india
backgroundobject
review
experi
present
treatment
sacrococcyg
teratoma
sct
designmethod
juli
may
chart
patient
sct
retrospect
review
result
femal
male
age
time
surgeri
rang
day
year
median
day
seven
patient
underw
surgeri
within
week
life
antenat
diagnos
patient
underw
surgeri
year
neoadjuv
chemotherapi
non
resolv
perian
abscess
reason
delay
surgeri
ten
patient
altman
type
type
ii
patient
type
iii
eight
patient
underw
ct
scan
preop
ultrasound
two
patient
giant
sct
serum
afp
level
rang
ngml
level
rais
case
malign
other
level
fell
normal
within
year
patient
one
patient
normal
afp
matur
histolog
develop
recurr
year
two
patient
giant
benign
malign
tumor
develop
neurogen
bowel
bladder
ten
patient
matur
histolog
immatur
remain
malign
histolog
postop
mortal
one
patient
matur
histolog
type
iii
morpholog
die
month
post
oper
due
unrel
caus
median
follow
year
rang
year
recent
telephon
follow
survivor
diseas
free
good
qualiti
life
conclus
surgic
excis
sct
associ
good
outcom
serum
afp
level
may
take
year
normal
recurr
occur
even
matur
histolog
henc
long
term
follow
requir
neurogen
bladder
bowel
incontin
may
associ
larg
benign
malign
tumor
n
pushker
r
n
ms
india
institut
medic
new
delhi
ophthalmolog
ansari
new
delhi
india
india
institut
medic
new
delhi
ocular
patholog
ansari
new
delhi
india
backgroundobject
assess
frequenc
occurr
orbit
periorbit
tumor
paediatr
age
group
oper
centr
designmethod
retrospect
studi
patient
age
less
year
oper
orbit
periorbit
tumor
centr
includ
result
total
patient
includ
studi
mean
age
present
year
among
male
femal
case
dermoid
tumor
conjunctiv
nevu
capillari
hemangioma
neurofibroma
rhabdomyosarcoma
inclus
cyst
lymphangioma
pyogen
granuloma
sebac
cyst
basal
cell
carcinoma
pilomatrixoma
case
neuroblastoma
reactiv
follicular
lymphoma
squamou
cell
carcinoma
apocrin
cyst
inflammatori
pseudotumor
lymphoblast
lymphoma
follicular
conjunctiv
hyperplasia
chalazion
conclus
paediatr
patient
oper
orbit
periorbit
tumor
centr
dermoid
found
common
tumor
requir
surgic
intervent
r
meel
n
n
ms
india
institut
medic
new
delhi
ophthalmolog
ansari
new
delhi
india
india
institut
medic
new
delhi
ocular
patholog
ansari
new
delhi
india
backgroundobject
studi
clinic
radiolog
featur
ocular
orbit
dermoid
paediatr
age
group
designmethod
retrospect
case
seri
analys
clinic
radiolog
featur
ocular
orbit
dermoid
patient
less
year
age
oper
centr
includ
studi
result
total
patient
includ
studi
mean
age
patient
year
patient
male
femal
case
limbal
dermoid
case
intern
angular
dermoid
locat
frontonas
sutur
line
case
extern
angular
dermoid
locat
frontozygomat
sutur
line
case
epibulbar
dermoid
lipodermoid
case
limbal
dermoid
bilater
case
associ
goldenhar
syndrom
major
case
show
cystic
lesion
fat
densiti
imag
ultrasound
biomicroscopi
comput
tomographi
none
patient
intracrani
extens
conclus
dermoid
common
benign
tumor
paediatr
eye
orbit
may
present
ocular
surfac
mass
periocular
tumor
case
success
manag
surgic
excis
j
stefanowicz
e
k
e
k
l
r
b
g
b
e
j
g
j
k
medic
univers
depart
hematolog
oncolog
poland
univers
gdansk
depart
haematolog
oncolog
poland
univers
gdansk
depart
patholog
neuropatholog
poland
hospit
depart
pediatr
surgeri
poland
mother
child
clinic
oncolog
surgeri
children
adolesc
warsaw
poland
univers
hospit
depart
pediatr
hematolog
cracow
poland
copernicu
univers
depart
hematolog
oncolog
bydgoszcz
poland
memori
health
institut
depart
oncolog
warsaw
poland
hospit
divis
pediatr
hematolog
oncolog
kielc
poland
pediatr
oncolog
center
depart
pediatr
hematolog
oncolog
poland
medic
depart
clinic
pediatr
hematolog
bone
marrow
transplant
wroclaw
poland
univers
bialystok
depart
pediatr
oncolog
hematolog
bialystok
poland
univers
depart
pediatr
hematolog
oncolog
warsaw
poland
silesia
children
care
health
medic
univers
silesia
depart
pediatr
haematolog
chemotherapi
katowic
poland
univers
depart
pediatr
oncolog
hematolog
lublin
poland
univers
silesia
depart
pediatr
hematolog
chemotherapi
katowic
poland
medic
univers
szczecin
depart
oncolog
szczecin
poland
univers
depart
pediatr
hematolog
poland
backgroundobject
aim
studi
evalu
result
treatment
children
adolesc
testicular
tumor
poland
designmethod
statist
analysi
perform
clinic
data
result
treatment
patient
testicular
tumor
report
databas
extracrani
germ
cell
tumor
polish
pediatr
solid
tumour
group
year
result
studi
includ
patient
age
year
old
treat
accord
tgm
protocol
mean
age
respond
year
median
whole
group
children
yr
form
major
patient
yr
result
treatment
compar
age
group
os
group
children
yr
vs
children
yr
ef
vs
secretori
tumor
found
result
treatment
differ
group
secretori
tumor
vs
vs
mean
afp
concentr
median
rang
iuml
prognost
factor
analys
histolog
structur
mix
tumor
yolk
sack
tumor
embryon
carcinoma
stage
diseas
stage
ii
iii
stage
iv
risk
group
high
risk
group
standard
risk
group
conclus
result
treatment
patient
development
age
testicular
tumor
poland
good
signific
prognost
factor
stage
risk
group
cardellicchio
c
p
children
hospit
oncologyhematolog
unit
firenz
itali
backgroundobject
colon
carcinoma
rare
diseas
pediatr
popul
male
without
strong
famili
histori
cancer
present
metastat
medium
grade
differenti
methyl
mgmt
gene
amplif
met
without
alk
trka
braf
gene
rearrang
die
month
five
treatment
line
whole
exom
sequenc
employ
identifi
variant
small
insertiondelet
copi
number
abnorm
patient
parent
germlin
designmethod
dna
extract
patient
parent
blood
dna
librari
construct
sequenc
illumina
acgh
perform
result
whole
exom
sequenc
highlight
exon
gene
variant
inherit
parent
exon
pole
gene
variant
g
inherit
father
exon
variant
inherit
mother
exon
atm
gene
variant
g
inherit
parent
use
array
cgh
analysi
found
interstiti
delet
gene
inherit
mother
interstiti
delet
gene
inherit
father
conclus
mutat
identifi
homozygos
gene
involv
embryogenesi
tumorigenesi
process
shown
human
gene
mutat
databas
associ
increas
risk
colorect
carcinoma
variant
pole
atm
gene
express
heterozyg
present
uncertain
pathogen
role
report
literatur
clinvar
archiv
show
correl
clinic
signific
variat
phenotyp
relat
increas
suscept
colon
cancer
pole
gene
variant
identifi
patient
may
correl
earli
onset
aggress
cours
instead
hard
specul
role
delet
found
gene
absenc
protein
express
studi
w
kamiyango
j
j
p
p
n
colleg
medicin
children
foundat
malawi
pediatr
lilongw
malawi
children
hospit
pediatr
houston
usa
backgroundobject
kaposi
sarcoma
ks
among
common
childhood
cancer
africa
continu
occur
high
number
despit
increas
avail
antiretrovir
therapi
art
although
year
surviv
estim
pediatr
ks
report
throughout
region
outcom
describ
designmethod
retrospect
review
pediatr
ks
databas
children
adolesc
diagnos
ks
pediatr
hiv
referr
center
lilongw
malawi
survivorship
determin
patient
diagnos
still
aliv
last
two
survivor
treat
chemotherapi
plu
art
accord
malawian
nation
guidelin
two
except
receiv
art
alon
typic
patient
receiv
cycl
bleomycin
vincristin
month
evalu
characterist
survivor
demograph
durat
surviv
time
chemotherapi
need
line
chemotherapi
art
describ
result
survivor
among
case
pediatr
ks
median
age
time
ks
diagnosi
among
survivor
year
interquartil
rang
iqr
femal
median
overal
surviv
year
iqr
longest
survivor
aliv
year
date
ks
diagnosi
fourteen
patient
experienc
relaps
requir
addit
dose
chemotherapi
remain
aliv
time
data
collect
median
time
chemotherapi
year
iqr
longest
durat
reach
year
total
patient
still
line
art
receiv
line
art
conclus
surviv
possibl
children
adolesc
ks
malawi
despit
myriad
limit
major
patient
abl
achiev
diseas
control
chemotherapi
art
half
children
still
line
art
regimen
j
villiera
w
p
p
n
colleg
medicin
children
foundat
malawi
pediatr
lilongw
malawi
children
hospit
pediatr
houston
usa
backgroundobject
initi
eight
year
pediatr
kaposi
sarcoma
ks
program
lilongw
malawi
never
survivor
pulmonari
ks
n
treatment
bleomycin
vincristin
two
patient
die
within
month
longest
durat
surviv
month
programmat
shift
implement
initi
patient
pulmonari
ks
chemotherapi
regimen
intensifi
ad
doxorubicin
report
case
seri
pulmonari
ks
patient
improv
surviv
designmethod
evalu
seri
children
present
pulmonari
ks
manifest
larg
serosanguin
pleural
effus
addit
characterist
hyperpig
ks
skin
lesion
woodi
edema
patient
treat
intensifi
chemotherapi
regimen
doxorubicin
bleomycin
vincristin
cycl
total
given
everi
week
plu
base
antiretrovir
therapi
clinic
characterist
treatment
respons
describ
result
three
patient
one
femal
pulmonari
ks
achiev
diseas
control
prolong
surviv
patient
age
present
year
present
larg
serosanguin
pleural
effus
sever
respiratori
distress
requir
supplement
oxygen
via
nasal
cannula
durat
rang
week
multipl
thoracentesi
procedur
rang
tap
ultim
achiev
resolut
hypoxia
effus
one
patient
concurr
skin
lymph
node
ks
lesion
two
characterist
woodi
edema
pleural
fluid
cytolog
evalu
perform
anticip
none
yield
malign
ks
cell
three
children
aliv
partial
remiss
stabl
diseas
achiev
overal
surviv
durat
month
chemotherapi
respect
durat
month
conclus
improv
surviv
may
achiev
pediatr
pulmonari
ks
patient
receiv
intensifi
chemotherapi
antiretrovir
therapi
longer
requir
determin
definit
outcom
f
akici
g
z
g
e
sultan
suleyman
train
research
hospit
pediatr
hematolog
oncolog
istanbul
turkey
univers
atak
hospit
depart
pediatr
bone
marrow
transplant
istanbul
turkey
univers
school
medicin
pediatr
hematolog
oncolog
istanbul
turkey
sultan
suleyman
train
research
hospit
pediatr
surgeri
istanbul
turkey
univers
school
medicin
radiat
oncolog
istanbul
turkey
backgroundobject
occurr
second
malign
sm
import
late
event
follow
treatment
childhood
cancer
fold
greater
thn
normal
popul
incid
first
year
pirmari
diagnosi
designmethod
incid
sm
studi
popul
patient
minumum
year
follow
cessat
chemoradiotherapi
radiotherapi
childhood
cancer
june
januari
studi
includ
patient
treat
inpati
outpati
clinic
kanuni
sultan
research
train
hospit
result
sm
found
patient
mean
time
occur
sm
year
year
case
girl
year
old
diagnosi
nodular
scleros
hodgkin
lymphoma
stage
treat
radiotherapi
chemotherapi
develop
thyroid
papillari
carcinoma
year
primari
diagnosi
case
boy
year
old
diagnos
hodgkin
lymhoma
develop
hepatocellular
carcinoma
year
treatment
case
b
cell
lymphoma
patient
year
old
diagnos
epidermoid
carcinoma
extern
ear
year
case
year
old
male
patient
develop
adren
cortex
carcinoma
year
treat
success
burkitt
lymphoma
case
femal
patient
diagnos
breast
carcinoma
year
acut
lymphoblast
leukemia
treatment
case
mucoepidermoid
carcinoma
parotid
gland
seen
year
completit
chemotherapi
age
conclus
sm
solid
neoplasm
one
patient
thyroid
carcinoma
could
depend
thyroid
irradi
alkalyt
agent
could
caus
neoplasm
continu
mandatori
treatment
childhood
cancer
sinc
prognosi
sm
unfavor
earli
recognit
prevent
import
fonseca
r
hospit
sick
children
paediatr
haematolog
oncolog
toronto
canada
backgroundobject
rhabdoid
tumor
rt
rare
cancer
defin
loss
function
alter
encod
critic
compon
swisnf
complex
aris
brain
call
atyp
teratoidrhabdoid
tumor
atrt
variou
locat
call
malign
rhabdoid
tumor
mrt
atrt
mrt
frequent
lethal
diseas
best
therapeut
approach
remain
determin
herein
describ
sick
kid
experi
designmethod
patient
diagnos
mrt
hospit
sick
children
identifi
chart
review
demograph
data
treatment
detail
surviv
inform
collect
result
identifi
patient
diagnos
mrt
median
age
diagnosi
year
month
year
femal
male
percent
tumor
extrem
nasopharyng
multifoc
skull
base
chest
wall
neck
patient
present
advanc
diseas
stage
iii
iv
patient
present
multifoc
diseas
correspond
patient
diagnos
rhabdoid
tumor
predisposit
syndrom
median
time
progress
month
rang
month
month
patient
treat
multimod
therapi
includ
chemotherapi
patient
radiat
therapi
patient
surgeri
patient
patient
aliv
free
diseas
patient
succumb
diseas
conclus
mrt
continu
diseas
poor
outcom
young
patient
patient
present
metastat
diseas
dismal
prognosi
insight
biolog
entiti
urgent
need
guid
therapeut
approach
develop
clinic
trial
r
vianna
e
v
fn
j
f
p
nacion
de
pediatr
surgeri
rio
de
janeiro
brazil
nacion
de
pediatr
research
nurs
rio
de
janeiro
brazil
nacion
de
pediatr
oncolog
rio
de
janeiro
brazil
nacion
de
patholog
rio
de
janeiro
brazil
backgroundobject
children
case
genitourinari
rhabdomyosarcoma
paratesticular
origin
prognosi
paratesticular
rhabdomyosarcoma
rm
favor
approxim
patient
local
diseas
diagnosi
purpos
studi
report
retrospect
review
paratesticular
rm
children
treat
pediatr
oncolog
depart
one
institut
brazil
prognost
surgic
histopatholog
aspect
analyz
designmethod
total
twenti
five
patient
age
rang
month
year
old
patholog
confirm
diagnosi
paratesticular
rm
treat
institut
result
median
age
present
year
rang
month
year
sixteen
patient
year
old
eighteen
patient
initi
surgeri
hospit
seven
need
second
surgeri
one
third
patient
underw
initi
surgeri
outsid
institut
requir
second
surgeri
three
hemiscrotectomi
four
lymphadenectomi
partial
cystectomi
perform
one
patient
due
vesic
metastasi
histopatholog
classif
rm
embryon
alveolar
four
classifi
rm
two
patient
treat
follow
intern
rhabdomyosarcoma
studi
group
european
pediatr
soft
sarcoma
group
protocol
sinc
patient
receiv
chemotherapi
seven
receiv
radiotherapi
overal
surviv
os
follow
month
year
median
year
mortal
among
patient
year
age
patient
year
aliv
conclus
os
wors
patient
year
old
confirm
current
data
patient
underw
initi
surgeri
hospit
need
second
surgeri
frequent
includ
hemiscrotectomi
continu
effort
requir
educ
provid
appropri
workup
scrotal
mass
avoid
scrotal
violat
z
jenovari
p
e
z
e
univers
depart
pediatr
budapest
hungari
univers
depart
pediatr
budapest
hungari
backgroundobject
concern
optim
primer
surgeri
case
papillari
thyroid
carcinoma
move
total
thyroidectomi
region
lymph
node
biopsi
first
attempt
procedur
case
provid
opportun
postop
iodin
isotop
therapi
evid
result
procedur
designmethod
retrospect
analyz
data
children
underw
primari
total
thyroidectomi
unit
result
patient
found
mean
age
year
mf
ratio
papillari
thyroid
carcinoma
proven
fnab
histolog
postop
us
mri
done
pulmonari
metastasi
detect
patient
region
lymph
node
enlarg
radiolog
patient
underw
lymph
node
biopsi
intraop
suspect
nodul
central
neck
lymph
node
dissect
done
case
later
neck
dissect
never
attempt
primer
procedur
recurr
laryng
nerv
parathyroid
gland
least
identifi
preserv
none
patient
recurr
nerv
lesion
perman
hypocalcemia
residu
thyroid
tissu
patient
receiv
postop
iodin
isotop
therapi
patholog
lymph
node
enlarg
postop
posit
scan
mri
patient
isotop
treatment
twice
one
patient
time
final
underw
extend
region
lymph
node
dissect
averag
follow
month
month
conclus
primari
total
thyroidectomi
papillari
thyroid
carcinoma
effect
safe
procedur
complic
recurr
nerv
injuri
hypocalcemia
minimis
experienc
surgeon
postop
iodin
isotop
therapi
seem
less
effect
patholog
enlarg
lymph
node
case
primer
region
lymph
node
dissect
affect
region
prior
isotop
therapi
e
kabickova
r
l
faculti
charl
univers
univers
hospit
motol
pediatr
hematolog
oncolog
pragu
czech
republ
faculti
charl
univers
univers
hospit
motol
radiolog
pragu
czech
republ
faculti
charl
univers
univers
hospit
motol
patholog
molecular
medicin
pragu
czech
republ
homolc
hospit
pet
centr
pragu
czech
republ
backgroundobject
metastat
melanoma
children
rare
fatal
diseas
introduct
immun
checkpoint
inhibitor
antibodi
dramat
improv
clinic
outcom
adult
patient
advanc
melanoma
data
checkpoint
inhibitor
treatment
children
melanoma
limit
designmethod
present
two
case
primari
metastat
melanoma
uncommon
locat
children
treat
immun
checkpoint
inhibitor
patient
diagnos
treat
centr
within
last
year
result
first
patient
girl
metastat
melanoma
unknown
primari
site
mup
multifoc
viscer
infiltr
second
patient
boy
primari
leptomening
melanoma
neurocutan
melanosi
braf
mutat
absent
due
signific
melanoma
dissemin
urgent
control
diseas
requir
patient
start
chemotherapi
cvd
cisplatin
vinblastin
dacarbazin
girl
mup
reach
partial
respons
pr
cycl
cvd
continu
ipilimumab
monotherapi
mgkg
everi
week
dose
prolong
stabl
diseas
sd
five
week
last
ipilimumab
administr
diseas
progress
dp
document
cvd
cycl
second
pr
observ
one
month
last
cvd
cours
pembrolizumab
monotherapi
mgkg
start
girl
expir
rapidli
progress
diseas
within
day
initi
dose
pembrolizumab
boy
cn
melanoma
sd
cours
cvd
decid
continu
palli
craniospin
irradi
gy
monotherapi
pembrolizumab
mgkg
everi
week
start
radiotherapi
object
respons
observ
radiotherapi
immunotherapi
die
day
dose
pembrolizumab
cn
melanoma
progress
conclus
immunotherapi
checkpoint
inhibitor
patient
well
toler
chang
diseas
cours
e
v
shamanskaya
n
research
center
pediatr
hematolog
oncolog
immunolog
clinic
oncolog
moscow
russia
petrov
institut
oncolog
laboratori
molecular
oncolog
russia
research
center
pediatr
hematolog
oncolog
immunolog
patholog
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
cytogenet
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
surgeri
moscow
russia
backgroundobject
inflammatori
myofibroblast
tumor
imt
rare
type
childhood
malign
intermedi
biolog
behavior
aim
studi
analyz
clinic
morpholog
molecular
featur
imt
cohort
patient
treat
russian
feder
center
designmethod
nine
patient
imt
period
includ
analys
diagnosi
establish
histolog
examin
alk
immunostain
done
two
differ
antibodi
alk
ultra
alk
rearrang
alk
gene
detect
fish
alk
pdgfrb
fusion
gene
analyz
pcr
result
median
age
diagnosi
month
rang
month
case
tumor
locat
abdomin
caviti
histolog
type
tumor
repres
compactspindl
cell
variant
myxoidvascular
hypocellular
fibrou
express
alk
protein
observ
case
case
express
detect
two
antibodi
case
express
alk
antibodi
posit
reaction
alk
antibodi
ultra
neg
tumor
follow
transloc
detect
case
tumor
transloc
detect
tumor
transloc
detect
case
posit
express
alk
protein
patient
aliv
median
follow
month
rang
month
conclus
work
allow
conduct
studi
clinic
morpholog
characterist
imt
cohort
children
russia
shown
case
express
alk
protein
correl
presenc
gene
rearrang
c
n
kalkan
n
univerc
oncolog
pediatr
oncolog
ankara
turkey
univerc
medic
faculti
pediatr
oncolog
ankara
turkey
univerc
medic
faculti
radiolog
ankara
turkey
univerc
medic
faculti
pediatr
patholog
ankara
turkey
univerc
medic
faculti
patholog
ankara
turkey
backgroundobject
although
lung
cancer
common
invas
type
cancer
worldwid
rare
children
goal
direct
treatment
besid
chemotherapi
becom
popular
last
decad
crizotinib
tyrosin
kinas
inhibitor
shown
affect
surviv
nsclc
patient
anaplast
lymphoma
kinas
alk
oncogen
transloc
designmethod
adolesc
case
adenocarcinoma
crizotinib
treatment
report
result
patient
complaint
night
fever
lymph
node
enlarg
weight
loss
six
month
durat
chemotherapi
start
epitheli
neoplasm
thymoma
type
diagnos
supraclavicular
lymph
node
metastasi
biopsi
lung
nodul
patient
refer
hospit
due
respons
treatment
histopatholog
evalu
lymph
node
biopsi
hospit
reveal
lung
adenocarcinoma
metastasi
mass
cm
right
lung
middl
lobe
bilater
parenchym
subpleur
nodular
lesion
focal
area
consolid
sign
lymphang
carcinomatosi
detect
two
cours
docetaxel
gemcitabin
administ
initi
crizotinib
mgdose
bid
start
sinc
immunohistochemistri
posit
first
assess
treatment
show
excel
clinic
radiolog
respons
although
primari
mass
lesion
regress
month
crizotinib
treatment
gy
cranial
radiotherapi
administ
due
brain
metastasi
subsequ
cisplatin
pemetrex
treatment
start
conclus
lung
cancer
rare
tumor
childhood
constitut
childhood
cancer
illustr
case
remind
adenocarcinoma
lack
clinic
patholog
correl
emphas
assess
monoclon
antibodi
therapi
check
presenc
oncogen
alk
although
treatment
challeng
patient
present
advanc
stage
diseas
current
surviv
rate
significantli
improv
goal
direct
therapi
p
khullar
k
k
hospit
medic
research
centr
radiat
oncolog
new
delhi
india
backgroundobject
pediatr
nasopharyng
carcinoma
npc
account
pediatr
tumor
limit
data
clinic
featur
treatment
result
prognost
factor
outcom
late
toxic
pediatr
npc
india
designmethod
analysi
carri
consecut
patient
pediatr
npc
regist
center
may
april
year
patient
record
retrospect
review
data
obtain
case
record
file
patient
treat
neoadjuv
chemoradiotherapi
ctrt
cisplatin
follow
cisplatin
concurr
ctrt
cisplatin
result
median
age
year
rang
year
male
femal
ratio
median
durat
symptom
month
rang
year
ajcc
stage
distribut
stage
stage
stage
distant
metastasi
present
seen
patient
complet
respons
seen
overal
respons
observ
case
median
time
month
overal
surviv
os
rate
control
lrc
rate
distant
surviv
dmf
rate
respect
multivari
analysi
p
stage
iv
p
independ
advers
prognost
factor
os
signific
reduct
trismu
xerostomia
observ
patient
treat
intens
modul
radiotherapi
imrt
conclus
patient
pediatr
npc
present
advanc
stage
diseas
center
differ
respons
rate
outcom
seen
two
schedul
ctrt
neoadjuv
vs
concurr
local
control
could
achiev
major
patient
howev
distant
metastasi
common
reason
relaps
reduc
late
toxic
imrt
might
futur
direct
manag
pediatr
npc
ss
kilic
univers
faculti
medicin
pediatr
surgeri
adana
turkey
backgroundobject
tuber
sclerosi
complex
tsc
genet
diseas
effect
cell
develop
epilepsi
mental
retard
develop
hamartoma
differ
part
bodi
could
sign
tsc
renal
brain
basi
tumor
neuroendocrin
tumor
pancrea
could
develop
tsc
patient
solid
pseudopapillari
tumor
pancreas
sptp
low
grade
malign
tumor
adolesc
age
designmethod
cukurova
univers
medic
faculti
hospit
record
patient
oper
pancreat
mass
investig
result
abdomin
magnet
reson
investig
made
year
old
male
tsc
patient
nodulari
lesion
measur
cm
found
tail
pancrea
nodulari
lesion
suppos
hamartoma
pancrea
develop
secondari
tsc
patient
follow
hypoecho
sharp
edg
lesion
measur
cm
found
ultrasound
us
investig
tail
pancrea
lesion
solid
featur
found
comput
tomographi
caus
increas
lesion
measur
oper
decis
make
solid
lesion
measur
cm
tail
pancrea
found
oper
tail
pancrea
detach
side
splenic
arteri
vein
tri
detach
lesion
abl
distal
pancreatectomi
includ
lesion
made
use
surgic
stapler
contain
splenic
arteri
vein
spleen
appear
normal
preserv
patholog
report
lesion
sptp
tumor
free
surgic
board
one
month
later
us
made
blood
flow
spleen
found
normal
residu
tumor
tissu
patient
follow
treatment
pediatr
oncolog
conclus
patholog
pancrea
could
develop
tsc
patient
sptp
seen
rare
lesion
tsc
patient
follow
hamartoma
pancrea
rememb
could
sptp
kizmazoglu
n
e
k
eylul
univers
institut
oncolog
pediatr
oncolog
turkey
eylul
univers
faculti
medicin
pediatr
turkey
eylul
univers
faculti
medicin
dept
otorhinolaryngolog
turkey
backgroundobject
aim
studi
anal
clinic
characterist
treatment
respons
patient
headneck
hemangioma
designmethod
medic
record
patient
headneck
hemangioma
evalu
retrospect
result
median
age
diagnosi
local
lesion
head
neck
patient
remain
patient
also
hemangioma
part
bodyloc
hemangioma
follow
periorbit
cheek
cervic
scalp
periauricular
mouth
lip
forehead
subglott
nasal
paroti
sixtysix
patient
follow
without
medic
treatmenttreat
indic
local
complic
haemorrhag
ulcer
infect
life
threat
organ
dysfunct
cosmet
median
period
mo
remain
patient
requir
medic
treatment
propranolol
corticosteroid
two
case
case
chemotherapeut
vincristin
vinblastin
cyclophosphamid
use
one
case
major
case
receiv
propranolol
observ
propranolol
relat
side
effect
median
durat
propranolol
treatment
mo
day
mo
patient
still
receiv
propranololtreat
cessat
done
casescomplet
regress
achiev
patient
partial
regress
achiev
case
propranolol
patient
subglott
hemangioma
problemat
case
respiratori
feed
difficultiestwo
requir
tracheostomycomplet
regress
occur
subglott
hemangioma
medic
treatmentocular
complic
ambylopia
strabismu
etc
occur
patient
periorbit
hemangioma
despit
medic
treatment
conclus
although
childhood
hemangioma
regress
spontan
headneck
hemangioma
usual
requir
medic
treatment
risk
ocular
feed
respiratori
complic
novaday
propranolol
well
toler
effect
safe
drug
option
treatment
childhood
hemangioma
r
meel
n
india
institut
medic
scienc
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
india
institut
medic
scienc
dept
ocular
dr
rajendra
prasad
centr
ophthalm
scienc
new
delhi
india
india
institut
medic
scienc
dept
medic
dr
bra
irch
new
delhi
india
backgroundobject
peripher
primit
neuroectoderm
tumor
ppnet
belong
ewe
sarcoma
famili
tumor
primari
pnet
constitut
childhood
soft
tissu
tumor
primari
pnet
orbit
rare
hand
case
report
literatur
designmethod
retrospect
review
clinic
record
imag
histopatholog
primari
orbit
ppnet
present
childhood
treat
center
jan
dec
year
result
clinic
imag
histopatholog
detail
nine
pediatr
patient
primari
orbit
ppnet
analyz
median
age
present
year
age
rang
month
year
one
case
present
congenit
pnet
orbit
male
femal
children
durat
symptom
rang
day
month
month
common
present
complaint
proptosi
follow
eyelid
swell
imag
show
variabl
enhanc
mass
lesion
heterogen
attenu
calcif
densiti
case
calcifi
tumor
matrix
seen
radiat
spicul
one
case
bone
eros
extens
seen
case
metastasi
foot
present
one
case
present
diagnosi
made
histopatholog
examin
incis
excis
biopsi
specimen
case
case
diagnos
fine
needl
aspir
biopsi
case
show
posit
protein
immunohistochemistri
neg
pa
conclus
primari
pnet
rare
malign
occur
pediatr
orbit
major
patient
seri
present
larg
tumor
extraorbit
extens
diseas
time
present
nana
garcia
e
de
de
r
gutierrez
oncolog
ciudad
de
bueno
air
argentina
de
ricardo
gutierrez
patholog
bueno
air
argentina
backgroundobject
lipoblastoma
lipoblastomatosi
rare
benign
mesenchym
tumor
occur
infanc
earli
childhood
gener
boy
aim
studi
report
clinic
characterist
diagnost
strategi
type
treatment
outcom
pediatr
patient
p
lipoblastomalipoblastomatosi
compar
result
publish
report
designmethod
retrospect
descript
studi
review
clinic
report
p
admit
oncolog
unit
hospit
de
ricardo
gutierrez
januari
januari
result
six
p
admit
year
repres
p
treat
unit
boy
age
rang
month
clinic
present
fast
grow
painless
mass
case
local
paravertebr
suprapub
gluteal
inici
diagnost
method
ultrasound
comput
tomographi
magnet
nuclear
reson
maximum
tumor
diamet
rang
cm
fine
needl
aspir
fna
perform
compat
cytolog
patholog
diagnosi
lipoblastoma
diffus
lipoblastomatosi
treatment
surgeri
complet
resect
p
without
margin
median
time
month
r
month
none
p
relaps
remain
aliv
conclus
repres
small
percentag
diagnosi
unit
p
younger
year
boy
use
ultrasound
fna
inici
diagnosi
approach
biopsi
confirm
surgeri
treatment
strategi
p
relaps
howev
time
short
result
similar
publish
report
although
rare
tumor
consid
infant
children
painless
fast
grow
tumor
oliveira
mc
gt
dr
bk
rg
rc
v
plta
evp
children
cancer
hospit
pediatr
surgeri
depart
barreto
brazil
medic
school
surgeri
orthoped
pediatr
surgeri
botucatu
brazil
backgroundobject
ewe
sarcomaprimit
neuroectoderm
tumor
ewspnet
extrem
rare
newborn
less
newborn
day
congenit
ewspnet
soft
tissu
report
english
literatur
prognosi
gener
poor
babi
surviv
month
life
designmethod
describ
newborn
diagnos
metastat
retroperiton
ewspnet
cutan
lesion
result
newborn
femal
admit
due
multipl
progress
skin
nodul
associ
hemothorax
sign
central
nervou
system
involv
cesarean
neonat
without
famili
histori
genet
diseas
physic
examin
reveal
multipl
nodul
firm
constanc
character
blueberri
muffin
lesion
also
found
bilater
ocular
proptosi
posterior
mass
hard
poorli
defin
limit
comput
tomographi
ct
detect
massiv
solid
retroperiton
mass
measur
cm
x
cm
hypodens
calcif
involv
aorta
angl
higher
degre
invad
superior
mediastinum
left
pleural
caviti
widen
posterior
intercost
space
left
encompass
costal
arch
extend
posterior
wall
invad
left
paravertebr
musculatur
reach
skin
also
hypodens
solid
nodul
contrast
enhanc
distribut
liver
spleen
adren
pancrea
area
compat
hematogen
lymphat
metastas
sinc
mass
unresect
submit
biopsi
skin
lesion
initi
empir
chemotherapi
protocol
neuroblastoma
patholog
examin
found
histolog
evid
malign
small
round
tumor
cell
tumor
cell
immunohistochem
posit
compat
ewe
sarcoma
primit
neuroectoderm
tumor
given
aggress
diseas
two
day
diagnosi
newborn
die
conclus
report
illustr
extrem
difficulti
manag
newborn
congenit
metastat
ewspnet
sinc
tumor
highli
aggress
prognosi
terribl
treatment
challeng
x
peng
x
medic
univers
school
public
health
beij
china
children
capit
medic
univers
center
clinic
epidemiolog
medicin
beij
china
children
capit
medic
univers
hematolog
oncolog
center
beij
china
backgroundobject
grow
number
studi
commit
explor
role
mutat
develop
ppb
howev
major
report
case
caucasian
therefor
consecut
case
sporad
ppb
beij
children
hospit
test
order
describ
mutat
statu
clinic
characterist
chines
patient
ppb
add
evid
understand
pathogenesi
ppb
designmethod
medic
histori
famili
histori
children
ppb
collect
blood
sampl
children
ppb
first
degre
rel
test
mutat
sequenc
whole
genom
sequenc
peripher
blood
proband
proband
parent
twin
sister
ffpe
proband
tumor
tissu
perform
particip
parent
sign
consent
form
genet
test
medic
histori
collect
result
twelv
patient
pleuropulmonari
blastoma
patient
suffer
type
ii
pleuropulmonari
blastoma
patient
suffer
type
iii
pleuropulmonari
blastoma
respect
evalu
germlin
mutat
seven
patient
identifi
deleteri
mutat
among
mutat
lead
prematur
protein
truncat
result
frameshift
mutat
nonsens
mutat
anoth
one
case
carri
mutat
suspect
deleteri
affect
splice
site
case
total
somat
mutat
consist
nonsens
mutat
locat
within
tdg
missens
mutat
two
mutat
posit
case
found
lung
cyst
preced
diagnosi
ppb
furthermor
one
child
found
remark
famili
histori
thyroid
diseas
conclus
germlin
mutat
frequenc
chines
patient
ppb
similar
publish
studi
routin
test
might
benefit
improv
accuraci
awar
differenti
diagnosi
type
ppb
diseas
especi
lung
cyst
sadek
alexandria
pediatr
surgeri
alexandria
egypt
backgroundobject
ovarian
tumor
children
rare
compris
childhood
tumorsjuvenil
granulosa
cell
tumor
rare
subtyp
sex
cell
tumor
studi
aim
report
studi
case
juvenil
granulosa
cell
tumor
period
year
designmethod
case
juvenil
granulosa
cell
tumor
treat
period
year
main
univers
hospit
reportedthey
studi
concern
age
way
clinic
present
tumor
marker
alpha
phetoprotein
afp
human
chorion
gonadotroph
hormon
hcg
imag
done
diagnosi
treatment
procedur
follow
also
report
result
nine
case
granulosa
cell
tumor
report
case
retrospect
case
prospect
eight
case
age
rang
year
one
case
month
old
case
present
precoci
puberti
form
breast
hypertrophi
extens
suprapub
hair
case
suprapub
hair
enlarg
clitori
one
case
suprapub
hair
huge
swell
one
case
vagin
bleed
one
case
tumor
marker
afp
hcg
neg
reveal
unilater
solid
ovarian
tumor
case
huge
ovarian
swell
mix
solid
cystic
element
one
case
small
ovarian
cyst
one
case
case
treat
follow
unilater
oophorectomi
case
partial
oophorectomi
one
caseth
histopatholog
studi
reveal
benign
granulosa
cell
tumor
reveal
regress
sign
puberti
period
rang
day
conclus
juvenil
granulosa
cell
tumor
consid
prepubert
girl
puberti
neg
tumor
marker
afp
hcg
differenti
function
germ
cell
tumor
includ
ovarian
carcinoma
unilater
oophorectomi
cur
treatment
mostli
benign
saakyan
helmholtz
research
institut
eye
diseas
ocular
oncolog
radiolog
moscow
russia
backgroundobject
purpos
analyz
clinic
profil
surviv
young
patient
uveal
melanoma
designmethod
retrospect
seri
patient
uveal
melanoma
treat
patient
age
younger
male
femal
mean
age
patient
year
case
tumor
unilater
patient
examin
standard
ophthalmolog
procedur
also
ultrasound
color
doppler
imag
oct
fluorescein
angiographi
tumor
treat
ruthenium
plaqu
brachyterapi
case
transpupillari
thermotherapi
proton
beam
therapi
case
enucl
case
result
patient
divid
group
organ
preserv
treatment
without
first
group
mean
tumor
height
mm
second
group
mm
enucl
perform
case
case
monitor
group
demonstr
surviv
surviv
vs
surviv
surviv
group
conclus
increas
incid
uveal
melanoma
young
patient
last
year
common
medium
larg
tumor
size
demonstr
good
result
local
treatment
cap
rcp
af
ja
sr
mj
lf
srr
lg
ca
scride
preto
school
medicin
univers
paulo
pediatr
preto
brazil
children
center
pediatr
campina
brazil
backgroundobject
although
childhood
adrenocort
tumor
act
rare
neoplasm
incid
brazil
particularli
higher
current
reliabl
biomark
predict
diagnosi
prognosi
act
children
aim
find
potenti
biomark
act
prognosi
valid
express
two
mirna
found
differenti
express
mirna
profil
conduct
pediatr
act
sampl
designmethod
valid
express
evalu
act
pediatr
tumor
adren
pediatr
sampl
comparison
mirna
profil
clinicalbiolog
featur
perform
test
curv
test
surviv
ef
analysi
rel
risk
rr
multivari
analysi
cox
regress
model
result
overexpress
tumor
sampl
p
also
show
signific
associ
viril
tumor
mutat
express
significantli
higher
patient
classifi
sandrini
stage
iv
relapsemetastasi
unfavor
event
patient
express
level
higher
median
show
lower
ef
versu
rr
ic
multivari
analysi
show
overexpress
independ
prognost
factor
p
analyz
associ
tumor
size
advanc
stage
moreov
present
neg
correl
inhibitor
wnt
pathway
contrari
show
posit
correl
mycc
import
wnt
pathway
conclus
observ
overexpress
act
compar
sampl
higher
express
tumor
seem
relat
poor
prognosi
pediatr
act
interestingli
mirna
show
signific
opposit
correl
gene
wnt
signal
ptahway
suggest
possibl
relationship
mirna
essenti
pathway
adren
develop
r
veselska
j
p
p
k
j
j
hospit
brno
depart
pediatr
oncolog
brno
czech
republ
ann
univers
hospit
intern
clinic
research
center
brno
czech
republ
school
scienc
depart
experiment
biolog
brno
czech
republ
school
medicin
depart
pediatr
oncolog
brno
czech
republ
univers
ceitec
mu
center
molecular
medicin
brno
czech
republ
backgroundobject
infantil
myofibromatosi
im
belong
famili
soft
tissu
tumor
major
show
benign
behavior
resist
malign
form
also
known
although
molecular
mechan
im
pathogenesi
complet
explain
studi
suggest
associ
mutat
growth
factor
receptor
beta
pdgfrb
gene
relat
gene
diseas
designmethod
analyz
detail
primari
im
cell
line
well
fresh
frozen
tumor
tissu
two
sibl
suffer
im
human
array
employ
detect
phosphoryl
statu
receptor
tyrosin
kinas
rtk
protein
kinas
mapk
import
downstream
signal
protein
express
phosphoryl
select
candid
protein
involv
pdgfr
signal
determin
use
immunoblot
sequenc
use
uncov
germin
mutat
gene
result
tumor
sampl
sibl
show
rel
highest
phosphoryl
level
pdgfrb
implic
pdgfrbetamapk
signal
axi
subsequ
sequenc
reveal
heterozyg
missens
mutat
pdgfrb
gene
furthermor
germin
mutat
ptprj
gene
product
specif
bind
dephosphoryl
kinas
detect
sibl
subsequ
vitro
experi
use
primari
cell
line
focus
test
differ
inhibitor
examin
cell
viabil
respons
pdgfrbmapk
signal
axi
result
show
sunitinib
ie
rtk
inhibitor
abl
inhibit
pdgfrb
effect
downstream
mapk
margin
conclus
accord
vitro
experi
sunitinib
repres
suitabl
treatment
im
result
verifi
posit
therapeut
respons
administr
sunitinib
sibl
acknowledg
studi
support
grant
azv
mzcr
x
yang
j
j
q
j
hospit
zhejiang
univers
school
medicin
depart
ultrasound
hangzhou
china
hospit
zhejiang
univers
school
medicin
depart
surgic
oncolog
hangzhou
china
backgroundobject
studi
investig
sonograph
featur
vagin
malign
girl
efficaci
transperin
tp
conjunct
transabdomin
ta
ultrasonographi
diagnosi
vagin
malign
girl
designmethod
imag
data
case
vagin
malign
center
januari
decemb
retrospect
analyz
characterist
ultrasonographi
ct
mr
summar
case
confirm
patholog
patient
age
form
group
case
vagin
endoderm
sinu
tumor
case
embryon
rhabdomyosarcoma
one
nephroblastoma
one
metastat
neuroblastoma
patient
underw
transperin
tp
conjunct
transabdomin
ta
ultrasonographi
underw
ct
mr
result
result
transperin
transabdomin
ultrasonographi
case
pelvic
hypoecho
mass
could
shown
transabdomin
ultrasonographi
case
combin
intrauterin
hematocel
howev
could
clearli
display
size
border
blood
flow
vagin
hypoecho
occup
relationship
occup
vagina
transperin
ultrasonographi
obviou
necrot
liquefact
calcif
mass
process
case
chemotherapi
vagin
tumor
could
clearli
shown
transabdomin
ultrasonographi
tumor
shrinkag
still
clearli
shown
transperin
ultrasonographi
ten
case
underw
ct
examin
lesion
appear
soft
tissu
mass
heterogen
densiti
variabl
necrosi
cystic
degener
unenhanc
ct
twelv
case
underw
mr
examin
mass
uniformli
isointens
imag
heterogen
hyperintens
imag
heterogen
enhanc
especi
peripher
note
ct
mri
imag
conclus
vagin
malign
often
characterist
echo
patten
transperin
conjunct
transabdomin
ultrasonographi
help
diagnos
follow
vagin
malignanciestherefor
ultrasound
may
prefer
initi
investig
case
vagin
malign
inexpens
techniqu
mf
gutierrez
garcia
r
de
ricardo
gutierrez
pediatr
oncolog
capit
feder
argentina
backgroundobject
treatment
cladibrin
singl
drug
cytarabin
higt
dose
day
effect
children
refractori
reactiv
lch
previou
treatment
regimen
object
describ
experi
reduc
dose
plu
cytarabin
scheme
refractori
reactiv
patient
p
lch
follow
acut
toxic
designmethod
retrospect
analysi
patient
record
treat
januari
februari
refractori
reactiv
lch
standard
therapi
patient
receiv
mg
daili
day
cytarabin
mg
day
day
cours
repeat
everi
week
result
fifti
one
patient
lch
admit
indic
period
treat
plu
alon
median
age
diagnosi
month
rang
month
patient
multisystem
lch
diagnosi
four
patient
risk
organ
involv
snc
tumor
lesion
median
previu
chemotherapi
seven
patient
evalu
one
patient
exclud
sever
liver
toxic
first
day
infus
grade
total
perform
patient
receiv
cours
admiss
due
febril
neutropenia
episod
grade
haematolog
toxic
seven
seven
patient
present
activ
diseas
nad
median
follow
month
rang
month
conclus
experi
treatment
reduc
dose
cladribin
cytarabin
refractori
reactiv
lch
patient
useful
obtain
sustain
nad
toler
toxic
madni
r
children
hospit
hematolog
oncolog
birmingham
unit
kingdom
children
hospit
histopatholog
birmingham
unit
kingdom
heartland
hospit
histopatholog
birmingham
unit
kingdom
backgroundobject
histiocyt
dendrit
cell
neoplasm
rare
malign
disord
origin
tissu
macrophag
histiocyt
incid
estim
per
per
year
europ
past
disord
misdiagnos
lymphoma
especi
diffus
larg
b
cell
lymphoma
anaplast
larg
cell
lymphoma
howev
classif
diagnosi
simplifi
histor
histiocyt
sarcoma
hs
associ
unfavour
prognosi
consensu
treatment
strategi
literatur
avail
form
case
report
variabl
treatment
protocol
use
variabl
success
case
tumour
respond
poorli
treatment
commonli
use
langerhan
cell
histiocytosi
designmethod
case
report
result
describ
year
old
patient
multifoc
hs
present
multipl
soft
tissu
boni
lesion
involv
maxilla
mandibl
diseas
also
present
abdomen
tibia
femur
initi
impress
histopatholog
favour
myeloid
malign
commenc
treatment
accord
aml
protocol
immunohistochem
investig
conclud
diagnosi
hs
basi
posit
lysozym
good
respons
initi
aml
therapi
knowledg
optimum
treatment
strategi
hs
continu
chemotherapi
regimen
current
month
treatment
maintain
clinic
radiolog
remiss
conclus
conclud
hs
success
treat
chemotherapi
alon
commonli
use
acut
myeloid
leukaemia
without
signific
toxic
mitchel
u
r
g
j
paediatr
oncolog
southampton
children
hospit
southampton
unit
kingdom
southampton
child
health
southampton
unit
kingdom
backgroundobject
langerhan
cell
histiocytosi
lch
describ
clinic
spectrum
diseas
caus
clonal
prolifer
patholog
langerhan
cell
infiltr
tissu
aim
characteris
diseas
present
south
england
southampton
princip
treatment
centr
ptc
past
year
due
clinic
concern
regard
increas
incid
complex
clinic
lch
present
recent
year
designmethod
retrospect
data
collect
demograph
diseas
site
treatment
modal
diagnosisrelaps
remiss
free
period
outcom
latest
evalu
result
children
treat
cancer
southampton
ptc
past
year
case
lch
identifi
median
age
yr
month
account
patient
male
femal
ratio
present
diseas
diseas
children
identifi
diabet
insipidu
case
biopsi
case
lch
identifi
major
children
singl
system
diseas
uncompl
cours
diseas
recurr
last
follow
bone
diseas
treat
curettag
except
one
alreadi
resolv
time
review
therefor
observ
case
patient
complic
cours
suffer
relaps
patient
least
relaps
need
salvag
therapi
overal
case
risk
organ
diseas
conclus
present
centr
experi
lch
past
year
wit
spike
incid
lch
howev
data
requir
delin
clear
trend
increas
incid
novel
strategi
evalu
monitor
braf
blood
urin
employ
latest
intern
lch
iv
trial
offer
opportun
better
understand
risk
factor
diseas
sever
nguyen
c
hospit
ho
chi
minh
vietnam
backgroundobject
hemophagocyt
lymphohistiocytosi
hlh
hyperinflammatori
condit
whether
primari
secondari
prompt
initi
hlh
therapi
mandatori
prevent
irrevers
tissu
damag
identifi
risk
factor
mortal
vietnames
children
hlh
treat
protocol
designmethod
conduct
prospect
studi
jan
dec
diagnosi
hlh
children
hospit
ho
chi
minh
citi
vietnam
compat
diagnost
criteria
propos
hlh
studi
group
histiocyt
societi
patient
fulfil
least
five
follow
sign
laboratori
find
enrol
fever
higher
day
splenomegali
hepatomegali
cytopenia
affect
three
lineag
peripher
blood
hemoglobin
gl
leucopenia
neutropenia
thrombocytopenia
hypertriglyceridemia
mmoll
hypofibrinogenemia
gl
hyperferritinemia
mgl
hemophagocytosi
bone
marrow
lymph
node
result
total
patient
median
age
year
rang
year
male
femal
ratio
enrol
studi
patient
treat
protocol
median
time
diagnosi
treatment
day
rang
overal
surviv
rate
median
year
patient
achiev
complet
resolut
activ
diseas
develop
reactiv
die
factor
independ
associ
mortal
includ
persist
elev
ferritin
level
central
nervou
system
involv
sever
liver
failur
gastrointestin
bleed
persist
fever
week
induct
therapi
conclus
earli
diagnosi
prompt
manag
hlh
children
close
mortal
risk
factor
improv
patient
surviv
raj
b
institut
rotari
cancer
aiim
medic
onolog
depart
new
delhi
india
backgroundobject
langerhan
cell
histiocytosi
lch
rare
diseas
limit
data
publish
india
regard
outcom
designmethod
perform
retrospect
analysi
patient
lch
treat
institut
rotari
cancer
hospit
new
delhi
august
result
patient
regist
august
median
age
year
male
femal
ratio
median
time
symptom
diagnosi
month
boni
swell
fever
skin
rash
common
present
complaint
boni
lytic
lesion
anemia
lung
involv
jaundic
bone
marrow
involv
seen
patient
respect
patient
divid
three
risk
categori
multifocalunifoc
bone
b
soft
tissu
involv
organ
dysfunct
c
organ
dysfunct
patient
treat
protocol
prednisolon
vinblastin
etoposid
respons
assess
done
week
end
treatment
suspect
diseas
progress
patient
receiv
treatment
complet
respons
cr
observ
partial
respons
stabl
diseas
prsd
wherea
diseas
progress
week
therapi
patient
progress
among
took
treatment
prednisolon
vinblastin
etoposid
cladribin
use
treatment
cr
line
therapi
progress
free
surviv
pf
month
ci
overal
surviv
os
year
ci
multivari
analysi
total
bilirubin
gdl
week
respons
p
risk
categori
signific
predictor
pf
conclus
largest
indian
seri
lch
outcom
result
compar
western
popul
pf
year
os
p
techavichit
k
c
p
univers
pediatr
bangkok
thailand
univers
patholog
bangkok
thailand
sick
children
univers
toronto
laboratori
medicin
toronto
canada
backgroundobject
juvenil
xanthogranuloma
jxg
rare
primarili
pediatr
cell
histiocytosi
braf
mutat
observ
approxim
lch
addit
mutat
recent
identifi
diseas
ecd
none
lesion
designmethod
retrospect
review
result
patient
present
headach
recurr
vomit
mri
brain
reveal
multipl
intracrani
mass
biopsi
right
tempor
lesion
origin
report
jxg
lesion
found
braf
mutat
braf
immunohistochemistri
subsequ
confirm
molecular
method
patient
develop
intract
seizur
time
diagnosi
cerebellar
lesion
identifi
biopsi
origin
diagnos
diseas
rdd
basi
immunohistochem
profil
although
lesion
show
typic
featur
rdd
patient
brought
medic
attent
due
bilater
proptosi
multipl
cranial
lesion
biopsi
right
pariet
bone
lesion
report
jxg
bone
marrow
studi
bone
scintigraphi
imag
chest
abdomen
perform
patient
evid
extracrani
diseas
involv
patient
patient
receiv
intuit
chemotherapi
regimen
lch
consist
vinblastin
prednisolon
cytarabin
methotrex
total
week
three
patient
underw
radiotherapi
primari
affect
site
vari
dose
radiat
median
follow
time
month
patient
aliv
partial
complet
diseas
respons
conclus
report
detect
braf
mutat
jxg
patient
indol
present
target
braf
inhibitor
may
potenti
role
refractori
jxg
case
mutat
studi
braf
statu
lager
seri
jxg
warrant
mustafa
n
r
e
cancer
institut
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
backgroundobject
medulloblastoma
mb
common
malign
brain
tumor
childhood
occur
age
peak
incid
year
aim
assess
outcom
prognost
factor
among
mb
pediatr
patient
nation
cancer
institut
cairo
univers
designmethod
retrospect
studi
includ
elig
patient
establish
diagnosi
medulloblastoma
period
januari
decemb
result
among
patient
male
median
age
diagnosi
year
rang
year
vomit
frequent
present
symptom
follow
headach
detect
patient
respect
major
patient
high
risk
patient
infantil
year
patient
standard
risk
median
follow
period
month
rang
overal
surviv
os
surviv
pf
rate
respect
presenc
postop
residu
spinal
seedl
stage
complet
chemotherapi
protocol
signific
differ
regard
surviv
rate
p
p
respect
signific
differ
patient
present
age
year
versu
year
old
regard
surviv
rate
os
versu
respect
also
histopatholog
impact
surviv
end
studi
patient
aliv
patient
dead
patient
lost
follow
two
patient
relaps
treatment
conclus
outcom
patient
studi
favor
compar
intern
trial
patient
advanc
stage
incomplet
surgic
resect
poorer
outcom
mortal
caus
infect
sepsi
rais
import
strict
infect
control
strong
support
care
measur
e
hospit
sick
children
toronto
canada
backgroundobject
atyp
teratoid
rhabdoid
tumour
atrt
rare
highli
lethal
embryon
brain
tumour
occur
children
predominantli
younger
three
year
old
recent
studi
led
advanc
treatment
stratif
base
epi
transcript
profil
howev
prognosi
despit
aggress
chemotherapi
remain
poor
patient
designmethod
perform
systemat
literatur
compar
treatment
strategi
atrt
patient
diagnos
treatment
inform
includ
chemotherapi
radiat
surgeri
clinic
inform
age
tumour
locat
curat
patient
sub
classifi
chemotherapi
regimen
chemic
class
also
evalu
effect
specif
deliveri
method
intrathec
chemotherapi
hdct
multivari
cox
regress
surviv
analys
perform
assess
efficaci
differ
treatment
strategi
result
patient
analyz
receiv
either
focal
whole
brain
spine
radiat
hdct
administ
patient
respect
report
collect
report
post
patient
treat
heterogen
differ
protocol
result
differ
clinic
outcom
multivari
cox
regress
analys
reveal
statist
signific
differ
variou
treatment
strategi
chemotherapeut
agent
accord
certain
patient
characterist
age
tumour
locat
conclus
result
strongli
indic
patient
clinic
demograph
significantli
influenc
treatment
success
chemic
class
drug
may
benefit
type
atrt
person
approach
take
account
patient
age
tumour
locat
molecular
subtyp
requir
order
tailor
treatment
strategi
appropri
alkofid
e
ha
hind
k
faisal
specalist
hospit
research
center
pediatr
hematolog
oncolog
riyadh
saudi
arabia
faisal
specialist
hopsit
research
center
neurosci
riyadh
saudi
arabia
faisal
specalist
hospit
research
center
neurosci
riyadh
saudi
arabia
faisal
specalist
hospit
research
center
neurosci
riyadh
saudi
arabia
faisal
specalist
hospit
research
center
raidat
oncolog
riyadh
saudi
arabia
faisal
specalist
hospit
research
center
radiat
oncolog
riyadh
saudi
arabia
faisal
specalist
hospit
research
center
dept
path
lab
medicin
riyadh
saudi
arabia
faisal
specalist
hospit
research
center
dept
path
lab
medicin
riyadh
saudi
arabia
unvers
medic
colleg
riyadh
saudi
arabia
backgroundobject
atyp
teratoid
rhabdoid
tumor
atrt
rare
aggress
tumor
poor
prognosi
account
childhood
malign
primarili
occur
children
age
three
though
may
seen
older
age
group
designmethod
medic
chart
pediatr
patient
diagnos
atrt
king
faisal
specialist
hospit
research
centr
riyadh
saudi
arabia
review
treatment
profil
outcom
data
analyz
result
forti
three
case
evalu
median
age
diagnosi
among
male
year
compar
year
among
femal
patient
underw
surgeri
biopsi
subtot
resect
str
gross
total
resect
gtr
insert
patient
prior
surgeri
surgeri
one
tumor
immunoneg
ini
diseas
local
dissemin
base
chemotherapi
given
patient
nineteen
patient
receiv
radic
dose
radiat
therapi
eight
patient
receiv
focal
irradi
whole
craniospin
axi
irradi
follow
local
boost
primari
lesion
patient
treat
focal
radiat
clinic
radiolog
cytolog
evid
spinal
seed
total
radiat
dose
local
field
rang
gy
fraction
craniospin
axi
radiat
dose
rang
gy
gy
last
patient
aliv
cr
sd
remain
diseas
progress
pd
median
month
probabl
five
year
overal
surviv
median
surviv
time
month
ci
conclus
atrt
outcom
remain
unsatisfactori
despit
multimod
treatment
target
strategi
util
agent
mimick
effect
h
may
hold
promis
futur
studi
aggress
tumor
p
angelini
k
ormond
street
hospit
paediatr
oncolog
london
unit
kingdom
ormond
street
hospit
neurosurgeri
london
unit
kingdom
ormond
street
hospit
neurosci
london
unit
kingdom
backgroundobject
infant
medulloblastoma
patient
suffer
sever
cognit
sequela
convent
treatment
particularli
radiotherapi
present
result
protocol
compris
induct
chemotherapi
focal
radiotherapi
consolid
chemotherapi
outcom
survivor
designmethod
patient
treat
patient
underw
attempt
surgic
resect
follow
induct
chemotherapi
cyclophosphamid
carboplatin
vincristin
radiotherapi
administ
base
initi
stage
tumour
respons
post
radiotherapi
patient
receiv
cycl
consolid
chemotherapi
lomustin
cisplatin
vincristin
result
nineteen
patient
receiv
radiotherapi
focal
craniospin
csi
os
ef
twelv
patient
relaps
die
long
term
survivor
two
lost
gross
tumour
resect
desmoplast
variant
radiotherapi
either
focal
csi
correl
better
os
ef
metastas
gender
age
diagnosi
impact
twelv
evalu
patient
report
one
long
term
sequela
tumour
treatment
fourteen
patient
includ
survivor
development
assess
year
diagnosi
six
learn
difficulti
three
femal
moder
learn
difficulti
three
boy
sever
learn
disabl
children
languag
difficulti
one
averag
cognit
six
patient
normal
iq
problem
conclus
studi
confirm
patient
desmoplast
medulloblastoma
favour
prognosi
delay
radiotherapi
reduc
field
radiat
lead
normal
outcom
mild
deficit
survivor
howev
report
second
malign
patient
concern
bring
question
whole
approach
tumour
k
bull
c
j
k
c
southampton
clinic
experiment
scienc
southampton
unit
kingdom
southampton
school
psycholog
southampton
unit
kingdom
southampton
southampton
health
technolog
assess
centr
southampton
unit
kingdom
exet
medic
school
exet
unit
kingdom
backgroundobject
qualiti
life
children
treat
brain
tumour
risk
significantli
impair
adulthood
includ
cognit
function
emot
behaviour
social
issu
howev
typic
systemat
screen
problem
referr
appropri
servic
often
reactiv
rather
proactiv
test
feasibl
individualis
applic
outcom
measur
prom
improv
commun
outpati
consult
need
select
appropri
prom
base
avail
evid
measur
properti
designmethod
conduct
systemat
search
medlin
embas
psycinfo
identifi
evid
studi
evalu
measur
properti
english
languag
version
prom
suitabl
use
children
treat
brain
tumour
two
review
independ
screen
titl
abstract
search
select
articl
like
yield
relev
result
full
text
extract
list
read
review
confirm
relev
ascertain
contribut
evid
base
review
team
consid
evid
decid
extent
prom
consid
robust
measur
qualiti
life
individu
children
treat
brain
tumour
result
duplic
remov
systemat
search
identifi
possibl
relev
studi
prom
psychometr
evalu
use
children
treat
brain
tumour
date
studi
titl
abstract
screen
includ
next
stage
review
process
conclus
present
evid
review
inform
select
prom
use
children
treat
brain
tumour
subsequ
stage
research
decis
final
select
prom
made
consult
famili
clinician
cf
classen
children
hospit
oncolog
hematolog
rostock
germani
backgroundobject
glioblastoma
multiform
still
lethal
diagnosi
patient
oper
radiotherapi
effect
reduc
tumor
burden
howev
strong
adjuv
therapi
lack
base
cancer
stem
cell
hypothesi
expect
increas
tumorigen
glioblastoma
cell
object
analys
might
influenc
differ
cultur
condit
vitro
cell
line
establish
individu
patient
order
identifi
therapeut
target
act
epigenet
regul
sinc
continu
exposur
temozolomid
part
standard
treatment
effect
stem
analys
doxycyclin
polycycl
antibiot
inhibit
protein
biosynthesi
bind
small
subunit
bacteri
ribosom
sinc
act
similarli
subunit
mitochondri
ribosom
could
critic
part
metabol
cell
might
also
inhibit
stem
cell
format
designmethod
patient
deriv
cell
grown
classic
cell
cultur
fetal
calf
serum
cancer
stem
cell
cultur
serum
free
supplement
growth
factor
adher
spheroid
cultur
set
analys
effect
continu
treatment
cytostat
drug
temozolomid
without
doxycyclin
result
found
cell
cultiv
upon
stem
cell
cultur
condit
display
increas
tumorigen
vitro
compar
respect
serum
cultur
counterpart
cell
cultiv
spheroid
achiev
phenotyp
adher
cell
interestingli
similar
effect
observ
treatment
temozolomid
furrther
doxycylin
studi
tumorigen
model
fact
revers
effect
temozolomid
conclus
summari
found
numer
modif
growth
condit
phenotyp
tumorigen
glioblastoma
cell
may
influenc
thu
open
new
option
target
approach
glioblastoma
therapi
v
dreneva
v
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
backgroundobject
progress
treatment
children
brain
tumor
led
signific
increas
surviv
howev
radiotherapi
chemotherapi
produc
dramat
impact
survivor
health
state
henc
question
effect
cognit
motor
rehabilit
survivor
great
interest
aim
research
studi
applic
new
method
motor
execut
function
develop
evalu
effect
relat
rehabilit
therapi
patient
brain
tumor
designmethod
cohort
includ
children
posterior
fossa
tumor
male
femal
median
diagnos
medulloblastoma
pilocyt
astrocytoma
anaplast
ependymoma
diffus
brainstem
glioma
neurinoma
fibrillar
meningioma
depend
treatment
protocol
patient
receiv
surgeri
patient
receiv
surgeri
radiotherapi
patient
receiv
surgeri
chemotherapi
patient
receiv
three
type
intervent
remiss
period
vari
month
patient
receiv
occup
therapi
consist
session
dynavis
train
devic
design
enhanc
integr
attent
skill
result
find
reveal
signific
improv
reaction
time
patient
p
femal
show
better
perform
p
explain
earlier
psychomotor
matur
girl
group
patient
receiv
surgic
intervent
demonstr
better
result
compar
other
p
perform
score
significantli
correl
ophthalmolog
diagnos
p
signific
age
differ
found
neg
feedback
receiv
patient
time
work
devic
conclus
result
suggest
dynavis
success
appli
train
reaction
time
integr
rehabilit
pediatr
cancer
survivor
dreneva
v
rogachev
nation
research
center
pediatr
oncolog
immunolog
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
backgroundobject
childhood
brain
tumor
treatment
close
associ
cognit
impair
occur
substanti
proport
patient
aim
investig
evalu
impact
rehabilit
therapi
includ
execut
function
train
paramet
work
memori
sustain
attent
process
speed
posterior
fossa
tumor
survivor
designmethod
children
boy
girl
median
includ
diagnos
medulloblastoma
pilocyt
astrocytoma
anaplast
ependymoma
diffus
brainstem
glioma
neurinoma
fibrillar
meningioma
execut
function
train
perform
patient
time
period
state
execut
function
train
evalu
cambridg
neuropsycholog
test
autom
batteri
cantab
result
patient
demonstr
signific
improv
spatial
work
memori
capac
p
delay
pattern
recognit
p
increas
tendenc
reveal
abil
manipul
visuospati
inform
p
immedi
pattern
recognit
p
conclus
result
indic
effect
execut
function
train
childhood
brain
tumor
patient
also
show
cantab
sensit
method
neuropsycholog
assess
pediatr
cancer
survivor
l
druy
l
g
e
g
scientif
practic
center
pediatr
oncolog
pediatr
depart
hematolog
oncolog
moscow
russia
scientif
practic
center
pediatr
oncolog
laboratori
cytogenet
molecular
genet
moscow
russia
scientif
practic
center
pediatr
oncolog
laboratori
molecular
biolog
moscow
russia
scientif
practic
center
pediatr
oncolog
depart
patholog
anatomi
moscow
russia
scientif
practic
center
pediatr
oncolog
depart
pediatr
surgeri
moscow
russia
scientif
practic
center
pediatr
oncolog
depart
radiat
therapi
moscow
russia
scientif
practic
center
pediatr
oncolog
depart
medic
rehabilit
moscow
russia
children
hospit
pediatr
oncolog
ward
yekaterinburg
russia
clinic
hospit
depart
pediatr
oncolog
st
petersburg
russia
region
children
hospit
depart
pediatr
oncolog
hematolog
chelyabinsk
russia
children
hospit
depart
pediatr
oncolog
hematolog
orenburg
russia
region
chuldren
hospit
depart
pediatr
oncolog
hematolog
nizhnevartovsk
russia
region
children
hospit
depart
pediatr
oncolog
hematolog
barnaul
russia
scientif
practic
center
pediatr
oncolog
depart
neurooncolog
moscow
russia
scientif
practic
center
pediatr
oncolog
institut
pediatr
radiolog
nuclear
medicin
moscow
russia
scientif
practic
center
pediatr
oncolog
medic
administr
moscow
russia
backgroundobject
medulloblastoma
common
cn
malign
childhood
known
signific
clinic
heterogen
distinct
molecular
subgroup
wnt
shh
group
unequ
outcom
distinguish
designmethod
pilot
studi
aim
investig
clinic
signific
molecular
group
medulloblastoma
russian
cohort
patient
analyz
profil
gene
express
p
northcott
et
al
slight
modif
ffpe
tumor
sampl
patient
year
age
nanostr
technolog
patient
treat
accord
hit
protocol
median
time
achiev
month
result
patient
metastat
dissemin
incomplet
resect
residu
diseas
larger
molecular
group
distribut
follow
group
group
patient
classic
histolog
variant
medulloblastoma
includ
group
except
shh
anaplast
group
correspond
desmoplasticnodular
histolog
shh
group
infant
howev
patient
year
desmoplast
medulloblastoma
belong
group
patient
respect
infant
desmoplast
variant
treat
chemotherapi
hit
skk
excel
outcom
even
case
metastat
diseas
group
patient
poor
outcom
surviv
ef
patient
respond
therapi
relaps
group
wnt
patient
seri
excel
outcom
group
patient
except
one
year
age
receiv
craniospin
irradi
differ
ef
molecular
subgroup
signific
trend
conclus
studi
confirm
prognost
signific
molecular
group
medulloblastoma
nanostr
fast
reliabl
method
purpos
could
offer
routin
clinic
practic
r
echebarria
r
adan
ojinaga
ricondo
de
n
bilbao
mj
martinez
garcia
l
galbarriatu
e
ruiz
de
gopegui
l
zaldumbid
martin
aurtenetx
l
collazo
navaja
astigarraga
universitario
cruce
pediatr
hematolog
oncolog
unit
bilbao
spain
universitario
cruce
pediatr
neurolog
departa
bilbao
spain
marqu
de
valdecilla
neurosurgeri
departa
santand
spain
universitario
cruce
neurosurgeri
departa
bilbao
spain
universitario
cruce
depart
patholog
anatomi
bilbao
spain
universitario
cruce
biocruc
health
research
institut
bilbao
spain
universitario
cruce
pediatr
oncolog
psycholog
pediatr
hematolog
oncolog
unit
bilbao
spain
backgroundobject
treatment
young
children
central
nervou
system
cn
tumor
remain
challeng
object
avoid
radiat
therapi
due
long
term
sequela
controversi
chemotherapi
hdct
difficult
manag
patient
present
experi
children
cn
tumor
less
five
year
designmethod
review
cn
tumor
children
five
year
diagnos
collect
analyz
data
clinic
histolog
treatment
sequela
result
infant
identifi
male
mean
age
rang
tumor
site
supratentori
infratentori
dissemin
diagnosi
histolog
astrocyt
tumor
embryon
glioma
ependym
neural
selar
tumor
melanocyt
choroid
plexu
tumor
afect
hypothalamushypophysi
manag
includ
surgeri
complet
resect
partial
resect
biopsi
subtot
resect
biopsi
case
glioma
dipg
hypophysi
tumor
chemotherapi
administ
beyond
first
line
hdct
radiotherapi
administ
focal
ependymoma
medulloblastoma
pnet
craneospin
medulloblastoma
ependymoma
observ
without
therapi
case
predominantli
glioma
overal
surviv
median
month
frequent
sequela
neurolog
ophthalmolog
three
case
present
sequela
conclus
manag
children
less
cn
tumor
remain
challeng
consid
care
age
histolog
local
therapeut
decis
chemotherapi
administ
case
may
contribut
delay
rt
patient
role
hdct
young
children
need
analyz
larger
studi
survivor
tumor
treatment
sequela
frequent
import
w
grajkowska
k
j
e
b
children
memori
health
institut
patholog
warsaw
poland
children
memori
health
institut
neurolog
epileptolog
warsaw
poland
children
memori
health
institut
neurosurgeri
warsaw
poland
children
memori
health
institut
radiolog
warsaw
poland
children
memori
health
institut
oncolog
warsaw
poland
backgroundobject
subependym
giant
cell
astrocytoma
sega
brain
tumor
associ
tuber
sclerosi
complex
tsc
usual
grow
second
decad
life
may
develop
first
month
life
aim
work
establish
incid
clinic
histopatholog
molecular
featur
well
outcom
congenit
sega
tsc
patient
designmethod
cohort
tsc
patient
review
identifi
case
grow
hydrocephalu
produc
sega
first
three
month
life
clinic
present
size
tumor
growth
rate
histopaholog
mutat
analysi
treatment
appli
well
outcom
evalu
result
twelv
patient
present
sega
first
three
month
life
document
sega
growth
develop
hydrocephalu
nine
patient
mutat
analysi
done
gene
mutat
identifi
mean
maximum
sega
diamet
baselin
mm
seven
patient
underw
sega
surgeri
relat
complic
observ
case
two
patient
receiv
everolimu
primari
treatment
conclus
congenit
sega
develop
tsc
patient
patient
mutat
especi
mutat
prone
develop
sega
earlier
childhood
screen
sega
birth
young
infant
sega
surgeri
mtor
inhibitor
consid
treatment
option
work
support
intern
fund
children
memori
health
institut
warsaw
poland
grant
titl
identif
molecular
background
epilepsi
patient
tuber
sclerosi
complex
gupta
h
k
india
institut
medic
scienc
radiotherapi
new
delhi
india
backgroundobject
craniopharyngioma
rare
tumor
sellar
region
data
demograph
detail
symptomatolog
treatment
respons
limit
indian
designmethod
patient
includ
retrospect
analysi
present
clinic
radiat
oncolog
depart
surgeri
year
treatment
chart
review
updat
data
institut
result
total
patient
treat
age
present
rang
yearsth
sex
distribut
male
femal
present
symptom
visual
symptom
patient
hormon
imbal
neurolog
deficit
patient
seizur
patient
rais
intracrani
tension
patient
lesion
size
cm
patient
cm
patient
baselin
tsh
level
avail
patient
rais
decreas
baselin
gh
level
avail
patient
rais
decreas
baselin
prolactin
level
avail
patient
rais
decreas
baselin
acth
level
avail
patient
rais
decreas
radiat
deliv
crt
patient
imrt
patient
srt
patient
radiat
dose
gray
fraction
gray
patient
complet
respons
patient
partial
respons
stabl
diseas
progress
diseas
patient
recur
local
site
patient
underw
surgeri
patient
progress
diseas
last
follow
grade
toxic
document
univari
analysi
done
avail
data
detect
associ
age
sex
hormon
perturb
lesion
size
respons
primari
therapi
recurr
conclus
craniopharyngioma
good
respons
surgeri
radiat
n
p
r
p
p
n
n
jc
verschuur
timon
children
hospit
depart
pediatr
oncolog
marseil
franc
timon
children
hospit
depart
neuroradiolog
marseil
franc
timon
children
hospit
marseil
franc
hospit
depart
pediatr
oncolog
nanci
franc
lambret
centr
pediatr
oncolog
unit
lill
franc
curi
pediatr
depart
pari
franc
depart
paediatr
haematolog
oncolog
lyon
franc
hautepierr
strasbourg
franc
timon
children
hospit
depart
clinic
pharmaci
marseil
franc
backgroundobject
investig
activ
metronom
regimen
relapsingrefractori
pediatr
brain
tumour
bt
defin
surviv
pf
cycl
month
therapi
designmethod
patient
year
age
progress
bt
adequ
organ
function
treatment
consist
cycl
oral
celecoxib
bid
daili
mg
accord
bw
weekli
iv
vinblastin
oral
cyclophosphamid
qd
week
altern
oral
methotrex
twice
week
week
rest
period
maximum
treatment
year
kepner
chang
model
use
patient
first
stage
primari
object
reach
patient
addit
patient
recruit
regimen
consid
efficaci
pf
cycl
alpha
beta
result
patient
includ
group
ependymoma
medulloblastoma
mb
high
grade
glioma
hgg
dpig
low
grade
glioma
lgg
one
patient
hgg
stabil
year
one
ependymoma
stabil
month
none
hgg
ependymoma
mb
stabil
patient
lgg
median
age
year
median
durat
ill
year
patient
receiv
vinblastin
previous
pr
observ
sd
pd
one
non
evalu
cycl
median
number
cycl
rang
seven
patient
receiv
least
year
therapi
treatment
interrupt
temporarili
patient
grade
toxic
conclus
metronom
regimen
activ
patient
bt
especi
lgg
even
patient
receiv
vinblastin
previous
studi
support
enfant
et
foundat
r
x
f
akhter
j
x
l
zhou
women
children
medic
center
guangzhou
institut
pediatr
guangzhou
china
institut
pediatr
pediatr
depart
guangzhou
china
bioscienc
center
depart
pharmacolog
toxicolog
kansa
usa
backgroundobject
despit
aggress
therapi
includ
combin
surgeri
radiotherapi
chemotherapi
gbm
remain
highli
aggress
brain
cancer
worst
prognosi
central
nervou
system
diseas
median
surviv
period
gbm
patient
approxim
one
year
temozolomid
tmz
first
line
chemotherapi
drug
gbm
commonli
use
adjunct
treatment
glioma
extend
median
surviv
month
month
eventu
chemotherapi
becom
impair
develop
chemoresist
target
degrad
unneed
dysfunct
mitochondria
deregul
link
human
cancer
mitophagi
relat
stress
toler
enabl
cell
surviv
maintain
energi
product
lead
tumor
growth
therapeut
resist
object
investig
whether
tmz
induc
mitophagi
gbm
cell
line
designmethod
glioblstoma
resist
cell
line
treat
tmz
differ
time
interv
induc
mitophagi
confoc
microscopi
flow
cytometeri
use
monitor
mitophagi
result
membran
potenti
result
depict
show
loss
signific
loss
observ
cell
line
show
loss
show
compar
higher
loss
ro
assay
result
depict
cell
show
slightli
higher
ro
posit
cell
treat
cell
control
similar
result
observ
signific
differ
observ
treat
cell
control
compar
conclus
studi
present
tmz
could
induc
mitochondri
membran
potenti
decreas
ro
level
increas
gbm
cell
line
basi
result
specul
tmz
resist
may
correl
mitophagi
studi
need
explor
mitophagi
mechan
gbm
tmz
resist
l
c
e
leon
nacion
edgardo
rebagliati
pediatr
oncolog
lima
peru
nacion
edgardo
rebagliati
fellow
pediatr
oncolog
lima
peru
backgroundobject
medulloblastoma
embryon
tumor
aggress
behavior
commonli
seen
children
adult
aim
studi
determin
epidemiolog
treatment
pattern
implic
surviv
children
medulloblastoma
designmethod
total
patient
younger
year
diagnos
medulloblastoma
januari
decemb
evalu
retrospect
cohort
institut
prognost
factor
age
risk
surgeri
metast
leptomening
dissemin
time
delay
surgeri
radiat
chemotherapi
analyz
result
median
time
month
rang
month
patient
diseas
overal
surviv
os
rate
diseas
free
surviv
df
respect
patient
diseas
os
df
rate
respect
median
durat
symptom
day
rang
percent
patient
present
stage
local
tumor
patient
receiv
radiat
year
craniospin
irradi
gray
follow
boost
gray
median
time
radiat
day
rang
multivari
analysi
group
risk
independ
prognost
factor
os
along
metastat
diseas
risk
posit
csf
delay
start
radiat
therapi
day
associ
inferior
os
conclus
children
older
year
delay
radiat
start
surgeri
signific
factor
unfavor
prognosi
earli
treatment
addit
quickli
diagnosi
key
manag
medulloblastoma
still
need
achiev
levashov
g
n
v
hematolog
oncolog
institut
fsbi
nn
blokhin
russian
cancer
research
center
pediatr
hematolog
oncolog
institut
moscow
russia
diagnost
treatment
tumor
institut
fsbi
nn
blokhin
russian
cancer
research
center
experiment
diagnost
treatment
tumor
institut
moscow
russia
fsbi
nn
blokhin
russian
cancer
research
center
depart
patholog
moscow
russia
nn
burdenko
neurosurg
institut
depart
neuropatholog
moscow
russia
neurosurgeri
nn
burdenko
neurosurg
institut
depart
neurosurgeri
moscow
russia
backgroundobject
accord
data
intern
pediatr
protocol
reveal
marker
unfavor
outcom
gene
amplif
express
drug
resist
protein
tumor
specimen
unknown
aim
studi
estim
mgmt
protein
express
medulloblastoma
specimen
designmethod
mgmt
protein
express
assess
immunohistochem
method
use
clone
abcam
dako
genetex
santacruz
thermo
mgmt
posit
specimen
defin
weak
moder
strong
colour
tumor
nuclei
cytoplasm
mgmt
nuclei
number
posit
tumor
cell
mgmt
posit
specimen
defin
moder
strong
colour
tumor
nuclei
cytoplasm
membran
number
posit
tumor
cell
result
posit
sampl
reveal
sampl
infant
children
p
infant
children
p
infant
children
p
mgmt
infant
children
p
also
determin
signific
correl
posit
specimen
molecular
subgroup
medulloblastoma
shh
group
group
p
conclus
data
suggest
absenc
express
infant
medulloblastoma
specimen
could
decreas
effect
methotrex
group
etoposid
could
show
effect
shh
group
medulloblastoma
levashov
g
n
v
hematolog
oncolog
institut
fsbi
nn
blokhin
russian
cancer
research
center
pediatr
hematolog
oncolog
institut
moscow
russia
diagnost
treatment
tumor
institut
fsbi
nn
blokhin
russian
cancer
research
center
experiment
diagnost
treatment
tumor
institut
moscow
russia
fsbi
nn
blokhin
russian
cancer
research
center
depart
patholog
moscow
russia
nn
burdenko
neurosurg
institut
depart
neuropatholog
moscow
russia
neurosurgeri
nn
burdenko
neurosurg
institut
depart
neurosurgeri
moscow
russia
backgroundobject
aim
studi
estim
express
protein
vegf
pdgfrb
gcsfr
transcript
factor
medulloblastoma
specimen
designmethod
protein
express
assess
immunohistochem
method
use
clone
daco
polyclon
dako
santacruz
santacruz
cellmarqu
genetex
genetex
antibodi
posit
specimen
defin
weak
moder
strong
colour
tumor
membran
cytoplasm
vegf
vegfr
pdgfr
gcsfr
cytoplasm
nuclei
number
posit
tumor
cell
result
estim
vegf
posit
specimen
within
group
posit
sampl
reveal
sampl
pdgfrb
gcsfr
amplif
group
posit
specimen
present
patient
statu
predominantli
shh
medulloblastoma
gcsfr
posit
specimen
present
patient
statu
predominantli
shh
group
medulloblastoma
determin
signific
correl
posit
specimen
age
group
infant
children
amplif
conclus
data
suggest
childhood
medulloblastoma
character
low
activ
autocrin
mechan
stimul
vegfvegfr
signal
pathway
decreas
level
transcript
factor
exclud
variant
amplif
high
activ
signal
pathway
lo
n
j
e
u
j
p
k
columbia
cancer
agenc
radiat
therapi
vancouv
canada
british
columbia
surgeri
vancouv
canada
toronto
radiat
oncolog
toronto
canada
margaret
cancer
centr
radiat
medicin
program
toronto
canada
hospit
sick
children
hematologyoncolog
toronto
canada
toronto
paediatr
toronto
canada
columbia
children
hospit
hematologyoncolog
vancouv
canada
british
columbia
pediatr
vancouv
canada
columbia
children
hospit
neurolog
vancouv
canada
margaret
cancer
centr
hematologyoncolog
toronto
canada
toronto
medicin
toronto
canada
backgroundobject
studi
aim
determin
outcom
complic
intracrani
germ
cell
tumour
igct
adolesc
young
adult
aya
accord
differ
therapeut
approach
designmethod
ten
patient
igct
age
manag
either
princess
margaret
cancer
centr
british
columbia
cancer
agenc
chart
patient
retrospect
review
analys
perform
calcul
outcom
complic
rate
year
treatment
result
median
durat
year
nineti
patient
germinoma
germ
cell
tumour
nggct
thirteen
patient
present
spinal
metastat
diseas
surviv
pf
overal
surviv
os
patient
germinoma
pf
craniospin
radiat
therapi
csrt
chemotherapi
whole
ventricular
rt
wvrt
tumour
bed
rt
tbrt
chemotherapi
csrt
alon
wvrt
whole
brain
rt
tbrt
alon
p
os
respect
patient
nggct
pf
csrt
chemotherapi
csrt
alon
tbrt
chemotherapi
os
respect
complic
includ
rate
hypopituitar
seizur
disord
second
neoplasm
cerebrovascular
event
visual
deterior
hear
loss
tinnitu
rt
alon
chemotherapi
rt
neurocognit
impair
either
diseas
treatment
csrt
wbrt
wvrt
tbrt
conclus
demonstr
excel
overal
outcom
largest
studi
igct
aya
knowledg
high
relaps
rate
observ
without
chemotherapi
germinoma
tbrt
chemotherapi
nggct
acknowledg
fund
brain
tumour
foundat
canada
mehmood
khanum
memori
cancer
hospit
research
centr
radiat
oncolog
lahor
pakistan
backgroundobject
retrospect
examin
incid
outcom
treatment
type
especi
use
radiotherapi
medulloblastoma
patient
designmethod
outcom
accord
treatment
group
statu
gender
age
use
radiotherapi
first
line
treatment
present
result
patient
treat
year
male
femal
patient
diseas
metastat
diseas
patient
age
greater
proport
diseas
vs
older
first
line
therapi
chemotherapi
patient
radiotherapi
decreas
first
group
second
group
combin
chemotherapi
radiotherapi
patient
period
high
dose
chemotherapi
use
alon
radiotherapi
surviv
year
patient
receiv
radiotherapi
receiv
radiotherapi
p
stage
vs
age
year
also
significantli
relat
surviv
cox
hazard
model
differ
surviv
gender
period
conclus
improv
surviv
studi
time
period
use
radiotherapi
first
line
import
prognost
factor
younger
children
year
present
wors
stage
independ
effect
young
age
stage
prognosi
much
lower
extent
use
radiotherapi
first
line
therapi
tashvighi
aa
hedayati
n
pediatr
cancer
treatment
research
center
oncolog
tehran
iran
research
center
shahid
beheshti
univers
medic
scienc
tehran
iran
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
literatur
treat
pediatr
ependymoma
iran
scarc
thu
design
studi
review
clinic
care
treatment
regimen
iranian
pediatr
patient
ependymoma
designmethod
data
gather
medic
record
retrospect
base
definit
inclus
exclus
criteria
patient
younger
year
approv
histopatholog
report
confirm
diagnosi
ependymoma
patient
divid
two
subgroup
base
age
diagnosi
ie
year
vs
year
type
initi
surgic
procedur
ie
surgeri
vs
biopsi
final
parametr
nonparametr
statist
analys
done
spss
softwar
ver
result
total
elig
patient
enrol
studi
patient
categor
younger
group
older
group
major
patient
underw
initi
partial
surgic
resect
six
biopsi
thirti
patient
delay
diagnosi
month
onset
clinic
sign
symptom
patient
experienc
ependymoma
recurr
median
durat
month
overal
surviv
surviv
rate
respect
time
review
patient
die
variou
caus
conclus
conclud
accur
diseas
stage
histopatholog
report
standard
radiotherapi
chemotherapi
regimen
need
implement
iran
improv
clinic
care
pediatr
patient
ependymoma
acknowledg
thank
colleagu
medic
record
depart
mpctrc
provid
medic
document
review
mr
tim
hammond
assist
graphic
design
figur
dr
angela
mcarthur
edit
manuscript
moschovi
g
athen
medic
school
pediatr
hematologyoncolog
unit
athen
greec
aghia
sofia
children
hospit
depart
imag
athen
greec
athen
medic
school
pediatr
depart
athen
greec
backgroundobject
children
neurofibromatosi
develop
optic
pathway
glioma
result
impair
protein
regul
ra
activ
import
earli
diagnosi
optic
pathway
glioma
children
order
elimin
impair
visual
activ
designmethod
twenti
one
children
optic
pathway
glioma
diagnos
treat
unit
enrol
studi
patient
divid
three
group
group
seven
patient
without
spot
diagnos
symptom
caus
tumor
group
ii
seven
patient
spot
routin
earli
age
group
iii
seven
patient
spot
without
routin
diagnos
due
visual
loss
heavi
decreas
visual
activ
patient
receiv
chemotherapi
accord
gene
statu
patient
remain
except
one
die
caus
result
age
diagnosi
optic
pathway
glioma
rang
year
medium
year
group
age
rang
year
median
year
total
visual
loss
biopsi
note
two
case
group
ii
patient
age
rang
year
median
year
progress
decreas
visual
activ
diagnosi
receiv
chemotherapi
signific
improv
visual
activ
note
group
iii
patient
age
rang
year
median
year
receiv
chemotherapi
improv
visual
activ
conclus
children
au
lait
spot
need
care
monitor
visual
activ
imag
optic
glioma
earli
diagnosi
tumor
detect
visual
impair
may
help
improv
visual
activ
chemotherapi
chemotherapi
effect
delay
diagnosi
optic
pathway
glioma
hl
k
j
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
depart
neuroradiolog
germani
von
ossietzki
oldenburg
depart
psycholog
oldenburg
germani
backgroundobject
qualiti
surviv
childhood
craniopharyngioma
cp
frequent
impair
hypothalam
involv
hi
sequela
obes
neuropsycholog
deficit
oxytocin
oxi
produc
hypothalamu
secret
posterior
pituitari
gland
play
major
role
regul
behavior
bodi
composit
designmethod
studi
oxi
saliva
concentr
analyz
cp
healthi
control
oxi
measur
saliva
standard
breakfast
associ
gender
bodi
mass
index
bmi
hi
diabet
insipidu
irradi
analyz
furthermor
emot
recognit
abil
analyz
regard
oxi
concentr
saliva
urin
nasal
administr
iu
oxi
cp
hypothalam
lesion
grade
limit
anterior
hypothalamu
grade
ii
involv
mammillari
bodi
posterior
hypothalamu
percept
identif
emot
express
test
use
geneva
multimod
emot
portray
gemep
corpu
mental
state
assess
multidimension
mood
questionnair
result
cp
preoper
hi
show
similar
oxi
level
compar
cp
without
hi
control
howev
cp
grade
hypothalam
lesion
present
lower
oxi
level
fast
condit
compar
cp
grade
ii
lesion
cp
without
hypothalam
lesion
cp
patient
chang
oxi
level
breakfast
correl
bmi
pilot
trial
nasal
administr
oxi
well
toler
result
increas
oxi
concentr
saliva
urin
oxi
administr
cp
grade
hypothalam
lesion
show
improv
emot
identif
compar
cp
grade
lesion
conclus
cp
patient
continu
secret
oxi
especi
anterior
hypothalam
area
involv
oxi
show
less
variat
due
nutrit
oxi
might
posit
effect
emot
percept
cp
specif
lesion
anterior
hypothalam
area
nakano
k
h
k
j
h
k
cancer
center
research
institut
divis
brain
tumor
translat
research
tokyo
japan
citi
gener
hospit
depart
patholog
osaka
japan
cancer
center
research
institut
divis
genom
biolog
tokyo
japan
cancer
center
hospit
depart
patholog
clinic
laboratori
tokyo
japan
citi
gener
hospit
depart
pediatr
neurosurgeri
osaka
japan
citi
gener
hospit
depart
pediatr
hematologyoncolog
osaka
japan
backgroundobject
investig
novel
oncogen
fusion
gene
identifi
pediatr
glioma
potenti
novel
therapeut
target
designmethod
rna
sequenc
perform
three
pediatr
low
grade
glioma
harbor
oncogen
driver
mutat
known
glioma
braf
discov
novel
oncogen
gene
fusion
presenc
candid
fusion
gene
clinic
sampl
verifi
fluoresc
hybrid
express
revers
transcript
polymeras
chain
reaction
immunohistochem
stain
sever
oncogen
signal
transduct
pathway
oncogen
phenotyp
mediat
candid
also
analyz
immunoblot
focu
form
assay
invas
assay
use
glioma
cell
line
overexpress
candid
result
identifi
novel
fusion
gene
glioma
femal
patient
express
fusion
rna
protein
clinic
sampl
confirm
immunoblot
analysi
cell
lysat
glioma
cell
line
express
fusion
gene
demonstr
elev
activ
growth
signal
akt
mtor
furthermor
glioma
cell
line
transfect
fusion
gene
demonstr
enhanc
format
foci
focu
form
assay
elev
invas
transwel
invas
assay
block
treatment
inhibitor
crizotinib
conclus
novel
fusion
gene
identifi
pediatr
low
grade
glioma
oncogen
activ
via
signal
could
potenti
serv
novel
therapeut
target
glioma
possess
fusion
gene
fg
f
alpaslan
h
c
c
karadeniz
univers
medic
faculti
pediatr
oncolog
ankara
turkey
yildirim
beyazit
research
hospit
medic
genet
ankara
turkey
backgroundobject
neurofibromatosi
type
autosom
domin
disord
caus
heterozyg
mutat
neurofibromin
gene
chromosom
describ
result
next
gener
sequenc
ng
patient
present
clinic
featur
gazi
univers
depart
pediatr
oncolog
designmethod
dna
isol
peripher
blood
use
magna
pure
lc
dna
isol
kit
ion
ampliseq
custom
nf
panel
design
use
massiv
parallel
sequenc
target
region
exon
utr
splice
site
gene
mutat
survey
done
use
ion
report
alamut
visual
softwar
differ
mutat
databas
tool
accord
acmg
variant
classif
interpret
guidelin
detect
mutat
link
clinic
data
confirm
dna
sequenc
capillari
electrophoresi
use
appli
biosystem
result
studi
includ
male
femal
patient
median
age
year
sixteen
patient
diagnos
accord
clinic
criteria
two
patient
multipl
spot
famili
histori
present
patient
three
patient
optic
glioma
one
patient
diagnos
atyp
meningioma
surgic
excis
detect
genet
variant
patient
via
ng
type
mutat
follow
like
benign
variant
uncertain
signific
vu
like
pathogen
vu
pathogen
pathogen
one
pathogen
variant
heterozygot
exon
previous
describ
databas
ithu
ndicat
novel
mutat
conclus
describ
novel
gene
mutat
turkish
patient
lack
mutat
detect
patient
indic
method
ng
must
use
mutat
screen
v
f
r
r
r
e
e
r
c
n
c
j
pediatr
oncolog
guadalajara
mexico
nacion
de
noviembr
pediatr
oncolog
ciudad
de
mexico
mexico
hospit
miguel
hidalgo
de
aguascalient
pediatr
oncolog
aguascalient
mexico
gener
region
de
pediatr
oncolog
leon
mexico
para
el
imiem
pediatr
oncolog
toluca
mexico
nacion
la
raza
pediatr
oncolog
ciudad
de
mexico
mexico
nacion
de
pediatr
oncolog
ciudad
de
mexico
mexico
infantil
de
morelia
eva
samano
de
mateo
pediatr
oncolog
morelia
mexico
de
especialidad
del
la
mujer
pediatr
oncolog
queretaro
mexico
gener
de
eduardo
liceaga
pediatr
oncolog
ciudad
de
mexico
mexico
gener
de
tijuana
pediatr
oncolog
tijuana
mexico
universitario
dr
jose
e
unal
pediatr
oncolog
monterrey
mexico
infantil
de
especialidad
pediatr
oncolog
chihuahua
mexico
del
dr
federico
santo
pediatr
oncolog
coahuila
mexico
estat
de
de
colima
pediatr
oncolog
colima
mexico
infantil
e
integr
de
la
mujer
del
estado
de
sonora
pediatr
oncolog
sonora
mexico
del
dif
del
estado
de
hidalgo
pediatr
oncolog
pachuca
mexico
del
dr
rodolfo
nieto
pediatr
oncolog
tabasco
mexico
materno
infantil
de
issemym
pediatr
oncolog
toluca
mexico
children
hospit
pediatr
columbu
mexico
backgroundobject
medulloblastoma
common
malign
brain
tumor
children
data
develop
countri
limit
describ
experi
pediatr
medulloblastoma
mexico
object
describ
clinic
featur
mexican
children
medulloblastoma
draw
comparison
differ
chemotherapi
regimen
use
determin
patient
overal
os
surviv
ef
determin
clinic
risk
factor
death
relaps
designmethod
conduct
retrospect
multivari
analysi
patient
medulloblastoma
hospit
around
mexico
statist
method
use
curv
surviv
test
model
patient
divid
two
group
children
year
age
diseas
tumor
compromis
group
patient
without
previous
mention
characterist
classifi
result
total
patient
includ
averag
age
diagnosi
year
histolog
classic
desmoplast
anaplasticlarg
cell
specifi
accord
chang
classif
chemotherapi
regimen
use
ice
other
regimen
better
os
compar
ice
vs
averag
radiat
therapi
dose
craniospin
posterior
fossa
hazard
ratio
calcul
p
follow
residu
tumor
anaplast
presenc
metastasi
ice
protocol
conclus
commonli
use
chemotherapi
regimen
ice
relat
significantli
lower
os
patient
residu
tumor
anaplast
histolog
metastasi
also
associ
lower
os
need
prospect
clinic
trial
better
defin
surviv
risk
factor
outcom
mexico
e
salnikova
l
e
e
e
rogachev
nation
research
center
pediatr
oncolog
immunolog
neurooncolog
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
surgeri
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
patomorfolog
moscow
russia
n
burdenko
scientif
research
neurosurgeri
institut
neuropatomorfolog
moscow
russia
german
cancer
research
center
patomorfolog
heidelberg
germani
state
budgetari
institut
russian
scientif
center
roentgenoradiolog
oncolog
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
polyclin
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
radiotherapi
moscow
russia
state
budgetari
institut
russian
scientif
center
roentgenoradiolog
radiolog
moscow
russia
children
citi
hospit
oncolog
moscow
russia
region
clinic
hospit
oncogematolog
khabarovsk
russia
region
oncolog
clinic
children
dep
orenburg
russia
region
oncolog
clinic
children
dep
balashiha
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
medic
rehabilit
scientif
center
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
director
gener
moscow
russia
backgroundobject
current
diagnost
capabl
enabl
modifi
risk
group
individu
treatment
patient
medulloblastoma
evalu
treatment
result
patient
year
median
primarili
diagnos
medulloblastoma
mb
depend
current
risk
factor
designmethod
retrospect
analyz
data
patient
observ
rogachev
center
septemb
till
februari
molecular
genet
test
perfom
case
dkfz
germani
diagnos
case
shh
wnt
mycmycn
loss
case
hit
treatment
regimen
use
patient
classicanapldesmo
without
region
mtxwith
intraventricularintrathec
mtx
withwithout
rt
pd
case
aliv
classicanapldesmo
without
region
mtxwith
intraventricularintrathec
mtx
withwithout
rt
pd
case
aliv
shh
classicanapldesmo
without
region
mtxwith
intraventricularintrathec
mtx
withwithout
rt
pd
case
aliv
result
os
pf
pf
withwithout
pf
classicanapldesmo
withwithout
region
mtx
rt
pf
singl
patient
aliv
without
pd
classicanapl
withoutwith
local
mtx
withwithout
rt
shh
pf
rpatient
aliv
without
pd
desmo
intraventrmtx
patient
without
region
mtx
aliv
without
pd
withwithout
rt
conclus
worst
prognosi
group
patient
year
r
strategi
treatment
verif
addit
studi
need
r
w
k
h
sankaran
institut
medic
scienc
depart
medic
oncolog
ernakulam
india
institut
medic
scienc
depart
radiat
oncolog
ernakulam
india
backgroundobject
treatment
outcom
medulloblastoma
optim
therapi
surgeri
radiat
chemotherapi
led
overal
surviv
os
rate
develop
countri
standard
high
risk
diseas
respect
resourc
limit
set
similar
outcom
possibl
new
challeng
includ
treatment
relat
side
effect
studi
assess
outcom
medulloblastoma
tertiari
care
set
patient
designmethod
total
case
medulloblastoma
year
treat
januari
januari
patient
classifi
standard
risk
high
risk
diseas
base
modifi
chang
criteria
prognost
valu
age
sex
risk
categori
histopatholog
variant
assess
univari
analysi
use
test
nonparametr
os
curv
comput
use
estim
test
use
compar
surviv
accord
histolog
subtyp
result
total
case
elig
analysi
median
age
diagnosi
year
median
month
os
confid
interv
ci
standard
risk
diseas
respect
case
regular
medic
provid
post
complet
therapi
case
document
mild
cognit
declin
though
formal
test
case
regularli
follow
endocrin
sequela
case
diagnos
growth
hormon
defici
conclus
base
institut
data
found
medulloblastoma
outcom
similar
report
develop
countri
howev
new
challeng
exist
manag
treatment
relat
side
effect
patient
underli
current
need
care
popul
cancer
survivor
v
drenyova
v
rogachev
nation
research
center
clinic
rehabilit
research
center
patient
remiss
russkoy
pole
moscow
russia
state
univers
faculc
biolog
moscow
russia
backgroundobject
cerebellum
play
crucial
role
motor
control
plan
lesion
cerebellum
lead
oculomotor
impair
medulloblastoma
sever
diseas
local
mostli
area
vermi
hemispher
cerebellum
presenc
malign
growth
therapi
toxic
lead
stabl
invalid
designmethod
assess
feasibl
test
gaze
stabil
target
patient
medulloblastoma
patient
underw
standard
cours
rehabilit
rehab
centr
russian
field
chekhov
russian
feder
five
patient
three
girl
two
boy
age
year
eight
normal
subject
three
girl
five
boy
age
year
particip
studi
eye
movement
record
arrington
research
hz
eye
tracker
experi
particip
perform
gaze
stabil
test
gst
involv
focus
four
target
left
right
eccentr
respect
two
gst
session
carri
first
second
rehabilit
cours
separ
month
interv
result
gaze
dispers
patient
higher
compar
normal
subject
p
instabl
relat
foremost
oculomotor
control
disord
patient
manifest
macrosaccad
oscil
nystagmu
intrus
saccad
squar
wave
jerk
decreas
gaze
dispers
four
patient
p
occur
second
gst
session
presum
caus
reduct
intrus
saccad
frequenc
context
inappropri
saccad
repres
higher
efficaci
voluntari
attent
control
conclus
patient
medulloblastoma
demonstr
poor
gaze
stabil
compar
normal
subject
posit
dynam
gaze
stabil
patient
achiev
rehabilit
cours
eye
movement
pattern
could
consid
object
indic
specif
oculomotor
disord
eye
track
method
repres
addit
diagnost
tool
rehabilit
practic
slavc
aa
j
l
k
c
univers
vienna
pediatr
vienna
austria
univers
vienna
neurosurgeri
vienna
austria
univers
vienna
radiotherapi
vienna
austria
univers
vienna
institut
neurolog
vienna
austria
backgroundobject
embryon
tumor
multilay
rosett
etmr
rare
new
entiti
character
express
alter
locu
etmr
occur
young
children
dismal
prognosi
report
singl
institut
experi
seven
consecut
patient
designmethod
seven
patient
diagnos
etmr
diagnosi
establish
prospect
characterist
histopatholog
featur
immunostain
amplif
locu
five
patient
retrospect
confirm
addit
patient
origin
diagnos
cn
pnet
central
nervou
system
primit
neuroectoderm
tumor
tumor
locat
supratentori
patient
median
age
diagnosi
month
rang
male
femal
ratio
result
patient
gtr
near
total
resect
first
five
patient
treat
accord
high
risk
pnet
atrt
atyp
teratoid
rhabdoid
tumor
protocol
includ
chemotherapi
three
patient
five
patient
recur
median
month
rang
except
one
patient
die
high
dose
chemotherapi
succumb
diseas
median
month
rang
follow
case
report
moze
et
al
last
two
patient
treat
primari
focal
radiotherapi
intrathec
therapi
concomit
temozolomid
follow
cours
temozolomid
patient
cr
month
diagnosi
conclus
complet
surgic
remov
follow
earli
focal
radiotherapi
temozolomid
seem
superior
intens
convent
therapi
includ
chemotherapi
moze
p
hauser
p
hortobagyl
et
al
evalu
good
tumor
respons
embryon
tumor
abund
neuropil
true
rosett
etantr
j
neurooncol
e
slobina
f
n
scientif
center
roentgenoradiolog
radiotherapi
children
diseas
moscow
russia
backgroundobject
demonstr
possibl
clinic
applic
modern
method
radiat
therapi
anaplast
ependymoma
designmethod
januari
februari
five
patient
median
age
year
anaplast
ependymoma
receiv
complex
treatment
accord
protocol
consist
cours
weekli
chemotherapi
extern
beam
irradi
volum
craniospin
irradi
csr
dose
per
fraction
total
dose
gy
follow
local
irradi
postop
bed
remov
tumor
dose
per
fraction
total
dose
carri
preliminari
radiotherapi
plan
perform
use
conform
radiotherapi
optim
imrt
patient
analyz
receiv
histogram
dvh
vmat
use
csr
patient
patient
local
irradi
patient
treatment
perform
use
coplanar
treatment
arch
patient
use
therapeut
arch
radiotherapi
use
vmat
technolog
perform
use
eclips
plan
system
truebeam
linear
acceler
result
compar
result
preliminari
plan
imrt
vmat
total
treatment
time
reduc
minut
imrt
minut
vmat
number
monitor
unit
mu
decreas
time
averag
vmat
coverag
plan
treatment
volum
treatment
isodos
significantli
differ
imrt
vmat
signific
reduct
radiat
load
organ
earli
late
side
effect
radiat
therapi
rtog
scale
minim
conclus
use
vmat
open
new
possibl
treatment
oncolog
diseas
children
due
describ
properti
risk
develop
induc
secondari
tumor
decreas
time
find
child
treatment
unit
significantli
reduc
sumerau
j
l
e
hospit
motol
depart
pediatr
hematolog
oncolog
pragu
czech
republ
hospit
motol
depart
imag
method
pragu
czech
republ
univers
depart
patholog
molecular
medicin
pragu
czech
republ
backgroundobject
pediatr
glioma
common
brain
tumor
children
character
alter
rasmapk
pathway
although
frequent
cure
complet
resect
patient
unresect
lesion
experi
multipl
progress
increas
risk
neurolog
sequela
designmethod
present
experi
target
therapi
patient
recurr
low
grade
glioma
treat
time
progress
either
braf
inhibitor
dabrafenib
trametinib
accord
molecular
alter
detect
tumor
tissu
result
two
patient
year
old
boy
recurr
thalam
pxa
old
boy
rapidli
progress
optic
pathway
glioma
start
dabrafenib
treatment
dose
mgkgday
upon
braf
activ
mutat
detect
recurr
tumor
boy
experienc
profound
radiolog
respons
rapid
clinic
improv
toxic
seen
except
itchi
macular
rash
older
boy
last
two
week
immedi
begin
treatment
two
patient
year
old
boy
opg
year
old
girl
posterior
fossabrainstem
glioma
braf
fusion
treat
trametinib
dose
mgkgday
patient
obtain
diseas
stabil
treatment
girl
repeatedli
experienc
grade
papulopustular
rash
conclus
dabrafenib
activ
well
toler
among
patient
braf
pediatr
recurr
glioma
trametinib
least
stabil
tumor
braf
fusion
minim
toxic
e
tan
k
j
k
ts
women
children
hospit
paediatr
haematolog
oncolog
singapor
singapor
ormond
street
hospit
depart
neurosurgeri
london
unit
kingdom
great
ormond
street
institut
child
health
development
biolog
cancer
programm
london
unit
kingdom
ormond
street
hospit
depart
haematolog
oncolog
london
unit
kingdom
backgroundobject
paediatr
meningioma
constitut
paediatr
cn
tumour
differ
adult
meningioma
certain
aspect
current
manag
recommend
includ
complet
resect
care
patholog
review
multidisciplinari
discuss
regard
postop
treatment
designmethod
retrospect
analysi
children
meningioma
diagnos
conduct
data
patient
demograph
tumour
characterist
treatment
outcom
obtain
hospit
record
histopatholog
specimen
review
align
subtyp
grade
classif
result
median
age
diagnosi
year
rang
male
femal
ratio
nine
patient
neurofibromatosi
one
neurofibromatosi
two
previou
cranial
radiotherapi
histopatholog
review
confirm
major
meningioma
low
grade
grade
ii
two
rhabdoid
meningioma
grade
iii
one
die
within
month
despit
complet
resect
cr
radiotherapi
wherea
patient
still
aliv
year
cr
three
multipl
meningioma
intracrani
spinal
compart
one
third
patient
meningioma
skull
base
tumour
locat
intraventricular
convex
spinal
extracrani
two
involv
optic
nerv
sheath
one
occur
maxillari
sinu
antrum
sylvian
fissur
patient
biopsi
incomplet
resect
achiev
complet
resect
achiev
oper
procedur
patient
adjuv
radiotherapi
part
primari
treatmentmedian
year
rang
relaps
occur
complet
resect
incomplet
resect
adjuv
radiotherapi
conclus
strong
associ
reinforc
recommend
genet
referr
look
associ
syndrom
age
extent
resect
histolog
grade
factor
consider
postop
treatment
relaps
higher
without
complet
resect
g
alencastro
veiga
k
bezerra
rc
peixoto
l
af
c
alv
antun
v
silva
ca
l
gonzaga
tone
preto
medic
school
univers
sao
paulo
pediatr
ribeirao
preto
brazil
usp
pediatr
preto
brazil
de
recherch
en
de
montpelli
franc
montpelli
franc
usp
genet
preto
brazil
backgroundobject
medulloblastoma
mb
common
malign
brain
tumor
children
classifi
subgroup
wnt
shh
group
group
despit
current
therapi
display
good
outcom
patient
mb
shh
mutant
poor
prognosi
due
primari
resist
chemotherapi
progress
metastasi
studi
identifi
rna
bind
protein
name
overexpress
mb
shh
mutant
cell
line
allel
loss
patient
perform
knockout
gene
mutant
cell
line
prior
investig
role
apoptosi
prolifer
designmethod
assess
mrna
level
mb
cell
line
patient
mb
perform
real
time
pcr
use
taqman
probe
platform
methyl
array
illumina
use
ass
copi
number
profil
patient
mb
trough
lentivir
transduct
flow
sort
cell
gener
crispr
ko
mutant
mb
cell
line
perform
vitro
prolifer
assay
use
cell
count
fitc
kit
apoptosi
assay
experi
perform
thrice
anova
perform
statist
analysi
result
studi
identifi
reduct
cellular
prolifer
increas
apoptosi
level
ko
cell
line
moreov
treat
doxorubicin
identifi
decreas
prolifer
compar
untreat
control
compar
treat
control
apoptosi
ko
cell
went
earli
apoptosi
late
apoptosi
also
detect
increas
protein
level
phosphoryl
ko
cell
line
conclus
data
suggest
new
role
neg
regul
famili
member
potenti
oncogen
suppressor
apoptosi
driver
prolifer
promot
chemoresist
finanti
support
fapesp
process
af
gav
cap
cg
ja
sr
ca
lg
tone
preto
medic
school
usp
genet
preto
brazil
preto
medic
school
usp
surgeri
preto
brazil
infantil
boldrini
pediatr
campina
sp
brazil
preto
medic
school
usp
pediatr
preto
brazil
backgroundobject
medulloblastoma
mb
common
tumor
central
nervou
system
childhood
mb
molecular
classif
base
sever
studi
divid
four
molecular
subgroup
wnt
shh
group
group
facilit
diagnosi
treatment
search
potenti
target
found
member
mst
kinas
famili
mammalian
steril
twenti
like
sever
studi
shown
involv
mst
carcinogenesi
differ
tumor
type
studi
show
relationship
development
pathway
associ
mb
therefor
aim
studi
analyz
express
mst
kinas
mb
sampl
investig
differ
mst
express
among
molecular
subgroup
designmethod
analyz
express
sampl
mb
cell
line
mb
human
cerebellum
control
analysi
use
taqman
gene
probe
endogen
control
gu
hprt
comparison
mst
express
tumor
sampl
versu
cerebellum
molecular
subgroup
perform
use
test
result
upregul
tumor
cell
line
compar
cerebellum
express
differ
compar
tumor
cell
line
control
analysi
gene
express
among
molecular
subgroup
show
differ
express
compar
group
shhwnt
group
upregul
group
shhwnt
express
also
differ
molecular
subgroup
group
wnt
downregul
compar
other
group
wnt
x
shh
wnt
x
group
wnt
x
group
conclus
express
show
relationship
molecular
subgroup
mb
may
relat
molecular
pathway
like
wnt
shh
studi
novel
assay
conduct
understand
better
find
j
trubicka
j
r
w
k
b
children
memori
health
institut
patholog
warsaw
poland
berlin
institut
medic
genet
human
genet
berlin
germani
berlin
center
regen
therapi
berlin
germani
medic
univers
depart
medic
genet
warsaw
poland
children
memori
health
institut
depart
medic
genet
warsaw
poland
children
memori
health
institut
depart
oncolog
warsaw
poland
backgroundobject
agent
interfer
dna
repair
mechan
employ
therapeut
compound
pediatr
oncolog
furthermor
alter
dna
repair
gene
patient
may
affect
repair
effici
respons
therapi
purpos
studi
establish
relationship
presenc
abnorm
select
dna
repair
gene
toxic
chemotherapi
children
medulloblastoma
designmethod
code
sequenc
gene
investig
use
target
gene
sequenc
nbn
pathogen
variant
sanger
sequenc
altogeth
patient
three
patient
presenc
rare
advers
event
ae
detect
variant
analyz
gene
whole
exom
sequenc
perform
presenc
identifi
variant
correl
occurr
rare
ae
clinic
featur
molecular
group
tumour
result
potenti
pathogen
variant
dna
repair
gene
identifi
eight
fifteen
patient
suffer
toxic
chemotherapi
alter
gene
includ
variant
variant
fancm
variant
variant
variant
addit
two
known
nbn
gene
variant
patient
defect
either
nbn
gene
suffer
rare
ae
frequent
control
group
conclus
result
base
largest
systemat
studi
medulloblastoma
provid
preliminari
evid
link
defect
dna
repair
gene
treatment
relat
toxic
suggest
patient
presenc
dna
repair
gene
variant
special
vigil
current
appli
therapeut
regiment
requir
also
potenti
revis
mode
treatment
consid
patient
futur
work
support
nation
scienc
centr
n
fund
cmhi
j
e
l
j
n
van
b
mc
b
van
damm
universitair
saint
luc
pediatr
hematolog
oncolog
woluw
saint
lambert
belgium
ziekenhuizen
leuven
pediatr
hematolog
oncolog
leuven
belgium
de
enfant
rein
fabiola
pediatr
hematologyoncolog
brussel
belgium
pediatr
hematologyoncolog
belgium
hospit
ghent
pediatr
hematologyoncolog
ghent
belgium
hospit
antwerpen
pediatr
hematologyoncolog
antwerp
belgium
cancer
registri
belgian
cancer
registri
brussel
belgium
hospit
leuven
neurosurgeri
leuven
belgium
universitair
saint
luc
pediatr
neurolog
woluw
saint
lambert
belgium
backgroundobject
brain
tumour
repres
cancer
children
younger
one
year
studi
describ
brain
tumour
age
group
limit
reveal
differ
compar
older
paediatr
popul
aim
describ
brain
tumour
children
one
year
age
belgium
defin
differ
older
children
designmethod
retrospect
analysi
record
patient
diagnos
primari
intracrani
neoplasm
first
year
life
belgium
elig
patient
retriev
hospit
databas
belgian
paediatr
oncolog
depart
belgian
cancer
registri
brain
metastas
vascular
malform
spinal
tumour
hamartoma
exclud
variou
paramet
clinic
present
intracrani
localis
histolog
subtyp
late
morbid
outcom
record
result
sixti
patient
met
inclus
criteria
median
age
diagnosi
month
fifteen
percent
tumor
metastat
diagnosi
median
time
month
median
interv
day
frequent
tumour
type
pilocyt
astrocytoma
atyp
teratoidrhabdoid
tumour
glioblastoma
sign
intracrani
hypertens
present
case
common
sign
vomit
bulg
fontanel
hydrocephalu
present
clinic
present
correl
anatom
localis
overal
surviv
surviv
vari
significantli
histolog
type
grade
complet
surgic
resect
howev
age
localis
age
diagnosi
prediagnosi
symptom
interv
primari
dissemin
correl
overal
surviv
conclus
infant
brain
tumour
present
sign
intracrani
hypertens
outcom
determin
histolog
complet
resect
outcom
compar
favour
seri
literatur
possibl
due
higher
proport
low
grade
lesion
seri
describ
clinic
characterist
treatment
outcom
infant
brain
tumour
infant
era
molecular
diagnost
therapeut
l
van
den
wyngaert
g
k
c
j
hospit
leuven
pediatr
leuven
belgium
backgroundobject
thank
medic
advanc
last
decad
children
brain
tumor
reach
adulthood
often
measur
qualiti
life
hrqol
neuropsycholog
function
therefor
becom
increasingli
import
studi
aim
examin
impact
neurocognit
function
hrqol
patient
immedi
diagnosi
designmethod
children
diagnos
brain
tumor
univers
hospit
leuven
follow
neuropsycholog
assess
total
patient
mean
age
diagnosi
year
includ
diagnos
pilocyt
astrocytoma
medulloblastoma
ependymoma
craniopharyngioma
atyp
brain
tumor
neuropsycholog
assess
acquir
within
maximum
six
month
diagnosi
well
two
year
assess
includ
object
measur
cognit
intellig
memori
function
attent
execut
function
subject
measur
hrqol
pedsqltm
brain
tumor
modul
pair
pearson
correl
use
assess
relationship
neurocognit
variabl
hrqol
popul
result
base
pair
attent
execut
function
declin
time
consist
literatur
found
signific
correl
neurocognit
variabl
gener
measur
hrqol
diagnosi
signific
associ
memori
hrqol
found
p
interestingli
measur
show
differ
correl
specif
hrqol
correl
perform
intellig
execut
function
p
r
p
correl
subscal
hrqol
show
diagnosi
associ
verbal
intellig
cognit
p
attent
cognit
p
conclus
newli
aris
correl
two
year
suggest
stronger
link
attent
execut
function
strongli
declin
neurocognit
function
popul
subject
measur
hrqol
possibl
parent
expect
daili
life
function
also
chang
throughout
time
b
yilmaz
n
g
e
b
univers
pendik
train
research
hospit
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
central
nervou
system
cn
tumor
common
solid
tumor
childhood
instut
one
major
referr
center
pediatr
brain
tumor
turkey
aim
analyz
children
brain
tumor
diagnos
treat
center
studi
designmethod
retrospect
studi
pediatr
patient
brain
tumor
treat
sixteen
patient
lost
patient
includ
analysi
demograph
inform
histolog
subtyp
stage
diagnosi
treatment
modal
outcom
evalu
retrospect
result
patient
male
femal
mean
age
year
rang
year
year
mean
durat
follow
month
mean
surviv
time
month
ci
common
local
infratentori
area
among
patient
glioma
common
histolog
form
grade
iv
stage
overal
surviv
os
import
factor
os
tumor
total
resectab
total
resect
patient
os
vs
gross
total
resect
gtr
vs
partial
resect
within
year
children
diffus
infiltr
pontin
glioma
dipg
atyp
teratoidrhabdoid
tumor
atrt
worst
prognosi
patient
die
first
year
treatment
conclus
develop
countri
use
molecular
studi
could
routin
perform
clinic
practic
brain
tumor
rel
common
cancer
among
childrenusu
first
import
step
therapi
patient
complet
resect
significantli
longer
surviv
despit
technolog
advanc
zakrzewska
w
k
r
k
pp
univers
lodz
depart
molecular
patholog
neuropatholog
lodz
poland
univers
lodz
depart
biostatist
translat
medicin
lodz
poland
mother
memori
hospit
research
institut
depart
neurosurgeri
lodz
poland
backgroundobject
current
knowledg
concern
molecular
biolog
pediatr
brain
tumor
still
unsatisfactori
moreov
data
concern
biolog
cn
neuron
mix
tumor
continu
enigmat
due
rare
occurrencethos
tumor
show
consider
genom
heterogen
even
case
histolog
featur
aim
studi
evalu
microrna
profil
pilocyt
astrocytoma
pa
ganglioglioma
gg
dysembryoplast
neuroepitheli
tumor
dnt
designmethod
total
group
case
equal
proport
histolog
type
incorpor
studi
materi
molecular
analys
obtain
standard
neurosurg
procedur
total
rna
extract
accord
standard
procedur
microarray
test
perform
use
mircuri
microrna
array
technolog
filtrat
mirna
elig
analysi
obtain
data
compar
use
analysi
varianc
anova
procedur
use
estim
fals
discoveri
rate
fdr
microrna
signific
anova
consid
elig
pairwis
comparison
use
result
pattern
express
chang
differ
consider
among
mirna
analys
subgroup
tumor
highest
express
dnt
elev
gg
show
elev
express
level
pa
convers
downregul
dnt
tumor
comparison
group
conclus
current
studi
provid
inform
regard
mirna
alter
relat
pediatr
low
grade
brain
tumor
especi
rel
rare
neuron
mix
tumor
tumor
type
show
characterist
mirna
express
profil
could
interest
particularli
case
pa
could
compon
dnt
well
main
manifest
plausibl
recurr
work
support
polish
ncn
grant
n
zhukova
r
l
p
k
n
jr
cancer
centr
royal
children
hospit
melbourn
vic
paediatr
adolesc
clinic
haematolog
oncolog
princess
margaret
hospit
children
perth
wa
radiolog
princess
margaret
hospit
children
perth
wa
radiolog
royal
children
hospit
melbourn
vic
backgroundobject
low
grade
glioma
lgg
difficult
treat
due
variabl
degre
chemosensit
common
proxim
vital
brain
structur
make
amen
surgic
resect
result
mani
children
experi
multipl
progress
diseas
requir
sever
line
therapi
life
histor
mainstream
therapi
radiat
defer
last
resort
due
numer
signific
side
effect
especi
young
children
multipl
chemotherapi
regiment
employ
encourag
outcom
singl
agent
vinblastin
carboplatin
vincristinecarboplatin
combin
demonstr
progress
free
surviv
pf
year
variabl
toxic
profil
remain
suboptim
irradi
tumour
pf
vascular
endotheli
growth
factor
vegf
import
tumour
neovascularis
increas
glioma
bevacizumab
human
monoclon
antibodi
vegf
shown
antineoplast
effect
multipl
malign
adult
paediatr
popul
designmethod
addit
bevacizumab
treatment
regimen
progress
lgg
result
durabl
stabilis
diseas
clinic
radiolog
improv
decreas
morbid
bevacizumab
ad
line
therapi
progress
plgg
combin
singl
agent
carboplatin
vinblastin
vincristinecarboplatin
bevacizumab
bevacizumab
administ
singl
iv
dose
biweekli
monthli
per
discret
treat
physician
clinic
radiolog
respons
assess
result
present
treatment
outcom
patient
progress
plgg
optic
pathwaymidlinethalamicspin
locat
dissemin
diseas
treat
approach
patient
given
dose
bevacizumab
respons
variabl
major
patient
partial
respons
toxic
accept
tumour
relat
morbid
prevent
case
conclus
avastin
use
treatment
plgg
l
p
l
z
b
j
k
zitterbart
memori
cancer
institut
region
centr
appli
molecular
oncolog
brno
czech
republ
hospit
brno
faculti
masaryk
univers
depart
pediatr
oncolog
brno
czech
republ
european
institut
technolog
molecular
oncolog
ii
brno
czech
republ
hospit
brno
faculti
masaryk
univers
depart
patholog
brno
czech
republ
backgroundobject
medulloblastoma
embryon
neuroectoderm
tumor
cerebellum
common
malign
brain
tumor
children
molecular
genet
studi
led
consensu
defin
four
main
subgroup
medulloblastoma
wnt
shh
group
group
base
transcript
profil
recent
quantit
proteom
develop
robust
approach
addit
genom
identifi
prognost
marker
drugabl
target
human
cancer
employ
shotgun
proteom
method
identifi
main
signal
compon
differ
molecular
clinic
subgroup
medulloblastoma
designmethod
briefli
medulloblastoma
tissu
lyse
use
urea
buffer
store
overnight
centrifug
minut
protein
concentr
determin
use
bca
protein
assay
kit
one
hundr
microgram
protein
digest
use
filter
aid
sampl
prepar
peptid
label
use
isobar
mass
tag
mix
togeth
final
sampl
analyz
use
orbitrap
elit
coupl
ultim
rslcnano
chromatograph
acquir
data
process
proteom
discover
result
list
quantifi
protein
tumor
proteom
obtain
subject
bioinformat
statist
evalu
cluster
reveal
proteom
analys
recapitul
subgroup
assign
medulloblastoma
identifi
protein
classifi
enrich
analysi
pathway
map
conclus
sum
demonstr
mass
proteom
approach
allow
distinguish
molecular
signatur
link
medulloblastoma
subgroup
studi
support
ministri
health
czech
republ
grant
azv
project
abdessalam
l
g
hospit
medic
center
pediatr
surgeri
omaha
usa
hospit
medic
center
pediatr
radiolog
omaha
usa
backgroundobject
neuroblastoma
common
solid
extracrani
tumor
pediatr
popul
one
difficult
locat
remov
tumor
within
central
abdomen
encasementabut
major
vascular
structur
make
remov
challeng
accompani
high
morbid
potenti
mortal
ct
scan
mri
use
primari
modal
preoper
plan
forefront
technolog
growth
world
medicin
print
augment
realiti
ar
first
use
technolog
help
preoper
plan
intraop
manag
patient
central
neuroblastoma
designmethod
ct
scan
done
mm
cut
prospect
patient
central
neuroblastoma
scan
review
surgeon
radiologist
determin
structur
model
technologist
work
close
radiologist
accur
render
digit
model
medic
segment
softwar
suit
comput
gener
model
review
surgeon
final
approv
use
augment
realiti
glass
final
model
print
piecem
fashion
eas
manipul
structur
result
last
three
patient
central
neuroblastoma
implement
technolog
excel
result
three
patient
success
remov
entir
tumor
associ
lymphadenopathi
major
minor
intraop
complic
conclus
print
augment
realiti
use
technolog
tool
go
beyond
two
dimension
world
ct
abil
physic
look
touch
print
give
surgeon
insight
precis
anatom
detail
complex
vascular
structur
provid
safer
oper
also
worth
note
patientfamili
satisfact
understand
heighten
result
physic
model
comparison
show
imag
ct
agarwala
r
vk
v
india
institut
medic
scienc
pediatr
surgeri
delhi
india
india
institut
medic
scienc
laboratori
oncolog
delhi
india
india
institut
medic
scienc
medic
oncolog
delhi
india
india
institut
medic
scienc
patholog
delhi
india
backgroundobject
incid
hepatoblastoma
hb
significantli
elev
patient
famili
adenomat
polyposi
carri
mutat
apc
tumor
suppressor
gene
suggest
role
activ
wnt
signal
pathway
tumor
pathogenesi
mutat
delet
exon
frequent
detect
hepatoblastoma
case
worldwid
mutat
presenc
correl
better
respons
neoadjuv
chemotherapi
better
overal
surviv
designmethod
analys
oncogen
mutat
missens
mutat
interstiti
delet
exon
perform
focus
exon
hbl
tumor
sampl
use
standard
pcr
follow
subsequ
dna
sequenc
mutat
identif
confirm
least
amplif
reaction
origin
dna
result
sampl
patient
age
rang
month
includ
standard
risk
sr
high
risk
hr
patient
patient
receiv
chemotherapi
cisplatin
monotherapi
srhb
plado
hrhb
poor
respons
neoadjuv
chemotherapi
seen
two
older
patient
month
could
resect
remain
underw
resect
five
patient
die
could
resect
discontinu
therapi
resect
patient
recurr
aliv
salvag
therapi
die
discontinu
therapi
progress
diseas
exon
gene
delet
detect
singl
patient
old
srhb
patient
good
respons
neoadjuv
chemotherapi
cr
resect
missens
mutat
gene
detect
correl
found
presenc
mutat
respons
neoadjuv
chemotherapi
ultim
outcom
conclus
beta
catenin
gene
delet
mutat
seem
rare
hepatoblastoma
india
may
import
pathogenesi
hepatoblastoma
sa
akbar
zf
n
aq
khanum
cancer
hospit
research
center
surgic
oncolog
lahor
pakistan
philip
hospit
breast
surgeri
llanelli
carmarthenshir
unit
kingdom
khan
univers
medic
colleg
karachi
pakistan
backgroundobject
total
implant
venou
access
devic
tivad
play
import
role
administ
chemotherapeut
agent
children
oncolog
disord
studi
aim
analyz
efficaci
prophylact
antibiot
time
insert
tivad
prevent
earli
central
line
associ
blood
stream
infect
clabsi
designmethod
consecut
patient
tivad
insert
januari
june
review
retrospect
natur
divis
patient
two
group
due
chang
surgeon
differ
surgic
practic
group
n
receiv
singl
dose
septemb
group
b
n
receiv
clabsi
defin
per
cdc
guidelin
result
group
compar
term
gender
ratio
type
malign
neutrophil
count
major
confound
factor
mean
age
significantli
higher
group
receiv
antibiot
versu
month
rate
clabsi
slightli
lower
group
receiv
antibiot
versu
differ
statist
insignific
devic
remov
first
month
case
group
group
b
tip
cultur
posit
group
receiv
antibiot
compar
group
insignific
although
number
small
assess
conclus
studi
advantag
use
prophylact
antibiot
time
insert
prevent
earli
postop
clabsi
establish
prospect
rct
recommend
r
angelico
r
c
mc
hospit
bambino
gesu
abdomin
transplant
hepatopancreaticbiliari
surgeri
roma
itali
napl
federico
ii
itali
depart
translat
medic
scienc
napl
itali
ismett
mediterranean
institut
transplant
advanc
special
therapi
surgeri
heart
transplant
depart
treatment
studi
cardiothorac
diseas
cardiothorac
transplant
palermo
itali
ismett
mediterranean
institut
transplant
advanc
special
therapi
radiolog
servic
palermo
itali
giovanni
di
cristina
children
hospit
palermo
itali
civili
children
hospit
pediatr
surgeri
brescia
itali
backgroundobject
advanc
hepatoblastoma
hbl
tumour
thrombi
extend
major
vessel
need
multimod
treatment
approach
combin
chemotherapi
surgeri
surgic
recommend
pretreat
extent
diseas
pretext
stage
strongli
advoc
primari
liver
transplant
lt
howev
tumour
thrombi
infiltr
inferior
vena
cava
ivc
right
atrium
lt
might
technic
challeng
associ
unfavour
surviv
rate
local
recurr
hbl
therefor
best
surgic
approach
clear
transplant
surgeon
explor
technic
altern
designmethod
boy
serum
afp
comput
tomographi
show
right
hepat
lobe
mass
suspici
hbl
tumour
thrombi
extend
right
hepat
vein
ivc
right
atrium
bilater
lung
lesion
pretext
iii
refer
month
chemotherapi
siopel
risk
protocol
hbl
decreas
lung
lesion
disappear
tumour
thrombi
still
present
child
underw
ant
situm
liver
resect
en
bloc
resect
hepat
lobe
retrosuprahepat
ivc
tumor
trombi
extend
right
atrium
ivc
replac
fresh
aortic
graft
compat
cadaver
donor
resect
remnant
liver
perfus
portal
vein
celsior
cool
ice
reimplant
anastomosi
left
hepat
vein
result
cours
unev
month
child
good
clinic
condit
normal
liver
function
test
afp
free
diseas
recurr
patent
aortic
graft
conclus
first
case
ant
situm
liver
resect
combin
hypotherm
cpb
ivc
replac
hbl
realist
option
avoid
lt
skill
transplant
surgeon
thank
improv
lt
techniqu
bhatnagar
hospit
bombay
hospit
pediatr
surgeri
mumbai
india
backgroundobject
rate
structur
hospit
india
show
huge
fluctuat
rang
complet
free
cost
public
hospit
govern
charit
institut
subsid
rate
autonom
corporatepriv
hospitalsnurs
home
vari
rate
structur
cost
treatment
pediatr
solid
tumor
vari
wide
one
facil
anoth
even
within
citi
parent
concern
regard
cost
therapi
child
diagnos
tumor
becom
difficult
satisfi
multipl
reason
foremost
lack
hospit
base
cost
analysi
data
henc
studi
compar
cost
analysi
differ
modal
treatment
solid
tumor
children
undertaken
designmethod
time
child
clinic
detect
solid
tumor
cost
studi
perform
includ
cost
hospit
bed
charg
cost
diagnost
studi
cost
chemotherapi
stage
wise
cost
surgeri
relat
cost
cost
intens
care
monitor
cost
consum
cost
radiotherapi
cost
support
therapi
cost
immun
treatment
ancillari
cost
like
accommod
food
travel
loss
wage
parent
etc
studi
studi
undertaken
take
account
recent
expens
tertiari
care
institut
mumbai
india
result
overal
expenditur
treatment
cost
analysi
stage
tumor
show
variou
cost
diagnosi
chemotherapi
consum
surgeri
intens
care
radiotherapi
support
treatment
cost
analysi
tumor
wise
stage
wise
reveal
advanc
diseas
cost
chemotherapi
intens
care
support
care
increas
drastic
conclus
cost
crucial
tool
counsel
stratifi
financi
statu
parent
thu
creat
pathway
achiev
complet
therapi
even
poor
section
societi
collin
j
children
hospit
westmead
paediatr
surgeri
westmead
australia
children
hospit
westmead
paediatr
oncolog
thorac
surgeri
westmead
australia
sydney
children
cancer
research
unit
sydney
australia
backgroundobject
reconstruct
larg
chest
wall
tumour
aim
creat
airtight
caviti
rigid
protect
thorac
content
stabil
permit
respir
aesthet
accept
result
describ
techniqu
use
prosthet
limit
especi
children
growth
deform
may
result
aim
review
outcom
use
absorb
materi
designmethod
retrospect
seri
includ
children
undergon
chest
wall
reconstruct
centr
strut
replac
cartilagebon
structur
porcin
dermal
collagen
patch
muscl
flap
avail
provid
replac
use
matrix
ingrowth
allow
complet
implant
resorpt
complic
function
cosmet
result
obtain
review
photographi
axial
imag
result
five
patient
includ
male
femal
median
age
year
rang
median
year
rang
patholog
includ
ewe
sarcoma
osteochondroma
chondromesenchym
hamartoma
sarcoma
median
rib
resect
rang
reconstruct
osteochondroma
requir
signific
adjac
rib
displac
subsequ
larg
thorac
defect
four
patient
remain
diseas
free
patient
suffer
metastat
ewe
relaps
local
control
persist
complic
includ
seroma
month
one
patient
steril
collect
month
anoth
drain
resolv
reconstruct
provid
good
initi
thorac
integr
enabl
earli
extub
cosmet
function
result
satisfactori
good
chest
wall
shape
function
restrict
daili
activ
includ
sport
patient
old
enough
pitfal
includ
pet
avid
prosthesi
consid
relaps
surveil
presenc
mild
scoliosi
note
imag
conclus
techniqu
absorb
chest
wall
reconstruct
pediatr
popul
good
function
cosmet
result
collin
j
v
e
j
children
hospit
westmead
paediatr
surgeri
westmead
australia
children
hospit
westmead
radiat
oncolog
westmead
australia
sydney
institut
medic
physic
camperdown
australia
children
hospit
westmead
paediatr
oncolog
thorac
surgeri
westmead
australia
sydney
children
cancer
research
unit
sydney
australia
backgroundobject
pelvic
brachytherapi
well
describ
associ
surgeri
obtain
local
control
rhabdomyosarcoma
pelvi
primari
benefit
organ
spare
techniqu
whilst
deliv
high
dose
target
volum
describ
use
brachytherapi
set
pelvi
paediatr
popul
designmethod
select
patient
pelvi
treat
institut
brachytherapi
case
identifi
theatr
databas
data
collat
retrospect
audit
report
techniqu
brachytherapi
associ
surgic
procedur
outcom
includ
overal
mortal
morbid
includ
bladder
bowel
function
result
three
femal
patient
age
rang
month
treat
pelvic
brachytherapi
institut
two
case
involv
brachytherapi
tumour
volum
transperin
cathet
place
imag
guidanc
third
case
involv
resect
placement
modifi
frieburg
flap
applic
pelvi
sciatic
notch
patient
receiv
high
dose
rate
brachytherapi
excel
dose
coverag
target
volum
organ
risk
dose
within
set
constraint
two
patient
surviv
year
post
intervent
evid
relaps
oldest
child
maintain
good
bladder
bowel
function
despit
initi
concern
urinari
incontin
ultrasound
demonstr
good
bladder
capac
void
manag
well
time
doubl
void
subsequ
contin
second
case
remain
young
assess
contin
one
mortal
remain
case
unexpectedli
develop
brainstem
metastas
six
week
post
treatment
conclus
initi
short
medium
term
follow
up
indic
use
pelvic
brachytherapi
may
extend
sarcoma
pelvi
highli
select
young
children
organ
spare
techniqu
k
corkum
g
e
j
robert
h
luri
children
hospit
chicago
surgeri
chicago
usa
robert
h
luri
children
hospit
chicago
oncolog
chicago
usa
backgroundobject
pulmonari
metastas
occur
frequent
children
solid
tumor
yet
optim
approach
evalu
treat
suspici
nodul
remain
unresolv
lung
biopsi
nodul
excis
may
indic
stage
diseas
guid
therapi
achiev
cure
object
evalu
current
nation
practic
address
pulmonari
nodul
patient
solid
tumor
designmethod
pediatr
health
inform
system
phi
databas
queri
patient
solid
tumor
associ
pulmonari
procedur
approach
maxim
extent
surgeri
stratifi
primari
tumor
locat
result
period
patient
hospit
pulmonari
metastat
diseas
underw
pulmonari
procedur
common
primari
tumor
bone
soft
tissu
kidney
adren
liver
biopsi
occur
patient
requir
intervent
thoracoscopythoracotomi
thoracoscopi
approach
patient
patient
requir
subsequ
thoracotomi
thoracotomi
initi
approach
patient
bone
tumor
account
half
case
patient
bone
tumor
also
like
undergo
multipl
procedur
solid
tumor
bone
primari
tumor
site
document
pulmonari
metastasi
center
anticip
lobectomi
predict
thoracotomi
icu
util
mechan
ventil
complic
common
open
case
compar
thoracoscop
percutan
approach
p
conclus
least
eight
percent
children
solid
tumor
current
undergo
lung
biopsi
resect
approach
extent
resect
vari
patient
hospit
factor
includ
primari
tumor
site
effort
requir
defin
optim
workup
treatment
algorithm
patient
maxim
diagnost
therapeut
yield
minim
complic
k
dong
w
x
hospit
fudan
univers
surgeri
shanghai
china
backgroundobject
soft
tissu
sarcoma
nrst
heterogen
group
tumor
encompass
mani
histolog
type
less
frequent
encount
account
childhood
malignanciesth
purpos
studi
summar
experi
diagnosi
treatment
soft
tissu
sarcoma
designmethod
perform
retrospect
analysi
data
soft
tissu
sarcoma
hospit
result
case
found
period
patholog
studi
show
type
synov
sarcoma
fibrosarcoma
pnet
hyalocyt
sarcoma
acin
soft
tissu
sarcoma
embryon
sarcoma
malign
small
cell
sarcoma
extraoss
ewe
sarcoma
case
load
type
respect
differ
tumor
locat
among
sarcoma
p
differ
therapeut
protocol
p
radic
oper
radic
oper
plu
chemotherapi
popular
therapeut
protocol
differ
use
chemotherapi
p
util
chemotherapi
pnet
malign
small
cell
sarcoma
acin
soft
tissu
sarcoma
embryon
sarcoma
util
chemotherapi
four
sarcoma
surviv
rate
surviv
rate
respect
case
fatal
rate
within
year
conclus
pediatr
nrst
mani
histolog
subtyp
although
prognosi
good
radic
oper
plu
chemotherapi
effect
improv
surviv
rate
soft
tissu
sarcoma
fuchimoto
k
n
k
h
n
h
univers
school
medicin
pediatr
surgeri
tokyo
japan
univers
school
medicin
surgeri
tokyo
japan
backgroundobject
prognosi
hepatoblastoma
depend
greatli
cur
treatment
surgic
resect
perform
world
first
transplant
use
icg
navig
technolog
case
recurr
hepatoblastoma
liver
transplant
designmethod
patient
boy
undergon
hepatectomi
explos
hepatoblastoma
age
year
age
year
rescu
live
bodi
liver
transplant
recurr
tumor
mother
act
donor
afp
level
increas
gradual
year
transplant
partial
hepatectomi
perform
tumor
recurr
transplant
liver
found
periton
dissemin
oper
simultan
resect
dissemin
lesion
diagnos
patholog
afp
level
increas
metastat
lesion
detect
liver
resect
dissemin
intrahepat
metastat
lesion
use
icg
navig
technolog
icg
administ
day
abdomin
oper
use
photodynam
eye
pder
hamamatsu
photon
nodul
liver
peritoneum
reveal
patholog
fetal
type
hepatoblastoma
result
transplant
intrahepat
multipl
recurr
occur
thereaft
perform
exploratori
laparotomi
use
icg
navig
purpos
consid
need
show
dissemin
lesion
control
confirm
recurr
local
liver
approv
ethic
review
board
perform
transplant
use
icg
navig
donor
father
patholog
show
tumor
local
liver
normal
chang
afp
level
conclus
icg
navig
use
detect
micro
lesion
detect
imag
nake
eye
periton
dissemin
intrahepat
metastas
liver
transplant
combin
icg
navig
provid
cur
treatment
hepatoblastoma
indic
potenti
new
surgic
treatment
tumor
h
gabra
north
children
hospit
paedaitr
surgeri
newcastl
upon
tyne
unit
kingdom
backgroundobject
frozen
section
use
routin
assess
suspect
tumour
adult
aid
surgic
decis
make
similar
applic
paediatr
tumour
remain
limit
especi
evalu
paediatr
paratesticular
lesion
diagnosi
reliant
clinic
imag
find
mani
benign
paratesticular
lesion
infanc
childhood
may
difficult
distinguish
malign
lesion
result
unnecessari
orchidectomi
designmethod
retrospect
seri
patient
underw
frozen
section
time
surgeri
suspect
testicular
paratesticular
lesion
review
clinic
inform
includ
age
histolog
diagnosi
record
result
case
old
infant
firm
mass
involv
testi
rhabdomyosarcoma
suspect
clinic
imag
atyp
frozen
section
diagnosi
confirm
benign
lesion
fibrou
hamartoma
infanc
mass
excis
testi
left
situ
case
year
old
boy
present
larg
complex
paratesticular
mass
close
abut
entir
testi
even
though
radiolog
suspect
benign
clinic
featur
suspici
orchidectomi
thought
pragmat
option
frozen
section
show
dysplasia
rete
testi
epididymi
confirm
standard
histolog
malign
chang
case
year
old
present
chronic
testicular
pain
uss
suspici
polar
testicular
lesion
frozen
section
show
normal
histolog
testi
spare
conclus
frozen
section
may
accur
diagnos
testicular
paratesticular
mass
though
orchidectomi
could
avoid
case
frozen
section
may
aid
surgic
decis
make
regard
spare
testi
select
paediatr
case
pathologist
must
endeavour
make
familiar
potenti
advantag
limit
frozen
section
role
intraop
frozen
section
warrant
multidisciplinari
evalu
p
kerimov
cancer
research
center
nn
blokhina
surgic
separ
tumor
thoracoabdomin
local
moscow
russia
backgroundobject
laparoscop
adrenalectomi
introduc
rel
recent
took
lead
posit
choos
volum
surgeri
adren
neoplasm
children
designmethod
present
result
treatment
patient
variou
adren
tumor
children
age
year
underw
laparoscop
oper
volum
laparoscop
adrenalectomi
la
right
la
left
male
patient
femal
common
neuroblastoma
diagnos
case
ganglioneuroma
diagnos
case
follow
diseas
observ
singl
observ
adrenocort
adenoma
adren
cortex
cancer
pheochromocytoma
gangloneuroblastoma
adrenocort
cancer
neurinoma
fibroma
result
durat
oper
rang
min
averag
blood
loss
ml
drainag
tube
instal
entir
patient
remov
first
day
oper
stay
intens
care
ward
day
lethal
outcom
case
access
convers
seriou
intraop
complic
diagnos
case
recurr
diseas
implant
metastas
malign
tumor
adren
gland
median
month
conclus
laparoscop
adrenalectomi
children
adren
tumor
patholog
effect
safe
method
accompani
minim
surgic
trauma
excel
cosmet
result
shorten
durat
postop
period
worsen
oncolog
prognosi
laparoscop
adrenalectomi
children
consid
prefer
surgeri
regardless
age
bodi
weight
patient
benign
malign
organ
tumor
v
khanna
r
roy
p
singh
r
harding
medic
colleg
associ
kalawati
saran
children
hospit
paediatr
surgeri
new
delhi
india
backgroundobject
studi
epidemiolog
treatment
challeng
logist
difficulti
manag
paediatr
solid
tumor
designmethod
prospect
observ
studi
till
includ
paediatr
solid
tumor
result
total
patient
includ
primari
diagnosi
wilm
tumor
wt
neuroblastoma
nb
germ
cell
tumor
gct
sacrococcyg
teratoma
sct
hepatoblastoma
hb
pnet
rhabdomyosarcoma
rm
miscellan
patient
wt
requir
chemotherapyradiotherapi
cog
protocol
could
receiv
radiotherapi
due
lack
necessari
infrastructur
hospit
financi
constraint
alreadi
overburden
centr
give
radiotherapi
two
patient
clear
cell
sarcoma
kidney
ccsk
rhabdoid
tumor
kidney
rtk
given
wt
chemotherapi
report
wilm
initi
histopatholog
report
ccsk
patient
aliv
diseas
rtk
patient
expir
month
nb
patient
high
risk
low
awar
diagnost
delay
render
present
hospit
advanc
stage
eleven
nb
patient
die
aliv
diseas
salvag
rate
remain
low
due
limit
access
myeloabl
treatment
bone
marrow
rescu
biolog
therapi
two
patient
sct
recurr
detect
late
due
logist
difficulti
get
alphafetoprotein
level
afp
done
patient
die
due
febril
neutropenia
addit
poor
nutrit
statu
initi
salvag
chemotherapi
five
patient
hb
standard
risk
sr
high
risk
hr
receiv
plado
three
underw
surgeri
aliv
diseas
free
conclus
lack
educ
poor
govern
support
system
referr
facil
decreas
surviv
cancer
patient
develop
nation
cancer
treatment
protocol
institution
depend
avail
resourc
technolog
research
dispos
multidisciplinari
tumor
treatment
facil
partnership
need
hour
r
v
sm
cheah
yt
cb
se
jcm
cy
ahp
univers
singapor
yong
loo
lin
school
medicin
singapor
singapor
women
children
hospit
depart
paediatr
medicin
singapor
singapor
women
children
hospit
depart
paediatr
surgeri
singapor
singapor
women
children
hospit
divis
nurs
singapor
singapor
women
children
hospit
depart
paediatr
subspecialti
haematolog
oncolog
servic
singapor
singapor
women
children
hospit
depart
paediatr
subspecialti
infecti
diseas
servic
singapor
singapor
quantit
medicin
medic
school
singapor
backgroundobject
prior
insert
pediatr
cancer
patient
preoper
antibiot
prophylaxi
employ
either
routin
base
blood
count
paramet
basi
practic
well
studi
aim
analys
preoper
risk
factor
associ
earli
bloodstream
infect
crbsi
insert
designmethod
retrospect
review
clinic
chart
pediatr
cancer
patient
place
januari
decemb
standard
skin
prepar
implant
techniqu
use
patient
though
preoper
antibiot
use
vari
demograph
diseas
factor
factor
preoper
blood
count
paramet
correl
occurr
earli
crbsi
within
first
postop
day
result
total
central
venou
cathet
place
studi
period
among
acut
lymphoblast
leukemia
acut
myleogen
leukemia
aml
patient
preoper
antibiot
administ
median
preoper
absolut
neutrophil
count
anc
rang
x
fifteen
crbsi
occur
median
rang
postop
day
cancer
type
significantli
associ
earli
crbsi
encount
patient
aml
leukemia
solid
tumour
respect
notabl
preoper
anc
x
use
prophylact
preoper
antibiot
associ
occurr
earli
crbsi
respect
surgeon
oper
factor
also
associ
earli
crbsi
howev
earli
crbsi
significantli
associ
earli
port
remov
within
day
insert
conclus
preoper
anc
x
use
preoper
antibiot
prophylaxi
found
associ
lower
incid
earli
crbsi
within
first
postop
day
g
de
lambert
f
c
c
v
h
hospit
aphp
paediatr
surgeri
le
kremlin
bicetr
franc
roussi
cancer
campu
brachytherapi
villejuif
franc
roussi
cancer
campu
paediatr
oncolog
villejuif
franc
backgroundobject
fertil
preserv
major
goal
children
cancer
spermatogonia
affect
dose
gy
dose
gy
may
lead
definit
steril
leydig
cell
resist
endocrin
function
maintain
exposur
dose
gy
prepubesc
male
describ
new
techniqu
testicular
transposit
patient
treat
brachytherapi
bladder
neck
andor
prostat
rhabdomyosarcoma
bp
rm
designmethod
medic
record
consecut
patient
treat
septemb
februari
studi
patient
underw
testicular
transposit
perform
bp
surgeri
suprapub
incis
extern
obliqu
aponeurosi
incis
spermat
cord
mobil
extern
inguin
ring
gubernaculum
attach
deliv
scrotum
testi
flip
care
taken
avoid
injuri
vessel
va
wrap
silicon
materi
sutur
abdomin
skin
transfix
stitch
face
anterior
superior
iliac
spine
end
brachytherapi
testi
reloc
scrotum
gener
anesthesia
remov
tube
stent
surgic
outcom
dosimetr
paramet
examin
result
five
patient
identifi
median
age
month
rang
month
embryon
bp
rm
receiv
chemotherapi
accord
rm
protocol
prior
local
treatment
patient
underw
conserv
surgeri
follow
brachytherapi
gy
could
testicular
transposit
one
testi
none
patient
intraop
postop
complic
median
radiat
dose
transpos
testi
gy
rang
gy
rang
testi
left
place
conclus
testicular
transposit
feasibl
order
potenti
preserv
fertil
futur
qualiti
life
children
undergo
brachytherapi
bp
rm
mishra
g
gandhi
cancer
institut
research
sector
pediatr
surgic
oncolog
delhi
india
gandhi
cancer
institut
research
sector
pediatr
hematolog
oncolog
delhi
india
gandhi
cancer
institut
research
sector
surgic
oncolog
delhi
india
backgroundobject
extrapulmonari
inflammatori
myofibroblast
tumor
imt
also
known
inflammatori
pseudotumor
rare
children
imt
known
fibroinflammatori
pseusosarcomat
appear
histopatholog
hpe
immunohistochemistri
ihc
use
tool
confirm
diagnosi
surgeri
mainstay
treatment
local
recurr
common
wish
share
experi
one
case
recurr
imt
abdomen
success
treat
surgeri
anaplast
lymphoma
kinas
alk
inhibitor
designmethod
retrospect
review
hospit
record
result
eleven
year
old
boy
present
loss
appetit
vomit
month
palpabl
left
lower
abdomin
mass
size
cm
imag
confirm
mesenter
mass
suggest
spindl
cell
tumor
fnac
underw
en
bloc
excis
mass
segment
colectomi
hpe
suggest
imt
kept
close
develop
local
relaps
right
abdomen
month
review
previou
hpe
reveal
imt
alk
posit
ihc
addit
sma
diffus
desmin
weak
start
crizotinib
close
partial
respons
reduct
size
becam
static
month
crizotinib
underw
laparotomi
resect
residu
calcifi
mass
ileocol
mesenteri
without
bowel
resect
hpe
confirm
residu
viabl
imt
postop
continu
crizotinib
month
diseas
free
month
last
surgeri
conclus
alk
posit
imt
consid
favor
prognost
marker
absenc
definit
adjuv
therapi
local
recurr
imt
alk
inhibitor
feasibl
option
target
therapi
rare
tumor
evidenc
case
report
howev
guidelin
avail
durat
recommend
treatment
r
malik
b
georg
hospit
nh
trust
depart
paediatr
oncolog
london
unit
kingdom
georg
hospit
nh
trust
depart
paediatr
surgeri
london
unit
kingdom
backgroundobject
anterior
mediastin
mass
pose
diagnost
challeng
due
cardiorespiratori
risk
associ
mass
exagger
gener
anaesthet
biopsi
review
institut
practic
assess
safeti
approach
designmethod
retrospect
case
record
review
patient
anterior
mediastin
mass
diagnosi
tertiari
paediatr
oncolog
surgeri
centr
patient
admit
januari
decemb
assess
clinic
present
method
tissu
diagnosi
complic
result
patient
median
age
year
rang
year
male
admit
diagnosi
amm
studi
period
fifteen
patient
present
respiratori
symptom
eleven
children
evid
tracheobronchi
compress
imag
histolog
diagnos
includ
hodgkin
lymphoma
non
hodgkin
lymphoma
leukaemia
lipoblastoma
teratoma
pnet
rhabdomyosarcoma
mediastin
metastasi
nasopharyng
carcinoma
sixteen
patient
lymph
node
biopsi
altern
tissu
pleural
peripher
blood
use
diagnosi
patient
eight
patient
imag
guid
core
biopsi
mediastin
mass
one
patient
mediastinoscop
biopsi
paratrach
node
ketamin
sedat
use
patient
patient
gener
anaesthet
anaesthet
complic
four
patient
need
admiss
picu
tumour
lysi
syndrom
two
patient
need
repeat
node
biopsi
post
steroid
one
inadequ
sampl
conclus
safe
tissu
diagnosi
anterior
mediastin
mass
obtain
personalis
multidisciplinari
approach
altern
tissu
local
anaesthet
must
use
appropri
ketamin
sedat
good
altern
high
risk
case
obviat
need
full
gener
anaesthet
rc
ribeiro
oliveira
v
children
cancer
hospit
pediatr
surgeri
depart
barreto
brazil
backgroundobject
central
vein
catheter
challeng
infant
even
experienc
hand
us
guidanc
becom
gold
standard
central
vein
catheter
last
two
decad
intern
jugular
vein
ijv
catheter
gener
rout
recommend
children
studi
concern
infant
intern
jugular
vein
subclavian
vein
scv
catheter
technic
success
rate
lower
adult
complic
frequent
recent
studi
show
use
techniqu
supraclavicular
brachiocephal
vein
bcv
catheter
infant
favor
approach
provid
high
technic
success
less
complic
studi
propos
assess
degre
difficulti
vein
catheter
compar
facil
guidewir
progress
brachiocephal
vein
intern
jugular
vein
punctur
designmethod
children
underw
bcv
ijv
catheter
pediatr
surgeri
depart
pediatr
oncolog
hospit
decemb
march
retrospect
analyz
demograph
featur
diseas
choos
vein
vein
side
guidewir
progress
complic
obtain
guidewir
progress
classifi
easi
difficult
result
procedur
perform
ivj
bcv
evalu
male
patient
femal
solid
tumor
hematolog
malign
median
month
age
kilogram
ivj
patient
guidewir
progress
classifi
difficult
compar
difficult
progress
group
show
statist
signific
bcv
vein
catheter
major
complic
occur
bcv
group
conclus
brachiocephal
vein
catheter
supraclavicular
easier
way
compar
intern
jugular
approach
children
possibl
explan
techniqu
enabl
visual
needl
bcv
longitudin
axi
prevent
vein
compress
us
oue
n
n
h
colleg
medicin
pediatr
surgeri
hyogo
japan
citi
gener
hospit
pediatr
surgeri
osaka
japan
medic
center
research
institut
matern
child
health
pediatr
surgeri
izumi
japan
univer
graduat
school
medicin
pediatr
surgeri
suita
japan
backgroundobject
usa
japan
standard
treatment
wilm
tumor
wt
primari
resect
follow
chemotherapi
howev
case
larg
tumor
hemorrhag
tumor
spillag
due
ruptur
extens
beyond
tumor
capsul
increas
surgic
risk
patient
case
chemotherapi
administ
prior
tumor
resect
present
studi
perform
preoper
imag
analys
identifi
factor
associ
surgic
risk
designmethod
patient
wt
treat
enrol
studi
patient
clinic
record
imag
result
includ
comput
tomographi
ct
scan
collect
retrospect
analyz
imag
factor
tumor
size
tumor
volum
relationship
among
larg
vessel
contralater
extens
tumor
evalu
relationship
surgic
factor
includ
oper
time
hemorrhag
tumor
spillag
unresect
analyz
result
oper
time
hemorrhag
per
bodi
weight
significantli
relat
tumor
size
area
volum
oper
time
significantli
longer
hemorrhag
significantli
case
compress
abdomin
aorta
andor
vena
cava
tumor
p
p
respect
extens
tumor
beyond
center
vertebr
bodi
p
p
respect
three
patient
unresect
tumor
four
tumor
spillag
tumor
patient
frequent
associ
larg
vessel
compress
contralater
extens
conclus
besid
tumor
size
larg
vessel
compress
contralater
extens
significantli
correl
surgic
risk
factor
easili
determin
use
ct
imag
therefor
use
predict
surgic
risk
unresect
tumor
decid
whether
use
preoper
chemotherapi
primari
treatment
strategi
larg
local
wt
n
j
l
krauel
gimenez
j
surgeri
montreal
canada
de
faculti
medicin
montreal
canada
sant
joan
de
pediatr
surgeri
barcelon
spain
backgroundobject
pediatr
cancer
frequent
affect
organ
surgeri
indic
case
public
address
complic
post
oper
bowel
obstruct
context
analys
data
year
period
determin
frequenc
etiolog
treatment
option
complic
designmethod
retrospect
data
analysi
patient
undergo
abdomin
surgeri
malign
tertiari
pediatr
hospit
data
collect
includ
demograph
tumor
characterist
detail
oper
procedur
detail
adjunct
treatment
chemotherapi
radiotherapi
incid
bowel
obstruct
detail
regard
manag
patient
obstruct
statist
compar
without
obstruct
use
chi
student
signific
report
p
result
analysi
includ
patient
median
year
mean
major
patient
femal
median
age
time
surgeri
entir
cohort
year
frequent
diagnosi
wilm
tumor
follow
neuroblastoma
hepatoblastoma
germ
cell
tumor
surgic
approach
open
procedur
case
fifteen
patient
postop
occlus
case
adhes
intern
hernia
sb
volvulu
mean
oper
time
min
vs
mean
blood
loss
vs
ml
p
significantli
higher
patient
bowel
obstruct
conserv
manag
attempt
case
obstruct
success
rate
mean
day
patient
requir
surgic
intervent
minim
invas
approach
success
two
patient
conclus
bowel
obstruct
signific
complic
abdomin
surgeri
cancer
children
conserv
manag
frequent
success
patient
requir
surgic
treatment
laparoscopi
valuabl
option
r
ribeiro
v
r
w
oliveira
l
children
cancer
hospit
pediatr
surgeri
barreto
brazil
children
cancer
hospit
pediatr
oncolog
barreto
brazil
backgroundobject
pancreat
tumor
rare
entiti
children
review
clinic
patholog
featur
pediatr
patient
pancreat
solid
pseudopapillari
neoplasm
psppn
also
call
frantz
tumor
singl
institut
designmethod
conduct
retrospect
analysi
demograph
data
clinic
featur
surgic
approach
outcom
patient
diagnos
psppn
result
six
patient
studi
period
solid
pseudopapillari
neoplasm
patient
femal
median
age
present
year
rang
year
abdomin
pain
present
symptom
shown
girl
preoper
imag
studi
includ
comput
tomographi
case
magnet
reson
imag
case
median
maximum
diamet
tumor
mm
rang
mm
none
patient
evid
metastasi
present
regard
pancreat
locat
three
patient
pancreat
head
tumor
two
underw
pancreaticoduodenectomi
one
nodulectomi
two
girl
tumor
tail
underw
distal
pancreatectomi
splenectomi
one
laparoscop
one
patient
pancreat
bodi
tumor
underw
distal
pancreatectomi
one
late
complic
relat
pancreat
pseudocyst
treat
drainag
octreotid
immunohistochemistri
chromogranin
neg
case
analyz
wherea
vimentin
posit
analyz
case
enolas
posit
three
case
analyzedno
adjuv
therapi
done
patient
aliv
without
evid
diseas
median
follow
month
month
conclus
present
experi
follow
data
children
psppn
agreement
multipl
clinic
seri
believ
despit
psppn
gener
benign
behavior
complet
resect
clear
margin
mandatori
achiev
best
outcom
rybakova
p
state
budgetari
institut
russian
cancer
research
center
nn
blokhin
ministri
health
russia
children
oncolog
moscow
russia
backgroundobject
develop
ration
surgeri
solid
pseudopapillari
tumor
spt
pancrea
implement
endosurgeri
designmethod
children
spt
oper
sinc
novemb
analyz
clinic
data
oper
option
result
treatment
result
patient
girl
age
year
median
local
tumor
pancrea
tail
bodi
head
size
sm
sm
children
underw
laparoscop
distal
pancreatectomi
splenic
preserv
laparoscop
central
resect
gastropancreatoduoden
resect
central
resect
pancrea
distal
subtot
resect
resect
superior
mesenter
vein
uncin
process
pancrea
resect
resect
duoden
wall
time
oper
min
bleed
complic
occur
patient
case
pancreat
pancreat
fistula
bleed
pancreat
branch
splenic
arteri
whippl
oper
pneumonia
reoper
complic
observ
period
patient
month
year
patient
aliv
without
evid
diseas
recurr
conclus
main
method
treatment
surgeri
howev
moder
risk
complic
tumor
local
great
attent
paid
prevent
postop
pancreat
promis
method
endosurgeri
provid
earli
rehabilit
cosmet
effect
sharoev
luka
clinic
research
centr
russia
oncolog
moscow
russia
luka
clinic
research
centr
russia
administr
moscow
russia
luka
clinic
research
centr
russia
paediatr
surgeri
moscow
russia
backgroundobject
water
jet
dissect
technolog
wjdt
particularli
advantag
liver
surgeri
isol
major
blood
vessel
adjac
tumor
also
spare
surround
hepat
parenchyma
russia
pioneer
wjdt
pediatr
oncolog
surgeri
object
review
estim
effect
wjdt
liver
resect
children
hepat
tumor
practic
designmethod
liver
resect
variou
anatom
type
use
wjdt
perform
children
hepat
tumor
technolog
erbejet
erb
vio
system
util
patient
data
prospect
collect
analyz
particular
consid
tumor
character
detail
surgic
procedur
result
mean
patient
age
year
week
year
malign
tumor
diagnos
case
follow
type
liver
resect
carri
hemihepatectomi
trisegmentectomi
bisegmentectomi
segmentectomi
procedur
complet
success
blood
transfus
requir
case
postop
bile
leak
occur
one
patient
complic
relat
techniqu
use
note
complet
tumor
clearanc
neg
surgic
margin
histolog
evid
case
mean
volum
tumor
remov
maximum
size
cm
largest
dimens
conclus
experi
wjdt
technic
straightforward
safe
effect
techniqu
liver
resect
variou
anatom
type
children
hepat
tumor
particular
infant
age
year
techniqu
allow
provis
reliabl
hemostasi
maxim
spare
hepat
parenchyma
therefor
believ
applic
wjdt
widespread
liver
resect
pediatr
oncolog
practic
r
souzaki
n
j
k
univers
depart
pediatr
surgeri
fukuoka
japan
univers
depart
pediatr
fukuoka
japan
univers
depart
anatom
patholog
fukuoka
japan
backgroundobject
navig
surgeri
use
indocyanin
green
icg
fluoresc
imag
metastasectomi
lung
hepatectomi
hepatoblastoma
hb
patient
report
howev
use
surgeri
hb
fulli
clarifi
furthermor
case
use
surgic
navig
thoracoscop
surgeri
vat
metastasectomi
lung
report
herein
report
experi
surgic
navig
metastasectomi
bilater
lung
includ
vat
procedur
hepatectomi
hb
patient
designmethod
pretext
iii
hb
patient
bilater
lung
metastasi
follow
chemotherapi
primari
tumor
lung
metastat
lesion
intraop
examin
use
infrar
fluoresc
imag
scope
administr
icg
preoper
result
navig
surgeri
use
icg
fluoresc
imag
perform
hb
patient
metastat
lesion
recogn
comput
tomographi
ct
lung
lesion
left
lung
cm
diamet
thoracotomi
perform
left
lung
right
lung
vat
perform
lesion
expect
detect
ct
palpabl
left
lung
although
one
lesion
detect
ct
exhibit
intens
fluoresc
right
lung
lesion
detect
ct
exhibit
intens
fluoresc
lesion
except
one
lesion
right
lung
detect
ct
patholog
proven
made
hb
cell
none
resect
stump
metastectomi
show
fluoresc
tumor
found
complet
resect
patholog
examin
although
liver
tumor
strongli
attach
diaphragm
lesion
seen
diaphragm
resect
conclus
navig
surgeri
use
icg
patient
hb
use
identifi
metastat
lesion
confirm
complet
resect
even
vat
swm
tip
yt
ph
ahp
women
children
hospit
depart
paediatr
surgeri
singapor
singapor
women
children
hospit
depart
diagnost
intervent
imag
singapor
singapor
backgroundobject
congenit
vascular
anomali
abdomin
great
vessel
uncommon
potenti
impact
surgic
procedur
affect
outcom
neg
yet
incid
clinic
impact
poorli
studi
sought
assess
incid
vascular
anomali
abdomin
great
vessel
patient
retroperiton
embryon
tumor
studi
impact
surgic
oncolog
outcom
designmethod
retrospect
analyz
imag
surgic
treatment
surviv
data
pediatr
patient
retroperiton
tumor
underw
resect
kk
women
children
hospit
januari
octob
preoper
scan
compar
correspond
intraop
observ
diseas
treatment
paramet
surviv
outcom
compar
use
test
method
respect
result
among
children
studi
primari
tumor
aros
kidney
adren
gland
paravertebr
patient
mean
age
diagnosi
year
sd
vascular
anomali
found
case
name
renal
adren
vessel
interestingli
vascular
anomali
associ
tumor
tumor
intraop
complic
common
patient
vascular
anomali
without
complet
tumor
resect
achiev
case
vascular
anomali
case
without
relaps
frequent
patient
vascular
anomali
without
statist
signific
presenc
vascular
anomali
extent
resect
intraop
complic
associ
overal
surviv
relaps
associ
overal
surviv
p
conclus
vascular
anomali
abdomin
great
vessel
occur
patient
retroperiton
tumor
vascular
anomali
associ
higher
rate
intraop
complic
diseas
relaps
impact
surviv
outcom
b
bojaxhiu
f
l
u
l
p
l
r
dc
radiat
oncolog
bern
switzerland
baden
radiolog
baden
switzerland
scherrer
institut
center
proton
therapi
villigen
psi
west
switzerland
backgroundobject
assess
rate
radiat
necrosi
rn
white
matter
lesion
wml
relat
neurolog
symptom
pediatr
patient
primari
brain
tumor
treat
pencil
beam
scan
pb
proton
therapi
pt
without
concomit
chemotherapi
paul
scherrer
institut
switzerland
designmethod
one
hundr
pediatr
patient
year
brain
tumor
treat
pb
pt
median
age
diagnosi
year
rang
post
pt
brain
parenchym
alter
wml
rn
defin
new
area
abnorm
signal
intens
imag
increas
signal
intens
imag
contrast
enhanc
occur
brain
parenchyma
includ
radiat
treatment
field
demonstr
abnorm
pt
median
period
surviv
patient
month
rang
result
one
hundr
patient
develop
parenchym
brain
alter
pt
patient
develop
rn
median
time
month
rang
asymptomat
grade
grade
toxic
occur
patient
respect
eighteen
patient
develop
wml
median
time
month
rang
asymptomat
grade
grade
toxic
occur
patient
respect
surviv
surviv
univari
analysi
chemotherapi
hydrocephalu
pt
ependymoma
signific
predictor
rn
conclus
children
treat
pt
demonstr
low
preval
symptomat
radiat
necrosi
white
matter
lesion
chemotherapi
administr
proton
therapi
ependymoma
hydrocephalu
initi
symptom
signific
risk
factor
associ
radiat
necrosi
children
brain
tumor
j
b
j
bachir
jhm
hospit
bristol
nh
foundat
trust
bristol
haematolog
oncolog
centr
bristol
unit
kingdom
royal
marsden
nh
foundat
trust
children
young
peopl
unit
sutton
unit
kingdom
roch
ltd
innov
pediatr
oncolog
drug
develop
basel
switzerland
ircc
istituto
nazional
dei
tumori
pediatr
oncolog
unit
milan
itali
roussi
depart
pediatr
adolesc
oncolog
villejuif
franc
colleg
london
hospit
nh
foundat
trust
depart
oncolog
london
unit
kingdom
roch
ltd
pediatr
oncolog
basel
switzerland
children
medic
center
depart
pediatr
oncolog
amsterdam
netherland
backgroundobject
local
control
key
part
treatment
locallocoregion
rhabdomyosarcoma
rm
often
involv
radiotherapi
withwithout
surgeri
role
radiotherapi
metastat
rm
uncertain
littl
publish
evid
guid
clinician
analyz
data
berni
trial
assess
benefit
radiotherapi
patient
metastat
rm
designmethod
berni
patient
age
month
year
metastat
rm
random
receiv
chemotherapi
withwithout
bevacizumab
surgeri
andor
radiotherapi
cycl
mainten
chemotherapi
radiotherapi
recommend
site
metastas
feasibl
investig
discret
allow
result
variabl
actual
radiotherapi
given
patient
categor
receiv
radiotherapi
site
diseas
partial
radiotherapi
radiotherapi
surviv
ef
overal
surviv
os
calcul
use
cox
proport
hazard
model
landmark
approach
patient
event
free
day
ie
end
cycl
month
includ
ef
os
variabl
adjust
treatment
random
diseas
type
alveolarembryonaloth
risk
group
age
metastat
lesion
count
analysi
exploratori
post
hoc
result
patient
rm
receiv
radiotherapi
partial
radiotherapi
radiotherapi
site
baselin
characterist
mostli
balanc
compar
proport
patient
receiv
bevacizumab
significantli
longer
os
hazard
ratio
hr
confid
interv
ci
ef
improv
ci
observ
group
versu
radiotherapi
ef
os
respect
radiotherapi
partial
radiotherapi
radiotherapi
site
conclus
radiotherapi
metastat
rm
associ
signific
os
benefit
albeit
small
patient
number
confirm
prospect
random
trial
c
c
g
p
k
p
solak
k
j
j
l
b
p
p
g
u
r
villejuif
franc
berard
radiotherapi
lyon
franc
christi
radiotherapi
manchest
unit
kingdom
cancer
network
univers
antwerp
radiat
oncolog
antwerp
belgium
vienna
radiotherapi
vienna
austria
banja
luka
member
affidea
group
radiotherapi
banja
luka
bosnia
herzegovina
hospit
center
sestr
milosrdnic
hospit
tumor
radiotherapi
zagreb
croatia
univers
hospit
radiotherapi
aarhu
denmark
gener
hospit
children
adolesc
radiotherapi
athen
greec
universitari
valldhebron
radiotherapi
barcelon
spain
institut
oncolog
radiotherapi
budapest
hungari
hospit
lithuanian
univers
health
scienc
lsmu
kauno
kliniko
radiotherapi
kauna
lithuania
therapi
center
czech
radiotherapi
pragu
czech
republ
luke
radiat
oncolog
centr
radiat
oncolog
dublin
ireland
radium
hospit
oncolog
oslo
norway
medic
center
utrecht
princess
maxima
center
pediatr
oncolog
radiotherapi
utrecht
netherland
turin
radiotherapi
turin
itali
leipzig
radiotherapi
leipzig
germani
backgroundobject
increas
focu
made
improv
qualiti
care
access
european
trial
paediatr
oncolog
inform
paediatr
radiotherapi
europ
wide
avail
aim
studi
provid
overview
resourc
organ
designmethod
expert
oncolog
invit
email
complet
questionnair
result
answer
countri
centr
proton
collect
centr
visit
minor
radiat
oncologist
treat
children
contrast
paediatr
oncologist
surgeon
often
dedic
countri
central
one
centr
access
format
unequ
europ
even
everyon
agre
fact
specif
knowledg
need
regard
techniqu
use
sometim
mean
patient
convent
radiotherapi
still
use
cobalt
never
rare
use
imrt
intens
modul
radiotherapi
use
hypofraction
treatment
defin
least
per
fraction
consid
gy
percent
access
paediatr
devic
person
immobil
radiat
treatment
easili
deliv
anaesthesia
centr
necessari
hypnosi
centr
countri
environ
mostli
adapt
children
dedic
dedic
wait
area
patient
inform
gift
possibl
listen
music
song
watch
cartoon
conclus
survey
provid
quantit
data
demonstr
current
healthcar
inequ
children
adolesc
need
radiotherapi
europ
nevertheless
effort
guarante
treatment
qualiti
local
environ
point
acknowledg
thank
european
napho
paediatrician
contribut
dissemin
survey
countri
well
everi
respond
ducass
g
c
v
f
c
j
x
l
h
g
c
claudiu
regaud
universitair
du
cancer
toulous
oncopol
radiat
oncolog
toulous
franc
claudiu
regaud
universitair
du
cancer
toulous
oncopol
depart
physic
toulous
franc
alexi
vautrin
radiat
oncolog
nanci
franc
gustav
roussi
radiat
oncolog
villejuif
franc
curi
depart
physic
pari
franc
curi
radiat
oncolog
pari
franc
du
cancer
de
montpelli
radiat
oncolog
montpelli
franc
marqui
radiat
oncolog
renn
franc
la
timon
radiat
oncolog
marseil
franc
jean
radiat
oncolog
reim
franc
gauducheau
radiat
oncolog
nant
franc
leclerc
radiat
oncolog
dijon
franc
paul
strauss
radiat
oncolog
strasbourg
franc
backgroundobject
compar
radiotherapi
plan
paramening
alveolar
rhabdomyosarcoma
skull
base
optim
ten
center
imrt
vmat
tomotherapi
proton
therapi
identifi
possibl
dose
distribut
differ
designmethod
dose
prescript
gy
fraction
involv
volum
chemotherapi
sequenti
boost
gy
fraction
reduct
volum
six
tomotherapi
vmat
imrt
step
shoot
passiv
scatter
proton
therapi
plan
complet
compar
also
evalu
commerci
avail
treatment
plan
system
tp
pt
plan
pencil
beam
scatter
raystat
provid
raysearch
comparison
perform
artiview
system
aquilab
result
institut
achiev
plan
object
ctv
whatev
modal
chosen
mean
conform
index
ci
respect
vmat
tomotherapi
proton
therapi
mean
standard
deviat
std
ctv
ptv
low
risk
respect
vmat
tomotherapi
proton
therapi
signific
correl
chosen
modal
dvh
target
organ
risk
oar
observ
optim
strategi
select
planner
play
key
role
deliv
dose
oar
cohort
small
enhanc
signific
spare
critic
structur
conclus
complex
pediatr
tumor
human
factor
constraint
impos
target
volum
oar
greater
dosimetr
impact
treatment
plan
radiat
deliveri
technolog
jl
habrand
j
c
bacless
radiat
oncolog
caen
franc
roussi
cancer
campu
radiat
oncolog
villejuif
franc
curi
radiat
oncolog
pari
franc
backgroundobject
assess
impact
particl
radiat
therapi
pt
toxic
sequela
pediatr
adolesc
patient
pt
popul
literatur
context
modern
technolog
emphasi
compar
clinic
studi
designmethod
perform
extens
review
publish
articl
pub
medlin
accord
follow
radiotherapi
english
toxic
acut
late
sequela
novel
technolog
exclud
case
report
editori
letter
inexploit
data
review
concentr
compar
studi
pt
photon
therapi
xrt
emphasi
clinic
evalu
result
pub
select
clinic
studi
repres
rang
small
medium
larg
larg
cohort
total
pt
address
xrt
xrt
technolog
pt
one
pub
pt
vs
xrt
pt
pub
pub
concern
proton
p
carbon
ion
c
main
type
toxic
per
pt
pub
investig
lung
cnsqualiti
life
qol
second
cancer
endocrin
acut
toxic
hn
respect
accord
impact
techniqu
im
pub
ps
pt
pub
xrt
pub
pub
accord
impact
toxic
lung
xrt
pt
ps
cnsqol
pt
xrt
pub
xrt
pt
pub
ps
pt
xrt
endocrin
pt
xrt
pub
acut
pt
xrt
pub
ps
hn
xrt
ps
cptxrt
pub
conclus
clinic
compar
studi
pt
xrt
perform
none
random
pt
relat
p
one
c
impact
toxic
still
controversi
although
acut
endocrin
cnsqol
tend
benefit
pt
earli
evalu
need
strengthen
literatur
c
hess
w
c
n
r
v
e
n
l
b
gener
hospit
radiat
oncolog
usa
florida
radiat
oncolog
fl
usa
anderson
cancer
center
radiat
oncolog
tx
usa
medicin
radiat
oncolog
specialist
radiat
oncolog
il
usa
pennsylvania
radiat
oncolog
pa
usa
univers
radiat
oncolog
st
mo
usa
clinic
radiat
oncolog
mn
usa
washington
radiat
oncolog
wa
usa
oklahoma
citi
radiat
oncolog
oklahoma
ok
usa
new
jersey
memori
sloan
ketter
cancer
center
radiat
oncolog
nj
usa
center
proton
therapi
radiat
oncolog
tx
usa
gener
hospit
program
coordin
oversight
research
protocol
pcorp
usa
backgroundobject
pediatr
proton
consortium
registri
ppcr
establish
expedit
research
prt
better
defin
role
pediatr
cancer
collect
import
late
effect
outcom
designmethod
ppcr
consent
registri
resid
redcap
platform
comprehens
integr
baselin
demograph
insur
statu
diseasehealth
inform
treatment
detail
proton
radiat
plan
vital
statu
late
toxic
surveil
imag
particip
site
offer
enrol
pediatr
patient
year
old
site
paid
per
capita
basi
per
capita
fund
ceas
report
patient
number
diagnos
data
field
complet
vari
budget
era
result
patient
enrol
across
site
common
cn
diagnos
medulloblastomapnet
ependymoma
glioma
craniopharyngioma
gct
rhabdomyosarcoma
bone
sarcoma
hodgkin
lymphoma
chordomachondrosarcoma
neuroblastoma
eleven
key
registri
field
includ
consent
date
dob
gender
race
refer
md
surgeri
chemotherapi
start
date
site
field
descript
total
dose
examin
miss
data
rang
per
field
per
capita
fund
ceas
thereaft
notabl
demograph
diagnosi
field
complet
unaffect
budget
cut
treatment
detail
miss
time
data
vital
statu
miss
time
budget
cut
rel
high
rate
miss
data
prior
fund
cut
highlight
challeng
obtain
patient
local
follow
proton
center
conclus
ppcr
accru
signific
diseas
specif
patient
cohort
answer
import
research
question
ppcr
site
pi
remain
engag
despit
lack
resourc
prompt
innov
new
data
collect
techniqu
innov
solut
data
collect
effici
includ
select
review
share
electron
medic
record
central
research
aid
patient
report
outcom
pro
ml
hol
b
j
n
b
r
davilla
p
j
h
j
l
medic
center
depart
pediatr
oncolog
amsterdam
netherland
medic
center
depart
maxillofaci
surgeri
head
neck
surgeri
amsterdam
netherland
medic
center
depart
radiat
oncolog
amsterdam
netherland
medic
center
depart
radiolog
amsterdam
netherland
center
pediatr
oncolog
univers
medic
center
utrecht
depart
radiat
oncolog
utrecht
netherland
depart
maxillofaci
lab
nijmegen
netherland
medic
center
depart
orbit
surgeri
amsterdam
netherland
marsden
hospit
depart
pediatr
oncolog
sutton
unit
kingdom
ormond
street
hospit
depart
pediatr
oncolog
london
unit
kingdom
medic
center
depart
maxillofaci
surgeri
amsterdam
netherland
marsden
hospit
depart
radiat
oncolog
sutton
unit
kingdom
colleg
london
depart
radiat
oncolog
london
unit
kingdom
backgroundobject
radiotherapi
plan
patient
pediatr
head
neck
cancer
multipl
organ
risk
taken
account
correspond
dose
constraint
consid
howev
dose
constrain
relat
facial
boni
growth
never
verifi
specif
facial
bone
purpos
studi
investig
relat
dose
facial
boni
structur
facial
growth
deform
designmethod
multicent
studi
includ
children
treat
head
rhabdomyosarcoma
averag
treatment
ebrt
brachytherapi
origin
radiotherapi
plan
facial
growth
deform
data
mean
year
base
stereophotograph
analysi
avail
boni
structur
within
field
view
reconstruct
plan
ct
scan
delin
result
delin
facial
structur
delin
boni
structur
plan
mean
maximum
dose
analys
regard
growth
deform
quantifi
correspond
facial
part
stereophotograph
result
growth
deform
sever
patient
treat
younger
age
patient
treat
older
correl
growth
deform
dose
indic
found
howev
overal
sever
growth
deform
observ
dose
exceed
boni
structur
suscept
growth
disrupt
other
exampl
mandibular
condyl
lacrim
bone
exhibit
growth
deform
receiv
mean
maximum
dose
bone
complex
p
conclus
found
signific
differ
suscept
growth
deform
differ
facial
boni
structur
futur
dose
constraint
specif
boni
structur
face
might
therefor
benefici
pediatr
radiotherapi
limit
facial
deform
research
base
larger
data
set
need
deriv
appropri
dose
constraint
facial
bone
kamer
b
n
univers
faculti
medicin
radiat
oncolog
izmir
turkey
univers
faculti
medicin
depart
pediatr
surgeri
izmir
turkey
univers
faculti
medicin
depart
ophthalmolog
izmir
turkey
uz
children
hospit
depart
pediatr
oncolog
izmir
turkey
univers
faculti
medicin
depart
pediatr
oncolog
izmir
turkey
univers
faculti
medicin
depart
neurosurgeri
izmir
turkey
univers
faculti
medicin
depart
radiat
oncolog
izmir
turkey
backgroundobject
radiotherapi
rt
import
compon
treatment
childhood
rhabdomyosarcoma
rm
brachytherapi
special
irradi
techniqu
give
possibl
protect
surround
healthi
tissu
organ
unnecessari
irradi
use
brachytherapi
favor
extern
rt
particular
site
childhood
rm
studi
present
result
ege
univers
hospit
designmethod
januari
octob
hdr
brachytherapi
use
part
treatment
case
rm
ege
univers
hospit
median
age
rang
malefemal
ratio
local
tumor
vagina
case
bladder
case
head
neck
case
orbita
case
pelvic
wall
case
biliari
tractu
case
ir
iii
iv
chemotherapi
regimen
use
rt
rt
dose
gy
combin
extern
brachytherapi
use
case
result
januari
octob
hdr
brachytherapi
use
part
treatment
case
rm
ege
univers
hospit
median
age
rang
malefemal
ratio
local
tumor
vagina
case
bladder
case
head
neck
case
orbita
case
pelvic
wall
case
biliari
tractu
case
ir
iii
iv
chemotherapi
regimen
use
rt
rt
dose
gy
combin
extern
brachytherapi
use
case
conclus
brachytherapi
effect
control
childhood
rm
care
plan
rt
extrem
import
maximum
benefit
late
effect
need
monitor
long
term
laskar
n
g
p
memori
hospit
radiat
oncolog
mumbai
india
memori
hospit
medic
physic
mumbai
india
memori
hospit
paediatr
oncolog
mumbai
india
memori
hospit
radiodiagnosi
mumbai
india
memori
hospit
bio
imag
mumbai
india
memori
hospit
patholog
mumbai
india
memori
hospit
surgic
oncolog
mumbai
india
memori
hospit
palli
medicin
mumbai
india
backgroundobject
evalu
diseas
outcom
children
nasopharyng
carcinoma
npc
treat
intens
modul
radiotherapi
imrt
tata
memori
hospit
designmethod
children
npc
treat
institut
median
age
year
year
major
patient
either
diseas
present
receiv
neoadjuv
chemotherapi
cth
follow
imrt
adjuv
cth
three
clinic
target
volum
ctv
defin
imrt
high
risk
ctv
fr
includ
nasopharyng
region
involv
node
intermedi
risk
ctv
fr
includ
nodal
region
adjac
involv
node
low
risk
ctv
fr
includ
uninvolv
nodal
level
beyond
intermedi
risk
ctv
cth
consist
bleomycin
methotrex
cisplatin
result
control
surviv
overal
surviv
cohort
respect
median
follow
mth
mth
patient
remain
aliv
diseas
free
three
patient
region
recurr
alon
salvag
reirradi
surgeri
cth
remain
diseas
free
patient
region
recurr
distant
metastas
die
progress
diseas
twenti
four
develop
distant
metastasi
oligometastas
salvag
rt
cth
diseas
free
remain
aliv
metastat
diseas
die
metastas
four
patient
die
cth
relat
complic
xerostomia
gr
ii
clinic
hypothyroid
autotox
gr
iii
visual
field
defect
dental
carri
major
toxic
conclus
combin
treatment
imrt
cth
result
accept
diseas
control
toxic
distant
metastasi
remain
major
caus
death
children
p
melchior
g
r
n
c
univers
hospit
radiat
oncolog
germani
univers
hospit
pediatr
hematolog
oncolog
germani
backgroundobject
report
clinic
outcom
children
wilm
tumour
wt
multimod
treatment
follow
protocol
special
regard
radiotherapi
designmethod
analysi
patient
unilater
wt
elig
abdomin
irradi
accord
histolog
subtyp
postop
treat
result
accord
protocol
children
elig
postop
abdomin
radiotherapi
port
median
follow
year
median
age
diagnosi
year
children
intermedi
risk
histolog
ir
stage
iii
children
high
risk
histolog
hr
diffus
anaplast
stage
ii
iii
blastem
type
stage
iii
elig
patient
irradi
abdomin
relaps
whole
cohort
local
failur
vs
irradi
children
patient
local
relaps
site
failur
local
recurr
combin
distant
metastasi
mean
time
first
event
year
local
recurr
occur
ir
nonirradi
vs
irradi
patient
hr
nonirradi
vs
irradi
patient
twelv
local
relaps
localis
flank
infield
failur
relaps
outsid
radiat
field
local
control
irradi
vs
nonirradi
group
hr
vs
ir
patient
port
conclus
children
wt
treat
port
excel
local
control
especi
ir
local
relaps
occur
insid
radiat
field
combin
distant
metastas
prospect
analys
necessari
evalu
new
highli
conform
radiat
techniqu
dg
l
dc
weber
scherrer
institut
protontherapi
center
cpt
villigen
switzerland
backgroundobject
studi
aim
report
two
case
vasculopathi
riv
pencil
beam
scan
pb
proton
therapi
pt
pediatr
craniopharyngioma
patient
b
evalu
local
dose
linear
energi
transfer
let
distribut
riv
designmethod
review
seri
patient
treat
paul
scherrer
institut
median
dose
gyrb
two
patient
show
riv
one
stenosi
right
ica
one
progress
multifoc
riv
region
circl
willi
month
irradi
respect
control
group
riv
select
base
field
arrang
tumour
size
ct
mri
pre
post
pt
use
contour
organ
risk
oar
bilater
ica
circl
willi
dvh
paramet
dose
distribut
analys
dose
weight
let
distribut
gy
kevmm
let
distribut
analys
result
dose
distribut
patient
control
group
present
riv
show
signific
differ
term
target
coverag
oar
spare
riv
structur
lower
dmean
without
signific
differ
dmax
patient
present
riv
toxic
treat
ipsilater
field
thu
result
mark
asymmetr
let
distribut
despit
high
let
area
distal
edg
ptv
signific
differ
found
maximum
mean
let
valu
riv
patient
toxic
control
patient
conclus
quantit
analysi
abl
show
signific
correl
deliv
dose
let
riv
ipsilater
plan
approach
seem
impact
presenc
vt
toxic
approach
gener
less
dosimetr
robust
one
result
asymmetr
let
distribut
high
let
valu
contralater
distal
edg
ptv
vk
ramaiah
cancer
institut
radiat
oncolog
bangalor
india
backgroundobject
convent
techniqu
cct
linear
acceler
base
conform
radiotherapi
crt
particl
therapi
without
incorpor
adopt
technolog
regular
posit
verif
differ
modal
may
avail
unpredict
variabl
manag
childhood
cancer
develop
countri
radiat
portal
tumor
target
delin
convent
fluoroscop
simul
scale
imag
solder
lead
wire
place
border
radiat
portal
everi
centimet
mark
adhes
tape
util
custom
radiat
field
need
sedat
anesthesia
mostli
rather
technolog
advanc
radiotherapi
techniqu
technolog
reduc
due
dosimetr
improv
without
alter
tumor
control
larg
outcom
result
novel
radiotherapi
technolog
techniqu
scenario
afford
wait
time
two
main
factor
determin
type
radiat
technolog
util
particular
patient
set
designmethod
retrospect
analysi
radiat
regist
pediatr
patient
cancer
treat
kidwai
cancer
institut
bangalor
result
patient
undergo
radiotherapi
pediatr
patient
center
pediatr
patient
diagnos
acut
lymphoblast
leukemia
undergon
prophylact
cranial
irradi
treat
cct
crtcost
radiotherapi
children
cancer
period
indian
nation
rupe
ie
total
money
spent
radiotherapi
patient
conclus
cct
still
appear
provid
treatment
larg
number
pediatr
patient
cancer
crt
benefit
spare
normal
tissu
tumor
boost
local
tumor
vk
ramaiah
l
cancer
institut
radiat
oncolog
bangalor
india
backgroundobject
radiotherapi
simul
process
treatment
simul
realli
given
radiat
portal
defin
simul
patient
posit
defin
target
area
region
subsequ
irradi
simul
achiev
done
convent
simul
comput
imag
howev
sever
set
equip
may
avail
radiat
equip
manag
patient
surfac
anatom
mark
landmark
util
radiat
portal
placement
convent
without
scale
may
littl
help
without
optic
distanc
indic
cross
hair
scale
account
magnif
need
improvis
radiat
simul
avail
technolog
develop
countri
effect
simul
children
cancer
util
custom
solder
lead
wire
scale
portal
lead
marker
convent
designmethod
adhes
porou
plastic
surgic
tape
stuck
scale
small
bit
solder
lead
wire
place
distanc
centimet
radiat
portal
mark
manual
util
anatom
surfac
landmark
lead
marker
place
border
portal
help
adhes
tape
custom
scale
stuck
bodi
within
field
view
patient
subject
radiat
portal
redefin
base
imag
scale
film
result
absenc
kind
simul
abl
plan
almost
children
cancer
present
centr
posit
rotat
movement
error
maginif
may
taken
care
correspond
defin
portal
surfac
anatom
landmark
conclus
one
first
studi
report
success
radiotherapi
simul
children
cancer
custom
simul
techniqu
acut
develop
countri
vk
bhasker
cancer
institut
radiat
oncolog
bangalor
india
india
institut
medic
sciec
radiotherapi
new
delhi
india
backgroundobject
children
cancer
need
radiotherapi
part
therapi
sometim
cooper
radiotherapi
immobil
simul
treatment
counsel
sedat
gener
anesthesia
combin
gener
prescrib
prevent
movement
children
radiotherapi
immobil
simul
treatment
sometim
patient
cooper
one
step
radiotherapi
process
situat
creat
dissimilar
condit
step
radiotherapi
plan
treatment
turn
manifest
simul
posit
treatment
posit
muscl
relax
anaesthesia
main
reason
posit
mismatch
two
differ
step
radiotherapi
process
paper
discuss
mismatch
variou
step
radiotherapi
devis
method
minim
mismatch
radiotherapi
plan
deliveri
use
thermoplast
immobil
devic
designmethod
patient
immobil
hospit
area
without
anaesthesia
appropri
counsel
patient
differ
area
simul
treatment
patient
immobil
immobil
devic
whole
process
radiotherapi
assess
snug
fit
immobil
devic
result
anaesthesia
induc
muscl
relax
respons
loosen
immobil
subsequ
geograph
tumor
miss
conclus
whole
radiotherapi
process
children
cancer
similar
circumst
ie
process
done
anaesthesia
process
without
anaesthesia
avoid
geometr
miss
tumor
radiotherapi
b
rombi
p
l
c
l
l
di
hospit
oncolog
depart
proton
therapi
center
trento
itali
chiara
hospit
anaesthesiolog
depart
trento
itali
chiara
hospit
paediatr
depart
trento
itali
backgroundobject
repetit
sedationanesthesia
sa
children
receiv
fraction
proton
beam
radiotherapi
pbt
requir
daili
set
multidisciplinari
team
high
degre
compet
induct
recoveri
phase
sever
week
typic
case
pbt
due
setup
treatment
complex
usual
requir
longer
sa
compar
photon
base
session
preliminari
experi
age
gender
children
receiv
daili
pbt
report
designmethod
record
pediatr
patient
year
review
june
march
proton
therapi
center
apss
trento
itali
receiv
pbt
patient
treat
cn
tumor
result
fourteen
children
age
year
three
patient
age
year
receiv
daili
median
number
fraction
seven
patient
median
age
year
receiv
irradi
csi
sedat
follow
local
primari
boost
perform
without
anesthesia
week
dedic
train
total
time
anesthesia
rang
minut
complex
case
ie
csi
use
propofol
death
cardiopulmonari
resuscit
aspir
requir
less
seriou
event
common
desatur
central
apnea
airway
obstruct
occur
sedationanesthesia
administr
stridor
laryngospasm
vomit
report
excess
secret
occur
case
unexpect
admiss
requir
conclus
occurr
undesir
effect
experi
low
strong
emphasi
teamwork
may
contribut
favor
event
rate
safe
implement
technic
clinic
complex
pbt
context
vennarini
b
p
gs
hospit
oncolog
therapi
center
trento
itali
bambino
children
hospit
neuroradiolog
imag
depart
rome
itali
bambino
children
hospit
neurosurgeri
neurosci
neurorehabilit
rome
itali
bambino
children
hospit
depart
pediatr
hematolog
oncolog
rome
itali
backgroundobject
evalu
acut
hematolog
toxic
craniospin
irradi
csi
proton
therapi
pt
children
hr
medulloblastoma
intens
myeloabl
chemotherapi
cht
designmethod
evalu
haematolog
toxic
ten
pediatr
patient
averag
age
rang
underw
csi
februari
decemb
patient
receiv
last
cht
cycl
carboplatin
one
month
irradi
patient
complet
pt
total
dose
two
phase
without
interrupt
first
phase
includ
whole
vertebr
bodi
second
phase
spinal
cord
exclud
vertebr
bodi
two
patient
administ
oral
temozolomid
treatment
white
blood
cell
wbc
hemoglobin
platelet
absolut
neutrophil
anc
count
end
first
phase
end
second
phase
pair
appli
statist
compar
p
valu
differ
phase
result
wbc
significantli
decreas
median
rang
significantli
increas
valu
significantli
differ
form
hemoglobin
significantli
chang
median
rang
platelet
significantli
decreas
median
rang
significantli
increas
valu
still
significantli
lower
anc
decreas
median
rang
significantli
increas
valu
significantli
differ
form
conclus
due
distal
pt
effect
deliv
csi
limit
dose
vertebr
bodi
around
reduc
acut
hematolog
toxic
treatment
could
use
reduc
also
growth
impair
rao
q
l
f
k
hopkin
univers
school
medicin
radiat
oncolog
molecular
radiat
scienc
baltimor
usa
univers
school
medicin
radiat
oncolog
palo
alto
usa
univers
school
medicin
depart
pediatr
palo
alto
usa
massachusett
medic
school
radiat
oncolog
worcest
usa
rhode
island
umass
qarc
lincoln
usa
backgroundobject
assess
tumor
coverag
dose
bone
skin
pediatr
patient
treat
imrt
vs
designmethod
elig
patient
enrol
arm
patient
age
year
receiv
neoadjuv
ifosfamidedoxorubicin
gy
surgeri
rt
boost
base
margin
rt
plan
avail
remot
review
imag
radiat
oncolog
core
iroc
rhode
island
databas
patient
extrem
st
proxim
long
bone
humerusfemurtibia
dose
deliv
clinic
target
volum
ctv
skin
contour
surfac
depth
mm
bone
analyz
result
patient
receiv
receiv
imrt
differ
distribut
site
treat
imrt
vs
except
vs
patient
treat
imrt
vs
upper
arm
st
differ
ctv
volum
patient
treat
imrt
howev
imrt
result
significantli
improv
ctv
coverag
prescript
dose
compar
median
ctv
coverag
vs
patient
without
skin
bolu
skin
significantli
lower
patient
treat
imrt
compar
mean
percentag
vs
respect
imrt
result
higher
bone
mean
vs
mean
vs
compar
differ
higher
dose
bone
radiat
techniqu
conclus
imrt
compar
may
result
improv
rt
target
coverag
reduc
dose
skin
increas
low
dose
exposur
bone
futur
studi
assess
dosimetr
find
translat
differ
clinic
toxic
outcom
e
n
r
c
b
g
hospit
essen
pediatr
oncolog
hematolog
essen
germani
hospit
essen
west
german
proton
therapi
centr
essen
wpe
essen
germani
backgroundobject
proton
therapi
pt
promis
altern
radiotherapi
solid
tumor
eloqu
region
recent
studi
deal
outcom
long
term
side
effect
pt
aim
studi
investig
feasibl
acut
toxic
simultan
chemotherapi
ct
pt
designmethod
retrospect
studi
enrol
consecut
patient
age
year
treat
west
german
proton
therapi
center
essen
germani
septemb
decemb
base
pt
registri
patient
record
data
patient
characterist
pretreat
recent
treatment
acut
advers
event
ae
collect
analyz
result
children
male
femal
median
age
year
suffer
cn
tumor
sarcoma
tumor
entiti
receiv
total
pt
cycl
pt
perform
patient
primari
treatment
recurr
patient
receiv
simultan
ct
sever
ae
sae
observ
pt
cycl
mostli
hematotox
infect
hospit
due
unexpect
event
mostli
infect
mucos
electrolyt
imbal
necessari
pt
cycl
group
simultan
ct
patient
could
receiv
recommend
ct
dose
time
schedul
frequenc
sae
signific
higher
group
simultan
ct
group
without
vs
test
p
conclus
regard
increas
number
children
pt
center
western
europ
data
demonstr
requir
well
experienc
interdisciplinari
team
adequ
infrastructur
manag
complex
patient
regard
infecti
neurolog
endocrinolog
problem
especi
individu
adjust
simultan
chemotherapi
support
german
children
cancer
foundat
k
watanab
h
h
k
n
children
hospit
depart
hematolog
oncolog
shizuoka
japan
cancer
center
hospit
divis
pediatr
nagaizumi
japan
children
hospit
depart
neurosurgeri
shizuoka
japan
japan
cancer
center
hospit
divis
proton
therapi
nagaizumi
japan
backgroundobject
proton
beam
therapi
pbt
offer
precis
target
convent
photon
radiat
therapi
may
limit
radiat
exposur
normal
tissu
therefor
pbt
increasingli
appli
treatment
childhood
cancer
attempt
reduc
toxic
second
malign
cooper
pediatr
oncolog
team
pbt
facil
crucial
includ
pbt
context
multimod
manag
children
cancer
appli
proton
therapi
childhood
cancer
close
collabor
cancer
center
children
hospit
shizuoka
prefectur
japan
year
designmethod
april
februari
children
cancer
shizuoka
children
hospit
refer
shizuoka
cancer
center
receiv
pbt
review
medic
record
retrospect
analyz
clinic
data
outcom
result
median
age
time
receiv
pbt
year
old
ten
patient
femal
patient
central
nervou
system
tumor
medulloblastoma
atyp
teratoidrhabdoid
tumor
choroid
plexu
carcinoma
brainstem
glioma
intracrani
germ
cell
tumor
ependymoma
malign
meningioma
undifferenti
sarcoma
patient
solid
tumor
neuroblastoma
ewe
sarcoma
pnet
undifferenti
sarcoma
hemangioma
patient
medulloblastoma
one
choroid
plexu
carcinoma
receiv
proton
beam
csi
irradi
dose
rang
gye
mostli
patient
aliv
median
follow
month
rang
sever
acut
toxic
conclus
pbt
may
appli
effect
safe
treatment
variou
childhood
cancer
close
collabor
region
cancer
center
children
hospit
studi
need
elucid
complic
pbt
patient
childhood
cancer
k
abe
n
k
h
h
univers
orthopaed
surgeri
kanazawa
japan
backgroundobject
prognosi
patient
sarcoma
dramat
improv
chemotherapi
howev
chemotherapeut
hardli
chang
year
develop
chemotherapi
musculoskelet
sarcoma
report
excel
respons
oncolog
outcom
even
excel
result
difficult
conduct
initi
clinic
trial
without
patent
citric
acid
also
report
could
enhanc
cytocid
effect
cisplatin
gastric
cancer
purpos
studi
evalu
cytocid
effect
cisplatin
combin
caffein
citrat
compar
cisplatin
combin
without
caffein
citric
acid
caffein
citrat
newli
emerg
candid
enhanc
anticanc
agent
designmethod
use
human
osteosarcoma
fibrosarcoma
cell
line
ho
cell
treat
cisplatin
combin
without
anhydr
caffein
citric
acid
caffein
citrat
cell
surviv
abil
cell
prolifer
mitochondri
membran
potenti
assess
cell
prolifer
assay
thymidin
analog
thymidin
analog
edu
assay
tetramethylrhodamin
ethyl
ester
tmre
assay
respect
moreov
combin
index
ci
caffein
citrat
calcul
combin
anhydr
caffein
citric
acid
synergi
evalu
ci
result
assay
cisplatin
combin
caffein
citrat
significantli
reinforc
anticanc
effect
compar
cisplatin
alon
combin
cisplatin
anhydr
caffein
combin
cisplatin
citric
acid
p
moreov
ci
condit
anticanc
agent
reinforc
effect
caffein
citrat
synergi
anhydr
caffein
citric
acid
result
observ
cell
line
base
result
file
patent
applic
conclus
first
report
cisplatin
combin
caffein
citrat
show
signific
greater
effect
although
analysi
mandatori
novel
treatment
expect
amelior
prognosi
patient
sarcoma
baron
g
offic
oncolog
hematolog
product
silver
spring
usa
backgroundobject
best
pharmaceut
children
act
author
food
drug
administr
fda
request
pediatr
studi
drug
approv
unapprov
indic
via
written
request
wr
fulfil
wr
provid
compani
market
exclus
entir
drug
moieti
histor
wr
issu
follow
approv
adult
indic
object
identifi
trend
associ
wr
issu
fda
oncolog
product
regard
time
issu
within
drug
develop
program
time
complet
drug
class
type
designmethod
review
fda
document
archiv
report
regulatori
track
system
perform
identifi
wr
issu
oncolog
drug
wr
review
mileston
date
amend
statu
regard
exclus
determin
result
wr
issu
oncolog
product
accept
overal
proport
wr
issu
prior
market
approv
drug
compar
seventeen
oncolog
product
grant
exclus
upon
complet
studi
outlin
wr
averag
time
issuanc
wr
exclus
determin
year
wr
issu
cytotox
target
therapi
proport
wr
issu
target
therapi
combin
greater
cytotox
drug
conclus
wr
power
tool
expedit
earli
evalu
safeti
effect
relev
drug
pediatr
cancer
modest
increas
observ
proport
wr
issu
prior
market
approv
drug
recent
year
increas
investig
target
therapi
reflect
chang
landscap
cancer
treatment
pediatr
patient
fda
encourag
parallel
drug
develop
program
appropri
adult
pediatr
cancer
indic
bordbar
univers
medic
scienc
school
medicin
pediatr
shiraz
iran
univers
medic
scienc
school
medicin
pediatr
shiraz
iran
backgroundobject
febril
neutropenia
frequent
observ
cancer
patient
follow
chemotherapi
experiment
anim
studi
shown
potenti
benefit
herbal
agent
allium
porrum
boost
immun
system
howev
find
confirm
human
subject
aim
studi
evalu
efficaci
allium
extract
bone
marrow
recoveri
time
children
cancer
suffer
febril
neutropenia
designmethod
random
clinic
trial
children
differ
kind
cancer
age
rang
year
admit
due
fever
neutropenia
enrol
patient
given
support
care
includ
antibiot
gcsf
treatment
group
treat
mg
allium
extract
form
capsul
twice
daili
day
patient
control
group
treat
similarli
placebo
capsul
total
white
blood
cell
wbc
absolut
neutrophil
count
anc
check
daili
basi
bone
marrow
recoveri
time
group
compar
result
wbc
anc
significantli
differ
group
patient
treatment
group
experienc
shorter
neutrophil
recoveri
compar
control
group
day
vs
day
respect
patient
treatment
group
discharg
hospit
mean
day
earlier
control
group
day
vs
day
reach
statist
signific
drug
well
toler
advers
effect
report
conclus
allium
may
effect
reduc
anc
recoveri
time
lead
earlier
discharg
hospit
drug
safe
seriou
advers
effect
report
larger
studi
requir
confirm
efficaci
safeti
p
l
mj
p
c
p
j
j
font
de
v
la
fe
pediatr
oncolog
unit
valencia
spain
fe
hospit
research
institut
genom
unit
valencia
spain
la
fe
depart
patholog
valencia
spain
la
fe
genet
unit
valencia
spain
fe
hospit
research
institut
laboratori
cellular
molecular
center
translat
medicin
valencia
spain
la
fe
pediatr
surgeri
depart
valencia
spain
gener
alicant
pediatr
oncolog
unit
alicant
spain
la
fe
depart
pharmaci
valencia
spain
backgroundobject
evalu
integr
advanc
genom
sequenc
technolog
clinic
manag
pediatricadolesc
patient
progressiverelaps
cancer
spain
designmethod
consecut
case
seri
patient
year
recurr
solid
tumor
includ
precis
medicin
research
project
analyz
project
develop
institut
open
recruit
patient
center
new
tumor
sampl
progressionrelaps
recommend
tumor
profil
perfom
use
two
commerci
next
gener
sequenc
ng
cancer
panel
ion
ampliseqtm
cancer
hotspot
panel
decemb
tumor
sampl
human
comprehens
cancer
generead
dnaseq
target
panel
sinc
januari
pair
blood
tumor
sampl
tumor
materi
mainli
fresh
frozen
tumor
sampl
mainli
obtain
time
last
relaps
previou
relaps
sixteen
patient
avail
tumor
sampl
recurr
profil
perform
tumor
sampl
diagnosi
genom
profil
result
review
follow
target
priorit
algorithm
tumor
board
basic
translat
research
molecular
biologist
pathologist
geneticist
pediatr
oncologist
result
decemb
februari
patient
nine
differ
hospit
includ
main
diagnosi
neuroblastoma
follow
cn
tumor
patient
except
three
suffer
least
one
relapseprogress
twenti
patient
least
one
somat
pathogen
mutat
detect
eleven
patient
least
one
action
target
alter
three
patient
identifi
germlin
pathogen
mutat
two
without
famili
histori
cancer
conclus
result
show
precis
medicin
appli
pediatr
adolesc
tumor
use
ng
technolog
feasibl
countri
commerci
cancer
panel
could
identifi
action
target
alter
patient
target
priorit
algorithm
interdisciplinari
tumor
board
discuss
foremost
import
verschuur
p
e
p
p
n
n
jc
b
n
timon
children
hospit
depart
pediatr
oncolog
marseil
franc
timon
children
hospit
depart
radiolog
marseil
franc
timon
children
hospit
marseil
franc
hospit
depart
pediatr
oncolog
nanci
franc
lambret
centr
pediatr
oncolog
unit
lill
franc
curi
pediatr
depart
pari
franc
berard
depart
paediatr
haematolog
oncolog
lyon
franc
hautepierr
strasbourg
franc
timon
children
hospit
depart
clinic
pharmaci
marseil
franc
backgroundobject
investig
activ
metronom
therapi
mt
relapsingprogress
pediatr
extracrani
solid
tumour
est
primari
object
progress
cycl
therapi
designmethod
patient
year
age
progress
est
adequ
organ
function
treatment
consist
cycl
oral
celecoxib
bid
weekli
vinblastin
oral
cyclophosphamid
qd
week
altern
oral
methotrex
twice
week
week
rest
maximum
treatment
year
chang
two
step
model
use
patient
first
stage
primari
object
reach
patient
addit
patient
includ
accord
group
neuroblastoma
nbl
sarcoma
st
bone
sarcoma
bs
miscellan
misc
irb
approv
obtain
result
patient
evalu
st
sd
cycl
patient
metastat
hemangioendothelioma
stabil
treat
month
misc
one
patient
stabil
one
year
bs
osteosarcoma
ewe
progress
nbl
patient
stabil
patient
sd
stop
mt
cycl
stabl
physician
choic
patient
remain
stabl
year
patient
progress
cycl
median
number
cycl
rang
grade
toxic
occur
patient
conclus
mt
activ
bs
misc
limit
though
interest
activ
nbl
st
patient
stabl
year
studi
support
enfant
et
foundat
houghtelin
cr
l
j
f
c
p
c
h
nation
health
system
hematologyoncolog
dc
usa
backgroundobject
patient
solid
tumor
refractori
standard
therapi
poor
prognos
salvag
therapi
toxic
ineffect
cell
therapi
success
hematolog
malign
offer
promis
altern
target
therapi
hypothes
cell
target
prame
survivin
express
mani
pediatr
solid
tumor
safe
administ
treat
relapsedrefractori
diseas
object
phase
clinic
trial
determin
safeti
administ
patient
refractoryrelaps
solid
tumor
secondari
object
includ
determin
diseas
respons
immun
reconstitut
designmethod
cell
expand
patient
peripher
blood
stimul
weekli
antigen
present
cell
express
overlap
peptid
librari
span
tumor
antigen
prame
survivin
presenc
cytokin
follow
releas
test
cytotox
assay
cultur
flow
cytometri
patient
infus
everi
week
dose
escal
studi
rang
dose
level
maximum
dose
level
clinic
immun
reconstitut
studi
perform
monitor
advers
effect
assess
diseas
immun
respons
result
gener
product
patient
enrol
relapsedrefractori
solid
tumor
neuroblastoma
osteosarcoma
wilm
tumor
ewe
sarcoma
pass
releas
criteria
safe
infus
patient
advers
event
date
patient
partial
respons
initi
later
progress
patient
progress
diseas
week
came
studi
current
enrol
addit
patient
character
persist
effect
vivo
conclus
date
infus
product
shown
safe
respons
mix
thu
far
continu
evalu
outlin
product
patient
sampl
function
specif
persist
l
ljungblad
n
j
ji
k
b
h
p
institutet
depart
women
children
health
stockholm
sweden
univers
agricultur
scienc
depart
food
scienc
stockholm
sweden
backgroundobject
long
chain
polyunsatur
fatti
acid
docosahexaeno
acid
dha
eicosapentaeno
acid
epa
anticanc
properti
implic
cancer
prevent
addit
tumor
growth
inhibit
vitro
vivo
effect
cytostat
drug
enhanc
dha
abund
brain
implic
neuroprotect
addit
supplement
posit
effect
children
neurodevelopment
disord
altogeth
result
suggest
exhibit
benefici
properti
adjuv
treatment
childhood
cancer
dietari
supplement
prevent
relaps
reduc
long
term
side
effect
childhood
cancer
survivor
designmethod
dose
escal
studi
design
find
dose
increas
index
optimum
level
without
secondari
object
evalu
supplement
effect
platelet
clot
abil
bodi
weight
composit
immuneprofil
inflammatori
paramet
lipid
peroxid
perceptioncognitionneuropsychiatr
symptom
includ
forti
children
age
median
remiss
complet
cancer
treatment
eight
fatti
acid
ml
fruit
juic
daili
day
food
frequenc
questionnair
perform
start
blood
urin
sampl
bodi
measur
behavior
questionnair
perform
studi
result
forti
complet
studi
complianc
seven
withdrew
voluntarili
sever
advers
event
regist
daili
intak
enrich
fruit
juic
significantli
increas
index
alreadi
conclus
daili
intak
increas
index
significantli
without
sever
advers
event
feasibl
high
complianc
strategi
provid
robust
evid
calcul
appropri
dosag
futur
trial
goal
promot
improv
surviv
less
side
effect
hl
jhm
b
j
j
glade
f
j
oldenburg
medic
campu
univers
oldenburg
depart
pediatr
pediatr
hematolog
oncolog
oldenburg
germani
children
medic
center
depart
pediatr
oncolog
amsterdam
netherland
roussi
depart
pediatr
adolesc
oncolog
villejuif
franc
ormond
street
hospit
depart
haematolog
oncolog
london
unit
kingdom
univers
medic
centr
depart
pediatr
new
york
usa
brain
univers
florida
preston
well
center
brain
tumor
therapi
gainesvil
usa
hospit
lo
keck
school
univers
southern
california
children
center
cancer
blood
diseas
lo
angel
usa
safeti
scienc
san
francisco
usa
roch
ltd
pediatr
oncolog
basel
switzerland
backgroundobject
bevacizumab
establish
safeti
profil
adult
data
children
limit
analysi
examin
effect
bev
growth
develop
pediatr
adolesc
patient
designmethod
data
height
weight
bodi
mass
index
bmi
bone
age
data
pool
five
trial
phase
ii
soft
tissu
sarcoma
phase
ii
glioma
phase
refractori
solid
tumor
phase
ii
osteosarcoma
phase
ii
glioma
medulloblastoma
ependymoma
patient
age
year
receiv
dose
bevacizumab
chemotherapi
chemotherapi
alon
analys
exploratori
descript
refer
growth
data
taken
year
centr
diseas
control
year
result
across
trial
mean
number
bevacizumab
administr
per
patient
rang
dose
everi
week
median
time
bevacizumab
plu
chemotherapi
month
rang
chemotherapi
month
rang
baselin
median
height
weight
bmi
close
refer
popul
mean
standard
deviat
score
sd
close
month
slight
declin
observ
mean
sd
height
weight
arm
cohort
patient
differ
tumor
treatment
remain
within
normal
rang
healthi
children
trend
similar
bmi
delay
growth
veloc
bone
age
patient
versu
chemotherapi
observ
regardless
age
gender
subgroup
analysi
patient
growth
develop
phase
consist
overal
result
conclus
analysi
bevacizumab
inclus
treatment
regimen
neg
impact
pediatr
growth
develop
beyond
chemotherapi
alon
r
nagasubramanian
k
n
b
l
ds
b
mc
sg
tw
children
hospit
oncolog
orlando
usa
children
univers
fred
hutchinson
cancer
research
center
oncolog
seattl
usa
lo
angel
pediatr
oncolog
lo
angel
usa
children
hospit
medic
oncolog
cincinnati
usa
hospit
lo
keck
school
univers
southern
california
oncolog
lo
angel
usa
jude
children
research
hospit
oncolog
memphi
usa
oncolog
clinic
develop
stamford
usa
oncolog
clinic
develop
south
san
francisco
usa
children
cancer
blood
disord
center
oncolog
boston
usa
texa
southwestern
medic
centerchildren
health
oncolog
dalla
usa
backgroundobject
larotrectinib
first
select
inhibitor
trkabc
clinic
develop
adult
phase
trial
demonstr
prolong
respons
patient
pt
trk
fusion
favor
toler
profil
designmethod
multicent
phase
studi
enrol
pt
refractori
solid
tumor
age
month
year
pt
dose
oral
bid
continu
schedul
either
capsul
solut
pharmacokinet
pk
dose
escal
permit
exposur
target
adult
recommend
phase
dose
bid
primari
object
defin
mtd
secondari
object
includ
pk
efficaci
use
recist
result
decemb
pt
trk
fusion
without
trk
fusion
median
age
year
enrol
dose
level
pt
enrol
fusion
ntrk
gene
heterogen
tumor
diagnos
infantil
fibrosarcoma
if
sarcoma
papillari
thyroid
cancer
common
ae
regardless
attribut
vomit
diarrhea
fatigu
pt
experienc
grade
ae
none
attribut
larotrectinib
dlt
observ
mtd
establish
pt
trk
fusion
without
trk
fusion
remain
treatment
median
month
among
trk
fusion
pt
vast
major
achiev
confirm
recist
respons
regardless
tumor
diagnos
respons
seen
pt
without
trk
fusion
pt
discontinu
therapi
includ
trk
fusion
pt
if
suffici
respons
allow
tumor
resect
pt
if
progress
document
acquir
resist
mutat
conclus
larotrectinib
demonstr
favor
toler
profil
independ
efficaci
pediatr
pt
harbor
trk
fusion
updat
safeti
efficaci
data
present
richard
l
n
j
kid
cancer
europ
research
advocaci
london
unit
kingdom
kid
cancer
research
advocaci
new
york
usa
backgroundobject
drug
develop
market
explicitli
paediatr
cancer
present
formid
challeng
case
studi
dinutuximab
antibodi
proven
effect
neuroblastoma
pivot
us
trial
gain
us
food
drug
administr
approv
reject
nation
institut
health
care
excel
nice
reimburs
uk
nation
health
servic
nh
cost
designmethod
chariti
base
us
uk
proven
play
vital
role
challeng
nice
apprais
process
suitabl
evalu
cost
effect
paediatr
rare
diseas
drug
reli
patient
repres
input
media
engag
parent
commun
awar
pro
bono
legal
assist
emot
expert
argument
submit
challeng
nice
decis
reject
drug
uk
result
first
appeal
nice
decis
chariti
challeng
success
upheld
despit
lack
input
engag
pharmaceut
compani
drug
compani
subsequ
withdrew
submiss
nice
reapprais
demand
exceed
avail
drug
suppli
drug
longer
provid
market
outsid
north
america
forese
futur
conclus
chariti
proven
play
vital
role
advoc
polici
regulatori
issu
affect
children
cancer
ccd
sa
af
pv
de
rgp
cg
lg
ca
scride
de
medicina
de
pediatr
preto
brazil
de
montpelli
institut
de
recherch
en
de
montpelli
montpelli
franc
de
medicina
de
genet
preto
brazil
de
medicina
de
surgeri
anatomi
preto
brazil
backgroundobject
treatment
glioblastoma
gb
remain
major
challeng
sinc
tumor
highli
resist
chemotherapi
recurr
extrem
common
poor
prognosi
patient
gb
due
intratumor
heterogen
invas
behavior
resist
apoptosi
hypox
tumor
microenviron
hypox
condit
gb
cell
upregul
express
carbon
anhydras
ca
shown
act
acidif
tumor
microenviron
previous
studi
found
antitumor
effect
downregul
pediatr
glioblastoma
cell
line
henc
aim
studi
valid
evalu
effect
indisulam
ca
apoptot
factor
bax
express
pediatr
gb
cell
line
designmethod
pediatr
gb
cell
line
pretreat
cobalt
chlorid
mimic
hypoxia
hour
cell
treat
incub
hour
gene
protein
express
bax
assess
use
western
blot
respect
result
indisulam
significantli
decreas
gene
express
p
upregul
p
similar
pattern
gene
express
observ
protein
express
downregul
protein
express
also
found
bax
p
p
greater
reduct
factor
conclus
studi
suggest
may
antitumor
effect
evidenc
inhibit
gene
protein
express
modul
apoptot
factor
thu
ca
could
particularli
relev
understand
mechan
glioma
cell
propag
resist
treatment
indisulam
may
interest
candid
develop
antitumor
therapi
base
inhibit
carbon
anhydras
shimizu
k
h
univers
school
medicin
pediatr
surgeri
japan
univers
school
medicin
gener
gastrointestin
surgeri
japan
univers
school
medicin
patholog
japan
backgroundobject
immun
checkpoint
inhibitor
use
innov
immunotherapi
cancer
metastas
thought
import
prognost
factor
pediatr
solid
tumor
efficaci
immun
checkpoint
inhibitor
lung
metastas
osteosarcoma
report
sever
murin
model
studi
combin
therapi
immun
checkpoint
inhibitor
primari
tumor
resect
evalu
use
murin
model
spontan
lung
metastasi
designmethod
mice
osteosarcoma
origin
mous
cell
transplant
subcutan
primari
tumor
lesion
thereaft
mice
divid
group
follow
control
group
receiv
intervent
cg
n
primari
tumor
resect
group
primari
tumor
resect
day
transplant
ptrg
n
tripl
antibodi
therapi
group
three
antibodi
intraperiton
day
atg
n
combin
therapi
group
primari
tumor
resect
day
three
antibodi
day
cmbg
n
surviv
curv
plot
use
method
compar
plot
test
lung
mice
group
patholog
evalu
result
cmbg
show
significantli
longer
surviv
three
group
p
six
mice
cmbg
surviv
week
tumor
transplant
patholog
studi
reveal
multipl
lung
metastas
week
tumor
transplant
group
lung
metastasi
week
tumor
transplant
cmbg
conclus
result
studi
suggest
combin
therapi
primari
tumor
resect
immun
checkpoint
inhibitor
could
cur
treatment
metastasi
pediatr
solid
tumor
teixeira
sebastian
faria
n
mohan
c
v
kill
c
gilberto
l
gonzaga
c
alberto
preto
medic
univers
paulo
depart
pediatr
preto
brazil
women
hospit
harvard
medic
school
neurosurgeri
boston
usa
preto
medic
univers
paulo
depart
genet
preto
brazil
preto
medic
univers
paulo
depart
surgeri
anatomi
preto
brazil
backgroundobject
carbon
anhydras
ca
enzym
highli
express
hypox
condit
consid
potenti
biomark
tumor
cell
promis
target
specif
therapi
hypoxia
genet
alter
lead
express
extracellular
face
glioblastoma
gbm
aggress
form
brain
cancer
dismal
prognosi
children
adult
ca
link
aggress
invas
behavior
cell
resist
therapi
indisulam
potent
sulfonamid
inhibitor
ca
use
drug
aim
studi
evalu
effect
inhibit
vitro
vivo
model
designmethod
pediatr
adult
gbm
cell
line
cultur
hypoxia
treat
effect
cell
prolifer
migrat
clonogen
capac
apoptosi
measur
vitro
vivo
antitumor
effect
assess
athym
nude
mice
inocul
mice
treat
ip
tumor
growth
potenti
treatment
toxic
monitor
surviv
endpoint
result
significantli
reduc
cell
prolifer
inhibit
clonogen
capac
p
increas
apoptosi
p
pediatr
adult
gbm
cell
also
reduc
cell
migrat
potenti
effect
radiotherapi
p
vitro
pediatr
cell
line
sensibl
treatment
result
intracrani
mous
xenograft
model
indic
cross
bbb
significantli
increas
anim
surviv
conclus
studi
provid
evid
therapeut
potenti
agent
tumor
cell
repres
attract
strategi
improv
adjuv
therapi
gbm
financi
support
fapesp
trippett
g
j
f
da
b
sloan
ketter
cancer
center
pediatr
development
therapeut
new
york
usa
roch
ltd
pediatr
oncolog
basel
switzerland
texa
health
scienc
center
pediatr
hematologyoncolog
san
antonio
usa
curi
depart
pediatr
pari
franc
et
doncologi
pediatr
adult
lyon
franc
pediatrico
bambino
univers
pavia
depart
pediatr
hematolog
oncolog
rome
itali
roch
ltd
pediatr
oncolog
mississauga
canada
pediatr
oncolog
san
francisco
usa
safeti
scienc
san
francisco
usa
oncolog
biomark
develop
san
francisco
usa
roussi
depart
pediatr
adolesc
oncolog
villejuif
franc
backgroundobject
atezolizumab
target
program
lead
enhanc
respons
studi
phase
iii
assess
safeti
pharmacokinet
preliminari
efficaci
atezolizumab
pediatricyoung
adult
patient
refractoryrelaps
solid
tumor
designmethod
patient
age
year
refractoryrelaps
nervou
system
solid
tumor
receiv
atezolizumab
everi
week
loss
clinic
benefit
year
old
maximum
dose
year
old
safetypharmacokinet
assess
across
tumor
type
initi
respons
assess
cohort
approxim
ten
patient
cohort
treat
result
februari
patient
median
age
year
rang
enrol
osteosarcoma
ewe
sarcoma
neuroblastoma
rhabdomyosarcoma
soft
tissu
sarcoma
wilm
tumor
hodgkin
lymphoma
hl
tumor
type
pharmacokinet
data
similar
report
adult
tumor
score
tumor
cell
tc
immun
cell
ic
express
express
rate
score
seen
patient
respect
hl
higher
tc
ic
express
score
compar
tumor
safeti
evalu
popul
receiv
atezolizumab
median
cycl
rang
advers
event
ae
patient
grade
ae
two
patient
ae
led
studi
drug
discontinu
common
ae
pyrexia
constip
fatigu
patient
hl
one
patient
rhabdoid
tumor
rt
partial
respons
conclus
pharmacokineticsafeti
profil
atezolizumab
pediatricyoung
adult
patient
similar
adult
preliminari
activ
seen
hl
rt
atyp
teratoid
rt
rt
cohort
open
explor
signal
k
waack
b
k
n
u
g
n
b
research
acceler
pediatr
trial
center
essen
germani
hospit
essen
pediatr
oncolog
pediatr
iii
essen
germani
hospit
dortmund
clinic
pediatr
dortmund
germani
univers
vestisch
und
jugendklinik
datteln
germani
herdeck
depart
integr
pediatr
adolesc
medicin
herdeck
germani
klinikum
krefeld
children
hospit
krefeld
germani
mutterhau
der
pediatr
oncolog
hematolog
trier
germani
medic
center
divis
pediatr
oncolog
stem
cell
transplant
aachen
germani
bonn
medic
center
depart
pediatr
hematolog
center
pediatr
bonn
germani
hospit
depart
divis
haematolog
oncolog
st
augustin
germani
clinic
cologn
depart
divis
pediatr
oncolog
hematolog
cologn
germani
saarland
depart
pediatr
hematolog
oncolog
homburg
germani
cologn
depart
pediatr
hematolog
oncolog
cologn
germani
backgroundobject
clinic
trial
could
potenti
therapeut
possibl
patient
without
treatment
option
regular
patient
care
trial
recruit
hamper
unevenli
geograph
distribut
three
five
studi
site
whole
germani
limit
recruit
radiu
kilomet
otherwis
patient
must
will
travel
center
visit
must
transfer
trial
center
even
situat
defin
virtual
studi
site
could
solv
challeng
situat
simultan
meet
stakehold
requir
designmethod
therefor
pediatr
oncolog
center
commit
form
network
cover
one
geograph
area
organ
one
studi
sitecentr
work
studi
offic
univers
essen
act
coordin
site
merg
associ
site
period
updat
everi
month
resourc
data
train
plan
equip
staff
analyz
strength
weak
balanc
particip
center
whatev
done
decentr
coordin
studi
offic
cover
task
central
activ
perform
accord
good
clinic
practic
structur
activ
supervis
scientif
lead
group
result
patient
enter
clinic
trial
near
patient
home
improv
patient
access
complianc
experiment
treatment
option
well
clinic
trial
site
act
one
singl
site
sponsor
ethic
committe
ec
compet
author
ca
spring
one
one
academ
studi
appli
model
ec
ca
conclus
studi
site
present
attract
structur
model
address
specif
requir
recruit
pediatr
oncolog
patient
earli
clinic
trial
unevenli
popul
area
state
like
germani
er
abdel
khalek
lm
n
zagazig
univers
pediatr
cairo
egypt
zagazig
univers
peditar
zagazig
egypt
zagazig
univers
pediatr
zagazig
egypt
backgroundobject
fatigu
crf
one
frequent
stress
symptom
children
cancer
profound
effect
qualiti
life
qol
aim
purpos
studi
find
preval
pattern
crf
children
cancer
treatment
designmethod
prospect
longitudin
descript
studi
conduct
children
cancer
age
year
receiv
inpati
chemotherapi
pediatr
oncolog
depart
zagazig
univers
pedql
multidimension
fatigu
scale
sociodemograph
data
form
given
patient
parent
well
healthi
control
children
particip
enrol
studi
start
new
round
chemotherapi
ctx
follow
day
next
cycl
hemoglobin
level
blood
indic
record
fatigu
measur
result
statist
signific
increas
fatigu
score
domain
treatment
tendenc
overestim
fatigu
parent
sleep
cognit
domain
peak
fatigu
occur
day
start
ctx
becom
better
toward
begin
next
cycl
signific
variat
total
fatigu
score
domain
accord
gender
age
present
howev
exist
regard
diagnosi
solid
tumor
associ
better
fatigu
score
lymphoma
leukemia
low
hemoglobin
level
associ
high
fatigu
score
domain
p
conclus
patient
problem
fatigu
first
day
start
cycl
ctx
assess
fatigu
done
everi
patient
undergo
ctx
repeat
differ
time
appli
time
tailor
intervent
prevent
fatigu
ahmad
children
hospit
institut
child
health
lahor
paediatr
haematologyoncolog
lahor
pakistan
backgroundobject
oncolog
depart
children
hospit
lahor
bed
unit
provid
free
treatment
new
childhood
cancer
case
yearth
aim
prospect
studi
analyz
burden
chemotherapi
induc
fn
assess
lead
risk
factor
designmethod
prospect
review
patient
fn
admit
juli
august
done
data
regard
clinic
featur
baselin
cbc
cours
therapi
hospit
stay
understand
caregiv
regard
fn
analyz
result
total
patient
age
rang
year
yr
includ
case
solid
tumor
last
chemotherapi
receiv
hour
last
week
rest
week
time
respiratori
tract
infect
gastrointestin
infect
mucos
focu
found
rest
manifest
present
one
hour
start
symptom
hour
day
day
durat
symptom
hb
gm
platelet
wbc
anc
stay
present
first
episod
fn
case
stay
hour
distanc
chl
travel
hr
treatment
reach
ptc
caregiv
adequ
awar
regard
fn
understand
knowledg
fn
social
issu
unawar
show
neglig
seek
treatment
conclus
health
educ
caregiv
health
profession
utmost
import
prevent
manag
fn
effect
need
capac
build
pediatr
oncolog
low
incom
countri
essenti
provis
standard
childhood
cancer
care
nassan
mustafa
hussien
cancer
center
pediatr
amman
jordan
tolido
intern
medicin
tolido
usa
clinic
intern
medicin
cleveland
usa
backgroundobject
accord
recent
guidelin
manag
febril
neutropenia
children
cancer
ct
imag
rule
fungal
infect
remain
essenti
tool
commonli
util
despit
risk
radiat
exposur
uncertain
yield
differ
diseas
categori
designmethod
obtain
institut
review
board
irb
approv
use
department
databas
pediatr
oncolog
network
databas
pond
identifi
patient
regist
june
juli
combin
data
pond
registri
data
collect
chart
review
one
excel
databas
result
identifi
patient
regist
pond
studi
period
median
follow
rang
patient
diagnos
leukemia
lymphoma
solid
tumor
central
nervou
system
cn
tumor
other
ct
scan
order
center
patient
regist
median
number
scan
per
patient
rang
total
surveil
scan
order
patient
surveil
scan
order
median
day
follow
onset
neutropenia
rang
day
major
surveil
scan
done
patient
leukemialymphoma
vs
solidcn
tumor
commonli
scan
site
chest
sinu
abdomen
posit
predict
valu
ppv
possibl
fungal
infect
scan
ppv
per
site
sinu
scan
chest
abdomen
differ
ppv
patient
leukemialymphoma
vs
solidcn
tumor
conclus
surveil
fungal
infect
commonli
order
patient
accord
clinic
practic
guidelin
leukemialymphoma
patient
commonli
scan
patient
solidcn
tumor
scan
chanc
fungal
infect
similar
leukemialymphoma
bauter
p
g
n
c
univers
hospit
pediatr
oncolog
stem
cell
transplant
ghent
belgium
univers
hospit
pediatr
pulmonolog
infecti
diseas
ghent
belgium
backgroundobject
febril
neutropenia
fn
common
complic
pediatr
hematologyoncolog
pho
current
guidelin
advoc
time
administr
empir
antibiot
antibiot
deliveri
patient
fn
min
increasingli
import
qualiti
measur
associ
improv
outcom
aim
studi
measur
time
antibiot
administr
taa
inpati
outpati
depart
target
taa
minut
designmethod
retrospect
studi
perform
taa
defin
time
prescript
administr
antibiot
inpati
time
admiss
hospit
antibiot
administr
outpati
result
studi
popul
involv
patient
male
mean
age
year
rang
year
repres
inpati
outpati
episod
inpati
mean
taa
minut
rang
outpati
minut
rang
total
within
target
taa
minut
even
within
minut
taa
hour
taa
outpati
fn
hour
episod
rang
minut
conclus
result
indic
taa
minut
higher
percentag
literatur
data
indic
fn
episod
taa
minut
taa
outpati
higher
inpati
possibl
explan
lie
time
involv
anamnesi
clinic
examin
upon
arriv
hospit
wait
time
laboratori
result
studi
confirm
effort
perform
keep
taa
propos
indic
depart
low
possibl
inpati
outpati
bhattacharyya
g
medic
center
paediatr
oncolog
kolkata
india
medic
center
microbiolog
kolkata
india
backgroundobject
pattern
respiratori
viral
infect
rvi
children
cancer
well
character
india
conduct
studi
determin
spectrum
incid
need
hospit
admiss
econom
burden
outcom
concomit
bacterialfung
infect
need
icu
care
death
rvi
unit
designmethod
data
prospect
collect
month
juli
children
treatment
cancer
present
cough
coryza
underw
multiplex
pcr
respiratori
virus
nose
throat
swab
result
posit
result
obtain
case
data
incomplet
case
final
analysi
done
case
fever
present
median
age
year
rang
year
sixti
percent
receiv
intens
chemotherapi
haematolymphoid
malign
commonest
virus
isol
influenza
b
respiratori
syncyti
viru
rsv
human
metapneumoviru
peak
month
incid
juli
septemb
raini
season
fifti
percent
patient
need
admiss
anc
episod
concomit
bacterialfung
infect
seen
case
median
durat
admiss
day
rang
day
median
cost
usd
rang
fifteen
patient
need
icu
admiss
concomit
bacterialfung
infect
ventil
invas
requir
patient
rsv
two
death
record
patient
rsv
concomit
bacteremia
conclus
rvi
add
significantli
burden
admiss
expens
influenza
vaccin
given
univers
may
prevent
signific
number
ill
admiss
programm
initi
center
data
prospect
collect
measur
impact
concomit
bacterialfung
infect
add
morbiditymort
acknowledg
manashpratim
gogoi
data
collect
r
bhalachandra
sampl
collect
anusha
harishankar
pcr
process
g
c
cintra
e
israelita
albert
einstein
pediatria
paulo
brazil
backgroundobject
intens
care
unit
gener
unit
bed
media
admissionsyear
attend
clinic
surgic
patient
whose
reason
admiss
may
elect
urgenc
emerg
object
know
profil
caus
admiss
disclosur
pediatr
oncohematolog
patient
pediatr
intens
care
picu
gener
hospit
designmethod
method
retrospect
analyz
oncohematolog
patient
admit
picu
result
result
admiss
oncohematolog
patient
indic
elect
urgenc
emerg
percent
femal
male
year
old
year
year
older
year
old
rapid
respons
team
attend
patient
evalu
local
staff
sent
picu
origin
emerg
room
oncolog
bone
transplant
unit
pediatr
unit
surgeri
room
caus
admiss
care
hemodynam
monitoringsepsi
respiratori
failur
mani
patient
submit
invas
procedur
central
venou
cathet
invas
arteri
pressur
enter
feed
bladder
cathet
none
patient
complic
infect
pressur
ulcer
eighti
percent
discharg
origin
unit
home
one
patient
die
conclus
oncohematolog
pediatr
patient
admit
picu
requir
special
intens
care
admit
emerg
urgenc
situat
discharg
back
origin
unit
home
inform
ad
alreadi
collect
picu
histor
seri
allow
data
accompani
compar
institut
j
calley
l
n
h
n
aberdeen
children
hospit
depart
paediatr
oncolog
aberdeen
unit
kingdom
backgroundobject
outcom
children
cancer
continu
improv
febril
neutropenia
fn
remain
major
caus
mortal
mortal
fn
episod
year
mortal
acut
lymphoblast
leukaemia
due
infect
rapid
antibiot
deliveri
minut
associ
improv
outcom
guidanc
avail
nation
institut
health
care
excel
nice
manag
servic
network
msn
children
young
peopl
cancer
scotland
regard
empir
antibiot
prescrib
centr
current
uniqu
scotland
practic
singl
agent
first
line
empir
antibiot
therapi
piperacillintazobactam
aim
assess
aetiolog
febril
episod
children
cancer
north
scotland
evalu
adequaci
empir
antibiot
polici
light
local
antibacteri
resist
pattern
designmethod
posit
microbiolog
data
paediatr
oncolog
patient
treat
year
provid
local
laboratori
analysi
isol
resist
pattern
compar
data
result
microbiolog
isol
demonstr
secular
trend
increas
environment
gram
neg
reduct
staph
aureu
increas
resist
key
antimicrobi
gram
posit
gram
neg
organ
estim
total
febril
episod
initi
dual
therapi
piperacillintazobactam
gentamicin
would
provid
superior
cover
compar
piperacillintazobactam
monotherapi
conclus
number
need
treat
improv
coverag
base
data
would
need
balanc
known
advers
effect
empir
aminoglycosid
decid
appropri
local
antimicrobi
polici
p
mj
p
v
b
universitario
la
fe
pediatr
oncolog
unit
valencia
spain
fe
hospit
research
institut
pharmacogenet
unit
valencia
spain
la
fe
system
depart
valencia
spain
la
fe
pediatr
oncolog
unit
valencia
spain
la
fe
plan
depart
valencia
spain
backgroundobject
integr
seamless
healthcar
data
multipl
hospit
data
sourc
identifi
toxic
pediatr
patient
designmethod
integr
dashboard
use
excel
dynam
tabl
powerpivot
healthcar
data
follow
hospit
sourc
chemotherapi
gestlab
clinic
laboratori
analysi
delphin
blood
bank
philip
icca
intens
care
unit
iri
hospit
lafe
orion
clinic
electron
medic
record
extract
transform
load
etl
data
integr
process
acquir
data
store
datamart
automat
integr
prior
inform
well
laboratori
toxic
grade
accord
ctcae
criteria
identif
chemotherapi
delaysdos
reduct
unplan
hospit
manual
data
extract
patient
medic
record
solid
tumor
treat
pediatr
oncolog
unit
comparison
automat
data
extract
reliabl
result
fine
tun
inform
tool
carri
follow
next
step
inform
tool
design
b
inform
tool
test
manual
data
extract
toxic
relat
chemotherapi
cours
comparison
c
inform
tool
test
manual
data
extract
toxic
relat
chemotherapi
cours
comparison
automat
data
extract
superior
manual
data
extract
regard
identif
laboratori
toxic
chemotherapi
dose
reduct
final
test
chemotherapi
cours
current
ongo
conclus
automat
data
extract
integr
healthcar
data
differ
hospit
data
sourc
superior
manual
data
extract
inform
tool
simplifi
data
extract
allow
earli
identif
toxic
improv
qualiti
care
acknowledg
work
fund
ayuda
mutua
h
j
caniza
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
backgroundobject
bloodstream
infect
may
result
transloc
gut
microorgan
bloodstream
immunocompromis
patient
januari
nation
healthcar
safeti
network
nhsn
releas
mucos
barrier
injuri
bloodstream
infect
identifi
subset
central
bloodstream
infect
clabsi
like
associ
mucos
barrier
injuri
infecti
diseas
id
global
pediatr
medicin
initi
mentor
infect
care
prevent
icp
team
pediatr
cancer
center
pcc
latin
america
separ
track
mbi
event
use
protocol
describ
report
determin
impact
remov
clabsi
rate
designmethod
data
collect
prospect
icp
team
hondura
ecuador
argentina
report
review
collect
standard
hai
surveil
monthli
report
data
januari
decemb
clabsi
rate
per
day
calcul
without
inclus
determin
rate
differ
result
four
pcc
averag
devic
util
ratio
rang
clabsi
report
met
criteria
overal
clabsi
rate
rang
per
remov
clabsi
rate
decreas
rang
per
gener
percent
chang
clabsi
rate
rang
among
pcc
remov
clabsi
rate
determin
produc
greatest
clabsi
rate
decreas
mexico
vs
per
common
pathogen
klebsiella
pneumonia
escherichia
coli
serratia
marcescen
conclus
result
support
separ
monitor
report
mbi
countri
allow
accur
detect
track
prevent
bloodstream
infect
j
carreti
b
h
p
cancer
environ
lyon
franc
adolesc
young
adult
cancer
depart
lyon
franc
backgroundobject
around
adolesc
young
adult
aya
year
diagnos
year
cancer
french
region
long
term
surviv
six
time
like
develop
second
primari
cancer
spc
compar
peer
risk
multifactori
depend
type
first
cancer
treatment
receiv
preval
risk
factor
smoke
overweight
sedentari
lifestyl
environment
exposur
project
aim
implement
clinic
program
base
adapt
physic
activ
cancer
prevent
recommend
aya
cancer
designmethod
patient
attend
adapt
physic
activ
session
activ
treatment
period
month
given
questionnair
physic
activ
ipaq
qualiti
life
eortc
baselin
end
treatment
particip
individu
inform
meet
spc
risk
prevent
respond
final
qol
questionnair
phone
year
result
far
aya
boy
girl
median
includ
complet
averag
particip
session
hospit
home
current
aya
complet
assess
preliminari
result
indic
increas
level
physic
activ
sedentari
time
seem
decreas
averag
hweek
hweek
aya
highli
satisfi
program
conclus
studi
respond
aya
need
support
inform
regard
physic
activ
spc
prevent
improv
qualiti
program
implement
gym
room
built
hospit
therapeut
educ
program
dedic
aya
develop
rl
ps
kjt
emm
oncolog
institut
iopgraaccunifesp
pediatr
sao
paulo
brazil
backgroundobject
malign
neoplasm
children
adolesc
trigger
malnutrit
may
underestim
diagnosi
diseas
consid
gener
adipos
index
bodi
mass
index
bmi
anthropometr
indic
may
abl
detect
earli
malnutrit
especi
time
diagnosi
diseas
howev
necessari
indic
present
good
correl
consecr
predict
muscular
mass
patient
arm
muscular
area
ama
neck
circumfer
nc
simpl
low
cost
easi
appli
clinic
practic
main
object
studi
verifi
correl
nc
measur
ama
children
adolesc
malign
neoplasm
diagnosi
diseas
designmethod
studi
evalu
children
adolesc
age
year
malign
neoplasm
pediatr
oncolog
special
institut
decemb
june
measur
nc
evalu
ama
calcul
arm
circumfer
skinfold
tricep
evalu
perform
train
evalu
follow
standard
anthropometr
techniqu
correl
nc
ama
perform
pearson
correl
result
among
new
case
patient
male
median
age
femal
sex
male
sexth
correl
nc
ama
linear
posit
strong
sex
femal
male
conclus
conclud
strong
correl
nc
ama
boy
girl
promis
indic
clinic
practic
practic
measur
low
cost
earli
detect
chang
nutrit
statu
individu
allow
rapid
intervent
implement
nutrit
therapi
rl
ps
kjt
emm
oncolog
institut
iopgraaccunifesp
pediatr
sao
paulo
brazil
backgroundobject
children
adolesc
malign
neoplasm
may
present
earli
malnutrit
find
may
underestim
bodi
mass
index
consid
due
variou
metabol
chang
hydrat
statu
side
effect
caus
therapi
antineoplast
anthropometr
measur
abl
earli
detect
malnutrit
specif
muscl
mass
deplet
calf
circumfer
cc
main
object
studi
verifi
correl
measur
cc
arm
muscl
area
ama
tricep
skinfold
tsf
bodi
mass
index
bmi
designmethod
studi
evalu
children
adolesc
year
age
malign
neoplasm
pediatr
oncolog
special
institut
octob
june
measur
cc
evalu
ama
calcul
arm
circumfer
ac
tsf
evalu
valu
weight
length
height
obtain
calcul
bmi
measur
perform
train
evalu
correl
cc
variabl
ama
bmi
tsf
perform
pearson
correl
result
among
patient
femal
mean
age
male
femal
analyz
correl
cc
independ
variabl
linear
posit
correl
cc
ama
cc
bmi
cc
tsf
conclus
conclud
strong
correl
calf
circumfer
independ
variabl
analyz
ama
bmi
tsf
result
greater
cc
ama
strengthen
cc
besid
easi
low
cost
measur
use
clinic
practic
strong
correl
ama
also
reflect
muscl
mass
store
good
indic
monitor
nutrit
statu
children
adolesc
malign
neoplasm
dillon
j
univers
hospit
nh
foundat
trust
paediatr
critic
care
oxford
unit
kingdom
backgroundobject
paediatr
cancer
remain
lead
caus
death
children
continu
advanc
treatment
support
care
help
improv
surviv
paediatr
oncolog
patient
make
signific
proport
admiss
paediatr
intens
care
unit
picu
aim
studi
assess
outcom
children
cancer
admit
picu
within
tertiari
hospit
designmethod
retrospect
analysi
picu
databas
system
carevu
phillip
tertiari
paediatr
hospit
perform
patient
age
year
oncolog
diagnosi
admit
june
march
includ
result
total
patient
admit
picu
occas
admiss
diagnosi
cn
malign
haematolog
solid
tumour
median
length
stay
day
longest
stay
day
admiss
care
medic
care
admiss
requir
ventil
support
medic
patient
three
ventil
admiss
also
requir
inotrop
support
medic
patient
two
admiss
requir
continu
venonegativen
haemofiltr
cvvh
one
hundr
seven
patient
surviv
discharg
home
three
patient
die
picu
medic
patient
one
patient
discharg
picu
surviv
discharg
hospit
conclus
larg
proport
oncolog
patient
admit
picu
requir
intervent
surviv
discharg
continu
treatment
regim
sever
factor
affect
durat
stay
patient
includ
reason
admiss
underli
diagnosi
number
intervent
requir
compar
data
previou
studi
result
suggest
picu
outcom
oncolog
patient
greatli
improv
term
surviv
w
dirksen
hospit
pediatr
hematolog
oncolog
germani
backgroundobject
pediatr
cancer
center
univers
hospit
muenster
children
adolesc
newli
diagnos
cancer
admit
per
year
receiv
treatment
intens
chemotherapi
nausea
vomit
among
frequent
time
distress
side
effect
chemotherapi
support
antiemet
drug
therapi
complementari
nurs
procedur
appli
observ
studi
evalu
use
aromatherapi
citru
oil
patient
popul
designmethod
aromatherapi
base
local
applic
natur
ether
oil
intact
skin
oil
act
nausea
via
olfactori
system
penetr
skin
surfac
profession
nurs
care
patient
nausea
vomit
especi
citru
oil
shown
efficaci
includ
lemon
orang
tangerin
grapefruit
essenti
oil
two
three
drop
ether
citru
oil
ad
clean
cotton
pad
local
appli
least
twice
daili
intact
skin
chest
close
head
result
patient
nausea
vomit
report
benefit
smell
citru
oil
overlay
smell
symptom
often
mitig
instanc
occurr
symptom
avoid
conclus
aromatherapi
citru
oil
suppport
antiemet
therapi
individu
prefer
smell
often
shape
person
memori
emot
highli
relev
therapeut
success
therefor
consid
choic
smell
combin
medic
standard
care
complementari
nurs
procedur
ad
valu
control
agon
side
effect
chemotherapi
therebi
enhanc
patient
complianc
subsequ
therapi
kn
da
silva
rv
cf
pd
nutrit
paulo
brazil
pediatr
paulo
brazil
backgroundobject
malnutrit
highlight
common
condit
cancer
patient
adequ
nutrit
conduct
taken
effect
nutrit
evalu
necessari
presenc
screen
tool
analyz
evalu
nutrit
risk
murphi
et
al
propos
specif
screen
tool
children
cancer
treatment
screen
tool
childhood
cancer
scan
rate
relationship
state
nutrit
risk
verifi
instrument
screen
children
teenag
cancer
designmethod
retrospect
studi
secondari
data
patient
seen
august
august
result
analyz
base
screen
perform
nutrit
team
period
compar
concomit
anthropometr
evalu
parametr
analyz
perform
stata
program
result
degre
nutrit
risk
cancer
patient
chang
accord
locat
caus
hospit
identifi
studi
diagnosi
nutrit
risk
relat
valu
bmi
bodi
mass
index
alter
observ
signific
relat
nutrit
risk
bodi
composit
teenag
conclus
found
scan
may
assist
clinic
practic
screen
patient
nutrit
risk
studi
perform
confirm
effect
especi
preschool
school
children
garofolo
ps
f
pediatr
paulo
brazil
pediatr
paulo
brazil
backgroundobject
malnutrit
cancer
patient
impair
prognosi
increas
cost
treatment
decreas
qualiti
life
studi
protocol
complianc
nutrit
outcom
malnourish
patient
cancer
oral
supplement
program
associ
outcom
type
supplement
sever
malnutrit
admiss
designmethod
clinic
trial
includ
patient
year
old
follow
anticanc
therapi
divid
two
group
mild
sever
malnutrit
sever
malnourish
receiv
industri
oral
supplement
io
three
week
wherea
mildli
malnourish
random
receiv
io
oral
supplement
ni
three
week
supplement
suppli
daili
energi
requir
new
approach
intervent
nai
indic
sever
malnourish
group
adequ
nutrit
respons
achiev
mildli
malnourish
io
subject
develop
sever
malnutrit
result
one
hundr
seventeen
patient
complet
follow
sever
mildli
malnourish
adequ
nutrit
outcom
observ
sever
condit
therefor
nai
analys
show
mild
malnutrit
io
group
ni
group
requir
nai
p
io
sever
malnutrit
significantli
associ
nutrit
outcom
io
demonstr
better
outcom
sever
malnutrit
wors
outcom
conclus
result
suggest
io
could
minim
nutrit
deficit
mainli
patient
mild
malnutrit
sever
malnutrit
associ
wors
nutrit
outcom
e
dray
r
c
hitchcock
medic
center
pediatr
intens
care
unit
west
lebanon
usa
nacion
de
oncologia
pediatrica
intens
care
guatemala
citi
guatemala
nacion
de
oncologia
pediatrica
nurs
educ
guatemala
citi
guatemala
jude
children
research
hospit
st
jude
global
memphi
usa
jude
children
research
hospit
st
jude
globalintens
care
memphi
usa
backgroundobject
hospit
children
cancer
popul
frequent
requir
critic
care
intens
intervent
surviv
children
cancer
low
set
depend
earli
recognit
cancer
diagnos
time
implement
treatment
protocol
manag
side
effect
prevent
deterior
recent
year
surviv
pediatr
oncolog
patient
critic
ill
center
improv
drastic
hospit
howev
continu
challeng
popul
result
poor
inpati
outcom
high
mortal
designmethod
sinc
de
centroamericana
ahopca
demonstr
collabor
improv
outcom
children
cancer
countri
use
ahopca
infrastructur
st
jude
children
research
hospit
sponsor
multidisciplinari
confer
februari
identifi
challeng
care
pediatr
oncolog
patient
critic
ill
set
identifi
opportun
multidisciplinari
collabor
result
nurs
oncologist
intensivist
attend
confer
ten
ahopca
member
countri
session
focus
qualiti
improv
method
intens
care
experi
hospit
elucid
challeng
goal
group
identifi
sever
major
challeng
provis
critic
care
pediatr
oncolog
patient
set
lack
adequ
physic
personnel
educ
resourc
inadequ
institut
support
provid
resist
allow
access
intens
care
resourc
patient
group
identifi
multidisciplinari
project
address
challeng
fit
framework
topic
address
qualiti
improv
research
educ
activ
conclus
meet
repres
first
multidisciplinari
confer
focus
intens
care
pediatr
oncolog
patient
central
america
experi
demonstr
hospit
face
similar
challeng
care
popul
challeng
identifi
address
innov
solut
form
result
multidisciplinari
collabor
p
p
p
n
central
hospit
pediatr
lilongw
malawi
children
hospit
pediatr
houston
usa
colleg
medicin
children
foundat
malawi
pediatr
lilongw
malawi
backgroundobject
malnutrit
critic
pediatr
oncolog
patient
increas
risk
complic
support
care
patient
malnutrit
essenti
howev
encount
challeng
treat
pediatr
oncolog
patient
accord
nutrit
rehabilit
unit
nru
clinic
guidelin
lilongw
malawi
two
reason
world
health
organ
malnutrit
guidelin
gener
focu
patient
year
age
protocol
often
struggl
identifi
cancer
patient
bulki
tumor
tumor
mass
misleadingli
contribut
child
weight
therebi
mask
malnutrit
especi
older
children
measur
arm
circumfer
muac
commonli
appli
designmethod
nutrit
supplement
program
implement
kamuzu
central
hospit
kch
juli
pediatr
oncolog
patient
receiv
supplement
feed
porridg
regardless
nutrit
statu
patient
mildmoder
malnutrit
receiv
therapeut
food
rutf
deriv
peanut
patient
sever
malnutrit
receiv
therapeut
milk
initi
follow
rutf
patient
underw
anthropometr
measur
includ
weight
height
muac
bodi
mass
index
bmi
schedul
evalu
evalu
describ
result
intervent
result
patient
median
age
year
interquartil
rang
diagnos
includ
solid
tumor
abdomen
lymphoma
solid
tumor
leukemia
one
patient
die
sever
malnutrit
found
moder
mild
sever
defin
bmi
muac
bmimuac
presenc
pit
edema
weight
month
interv
found
weight
gain
month
respect
chang
weight
loss
data
conclus
nutrit
supplement
improv
weight
gain
pediatr
oncolog
patient
malnutrit
howev
consist
comprehens
requir
addit
investig
caus
failur
improv
yelton
cl
school
medicin
wright
state
univers
medic
student
year
dayton
usa
school
medicin
wright
state
univers
wright
state
univers
student
dayton
usa
school
medicin
wright
state
univers
public
healthstatistician
dayton
usa
children
hospit
pediatr
hematolog
oncolog
dayton
usa
backgroundobject
current
child
cancer
survivor
america
studi
show
popul
reduc
physic
activ
compar
peer
led
mani
comorbid
children
oncolog
group
cog
guidelin
includ
exercis
recommend
pediatr
cancer
patient
post
treatment
object
studi
determin
pediatr
oncologist
awar
recommend
exercis
counsel
practic
barrier
exercis
counsel
designmethod
onlin
survey
modifi
abramson
et
al
person
exercis
habit
counsel
practic
primari
care
physician
nation
survey
sent
attend
physician
fellow
cog
member
list
result
attend
physician
fellow
return
complet
survey
almost
believ
exercis
import
familiar
cog
post
treatment
exercis
recommend
percent
attend
physician
report
counsel
least
half
patient
post
treatment
compar
fellow
p
test
patient
activ
treatment
attend
fellow
counsel
least
half
patient
p
fellow
report
enough
time
exercis
counsel
compar
attend
p
physician
counsel
patient
activ
treatment
counsel
verbal
recommend
least
daysweek
minut
time
physician
spent
counsel
seem
improv
patient
complianc
especi
least
minut
spent
conclus
although
physician
believ
exercis
import
pediatr
oncolog
patient
gap
knowledg
current
cog
recommend
addit
publish
guidelin
exercis
popul
research
investig
method
increas
physician
knowledg
regard
exercis
counsel
pediatr
cancer
patient
way
improv
counsel
practic
l
f
aa
p
child
cancer
oper
london
unit
kingdom
take
oper
cambridg
unit
kingdom
children
hospit
paediatr
yangon
myanmar
burma
backgroundobject
cost
transport
identifi
one
key
reason
patient
abandon
treatment
yangon
children
hospit
ych
myanmar
assess
found
abandon
high
ngo
pleas
take
work
partnership
world
child
cancer
address
issu
pilot
project
develop
understand
transport
need
paediatr
oncolog
patient
ych
designmethod
week
survey
conduct
understand
barrier
access
care
interview
conduct
criteria
establish
offer
transport
support
week
pilot
project
run
use
criteria
pilot
patient
support
grant
comput
programm
design
captur
accur
data
result
use
design
support
packag
aim
reduc
abandon
result
averag
monthli
household
incom
famili
ych
total
cost
amount
burmes
state
return
cost
travel
hospit
amount
monthli
household
incom
caregiv
stop
work
regularli
entir
diagnosi
famili
appoint
schedul
within
period
project
project
team
identifi
one
case
famili
return
famili
becam
close
project
team
contact
frequent
provid
updat
travel
arrang
caregiv
felt
connect
project
teamsoci
worker
often
ask
support
conclus
total
provid
transport
cost
patient
famili
ych
would
per
year
provid
amount
requir
round
trip
mean
children
return
outpati
appoint
treatment
result
lower
rate
abandon
grimshaw
children
hospit
alli
health
melbourn
australia
backgroundobject
physic
activ
may
benefit
children
undergo
intens
treatment
cancer
programm
challeng
implement
systemat
review
aim
investig
feasibl
physic
activ
intervent
intens
cancer
treatment
children
adolesc
designmethod
systemat
search
seven
electron
databas
cumul
index
nurs
alli
health
literatur
medic
literatur
analysi
retriev
system
onlin
publicpublish
medlin
psycholog
inform
databas
sportsdiscuss
excerpta
medica
databas
alli
complementari
medicin
databas
august
complet
risk
bia
assess
use
down
black
checklist
critic
review
qualit
studi
result
summaris
descript
across
eight
domain
feasibl
accept
demand
implement
adapt
practic
integr
expans
limit
effici
test
includ
effect
result
eleven
quantit
studi
one
qualit
studi
identifi
inclus
physic
activ
intervent
typic
supervis
individualis
programm
prescrib
varieti
activ
type
hospit
inpati
evid
physic
activ
intervent
intens
phase
cancer
treatment
accept
parent
children
safe
success
implement
trend
posit
effect
across
aspect
function
note
data
unavail
document
feasibl
domain
integr
adapt
expans
conclus
preliminari
evid
physic
activ
intervent
feasibl
accept
safe
potenti
benefici
children
cancer
work
need
done
understand
effect
way
implement
type
programm
guram
e
b
cambridg
paediatr
haematolog
oncolog
depart
cambridg
unit
kingdom
backgroundobject
vincristin
vinca
alkaloid
use
chemotherapeut
agent
multipl
paediatr
haematolog
solid
tumour
frequent
complic
neurolog
toxic
studi
suggest
polymorph
gene
contribut
neurotox
may
explain
variat
preval
side
effect
overal
prognosi
establish
link
mercaptopurin
toxic
polymorph
led
incorpor
target
genet
screen
therapi
suggest
potenti
tailor
vincristin
treatment
aim
identifi
case
neurotox
within
patient
popul
characteris
trend
toxic
investig
demograph
influenc
side
effect
designmethod
five
year
retrospect
studi
decemb
februari
focus
paediatr
patient
present
oncolog
unit
undergo
first
line
chemotherapi
acut
lymphoblast
leukaemia
low
grade
glioma
wilm
tumour
malign
chosen
heavi
burden
vincristin
treatment
protocol
neurotox
assess
use
common
terminolog
criteria
advers
event
ctcae
patient
record
studi
detail
neurotox
use
tool
subsequ
chang
made
dosag
vincristin
result
frequenc
neurotox
event
high
incid
neurotox
event
grade
sever
found
patient
experienc
one
event
motor
neurotox
modal
group
demograph
toxic
higher
amongst
femal
older
age
categori
ethnic
variat
trend
toward
increas
toxic
clear
relationship
tumour
type
neurotox
time
two
third
neuropathi
occur
within
first
three
month
conclus
pilot
studi
demonstr
high
rate
neurotox
within
subset
paediatr
haematolog
oncolog
popul
warrant
larger
studi
potenti
pharmacogenet
analysi
r
h
n
v
n
j
ganga
ram
hospit
pediatr
hematolog
oncolog
delhi
india
ganga
ram
hospit
depart
research
delhi
india
ganga
ram
hospit
depart
microbiolog
delhi
india
backgroundobject
invas
aspergillosi
ia
frequent
one
lethal
invas
fungal
infect
oncolog
patient
diagnosi
ia
difficult
reli
part
detect
galactomannan
gm
aim
object
studi
util
gm
assay
diagnos
ia
paediatr
oncolog
paediatr
critic
care
stem
cell
recipi
focu
place
evalu
assay
sensit
specif
neg
predict
valu
paediatr
patient
designmethod
retrospect
analysi
febril
neutropenia
prolong
febril
episod
immunocompromis
patient
juli
octob
done
standard
eortc
criteria
use
defin
fungal
infect
clinic
profil
gm
assay
radiolog
imag
need
mould
activ
antifung
therapi
assess
result
patient
episod
suspect
ia
enrol
studi
includ
haematolog
malign
stem
cell
transplant
recipi
patient
paediatr
icu
proven
probabl
observ
period
gm
assay
consid
posit
valu
sensit
specif
neg
predict
valu
assay
diagnos
ia
respect
conclus
data
suggest
gm
assay
good
neg
predict
valu
diagnos
ia
gm
eia
test
may
use
diagnos
andor
exclud
ia
paediatr
patient
low
incid
rate
probabl
proven
ia
studi
preclud
abil
make
definit
conclus
r
h
n
n
v
j
ganga
ram
hospit
pediatr
hematolog
oncolog
delhi
india
ganga
ram
hospit
depart
microbiolog
delhi
india
backgroundobject
galactomannan
gm
assay
use
wide
diagnost
marker
invas
aspergillosi
ia
immunocompromis
patient
studi
gm
involv
sever
neutropen
patient
screen
two
three
time
weekli
neutropen
risk
period
time
posit
galactomannan
depend
neutrophil
count
often
ignor
interpret
result
aim
object
aim
studi
determin
whether
diagnost
yield
gm
compar
neutropen
patient
without
microbiolog
document
ia
designmethod
retrospect
observ
analysi
episod
ia
occur
haematolog
depart
retrospect
classifi
accord
eortc
criteria
proven
probabl
possibl
ia
juli
octob
patient
data
analys
includ
neutrophil
count
galactomannan
assay
result
patient
enrol
episod
suspect
ia
includ
patient
hematolog
malign
stem
cell
transplant
recipi
thirti
four
episod
proven
probabl
ia
observ
gm
consid
posit
valu
patient
receiv
therapi
ia
anc
compar
posit
galactomannan
patient
receiv
treatment
ia
trend
toward
higher
gm
posit
lower
anc
observ
although
statist
signific
anc
patient
receiv
mould
activ
antifung
median
anc
gm
posit
gm
neg
ct
posit
ia
median
anc
gm
posit
gm
neg
conclus
galactomannan
may
fals
neg
patient
anc
kept
mind
interpret
result
h
hassan
b
leed
leed
institut
cancer
patholog
leed
unit
kingdom
teach
hospit
nh
trust
depeart
paediatr
haematolog
oncolog
leed
unit
kingdom
york
centr
review
dissemin
york
unit
kingdom
backgroundobject
death
directli
due
cancer
term
mortal
trm
appreci
differ
trm
death
critic
direct
strategi
improv
support
care
intervent
deliv
diseas
progress
howev
poorli
defin
report
clinic
trial
recent
global
collabor
develop
valid
classif
tool
attribut
system
studi
aim
evalu
newli
develop
definit
trm
attribut
system
singl
institut
region
paediatr
oncolog
centr
north
england
designmethod
thirti
medic
record
recent
death
children
cancer
two
four
week
prior
death
anonymis
present
particip
two
senior
physician
two
clinic
research
associ
independ
classifi
death
treatment
relat
mortal
treatment
relat
accord
algorithm
develop
trm
occur
review
appli
attribut
system
reliabl
assess
use
kappa
statist
k
result
reliabl
classif
deem
almost
perfect
cra
consult
confid
interv
ten
death
classifi
trm
infect
frequent
caus
identifi
review
disagre
primari
caus
death
eg
respiratori
vs
infect
appli
attribut
system
case
studi
identifi
algorithm
may
identifi
trm
death
patient
receiv
therapi
conclus
classif
caus
death
attribut
system
could
implement
differ
health
care
set
adapt
classif
tool
patient
receiv
intervent
caus
death
attribut
system
consid
h
hassan
b
leed
leed
institut
cancer
patholog
leed
unit
kingdom
teach
hospit
nh
trust
depart
paediatr
haematolog
oncolog
leed
unit
kingdom
york
centr
review
dissemin
york
unit
kingdom
backgroundobject
probiot
live
microorgan
confer
health
benefit
host
administ
adequ
amount
studi
updat
systemat
review
investig
efficaci
safeti
probiot
adult
paediatr
patient
diagnos
cancer
designmethod
updat
systemat
review
undertaken
prospero
registr
randomis
control
trial
rct
identifi
screen
multipl
databas
includ
analys
efficaci
case
report
includ
safeti
analysi
outcom
includ
reduct
incid
sever
diarrhoea
advers
event
possibl
data
combin
use
model
analysi
includ
children
undertaken
investig
strain
dosag
probiot
patient
characterist
result
twenti
one
studi
n
particip
includ
assess
efficaci
result
show
probiot
may
reduc
incid
diarrhoea
patient
cancer
odd
ratio
confid
interv
ci
studi
durat
pyrexia
standard
mean
differ
day
ci
studi
possibl
sever
diarrhoea
exampl
common
toxic
criteria
grade
diarrhoea
ci
studi
howev
studi
requir
assess
true
effect
insuffici
data
perform
subgroup
analysi
children
strain
dosag
due
mark
heterogen
twenti
five
studi
n
includ
safeti
analysi
five
case
report
particip
rct
show
bacteraemiafungaemiaposit
blood
cultur
conclus
remain
insuffici
studi
assess
true
effect
probiot
peopl
cancer
evid
suggest
probiot
may
benefici
studi
still
requir
particularli
children
ilhan
c
n
abdurrahman
yurtaslan
ankara
oncolog
train
research
hospit
pediatr
hematolog
oncolog
ankara
turkey
abdurrahman
yurtaslan
ankara
oncolog
train
research
hospit
clinic
biochemistri
ankara
turkey
backgroundobject
febril
neutropenia
fn
one
major
caus
morbid
mortal
patient
cancer
endotheli
damag
dysfunct
one
import
featur
sepsi
studi
sought
investig
role
serum
level
vascular
endotheli
growth
factor
vegf
solubl
tyrosin
predict
risk
sepsi
febril
neutropen
children
designmethod
januari
decemb
prospect
measur
concentr
vegf
onset
hour
fever
fn
episod
evalu
diagnost
accuraci
mediat
predictor
sepsi
bacteriemia
result
episod
fn
patient
median
year
evalu
common
diagnosi
acut
lymphoblast
leukemia
osteosarcoma
follow
ewe
sarcoma
fn
episod
complic
sepsi
fn
episod
microbiolog
agent
isol
baselin
level
pgml
rang
pgml
level
pgml
rang
pgml
p
higher
pgml
rang
pgml
p
vegf
level
pgml
rang
pgml
p
lower
patient
group
compar
healthi
individu
serum
concentr
significantli
higher
onset
fever
patient
sepsi
pgml
patient
without
sepsi
pgml
test
p
statist
signific
differ
vegf
level
patient
noncompl
fn
compar
patient
develop
sepsi
andor
bacteriemia
conclus
conclud
high
level
onset
fever
could
indic
sepsi
febril
neutropen
patient
pediatr
cancer
popul
v
ingli
l
c
kid
cancer
europ
care
connect
london
unit
kingdom
kid
cancer
research
advocaci
new
york
usa
backgroundobject
famili
children
affect
paediatr
cancer
benefit
emot
support
inform
empow
decis
make
diagnosi
throughout
diseas
treatment
inform
decis
augment
recognit
emot
need
social
knowledg
diseas
clinic
research
landscap
increasingli
famili
seek
access
clinic
trial
across
border
option
becom
limit
local
flexibl
approach
term
care
connect
famili
support
uniqu
paradigm
develop
offer
comprehens
support
children
famili
designmethod
care
connect
program
employ
team
led
famili
coordin
meet
need
individu
cancer
patient
famili
crucial
role
provid
trust
experienc
listen
identifi
key
need
provid
tailor
support
guidanc
throughout
cancer
journey
support
provid
remit
access
novel
therapi
home
abroad
includ
assess
navig
clinic
trial
landscap
guidanc
researcherclinician
network
treatment
cost
negoti
travel
logist
annual
parent
educ
confer
provid
insight
current
research
result
date
famili
worldwid
posit
impact
model
case
studi
three
famili
present
demonstr
necess
flexibl
illustr
rang
resourc
requir
support
cancer
care
approach
directli
help
famili
make
inform
decis
regard
palli
care
access
clinic
trial
oversea
improv
qualiti
life
survivorship
conclus
famili
empow
make
inform
decis
regard
child
cancer
care
approach
care
connect
appli
jaboma
hospic
palli
care
associ
kehpca
hope
cancer
kid
nairobi
kenya
backgroundobject
hope
cancer
kid
charit
organ
kenya
one
success
program
health
insur
program
cover
cost
relat
treat
childhood
cancer
kenyan
public
hospit
designmethod
made
possibl
nation
hospit
insur
fund
nhif
govern
state
corpor
provid
kenyan
citizen
attain
age
year
opportun
access
afford
sustain
qualiti
health
insur
establish
special
partnership
nhif
ensur
registr
children
adolesc
suffer
cancer
famili
usd
monthli
usd
yearli
whole
famili
well
orphan
subsid
rate
usd
monthli
usd
yearli
per
orphan
provid
special
reduc
one
month
activ
period
parent
regist
oppos
normal
three
month
activ
period
kenyan
result
februari
children
benefit
program
complet
treatment
success
still
go
treatment
die
get
new
patient
monthli
dire
need
support
children
affect
kenya
come
poor
background
cancer
treatment
costli
howev
ensur
children
suffer
cancer
access
treatment
conclus
result
give
hope
motiv
mani
parent
take
children
hospit
cancer
treatment
sinc
reliev
financi
burden
result
children
adolesc
suffer
cancer
kenya
abl
access
treatment
p
jain
n
v
ganga
ram
delhi
pediatr
hematolog
oncolog
delhi
india
backgroundobject
clinic
spectrum
dengu
fever
rang
mild
febril
ill
catastroph
haemorrhag
fever
manag
dengu
fever
children
malign
often
challeng
clinic
present
cours
risk
mortal
discuss
designmethod
retrospect
analys
data
children
develop
dengu
fever
treatment
malign
dengu
fever
diagnos
base
posit
result
evalu
patient
male
median
age
rang
underli
diagnos
includ
aml
solid
tumour
nine
intens
phase
treatment
post
hsct
relaps
aml
tumour
fever
present
complaint
patient
follow
vomit
abdomin
distens
unexplain
oliguria
unexpect
fall
platelet
count
median
minimum
platelet
count
interquartil
rang
mean
time
platelet
recoveri
day
rang
children
intens
treatment
patient
intens
treatment
significantli
higher
median
minimum
platelet
count
iqr
shorter
mean
time
platelet
recoveri
day
signific
bleed
manifest
sever
ill
plasma
leakag
found
children
intens
treatment
regimen
two
children
die
dengu
haemorrhag
fever
induct
consolid
chemotherapi
respect
probabl
due
delay
diagnos
dengu
fever
investig
dengu
sent
day
fever
epidem
done
day
fever
epidem
contribut
earli
diagnosi
prompt
manag
dengu
fever
mortal
conclus
high
index
suspicion
kept
dengu
infect
immunocompromis
children
suffer
malign
annual
epidem
aggress
support
mandatori
especi
intens
treatment
phase
magnusson
l
von
j
k
k
j
j
g
univers
departmend
women
children
health
uppsala
sweden
univers
departmend
women
children
clinic
psycholog
healthcar
uppsala
sweden
univers
depart
medic
hematolog
uppsala
sweden
academi
depart
clinic
pediatr
gothenburg
sweden
institut
depart
dental
medicin
stockholm
sweden
univers
hospit
depart
clinic
section
pediatr
oncologyhematolog
lund
sweden
institut
depart
clinic
intervent
technolog
stockholm
sweden
backgroundobject
oral
mucos
om
common
advers
effect
hematopoiet
stem
cell
transplant
hsct
oral
cryotherapi
oc
cool
mouth
chemotherapi
infus
shown
reduc
om
adult
effect
children
evalu
studi
aim
examin
oc
reduc
incid
sever
om
oral
toxic
score
use
opioid
children
undergo
hsct
designmethod
studi
multicent
random
clinic
trial
children
year
old
random
either
oc
standard
treatment
instruct
cool
mouth
ice
long
could
chemotherapi
infus
intend
time
least
minut
time
record
nurs
infus
child
evalu
treatment
questionnair
grade
mucos
record
use
day
transplant
engraft
use
opioid
collect
child
medic
chart
opioid
dose
convert
equival
intraven
dose
morphin
result
children
mean
age
year
includ
studi
children
random
oc
standard
care
complianc
oc
vari
consider
children
abl
use
oc
accord
protocol
sever
mucos
report
children
differ
two
group
children
use
opioid
mean
day
mean
total
dose
mg
iv
morphin
differ
use
opioid
two
group
conclus
oc
reduc
incid
sever
om
use
opioid
children
undergo
hsct
howev
complianc
oc
poor
especi
among
youngest
children
may
influenc
result
j
kearn
k
health
centr
pediatr
dentistri
halifax
canada
health
centr
pediatr
hematolog
depart
pediatr
halifax
canada
backgroundobject
recommend
dental
evalu
treatment
prior
commenc
oncolog
therapi
well
recogn
howev
data
dental
need
diagnosi
pediatr
oncolog
patient
scant
popul
base
studi
design
assess
report
oral
health
statu
dental
need
pediatr
oncolog
patient
time
diagnosi
well
treatment
provid
designmethod
ethic
approv
pediatr
oncolog
patient
maritim
provinc
manag
izaac
walton
killam
iwk
health
centr
januari
decemb
identifi
inclus
studi
part
routin
oncolog
care
plan
patient
undergo
chemotherapi
referr
dentistri
evalu
data
extract
pediatr
oncolog
hospit
databas
ii
dental
clinic
record
iii
electron
medic
record
total
number
patient
without
dental
need
time
diagnosi
treatment
render
method
treatment
cari
risk
statu
cr
comput
spss
version
use
statist
analysi
result
patient
male
femal
median
age
month
review
dentistri
includ
studi
among
patient
age
year
experienc
cari
respect
dental
patholog
observ
abscess
retain
primari
teeth
soft
tissu
patholog
previou
trauma
high
cr
observ
excel
oral
hygien
treatment
requir
patient
coordin
procedur
twenti
eight
patient
requir
extract
receiv
sealant
type
cancer
associ
incid
cari
conclus
substanti
burden
dental
diseas
requir
therapi
identifi
studi
popul
care
success
deliv
coordin
multidisciplinari
model
h
r
kebudi
g
kalyoncu
ny
e
n
n
e
e
e
univers
cerrahpasa
medic
faculti
pediatr
turkey
univers
oncolog
institut
pediatr
turkey
univers
cerrahpasa
medic
faculti
radiolog
turkey
pediatr
hospit
pediatr
hematolog
oncolog
ankara
turkey
univers
medic
faculti
pediatr
hematolog
oncolog
kayseri
turkey
univers
medic
faculti
pediatr
hematolog
oncolog
koca
turkey
univers
medic
faculti
pediatr
hematolog
oncolog
ankara
turkey
hospit
pediatr
hematolog
depart
ankara
turkey
univers
medic
faculti
pediatr
istanbul
turkey
sultan
research
train
hospit
pediatr
hematolog
oncolog
turkey
backgroundobject
children
leukemia
increas
risk
invas
fungal
infect
includ
hepatosplen
fungal
infect
hsfi
aim
assess
risk
factor
treatment
outcom
hsfi
children
leukemia
designmethod
retrospect
evalu
risk
factor
diagnost
approach
treatment
outcom
hsfi
children
leukemia
nine
center
turkey
result
hsfi
seen
children
leukemia
femal
male
precursor
biphenotyp
relaps
four
aml
relaps
one
cml
case
diagnos
radiolog
abdomin
ultrasound
perform
median
day
febril
neutropenia
also
computer
tomographi
magnet
reson
imag
twelv
patient
hepatosplen
five
splenic
nine
hepat
involv
episod
occur
end
induct
case
patient
receiv
steroid
prior
hsfi
case
diagnos
evalu
persist
febril
neutropenia
three
case
abdomin
pain
thirteen
case
back
pain
extend
shoulder
one
patient
liver
nodul
excis
mucor
diagnos
patholog
five
trucut
biopsi
done
patient
receiv
broad
spectrum
antibiot
due
febril
neutropenia
variou
antifung
liposom
amphotericin
b
caspofungin
voriconasol
micafungin
posaconasol
fifteen
patient
radiologicmicrobiolog
evid
fungal
infect
site
lung
brain
esophagu
eight
patient
transfer
icu
hemophagocytosi
observ
two
patient
two
patient
receiv
granulocyt
suspens
twenti
patient
recov
six
die
three
due
hsfi
three
due
progress
leukemia
conclus
suggest
abdomin
ultrasound
ad
standard
recommend
ct
lung
evalu
persist
febril
neutropenia
diagnos
hepatosplen
fungal
infect
mucor
consid
antifung
treatment
spectrum
khera
r
pediatr
chandigarh
india
backgroundobject
vitamin
folic
acid
fa
help
make
cell
stroma
conduc
prolifer
malign
clone
lower
middl
incom
countri
lmic
fraught
malnutrit
vitamin
defici
refrain
folat
supplement
patient
malign
lmic
question
evalu
incid
vitamin
defici
children
therapi
acut
lymphoblast
leukemia
designmethod
children
therapi
randomli
evalu
serum
folat
level
serum
folat
ngml
taken
defici
defici
statu
correl
undernutrit
weight
age
result
hundr
children
age
year
mainten
induct
chemotherapi
agesex
match
control
evalu
induct
therapi
eleven
children
undernourish
mean
level
pgml
defici
undernourish
mean
folat
level
ngml
child
defici
mainten
therapi
fourteen
children
undernourish
mean
level
defici
undernourish
mean
folat
level
defici
undernourish
mean
level
folat
lower
children
undernourish
mainten
differ
folat
level
gender
risk
group
control
group
defici
conclus
childhood
india
preval
fa
defici
gener
popul
higher
preval
undernourish
cohort
undernutrit
children
folat
defici
patient
undernutrit
greater
defici
remain
monster
tackl
lmic
counter
undernutrit
supplement
key
lmic
j
c
k
k
kulkarni
health
center
pediatr
hematolog
depart
pediatr
halifax
canada
backgroundobject
dysfunct
defin
inabl
flush
andor
draw
blood
common
complic
central
venou
cathet
cvc
tissu
plasminogen
activ
tpa
well
demonstr
revers
cvc
dysfunct
howev
associ
number
dose
tpa
requir
cvc
clear
hypothes
requir
increas
number
dose
tpa
increment
associ
requir
cvc
pediatr
oncolog
patient
designmethod
data
abstract
pediatr
oncolog
patient
maritim
provinc
manag
izaac
walton
killam
iwk
health
centr
januari
decemb
institut
ethic
approv
patient
requir
cvc
includ
data
combin
pediatr
oncolog
hospit
databas
iii
electron
medic
record
iv
pharmaci
databas
v
iwk
central
line
databas
result
studi
popul
receiv
dose
tpa
fiftyseven
patient
receiv
dose
tpa
mean
number
cvc
per
individu
patient
patient
need
cvc
requir
patient
receiv
dose
tpa
significantli
higher
mean
number
cvc
per
individu
patient
need
cvc
requir
patient
receiv
tpa
mean
number
cvc
per
individu
patient
need
cvc
requir
patient
receiv
dose
tpa
significantli
higher
compar
remaind
per
individu
patient
conclus
present
studi
demonstr
patient
requir
tpa
cvc
dysfunct
increment
risk
requir
cvc
base
number
tpa
dose
observ
may
indic
requir
tpa
may
identifi
patient
higher
risk
cvc
loss
valid
observ
aid
identif
high
risk
patient
design
strategi
mitig
cvc
loss
kwk
lam
hcw
univeristi
hong
kong
school
nurs
hong
kong
hong
kong
sar
backgroundobject
literatur
review
reflect
children
cancer
fail
attain
physic
activ
level
contract
diseas
scientif
evid
support
regular
physic
activ
benefici
effect
wherea
physic
inact
induc
increas
fatigu
muscl
catabol
atrophi
nevertheless
increas
concern
indic
increas
demand
famili
children
pose
specif
challeng
implement
intervent
uniqu
intens
treatment
phase
studi
aim
examin
feasibl
integr
experienti
train
program
coach
healthcar
profession
promot
regular
physic
activ
reduc
fatigu
enhanc
qualiti
life
among
hong
kong
chines
children
cancer
designmethod
randomis
control
trial
rct
within
subject
design
conduct
total
children
cancer
randomli
alloc
experiment
group
group
particip
experiment
group
receiv
home
visit
nurs
student
coach
month
placebo
control
group
receiv
amount
time
attent
home
visit
research
assist
mimic
receiv
experiment
group
particip
level
fatigu
physic
activ
muscl
strength
depress
qualiti
life
assess
time
recruit
month
interview
also
conduct
result
statist
signific
result
posit
trend
found
among
outcom
variabl
experiment
group
qualit
analysi
also
reveal
inform
happi
satisfi
experi
less
fatigu
improv
physic
activ
level
muscl
strength
mood
integr
program
found
feasibl
seriou
advers
effect
conclus
integr
experienti
train
program
coach
healthcar
profession
found
feasibl
safe
among
children
cancer
ck
li
j
x
j
h
c
x
x
q
r
x
c
n
h
l
k
univers
west
china
second
hospit
hematolog
oncolog
chengdu
china
chines
univers
hong
kong
paediatr
hong
kong
china
jiaotong
univers
school
medicin
affili
shanghai
children
medic
center
hematolog
oncolog
shanghai
china
hematolog
blood
diseas
hospit
chines
academi
medic
scienc
peke
union
medic
colleg
hematolog
oncolog
tianjin
china
medic
univers
affili
children
hospit
hematolog
oncolog
chongq
china
hospit
soochow
univers
hematolog
oncolog
suzhou
china
women
children
health
care
center
hematolog
oncolog
guangzhou
china
medic
univers
affili
nanfang
hospit
pediatr
guangzhou
china
hospit
fudan
univers
hematolog
oncolog
shanghai
china
hospit
shandong
univers
pediatr
jinan
china
children
hospit
affili
nanj
medic
univers
hematolog
oncolog
nanj
china
univers
scienc
technolog
tongji
medic
colleg
tongji
hospit
hematolog
oncolog
wuhan
china
univers
scienc
technolog
tongji
medic
colleg
union
hospit
pediatr
wuhan
china
children
hospit
hematolog
oncolog
kunm
china
provinci
children
hospit
hematolog
oncolog
nanchang
china
medic
univers
second
affili
hospit
pediatr
hefei
china
hospit
affili
shanghai
jiaotong
univers
hematolog
oncolog
shanghai
china
univers
affili
hospit
hemnatolog
oncolog
qingdao
china
northwest
women
children
hospit
hematolog
oncolog
xian
china
backgroundobject
infect
relat
mortal
irm
import
caus
treatment
failur
chemotherapi
china
children
cancer
group
studi
conduct
prospect
multicent
clinic
trial
chemotherapi
stratifi
accord
risk
group
studi
aim
analyz
incid
prognosi
septicemia
factor
associ
irm
designmethod
regular
report
advers
effect
ae
seriou
advers
effect
sae
requir
septicemia
ae
death
sae
annual
audit
particip
site
includ
random
check
septicemia
episod
result
subject
particip
hospit
recruit
total
patient
report
septicemia
male
femal
ratio
median
age
year
time
septicemia
induct
case
consolid
case
interim
maintenancereinduct
case
twelv
patient
die
irm
rate
patient
die
induct
consolid
interim
maintenancereinduct
accord
blood
cultur
gram
posit
gposit
staphylococcu
epidermidi
staphylococcu
aureu
streptococcu
pneumonia
enterococcu
gram
neg
gneg
e
coli
pseudomona
klebsiella
pneumonia
enterobact
cloaca
fungu
candida
among
fatal
case
due
gneg
one
due
gposit
one
due
fungu
interim
maintenancereinduct
phase
associ
higher
chanc
irm
p
associ
risk
group
gender
type
organ
conclus
patient
develop
septicemia
chemotherapi
mortal
rate
earli
institut
broad
spectrum
hospit
stay
induct
reduc
irm
interim
mainten
higher
irm
probabl
relat
manag
possibl
delay
start
antibiot
gneg
septicemia
higher
irm
educ
parent
earli
attent
medic
treatment
interim
mainten
strengthen
support
viva
children
cancer
foundat
hong
kong
b
lockart
k
v
k
e
children
hospit
hematologyoncolog
chicago
usa
children
hospit
pediatr
surgeri
chicago
usa
univers
reproduct
medicin
chicago
usa
backgroundobject
mani
children
adolesc
diagnos
cancer
surviv
adulthood
improv
outcom
research
demonstr
famili
concern
impact
treatment
futur
fertil
respons
increas
awar
famili
distress
surround
infertil
treatment
ann
robert
h
luri
children
hospit
initi
fertil
preserv
program
program
provid
counsel
educ
fertil
preserv
patient
risk
infertil
due
cancer
treatment
undergo
stem
cell
transplant
malign
malign
condit
report
experi
ovarian
tissu
cryopreserv
otc
patient
receiv
gonadotox
treatment
includ
chemotherapi
radiat
stem
cell
transplant
designmethod
review
data
number
fertil
preserv
consult
provid
femal
patient
sinc
start
fertil
preserv
program
inform
otc
perform
ann
robert
h
luri
children
hospit
chicago
januari
septemb
report
result
number
fertil
preserv
consult
femal
cancer
patient
increas
annual
five
femal
underw
otc
number
increas
major
patient
underw
otc
prior
initi
cancer
treatment
patient
mean
age
year
youngest
patient
five
month
age
mean
age
year
oldest
year
complic
note
otc
number
tissu
vial
preserv
rang
four
tissu
preserv
patient
conclus
ovarian
tissu
cryopreserv
feasibl
patient
b
lockart
r
k
e
e
v
h
k
children
hospit
hematologyoncolog
chicago
usa
medicin
urolog
chicago
usa
children
hospit
urolog
chicago
usa
children
hospit
pediatr
surgeri
chicago
usa
children
hospit
pediar
surgeri
chicago
usa
pittsburgh
mage
women
research
institut
pittsburgh
usa
backgroundobject
children
adolesc
diagnos
cancer
surviv
adulthood
increas
surviv
rate
research
demonstr
famili
concern
impact
treatment
fertil
respons
increas
awar
famili
distress
surround
infertil
treatment
ann
robert
h
luri
children
hospit
lch
initi
fertil
preserv
fp
servic
program
provid
counsel
educ
fp
patient
risk
infertil
due
cancer
treatment
undergo
stem
cell
transplant
malign
condit
august
lch
open
testicular
tissu
cryopreserv
ttc
protocol
aim
describ
earli
experi
ttc
designmethod
review
data
patient
underw
ttc
lch
august
march
result
date
male
undergon
ttc
lch
mean
age
ttc
year
rang
month
year
ten
patient
underw
ttc
prior
initi
cancer
treatment
testicular
sperm
extract
attempt
two
patient
prior
ttc
five
patient
receiv
chemo
three
treat
less
cyclophosphamid
prior
ttc
two
patient
receiv
chemotherapi
data
tissu
yield
avail
nine
two
patient
mean
vial
tissu
per
patient
obtain
rang
undifferenti
spermatogonia
stem
cell
note
tissu
testicular
biopsi
one
patient
develop
incision
infect
conclus
testicular
tissu
cryopreserv
safe
feasibl
male
prior
initi
chemotherapi
viabl
undifferenti
spermatogonia
stem
cell
found
sampl
patient
undergo
ttc
luri
children
hospit
fund
testicular
tissu
process
freez
depart
obstetr
gynecolog
reproduct
scienc
univers
pittsburgh
eah
loeffen
ht
van
der
wje
beatrix
children
univers
medic
center
groningen
depart
pediatr
oncologyhematolog
groningen
netherland
backgroundobject
third
children
cancer
febril
neutropenia
bacteri
infect
nevertheless
standard
care
compris
hospit
intraven
antibiot
sever
biomark
propos
predict
marker
bacteri
infect
popul
aim
evalu
role
procalcitonin
pct
diagnos
bacteri
infect
children
cancer
febril
neutropenia
designmethod
studi
popul
deriv
prospect
databas
studi
compris
children
cancer
present
febril
neutropenia
store
plasma
sampl
taken
admiss
andor
hour
determin
pct
level
consequ
explor
relat
presenc
bacteri
infect
posit
blood
cultur
posit
clinic
bacteri
focu
predefin
valu
base
previou
research
ngl
ngml
pct
result
febril
neutropen
episod
children
cancer
includ
episod
bacteri
infect
document
present
hour
median
valu
well
pct
significantli
higher
patient
bacteri
infect
compar
patient
without
bacteri
infect
biomark
valu
sensit
either
one
identifi
group
compris
popul
conclus
pct
promis
marker
identifi
bacteri
infect
children
cancer
febril
neutropenia
subsequ
project
incorpor
biomark
risk
assess
model
test
prospect
clinic
trial
eah
loeffen
rl
md
van
de
lcm
f
wje
obotgwg
pain
children
children
univers
medic
center
univers
groningen
depart
pediatr
oncologyhematolog
groningen
netherland
children
academ
medic
center
depart
pediatr
oncolog
amsterdam
netherland
hospit
sick
children
depart
pharmaci
research
institut
toronto
canada
hospit
sick
children
depart
anesthesia
pain
medicin
toronto
canada
backgroundobject
guidelin
support
care
children
cancer
need
pain
children
cancer
identifi
area
mani
clinician
seek
guidanc
aim
develop
clinic
practic
guidelin
cpg
pain
children
cancer
recommend
assess
pain
pharmacolog
prevent
treatment
pain
b
pain
c
pain
physic
psycholog
prevent
treatment
pain
b
pain
designmethod
intern
guidelin
panel
compris
core
group
six
work
group
includ
individu
phase
clinic
question
formul
topic
priorit
maximum
per
work
group
use
grade
methodolog
scope
possibl
outcom
clinic
question
delin
critic
import
outcom
decis
make
clinic
question
identifi
via
electron
vote
result
six
work
group
priorit
total
clinic
question
answer
systemat
literatur
review
number
critic
outcom
differ
per
question
minimum
maximum
conclus
develop
framework
cpg
develop
next
phase
systemat
literatur
review
undertaken
framework
use
formul
recommend
expect
final
guidelin
spring
arafah
h
l
h
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
institut
pediatr
oncolog
cairo
egypt
backgroundobject
patient
hematolog
malign
higher
risk
invas
fungal
infect
ifi
incid
ifi
highest
among
patient
acut
myeloid
leukemia
earli
detect
appropri
antifung
prophylaxi
help
decreas
incid
infect
relat
complic
designmethod
prospect
retrospect
histor
control
arm
studi
includ
newli
diagnos
acut
myeloid
leukemia
patient
treat
nation
cancer
institut
cairo
univers
prospect
group
patient
receiv
primari
voriconazol
prophylaxi
prophylact
arm
compar
patient
retrospect
control
non
prophylact
arm
regard
infecti
complic
incid
fungal
infect
result
median
age
year
almost
primari
invas
fungal
infect
ifi
occur
lung
ifi
occur
induct
phase
chemotherapi
primari
prophylaxi
voriconazol
highli
statist
signific
impact
reduct
incid
invas
fungal
infect
group
p
valu
patient
non
prophylact
arm
patient
enrol
prophylact
arm
develop
invas
fungal
infect
statist
signific
differ
detect
group
popul
age
gender
initi
tlc
initi
monocyt
count
risk
stratif
previou
hospit
incid
invas
fungal
infect
fungal
relat
mortal
report
patient
non
prophylact
arm
compar
prophylact
arm
median
durat
follow
month
overal
surviv
event
free
surviv
whole
group
patient
year
respect
voriconazol
accept
toxic
profil
conclus
anti
fungal
voriconazol
prophyalaxi
significantli
reduc
incid
fungal
infect
fungal
relat
mortal
pediatr
acut
myeloid
leukemia
patient
howev
effect
overal
surviv
pronounc
madney
h
h
l
pediatr
oncolog
cairo
egypt
cancer
hospit
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
radiolog
cairo
egypt
clinic
microbiolog
cairo
egypt
backgroundobject
infect
import
caus
morbid
mortal
children
undergo
antineoplast
chemotherapi
especi
acut
myeloid
leukemia
aml
patient
overal
cumul
risk
bacteremia
invas
fungal
infect
ifi
increas
induct
chemotherapi
fluoroquinolon
fql
significantli
reduc
mortal
fever
clinic
microbiolog
document
infect
howev
posit
effect
antibiot
prophylaxi
associ
increas
risk
harbor
bacilli
treatment
designmethod
compar
retrospect
prospect
studi
includ
newli
diagnos
acut
myeloid
leukemia
patient
treat
nation
cancer
institut
cairo
univers
prospect
group
group
b
receiv
primari
voriconazol
levofloxacin
prophylaxi
compar
retrospect
control
non
prophylact
arm
regard
microbiolog
outcom
correl
bacteremia
ifi
result
statist
signific
differ
group
regard
rate
gram
posit
bacteremia
group
b
group
p
valu
gram
neg
bacteremia
group
b
group
p
valu
higher
incid
bacteri
sepsi
group
b
group
p
valu
bacteri
sepsi
releas
mortal
group
b
group
p
valu
seen
levofloxacin
prophylaxi
arm
group
conclus
levofloxacin
prophylaxi
associ
increas
bacteri
sepsi
episod
bacteri
sepsi
mortal
pediatr
acut
myeloid
leukemia
patient
raju
c
l
r
cl
r
upon
tyne
hospit
great
north
children
hospit
newcastl
upon
tyne
unit
kingdom
upon
tyne
hospit
northern
medic
physic
clinic
engin
newcastl
upon
tyne
unit
kingdom
institut
cancer
research
wolfson
childhood
cancer
research
centr
newcastl
upon
tyne
unit
kingdom
backgroundobject
sensit
specif
ct
imag
diagnost
tool
investig
chest
infect
superior
plain
chest
cxr
howev
greater
radiat
exposur
need
sedat
addit
practic
preclud
use
ct
investig
investig
clinic
util
radiat
exposur
result
new
siemen
somatom
forc
scanner
designmethod
undertook
retrospect
patient
primaryrelaps
acut
leukaemia
diagnos
august
includ
patient
enrol
ukal
trial
clinic
episod
suspect
chest
infect
defin
febril
patient
investig
cxr
ct
chest
radiolog
report
review
radiat
effect
dose
patient
estim
use
convers
coeffici
dose
area
product
cxr
dose
length
product
ct
result
separ
episod
cxr
follow
ct
chest
identifi
patient
median
time
cxr
ct
chest
day
rang
day
ct
chest
perform
somatom
forc
scanner
ct
imag
ad
clinic
valuabl
inform
clinic
episod
data
avail
subsequ
treatment
chang
occur
patient
importantli
addit
radiat
deliv
somatom
forc
scanner
follow
cxr
significantli
less
compar
convent
ct
p
unpair
mean
rang
versu
mean
rang
respect
conclus
ct
imag
provid
treatment
modifi
inform
acut
leukaemia
patient
suspect
chest
infect
somatom
forc
scanner
enabl
reduc
investig
time
significantli
less
radiat
exposur
compar
convent
ct
versatil
technolog
clear
potenti
investig
chest
infect
select
popul
immunocompromis
patient
earli
diagnosi
appropri
direct
treatment
may
shorten
hospit
stay
improv
outcom
masako
si
univers
nurs
health
scienc
pediatr
nurs
oita
japan
univers
faculti
medicin
pediatr
child
neurolgi
yufu
japan
backgroundobject
studi
focus
pediatr
cancer
patient
use
ict
inpati
care
commun
school
analyz
interview
mother
elucid
experi
hospit
admiss
benefit
ict
interact
designmethod
studi
conduct
jan
oct
particip
six
mother
children
underw
inpati
care
cancer
school
three
interview
last
minut
held
particip
modifi
ground
theori
approach
use
qualit
analysi
studi
approv
research
ethic
committe
hospit
result
analysi
gener
total
categori
mother
talk
confus
difficulti
time
hospit
admiss
satisfi
posit
effect
hospit
school
relat
school
mother
consist
commun
school
regard
effect
treatment
mother
describ
stress
wit
child
endur
consequ
chemotherapi
benefit
interact
school
includ
interact
instil
daili
routin
conform
school
schedul
assist
nurs
prepar
mother
satisfi
nurs
joint
confer
mother
concern
anticip
discharg
includ
worri
readjust
school
support
school
gener
sens
ict
interact
prepar
school
child
return
friend
cooper
help
child
cope
school
life
difficulti
respons
mother
discharg
includ
difficulti
explain
child
ill
other
conclus
children
interact
school
ict
hospit
sourc
reassur
process
ict
interact
benefici
school
help
prepar
child
return
mccarthi
dl
dp
v
belfast
hospit
sick
children
children
oncolog
haematolog
belfast
unit
kingdom
backgroundobject
central
line
associ
bloodstream
infect
clabsi
frequent
caus
morbid
paediatr
patient
associ
signific
healthcar
cost
unit
singl
lumen
tunnel
central
venou
cathet
tcvc
preferenti
insert
brachial
vein
antecubit
fossa
tradit
place
central
line
utilis
adequ
vein
found
arm
multipl
lumen
line
requir
designmethod
aim
determin
baselin
rate
clabsi
ii
identifi
risk
factor
infect
iii
examin
differ
rate
infect
insert
site
retrospect
review
patient
tcvc
insert
januari
decemb
undertaken
infect
defin
possibl
probabl
definit
per
cdc
guidelin
logist
regress
analysi
use
establish
risk
factor
test
compar
rate
result
patient
mean
age
sd
children
leukaemia
solid
tumour
overal
line
infect
rate
per
cvc
day
infect
risk
higher
patient
haematolog
malign
p
line
p
subgroup
analysi
children
line
leukaemia
show
trend
lower
rate
infect
arm
line
vs
per
cvc
day
chang
infect
risk
seen
age
time
insert
neutropenia
time
insert
conclus
observ
low
rate
clabsi
risk
factor
infect
cohort
haematolog
malign
line
arm
line
low
rate
infect
differ
infect
rate
tcvc
site
previous
describ
therefor
prospect
monitor
requir
explor
observ
c
k
michaux
p
pediatr
ihop
pediatr
oncolog
lyon
franc
pediatr
ihop
institut
dosteopathi
lyon
franc
backgroundobject
punctur
headach
pdph
frequent
complic
lumbar
punctur
lp
defin
postur
headach
occur
within
hour
procedur
sometim
accompani
back
pain
nausea
vomit
dizzi
leakag
cerebrospin
fluid
dural
defect
produc
punctur
one
etiolog
hypothesi
osteopath
manipul
treatment
omt
spinal
column
order
soften
dura
mater
lp
could
contribut
reduc
symptomsour
aim
compar
incid
sever
pdph
children
undergo
lp
without
preliminari
omt
designmethod
prospect
monocentr
studi
includ
children
undergo
lp
diagnosi
treatment
april
decemb
oncolog
unit
everi
procedur
assign
without
preliminari
omt
depend
practition
work
day
occurr
durat
pdph
assess
day
patient
famili
use
feedback
form
sever
symptom
assess
visual
analog
scale
scale
result
total
lp
studi
omt
group
control
children
median
age
year
differ
found
pdph
incid
versu
p
pdph
seem
less
sever
shorter
patient
back
pain
day
without
omt
versu
omt
headach
day
without
omt
versu
omt
dural
cranial
dysfunct
found
case
conclus
result
demonstr
signific
benefit
use
omt
prevent
pdph
tendenc
reduc
intens
durat
post
lp
symptom
dysfunct
frequent
observ
popul
omt
deserv
better
investig
support
care
pediatr
oncolog
l
moor
childhood
cancer
foundat
sa
gauteng
south
region
saxonwold
south
africa
backgroundobject
cancer
diagnosi
caus
financi
stress
famili
result
children
access
health
servic
paediatr
oncolog
unit
thu
decreas
chanc
surviv
year
choc
childhood
cancer
foundat
provid
holist
care
support
children
live
cancer
famili
key
success
implement
comprehens
practic
support
programm
mean
reliev
financi
burden
famili
well
increas
adher
treatment
cycl
increas
chanc
surviv
designmethod
transport
fund
issu
daili
famili
household
altern
accommod
provid
choc
hous
live
far
ensur
children
get
treatment
centr
care
bag
contain
toiletri
toy
parent
handbook
provid
famili
admiss
hospit
inform
care
bag
guid
parent
treatment
cycl
access
relev
resourc
complet
need
assess
famili
provid
nutrit
support
form
food
parcel
return
home
result
transport
fund
accommod
play
signific
role
ensur
adher
complet
treatment
empow
famili
knowledg
help
better
understand
cope
arduou
treatment
cycl
therefor
adher
treatment
food
parcel
ensur
children
receiv
maintain
healthi
balanc
diet
treatment
anecdot
evid
interview
paediatr
oncologist
choc
beneficiari
differ
treatment
centr
south
africa
present
show
practic
support
contribut
toward
increas
adher
chanc
surviv
conclus
practic
support
part
multidisciplinari
approach
treatment
reduc
financi
burden
place
famili
increas
adher
treatment
increas
chanc
surviv
child
j
morgan
r
l
k
york
centr
review
dissemin
york
unit
kingdom
york
depart
health
scienc
york
unit
kingdom
backgroundobject
recent
systemat
review
found
outpati
care
children
low
risk
febril
neutropenia
safe
low
rate
treatment
failur
qualit
studi
suggest
earli
discharg
patient
may
accept
key
stakehold
current
studi
aim
explor
experi
percept
patient
parent
healthcar
profession
involv
paediatr
febril
neutropenia
care
unit
kingdom
designmethod
particip
includ
eight
focu
group
discuss
three
differ
centr
purpos
select
larg
nation
survey
differ
servic
structur
febril
neutropenia
manag
analysi
iter
use
constant
compar
method
triangul
across
centr
particip
group
result
particip
describ
quest
certainti
attempt
balanc
uncertainti
involv
understand
express
negoti
risk
illus
certainti
provid
strict
protocol
particip
assess
risk
use
formal
inform
stratif
tool
overlaid
emot
reaction
risk
experi
risk
within
situat
benefit
certainti
provid
protocol
result
frustrat
strict
constraint
perceiv
benefit
harm
inpati
care
particip
previous
experienc
inform
apprais
futur
treatment
strategi
work
demonstr
statist
identifi
systemat
review
interpret
use
key
stakehold
assess
risk
differ
famili
particular
view
harm
therapeut
option
differ
outcom
utilis
within
literatur
conclus
studi
highlight
previous
underestim
harm
admiss
febril
neutropenia
paternalist
natur
decis
make
along
frustrat
challeng
parti
involv
care
children
justifi
reassess
current
treatment
strategi
children
explor
introduct
share
decis
make
mukkada
fuent
rf
f
e
p
h
r
g
jude
children
research
hospit
infecti
diseas
memphi
usa
jude
children
research
hospit
patholog
memphi
usa
nacion
de
nino
benjamin
bloom
oncolog
san
salvador
el
salvador
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
backgroundobject
infect
identifi
one
key
driver
morbid
mortal
pediatr
patient
treat
cancer
low
middl
incom
countri
lmic
identifi
caus
organ
clinic
evolut
patient
febril
neutropenia
critic
implic
empir
therapi
set
howev
access
diagnost
test
particularli
fungal
viral
infect
limit
designmethod
prospect
ascertain
etiolog
clinic
outcom
group
pediatr
cancer
patient
present
febril
neutropenia
el
salvador
clinic
sociodemograph
laboratori
predictor
advers
clinic
outcom
addit
collect
result
captur
febril
neutropen
episod
novemb
june
patient
febril
prior
admiss
episod
median
delay
admiss
hour
iqr
hour
fever
categor
unknown
origin
episod
suspect
proven
bacteri
etiolog
fungal
viral
etiolog
episod
microorgan
recov
evalu
episod
bacteremia
diagnos
episod
cvc
associ
bloodstream
infect
episod
escherichia
coli
organ
frequent
isol
blood
cultur
howev
coagulas
neg
staphylococci
identifi
posit
blood
cultur
mortal
due
infect
intens
care
unit
admiss
infrequ
conclus
lmic
set
etiolog
febril
episod
frequent
unknown
howev
morbid
mortal
low
like
due
prompt
empir
therapi
increas
access
diagnost
test
particularli
viral
fungal
organ
may
improv
diagnost
precis
impact
clinic
outcom
resourc
use
remain
unknown
investig
includ
cost
effect
analys
requir
optim
manag
febril
neutropenia
lmic
j
nabarret
ap
noronha
f
b
laselva
de
lc
almeida
sm
fraga
v
odon
israelita
albert
einstein
centro
de
oncohematologia
de
paulo
brazil
israelita
albert
einstein
centro
de
oncohematologia
medico
oncohematologista
paulo
brazil
backgroundobject
mani
symptom
may
contribut
decreas
food
intak
treatment
distress
famili
intens
outpati
provid
greater
moment
famili
particip
nutrit
care
identifi
advers
effect
impact
better
nutrit
counsel
manag
designmethod
prospect
studi
conduct
juli
questionnair
appli
parent
caregiv
investig
symptom
impair
food
intak
children
nutrit
counsel
prefer
use
support
manag
symptom
result
total
questionnair
answer
mother
parent
peopl
among
frequent
diseas
leukemia
follow
lymphoma
diseas
eg
combin
immunodefici
syndrom
decreas
appetit
symptom
cite
follow
nauseavomit
mucositispain
swallow
dysgeusia
increas
appetit
alter
gastrointestin
tract
individu
verbal
guidanc
nutrit
counsel
mention
follow
practic
nutrit
workshop
written
guidanc
nutrit
speech
addit
form
nutrit
counsel
cite
exchang
experi
patient
practic
nutrit
workshop
children
guid
inappet
feed
phase
life
treatment
present
recip
menu
appropri
age
group
suggest
theme
news
approach
nutrit
counsel
conclus
decreas
appetit
disturb
symptom
treatment
best
way
approach
manag
nutrit
therapi
individu
verbal
guidanc
work
guid
manag
diet
plan
oncopediatr
outpati
clinic
contribut
person
human
care
nutrit
involv
empow
patientcaregiv
treatment
g
naidu
r
b
sa
witwatersrand
chri
hani
baragwanath
academ
hospit
paediatr
johannesburg
south
africa
research
council
mening
respiratori
pathogen
research
unit
johannesburg
south
africa
research
depart
scienc
nation
research
foundat
vaccin
prevent
faculti
health
nation
institut
communic
divis
nation
health
laboratori
mening
respiratori
pathogen
research
univers
witwatersrand
johannesburg
south
africa
backgroundobject
introduct
bacteria
commonli
caus
infect
children
cancer
relat
chemotherapi
stage
diseas
immun
dysfunct
neutropenia
malnutrit
surgeri
radiotherapi
aim
prospect
delin
bacteri
epidemiolog
infecti
morbid
mortal
children
cancer
designmethod
method
febril
episod
children
treat
cancer
studi
histori
examin
full
blood
count
differenti
blood
cultur
obtain
result
result
patient
enrol
haematolog
malign
hm
solid
tumour
st
male
median
age
month
least
one
microbiolog
confirm
septic
episod
mcse
hm
vs
st
p
suspect
septic
episod
sse
mean
hm
vs
st
p
incid
bacteraemia
vs
p
bacteraemia
vs
p
hm
st
incid
mcse
children
hm
hm
p
children
metastat
st
higher
incid
msce
compar
local
st
aor
p
children
sever
malnourish
muac
ama
frequent
gpb
isol
con
streptococcu
viridan
enterococcu
faecium
gnb
isol
escherichia
speci
acinetobact
speci
klebsiella
speci
fungal
mcsehundr
child
year
candida
albican
n
candida
parapsilosi
thirteen
death
due
sepsi
hm
conclus
advanc
diseas
st
nhl
stage
diseas
children
diseas
intens
treatment
independ
associ
sepsi
h
nguyen
thi
kim
h
chau
w
central
hospit
hue
pediatr
center
hue
vietnam
children
care
leagu
japan
ceo
tokyo
japan
backgroundobject
ketamin
atropin
increasingli
use
recent
year
effect
form
deep
sedationanaesthesia
children
develop
countri
develop
countri
like
vietnam
pioneer
trial
aim
evalu
effect
use
ketamin
plu
atropin
anaesthet
agent
paediatr
oncolog
procedur
studi
establish
protocol
anaesthesia
paediatr
oncolog
procedur
designmethod
descript
prospect
studi
paediatr
patient
sex
male
femal
age
month
year
median
age
year
bodi
weight
kg
carri
januari
march
patient
diagnos
either
acut
lymphoblast
leukaemia
acut
myeloid
leukaemia
underw
intrathec
chemotherapi
bone
marrow
aspir
diagnost
well
therapeut
purpos
result
total
number
procedur
bone
marrow
aspir
perform
time
intrathec
chemotherapi
given
time
procedur
success
dose
ketamin
atropin
use
mgkg
mg
respect
time
taken
anaesthesia
wear
short
minut
experienc
apnoea
hypotens
convuls
nystagmu
hyperact
excess
saliv
dream
vomit
none
patient
laryngospasm
transient
rash
patient
parent
satisfi
use
anaesthet
conclus
pioneer
trial
children
vietnam
mgkg
intraven
ketamin
mg
atropin
found
effect
suitabl
dose
children
requir
deep
sedat
pain
procedur
produc
minim
side
effect
establish
protocol
dose
continu
appli
order
reduc
pain
trauma
complic
practic
safe
mkf
nielsen
jf
k
lb
j
hb
univers
hospit
rigshospitalet
depart
pediatr
adolesc
medicin
copenhagen
denmark
univers
hospit
rigshospitalet
centr
inflamm
metabol
centr
physic
activ
research
cimcfa
copenhagen
denmark
clinic
faculti
medicin
univers
copenhagen
copenhagen
denmark
school
sport
scienc
depart
sport
medicin
oslo
norway
sogndal
western
norway
univers
appli
scienc
norway
backgroundobject
children
cancer
exhibit
reduc
physic
function
follow
treatment
rehabilit
includ
social
physic
activ
educ
children
teenag
cancer
respect
studi
examin
multimod
rehabilit
intervent
initi
diagnosi
includ
physic
activ
intervent
discuss
feasibl
barrier
physic
function
evalu
designmethod
children
age
year
mean
age
boy
diagnos
cancer
intervent
group
includ
diagnosi
three
month
particip
schedul
perform
includ
time
go
tug
st
flamingo
balanc
handgrip
strength
cardiopulmonari
exercis
test
cpet
bicycl
ergomet
result
first
month
children
complet
least
one
test
adher
rate
tug
st
balanc
handgrip
strength
cpet
associ
sever
barrier
overal
test
complet
failur
complet
cpet
mainli
due
medic
restrict
eg
physician
restrict
side
effect
motiv
logist
reason
account
respect
complet
test
one
seriou
advers
event
observ
one
child
faint
briefli
cpet
preliminari
result
show
chang
mlkgmin
max
watt
p
st
balanc
trend
impair
respect
signific
decreas
handgrip
strength
tug
observ
conclus
evalu
physic
function
childhood
cancer
safe
gener
feasibl
children
motiv
particip
howev
strenuou
test
cpet
accompani
sever
barrier
physician
restrict
side
effect
logist
challeng
preliminari
result
suggest
physic
activ
may
prevent
impair
cpet
earli
treatment
despit
intervent
strength
tug
declin
j
nonaka
k
univers
human
servic
faculti
health
social
work
school
nurs
yokosuka
japan
care
children
fukushima
medic
univers
school
nurs
nurs
fukushima
japan
backgroundobject
studi
examin
outcom
sibl
support
event
held
collabor
hospit
special
pediatr
nurs
universityto
examin
content
outcom
event
held
hospit
special
pediatr
annual
year
support
pediatr
cancer
patient
sibl
designmethod
studi
design
qualit
descript
studi
data
collect
analysi
result
observ
sibl
event
addit
volunt
famili
comment
impress
qualit
descript
analyz
ethic
consider
start
event
provid
obtain
consent
result
event
sibl
support
program
develop
upon
deliber
among
team
member
clarifi
purpos
particularli
point
convey
appropri
method
convey
siblingsth
sibl
support
event
mainli
aim
shine
spotlight
sibl
provid
opportun
express
emot
protagonist
learn
pediatr
hospit
enjoy
play
activ
number
particip
first
second
event
male
femal
male
femal
respect
age
rang
year
total
volunt
includ
nurs
univers
faculti
member
student
cl
conclus
futur
challeng
sibl
support
sibl
support
program
mainli
design
rel
young
children
therefor
futur
may
necessari
consid
content
age
group
development
task
period
use
differ
media
provid
effect
support
consider
individu
sibl
situat
furthermor
method
enhanc
may
also
import
provid
famili
support
convey
famili
messag
sibl
respect
sibl
support
like
contribut
improv
famili
function
p
obeng
v
j
l
b
c
g
p
l
r
aa
anoky
teach
hospit
paediatr
oncolog
child
health
director
kumasi
ghana
anoky
teach
hospit
depart
surgeri
kumasi
ghana
technic
univers
faculti
depart
pharmaceut
scienc
kumasi
ghana
backgroundobject
practic
support
bear
highest
correl
adher
studi
suggest
structur
function
social
support
correl
patient
adher
medic
regimen
caregiv
children
cancer
may
provid
medic
financi
spiritu
physic
support
combin
ensur
adher
medic
studi
object
find
strategi
adopt
caregiv
promot
treatment
adher
paediatr
oncolog
ghana
improv
treatment
outcom
designmethod
studi
prospect
conduct
paediatr
oncolog
unit
pou
komfo
anoky
teach
hospit
kath
ghana
octob
decemb
pou
serv
patient
everi
week
fifteen
patient
age
year
recruit
weekli
week
sampl
size
use
studi
data
default
adher
strategi
adopt
caregiv
improv
treatment
adher
obtain
inform
consent
ethic
approv
sought
studi
commenc
result
default
rate
adher
treatment
share
strategi
enhanc
treatment
adher
strategi
adher
treatment
caregiv
perspect
financi
emot
support
famili
friend
kath
pou
church
colleagu
worker
obtain
loan
bank
educ
counsel
healthcar
profession
pou
motiv
save
children
sell
properti
also
enumer
conclus
financi
emot
support
obtain
loan
bank
educ
counsel
healthcar
profession
pou
motiv
save
children
sell
properti
strategi
adopt
caregiv
promot
treatment
adher
studi
strategi
inform
outcom
improv
intervent
ogasawara
children
hospit
nurs
azumino
japan
children
hospit
azumino
japan
backgroundobject
side
effect
cancer
survivor
identifi
factor
reduc
patient
qualiti
life
potenti
threaten
surviv
accordingli
conduct
transit
program
childhood
cancer
survivor
provid
better
understand
diseas
late
effect
relat
treatment
although
program
teach
patient
skill
becom
readi
care
adult
difficulti
numer
patient
due
reluct
join
therefor
conduct
studi
investig
caus
patient
reluct
designmethod
one
hundr
particip
recruit
nagano
children
hospit
june
march
inclus
criteria
discharg
follow
intens
chemotherapyradiotherapi
childhood
cancer
age
year
abl
develop
skill
questionnair
survey
conduct
determin
patient
reluct
engag
program
medic
record
retrospect
analyz
subject
background
statist
analysi
perform
use
test
fisher
exact
test
accord
group
size
result
patient
meet
studi
inclus
criteria
show
reluct
engag
program
univari
analysi
reveal
onset
age
year
p
absenc
guardian
support
p
receiv
autolog
stem
cell
transplant
p
current
histori
receiv
treatment
relat
late
effect
p
embarrass
physic
condit
p
cognit
social
develop
abnorm
p
significantli
associ
patient
hesit
particip
program
conclus
multipl
risk
factor
contribut
patient
reluct
engag
transit
program
resolv
issu
may
improv
patient
complianc
facilit
develop
skill
h
pariuri
j
j
hospit
research
center
oakland
pediatr
hematolog
oncolog
oakland
usa
backgroundobject
glucocorticoid
play
essenti
role
treatment
multipl
pediatr
malign
associ
increas
behavior
disturb
aim
investig
efficaci
util
potassium
chlorid
kcl
supplement
reduc
neuropsychiatr
effect
among
pediatr
patient
acut
lymphoblast
leukemia
although
util
anecdot
institut
prior
studi
systemat
report
data
potenti
therapeut
benefit
designmethod
chart
pediatr
patient
receiv
kcl
supplement
intent
reduc
neuropsychiatr
effect
retrospect
review
baselin
visit
analyz
primari
outcom
degre
behavior
disturb
base
subject
measur
treat
physician
parent
result
seventeen
children
includ
median
age
year
major
mainten
therapi
nine
patient
receiv
dexamethason
eight
receiv
prednison
patient
receiv
kcl
median
dose
divid
bid
conjunct
day
corticosteroid
parent
report
improv
neuropsychiatr
effect
kcl
supplement
side
effect
report
conclus
oral
kcl
supplement
appear
benefici
reduc
psychiatr
event
children
report
advers
effect
notabl
intervent
neuropsychiatr
symptom
includ
hydrocortison
antipsychot
medic
potenti
secondari
effect
futur
prospect
random
studi
necessari
better
examin
effect
goal
reduc
psychosoci
impact
corticosteroid
patient
famili
treatment
pianovski
c
l
erasto
gaertner
pediatr
curitiba
brazil
de
clinica
hcufpr
pediatr
curitiba
brazil
backgroundobject
methotrex
mtx
one
wide
use
agent
administr
methotrex
hdmtx
follow
folin
acid
rescu
import
compon
treatment
varieti
childhood
cancer
hdmtx
safe
administ
patient
normal
renal
function
use
alkalin
hydrat
pharmacokinet
guid
folin
acid
rescu
despit
measur
renal
dysfunct
continu
occur
prompt
recognit
treatment
renal
dysfunt
essenci
prevent
potenci
toxic
especi
mucos
myelosuppress
nephrotox
delay
diagnosi
acut
kidney
injuri
aki
use
convent
biomark
like
serum
creatinin
one
import
obstacl
appli
effect
earli
intervent
sever
new
biomark
evalu
quest
earli
diagnosi
aki
among
neutrophil
lipocalin
ngal
appear
promisingthi
studi
evalu
compar
urinari
ngal
level
correl
methotrex
induc
nephrotox
designmethod
prospect
studi
chang
serum
creatinin
urinari
ngal
compar
hour
hour
hour
day
receiv
hdmtx
intraven
infus
result
seventeen
pediatr
cancer
patient
receiv
hdmtx
chemotherapi
studi
includ
develop
injuri
classifi
pediatr
risk
injuri
failur
loss
end
stage
kidney
prifl
aki
regist
urinari
ngal
increas
treatment
conclus
aki
regist
prifl
criteria
ngal
use
earli
biomark
aki
situat
j
c
f
n
r
b
pizer
hey
children
hospit
paediatr
oncolog
liverpool
unit
kingdom
hey
children
hospit
microbiolog
liverpool
unit
kingdom
hey
children
hospit
infecti
diseas
liverpool
unit
kingdom
backgroundobject
diarrhoea
common
paediatr
oncolog
patient
caus
infect
factor
rotaviru
histor
common
pathogen
caus
diarrhoea
howev
although
stool
sampl
commonli
sent
virolog
valu
test
paediatr
oncolog
patient
diarrhoea
unclear
conduct
servic
evalu
estim
diagnost
yield
rotaviru
test
paediatr
oncolog
patient
felt
import
undertak
review
follow
introduct
rotaviru
immunis
juli
designmethod
computeris
microbiolog
record
alder
hey
children
hospit
januari
decemb
seven
year
review
retrospect
examin
stool
test
rotaviru
antigen
detect
patent
treat
region
paediatr
oncolog
unit
review
focus
rotaviru
test
virus
consist
undertaken
repeat
sampl
submit
test
within
period
assum
part
episod
test
perform
result
total
sampl
review
reject
repeat
sampl
taken
within
two
week
total
sampl
form
basi
analysi
sampl
posit
rotaviru
total
patient
age
year
male
femal
result
year
positivesnumb
test
percentag
follow
conclus
comprehens
servic
evalu
stool
test
perform
rotaviru
perform
paediatr
oncolog
patient
period
demonstr
incid
rotaviru
posit
diminish
sinc
introduct
rotaviru
immunis
one
posit
test
sampl
base
result
suggest
littl
util
routin
rotaviru
test
children
young
peopl
cancer
present
diarrhoea
c
mata
b
ponc
h
gonzalo
e
c
garrido
b
santiago
aguilar
de
la
san
gregorio
pediatr
spain
gregorio
pediatr
spain
gregorio
pediatr
infecti
diseas
spain
backgroundobject
invas
fungal
infect
ifi
signific
caus
morbid
mortal
children
hematolog
malign
diseas
aim
describ
epidemiolog
outcom
ifi
unit
period
designmethod
medic
record
pediatr
patient
admit
unit
ifi
review
clinic
characterist
mold
yeast
infect
proport
time
analyz
result
patient
includ
male
median
age
year
studi
hematolog
malign
solid
tumor
benign
hematolog
condit
overal
patient
undergon
haematolog
stem
cell
transplant
hsct
allogen
suffer
graft
versu
host
diseas
gvhd
acut
antifung
prophylaxi
micafungin
fluconazol
regard
outcom
need
picu
admiss
die
mold
common
caus
ifi
bronchopulmonari
diseas
includ
confirm
aspergillu
yeast
infect
includ
fungemia
urinari
infect
mostli
caus
candida
albican
candida
parapsilopsi
patient
mold
infect
older
vs
year
higher
initi
pcr
vs
higher
incid
hsct
vs
p
gvhd
vs
antifung
prophylaxi
vs
p
picu
admiss
vs
mortal
vs
compar
first
patient
second
period
patient
latter
increas
proport
mold
infect
vs
coincid
higher
incid
hsct
vs
gvhd
vs
antifung
prophylaxi
vs
conclus
second
period
time
increas
proport
mold
infect
yeast
infect
higher
sever
paramet
along
intens
myeloabl
chemotherapi
regimen
increas
surviv
diseas
last
decad
p
priya
r
j
india
institut
medic
scienc
pediatr
delhi
india
backgroundobject
malnutrit
commonli
seen
pediatr
oncolog
patient
particularli
resourc
poor
countriesther
pauciti
data
factor
affect
nutrit
statu
treatment
outcom
malnutrit
present
studi
done
estim
preval
malnutrit
children
malign
ascertain
degre
malnutrit
hematolog
vs
malign
determin
factor
associ
malnutrit
follow
malnourish
children
variou
childhood
cancer
effect
final
outcom
designmethod
retrospect
review
record
children
year
treat
oncolog
clinic
india
institut
medic
scienc
tertiari
medic
institut
india
januari
done
relev
data
retriev
analys
children
less
month
underli
genet
diagnosi
immunodefici
associ
malabsorpt
syndrom
chronic
system
diseas
exclud
result
total
newli
diagnos
children
malign
enrol
studi
period
f
children
retinoblastoma
constitut
maximum
number
patient
follow
acut
leukemia
lymphoma
other
total
children
underweight
stunt
wast
malnutrit
children
solid
tumor
children
hematolog
malign
children
advanc
tumor
malnourish
compar
children
earli
diseas
stage
result
signific
effect
socioeconom
statu
effect
treatment
outcom
conclus
preval
malnutrit
variou
studi
diagnosi
vari
patient
children
underweight
stunt
wastedmalnutrit
sever
advanc
stage
malign
also
lag
period
onset
symptom
start
treatmentsolid
tumor
associ
greater
degre
malnutrit
signific
effect
socioeconom
statu
nutrit
statist
signific
effect
malnutrit
final
outcom
g
pugh
r
h
colleg
london
depart
behaviour
scienc
health
london
unit
kingdom
colleg
hospit
nh
foundat
trust
clinic
haematolog
london
unit
kingdom
sargent
research
polici
london
unit
kingdom
colleg
london
depart
behaviour
health
scienc
london
unit
kingdom
backgroundobject
current
health
behaviour
intervent
avail
unit
kingdom
support
teenag
young
adult
cancer
survivor
tyac
cancer
diagnosi
form
studi
conduct
group
demonstr
uk
tyac
desir
health
behaviour
inform
physic
activ
diet
smoke
alcohol
consumpt
sun
safeti
deliv
multipl
format
variou
throughout
cancer
pathway
health
profession
also
identifi
import
sourc
inform
tyac
howev
littl
known
health
profession
provis
lifestyl
advic
young
peopl
cancer
care
designmethod
onlin
survey
conduct
assess
tya
health
profession
awar
lifestyl
guidanc
provis
lifestyl
advic
tyac
care
health
profession
view
lifestyl
inform
format
deliveri
also
explor
result
health
profession
nurs
alli
health
profession
physician
complet
survey
major
respond
awar
lifestyl
guidanc
cancer
patient
howev
less
half
tya
health
profession
abl
success
recal
sourc
guidelin
less
third
report
prove
specif
advic
major
patient
health
behaviour
mani
health
profession
felt
right
person
provid
advic
cite
lack
resourc
key
barrier
advic
provis
major
report
interest
resourc
contain
relev
lifestyl
inform
could
given
young
peopl
cancer
conclus
tya
health
profession
awar
lifestyl
guidanc
provis
advic
regard
health
behaviour
clear
comprehens
guidanc
written
specif
tya
health
profession
could
overcom
report
barrier
improv
profession
confid
address
provid
advic
lifestyl
young
peopl
cancer
k
riad
egypt
cancer
institut
pediatr
oncolog
assiut
egypt
egypt
cancer
institut
anesthesiolog
pain
manag
assiut
egypt
backgroundobject
cancer
children
potenti
curabl
diseas
deal
pain
integr
part
symptom
manag
pediatr
cancer
patient
gener
proper
recognit
underli
pathophysiolog
variou
caus
pain
essenti
pain
manag
amelior
suffer
realm
holist
care
children
cancer
aim
studi
address
meticul
analyz
spectrum
pain
characterist
children
cancer
institut
univers
cancer
center
unravel
pain
profil
patient
experi
develop
countri
designmethod
hospit
base
prospect
studi
conduct
involv
pediatr
cancer
patient
present
pain
due
cancer
treatment
period
jan
evalu
patient
document
pain
cycl
pain
caus
type
locat
also
pain
treatment
characterist
done
result
total
pain
cycl
document
compris
treatment
day
rang
day
pain
frequent
caus
pain
studi
oral
mucosa
frequent
site
pain
strongli
correl
nhl
diagnosi
leukemia
strongli
correl
extrem
locat
bone
pain
viscer
pain
often
associ
lymphoma
neuropath
pain
least
frequent
type
pain
howev
associ
higher
initi
pain
intens
score
longer
pain
cycl
durat
conclus
children
cancer
develop
countri
still
pain
counterpart
develop
countri
pain
experi
may
indirectli
reflect
present
childhood
cancer
could
surrog
profil
tumor
locat
metastat
site
degre
treatment
intens
likewis
context
diseas
state
either
diagnosi
treatment
progress
k
riad
f
r
h
egypt
cancer
institut
pediatr
oncolog
assiut
egypt
univers
hospit
pediatr
depart
unit
assiut
egypt
univers
hospit
clinic
oncolog
depart
assiut
egypt
backgroundobject
cardiotox
survivor
childhood
cancer
initi
present
cardiac
abnorm
left
undetect
untreat
lead
clinic
cardiac
dysfunct
present
studi
aim
evalu
earli
myocardi
chang
develop
anthracyclin
therapi
designmethod
prospect
studi
preanthracyclin
postanthracyclin
echocardiograph
electrocardiograph
paramet
analyz
cardiac
dysfunct
demograph
inform
includ
age
sex
type
anthracyclin
cumul
dose
record
well
result
studi
patient
childhood
cancer
includ
male
femal
mean
age
year
enrol
normal
baselin
postanthracyclin
echocardiograph
electrocardiograph
paramet
compar
myocardi
chang
doxorubicin
alon
use
patient
daunorubicin
alon
children
receiv
high
dose
anthracyclin
cumul
dose
qtc
interv
significantli
prolong
chemotherapi
baselin
read
p
signific
increas
left
ventricular
dimens
myocardi
function
paramet
significantli
deterior
children
receiv
anthracyclin
p
incid
cardiac
dysfunct
found
femal
patient
myocardi
dysfunct
significantli
higher
among
children
receiv
high
cumul
dose
doxorubicin
p
conclus
incid
subclin
cardiac
dysfunct
high
children
treat
anthracyclin
requir
identifi
establish
optim
prevent
manag
strategi
balanc
oncolog
efficaci
safeti
n
salifu
b
n
g
r
g
memori
hospit
pediatr
oncolog
mumbai
india
memori
hospit
microbiolog
mumbai
india
backgroundobject
colon
resist
organ
mdro
associ
higher
morbid
mortal
children
cancer
expert
group
european
confer
infect
leukemia
develop
guidelin
empir
antibiot
therapi
febril
neutropen
patient
escal
strategi
employ
base
colon
organ
among
factor
unit
employ
polici
base
colon
due
high
incid
mdro
infect
bsi
retrospect
audit
practic
done
determin
use
designmethod
record
examin
rectal
swab
patient
regist
malign
obtain
within
seven
day
present
blood
cultur
taken
febril
episod
peripher
vein
also
cultur
present
data
collat
analyz
descript
analyt
tool
result
rectal
swab
posit
rate
cultur
incid
mdro
extend
spectrum
produc
organ
esblo
colon
respect
overal
blood
cultur
posit
pair
posit
rectal
swab
posit
blood
cultur
mdro
colon
seen
cultur
pair
patient
colon
esblo
patient
rectal
mdro
colon
develop
mdro
bsi
p
grew
esblo
signific
associ
also
seen
patient
colon
esblo
whose
blood
cultur
isol
organ
sensit
p
patient
colon
esblo
bsi
mdro
conclus
high
incid
mdro
esblo
colon
present
pediatr
malign
patient
center
develop
bsi
mdro
esblo
baselin
colon
statu
organ
significantli
correl
antibiot
strategi
would
justifi
manag
febril
neutropenia
subject
popul
h
sankaran
v
p
institut
medic
scienc
depart
medic
oncolog
ernakulam
india
institut
medic
scienc
depart
nurs
ernakulam
india
backgroundobject
use
pediatr
earli
warn
score
pew
system
identifi
deterior
pediatr
oncolog
patient
develop
world
extens
studi
implement
howev
mani
pew
system
complex
difficult
implement
resourc
limit
set
prospect
studi
perform
implement
adapt
pew
system
reduc
pediatr
code
event
designmethod
physiolog
paramet
qualit
measur
heart
rate
respiratori
rate
respiratori
distress
parent
concern
comorbid
oxygen
need
conscious
use
design
pew
system
studi
period
compar
primari
outcom
measur
month
implement
pew
octob
primari
outcom
measur
defin
pediatr
code
event
sepsi
relat
icu
transfer
pew
sensit
specif
pew
system
calcul
end
studi
period
test
determin
health
care
provid
recognit
abnorm
physiolog
paramet
conduct
implement
pew
system
result
inpati
pediatr
oncolog
admiss
avail
analysi
statist
signific
could
evalu
pediatr
code
implement
event
compar
event
implement
sensit
pew
system
identifi
patient
requir
icu
admiss
specif
use
pew
cutoff
length
icu
stay
significantli
decreas
vs
day
implement
provid
recognit
abnorm
vital
sign
increas
implement
pew
system
conclus
knowledg
first
pew
system
implement
india
studi
demonstr
feasibl
benefit
pew
system
indian
environ
studi
done
decreas
pew
cutoff
score
increas
sensit
tool
set
make
generaliz
hospit
india
j
sastri
k
hospit
children
haematolog
oncolog
glasgow
unit
kingdom
backgroundobject
bacteri
infect
major
obstacl
treatment
febril
neutropenia
paediatr
patient
improv
manag
strategi
includ
use
antibacteri
drug
target
bacteria
reduc
mortal
neutropen
patient
develop
blood
stream
sever
infect
howev
develop
bacteria
aspseudomona
aeruginosa
staphylococcu
aureu
vancomycin
resist
enterococcu
pose
major
threat
patient
audit
aim
determin
preval
antibiot
resist
unit
first
line
agent
use
piperacillin
tazobactam
tazocin
gentamicin
designmethod
collect
retrospect
result
microbiolog
test
varieti
specimen
includ
blood
cultur
sensit
variou
antibiot
posit
cultur
period
month
januari
octob
paediatr
patient
admit
unit
includ
data
obtain
electron
record
kept
bacteriolog
depart
result
total
posit
microbiolog
test
note
audit
period
show
resist
one
antibiot
blood
cultur
posit
resist
least
one
drug
total
posit
cultur
sensit
tazocin
record
resist
note
posit
blood
cultur
tazocin
sensit
report
resist
meropenem
sensit
report
posit
cultur
resist
amikacin
sensit
report
posit
cultur
resist
conclus
view
preval
high
resist
tazocin
addit
gentamicin
justifi
unit
altern
singl
agent
meropenem
could
consid
patient
gentamicin
contraindicatedcontinu
vigil
essenti
choos
appropri
empir
antibiot
j
sastri
l
k
e
hospit
children
haematolog
oncolog
glasgow
unit
kingdom
backgroundobject
invas
fungal
infect
ifi
import
concern
immunocompromis
patient
treatment
infect
difficult
establish
emphasi
place
strategi
prevent
use
high
effici
particul
air
filter
isol
use
anti
fungal
prophylact
drug
audit
undertaken
studi
preval
fungal
infect
among
paediatr
patient
determin
effect
unit
antifung
prophylaxi
prevent
ifi
designmethod
retrospect
audit
involv
immunocompromis
patient
treat
unit
posit
fungal
cultur
aspergillu
pcr
six
month
period
februari
juli
patient
identifi
use
electron
databas
microbiolog
virolog
depart
proforma
use
collect
inform
hospit
electron
patient
record
case
note
result
posit
fungal
cultur
aspergillu
pcr
test
detect
translant
fungal
infect
patient
male
femal
localis
ifi
candida
albican
parpsilosi
lambica
other
saccharomyc
aspergillu
monilla
yeast
speci
specimen
fungi
cultur
detect
includ
surfac
swab
urin
stool
blood
tissu
ifi
note
patient
lung
blood
spleen
ifi
result
icu
admiss
splenectomi
loss
cvad
interrupt
chemotherapi
patient
anti
fungal
prophylaxi
develop
ifi
conclus
fungal
infect
superfici
ifi
note
minor
patient
result
advers
outcom
children
anti
fungal
prophylaxi
cohort
never
develop
ifi
although
number
small
unit
antifung
polici
need
align
intern
protocol
prevent
ifi
signific
risk
n
k
schroeder
univers
pediatr
hematolog
oncolog
durham
usa
univers
surgeri
durham
usa
univers
medicin
durham
usa
medic
centr
oncolog
mwanza
tanzania
univers
pediatr
hematolog
oncolog
raleigh
usa
backgroundobject
although
support
prevent
care
play
crucial
role
success
manag
childhood
cancer
littl
known
use
intervent
low
resourc
set
cost
associ
treatment
essenti
inform
develop
pediatr
cancer
program
examin
usag
pattern
direct
cost
support
prevent
care
treatment
children
cancer
tanzania
bugando
medic
center
one
two
hospit
countri
treat
pediatr
cancer
designmethod
retrospect
chart
review
hospit
admiss
clinic
visit
januari
perform
util
cost
prevent
care
laboratori
imag
medic
evalu
prevent
chemotherapi
toxic
support
care
blood
transfus
antibiot
infect
studi
record
convers
local
currenc
tsh
intern
dollar
intl
perform
tradabl
good
ie
medic
convert
use
prevail
exchang
rate
good
clinic
lab
suppli
convert
use
purchas
power
pariti
exchang
rate
obtain
world
bank
result
file
patient
avail
chemotherapi
encount
lab
monitor
toxic
prescrib
receiv
intraven
fluid
patient
receiv
chemotherapi
echocardiogram
mean
cost
incur
prevent
support
care
per
patient
respect
taken
togeth
account
less
total
treatment
cost
conclus
find
show
although
capac
deliv
support
prevent
cancer
care
pediatr
patient
tanzania
servic
alway
routin
deliv
patient
rel
low
cost
servic
demonstr
merit
includ
pediatr
cancer
program
low
resourc
set
l
schwartz
e
p
lp
j
children
hospit
philadelpia
pediatricsoncolog
philadelphia
usa
colleg
medicin
medicin
philadelphia
usa
sloan
ketter
cancer
center
integr
medicin
new
york
usa
backgroundobject
integr
medicin
im
eg
massag
acupunctur
mediat
herb
explor
adult
oncolog
limit
research
pediatr
oncolog
understand
use
complementari
therapi
pediatr
oncolog
well
belief
barrier
support
im
help
inform
treatment
discuss
patient
aim
survey
parent
adolescentyoung
adult
patient
aya
gaug
use
perspect
relat
im
designmethod
conveni
sampl
patient
yo
parent
requir
match
dyad
provid
inform
demograph
treatment
use
perceiv
benefit
im
method
attitud
belief
complementari
altern
medicin
abcam
scale
use
rate
expect
benefit
perceiv
barrier
subject
norm
descript
statist
use
summar
scale
score
rate
im
use
use
calcul
relationship
im
use
result
parent
particip
femal
white
complet
least
colleg
children
mage
complet
treatment
aya
patient
n
mage
male
white
complet
treatment
use
im
treatment
sinc
cancer
diagnosi
parent
patient
express
art
therapi
commonli
report
method
among
parent
patient
rate
perceiv
benefit
im
high
parent
endors
want
relax
techniqu
children
aya
patient
interest
massag
parent
report
im
use
associ
level
educ
subject
norm
score
benefit
barrier
subject
norm
score
associ
im
use
aya
patient
conclus
use
im
common
pediatr
oncolog
routin
discuss
patient
c
signorelli
ce
je
g
jm
kh
j
jk
rj
children
hospit
kid
cancer
centr
randwick
australia
lucern
depart
health
scienc
health
polici
lucern
switzerland
institut
australian
new
zealand
children
haematologyoncolog
group
clayton
australia
haematologyoncolog
depart
clinic
haematologyoncolog
adelaid
australia
melbourn
victorian
comprehens
cancer
centr
melbourn
australia
backgroundobject
popul
children
surviv
cancer
grow
import
promot
essenti
lifelong
care
becom
critic
howev
mani
survivor
disengag
care
mandat
altern
model
care
encourag
survivor
engag
facilit
explor
survivor
parent
prefer
regard
deliveri
survivorship
care
designmethod
australian
new
zealand
survivor
parent
survivor
age
less
year
complet
survey
option
interview
care
prefer
use
multipl
logist
regress
identifi
clinicaldemograph
associ
prefer
survivorship
care
result
survivor
mean
age
parent
child
mean
age
complet
survey
complement
interview
survivor
disengag
care
receiv
care
last
year
report
significantli
greater
dissatisfact
healthcar
receiv
versu
clinic
attende
dissatisfi
p
survivor
prefer
clinic
separ
pediatr
patient
patient
activ
treatment
end
treatment
one
five
year
complet
equal
endors
among
survivor
prefer
time
begin
care
survivor
treat
oncologist
favor
profession
primari
care
physician
least
prefer
survivor
diagnosi
worri
risk
recurr
report
fewer
late
effect
unmet
inform
need
like
prefer
versu
survivorship
care
conclus
incorpor
survivor
prefer
futur
model
care
may
improv
engag
essenti
well
satisfact
care
ensur
survivorship
need
better
met
may
help
reduc
physic
psychosoci
burden
survivor
follow
treatment
pediatr
cancer
n
tacyildiz
e
h
g
univers
med
school
pediatr
ankara
turkey
faculti
medicin
pediatr
oncolog
ankara
turkey
univers
med
school
pediatr
oncolgi
ankara
turkey
univers
med
school
pediatr
oncolog
ankara
turkey
univers
school
medicin
univers
school
medicin
pediatr
oncolog
ankara
turkey
backgroundobject
complamantari
altarn
medicin
cam
mostli
tradit
treatment
modal
cancer
patient
may
involv
either
inform
doctor
sinc
treatment
modal
may
interfer
chemotherapi
import
know
patient
get
designmethod
frequenc
reason
use
cam
type
cam
method
characterist
patient
use
cam
among
children
monitor
diagnosi
cancer
ankara
univers
school
medicin
studi
pediatr
cancer
patient
famili
appli
survey
form
inpati
outpati
clinic
result
mean
age
mak
year
male
averag
age
patient
use
cam
mean
age
p
nt
use
cam
group
patient
lower
statu
tend
use
cam
advanc
stage
patient
found
increas
frequenc
use
cam
patient
particip
studi
mention
pray
patient
use
cam
method
well
patient
use
cam
mostli
use
honey
bee
pollenmilk
molass
almost
famili
found
appli
religi
help
patient
hodja
read
holi
passag
believ
beneficiari
patient
use
cam
inform
doctor
common
reason
consult
physician
thought
possibl
reject
conclus
patient
use
cam
method
without
knowledg
physician
none
patient
use
cam
instead
medic
treatment
patient
admit
hospit
must
suffici
inform
possibl
side
effect
cam
given
opportun
discuss
doctor
l
tanner
hospit
clinic
minnesota
physic
medicin
rehabilit
servic
minneapoli
usa
backgroundobject
survivor
pediatr
acut
lymphocyt
leukemia
muscl
strength
deficit
symptom
peripher
neuropathi
rang
motion
limit
month
year
treatment
proactiv
physic
therapi
intervent
stoplight
program
slp
implement
singl
institut
goal
prevent
minim
deficit
bodi
function
activ
limit
children
complet
slp
treatment
test
within
healthi
norm
development
age
studi
continu
measur
function
treatment
evalu
longer
term
impact
slp
studi
object
measur
bodi
function
activ
limit
survivor
complet
slp
compar
histor
control
group
survivor
complet
cancer
treatment
slp
implement
designmethod
studi
two
cohort
pediatr
survivor
age
year
assess
month
complet
treatment
measur
administ
physic
therapist
includ
test
motor
profici
ankl
rang
motion
arom
use
assess
differ
group
correl
analyz
arom
motor
test
result
result
histor
control
group
slp
intervent
group
differ
significantli
mean
age
year
time
treatment
month
slp
group
significantli
better
arom
p
scale
score
bilater
coordin
p
run
speedagil
p
strength
p
arom
posit
correl
survivor
strengthagil
percentil
rank
conclus
slp
innov
proactiv
physic
therapi
intervent
continu
significantli
impact
children
treatment
creativ
approach
need
support
healthi
develop
children
cancer
treatment
b
w
bu
teach
hospit
depart
child
health
accra
ghana
backgroundobject
level
pain
assess
manag
among
nurs
recent
declin
studi
sought
find
barrier
effect
pain
assess
manag
designmethod
ten
nurs
work
pediatr
oncolog
unit
korl
teach
hospit
randomli
select
studi
result
major
nurs
sixti
percent
within
age
bracket
group
one
fourti
year
eighti
percent
obtain
bachelor
degre
nurs
major
five
year
experi
oncolog
nurs
research
reveal
nurs
abreast
use
analges
pain
manag
skill
psychosoci
diversion
therapi
thu
unavail
analges
morphin
parent
afford
barrier
effect
pain
manag
often
children
assess
onset
pain
cri
verbal
twenti
percent
nurs
note
pain
assess
tool
readili
avail
unit
nineti
percent
nurs
find
pain
assess
procedur
time
consum
sixti
percent
perceiv
femal
patient
exagger
pain
order
get
morphin
thu
fear
administ
opioid
accord
seventi
percent
nurs
doctor
will
prescrib
morphin
suggest
pain
assess
thu
barrier
pain
manag
assess
conclus
conclus
nurs
need
educ
earli
identif
pain
children
infant
cancer
use
behavior
pain
assess
scale
flacc
sinc
pain
effect
manag
detect
earli
well
assess
manag
pain
consist
ward
fund
rais
support
parent
purchas
morphin
diversion
therapi
activ
like
puzzl
game
encourag
unit
tondo
c
f
c
c
f
v
degli
studi
di
firenz
pediatr
oncolog
hematolog
unit
firenz
itali
backgroundobject
patient
diagnosi
subject
potenti
fatal
complic
last
year
score
system
develop
base
rapidli
assess
clinic
paramet
call
pediatr
earli
warn
score
pew
detect
critic
event
time
manner
rapidli
activ
emerg
team
studi
aim
find
adapt
system
pediatr
patient
diagnosi
call
evalu
accuraci
reflect
level
clinic
impair
observ
patient
designmethod
modifi
pew
order
includ
clinic
paramet
reflect
neurocognit
cardiovascular
respiratori
urinari
state
pediatr
patient
diagnosi
retrospect
pilot
studi
conduct
patient
requir
admiss
pediatr
intens
care
unit
picu
measur
score
admiss
correl
score
outcom
result
patient
admit
picu
lower
score
averag
reach
better
outcom
surviv
rate
prove
lower
vs
patient
higher
score
admiss
averag
correl
neg
prognost
factor
use
mechan
ventil
conclus
pilot
studi
demonstr
capabl
predict
clinic
serious
pediatr
patient
diagnosi
conduct
perspect
multicent
observ
studi
aim
consist
valid
abil
precoci
identifi
patient
requir
emerg
consult
potenti
take
respons
patient
picu
j
de
pediatr
oncolog
mexico
citi
mexico
backgroundobject
alternativecomplementari
medicin
acm
refer
medic
practic
accord
standard
medic
commun
acm
use
frequent
use
patient
chronic
catastroph
diseas
treat
physician
ignor
use
report
frequenc
use
mexico
rang
accord
variou
survey
designmethod
includ
patient
pediatr
oncolog
servic
institut
receiv
treatment
least
three
month
structur
questionnair
administ
person
singl
interview
pediatr
oncologist
record
cancer
type
acm
use
parentguardian
age
educ
level
present
descript
statist
sampl
clinic
find
mean
standard
deviat
proport
comparison
pearson
test
result
parent
interview
use
form
acm
herb
miner
frequent
use
follow
diet
nutrit
mind
bodi
spirit
therapi
frequent
cancer
hematolog
malign
proport
versu
solid
tumor
parent
educ
level
associ
frequent
acm
use
mother
age
father
age
significantli
relat
frequent
acm
use
especi
older
conclus
studi
popul
use
frequent
acm
adjuv
therapi
hematolog
solid
tumor
subject
attempt
abandon
convent
treatment
reli
sole
acm
studi
may
lead
studi
assess
result
obtain
patient
receiv
acm
j
de
pediatr
oncolog
mexico
citi
mexico
backgroundobject
approxim
patient
childhood
cancer
chemotherapi
treatment
episod
febril
neutropenia
fn
percentag
posit
blood
cultur
correl
risk
overal
infect
purpos
present
studi
describ
percentag
posit
blood
cultur
infecti
diseas
agent
designmethod
review
blood
cultur
patient
childhood
cancer
august
decemb
institut
describ
percentag
neg
posit
blood
cultur
identifi
diseas
agent
case
posit
test
demograph
clinic
characterist
describ
mean
proport
accord
variabl
type
result
includ
blood
cultur
patient
averag
age
year
cultur
result
neg
posit
percent
patient
femal
male
accord
type
cancer
acut
lymphoblast
leukemia
repres
popul
osteosarcoma
germ
cell
tumor
rest
patient
hodgkin
diseas
rhabdomyosarcoma
gram
posit
bacteria
isol
posit
cultur
gram
neg
bacteria
posit
cultur
frequent
gram
posit
bacteria
staphylococcu
epidermidi
follow
staphylococu
aureu
staphylococcu
homini
frequent
gram
neg
bacteria
escherichia
coli
follow
klebsiella
pneumonia
acinetobact
baumanii
gram
posit
bacteria
frequent
isol
femal
patient
wherea
gram
neg
bacteria
frequent
isol
male
patient
conclus
percentag
posit
blood
cultur
practic
rel
high
compar
seri
frequent
infecti
diseas
gram
posit
agent
although
statist
signific
found
differ
diseas
agent
accord
gender
k
viani
neto
g
ac
b
v
e
r
v
odon
de
tratamento
infantil
divis
instituto
da
hospit
da
sao
paulo
univers
medic
school
nutrit
sao
paulo
brazil
univers
divis
pediatr
hematologyoncologystem
cell
transplant
new
york
usa
univers
mcmaster
children
hamilton
health
scienc
depart
pediatr
hamilton
canada
de
tratamento
infantil
divis
instituto
da
hospit
da
sao
paulo
univers
medic
school
depart
pediatr
sao
paulo
brazil
backgroundobject
relationship
nutrit
statu
ns
diagnosi
surviv
pediatr
oncolog
describ
sever
author
consid
overal
import
ns
patient
object
studi
determin
ns
children
cancer
diagnosi
compar
ns
patient
solid
tumor
st
hematolog
malign
hm
central
nervou
system
tumor
cnst
compar
ns
distribut
two
differ
anthropometr
paramet
designmethod
retrospect
studi
data
weight
height
arm
circumfer
muac
measur
within
day
diagnosi
collect
nutrit
servic
record
hospit
sao
paulo
brazil
comparison
ns
classifi
bodi
mass
index
z
score
bmiz
use
growth
chart
muac
percentil
ns
classif
bmiz
muac
compar
use
test
result
includ
patient
studi
mean
age
year
diagnos
distribut
hm
st
cnst
overal
accord
bmiz
patient
adequ
adequ
adequ
wherea
muac
percentil
classifi
adequ
adequ
adequ
without
statist
differ
anthropometr
paramet
regard
patient
hm
st
cnst
group
equival
bmiz
howev
differ
muac
percentil
although
hm
present
diverg
bmiz
muac
children
st
muac
bmiz
revers
true
cnst
muac
bmiz
conclus
undernutrit
preval
studi
time
higher
gener
popul
brazilian
childrenadolesc
especi
patient
st
cnst
muac
appear
sensit
bmiz
indic
undernutrit
diagnosi
patient
st
l
xalafova
rs
clinic
nation
center
oncolog
nco
azerbaijan
baku
azerbaijan
background
recent
studi
identifi
import
function
vitamin
vd
regul
cell
prolifer
differenti
apoptosi
addit
vitamin
defici
vdd
link
increas
cancer
risk
prompt
us
screen
vdd
children
cancer
procedur
month
center
survey
done
children
level
vd
age
sex
time
sampl
presenc
malign
tumor
determin
concentr
serum
measur
patient
time
diagnosi
treatment
level
categor
normal
insuffici
defici
time
sampl
collect
classifi
four
season
age
rang
month
year
result
evalu
total
patient
studi
diagnos
malign
disord
nmd
vdd
detect
patient
malign
particularli
alarm
fact
vdd
patient
detect
prior
start
treatment
vdi
identifi
case
normal
level
patient
boy
prevail
girl
vdd
determin
children
age
year
children
nmd
vdd
determin
vdi
case
conclus
azerbaijan
countri
sunni
hoursyear
despit
discov
vdd
case
pediatr
cancer
patient
children
nmd
survey
research
need
determin
whether
vdd
caus
malign
consequ
studi
support
intak
vitamin
possibl
prevent
cancer
children
l
xavier
del
rio
santo
n
duran
cancer
hospit
nutrit
franca
brazil
cancer
hospit
nutrit
barreto
brazil
backgroundobject
mani
question
relat
nutrit
clinic
practic
multidisciplinari
team
investig
doubt
implement
intervent
could
way
address
uncertainti
minim
error
relat
nutrit
support
aim
studi
investig
evalu
describ
knowledg
relat
nutrit
nurs
nutrit
dietet
team
children
cancer
hospit
educ
intervent
designmethod
team
approach
defin
correspond
cupbear
kitchen
assist
nurs
nurs
technician
intens
care
unit
hematopoiet
stem
cell
transplant
ward
two
questionnair
prepar
one
team
appli
first
day
two
intervent
occur
subject
neutropenia
type
diet
feed
rout
discuss
second
questionnair
applic
occur
result
analyz
statist
packag
spss
result
profession
particip
studi
howev
fifteen
perform
second
questionnair
score
obtain
nutrit
dietet
team
first
questionnair
point
poor
regular
grade
nurs
team
score
point
first
moment
poor
bad
grade
signific
increas
p
score
second
questionnair
team
go
regular
good
grade
first
team
bad
great
grade
second
team
comparison
demograph
characterist
nurs
team
sector
work
time
statist
differ
answer
second
questionnair
conclus
good
retent
rate
demonstr
particip
stage
studi
necessari
associ
theori
practic
perform
team
k
ali
institut
blood
diseas
bone
marrow
transplant
pharmaci
karachi
pakistan
backgroundobject
background
conduct
studi
determin
advers
implic
metabol
profil
dlbcl
patient
deal
chop
concis
determin
chang
metabol
profil
correl
dose
intens
ratio
find
studi
help
choic
physician
discontinu
therapi
delay
treatment
altern
regimen
designmethod
prospect
studi
conduct
nation
institut
blood
diseas
bone
marrow
transplant
studi
baselin
read
liver
enzym
urea
creatinin
electrolyt
level
taken
treat
control
read
read
aforesaid
paramet
taken
day
mean
read
calcul
compar
common
terminolog
criteria
advers
event
ctcae
find
differ
biochem
paramet
baselin
control
group
day
treatment
group
identifi
type
toxic
mild
moder
sever
defin
ctcae
result
among
patient
chop
therapi
signific
differ
alp
direct
bilirubin
sgpt
observ
treatment
wherea
among
patient
signific
differ
observ
biochem
analysi
conclus
despit
fact
subject
baselin
metabol
biochem
investig
impair
correct
rigor
rather
post
chemotherapi
effect
chop
cycl
lead
fatal
life
threaten
renal
hepat
toxic
far
safeti
concern
safest
chop
term
toxic
bjork
sundler
k
health
welfar
child
research
depart
univers
sweden
care
scienc
work
life
social
univers
sweden
medicin
depart
health
lund
univers
lund
sweden
nurs
depart
health
univers
sweden
backgroundobject
elucid
parent
live
experi
lose
child
cancer
designmethod
hermeneut
phenomenolog
approach
chosen
five
parent
interview
one
wrote
narr
experi
lose
child
cancer
result
analysi
one
essenti
theme
identifi
like
cover
wet
black
blanket
relat
essenti
theme
six
relat
theme
emerg
feel
conflict
emot
tri
get
readi
moment
death
parent
continu
death
keep
spirit
aliv
work
sorrow
want
comprehend
life
new
integr
whole
conclus
lose
child
cancer
one
pain
situat
parent
live
life
forev
chang
parent
need
find
way
learn
live
without
child
give
palli
care
child
care
need
holist
focu
child
famili
staff
import
meet
parent
child
death
abl
identifi
need
extens
support
holm
medic
center
psychiatri
dalla
usa
backgroundobject
abstract
part
symposium
submiss
psychosoci
care
model
end
life
bereav
support
prepar
death
child
except
distress
famili
provid
best
care
imper
institut
infrastructur
exist
promot
highli
collabor
work
project
describ
develop
integr
interdisciplinari
palli
care
team
within
oncolog
servic
larg
pediatr
hospit
compar
current
standard
care
purpos
team
improv
qualiti
care
children
highest
risk
death
cohes
assimil
medic
psychosoci
profession
alreadi
provid
servic
parallel
designmethod
prior
develop
team
care
follow
tradit
multidisciplinari
model
oncologist
focus
medic
aspect
care
refer
subspecialti
concern
collabor
amongst
subspecialti
inconsist
lead
conflict
intervent
contradictori
goal
care
moral
distress
respons
difficulti
group
expert
develop
interdisciplinari
approach
support
famili
use
integr
care
model
result
includ
case
exampl
illustr
integr
model
care
adolesc
girl
metastat
alveolar
rhabdomyosarcoma
parent
untreat
paranoid
schizophrenia
highli
integr
approach
led
sever
improv
outcom
improv
commun
meant
frequent
crise
manag
adequ
streamlin
care
prevent
repeatedcompet
intervent
increas
interdepend
psychosoci
team
member
allow
focu
unifi
goal
led
peac
death
experi
conclus
ultim
goal
palli
care
identifi
amelior
suffer
seem
best
achiev
holist
care
child
famili
team
specialist
work
toward
consist
goal
develop
team
learn
true
interdisciplinari
collabor
improv
experi
child
death
famili
provid
b
lee
j
k
children
cancer
blood
disord
center
radiat
oncolog
boston
usa
women
hospit
radiat
oncolog
boston
usa
medic
school
radiat
oncolog
boston
usa
backgroundobject
palli
radiat
therapi
prt
pediatr
cancer
patient
often
use
treat
pain
neurolog
symptom
condit
progress
cancer
affect
qualiti
life
decis
pursu
addit
therapi
toward
end
child
life
may
challeng
one
perceiv
risk
versu
benefit
ratio
may
alter
depend
parent
knowledg
expect
prt
child
goal
studi
explor
parent
expect
prt
whether
outcom
met
expect
designmethod
nineteen
children
refer
prt
enrol
prospect
studi
time
initi
consult
parent
counsel
regard
indic
prt
expect
outcom
treatment
one
three
month
follow
treatment
complet
questionnair
given
parent
evalu
result
treatment
compar
initi
expect
prt
descript
statist
use
analyz
result
questionnair
result
compar
initi
expect
prt
report
outcom
prt
child
much
better
expect
report
slightli
better
result
report
outcom
consist
expect
report
result
slightli
wors
parent
report
outcom
much
wors
expect
conclus
radiat
therapi
import
modal
palli
care
children
cancer
studi
found
larg
major
parent
believ
result
prt
better
expect
find
may
valu
futur
patient
whose
parent
must
make
difficult
decis
mulyowa
cancer
institut
oncolog
kampala
uganda
backgroundobject
although
major
childhood
cancer
curabl
yet
true
low
resourc
countri
uganda
cancer
care
uganda
cancer
institut
jan
dec
new
cancer
case
regist
among
children
mortal
rate
annual
everi
children
diagnos
cancer
surviv
past
one
year
cancer
diagnosi
review
factor
contribut
poor
outcom
potenti
solut
designmethod
observ
result
major
children
present
advanc
diseas
cancer
diagnosi
chemotherapi
prescrib
palli
intent
frequent
high
rate
complic
observ
famili
involv
decis
regard
role
palli
chemotherapi
end
life
low
concept
qualiti
life
cancer
patient
advanc
cancer
well
perceiv
among
caretak
clinician
uci
nurs
play
integr
role
identifi
symptom
provid
care
coordin
assur
clear
commun
conclus
educ
initi
patient
famili
provid
essenti
oncolog
nurs
play
key
role
multidisciplinari
team
approach
paediatr
patient
end
life
care
naifeh
khouri
g
univers
beirut
hariri
school
nurs
beyrouth
lebanon
backgroundobject
background
palli
care
pc
end
eol
care
evolv
worldwid
lebanon
pc
provid
good
better
outcom
cur
care
alon
cost
effect
allevi
pain
suffer
patient
caregiv
nurs
educ
leader
intern
nation
indic
need
includ
concept
pc
eol
care
curricula
profession
nurs
cope
death
die
potenti
outcom
patient
purpos
assess
effect
pc
continu
educ
intervent
regist
nurs
rn
american
univers
medic
center
aubmc
recommend
futur
educ
program
designmethod
method
quasi
experiment
particip
conveni
sampl
aubmc
rn
deal
pc
elo
care
differ
clinic
unit
program
workshop
basic
pc
elo
care
local
pc
expert
provid
program
content
adapt
educ
physician
end
life
care
curriculum
epec
test
consist
multipl
choic
question
analysi
demograph
characterist
summar
use
descript
statist
differ
measur
mean
standard
deviat
sd
use
pair
test
test
use
less
consid
signific
result
result
thirti
nine
particip
complet
mean
pretest
score
sd
test
sd
rang
pair
test
show
signific
increas
pre
post
test
score
p
confid
interv
mean
differ
conclus
conclus
provid
structur
workshop
rn
improv
pc
eol
care
r
n
diaz
c
c
de
jesu
la
children
hospit
pediatr
managua
nicaragua
justin
pediatr
hospit
pediatr
montreal
canada
hospitali
universitair
vaudoi
pediatr
lausann
switzerland
de
jesu
la
children
hospit
pediatr
managua
nicaragua
backgroundobject
pediatr
palli
care
ppc
unargu
essenti
global
north
south
refer
univers
right
health
follow
world
health
assembl
resolut
palli
care
nicaragua
launch
first
nation
pediatr
palli
care
program
collabor
two
ngo
associazion
per
laiuto
medico
al
centro
america
du
mond
object
includ
healthcar
workforc
train
essenti
drug
suppli
provis
within
framework
ppc
educ
program
intend
nurs
care
children
life
limitng
diseas
nation
referr
children
hospit
managua
develop
designmethod
novemb
decemb
train
nurs
educ
provid
educ
basic
cours
ppc
nurs
variou
depart
pediatr
hospit
test
test
administ
nurs
assess
chang
gener
ppc
knowledg
highest
possibl
test
score
point
comparison
mean
result
perform
result
nurs
depart
took
part
whole
educ
program
mean
result
point
wherea
mean
result
point
differ
observ
assess
knowledg
particip
conclus
mark
differ
assess
demonstr
posit
impact
educ
program
rais
awar
regard
need
palli
care
wit
across
hospit
demand
consult
increas
notabl
educ
health
care
profession
essenti
sustain
effici
qualiti
provis
ppc
posit
outcom
open
door
addit
theoret
practic
train
nurs
well
target
health
care
profession
involv
care
pediatr
palli
care
patient
final
need
review
tool
use
evalu
educ
intervent
field
palli
care
l
e
sarfo
v
j
anoky
teach
hospit
child
health
kumasi
ghana
anoky
teach
hospit
research
develop
unit
kumasi
ghana
backgroundobject
paediatr
cancer
unit
child
health
depart
komfo
anoky
teach
hospit
kath
one
two
main
childhood
cancer
treatment
center
ghana
new
patient
visit
unit
requir
palliat
die
death
occur
hospit
aim
assess
train
need
medic
practition
depart
set
paediatr
cancer
designmethod
medic
practition
complet
survey
assess
particip
commun
skill
practic
care
regard
paediatr
cancer
patient
respons
rank
likert
scale
analys
simpl
proport
result
practition
doctor
nurs
complet
survey
particip
report
ever
undertak
care
respons
doctor
nurs
report
receiv
formal
train
doctor
report
receiv
formal
instruct
contact
famili
patient
death
compar
nurs
survey
particip
report
lack
formal
instruct
seek
support
regard
situat
doctor
nurs
feel
adequ
train
undertak
withdraw
limit
therapi
wherea
doctor
nurs
felt
adequ
train
provid
symptom
manag
end
life
particip
report
adequ
train
experi
commun
issu
famili
report
feel
knowledg
compet
comfort
commun
doctor
compar
nurs
report
adequ
train
experi
provid
spiritu
support
die
children
famili
particip
survey
felt
compet
comfort
includ
children
discuss
prepar
death
conclus
formal
train
care
set
paediatr
cancer
appear
inadequ
signific
gap
commun
skill
withdraw
limit
therapi
symptom
manag
g
jc
timon
oncologi
marseil
franc
backgroundobject
pediatr
palli
care
field
primari
import
improv
qualiti
life
children
cancer
studi
aim
describ
practic
palli
care
institut
studi
time
inclus
death
treatment
length
hospit
locat
death
use
commun
palli
servic
symptom
children
die
cancer
designmethod
studi
retrospect
singl
center
chart
review
everi
child
treat
institut
deceas
june
june
symptom
assess
chart
examin
three
month
death
result
patient
die
cancer
two
year
discuss
palli
care
staff
activ
treat
pediatr
palli
care
unit
median
durat
palli
phase
month
rang
patient
die
hospit
time
mean
number
antineoplast
treatment
per
patient
includ
clinic
trial
symptom
order
frequenc
pain
fatigu
poor
appetit
digest
disord
preval
underestim
medic
chart
conclus
report
palli
activ
allow
improv
practic
resourc
alloc
avail
innov
treatment
palli
purpos
high
howev
great
variabl
durat
palli
care
use
palli
resourc
definit
group
children
requir
earli
initi
palli
care
well
standard
palli
care
assess
intervent
necessari
j
wang
children
medic
center
depart
hematologyoncolog
shanghai
china
backgroundobject
evalu
feasibl
effect
palli
care
consult
pcc
team
servic
model
oncolog
unit
pediatr
tertiari
hospit
china
designmethod
core
palli
care
consult
team
consist
pediatr
oncologist
pediatr
oncolog
nurs
social
worker
doctor
leader
interdisciplinari
team
respons
coordin
care
plan
develop
patient
refer
team
pediatr
oncologist
pcc
team
deliv
palli
care
servic
outpati
clinic
consult
hour
hotlin
hospic
room
locat
observ
ward
team
also
provid
teach
support
health
care
profession
result
total
patient
famili
refer
sinc
referr
reason
refractori
pain
patient
care
patient
diagnos
includ
leukemia
solid
tumor
boy
girl
age
month
year
among
patient
care
die
commun
hospit
oncolog
ward
hospit
separ
role
pcc
team
case
provid
support
local
hospit
colleagu
oncolog
unit
anoth
patient
receiv
direct
care
pcc
team
die
hospic
room
die
home
main
symptom
last
month
pain
anorexia
fatigu
dyspnea
fever
edema
infect
bleed
depress
fear
anxieti
insomnia
direct
indirect
intervent
pcc
team
show
posit
impact
suffer
relief
death
prepar
conclus
palli
care
consult
team
close
attach
provid
profession
support
convent
health
care
cost
save
conclud
model
may
play
import
role
pediatr
palli
care
develop
countri
medic
resourc
insuffici
c
abat
c
de
psycholog
montreal
canada
montreal
canada
de
pediatr
montreal
canada
backgroundobject
qualiti
life
qol
essenti
compon
care
children
cancer
young
survivor
often
inform
parent
signific
other
assess
qol
reliabl
difficult
due
diverg
child
parent
rate
systemat
review
perform
synthes
size
differ
child
parent
rate
qol
stage
cancer
identifi
moder
differ
rate
designmethod
systemat
search
pubm
psycinfo
embas
cinalh
refer
list
reveal
pertin
articl
publish
decemb
elig
criteria
includ
qol
rate
patient
year
old
cancer
treatment
least
one
parent
valid
instrument
two
independ
review
extract
data
conduct
qualiti
assess
standard
tool
line
prisma
recommend
random
effect
compar
qol
across
score
subscor
overal
physic
psychosoci
comput
effect
size
confid
interv
addit
analys
differ
qol
rate
cancer
diagnosi
cancer
trajectori
instrument
underway
result
articl
elig
possibl
percent
studi
recruit
children
treatment
treatment
includ
mix
sampl
describ
children
parent
differ
age
diagnosi
time
sinc
diagnosi
cancer
type
qol
measur
median
icc
overal
qol
quartil
median
cohen
quartil
preliminari
analys
yield
mean
moder
effect
size
child
parent
rate
moder
studi
indic
differ
associ
child
age
child
gender
clinic
histori
parent
mood
conclus
disagr
among
children
parent
highlight
import
gather
qol
assess
multipl
respond
identifi
vulner
patient
futur
research
explain
disagr
develop
new
method
interpret
multipl
report
filand
u
af
l
g
univers
hospit
astrid
lindgren
children
pediatr
oncolog
stockholm
sweden
backgroundobject
famili
shock
child
diagnos
cancer
need
learn
understand
diseas
treatment
prerequisit
feel
confid
take
care
child
health
care
legal
oblig
provid
adequ
inform
time
extrem
difficult
absorb
mani
year
famili
children
cancer
unit
got
folder
inform
childhood
cancer
unit
routin
instruct
act
child
exhibit
acut
symptom
problem
howev
keep
inform
updat
childhood
cancer
mobil
app
develop
complement
verbal
inform
make
possibl
get
answer
question
aris
home
avoid
mix
messag
healthcar
staff
help
parent
inform
close
person
designmethod
special
group
variou
clinic
profess
form
work
app
togeth
hospit
innov
centr
enterpris
platform
text
inform
folder
updat
context
word
discuss
frequent
meet
feedback
patient
rel
gather
workshop
questionnair
mail
signific
part
translat
four
common
foreign
languag
english
spanish
somali
arab
process
workshop
interpret
parent
result
app
soon
use
major
famili
unit
constantli
develop
conclus
childhood
cancer
app
meet
consider
need
parent
rel
staff
crucial
take
help
expert
platform
construct
flower
j
c
children
hospit
pediatr
psycholog
columbu
usa
backgroundobject
abstract
part
symposium
submiss
apadivis
hematologyoncologybmt
sig
entitl
psychosoci
care
model
end
life
bereav
support
nationwid
children
hospit
largest
children
hospit
unit
state
psychosoci
oncolog
team
develop
model
care
enhanc
care
die
children
embodi
collabor
approach
integr
medic
psychosoci
palli
servic
comprehens
coordin
integr
program
model
assess
treat
emot
symptom
burden
facilit
commun
provid
anticipatori
guidanc
support
patientsfamili
facilit
staff
commun
support
designmethod
program
address
special
need
die
children
collabor
team
approach
patient
assess
treat
via
larg
comprehens
psychosoci
team
provid
anticipatori
grief
support
facilit
relationship
focus
continu
care
medic
care
confer
convers
assist
patientfamili
commun
round
advanc
care
plan
legaci
build
palliativeoncolog
round
team
huddl
document
death
notif
protocol
develop
improv
staff
commun
addit
provid
support
staff
follow
patient
death
debriefingsremembr
result
larg
program
multipl
provid
often
challeng
know
provid
specif
servic
ensur
famili
receiv
need
care
increas
commun
within
team
ensur
support
enhancestreamlin
servic
delin
servic
provis
conclus
psychosoci
oncolog
team
nch
improv
commun
among
medic
psychosoci
palli
team
member
enhanc
opportun
provid
support
around
child
death
field
high
level
burnout
stress
open
commun
support
among
team
member
serv
enhanc
servic
provid
patient
also
reduc
staff
distress
comparison
model
psychosoci
standard
care
relat
palli
care
bereav
review
c
stanley
van
der
k
p
p
n
project
malawi
kamuzu
central
hospit
cancer
program
lilongw
malawi
children
foundat
oncolog
lilongw
malawi
backgroundobject
lymphoma
commonest
pediatr
cancer
africa
ssa
princip
contribut
factor
suboptim
outcom
frequent
loss
ltfu
howev
risk
factor
reason
ltfu
among
famili
children
lymphoma
ssa
clear
aim
assess
risk
factor
reason
ltfu
among
pediatr
lymphoma
patient
malawi
designmethod
conduct
mix
method
studi
among
children
year
old
newli
diagnos
lymphoma
prospect
enrol
lilongw
malawi
children
receiv
standard
diagnosi
treatment
follow
two
year
ltfu
defin
failur
attend
prescrib
chemotherapi
visit
within
four
week
visit
within
three
month
child
guardian
household
characterist
associ
ltfu
assess
use
cox
model
interview
conduct
primari
caregiv
children
experienc
ltfu
result
children
newli
diagnos
lymphoma
burkitt
hodgkin
lymphoma
male
median
age
year
interquartil
rang
iqr
ltfu
lack
guardian
formal
educ
travel
time
hour
clinic
independ
associ
ltfu
adjust
hazard
ratio
ahr
confid
interv
ci
ahr
ci
respect
frequent
reason
ltfu
mention
guardian
commun
influenc
suboptim
clinic
environ
logist
challeng
transport
cost
treatment
side
effect
toxic
loss
hope
altern
healer
belief
cure
conclus
ltfu
driven
guardian
household
characterist
child
characterist
find
highlight
famili
risk
ltfu
opportun
improv
retent
care
pediatr
cancer
patient
ssa
j
hoag
k
colleg
wisconsin
depart
pediatr
milwauke
usa
backgroundobject
propos
symposium
repres
collabor
amongst
hematologyoncologyblood
marrow
transplant
bmt
special
interest
group
societi
pediatr
psycholog
american
psycholog
associ
standard
psychosoci
care
children
cancer
publish
landmark
special
edit
pediatr
blood
cancer
two
standard
dealt
palli
care
bereav
minimum
care
establish
remain
unclear
institut
use
guidelin
within
exist
infrastructur
improv
refin
practic
model
therefor
object
symposium
describ
psychosoci
care
model
end
life
bereav
support
across
three
institut
vari
size
resourc
geograph
divers
aid
understand
current
practic
designmethod
propos
present
reflect
variou
approach
collabor
care
across
disciplin
end
life
facilit
honest
respect
commun
patient
famili
improv
advanc
care
plan
assist
memori
make
present
also
discuss
bereav
institut
famili
well
staff
result
descript
program
data
present
includ
hospit
patient
demograph
composit
palli
bereav
team
time
introduct
intervent
program
evalu
barrier
implement
address
conclus
symposium
highlight
variou
way
implement
standard
psychosoci
care
provid
end
life
bereav
care
children
cancer
famili
author
correspond
abstract
staci
flower
jeffrey
karst
suzann
holm
k
long
v
c
univers
psycholog
brain
scienc
boston
usa
children
hospit
center
biobehavior
health
columbu
usa
univers
depart
psycholog
brain
scienc
boston
usa
pittsburgh
psycholog
pittsburgh
usa
children
health
system
center
healthcar
deliveri
scienc
wilmington
usa
jefferson
univers
sidney
kimmel
medic
colleg
philadelphia
usa
backgroundobject
despit
increas
research
understand
sibl
psychosoci
adjust
cancer
remain
limit
updat
systemat
review
summar
main
find
limit
current
sibl
literatur
provid
clinic
recommend
offer
futur
research
direct
designmethod
search
medlinepubm
cinahl
psycinfo
yield
articl
publish
sinc
relat
sibl
psychosoci
function
pediatr
cancer
quantit
qualit
four
mix
method
met
inclus
criteria
rate
scientif
merit
find
extract
synthes
result
mean
level
anxieti
depress
gener
adjust
eg
symptom
intern
extern
gener
distress
similar
across
sibl
comparison
sampl
mani
sibl
report
moderatesever
level
posttraumat
stress
sibl
display
poorer
academ
function
absente
peer
peer
relationship
similar
comparison
find
regard
qualiti
life
mix
adult
sibl
may
higher
risk
cardiovascular
diseas
engag
riski
heavi
drink
comparison
risk
factor
poor
adjust
includ
low
social
support
poorer
famili
function
lower
incom
nonwhit
race
shorter
time
sinc
diagnosi
find
inconsist
qualit
studi
report
theme
sibl
matur
compass
autonomi
along
strong
neg
emot
uncertainti
famili
disrupt
limit
parent
support
school
problem
alter
friendship
unmet
need
conclus
limit
longitudin
studi
lack
sibl
often
consid
control
patientssurvivor
sampl
characterist
eg
age
raceethn
time
sinc
cancer
diagnosi
rare
consid
conclus
despit
methodolog
limit
literatur
indic
strong
need
sibl
psychosoci
care
focus
identifi
sibl
facilit
famili
commun
cancer
bolster
sibl
social
support
knowledg
cancer
involv
futur
research
implement
longitudin
design
focus
mechan
moder
sibl
adjust
would
inform
optim
time
target
sibl
psychosoci
care
psihogio
j
j
l
children
hospit
philadelphia
pediatr
philadelphia
usa
backgroundobject
approxim
aya
cancer
report
elev
stress
symptom
ptss
aya
differenti
thyroid
cancer
dtc
often
exclud
psychosoci
research
clinic
initi
due
good
prognosi
treatment
outsid
cancer
center
enhanc
understand
adapt
studi
describ
clinic
rate
aya
caregiv
ptss
famili
risk
correl
ptss
designmethod
aya
dtc
femal
white
caregiv
mother
complet
questionnair
diagnosi
month
later
includ
ptsd
ptss
psychosoci
assess
tool
famili
risk
pedsql
hrqol
evalu
clinic
signific
rate
ptss
famili
risk
assess
respons
establish
cut
point
multipl
regress
manova
examin
relationship
ptss
correl
result
among
aya
report
clinic
signific
ptss
among
caregiv
report
clinic
signific
ptss
endors
famili
risk
associ
intervent
need
mean
aya
hrqol
pair
show
signific
chang
ptss
famili
risk
lower
hrqol
p
associ
aya
ptss
aya
least
one
complic
report
greater
ptss
higher
famili
risk
associ
greater
caregiv
ptss
conclus
compar
childhood
cancer
sampl
subset
aya
dtc
caregiv
clinic
level
ptss
persist
ptss
year
combin
famili
risk
highlight
import
convey
psychosoci
screen
aya
treat
endocrin
set
aya
hrqol
similar
newli
diagnos
cancer
patient
may
target
reduc
ptss
b
g
l
f
schult
calgari
psycholog
calgari
canada
calgari
medicin
calgari
canada
guelph
psycholog
guelph
canada
calgari
oncolog
calgari
canada
backgroundobject
pediatr
cancer
patient
parent
often
stay
hospit
extend
period
time
report
disrupt
sleep
studi
aim
examin
object
subject
measur
sleep
qualiti
pediatr
cancer
patient
parent
receiv
overnight
oncolog
care
designmethod
sixteen
patient
male
mean
year
parent
particip
three
consecut
day
patient
parent
wore
actigraphi
watch
complet
daili
sleep
diari
patient
also
complet
child
depress
inventori
multidimension
anxieti
scale
children
child
sleep
habit
questionnair
pediatr
qualiti
life
pedsql
multidimension
fatigu
scale
pedsql
gener
core
parent
addit
complet
state
trait
anxieti
inventori
adult
abbrevi
pittsburgh
sleep
qualiti
index
proxi
pedsql
mulidimension
anxieti
scale
proxi
pedsql
gener
core
daili
profil
mood
state
questionnair
result
preliminari
find
indic
pediatr
oncolog
patient
symptom
sleep
disrupt
andor
fatigu
base
upon
measur
child
sleep
habit
anxieti
sleep
qualiti
addit
pedsql
multifatigu
scale
indic
children
report
greater
gener
cognit
sleeprest
fatigu
comparison
publish
norm
conclus
data
obtain
research
help
identifi
way
decreas
effect
import
physiolog
consequ
current
cancer
care
practic
research
sleep
disturb
hospit
pediatr
cancer
patient
parent
aid
better
understand
development
framework
guid
interventionprevent
program
provid
benefit
optim
child
parent
health
hospit
stay
p
wolter
b
k
b
k
j
cancer
institut
pediatr
oncolog
branch
bethesda
usa
institut
health
clinic
center
bethesda
usa
biomed
research
inc
clinic
research
directorateclin
monitor
research
nci
campu
frederick
maryland
usa
institut
diabet
digest
kidney
diseas
obes
branch
bethesda
usa
univers
mechan
industri
engin
boston
usa
inc
clinic
scienc
melbourn
australia
tennesse
health
scienc
center
depart
pediatr
memphi
usa
backgroundobject
cranial
radiat
therapi
crt
pediatr
brain
tumor
contribut
neurocognit
late
effect
cognit
rehabilit
intervent
sore
need
studi
indic
physic
activ
pa
improv
brain
mechan
cognit
function
aim
pilot
random
control
trial
rct
assess
feasibl
preliminari
efficaci
novel
home
pa
intervent
children
treat
crt
brain
tumor
designmethod
children
year
two
year
cognit
late
effect
random
immedi
intervent
group
iig
follow
home
program
increas
pa
maintain
pa
week
delay
intervent
group
dig
monitor
usual
pa
week
follow
program
psychologist
taught
accept
commit
therapi
techniqu
facilit
pa
engag
particip
use
acceleromet
websit
track
reward
pa
mvpa
group
underw
fast
blood
draw
measur
circul
growth
factor
treadmil
evalu
cognit
assess
first
week
repeat
cognit
assess
second
week
includ
cogstat
computer
test
norm
particip
repeat
cogstat
test
immedi
treadmil
evalu
result
six
children
mean
year
enrol
complet
pilot
studi
baselin
program
increas
weekli
mvpa
total
mean
minut
treadmil
evalu
improv
cogstat
visual
memori
score
total
mean
iig
show
greater
increas
visual
memori
score
compar
dig
period
versu
point
likert
scale
particip
report
like
program
find
help
conclus
pilot
data
suggest
feasibl
innov
home
pa
intervent
children
treat
brain
tumor
provid
preliminari
evid
increas
mvpa
potenti
cognit
benefit
support
larger
rct
akiko
k
school
health
scienc
nurs
faculti
medicin
univers
tokyo
background
adolesc
cancer
awc
show
strength
posit
attitud
sens
purpos
resourc
refer
maintain
peer
school
life
social
relationship
normal
life
purpos
studi
develop
resourc
posit
attitud
purpos
gain
resili
awc
method
yin
descript
case
studi
use
studi
approv
institut
review
board
interview
guid
perform
author
privat
room
cancer
experi
cope
strategi
hope
social
support
phase
earli
inpati
inpati
near
discharg
outpati
ask
interview
last
minut
result
particip
compris
male
femal
year
old
month
outpati
interview
data
classifi
resourc
posit
attitud
purpos
phase
result
exhibit
graphic
pattern
newli
diagnos
awc
one
averag
pattern
shown
tempor
pattern
wave
posit
attitud
higher
purpos
posit
attitud
encount
gentli
wave
path
low
phase
purpos
steep
one
inpati
near
discharg
resourc
found
parent
friend
use
other
parent
work
earli
inpati
phase
friend
phase
conclus
awc
use
resourc
depend
phase
fewer
resourc
make
purpos
intervent
may
need
make
purpos
improv
resili
keyword
adolesc
cancer
resili
resourc
posit
attitud
sens
purpos
c
baggott
use
univers
cancer
clinic
trial
offic
palo
alto
usa
backgroundobject
children
cancer
requir
complex
home
medic
regimen
typic
facilit
parent
despit
critic
natur
drug
nonadher
regimen
commonplac
relat
intent
factor
eg
avoid
toxic
effect
unintent
factor
eg
forget
medic
error
medic
link
poor
outcom
among
children
cancer
thorough
accur
assess
patient
medic
use
essenti
collect
data
promot
earli
detect
untoward
symptom
pattern
identifi
patientfamili
misconcept
medic
regimen
detail
identifi
patientsfamili
struggl
medic
adher
provid
requir
data
clinic
trial
current
practic
interview
parent
elicit
drug
use
prior
week
time
consum
prone
recal
error
furthermor
practic
provid
feedback
medic
use
pattern
numer
technolog
solut
eg
smartphon
smartwatch
electron
pillbox
avail
promot
medic
adher
efficaci
evalu
sampl
parent
childhood
cancer
patient
primari
object
project
determin
challeng
exist
medic
administrationrecord
practic
optim
featur
includ
technolog
solut
medic
track
designmethod
parent
children
receiv
chemotherapi
cancer
particip
interview
elicit
percept
challeng
medic
adher
view
technolog
avail
potenti
technolog
solut
facilit
medic
track
promot
adher
medic
regimen
sampl
consist
mother
father
whose
children
receiv
chemotherapi
least
month
remain
treatment
time
interview
result
result
summar
poster
format
conclus
elicit
view
challeng
solut
medic
track
parent
childhood
cancer
patient
may
inform
strategi
promot
success
adopt
technolog
solut
promot
medic
adher
j
bartholomew
merci
hospit
hematologyoncolog
kansa
citi
usa
al
masri
pediatr
oncolog
beit
jala
palestinian
author
backgroundobject
due
polit
econom
forc
children
cancer
palestin
essenti
access
care
vision
develop
region
pediatr
oncolog
center
becam
realiti
collabor
effort
maxim
care
avail
children
establish
kansa
citi
kc
unit
state
beit
jala
bj
palestinian
territori
designmethod
seri
train
session
nurs
kc
provid
initi
nurs
educ
focus
oncolog
diseas
anticip
seen
emerg
care
would
need
center
bj
develop
nurs
educ
progress
infect
control
safe
handl
agent
patient
support
care
focu
recent
shift
develop
nurs
polici
procedur
provid
consist
care
strengthen
interdisciplinari
commun
questionnair
provid
nurs
huda
al
masri
pediatr
cancer
depart
assess
nurs
care
level
comfort
prior
post
educ
session
relat
chemotherapi
safeti
support
care
patientfamili
educ
consist
care
team
commun
result
questionnair
clearli
demonstr
confid
nurs
care
develop
educ
intervent
provid
kc
nurs
huda
al
masri
acknowledg
abil
safe
provid
care
educ
patient
famili
diagnosi
treatment
side
effect
advoc
patient
recept
team
environ
conclus
knowledg
gain
regard
oncolog
diagnos
process
treatment
emerg
manag
increas
nurs
abil
confid
provid
qualiti
care
success
bj
program
replic
gaza
j
chanapai
p
p
n
p
children
hospit
pediatr
oncohemato
hsct
bangkok
thailand
univers
pediatr
oncolog
bangkok
thailand
backgroundobject
background
mucos
common
complic
patient
underw
hematopoiet
stem
cell
transplant
hsct
mucos
grade
mild
sympyom
sever
pain
unabl
eat
caus
nutrit
insuffici
care
plan
mucos
may
help
relief
patient
suffer
improv
nutrit
statu
object
develop
care
plan
mucos
thalassem
patient
heploident
hematopoiet
stem
cell
transplant
hsct
designmethod
method
retrospect
analyz
frequenc
sever
mucos
patient
thalassemia
haploident
hematopoiet
stem
cell
transplant
hsct
develop
care
plan
use
collect
data
mucos
result
sever
beta
thalassem
patient
median
age
year
rang
year
receiv
hematopoiet
stem
cell
mother
father
insttut
januari
decemb
prepar
regimen
includ
rabbit
antithymocyt
globulin
fludarabin
intraven
busulfanal
patient
develop
mucos
sever
grade
n
record
mucos
grade
everyday
found
patient
suffer
withmucos
first
week
hsct
grade
occur
day
grade
day
grade
day
grade
day
use
data
plan
nurs
care
evalu
nutrit
intak
support
sinc
day
chang
oral
intraven
medic
sinc
day
consid
parenter
nutrit
sinc
day
wean
parenter
support
encourag
oral
intak
sinc
day
result
median
length
stay
day
conclus
use
data
mucos
success
develop
use
care
plan
mucos
thalassemia
patient
undergo
hematopoiet
stem
cell
transplant
hsct
k
coish
k
b
e
nation
health
system
hemeonchsct
unit
dc
usa
backgroundobject
hematopoiet
stem
cell
transplant
hsct
regist
nurs
institut
note
increas
incid
sever
dermat
iad
defin
perian
excori
diaper
patient
undergo
hsct
myeloabl
prepar
regimen
requir
hsct
induc
prolong
neutropenia
increas
risk
infect
delay
wound
heal
increas
risk
skin
breakdown
prevent
complic
caus
increas
pain
cost
length
stay
designmethod
cyanoacryl
liquid
skin
barrier
use
posit
outcom
treat
expedit
heal
iad
interdisciplinari
qualiti
improv
qi
project
hsct
team
implement
prophylact
use
cyanoacryl
incontin
patient
undergo
hsct
patient
met
elig
consent
began
prophylact
perian
cyanoacryl
use
upon
admiss
myeloabl
preparatori
regimen
use
cyanoacryl
continu
engraft
incontin
patient
receiv
thiotepa
exclud
adhes
product
permiss
skin
wound
team
member
provid
educ
staff
caregiv
applic
cyanoacryl
provid
ad
cyanoacryl
applic
order
elig
consent
hsct
patient
result
sixti
seven
percent
patient
met
criteria
particip
prevent
applic
cyanoacryl
perian
area
perian
breakdown
observ
four
patient
hsct
admiss
remain
two
patient
consent
cyanoacryl
experienc
sever
iad
necessit
wound
consult
intraven
pain
medic
one
patient
develop
incontin
admiss
prompt
immedi
implement
prevent
cyanoacryl
patient
develop
iad
conclus
use
cyanoacryl
vulner
pediatr
patient
prevent
infect
due
skin
breakdown
succes
qualiti
initi
innov
project
expand
meet
need
incontin
patient
risk
sever
iad
torr
merci
hospit
pediatr
hematologyoncolog
kansa
citi
usa
backgroundobject
caregiv
pediatr
oncolog
patient
limit
english
profici
face
challeng
navig
english
speak
medic
system
us
object
present
bilingu
materi
improv
patient
care
complianc
designmethod
descript
materi
success
util
improv
patient
care
servic
medic
complianc
hispan
caregiv
limit
english
profici
materi
demonstr
poster
result
bilingu
patient
face
sheet
includ
cancer
diagnosi
central
line
detail
oncolog
contact
inform
strict
instruct
regard
time
collect
blood
cultur
initi
antibiot
patient
cancer
provid
caregiv
medic
visit
outsid
facil
mani
patient
live
long
distanc
main
hospit
languag
interpret
tool
decreas
triag
time
shorten
time
obtain
antibiot
patient
fever
neutropenia
bilingu
medic
calendar
medic
list
improv
complianc
includ
adher
oral
chemotherapi
bilingu
oncolog
essenti
entail
side
effect
monitor
home
paramet
contact
provid
servic
use
bilingu
pill
box
made
medic
team
proven
instrument
medic
adher
complic
experiment
therapeut
protocol
permit
deviat
protocol
conclus
appropri
bilingu
materi
improv
patient
care
access
decreas
triag
time
time
antibiot
administr
improv
medic
complianc
rn
gill
h
n
khanum
memori
cancer
hospit
research
center
pediatr
oncologyhematolog
inpati
depart
lahor
pakistan
backgroundobject
studi
permit
us
know
nurs
care
convent
gave
nurs
shaukat
khanum
memori
cancer
hospit
research
center
patient
burkitt
lymphoma
got
first
cycl
copadm
nurs
challeng
complex
therapi
regimen
manag
acut
long
term
effect
toxic
nurs
care
includ
symptom
manag
encourag
support
patient
hospit
stay
designmethod
retrospect
investig
nurs
note
patient
burkitt
lymphoma
patient
receiv
first
cycl
copadm
shaukat
khanum
memori
cancer
hospit
research
center
year
decemb
jan
inform
includ
age
sex
financi
statu
durat
hospit
stay
common
issu
experienc
complet
examin
nurs
note
evalu
regard
motiv
dietari
advis
result
patient
review
male
median
age
diagnosi
year
patient
admit
though
ear
day
post
copadm
hospit
stay
nurs
patient
proport
span
hospit
stay
day
symptom
persist
day
includ
oral
mucos
nausea
diarrhea
fever
oral
intak
decreas
primari
contribut
element
oral
mucos
nausea
vomit
abdomin
discomfort
dislik
food
persist
nurs
care
includ
regular
oral
care
counsel
dietari
improv
patient
encount
psycholog
disturb
emin
reason
social
separ
home
sick
fear
diseas
progress
long
term
toxic
chemotherapi
frequent
counsel
session
attend
nurs
conduct
activ
listen
employ
play
therapi
provis
cartoon
movi
stori
book
conclus
individu
assess
dedic
effort
nurs
staff
facilit
patient
cope
problem
encount
receiv
first
cycl
intens
chemotherapi
copadm
h
hansson
g
p
ab
univers
hospit
rigshospitalet
paediatr
haematolog
oncolog
depart
copenhagen
denmark
backgroundobject
result
intens
complex
treatment
regimen
patient
increas
need
nurs
care
develop
tool
call
pimi
systemat
document
measur
nurs
care
need
children
cancer
use
nurs
resourc
object
studi
assess
feasibl
tool
balanc
nurs
care
need
amount
nurs
resourc
need
demand
designmethod
pimi
record
daili
compris
two
part
classif
patient
need
nurs
care
evalu
place
one
six
care
categori
refer
optim
number
nurs
need
meet
patient
need
comparison
optim
number
nurs
actual
number
nurs
avail
reliabl
studi
statist
valid
data
collect
day
pediatr
hematolog
oncolog
ward
bed
februari
decemb
analyz
descript
statist
result
ward
day
optim
nurs
staf
day
optim
level
day
level
daili
averag
children
rang
optim
number
nurs
need
rang
actual
number
nurs
nurs
care
rang
number
nurs
nurs
care
year
experi
rang
conclus
pimi
easi
accur
use
result
document
children
need
nurs
care
match
actual
staf
level
pimi
use
daili
alloc
nurs
base
children
nurs
care
need
manag
nurs
resourc
appropri
n
j
children
medic
center
hematolog
oncolog
shanghai
china
children
medic
center
nurs
depart
shanghai
china
backgroundobject
background
oral
mucos
one
frequent
complic
chemotherapi
occur
approxim
children
receiv
treatment
cancer
recent
suggest
use
laser
could
reduc
grade
oral
mucos
allevi
symptom
recommend
made
adult
patient
pediatr
patient
data
effect
laser
therapi
pediatr
patient
limit
object
synthes
avail
clinic
evid
effect
laser
therapi
lllt
prevent
treatment
oral
mucos
om
designmethod
perform
use
trial
identifi
pubm
march
embas
march
cochran
librari
cnki
chines
march
data
occurr
durat
sever
oral
mucos
collect
random
control
studi
clinic
control
studi
compar
lllt
routin
qualifi
prevent
treatment
chemotherapi
critic
apprais
analyz
result
found
qualifi
clinic
trial
total
pediatr
patient
methodolog
qualiti
accept
signific
prevent
effect
lllt
rel
risk
ci
grade
ii
higher
om
occur
signific
prevent
effect
rel
risk
ci
om
occur
prophylact
lllt
om
sever
could
decreas
significantli
combin
effect
size
ci
could
done
effect
lllt
treatment
om
conclus
recommend
could
made
support
lllt
prevent
om
pediatr
patient
effect
lllt
treatment
om
could
promis
decreas
pain
durat
futur
research
identifi
proper
characterist
lllt
determin
feasibl
clinic
set
k
kamibeppu
school
health
scienc
nurs
faculti
univers
tokyo
depart
famili
nurs
tokyo
japan
backgroundobject
posit
health
defin
develop
strength
resourc
gain
resili
resourc
refer
maintain
peer
school
life
social
relationship
normal
life
purpos
studi
develop
resourc
gain
posit
attitud
purpos
resili
adolesc
cancer
awc
designmethod
yin
descript
case
studi
use
data
analyz
logic
studi
approv
institut
review
board
physician
identifi
potenti
particip
appoint
list
interview
guid
social
network
map
use
assess
tool
perform
author
privat
room
last
minut
occur
particip
wait
result
blood
test
interview
proceed
broad
safe
question
specif
sensit
one
particip
ask
cancer
experi
posit
cope
hope
social
support
research
conduct
interview
demograph
health
inform
obtain
form
patient
chart
result
particip
compris
mall
femal
five
newli
diagnos
experienc
relaps
age
pf
newli
diagnos
particip
reed
year
particip
relaps
age
year
conclus
posit
attitud
purpos
relat
resourc
p
johnson
merci
hospit
hematologyoncolog
kansa
citi
usa
backgroundobject
advanc
practic
regist
nurs
aprn
essenti
part
us
health
care
system
mani
seek
volunt
short
term
global
health
program
expand
worldview
provid
care
margin
popul
intern
council
nurs
icn
creat
scope
practic
code
ethic
follow
aprn
practic
intern
howev
wide
known
addit
mani
countri
fulli
recogn
aprn
role
healthcar
servic
provid
designmethod
purpos
project
explor
aprn
percept
scope
practic
current
intern
standard
practic
item
survey
conduct
among
member
american
academi
nurs
practition
intern
special
interest
group
particip
intern
short
term
global
health
program
particip
ask
scope
practic
use
intern
practic
awar
practic
guidelin
ethic
dilemma
encount
regard
scope
practic
result
nineteen
respond
qualifi
survey
half
famili
nurs
practition
particip
five
trip
intern
believ
recogn
aprn
mani
countri
list
recogn
aprn
follow
us
scope
practic
express
concern
number
patient
seen
limit
resourc
express
love
work
feel
ethic
challeng
ethic
practic
rang
nation
guidelin
person
belief
conclus
aprn
particip
short
term
global
health
program
mind
host
countri
expect
regard
scope
practic
nation
recognit
role
continu
discuss
intern
role
aprn
help
increas
access
vulner
popul
reduc
stress
provid
killela
north
carolina
chapel
hill
nurs
raleigh
usa
north
carolina
chapel
hill
nurs
chapel
hill
usa
backgroundobject
complet
treatment
contain
stress
transit
children
cancer
famili
stress
associ
time
period
amplifi
social
support
associ
regular
hospit
outpati
visit
less
frequent
thu
gap
social
network
famili
creat
use
social
media
present
possibl
sourc
support
fill
gap
exploratori
studi
aim
qualifi
type
support
evid
one
famili
publicli
avail
onlin
blog
detail
experi
period
follow
complet
treatment
designmethod
implement
schaefer
theori
social
support
differenti
among
emot
support
inform
support
tangibl
support
paper
use
direct
content
analysi
scrutin
blog
post
written
follow
treatment
complet
sort
content
social
support
domain
result
common
form
social
support
observ
inform
support
two
categori
inform
medic
procedur
inform
famili
life
second
common
form
social
support
emot
support
divid
express
fear
stress
associ
diseas
recurr
quest
achiev
new
normal
lastli
third
form
social
support
tangibl
support
least
common
express
mostli
term
gratitud
support
conclus
paper
serv
provid
inform
necessari
futur
studi
develop
nurs
intervent
wide
distribut
blog
mean
improv
social
support
among
parent
caregiv
children
complet
treatment
n
nakagaki
women
univers
nurs
ichikawa
japan
backgroundobject
purpos
studi
make
clear
prepar
util
pictur
book
influenc
children
cope
abil
admit
hospit
designmethod
subject
studi
eight
children
year
old
leukaemia
children
hospit
nurs
explain
children
necess
hospit
visit
hour
hospit
life
variou
staff
use
pictur
book
time
explan
minut
hospit
first
time
c
ward
hospit
period
day
data
collect
day
day
last
day
hospit
mean
particip
observ
method
children
reaction
toward
hospit
observ
analyz
code
children
reaction
focus
state
hospit
life
code
result
classifi
subcategori
categori
core
categori
result
deriv
core
categori
follow
children
made
mind
stay
hospit
join
prepar
hospit
made
effort
order
get
loneli
stay
away
famili
could
spend
hospit
life
depend
nurs
spent
hospit
relax
feel
posit
feel
toward
hospit
life
could
posit
receiv
medic
practic
persev
hospit
feel
achiev
conclus
children
becam
abl
imagin
hospit
life
somehow
receiv
prepar
famili
cooper
children
abl
commun
nurs
share
pictur
book
prepar
hospit
therefor
children
could
build
mutual
trust
relationship
nurs
entrust
nurs
hospit
life
consid
children
evad
prospect
critic
situat
hospit
receiv
prepar
util
pictur
book
j
ogawa
k
univers
school
nurs
nutrit
chiba
japan
children
hospit
nurs
chiba
japan
univers
medic
center
nurs
ichihara
japan
univers
hospit
nurs
chiba
japan
backgroundobject
guidelin
prevent
occup
exposur
anticanc
drug
publish
japan
howev
insuffici
cover
pediatr
oncolog
area
studi
aim
find
percept
occup
exposur
among
pediatr
oncolog
nurs
designmethod
origin
questionnair
prevent
occup
exposur
mail
nurs
work
hospit
nurs
hospit
cancer
children
treat
result
got
nurs
respond
includ
nurs
report
hospit
rule
occup
exposur
found
nurs
take
prevent
measur
dispos
child
excreta
nurs
educ
famili
caregiv
children
prevent
exposur
nurs
take
prevent
measur
handl
linen
contamin
excreta
nurs
explain
laundri
take
laundri
home
famili
specif
exposur
measur
concern
handl
excreta
linen
variou
wear
glove
use
person
protect
equip
nurs
clean
children
time
diaper
chang
nurs
appli
ointment
protect
exposur
administr
anticanc
drug
children
nurs
respond
put
glove
protect
time
oral
anticanc
drug
administr
nurs
explain
famili
caregiv
import
nurs
take
prevent
measur
handl
empti
bag
oral
anticanc
drug
conclus
clear
prevent
exposur
anticanc
drug
medic
staff
pediatr
oncolog
ward
suffici
need
guidelin
special
childhood
cancer
treatment
patient
sibl
mother
get
pregnant
much
vulner
ordin
adult
h
pett
children
hospit
haematolog
oncolog
birmingham
unit
kingdom
backgroundobject
complex
number
cost
medic
within
oncolog
continu
rise
nurs
busi
bed
princip
treatment
centr
report
spend
less
time
patient
bedsid
time
drug
prepar
room
famili
comment
alway
knew
find
nurs
drug
prepar
room
compound
trust
drug
administr
polici
requir
train
staff
whole
process
project
sought
explor
possibl
pharmaci
technician
part
tradit
nurs
role
prepar
drug
trolley
medicin
document
administr
complet
thu
releas
nurs
time
care
economi
paediatr
nurs
recruit
challeng
object
improv
time
deliveri
medicin
reduc
avoid
medicin
wast
integr
pharmaci
role
paediatr
oncolog
ward
team
ncreas
effici
designmethod
initi
observ
studi
undertaken
identifi
busiest
time
day
intraven
oral
drug
administrationthi
time
use
focu
initi
intervent
aim
maximum
impact
train
packag
dissemin
technician
checklist
introduc
base
monograph
result
oral
drug
round
undertaken
nurs
pharmaci
technician
reduc
averag
take
minut
releas
time
nurs
care
addit
reduct
medic
prescrib
error
near
miss
incid
per
day
conclus
pharmaci
technician
nurs
combin
oral
intraven
medic
administr
improv
patient
staff
experi
releas
nurs
time
continu
high
incid
report
cultur
within
clinic
area
overal
associ
harm
level
reduc
proactiv
protocol
driven
approach
safeti
medic
embed
c
rodger
k
k
univers
school
nurs
durham
usa
colleg
medicin
pediatr
houston
usa
robert
h
luri
children
hospit
stem
cell
transplant
chicago
usa
backgroundobject
hematopoiet
stem
cell
transplant
hsct
caus
frequent
distress
symptom
continu
first
day
post
hsct
known
acut
recoveri
phase
current
hsct
symptom
research
focus
symptom
preval
specif
point
time
littl
evid
regard
complex
symptom
chang
time
primari
aim
studi
identifi
symptom
trajectori
pattern
among
adolesc
acut
hsct
recoveri
designmethod
repeat
measur
design
use
elicit
symptom
experi
adolesc
age
year
receiv
allogen
hsct
sign
consentass
demograph
inform
obtain
medic
record
adolesc
complet
memori
symptom
assess
scale
msa
prior
hsct
adolesc
complet
msa
one
two
three
month
post
hsct
result
data
collect
complet
june
symptom
trajectori
includ
symptom
frequenc
sever
distress
evalu
occur
separ
three
symptom
characterist
descript
statist
standard
linear
regress
use
examin
data
time
conclus
find
studi
allow
healthcar
provid
easili
recogn
even
anticip
patient
symptom
acut
hsct
recoveri
provid
meaning
symptom
discuss
patient
provid
anticipatori
guidanc
promot
strategi
best
help
patient
manag
symptom
studi
fund
alex
lemonad
stand
foundat
santacroc
j
j
j
univers
north
carolina
chapel
hill
school
nurs
lineberg
comprehens
cancer
center
chapel
hill
usa
univers
nell
hodgson
woodruff
school
nurs
atlanta
usa
univers
north
carolina
chapel
hill
school
medicin
lineberg
comprehens
cancer
center
chapel
hill
usa
backgroundobject
puls
wave
veloc
pwv
accur
mean
estim
arteri
stiff
thu
risk
cvd
adult
studi
purpos
examin
feasibl
measur
pwv
clinic
visit
estim
risk
cvd
children
recent
complet
cancer
therapi
relat
pwv
measur
refer
valu
designmethod
includ
children
age
year
month
post
treatment
treatment
regimen
incorpor
anthracyclin
exclud
children
histori
anoth
medic
condit
eg
diabet
known
heighten
risk
cvd
sphygmocor
px
devic
atcor
sydney
australia
interfac
laptop
comput
use
conduct
pwv
measur
train
profession
perform
anthropometr
measur
eg
weight
height
blood
pressur
surfac
distanc
carotid
site
jugular
notch
jugular
notch
femor
site
enter
laptop
pwv
calcul
pwv
measur
discard
repeat
heart
rate
vari
carotid
femor
site
captur
result
particip
male
white
mean
age
year
mean
time
sinc
treatment
month
devic
tonometri
probe
fail
prepar
clinic
first
data
collect
second
probe
hand
experienc
technic
issu
particip
lay
quietli
exam
tabl
otherwis
cooper
pwv
measur
femor
site
captur
challeng
achiev
particip
bodi
mass
index
bmi
plot
compar
pwv
measur
refer
valu
healthi
children
sex
age
show
associ
pwv
bmi
conclus
measur
pwv
clinic
visit
children
recent
complet
cancer
therapi
feasibl
pwv
measur
potenti
inform
evalu
precis
intervent
control
risk
cvd
new
survivor
childhood
cancer
g
sayaka
univers
graduat
school
medicin
depart
child
health
nurs
miyagi
japan
center
child
health
develop
nurs
depart
tokyo
japan
center
child
health
develop
children
cancer
center
tokyo
japan
backgroundobject
children
adolesc
cancer
face
difficulti
return
school
complet
therapi
standard
guidelin
support
school
reentri
children
cancer
japanin
studi
aim
develop
guidelin
assess
support
school
reentri
children
cancer
provid
equal
situat
japan
designmethod
first
identifi
paper
onlin
literatur
retriev
system
past
year
use
search
word
childhood
cancer
chronic
diseas
school
reentri
collect
fundament
inform
establish
guidelin
five
expert
medic
care
educ
research
children
cancer
evalu
paper
use
delphi
method
subsequ
interview
conduct
clinic
nurs
special
pediatr
cancer
care
confirm
valid
guidelin
result
although
support
program
school
reentri
provid
hospit
japan
vari
basic
element
common
addit
schedul
confer
prepar
request
letter
find
import
affirm
consensu
patient
parent
individu
reentri
plan
confer
held
doctor
nurs
charg
class
teacher
supervisor
patient
parent
soon
complet
initi
treatment
two
four
week
discharg
point
address
meet
includ
inform
diseas
concern
peopl
school
method
facilit
adjust
classmat
concern
school
healthcar
personnel
involv
conclus
guidelin
provid
concret
method
school
reentri
children
cancer
patient
parent
medic
staff
educ
lead
fulfil
support
pediatr
cancer
patient
c
im
p
j
j
univers
school
health
welfar
halmstad
sweden
backgroundobject
leukaemia
common
cancer
form
children
worldwid
diseas
encroach
child
daili
life
influenc
live
condit
lifestyl
addit
diseas
treatment
unpleas
experi
caus
pain
nausea
suffer
treatment
children
stay
hospit
long
frequent
period
signific
effect
everyday
life
improv
increas
qualiti
care
children
throughout
cancer
trajectori
import
could
lead
better
experi
children
reduc
suffer
relat
treatmentth
object
explor
care
environ
accord
sedat
chemotherapi
paediatr
leukemia
designmethod
studi
follow
approach
ground
theori
base
interview
practition
involv
paediatr
oncolog
care
process
paediatrician
anaesthetist
nurs
anaesthetist
result
main
concern
emerg
creat
shelter
place
mean
healthcar
profession
work
best
provid
sedat
chemotherapi
depart
instead
oper
theatr
shelter
place
consist
familiar
place
nearbi
hospit
bed
shelter
place
creat
atmospher
embrac
calm
protect
child
outsid
world
reduc
environment
difficulti
event
shelter
place
provid
temporari
opportun
feel
safe
protect
decreas
anxieti
fear
adapt
situat
need
shelter
place
minim
interfer
care
process
daili
life
conclus
work
best
creat
shelter
place
sedat
chemotherapi
promot
adopt
approach
uchida
f
n
j
j
colleg
nurs
school
nurs
komagan
japan
colleg
nurs
school
ob
nurs
komagan
japan
children
hospit
depart
nurs
chiba
japan
children
medic
center
depart
matern
child
health
yokohama
japan
luke
intern
hospit
depart
nurs
tokyo
japan
univers
human
servic
child
health
nurs
yokosuka
japan
univers
school
nurs
nutrit
chiba
japan
human
environ
child
health
nurs
okazaki
japan
backgroundobject
japanes
societi
pediatr
oncolog
nurs
studi
group
develop
nurs
care
guidelin
children
cancer
standard
children
cancer
nurs
japan
addit
examin
degre
import
frequenc
nurs
practic
base
guidelin
evalu
guidelin
result
nurs
recogn
almost
nurs
practic
guidelin
import
howev
nurs
felt
difficulti
implement
nurs
care
despit
recognit
studi
examin
factor
influenc
nurs
practic
improv
children
cancer
nurs
japan
designmethod
sent
two
differ
questionnair
ward
children
cancer
hospit
questionnair
compos
follow
two
categori
frequenc
nurs
practic
ask
frequent
bring
practic
action
base
item
guidelin
hospit
environ
ask
team
compos
arrang
certifi
nurs
specialist
physic
environ
children
ward
analyz
answer
ward
complet
answer
question
two
categori
order
see
relationship
frequenc
nurs
practic
hospit
environ
ward
univers
hospit
children
hospit
gener
hospit
data
analysi
conduct
test
use
spss
statist
result
found
follow
hospit
environ
factor
especi
strong
influenc
frequenc
nurs
practic
arrang
certifi
nurs
presenc
nurs
care
guidelin
presenc
system
children
presenc
teen
room
conclus
result
influenc
factor
nurs
practic
reveal
enhanc
factor
ward
rais
qualiti
nurs
practic
v
c
p
l
e
de
mc
canella
j
e
sobral
da
univers
rio
de
janeiro
pediatr
institut
ippmg
rio
de
janeiro
brazil
salamanca
cancer
research
center
salamanca
spain
backgroundobject
interact
cancer
immun
cell
influenc
treatment
respons
prognosi
propos
strategi
aim
character
infiltr
immun
cell
solid
tumor
metastat
site
pediatr
patient
cancer
use
multiparamet
flow
cytometri
mfc
designmethod
sampl
obtain
diagnosi
patient
suspici
pediatr
cancer
male
femal
mfc
panel
marker
use
identif
character
tumor
immun
cell
u
test
use
continu
variabl
spss
version
chicago
il
result
patient
cancer
inflammatoryreact
diseas
within
solid
tumor
found
revers
ratio
neuroblast
adren
renal
germ
cell
tumor
convers
ratio
soft
tissu
sarcoma
nasopharyng
carcinoma
inflammatoryreact
mass
statist
signific
differ
p
percentag
cell
soft
tissu
sarcoma
nasopharyng
carcinoma
also
nasopharyng
carcinoma
germ
cell
tumor
concern
bm
sampl
bm
infiltr
neuroblast
tumor
significantli
total
cell
bm
patient
neuroblast
tumor
also
reactiveinflammatori
bm
conclus
data
show
differ
pattern
cell
tumor
infiltr
accord
diseas
categori
differ
relat
distinct
pattern
tumor
aggress
addit
infiltr
neuroblast
cell
seem
induc
increas
total
cell
bm
investig
necessari
elucid
role
differ
e
cecen
z
e
e
h
univers
basic
oncolog
izmir
turkey
univers
depart
laboratori
anim
scienc
izmir
turkey
backgroundobject
neuroblastoma
common
solid
tumor
children
half
patient
present
neuroblastoma
metastat
diseas
time
diagnosi
overal
prognosi
poor
despit
intens
therapi
flubendazol
demonstr
exert
activ
leukaemia
myeloma
neuroblastoma
cell
aim
studi
investig
antitumor
activ
flubendazol
neuroblastoma
designmethod
effect
flubendazol
neuroblastoma
cell
line
measur
vitro
use
mtt
assay
cell
inject
subcutan
nude
mice
twenti
male
mice
use
mice
group
mice
divid
group
group
control
group
group
ii
flubendazol
group
mgkgday
group
iii
cisplatin
group
mgkgday
group
iv
flubendazolecisplatin
group
group
treat
everi
day
next
day
sacrif
section
stain
hematoxylin
eosin
h
e
electr
evok
auditori
brainstem
respons
eabr
evalu
mice
statist
analysi
perform
use
spss
signific
data
analyz
use
p
consid
signific
result
dose
flubendazol
determin
mgkg
flubendazol
administ
accordingli
rate
necrobiyosi
tumor
evalu
tumor
necrosi
higher
group
ii
iii
iv
compar
group
control
rate
tumor
necrosi
group
ii
ii
iv
respect
group
except
control
group
serum
creatinin
level
increas
conclus
flubendazol
show
toxic
effect
cisplatin
led
cell
death
similar
level
cisplatin
applic
data
clinic
practic
requir
studi
garofolo
kjt
p
pediatr
paulo
brazil
backgroundobject
pa
direct
measur
cell
stabil
interpret
indic
membran
integr
predictor
bodi
cell
mass
prognosi
indic
surviv
clinic
situat
use
describ
valid
even
situat
oscil
hydrat
state
know
pa
valu
bia
patient
cancer
character
sampl
indic
compar
pa
valu
refer
valu
healthi
pediatr
popul
designmethod
pilot
studi
pediatr
patient
diagnos
malign
neoplasm
studi
use
bia
describ
respons
live
organ
extern
appli
current
measur
opposit
flow
appli
current
tissu
result
patient
chemotherapi
andor
radiotherapi
new
case
hematopoiet
stem
cell
transplant
evalu
averag
year
male
differ
age
gender
tumor
central
nervou
system
leukemia
main
diagnos
studi
diseas
recurr
account
total
underweight
overweight
bmi
total
sampl
af
mean
femal
male
compar
healthi
pediatr
popul
oncolog
patient
present
lower
af
mean
vs
conclus
despit
small
number
sampl
pa
lower
found
healthi
pediatr
popul
demonstr
studi
shown
low
pa
valu
critic
ill
patient
associ
poor
nutrit
statu
poorer
clinic
outcom
higher
mortal
n
de
basqu
countri
physic
anthropolog
anim
physiolog
leioa
spain
hospit
cruce
depart
pediatr
bilbao
spain
hospit
la
paz
depart
oncohaematolog
madrid
spain
hospit
donostia
depart
paediatr
san
spain
health
research
institut
biocruc
health
research
institut
bilbao
spain
backgroundobject
vincristin
vcr
import
compon
childhood
acut
lymphoblast
leukemia
therapi
often
caus
sensori
motor
neurotox
neurotox
could
lead
dose
reduct
treatment
discontinu
sever
studi
associ
peripher
neurotox
polymorph
gene
involv
pharmacokinet
pk
pharmacodynam
pd
vcr
nowaday
well
known
gene
regul
microrna
mirna
snp
mirna
could
modifi
level
function
therefor
aim
studi
determin
whether
snp
mirna
could
associ
neurotox
designmethod
associ
analysi
perform
cohort
spanish
children
treat
lalshop
protocol
select
snp
describ
maf
snp
mirna
could
regul
vcr
pkpd
gene
genotyp
perform
veracod
goldeng
platform
result
statist
signific
associ
found
mirna
snp
neurotox
induct
phase
signific
result
studi
found
seed
region
variant
allel
show
decreas
risk
peripher
neurotox
mirna
could
target
vcr
transport
gene
conclus
present
studi
detect
snp
seed
region
could
alter
vcr
transport
gene
express
consequ
affect
neurotox
patient
pediatr
project
support
basqu
govern
q
shu
zhejiang
univers
school
medicin
depart
surgeri
hangzhou
china
backgroundobject
analyz
clinicopatholog
featur
congenit
hemangioma
nich
evalu
express
wilm
tumor
nich
designmethod
patient
hospit
diagnos
nich
januari
may
includ
studi
control
group
includ
patient
diagnos
vascular
malform
vm
base
appear
hemangioma
flat
slightli
boss
nich
divid
two
group
boss
group
group
patholog
characterist
express
analyz
result
nich
case
includ
male
femal
age
mean
immunohistochem
studi
show
cytoplasm
stain
nich
posit
endotheli
cell
pericyt
signific
differ
posit
rate
express
nich
vm
fisher
exact
probabl
test
p
intens
diffus
express
nich
includ
small
vessel
lobul
irregular
stellat
vessel
anomal
vessel
fibrou
tissu
lobul
differ
posit
rate
express
nich
vm
observ
express
level
group
significantli
higher
boss
group
person
respect
p
express
posit
correl
nich
person
correl
test
p
conclus
nich
boss
type
common
express
nich
specimen
differ
express
level
type
boss
type
express
nich
posit
correl
onofr
quintero
van
helvoort
e
sr
morini
da
lf
maschietto
cancer
hospit
molecular
oncolog
research
center
barreto
brazil
center
research
energi
materi
cnpem
nation
laboratori
bioscienc
lnbio
campina
brazil
children
cancer
hospit
barreto
children
cancer
hospit
barreto
brazil
cancer
hospit
depart
patholog
barreto
brazil
backgroundobject
osteosarcoma
compris
tumor
children
adolesc
aggress
diseas
metastat
patient
evolv
poor
clinic
outcom
hypothes
dna
methyl
chang
could
associ
mechan
involv
transform
progress
osteosarcoma
designmethod
profil
dna
methyl
sampl
patient
osteosarcoma
nine
normal
bone
tissu
use
illumina
humanmethyl
beadchip
array
methyl
data
correct
technic
bia
cellular
composit
effect
result
supervis
comparison
use
bayesian
framework
linear
model
identifi
differenti
methyl
cpg
site
dmss
pvalu
methyl
differ
osteosarcoma
bone
sampl
major
cpg
site
show
hypermethyl
state
osteosarcoma
sampl
addit
bumphunt
analysi
identifi
differenti
methyl
region
dmr
found
tumor
exhibit
hypermethyl
state
dmr
control
pten
express
pten
associ
increas
tumor
growth
osteosarcoma
cell
dm
dmr
level
methyl
chang
identifi
enrich
chromatin
assembl
remodel
dna
pack
gene
transcript
control
suggest
dna
methyl
may
involv
osteosarcoma
diseas
also
enrich
skelet
system
morphogenesi
develop
potint
involv
dna
methyl
disrupt
mechan
control
bone
cell
differenti
conclus
analysi
reveal
dna
methyl
chang
might
associ
cellular
transform
osteosarcoma
chang
may
control
express
gene
relat
biolog
process
involv
disrupt
correct
cell
differenti
transform
final
osteosarcoma
show
tendenc
hypermethyl
state
compar
normal
bone
sampl
jv
rm
pa
b
de
maschietto
center
research
energi
materi
cnpem
nation
laboratori
bioscienc
lnbio
campina
brazil
center
nation
institut
cancer
depart
pediatr
hematolog
oncolog
program
rio
de
janeiro
brazil
center
nation
institut
cancer
depart
patholog
rio
de
janeiro
brazil
backgroundobject
wilm
tumor
wt
relaps
rate
surviv
remain
approxim
blastem
predomin
wt
higer
risk
relaps
associ
resist
chemotherapi
capac
form
distant
metastasi
dna
methyl
chang
could
associ
mechan
involv
ws
progress
resist
aim
identifi
underli
mechan
involv
metastasi
format
wt
designmethod
comprehens
dna
methyl
use
illumina
beadchip
array
appli
match
kidney
wt
blastem
compon
metastat
tissu
patient
treat
siop
protocol
methyl
data
correct
technic
effect
cellular
composit
result
bayesian
framework
linear
model
consid
comparison
identifi
differenti
methyl
posit
dmp
adjp
wt
kidney
metastasi
methyl
pattern
dmp
show
whilst
wt
display
hypomethyl
profil
compar
kidney
metastat
sampl
hypermethyl
profil
compar
dmp
enrich
manl
biolog
process
involv
wih
embron
develop
morphogenesi
cellular
differenti
also
relat
gene
enrich
pathway
relat
metabol
mtor
signal
pathway
sever
gene
role
nephrogenesi
disrupt
wt
appear
differenti
methyl
analysi
agreement
literatur
identifi
differenti
methyl
region
dmr
gaussian
kernel
algorithim
dmrcate
appli
wt
kidney
tissu
analysi
show
dmr
wt
kidney
sampl
locat
next
gene
includ
catalyz
reaction
involv
drug
metabol
conclus
altogeth
found
wilm
tumor
exhibit
hypomethyl
state
compar
normal
kidney
hypomethyl
compar
metastat
sampl
methyl
chang
could
control
express
gene
associ
wilm
tumor
progress
j
neradil
p
k
p
r
j
univers
dept
experiment
biolog
brno
czech
republ
hospit
brno
school
masaryk
univers
depart
pediatr
oncolog
brno
czech
republ
ann
univers
hospit
intern
clinic
research
center
brno
czech
republ
backgroundobject
main
aim
studi
identifi
activ
rtk
signal
pathway
well
downstream
signal
pathway
pediatr
refractori
andor
relaps
solid
tumor
primari
sampl
tumor
tissu
taken
individu
patient
well
pair
sampl
ie
primari
tumor
sampl
relaps
tumor
sampl
analyz
detail
find
possibl
target
person
biolog
therapi
use
monoclon
antibodi
inhibitor
designmethod
experiment
approach
includ
rtk
mapk
phosphoryl
protein
array
determin
pattern
activ
two
group
signal
transduc
array
allow
us
identifi
activ
human
rtk
downstream
signal
molecul
result
till
march
analyz
sampl
total
patient
examin
primari
tumor
patient
primari
relaps
tumor
patient
analyz
three
subsequ
tumor
sampl
accord
classif
frequent
tumor
type
soft
tissu
sarcoma
cn
tumor
bone
tumor
number
sampl
allow
us
perform
also
detail
analysi
rtk
downstream
signal
profil
clearli
show
histogenet
differ
group
tumor
clearli
differ
also
cell
signal
activ
furthermor
also
demonstr
chang
cell
signal
pattern
administr
inhibitor
cours
diseas
patient
suffer
rhabdomyosarcoma
maffucci
syndrom
multipl
infantil
myofibromatosi
conclus
summar
obtain
result
bring
complet
new
inform
concern
chang
rtk
downstream
activ
pattern
associ
cours
diseas
may
import
determin
person
therapi
children
support
project
ministri
healthcar
czech
republ
f
postema
c
l
f
c
r
h
medic
center
pediatr
oncolog
amsterdam
netherland
medic
center
clinic
genet
amsterdam
netherland
medic
centr
groningen
genet
groningen
netherland
univers
medic
centr
clinic
genet
amsterdam
netherland
univers
medic
centr
human
genet
groningen
netherland
medic
centr
utrecht
genet
utrecht
netherland
medic
centr
clinic
genet
rotterdam
netherland
medic
center
pediatr
amsterdam
netherland
backgroundobject
recognis
tumour
predisposit
syndrom
tp
patient
childhood
cancer
major
clinic
relev
presenc
tp
may
suggest
type
tumour
child
present
overview
childhood
tumour
reason
refer
child
genet
consult
designmethod
perform
pubm
search
review
incid
tpss
children
tumour
type
list
intern
classif
childhood
cancer
third
edit
result
discuss
nation
consensu
meet
repres
clinic
geneticist
six
academ
paediatr
oncolog
centr
netherland
tp
incid
consid
high
probabl
therefor
reason
referr
clinic
geneticist
result
literatur
search
result
data
incid
tp
tumour
tumour
type
tp
incid
higher
report
addit
consensu
meet
expert
agre
children
carcinoma
alway
refer
clinic
genet
consult
well
may
point
tp
conclus
present
overview
paediatr
tumour
high
probabl
tp
facilit
paediatr
oncologist
decid
patient
refer
genet
consult
mere
base
type
tumour
synakiewicz
n
g
j
univers
gdansk
depart
hematolog
oncolog
poland
univers
bialystok
depart
pediatr
oncolog
bialystok
poland
univers
lodz
depart
hematolog
diabetolog
lodz
poland
univers
gdansk
depart
environment
toxicolog
poland
univers
gdansk
depart
clinic
nutrit
poland
backgroundobject
pediatr
cancer
remain
one
main
caus
death
pediatr
popul
low
detect
rate
earli
stage
singl
substanc
known
sensit
specif
enough
detect
cancer
cell
play
role
earli
biomark
malign
neoplast
diseas
metabol
condit
uniqu
metabol
thu
amino
acid
level
alter
plasma
consid
play
role
carcinogenesi
cours
diseas
designmethod
seventi
seven
children
cancer
includ
hematolog
malign
leukemia
hodgkin
lymphoma
solid
tumor
nephroblastoma
neuroblastoma
soft
tissu
sarcoma
malign
brain
tumor
germ
cell
tumor
enrol
multicent
studi
amino
acid
determin
highperform
liquid
chromatographi
fluorometr
detect
result
result
reveal
signific
differ
children
cancer
healthi
control
conclus
report
suggest
amino
acid
profil
may
use
cancer
diagnos
may
consid
earli
tumor
biomark
studi
specif
group
necessari
verifi
metabol
pattern
characterist
pediatr
cancer
l
wiltsi
c
k
park
cancer
institut
pediatr
buffalo
usa
llc
patholog
buffalo
usa
backgroundobject
tumor
molecular
profil
hold
promis
person
diagnost
prognost
therapeut
decis
make
due
cost
limit
avail
molecular
profil
data
pediatr
tumor
limit
small
number
center
perform
larg
scale
genom
wide
screen
molecular
alter
pediatr
tumor
identifi
pediatr
tumor
potenti
action
alter
omniseq
comprehens
new
york
state
approv
sequenc
assay
util
target
approach
molecular
profil
screen
tumor
dna
rna
identifi
somat
variant
gene
focus
genom
alter
known
associ
cancer
designmethod
analyz
omniseq
comprehens
profil
high
risk
solid
tumor
brain
tumor
pediatr
patient
treat
buffalo
ny
juli
march
result
review
ongo
pediatr
molecular
tumor
board
result
tumor
sampl
patient
age
year
analyz
result
avail
within
week
obtain
sampl
test
case
least
one
variant
identifi
patient
mean
variantspati
eight
patient
variant
consid
potenti
action
six
patient
lesion
target
agent
clinic
trial
meet
elig
requir
one
patient
inflammatori
myofibroblast
sarcoma
molecular
test
identifi
alk
gene
fusion
identifi
fish
aid
identifi
diagnosi
led
target
therapi
crizotinib
first
line
therapi
conclus
omniseq
comprehens
identifi
action
variant
children
high
risk
solid
brain
tumor
rate
similar
publish
result
genom
wide
molecular
profil
approach
result
pilot
studi
highlight
potenti
role
cost
effect
target
approach
molecular
profil
pediatr
oncolog
patient
r
jm
de
pedro
u
gonzalez
echebarria
r
adan
rodriguez
astigarraga
universitario
cruce
pediatr
hematolog
oncolog
unit
bilbao
spain
universitario
cruce
nuclear
medicin
servic
bilbao
spain
backgroundobject
evalu
correl
anatomopatholog
ap
tumour
necrosi
musculoskelet
tumour
respons
observ
petct
designmethod
retrospect
descript
studi
collect
data
pediatr
new
diagnos
bone
soft
tissu
sarcoma
st
tertiari
hospit
last
year
januari
result
seventeen
patient
newli
diagnos
year
ewe
sarcoma
es
osteosarcoma
os
st
rhabdomyosarcoma
rm
within
es
patient
underw
petct
two
present
complet
respons
coincid
ap
tumor
necrosi
two
other
present
good
partial
respons
imag
test
tumour
necrosi
respect
last
patient
present
partial
respons
petct
could
undergo
surgeri
inoper
case
os
two
petct
scan
perform
evalu
present
partial
respons
necrosi
respect
st
petct
perform
patient
one
complet
respons
could
undergo
surgeri
high
surgic
risk
three
patient
petct
show
good
partial
respons
complet
necrosi
two
partial
necrosi
conclus
seri
petct
valuabl
diagnost
tool
initi
extens
studi
evalu
chemotherapi
respons
bone
soft
tissu
tumor
studi
need
demonstr
degre
direct
correl
tumour
necrosi
histolog
piec
c
karadeniz
lu
u
fg
u
atay
univers
school
medicin
pediatr
oncolog
ankara
turkey
univers
school
medicin
nuclear
medicin
istanbul
turkey
univers
school
medicin
nuclear
medicin
ankara
turkey
univers
school
medicin
pediatr
hematolog
ankara
turkey
backgroundobject
petmri
recent
introduc
altern
petct
pediatr
patient
expect
one
main
target
group
petmri
consider
less
ioniz
radiat
compar
petct
aim
studi
compar
fdg
petct
petmri
group
pediatr
oncolog
patient
term
anatom
correl
fdg
posit
lesion
designmethod
total
pediatr
oncolog
patient
includ
studi
median
age
year
rang
year
nine
patient
diagnos
lymphoma
hodgkin
lymphoma
neuroblastoma
rhabdomyosarcoma
langerhan
cell
histiocytosi
ewe
sarcoma
ovarian
cancer
glioblastoma
multiform
pelvic
germ
cell
tumor
renal
clear
cell
carcinoma
conjunctiv
squamou
cell
carcinoma
total
sequenti
fdg
petct
ge
discoveri
st
petmri
ge
signa
petmr
examin
perform
day
inject
mean
mci
mbq
fdg
petmri
perform
first
patient
petct
obtain
first
rest
patient
imag
evalu
nuclear
medicin
physician
separ
result
lesion
base
analysi
total
sequenti
petct
petmri
examin
concordantli
neg
among
fdg
posit
lesion
sequenti
petct
petmri
examin
maximum
lesionspati
posit
ct
mri
remain
fdg
posit
lesion
central
nervou
system
bone
marrow
lymph
node
soft
tissu
lesion
could
differenti
use
ct
although
could
demarc
use
mri
conclus
petmri
show
better
anatom
correl
fdg
posit
lesion
compar
petct
pediatr
patient
therefor
fdg
petmri
reduc
ioniz
radiat
better
contrast
resolut
soft
tissu
bone
marrow
may
prefer
altern
petct
pediatr
popul
j
murray
h
l
children
health
care
system
hematolog
oncolog
center
fort
worth
usa
children
health
care
system
radiolog
fort
worth
usa
children
health
care
system
patholog
fort
worth
usa
backgroundobject
magnet
reson
imag
mri
featur
differ
variou
childhood
brain
tumor
advanc
mri
techniqu
includ
imag
dwi
add
vital
inform
convent
sequenc
potenti
crucial
creat
appropri
differenti
diagnosi
ependymoma
third
common
malign
brain
tumor
youth
remain
challeng
respect
imag
differenti
diagnosi
recogn
critic
differ
dwi
characterist
supratentori
st
infratentori
ependymoma
children
designmethod
follow
irb
approv
mri
neuropatholog
consecut
diagnos
children
intracrani
ependymoma
abstract
tumor
locat
st
vs
diffus
characterist
tumor
grade
cramer
v
test
appli
result
mean
age
diagnosi
year
boy
girl
eighteen
patient
tumor
st
tumor
ten
tumor
anaplast
histolog
grade
iii
classic
histolog
grade
ii
eleven
tumor
show
restrict
diffus
dwi
facilit
diffus
equival
surround
brain
tumor
show
restrict
diffus
st
none
restrict
tumor
anaplast
histolog
tumor
anaplasia
relationship
tumor
locat
restrict
diffus
signific
strongli
associ
p
cramer
v
conclus
imag
supplement
convent
mri
sequenc
formul
critic
differenti
diagnosi
children
brain
tumor
analysi
show
dramat
differ
diffus
characterist
st
ependymoma
independ
tumor
grade
supratentori
tumor
tend
show
restrict
diffus
tumor
irrespect
grade
restrict
postul
physiolog
tumor
microenvironment
factor
account
observ
awar
dwi
differ
ependymoma
may
help
refin
initi
differenti
diagnosi
l
state
children
hospit
philadelphia
univers
pennsylvania
radiolog
philadelphia
usa
backgroundobject
purpos
studi
determin
relationship
depict
brown
adipos
tissu
bat
positron
emiss
tomographycomput
tomographi
petct
pediatr
patient
hodgkin
lymphoma
diseas
season
designmethod
total
petct
studi
subject
boy
girl
age
rang
year
diagnos
hodgkin
lymphoma
retrospect
review
uptak
anatom
distribut
bat
evalu
petct
scan
everi
subject
time
initi
diagnosi
complet
chemotherapi
comparison
regard
presenc
bat
two
time
interv
perform
subject
use
mcnemar
test
correl
bat
presenc
children
gender
anthropometr
data
bodi
mass
index
height
examin
paramet
fdg
glucos
well
season
perform
result
petct
studi
show
diseas
activ
wherea
petct
presenc
hodgkin
lymphoma
diseas
identifi
among
patient
activ
diseas
petct
studi
high
bat
uptak
wherea
among
patient
activ
diseas
bat
uptak
observ
examin
differ
margin
signific
signific
relationship
bat
uptak
season
petct
studi
perform
final
bat
uptak
associ
examin
paramet
includ
fdg
dose
conclus
find
show
margin
correl
bat
uptak
diseas
state
howev
contrari
studi
demonstr
studi
bat
uptak
associ
season
petct
examin
perform
fdg
dosag
zakaria
faisal
univers
colleg
medicin
al
ahsa
saudi
arabia
background
object
background
abdomin
mass
still
pose
major
challeng
pediatrcialn
surgeon
aim
work
studi
design
evalu
role
diagnost
laparoscopi
investig
equivoc
pediatr
mass
undergon
imag
modal
designmethod
combin
prospect
retrospect
multicentr
studi
period
year
januari
decemb
inclus
criteria
children
month
age
year
studi
exclus
criteria
document
diagnosi
imag
modal
includ
sonograph
ct
guid
biopsi
patient
underw
multiport
diagnost
laparoscopi
biopsi
mass
specimen
hispatolog
assess
use
h
e
stain
specimen
immunohistochem
studi
patient
mean
follow
year
result
total
patient
recruit
studi
male
girl
male
femal
ratio
age
rang
month
year
mean
age
total
studi
group
patient
diagnos
neuroblastoma
percentag
nephroblastoma
remain
abdomin
lymphoma
patient
show
complic
relat
procedur
patient
mean
follow
year
case
differ
diagnosi
clinic
stage
grade
grade
ii
neither
intraop
post
oper
complic
record
techniqu
mean
oper
time
record
min
earliest
group
yet
declin
min
latest
group
due
advanc
learn
curv
conclus
laparoscopi
accur
safe
use
sole
tool
biops
solid
abdomin
tumor
pediatr
zakaria
faisal
univers
colleg
medicin
al
ahsa
saudi
arabia
backgroundobject
preliminari
studi
suggest
ultrasonograph
us
elastographi
may
use
differenti
benign
malign
cervic
lymph
node
therebi
inform
decis
perform
biopsi
facilit
current
studi
aim
evalu
accuraci
reliabl
us
elastographi
distinguish
malign
pediatr
malign
cervic
lymphadenopathi
benign
lesion
designmethod
total
lymph
node
children
age
rang
form
year
male
femal
ratio
preliminari
diagnosi
primari
head
neck
cancer
examin
sonographi
power
doppler
ultrasound
elastographi
elastograph
pattern
determin
distribut
percentag
lymph
node
area
low
elast
hard
pattern
absent
small
hard
area
pattern
hard
area
occupi
entir
lymph
node
pattern
consid
metastat
ultrasound
guid
aspir
cytolog
done
lymph
node
result
major
metastat
lymph
node
elastographi
pattern
find
observ
benign
lymph
node
p
elastographi
pattern
sensit
specif
ppv
npv
overal
accuraci
differenti
benign
malign
lymph
node
hand
b
mode
criteria
best
accuraci
given
abnorm
hilum
accuraci
power
doppler
ultrasound
pattern
conclus
accuraci
sonoelastographi
higher
sonograph
modal
elucid
patholog
diagnosi
cervic
lymphadenopathi
distinguish
benign
malign
lesion
may
replac
lymph
node
biopsi
futur
moreov
integr
lymph
node
sonoelastographi
follow
patient
known
head
neck
cancer
may
reduc
number
biopsi
g
afungchwi
k
p
v
p
j
baptist
convent
health
servic
childhood
cancer
program
bamenda
cameroon
baptist
hospit
pediatr
oncolog
mbingo
cameroon
children
stellenbosch
univers
depart
childhealth
cape
town
south
africa
baptist
hospit
pediatr
oncolog
kumbo
cameroon
backgroundobject
resourc
poor
countri
mani
children
cancer
diagnos
late
stage
make
cure
imposs
awadelkarim
et
al
sullivan
et
al
childhood
cancer
symptom
usual
miss
commun
health
profession
due
unfamiliar
sign
even
refer
suspicion
cancer
lack
transport
mean
becom
major
caus
delay
afungchwi
et
al
object
project
promot
earli
diagnosi
prompt
treatment
childhood
cancer
use
train
ambassador
mobil
money
designmethod
health
profession
promin
tradit
healer
health
district
invit
respect
district
health
servic
train
train
includ
topic
biolog
cancer
earli
warn
sign
childhood
cancer
avail
care
children
cancer
cameroon
three
traine
health
district
select
childhood
cancer
ambassador
provid
mobil
phone
mobil
money
account
transport
everi
suspect
patient
treatment
centr
result
health
care
provid
includ
tradit
healer
train
ambassador
select
equip
referr
percentag
point
increas
p
knowledg
childhood
cancer
among
traine
proport
traine
provid
health
educ
childhood
cancer
commun
expect
increas
p
total
childhood
cancer
warn
sign
leaflet
distribut
cost
train
per
traine
conclus
sanofiespoir
mcm
award
provid
opportun
build
capac
childhood
cancer
earli
diagnosi
northwest
cameroon
project
potenti
becom
formal
surveil
model
childhood
cancer
expand
cover
entir
region
would
creat
net
child
cancer
could
filter
undiagnos
ahmad
n
hospit
institut
child
health
paediatr
haematologyoncolog
lahor
pakistan
backgroundobject
punjab
pakistan
million
popul
dedic
pediatr
hematologyoncolog
center
result
delay
diagnosi
poor
manag
major
children
object
studi
evalu
challeng
face
pediatr
hematologyoncolog
servic
resourc
limit
set
like
children
hospit
lahor
bed
unit
bed
occup
new
admiss
per
month
new
childhood
cancer
case
year
designmethod
retrospect
review
case
enrol
die
depart
januari
decemb
epidemiolog
diagnosi
treatment
stay
hospit
caus
death
analyz
result
among
patient
analyz
year
f
ratio
diagnosi
establish
admiss
diagnosi
confirm
die
case
definit
treatment
start
diagnos
solid
major
aplast
anemia
aml
other
like
md
factor
vii
defici
febril
neutropenia
sepsi
major
killer
die
due
relaps
progress
diseas
caus
death
analyz
type
diagnosi
stay
hospit
definit
treatment
given
case
diagnos
death
case
start
treatment
case
die
within
hr
admiss
stay
week
case
travel
km
reach
children
hospit
lahor
conclus
urgent
need
capac
build
center
train
health
profession
implement
effect
infect
control
measur
effici
psycho
social
support
famili
decreas
morbid
mortal
center
k
bennett
j
n
health
scienc
univers
wit
donald
gordon
medic
charlott
maxek
johannesburg
academ
hospit
depart
paediatr
oncolog
johannesburg
south
africa
health
scienc
univers
charlott
maxek
johannesburg
academ
hospit
depart
paediatr
oncolog
johannesburg
south
africa
backgroundobject
data
surviv
rate
children
cancer
avail
two
south
african
centr
report
rate
lower
report
similar
incom
set
south
america
eastern
europ
aim
studi
analys
surviv
rate
children
cancer
treat
two
larg
referr
centr
state
privat
set
designmethod
retrospect
review
includ
children
diagnos
malign
two
pediatr
oncolog
unit
januari
decemb
treatment
regimen
unit
ident
doctor
work
set
diagnos
confirm
histolog
descript
statist
analys
cox
regress
model
present
result
children
present
outsid
south
africa
median
follow
year
iqr
common
cancer
leukaemia
brain
tumor
lymphoma
hiv
incid
overal
surviv
calcul
highest
surviv
rate
children
hodgkin
lymphoma
retinoblastoma
nephroblastoma
lowest
note
children
osteogen
sarcoma
neuroblastoma
children
treat
privat
institut
higher
surviv
rate
state
fund
hospit
vs
conclus
overal
surviv
rate
higher
children
treat
privat
fund
unit
may
reflect
differenti
access
specialist
care
earlier
referr
privat
set
borja
mj
axxi
pediatrica
quito
ecuador
metropolitano
patholog
quito
ecuador
backgroundobject
approxim
thirti
percent
pediatr
cancer
children
adolesc
solid
tumor
frequent
type
brain
tumor
wilm
tumor
neuroblastoma
hepatoblastoma
osteosarcoma
differ
solid
tumor
childhood
adulthood
well
delimit
transit
period
year
old
brain
tumor
common
form
solid
tumor
howev
accord
year
old
higher
incid
osteosarcoma
ewe
tumor
lymphoma
found
compar
children
show
notic
chang
solid
tumor
distribut
children
reach
adolesc
objet
determin
incid
solid
malign
tumor
adolesc
children
hospit
ecuador
januari
august
designmethod
descript
retrospect
studi
includ
patient
old
inclus
criteria
diagnost
malign
solid
tumor
confirm
patholog
area
result
patient
fifti
six
admit
malign
solid
tumor
male
mean
age
diagnosi
year
old
cn
tumor
highest
incid
follow
lymphoma
osteosarcoma
germ
cell
tumor
ewe
sarcoma
neuroblastoma
hepat
adenocarcinoma
undifferenti
tumor
other
distribut
type
similar
epidemiolog
malign
solid
tumor
describ
literatur
howev
select
bia
possibl
due
enrol
popul
admit
pediatr
hospit
conclus
cn
tumor
common
malign
tumor
found
osteosarcoma
appear
less
frequent
compar
intern
seri
addit
greater
number
expect
male
diagnos
although
epidemiolog
distribut
solid
tumor
children
adolesc
differ
evid
shown
higher
surviv
incom
adolesc
could
expect
better
psycholog
support
accur
treatment
special
pediatr
center
despit
differ
epidemiolog
h
danysh
j
p
mc
colleg
medicin
depart
pediatr
houston
usa
arizona
colleg
nurs
tucson
usa
minnesota
school
nurs
minneapoli
usa
univers
school
nurs
durham
usa
backgroundobject
acut
neurotox
among
pediatr
patient
acut
lymphoblast
leukemia
often
result
treatment
interrupt
potenti
reduc
treatment
efficaci
despit
clinic
signific
effect
subsequ
treatment
therefor
evalu
impact
acut
delay
modif
mtx
treatment
among
pediatr
patient
designmethod
identifi
patient
treat
protocol
reach
mainten
therapi
texa
children
hospit
univers
arizona
defin
occurr
symptom
eg
seizur
aphasia
receiv
mtx
led
chang
mtx
therapi
differ
time
diagnosi
start
mainten
cumul
intraven
mtx
dose
number
intrathec
mtx
cours
end
induct
start
mainten
compar
statu
use
multipl
linear
regress
adjust
age
diagnosi
sex
ethnic
risk
stratif
result
averag
patient
year
age
diagnosi
rang
major
male
hispan
assign
high
high
risk
treatment
arm
total
patient
experienc
acut
three
subsequ
relaps
die
adjust
demograph
risk
group
experienc
acut
receiv
lower
dose
intraven
mtx
confid
interv
ci
fewer
intrathec
mtx
cours
ci
p
start
mainten
therapi
compar
without
occurr
significantli
delay
start
mainten
therapi
conclus
chemotherapi
pediatr
result
patient
receiv
significantli
less
intraven
intrathec
mtx
futur
work
need
determin
whether
modif
therapi
follow
acut
compromis
treatment
efficaci
outcom
includ
relaps
surviv
f
erdmann
g
j
cancer
societi
research
center
unit
survivorship
copenhagen
denmark
agenc
research
cancer
section
environ
radiat
lyon
franc
univers
depart
bioinformat
biomathemat
dc
usa
nacion
central
american
institut
studi
toxic
substanc
heredia
costa
rica
backgroundobject
higher
childhood
cancer
incid
rate
particularli
leukemia
report
countri
compar
low
countri
howev
estim
childhood
cancer
incid
global
hamper
lack
reliabl
data
develop
countri
includ
latin
american
region
costa
rica
one
develop
countri
nationwid
cancer
registri
enabl
analysi
incid
data
childhood
leukemia
designmethod
data
incid
leukemia
children
year
age
report
nation
cancer
registri
costa
rica
analyz
leukemia
type
age
diagnosi
gender
region
result
period
total
children
leukemia
report
result
overal
incid
rate
asr
ratio
highest
rate
observ
children
age
year
frequent
leukemia
type
lymphoid
leukemia
asr
observ
rate
rank
among
highest
world
low
rate
observ
leukemia
infant
larg
driven
low
lymphoid
leukemia
rate
respect
geograph
differ
higher
leukemia
rate
observ
huetar
atlantica
huetar
nort
region
region
character
extens
agricultur
field
conclus
pattern
childhood
leukemia
incid
costa
rica
closer
report
countri
report
develop
countri
research
need
investig
factor
may
drive
high
overal
leukemia
rate
low
rate
observ
infant
well
region
differ
studi
suggest
use
caution
interpret
global
incid
differ
sinc
observ
develop
countri
pediatr
oncolog
clinic
nationwid
registr
show
small
differ
incid
pattern
countri
farrag
mh
egypt
cancer
assiut
univers
depart
pediatr
oncolog
assiut
egypt
assiut
univers
depart
pediatr
assiut
egypt
backgroundobject
previou
epidemiolog
studi
focus
patient
develop
countri
capit
larg
citi
develop
countri
peopl
rural
area
develop
countri
may
differ
genet
environment
life
style
issu
designmethod
retrospect
studi
perform
review
chart
newli
diagnos
children
cancer
start
treatment
depart
pediatr
oncolog
south
egypt
cancer
institut
seci
analyz
data
includ
age
sex
diagnosi
stage
diseas
respons
initi
cours
therapi
date
relaps
occur
last
clinic
result
treatment
result
children
male
femal
malign
start
therapi
seci
median
age
first
present
year
year
diagnos
commonli
leukemia
lymphoma
solid
tumor
rare
brain
tumor
present
patient
acut
lymphoblast
leukemia
consid
high
risk
group
patient
lymphoma
nhl
present
late
stage
neuroblastoma
patient
present
stage
iv
initi
cours
therapi
patient
acut
myeloid
leukemia
aml
nhl
neuroblastoma
respect
complet
remiss
initi
cours
chemotherapi
patient
aml
nhl
neuroblastoma
respect
die
patient
compliant
therapi
overal
relaps
rate
median
time
diagnosi
till
relaps
month
death
mainli
therapi
relat
five
year
overal
event
free
surviv
respect
conclus
essenti
establish
countri
base
cancer
registri
develop
countri
enabl
plan
c
fiori
carla
de
pediatr
oncolog
cascavel
brazil
background
object
introduct
childhood
cancer
rare
diseas
second
lead
caus
death
year
old
otherwis
cure
rate
reach
diagnos
earli
precoc
detect
consider
reduc
complic
treatment
contribut
increas
cure
object
evalu
degre
tumor
involv
children
adolesc
cancer
train
health
profession
design
method
methodolog
health
profession
train
sinc
partnership
ronald
mcdonald
institut
earli
diagnosi
cancer
children
adolesc
program
analyz
children
younger
year
old
attend
januari
decemb
cancer
hospit
cascavel
brazil
leukemia
consider
low
risk
lr
high
risk
hr
accord
age
leukometri
diagnosi
lr
month
year
old
leukocyt
hr
month
year
old
leukocyt
solid
tumor
consider
stage
lr
iii
hr
iiiiv
result
result
patient
attend
period
consid
high
risk
low
risk
predomin
hr
lr
per
year
predomin
lr
hr
conclus
comment
preliminari
analysi
data
allow
us
observ
children
adolesc
cancer
advanc
diseas
diagnosi
observ
chang
stage
diagnosi
patient
come
local
diseas
possibl
chang
low
risk
high
risk
diseas
may
relat
train
activ
result
earli
diagnosi
program
develop
west
northwest
southwest
sinc
fuent
alabi
g
f
c
l
nacion
de
benjamin
bloom
pediatr
oncolog
san
salvador
el
salvador
de
oncologia
pediatrica
unop
pediatr
oncolog
guatemala
guatemala
oncopediatrico
hospitalario
de
hospit
base
pediatr
cancer
registri
bueno
air
argentina
jude
children
research
hospit
global
pediatr
intern
outreach
program
usa
jude
children
research
hospit
global
pediatr
outreach
program
usa
cancer
institut
pediatr
oncolog
usa
backgroundobject
cancer
registri
pbcr
provid
measur
incid
surviv
ration
health
care
plan
epidemiolog
research
incid
pediatr
cancer
guatemala
el
salvador
g
es
estim
base
intern
model
sinc
g
es
engag
systemat
collect
data
yield
epidemiolog
profil
childhood
cancer
impact
health
care
system
designmethod
registro
oncologia
america
initi
g
es
provid
pbcr
children
countri
cancer
registrar
identifi
case
search
patholog
laboratori
report
medic
radiat
record
neither
registri
current
access
death
certif
case
record
use
intern
classif
version
use
intern
classif
childhood
cancer
incid
rate
per
popul
calcul
standard
world
popul
incid
rate
g
es
compar
rate
argentina
result
overal
incid
el
salvador
guatemala
compar
incid
argentina
expect
vs
observ
incid
guatemala
el
salvador
countri
incid
lower
expect
neuroblastoma
retinoblastoma
renal
tumor
germ
cell
tumor
brain
tumor
incid
hepat
tumor
higher
expect
conclus
demonstr
number
children
access
pediatr
cancer
care
lower
would
due
limit
access
primari
care
lack
recognit
diseas
primari
care
compet
mortal
identif
factor
alreadi
influenc
strategi
improv
access
care
servic
control
childhood
cancer
k
e
j
c
j
p
n
g
e
n
r
p
children
hospit
cancer
hematolog
center
houston
usa
colleg
medicin
pediatr
houston
usa
backgroundobject
approxim
children
per
year
develop
cancer
global
africa
ssa
major
die
due
lack
incorrect
diagnosi
lack
access
medic
inadequ
healthcar
infrastructur
contrast
children
diagnos
cancer
us
cure
inequ
compel
us
improv
pediatr
cancer
care
ssa
designmethod
texa
children
cancer
hematolog
center
txch
baylor
colleg
medicin
intern
pediatr
aid
initi
bipai
creat
comprehens
program
call
global
hope
pediatr
excel
aim
build
capac
improv
pediatr
hematologyoncolog
pho
infrastructur
select
ssa
countri
partner
local
govern
key
stakehold
global
hope
implement
model
base
local
need
focu
capac
build
global
hope
educ
broad
array
healthcar
role
ssa
support
deliveri
comprehens
care
comprehens
model
aim
address
clinic
care
research
educ
administr
goal
creat
sustain
model
improv
health
care
access
outcom
stakehold
commun
involv
environ
oper
excel
result
sinc
across
four
ssa
countri
global
hope
increas
capac
local
healthcar
workforc
train
healthcar
worker
improv
care
children
cancer
blood
disord
demonstr
improv
outcom
site
includ
increas
case
identif
improv
diagnost
increas
number
children
receiv
care
better
access
medic
conclus
global
hope
repres
first
step
toward
ultim
transform
goal
cure
equiti
children
cancer
blood
disord
ssa
deliv
local
sustain
workforc
infrastructur
h
r
khedr
l
l
k
p
cancer
institut
cairo
univers
children
cancer
hospit
egypt
cche
pediatr
oncolog
cairo
egypt
cancer
institut
cairo
univers
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
institut
cairo
univers
children
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
children
hospit
pediatr
oncolog
colmbu
ohio
usa
farber
boston
children
cancer
institut
pediatr
neurosurg
oncolog
boston
usa
farber
boston
children
cancer
institut
pediatr
oncologybmt
boston
usa
farber
boston
children
cancer
institut
nurs
depart
boston
usa
farber
boston
children
cancer
institut
pediatr
oncolog
neuroncolog
boston
usa
cancer
hospit
egypt
cche
nurs
depart
cairo
egypt
backgroundobject
children
diagnos
cancer
countri
lmic
inferior
outcom
compar
high
incom
countri
issu
resourc
avail
major
problem
qualiti
train
tradit
method
clinic
practic
decis
make
center
senior
person
team
ensur
real
chang
local
base
specialist
strong
emphasi
critic
think
use
approach
need
designmethod
children
cancer
hospit
egypt
boston
children
hospit
dfbch
harvard
medic
school
develop
month
pediatr
oncolog
fellowship
train
program
follow
american
academi
pediatr
fellowship
guidelinesth
primari
object
program
implement
share
educ
model
develop
highli
educ
physician
abl
follow
approach
commit
sustain
practic
lmic
result
dfbch
staff
provid
ongo
educ
fellow
visit
everi
month
weekli
video
session
fellow
case
present
journal
club
weekli
confer
call
fellowship
program
staff
ensur
goal
object
fellow
program
meteach
current
fellow
spend
weeksyear
boston
particip
base
round
remaind
curriculum
take
place
incorpor
array
individu
small
group
modul
specif
creat
program
three
class
fellow
enrol
senior
class
graduat
spring
conclus
train
fellow
follow
standard
appli
north
american
candid
feasibl
potenti
advanc
qualiti
educ
expertis
lmic
focus
educ
next
gener
clinician
opportun
implement
mani
import
principl
clinic
care
realiz
h
lashkari
r
n
j
h
k
medic
colleg
paediatr
mangalor
india
medic
colleg
hospit
pediatr
mangalor
india
medic
colleg
hospit
manip
univers
pediatr
mangalor
india
medic
colleg
manip
univers
pediatr
mangalor
india
medic
colleg
hospit
mangalor
pediatr
mangalor
india
medic
colleg
pediatr
mangalor
india
backgroundobject
essenti
know
rout
present
time
prior
diagnosi
primari
secondari
care
avoid
delay
diagnosi
play
import
role
better
surviv
strategi
childhood
cancersto
describ
averag
time
taken
child
cancer
present
get
diagnos
oncolog
unit
designmethod
retrospect
cohort
studi
children
diagnos
cancer
jan
dec
pediatr
oncolog
unit
kmc
hospit
mangalor
india
time
present
ttp
defin
time
initi
symptom
time
seen
pediatrician
time
diagnosi
ttd
defin
time
initi
symptom
diagnosi
pediatr
oncolog
unit
patient
pathway
diagnosi
map
rout
differ
cancer
compar
result
total
children
regist
childhood
cancer
period
data
children
age
yr
diagnos
period
collect
major
boy
acut
leukemia
diagnos
case
ttp
vari
day
nearli
two
third
present
within
week
onset
symptom
ttd
vari
day
mean
day
leukemia
group
solid
tumor
group
ttp
day
wherea
ttd
vari
day
averag
day
acut
lymphoblast
leukaemia
skelet
manifest
longest
ttd
day
lymphoma
ttd
day
ttp
day
conclus
major
children
diagnos
cancer
present
via
referr
pediatrician
rout
vari
tumor
typesthi
part
ongo
studi
look
challeng
diagnos
cancer
identifi
wide
rang
relat
factor
potenti
delay
diagnosi
j
lubega
p
cancer
institut
pediatr
oncolog
kampala
uganda
nation
hospit
pediatr
dar
es
salaam
tanzania
backgroundobject
surviv
children
cancer
east
africa
poor
due
shortag
dedic
standard
pediatr
cancer
servic
skill
workforc
local
appropri
pediatr
cancer
manag
guidelin
peacoc
cooper
group
pediatr
cancer
center
six
member
state
east
african
commun
sustain
improv
outcom
children
cancer
region
designmethod
peacoc
creat
novemb
ocean
road
cancer
hospit
dar
es
salaam
tanzania
pediatr
oncolog
expert
work
auspic
east
africa
region
oncolog
center
excel
fund
member
state
loan
african
develop
bank
expert
work
group
ewg
note
follow
topmost
challeng
pediatr
oncolog
across
center
east
africa
late
present
patient
advanc
tumor
complic
inconsist
access
chemotherapi
poor
access
blood
product
transfus
poor
access
radiotherapi
lack
local
treatment
support
care
guidelin
lack
dedic
infrastructur
personnel
foster
region
collabor
share
resourc
ewg
agre
form
peacoc
includ
pediatr
cancer
unit
east
africa
variou
intern
collabor
result
peacoc
evalu
current
pediatr
cancer
unit
east
africa
includ
treatment
guidelin
epidemiolog
care
fund
research
activ
tertiari
specialist
skill
develop
consortium
adapt
current
region
practic
best
intern
practic
develop
guidelin
region
conclus
peacoc
conduct
cooper
group
clinic
trial
establish
harmon
region
pediatr
cancer
registri
conduct
pediatr
cancer
train
program
benchmark
qualiti
pediatr
cancer
care
region
f
makka
b
univers
school
public
health
health
manag
boston
usa
univers
school
public
health
global
health
boston
usa
farber
cancer
institut
global
health
institut
boston
usa
backgroundobject
pediatr
cancer
global
health
problem
countri
lmic
plan
initi
expand
pediatr
oncolog
servic
guidanc
publish
literatur
limit
due
focu
countri
academ
medic
center
largest
pediatr
oncolog
hospit
world
children
cancer
hospit
egypt
cche
strive
provid
free
care
without
discrimin
high
demand
push
cche
start
process
expand
space
servic
project
explor
expans
strategi
cche
consid
local
context
goal
creat
generaliz
resourc
lmic
refer
designmethod
use
qualit
research
method
form
interview
key
inform
includ
member
senior
manag
staff
cche
commun
member
interview
conduct
two
week
januari
session
last
minut
find
structur
process
map
stakehold
analysi
swot
analysi
final
report
result
cche
face
mani
challeng
progress
flotat
egyptian
currenc
spatial
restrict
expans
throughout
interview
identifi
sever
major
attribut
instrument
help
overcom
barrier
visionari
leadership
strong
intern
collabor
earli
invest
extern
consult
bring
best
practic
emphasi
extens
plan
conclus
mani
challeng
present
cche
expans
also
like
face
pediatr
oncolog
facil
lmic
seek
expand
pediatr
oncolog
unit
believ
facil
may
benefit
find
studi
e
e
j
e
univers
hospit
depart
pediatr
hematolog
oncolog
bratislava
slovak
republ
agenc
research
cancer
section
cancer
surveil
lyon
franc
ss
cyril
methodiu
depart
faculti
natur
scienc
trnava
slovak
republ
univers
slovak
medic
univers
depart
pediatr
oncolog
hematolog
bystrica
slovak
republ
children
pavol
jozef
safarik
univers
depart
pediatr
hematolog
oncolog
kosic
slovak
republ
backgroundobject
aim
studi
report
cancer
incid
time
trend
children
adolesc
regist
slovak
clinic
cancer
registri
children
adolesc
period
designmethod
data
collect
three
region
pediatr
treatment
center
malign
benign
borderlin
malign
includ
cancer
registri
nation
coverag
record
detail
clinic
inform
diagnosi
treatment
patient
tumour
classifi
use
intern
classif
childhood
cancer
edit
offici
popul
figur
use
calcul
incid
rate
result
case
regist
year
world
standard
annual
incid
rate
asr
per
million
frequent
leukaemia
follow
cn
tumour
lymphoma
neuroblastoma
incid
rate
highest
among
infant
lower
age
year
year
lowest
age
year
averag
annual
increas
studi
period
age
overal
increas
neuroblastoma
conclus
observ
incid
rate
children
age
year
compar
report
countri
eastern
europ
nation
cancer
registri
slovakia
low
rate
report
adolesc
due
data
incomplet
continu
monitor
time
trend
need
futur
import
put
place
mechan
data
exchang
nation
registri
cancer
age
improv
data
qualiti
complet
sourc
provid
reliabl
detail
data
research
public
health
acknowledg
nation
scholarship
program
slovak
republ
k
matsumoto
k
e
center
child
health
develop
children
cancer
center
tokyo
japan
center
child
health
develop
clinic
epidemiolog
research
center
pediatr
cancer
tokyo
japan
hospit
organ
nagoya
medic
center
clinic
research
center
nagoya
japan
univers
school
medicin
depart
pediatr
tokyo
japan
univers
depart
pediatr
surgeri
hiroshima
japan
backgroundobject
japan
use
exist
hospit
care
childhood
cancer
aris
patient
yearli
aim
integr
provid
uniform
access
pediatr
cancer
treatment
ministri
health
labour
welfar
elect
core
hospit
seven
region
block
japan
aim
studi
determin
demograph
profil
childhood
cancer
patient
japan
elect
core
hospit
designmethod
collect
data
publish
registri
japanes
societi
pediatr
hematologyoncolog
would
cover
approxim
patient
cancer
japan
collect
data
analyz
reveal
chang
elect
core
hospit
result
exist
hospit
care
pediatr
cancer
patient
japan
among
univers
hospit
children
hospit
percent
hospit
care
case
per
year
center
cover
cancer
patient
japan
core
hospit
elect
high
volum
center
cover
pediatr
cancer
patient
number
hospit
could
care
leukemialymphoma
patient
decreas
high
volum
center
eukemialymphoma
cover
patient
japan
increas
elect
core
hospit
also
number
hospit
could
care
solid
tumor
includ
brain
tumor
decreas
coverag
rate
solid
tumor
patient
high
volum
center
solid
tumor
increas
conclus
integr
pediatr
patient
solid
tumor
hematolog
malign
realiz
japan
elect
core
hospit
c
monsereenusorn
p
p
c
c
hospit
colleg
medicin
depart
pediatr
bangkok
thailand
children
cancer
blood
disord
center
depart
pediatr
oncolog
usa
children
research
hospit
depart
global
pediatr
medicin
tn
usa
gener
hospit
depart
pediatr
manila
philippin
backgroundobject
pediatr
solid
tumor
treatment
requir
complex
multidisciplinari
care
object
studi
identifi
barrier
effect
treatment
pediatr
solid
tumor
asia
sea
inform
develop
target
strategi
improv
outlook
children
solid
tumor
sea
designmethod
physician
receiv
individu
link
survey
question
survey
includ
topic
patient
care
team
hospitalinfrastructur
abandon
barrier
treatment
analysi
done
countri
classifi
world
bank
method
low
lic
lmic
umic
high
incom
countri
hic
result
survey
sent
physician
respons
center
countri
receiv
neuroblastoma
common
diseas
present
late
present
sea
follow
osteosarcoma
ewe
sarcoma
soft
tissu
sarcoma
term
laboratori
methotrex
level
still
avail
center
countri
solid
tumor
case
encount
inconclus
diagnosi
patholog
infect
still
lead
caus
death
among
sea
countri
surgeri
limb
spare
surgeri
perform
less
case
higher
rate
umic
howev
extern
prosthes
seldom
avail
particular
lmic
rate
abandon
highest
bone
tumor
soft
tissu
sarcoma
neuroblastoma
import
barrier
solid
tumor
treatment
financi
constraint
follow
commut
infect
abandon
fear
surgeri
radiat
lack
legal
support
conclus
barrier
effect
treatment
pediatr
solid
tumor
sea
late
present
limit
resourc
laboratori
patholog
inadequ
support
care
limit
access
limb
spare
surgeri
prosthesi
treatment
abandon
result
inform
develop
specif
strategi
solv
barrier
pediatr
solid
tumor
treatment
sea
e
k
c
p
colleg
medicin
section
houston
usa
backgroundobject
langerhan
cell
histiocytosi
lch
myeloid
neoplasia
median
diagnosi
age
month
studi
pediatr
malign
matern
perinat
characterist
success
evalu
determin
impact
inborn
variat
diseas
risk
therefor
review
registri
data
determin
factor
influenc
risk
lch
designmethod
studi
popul
includ
children
lch
born
texa
period
identifi
texa
cancer
registri
birth
certif
control
randomli
select
ratio
period
match
birth
year
evalu
impact
factor
identifi
vital
record
includ
gestat
age
birthweight
parent
raceethn
uncondit
logist
regress
use
gener
adjust
odd
ratio
aor
confid
interv
ci
evalu
associ
select
factor
risk
lch
result
overal
black
mother
less
like
give
birth
offspr
develop
lch
compar
white
nhw
mother
aor
ci
howev
hispan
mother
increas
risk
give
birth
offspr
develop
lch
aor
ci
furthermor
risk
lch
stronger
among
children
born
two
hispan
parent
compar
children
born
two
nhw
parent
aor
ci
mother
born
mexico
versu
us
resid
along
border
less
like
give
birth
offspr
develop
lch
aor
ci
aor
ci
respect
conclus
matern
parent
raceethn
strongli
associ
lch
risk
mother
resid
along
border
time
infant
birth
mother
less
like
give
birth
offspr
develop
lch
find
highlight
novel
risk
factor
warrant
assess
futur
studi
k
roka
mc
e
k
r
medic
school
divis
pediatr
first
depart
pediatr
athen
greec
medic
school
first
depart
pediatr
athen
greec
medic
school
medic
genet
athen
greec
sophia
children
hospit
depart
neurosurgeri
athen
greec
sophia
children
hospit
radiolog
depart
athen
greec
sophia
children
hospit
patholog
depart
athen
greec
backgroundobject
neurofibromatosi
nf
distinct
affect
individu
develop
benign
malign
tumor
predominantli
affect
order
standard
improv
patient
nf
first
refer
establish
designmethod
describ
spectrum
malign
patient
nf
examin
januari
februari
clinic
diagnosi
base
health
patient
evalu
includ
neurologist
dermatologist
oncologist
ophthalmologist
well
psychologist
provid
famili
regular
patient
arrang
result
patient
age
median
examin
includ
analysi
clinic
diagnosi
patient
perform
patient
confirm
patient
patient
evalu
still
ongo
among
patient
famili
affect
children
patient
refer
due
posit
opg
found
patient
visual
deterior
receiv
chemotherapi
two
sibl
opg
present
blind
diagnos
two
patient
locat
left
respect
neurofibroma
diagnos
patient
one
also
one
larg
cervic
neurofibroma
caus
distress
bilater
caus
previou
histori
two
resect
meningioma
observ
two
three
patient
indic
oncolog
intervent
need
patient
conclus
establish
neurofibromatosi
improv
provid
necessari
contribut
earli
diagnosi
time
therapeut
intervent
author
thank
special
account
research
grant
nation
kapodistrian
univers
athen
fund
attend
meet
rykov
v
pediatr
oncolog
hematolog
fsbsi
nn
blokhin
rcrc
gener
oncolog
moscow
russia
backgroundobject
studi
present
analysi
extern
audit
result
deliveri
medic
care
children
cancer
conduct
region
russian
feder
central
volga
south
feder
district
designmethod
author
analyz
clinic
histori
children
solid
tumor
receiv
special
treatment
oncolog
depart
region
children
hospit
period
evalu
avail
equip
exist
compet
staff
result
studi
reveal
patient
boy
girl
age
year
mean
age
year
malign
tumor
number
hospit
total
number
patient
day
averag
patient
stage
diseas
ii
iii
iv
unknown
stage
clinic
guidelin
violat
treatment
patient
conclus
seem
reason
develop
recommend
justifi
expedi
individu
stage
treatment
patient
differ
region
russian
feder
accord
distanc
feder
center
size
densiti
well
incid
child
popul
order
ensur
optim
rout
patient
improv
commiss
also
necessari
strengthen
oncolog
alert
primari
care
physician
pediatrician
earli
detect
cancer
includ
routin
inspect
b
sevinir
g
univers
medic
faculti
pediatr
oncolog
bursa
turkey
backgroundobject
earli
diagnosi
promot
prognosi
childhood
cancersour
aim
evalu
durat
first
symptom
exact
diagnosi
time
children
diagnos
lymphoma
solid
tumor
designmethod
data
patient
appli
univers
medic
faculti
depart
pediatr
oncolog
diagnos
lymphoma
solid
tumor
januari
novemb
retrospect
analysedth
time
first
complaint
appli
physician
time
admiss
get
diagnos
total
time
first
complaint
final
diagnosi
determinedthes
data
compar
age
sex
diagnosi
result
median
age
monthsth
common
diagnosi
lymphoma
brain
tumor
germ
cell
tumor
patient
firstli
appli
pediatrician
gener
practition
specialti
median
time
durat
first
admiss
day
median
time
referr
patient
oncolog
center
day
median
diagnos
time
patient
day
median
time
onset
symptom
final
diagnosi
day
day
first
admiss
time
patien
diagnos
lymphoma
hodgkin
lymphoma
osteosarcoma
soft
tissu
sarcoma
thyroid
carcinoma
day
first
admiss
time
patient
significantli
less
day
diagnos
neuroblastoma
renal
tumor
hepatoblastoma
referr
time
patient
hodgkin
lymphoma
osteosarcoma
daysth
admiss
time
longer
day
adolesc
patientstim
diagnosi
longer
patient
addmit
physian
pediatrician
pediatr
surgeon
conclus
studi
referr
diagnos
time
prolong
especi
physician
rare
examin
children
shad
j
c
w
j
hospit
sinai
pediatr
hematologyoncolog
baltimor
usa
aslan
project
organ
washington
dc
usa
cancer
institut
univers
rochest
medic
center
pediatr
hematologyoncolog
rochest
usa
anbessa
special
hospit
pediatr
hematologyoncolog
addi
ababa
ethiopia
univers
special
hospit
pediatr
hematologyoncolog
jimma
ethiopia
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
beth
israel
medic
center
pediatr
hematologyoncolog
ret
newark
usa
hospit
sick
children
haematologyoncolog
toronto
canada
nurs
univers
california
san
francisco
physiolog
nurs
san
francisco
usa
backgroundobject
despit
estim
case
pediatr
cancer
annual
ethiopia
qualifi
pediatr
oncologist
pediatr
oncolog
nurs
oncolog
pharmacist
dedic
infrastructur
children
cancer
intermix
gener
pediatr
popul
palli
carepain
medic
rare
offer
treatment
address
issu
aslan
project
us
organ
ngo
introduc
pilot
project
build
pediatr
cancer
system
tikur
anbessa
special
hospit
tash
st
jude
support
aslan
open
second
ethiopian
site
jimma
univers
special
hospit
jush
serv
area
million
peopl
prior
pediatr
oncolog
capac
designmethod
aslan
model
focus
human
resourc
hr
capac
build
fellowship
train
infrastructur
develop
familypsychosoci
support
initi
tash
aslan
provid
nearli
full
financi
support
project
jush
aslan
refin
model
enhanc
local
partner
ownership
improv
hr
train
partnership
lmic
institut
aslan
priorit
advocaci
relationship
build
feder
ministri
health
fmoh
result
tash
unit
robust
novemb
patient
visit
collect
servic
famili
support
reduc
treatment
abandon
substanti
jush
treat
children
sinc
august
administ
dose
chemotherapi
signific
error
fmoh
priorit
childhood
cancer
form
nation
task
forc
pediatr
cancer
siop
cci
engag
within
countri
ethiopian
hospit
adopt
aslan
model
train
continu
specialti
conclus
full
engag
stakehold
govern
major
institut
ngo
critic
larg
build
trust
joint
ownership
project
continu
refin
model
necessari
adapt
needscapac
partner
institut
aslan
model
may
replic
success
within
lmic
j
slone
j
r
n
j
colleg
medicinetexa
children
hospit
pediatr
houston
usa
illinoi
colleg
medicin
pediatr
peoria
usa
children
hospit
pediatr
littl
rock
usa
reuter
london
unit
kingdom
charlott
maxek
johannesburg
academ
hospit
faculti
health
scienc
johannesburg
south
africa
backgroundobject
train
pediatr
oncolog
workforc
essenti
provid
optim
treatment
children
cancer
countri
lmic
train
opportun
exist
inform
often
difficult
find
effort
promot
global
childhood
cancer
educ
aim
improv
upon
previou
initi
consolid
inform
provid
develop
new
enhanc
web
site
social
media
campaign
increas
awar
designmethod
intern
societi
paediatr
oncolog
develop
countri
educ
train
work
group
et
wg
launch
onlin
databas
train
program
octob
better
engag
stakehold
site
paediatr
oncolog
intern
network
train
educ
point
launch
new
websit
wwwcancerpointecom
social
media
campaign
facebook
twitter
linkedin
accompani
new
site
launch
octob
googl
analyt
util
monitor
websit
traffic
reach
site
result
first
five
month
wwwcancerpointecom
launch
page
view
increas
compar
time
period
initi
site
vs
site
access
countri
countri
vs
previous
social
media
campaign
includ
facebook
like
twitter
follow
first
five
month
social
media
referr
account
referr
new
site
without
similar
campaign
traffic
first
site
origin
social
media
conclus
rebrand
launch
social
media
campaign
effect
increas
web
traffic
expos
new
train
opportun
healthcar
provid
lmic
data
lack
regard
impact
patient
care
believ
initi
program
ad
site
abil
greatli
improv
qualiti
educ
train
l
f
na
r
b
r
nacion
de
pediatr
oncolog
depart
mexico
citi
mexico
nacion
de
noviembr
issst
pediatr
oncolog
depart
mexico
citi
mexico
materno
infantil
issemym
pediatr
onolog
depart
estado
de
mexico
backgroundobject
worldwid
higher
surviv
rate
report
pediatr
patient
cancer
due
earli
diagnosi
better
support
treatment
earli
detect
complic
middl
incom
countri
like
mexico
mortal
pediatr
patient
cancer
still
high
designmethod
aim
know
frequenc
main
caus
death
pediatr
patient
cancer
regist
three
public
health
institut
mexico
januari
decemb
result
two
thousand
three
hundr
patient
regist
studi
period
die
one
hundr
twenti
patient
diagnos
leukemia
rest
solid
tumor
point
fifteen
percent
male
patient
acut
lymphoblast
leukemia
treatment
phase
highest
number
death
induct
main
caus
death
toxic
patient
solid
tumor
treatment
phase
highest
number
death
occur
neoadjuv
die
toxic
diseas
progress
toxic
event
patient
solid
tumor
patient
septic
shock
caus
death
time
diagnosi
death
patient
leukemia
month
compar
patient
solid
tumor
month
conclus
patient
acut
leukemia
die
secondari
toxic
induct
phase
main
caus
death
patient
solid
tumor
toxic
diseas
progress
mortal
patient
solid
tumor
occur
earlier
particular
attent
paid
earli
detect
complic
avoid
mortal
caus
middl
incom
countri
zobeck
p
p
j
children
hospitalbaylor
colleg
medicin
pediatr
houston
usa
colleg
medicin
pediatr
houston
usa
marina
hospit
pediatr
gaboron
botswana
backgroundobject
pediatr
cancer
treatment
abandon
ta
major
caus
prevent
morbid
mortal
countri
lmic
recent
public
estim
africa
ssa
averag
ta
comprehens
studi
publish
ta
botswana
measur
previous
object
determin
preval
ta
pediatr
cancer
patient
tertiari
referr
center
botswana
investig
predispos
factor
ta
avail
literatur
designmethod
sinc
botswana
ministri
health
well
partner
baylor
colleg
medicinetexa
children
hospit
oper
pediatr
program
countri
princess
marina
hospit
pmh
analyz
data
botswana
pediatr
oncolog
databas
children
diagnos
malign
pmh
januari
decemb
result
patient
cohort
seven
met
criteria
abandon
two
abandon
final
outcom
abandon
four
patient
femal
five
solid
tumor
includ
two
osteosarcoma
two
teratoma
median
time
abandon
diagnosi
week
statist
signific
risk
factor
ta
identifi
includ
live
outsid
capit
citi
possess
privat
medic
aid
hiv
statu
metastas
diagnosi
solid
tumor
outsid
central
nervou
system
conclus
found
ta
pmh
botswana
low
compar
recent
publish
averag
estim
ta
ssa
countri
although
precis
comparison
difficult
due
limit
data
avail
region
research
need
hospit
countri
level
better
quantifi
magnitud
problem
facilit
comparison
explor
region
nation
risk
factor
ta
given
center
er
abdel
khalek
l
n
abdel
zagazig
univers
pediatr
cairo
egypt
univers
pediatr
zagazig
egypt
medicin
zagazig
univers
pediatr
zagazig
egypt
univers
clinic
patholog
zagazig
egypt
backgroundobject
pediatr
cancer
survivor
risk
renal
injuri
compar
healthi
children
littl
known
renal
dysfunct
vulner
group
aim
work
detect
earli
chronic
kidney
dysfunct
ckd
survivor
egyptian
children
solid
tumor
order
prevent
develop
renal
impair
designmethod
investig
children
age
year
cure
differ
solid
tumor
year
end
treatment
twenti
healthi
age
children
ad
control
group
particip
subject
histori
take
physic
assess
laboratori
investig
includ
urin
analysi
serum
creatinin
bun
estim
glomerular
filtrat
rate
gfr
calcul
chronic
kidney
diseas
diagnos
accordingli
addit
serum
lipocalin
ngal
determin
result
survivor
solid
tumor
show
evid
subclin
ckd
compar
control
group
averag
year
cessat
therapi
creatinin
level
case
control
insignific
gfr
median
versu
serum
median
versu
mgl
ngal
level
median
versu
pg
ml
control
group
signific
posit
correl
serum
serum
ngal
p
neg
correl
ngal
gfr
conclus
subclin
renal
dysfunct
could
found
survivor
ngal
cystatin
c
altogeth
connect
measur
gfr
higher
diagnost
accuraci
serum
creatinin
discrimin
normal
earli
stage
renal
injuri
renal
function
survivor
help
us
promot
health
survivor
h
ani
k
kidscan
pediatr
program
new
delhi
india
backgroundobject
cancer
signific
stressor
patient
famili
complet
treatment
survivor
sibl
caregiv
develop
persist
traumat
stress
reaction
experienc
stress
symptom
often
part
process
come
term
event
survivor
parent
howev
requir
intens
therapeut
intervent
approach
societi
enhanc
psycholog
adjust
emot
designmethod
may
cankid
initi
survivor
assist
program
aim
identifi
understand
rectifi
uniqu
need
challeng
survivor
parent
reduc
experi
trauma
issu
survivorship
program
combin
special
intervent
provid
survivor
caregiv
distress
therapeut
intervent
share
care
session
enhanc
psycholog
well
result
howev
survivor
report
possess
higher
risk
depress
low
self
esteem
marit
fertil
issu
mood
swing
accept
degre
anxieti
possibl
recurr
seriou
psychiatr
disord
obsess
compuls
disord
bipolar
disord
schizophrenia
found
uncommon
parent
concern
relaps
sibl
issu
mood
swing
survivor
base
pre
post
intervent
assess
report
greater
benefit
particip
cognit
behavior
stress
manag
intervent
show
posit
psycholog
respons
less
anxieti
fear
enhanc
greater
feel
relief
peac
purpos
live
conclus
must
recogn
cancer
survivor
appear
possess
slightli
higher
risk
major
depress
psycholog
complic
continu
exist
across
survivorship
trajectorythi
kind
ongo
cognit
behaviour
stress
manag
intervent
help
identifi
issu
also
resolv
psycholog
complic
relat
surviviorship
posit
outcom
f
arreguin
b
br
ag
rc
sb
pc
dm
medico
nacion
de
noviembr
issst
pediatr
oncolog
mexico
citi
mexico
medico
nacion
de
noviembr
issst
pediatr
oncolog
mexico
mexico
medico
nacion
de
noviembr
issst
pediatr
oncolog
pediatr
oncolog
mexico
medico
nacion
de
noviembr
pediatr
oncolog
mexico
mexico
backgroundobject
last
year
surviv
rate
childhood
cancer
improv
around
world
current
eight
everi
ten
children
surviv
year
beyond
diagnosi
advers
healthrel
outcom
sequeala
cancer
treatment
issst
institut
secur
social
servic
state
worker
third
level
institut
mexico
citi
take
care
mexico
total
popul
medic
nation
center
de
noviembr
cmn
de
noviembr
main
refer
hospit
cancer
pediatr
patient
receiv
around
new
casesyear
march
creat
first
survivorship
pediatr
cancer
clinic
nation
strategi
vulner
popul
designmethod
cmn
de
noviembr
main
refer
third
level
hospit
adult
children
sever
condit
complet
routin
health
care
clinician
medic
specialti
implement
model
base
childhood
cancer
survivor
studi
adjust
low
incom
countri
open
first
surveil
clinic
pediatr
cancer
patient
result
reclut
cancer
survivor
femal
predomin
vs
adolesc
frequent
group
year
old
common
late
effect
alter
pituitari
disfunct
overweight
obes
metabol
syndrom
neurocognit
deficit
scoliosi
ovarian
disfunct
infertil
neurosensori
deficit
renal
insuffici
conclus
ideal
approach
childhood
cancer
survivor
care
involv
model
routin
health
care
person
plan
surveil
difficult
low
incom
countri
follow
need
strengthen
relat
primari
care
doctor
follow
practic
guidelin
earli
detect
cancer
treatment
morbid
work
expertis
group
order
maxim
qualiti
life
outcom
data
need
r
barr
l
v
c
univers
pediatr
canada
health
scienc
nuclear
medicin
hamilton
canada
univers
nuclear
medicin
canada
health
scienc
pediatr
hamilton
canada
backgroundobject
sarcopen
obes
gain
fat
mass
loss
skelet
report
occur
earli
treatment
ascrib
mainli
influenc
glucocorticosteroid
appar
paradox
risk
doubl
jeopardi
metabol
frailti
syndrom
survivorship
associ
advers
effect
overal
health
surviv
result
ad
burden
morbid
prematur
age
sought
determin
whether
clinic
phenotyp
persist
long
term
survivor
designmethod
cohort
adolesc
young
adult
year
diagnosi
enrol
studi
bone
health
bodi
composit
treat
dana
farber
cancer
institut
protocol
measur
fat
mass
lean
bodi
mass
appendicular
lean
mass
alm
correspond
indic
provid
dual
energi
absorptiometri
holog
discoveri
model
also
gave
valu
bone
miner
content
densiti
skelet
muscl
mass
smm
deriv
equat
smm
kg
alm
kg
result
basi
fat
mass
index
fmi
femal
male
overweight
obes
obes
proport
respect
one
subject
low
smm
base
posit
z
score
fmi
neg
z
score
almi
subject
met
definit
sarcopen
obes
discord
fat
mass
lean
mass
conclus
sarcopen
obes
preval
long
term
survivor
given
attend
risk
prematur
age
mortal
find
offer
encourag
research
prevent
amelior
clinic
phenotyp
improv
overal
health
extend
surviv
barr
r
et
al
bmj
open
bindal
n
g
p
memori
centr
radiat
oncolog
mumbai
india
memori
centr
medic
physic
mumbai
india
memori
centr
pediatr
oncolog
mumbai
india
memori
centr
radiodiagnosi
mumbai
india
memori
centr
nuclear
medicin
mumbai
india
memori
centr
patholog
mumbai
india
memori
centr
surgic
oncolog
mumbai
india
memori
centr
radiat
oncolog
palli
medicin
mumbai
india
backgroundobject
evalu
sensorineur
hear
loss
snhl
children
nasopharyng
carcinoma
npc
treat
radiat
therapi
imrt
cisplatin
base
chemotherapi
cth
designmethod
children
npc
treat
neoadjuv
cisplatin
base
cth
follow
imrt
nasopharynx
neck
nodal
region
adjuv
cth
evalu
late
auditori
toxic
form
snhl
post
treatment
audiogram
avail
children
ear
total
pure
tone
audiogram
month
post
rt
evalu
retrospect
snhl
grade
note
scale
iv
accord
siop
ototox
criteria
chemotherapi
dose
mean
cochlear
dose
analys
associ
grade
iiiiv
ototox
result
median
audiolog
month
siop
grade
ii
iii
iv
ototox
observ
ear
respect
grade
iiiiv
account
case
except
three
patient
receiv
cumul
cisplatin
dose
threshold
cisplatin
dose
observ
correl
ototox
averag
cochlear
dmean
gy
patient
develop
grade
iiiiv
snhl
use
pearson
chi
squar
test
cochlear
dmean
threshold
gy
observ
associ
higher
incid
develop
grade
iiiiv
snhl
dose
fail
show
signific
associ
conclus
sever
ototox
seen
ear
children
receiv
radiat
chemotherapi
significantli
receiv
mean
cochlear
dose
gy
suggest
threshold
radiat
dose
cochlea
cumul
cisplatin
dose
adult
studi
may
applic
paediatr
popul
prospect
studi
requir
determin
cochlear
toler
dose
children
n
z
h
z
f
univers
faculti
medicin
pediatr
oncolog
izmir
turkey
univers
faculti
medicin
pediatr
endocrinolog
izmir
turkey
univers
faculti
medicin
medic
genet
izmir
turkey
univers
faculti
medicin
nuclear
medicin
izmir
turkey
backgroundobject
insuffici
common
healthi
children
adolesc
preval
gener
popul
survivor
childhood
cancer
increas
risk
varieti
advers
medic
outcom
potenti
risk
factor
impari
statu
popul
includ
poor
diet
exposur
chemotherapi
steroid
radiotherapi
vitamin
perform
effect
via
nuclear
vitamin
receptor
vdr
show
extens
polymorph
studi
frequenc
fok
vdr
gene
polymorph
statu
correl
bone
miner
densiti
bmd
designmethod
studi
includ
pediatr
cancer
survivor
ege
univers
dept
pediatr
oncolog
subject
full
histori
take
clinic
examin
peripher
venou
blood
took
patient
genom
dna
extract
fok
gene
serum
calcium
phosphoru
alkalin
phosphatas
parathormon
level
obtain
urin
calciumcreatin
measur
bone
miner
densiti
bmd
fok
gene
polymorph
result
compar
control
group
turkish
healthi
peopl
result
diagnosi
patient
leukemia
lymphoma
solid
tumor
median
age
patient
cancer
diagnosi
year
studi
year
patient
patient
insuffici
defici
fok
gene
polymorph
found
bmd
measur
osteopenia
osteoporosi
patient
solid
tumor
affect
despit
lack
routin
exposur
steroid
conclus
pediatr
cancer
survivor
frequenc
fok
gene
polymorph
similar
control
group
preval
insuffici
defici
cancer
survivor
high
accord
gener
popul
prospect
studi
evalu
long
term
bone
health
survivor
cancer
requir
g
chinnaswami
v
g
p
memori
hospit
depart
pediatr
medic
oncolog
mumbai
india
backgroundobject
long
term
survivor
childhood
cancer
ccss
known
higher
preval
life
threaten
fatal
health
condit
nci
ctcae
grade
compar
normal
popul
includ
second
malign
neoplasm
smn
benign
second
neoplasm
sn
late
recurr
although
describ
larg
cohort
us
europ
data
avail
lmic
designmethod
total
ccss
enrol
complet
therapi
act
clinic
hospit
sinc
survivor
kept
follow
base
primari
diseas
treatment
receiv
expect
long
term
toxic
data
regard
smnsn
recurr
death
obtain
databas
result
ccss
median
age
year
follow
median
durat
year
nearli
lost
long
term
followup
variou
stage
ccss
detect
grade
late
recurr
smn
sn
addit
death
commonest
tumor
late
recurr
hodgkin
lymphoma
hl
ewe
sarcoma
mean
time
recurr
year
multipl
recurr
high
subsequ
mortal
common
smn
carcinoma
thyroid
parotid
other
ewe
sarcoma
osteosarcoma
mean
time
develop
year
commonest
sn
schwannoma
meningioma
hl
survivor
document
due
late
organ
toxic
renal
failur
cardiac
failur
moyamoya
diseas
follow
recurr
smn
unrel
death
rheumat
heart
diseas
accid
malaria
dengu
conclus
increas
surviv
need
long
term
surveil
ccss
late
recurr
second
malign
ascertain
true
number
long
term
toxic
need
rigor
follow
challeng
given
health
system
network
lmic
l
embri
pediatr
san
tx
usa
school
san
tx
usa
health
school
public
health
san
antonio
depart
health
promot
behavior
scienc
san
antonio
usa
backgroundobject
initi
target
uptak
human
papillomaviru
hpv
vaccin
improv
rate
nation
howev
diseas
remain
signific
health
concern
although
childhood
cancer
survivor
increas
risk
diseas
particularli
histori
stem
cell
transplant
sct
radiat
therapi
target
group
initi
south
texa
hpv
vaccin
uptak
among
lowest
state
studi
aim
includ
evalu
hpv
vaccin
rate
among
pediatr
cancer
survivor
south
texa
demograph
clinic
factor
associ
hpv
vaccin
uptak
popul
designmethod
retrospect
chart
review
childhood
cancer
survivor
identifi
patient
potenti
elig
receiv
hpv
vaccin
review
vaccin
record
texa
immtrac
vaccin
registri
electron
clinic
record
verifi
hpv
vaccin
statu
demograph
clinic
variabl
collect
includ
dob
gender
raceethn
cancer
diagnosi
cancer
treatment
result
record
review
survivor
deem
receiv
least
one
vaccin
complet
seri
femal
initi
complet
seri
howev
among
male
initi
complet
approxim
sampl
hispaniclatino
among
patient
initi
vaccin
seri
complet
rate
initi
complet
also
low
white
black
patient
furthermor
patient
receiv
therapi
radiat
sct
increas
uptak
hpv
vaccin
compar
patient
receiv
chemotherapi
conclus
hpv
vaccin
rate
among
childhood
cancer
survivor
south
texa
lower
gener
popul
region
nation
given
increas
suscept
secondari
malign
studi
demonstr
clear
need
enhanc
effort
increas
hpv
vaccin
rate
popul
v
forster
j
w
f
van
gilgan
centr
research
hospit
sick
children
genet
genom
biolog
toronto
canada
univers
northern
institut
cancer
research
newcastl
upon
tyne
unit
kingdom
backgroundobject
advers
neurolog
event
common
treatment
pediatr
acut
lymphoblast
leukaemia
includ
seizur
stroke
like
syndrom
leukoencephalopathi
addit
chronic
neurotox
emerg
worri
late
effect
treatment
survivor
experienc
decreas
execut
function
process
speed
memori
function
survivor
also
increas
risk
experienc
learn
difficulti
social
withdraw
issu
inattent
hyperact
disord
methotrex
chemotherapi
agent
mainstay
pediatr
leukemia
treatment
regimen
global
wide
implic
caus
neurolog
side
effect
hypothesis
methotrex
disrupt
dna
methyl
via
effect
methionin
key
methyl
compon
previous
describ
involv
regul
gene
involv
myelin
designmethod
use
neural
cell
line
oligodendrocyt
deriv
induc
pluripot
stem
cell
ipsc
treat
methotrex
assay
chang
dna
methyl
consequenti
effect
gene
express
use
methyl
array
rnaseq
respect
gene
correspond
methyl
express
chang
select
confirm
express
qpcr
assess
protein
level
result
identifi
methyl
concomit
express
chang
gene
involv
neurodevelopment
pathway
neurolog
disord
particular
interest
demethyl
consequenti
increas
gene
express
vital
compon
insulin
signal
pathway
highli
express
neural
tissu
implic
regul
cognit
perform
also
detect
alter
methyl
within
gene
encod
major
protein
compon
myelin
identifi
increas
methyl
methotrex
treatment
oligodendrocyt
result
correspond
reduct
transcript
level
protein
conclus
work
provid
insight
regard
biolog
mechan
behind
neurolog
side
effect
implic
alter
insulin
signal
myelin
pathway
potenti
caus
factor
neurotox
aj
friend
r
e
k
leed
school
medicin
leed
unit
kingdom
southampton
school
medicin
southampton
unit
kingdom
univers
london
school
medicin
london
unit
kingdom
backgroundobject
survivor
young
peopl
cancer
known
increas
risk
psycholog
distress
includ
cognit
difficulti
howev
littl
known
emot
behaviour
problem
aim
collat
evid
preval
mental
health
problem
survivor
childhood
cancer
designmethod
standard
systemat
review
perform
exclud
paper
cognit
function
search
pubm
embaseovid
cinahl
web
scienc
databas
use
follow
strategi
result
initi
search
result
return
paper
discard
paper
cover
cognit
function
explor
intervent
rather
preval
paper
remain
found
report
increas
antidepress
use
higher
rate
psycholog
distress
long
term
survivor
cyp
cancer
compar
control
although
mani
sibl
survivor
like
difficultiesth
major
data
came
associ
high
risk
bia
also
data
hospit
admiss
mental
health
problem
analysi
prescrib
data
primari
care
found
paper
report
primari
mental
health
problem
despit
common
place
mental
ill
diagnos
treat
mani
set
conclus
need
accur
ascertain
preval
mental
health
problem
group
data
primari
care
would
significantli
improv
understand
issu
would
essenti
futur
servic
plan
hope
futur
work
link
primari
care
record
cancer
registri
go
way
address
gap
knowledg
e
hiyama
univers
hospit
peditr
surgeri
hiroshima
japan
univers
natur
scienc
center
basic
research
develop
hiroshima
japan
medic
center
peditr
surgeri
kure
japan
backgroundobject
cisplatin
anthracyclin
wide
use
anticanc
agent
hepatoblastoma
hb
japanes
studi
group
pediatr
liver
tumor
jplt
studi
evalu
efficaci
cisplatinpirarubicin
cita
regimen
hb
avoid
ototox
cardiotox
secondari
malign
effect
import
improv
outcom
childhood
hb
designmethod
studi
hb
children
elig
inclus
among
evalu
late
effect
includ
ototox
cardiotox
maldevelop
secondari
malign
surviv
case
among
patient
whose
germlin
dna
sampl
avail
inform
consent
genotyp
perform
use
illumina
human
omni
express
beadchip
illumina
linkag
disequilibrium
ld
polymorph
snp
select
strategi
use
identifi
minim
set
inform
variant
associ
snp
toxic
assess
use
logist
regress
ototox
determin
audiometri
andor
auditori
respons
cardiotox
mainli
determin
standard
echocardiographi
result
among
surviv
case
test
snp
analysi
ototox
cardiotox
maldevelop
secondari
malign
determin
dose
cisplatin
andor
pirarubicin
seem
correl
occurr
significantli
identifi
inherit
genet
variat
three
snp
includ
snp
includ
associ
ototox
two
snp
associ
cardiotox
moreov
find
candid
genet
variat
correl
maldevelop
secondari
malign
conclus
risk
variant
snp
strongli
predispos
patient
toxic
includ
ototox
cardiac
toxic
use
chemotherapi
result
point
new
biolog
underli
late
toxic
effect
palatinumanthoracyclin
agent
pay
biolog
assess
next
protocol
avoid
toxic
effect
chemotherapeut
agent
lb
kenney
b
n
p
boston
children
hosptial
pediatr
oncolog
boston
usa
hitchcock
medic
center
pediatr
hematolog
oncolog
hanov
usa
children
hospit
clinic
research
center
boston
usa
children
hospit
neurolog
boston
usa
backgroundobject
mani
clinic
issu
encount
care
childhood
cancer
survivor
uniqu
popul
studi
investig
manag
outcom
often
avail
pilot
modifi
methodolog
develop
region
guidelin
care
survivor
identifi
area
clinic
disagr
designmethod
member
consortium
new
england
childhood
cancer
survivor
connecc
survey
identifi
clinic
challeng
encount
care
survivor
five
vignett
neurolog
outcom
develop
base
frequent
clinic
issu
describ
purpos
sampl
chosen
repres
specialti
gener
physician
geograph
divers
connecc
institut
systemat
review
medic
literatur
identifi
risk
factor
intervent
complet
summari
evid
made
avail
particip
modifi
delphi
approach
requir
three
round
anonym
survey
data
collect
establish
practic
norm
systemat
build
consensu
among
expert
particip
result
particip
complet
round
survey
question
address
practic
norm
relat
clinic
scenario
respons
code
modal
manag
option
question
describ
round
survey
ask
particip
agreedisagre
modal
manag
option
provid
ration
respons
respond
manag
question
particip
reach
consensu
agreement
condit
agreement
disagr
round
questionnair
attempt
negoti
consensu
area
disagr
share
summar
rational
provid
particip
manag
decis
conclus
region
expert
success
recruit
retain
develop
clinic
practic
guidelin
manag
rare
outcom
encount
care
childhood
cancer
survivor
use
modifi
delphi
methodolog
area
manag
controversi
identifi
research
f
khan
l
rochest
school
medicin
rochest
usa
rochest
jame
p
wilmot
cancer
center
rochest
usa
hospit
pittsburgh
pediatr
pulmonolog
pittsburgh
usa
rochest
radiat
oncolog
rochest
usa
backgroundobject
pulmonari
dysfunct
preval
potenti
debilit
late
effect
radiat
therapi
rt
use
treat
children
cancer
postul
age
surrog
respiratori
development
statu
might
associ
vulner
pulmonari
injuri
designmethod
children
treat
institut
lung
radiat
undergon
pulmonari
function
test
pft
analyz
data
collect
includ
age
treatment
radiat
chemotherapi
surgeri
radiat
dose
locat
spirometri
plethysmographi
result
pft
normal
accord
age
gender
height
ethnic
transform
standard
obstruct
diseas
defin
restrict
ztlc
abnorm
diffus
zdlco
determin
incid
obstruct
restrict
diffus
abnorm
popul
estim
rel
risk
develop
pulmonari
abnorm
result
mean
age
year
rang
time
diagnosi
year
rang
cumul
incid
pulmonari
abnorm
incid
diffus
abnorm
obstruct
restrict
diseas
respect
year
year
rt
diffus
restrict
obstruct
abnorm
year
compar
patient
year
year
year
rt
significantli
increas
risk
abnorm
pft
follow
ci
ci
respect
p
although
statist
signific
lost
adjust
bleomycin
use
time
sinc
rt
associ
remain
examin
type
abnorm
p
conclus
pulmonari
function
abnorm
common
among
cohort
childhood
cancer
survivor
treat
lung
radiat
diffus
obstruct
diseas
common
restrict
diseas
younger
age
treatment
associ
increas
risk
develop
pulmonari
dysfunct
presum
due
development
immatur
j
korzeniewska
b
dembowska
children
memori
health
institut
pediatr
oncolog
warsaw
poland
backgroundobject
vision
loss
context
pediatr
oncolog
due
neurofibromatosi
retinoblastoma
brain
tumor
case
vision
loss
could
partial
total
occur
immedi
progress
diseas
touch
children
variou
age
level
develop
symptom
vision
loss
variabl
determin
differ
way
earli
intervent
psycholog
support
designmethod
whole
oncolog
popul
center
search
vision
deficit
assess
special
need
determin
specif
mechan
sensori
loss
prepar
recommend
psycholog
procedur
includ
challeng
assess
popul
effect
vision
function
assess
psycholog
earli
rehabilit
stimul
psycholog
support
parent
decis
make
child
treatment
rehabilit
educ
result
dynam
diseas
caus
progress
optic
pathway
glioma
decreas
vision
abil
symptom
grade
vision
loss
due
childhood
brain
tumor
depend
local
lesion
eg
posterior
fossa
tumor
doubl
vision
strabismu
nystagmu
frontal
lobe
risk
total
vision
loss
occipit
lobe
cortic
visual
impair
cvi
total
vision
loss
legal
blind
chiasma
optic
nerv
hemianopia
loss
peripher
vision
tunnel
vision
sampl
observ
also
relat
local
brain
damag
consequ
tumor
vision
loss
complex
mechan
clear
retinoblastoma
progress
diseas
caus
gradual
vision
loss
patient
adapt
limit
show
signific
behavior
disturb
consequ
lack
sight
child
small
give
feedback
sigh
behavior
reaction
connect
vision
loss
misdiagnos
delay
diagnos
confus
caregiv
conclus
vision
impair
oncolog
popul
specif
requir
special
psycholog
procedur
earli
intervent
start
time
treatment
neu
v
r
j
k
v
ft
w
j
medic
center
mainz
center
pediatr
adolesc
depart
pediatr
hematologyoncologyhemostaseolog
mainz
germani
sport
univers
cologn
institut
cardiovascular
research
sport
depart
molecular
cellular
sport
medicin
cologn
germani
univers
hospit
depart
pediatr
hematolog
hemostaseolog
leipzig
germani
heidelberg
institut
sport
sport
scienc
heidelberg
germani
hospit
cologn
depart
intern
center
integr
oncolog
bonn
cologn
germani
backgroundobject
childhood
cancer
associ
variou
sequela
physic
psycholog
social
level
previou
studi
show
reduc
physic
activ
level
survivor
childhood
cancer
treatment
cct
may
consider
impact
child
develop
qualiti
life
social
particip
cardiovascular
health
aim
studi
evalu
physic
activ
behavior
pa
children
adolesc
intens
cct
designmethod
prospect
multicent
studi
children
adolesc
formerli
treat
type
cancer
enrol
mean
age
year
pa
assess
complet
intens
treatment
phase
time
sinc
diagnosi
year
use
adapt
version
pa
questionnair
german
questionnair
includ
item
ask
level
intens
pa
cct
time
studi
particip
ie
complet
intens
cct
result
compar
healthi
control
mean
age
year
result
compar
time
cct
patient
report
significantli
lower
pa
level
cct
evalu
visual
analog
scale
p
healthi
control
report
higher
pa
level
patient
cct
p
time
pa
spent
low
intens
level
lower
cct
p
patient
particip
sport
club
activ
cct
cct
wherea
healthi
control
particip
conclus
conclus
children
adolesc
treat
cancer
report
modifi
pa
behavior
cct
comparison
time
cct
well
comparison
healthi
control
studi
need
investig
consequ
physic
inact
cct
examin
subsequ
physic
activ
behavior
influenc
posit
h
ottensmei
pg
je
bo
k
von
g
von
c
j
rd
u
j
wuerzburg
hospit
depart
pediatr
oncolog
wuerzburg
germani
wuerzburg
hospit
depart
pediatr
comprehens
cancer
center
mainfranken
wuerzburg
germani
clinic
hospit
depart
pediatr
hematolog
oncolog
cleveland
usa
medic
center
wuerzburg
depart
pediatr
hematolog
oncolog
wuerzburg
germani
medic
centr
depart
pediatr
hematolog
oncolog
hamburg
germani
essen
pediatr
iii
oncolog
essen
germani
hospit
geneva
depart
pediatr
adolesc
medicin
divis
pediatr
oncolog
geneva
switzerland
hospit
rostock
depart
hematolog
oncolog
rostock
germani
medic
center
wuerzburg
depart
hit
nation
refenr
center
wuerzburg
germani
medic
center
wuerzburg
depart
pediatr
neurosurgeri
wuerzburg
germani
leipzig
depart
radiotherapi
leipzig
germani
bonn
depart
pediatr
oncolog
bonn
germani
backgroundobject
background
medulloblastoma
mb
ependymoma
ed
primit
neuroectoderm
tumor
pnet
young
children
associ
unfavor
mental
outcom
multimod
treatment
therefor
craniospin
radiotherapi
csi
often
delay
replac
intrathec
methotrex
mtxith
system
chemotherapi
designmethod
procedur
octob
march
n
surviv
children
treat
within
hit
protocol
age
year
prospect
assess
two
neuropsychologist
wuerzburg
team
follow
test
systemat
appli
kaufman
assess
batteri
children
measur
mental
process
composit
mpc
colour
progress
matric
cpm
development
test
visual
motor
integr
vmi
tap
test
tp
und
der
continu
perform
test
data
n
patient
includ
analysi
result
result
children
stratifi
accord
diagnosi
mb
ed
pnet
clinic
respons
averag
iq
patient
mpc
iq
sd
howev
valu
differ
larg
among
variou
treatment
group
exampl
result
mb
patient
treat
system
chemotherapi
follow
rt
shown
dmb
good
respond
csi
mpc
iq
dmb
poor
respond
csi
mpc
iq
cmb
good
respond
csi
mpc
iq
cmb
poor
respond
csi
mpc
iq
ep
ii
infratentori
local
rt
mpc
iq
ep
iii
infratentori
local
rt
mpc
iq
interestingli
patient
infratentori
ed
found
within
normal
age
rang
conclus
conclus
longitudin
assess
hit
cohort
found
multimod
therapi
without
csi
mb
patient
result
improv
mental
outcom
measur
neuropsycholog
project
support
german
childhood
cancer
foundat
k
raghubar
k
k
em
md
colleg
medicin
pediatr
houston
usa
cincinnati
colleg
medicin
radiat
oncolog
cincinnati
usa
cincinnati
colleg
medicin
radiolog
cincinnati
usa
brain
univers
calgari
psycholog
calgari
canada
krieger
institut
neuropsycholog
baltimor
usa
backgroundobject
advanc
radiat
oncolog
provid
new
opportun
studi
neurocognit
outcom
radiat
therapi
rt
pediatr
patient
treat
brain
tumor
specif
advanc
allow
consider
multidimension
inher
individu
rt
treatment
plan
examin
relationship
rt
neurocognit
outcom
present
studi
investig
relationship
biophys
physic
dose
metric
well
relat
neurocognit
abil
name
learn
memori
designmethod
studi
base
subsampl
n
particip
longitudin
prospect
studi
brisc
brain
radiat
investig
studi
consortium
particip
includ
studi
diagnos
age
year
receiv
rt
follow
surgic
intervent
detail
dose
reconstruct
metric
collect
result
neuropsycholog
evalu
complet
averag
month
report
physic
mean
dose
prescrib
dose
max
dose
biophys
gener
equival
uniform
dose
integr
biolog
effect
dose
dose
metric
whole
brain
right
left
hippocampu
evalu
correl
learn
memori
subtest
children
memori
scale
result
biophys
dose
metric
highli
correl
physic
metric
mean
dose
spearman
correl
prescrib
dose
although
prescrib
dose
uncorrel
measur
learn
memori
biophys
metric
mean
dose
correl
measur
later
find
obtain
conclus
preliminari
find
suggest
limit
advantag
biophys
dose
metric
physic
metric
mean
dose
calcul
specif
region
brain
implic
evalu
understand
relat
rt
neurocognit
function
discuss
wm
rash
mh
el
cancer
research
cairo
egypt
forc
colleg
medicin
research
cairo
egypt
berlin
medicin
berlin
germani
backgroundobject
thyroid
carcinoma
rare
tumor
pediatr
account
newli
diagnos
childhood
carcinoma
unit
state
accord
seer
databas
incid
rate
thyroid
carcinoma
children
year
age
per
per
adolesc
age
year
report
larg
cohort
studi
thyroid
carcinoma
associ
increas
risk
second
primari
malign
treatment
aim
assess
risk
subsequ
malign
among
survivor
pediatr
thyroid
cancer
designmethod
use
us
seer
surveil
research
program
nation
cancer
institut
bethesda
md
usa
databas
perform
studi
seer
stat
version
use
extract
data
seer
databas
cohort
analysi
consist
pediatr
cancer
patient
age
less
year
diagnos
primari
thyroid
cancer
identifi
site
code
report
seer
databas
identifi
subsequ
malign
popul
queri
perform
obtain
addit
record
new
tumor
diagnosi
patient
subsequ
malign
occur
year
origin
thyroid
cancer
diagnosi
includ
except
thyroid
cancer
second
malign
result
total
patient
diagnos
primarili
thyroid
carcinoma
incid
subsequ
malign
patient
develop
third
malign
femal
repres
male
repres
subsequ
malign
pediatr
cancer
survivor
diagnos
thyroid
cancer
includ
mani
site
high
percent
femal
breast
salivari
gland
conclus
thyroid
cancer
rare
tumor
childhood
risk
develop
second
malign
pediatr
cancer
survivor
mandat
presenc
precis
plan
longer
schmid
b
j
r
p
j
von
hauner
children
ludwig
maximilian
univers
pediatr
hematolog
oncolog
munich
germani
herzzentrum
institut
prevent
technic
univers
munich
depart
pediatr
cardiolog
congenit
heart
diseas
munich
germani
herzzentrum
technic
univers
munich
depart
pediatr
cardiolog
congenit
heart
diseas
munich
germani
prevent
technic
univers
munich
depart
pediatr
cardiolog
congenit
heart
diseas
munich
germani
backgroundobject
adult
survivor
pediatr
cancer
high
risk
develop
late
cardiovascular
event
import
risk
factor
cumul
dose
anthracyclin
therapi
goal
prospect
studi
detect
alter
regard
vascular
structur
function
exercis
capac
base
dose
anthracyclin
given
designmethod
survivor
pediatr
cancer
male
diagnos
median
age
year
examin
averag
age
year
patient
cumul
dose
anthracyclin
compar
patient
anthracyclin
patient
asymptomat
nyha
class
quantifi
dysfunct
left
ventricl
eject
fraction
ef
determin
echocardiographi
cardiac
biomark
plasma
natriuret
protein
level
measur
addit
cardiopulmonari
exercis
test
perform
detect
limit
exercis
capac
result
ef
reduc
ef
male
femal
survivor
differ
group
high
moder
anthracyclin
dosag
elev
ngml
male
femal
survivor
significantli
higher
group
high
compar
group
moder
anthracyclin
associ
ef
cardiopulmonari
exercis
capac
significantli
lower
group
high
moder
anthracyclin
dosag
conclus
ef
level
cardiopulmonari
exercis
test
import
paramet
detect
earli
impair
cardiovascular
function
asymptomat
survivor
childhood
cancer
iren
schmid
barbara
reiner
contribut
equal
work
r
seth
india
institut
medic
scienc
pediatr
delhi
india
india
institut
medic
scienc
cardiolog
delhi
india
backgroundobject
background
improv
surviv
childhood
cancer
cancer
survivor
increas
studi
assess
morbid
childhood
cancer
treatment
develop
countri
object
studi
preval
spectrum
late
effect
cancer
treatment
pediatr
cancer
survivor
designmethod
methodolog
evalu
first
patient
complet
year
treatment
complet
clinic
done
detail
primari
diagnosi
treatment
receiv
current
clinic
statu
note
spectrum
late
effect
ascertain
appropri
investig
result
hematolog
malign
compris
total
casescommonest
primari
diagnosi
compris
acut
lymphoblast
leukemia
retinoblastoma
hodgkin
lymphoma
median
age
evalu
year
year
respect
survivor
minim
disabl
growth
retard
underweight
moder
disabl
need
medic
attent
hbsag
posit
myocardi
dysfunct
azoospermia
hypothyroid
major
life
threaten
disabl
mental
retard
liver
diseas
mortal
eleven
patient
relaps
five
patient
expir
two
second
malign
record
cohort
patient
period
conclus
late
effect
concern
howev
sever
disabl
grade
seen
survivor
tackl
lifelong
childhood
cancer
survivor
recommend
defin
accur
morbid
occurr
secondari
neoplasm
facilit
time
diagnosi
implement
remedi
prevent
intervent
optimis
health
outcom
awar
toward
exist
late
effect
cancer
therapi
requir
among
parent
patient
health
profession
l
shat
e
e
e
state
paediatr
medic
univers
divis
paediatr
oncolog
radiotherapi
st
petersburg
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
divis
neurooncolog
moscow
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
patholog
depart
moscow
russia
burdenko
neurosurg
russian
academi
medic
scienc
divis
patholog
moscow
russia
hospit
murmansk
depart
paediatr
haematolog
endocrinolog
murmansk
russia
republican
clinic
hospit
departm
paediatr
oncolog
haematolog
kazan
russia
rogachev
nation
research
center
pediatr
oncolog
immunolog
consult
depart
moscow
russia
region
hospit
paediatr
oncolog
haematolog
khabarovsk
russia
scientif
center
radiolog
depart
moscow
russia
backgroundobject
multimod
therapi
improv
surviv
childhood
tumoursth
develop
neoplasm
subsequ
therapeut
cranial
irradi
rare
seriou
potenti
fatal
complic
designmethod
analysi
includ
patient
pt
subsequ
glioblastoma
sg
sever
institut
underw
cranial
neck
irradi
case
treat
primari
diseas
acut
lymphoblast
leukaemia
pt
pt
choroid
plexu
papilloma
pt
lymphoma
pt
glioma
aros
within
previou
radiat
field
satisfi
wide
use
criteria
definit
radiat
induc
neoplasm
median
rt
dose
administ
gy
dosag
rang
gy
total
bodi
irradi
tbi
use
one
patient
bone
marrow
transplant
median
latenc
period
year
diagnosi
sg
major
sg
occur
initi
year
diagnos
year
patient
underw
surgeri
resect
follow
standard
fraction
local
radiat
chemotherapi
result
analysi
use
illustr
overal
surviv
os
curv
os
rate
year
respect
conclus
case
paediatr
neoplasm
treat
standard
fraction
radiat
tbi
use
glioma
consid
possibl
side
effect
patient
follow
long
term
even
longer
period
risk
relaps
primari
cancer
pass
c
sleur
j
g
l
v
hospit
leuven
pediatr
oncolog
leuven
belgium
hospit
leuven
radiolog
leuven
belgium
backgroundobject
apo
cholesterol
transport
play
import
role
neuron
plastic
given
lack
evid
neurodevelop
childhood
cancer
patient
studi
aim
explor
potenti
brain
lesion
survivor
link
cognit
allel
designmethod
acquir
neurocognit
data
survivor
pediatr
solid
tumor
control
year
patient
treat
sinc
neuropsycholog
assess
includ
intellig
verbal
auditori
memori
attent
measur
flair
imag
investig
white
matter
lesion
dna
sampl
examin
apo
polymorph
first
compar
behavior
score
object
assess
wai
avlt
rvdlt
ant
subject
questionnair
stai
cfq
brief
depress
bdi
se
covari
risk
white
matter
lesion
within
patient
group
predict
apo
genotyp
ie
presenc
vs
absenc
allel
cognit
score
within
patient
group
compar
patient
subgroup
well
white
matter
lesion
present
vs
absent
subgroup
result
cognit
score
appear
lower
wai
work
memori
wai
process
speed
rvdlt
total
brief
work
memori
pedsql
total
score
wm
lesion
present
patient
vs
control
risk
wm
lesion
predict
allel
result
correct
categor
lesion
patient
model
neither
factor
relat
cognit
conclus
survivor
solid
tumor
mainli
complain
work
memori
also
show
lower
object
score
process
speed
visual
memori
qol
heterogen
wm
lesion
suggest
impact
cognit
differ
depend
locat
type
lesion
apo
genotyp
could
potenti
biomark
lesion
j
stefanowicz
e
medic
univers
depart
hematolog
oncolog
poland
univers
gdansk
depart
famili
medicin
gdansk
poland
univers
gdansk
depart
oncolog
gdansk
poland
haematolog
oncolog
ludwik
rydygi
collegium
medicum
bydgoszcz
nicolau
copernicu
univers
torun
depart
haematolog
oncolog
depart
haematolog
oncolog
poland
backgroundobject
studi
present
analysi
sonograph
laboratori
paramet
solitari
kidney
preval
chronic
kidney
diseas
ckd
wilm
tumor
survivor
wt
designmethod
wt
complet
treatment
wilm
tumor
wt
healthi
individu
enrol
studi
studi
protocol
consist
complet
medic
histori
sonograph
examin
solitari
kidney
estim
glomerular
filtrat
rate
egfr
schwartz
mdrd
formula
albumin
urin
excret
acr
blood
pressur
measur
result
sonograph
sing
kidney
damag
observ
wt
hypertrophi
solitari
kidney
occur
case
mean
volum
solitari
kidney
volum
sum
two
kidney
control
group
mean
egfr
wt
group
vs
control
group
p
six
wt
valu
egfr
increas
albumin
urin
excret
acr
observ
wt
individu
control
group
conclus
sonograph
imag
solitari
kidney
wt
differ
sonograph
imag
control
group
frequent
detect
abnorm
hyperecho
ring
around
renal
pyramid
differ
sonograph
imag
solitari
kidney
accord
chemotherapi
sonograph
examin
wt
ought
perform
detect
eventu
tumor
recurr
also
assess
risk
ckd
progress
deterior
renal
function
person
involv
write
paper
report
conflict
interest
alatta
univers
school
public
health
global
health
boston
usa
cancer
hospit
egypt
qualiti
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
healthcar
scienc
academi
cairo
egypt
farber
cancer
institut
global
health
initi
boston
usa
backgroundobject
patient
experi
within
health
care
system
term
equiti
qualiti
influenc
percept
access
project
explor
referr
mechan
children
cancer
hospit
egypt
cche
cairo
assess
percept
famili
member
toward
equiti
qualiti
dimens
associ
access
pediatr
oncolog
care
designmethod
singl
site
mix
method
studi
data
collect
interview
use
structur
interview
guid
includ
probe
question
sampl
size
famili
member
randomli
select
interview
focu
group
mother
father
conduct
expand
parent
opinion
referr
process
overal
experi
result
respond
report
follow
factor
decid
seek
care
cche
experi
outsid
cche
dissatisfact
healthcar
provid
knowledg
attitud
behavior
fragment
system
equip
hospit
perceiv
qualiti
cche
servic
advanc
special
facil
effect
treatment
high
surviv
rate
reput
cche
trust
cche
brand
awar
word
mouth
televis
ad
doctor
recommend
equiti
cche
mission
equal
access
free
charg
treatment
conclus
effici
patient
centr
referr
process
vital
element
high
qualiti
care
servic
recommend
includ
suggest
increas
engag
famili
care
incorpor
famili
member
feedback
qualiti
improv
effort
collabor
nation
exist
cancer
center
streamlin
referr
system
access
plan
outreach
program
health
care
provid
rural
area
improv
commun
skill
conduct
survey
expand
public
percept
toward
differ
access
element
sultan
n
hussein
cancer
center
depart
pediatr
amman
jordan
hussein
cancer
center
depart
radiolog
amman
jordan
sick
children
divis
hematolog
oncolog
toronto
canada
waterloo
school
public
health
health
system
global
health
econom
ontario
canada
jude
children
research
hospit
depart
global
pediatr
medicin
memphi
usa
backgroundobject
past
year
king
hussein
cancer
center
khcc
establish
multidisciplinari
cancer
care
program
becom
import
region
hub
oncolog
year
center
treat
new
cancer
patient
jordan
surround
region
khcc
provid
medic
equip
servic
includ
oper
room
bed
intens
care
unit
includ
dedic
pediatr
icu
bed
emerg
data
khcc
shown
outcom
mani
pediatr
malign
treat
hospit
approach
seen
countri
hic
cost
childhood
cancer
treatment
upper
countri
umic
like
jordan
howev
well
investig
aim
research
determin
cost
oper
nation
childhood
cancer
treatment
center
jordan
help
priorit
futur
intervent
childhood
cancer
treatment
provid
analyt
framework
model
futur
cost
analys
elsewher
designmethod
conduct
studi
evalu
expens
childhood
cancer
treatment
cover
budget
financ
model
jordan
expenditur
categor
personnel
room
board
outpati
clinic
pharmaci
patholog
surgeri
radiat
imag
estim
unit
cost
per
bed
multipli
world
health
organ
tabl
unit
cost
tertiari
hospit
averag
length
stay
khcc
day
total
number
inpati
visit
per
year
result
calcul
total
cost
base
annual
case
diagnos
admit
khcc
assess
compar
cost
estim
outcom
data
conclus
cost
result
studi
inform
polici
maker
stakehold
jordan
plan
implement
priorit
childhood
cancer
treatment
program
describ
method
also
provid
templat
umic
conduct
similar
analys
k
chawla
p
r
c
kidscan
cepaa
delhi
india
kidscan
capac
build
parent
survivor
group
delhi
india
kidscan
cepaa
resourc
mobil
delhi
india
kidscan
cepaa
kck
delhi
india
backgroundobject
childhood
cancer
control
plan
polici
india
surviv
outcom
estim
low
awar
childhood
cancer
gold
color
gold
ribbon
gold
glow
symbol
low
focus
advocaci
campaign
brand
adopt
new
theme
year
built
promot
gold
color
brand
pink
breast
cancer
therebi
engag
stakehold
designmethod
go
gold
india
campaign
launch
invok
childhood
cancer
intern
hash
tag
act
kid
cancer
specif
theme
taj
goe
gold
februari
intern
childhood
cancer
day
iccd
septemb
childhood
cancer
awar
month
iccd
children
cancer
decor
light
gold
taj
mahal
cut
out
cancer
center
lit
hospit
manag
nurs
doctor
day
pediatr
oncolog
profession
pin
gold
ribbon
survivor
day
deserv
best
cancer
treatment
care
support
poster
essay
competit
spearhead
span
month
survivor
pin
gold
ribbon
ran
pledg
campaign
onlin
offlin
septemb
saw
car
ralli
uttar
pradesh
social
mobil
campaign
bring
children
parent
survivor
agra
taj
go
gold
campaign
follow
year
go
gold
warrior
angel
inspir
one
song
use
yellow
wristband
result
taj
went
gold
septemb
adorn
gold
ribbon
light
gold
taj
cut
out
first
ever
childhood
cancer
exhibit
children
parent
taj
mahal
extens
media
coverag
pledg
collect
india
oversea
state
govern
announc
format
task
forc
india
central
govern
health
ministri
pledg
support
conclus
sustain
attract
advocaci
campaign
strong
imag
brand
need
built
year
year
engag
stakehold
g
p
bahl
j
k
n
b
memori
hospit
depart
pediatr
medic
oncolog
mumbai
india
foundat
cuddl
foundat
mumbai
india
backgroundobject
malnutrit
pediatr
cancer
patient
advers
influenc
treatment
outcom
addit
treatment
toxic
detriment
effect
nutrit
statu
earli
aggress
nutrit
intervent
found
improv
nutrit
statu
turn
overal
outcom
analys
impact
earli
intervent
nutrit
statu
children
across
hospit
india
nutrit
intervent
support
ngo
cuddl
foundat
cf
organ
india
focus
provid
holist
nutrit
intervent
children
afflict
cancer
designmethod
children
newli
diagnos
cancer
age
year
coexist
sever
acut
malnutrit
sam
jan
dec
includ
studi
weight
age
height
age
weight
length
bmi
muac
tricep
skin
fold
thick
tsft
measur
z
scorespercentil
calcul
baselin
month
assess
nutrit
intervent
includ
incorpor
readi
use
therapeut
food
rutf
nutrit
supplement
includ
micronutri
vitamin
folat
calcium
found
defici
close
monitor
dedic
nutritionist
recruit
ngo
result
newli
diagnos
pediatr
cancer
children
sam
enrol
mean
age
studi
group
year
averag
bmi
improv
week
correspondingli
median
weight
shift
kg
month
show
improv
nutrit
statu
intervent
convert
mild
malnutritionnorm
nutrit
improv
moder
malnutrit
statu
continu
sam
conclus
earli
aggress
nutrit
intervent
cancer
children
malnutrit
significantli
improv
nutrit
statu
impact
posit
chemotherapi
toler
long
term
outcom
ngo
cf
focuss
holist
nutrit
support
play
import
role
improv
outcom
lmic
malnutrit
highli
preval
children
cancer
n
scobi
h
c
sullen
switzerland
kick
cancer
brussel
belgium
backgroundobject
grow
recognit
across
parentpati
profession
commun
promis
new
drug
children
teenag
cancer
develop
quickli
enough
problem
requir
urgent
approach
problem
medic
also
econom
pharmaceut
compani
consid
adult
popul
key
custom
base
childhood
cancer
neglect
made
rare
ill
none
offer
lucr
market
commerci
develop
drug
designmethod
mani
group
chariti
work
similar
aim
aim
provid
platform
acceler
platform
mobil
support
banner
unit
childhood
teenag
cancer
aim
build
upon
grow
desir
chang
order
save
children
cancer
allow
other
access
better
kinder
new
drug
approach
work
support
collabor
stakehold
share
idea
identifi
solut
togeth
amplifi
voic
children
teenag
cancer
result
basic
chang
european
law
well
collabor
fund
idea
could
transform
situat
har
major
advanc
made
biolog
scienc
benefit
children
conclus
paediatr
medicin
regul
promot
research
children
ill
howev
regard
cancer
particular
live
promis
held
provid
safe
effici
medicin
specif
reform
pmr
would
ensur
everi
time
drug
compani
develop
new
treatment
adult
drug
potenti
combat
childhood
ill
evalu
altern
fund
model
also
explor
would
signific
impact
health
young
peopl
gener
particular
would
benefit
cancer
l
vasquez
r
e
nation
hospit
pediatr
oncolog
lima
peru
institut
neoplast
diseas
pediatr
oncolog
lima
peru
backgroundobject
abandon
major
caus
treatment
failur
poor
surviv
children
cancer
low
middl
incom
countri
although
countri
well
document
aim
studi
examin
preval
associ
factor
treatment
abandon
pediatr
patient
cancer
designmethod
analyz
clinic
data
two
major
institut
peru
childhood
cancer
definit
treatment
abandon
use
siop
intern
societi
paediatr
oncolog
podc
paediatr
oncolog
develop
countri
abandon
treatment
work
group
recommend
result
total
children
diagnos
malign
solid
tumor
retrospect
review
abandon
treatment
univari
logist
regress
analysi
show
signific
higher
abandon
rate
children
live
southern
p
eastern
citi
peru
prolong
travel
time
tertiari
center
hour
p
rural
set
p
lack
parent
formal
job
p
accord
cancer
diagnosi
children
retinoblastoma
abandon
rate
p
compar
solid
tumor
trend
decreas
abandon
rate
time
multivari
regress
analys
rural
origin
lack
formal
parent
employ
independ
predict
abandon
conclus
treatment
abandon
preval
countri
high
close
relat
factor
outcom
could
substanti
improv
strategi
help
prevent
abandon
therapi
base
result
c
wong
p
l
l
k
c
children
cancer
blood
disord
center
pediatr
oncolog
boston
usa
jude
children
research
hospit
global
pediatr
medicin
memphi
usa
backgroundobject
consensu
lack
priorit
collect
monitor
benchmark
pediatr
oncolog
po
qualiti
care
qoc
indic
distinct
resourc
set
measur
indic
shift
illustr
capac
reflect
perform
cancer
care
deliveri
need
assess
identifi
gap
improv
qoc
object
develop
pilot
consensu
po
indic
measur
qoc
countri
designmethod
systemat
grey
literatur
review
gener
potenti
indic
multidisciplinari
group
expert
reach
consensu
modifi
delphi
process
indic
rate
two
consecut
round
use
likert
scale
survey
agre
disagre
base
import
feasibl
po
set
round
particip
individu
categor
indic
applic
one
four
tier
rang
basic
advanc
rank
number
top
percentil
indic
tier
round
roundtabl
discuss
review
result
modif
indic
follow
round
consensu
reach
upon
agreement
median
consecut
round
result
initi
consensu
reach
top
indic
tier
tier
respect
indic
address
rang
domain
includ
safeti
support
care
treatment
abandon
surviv
four
indic
repres
across
tier
relat
proport
patient
document
treatment
plan
avail
provid
compliant
provid
patient
treat
accord
standard
treatment
plan
monitor
outcom
year
surviv
rate
conclus
pilot
led
consensu
po
qoc
indic
set
vari
across
tier
base
resourc
avail
valid
indic
larger
group
expert
develop
measur
strategi
follow
n
alexand
j
n
f
sick
children
pediatr
hematolog
oncolog
toronto
canada
sick
children
inform
servic
toronto
canada
backgroundobject
scan
appropri
journal
relev
articl
stay
updat
interpret
impact
new
research
challeng
expand
field
pediatr
hematolog
oncolog
follow
pilot
journal
review
initi
fellow
particip
screen
apprais
relev
articl
journal
write
summari
issu
year
onlin
expans
propos
broaden
educ
opportun
particip
facilit
interact
discuss
aim
creat
open
access
onlin
interact
learn
resourc
relev
current
literatur
pediatr
hematolog
oncolog
facilit
practic
journal
screen
summar
critic
apprais
hypothes
particip
bestbit
initi
improv
journal
read
habit
screen
journal
critic
apprais
journal
articl
conveni
way
keep
date
new
literatur
designmethod
need
assess
sent
pediatr
hematolog
oncolog
fellow
staff
across
canada
invit
regist
onlin
particip
journal
review
learn
activ
follow
initi
design
develop
wwwbestbitsca
first
phase
initi
launch
schedul
journal
review
develop
assign
journal
review
relev
articl
read
apprais
select
use
standard
framework
summari
interpret
submit
onlin
extens
editori
review
journal
review
post
onlin
result
onlin
particip
survey
editori
review
websit
statist
use
evalu
particip
provid
feedback
learn
activ
process
analyz
number
hour
articl
read
proport
articl
read
complet
stay
updat
particip
conclus
stay
updat
pediatr
hematolog
oncolog
literatur
challeng
creat
open
access
relev
resourc
may
use
practition
promot
journal
read
critic
apprais
develop
involv
interact
virtual
journal
club
educ
activ
e
ishigami
n
j
j
g
p
k
e
r
children
hospit
cancer
hematolog
center
houston
usa
colleg
medicin
pediatr
houston
usa
colleg
medicin
children
pediatr
kampala
uganda
backgroundobject
estim
children
develop
cancer
annual
train
pediatr
hematologyoncolog
pho
expert
provid
care
africa
ssa
major
die
sustain
improv
qualiti
care
ssa
texa
children
cancer
hematolog
center
txch
baylor
colleg
medicin
intern
pediatr
aid
initi
bipai
partner
ministri
health
republ
uganda
ugandan
partner
creat
east
africa
pediatr
hematolog
oncolog
train
eaphot
fellowship
designmethod
goal
eaphot
fellowship
increas
pho
expert
number
east
africa
two
year
curriculum
includ
didact
supervis
clinic
experi
program
direct
txch
faculti
uganda
compliment
rotat
txch
faculti
curriculum
includ
onlin
lectur
togeth
electron
track
fellow
progress
weekli
tumor
board
txch
faculti
leadership
seminar
access
texa
medic
center
librari
fellow
util
txch
global
consult
system
immedi
help
difficult
case
second
year
fellowship
focus
clinic
qualiti
improv
research
result
march
total
fellow
uganda
tanzania
kenya
enrol
pho
fellowship
program
onlin
lectur
system
well
receiv
fellow
access
didact
lectur
time
fellow
spend
hour
weekli
review
lectur
posit
evalu
faculti
lectur
overal
fellowship
effect
receiv
eaphot
program
model
adopt
makerer
univers
colleg
health
scienc
kampala
uganda
cancer
institut
develop
train
program
conclus
program
track
train
build
critic
mass
pho
specialist
east
africa
region
similar
program
plan
botswana
train
pediatr
southern
africa
region
k
n
r
e
children
hospit
pediatr
houston
usa
colleg
medicin
pediatr
houston
usa
children
hospit
cancer
hematolog
houston
usa
backgroundobject
effort
improv
outcom
children
cancer
blood
disord
develop
countri
texa
children
cancer
hematolog
center
global
hope
hematolog
oncolog
pediatr
excel
program
aim
build
capac
strengthen
healthcar
infrastructur
africa
ssa
activ
requir
signific
invest
money
expertis
resourc
given
level
invest
need
strong
busi
manag
critic
overal
success
effort
designmethod
method
busi
manag
vari
set
within
ssa
western
partner
challeng
includ
work
bureaucrat
govern
healthcar
system
understand
differ
exist
busi
practic
regul
vari
necessari
focu
achiev
highest
level
practic
possibl
end
approach
understand
local
practic
regul
identifi
differ
work
local
leadership
strengthen
practic
need
exampl
strategi
includ
facil
plan
mainten
financi
manag
monitor
evalu
system
e
inform
system
manag
gener
oper
manag
accomplish
creat
implement
standard
oper
procedur
sop
mean
clarifi
process
role
respons
increas
transpar
busi
oper
result
process
develop
sop
prove
help
obtain
stakehold
input
support
revis
new
process
adjust
exist
process
prove
challeng
imposs
date
outcom
includ
improv
financi
report
manag
capabilti
increas
confid
program
stakehold
thu
increas
program
fundabl
sustain
addit
advanc
data
collect
manag
report
e
accomplish
add
breadth
depth
inform
program
report
conclus
good
busi
practic
view
requir
global
health
program
ensur
program
success
sustain
e
ishigami
n
l
c
k
children
hospit
pediatr
houston
usa
colleg
medicin
pediatr
houston
usa
backgroundobject
grant
fund
play
signific
role
fund
global
health
center
quit
success
obtain
grant
fund
texa
children
cancer
hematolog
center
txch
mani
year
experi
tradit
us
base
grant
manag
experi
proven
help
support
rapidli
expand
global
hope
pediatr
excel
program
uniqu
challeng
requir
adapt
approach
grant
manag
global
set
designmethod
new
challeng
includ
complex
collabor
across
countri
difficulti
commun
differ
grant
manag
financ
cash
procur
process
pace
regulatori
process
lack
resourc
global
site
challeng
make
difficult
princip
investig
accomplish
project
spend
grant
fund
plan
exampl
execut
us
institut
global
institut
difficult
obtain
challeng
implement
due
reimburs
base
cash
flow
practic
better
manag
portfolio
global
grant
txch
form
work
group
represent
administr
research
leadership
postaward
staff
pi
key
stakehold
review
new
grant
opportun
monitor
progress
award
grant
result
work
team
serv
overcom
mani
challeng
make
grant
fund
difficult
spend
exampl
clearer
commun
pi
grant
manag
help
overcom
roadblock
subaward
rebudget
report
dedic
postaward
staff
increas
project
familiar
thu
improv
respons
time
increas
team
moral
key
realiz
need
increas
support
pi
global
project
due
oper
challeng
face
global
set
conclus
strong
grant
manag
vital
success
global
health
program
grant
manag
oper
support
need
meet
uniqu
challeng
n
kagoro
e
p
j
j
g
k
e
colleg
medicin
pediatr
houston
usa
children
hospit
pediatr
houston
usa
backgroundobject
dire
lack
specialist
pediatr
oncolog
africa
literatur
show
signific
number
physician
migrat
countri
obtain
specialist
clinic
train
return
east
africa
pho
fellowship
develop
uganda
build
critic
mass
pho
specialist
uganda
east
africa
region
formal
train
accredit
goal
program
develop
pho
fellowship
curriculum
local
limit
set
low
cost
ensur
program
sustain
address
lack
local
pho
expertis
reduc
cost
send
fellow
us
base
institut
train
integr
onlin
didact
platform
pho
fellowship
onlin
train
compris
record
lectur
texa
children
cancer
hematolog
center
txch
baylor
colleg
medicin
bcm
exepert
access
blackboard
designmethod
committe
african
expertis
compris
pediatr
oncologist
hematologist
psychosociologist
creat
spearhead
process
format
review
adapt
lectur
content
local
set
txch
pho
specialist
invit
creat
lectur
cover
curriculum
topic
edit
review
approv
committe
approv
pho
specialist
voic
record
lectur
upload
interact
tool
onto
blackboard
result
faculti
member
txchbcm
record
present
upload
part
curriculum
fellow
subsequ
expos
numer
pho
specialti
addit
requir
faculti
member
travel
uganda
present
program
save
annual
expenditur
usd
conclus
content
lectur
period
updat
ensur
remain
relev
furthermor
end
two
year
fellowship
fellow
particip
exit
survey
order
attain
feedback
experi
lectur
cours
mishra
r
g
pediatr
surgic
oncolog
rajiv
gandhi
cancer
institut
research
centr
delhi
india
plastic
reconstruct
surgeri
rajiv
gandhi
cancer
institut
research
centr
delhi
india
surgic
oncolog
rajiv
gandhi
cancer
institut
research
centr
delhi
india
pediatr
hematolog
oncolog
rajiv
gandhi
cancer
institut
research
centr
delhi
india
background
ewe
sarcoma
es
head
neck
rare
compris
case
jaw
lesion
present
distinct
surgic
challeng
due
cosmet
inadequaci
function
impair
wish
present
child
es
mandibl
success
manag
resect
free
fibular
flap
reconstruct
design
method
retrospect
review
hospit
record
result
left
jaw
swell
month
workup
confirm
local
es
left
mandibl
midlin
cycl
chemotherapi
vaci
partial
respons
sinc
radiat
pose
higher
long
term
complic
parent
chose
surgeri
underw
segment
resect
left
mandibl
includ
teeth
left
lower
jaw
right
premolar
preserv
left
angl
mandibl
reveal
clear
margin
reconstruct
done
plastic
reconstruct
surgeon
use
free
fibular
flap
harvest
vascular
fibula
remodel
osteotomi
accur
measur
calcul
give
exact
shape
excis
mandibl
fixat
screw
plate
allow
growth
potenti
vascular
anastomosi
perform
use
sutur
tracheostomi
done
prevent
airway
obstruct
surgeri
requir
blood
transfus
elect
ventil
hour
recov
smoothli
tracheostomi
tube
remov
day
free
flap
healthi
histopatholog
show
necrosi
huvo
grade
neg
margin
henc
radiat
avoid
cosmet
appear
excel
soft
diet
resum
one
month
chemotherapi
restart
child
well
month
surgeri
await
dental
implant
discuss
free
fibular
flap
reconstruct
es
mandibl
give
excel
cosmet
function
result
thorough
literatur
search
reveal
report
children
younger
year
long
term
follow
puberti
recommend
growth
discrep
may
need
distract
osteotomi
r
chennamaneni
l
institut
medic
scienc
medic
oncolog
hyderabad
india
backgroundobject
acut
lymphoblast
leukaemia
common
childhood
cancer
account
respectivelywith
recent
advanc
therapi
support
care
surviv
rate
improv
dramat
still
lower
develop
countri
compar
develop
countriesin
present
studi
analyz
outcom
pediatr
institut
designmethod
singl
centr
retrospect
studypati
diagnosi
age
year
present
januari
decemb
institut
evalu
result
total
patient
analyzedth
median
age
present
year
male
femal
ratio
median
hemoglobin
leukocyt
count
platelet
count
seen
patient
respect
evalu
cytogenet
present
patient
high
risk
cytogeneticstreat
protocol
use
complet
respons
partial
respons
induct
failur
seen
patient
respectivelyth
baselin
characterist
compar
among
group
except
higher
median
leukocyt
count
surviv
ef
overal
surviv
os
entir
studi
popul
respectivelyth
ef
os
respectivelyon
univari
analysi
male
sex
organomegali
leukocyt
count
lakh
lack
respons
signific
impact
ef
os
ef
respect
os
respect
age
lymphadenopathi
mediastin
mass
lineag
vs
signific
impacthigh
risk
cytogenet
signific
impact
ef
os
ef
conclus
constitut
major
studi
male
sex
organomegali
lakh
leukocyt
count
lack
respons
signific
impact
ef
os
indic
long
way
go
term
achiev
outcom
equival
western
publish
literatur
r
parasol
g
f
n
g
g
hospit
pediatr
napoli
itali
hospit
depart
neurosci
napoli
itali
hospit
paediatr
neuroradiolog
unit
napoli
itali
backgroundobject
central
nervou
system
cn
frequent
site
relaps
pediatr
acut
lymphoblast
leukemia
tripl
intrathec
therapi
tit
cytarabin
methotrex
prednison
mainstay
therapi
cn
relaps
howev
tit
may
provok
signific
toxic
cn
describ
case
child
earli
isol
cn
relaps
show
massiv
leukoencephalopathi
first
tit
designmethod
therapi
discontinu
diseas
restag
diagnost
lumbar
punctur
show
turbid
cerebrospin
fluid
csf
pleocytosi
cellsul
cytospin
confirm
presenc
blast
patient
show
neg
physic
neurolog
examin
normal
blood
count
suddenli
tit
perform
reduc
abnorm
liquor
pleocytosi
prevent
toxic
tumor
lysi
syndrom
patient
receiv
hydrat
allopurinol
desamethason
acetazolamid
seizur
prophylaxi
levetiracetam
hour
patient
show
hyperthens
skin
rash
hallucin
hypothonia
lower
limb
complet
paralisi
leg
brain
reson
mri
show
diffus
hyperintens
white
matter
particularli
subcort
cerebellar
area
optic
chiasm
brainstem
sequenc
pattern
interpret
grade
iv
leukoencephalopathi
child
transfer
intens
care
unit
due
respiratori
distress
requir
intub
diagnost
lumbar
punctur
perform
follow
day
show
csf
neg
result
patient
persist
deep
coma
day
restart
spontan
breath
wake
show
rapid
neurolog
amelior
system
chemotherapi
mtx
restart
without
addit
neurotox
dosag
interleukin
level
csf
ongo
conclus
sever
rapid
event
onset
associ
quickli
csf
remiss
suggest
neurotox
could
relat
cytokin
releas
syndrom
due
massiv
blast
lysi
rather
direct
drug
damag
cn
csf
dose
could
clarifi
pathogenesi
event
ph
hung
h
vu
central
hospit
pediatr
center
hue
vietnam
central
hospit
pediatr
center
vietnam
vietnam
backgroundobject
adequ
nutrit
one
compon
support
palli
care
play
import
role
success
childhood
cancer
treatment
howev
issu
paid
much
attent
vietnam
purpos
studi
assess
nutrit
statu
dietari
intak
children
cancer
knowledg
practic
children
care
mother
feed
children
designmethod
cross
section
studi
conduct
children
cancer
age
month
year
children
measur
weight
height
food
intak
data
taken
mother
interview
feed
knowledg
practic
result
result
show
malnutrit
account
height
energi
consumpt
less
energi
need
age
diseas
protein
energi
consumpt
rate
account
dietari
intak
milk
beef
egg
conclus
nutrit
import
part
health
children
especi
import
children
get
cancer
treatment
center
malnutrit
height
children
cancer
center
high
nutrit
knowledg
practic
childhood
cancer
care
feed
mother
quit
poor
order
improv
situat
provid
educ
nutrit
mother
need
ibragimova
hematolog
blood
transfus
children
tashkent
uzbekistan
backgroundobject
accord
author
optim
therapeut
approach
acut
biphenotyp
leukemia
may
includ
aggress
chemotherapi
stem
cell
transplant
support
seriou
research
paper
assess
effect
chemotherapi
protocol
methotrex
treatment
acut
biphenotyp
leukemia
designmethod
patient
biphenotyp
acut
leukemia
averag
age
patient
ratio
gender
male
femal
immunolog
studi
bone
marrow
patient
blast
cell
linearli
mix
immunophenotyp
b
myelo
morpholog
cytochem
featur
blast
cell
refer
lymphoblast
initi
data
patient
spleen
less
cm
initi
leukocyt
count
thousand
one
patient
bcr
abl
bcr
abl
pcr
day
induct
receiv
addit
imatinib
daili
insid
result
patient
acut
leukemia
treat
children
depart
research
institut
hematolog
uzbekistan
period
patient
diagnos
acut
biphenotyp
leukemia
treat
induct
regimen
earli
respons
day
treatment
patient
ascertain
patient
went
clinic
remiss
induct
cours
induct
patient
sever
sepsi
bronchopneumonia
day
patient
achiev
clinic
remiss
patient
receiv
consolid
chemotherapi
accord
plan
group
low
dose
mtx
intramuscularli
weekli
addit
lumbar
punctur
three
cytotox
drug
median
month
surviv
overal
surviv
estim
conclus
chemotherapi
regimen
shown
high
efficaci
signific
reduct
toxic
use
protocol
enabl
outpati
treatment
z
kanakkand
kandi
hospit
pediatr
hematolog
ooncolog
abu
dhabi
unit
arab
emir
backgroundobject
publish
literatur
gc
children
scant
comprehens
review
publish
literatur
conduct
understand
current
outcom
childhood
gc
designmethod
search
medlin
embas
use
keyword
leukemia
child
gulf
countri
carri
studi
report
outcom
surviv
relat
publish
includ
result
search
compar
merg
refer
list
includ
studi
search
identifi
elig
studi
result
number
studi
publish
scarc
studi
identifi
singl
centr
studi
multicentr
studi
gc
met
inclus
criteria
total
children
childrenstudi
median
age
present
year
major
studi
minimum
residu
diseas
mrd
use
major
case
treatment
consist
chemotherapi
consider
variat
chemotherapi
use
among
differ
canter
differ
chemotherapi
use
commonli
often
without
minim
residu
diseas
mrd
base
risk
stratif
one
multicent
studi
publish
yet
median
overal
surviv
os
rang
event
free
surviv
ef
rang
report
rate
abandon
limit
data
side
effect
also
limit
conclus
surviv
outcom
children
gc
encourag
lack
public
mani
center
make
difficult
understand
current
practic
outcom
mani
center
recommend
co
ordin
multicentr
approach
collabor
western
center
treat
analyz
experi
address
sever
question
role
children
cancer
registri
entir
gulf
countri
effect
use
highli
recommend
khattab
e
g
z
h
n
salman
arm
forc
hospit
princ
sultan
oncolog
tabuk
saudi
arabia
masheet
arm
forc
hospit
oncolog
abha
saudi
arabia
salman
arm
forc
hospit
oncolog
tabuk
saudi
arabia
salman
arm
forc
hospit
pediatr
tabuk
saudi
arabia
cancer
hospit
oncolog
tanta
egypt
backgroundobject
childhood
acut
lymphoblast
leukemia
cure
rate
reach
progress
result
combin
chemotherapi
central
nervou
system
prevent
therapi
mainten
chemotherapi
cytogenet
immunophenotyp
earli
treatment
respons
refin
risk
categor
center
use
children
cancer
group
ccg
regimen
object
find
relaps
time
site
surviv
percentag
relaps
case
assess
event
free
surviv
ef
overal
surviv
os
death
caus
designmethod
januari
decemb
children
collect
bone
marrow
bm
immunophenotyp
cytogenet
data
gather
cerebrospin
fluid
csf
earli
treatment
respons
minim
residu
diseas
mrd
collect
relaps
time
site
determin
well
ef
os
result
patient
age
rang
year
median
year
immunophenotyp
unknown
csf
posit
cytogenet
normal
hyperdiploidi
one
mll
runx
telaml
earli
respons
therapi
avail
rapid
earli
respons
slow
earli
respons
posit
mrd
neg
chemotherapi
base
ccg
regimen
relaps
incid
earli
combin
isol
bm
surviv
earli
relaps
bm
combin
cn
surviv
late
relaps
bm
combin
cn
surviv
surviv
relaps
case
allogen
stem
cell
transplant
sct
await
sct
cure
chemotherapi
ef
os
death
caus
refractori
toxic
death
secondari
neoplasm
year
glioblastoma
multiform
die
car
accid
conclus
ccg
chemotherapi
regimen
appli
risk
stratif
would
favor
outcom
k
lee
j
j
e
j
nation
univers
pediatr
daegu
republ
korea
cathol
univers
medic
center
pediatr
daegu
republ
korea
backgroundobject
chromosom
abnorm
found
leukemia
solid
tumor
sinc
nowel
hungerford
discov
first
review
result
cytogenet
studi
year
cytogenet
studi
done
variou
sampl
peripher
blood
clinic
diagnosi
chromosom
abnorm
patient
reproduct
problem
amniot
fluid
cadav
genet
counsel
prenat
diagnosi
peripher
blood
bone
marrow
andor
tumor
mass
cancer
patient
pediatr
cytogenet
laboratori
kyungpook
nation
univers
hospit
daegu
republ
korea
designmethod
type
cancer
variou
cancer
patient
sampl
collect
diagnosi
remiss
relaps
mitogen
appli
cancer
cytogenet
studi
stain
band
appli
chromosom
prepar
chromosom
studi
done
case
data
analyz
exclud
case
cell
growth
date
sampl
peripher
blood
amniot
fluid
chorion
villi
bone
marrow
bm
tissu
case
annual
number
examin
recent
year
result
male
femal
ratio
mean
age
yo
yo
bm
sampl
cancer
patient
numer
aberr
found
case
hypodiploidi
hyperdiploidi
hypotriploidi
hypertriploidi
hypotetraploidi
hypertetraploidi
structur
abnorm
found
philadelphia
chromosom
partial
trisomi
monosomi
philadelphia
chromosom
found
two
childhood
cml
patient
conclus
cell
cultur
studi
realiz
certain
factor
caus
chromosom
abnorm
mitosi
perhap
prophas
cytogenet
studi
cancer
patient
conveni
essenti
tool
diagnosi
process
remiss
relaps
classic
sinc
v
nwatah
n
e
hospit
abuja
depart
paediatr
abuja
nigeria
hospit
abuja
depart
hematolog
abuja
nigeria
backgroundobject
acut
leukemia
common
childhood
malign
occurr
low
middl
incom
countri
pattern
present
vari
depend
sever
factor
object
report
determin
pattern
present
acut
leukemia
children
tertiari
hospit
nigeria
designmethod
retrospect
studi
children
manag
acut
leukemia
paediatr
depart
year
period
patient
adequ
record
review
data
collect
includ
patient
demograph
clinic
featur
treatment
outcom
result
male
femal
age
month
year
mean
year
sd
middl
class
predomin
statu
caregiv
percent
patient
refer
tertiari
health
centr
secondari
health
centr
pattern
clinic
featur
fever
pallor
splenomegali
specif
leukemia
type
ratio
acut
myeloid
leukemia
aml
acut
lymphoblast
leukemia
parent
three
patient
took
children
away
commenc
treatment
one
patient
complet
treatment
die
complet
treatment
nearli
half
patient
lost
follow
seek
altern
care
patient
remiss
last
follow
lost
found
significantli
associ
socioeconom
statu
age
sex
respect
conclus
acut
lymphoblast
leukemia
remain
predomin
type
childhood
leukemia
set
major
patient
present
fever
pallor
moreov
default
plagu
treatment
complet
e
n
e
stiakaki
univers
hospit
heraklion
pediatr
heraklion
crete
greec
gener
hospit
blood
transfus
center
heraklion
crete
greec
backgroundobject
acut
lymphoblast
leukemia
commonest
childhood
malign
mani
case
present
musculoskelet
manifest
bone
lession
also
manifest
treatment
complic
pathogenesi
bone
disord
children
clarifi
thoroughli
far
recent
biolog
bone
metabol
studi
extens
new
molecul
identifi
osteoprotogerin
opg
protein
inhibit
loss
bone
protein
ranklrank
osteoclast
activ
molecul
dickkopf
solubl
inhibitor
osteoblast
activ
pathway
studi
opg
ranklrank
system
childhood
designmethod
forti
patient
boy
age
year
old
mean
age
year
lineag
studi
patient
receiv
treatment
accord
current
protocol
risk
stratif
group
median
high
risk
three
relaps
serum
valu
opg
rankl
determin
diagnosi
end
treatment
statist
analysi
made
use
pair
result
statist
signific
decreas
osteoprotogerin
valu
estim
end
treatment
compar
level
diagnosi
rankl
valu
determin
increas
end
treatment
compar
diagnosi
without
statist
signifig
although
bone
manifest
diagnosi
treatment
document
patient
statist
signific
differ
opg
rankl
valu
children
without
bone
manifest
conclus
accord
preliminari
result
signific
decreas
opg
valu
estim
diagnosi
treatment
completionth
precis
role
opg
ranklrank
childhood
need
investig
yl
tang
lb
c
xj
xq
first
affili
hospit
sun
univers
depart
pediatr
guangzhou
china
backgroundobject
acut
lymphoblast
leukemia
common
pediatr
malign
treatment
effect
earli
recurr
bad
need
identifi
mirna
predict
risk
earli
relaps
pediatr
patient
designmethod
use
analysi
three
diagnost
bone
marrow
sampl
three
earli
relaps
bone
marrow
sampl
determin
mirna
express
profil
associ
earli
relaps
six
mirna
select
confirm
perform
real
time
quantit
pcr
diagnost
sampl
ten
earli
relaps
sampl
apoptosi
prolifer
analyz
use
sirna
transfect
mt
assay
western
blot
flow
cytometri
result
result
demonstr
earli
relaps
sampl
compar
diagnost
sampl
promot
cell
prolifer
suppress
cell
apoptosi
neg
regul
express
tumor
box
cell
remark
inhibit
express
downstream
target
bim
meanwhil
knockdown
induc
express
downstream
target
furthermor
inhibit
cell
prolifer
induc
cell
apoptosi
promot
express
bim
cell
conclus
result
provid
possibl
underli
molecular
mechan
explain
associ
earli
relaps
pediatr
suggest
approach
inhibit
express
induc
express
may
offer
promis
therapeut
strategi
earli
relaps
treatment
khvedelidz
central
hospit
hematologyoncolog
tbilisi
georgia
backgroundobject
children
syndrom
ds
higher
risk
develop
acut
lymphoblast
leukemia
acut
myeloid
leukemia
despit
higher
treatment
relat
toxic
therapi
syndrom
relat
childhood
acut
leukemia
wide
appreci
across
mani
clinic
trial
designmethod
clinic
record
children
syndrom
associ
acut
leukemia
admit
last
year
retrospect
analyz
patient
treat
iashvili
children
central
hospit
depart
hematologyoncolog
facil
georgia
provid
care
children
hematolog
malign
result
children
male
femal
syndrom
admit
sinc
januari
median
age
patient
month
rang
month
three
diagnos
four
present
consid
overal
number
new
case
acut
childhood
leukemia
case
admit
hospit
sinc
syndrom
associ
acut
leukemia
account
approxim
case
despit
wide
appreci
higher
risk
develop
acut
megakaryocyt
leukemia
children
syndrom
none
analyz
case
show
morpholog
phenotyp
patient
diagnos
common
patient
treat
case
protocol
patient
good
treatment
respons
stay
diseas
free
one
patient
experienc
induct
failur
anoth
develop
bone
marrow
relaps
day
induct
patient
die
diseas
conclus
incid
syndrom
associ
acut
leukemia
childhood
georgia
compar
report
rate
countri
although
accord
data
case
outnumb
patient
also
observ
trend
higher
event
free
surviv
patient
compar
naseer
p
k
c
k
jerbai
wadia
hospit
children
depart
pediatr
mumbai
india
backgroundobject
acut
leukemia
constitut
common
childhood
cancer
worldwid
india
past
year
outcom
acut
myeloid
leukemia
aml
children
improv
substanti
limit
data
childhood
aml
india
designmethod
retrospect
analysi
patient
aml
jan
till
march
done
demograph
data
collect
cytogenet
obtain
risk
stratif
classif
induct
follow
high
dose
cytarabin
cycl
consolid
follow
year
mainten
cytarabin
remiss
relaps
rate
calcul
respect
risk
stratif
follow
data
analyz
result
patient
belong
year
male
femal
ratio
studi
includ
patient
aml
apml
patient
treat
deni
treatment
post
induct
remiss
seen
failur
post
induct
remiss
rate
mrd
respect
failur
rate
low
intermedi
high
risk
patient
none
low
risk
patient
relaps
wherea
patient
relaps
intermedi
high
risk
respect
complet
treatment
year
overal
surviv
rest
relaps
treat
patient
post
induct
death
due
sepsi
bleed
manifest
caus
hyperleukocytosi
low
surviv
rate
due
low
socioeconom
strata
poor
support
care
non
avail
bone
marrow
transplant
facil
conclus
low
risk
group
good
remiss
rate
none
relaps
yet
high
percentag
relaps
intermedi
high
risk
group
improv
overal
surviv
intermedi
high
risk
patient
risk
base
chemotherapi
optim
support
care
afford
transplant
facil
mandatori
even
low
resourc
set
sarashina
h
n
k
f
h
medic
univers
pediatr
asahikawa
japan
children
medic
center
divis
medicin
yokohama
japan
backgroundobject
noonan
syndrom
ns
rasopathi
character
facial
dysmorphi
development
disord
short
statur
wide
spectrum
heart
defect
hematolog
disord
myeloprolif
diseas
acut
lymphoid
leukemia
report
patient
ns
patient
somat
mutat
may
detect
juvenil
myelomonocyt
leukemia
jmml
pediatr
common
acut
lymphoid
leukemia
pediatr
acut
monocyt
leukemia
fab
designmethod
case
present
present
clinic
molecular
character
childhood
ns
patient
tyrosin
intern
tandem
duplic
acut
myeloid
leukemia
aml
patient
male
present
swollen
bleed
gum
enlarg
hepatomegali
splenomegali
complet
blood
count
reveal
thrombocytopenia
leukocytosi
bone
marrow
aspir
consist
monoblast
stain
nonspecif
esteras
peroxidas
diagnos
aml
moreov
genet
test
reveal
mutat
clinic
characterist
short
statur
distinct
facial
featur
mutat
detect
genet
test
noonan
syndrom
diagnos
receiv
remiss
induct
therapi
short
term
remiss
aml
relaps
mainten
therapi
underw
stem
cell
transplant
sct
die
progress
diseas
comprehens
mutat
analysi
panel
perform
use
target
sequenc
leukem
cell
onset
result
case
mll
partial
tandem
duplic
mutat
identifi
analysi
conclus
aml
ns
extrem
rare
case
discuss
patient
ns
result
genet
analysi
leukem
cell
l
b
ahm
b
k
b
h
emir
abdelkad
hematologyoncolog
oran
algeria
de
de
doran
biostatistiqu
oran
albania
medical
infantil
saint
theres
hematologyoncolog
annaba
algeria
de
de
doran
biostatistiqu
oran
algeria
premier
novembr
oran
algeria
oran
biostatistiqu
oran
algeria
h
u
oran
hematolog
oran
algeria
h
u
oran
oran
algeria
background
object
summari
lymphoma
nhl
occupi
first
place
cancersin
childhood
year
frequenc
accord
statist
given
regist
cancer
algier
object
studi
describ
epidemiolog
clinic
histolog
profil
paediatr
nhlin
western
southwest
region
algeria
decad
designmethod
observ
studi
file
patient
less
year
old
hospitalis
emir
abdelkadercentr
cea
diagnosi
nhl
lmnh
defin
accord
clinic
cytolog
andor
histolog
criteria
registr
analysi
data
perform
softwar
spss
version
result
children
regist
lmnh
ten
year
peak
incid
nhlwa
observ
year
nhl
rare
age
year
abdomin
sitewa
frequent
rate
unusu
site
diseas
observ
patient
stade
iii
predomin
site
seri
lymphoblastichistolog
type
frequent
rate
follow
burkitt
type
type
conclus
nhlare
frequent
children
clinic
differ
adult
nhl
theextranod
diseas
patholog
earli
diagnosi
remain
prioriti
themanag
r
u
gonzalez
jm
de
pedro
r
adan
astigarraga
universitario
cruce
pediatr
hematolog
oncolog
unit
bilbao
spain
universitario
cruce
nuclear
medicin
servic
bilbao
spain
backgroundobject
evalu
respons
chemotherapi
ch
pediatr
patient
hodgkin
lymphoma
hl
lymphoma
nhl
decid
correct
therapeut
attitud
designmethod
retrospect
observ
studi
pediatr
hl
nhl
diagnos
tertiari
hospit
last
year
januari
result
review
patient
hl
male
nhl
burkitt
lymphoma
male
anoth
lymphoblast
lymphoma
mean
male
rest
anaplast
larg
cell
lymphoma
within
lymphocyt
predomin
half
ia
stage
resolv
exclus
surgeri
remaind
iia
stage
requir
ch
without
radiotherapi
rt
present
complet
respons
petct
remain
patient
classic
subtyp
patient
stage
ia
iia
iiia
iv
requir
ch
sinc
present
partial
morpholog
respons
complet
metabol
petct
singl
patient
stage
iv
also
requir
rt
partial
respons
patient
current
complet
remiss
rc
among
burkitt
l
requir
increas
risk
group
present
partial
respons
one
case
confirm
biopsi
current
cr
one
treatment
one
deceas
remain
three
requir
group
increas
complet
respons
ch
induct
within
patient
lymphoblast
lymphoma
anaplast
cr
one
petct
scan
use
evalu
respons
conclus
use
petct
establish
case
hl
make
decis
regard
therapeut
attitud
nevertheless
need
studi
nhl
seem
reason
presenc
partial
metabol
respons
induct
nhl
lead
increas
risk
group
n
kurucu
c
b
b
univers
faculti
medicin
depart
pedatr
oncolog
ankara
turkey
univers
faculti
medicin
depart
patholog
ankara
turkey
backgroundobject
primari
bone
lymphoma
pbl
constitut
less
lymphoma
nhl
object
studi
report
institut
experi
bone
lymphoma
period
designmethod
children
nhl
admit
pediatr
oncolog
depart
hacettep
univers
ten
children
primari
bone
lymphoma
except
fascial
bone
cranium
evalu
retrospect
result
six
male
four
femal
median
age
month
common
complaint
pain
swell
median
durat
symptom
month
common
tumor
locat
femur
tibia
two
patient
local
lymph
node
involv
two
polyoss
diseas
histopatholog
subtyp
precursor
cell
lymphoma
three
patient
anaplast
larg
cell
lymphoma
one
precursor
b
cell
lymphoma
one
unclassifi
five
patient
treat
variou
chemotherapeut
regimen
accord
histopatholog
subtyp
three
patient
receiv
radiotherapi
recurr
observ
four
patient
within
median
month
three
lost
one
die
infect
two
patient
die
diseas
progress
three
die
complic
six
patient
aliv
diseas
free
median
month
overal
event
free
surviv
rate
polyoss
diseas
shorter
overal
surviv
rate
monooss
type
vs
conclus
although
secondari
involv
bone
lymphoma
uncommon
lymphoma
origin
bone
rare
case
seen
decad
primari
bone
lymphoma
constitut
nhl
case
lymph
node
involv
polyoss
diseas
wors
prognosi
adult
multicent
studi
case
necessari
determin
prognost
factor
childhood
bone
lymphoma
c
zhang
children
hospit
surgic
pediatr
oncolog
zhengzhou
china
backgroundobject
summar
featur
children
primari
gastrointestin
lymphoma
complic
intussuscept
designmethod
patient
record
hospit
zhengzhou
retriev
case
whose
initi
diagnosi
intussuscept
discharg
diagnosi
includ
lymphomaclin
data
patient
primari
gastrointestin
lymphoma
complic
intussuscept
extens
treat
depart
januari
decemb
retrospect
analyz
result
patient
pgil
present
intussuscept
initi
age
case
intussuscept
appear
repeatedli
case
case
patient
receiv
surgic
treatment
among
abnorm
lump
found
intussusceptum
case
local
intestin
wall
thicken
rigid
case
suspici
focal
necrosi
around
rigid
wallloc
resect
perform
success
case
without
postop
complic
intestin
obstruct
anastomot
leakag
stricturepatholog
examin
reveal
case
diffus
larg
lymphoma
lymphoma
case
classifi
tumor
stage
remain
case
stage
case
treat
chemotherapi
given
treatment
die
month
operationdur
median
period
month
tumor
recurr
found
case
conclus
children
recurr
intussuscept
episod
atyp
age
pgil
concernedabnorm
mass
intestin
wall
intestin
wall
stiff
leather
mesenter
mass
resect
patholog
examin
earli
postop
chemotherapi
provid
children
pgil
good
prognosi
v
h
j
hope
comprehens
cancer
center
pediatr
hematologyoncolog
hematopoiet
stem
cell
transplant
ca
usa
children
hospit
pediatr
hematologyoncolog
ca
usa
hope
alpha
clinic
hematologyoncolog
cell
therapeut
ca
usa
hospit
medic
center
intern
medicin
mi
usa
backgroundobject
congenit
dyserythropoiet
anemia
cda
group
rare
anemia
disord
bone
marrow
dyserythropoiesi
secondari
hemochromatosi
cda
classifi
three
major
type
ii
iii
base
bone
marrow
morpholog
genet
mutat
inherit
pattern
allogen
hematopoiet
stem
cell
transplant
hsct
cure
cda
report
case
use
sibl
match
unrel
donor
designmethod
case
report
result
report
male
cda
requir
monthli
blood
transfus
deferasirox
refer
center
hsct
evalu
due
lack
sibl
match
unrel
donor
decis
made
proceed
haploident
hsct
father
condit
regimen
consist
antithymocyt
globulin
busulfan
fludarabin
cyclophosphamid
ptci
follow
unev
infus
mobil
hematopoiet
stem
cell
tacrolimu
use
prevent
diseas
gvhd
myeloid
platelet
engraft
record
day
day
respect
patient
toler
treatment
well
minim
advers
effect
evalu
bone
marrow
day
show
marrow
mild
erythrocyt
hyperplasia
adequ
granulopoiesi
treatment
cours
experienc
episod
infect
mild
mild
resolv
one
year
peripher
count
reveal
wbc
hemoglobin
hematocrit
platelet
patient
condit
remain
stabl
remain
transfus
free
resum
normal
childhood
happili
attend
school
conclus
cda
rare
disord
pauciti
data
regard
manag
hsct
cure
avail
today
experi
show
haploident
donor
good
altern
sibl
match
unrel
donor
unavail
advanc
condit
regimen
use
ptci
suggest
haploident
hsct
could
option
cda
treatment
futur
kohli
n
r
phobmt
gurgaon
india
phobmt
gurugram
india
backgroundobject
haploident
stem
cell
transplant
sct
deplet
graft
report
patient
neuroblastoma
wherea
cell
replet
graft
cyclophosphamid
ptci
rare
report
treatment
relapsedrefractori
solid
tumour
need
evalu
vo
unavail
donor
cost
issu
develop
countri
assococi
cell
deplet
graftsw
evalu
patient
refractori
solid
tumour
designmethod
six
patient
refractori
solid
tumour
evalu
prospect
patient
neuroblastoma
stage
diseas
post
relaps
fifth
patient
ewe
sarcoma
cn
skelet
relaps
bone
marrow
involv
sixth
patient
retinoblastoma
hepat
skelet
relaps
patient
complet
remiss
sct
except
two
neuroblastoma
partial
remiss
patient
neuroblastoma
receiv
mibg
bortezomib
base
chemotherapi
transplant
condit
patient
receiv
fludarabin
flu
cyclophosphamid
cy
total
bodi
irradi
tbi
except
one
patient
neuroblastoma
receiv
melphalan
fluci
patient
receiv
ptci
part
gvhd
prophylaxi
result
post
sct
one
patient
neuroblastoma
die
due
diseas
die
due
progress
cn
diseas
third
patient
complet
remiss
grade
chronic
liver
gvhd
treatment
month
fourth
patient
neuroblastoma
relaps
month
palli
chemotherapi
wrist
protocol
year
post
transplant
patient
ewe
sarcoma
complet
remiss
day
post
hsct
chronic
gvhd
skin
treatment
sixth
patient
retinoblastoma
short
followup
neutrophil
engraft
day
conclus
haploident
sct
ptci
seem
feasibl
efficaci
treatment
refractori
solid
tumour
need
evalu
long
term
outcom
ramzan
hospit
pediatr
hematolog
oncolog
bmt
jaipur
india
backgroundobject
anemia
dba
rare
congenit
hypoplast
anemia
usual
present
infanc
childhood
cur
therapi
dba
haematopoiet
stem
cell
transplant
hsct
publish
case
use
match
relat
unrel
donor
hsct
myeloabl
condit
regimen
designmethod
haploident
hsct
dba
scarc
mention
literatur
report
year
old
girl
diagnos
dba
age
month
steroid
refractori
chronic
transfus
therapi
result
view
suitabl
donor
underw
haploident
mismatch
relat
cell
replet
pbsc
hsct
abo
compat
father
util
myeloabl
condit
regimen
includ
intraven
busulfan
total
dose
fludarabin
total
dose
thiotepa
rabbit
atg
mgkg
also
treat
class
ii
hla
antibodi
mean
fluoresc
index
follow
one
cycl
fludarabin
total
dose
dexamethason
prior
hsct
prevent
reject
repeat
hla
antibodi
titer
done
post
transplant
cyclophosphamid
tacrolimu
mycophenol
mofetil
use
gvhd
prophylaxi
total
stem
cell
dose
x
recipi
neutrophil
engraft
day
full
donor
chimer
post
hsct
steroid
refractori
grade
iii
acut
gut
gvhd
non
respons
adequ
dose
etanercept
mesenchym
stem
cell
basiliximab
infliximab
eventu
respond
equin
atg
oral
methotrex
immunosuppress
wean
slowli
month
follow
full
donor
chimer
hemoglobin
reticulocyt
almost
complet
immun
reconstitut
hematopoiet
stem
cell
conclus
haploident
hsct
repres
effect
option
cure
patient
dba
ahmad
n
fs
children
hospit
institut
child
health
lahor
paediatr
haematologyoncolog
lahor
pakistan
backgroundobject
oncolog
depart
children
hospit
lahor
bed
unit
provid
treatment
new
childhood
cancer
case
year
admiss
per
month
bed
occup
rate
around
aim
retrospect
studi
analyz
spectrum
neuroblastoma
burden
high
risk
malign
public
sector
tertiari
center
lack
mibg
scan
amplif
stem
cell
transplant
servic
designmethod
prospect
review
patient
neuroblastoma
enrol
june
decemb
done
data
regard
age
sex
type
stage
clinic
featur
bone
bone
marrow
involv
cours
therapi
outcom
make
diagnosi
tissu
biopsi
result
total
patient
age
rang
year
median
age
yr
includ
f
ratio
case
infantil
type
stage
iii
present
stage
iv
mainli
abdomin
mass
main
present
complaint
paraplegia
nasal
polyp
neck
mediastin
involv
boni
mass
proptosi
multipl
present
travel
reach
primari
treatment
center
bone
involv
present
bone
marrow
involv
success
complet
chemotherapi
abandon
treatment
expir
due
progress
diseas
infect
put
palli
rx
present
chemotherapi
conclus
resourc
limit
set
neuroblastoma
stage
iv
challeng
malign
deal
intens
need
increas
capac
build
diagnos
treat
earli
implement
effect
infect
control
measur
better
surviv
option
patient
j
greensher
j
j
health
hofstra
northwel
school
medicin
hempstead
usa
island
jewish
medic
center
depart
patholog
transfus
medicin
new
hyde
park
usa
children
medic
center
divis
pediatr
hematolog
oncolog
stem
cell
transplant
new
hyde
park
usa
backgroundobject
opsoclonu
myoclonu
ataxia
syndrom
oma
phenomenon
affect
neuroblastoma
case
oma
chronic
cours
caus
signific
morbid
therapeut
plasma
exchang
tpe
effect
treat
neurolog
disord
present
case
paraneoplast
oma
refractori
common
treatment
resolv
tpe
designmethod
case
report
boy
achiev
complet
remiss
otherwis
refractori
oma
tpe
remiss
undergo
tpe
relaps
year
later
result
boy
present
week
chaotic
eye
movement
jerk
extrem
diminish
truncal
support
trembl
loss
motor
mileston
mass
celiac
axi
diagnos
neuroblastoma
paraneoplast
oma
two
cycl
chemotherapi
includ
carboplatin
etoposid
doxorubicin
cyclophosphamid
result
complet
cancer
remiss
oma
persist
year
oral
prednison
puls
dexamethason
monthli
intraven
immunoglobulin
ivig
cours
rituximab
cours
cyclophosphamid
year
adrenocorticotrop
hormon
sever
month
mycophenol
mofetil
trial
without
resolut
symptom
ultim
patient
achiev
rapid
remiss
initi
tpe
rituximab
monthli
ivig
follow
remiss
continu
monthli
taper
tpe
receiv
treatment
total
year
without
relaps
oma
follow
viral
ill
evid
neuroblastoma
recurr
within
month
restart
treatment
tpe
oral
prednisolon
ivig
rituximab
patient
achiev
remiss
maintain
oma
score
cours
tpe
treatment
without
taper
wean
oral
steroid
conclus
tpe
prefac
complet
remiss
oma
patient
highli
refractori
diseas
initi
relaps
import
case
demonstr
potenti
efficaci
tpe
oma
kazancev
p
r
cancer
research
center
depart
thoracoabdomin
children
oncolog
surgeri
institut
pediatr
oncolog
moscow
russia
backgroundobject
improv
result
treatment
patient
neuroblastoma
designmethod
patient
neuroblastoma
receiv
treatment
dog
research
institut
median
time
month
studi
includ
boy
girl
age
patient
rang
year
averag
age
year
patient
divid
group
depend
regimen
chemotherapyh
program
treatment
includ
induct
ht
surgic
treatment
ct
radiat
therapi
biotherapi
retino
acid
four
patient
group
receiv
complet
respons
good
partial
respons
end
phase
induct
chemotherapi
receiv
system
radiotherapi
result
effect
induct
chemotherapi
group
ii
group
bone
marrow
cleans
induct
chemotherapi
significantli
frequent
group
cours
patient
patient
group
bone
marrow
sanat
patient
ii
group
bone
marrow
sanat
reach
os
patient
stage
group
group
ii
ef
group
ii
group
found
system
radiotherapi
significantli
correl
absenc
progress
relaps
diseas
radic
surgeri
affect
prognosi
diseas
conclus
induct
ht
topotecan
use
group
show
higher
direct
efficaci
os
ef
group
higher
patient
end
induct
phase
activ
residu
tumor
tissu
determin
perform
system
radiotherapi
inc
e
r
e
h
k
n
eylul
univers
institut
oncolog
dept
pediatr
oncolog
izmir
turkey
eylul
univers
institut
oncolog
dept
basic
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
patholog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiodiagnost
izmir
turkey
eylul
univers
faculti
medicin
dept
pediatr
surgeri
izmir
turkey
backgroundobject
evalu
clinic
characterist
outcom
turkish
pediatr
oncolog
group
tpog
neuroblastoma
treatment
protocol
patient
neuroblastoma
designmethod
patient
neuroblastoma
elig
mycn
statu
investig
inss
stage
cog
risk
stratif
system
use
protocol
use
low
rg
surgeri
surgeri
plu
chemotherapi
chemotherapi
intermedi
rg
extra
chemotherapi
given
maintan
therapi
given
week
high
rg
convent
ct
high
dose
ct
asct
mainten
therapi
use
month
result
nine
one
two
patient
one
die
median
time
os
ef
rate
cr
achiev
primari
surgeryct
two
case
cr
achiev
three
patient
ctdelay
surgeri
incomplet
primari
surgeri
perform
two
patient
achiev
ctsurgeri
delay
surgeri
perform
four
irg
induct
ctsurgeri
respons
crpr
rt
perform
primari
tumor
patient
metastasi
one
median
follow
time
ef
os
incomplet
primari
surgeri
perform
patient
induct
ctsurgeri
respons
crpr
delay
surgeri
perform
radiotherapi
perform
primari
tumor
ef
nine
patient
refractori
diseas
six
system
relaps
median
relaps
time
median
follow
time
os
respect
two
patient
die
relat
asct
die
progress
conclus
neuroblastoma
treatment
standart
stage
risk
group
primari
tumor
site
found
significantli
relat
surviv
rate
surviv
rate
accept
consist
literatur
inc
e
r
h
k
eylul
univers
institut
oncolog
dept
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
patholog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiat
oncolog
izmir
turkey
eylul
univers
institut
oncolog
dept
basic
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiaodiagnost
izmir
turkey
eylul
univers
faculti
medicin
dept
pediatr
surgeri
izmir
turkey
backgroundobject
evalu
clinic
characterist
respons
treatment
patient
relapserefractori
neuroblastoma
designmethod
medic
record
patient
relapserefractori
neuroblastoma
treatment
protocol
evalu
retrospect
clinic
characterist
relaps
type
treatment
anal
result
median
age
relaps
one
patient
lowrg
highrg
patient
mycn
amplifi
patient
aber
detect
mycn
case
del
detect
one
case
shimada
unfavour
patient
tumor
local
surren
paraspin
midlin
metastasi
site
bone
bone
marrow
lymph
node
lung
cn
patient
refractori
diseas
patient
system
relaps
one
patient
primari
relaps
median
relaps
time
median
progress
time
refractori
patient
averag
cours
cours
tcv
topotecan
cyclophosspamid
vincristin
given
patient
three
cours
ice
given
patient
topotecan
temozolamid
metronom
treatment
given
one
patient
high
dose
chemotharapyasct
perform
total
patient
seven
receiv
tcv
receiv
ice
remiss
achiev
nine
patient
despit
hdctasct
tcv
ice
metronom
therapi
rist
protocol
temozolomid
given
case
remain
two
patient
die
four
refractori
case
without
asct
histori
receiv
tcv
ice
vinorelbinetemozolamid
treatment
also
tcv
ice
rist
protocol
metronom
oral
cyclophospamideetoposid
given
line
relaps
treatment
median
os
relaps
patient
nine
patient
follow
year
conclus
patient
relaps
neuroblastoma
advanc
stage
diseas
unfavour
histolog
mycn
amplif
progress
free
surviv
time
prolong
year
relapserefractori
neuroblastoma
behav
chronic
diseas
differ
multipl
treatment
strategi
q
vu
n
l
h
c
n
n
h
l
v
h
children
hospit
human
genet
depart
hanoi
vietnam
children
hospit
oncolog
depart
hanoi
vietnam
children
hospit
surgeri
depart
hanoi
vietnam
children
hospit
radiolog
depart
hanoi
vietnam
children
hospit
patholog
depart
hanoi
vietnam
intern
hospit
oncolog
depart
hanoi
vietnam
univers
hanoi
nation
univers
genet
depart
hanoi
vietnam
children
hospit
emerg
depart
hanoi
vietnam
backgroundobject
neuroblastoma
popular
pediatr
solid
tumor
first
year
treatment
base
risk
stratif
vietnam
focu
treatment
risk
patient
studi
neuroblastoma
patient
year
evalu
result
treatment
follow
siopel
protocol
designmethod
patient
classifi
risk
group
use
inrg
classif
treat
follow
siopel
protocol
follow
patient
month
treatment
collect
inform
result
risk
patient
year
patient
treat
siopel
protocol
ratio
complet
partial
respons
studi
end
protocol
end
studi
respect
low
low
risk
patient
complet
respons
aggress
patient
intermedi
group
spontan
regress
found
patient
ms
stage
year
ef
conclus
siopel
protocol
risk
neuroblastoma
patient
adapt
give
good
result
treatment
vietnames
patient
zhang
b
z
w
g
x
x
children
hospit
affili
capit
medic
univers
hematolog
oncolog
center
beij
china
backgroundobject
describ
clinic
featur
post
autolog
stem
cell
transplant
high
risk
neuroblastoma
patient
delet
clinic
outcom
goal
make
progress
better
surviv
rate
life
qualiti
designmethod
retrospect
studi
patient
delet
attend
pediatr
hematolog
oncolog
centr
april
april
receiv
systemat
treatment
care
perform
result
total
patient
delet
includ
male
femal
averag
age
month
case
bone
marrow
metastasi
case
multipl
bone
metastasi
gene
amplif
detect
patient
treat
cours
chemotherapi
oper
amount
reinfus
stem
cell
median
time
month
month
patient
stabl
state
mainten
treatment
retino
acid
three
case
recurr
tumor
progress
month
reinfus
respect
one
occur
bone
marrow
recurr
intracrani
metastasi
month
retino
acid
chemotherapi
complet
conclus
patient
delet
high
risk
develop
bone
marrow
bone
metastas
associ
gene
amplif
autolog
stem
cell
transplant
safe
effect
therapeut
method
howev
month
reinfus
retino
acid
mainten
therapi
tumor
progress
may
happen
lead
poor
prognosi
suggest
strength
system
treatment
patient
quiet
enough
therefor
close
clinic
monitor
need
stem
cell
transfus
intensif
chemotherapi
month
interv
second
dose
autolog
stem
cell
transplant
may
primari
mean
prevent
diseas
progress
zhang
w
tongren
hospit
capit
medic
univers
pediatr
beij
china
backgroundobject
studi
clinic
outcom
nb
associ
differ
risk
factor
analyz
clinic
data
nb
patient
collect
past
nine
year
beij
tongren
hospit
designmethod
patient
nb
collect
januari
januari
march
treat
induct
consolid
treatmentth
averag
time
month
use
spss
softwar
analyzing
clinic
data
use
spss
softwar
studi
relationship
outcom
nb
differ
risk
factor
result
case
patient
male
patient
femal
averag
age
patient
year
oldth
os
nb
patient
patient
nb
dead
medium
surviv
time
patient
nb
monthsth
medium
surviv
time
patient
hr
nb
year
os
medium
surviv
time
patient
ir
nb
year
os
patient
recurr
nb
follow
patient
ir
group
nb
appear
recurr
year
os
patient
hr
nb
relaps
conclus
relaps
older
age
main
risk
factor
nb
matter
group
prognosi
ir
nb
good
prognosi
hr
nb
poor
therefor
would
like
resolv
problem
better
prognosi
diagnosi
earli
reduc
relaps
use
reason
diagnosi
treatment
technolog
improv
surviv
outcom
nb
special
hr
group
patient
improv
surviv
outcom
g
ersoy
b
c
odaman
f
gn
sultan
suleyman
train
research
hospit
pediatr
hematolog
oncolog
istanbul
turkey
univers
school
medicin
pediatr
hematolog
oncolog
depart
istanbul
turkey
backgroundobject
solitari
fibrou
tumor
sft
rare
mostli
benign
neoplasm
origin
mesenchym
spindl
cell
sft
rare
origin
kidney
designmethod
descirib
case
malign
renal
origin
sft
four
local
recurr
metastas
result
year
old
male
patient
admit
clinic
hematuria
investig
reveal
abdomin
mass
mm
radic
nephrotomi
plan
patholog
diagnosi
lesion
renal
sft
tumor
defin
malign
tumor
total
resect
monthli
plan
patient
one
year
later
ultrasound
reveal
recurr
mass
lesion
primari
tumor
side
excis
total
patholog
diagnosi
primari
tumor
surgeri
radiotherapi
tumor
site
salvag
chemotherapi
ifosfamid
cisplatin
etoposid
appli
residu
recurr
mass
found
end
therapi
howev
month
later
cm
nodul
contrast
enhanc
mass
lesion
near
vertebra
record
magnet
reson
imag
mri
lesion
surgic
remov
diagnos
primari
tumor
altern
chemotherapi
protocol
appli
oper
monthli
continu
howev
month
recurr
mass
renal
pelvic
region
found
surgeri
lesion
size
cm
cm
found
resect
altern
chemotherapi
regimen
use
patient
bevacisumab
treatment
conclus
renal
sft
describ
literatur
time
malign
tumour
mostli
seen
adulthood
patient
younger
year
old
benign
tumor
case
youngest
patient
describ
literatur
malign
solitari
fibrou
tumour
e
levchenko
e
research
institut
oncolog
thorac
surgeri
pesochniy
russia
research
institut
oncolog
paediatr
oncolog
pesochniy
russia
research
institut
oncolog
anesthesiolog
pesochniy
russia
backgroundobject
aim
report
first
clinic
case
success
chemoperfus
lung
pleural
caviti
child
wilm
tumor
designmethod
march
right
kidney
mass
lesion
found
tumor
resect
right
nephroureterectomi
perform
local
clinic
patient
receiv
subsequ
chemotherapi
stage
iii
blastem
type
nephroblastoma
accord
siop
protocol
may
routin
reveal
earli
relaps
multipl
lung
metastas
abroad
chemotherapi
cycl
subsequ
gy
irradi
chemotherapi
autolog
hemopoiet
stem
cell
transplant
perform
may
chest
ct
scan
reveal
second
earli
relaps
lung
involv
june
left
thoracotomi
perform
intraop
revis
reveal
two
metastas
lower
lobe
addit
subpleur
lesion
mm
diamet
wedg
resect
lower
lobe
left
lung
revis
yield
anoth
central
locat
lesion
mm
diamet
segment
anatom
resect
segment
perform
anoth
three
nodular
lesion
mm
diamet
found
pariet
pleura
diaphragm
partial
pleurectomi
intraop
morpholog
result
indic
metastat
pleural
involv
nephroblastoma
therfor
lung
disconnect
circul
blood
vessel
cannul
normotherm
lung
perfus
mcg
dactinomycin
svi
perform
due
pariet
pleura
involv
found
follow
addit
hypertherm
pleural
perfus
mg
cisplatin
result
postop
recoveri
unev
ct
scan
show
sign
lung
involv
conclus
case
describ
illustr
feasibl
safeti
local
lung
pleura
chemoperfus
heavili
pretreat
chemoresist
pediatr
cancer
patient
b
kumar
v
rn
gandhi
post
graduat
institut
medic
india
paediatr
surgic
superspeci
lucknow
india
gandhi
post
graduat
institut
medic
india
patholog
lucknow
india
gandhi
post
graduat
institut
medic
india
radiodiagnosi
lucknow
india
backgroundobject
wilm
tumour
account
almost
rare
renal
tumour
includ
stromal
tumour
constitut
paediatr
renal
mass
differenti
import
better
outcom
tumour
differ
chemotherapi
protocol
clear
cell
sarcoma
rhabdoid
tumour
ewe
pnet
tumour
kidney
rare
tumour
consid
unfavor
tumoru
due
aggress
natur
late
present
aim
present
characterist
diseas
cours
manag
final
outcom
rare
renal
tumour
patient
show
rel
better
outcom
designmethod
retrospect
review
electron
hospit
oper
theatr
record
patient
renal
malign
mass
juli
juli
manag
centr
detail
patient
evalu
includ
demographi
clinic
present
investig
grade
patholog
manag
final
outcom
last
januari
clinic
examin
ultrasonographi
tool
result
juli
juli
six
patient
renal
tumour
manag
final
diagnosi
clear
cell
sarcoma
patient
rhabdoid
tumour
patient
ewingspnet
tumour
patient
almost
patient
present
stage
iiiii
receiv
chemotherapi
follow
surgeri
chemoradiotherapi
one
patient
clear
cell
sarcoma
could
oper
show
partial
respons
chemotherapi
die
due
chemotherapi
relat
toxic
patient
without
recurr
period
rang
month
conclus
clinic
characterist
rare
renal
tumour
similar
wilm
tumour
preoper
diagnosi
almost
imposs
without
histopathologyimmunohistochemistri
even
modern
imag
techniqu
tumour
progress
rapidli
may
result
fatal
outcom
earli
diagnosi
multimod
intervent
form
surgerychemradiotherapi
essenti
better
outcom
e
f
b
j
medic
center
de
noviembr
issst
pediatr
oncolog
mexico
citi
mexico
backgroundobject
ewe
sarcoma
occur
frequent
second
decad
life
compris
pediatr
tumor
current
protocol
surviv
local
diseas
around
metastat
diseas
designmethod
descript
longitudin
observ
studi
includ
ewe
sarcoma
nation
medic
center
de
noviembr
issst
period
januari
decemb
result
male
predomin
observ
mean
age
present
year
minimum
maximum
age
year
total
case
osseou
extraoss
case
locat
metastas
case
repres
respect
durat
onset
symptom
diagnosi
vari
month
averag
month
primari
site
bone
diseas
lower
extrem
lower
limb
primari
site
extraoss
diseas
head
thorac
wall
durat
vari
month
month
averag
month
overal
surviv
patient
local
diseas
overal
surviv
metastat
diseas
conclus
predomin
observ
male
gender
mean
age
present
year
said
result
differ
report
studi
likewis
predomin
extraoss
local
observ
overal
surviv
higher
observ
studi
b
dubashi
institut
postgradu
medic
educ
research
jipmer
medic
oncolog
puducherri
india
institut
postgradu
medic
educ
research
jipmer
radiotherapi
puducherri
india
backgroundobject
spine
usual
account
primari
site
ewe
sarcoma
usual
present
malign
spinal
cord
compress
necessit
earli
workup
treatment
local
therapi
challeng
present
seri
clinic
present
manag
outcom
primari
ewe
sarcoma
spine
children
designmethod
case
record
children
period
diagnosi
bone
sarcoma
present
depart
medic
oncolog
region
cancer
centr
screen
primari
spinal
ewe
sarcoma
clinic
manifest
treatment
detail
includ
chemotherapi
surgeri
radiotherapi
surviv
outcom
note
result
seven
children
primari
spinal
ewe
sarcoma
identifi
studi
period
median
age
year
f
ratio
five
children
present
two
patient
develop
flaccid
paraplegia
work
primari
site
present
includ
cervic
cervic
thorac
lumbosacr
two
patient
metastasi
bone
present
three
patient
underw
laminectomi
excis
mass
patient
receiv
radiotherapi
non
metastat
patient
treat
vaci
protocol
patient
metastasi
treat
vac
protocol
date
analysi
patient
progress
diseas
treatment
succumb
ill
patient
complet
treatment
aliv
free
diseas
neurolog
deficit
one
patient
undergo
chemotherapi
conclus
primari
spinal
ewe
sarcoma
rare
tumour
requir
multimod
treatment
surgeri
chemotherapi
radiotherapi
present
oncolog
emerg
poor
outcom
therapi
term
respons
surviv
n
eker
b
g
e
b
univers
pediatr
hematolog
oncolog
istanbul
turkey
backgroundobject
ewe
sarcoma
es
second
common
primari
bone
malign
pediatr
patient
usual
tumor
occur
bone
sometim
olsa
orgin
soft
tissu
tumor
agress
treatment
involv
multidurg
chemotherapi
radiotherapi
surgeri
aim
studi
determin
outcom
ewe
sarcoma
pediatr
patient
treat
instut
designmethod
retrospect
studi
pediatr
patient
ewe
sarcoma
treat
result
period
patient
identifi
ewe
sarcoma
hospit
databas
record
analyz
retrospect
patient
male
femal
mean
age
year
rang
year
patient
receiv
chemotherapi
protocol
present
protocol
involv
ifosfamid
etoposid
vincristin
doxorubicin
cyclophosphamid
actinomycin
cycl
chemotherapi
surgeri
perform
patient
radiotherapi
perform
patient
viabl
cell
patholog
examin
patient
chemotherapi
chang
continu
radiotherapi
second
chemotherapi
protocol
invov
vincristin
cyclophosphamid
topotecan
present
patient
metastat
diseas
follow
patient
relaps
event
free
surviv
overal
surviv
metastat
diseas
present
signific
factor
overal
surviv
conclus
manag
child
adolesc
ewe
sarcoma
best
carri
special
center
care
multidisciplinari
team
order
obtain
best
outcom
patient
earli
diagnosi
import
metastat
diseas
present
reduc
overal
surviv
e
senzhapova
hematolog
oncolog
institut
fsbi
nn
blokhin
russian
cancer
research
center
pediatr
hematolog
oncolog
moscow
russia
diagnost
treatment
tumor
institut
fsbi
nn
blokhin
russian
cancer
research
center
experiment
diagnost
treatment
tumor
moscow
russia
backgroundobject
treatment
result
refractori
childhood
osteosarcoma
satisfactori
accord
data
differ
pilot
trial
surviv
curv
dramat
tend
zero
median
month
role
protein
express
marker
drug
resist
gemcitabin
docetaxel
chemotherapi
childhood
osteosarcoma
unknown
designmethod
aim
studi
estim
protein
express
biopsi
specimen
tumor
tissu
sampl
poor
respons
grade
ii
tumor
cell
necrosi
rate
neoadjuv
chemotherapi
surgeri
primari
site
protein
express
assess
immunohistochem
method
use
polyclon
protein
tech
monoclon
clone
santa
cruz
antibodi
posit
specimen
defin
weak
moder
strong
colour
tumor
nuclei
number
posit
tumor
cell
percent
posit
specimen
defin
moder
strong
colour
tumor
nuclei
cytoplasm
number
posit
tumor
cell
percent
patient
treat
accord
therapi
like
result
posit
sampl
reveal
biopsi
specimen
postop
specimen
posit
sampl
reveal
biopsi
specimen
postop
specimen
posit
posit
sampl
reveal
biopsi
specimen
postop
specimen
determin
signific
correl
express
marker
metastat
statu
patient
conclus
data
suggest
optim
time
use
gemcitabin
docetaxel
could
adjuv
chemotherapi
faranoush
aa
hedayati
n
pediatr
cancer
treatment
research
center
oncolog
tehran
iran
univers
medic
scienc
bahrami
hospit
tehran
iran
research
center
shahid
beheshti
univers
medic
scienc
tehran
iran
backgroundobject
one
utmost
import
challeng
iranian
health
system
pediatr
malign
osteosarcoma
common
primari
bone
tumor
low
surviv
rate
iran
design
studi
choos
best
strategi
chemotherapi
goal
improv
surviv
rate
patient
designmethod
studi
conduct
retrospect
analyt
cohort
match
project
random
sampl
impli
children
less
year
old
approv
patholog
report
osteosarcoma
patient
match
inclus
criteria
categor
two
group
administ
high
dose
methotrex
hd
mtx
individu
mtx
failur
event
surviv
rate
group
estim
spss
softwar
version
result
fourti
one
elig
patient
non
hd
mtx
hd
mtx
group
mean
age
year
evalu
patient
hd
mtx
mtx
group
confer
relaps
metastasi
median
time
event
one
nine
month
patient
hd
mtx
non
hd
mtx
group
respect
surviv
rate
patient
hd
mtx
mtx
versu
also
median
time
diseas
free
surviv
rate
non
hd
mtx
patient
month
versu
one
month
conclus
find
reveal
surviv
rate
delay
failur
event
patient
administ
non
hd
mtx
studi
design
iranian
pediatr
patient
author
suggest
use
mtx
regiment
iran
pediatr
osteosarcoma
patient
acknowledg
author
thank
staff
medic
document
unit
research
depart
mpctrc
servic
thank
orthoped
surgeon
radiotherapi
unit
provid
assist
clinic
procedur
b
n
ag
tokuc
b
univers
medic
faculti
paediatr
haematolog
oncolog
istanbul
turkey
backgroundobject
studi
present
clinic
outcom
midterm
follow
patient
childhood
osteosarcoma
necrosi
rate
accord
presenc
metastasi
initi
diagnosi
designmethod
retrospect
analysi
prospect
collect
singl
center
databas
evalu
thirti
one
patient
diagnosi
osteosarcoma
enrol
decemb
februari
demograph
variabl
necrosi
degre
rate
recurr
rate
remiss
surviv
analyz
accord
presenc
metastasi
initi
diagnosi
result
patent
age
rang
year
initi
diagnosi
femal
male
mean
period
rang
month
averag
month
metastas
case
local
invas
case
initi
diagnosi
chemotherapi
surgic
therapi
perform
patient
rate
necrosi
rang
patient
follow
period
recurr
observ
case
mortal
observ
complet
remiss
detect
case
overal
surviv
rate
mean
surviv
time
month
ci
statist
signific
differ
surviv
group
includ
presenc
metastasi
time
diagnosi
necrosi
nonmetastat
time
diagnosi
necrosi
p
conclus
data
show
surviv
rate
midterm
follow
differ
demonstr
surviv
accord
presenc
metastasi
initi
diagnosi
merkulov
v
cancer
research
center
nn
blokhin
head
neck
tumor
moscow
russia
cancer
research
center
nn
blokhin
head
neck
depart
moscow
russia
backgroundobject
esthesioneuroblastoma
rare
malign
tumor
efficaci
transnas
endoscop
remov
tumor
treatment
adult
patient
enb
doubt
howev
possibl
type
surgic
treatment
enb
studi
suffici
designmethod
studi
includ
patient
mean
patient
age
diagnosi
year
stage
accord
stage
determin
iii
iv
case
intracrani
spread
observ
case
patient
got
chemotherapi
radiat
therapi
chemotherapi
includ
cours
vincristin
day
cyclophosphamid
day
doxorubicin
day
carboplatin
day
chemotherapi
administ
neoadjuv
regim
patient
radiat
therapi
perform
patient
primari
tumor
rt
gy
perform
patient
irradi
lymph
node
gy
complex
therapi
includ
surgic
treatment
carri
patient
transnas
remov
tumor
perform
patient
one
remov
tumor
transnas
access
conduct
twice
second
oper
perform
recurr
diseas
result
current
patient
live
month
year
one
patient
withdrew
studi
immedi
diagnosi
die
tumor
progress
conclus
base
data
show
effect
integr
treatment
common
stage
enb
case
transnas
endoscop
remov
tumor
reach
radic
promis
type
treatment
requir
studi
definit
clear
criteria
inclus
scheme
therapi
protocol
enb
children
buletov
v
cancer
research
center
nn
blokhin
head
neck
tumor
moscow
russia
cancer
research
center
nn
blokhin
head
neck
depart
moscow
russia
backgroundobject
current
method
transnas
endoscop
surgeri
tec
becom
increasingli
popular
treatment
nasal
caviti
skull
base
paramenegi
local
work
first
experi
tec
children
malign
tumor
russia
designmethod
transnaz
surgic
oper
perform
patient
femal
patient
male
patient
case
tumor
remov
perform
case
cytoreduct
tumor
resect
biopsi
performedth
youngest
patient
time
oper
day
oldest
patient
year
monthth
histolog
composit
neoplasm
differ
rhabdomyosarcoma
glioma
burkitt
lymphoma
angoima
other
patient
aliv
moment
patient
die
month
end
special
treatment
estezioneeroblastoma
result
patient
aliv
moment
patient
die
month
end
special
treatment
estezioneeroblastoma
surgic
complic
intraop
cavern
sinu
lesion
complic
postop
period
conclus
endonas
surgeri
help
modern
endoscopi
techniqu
play
import
role
formul
diagnosi
subsequ
treatment
detect
relaps
modern
world
method
choos
treatment
benign
neoplasm
also
malign
neoplasm
nasal
caviti
base
skull
paramenengi
local
import
note
use
modern
technolog
patient
differ
age
achiev
main
goal
endoscop
intervent
complet
visual
control
perform
manipul
safeti
preserv
mucosa
anatom
structur
minim
traumat
patient
absenc
skin
incis
easi
toler
adult
children
possibl
without
long
period
rehabilit
postop
period
c
duan
x
w
q
x
children
hospit
heamatologyoncolog
beij
china
backgroundobject
malign
rhabdoid
tumor
mrt
rare
highli
aggress
pediatr
malign
primarili
develop
infanc
earli
childhood
despit
exist
standard
intens
multimod
therapi
prognosi
patient
mrt
still
dismal
add
current
knowledg
report
case
mrt
head
neck
region
treat
anthracyclin
chemotherapi
brachytherapi
designmethod
clinic
record
patient
head
neck
mrt
treat
beij
children
hospit
oct
may
retrospect
studi
result
medic
record
two
boy
onset
age
respect
studi
one
patient
primari
tumor
site
right
neck
anoth
patient
primari
tumor
site
left
neck
metastasi
right
nasopharynx
multipl
facial
bone
primari
tumor
size
cm
respect
stage
iii
unresect
immunohistochem
result
show
neg
treat
chemotherapi
biopsi
done
chemotherapi
protocol
follow
vincristin
cyclophosphamid
doxorubicin
week
cyclophosphamid
carboplatin
etoposid
week
particl
implant
done
cycl
chemotherapi
respect
evalu
show
good
partial
remiss
tumor
treatment
complet
patient
iv
grade
neutropenia
degre
anemiaand
thrombocytopeniaboth
patient
suffer
grade
skin
reaction
seed
implant
manifest
erythema
mild
edema
local
skin
improv
within
week
time
month
month
respect
two
patient
remain
stabl
conclus
anthracyclin
intens
chemotherapi
combin
particl
implant
may
promis
treatment
option
mrt
without
distant
metastasi
z
fadoo
n
ar
khan
univers
oncolog
karachi
pakistan
khan
univers
pediatr
child
health
karachi
pakistan
backgroundobject
pauciti
data
regard
demograph
characterist
outcom
bone
soft
tissu
sarcoma
develop
world
includ
pakistan
analyz
clinic
featur
outcom
children
bone
soft
tissu
sarcoma
treat
last
year
aga
khan
univers
hospit
designmethod
record
patient
treat
januari
decemb
aga
khan
univers
hospit
histolog
confirm
diagnosi
bone
soft
tissu
sarcoma
review
curv
creat
assess
overal
surviv
os
event
free
surviv
ef
relaps
death
outcom
result
forti
three
patient
elig
bone
tumor
osteosarcoma
ewe
sarcoma
soft
tissu
sarcoma
rhabdomyosarcoma
along
fibrosarcoma
synovi
sarcoma
respect
patient
metastat
diseas
osteosarcoma
ewe
rhabdomyosarcoma
respect
median
age
bone
sarcoma
year
soft
tissu
sarcoma
year
distal
femur
involv
site
bone
tumor
paramening
common
site
rhabdomyosarcoma
patient
receiv
minim
therapi
relaps
therapi
estim
ef
ci
os
year
ci
conclus
outcom
sarcoma
develop
world
poor
due
multipl
factor
delay
present
poor
toler
therapi
poor
nutrit
statu
baselin
abandon
therapi
lack
easi
access
medic
care
due
financi
constraint
major
factor
respons
k
r
h
e
eylul
univers
institut
oncolog
dept
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
otorhinolaryngolog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiodiagnost
izmir
turkey
eylul
univers
faculti
medicin
dept
patholog
izmir
turkey
backgroundobject
evalu
head
neck
local
rhabdomyosarcoma
center
designmethod
medic
record
patient
head
neck
local
rm
analyz
retrospect
result
median
age
diagnosi
yr
local
tumor
follow
paramening
hard
accord
ir
tnm
stage
distribut
stage
stage
ii
stage
iii
stage
iv
clinic
group
primari
surgeri
perform
three
patient
patient
receiv
chemotherapi
initi
treatment
ir
base
treatment
regimen
use
patient
cog
protocol
use
patient
rtwa
given
primari
site
except
two
lost
follow
total
resect
secondari
surgeri
perform
one
patient
cheek
primari
chemo
tumor
median
time
mo
yr
four
patient
lost
follow
month
diseas
month
without
diseas
rate
os
rate
rate
rate
total
patient
die
progress
diseas
median
month
mo
two
patient
die
refractori
progress
diseas
month
nine
patient
relaps
median
relaps
time
mo
three
patient
relaps
diseas
aliv
relaps
treatment
go
treatment
resist
patient
aliv
second
line
surgeri
ned
five
patient
relaps
diseas
die
progress
despit
anticanc
treatment
conclus
fourti
percent
patient
advanc
stage
diseas
patient
clinic
group
local
control
problem
overal
event
free
surviv
rate
accept
miyamura
h
n
k
f
h
n
k
univers
graduat
school
medicin
pediatr
osaka
japan
univers
graduat
school
medicin
orthoped
surgeri
osaka
japan
univers
graduat
school
medicin
radiolog
osaka
japan
backgroundobject
ewe
sarcoma
es
rare
malign
bone
soft
tissu
prognosi
advanc
metastat
es
remain
poor
treatment
strategi
establish
report
two
case
advanc
es
treat
tandem
chemotherapi
allogen
stem
cell
transplant
sct
surviv
without
diseas
year
therefor
may
effect
treatment
strategi
advanc
es
designmethod
patient
girl
es
origin
right
ilium
multipl
lung
metastas
patient
girl
es
origin
left
ilium
multipl
lung
metastas
receiv
chemotherapi
radiat
therapi
primari
legion
perform
first
chemotherapi
autolog
stem
cell
transplant
sct
underw
surgic
resect
primari
lesion
hematolog
recoveri
treatment
respons
good
achiev
complet
respons
perform
second
chemotherapi
cylpam
allogen
sct
donor
patient
sibl
sever
advers
event
includ
gvhd
detect
donor
patient
hla
loci
mismatch
mother
kir
ligand
mismatch
moder
engraft
syndrom
occur
although
sever
gvhd
detect
result
patient
surviv
without
diseas
month
month
respect
conclus
report
two
case
advanc
es
treat
chemotherapi
local
radiat
therapi
plu
tandem
chemotherapi
autolog
allogen
stem
cell
rescu
surviv
without
diseas
progress
year
report
es
express
tumor
antigen
recogn
cell
make
allogen
sct
effect
option
intens
tandem
chemotherapi
alkyl
agent
allogen
tumor
immunotherapi
could
effect
treatment
strategi
advanc
es
alkofid
h
sk
siddiqui
g
faisal
specialist
hopsit
research
center
pediatr
hematolog
oncolog
riyadh
saudi
arabia
khale
eye
specialist
hopsit
opthalmolog
riyadh
saudi
arabia
univers
medcial
colleg
riyadh
saudi
arabia
faisal
specialist
hopsit
research
center
oncolog
center
riyadh
saudi
arabia
backgroundobject
determin
clinic
profil
outcom
patient
retinoblastoma
rb
underw
unilater
bilater
enucl
backdrop
intern
intraocular
retinoblastoma
classif
abc
classif
tnm
stage
system
designmethod
medic
chart
pediatr
year
patient
retinoblastoma
underw
enucl
treat
king
faisal
specialist
hospit
research
centr
kfshrc
king
khale
eye
specialist
hospit
riyadh
saudi
arabia
review
result
among
cohort
femal
median
age
diagnosi
month
retinoblastoma
unilater
bilater
trilater
patient
one
metastat
diseas
present
enucl
perform
patient
intern
classif
intraocular
retinoblastoma
carri
eye
group
e
group
group
c
follow
group
b
patient
underw
chemotherapi
chemoreduct
andor
chemoprevent
receiv
chemoreduct
chemoprevent
chemoreduct
chemoprevent
patient
receiv
thermotherapi
cryotherapi
intraven
carboplatin
inform
tnm
classif
iirb
avail
patient
patient
classifi
stage
stage
e
patient
receiv
extern
beam
orbit
radiotherapi
ebort
evalu
case
cr
stabl
diseas
remain
progress
diseas
mortal
bilater
unilater
tumor
probabl
five
year
overal
surviv
whole
cohort
group
e
group
conclus
iirb
essenti
make
decis
enucl
howev
tnm
classif
play
pivot
role
decid
treatment
rb
patient
avoid
treatment
kt
sy
cmj
bl
women
children
hospit
paediatr
haematolog
oncolog
singapor
singapor
backgroundobject
retinoblastoma
commonest
primari
intraocular
malign
childhood
bone
marrow
examin
lumbar
punctur
cerebrospin
fluid
csf
cytolog
done
togeth
eua
initi
metastat
work
patient
retinoblastoma
institut
howev
routin
practic
centr
retrospect
studi
aim
determin
preval
metastasi
diagnosi
evalu
valu
investig
patient
retinoblastoma
treat
kk
women
children
hospit
singapor
kkh
designmethod
studi
approv
singhealth
central
institut
review
board
retrospect
analysi
patient
retinoblastoma
may
march
perform
result
patient
includ
boy
girl
unilater
diseas
bilater
diseas
trilater
diseas
median
age
present
month
rang
month
unilater
diseas
month
rang
month
bilater
diseas
two
patient
posit
famili
histori
four
patient
metastat
diseas
present
kkh
one
csf
cut
optic
nerv
show
involv
one
bone
marrow
involv
blood
count
abnorm
diagnosi
one
initi
treatment
oversea
present
kkh
metastat
relaps
bone
marrow
csf
liver
bone
patient
suprasellar
extens
mri
csf
posit
cost
bone
marrow
lumbar
punctur
test
sgd
usd
conclus
preval
metastasi
diagnosi
low
institut
patient
metastasi
pick
mean
like
clinic
examin
blood
count
mri
histolog
optic
nerv
involv
necessari
investig
patient
retinoblastoma
thu
save
substanti
financi
time
cost
patient
institut
u
imam
f
aid
institut
child
health
pediatr
oncolog
karachi
pakistan
backgroundobject
retinoblastoma
primari
intra
ocular
neoplasm
childhood
present
young
age
leukocoria
studi
aim
determin
clinico
radiolog
featur
retinoblastoma
period
nine
year
use
exist
hospit
record
sheet
designmethod
record
children
retinoblastoma
deriv
hospit
sheet
treat
pediatr
oncolog
depart
nation
institut
child
health
karachi
januari
decemb
use
special
design
performa
inform
consent
parent
result
patient
retinoblastoma
male
femal
age
rang
month
averag
mean
sd
age
month
clinic
present
orbit
proptosi
children
refer
outsid
karachi
bilater
diseas
significantli
high
children
year
age
compar
children
year
p
famili
histori
retinoblastoma
neg
children
bilater
tumor
mean
time
lag
month
appear
first
symptom
consult
oncologist
patient
refer
tumor
recurr
primari
enucl
frequenc
high
children
year
age
children
compar
patient
year
children
p
patient
metastat
diseas
cn
involv
notic
patient
conclus
high
frequenc
advanc
stage
diseas
suggest
late
referr
treatment
facil
signific
percentag
children
regist
tumor
recurr
find
reflect
lack
multidisciplinari
approach
patient
manag
therefor
integr
effort
need
creat
awar
among
mass
healthcar
personnel
earli
referr
uniform
patient
evalu
manag
e
unal
cabi
kavlak
n
h
k
g
faculti
medicin
pediatr
ankara
turkey
faculti
medicin
ophthalmolog
ankara
turkey
backgroundobject
rb
case
diagnos
advanc
intraocular
stage
orbit
metastat
diseas
turkeyw
aim
determin
durat
diagnosi
paramet
affect
period
relat
clinic
stage
designmethod
enrol
rb
patient
data
obtain
survey
famili
patient
file
review
clinic
stage
exact
date
diagnosi
start
date
treatment
obtain
famili
questionnair
address
parent
paramet
could
effect
clinic
diagnosi
stage
question
durat
detect
first
symptom
diagnosi
evalu
divid
part
patient
relat
delay
diagnosi
delay
diagnosi
due
doctor
delay
treatment
result
age
diagnosi
year
median
common
find
leucocoria
strabismu
patient
famili
relat
delay
diagnosi
day
median
day
doctor
relat
day
median
day
total
diagnosi
delay
rang
day
median
eye
group
e
group
group
c
group
b
group
patient
underw
enucl
group
e
delay
diagnosi
longer
group
famili
low
se
diagnosi
delay
higher
diagnosi
delay
famili
high
se
famili
rb
retinoblastoma
patient
diagnos
earlier
patient
diagnos
first
second
third
fourth
ophthalmologist
respect
conclus
studi
delay
time
rb
diagnosi
shorter
studi
howev
half
patient
diagnos
advanc
intraocular
stage
think
import
effect
paramet
delay
diagnosi
insuffici
awar
famili
especi
healthcar
worker
w
han
children
hospit
depart
surgic
oncolog
bei
jing
china
backgroundobject
evalu
clinic
diagnosi
treatment
focal
nodular
hyperplasia
fnh
children
liver
designmethod
case
focal
nodular
hyperplasia
liver
confirm
oper
patholog
hospit
investig
retrospect
result
age
onset
rang
year
old
primari
clinic
manifest
case
fever
case
vomit
case
abnorm
liver
function
case
abdomin
distens
case
abdomin
pain
case
intussuscept
case
tumor
famili
histori
lung
cancer
lesion
found
case
afp
measur
mildli
elev
case
normal
case
increas
case
normal
hepat
b
viru
infect
patient
posit
patholog
perform
case
typic
patient
underw
gross
surgic
resect
complic
death
postop
well
periop
afp
decreas
normal
surgeri
case
two
case
investig
liver
function
abnorm
amelior
surgeri
year
patient
surviv
event
free
conclus
genet
predisposit
fnh
obviou
diseas
lead
abnorm
liver
function
afp
misdiagnosi
common
although
fatal
surgic
resect
import
treatment
also
rule
malign
liver
g
belokon
cancer
institut
mph
ukrain
pediatr
oncolog
kiev
ukrain
institut
surgeri
transplantolog
name
oo
shalymov
liver
transplant
kiev
ukrain
cancer
institut
depart
pediatr
oncolog
kiev
ukrain
cancer
institut
pediatr
oncolog
kiev
ukrain
backgroundobject
malign
liver
tumor
make
number
tumor
child
age
yearli
incid
case
per
million
children
age
year
designmethod
posthoc
analysi
ukrain
stage
surgic
treatment
hepatoblastoma
children
transplant
liver
perform
among
orthotop
transplant
later
section
liver
live
rel
donor
mother
execut
five
patient
stage
surgic
treatment
one
patient
hepatectomi
total
pancreatectomi
gastroduodenectomi
splenectomi
extend
lymphadenectomi
esophagojejunostomi
mesocav
shunt
orthotop
transplant
left
later
section
liver
live
rel
donor
mother
cava
portal
transposit
transplant
concern
recurr
hepatoblastoma
expand
hepatectomi
execut
one
patient
averag
age
children
transplant
liver
carri
made
year
chemotherapi
accord
clinic
protocol
siopel
carri
patient
group
high
risk
result
averag
time
execut
oper
made
hour
postop
period
biloma
resect
surfac
graft
develop
patient
remov
way
punctur
complet
remiss
diseas
record
patient
transplant
liver
execut
surviv
rate
patient
hepatoblastoma
transplant
liver
execut
make
surviv
graft
made
conclus
execut
transplant
liver
children
hepatoblastoma
liver
difficult
stage
multimod
therapi
demand
consider
materi
technic
support
allow
achiev
good
remot
result
statist
authent
arafah
g
n
w
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
hospit
cairo
pediatr
oncolog
cairo
egypt
hospit
cairo
pediatr
oncolog
cairo
egypt
hospit
cairo
surgic
oncolog
cairo
egypt
hospit
cairo
patholog
cairo
egypt
hospit
cairo
radiodiagnosi
cairo
egypt
hospit
cairo
clinic
trial
unit
cairo
egypt
hospit
cairo
clinic
research
cairo
egypt
backgroundobject
suboptim
outcom
remain
sever
group
patient
malign
extracrani
germ
cell
tumor
mgct
includ
patient
extragonad
tumor
advanc
metastat
diseas
futur
studi
direct
toward
intensifi
therapi
poor
risk
group
long
term
follow
late
effect
designmethod
high
risk
patient
mgct
treat
cche
retrospect
analys
epidemiolog
surviv
outcom
treat
accord
protocol
adopt
high
risk
juli
till
end
decemb
patient
follow
june
result
elig
patient
mgct
high
risk
mean
age
year
male
femal
ratio
extragonad
tumor
case
femal
male
versu
ovarian
case
sacrococcyg
site
predomin
femal
mediastin
follow
sacrococcyg
site
predomin
male
main
histolog
type
extragonad
case
yolk
sac
tumor
follow
mix
gct
germinoma
main
histolog
type
ovarian
case
dysgerminoma
follow
yolk
sac
tumor
mix
gct
extragonad
site
five
year
os
stage
iii
iv
respect
five
year
ef
stage
iii
iv
respect
ovarian
case
five
year
os
ef
stage
iii
stage
iv
signific
p
valu
five
year
os
ef
year
age
conclus
poor
outcom
high
risk
mgct
necessit
intensifi
therapi
especi
metastat
tumor
improv
risk
stratif
system
novel
approach
effici
salvag
protocol
need
improv
outcom
poor
risk
patient
b
kumar
vd
rn
gandhi
post
graduat
institut
medic
scienc
paediatr
surgic
superspeci
lucknow
india
gandhi
post
graduat
institut
medic
scienc
radiodiagnosi
lucknow
india
gandhi
post
graduat
institut
medic
scienc
patholog
lucknow
india
backgroundobject
primari
germ
cell
tumour
rare
account
germ
cell
tumour
prognosi
usual
excel
complet
excis
manag
distinct
challeng
aim
studi
present
problem
morbid
associ
manag
tumour
designmethod
retrospect
evalu
patient
retroperitonealabdomin
mass
juli
juli
centr
hospit
record
diagnosi
germ
cell
tumour
detail
patient
review
includ
demographi
clinic
present
investig
problem
patholog
manag
final
outcom
result
juli
juli
patient
retroperitonealabdomin
germ
cell
tumour
manag
diagnos
yolk
sac
tumour
yst
patient
teratoma
patient
patient
femal
age
rang
month
year
median
age
month
patient
respiratori
problem
sub
acut
bowel
obstruct
time
present
patient
yst
patient
immatur
teratoma
receiv
chemotherapi
almost
complet
excis
perform
patient
problem
includ
excess
bleed
excis
part
adjac
organ
hypothermia
respiratori
problem
chemo
relat
toxic
adhes
bowel
obstruct
occur
patient
month
post
surgeri
requir
adhesiolysi
patient
die
lost
rest
patient
without
recurr
period
rang
month
conclus
manag
retroperitonealabdomin
germ
cell
tumour
gct
challeng
variou
surgic
difficulti
morbid
associ
resect
tumour
depend
clinic
present
size
site
tumour
age
patient
ag
tokuc
n
b
b
univers
medic
faculti
paediatr
oncolog
istanbul
turkey
backgroundobject
germ
cell
tumor
gct
account
childhood
tumor
commonli
seen
year
year
old
gct
commonli
local
gonad
examin
patient
diagnos
treat
gct
center
retrospect
designmethod
sixti
two
children
adolesc
diagnos
treat
gct
center
analyz
retrospect
result
patient
age
rang
day
year
patient
girl
boy
common
tumor
local
patient
gonad
sixteen
patient
metastat
diseas
present
common
histolog
subtyp
matur
teratoma
patient
patient
yolk
sac
tumor
afp
elev
case
wherea
chorion
gonadotropin
elev
case
case
treat
total
surgic
resect
nt
receiv
chemotherapi
six
patient
receiv
radiotherapi
addit
surgeri
chemotherapi
patient
receiv
bep
bleomycin
etoposid
cisplatin
first
line
chemotherapi
follow
patient
relaps
five
year
overal
surviv
rate
patient
retrospect
conclus
germ
cell
tumor
favor
outcom
children
tumor
cure
surgic
resect
follow
chemotherapi
radiotherapi
select
patient
result
data
analysi
found
surviv
rate
similar
current
literatur
data
f
jl
reguerr
guyon
pediatr
saint
deni
de
la
reunion
reunion
guyon
pediatr
surgeri
saint
deni
de
la
reunion
reunion
mayott
pediatr
depart
mamoudz
mayott
backgroundobject
inflammatori
myofibroblast
tumor
imt
rare
tumor
children
young
adult
consid
intermedi
malign
rare
metastas
imt
present
anaplast
lymphoma
kinas
alk
rearrang
report
case
girl
develop
lung
tumor
brain
metastasi
limit
alk
amplif
treat
crizotinib
designmethod
decemb
patient
arriv
mayott
hospit
cough
hemoptysi
one
year
also
seizur
arriv
radiolog
thorac
explor
show
tumor
left
inferior
lobe
brain
mri
show
five
brain
lesion
especi
one
frontal
lobe
microscop
partial
brain
tumor
resect
perform
pulmonari
tumor
complet
remov
lobectomi
patholog
exam
show
imt
neg
alk
rearrang
form
cell
steroid
alon
week
chemotherapi
methotrexatevinblastin
introduc
improv
neurolog
lesion
crizotinib
initi
compassion
dose
twice
daili
result
crizotinib
chemic
inhibitor
alk
transit
also
inhibit
tyrosin
kinas
receptor
shown
effect
lung
carcinoma
also
test
success
tumor
notabl
anaplast
lymphoma
certain
paediatr
cancer
previou
report
suggest
crizotinib
cross
barrier
may
unabl
control
cn
imt
case
complet
remiss
brain
metastasi
achiev
week
crizotinib
despit
multipl
brain
local
low
alk
posit
tumor
cell
rate
recurr
thorac
brain
lesion
observ
year
conclus
case
suggest
therapi
crizotinib
may
strengthen
current
strategi
imt
even
cn
tumor
nguyen
hospit
ho
chi
minh
vietnam
backgroundobject
kaposiform
hemangioendothelioma
khe
rare
vascular
tumor
case
associ
phenomenon
kmp
constel
thrombocytopenia
coagulopathi
purpura
report
result
corticosteroid
vincristin
manag
khe
kmp
designmethod
retrospect
analyz
medic
record
patient
khe
kmp
treat
corticosteroid
vincristin
children
hospit
ho
chi
minh
vietnam
januari
decemb
result
six
case
median
age
month
month
male
femal
ratio
treat
corticosteroid
vincristin
patient
larg
khe
develop
lumbar
region
extrem
face
retroperitoneum
clinic
manifest
includ
anemia
purpura
gastrointestin
bleed
infect
ulcer
hemangioendothelioma
acut
respiratori
distress
due
presenc
tumor
compress
diagnosi
median
platelet
count
fibrinogen
level
gl
gl
respect
durat
corticosteroid
therapi
week
vincristin
given
intraven
mgkg
per
dose
weekli
four
time
follow
monthli
six
time
one
patient
partial
respons
use
vincristin
month
rate
complet
partial
respons
case
case
case
respect
median
month
platelet
count
normal
week
fibrinogen
level
return
normal
week
reduct
size
tumor
achiev
week
week
recurr
rate
kmp
case
vincristin
mild
transient
side
effect
compar
corticosteroid
conclus
therapi
corticosteroid
vincristin
one
option
unresect
khe
kmp
je
park
ok
univers
school
medicin
pediatr
suwon
republ
korea
univers
school
medicin
radiat
onvolog
suwon
republ
korea
backgroundobject
juvenil
xanthogranuloma
jxg
rare
benign
disord
one
diseas
classifi
cell
histiocytosi
whose
etiolog
pathogenesi
still
unclear
jxg
gener
character
solitari
multipl
cutan
nodul
resolv
spontan
year
howev
uncommonli
possibl
present
disord
progress
symptomat
system
disord
involv
multipl
organ
designmethod
review
chart
case
system
jxg
involv
bone
marrow
multipl
bone
skin
treatment
acut
lymphoblast
leukemia
result
adolesc
patient
suffer
unexplain
prolong
fever
scalp
pain
hip
joint
pain
right
knee
joint
pain
week
treatment
cours
interim
mainten
chemotherapi
accord
patholog
find
bone
marrow
evid
leukemia
relaps
find
diffus
infiltr
histiocyt
sever
giant
cell
posit
neg
protein
bone
skin
biopsi
confirm
find
symptom
resolv
sinc
mainten
chemotherapi
includ
vincristin
dexamethason
methotrex
bone
marrow
involv
jxg
rare
report
occur
less
year
age
case
report
boy
acut
lymphoblast
leukemia
treatment
conclus
experienc
system
jxg
involv
bone
marrow
multipl
bone
skin
treatment
acut
lymphoblast
leukemia
echebarria
r
r
adan
n
bilbao
ricondo
de
ojinaga
l
galbarriatu
e
ruiz
de
gopegui
aurtenetx
martin
l
zaldumbid
astigarraga
universitario
cruce
pediatr
hematolog
oncolog
unit
bilbao
spain
universitario
cruce
neurosurgeri
unit
bilbao
spain
universitario
cruce
biocruc
health
research
institut
bilbao
spain
universitario
cruce
patholog
anatomi
unit
bilbao
spain
backgroundobject
central
nervou
system
cn
tumor
first
year
life
specif
pediatr
brain
tumor
group
difficulti
diagnosi
treatment
associ
wors
prognosi
sequela
compar
older
children
review
seri
experi
designmethod
retrospect
studi
infant
one
year
life
diagnos
cn
tumor
clinic
histolog
treatment
sequela
data
collect
result
fourteen
infant
identifi
male
median
age
diagnosi
month
rang
supratentori
without
dissemin
case
csf
posit
astrocyt
tumor
repres
largest
group
tumor
low
grade
glioma
embryon
neural
choroid
plexu
melanocyt
tumor
respect
ependym
tumor
report
therapi
includ
surgeri
partial
resect
biopsi
complet
resect
chemotherapi
chemotherapi
hdch
radiat
therapi
administ
case
surviv
median
follow
month
among
survivor
frequent
sequela
neurolog
ophthalmolog
one
case
sequel
conclus
review
surviv
infant
diagnos
cn
tumor
first
year
life
signific
sequela
observ
local
supratentori
mass
without
dissemin
common
present
neurosurg
procedur
achiev
complet
resect
radiotherapi
avoid
manag
cn
tumor
age
complic
role
hdch
remain
defin
guram
j
b
k
hospit
depart
paediatr
oncolog
cambridg
unit
kingdom
hospit
depart
patholog
cambridg
unit
kingdom
backgroundobject
diffus
leptomening
glioneuron
tumor
rare
brain
tumor
distinct
molecular
profil
aggress
biolog
behavior
lesion
often
present
insidi
onset
progress
rapidli
lead
death
median
surviv
report
month
natur
histori
rare
entiti
fulli
understood
designmethod
describ
rare
case
diagnos
post
mortem
month
old
boy
present
weight
loss
vomit
mri
head
spine
demonstr
extens
leptomening
spread
spinal
intracrani
compart
suggest
neoplast
process
leptomening
biopsi
reveal
low
grade
primari
glial
lesion
oper
option
therefor
commenc
treatment
siop
studi
howev
demonstr
progress
diseas
spite
chemotherapi
radiolog
clinic
loss
speech
seizur
later
develop
hydrocephalu
shunt
insert
deterior
pass
away
age
year
result
macroscop
histolog
molecular
find
characterist
diffus
leptomening
gioneuron
tumour
immunohistochem
tumour
cell
express
synaptophysin
neg
neun
gfap
mutant
prolifer
index
less
interphas
fluoresc
situ
hybridis
ifish
show
concurr
gene
fusion
loss
conclus
case
demonstr
need
biolog
marker
integr
marker
order
diagnost
prognost
risk
stratif
r
h
k
n
eylul
univers
institut
oncolog
dept
pediatr
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiat
oncolog
izmir
turkey
eylul
univers
faculti
medicin
dept
radiodiagnost
izmir
turkey
backgroundobject
evalu
characterist
treatment
respons
diffus
pon
glioma
center
designmethod
medic
file
patient
malign
cn
tumor
analyz
retrospect
patient
pon
glioma
three
went
anoth
center
one
diagnos
demyelinizan
diseas
one
encephelat
lesion
laterli
patient
exclud
patient
found
evalu
result
median
age
diagnosi
yr
age
distrubut
yr
patient
yr
patient
yr
patient
frequent
complaint
cranial
nerv
paralysi
visial
impair
headach
power
loss
speech
disord
surgeri
perform
extrins
compon
mass
patient
sixteen
patient
receiv
radiotherapi
two
patient
die
rt
week
sixth
month
rt
total
dose
vari
gy
thirteen
patient
receiv
chemotherapi
four
patient
die
chemo
one
patient
still
receiv
rt
chemotherapi
protocol
chang
year
mopp
mechlorethamin
vincristin
prednison
procarbazin
patient
nopp
nitrosourea
vincristin
prednison
procarbazin
patient
ice
ifosfamid
carboplatin
cisplatin
five
patient
oral
cyclophosphamid
one
patient
temozolamid
one
patient
bevacizumab
one
patient
median
progress
free
surviv
rate
progress
free
surviv
rate
one
year
median
dead
time
one
year
two
year
overal
surviv
rate
respect
conclus
diffus
pon
glioma
group
tumor
helpless
experienc
treatment
despit
radiotherapi
chemotherapi
patient
still
die
progress
free
overal
surviv
rate
patient
similar
literatur
need
new
therapi
agent
improv
progress
free
surviv
rate
p
ivanovski
l
univers
hospit
gener
pediatr
belgrad
serbia
santa
maria
reggio
itali
clinic
genet
depart
obstetr
reggio
emilia
itali
belgrad
chemic
faculti
belgrad
serbia
backgroundobject
achiv
new
siop
mission
child
shoud
contract
cancer
designmethod
comprehens
read
paper
cancer
epidemiolog
pathogenesi
creat
theori
cancer
prevent
result
literatur
data
neoplasm
origin
termin
differenti
cell
tdc
purkinj
neuron
betz
neuron
alpha
motoneuron
indic
carcinogenesi
occur
cell
mitot
potenti
consequ
mitot
cross
mco
loss
heterozygos
loh
mechan
respons
disabl
tumor
suppressor
gene
known
cancer
far
deriv
cell
possess
mitot
activ
cancer
privileg
cell
larger
bodi
cell
burden
longer
life
mean
mitos
mco
loh
greater
chanc
cancer
develop
syndrom
lf
rare
autosom
domin
hereditari
disord
carrier
cancer
develop
germlin
heterozyg
mutat
mutat
present
bodi
cell
includ
tdc
classic
frequent
lf
malign
sarcoma
cancer
breast
brain
especi
glioblastoma
adrenocort
carcinoma
leukemia
lymphoma
despit
exagger
predisposit
cancer
develop
cancer
origin
tdc
seen
lf
person
far
malign
cell
tumor
lf
homozyg
mutat
loh
present
gener
mco
event
mitos
cell
conclus
experi
mice
anim
lf
model
must
done
protect
mice
mco
inhibitor
inhibitor
commerci
avail
experi
result
cancer
prevent
scientist
must
search
mco
inhibitor
would
oral
supplement
human
life
present
drug
choic
acidum
acetylsalicylicum
use
cancer
chemoprevent
molecul
must
modifi
elimin
hemorrhag
side
effect
kantar
h
hekimci
k
n
univers
school
medicin
pediatr
oncolog
divis
izmir
turkey
univers
school
medicin
radiat
oncolog
izmir
turkey
univers
school
medicin
pediatr
neurosurgeri
izmir
turkey
backgroundobject
prognosi
grade
iii
ependymoma
chang
year
requir
approach
analysi
aim
analyz
demograph
featur
treatment
result
anaplast
ependymoma
institut
designmethod
thirteen
patient
age
mean
month
diagnos
grade
iii
ependymoma
surgeri
femal
male
tumor
locat
infratentori
spinal
patient
supratentori
patient
result
treatment
patient
amen
resect
underw
subtot
resect
nine
patient
given
cs
radiat
therapi
gy
primari
gy
spinal
three
cranial
radiat
one
primari
spinal
irradi
chemotherapi
regimen
except
two
patient
treat
vincristin
procarbazin
prednisolon
patient
treat
accord
pog
posterior
fossa
studi
cisplatinum
plu
etoposid
cycl
cyclofosfamid
plu
vincristin
cycl
seven
patient
also
given
intratec
methotrex
weekli
leptomening
involv
mean
durat
month
period
three
patient
recur
die
diseas
surviv
analysi
ef
rate
os
rate
conclus
grade
iii
ependymoma
difficult
group
tumor
surgeri
follow
radiat
standard
treatment
type
analysi
resect
type
tumor
site
significantli
relat
prognosi
c
karadeniz
fg
h
univers
school
medicin
pediatr
oncolog
ankara
turkey
univers
school
medicin
pediatr
neurosurgeri
ankara
turkey
univers
school
medicin
patholog
ankara
turkey
univers
school
medicin
radiat
oncolog
ankara
turkey
backgroundobject
evalu
clinic
characterist
outcom
pediatr
patient
ependymoma
designmethod
total
patient
boy
girl
newli
diagnos
ependymoma
retrospect
evalu
analysi
demograph
histolog
clinic
data
includ
treatment
modal
surviv
analys
made
histopatholog
examin
evalu
accord
world
health
organ
classif
tumor
classifi
grade
grade
iii
ependymoma
result
median
age
time
diagnosi
year
median
time
month
rang
month
common
site
ependymoma
posterior
fossa
region
primari
tumor
local
spinal
cord
patient
thirteen
nine
patient
grade
ii
iii
histolog
respect
two
patient
evid
spinal
metastat
diseas
diagnosi
treatment
consist
surgeri
radiotherapi
chemotherapi
gross
total
resect
subtot
resect
achiev
case
respect
radiotherapi
administ
patient
patient
receiv
also
chemotherapi
frequent
use
regimen
three
patient
experienc
tumor
progressionrelaps
ten
patient
aliv
without
diseas
ten
year
overal
event
free
surviv
rate
patient
respect
statist
signific
differ
overal
surviv
patient
compar
accord
subgroup
consist
grade
ii
vs
iii
gross
total
less
gross
total
surgeri
without
adjuv
chemotherapi
p
conclus
ependymoma
local
invas
tumor
occasion
spinal
metastas
despit
multimod
treatment
includ
surgeri
radiotherapi
chemotherapi
surviv
rate
satisfactori
role
chemotherapi
ependymoma
need
defin
larger
seri
clinic
trial
c
khaiman
sl
k
p
p
chulalongkorn
memori
hospit
divis
pediatr
hematolog
depart
pediatr
bangkok
thailand
univers
depart
faculti
medicin
bangkok
thailand
background
object
background
intracrani
germ
cell
tumor
igct
consid
rare
highli
curabl
neoplasm
incid
igct
eastern
asia
high
compar
western
countri
object
studi
clinic
characterist
outcom
children
igct
designmethod
retrospect
review
patient
diagnos
igct
depart
pediatr
king
chulalongkorn
memori
hospit
result
eighteen
patient
diagnos
igct
male
femal
age
rang
year
median
year
present
symptom
consist
hydrocephalu
patient
weak
patient
diabet
insipidu
patient
visual
disturb
patient
increas
intracrani
pressur
patient
histopatholog
diagnosi
germinoma
ten
patient
yolk
sac
tumor
patient
mix
germ
cell
patient
elev
marker
reveal
approxim
patient
tumor
site
pineal
gland
patient
suprasellar
patient
thalam
cerebellar
patient
rest
multifoc
four
patient
leptomening
involv
treatment
includ
total
remov
three
partial
remov
four
rest
underw
biopsi
adjuv
chemotherapi
given
patient
radiotherapi
given
patient
craniospin
radiat
csi
given
leptomening
metastasi
median
follow
month
five
patient
experienc
relaps
four
die
diseas
overal
surviv
germinomat
igct
igct
conclus
treatment
outcom
germinomat
igct
favour
outcom
leptomening
metastasi
igct
poor
innov
therapi
develop
improv
outcom
mehmood
khanum
memori
cancer
hospit
research
centr
radiat
oncolog
lahor
pakistan
backgroundobject
retrospect
report
acut
toxic
outcom
pediatr
medulloblastoma
patient
treat
csi
use
cranial
spinal
photon
institut
designmethod
septemb
august
patient
treat
patient
receiv
gy
rbe
csi
tumor
bed
boost
gy
rbe
hr
rbe
gy
rbe
respect
spine
boost
rbe
gy
rbe
patient
receiv
concurr
weekli
vincristin
hr
patient
receiv
addit
daili
carboplatin
toxic
document
accord
result
median
age
year
rang
femal
baselin
mean
neuropsycholog
abil
across
broad
rang
perform
base
measur
parent
report
function
averag
rang
wechsler
iq
rang
toxic
grade
toxic
nauseavomit
anorexia
max
weight
loss
decreas
hemoglobin
leukopenia
thrombocytopenia
patient
leukopenia
also
thrombocytopenia
medulloblastoma
treat
spine
boost
vincristin
carboplatin
bone
marrow
toxic
occur
hr
patient
patient
receiv
carboplatin
hepat
renal
toxic
mild
patient
avail
audiogram
median
month
end
rt
rang
hear
loss
none
patient
detail
imag
avail
none
radiat
necrosi
data
avail
patient
median
follow
month
rang
aliv
without
diseas
aliv
cerebellar
thecal
sac
recurr
aliv
ventricular
recurr
conclus
csi
techniqu
safe
observ
gi
bone
marrow
hepat
renal
toxic
depend
chemotherapi
regimen
gg
pared
e
hospit
oncolog
pediatr
lima
peru
backgroundobject
brain
germin
tumor
infrequ
good
prognosi
multimod
treatment
designmethod
descript
retrospect
studi
brain
germin
tumor
year
result
popul
case
oncolog
patient
brain
tumor
nine
brain
germ
cell
tumor
last
year
mean
age
year
five
boy
four
girl
male
femal
sex
ratio
race
indian
white
clinic
headach
vomit
diplopia
polyuria
ptosi
seizur
four
suprasellar
region
three
sellar
region
one
bifoc
one
infrasellar
diabet
insipidu
requir
vasopressin
hormon
defici
requir
corticosteroid
thyroid
hormon
one
present
low
growth
hormon
diagnosi
five
patient
underw
radic
resect
three
patient
underw
biopsi
one
patient
underw
gross
total
resect
histopatholog
germinoma
seven
patient
germinomat
two
case
immatur
teratoma
patient
demonstr
chromosom
delet
transloc
serum
elev
one
seven
case
germinoma
elev
two
case
immatur
teratoma
first
case
eight
year
old
boy
diagnos
receiv
radiotherapi
alon
surgeri
six
month
later
sinc
chemotherapi
administ
complementari
surgeri
radiotherapi
four
cours
altern
time
report
seven
patient
aliv
remiss
diseas
overal
surviv
month
median
surviv
month
conclus
germin
tumor
cn
uncommon
peru
oppos
germin
gonad
tumor
brain
germin
tumor
frequent
boy
suprasellar
local
germinoma
subtyp
frequent
chemotherapi
complementari
surgeri
radiotherapi
demonstr
good
respons
avoid
need
second
surgeri
high
surviv
k
zakrzewski
e
w
pp
mother
memori
hospit
research
institut
depart
neurosuregri
poland
children
memori
health
institut
depart
patholog
warsaw
poland
univers
depart
molecular
patholog
neuropatholog
poland
backgroundobject
intracrani
meningioma
rel
rare
tumor
children
account
less
primari
brain
tumor
part
affect
patient
phakomatos
children
post
cn
irradi
ectop
meningioma
skull
bone
extrem
rare
entiti
pediatr
popul
designmethod
describ
case
boy
present
histori
solid
mass
right
frontal
bone
ct
examin
reveal
tumor
x
mm
diamet
locat
within
right
frontal
bone
destruct
normal
layer
visibl
mark
spicul
periost
reaction
mri
examin
confirm
right
frontal
bone
tumor
x
x
mm
diamet
slightli
compress
adjac
brain
structur
contrast
administr
small
homogen
enhanc
tumor
mark
fragmentari
enhanc
adjac
dura
suggest
possibl
infiltr
intracrani
abnorm
note
result
bone
tumor
resect
total
subsequ
cranioplasti
infiltr
dura
observ
histolog
examin
transit
meningioma
grade
diagnos
seri
follow
mri
examin
slowli
grow
subdur
extracerebr
mass
region
note
one
year
inilti
surgeri
patient
oper
subdur
meningioma
attach
inner
wall
dura
resect
subsequ
duraplasti
histolog
examin
reveal
transit
meningioma
grade
ident
tumor
locat
within
bone
postop
unev
tumor
recurr
mri
examin
conclus
ectop
meningioma
childhood
may
present
separ
tumor
skull
without
macroscop
visibl
cross
destroy
dura
howev
may
follow
second
subdur
extracereballar
tumor
histolog
pattern
c
vilanova
sanchez
l
j
rj
jh
children
hospit
pediatr
center
colorect
pelvic
reconstruct
columbu
usa
children
hospit
hematologyoncologybon
marrow
transplant
columbu
usa
children
ohio
state
univers
colleg
medicin
pediatr
center
colorect
pelvic
reconstruct
columbu
usa
children
ohio
state
univers
colleg
medicin
pediatr
surgeri
columbu
usa
backgroundobject
despit
variabl
present
sacrococcyg
tumor
sct
patient
without
anorect
malform
arm
appear
histolog
similar
purpos
studi
identifi
differ
oncolog
outcom
two
group
designmethod
retrospect
review
perform
util
institut
cancer
databas
colorectalpelv
reconstruct
databas
patient
sacrococcyg
presacr
mass
data
captur
includ
age
surgic
resect
altman
classif
histopatholog
recurr
result
patient
compris
cohort
arm
median
age
resect
older
arm
month
rang
day
year
without
arm
month
rang
day
year
patient
arm
altman
type
tumor
histopatholog
includ
matur
teratoma
yolk
sac
tumor
lipoma
unknown
altman
classif
patient
without
arm
includ
type
type
type
type
unknown
histopatholog
patient
sct
without
arm
includ
matur
teratoma
immatur
teratoma
malign
teratomagerm
cell
tumor
ganglioneuroma
unknown
altman
classif
statist
differ
group
p
recurr
arm
median
time
year
without
arm
median
time
year
recurr
statist
differ
two
group
three
recurr
due
failur
coccyx
resect
arm
group
event
free
surviv
ci
arm
group
ci
group
conclus
presacr
mass
patient
arm
resect
later
age
like
higher
altman
classif
high
rate
recurr
without
complet
remov
coccyx
initi
oper
c
grimaldi
l
children
hospit
ircc
surgeri
rome
itali
children
hospit
ircc
oncohematolog
rome
itali
children
hospit
ircc
radiolog
rome
itali
backgroundobject
caval
encas
retroperiton
tumor
rare
complic
pediatr
malign
data
extens
tumor
resect
simultan
caval
replac
adult
scant
furthermor
report
exist
pediatr
popul
adult
indic
challeng
surgeri
mainli
oncolog
absent
inadequ
respons
chemotherapi
clinic
treatment
symptom
caval
obstruct
renal
failur
lower
limb
edema
children
procedur
still
consid
salvag
treatment
without
clearli
extablish
indic
designmethod
data
retrospect
collect
institut
cancer
data
base
januari
februari
result
three
patient
adren
neuroblastoma
renal
cell
carcinoma
underw
tumor
resect
inferior
vena
cava
ivc
replac
one
patient
neuroblastoma
underw
auto
transplant
kidney
one
patient
aliv
diseas
free
month
surgeri
two
patient
die
recurr
diseas
month
surgeri
respect
one
patient
conduit
patent
follow
month
patient
thrombosi
conduit
demonstr
short
term
surgeri
day
respect
none
patient
sign
caval
obstruct
thrombosi
conduit
experienc
patient
anastomos
renal
vein
patent
last
follow
conclus
small
interest
seri
howev
limit
pediatr
patient
long
major
vascular
reconstruct
possibl
experienc
surgeon
tailor
reconstruct
techniqu
anatomi
extens
lesion
low
mobil
good
function
hishiki
k
c
k
k
center
child
health
develop
surgic
oncolog
tokyo
japan
center
child
health
develop
pediatr
surgeri
tokyo
japan
center
child
health
develop
children
cancer
center
tokyo
japan
center
child
health
develop
radiolog
tokyo
japan
backgroundobject
role
surgic
resect
treatment
neuroblastoma
matter
debat
postul
advantag
aggress
surgeri
indic
complet
tumor
resect
lead
better
prognosi
howev
question
specul
tumor
respond
better
chemotherapi
like
remov
easili
compar
chemoresist
tumor
conduct
retrospect
review
institut
experi
elimin
correl
respons
induct
chemotherapi
surgic
resect
designmethod
medic
record
patient
metastat
neuroblastoma
underw
definit
surgeri
institut
review
system
respons
induct
chemotherapi
evalu
use
curi
score
cs
quantit
paramet
metastat
diseas
surgic
outcom
case
one
cs
end
induct
chemotherapi
compar
whose
cs
erad
result
case
tumor
abdomin
origin
four
mediastin
tumor
use
idrf
measur
predict
safe
resect
risk
neuroblastoma
evalu
predict
complex
definit
surgeri
clearanc
idrf
induct
chemotherapi
correl
clearanc
cs
result
surgeri
resect
obtain
case
five
case
result
resect
statist
correl
cs
extent
resect
presenc
cs
signific
predictor
lower
overal
surviv
wherea
extent
surgeri
affect
overal
surviv
conclus
studi
suggest
good
respons
induct
chemotherapi
evalu
curi
score
guarante
easier
complet
resect
primari
tumor
tumor
easi
remov
poor
respond
vice
versa
precis
evalu
use
larger
cohort
warrant
verifi
find
jan
terwisscha
van
c
van
de
h
j
g
center
pediatr
surgeri
utrecht
netherland
universitair
de
pediatr
surgeri
switzerland
center
pediatr
oncolog
utrecht
netherland
backgroundobject
sinc
surgic
care
pediatr
solid
tumor
netherland
central
princess
center
pediatr
oncolog
utrecht
aim
studi
evalu
surgic
complic
mortal
neuroblastoma
nbl
wilm
tumor
wt
sinc
start
central
designmethod
prospect
observ
cohort
studi
conduct
includ
children
diagnos
treat
either
neuroblastoma
wt
princess
center
surgeri
relat
complic
mortal
document
outcom
compar
cohort
pediatr
solid
tumor
result
primari
tumor
resect
nbl
perform
children
perop
complic
rate
vs
postop
complic
rate
vs
postop
picu
support
due
complic
necessari
vs
secondari
surgeri
complic
perform
vs
surgeri
relat
mortal
occur
vs
surgeri
wt
perform
children
perop
complic
rate
vs
tumor
ruptur
occur
vs
postop
complic
rate
vs
postop
picu
support
surgic
complic
necessari
vs
secondari
surgeri
complic
perform
vs
surgeri
relat
mortal
occur
vs
conclus
seri
surgeri
relat
complic
mortal
children
treat
neuroblastoma
wilm
tumor
sinc
start
central
pediatr
oncolog
care
netherland
analyz
perop
complic
rate
neuroblastoma
clearli
improv
sinc
start
central
care
percentag
surgeri
relat
advers
event
wilm
tumor
similar
z
jenovari
z
e
univers
depart
pediatr
budapest
hungari
univers
depart
pediatr
budapest
hungari
backgroundobject
bilater
wilm
tumour
primer
nephrectomi
affect
side
nephron
spare
surgeri
side
accept
method
follow
studi
prove
worsen
kidney
function
evid
yet
regard
optim
way
preserv
maxim
renal
tissu
provid
suffici
oncolog
treatment
designmethod
retrospect
analys
data
patient
treat
unit
synchron
bilater
wilm
tumour
last
year
result
patient
found
infant
first
admiss
av
month
malefemal
ratio
none
pulmonari
metastasi
lymph
node
enlarg
patient
underw
primer
surgeri
first
patient
bilater
enucl
unilater
nephrectomi
chemotherapi
patient
underw
oper
first
patient
unilater
nephrectomi
wedg
resect
contralater
tumour
patient
postop
chemotherapi
worsen
kidney
function
follow
patient
underw
stage
surgeri
start
less
affect
side
preoper
chemotherapi
time
oper
determin
regular
mri
us
none
patient
underw
biopsi
histolog
taken
oper
favor
unfavor
one
case
stage
contralater
surgeri
attempt
chemo
cycl
time
determin
radiolog
also
follow
chemotherapi
none
patient
got
radiotherapi
one
patient
tumour
free
side
signific
renal
tissu
normal
kidney
function
one
tumour
recurr
occur
surgeri
done
mean
follow
year
year
conclus
preoper
chemotherapi
may
decreas
rate
nephrectomi
stage
nephron
spare
surgeri
carri
preoper
chemotherapi
interv
postop
chemotherapi
seem
safe
effect
way
preserv
maxim
amount
renal
tissu
b
jindal
k
kk
bk
depart
pediatr
surgeri
pondicherri
india
backgroundobject
approxim
children
wilm
tumor
present
bilater
diseas
bilater
wt
usual
associ
presenc
nephrogen
rest
congenit
malform
predispos
syndrom
major
challeng
bilater
diseas
achiev
cure
time
preserv
suffici
function
renal
tissu
normal
growth
develop
renal
failur
major
contributor
morbid
mortal
plan
review
case
bilater
wt
treat
institut
factor
contribut
morbid
mortal
designmethod
retrospect
review
case
record
bilater
wt
treat
hospit
year
outcom
result
total
case
bilater
wt
oper
last
year
six
case
five
synchron
one
metachron
bilater
wt
two
syndrom
associ
one
denysh
drash
syndrom
wagr
syndrom
one
addit
associ
hors
shoe
kidney
anomali
two
underw
sequenti
partial
nephrectomi
synchron
bilater
wt
two
simultan
nephrectomi
tumorectomi
one
hors
shoe
kidney
bilater
wt
underw
left
nephrectomi
partial
nephrectomi
side
six
patient
three
expir
two
lost
follow
one
well
year
follow
conclus
renal
failur
major
contributor
morbiditymort
bilater
wt
incid
high
develop
countri
due
late
present
associ
glomerulopathi
denysh
drash
syndrom
wagr
syndrom
condit
incid
renal
failur
increas
respect
nephron
spare
surgeri
nss
aim
prevent
renal
insuffici
rather
achiev
neg
surgic
margin
dealt
radiotherapi
sequenti
nephrectomi
simultan
nss
still
debat
point
confer
small
studi
oliveira
ff
v
rc
children
cancer
hospit
pediatr
surgeri
depart
barreto
brazil
backgroundobject
venou
access
essenti
children
treat
malign
diseas
peripher
insert
central
cathet
picc
shown
valuabl
altern
tradit
devic
provid
central
access
patient
picc
use
mani
year
develop
countri
studi
focus
pediatr
oncolog
patient
develop
countri
purpos
studi
evalu
initi
experi
picc
special
regard
feasibl
cathet
life
complic
reason
remov
children
cancer
develop
countri
pediatr
hospit
designmethod
retrospect
analysi
pediatr
oncolog
patient
underw
picc
line
insert
pediatr
surgeri
team
institut
march
march
enrol
studi
demograph
featur
primari
diagnosi
cathet
day
reason
remov
complic
review
result
picc
insert
children
period
median
cathet
life
day
rang
day
total
cathet
day
complic
rate
per
cathet
day
record
common
reason
cathet
remov
suspect
infect
occlus
dislodg
breakag
rate
per
cathet
day
respect
compar
solid
tumor
hematolog
malign
higher
median
cathet
perman
vs
lymphoma
show
highest
median
conclus
picc
line
feasibl
provid
reliabl
intranegativen
access
children
suffer
malign
although
better
care
proper
dress
import
minim
prematur
remov
suspect
infect
educ
parent
nurs
team
guidelin
need
improv
complic
rate
j
burn
children
hospit
depart
paediatr
surgeri
urolog
birmingham
unit
kingdom
children
hospit
depart
histopatholog
birmingham
unit
kingdom
children
hospit
depart
intervent
radiolog
birmingham
unit
kingdom
children
hospit
depart
medic
oncolog
birmingham
unit
kingdom
backgroundobject
percutan
renal
tumour
biopsi
crucial
plan
neoadjuv
chemotherapi
time
surgic
resect
uk
number
core
taken
oper
depend
result
inadequ
tissu
diagnosi
tumour
ruptur
consequ
upstag
studi
attempt
defin
minimum
number
core
requir
diagnosi
document
incid
tumour
ruptur
relat
number
core
sampl
taken
designmethod
biopsi
techniqu
ultrasound
guid
percutan
method
case
use
coaxial
techniqu
retrospect
review
prospect
collect
data
percutan
trucut
renal
tumour
biopsi
taken
februari
septemb
includ
analysi
inadequ
data
number
core
taken
exclud
data
demograph
diagnosi
diagnost
adequaci
number
core
collect
detail
whether
immunohistochemistri
genet
tissu
type
perform
biopsi
tissu
also
collect
result
renal
unit
biopsi
f
diagnosi
includ
wilm
tumour
case
tumour
mesoblast
nephroma
primit
neuroectoderm
tumour
rhabdomyosarcoma
nephroblastomatosi
oxalosi
normal
neuroblastoma
rhabdoid
desmoplast
srct
median
number
core
rang
biopsi
median
rang
number
core
one
tumour
ruptur
follow
biopsi
patient
core
taken
lowest
number
core
biopsi
diagnost
accuraci
lowest
number
abl
give
diagnosi
immunohistochemistri
genet
core
conclus
three
good
core
minimum
number
requir
diagnosi
subject
oper
depend
one
singl
good
core
contain
enough
tissu
diagnosi
immunohistochemistri
genet
investig
tumour
site
ongo
rybakova
state
budgetari
institut
russian
cancer
research
center
nn
blokhin
ministri
health
russia
children
oncolog
moscow
russia
backgroundobject
diagnost
endosurgeri
success
approv
adult
oncolog
data
use
method
children
oncolog
foreign
literatur
designmethod
defin
possibl
endosurgeri
diagnosi
tumor
thorac
abdomin
local
children
result
diagnost
purpos
carri
oper
children
laparoscop
thoracoscop
biopsi
except
diagnost
biopsi
execut
thoracoscop
resect
lung
children
purpos
diagnost
progress
diseas
confirm
metastat
defeat
inflammatori
process
made
diagnost
oper
age
patient
vari
month
year
children
one
year
durat
thoracoscop
laparoscop
biopsi
made
minut
minut
averag
minut
blood
loss
diagnost
oper
averag
ml
intraop
complic
case
postop
endosurgeri
oper
patient
special
treatment
carri
repeat
oper
alreadi
radic
volum
written
continu
treatment
resid
profil
establishmentth
averag
time
begin
special
treatment
made
day
conclus
advantag
use
endosurgeri
children
oncolog
earli
term
begin
special
treatment
small
injuri
minimum
blood
loss
low
number
postop
complic
earli
activ
patient
reduct
term
stay
hospit
good
cosmet
effect
perform
endosurgeri
oper
children
malign
tumor
possibl
age
sever
week
thu
oncolog
principl
perform
surgeri
nt
broken
also
age
child
nt
limit
factor
perform
endosurgeri
oper
c
jc
g
g
b
nacion
de
drcarlo
herrera
pediatr
surgic
oncolog
depart
san
costa
rica
nacion
de
drcarlo
herrera
pediatr
medic
oncolog
depart
san
costa
rica
nacion
de
drcarlo
herrera
pediatr
surgic
oncolog
pediatr
medic
oncolog
depart
san
costa
rica
nacion
de
drcarlo
herrera
depart
pediatr
immunolog
rheumatolog
san
costa
rica
nacion
de
drcarlo
herrera
flow
cytometri
laboratori
special
studi
research
san
costa
rica
backgroundobject
neuroblastoma
ms
specif
characterist
includ
presenc
month
age
metastas
liver
skin
bone
marrow
aim
present
case
primari
immunodefici
etiolog
clinic
find
child
suspect
neuroblastoma
ms
designmethod
retrospect
analysi
medic
record
patient
admit
nation
children
hospit
costa
rica
first
examin
oncolog
servic
subsequ
diagnosedtr
pediatr
immunolog
rheumatolog
depart
sirp
result
femal
previou
admiss
due
bronchiol
oxygen
depend
consult
irrit
fever
diarrhea
mother
mention
day
evolut
skin
nodul
physic
examin
hepatomegali
subcutan
nodul
document
abdomin
ultrasound
document
solid
nodul
right
adren
gland
hepatomegali
multipl
dissemin
solid
nodular
lesion
upon
clinic
suspicion
biopsi
subcutan
nodul
bone
marrow
aspiratebiopsi
perform
skin
biopsi
report
malign
cultur
nocardia
farcinica
bone
marrow
aspir
report
absenc
lymphocyt
therefor
assess
sirp
request
review
previou
blood
count
show
persist
lymphopenia
patient
requir
hospit
intens
care
unit
infect
treatment
subcutan
noduletracheobronchi
aspir
nocardia
farcinica
septicemia
due
granulicatela
adiacen
tracheobronchi
aspir
candida
albican
bcgiti
peripher
blood
lymphocyt
subset
count
compat
sever
combin
immunodefici
scid
nk
abdomin
ultrasound
show
multipl
hepat
calcifi
nodul
right
adren
nodul
partial
organ
microcalcif
patient
receiv
bone
marrow
transplant
hla
ident
mother
month
diagnosi
conclus
blood
count
assess
neonatalinf
mass
rule
leukopenia
immunodefici
think
malign
classic
featur
classifi
neoplast
origin
without
rule
patholog
c
rinaldo
j
h
haapa
copeland
p
c
harila
univers
hospit
pediatr
oncolog
stockholm
sweden
backgroundobject
today
approxim
pediatr
cancer
patient
experi
treatment
failur
die
diseas
huge
effort
academ
pharmaceut
result
mani
potenti
compound
clinic
test
itcc
innov
therapi
childhood
cancer
umbrella
organ
experiment
clinic
trial
europ
current
center
particip
aim
enabl
swedish
pediatr
patient
relaps
refractori
cancer
includ
earli
phase
clinic
trial
precis
medicin
diseas
long
term
aim
increas
surviv
rate
qualiti
life
children
adolesc
cancer
designmethod
innov
clinic
trial
unit
pediatr
oncolog
unit
karolinska
univers
hospit
stockholm
accredit
itcc
center
januari
two
senior
consult
two
experienc
pediatr
oncolog
research
nurs
appoint
time
need
addit
research
nurs
administr
staff
prioriti
result
work
plan
larg
defin
includ
design
organ
structur
requir
human
resourc
facil
financi
requir
educ
staff
administr
work
yearli
open
clinic
trial
approv
compet
author
ethic
board
final
first
patient
enrol
inform
studi
financi
support
increas
help
barncancerfonden
entrepreneur
good
other
addit
applic
pend
conclus
initi
manag
phase
iii
clinic
trial
unit
pediatr
cancer
patient
sweden
utmost
signific
part
futur
develop
pediatr
cancer
treatment
stimul
clinician
research
plan
conduct
experiment
trial
question
unit
import
educ
benefit
young
health
care
staff
special
prior
pediatr
cancer
posit
aguilar
de
la
b
ponc
c
mara
fernandez
j
huerta
e
cela
de
oncohematolog
section
pediatr
gregorio
gener
univers
hospit
madrid
spain
backgroundobject
cancer
may
consid
hypercoagul
state
therefor
venou
thromboembol
frequent
complic
adulthood
even
though
also
frequent
pediatr
oncolog
patient
risk
factor
prophilaxistreat
well
describ
designmethod
analys
patient
year
old
present
thrombosi
venou
thromboembol
vte
cancer
treatment
follow
result
patient
studi
femal
median
age
diagnosi
cancer
year
old
ds
median
time
cancer
diagnosi
vte
month
ds
symptom
present
underli
malign
solid
tumour
wilm
tumour
frequent
acut
leukemia
lymphoblast
acut
promyelocyt
leukemia
apl
common
risk
factor
presenc
central
venou
cathet
cvc
hospit
recent
surgeri
recent
treatment
corticosteroid
asparaginas
mechan
ventil
patient
blood
group
inherit
thrombophil
factor
studi
obes
sepsi
risk
factor
vte
studi
patient
receiv
specif
treatment
vte
enoxaparin
vte
diagnosi
therapi
substitut
afterward
acenocumarol
durat
therapi
patient
longer
specif
malign
treatment
regard
result
vte
complet
resolv
patient
die
apl
induct
treatment
conclus
children
cancer
risk
develop
secondari
vte
small
studi
common
risk
factor
describ
cvc
place
solid
tumour
versu
haematolog
malign
still
much
learn
risk
factor
need
specif
guidelin
treatment
prophylaxi
mj
di
dm
c
barton
hey
children
hospit
nh
foundat
trust
depart
paediatr
oncolog
liverpool
unit
kingdom
hey
children
hospit
nh
foundat
trust
depart
paediatr
respiratori
medicin
liverpool
unit
kingdom
hey
children
hospit
nh
foundat
trust
depart
paediatr
haematolog
liverpool
unit
kingdom
backgroundobject
report
case
teenag
patient
newli
diagnos
cell
acut
lymphoblast
leukaemia
present
chylou
pleural
effus
secondari
signific
mediastin
lymphadenopathi
describ
experi
manag
condit
review
current
literatur
designmethod
patient
continu
receiv
chemotherapi
treat
leukaemia
conserv
medic
approach
taken
intens
dietet
input
institut
minim
fat
diet
incorpor
exchang
system
major
dietet
challeng
provid
suffici
calori
protein
intak
requir
fat
free
nutrit
supplement
eg
paediasur
plu
juic
patient
found
unpalat
subsequ
supplement
parenter
nutrit
commenc
clinic
condit
improv
fat
content
diet
gradual
increas
parenter
nutrit
stop
medium
chain
triglycerid
supplement
ad
relax
dietari
restrict
base
clinic
assess
result
eventu
chylothorax
fulli
resolv
clinic
radiolog
conserv
manag
alon
patient
struggl
significantli
dietari
restrict
requir
signific
nutrit
counsel
adapt
diet
aid
complianc
conclus
best
practic
guidelin
manag
chylothorax
singl
systemat
review
identifi
lack
consensu
manag
option
strongest
evid
come
case
report
highli
heterogen
lack
clinic
detail
case
report
provid
greater
detail
crucial
role
dietet
support
manag
chyle
leak
lack
previou
report
research
need
gener
robust
clinic
guidanc
j
calley
l
n
h
n
aberdeen
children
hospit
depart
paediatr
oncolog
aberdeen
unit
kingdom
backgroundobject
outcom
children
cancer
continu
improv
febril
neutropenia
remain
major
caus
mortal
earli
recognit
particularli
rapid
antibiot
improv
outcom
whilst
appropri
care
allow
safe
discharg
standard
care
propos
nation
institut
health
care
excel
nice
manag
servic
network
msn
children
young
peopl
cancer
scotland
aim
audit
manag
fever
paediatr
oncolog
patient
present
tertiari
centr
north
scotland
implement
qualiti
improv
qi
intervent
support
care
deliveri
designmethod
retrospect
sampl
first
episod
fever
retriev
case
note
paediatr
oncolog
patient
treat
year
analys
perform
key
standard
clinic
assess
earli
intervent
decis
result
manag
episod
patient
analys
febril
neutropenia
febril
within
target
time
minut
patient
assess
doctor
blood
cultur
perform
empir
antibiot
administ
paediatr
earli
warn
score
seen
earlier
like
receiv
antibiot
within
target
time
vs
p
adher
local
empir
antibiot
polici
patient
appropri
hour
respect
conclus
clinic
assess
intervent
within
first
minut
identifi
key
target
area
qi
febril
neutropenia
manag
proforma
develop
implement
part
wider
qi
project
alongsid
updat
famili
inform
reinforc
emerg
care
standard
team
train
implement
programm
regular
audit
mh
chen
lh
wy
yl
kp
yc
chi
univers
scienc
technolog
nurs
hualien
taiwan
roc
taiwan
univers
nurs
taipei
taiwan
roc
taiwan
univers
psycholog
taipei
taiwan
roc
univers
mathematici
taipei
taiwan
roc
backgroundobject
studi
purpos
explor
famili
parent
treatment
decis
make
qualiti
life
child
diagnos
cancer
hospit
designmethod
institut
review
board
hospit
approv
studi
procedur
research
design
use
indepth
interview
focu
group
discuss
approach
parent
children
diagnos
cancer
hospitalus
particip
observ
studi
approach
data
collect
theme
uncov
interview
data
set
rigor
method
data
analysi
record
data
process
record
interview
particip
observ
data
analysi
author
parent
result
cancer
treatment
decis
made
parent
hospit
children
treat
cancer
mainli
includ
choos
appropri
hospit
treatment
process
fourth
theme
qualiti
life
physiolog
sleep
disturb
due
treatment
children
prone
feel
tire
catch
cold
psycholog
concern
side
effect
treatment
children
b
children
emot
chang
invas
treatment
feel
guilti
children
famili
neglect
feel
difficult
reconcil
demand
work
care
sick
children
chang
everyday
live
diet
mainli
compos
food
time
isol
home
environ
live
one
tribe
use
support
system
mutual
support
among
husband
wive
sibl
paramed
staff
conclus
expect
find
studi
could
provid
famili
member
paramed
staff
posit
forc
support
heal
children
rl
ps
kjt
emm
oncolog
institut
iopgraaccunifesp
pediatr
sao
paulo
brazil
backgroundobject
malnutrit
children
adolesc
malign
neoplasm
may
underestim
diagnosi
diseas
consid
bodi
mass
index
anthropometr
measur
abl
detect
earli
malnutrit
neck
circumfer
nc
simpl
inexpens
easili
applic
measur
clinic
practic
arm
muscular
area
ama
recogn
literatur
good
indic
muscl
mass
deplet
main
object
studi
verifi
correl
measur
nc
ama
designmethod
studi
evalu
children
adolesc
year
age
malign
neoplasm
special
pediatr
oncolog
institut
octob
june
measur
nc
evalu
ama
calcul
arm
circumfer
skinfold
tricep
perform
train
evalu
follow
anthropometr
techniqu
standard
literatur
test
perform
verifi
associ
inadequaci
ama
sex
signific
level
p
correl
nc
ama
perform
pearson
correl
result
among
patient
femal
mean
age
femal
male
correl
nc
ama
linear
posit
strong
higher
correl
coeffici
male
femal
vs
signific
differ
sex
inadequaci
ama
conclus
conclud
strong
correl
nc
ama
higher
outcom
male
addit
nc
simpl
measur
easi
appli
use
clinic
practic
de
lucio
depart
sta
cruz
de
tenerif
spain
backgroundobject
emplac
subcutan
port
ssqp
pediatr
patient
daili
routin
last
year
also
use
oncolog
patient
also
children
chronic
diseas
littl
complic
designmethod
medic
record
pediatr
patient
year
age
underw
ssqp
hospit
servic
variabl
analyz
includ
gender
age
diseas
diagnost
diseas
time
diagnosi
colloc
absolut
neutrophil
platelet
count
procedur
vein
use
complic
year
result
total
ssqp
place
patient
male
femal
eighti
four
case
malign
diseas
malign
acut
lymphoblasticmyeloblast
leukemia
lymphoma
common
diagnosi
median
age
diagnosi
year
year
time
diagnost
colloc
day
malign
case
exclud
two
cerebr
tumor
opsoclonu
syndrom
group
month
right
intern
jugular
vein
use
first
locat
case
median
absolut
neutrophil
count
procedur
rang
median
platelet
rang
median
weight
kilogram
rang
total
patient
complic
cathet
malfunct
solv
urokinas
local
posit
blood
cultur
hematoma
skin
infect
broken
system
hemotorax
first
month
patient
complic
within
first
week
procedur
new
ssqp
place
patient
differ
caus
infect
cathet
brokenmalfunct
relaps
year
conclus
conclud
ssqp
use
safe
pediatr
patient
low
risk
complic
earli
colloc
carri
addit
complic
comparison
servic
bc
elia
p
do
santo
maia
n
dorascenzi
magri
de
oncologia
pediatrica
nutrit
paulo
brazil
de
oncologia
nutrit
paulo
brazil
backgroundobject
parenter
nutrit
pn
consist
provid
macro
micronutri
directli
circulatori
system
patient
unabl
receiv
enter
nutrit
therapi
ent
consid
patient
cancer
treatment
undergo
intens
treatment
compromis
nutrit
statu
pn
altern
meet
patient
current
need
present
studi
goal
evalu
use
pn
intens
care
unit
icu
pediatr
oncolog
special
care
unit
scu
designmethod
retrospect
observ
studi
perform
pediatr
oncolog
institut
includ
patient
age
year
old
hospit
icu
scu
hour
use
pn
result
sampl
hospit
patient
indic
pn
main
clinic
diagnos
tumor
central
nervou
system
osteosarcoma
main
indic
pn
diagnosi
typhliti
accord
bodi
mass
index
malnutrit
eutrophi
use
arm
circumfer
adequ
fast
time
begin
pn
rang
day
hydroelectrolyt
disord
hemodynam
instabl
schedul
exam
main
reason
prolong
fast
earli
onset
pn
conclus
case
enter
rout
contraind
pn
may
provid
better
control
complex
diseas
state
studi
analyz
practic
pediatr
oncolog
patient
scarc
indic
studi
need
z
salcioglu
g
k
g
f
e
b
e
c
gn
sultan
suleyman
train
research
hospit
pediatr
hematolog
oncolog
istanbul
turkey
sultan
suleyman
train
research
hospit
blood
bank
depart
istanbul
turkey
backgroundobject
thrombocytopenia
commonli
encount
problem
patient
treat
chemotherapeut
agent
patient
transfus
random
donor
platelet
rdp
apheresi
deriv
platelet
adp
bleed
prophylaxi
designmethod
studi
continu
januari
april
assess
indic
use
adp
instead
rdp
pediatr
hematolog
oncolog
clinic
patient
data
collect
retrospect
blood
bank
record
patient
registri
hospit
databas
result
adp
reserv
patient
whose
age
year
old
common
patient
group
follow
aml
wilm
tumor
patient
glanzmann
thrombasthenia
patient
lymphoma
patient
neuroblastoma
patient
respect
adp
order
per
patient
adp
prepar
two
bag
mostli
form
follow
form
respect
apheresi
thrombocyt
use
mostli
prophylaxi
bleed
mortal
bleed
observ
studi
period
platelet
count
transfus
med
complet
unit
adp
one
bag
adp
dispos
due
expir
date
use
conclus
prepar
adp
singl
donor
expens
procedur
usag
upcom
expir
date
thrombocyt
concentr
must
monitor
close
blood
bank
result
understood
clinic
need
revis
indic
thrombocyt
concentr
use
need
focu
educ
thrombocyt
concentr
use
feroz
khan
univers
hospit
ibn
zohar
daycar
oncolog
karachi
pakistan
backgroundobject
incid
extravas
monitor
key
qualiti
indic
oncolog
area
howev
work
toward
precis
need
assess
knowledg
hand
capac
nurs
identifi
earli
manag
cytotox
extravas
identifi
designmethod
clinic
audit
identifi
strategi
assess
help
exist
best
practic
institut
guidelin
checklist
develop
pilot
oncolog
nurs
work
day
care
oncolog
valid
gain
clinic
audit
perform
juli
august
initi
observ
made
nurs
assess
cytotox
administr
patient
second
phase
staff
ask
demonstr
manag
extravas
simul
base
set
result
around
patient
assess
condit
last
cannul
site
howev
discolor
iv
site
identifi
notifi
physician
floor
hand
manag
extravas
nurs
abl
aspir
residu
cytotox
skin
comfort
inject
hydrocortison
extravs
site
conclus
strong
need
hand
train
extravas
assess
manag
identifi
oncolog
nurs
video
base
simul
base
learn
taken
strategi
train
oncolog
nurs
rare
occur
situat
like
extravas
r
huynh
vs
c
long
school
medicin
san
texa
usa
pediatr
hematologyoncolog
san
texa
usa
backgroundobject
though
vietnam
becom
one
top
fastest
grow
economi
global
lmic
still
need
improv
pediatr
oncolog
care
surviv
rate
low
report
vietnam
although
risen
beyond
point
rate
remain
well
western
develop
counterpart
low
surviv
rate
attribut
differ
chemotherapi
treatment
well
inexperi
support
care
prevent
measur
central
line
associ
blood
stream
infect
clabsi
monitor
designmethod
medic
director
three
institut
ho
chi
minh
citi
vietnam
citi
children
hospit
children
hospit
children
hospit
survey
determin
central
line
infect
identifi
monitor
pediatr
hematologyoncolog
patient
popul
question
includ
whether
director
familiar
recent
aspic
guidelin
prevent
clabsi
monitor
polici
current
estim
educ
staff
use
approach
implement
develop
infrastructur
polici
monitor
rate
long
term
staff
member
survey
also
provid
insight
gap
care
result
though
limit
mani
resourc
two
survey
institut
report
major
pediatr
oncolog
patient
use
central
line
regularli
one
hospit
yet
begun
care
pediatr
oncolog
patient
three
howev
current
polici
procedur
place
clabsi
monitor
estim
infect
rate
report
vari
wide
rang
hospit
director
view
initi
respons
support
care
train
posit
direct
observ
reveal
inconsist
unanticip
problem
ineffect
occlus
dress
adhes
within
humid
environ
conclus
report
clabsi
rate
pediatr
cancer
hospit
within
southern
vietnam
report
repres
initi
commit
toward
qualiti
improv
effort
improv
take
place
time
detail
provid
ks
lee
de
hr
sy
tk
jk
jy
nation
univers
hospit
depart
pediatr
daegu
republ
korea
backgroundobject
era
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
pcp
decreas
rare
howev
limit
report
transmiss
diseas
cours
pcp
pediatr
immunocompromis
patient
tmpsmx
prophylaxi
recent
cluster
pcp
report
hospit
construct
set
investig
studi
assess
risk
factor
pcp
outbreak
designmethod
retrospect
review
medic
record
pediatr
patient
diagnos
hematolog
malign
solid
tumor
receiv
chemotherapi
kyungpook
nation
univers
children
hospit
octob
march
among
patient
diagnos
pneumonia
chemotherapi
medic
record
patient
respond
empir
antibiot
therapi
commun
acquir
pneumonia
hospit
acquir
pneumonia
review
clinic
characterist
review
result
octob
march
four
patient
receiv
chemotherapi
tmpsmx
prophylaxi
diagnos
proven
suspect
pcp
case
occur
within
month
period
august
decemb
hospit
construct
durat
episod
overlap
time
suggest
possibl
transmiss
chemotherapi
acut
lymphoblast
leukemia
one
consolid
three
mainten
chemotherapi
three
pcp
patient
mainten
chemotherapi
clinic
improv
tmpsmx
treatment
adjuv
corticosteroid
therapi
pcp
patient
consolid
chemotherapi
expir
due
progress
acut
respiratori
distress
syndrom
pneumothorax
receiv
mechan
ventil
support
two
patient
show
pneumocysti
carinii
pcr
posit
two
patient
show
neg
result
conclus
cluster
pcp
signific
term
air
born
transmiss
pneumocysti
hospit
construct
set
consid
high
morbid
mortal
pcp
respiratori
isol
suspect
patient
construct
environment
reservoir
control
also
import
addit
accur
diagnosi
earli
treatment
n
kisbi
n
famili
support
leed
unit
kingdom
teach
hospit
trust
oncolog
outreach
team
leed
unit
kingdom
backgroundobject
candlelight
provid
support
famili
affect
childhood
cancer
year
part
support
specif
sibl
group
children
affect
childhood
cancer
develop
group
support
wider
member
multidisciplinari
team
overal
aim
undertak
work
directli
sibl
everi
brother
sister
opportun
receiv
support
within
environ
feel
safe
comfort
sibl
often
view
forgotten
group
need
overlook
sibl
tri
come
term
sever
brother
sister
ill
may
give
rise
number
conflict
emot
designmethod
candlelight
group
offer
time
opportun
sibl
situat
also
give
opportun
focu
even
hour
opportun
group
provid
chanc
talk
profession
directli
involv
care
famili
enabl
ask
question
may
feel
uncomfort
ask
famili
fear
upset
importantli
provid
space
sibl
time
fun
group
held
per
month
altern
children
go
treatment
bereav
sibl
three
time
per
year
group
come
togeth
trip
monthli
group
held
candlelight
squar
result
candlelight
fun
help
forget
stuff
go
home
candlelight
help
peopl
make
friend
candlelight
alway
say
feel
conclus
feedback
result
state
sibl
group
provid
much
need
support
sibl
affect
childhood
cancer
madney
k
l
cancer
institut
cairo
univers
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
pediatr
oncolog
cairo
egypt
cancer
hospit
egypt
clinic
patholog
cairo
egypt
cancer
hospit
egypt
clinic
microbiolog
cairo
egypt
cancer
hospit
egypt
clinic
research
cairo
egypt
backgroundobject
invas
fusariosi
though
rare
may
caus
dissemin
infect
patient
hematolog
malign
hematopoiet
stem
cell
transplant
recipi
mortal
attribut
fusarium
infect
immunocompromis
patient
rang
designmethod
report
case
acut
myeloid
leukemia
male
patient
year
old
admit
hospit
children
cancer
hospit
egypt
patient
start
induct
chemotherapi
micafungin
prophylaxi
chemotherapi
accord
polici
day
induct
patient
multipl
skin
lesion
start
erythemat
rais
papul
indur
pain
central
area
necrosi
well
target
lesion
perfor
nasal
septum
patient
shift
broader
spectrum
liposom
amphotericin
b
result
fusarium
isol
blood
cultur
fungal
screen
done
includ
ct
chest
sinus
abdomen
show
non
specif
bilater
pulmonari
infiltr
sinus
fundu
examin
free
biopsi
taken
skin
lesion
show
fungal
hypha
septat
branch
associ
round
bulbou
end
consist
fusarium
infect
clinic
improv
heal
ulcer
skin
lesion
resolut
pulmonari
infiltr
recoveri
neutropenia
bone
marrow
aspir
done
assess
respons
treatment
show
complet
remiss
patient
discharg
voriconazol
achiev
therapeut
level
reassess
cycl
chemotherapi
show
clinic
radiolog
improv
patient
kept
voriconazol
secondari
prophylaxi
conclus
fusariosi
though
rare
suspect
cover
appropri
antifung
presenc
suspect
cutan
lesion
immunocompromis
patient
due
lack
clinic
trial
critic
role
immun
reconstitut
outcom
fusariosi
optim
treatment
strategi
patient
sever
fusarium
infect
remain
unclear
revers
immunosuppress
recommend
whenev
possibl
l
p
marec
berard
et
doncologi
pediatriqu
ihop
centr
berard
lyon
franc
backgroundobject
nutrit
state
major
prognost
factor
pediatr
oncolog
enter
feed
gastrostomi
increasingli
use
prevent
treat
malnutrit
popul
main
object
studi
describ
immedi
late
complic
aris
gastrostomi
placement
procedur
designmethod
perform
retrospect
monocentr
observ
studi
children
treat
pediatr
oncolog
center
benefit
placement
button
gastrostomi
oncolog
treatment
result
thirti
three
patient
male
femal
mean
age
year
benefit
button
gastrostomi
placement
fourteen
malnourish
time
diagnosi
time
gastrostomi
insert
averag
month
later
percutan
radiolog
placement
use
case
prophylact
antibiot
prescrib
patient
enter
feed
start
averag
day
procedur
mean
delay
insert
remov
month
report
side
effect
aris
first
day
later
consist
leak
infect
requir
gener
local
antibiot
treatment
vomit
granul
tissu
format
bedsor
accident
remov
time
button
remov
patient
still
undernourish
conclus
gastrostomi
feed
chronic
pediatr
diseas
well
describ
pediatr
oncolog
benefit
clearli
demonstr
respons
numer
late
complic
could
disturb
oncolog
treatment
plan
complic
could
avoid
earlier
nutrit
evalu
support
e
neumann
children
hospit
nh
foundat
trust
haematologyoncolog
birmingham
unit
kingdom
backgroundobject
background
chemotherapi
remain
treatment
mani
paediatr
cancer
condit
research
wood
et
al
found
nausea
vomit
cinv
document
distress
childhood
cancer
treatment
research
among
adult
popul
found
cancer
nurs
play
integr
role
manag
cinv
knowledg
understand
lack
compar
data
avail
within
paediatr
field
aim
explor
understand
nurs
knowledg
cinv
identifi
futur
learn
need
ultim
improv
patient
care
improv
knowledg
symptom
staff
designmethod
method
quantit
studi
adapt
previous
use
questionnair
explor
nurs
understand
cinv
work
principl
treatment
centr
ptc
three
level
paediatr
oncolog
share
care
unit
poscu
within
unit
kingdom
purpos
sampl
techniqu
utilis
questionnair
target
popul
regist
nurs
work
four
site
result
analys
use
descript
inferenti
statist
demonstr
nurs
overal
understand
knowledg
cinv
relat
paediatr
cancer
result
result
respons
rate
overal
knowledg
gap
exist
amongst
nurs
research
site
signific
differ
knowledg
level
ptc
poscu
nurs
observ
nurs
awar
avail
assess
tool
cinv
conclus
conclus
nurs
knowledg
distress
symptom
need
increas
order
improv
patient
care
experi
popular
choic
receiv
educ
face
face
onlin
modul
learn
featur
least
popular
choic
among
particip
signific
gap
knowledg
regard
avail
assess
tool
therefor
knowledg
increas
subject
j
nonaka
univers
human
servic
faculti
health
social
work
school
nurs
yokosuka
japan
colleg
nurs
nurs
nagano
japan
backgroundobject
questionnair
survey
conduct
support
sibl
children
diseas
disabl
involv
ward
manag
free
descript
analyz
clarifi
current
statu
challeng
support
designmethod
subject
seventi
ward
manag
support
sibl
children
hospit
pediatr
throughout
japandata
collect
method
procedur
questionnair
distribut
envelop
facil
previous
consent
cooper
studi
analyt
method
content
collect
descript
analyz
group
base
semant
similar
differ
creat
categori
approv
research
ethic
committe
research
facil
previous
obtain
result
respond
background
among
ward
manag
hospit
special
pediatr
throughout
japan
facil
respond
exampl
sibl
support
support
pediatr
patient
sibl
support
sibl
allow
enter
ward
support
discharg
home
make
environment
tempor
arrang
sibl
famili
stay
togeth
hold
event
sibl
provid
explan
sibl
desir
expect
system
organ
relat
sibl
support
outpati
divis
make
environment
systemat
arrang
sibl
famili
stay
togeth
organ
system
take
care
sibl
develop
human
resourc
perform
nurs
care
famili
statu
sibl
support
respond
note
follow
issu
insuffici
manpow
risk
infect
individu
approach
altern
equip
use
conclus
ward
manag
made
environment
tempor
systemat
arrang
coordin
visit
gave
consider
awar
also
note
care
consid
appropri
method
support
patient
sibl
support
difficult
requir
suffici
consider
highlight
necess
establish
system
ward
manag
provid
sibl
famili
support
platschek
v
b
hk
sport
univers
cologn
institut
movement
neurosci
cologn
germani
cologn
depart
pediatr
oncolog
children
hospit
cologn
germani
backgroundobject
fatigu
one
frequent
sever
symptom
experienc
pediatr
oncolog
patient
treatment
fatigu
multidimension
distress
symptom
affect
qualiti
life
uncertainti
regard
predict
power
physic
activ
prior
diseas
rel
factor
fatigu
outcom
pediatr
cancer
patient
designmethod
eleven
pediatr
cancer
patient
femal
mean
year
pedsql
multidimension
fatigu
scale
questionnair
complet
cancer
therapi
type
cancer
present
studi
leukemia
lymphoma
sarcoma
neuroblastoma
standard
treatment
pediatr
patient
adjuv
chemotherapi
accord
nation
protocol
daili
activ
level
diseas
retrospect
interrog
hour
divis
activ
time
sleep
sit
lie
awak
bed
begin
treatment
pearson
correl
student
use
analyz
data
result
mean
time
start
cancer
therapi
fatigu
questionnair
day
mean
activ
level
diseas
hour
per
day
rang
hour
patient
higher
activ
level
diseas
show
signific
higher
fatigu
score
cancer
therapi
higher
score
indic
lower
fatigu
howev
age
gender
less
sever
impact
fatigu
outcom
conclus
activ
statu
diseas
seem
power
predictor
fatigu
among
pediatr
oncolog
patient
factor
like
gender
age
find
emphas
import
physic
activ
lessen
side
effect
cancer
therapi
roja
diachinski
children
hospit
pediatr
hematolog
oncolog
edmtonon
canada
children
hospit
pediatr
hematolog
oncolog
edmonton
canada
backgroundobject
ifosfamid
ifo
commonli
use
chemotherapi
agent
pediatr
solid
tumor
known
side
effect
ifo
renal
tubulopathi
rt
limit
data
suggest
nac
prevent
nephropathi
induc
ifo
aim
report
cohort
children
rt
secondari
ifo
success
treat
nac
designmethod
case
seri
children
solid
tumor
age
year
rt
secondari
ifo
treat
nac
result
two
patient
fulfil
criteria
patient
receiv
nac
intraven
post
ifo
follow
hour
hour
hour
patient
one
relaps
rhabdomyosarcoma
receiv
ifo
etoposid
day
carboplatin
day
extend
eight
cours
patient
two
osteosarcoma
previous
treat
methotrex
cisplatin
doxorubicin
ten
week
subsequ
requir
oral
replac
magnesium
receiv
two
cours
ifo
etoposid
five
day
patient
receiv
mesna
per
institut
guidelin
patient
one
develop
rt
cours
patient
two
cours
signific
hypophosphatemia
hypomagnesemia
hypokalemia
hyponatremia
acidosi
requir
intraven
replac
sodium
chlorid
potassium
phosphat
magnesium
follow
two
week
oral
replac
patient
one
receiv
nac
cours
patient
two
cours
first
cours
nac
patient
develop
mild
hypophosphatemia
hypomagnesemia
acidosi
electrolyt
normal
requir
day
oral
potassium
phosphat
magnesium
patient
one
requir
electrolyt
replac
cours
conclus
report
two
patient
solid
tumor
rt
secondari
ifo
respond
treatment
nac
given
concomitantli
ifo
prospect
studi
requir
confirm
therapeut
approach
f
n
yazici
b
univers
depart
pediatr
adana
turkey
univers
depart
pediatr
surgeri
adana
turkey
univers
depart
patholog
adana
turkey
backgroundobject
intestin
mucor
mycosi
rare
frequent
fatal
condit
patient
designmethod
male
diagnos
stage
iii
nhl
anoth
hospit
admiss
center
first
cours
chemotherapi
experienc
tumor
lysi
posterior
revers
ensefalopathi
syndrom
press
detect
low
creatinin
clearenc
panhypogammaglobulinemia
b
type
lymphopenia
partial
respons
lymphoma
immunosupress
type
could
adress
primari
secondari
intraven
immunoglobulin
ivig
administ
b
block
bfm
regimen
start
febril
neutropenia
occur
earli
meropenem
teicoplanin
fluconazol
given
empric
treatment
amikacin
ad
resist
fever
day
antibiot
abdomin
cramp
vomit
fluid
level
plain
nasogastr
decompress
metronidazol
caspofungin
start
day
conserv
manag
cytolog
improv
laparotomi
made
jejun
ileal
segment
necrosi
perfor
ileostomi
segmentari
jejun
resect
made
day
second
surgeri
made
resect
ileum
necrosi
specimen
show
mucor
mycosi
liposom
amfoterisin
b
start
result
complet
treatment
febril
neutropenia
cours
vinkristin
doxorubicin
cyclophosphamid
etoposid
given
third
surgeri
done
abcess
day
second
surgeri
mucor
mycosi
display
specimenamphotericin
b
continu
day
switch
posaconazol
kidney
function
chemotherapi
could
continu
due
fungal
infect
nephrotox
weekli
rituximab
adminest
cours
patient
still
remiss
month
primari
diseas
conclus
patient
present
rare
highli
lethal
fungal
infect
induct
treatment
burkitt
lymphoma
treat
surgic
resect
antifung
treatment
nandaula
cancer
institut
palli
care
research
kampala
uganda
backgroundobject
mani
peopl
live
die
pain
uganda
studi
done
describ
famili
leader
differ
commun
impact
commun
base
servic
deliveri
intervent
major
object
see
childern
care
digin
especi
diagnos
termin
ill
designmethod
differ
modul
use
uganda
rapid
evalu
field
techniqu
commun
done
get
data
three
sourc
observ
clinic
encount
interview
inform
local
healthi
leader
forget
data
collect
statist
result
interview
termin
ill
caregiv
repres
leader
site
antivir
use
effect
children
valu
treat
digniti
respect
without
discrimin
support
home
reduc
physic
emot
financi
burden
travel
care
health
facil
practic
support
instruct
feed
bath
patient
facilit
good
death
home
inform
given
commun
mobil
phone
enabl
access
clinic
social
support
work
client
repres
commun
leader
report
care
hivaid
children
especi
poor
commun
stress
also
reward
resili
forc
good
treatment
therapi
conclus
programm
new
report
success
integr
symptom
control
practic
physic
care
educ
spiritu
care
children
holist
pediatr
palli
care
deliv
effect
face
commun
leader
integr
public
health
approach
sarpong
bu
teach
hospit
depart
child
health
accra
ghana
backgroundobject
high
treatment
abandon
rate
major
contributor
treatment
failur
develop
countri
children
receiv
treatment
cancer
abandon
treatment
ghana
year
intern
twin
project
commenc
continu
declin
number
children
interrupt
treatment
paper
assess
factor
motiv
parent
continu
treatment
despit
daunt
constraint
contribut
twin
project
toward
progress
made
designmethod
key
project
activ
includ
train
workshop
internship
treatment
sponsorship
psychosoci
support
set
data
regist
analysi
data
two
regist
establish
consist
declin
treatment
abandon
aid
questionnair
parent
randomli
select
interview
januari
decemb
stata
version
use
data
analysi
descript
statist
employ
result
present
result
total
children
present
cancer
treatment
two
centr
particip
studi
parent
femal
male
major
said
treatment
sponsorship
key
enabl
condit
help
continu
treatment
psychosoci
support
peer
import
factor
urg
parent
factor
motiv
financi
support
extend
famili
sourc
believ
love
conclus
psychosoci
support
treatment
sponsorship
combin
cite
respond
import
factor
contribut
lower
treatment
abandon
rate
intern
twin
partnership
activ
includ
train
psychosoci
support
treatment
sponsorship
hold
potenti
lower
treatment
abandon
rate
develop
countri
advocaci
sustain
treatment
fund
govern
import
treatment
abandon
could
elimin
develop
countri
alderf
goldish
behalf
sparccc
summit
dupont
hospit
children
center
healthcar
deliveri
scienc
wilmington
usa
partnership
research
care
childhood
cancer
usa
backgroundobject
purpos
present
describ
process
outcom
sibl
research
summit
day
gather
research
clinician
advoc
sibl
children
cancer
focus
upon
set
agenda
advocaci
research
care
sibl
children
cancer
designmethod
novemb
sibl
partnership
advocaci
research
care
childhood
cancer
sparccc
host
sibl
research
summit
philadelphia
financi
support
alex
lemonad
stand
foundat
alsf
introductori
remark
member
sparccc
alsf
panel
adolesc
young
adult
sibl
told
stori
cancer
impact
famili
research
clinician
advoc
introduc
work
recent
systemat
review
sibl
literatur
present
group
set
identifi
prioriti
move
advocaci
research
care
sibl
children
cancer
forward
result
four
prioriti
area
identifi
discuss
identifi
measur
ultim
cost
childhood
cancer
sibl
ie
psychosoci
develop
achiev
financi
screen
sibl
children
cancer
unmet
need
adjust
difficulti
provid
appropri
level
care
eg
educ
monitor
intervent
develop
intervent
empir
evalu
new
exist
intervent
sibl
eg
oncolog
camp
supersib
advanc
educ
awar
within
famili
commun
eg
school
healthcar
system
regard
psychosoci
issu
face
sibl
famili
children
cancer
influenc
healthcar
polici
ie
includ
sibl
care
conclus
progress
made
understand
address
psychosoci
need
sibl
children
cancer
howev
coordin
intern
collabor
key
stakehold
need
propel
effort
forward
acknowledg
gener
support
alsf
cigna
thank
sibl
research
summit
particip
e
atwood
f
fuent
l
th
chan
school
public
health
global
health
popul
boston
usa
nacion
de
oncologia
pediatrica
pediatr
oncolog
guatemala
citi
guatemala
bloom
nation
children
hospit
centro
medico
ayudam
vivir
san
salvador
el
salvador
infantil
teleton
de
oncologia
pediatr
oncolog
queretaro
mexico
farberboston
children
cancer
blood
disord
center
global
health
institut
boston
usa
backgroundobject
best
practic
identifi
match
inform
need
parent
time
child
diagnosi
cancer
current
unknown
research
countri
even
limit
also
littl
guidanc
deliv
inform
parent
set
aspect
consid
develop
inform
includ
socioeconom
level
parent
cultur
languag
barrier
avail
qualifi
personnel
resourc
creat
educ
materi
studi
assess
famili
receiv
inform
explor
need
regard
import
topic
desir
method
commun
designmethod
qualit
studi
design
interview
conduct
english
spanish
use
structur
guid
key
inform
includ
parent
physician
nurs
psychosoci
staff
administr
foundat
leadership
volunt
commun
govern
profession
studi
site
includ
unidad
guatemala
benjamin
bloom
hospit
el
salvador
hospit
infantil
de
mexico
nvivo
use
themat
analysi
result
across
site
common
question
child
cancer
discuss
children
educ
need
includ
explain
origin
cancer
address
percept
guilt
myth
cancer
care
child
home
adher
treatment
prefer
commun
medium
audiovisu
tool
video
internet
radio
secondari
option
conclus
studi
demonstr
educ
need
parent
differ
despit
geograph
proxim
share
languag
develop
educ
program
set
challeng
crucial
maintain
famili
particip
studi
use
guid
program
want
develop
educ
materi
research
could
evalu
effect
inform
educ
parent
children
medic
center
israel
pediatr
israel
backgroundobject
adolesc
hormon
physic
mental
chang
occur
chang
effect
bodi
imag
self
esteem
sexual
health
complex
teenag
cancer
patient
diseas
therapi
effect
neg
bodi
imag
self
esteem
object
identifi
variabl
affect
self
esteem
bodi
imag
sexual
among
teenag
cancer
patient
designmethod
year
data
collect
via
interview
adolesc
cancer
patient
treat
depart
pediatr
hematolog
oncolog
scmci
result
fourteen
adolesc
boy
girl
particip
averag
age
year
femal
adolesc
possess
lower
bodi
imag
male
counterpart
p
decreas
found
bodi
imag
among
male
adolesc
underw
fertil
preserv
procedur
compar
p
femal
teenag
gnrh
antagonist
treatment
report
significantli
higher
bodi
imag
compar
treat
p
adolesc
engag
sexual
prior
ill
experienc
decreas
bodi
imag
pearson
test
show
posit
correl
p
bodi
imag
neg
correl
p
bodi
imag
side
effect
regress
analysi
demograph
data
sexual
relat
variant
found
higher
satisfact
bodi
imag
p
intim
behavior
prior
ill
p
parent
marit
statu
marri
predict
higher
treatment
conclus
bodi
imag
neg
affect
cancer
treatment
percept
side
effect
teenag
greater
decreas
need
comprehens
prepar
prior
fertil
preserv
procedur
medic
treatment
explan
emot
support
adolesc
prepar
intervent
studi
effect
fertil
preserv
procedur
need
k
van
h
de
v
vl
vn
g
center
psychosoci
research
healthcar
innov
utrecht
netherland
children
amc
pediatr
oncolog
amsterdam
netherland
jude
children
research
hospit
psycholog
memphi
usa
children
radboud
univers
medic
center
medic
psycholog
nijmegen
netherland
medic
center
pediatr
hematologyoncolog
amsterdam
netherland
backgroundobject
cancer
diagnosi
influenc
health
relat
qualiti
life
hrqol
object
studi
describ
hrqol
adolesc
age
year
activ
treatment
cancer
compar
healthi
peer
get
insight
oncolog
specif
hrqol
treatment
designmethod
hrqol
measur
use
pedsql
pediatr
qualiti
life
inventori
mean
scale
score
compar
adolesc
cancer
healthi
refer
group
use
manova
analysi
measur
hrqol
pedsql
cancer
modul
use
score
dichotom
absenc
problem
never
preval
problem
often
almost
often
percentag
calcul
determin
proport
adolesc
report
problem
pedsql
cancer
modul
result
adolesc
activ
cancer
treatment
report
significantli
lower
physic
mcancer
mcontrol
emot
social
mcancer
school
psychosoci
total
hrqol
score
ps
effect
size
small
larg
preval
cancer
specif
hrqol
problem
highest
item
pain
hurt
joint
muscl
nausea
nausea
treatment
food
nt
tast
good
nausea
smell
food
worri
relaps
side
effect
cognit
problem
pay
attent
physic
appear
look
good
domain
conclus
lower
hrqol
cancer
specif
problem
experienc
physic
psychosoci
domain
monitor
hrqol
utmost
import
adequ
support
adolesc
intervent
focu
physic
aspect
reliev
pain
nausea
also
inform
treatment
decreas
worri
help
schoolwork
support
deal
bodi
imag
v
crabtre
h
j
la
jude
children
research
hospit
psycholog
memphi
usa
jude
children
research
hospit
biostatist
memphi
usa
tennesse
health
scienc
center
ophthalmolog
memphi
usa
jude
children
research
hospit
oncolog
memphi
usa
backgroundobject
fatigu
one
consist
distress
symptom
report
pediatr
oncolog
patient
bright
white
light
shown
prevent
increas
fatigu
adult
breast
cancer
patient
reduc
fatigu
adult
cancer
survivor
howev
definit
intervent
reduc
fatigu
develop
pediatr
oncolog
patient
current
studi
design
estim
feasibl
accept
bright
white
light
intervent
decreas
fatigu
adolescentsyoung
adult
aya
newli
diagnos
receiv
treatment
solid
tumor
includ
lymphoma
designmethod
aya
age
diagnos
solid
malign
includ
lymphoma
past
day
begun
therapi
approach
particip
particip
random
receiv
dim
red
light
drl
n
bright
white
light
bwl
n
minut
upon
awaken
daili
eight
week
side
effect
assess
weekli
via
modifi
systemat
assess
treatment
emerg
effect
safte
result
feasibl
intervent
priori
defin
least
particip
consent
particip
preliminari
data
check
approach
particip
consent
demonstr
initi
evid
feasibl
determin
accept
stop
rule
develop
evalu
side
effect
extrem
headach
eye
strain
first
particip
complet
intervent
preliminari
find
demonstr
drl
patient
report
extrem
headach
eye
strain
one
bwl
patient
report
extrem
blur
vision
week
bwl
patient
report
extrem
headach
conclus
preliminari
find
feasibl
accept
trial
bright
white
light
reduc
fatigu
aya
newli
diagnos
solid
tumor
demonstr
use
light
therapi
feasibl
accept
measur
fatigu
mood
adher
continu
collect
provid
addit
inform
regard
potenti
efficaci
promis
intervent
viola
k
cancer
institut
new
jersey
medicinepopul
scienc
new
brunswick
usa
cancer
institut
new
jersey
medicin
new
brunswick
usa
backgroundobject
childhood
cancer
survivor
grow
popul
risk
advers
late
effect
treatment
survivor
requir
lifelong
care
howev
less
survivor
obtain
necessari
care
mani
survivor
lost
transit
pediatr
adult
care
partial
due
low
transit
readi
skill
motiv
resourc
make
transit
intervent
develop
improv
transit
readi
among
adolesc
young
adult
aya
cancer
studi
aim
identifi
content
intervent
aya
survivor
designmethod
initi
interview
aya
survivor
pediatr
cancer
identifi
barrier
facilit
care
next
conduct
interview
aya
survivor
age
femal
parent
medic
provid
identifi
essenti
compon
intervent
inform
interview
model
readi
transit
basic
content
intervent
develop
three
aya
survivor
gave
feedback
intervent
modul
themat
content
analysi
two
independ
rater
use
identifi
target
intervent
result
major
theme
modul
includ
understand
treatment
survivorship
care
plan
logist
manag
health
care
insur
negoti
famili
involv
care
deal
emot
stay
healthi
context
life
transit
initi
feedback
aya
survivor
indic
content
relev
includ
interact
element
narrat
present
video
tailor
feedback
make
intervent
engag
conclus
incorpor
aya
survivor
parent
provid
design
phase
essenti
content
develop
program
current
refin
content
use
random
control
trial
aya
childhood
cancer
survivor
fawaz
f
bairouni
univers
hospit
cancer
pediatr
depart
damascu
syria
cancer
institut
center
cancer
genet
prevent
boston
usa
backgroundobject
childhood
cancer
challeng
child
hisher
parent
medic
care
provid
limit
resourc
countri
war
condit
violenc
present
treatment
much
harder
physic
emot
involv
designmethod
observ
discuss
colleagu
patient
parent
year
much
syria
experienc
war
report
way
occurr
war
associ
hardship
add
multipl
burden
challeng
threaten
psycholog
equilibrium
cope
effort
patient
parent
provid
observ
occur
depart
pediatr
oncolog
al
bairouni
hospit
damascu
one
syrian
hospit
offer
special
pediatr
cancer
treatment
result
disempower
major
psycholog
burden
fear
anxieti
loss
hope
also
difficult
psycholog
challeng
face
treat
cancer
wartim
includ
chang
life
prioriti
child
hisher
famili
lack
medic
avail
increas
cost
difficulti
danger
transport
patient
hospit
locat
heavi
result
psycholog
impact
patient
parent
medic
care
provid
exposur
war
worri
safeti
near
distant
famili
member
affect
medic
care
provid
attent
avail
energi
well
conclus
childhood
cancer
complic
problem
syria
unsaf
hospit
locat
difficulti
transport
wartim
problem
creat
challeng
childhood
cancer
manag
increas
psycholog
burden
face
patient
famili
health
care
provid
haley
e
k
r
leed
school
medicin
leed
unit
kingdom
teach
hospit
trust
paediar
oncolog
leed
unit
kingdom
backgroundobject
children
brain
cancer
known
like
suffer
suicid
ideat
depress
oncolog
counterpart
hypothesis
need
psycholog
input
would
higher
paediatr
patient
compar
paediatr
oncolog
patient
aim
assess
need
psycholog
servic
within
paediatr
oncolog
depart
alter
servic
meet
demand
designmethod
patient
data
collat
databas
within
paediatr
oncolog
depart
ltht
five
year
period
collect
inform
patient
age
diagnosi
gender
tumour
type
treatment
receiv
includ
number
psycholog
referr
made
reason
referr
treatment
type
combin
code
interpret
result
data
collect
patient
refer
clinic
psycholog
servic
within
ltht
nearli
patient
refer
psycholog
compar
oncolog
group
signific
differ
gender
age
common
treatment
signific
major
referr
chemotherapi
potenti
due
long
hospit
stay
disrupt
daili
life
conclus
result
consist
exist
research
strengthen
argument
target
specialis
psycholog
support
group
clinic
implic
servic
discuss
c
hungr
lb
cj
farber
cancer
institut
pediatr
oncolog
boston
usa
backgroundobject
health
implic
survivor
victim
ident
describ
adult
cancer
survivor
littl
known
ident
childhood
cancer
survivor
cc
studi
investig
cc
parent
view
child
survivorship
ident
associ
ident
child
function
designmethod
cc
femal
mean
prospect
cohort
studi
rate
identif
survivor
victim
ident
scale
perceiv
impact
cancer
ident
frequenc
thought
cancer
parent
complet
parallel
rate
percept
child
ident
impact
cancer
child
frequenc
thought
child
cancer
ident
term
dichotom
high
low
cutoff
current
function
assess
pedsql
result
overal
cc
parent
endors
victim
ident
major
cc
parent
endors
survivor
ident
pedsql
score
associ
parent
child
rate
either
ident
within
dyad
signific
number
parent
thought
cancer
frequent
child
also
dyad
disagre
significantli
endors
survivor
ident
dyad
gave
discrep
rate
result
parent
endors
child
survivor
child
dyad
agre
significantli
impact
cancer
child
ident
conclus
cc
parent
identifi
term
victim
though
commonli
identifi
term
survivor
although
dyad
agre
impact
cancer
cc
ident
parent
overal
thought
cancer
frequent
like
child
see
cc
survivor
notabl
cc
ident
relat
futur
studi
could
explor
function
implic
survivorship
ident
r
johnson
b
p
cf
b
j
bridg
children
hospitalmulticar
health
system
pediatr
hematologyoncolog
tacoma
usa
bridg
children
hospitalmulticar
health
system
multicar
institut
research
innov
tacoma
usa
australia
canteen
australia
nsw
australia
backgroundobject
facil
program
target
adolesc
young
adult
aya
age
emerg
within
commun
cancer
center
unit
state
describ
format
first
meet
commun
aya
stakehold
council
report
discuss
theme
prioriti
group
designmethod
creat
stakehold
council
identifi
healthcar
need
prefer
aya
treat
commun
cancer
center
group
includ
nine
patientssurvivor
two
parent
one
spous
one
sibl
two
research
child
life
specialist
conven
workshop
moder
canteen
australia
particip
share
compar
healthcar
experi
identifi
unmet
need
workshop
note
analyz
use
induct
content
analysi
identifi
theme
group
also
priorit
topic
futur
discuss
action
result
experi
aya
treat
commun
center
vari
wide
major
report
satisfact
cancer
treatment
experi
experi
ident
express
advocaci
major
theme
discuss
group
enthusiast
share
stori
advoc
other
identifi
topic
futur
discuss
identifi
rank
greatest
need
aya
commun
medic
center
peer
connect
identifi
press
need
follow
govern
advocaci
improv
program
financi
support
complementari
medicin
research
clinic
trial
staff
educ
choic
voic
fertil
survivorship
mental
health
servic
conclus
aya
report
posit
treatment
experi
commun
medic
center
desir
peer
connect
financi
support
empower
healthcar
kamalyan
j
b
l
l
l
g
hospit
complex
yerevan
state
medic
univers
clinic
chemotherapi
yerevan
armenia
children
cancer
blood
disord
center
depart
psychosoci
oncolog
palli
care
boston
usa
children
cancer
blood
disord
center
global
health
initi
boston
usa
children
cancer
blood
disord
center
pediatr
stem
cell
transplant
center
boston
usa
backgroundobject
histor
armenia
cancer
view
exclus
medic
issu
comprehens
psychosoci
servic
offer
patient
effort
integr
psycholog
care
multidisciplinari
cancer
care
develop
psychosoci
oncolog
program
aim
provid
support
pediatr
adult
cancer
patient
famili
begin
time
diagnosi
continu
throughout
cours
treatment
thu
march
clinic
chemotherapi
muratsan
hospit
complex
yerevan
state
medic
univers
support
children
cancer
blood
disord
center
global
health
initi
dfbc
ghi
citi
smile
foundat
first
psychosoci
oncolog
program
armenia
establish
program
staf
two
psychologist
designmethod
program
develop
includ
review
analysi
exampl
deliveri
care
high
countri
lmic
design
psychosoci
model
care
creation
need
assess
tool
format
clinic
progress
note
translat
materi
patient
famili
provid
develop
mechan
involv
volunt
servic
activ
other
carri
ongo
consult
specialist
dfbc
ghi
result
result
program
develop
follow
servic
avail
patient
famili
psychosoci
assess
individu
psychotherapi
patient
famili
group
counsel
children
parent
bereav
support
psychoeduc
organ
sociocultur
activ
first
year
children
parent
pediatr
patient
discret
visit
adult
patient
rel
adult
patient
visit
receiv
psychosoci
support
conclus
psychosoci
program
oncolog
patient
success
implement
lmic
program
serv
model
cancer
deliveri
program
armenia
replic
lmic
k
kamibeppu
k
r
h
r
h
universti
tokyo
depart
famili
graduat
school
medicin
tokyo
japan
women
medic
univers
school
nurs
tokyo
japan
univers
divis
health
graduat
school
medicin
osaka
japan
children
hospit
nurs
depart
miyagi
japan
children
hospit
depart
hematologyoncolog
miyagi
japan
univers
graduat
school
medicin
miyagi
japan
backgroundobject
clarifi
struggl
famili
experienc
two
big
trauma
childhood
cancer
great
east
japan
earthquak
disast
designmethod
studi
part
ongo
longitudin
studi
start
april
conduct
interview
everi
month
year
famili
experienc
childhood
cancer
earthquak
analyz
first
interview
famili
content
analysi
result
children
diagnos
aml
neuroblastoma
etc
age
four
famili
experienc
diseas
disast
begin
hospit
almost
children
miss
famili
schoolmat
mother
suppress
fear
prognosi
face
children
diseas
optimist
father
tend
give
prioriti
work
father
emot
support
encourag
mother
parent
need
famili
member
assist
ie
healthi
sibl
grandpar
share
diagnosi
sibl
somat
psycholog
distress
prolong
hospit
one
play
mother
role
home
impact
disast
vari
accord
caus
earthquak
tsunami
radioact
contamin
degre
damag
receiv
famili
increas
cohes
face
diseas
overcam
disast
opposit
direct
famili
gain
strength
overcom
disast
struggl
diseas
construct
survivor
young
adulthood
reaffirm
happi
mean
live
normal
life
conclus
although
famili
experienc
two
big
trauma
abl
struggl
second
one
mighti
heart
case
famili
increas
cohes
first
one
analyz
longitudin
narr
clarifi
challeng
might
effect
trauma
famili
mfm
manha
cd
feder
de
paulo
departa
clinic
experiment
oncolog
paulo
brazil
backgroundobject
cancer
diagnosi
neg
affect
biopsychosoci
function
adolesc
young
adult
aya
studi
aim
describ
level
relationship
distress
biopsychosoci
unmet
need
sampl
brazilian
aya
patient
cancer
designmethod
studi
conduct
among
aya
patient
cancer
age
year
treat
brazilian
public
hospit
assess
use
distress
thermomet
hospit
anxieti
depress
scale
function
assess
cancer
therapi
gener
descript
statist
obtain
measur
frequenc
examin
identifi
common
unmet
need
relationship
distress
unmet
need
explor
result
aya
patient
mostli
male
singl
white
diagnos
central
nervou
system
hematolog
genitourinari
cancer
advanc
diseas
stage
aya
report
greater
distress
commonli
relat
practic
emot
physic
problem
financi
worri
nervous
sad
pain
fatigu
memori
concentr
sleep
highest
score
howev
report
clinic
symptom
anxieti
depress
aya
patient
report
poor
level
qualiti
life
percentil
us
norm
distress
symptom
anxietydepress
qualiti
life
significantli
associ
biopsychosoci
problem
report
p
higher
level
distress
predict
symptom
anxieti
p
depress
p
emot
p
physic
p
problem
conclus
brazilian
aya
patient
report
high
level
number
unmet
need
substanti
distress
strong
associ
found
increas
distress
unmet
need
find
suggest
need
psychosoci
intervent
brazilian
cancer
patient
target
help
cope
biopsychosoci
distress
preliminari
data
highlight
opportun
servic
better
meet
aya
need
p
mehta
j
k
e
p
j
g
e
colleg
medicin
pediatr
houston
usa
children
hospit
cancer
hematolog
center
houston
usa
backgroundobject
txch
global
hope
oper
project
africa
ssa
placement
leadership
posit
set
present
signific
challeng
beyond
scope
orient
expand
reflect
practic
leadership
seminar
rp
l
method
provid
ongo
leadership
educ
team
member
ssa
fellow
east
african
pediatr
fellowship
program
designmethod
one
hour
teleconfer
seminar
routin
conduct
faculti
staff
fellow
site
africa
seminar
particip
present
current
challeng
season
faculti
guid
discuss
disciplin
analysi
includ
diagnosi
situat
plan
strateg
action
leadership
dimens
health
care
profession
role
result
topic
cover
seminar
includ
challeng
introduc
new
countri
bring
new
staff
member
onto
team
negoti
care
deliv
ancillari
servic
petit
resourc
within
context
larger
local
organ
negoti
chang
medic
personnel
provid
separ
institut
negoti
chang
within
extern
institut
directli
affect
program
function
questionnair
indic
particip
strongli
agre
scale
follow
statement
seminar
improv
abil
analyz
complic
clinic
servic
situat
navig
polit
effect
build
relationship
improv
patient
care
conclus
global
leadership
seminar
demonstr
success
help
ssa
staff
traine
improv
leadership
capac
negoti
chang
effect
c
nicola
univers
technolog
nurs
limassol
cypru
backgroundobject
studi
among
parent
children
cancer
focus
anxieti
depress
stress
less
overal
measur
qualiti
life
hrqol
designmethod
literatur
review
scopu
cinahl
term
mother
carer
etc
child
adolesc
etc
cancer
oncolog
etc
qualiti
life
hrqol
etc
combin
select
criteria
mother
predomin
mix
sampl
children
age
activ
treatment
palli
quantit
measur
qualiti
life
compar
eg
popul
norm
control
group
correl
baselin
intervent
english
languag
prior
result
studi
review
among
fulfil
criteria
mother
mix
separ
result
mother
addit
sampl
predomin
mother
except
seri
studi
canada
n
studi
small
sampl
size
n
european
studi
origin
limit
number
set
correl
studi
eg
cope
anxieti
depress
sleep
qualiti
intern
comparison
eg
vs
famili
time
sinc
diagnosi
group
longitudin
etc
extern
ie
mother
healthi
children
diagnosi
popul
norm
commonli
use
studi
extern
comparison
qualiti
life
significantli
reduc
amongst
mother
parent
children
cancer
despit
heterogen
studi
commonli
effect
size
rang
sd
mental
health
sd
physic
health
dimens
conclus
physic
health
well
mental
health
aspect
qualiti
life
appear
affect
vulner
group
highlight
need
monitor
incorpor
qol
outcom
measur
assess
effect
psychosoci
intervent
programsth
main
messag
qualiti
life
compromis
mother
children
cancer
n
f
z
l
sao
paulo
faculti
letter
ribeirao
preto
ribeirao
preto
brazil
cancer
institut
pediatr
oncolog
branch
bethesda
usa
backgroundobject
given
import
cultur
appropri
tool
initi
advanc
care
plan
convers
young
adult
adapt
voic
choicestm
vmc
brazil
underway
designmethod
vmc
translat
portugues
bilingu
translat
synthesi
version
defin
submit
semant
valid
expert
patient
age
undergo
cancer
treatment
invit
evalu
modifi
version
term
clariti
cultur
age
appropri
help
stress
revis
version
english
bilingu
translat
discuss
vmc
author
refin
final
portugues
version
quantit
data
analyz
descript
analysi
qualit
data
evalu
themat
content
analysi
result
nine
expert
patient
enrol
overal
expert
evalu
tool
total
adequ
adequ
regard
document
structur
relev
topic
cover
adequaci
use
across
set
suggest
adapt
focus
cultur
legal
linguist
aspect
document
revis
introduc
patient
patient
consid
topic
cover
age
cultur
appropri
similarli
particip
found
topic
help
help
except
section
address
funer
plan
describ
help
endors
stress
patient
feedback
focus
cultur
aspect
incorpor
tool
treatment
trajectori
conclus
obtain
feedback
semant
valid
essenti
ensur
appropri
linguist
cultur
adapt
studi
adapt
version
vmc
portugues
implement
evalu
tool
feasibl
identifi
potenti
burden
benefit
use
acknowledg
studi
support
grant
sao
paulo
research
foundat
fapesp
part
nih
intramur
research
program
ogez
cj
k
r
v
research
center
montreal
canada
de
psycholog
montreal
canada
de
kinesiolog
montreal
canada
de
dietet
montreal
canada
backgroundobject
two
manual
intervent
program
effect
reduc
parent
distress
child
treat
cancer
bright
idea
sccip
program
bear
limit
relat
dissemin
focu
individu
vs
famili
etc
want
deal
new
integr
program
take
best
current
avail
aim
preliminari
studi
refin
design
integr
program
regain
control
togeth
intervent
support
parent
designmethod
sequenti
studi
call
two
step
parent
invit
inform
session
intervent
project
complet
questionnair
object
procedur
manual
tool
descript
analysi
questionnair
respons
area
improv
discuss
focu
group
parent
process
repeat
profession
descript
analys
questionnair
respons
computer
themat
analysi
nvivo
allow
organ
differ
categori
recommend
program
refin
result
six
parent
six
profession
particip
studi
result
show
strength
program
pertin
solv
problem
practic
approach
coupl
intervent
main
area
improv
access
languag
manual
adapt
program
differ
cultur
discuss
program
recommend
particip
chang
made
accordingli
final
version
avail
formal
phase
ii
avail
core
featur
present
conclus
studi
illustr
necessari
includ
parent
final
user
elabor
intervent
program
final
version
avail
gradual
implement
test
feasibl
accept
effect
okur
eo
e
fg
eg
c
univers
pediatr
oncolog
ankara
turkey
univers
pediatr
psychiatri
ankara
turkey
backgroundobject
aim
prospect
studi
investig
preval
anxieti
depress
burnout
posttraumat
stress
disord
pediatr
oncolog
patient
mother
designmethod
children
adolesc
age
year
activ
treat
remiss
gazi
univers
pediatr
oncolog
depart
mother
recruit
studi
group
control
group
anxieti
depress
burnout
consist
children
without
chronic
diseas
admit
gener
pediatr
clinic
outpati
mother
questionnair
measur
anxieti
depress
administ
children
mother
stress
disord
ptsd
scale
children
mother
perform
survey
presenc
clinician
control
group
ptsd
consist
children
mother
experi
seriou
traumat
event
traffic
accid
earthquak
close
rel
death
result
signific
differ
regard
anxieti
depress
burn
term
scale
score
children
remiss
children
treatment
mother
children
treatment
significantli
traumat
anxiou
children
remiss
howev
signific
differ
burnout
symptom
mother
children
treatment
mother
children
remiss
children
cancer
depress
worri
control
group
mother
healthi
children
significantli
less
depress
anxiou
mother
children
treatment
remiss
found
significantli
ptsd
symptom
patient
treatment
remiss
children
mother
patient
ptsd
control
group
conclus
find
suggest
pediatr
cancer
signific
stressor
children
mother
clinician
awar
psychiatr
symptom
children
underw
condit
palomo
jz
lugo
le
j
mier
jf
gaytan
mier
cabrera
l
barcena
sadowinski
infantil
de
federico
oncolog
mexico
nacion
de
perinatologia
isidro
espinoza
de
lo
rey
subdireccion
investigacion
en
intervencion
comunitaria
mexico
region
alta
especialidad
ixtapaluca
pediatr
ixtapaluca
mexico
infantil
de
federico
nurs
mexico
infantil
de
federico
patholog
mexico
backgroundobject
patient
bone
tumour
bt
undergo
extens
aggress
chemotherapi
treatment
surgeri
signific
acut
effect
patient
consid
high
surviv
rate
childhood
cancer
physic
psychosoci
effect
well
assess
qualiti
life
hrqol
becom
new
focu
clinic
research
patient
diagnos
high
risk
poor
hrqol
compar
childhood
cancer
survivor
asses
qualiti
life
survivor
childhood
bt
designmethod
descript
observ
studi
conduct
hospit
infantil
de
mexico
federico
elig
studi
particip
enrol
august
juli
particip
complet
questionnair
instrument
measur
ten
dimens
physic
psycholog
mood
emot
autonomi
parent
relat
home
life
social
support
peer
school
environ
social
accept
bulli
financi
resourc
test
item
rate
scale
high
score
indic
good
qualiti
life
result
thirteen
bt
survivor
year
old
follow
least
one
year
complet
treatment
particip
studi
twelv
patient
osteosarcoma
one
ewe
sarcoma
seven
male
four
metastasi
diagnosi
seven
undergon
amput
score
point
physic
psycholog
autonomi
school
environ
social
support
social
accept
conclus
although
mani
bt
survivor
report
excel
function
hrqol
outcom
signific
number
report
disabl
impair
cohort
includ
reassess
observ
chang
score
perceiv
disabl
time
clearli
warrant
hope
studi
help
provid
patient
famili
need
inform
anticip
outcom
maxim
function
rhqol
park
jm
hj
hy
bk
jy
sk
yh
yj
hs
ja
yj
hw
jk
mj
sk
hs
hj
kd
hy
nation
univers
colleg
medicin
pediatr
cheongju
republ
korea
univers
colleg
medicin
pediatr
daegu
republ
korea
cancer
center
pediatr
oncolog
goyang
republ
korea
nation
univers
school
medicin
pediatr
daegu
republ
korea
univers
univers
ulsan
colleg
medicin
pediatr
ulsan
republ
korea
univers
colleg
medicin
pediatr
seoul
republ
korea
univers
colleg
medicin
pediatr
daegu
republ
korea
cancer
center
hospit
pediatr
seoul
republ
korea
nation
univers
colleg
medicin
pediatr
daejon
republ
korea
univers
colleg
medicin
pediatr
busan
republ
korea
univers
busan
paik
hospit
pediatr
busan
republ
korea
univers
colleg
medicin
pediatr
cheonan
republ
korea
univers
colleg
medicin
pediatr
incheon
republ
korea
nation
univers
bundang
hospit
pediatr
seongnam
republ
korea
research
seoul
nation
univers
colleg
medicin
pediatr
seoul
republ
korea
backgroundobject
success
return
school
cancer
diagnosi
import
facilit
child
normal
learn
attain
academ
skill
absente
vulner
cancer
survivor
might
exacerb
learn
challeng
studi
address
issu
peer
relationship
school
attend
academ
achiev
designmethod
juli
decemb
institut
korea
particip
studi
behalf
korean
societi
pediatr
hematolog
oncolog
kspho
studi
children
treat
cancer
time
studi
older
year
questionnair
use
studi
result
approxim
survivor
suffer
lack
friend
bulli
report
survivor
differ
experienc
bulli
accord
diseas
categori
howev
survivor
return
primari
school
report
higher
incid
bulli
compar
survivor
return
middl
high
school
percentag
children
miss
class
day
month
higher
survivor
brain
tumor
tumor
vs
survivor
report
miss
school
due
physic
ill
fatigu
medic
care
parent
concern
approxim
children
report
learn
difficulti
mainli
due
difficulti
understand
materi
concentr
class
children
receiv
hospit
school
support
cancer
treatment
repeat
less
often
children
vs
school
mark
korean
languag
english
physic
educ
wors
children
brain
tumor
children
tumor
conclus
studi
demonstr
survivor
cancer
requir
special
care
attent
return
school
treat
brain
tumor
remain
particularli
vulner
perez
c
r
l
state
univers
psycholog
stillwat
usa
oklahoma
health
scienc
center
pediatr
hematolog
oncolog
oklahoma
citi
usa
backgroundobject
subset
caregiv
children
newli
diagnos
cancer
risk
psycholog
distress
parent
ill
uncertainti
iu
barrier
care
link
parent
distress
previou
research
indic
iu
may
mediat
relationship
barrier
care
distress
evalu
pathway
barrier
care
may
impact
iu
present
studi
assess
relationship
distinct
barrier
care
ie
pragmat
skill
expect
margin
knowledgebelief
specif
compon
iu
ie
ambigu
lack
clariti
lack
inform
designmethod
caregiv
children
newli
diagnos
cancer
recruit
midwest
medic
center
complet
barrier
care
questionnair
bcq
parent
percept
uncertainti
scale
ppu
part
larger
studi
parent
adapt
pediatr
cancer
diagnosi
result
expect
significantli
predict
ambigu
lack
clariti
p
lack
inform
margin
significantli
predict
ambigu
lack
clariti
lack
inform
skill
significantli
predict
ambigu
lack
inform
knowledgebelief
significantli
predict
ambigu
lack
clariti
pragmat
significantli
predict
ambigu
conclus
caregiv
perceiv
low
qualiti
care
person
neg
experi
child
care
experienc
higher
ambigu
deficit
clariti
inform
concern
ill
parent
report
lower
confid
abil
manag
child
medic
care
experienc
ambigu
lack
inform
regard
ill
treatment
lastli
parent
disagre
medic
profession
care
report
increas
ambigu
lack
clariti
result
suggest
parent
perceiv
care
low
qualiti
parent
disagre
medic
treatment
experienc
higher
iu
improv
commun
relationship
caregiv
clinic
team
may
reduc
barrier
iu
potenti
attenu
distress
n
b
k
g
f
schult
calgari
psycholog
calgari
canada
children
hospit
transplant
program
calgayar
canada
children
hospit
transplant
program
calgari
canada
children
hospit
long
term
survivor
clinic
calgari
canada
children
hospit
transplant
program
calgari
canada
backgroundobject
increas
surviv
children
treat
pediatr
cancer
attent
turn
health
aim
current
studi
examin
treatment
intens
risk
factor
poor
hrql
qualiti
life
pediatr
cancer
survivor
hypothes
higher
treatment
intens
would
associ
lower
hrql
howev
also
hypothes
famili
psychosoci
function
includ
famili
cohes
social
support
avail
resourc
would
buffer
survivor
deleteri
consequ
high
treatment
intens
designmethod
pediatr
cancer
survivor
mean
yr
rang
yr
parent
recruit
routin
appoint
survivor
clinic
complet
questionnair
address
hrql
pedsql
famili
psychosoci
risk
pat
intens
treatment
determin
via
standard
tool
intens
treatment
rate
scale
independ
rate
two
health
care
provid
result
multipl
regress
analys
reveal
control
age
sex
parent
psycholog
distress
treatment
intens
b
p
psychosoci
famili
risk
b
p
neg
predict
report
hrql
psychosoci
famili
risk
moder
associ
parent
psycholog
distress
child
hrql
b
conclus
higher
level
treatment
intens
cancer
put
children
risk
poor
hrql
turn
implic
social
mental
health
outcom
current
studi
resili
effect
observ
children
histori
high
level
treatment
intens
buffer
experienc
poor
qualiti
life
low
psychosoci
famili
risk
eg
robertson
j
r
c
children
hospit
behaviour
scienc
kid
cancer
centr
randwick
australia
univers
new
south
wale
disciplin
school
women
children
health
randwick
australia
children
hospit
kid
cancer
centr
randwick
australia
backgroundobject
famili
children
diagnos
cancer
face
difficult
treatment
decis
includ
radiat
therapi
fertil
preserv
enrol
research
studi
mani
patient
parent
find
difficult
understand
rational
implic
treatment
option
may
also
risk
experienc
decision
anxieti
conflict
uncertainti
distress
aim
qualit
explor
process
parent
young
peopl
face
treatment
decis
well
inform
need
prefer
designmethod
conduct
interview
recent
diagnos
adolesc
parent
interview
audio
record
transcrib
verbatim
analys
via
content
analysi
use
nvivo
date
adolesc
mean
parent
mean
age
complet
interview
studi
still
recruit
anticip
studi
close
result
date
adolesc
mean
parent
mean
age
complet
interview
earli
find
suggest
famili
often
engag
share
relationship
clinician
major
influenc
decis
process
parent
tend
includ
child
major
decis
eg
clinic
trial
enrol
due
age
child
howev
acknowledg
import
children
involv
decis
eg
pain
relief
parent
express
dissatisfact
level
barrier
involv
includ
feel
distress
overwhelm
inform
conclus
pediatr
oncolog
complex
famili
requir
clearer
inform
provid
multipl
modal
guidanc
engag
share
emot
support
throughout
decis
process
find
contribut
develop
delta
onlin
support
famili
decid
whether
enrol
pediatr
oncolog
clinic
trial
scott
j
k
k
h
jude
children
research
hospit
psycholog
memphi
usa
backgroundobject
research
routin
dissemin
result
follow
particip
studi
howev
increas
acknowledg
benefit
return
result
far
outweigh
potenti
risk
research
endors
return
research
result
anoth
compon
ethic
research
among
pediatr
popul
specif
import
determin
prefer
famili
would
like
receiv
research
result
guidelin
develop
clear
summari
result
current
studi
explor
practic
return
result
famili
childhood
cancer
survivor
follow
particip
computer
cognit
train
program
use
children
oncolog
group
cog
guidelin
designmethod
previou
studi
survivor
childhood
acut
lymphoblast
leukemia
brain
tumor
bt
n
identifi
cognit
deficit
randomli
assign
particip
computer
cognit
intervent
assign
follow
conclus
previou
studi
particip
famili
contact
postal
letter
phone
call
andor
patient
approach
provid
summari
result
computer
cognit
train
studi
survey
gaug
interpret
summari
reaction
result
prefer
regard
return
result
result
particip
return
survey
caregiv
indic
perceiv
result
import
help
relev
child
easi
understand
result
provid
summari
mostli
interpret
posit
manner
mani
endors
satisfact
andor
relief
mani
caregiv
prefer
receiv
research
result
postal
letter
email
conclus
summari
benefit
return
research
result
regard
effect
computer
train
childhood
cancer
survivor
far
outweigh
perceiv
risk
practic
regularli
return
research
result
directli
benefit
famili
make
futur
decis
addit
dissemin
accur
nuanc
research
result
k
shimmon
b
p
teach
hospit
paediatr
psycholog
leed
unit
kingdom
york
centr
review
dissemin
york
unit
kingdom
backgroundobject
long
term
psycholog
effect
childhood
cancer
upon
parent
studi
extens
yet
uncertainti
remain
degre
natur
posit
neg
psycholog
sequela
paper
updat
expand
upon
review
assess
literatur
publish
posit
neg
long
term
psycholog
late
effect
parent
childhood
cancer
survivor
cc
report
least
five
year
child
diagnosi
andor
two
year
end
child
treatment
designmethod
standard
systemat
review
method
employ
two
independ
review
conduct
search
databas
cinahl
embas
psychinfo
pubm
perform
qualiti
apprais
use
qualsyst
tool
extract
data
possibl
paper
review
assess
ad
total
final
includ
synthesi
data
undertaken
use
narr
framework
heterogen
underli
data
collect
preclud
quantit
result
total
new
studi
includ
parent
ad
overal
major
studi
report
differ
level
psycholog
distress
parent
survivor
compar
norm
small
subset
report
elev
level
post
traumat
stress
symptom
ptss
two
addit
studi
found
lower
ptss
andor
higher
post
traumat
growth
pg
factor
associ
neg
long
term
late
effect
includ
avoid
cope
style
age
parent
caregiv
strain
conflict
famili
function
conclus
littl
evid
suggest
child
cancer
result
gener
increas
level
psycholog
distress
parent
long
term
opportun
person
growth
may
experienc
other
event
trigger
ptss
clinic
implic
find
argu
awar
specif
referr
requir
tremolada
g
g
psycholog
depart
develop
social
psycholog
padova
itali
oncologico
veneto
pediatr
radiotherapi
unit
padua
itali
hospit
padua
depart
child
woman
oncolog
hematolog
divis
padua
itali
backgroundobject
due
advanc
chemotherapi
support
care
last
year
number
childhood
cancer
survivor
fortun
increas
unfortun
could
sever
neg
effect
link
cancer
treatment
studi
adopt
approach
cross
narr
data
come
questionnair
identifi
possibl
signific
predictor
psychopatholog
symptom
qualiti
daili
life
relationship
characterist
aim
studi
assess
qualiti
daili
life
famili
social
relationship
pediatr
cancer
survivor
adopt
mix
method
identifi
possibl
factor
impact
depress
symptomatolog
designmethod
particip
consist
italian
aya
cancer
survivor
mean
age
diagnosi
year
treat
haematolog
diseas
solid
tumour
mean
year
ecocultur
famili
interview
tremolada
et
al
new
version
aya
cancer
survivor
took
place
dh
clinic
medic
control
interview
result
psychometr
reliabl
solid
extract
good
intern
consist
gener
dimens
item
questionnair
measur
feel
emot
ccss
brief
cope
administ
well
result
hierarch
regress
analysi
show
depress
symptom
f
p
predict
age
diagnosi
beta
p
relationship
parent
beta
p
cope
strategi
beta
p
medic
sociodemograph
variabl
nt
impact
significantli
conclus
good
relationship
parent
older
age
diagnosi
identifi
protect
factor
depress
symptomatolog
cope
strategi
repres
risk
factor
empir
data
lead
focus
intervent
c
west
l
j
manitoba
colleg
nurs
winnipeg
canada
univers
faculti
health
studi
winnipeg
canada
calgari
faculti
nurs
calgari
canada
backgroundobject
pediatr
hematopoiet
stem
cell
transplant
hsct
highli
intens
treatment
children
famili
member
experi
signific
ill
distress
includ
anxieti
depress
stress
symptom
distress
famili
member
play
pivot
role
level
distress
experienc
ill
children
hsct
key
limit
exist
research
famili
primarili
studi
perspect
individu
famili
member
famili
unit
studi
use
famili
art
framework
identifi
main
factor
influenc
famili
transit
hsct
well
specif
famili
need
outcom
designmethod
retrospect
pilot
studi
conduct
use
constructivist
ground
theori
fifteen
famili
member
parentsprimari
caregiv
recipi
sibl
six
famili
particip
two
qualit
interview
second
interview
particip
drew
imag
experienc
hsct
treatment
research
guid
famili
member
dialogu
imag
process
famili
member
ask
imag
question
answer
question
imag
result
induct
deriv
theori
famili
transit
hsct
develop
trajectori
includ
relationship
dynam
within
famili
health
care
team
power
modul
transit
highli
tenuou
process
famili
fragment
occur
hospit
experi
trauma
occur
particularli
parent
caregiv
live
transplant
room
hoursday
sustain
ill
child
hospit
famili
member
experienc
one
two
domin
pattern
interact
health
care
profession
famili
famili
follow
discharg
famili
struggl
reintegr
hold
unvoic
experi
trauma
differ
famili
member
conclus
identifi
crucial
need
target
famili
art
intervent
transit
hsct
acknowledg
children
hospit
research
institut
manitoba
oper
grant
k
westmoreland
van
der
c
p
b
pediatr
hematolog
oncolog
lilongw
malawi
north
carolina
pediatr
hematolog
oncolog
chapel
hill
usa
oncolog
lilongw
malawi
cancer
program
director
lilongw
malawi
malawi
school
medicin
oncolog
infecti
diseas
lilongw
malawi
north
carolina
oncolog
infecti
diseas
chapel
hill
usa
north
carolina
health
polici
manag
chapel
hill
usa
backgroundobject
measur
qualiti
life
hrqol
among
cancer
patient
import
comprehens
holist
assess
outcom
intern
valid
tool
measur
hrqol
avail
effort
translat
cultur
valid
tool
africa
ssa
scarc
designmethod
outcom
measur
inform
system
short
form
assess
six
hrqol
domain
mobil
anxieti
depress
fatigu
peer
relationship
pain
interfer
ask
four
question
per
domain
pain
intens
question
also
includ
instrument
translat
chichewa
two
forward
independ
translat
reconcili
back
translat
three
independ
review
final
harmon
cultur
valid
conduct
five
cognit
interview
baselin
questionnair
collect
children
enrol
ongo
prospect
lymphoma
cohort
kamuzu
central
hospit
lilongw
psychometr
valid
assess
use
spearman
correl
among
item
within
across
domain
cronbach
alpha
intern
consist
reliabl
within
domain
known
group
valid
result
interview
discov
translat
abl
walk
one
block
cultur
applic
therefor
item
chang
length
one
soccer
pitch
lymphoma
patient
complet
questionnair
item
within
domain
correl
item
outsid
domain
support
structur
valid
reliabl
scale
satisfactori
rang
alpha
children
hemoglobin
gdl
wors
fatigu
hrqol
hemoglobin
gdl
children
lanski
perform
statu
lp
wors
mobil
hrqol
lp
conclus
translat
cultur
valid
chichewa
malawi
success
pediatr
cancer
care
research
program
expand
ssa
vital
incorpor
assess
hrqol
use
instrument
valid
within
local
context
l
wiener
pediatr
oncolog
branch
bethesda
usa
backgroundobject
sibl
often
select
donor
match
patient
malign
nonmalign
hematolog
diseas
research
prepar
sibl
donor
stem
cell
donat
limit
current
data
suggest
sibl
donor
risk
depress
anxieti
withdraw
behavior
problem
lower
even
donat
procedur
explain
sibl
found
difficulti
understand
inform
experi
anxieti
prospect
studi
examin
educ
tool
transplant
knowledg
sibl
stem
cell
donor
current
avail
designmethod
studi
design
assess
donor
comprehens
donat
procedur
compar
knowledg
anxieti
prior
post
educ
intervent
particip
includ
sibl
pediatr
patient
age
assess
baselin
knowledg
state
anxieti
obtain
consentass
meet
medic
team
donor
stratifi
group
age
donor
age
play
adapt
version
shoptalk
donor
age
provid
workbook
design
sibl
stem
cell
donor
knowledg
anxieti
reassess
hour
follow
intervent
month
later
result
sibl
donor
enrol
complet
time
point
knowledg
stem
cell
help
cancer
patient
good
baselin
area
lack
includ
stem
cell
collect
possibl
complic
post
donat
transplant
trend
increas
knowledg
reduc
anxieti
found
post
intervent
enrol
ongo
conclus
preliminari
result
suggest
educ
provid
inform
via
game
workbook
increas
knowledg
may
reduc
anxieti
sibl
donor
provid
detail
inform
donat
discuss
procedur
tail
individu
learn
style
supplement
addit
visual
inform
r
woodgat
p
manitoba
radi
faculti
health
colleg
nurs
winnipeg
canada
backgroundobject
sinc
participatori
visual
approach
qualit
research
grown
popular
creativ
approach
work
toward
facilit
authent
express
complex
realiti
peopl
engag
research
well
affect
connect
peopl
environ
life
situat
purpos
present
describ
use
participatori
visual
approach
includ
advantag
challeng
opportun
research
seek
advanc
understand
children
youth
perspect
cancer
cancer
prevent
designmethod
advantag
challeng
opportun
work
participatori
visual
approach
includ
draw
photovoic
qualit
research
glean
literatur
research
conduct
first
author
result
participatori
visual
approach
draw
photographi
enabl
children
youth
qualit
research
convers
think
want
repres
perspect
experi
participatori
visual
method
abl
produc
power
metaphor
liter
depict
live
realiti
nonetheless
procedur
ethic
relat
challeng
work
participatori
visual
approach
variou
stage
activ
interpret
dissemin
result
includ
issu
data
valid
authent
conclus
insight
deriv
literatur
research
provid
standard
advanc
participatori
visual
approach
qualit
research
seek
advanc
understand
children
youth
perspect
cancer
cancer
prevent
enhanc
didact
qualiti
research
consider
extend
participatori
visual
approach
care
follow
complet
research
two
area
approach
could
develop
great
promis
r
woodgat
p
manitoba
radi
faculti
health
colleg
nurs
winnipeg
canada
backgroundobject
number
ethic
challeng
emerg
engag
children
youth
qualit
research
purpos
present
discuss
mitig
ethic
challeng
research
seek
advanc
understand
children
youth
live
cancer
complex
condit
designmethod
ethic
challeng
qualit
research
explor
bring
forward
exampl
first
author
research
program
focus
signific
multipl
perspect
valu
gaug
need
young
peopl
live
cancer
complex
condit
studi
address
children
youth
think
ill
contribut
build
insight
live
experi
ill
result
addit
highlight
ethic
challeng
work
children
youth
research
case
ethic
consider
need
extend
beyond
research
ethic
board
protocol
made
sustain
mind
presenc
propos
novel
inclus
framework
research
navig
ethic
challeng
research
involv
move
research
field
care
forethought
attent
pace
recept
attent
awar
take
place
potenti
authent
express
particip
sustain
mind
presenc
includ
follow
characterist
becom
highli
develop
within
research
open
curios
ii
empathi
accept
iii
recept
attent
deep
listen
iv
relat
engag
v
flexibl
reflex
vi
vii
nonjudgment
respect
conclus
sustain
mind
presenc
research
abl
provid
safe
comfort
research
environ
consid
young
person
physic
psycholog
state
avoid
place
demand
young
peopl
could
caus
harm
physic
psycholog
make
care
prepar
exit
field
zadeh
bedoya
h
k
l
k
p
c
l
cancer
institut
pediatr
oncolog
branch
bethesda
usa
nation
medic
center
center
translat
research
washington
usa
nation
medic
center
pediatr
hematologyoncolog
washington
usa
nation
medic
center
center
cancer
blood
disord
washington
usa
hospit
orang
counti
hyundai
cancer
institut
orang
usa
cancer
institut
young
adult
program
boston
usa
children
medic
center
aya
oncolog
program
fort
worth
usa
backgroundobject
young
adult
ya
die
cancer
year
make
lead
caus
death
age
group
ac
advanc
care
plan
acp
document
provid
patient
opportun
express
prefer
care
make
inform
decis
famili
provid
describ
discomfort
initi
convers
aya
studi
aim
understand
whether
aya
acp
convers
famili
member
friend
health
care
provid
barrier
perceiv
designmethod
particip
age
cancer
life
threaten
ill
administ
questionnair
determin
whether
engag
commun
famili
friend
andor
health
care
provid
prefer
care
becom
serious
ill
perceiv
barrier
convers
also
assess
studi
open
cancer
center
result
aya
complet
questionnair
percent
particip
indic
eol
plan
convers
famili
member
spoken
friend
health
care
provid
perceiv
barrier
commun
includ
upset
famili
desir
maintain
normal
life
friend
feel
comfort
initi
discuss
acp
health
care
provid
conclus
particp
commun
regard
eol
prefer
either
famili
friend
health
care
provid
given
import
plan
challeng
ensur
convers
occur
medic
team
intervent
develop
enhanc
provid
comfort
initi
discuss
help
help
patient
commun
famili
friend
import
eol
near
borja
mj
axxi
pediatrica
quito
ecuador
metropolitano
quito
ecuador
backgroundobject
accord
literatur
tumor
children
year
old
involv
cn
howev
percentag
decreas
end
adolesc
adult
cn
tumor
childhood
locat
posterior
fossa
common
type
astrocytoma
due
differ
epidemiolog
manag
app
nci
recommend
children
seek
diagnos
treatment
special
pediatr
center
cancer
accord
studi
children
receiv
care
institut
show
higher
surviv
rate
howev
surviv
outcom
adolesc
cn
tumor
shown
improv
dispart
show
adolesc
higher
mortal
henc
understand
distribut
cn
cancer
group
contribut
better
individu
treatment
objet
determin
incid
cn
tumor
adolesc
children
hospit
ecuador
januari
august
designmethod
descript
retrospect
studi
includ
patient
year
old
inclus
criteria
age
old
diagnost
cn
cancer
confirm
radiolog
patholog
area
result
n
children
total
patient
diagnos
cn
tumor
case
found
male
mean
age
diagnosi
ten
year
old
percent
correspond
posterior
fosa
global
common
type
astrocytoma
least
ependimoma
result
similar
previous
find
england
us
popul
admit
pediatr
hospit
enrol
caus
select
bia
conclus
cancer
treatment
adolesc
still
challeng
poor
improv
surviv
rate
seen
despit
chang
manag
studi
show
incid
cn
cancer
adolesc
year
old
similar
distribut
children
describ
previou
studi
therefor
caus
rather
distribut
relat
surviv
outcom
new
factor
need
investig
elmadhoun
n
th
chan
school
public
health
health
polici
manag
boston
usa
farberboston
children
hospit
global
health
initi
boston
usa
backgroundobject
project
children
cancer
hospit
cche
aim
defin
new
patient
process
solid
tumor
patient
studi
patient
flow
analyz
process
abl
identifi
root
caus
suggest
action
recommend
improv
cche
largest
special
children
cancer
hospit
world
locat
cairo
egypt
hospit
offer
high
qualiti
pediatr
oncolog
care
complet
free
charg
experi
high
demand
necessit
continu
improv
handl
new
patient
order
make
process
effici
enhanc
patient
experi
designmethod
project
aim
appli
lean
manag
six
sigma
tool
defin
new
patient
process
collect
data
new
patient
process
studi
patient
flow
identifi
root
caus
also
use
incorpor
dana
farberboston
children
qualiti
improv
polici
toolkit
result
key
find
project
includ
full
process
map
new
patient
solid
tumor
process
dana
farber
boston
children
well
visual
tool
util
leansix
sigma
addit
draft
list
ten
preliminari
recommend
improv
present
team
conclus
recommend
laid
groundwork
establish
new
patient
clinic
meet
high
patient
volum
enhanc
patient
experi
c
fiori
carla
c
mi
f
de
pediatr
oncolog
cascavel
brazil
backgroundobject
introduct
develop
countri
cure
rate
cancer
children
exce
realiti
far
achiev
brazil
main
reason
difficulti
health
profession
diagnos
diseas
earli
cancer
hospit
cascavel
uopeccan
partnership
ronald
mcdonald
institut
earli
diagnosi
cancer
children
adolesc
program
train
profession
health
pediatr
municip
object
train
profession
health
pediatrician
order
contribut
earli
identif
cancer
children
adolesc
reduc
time
onset
sign
symptom
diagnosi
special
center
designmethod
methodolog
health
profession
sever
citi
parana
train
april
decemb
receiv
basic
inform
children
cancer
adolesc
epidemiolog
sign
symptom
suspicion
care
need
attent
children
adolesc
cancer
group
form
profession
hour
cours
result
result
train
profession
doctor
nurs
technician
nurs
assist
commun
health
agent
upper
level
profession
auxiliari
conclus
comment
among
diagnos
case
cancer
children
brazil
mani
refer
treatment
center
diseas
advanc
stage
one
goal
campaign
encourag
educ
prevent
action
spread
knowledg
peopl
diseas
observ
last
three
year
cha
nge
stage
diagnosi
patient
come
refer
center
children
come
local
diseas
shorten
time
suspicion
cancer
earli
diagnosi
treatment
certainli
contribut
increas
expect
cure
develop
countri
f
h
hami
genet
faculti
scienc
ibn
tofail
univers
kenitra
morocco
azhar
oncolog
center
rabat
morocco
backgroundobject
studi
conduct
determin
epidemiolog
characterist
childhood
cancer
morocco
designmethod
descript
retrospect
analysi
childhood
cancer
case
diagnos
treat
al
azhar
oncolog
center
rabat
period
year
result
studi
period
children
age
diagnos
cancer
al
azhar
oncolog
center
account
new
cancer
case
report
period
nearli
boy
ratio
averag
age
diagnosi
year
quarter
report
case
diagnos
first
five
year
life
highest
rate
children
note
year
age
brain
tumor
common
childhood
cancer
follow
cavum
cancer
among
detect
case
diagnos
metastat
diseas
die
studi
period
conclus
although
rare
cancer
children
substanti
impact
public
health
morocco
nation
cancer
registri
assist
better
plan
resourc
alloc
manag
includ
psychosoci
support
improv
qualiti
life
childhood
cancer
survivor
famili
n
shrivastava
f
g
de
th
chan
school
public
health
health
polici
manag
boston
usa
nacion
de
pediatr
oncolog
guatemala
citi
guatemala
vivir
pediatr
oncolog
guatemala
citi
guatemala
children
cancer
blood
disord
center
pediatr
oncolog
boston
usa
backgroundobject
financi
plan
resourc
establish
new
pediatr
oncolog
facil
countri
lmic
limit
unidad
nacion
de
unop
guatemala
nation
pediatr
cancer
hospit
partnership
foundat
vivir
ayuvi
sustain
oper
year
recent
expand
new
clinic
site
studi
aim
examin
financi
plan
practic
unop
ayuvi
highlight
import
lesson
learn
assess
impact
effect
budget
improv
outcom
children
cancer
guatemala
designmethod
key
inform
interview
conduct
staff
member
physician
administr
account
staff
volunt
fundrais
english
spanish
unop
ayuvi
interview
content
transcrib
analyz
identifi
recur
theme
inform
also
provid
relev
financi
plan
document
result
interviewe
emphas
import
divers
fund
sourc
includ
govern
corpor
sponsorship
local
intern
fundrais
prevent
relianc
sole
funder
budget
respond
highlight
import
gather
local
epidemiolog
data
forecast
diseas
burden
patient
demand
data
use
determin
requir
number
patient
bed
necessari
quantiti
equip
requir
clinic
staff
directli
influenc
construct
oper
budget
inform
note
sever
cost
uniqu
pediatr
cancer
hospit
includ
increas
need
isol
area
infecti
diseas
care
immunocompromis
patient
need
plan
lodg
parent
locat
stay
longer
treatment
conclus
unop
abil
increas
guatemala
overal
surviv
rate
pediatr
cancer
year
made
possibl
part
due
strateg
effect
financi
manag
institut
continu
success
highlight
feasibl
provid
access
care
children
live
cancer
set
e
rumyantsev
v
l
research
center
pediatr
hematolog
oncolog
immunolog
rehabilit
centr
russko
pole
moscow
russia
research
center
pediatr
hematolog
oncolog
immunolog
administr
moscow
russia
backgroundobject
consequ
chemoradiotherapi
preserv
year
complet
treatment
children
adolesc
aim
research
analysi
rehabilit
care
children
adolesc
russian
feder
cure
malign
neoplasm
designmethod
rehabilit
care
patient
oncohematolog
patholog
center
clinic
russian
feder
studi
within
framework
multicent
studi
sourc
data
offici
statist
report
questionnair
physician
includ
paramet
studi
parent
interview
prepar
questionnair
result
rehabilit
patient
cure
malign
neoplasm
carri
rehabilit
depart
region
hospit
special
rehabilit
center
citi
children
receiv
rehabilit
cours
special
shift
children
sanatorium
dispensari
nation
scientif
practic
center
pediatr
hematolog
oncolog
immunolog
name
dmitri
rogachev
method
center
deliveri
test
rehabilit
technolog
survivor
receiv
rehabilit
cours
connect
insuffici
number
rehabilit
ward
late
effect
antitumor
therapi
regist
patient
aim
rehabilit
organ
function
health
disord
manifest
depriv
desocialis
caus
need
develop
technolog
drug
nutrit
neurocognit
physic
psycholog
social
rehabilit
recov
patient
parent
survey
reveal
interest
famili
patient
expand
rehabilit
opportun
prefer
rehabilit
condit
special
center
conclus
doctor
emphas
lack
train
personnel
field
restor
medicin
absenc
evid
base
criteria
causal
pattern
develop
reveal
symptomatolog
premorbidcomorbid
condit
limit
effect
rehabilit
program
patient
oncohematolog
diseasesth
expens
compulsori
medic
insur
social
protect
system
ensur
access
famili
children
cure
malign
tumor
